No	O
drug	O
,	O
nutritional	O
supplement	O
,	O
food	O
or	O
herb	O
interactions	O
have	O
yet	O
been	O
reported	O
.	O

No	O
formal	O
drug	O
/	O
drug	O
interaction	O
studies	O
with	O
Plenaxis	S-brand
were	O
performed	O
.	O

Cytochrome	O
P	O
-	O
450	O
is	O
not	O
known	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
Plenaxis	S-brand
.	O

Plenaxis	S-brand
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
96	O
to	O
99	O
%	O
)	O
.	O

Laboratory	O
Tests	O
Response	O
to	O
Plenaxis	S-brand
should	O
be	O
monitored	O
by	O
measuring	O
serum	O
total	O
testosterone	S-drug
concentrations	O
just	O
prior	O
to	O
administration	O
on	O
Day	O
29	O
and	O
every	O
8	O
weeks	O
thereafter	O
.	O

Serum	O
transaminase	O
levels	O
should	O
be	O
obtained	O
before	O
starting	O
treatment	O
with	O
Plenaxis	S-brand
and	O
periodically	O
during	O
treatment	O
.	O

Periodic	O
measurement	O
of	O
serum	O
PSA	O
levels	O
may	O
also	O
be	O
considered	O
.	O

Formal	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ORENCIA	S-brand
.	O

Population	O
pharmacokinetic	O
analyses	O
revealed	O
that	O
MTX	S-drug
,	O
NSAIDs	S-group
,	O
corticosteroids	S-group
,	O
and	O
TNF	B-group
blocking	I-group
agents	E-group
did	O
not	O
influence	O
abatacept	S-drug
clearance	O
.	O

The	O
majority	O
of	O
patients	O
in	O
RA	O
clinical	O
studies	O
received	O
one	O
or	O
more	O
of	O
the	O
following	O
concomitant	O
medications	O
with	O
ORENCIA	S-brand
:	O
MTX	S-drug
,	O
NSAIDs	S-group
,	O
corticosteroids	S-group
,	O
TNF	B-group
blocking	I-group
agents	E-group
,	O
azathioprine	S-drug
,	O
chloroquine	S-drug
,	O
gold	S-drug
,	O
hydroxychloroquine	S-drug
,	O
leflunomide	S-drug
,	O
sulfasalazine	S-drug
,	O
and	O
anakinra	S-drug
.	O

Concurrent	O
administration	O
of	O
a	O
TNF	B-group-EF-1
antagonist	E-group-EF-1
with	O
ORENCIA	S-brand-EF-2
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
and	O
no	O
significant	O
additional	O
efficacy	O
over	O
use	O
of	O
the	O
TNF	B-group
antagonists	E-group
alone	O
.	O

Concurrent	O
therapy	O
with	O
ORENCIA	S-brand-AD-1
and	O
TNF	B-group-AD-2
antagonists	E-group-AD-2
is	O
not	O
recommended	O
.	O

There	O
is	O
insufficient	O
experience	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ORENCIA	S-brand-AD-1
administered	O
concurrently	O
with	O
anakinra	S-drug-AD-2
,	O
and	O
therefore	O
such	O
use	O
is	O
not	O
recommended	O
.	O

Formal	O
drug	O
interaction	O
studies	O
with	O
Abciximab	S-drug
have	O
not	O
been	O
conducted	O
.	O

Abciximab	S-drug
has	O
been	O
administered	O
to	O
patients	O
with	O
ischemic	O
heart	O
disease	O
treated	O
concomitantly	O
with	O
a	O
broad	O
range	O
of	O
medications	O
used	O
in	O
the	O
treatment	O
of	O
angina	O
myocardial	O
infarction	O
and	O
hypertension	O
.	O

These	O
medications	O
have	O
included	O
heparin	S-drug
,	O
warfarin	S-drug
,	O
beta	B-group
-	I-group
adrenergic	I-group
receptor	I-group
blockers	E-group
,	O
calcium	B-group
channel	I-group
antagonists	E-group
,	O
angiotensin	B-group
converting	I-group
enzyme	I-group
inhibitors	E-group
,	O
intravenous	O
and	O
oral	O
nitrates	S-group
,	O
ticlopidine	S-drug
,	O
and	O
aspirin	S-brand
.	O

Heparin	S-drug
,	O
other	O
anticoagulants	S-group
,	O
thrombolytics	S-group
,	O
and	O
anti	B-group
platelet	I-group
agents	E-group
are	O
associated	O
with	O
an	O
increase	O
in	O
bleeding	O
.	O

Patients	O
with	O
HACA	O
titers	O
may	O
have	O
allergic	O
or	O
hypersensitivity	O
reactions	O
when	O
treated	O
with	O
other	O
diagnostic	S-group
or	O
therapeutic	B-group
monoclonal	I-group
antibodies	E-group
.	O

The	O
concomitant	O
intake	O
of	O
alcohol	S-drug
and	O
Acamprosate	S-drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
alcohol	S-drug
or	O
acamprosate	S-drug
.	O

Pharmacokinetic	O
studies	O
indicate	O
that	O
administration	O
of	O
disulfiram	S-drug
or	O
diazepam	S-drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
acamprosate	S-drug
.	O

Co	O
-	O
administration	O
of	O
naltrexone	S-drug-ME-1
with	O
Acamprosate	S-drug-ME-2
produced	O
a	O
25	O
%	O
increase	O
in	O
AUC	O
and	O
a	O
33	O
%	O
increase	O
in	O
the	O
Cmax	O
of	O
acamprosate	S-drug
.	O

No	O
adjustment	O
of	O
dosage	O
is	O
recommended	O
in	O
such	O
patients	O
.	O

The	O
pharmacokinetics	O
of	O
naltrexone	S-drug
and	O
its	O
major	O
metabolite	O
6	B-drug_n
-	I-drug_n
beta	I-drug_n
-	I-drug_n
naltrexol	E-drug_n
were	O
unaffected	O
following	O
co	O
-	O
administration	O
with	O
Acamprosate	S-drug
.	O

Other	O
concomitant	O
therapies	O
:	O
In	O
clinical	O
trials	O
,	O
the	O
safety	O
profile	O
in	O
subjects	O
treated	O
with	O
Acamprosate	S-drug
concomitantly	O
with	O
anxiolytics	S-group
,	O
hypnotics	S-group
and	O
sedatives	S-group
(	O
including	O
benzodiazepines	S-group
)	O
,	O
or	O
non	B-group
-	I-group
opioid	I-group
analgesics	E-group
was	O
similar	O
to	O
that	O
of	O
subjects	O
taking	O
placebo	O
with	O
these	O
concomitant	O
medications	O
.	O

Patients	O
taking	O
Acamprosate	S-drug-EF-1
concomitantly	O
with	O
antidepressants	S-group-EF-2
more	O
commonly	O
reported	O
both	O
weight	O
gain	O
and	O
weight	O
loss	O
,	O
compared	O
with	O
patients	O
taking	O
either	O
medication	O
alone	O
.	O

Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
blood	O
glucose	O
control	O
.	O

These	O
drugs	O
include	O
the	O
thiazides	S-group
and	O
other	O
diuretics	S-group
,	O
corticosteroids	S-group
,	O
phenothiazines	S-group
,	O
thyroid	B-group
products	E-group
,	O
estrogens	S-group
,	O
oral	O
contraceptives	S-group
,	O
phenytoin	S-drug
,	O
nicotinic	B-drug
acid	E-drug
,	O
sympathomimetics	S-group
,	O
calcium	B-group
channel	I-group
-	I-group
blocking	I-group
drugs	E-group
,	O
and	O
isoniazid	S-drug
.	O

When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
Acarbose	S-drug
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
blood	O
glucose	O
control	O
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
patients	O
receiving	O
Acarbose	S-drug
in	O
combination	O
with	O
sulfonylureas	S-group
or	O
insulin	S-drug
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
any	O
evidence	O
of	O
hypoglycemia	O
.	O

Intestinal	B-group-ME-1
adsorbents	E-group-ME-1
(	O
e.	O
g.	O
,	O
charcoal	S-drug-ME-1
)	O
and	O
digestive	B-group
enzyme	I-group
preparations	E-group
containing	O
carbohydrate	O
-	O
splitting	O
enzymes	O
(	O
e.	O
g.	O
,	O
amylase	S-drug-ME-1
,	O
pancreatin	S-drug-ME-1
)	O
may	O
reduce	O
the	O
effect	O
of	O
Acarbose	S-drug-ME-2
and	O
should	O
not	O
be	O
taken	O
concomitantly	O
.	O

Acarbose	S-drug-ME-1
has	O
been	O
shown	O
to	O
change	O
the	O
bioavailabillty	O
digoxin	S-drug-ME-2
when	O
they	O
are	O
co	O
-	O
administered	O
,	O
which	O
may	O
require	O
digoxin	S-drug
dose	O
adjustment	O
.	O

Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
Acarbose	S-drug
has	O
no	O
effect	O
on	O
either	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
digoxin	S-drug
,	O
nifedipine	S-drug
,	O
propranolol	S-drug
,	O
or	O
ranitidine	S-drug
.	O

Acarbose	S-drug
did	O
not	O
interfere	O
with	O
the	O
absorption	O
or	O
disposition	O
of	O
the	O
sulfonylurea	S-drug
glyburide	S-drug
in	O
diabetic	O
patients	O
.	O

Acarbose	S-drug
may	O
affect	O
digoxin	S-drug
bioavailabillty	O
and	O
may	O
require	O
dose	O
adjustment	O
of	O
digoxin	S-drug
by	O
16	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
8	O
-	O
23	O
%	O
)	O
,	O
decrease	O
mean	O
C	O
max	O
digoxin	S-drug
by	O
26	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
16	O
-	O
34	O
%	O
)	O
and	O
decrease	O
mean	O
trough	O
concentrations	O
of	O
digoxin	S-drug
by	O
9	O
%	O
(	O
90	O
%	O
confidence	O
limit	O
:	O
19	O
%	O
decrease	O
to	O
2	O
%	O
increase	O
)	O
.	O

The	O
amount	O
of	O
metformin	S-drug
absorbed	O
while	O
taking	O
Acarbose	S-drug
was	O
bioequivalent	O
to	O
the	O
amount	O
absorbed	O
when	O
taking	O
placebo	O
,	O
as	O
indicated	O
by	O
the	O
plasma	O
AUC	O
values	O
.	O

However	O
,	O
the	O
peak	O
plasma	O
level	O
of	O
metformin	S-drug-ME-1
was	O
reduced	O
by	O
approximately	O
20	O
%	O
when	O
taking	O
Acarbose	S-drug-ME-M
due	O
to	O
a	O
slight	O
delay	O
in	O
the	O
absorption	O
of	O
metformin	S-drug-ME-2
.	O

There	O
is	O
little	O
if	O
any	O
clinically	O
significant	O
interaction	O
between	O
Acarbose	S-drug
and	O
metformin	S-drug
.	O

Catecholamine	B-group-EF-1
-	I-group-EF-1
depleting	I-group-EF-1
drugs	E-group-EF-1
,	O
such	O
as	O
reserpine	S-drug-EF-1
,	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

Patients	O
treated	O
with	O
acebutolol	S-drug-AD-1
plus	O
catecholamine	B-group-AD-2
depletors	E-group-AD-2
should	O
,	O
therefore	O
,	O
be	O
observed	O
closely	O
for	O
evidence	O
of	O
marked	O
bradycardia	O
or	O
hypotension	O
which	O
may	O
present	O
as	O
vertigo	O
,	O
syncope	O
/	O
presyncope	O
,	O
or	O
orthostatic	O
changes	O
in	O
blood	O
pressure	O
without	O
compensatory	O
tachycardia	O
.	O

Exaggerated	O
hypertensive	O
responses	O
have	O
been	O
reported	O
from	O
the	O
combined	O
use	O
of	O
beta	B-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
antagonists	E-group-EF-1
and	O
alpha	B-group-EF-2
-	I-group-EF-2
adrenergic	I-group-EF-2
stimulants	E-group-EF-2
,	O
including	O
those	O
contained	O
in	O
proprietary	O
cold	O
remedies	O
and	O
vasoconstrictive	O
nasal	O
drops	O
.	O

Patients	O
receiving	O
beta	B-group
-	I-group
blockers	E-group
should	O
be	O
warned	O
of	O
this	O
potential	O
hazard	O
.	O

Blunting	O
of	O
the	O
antihypertensive	O
effect	O
of	O
beta	B-group-EF-1
-	I-group-EF-1
adrenoceptor	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
by	O
nonsteroidal	B-group-EF-2
anti	I-group-EF-2
-	I-group-EF-2
inflammatory	I-group-EF-2
drugs	E-group-EF-2
has	O
been	O
reported	O
.	O

No	O
significant	O
interactions	O
with	O
digoxin	S-drug
,	O
hydrochlorothiazide	S-drug
,	O
hydralazine	S-drug
,	O
sulfinpyrazone	S-drug
,	O
oral	O
contraceptives	S-group
,	O
tolbutamide	S-drug
,	O
or	O
warfarin	S-drug
have	O
been	O
observed	O
.	O

DIAMOX	S-brand-ME-1
modifies	O
phenytoin	S-drug-ME-2
metabolism	O
with	O
increased	O
serum	O
levels	O
of	O
phenytoin	S-drug-ME-2
.	O

This	O
may	O
increase	O
or	O
enhance	O
the	O
occurrence	O
of	O
osteomalacia	O
in	O
some	O
patients	O
receiving	O
chronic	O
phenytoin	S-drug
therapy	O
.	O

Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
chronic	O
concomitant	O
therapy	O
.	O

By	O
decreasing	O
the	O
gastrointestinal	O
absorption	O
of	O
primidone	S-drug
,	O
DIAMOX	S-brand-ME-1
may	O
decrease	O
serum	O
concentrations	O
of	O
primidone	S-drug-ME-2
and	O
its	O
metabolites	O
,	O
with	O
a	O
consequent	O
possible	O
decrease	O
in	O
anticonvulsant	O
effect	O
.	O

Caution	O
is	O
advised	O
when	O
beginning	O
,	O
discontinuing	O
,	O
or	O
changing	O
the	O
dose	O
of	O
DIAMOX	S-brand-AD-1
in	O
patients	O
receiving	O
primidone	S-drug-AD-2
.	O

Because	O
of	O
possible	O
additive	O
effects	O
with	O
other	O
carbonic	B-group
anhydrase	I-group
inhibitors	E-group
,	O
concomitant	O
use	O
is	O
not	O
advisable	O
.	O

Acetazolamide	S-drug-EF-1
may	O
increase	O
the	O
effects	O
of	O
other	O
folic	B-group-EF-2
acid	I-group-EF-2
antagonists	E-group-EF-2
.	O

Acetazolamide	S-drug
may	O
increase	O
or	O
decrease	O
blood	O
glucose	O
levels	O
.	O

Consideration	O
should	O
be	O
taken	O
in	O
patients	O
being	O
treated	O
with	O
antidiabetic	S-drug
agents	O
.	O

Acetazolamide	S-drug-ME-1
decreases	O
urinary	O
excretion	O
of	O
amphetamine	S-drug-ME-2
and	O
may	O
enhance	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
effect	O
.	O

Acetazolamide	S-drug-ME-1
reduces	O
urinary	O
excretion	O
of	O
quinidine	S-drug-ME-2
and	O
may	O
enhance	O
its	O
effect	O
.	O

Acetazolamide	S-drug-EF-1
may	O
prevent	O
the	O
urinary	O
antiseptic	O
effect	O
of	O
methenamine	S-drug-EF-2
.	O

Acetazolamide	S-drug-ME-1
increases	O
lithium	S-drug-ME-2
excretion	O
and	O
the	O
lithium	S-drug
may	O
be	O
decreased	O
.	O

Acetazolamide	S-drug-EF-1
and	O
sodium	B-drug-EF-2
bicarbonate	E-drug-EF-2
used	O
concurrently	O
increases	O
the	O
risk	O
of	O
renal	O
calculus	O
formation	O
.	O

Acetazolamide	S-drug-ME-1
may	O
elevate	O
cyclosporine	S-drug-ME-2
levels	O
.	O

Concomitant	O
use	O
with	O
iron	B-group
supplements	O
may	O
result	O
in	O
the	O
reduced	O
absorption	O
of	O
iron	S-drug
.	O

Co	O
-	O
administration	O
of	O
probenecid	S-drug-ME-1
with	O
acyclovir	S-drug-ME-2
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
half	O
-	O
life	O
and	O
the	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
.	O

Urinary	O
excretion	O
and	O
renal	O
clearance	O
were	O
correspondingly	O
reduced	O
.	O

The	O
clinical	O
effects	O
of	O
this	O
combination	O
have	O
not	O
been	O
studied	O
.	O

Ethanol	S-drug
:	O
Clinical	O
evidence	O
has	O
shown	O
that	O
etretinate	S-drug
can	O
be	O
formed	O
with	O
concurrent	O
ingestion	O
of	O
acitretin	S-drug-ME-1
and	O
ethanol	S-drug-ME-2
.	O

Glibenclamide	S-drug
:	O
In	O
a	O
study	O
of	O
7	O
healthy	O
male	O
volunteers	O
,	O
acitretin	S-drug-EF-1
treatment	O
potentiated	O
the	O
blood	O
glucose	O
lowering	O
effect	O
of	O
glibenclamide	S-drug-EF-2
(	O
a	O
sulfonylurea	S-group
similar	O
to	O
chlorpropamide	S-drug
)	O
in	O
3	O
of	O
the	O
7	O
subjects	O
.	O

Repeating	O
the	O
study	O
with	O
6	O
healthy	O
male	O
volunteers	O
in	O
the	O
absence	O
of	O
glibenclamide	S-drug
did	O
not	O
detect	O
an	O
effect	O
of	O
acitretin	S-drug
on	O
glucose	O
tolerance	O
.	O

Careful	O
supervision	O
of	O
diabetic	O
patients	O
under	O
treatment	O
with	O
Soriatane	S-brand
is	O
recommended	O
.	O

Hormonal	B-group
Contraceptives	E-group
:	O
It	O
has	O
not	O
been	O
established	O
if	O
there	O
is	O
a	O
pharmacokinetic	O
interaction	O
between	O
acitretin	S-drug
and	O
combined	B-group
oral	I-group
contraceptives	E-group
.	O

However	O
,	O
it	O
has	O
been	O
established	O
that	O
acitretin	S-drug-EF-1
interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin	S-drug-EF-2
minipill	O
preparations	O
.	O

Microdosed	O
minipill	O
progestin	S-drug-AD-1
preparations	O
are	O
not	O
recommended	O
for	O
use	O
with	O
Soriatane	S-drug-AD-2
.	O

It	O
is	O
not	O
known	O
whether	O
other	O
progestational	B-group
contraceptives	E-group
,	O
such	O
as	O
implants	O
and	O
injectables	O
,	O
are	O
adequate	O
methods	O
of	O
contraception	O
during	O
acitretin	S-drug
therapy	O
.	O

Methotrexate	S-drug
:	O
An	O
increased	O
risk	O
of	O
hepatitis	O
has	O
been	O
reported	O
to	O
result	O
from	O
combined	O
use	O
of	O
methotrexate	S-drug-EF-1
and	O
etretinate	S-drug-EF-2
.	O

Consequently	O
,	O
the	O
combination	O
of	O
methotrexate	S-drug-AD-1
with	O
acitretin	S-drug-AD-2
is	O
also	O
contraindicated	O
.	O

Phenytoin	S-drug
:	O
If	O
acitretin	S-drug-ME-1
is	O
given	O
concurrently	O
with	O
phenytoin	S-drug-ME-2
,	O
the	O
protein	O
binding	O
of	O
phenytoin	S-drug
may	O
be	O
reduced	O
.	O

Tetracyclines	S-group
:	O
Since	O
both	O
acitretin	S-drug-EF-1
and	O
tetracyclines	S-group-EF-2
can	O
cause	O
increased	O
intracranial	O
pressure	O
,	O
their	O
combined	O
use	O
is	O
contraindicated	O
.	O

Vitamin	B-group
A	E-group
and	O
oral	O
retinoids	S-group
:	O
Concomitant	O
administration	O
of	O
vitamin	B-group-AD-1
A	E-group-AD-1
and	O
/	O
or	O
other	O
oral	O
retinoids	S-group-AD-1
with	O
acitretin	S-drug-AD-2
must	O
be	O
avoided	O
because	O
of	O
the	O
risk	O
of	O
hypervitaminosis	O
A	O
.	O

Other	O
:	O
There	O
appears	O
to	O
be	O
no	O
pharmacokinetic	O
interaction	O
between	O
acitretin	S-drug
and	O
cimetidine	S-drug
,	O
digoxin	S-drug
,	O
or	O
glyburide	S-drug
.	O

Investigations	O
into	O
the	O
effect	O
of	O
acitretin	S-drug
on	O
the	O
protein	O
binding	O
of	O
anticoagulants	B-group
of	I-group
the	I-group
coumarin	I-group
type	E-group
(	O
warfarin	S-drug
)	O
revealed	O
no	O
interaction	O
.	O

Laboratory	O
Tests	O
If	O
significant	O
abnormal	O
laboratory	O
results	O
are	O
obtained	O
,	O
either	O
dosage	O
reduction	O
with	O
careful	O
monitoring	O
or	O
treatment	O
discontinuation	O
is	O
recommended	O
,	O
depending	O
on	O
clinical	O
judgement	O
.	O

Blood	O
Sugar	O
:	O
Some	O
patients	O
receiving	O
retinoids	S-group
have	O
experienced	O
problems	O
with	O
blood	O
sugar	O
control	O
.	O

In	O
addition	O
,	O
new	O
cases	O
of	O
diabetes	O
have	O
been	O
diagnosed	O
during	O
retinoid	S-group
therapy	O
,	O
including	O
diabetic	O
ketoacidosis	O
.	O

In	O
diabetics	O
,	O
blood	O
-	O
sugar	O
levels	O
should	O
be	O
monitored	O
very	O
carefully	O
.	O

Lipids	O
:	O
In	O
clinical	O
studies	O
,	O
the	O
incidence	O
of	O
hypertriglyceridemia	O
was	O
66	O
%	O
,	O
hypercholesterolemia	O
was	O
33	O
%	O
and	O
that	O
of	O
decreased	O
HDL	O
was	O
40	O
%	O
.	O

Pretreatment	O
and	O
follow	O
-	O
up	O
measurements	O
should	O
be	O
obtained	O
under	O
fasting	O
conditions	O
.	O

It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
weekly	O
or	O
every	O
other	O
week	O
until	O
the	O
lipid	O
response	O
to	O
Soriatane	S-brand
has	O
stabilized	O
.	O

Liver	O
Function	O
Tests	O
:	O
Elevations	O
of	O
AST	O
(	O
SGOT	O
)	O
,	O
ALT	O
(	O
SGPT	O
)	O
or	O
LDH	O
were	O
experienced	O
by	O
approximately	O
1	O
in	O
3	O
patients	O
treated	O
with	O
Soriatane	S-brand
.	O

It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
prior	O
to	O
initiation	O
of	O
Soriatane	S-brand
therapy	O
,	O
at	O
1	O
-	O
to	O
2	O
-	O
week	O
intervals	O
until	O
stable	O
and	O
thereafter	O
at	O
intervals	O
as	O
clinically	O
indicated	O
.	O

Methotrexate	S-drug
:	O
HUMIRA	S-brand
has	O
been	O
studied	O
in	O
rheumatoid	O
arthritis	O
patients	O
taking	O
concomitant	O
MTX	S-drug
.	O

The	O
data	O
do	O
not	O
suggest	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
either	O
HUMIRA	S-brand
or	O
MTX	S-drug
.	O

Anakinra	S-drug
:	O
Concurrent	O
administration	O
of	O
anakinra	S-drug-EF-1
(	O
an	O
interleukin	B-group-EF-1
-	I-group-EF-1
1	I-group-EF-1
antagonist	E-group-EF-1
)	O
and	O
another	O
TNF	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agent	E-group-EF-2
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
,	O
an	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
anakinra	S-drug
used	O
in	O
combination	O
with	O
HUMIRA	S-brand
has	O
not	O
been	O
studied	O
.	O

Therefore	O
the	O
,	O
combination	O
of	O
anakinra	S-drug-EF-1
with	O
other	O
TNF	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
,	O
including	O
HUMIRA	S-brand-EF-2
,	O
may	O
also	O
result	O
i	O
n	O
similar	O
toxicities	O
.	O

As	O
DIFFERIN	S-brand
Gel	O
has	O
the	O
potential	O
to	O
produce	O
local	O
irritation	O
in	O
some	O
patients	O
,	O
concomitant	O
use	O
of	O
other	O
potentially	O
irritating	O
topical	O
products	O
(	O
medicated	O
or	O
abrasive	O
soaps	O
and	O
cleansers	O
,	O
soaps	O
and	O
cosmetics	O
that	O
have	O
a	O
strong	O
drying	O
effect	O
,	O
and	O
products	O
with	O
high	O
concentrations	O
of	O
alcohol	O
,	O
astringents	O
,	O
spices	O
or	O
lime	O
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Particular	O
caution	O
should	O
be	O
exercised	O
in	O
using	O
preparations	O
containing	O
sulfur	S-drug
,	O
resorcinol	S-drug
,	O
or	O
salicylic	B-drug
acid	E-drug
in	O
combination	O
with	O
DIFFERIN	S-brand
Gel	O
.	O

If	O
these	O
preparations	O
have	O
been	O
used	O
it	O
is	O
advisable	O
not	O
to	O
start	O
therapy	O
with	O
DIFFERIN	S-brand
Gel	O
until	O
the	O
effects	O
of	O
such	O
preparations	O
in	O
the	O
skin	O
have	O
subsided	O
.	O

Before	O
using	O
this	O
medication	O
,	O
tell	O
your	O
doctor	O
or	O
pharmacist	O
of	O
all	O
prescription	O
and	O
nonprescription	O
products	O
you	O
may	O
use	O
,	O
especially	O
of	O
:	O
aminoglycosides	S-group
(	O
e.g	O
.	O
,	O
gentamicin	S-drug
,	O
amikacin	S-drug
)	O
,	O
amphotericin	B-drug
B	E-drug
,	O
cyclosporine	S-drug
,	O
non	B-group
-	I-group
steroidal	I-group
anti	I-group
-	I-group
inflammatory	E-group
drugs	O
(	O
e.g	O
.	O
,	O
ibuprofen	S-drug
)	O
,	O
tacrolimus	S-drug
,	O
vancomycin	S-drug
.	O

Do	O
not	O
start	O
or	O
stop	O
any	O
medicine	O
without	O
doctor	O
or	O
pharmacist	O
approval	O
.	O

Intravenous	O
Adenocard	S-brand
(	O
adenosine	S-drug
)	O
has	O
been	O
effectively	O
administered	O
in	O
the	O
presence	O
of	O
other	O
cardioactive	O
drugs	O
,	O
such	O
as	O
quinidine	S-drug
,	O
beta	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
,	O
calcium	B-group
channel	I-group
blocking	I-group
agents	E-group
,	O
and	O
angiotensin	B-group
converting	I-group
enzyme	I-group
inhibitors	E-group
,	O
without	O
any	O
change	O
in	O
the	O
adverse	O
reaction	O
profile	O
.	O

Digoxin	S-drug-EF-1
and	O
verapamil	S-drug-EF-1
use	O
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
when	O
combined	O
with	O
Adenocard	S-brand-EF-2
.	O

Because	O
of	O
the	O
potential	O
for	O
additive	O
or	O
synergistic	O
depressant	O
effects	O
on	O
the	O
SA	O
and	O
AV	O
nodes	O
,	O
however	O
,	O
Adenocard	S-brand
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
presence	O
of	O
these	O
agents	O
.	O

The	O
use	O
of	O
Adenocard	S-brand-EF-1
in	O
patients	O
receiving	O
digitalis	S-group-EF-2
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
.	O

The	O
effects	O
of	O
adenosine	S-drug-EF-1
are	O
antagonized	O
by	O
methylxanthines	S-group-EF-2
such	O
as	O
caffeine	S-drug-EF-2
and	O
theophylline	S-drug-EF-2
.	O

In	O
the	O
presence	O
of	O
these	O
methylxanthines	S-group-AD-1
,	O
larger	O
doses	O
of	O
adenosine	S-drug-AD-2
may	O
be	O
required	O
or	O
adenosine	S-drug-AD-2
may	O
not	O
be	O
effective	O
.	O

Adenosine	S-drug-EF-1
effects	O
are	O
potentiated	O
by	O
dipyridamole	S-drug-EF-2
.	O

Thus	O
,	O
smaller	O
doses	O
of	O
adenosine	S-drug-EF-1
may	O
be	O
effective	O
in	O
the	O
presence	O
of	O
dipyridamole	S-drug-EF-2
.	O

Carbamazepine	S-drug
has	O
been	O
reported	O
to	O
increase	O
the	O
degree	O
of	O
heart	O
block	O
produced	O
by	O
other	O
agents	O
.	O

As	O
the	O
primary	O
effect	O
of	O
adenosine	S-drug-EF-1
is	O
to	O
decrease	O
conduction	O
through	O
the	O
A	O
-	O
V	O
node	O
,	O
higher	O
degrees	O
of	O
heart	O
block	O
may	O
be	O
produced	O
in	O
the	O
presence	O
of	O
carbamazepine	S-drug-EF-2
.	O

Co	O
-	O
administration	O
with	O
antifungal	B-group
agents	E-group
such	O
as	O
ketoconazole	S-drug
or	O
itraconazole	S-drug
is	O
not	O
recommended	O
.	O

Nafazodone	S-drug-AD-1
,	O
fluvoxamine	S-drug-AD-1
,	O
cimetidine	S-drug-AD-1
(	O
consider	O
Xanax	S-brand-AD-2
dose	O
reduction	O
)	O
.	O

Fluoxetine	S-drug
,	O
OCs	S-group
,	O
sertraline	S-drug
,	O
diltiazem	S-drug
,	O
macrolide	B-group
antibiotics	E-group
(	O
exercise	O
caution	O
)	O
.	O

No	O
drug	O
interaction	O
studies	O
were	O
performed	O
.	O

No	O
in	O
vitro	O
metabolism	O
studies	O
were	O
performed	O
.	O

Dexamethasone	S-drug
:	O
Steady	O
-	O
state	O
trough	O
concentrations	O
of	O
albendazole	B-drug
sulfoxide	E-drug
were	O
about	O
56	O
%	O
higher	O
when	O
8	O
mg	O
dexamethasone	S-drug-ME-1
was	O
coadministered	O
with	O
each	O
dose	O
of	O
albendazole	S-drug-ME-2
(	O
15	O
mg	O
/	O
kg	O
/	O
day	O
)	O
in	O
eight	O
neurocysticercosis	O
patients	O
.	O

Praziquantel	S-drug
:	O
In	O
the	O
fed	O
state	O
,	O
praziquantel	S-drug-ME-1
(	O
40	O
mg	O
/	O
kg	O
)	O
increased	O
mean	O
maximum	O
plasma	O
concentration	O
and	O
area	O
under	O
the	O
curve	O
of	O
albendazole	B-drug-ME-2
sulfoxide	E-drug-ME-2
by	O
about	O
50	O
%	O
in	O
healthy	O
subjects	O
(	O
n	O
=	O
10	O
)	O
compared	O
with	O
a	O
separate	O
group	O
of	O
subjects	O
(	O
n	O
=	O
6	O
)	O
given	O
albendazole	S-drug
alone	O
.	O

Mean	O
T	O
max	O
and	O
mean	O
plasma	O
elimination	O
half	O
-	O
life	O
of	O
albendazole	B-drug
sulfoxide	E-drug
were	O
unchanged	O
.	O

The	O
pharmacokinetics	O
of	O
praziquantel	S-drug
were	O
unchanged	O
following	O
coadministration	O
with	O
albendazole	S-drug
(	O
400	O
mg	O
)	O
.	O

Cimetidine	S-drug
:	O
Albendazole	B-drug-ME-1
sulfoxide	E-drug-ME-1
concentrations	O
in	O
bile	O
and	O
cystic	O
fluid	O
were	O
increased	O
(	O
about	O
2	O
-	O
fold	O
)	O
in	O
hydatid	O
cyst	O
patients	O
treated	O
with	O
cimetidine	S-drug-ME-2
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
(	O
n	O
=	O
7	O
)	O
compared	O
with	O
albendazole	S-drug
(	O
20	O
mg	O
/	O
kg	O
/	O
day	O
)	O
alone	O
(	O
n	O
=	O
12	O
)	O
.	O

Albendazole	B-drug
sulfoxide	E-drug
plasma	O
concentrations	O
were	O
unchanged	O
4	O
hours	O
after	O
dosing	O
.	O

Theophylline	S-drug
:	O
The	O
pharmacokinetics	O
of	O
theophylline	S-drug
(	O
aminophylline	S-drug
5.8	O
mg	O
/	O
kg	O
infused	O
over	O
20	O
minutes	O
)	O
were	O
unchanged	O
following	O
a	O
single	O
oral	O
dose	O
of	O
albendazole	S-drug
(	O
400	O
mg	O
)	O
in	O
6	O
healthy	O
subjects	O
.	O

No	O
information	O
provided	O

PROLEUKIN	S-brand
may	O
affect	O
central	O
nervous	O
function	O
.	O

Therefore	O
,	O
interactions	O
could	O
occur	O
following	O
concomitant	O
administration	O
of	O
psychotropic	B-group
drugs	E-group
(	O
e.g	O
.	O
,	O
narcotics	S-group
,	O
analgesics	S-group
,	O
antiemetics	S-group
,	O
sedatives	S-group
,	O
tranquilizers	S-group
)	O
.	O

Concurrent	O
administration	O
of	O
drugs	O
possessing	O
nephrotoxic	O
(	O
e.g	O
.	O
,	O
aminoglycosides	S-group-EF-1
,	O
indomethacin	S-drug-EF-1
)	O
,	O
myelotoxic	O
(	O
e.g	O
.	O
,	O
cytotoxic	S-group-EF-1
chemotherapy	O
)	O
,	O
cardiotoxic	O
(	O
e.g	O
.	O
,	O
doxorubicin	S-drug-EF-1
)	O
or	O
hepatotoxic	O
(	O
e.g	O
.	O
,	O
methotrexate	S-drug-EF-1
,	O
asparaginase	S-drug-EF-1
)	O
effects	O
with	O
PROLEUKIN	S-brand-EF-2
may	O
increase	O
toxicity	O
in	O
these	O
organ	O
systems	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
PROLEUKIN	S-brand
in	O
combination	O
with	O
any	O
antineoplastic	B-group
agents	E-group
have	O
not	O
been	O
established	O
.	O

In	O
addition	O
,	O
reduced	O
kidney	O
and	O
liver	O
function	O
secondary	O
to	O
PROLEUKIN	S-brand
treatment	O
may	O
delay	O
elimination	O
of	O
concomitant	O
medications	O
and	O
increase	O
the	O
risk	O
of	O
adverse	O
events	O
from	O
those	O
drugs	O
.	O

Hypersensitivity	O
reactions	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
combination	O
regimens	O
containing	O
sequential	O
high	O
dose	O
PROLEUKIN	S-brand-EF-1
and	O
antineoplastic	B-group-EF-2
agents	E-group-EF-2
,	O
specifically	O
,	O
dacarbazine	S-drug-EF-2
,	O
cis	B-drug-EF-2
-	I-drug-EF-2
platinum	E-drug-EF-2
,	O
tamoxifen	S-drug-EF-2
and	O
interferon	B-drug-EF-2
-	I-drug-EF-2
alfa	E-drug-EF-2
.	O

These	O
reactions	O
consisted	O
of	O
erythema	O
,	O
pruritus	O
,	O
and	O
hypotension	O
and	O
occurred	O
within	O
hours	O
of	O
administration	O
of	O
chemotherapy	O
.	O

These	O
events	O
required	O
medical	O
intervention	O
in	O
some	O
patients	O
.	O

Myocardial	O
injury	O
,	O
including	O
myocardial	O
infarction	O
,	O
myocarditis	O
,	O
ventricular	O
hypokinesia	O
,	O
and	O
severe	O
rhabdomyolysis	O
appear	O
to	O
be	O
increased	O
in	O
patients	O
receiving	O
PROLEUKIN	S-brand-EF-1
and	O
interferon	B-drug-EF-2
-	I-drug-EF-2
alfa	E-drug-EF-2
concurrently	O
.	O

Exacerbation	O
or	O
the	O
initial	O
presentation	O
of	O
a	O
number	O
of	O
autoimmune	O
and	O
inflammatory	O
disorders	O
has	O
been	O
observed	O
following	O
concurrent	O
use	O
of	O
interferon	B-drug-EF-1
-	I-drug-EF-1
alfa	E-drug-EF-1
and	O
PROLEUKIN	S-brand-EF-2
,	O
including	O
crescentic	O
IgA	O
glomerulonephritis	O
,	O
oculo	O
-	O
bulbar	O
myasthenia	O
gravis	O
,	O
inflammatory	O
arthritis	O
,	O
thyroiditis	O
,	O
bullous	O
pemphigoid	O
,	O
and	O
Stevens	O
-	O
Johnson	O
syndrome	O
.	O

Although	O
glucocorticoids	S-group-EF-1
have	O
been	O
shown	O
to	O
reduce	O
PROLEUKIN	S-brand-EF-2
-	O
induced	O
side	O
effects	O
including	O
fever	O
,	O
renal	O
insufficiency	O
,	O
hyperbilirubinemia	O
,	O
confusion	O
,	O
and	O
dyspnea	O
,	O
concomitant	O
administration	O
of	O
these	O
agents	O
with	O
PROLEUKIN	S-brand
may	O
reduce	O
the	O
antitumor	O
effectiveness	O
of	O
PROLEUKIN	S-brand
and	O
thus	O
should	O
be	O
avoided	O
.	O
12	O
Beta	B-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
and	O
other	O
antihypertensives	S-group-EF-1
may	O
potentiate	O
the	O
hypotension	O
seen	O
with	O
PROLEUKIN	S-brand-EF-2
.	O

Delayed	O
Adverse	O
Reactions	O
to	O
Iodinated	B-group
Contrast	I-group
Media	E-group
:	O
A	O
review	O
of	O
the	O
literature	O
revealed	O
that	O
12.6	O
%	O
(	O
range	O
11	O
-	O
28	O
%	O
)	O
of	O
501	O
patients	O
treated	O
with	O
various	O
interleukin	B-drug-EF-1
-	I-drug-EF-1
2	E-drug-EF-1
containing	O
regimens	O
who	O
were	O
subsequently	O
administered	O
radiographic	B-group-EF-2
iodinated	I-group-EF-2
contrast	I-group-EF-2
media	E-group-EF-2
experienced	O
acute	O
,	O
atypical	O
adverse	O
reactions	O
.	O

The	O
onset	O
of	O
symptoms	O
usually	O
occurred	O
within	O
hours	O
(	O
most	O
commonly	O
1	O
to	O
4	O
hours	O
)	O
following	O
the	O
administration	O
of	O
contrast	O
media	O
.	O

These	O
reactions	O
include	O
fever	O
,	O
chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
pruritus	O
,	O
rash	O
,	O
diarrhea	O
,	O
hypotension	O
,	O
edema	O
,	O
and	O
oliguria	O
.	O

Some	O
clinicians	O
have	O
noted	O
that	O
these	O
reactions	O
resemble	O
the	O
immediate	O
side	O
effects	O
caused	O
by	O
interleukin	B-drug
-	I-drug
2	E-drug
administration	O
,	O
however	O
the	O
cause	O
of	O
contrast	O
reactions	O
after	O
interleukin	O
-	O
2	O
therapy	O
is	O
unknown	O
.	O

Most	O
events	O
were	O
reported	O
to	O
occur	O
when	O
contrast	O
media	O
was	O
given	O
within	O
4	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
interleukin	B-drug
-	I-drug
2	E-drug
.	O

These	O
events	O
were	O
also	O
reported	O
to	O
occur	O
when	O
contrast	O
media	O
was	O
given	O
several	O
months	O
after	O
interleukin	B-drug
-	I-drug
2	E-drug
treatment	O
.	O

No	O
formal	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

The	O
duration	O
of	O
the	O
period	O
following	O
treatment	O
with	O
AMEVIVE	S-brand
before	O
one	O
should	O
consider	O
starting	O
other	O
immunosuppressive	S-group
therapy	O
has	O
not	O
been	O
evaluated	O
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
and	O
Fertility	O

In	O
a	O
chronic	O
toxicity	O
study	O
,	O
cynomolgus	O
monkeys	O
were	O
dosed	O
weekly	O
for	O
52	O
weeks	O
with	O
intravenous	O
alefacept	S-drug
at	O
1	O
mg	O
/	O
kg	O
/	O
dose	O
or	O
20	O
mg	O
/	O
kg	O
/	O
dose	O
.	O

One	O
animal	O
in	O
the	O
high	O
dose	O
group	O
developed	O
a	O
B	O
-	O
cell	O
lymphoma	O
that	O
was	O
detected	O
after	O
28	O
weeks	O
of	O
dosing	O
.	O

Additional	O
animals	O
in	O
both	O
dose	O
groups	O
developed	O
B	O
-	O
cell	O
hyperplasia	O
of	O
the	O
spleen	O
and	O
lymph	O
nodes	O
.	O

All	O
animals	O
in	O
the	O
study	O
were	O
positive	O
for	O
an	O
endemic	O
primate	O
gammaherpes	O
virus	O
also	O
known	O
as	O
lymphocryptovirus	O
(	O
LCV	O
)	O
.	O

Latent	O
LCV	O
infection	O
is	O
generally	O
asymptomatic	O
,	O
but	O
can	O
lead	O
to	O
B	O
-	O
cell	O
lymphomas	O
when	O
animals	O
are	O
immune	O
suppressed	O
.	O

In	O
a	O
separate	O
study	O
,	O
baboons	O
given	O
3	O
doses	O
of	O
alefacept	S-drug
at	O
1	O
mg	O
/	O
kg	O
every	O
8	O
weeks	O
were	O
found	O
to	O
have	O
centroblast	O
proliferation	O
in	O
B	O
-	O
cell	O
dependent	O
areas	O
in	O
the	O
germinal	O
centers	O
of	O
the	O
spleen	O
following	O
a	O
116	O
-	O
day	O
washout	O
period	O
.	O

The	O
role	O
of	O
AMEVIVE	S-brand
in	O
the	O
development	O
of	O
the	O
lymphoid	O
malignancy	O
and	O
the	O
hyperplasia	O
observed	O
in	O
non	O
-	O
human	O
primates	O
and	O
the	O
relevance	O
to	O
humans	O
is	O
unknown	O
.	O

Immunodeficiency	O
-	O
associated	O
lymphocyte	O
disorders	O
(	O
plasmacytic	O
hyperplasia	O
,	O
polymorphic	O
proliferation	O
,	O
and	O
B	O
-	O
cell	O
lymphomas	O
)	O
occur	O
in	O
patients	O
who	O
have	O
congenital	O
or	O
acquired	O
immunodeficiencies	O
including	O
those	O
resulting	O
from	O
immunosuppressive	S-group
therapy	O
.	O

No	O
carcinogenicity	O
or	O
fertility	O
studies	O
were	O
conducted	O
.	O

Mutagenicity	O
studies	O
were	O
conducted	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O

no	O
evidence	O
of	O
mutagenicity	O
was	O
observed	O
.	O

Pregnancy	O
(	O
Category	O
B	O
)	O

Women	O
of	O
childbearing	O
potential	O
make	O
up	O
a	O
considerable	O
segment	O
of	O
the	O
patient	O
population	O
affected	O
by	O
psoriasis	O
.	O

Since	O
the	O
effect	O
of	O
AMEVIVE	S-brand
on	O
pregnancy	O
and	O
fetal	O
development	O
,	O
including	O
immune	O
system	O
development	O
,	O
is	O
not	O
known	O
,	O
health	O
care	O
providers	O
are	O
encouraged	O
to	O
enroll	O
patients	O
currently	O
taking	O
AMEVIVE	S-brand
who	O
become	O
pregnant	O
into	O
the	O
Biogen	O
Pregnancy	O
Registry	O
by	O
calling	O
1	O
-	O
866	O
-	O
AMEVIVE	S-brand
(	O
1	O
-	O
866	O
-	O
263	O
-	O
8483	O
)	O
.	O

Reproductive	O
toxicology	O
studies	O
have	O
been	O
performed	O
in	O
cynomolgus	O
monkeys	O
at	O
doses	O
up	O
to	O
5	O
mg	O
/	O
kg	O
/	O
week	O
(	O
about	O
62	O
times	O
the	O
human	O
dose	O
based	O
on	O
body	O
weight	O
)	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
impaired	O
fertility	O
or	O
harm	O
to	O
the	O
fetus	O
due	O
to	O
AMEVIVE	S-brand
.	O

No	O
abortifacient	O
or	O
teratogenic	O
effects	O
were	O
observed	O
in	O
cynomolgus	O
monkeys	O
following	O
intravenous	O
bolus	O
injections	O
of	O
AMEVIVE	S-brand
administered	O
weekly	O
during	O
the	O
period	O
of	O
organogenesis	O
to	O
gestation	O
.	O

AMEVIVE	S-brand
underwent	O
trans	O
-	O
placental	O
passage	O
and	O
produced	O
in	O
utero	O
exposure	O
in	O
the	O
developing	O
monkeys	O
.	O

In	O
utero	O
,	O
serum	O
levels	O
of	O
exposure	O
in	O
these	O
monkeys	O
were	O
23	O
%	O
of	O
maternal	O
serum	O
levels	O
.	O

No	O
evidence	O
of	O
fetal	O
toxicity	O
including	O
adverse	O
effects	O
on	O
immune	O
system	O
development	O
was	O
observed	O
in	O
any	O
of	O
these	O
animals	O
.	O

Animal	O
reproduction	O
studies	O
,	O
however	O
,	O
are	O
not	O
always	O
predictive	O
of	O
human	O
response	O
and	O
there	O
are	O
no	O
adequate	O
and	O
well	O
-	O
controlled	O
studies	O
in	O
pregnant	O
women	O
.	O

Because	O
the	O
risk	O
to	O
the	O
development	O
of	O
the	O
fetal	O
immune	O
system	O
and	O
postnatal	O
immune	O
function	O
in	O
humans	O
is	O
unknown	O
,	O
AMEVIVE	S-brand
should	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
clearly	O
needed	O
.	O

If	O
pregnancy	O
occurs	O
while	O
taking	O
AMEVIVE	S-brand
,	O
continued	O
use	O
of	O
the	O
drug	O
should	O
be	O
assessed	O
.	O

Nursing	O
Mothers	O

It	O
is	O
not	O
known	O
whether	O
AMEVIVE	S-brand
is	O
excreted	O
in	O
human	O
milk	O
.	O

Because	O
many	O
drugs	O
are	O
excreted	O
in	O
human	O
milk	O
,	O
and	O
because	O
there	O
exists	O
the	O
potential	O
for	O
serious	O
adverse	O
reactions	O
in	O
nursing	O
infants	O
from	O
AMEVIVE	S-brand
,	O
a	O
decision	O
should	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
while	O
taking	O
the	O
drug	O
or	O
to	O
discontinue	O
the	O
use	O
of	O
the	O
drug	O
,	O
taking	O
into	O
account	O
the	O
importance	O
of	O
the	O
drug	O
to	O
the	O
mother	O
.	O

Geriatric	O
Use	O

Of	O
the	O
1357	O
patients	O
who	O
received	O
AMEVIVE	S-brand
in	O
clinical	O
trials	O
,	O
a	O
total	O
of	O
100	O
patients	O
were	O

65	O
years	O
of	O
age	O
and	O
13	O
patients	O
were	O

75	O
years	O
of	O
age	O
.	O

No	O
differences	O
in	O
safety	O
or	O
efficacy	O
were	O
observed	O
between	O
older	O
and	O
younger	O
patients	O
,	O
but	O
there	O
were	O
not	O
sufficient	O
data	O
to	O
exclude	O
important	O
differences	O
.	O

Because	O
the	O
incidence	O
of	O
infections	O
and	O
certain	O
malignancies	O
is	O
higher	O
in	O
the	O
elderly	O
population	O
,	O
in	O
general	O
,	O
caution	O
should	O
be	O
used	O
in	O
treating	O
the	O
elderly	O
.	O

Pediatric	O
Use	O

The	O
safety	O
and	O
efficacy	O
of	O
AMEVIVE	S-brand
in	O
pediatric	O
patients	O
have	O
not	O
been	O
studied	O
.	O

AMEVIVE	S-brand
is	O
not	O
indicated	O
for	O
pediatric	O
patients	O
.	O

Drug	O
/	O
Laboratory	O
Interactions	O
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Campath	S-brand
.	O

An	O
immune	O
response	O
to	O
Campath	S-brand
may	O
interfere	O
with	O
subsequent	O
diagnostic	O
serum	O
tests	O
that	O
utilize	O
antibodies	S-group

Intravenous	O
ranitidine	S-drug-ME-1
was	O
shown	O
to	O
double	O
the	O
bioavailability	O
of	O
oral	O
alendronate	S-drug-ME-2
.	O

The	O
clinical	O
significance	O
of	O
this	O
increased	O
bioavailability	O
and	O
whether	O
similar	O
increases	O
will	O
occur	O
in	O
patients	O
given	O
oral	O
H2	B-group
-	I-group
antagonists	E-group
is	O
unknown	O
;	O

no	O
other	O
specific	O
drug	O
interaction	O
studies	O
were	O
performed	O
.	O

Products	O
containing	O
calcium	S-drug-ME-1
and	O
other	O
multivalent	B-drug-ME-1
cations	E-drug-ME-1
likely	O
will	O
interfere	O
with	O
absorption	O
of	O
alendronate	S-drug-ME-2
.	O

Both	O
the	O
magnitude	O
and	O
duration	O
of	O
central	O
nervous	O
system	O
and	O
cardiovascular	O
effects	O
may	O
be	O
enhanced	O
when	O
ALFENTA	S-brand-EF-1
is	O
administered	O
in	O
combination	O
with	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
such	O
as	O
barbiturates	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
,	O
opioids	S-group-EF-2
,	O
or	O
inhalation	O
general	O
anesthetics	S-group-EF-2
.	O

Postoperative	O
respiratory	O
depression	O
may	O
be	O
enhanced	O
or	O
prolonged	O
by	O
these	O
agents	O
.	O

In	O
such	O
cases	O
of	O
combined	O
treatment	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

Limited	O
clinical	O
experience	O
indicates	O
that	O
requirements	O
for	O
volatile	B-group-ME-1
inhalation	I-group-ME-1
anesthetics	E-group-ME-1
are	O
reduced	O
by	O
30	O
to	O
50	O
%	O
for	O
the	O
first	O
sixty	O
(	O
60	O
)	O
minutes	O
following	O
ALFENTA	S-brand-ME-2
induction	O
The	O
concomitant	O
use	O
of	O
erythromycin	S-drug-ME-1
with	O
ALFENTA	S-brand-ME-2
can	O
significantly	O
inhibit	O
ALFENTA	S-brand
clearance	O
and	O
may	O
increase	O
the	O
risk	O
of	O
prolonged	O
or	O
delayed	O
respiratory	O
depression	O
.	O

Cimetidine	S-drug-ME-1
reduces	O
the	O
clearance	O
of	O
ALFENTA	S-brand-ME-2
.	O

Therefore	O
smaller	O
ALFENTA	S-brand
doses	O
will	O
be	O
required	O
with	O
prolonged	O
administration	O
and	O
the	O
duration	O
of	O
action	O
of	O
ALFENTA	S-brand
my	O
be	O
extended	O
.	O

Perioperative	O
administration	O
of	O
drugs	O
affecting	O
hepatic	O
blood	O
flow	O
or	O
enzyme	O
function	O
may	O
reduce	O
plasma	O
clearance	O
and	O
prolong	O
recovery	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
:	O
The	O
pharmacokinetic	O
and	O
pharmacodynamic	O
interactions	O
between	O
UROXATRAL	S-brand
and	O
other	O
alpha	B-group
-	I-group
blockers	E-group
have	O
not	O
been	O
determined	O
.	O

However	O
,	O
interactions	O
may	O
be	O
expected	O
,	O
and	O
UROXATRAL	S-brand-AD-1
should	O
NOT	O
be	O
used	O
in	O
combination	O
with	O
other	O
alpha	B-group-AD-2
-	I-group-AD-2
blockers	E-group-AD-2
.	O

No	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Effects	O
of	O
Other	O
Drugs	O
on	O
Aliskiren	S-drug
Based	O
on	O
in	O
-	O
vitro	O
studies	O
,	O
aliskiren	S-drug
is	O
metabolized	O
by	O
CYP	O
3A4	O
.	O

Co	O
-	O
administration	O
of	O
lovastatin	S-drug
,	O
atenolol	S-drug
,	O
warfarin	S-drug
,	O
furosemide	S-drug
,	O
digoxin	S-drug
,	O
celecoxib	S-drug
,	O
hydrochlorothiazide	S-drug
,	O
ramipril	S-drug
,	O
valsartan	S-drug
,	O
metformin	S-drug
and	O
amlodipine	S-drug
did	O
not	O
result	O
in	O
clinically	O
significant	O
increases	O
in	O
aliskiren	S-drug
exposure	O
.	O

Co	O
-	O
administration	O
of	O
irbesartan	S-drug-ME-1
reduced	O
aliskiren	S-drug-ME-2
Cmax	O
up	O
to	O
50	O
%	O
after	O
multiple	O
dosing	O
.	O

Co	O
-	O
administration	O
of	O
atorvastatin	S-drug-ME-1
resulted	O
in	O
about	O
a	O
50	O
%	O
increase	O
in	O
aliskiren	S-drug-ME-2
Cmax	O
and	O
AUC	O
after	O
multiple	O
dosing	O
.	O

Ketoconazole	S-drug
:	O
Co	O
-	O
administration	O
of	O
200	O
mg	O
twice	O
-	O
daily	O
ketoconazole	S-drug-ME-1
with	O
aliskiren	S-drug-ME-2
resulted	O
in	O
an	O
approximate	O
80	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
aliskiren	S-drug
.	O

A	O
400	O
mg	O
once	O
-	O
daily	O
dose	O
was	O
not	O
studied	O
but	O
would	O
be	O
expected	O
to	O
increase	O
aliskiren	S-drug
blood	O
levels	O
further	O
.	O

Effects	O
of	O
Aliskiren	S-drug
on	O
Other	O
Drugs	O
Aliskiren	S-drug
does	O
not	O
inhibit	O
the	O
CYP450	O
isoenzymes	O
(	O
CYP1A2	O
,	O
2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
CYP	O
3A	O
)	O
or	O
induce	O
CYP	O
3A4	O
.	O

Co	O
-	O
administration	O
of	O
aliskiren	S-drug
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
lovastatin	S-drug
,	O
digoxin	S-drug
,	O
valsartan	S-drug
,	O
amlodipine	S-drug
,	O
metformin	S-drug
,	O
celecoxib	S-drug
,	O
atenolol	S-drug
,	O
atorvastatin	S-drug
,	O
ramipril	S-drug
or	O
hydrochlorothiazide	S-drug
.	O

Warfarin	S-drug
:	O
The	O
effects	O
of	O
aliskiren	S-drug
on	O
warfarin	S-drug
pharmacokinetics	O
have	O
not	O
been	O
evaluated	O
in	O
a	O
well	O
-	O
controlled	O
clinical	O
trial	O
.	O

Furosemide	S-drug
:	O
When	O
aliskiren	S-drug-ME-1
was	O
co	O
-	O
administered	O
with	O
furosemide	S-drug-ME-2
,	O
the	O
AUC	O
and	O
Cmax	O
of	O
furosemide	S-drug
were	O
reduced	O
by	O
about	O
30	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Patients	O
who	O
are	O
applying	O
Panretin	S-brand-AD-1
gel	O
should	O
not	O
concurrently	O
use	O
products	O
that	O
contain	O
DEET	S-drug-AD-2
(	O
N	O
,	O
N	B-drug-AD-2
-	I-drug-AD-2
diethyl	I-drug-AD-2
-	I-drug-AD-2
m	I-drug-AD-2
-	I-drug-AD-2
toluamide	E-drug-AD-2
)	O
,	O
a	O
common	O
component	O
of	O
insect	O
repellent	O
products	O
.	O

Animal	O
toxicology	O
studies	O
showed	O
increased	O
DEET	S-drug
toxicity	O
when	O
DEET	S-drug
was	O
included	O
as	O
proof	O
of	O
the	O
formulation	O
.	O

Although	O
there	O
was	O
no	O
clinical	O
evidence	O
in	O
the	O
vehicle	O
-	O
controlled	O
studies	O
of	O
drug	O
interactions	O
with	O
systemic	O
antiretroviral	B-group
agents	E-group
,	O
including	O
protease	B-group
inhibitors	E-group
,	O
macrolide	B-group
antibiotics	E-group
,	O
and	O
azole	B-group
antifungals	E-group
,	O
the	O
effect	O
of	O
Panretin	S-brand
gel	O
on	O
the	O
steady	O
-	O
state	O
concentrations	O
of	O
these	O
drugs	O
is	O
not	O
known	O
.	O

No	O
drug	O
interaction	O
data	O
are	O
available	O
on	O
concomitant	O
administration	O
of	O
Panretin	S-brand
gel	O
and	O
systemic	O
anti	O
-	O
KS	O
agents	O
.	O

The	O
following	O
drug	O
interactions	O
were	O
observed	O
in	O
some	O
patients	O
undergoing	O
treatment	O
with	O
oral	O
allopurinol	S-drug
.	O

Although	O
the	O
pattern	O
of	O
use	O
for	O
oral	O
allopurinol	S-drug
includes	O
longer	O
term	O
therapy	O
,	O
particularly	O
for	O
gout	O
and	O
renal	O
calculi	O
,	O
the	O
experience	O
gained	O
may	O
be	O
relevant	O
.	O

Mercaptopurine	S-drug
/	O
Azathioprine	S-drug
:	O
Allopurinol	S-drug-ME-1
inhibits	O
the	O
enzymatic	O
oxidation	O
of	O
mercaptopurine	S-drug-ME-2
and	O
azathioprine	S-drug-ME-2
to	O
6	B-drug
-	I-drug
thiouric	I-drug
acid	E-drug
.	O

This	O
oxidation	O
,	O
which	O
is	O
catalyzed	O
by	O
xanthine	O
oxidase	O
,	O
inactivates	O
mercaptopurine	S-drug
.	O

In	O
patients	O
receiving	O
mercaptopurine	S-drug
(	O
Purinethol	S-brand
)	O
or	O
azathioprine	S-drug
(	O
Imuran	S-brand
)	O
,	O
the	O
concomitant	O
administration	O
of	O
300	O
-	O
600	O
mg	O
of	O
allopurinol	S-drug-AD-1
per	O
day	O
will	O
require	O
a	O
reduction	O
in	O
dose	O
to	O
approximately	O
one	O
-	O
third	O
to	O
one	O
-	O
fourth	O
of	O
the	O
usual	O
dose	O
of	O
mercaptopurine	S-drug-AD-2
or	O
azathioprine	S-drug-AD-2
.	O

Subsequent	O
adjustment	O
of	O
doses	O
of	O
mercaptopurine	S-drug
or	O
azathioprine	S-drug
should	O
be	O
made	O
on	O
the	O
basis	O
of	O
therapeutic	O
response	O
and	O
the	O
appearance	O
of	O
toxic	O
effects	O
.	O

Dicumarol	S-drug
:	O
It	O
has	O
been	O
reported	O
that	O
allopurinol	S-drug-ME-1
prolongs	O
the	O
half	O
-	O
life	O
of	O
the	O
anticoagulant	S-group
,	O
dicumarol	S-drug-ME-2
.	O

The	O
clinical	O
basis	O
of	O
this	O
drug	O
interaction	O
has	O
not	O
been	O
established	O
but	O
should	O
be	O
noted	O
when	O
allopurinol	S-drug
is	O
given	O
to	O
patients	O
already	O
on	O
dicumarol	S-drug
therapy	O
.	O

Consequently	O
,	O
prothrombin	O
time	O
should	O
be	O
reassessed	O
periodically	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O

Uricosuric	B-group
Agents	E-group
:	O
Since	O
the	O
excretion	O
of	O
oxipurinol	S-drug
is	O
similar	O
to	O
that	O
of	O
urate	O
,	O
uricosuric	B-group-ME-1
agents	E-group-ME-1
,	O
which	O
increase	O
the	O
excretion	O
of	O
urate	O
,	O
are	O
also	O
likely	O
to	O
increase	O
the	O
excretion	O
of	O
oxipurinol	S-drug-ME-2
and	O
thus	O
lower	O
the	O
degree	O
of	O
inhibition	O
of	O
xanthine	O
oxidase	O
.	O

The	O
concomitant	O
administration	O
of	O
uricosuric	B-group-ME-1
agents	E-group-ME-1
and	O
allopurinol	S-drug-ME-2
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
excretion	O
of	O
oxypurines	O
(	O
hypoxanthine	O
and	O
xanthine	O
)	O
and	O
an	O
increase	O
in	O
urinary	O
uric	O
acid	O
excretion	O
compared	O
with	O
that	O
observed	O
with	O
allopurinol	S-drug
alone	O
.	O

Although	O
clinical	O
evidence	O
to	O
date	O
has	O
not	O
demonstrated	O
renal	O
precipitation	O
of	O
oxypurines	O
in	O
patients	O
either	O
on	O
allopurinol	S-drug
alone	O
or	O
in	O
combination	O
with	O
uricosuric	B-group
agents	E-group
,	O
the	O
possibility	O
should	O
be	O
kept	O
in	O
mind	O
.	O

Thiazide	B-group
Diuretics	E-group
:	O
The	O
reports	O
that	O
the	O
concomitant	O
use	O
of	O
allopurinol	S-drug-EF-1
and	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
may	O
contribute	O
to	O
the	O
enhancement	O
of	O
allopurinol	S-drug
toxicity	O
in	O
some	O
patients	O
have	O
been	O
reviewed	O
in	O
an	O
attempt	O
to	O
establish	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
and	O
a	O
mechanism	O
of	O
causation	O
.	O

Review	O
of	O
these	O
case	O
reports	O
indicates	O
that	O
the	O
patients	O
were	O
mainly	O
receiving	O
thiazide	B-group
diuretics	E-group
for	O
hypertension	O
and	O
that	O
tests	O
to	O
rule	O
out	O
decreased	O
renal	O
function	O
secondary	O
to	O
hypertensive	O
nephropathy	O
were	O
not	O
often	O
performed	O
.	O

In	O
those	O
patients	O
in	O
whom	O
renal	O
insufficiency	O
was	O
documented	O
,	O
however	O
,	O
the	O
recommendation	O
to	O
lower	O
the	O
dose	O
of	O
allopurinol	S-drug
was	O
not	O
followed	O
.	O

Although	O
a	O
causal	O
mechanism	O
and	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
have	O
not	O
been	O
established	O
,	O
current	O
evidence	O
suggests	O
that	O
renal	O
function	O
should	O
be	O
monitored	O
in	O
patients	O
on	O
thiazide	B-group-AD-1
diuretics	E-group-AD-1
and	O
allopurinol	S-drug-AD-2
even	O
in	O
the	O
absence	O
of	O
renal	O
failure	O
,	O
and	O
dosage	O
levels	O
should	O
be	O
even	O
more	O
conservatively	O
adjusted	O
in	O
those	O
patients	O
on	O
such	O
combined	O
therapy	O
if	O
diminished	O
renal	O
function	O
is	O
detected..	O

Ampicillin	S-drug
/	O
Amoxicillin	S-drug
:	O
An	O
increase	O
in	O
the	O
frequency	O
of	O
skin	O
rash	O
has	O
been	O
reported	O
among	O
patients	O
receiving	O
ampicillin	S-drug-EF-1
or	O
amoxicillin	S-drug-EF-1
concurrently	O
with	O
allopurinol	S-drug-EF-2
compared	O
to	O
patients	O
who	O
are	O
not	O
receiving	O
both	O
drugs	O
.	O

The	O
cause	O
of	O
the	O
reported	O
association	O
has	O
not	O
been	O
established	O
.	O

Cytotoxic	B-group
Agents	E-group
:	O
Enhanced	O
bone	O
marrow	O
suppression	O
by	O
cyclophosphamide	S-drug-EF-1
and	O
other	O
cytotoxic	B-group-EF-1
agents	E-group-EF-1
has	O
been	O
reported	O
among	O
patients	O
with	O
neoplastic	O
disease	O
,	O
except	O
leukemia	O
,	O
in	O
the	O
presence	O
of	O
allopurinol	S-drug-EF-2
.	O

However	O
,	O
in	O
a	O
well	O
-	O
controlled	O
study	O
of	O
patients	O
with	O
lymphoma	O
on	O
combination	O
therapy	O
,	O
allopurinol	S-drug
did	O
not	O
increase	O
the	O
marrow	O
toxicity	O
of	O
patients	O
treated	O
with	O
cyclophosphamide	S-drug
,	O
doxorubicin	S-drug
,	O
bleomycin	S-drug
,	O
procarbazine	S-drug
and	O
/	O
or	O
mechlorethamine	S-drug
.	O

Chlorpropamide	S-drug
:	O
Chlorpropamides	O
plasma	O
half	O
-	O
life	O
may	O
be	O
prolonged	O
by	O
allopurinol	S-drug-ME-2
,	O
since	O
allopurinol	S-drug-ME-1
and	O
chlorpropamide	S-drug-ME-2
may	O
compete	O
for	O
excretion	O
in	O
the	O
renal	O
tubule	O
.	O

The	O
risk	O
of	O
hypoglycemia	O
secondary	O
to	O
this	O
mechanism	O
may	O
be	O
increased	O
if	O
allopurinol	S-drug-EF-1
and	O
chlorpropamide	S-drug-EF-2
are	O
given	O
concomitantly	O
in	O
the	O
presence	O
of	O
renal	O
insufficiency	O
.	O

Cyclosporin	S-drug
:	O
Reports	O
indicate	O
that	O
cyclosporine	S-drug-ME-1
levels	O
may	O
be	O
increased	O
during	O
concomitant	O
treatment	O
with	O
allopurinol	B-drug-ME-2
sodium	E-drug-ME-2
for	O
injection	O
.	O

Monitoring	O
of	O
cyclosporine	S-drug
levels	O
and	O
possible	O
adjustment	O
of	O
cyclosporine	S-drug
dosage	O
should	O
be	O
considered	O
when	O
these	O
drugs	O
are	O
co	O
-	O
administered	O
.	O

Tolbutamides	O
conversion	O
to	O
inactive	O
metabolites	O
has	O
been	O
shown	O
to	O
be	O
catalyzed	O
by	O
xanthine	O
oxidase	O
from	O
rat	O
liver	O
.	O

The	O
clinical	O
significance	O
,	O
if	O
any	O
,	O
of	O
these	O
observations	O
is	O
unknown	O
.	O

Ergot	B-group
-	I-group
Containing	I-group
Drugs	E-group
:	O
These	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine	S-drug-AD-1
-	O
containing	O
or	O
ergot	B-group-AD-1
-	I-group-AD-1
type	I-group-AD-1
medications	E-group-AD-1
(	O
like	O
dihydroergotamine	S-drug-AD-1
or	O
methysergide	S-drug-AD-1
)	O
and	O
AXERT	S-brand-AD-2
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
.	O

Monoamine	B-group
Oxidase	I-group
Inhibitors	E-group
:	O
Coadministration	O
of	O
moclobemide	S-drug-ME-1
resulted	O
in	O
a	O
27	O
%	O
decrease	O
in	O
almotriptan	S-drug-ME-2
clearance	O
and	O
an	O
increase	O
in	O
Cmax	O
of	O
approximately	O
6	O
%	O
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Other	O
5	B-group
-	I-group
HT1B	I-group
/	I-group
1D	I-group
Agonists	E-group
Concomitant	O
use	O
of	O
other	O
5	B-group-AD-1
-	I-group-AD-1
HT1B	I-group-AD-1
/	I-group-AD-1
1D	I-group-AD-1
agonists	E-group-AD-1
within	O
24	O
hours	O
of	O
treatment	O
with	O
AXERT	S-brand-AD-2
is	O
contraindicated	O
.	O

Propanolol	S-drug
:	O
The	O
pharmacokinetics	O
of	O
almotriptan	S-drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
propranolol	S-drug
.	O

Selective	B-group
Serotonin	I-group
Reuptake	I-group
Inhibitors	E-group
(	O
SSRIs	S-group
)	O
:	O
SSRIs	S-group-EF-1
(	O
e.g	O
.	O
,	O
fluoxetine	S-drug-EF-1
,	O
fluvoxamine	S-drug-EF-1
,	O
paroxetine	S-drug-EF-1
,	O
sertraline	S-drug-EF-1
)	O
have	O
been	O
rarely	O
reported	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5	B-group-EF-2
-	I-group-EF-2
HT1	I-group-EF-2
agonists	E-group-EF-2
.	O

If	O
concomitant	O
treatment	O
with	O
AXERT	S-brand-AD-1
and	O
an	O
SSRI	S-group-AD-2
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Verapamil	S-drug
:	O
Coadministration	O
of	O
almotriptan	S-drug-ME-1
and	O
verapamil	S-drug-ME-2
resulted	O
in	O
a	O
24	O
%	O
increase	O
in	O
plasma	O
concentrations	O
of	O
almotriptan	S-drug
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Coadministration	O
of	O
almotriptan	S-drug-ME-1
and	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	S-drug-ME-2
(	O
400	O
mg	O
q.d	O
.	O
for	O
3	O
days	O
)	O
resulted	O
in	O
an	O
approximately	O
60	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
and	O
maximal	O
plasma	O
concentrations	O
of	O
almotriptan	S-drug
.	O

Although	O
the	O
interaction	O
between	O
almotriptan	S-drug
and	O
other	O
potent	O
CYP3A4	O
inhibitors	O
(	O
e.g	O
.	O
,	O
itraconazole	S-drug-AD-1
,	O
ritonavir	S-drug-AD-1
,	O
and	O
erythromycin	S-drug-AD-1
)	O
has	O
not	O
been	O
studied	O
,	O
increased	O
exposures	O
to	O
almotriptan	S-drug
may	O
be	O
expected	O
when	O
almotriptan	S-drug-AD-2
is	O
used	O
concomitantly	O
with	O
these	O
medications	O
.	O

AXERT	S-brand
is	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O

Because	O
alosetron	S-drug
is	O
metabolized	O
by	O
a	O
variety	O
of	O
hepatic	O
CYP	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
of	O
alosetron	S-drug
.	O

Fluvoxamine	S-drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP1A2	O
and	O
also	O
inhibits	O
CYP3A4	O
,	O
CYP2C9	O
,	O
and	O
CYP2C19	O
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
40	O
healthy	O
female	O
subjects	O
received	O
fluvoxamine	S-drug
in	O
escalating	O
doses	O
from	O
50	O
to	O
200	O
mg	O
per	O
day	O
for	O
16	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	S-drug
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Fluvoxamine	S-drug-ME-1
increased	O
mean	O
alosetron	S-drug-ME-2
plasma	O
concentrations	O
(	O
AUC	O
)	O
approximately	O
6	O
-	O
fold	O
and	O
prolonged	O
the	O
half	O
-	O
life	O
by	O
approximately	O
3	O
-	O
fold	O
.	O

Concomitant	O
administration	O
of	O
alosetron	S-drug-AD-1
and	O
fluvoxamine	S-drug-AD-2
is	O
contraindicated	O
.	O

Concomitant	O
administration	O
of	O
alosetron	S-drug-AD-1
and	O
moderate	O
CYP1A2	O
inhibitors	O
,	O
including	O
quinolone	B-group-AD-2
antibiotics	E-group-AD-2
and	O
cimetidine	S-drug-AD-2
,	O
has	O
not	O
been	O
evaluated	O
,	O
but	O
should	O
be	O
avoided	O
unless	O
clinically	O
necessary	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

Ketoconazole	S-drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP3A4	O
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
38	O
healthy	O
female	O
subjects	O
received	O
ketoconazole	S-drug
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	S-drug
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Ketoconazole	S-drug-ME-1
increased	O
mean	O
alosetron	S-drug-ME-2
plasma	O
concentrations	O
(	O
AUC	O
)	O
by	O
29	O
%	O
.	O

Caution	O
should	O
be	O
used	O
when	O
alosetron	S-drug-AD-1
and	O
ketoconazole	S-drug-AD-2
are	O
administered	O
concomitantly	O
.	O

Coadministration	O
of	O
alosetron	S-drug-AD-1
and	O
strong	O
CYP3A4	O
inhibitors	O
,	O
such	O
as	O
clarithromycin	S-drug-AD-2
,	O
telithromycin	S-drug-AD-2
,	O
protease	B-group-AD-2
inhibitors	E-group-AD-2
,	O
voriconazole	S-drug-AD-2
,	O
and	O
itraconazole	S-drug-AD-2
has	O
not	O
been	O
evaluated	O
but	O
should	O
be	O
undertaken	O
with	O
caution	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

The	O
effect	O
of	O
induction	O
or	O
inhibition	O
of	O
other	O
pathways	O
on	O
exposure	O
to	O
alosetron	S-drug
and	O
its	O
metabolites	O
is	O
not	O
known	O
.	O

In	O
vitro	O
human	O
liver	O
microsome	O
studies	O
and	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
demonstrated	O
that	O
alosetron	S-drug
did	O
not	O
inhibit	O
CYP	O
enzymes	O
2D6	O
,	O
3A4	O
,	O
2C9	O
,	O
or	O
2C19	O
.	O

In	O
vitro	O
,	O
at	O
total	O
drug	O
concentrations	O
27	O
-	O
fold	O
higher	O
than	O
peak	O
plasma	O
concentrations	O
observed	O
with	O
the	O
1	O
-	O
mg	O
dosage	O
,	O
alosetron	S-drug
inhibited	O
CYP	O
enzymes	O
1A2	O
(	O
60	O
%	O
)	O
and	O
2E1	O
(	O
50	O
%	O
)	O
.	O

In	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
,	O
alosetron	S-drug
did	O
not	O
inhibit	O
CYP2E1	O
but	O
did	O
produce	O
30	O
%	O
inhibition	O
of	O
both	O
CYP1A2	O
and	O
N	O
-	O
acetyltransferase	O
.	O

Although	O
not	O
studied	O
with	O
alosetron	S-drug-EF-1
,	O
inhibition	O
of	O
N	O
-	O
acetyltransferase	O
may	O
have	O
clinically	O
relevant	O
consequences	O
for	O
drugs	O
such	O
as	O
isoniazid	S-drug-EF-2
,	O
procainamide	S-drug-EF-2
,	O
and	O
hydralazine	S-drug-EF-2
.	O

The	O
effect	O
on	O
CYP1A2	O
was	O
explored	O
further	O
in	O
a	O
clinical	O
interaction	O
study	O
with	O
theophylline	S-drug
and	O
no	O
effect	O
on	O
metabolism	O
was	O
observed	O
.	O

Another	O
study	O
showed	O
that	O
alosetron	S-drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
plasma	O
concentrations	O
of	O
the	O
oral	O
contraceptive	B-group
agents	E-group
ethinyl	B-drug
estradiol	E-drug
and	O
levonorgestrel	S-drug
(	O
CYP3A4	O
substrates	O
)	O
.	O

A	O
clinical	O
interaction	O
study	O
was	O
also	O
conducted	O
with	O
alosetron	S-drug
and	O
the	O
CYP3A4	O
substrate	O
cisapride	S-drug
.	O

No	O
significant	O
effects	O
on	O
cisapride	S-drug
metabolism	O
or	O
QT	O
interval	O
were	O
noted	O
.	O

The	O
effect	O
of	O
alosetron	S-drug
on	O
monoamine	O
oxidases	O
and	O
on	O
intestinal	O
first	O
pass	O
secondary	O
to	O
high	O
intraluminal	O
concentrations	O
have	O
not	O
been	O
examined	O
.	O

Based	O
on	O
the	O
above	O
data	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
,	O
it	O
is	O
unlikely	O
that	O
alosetron	S-drug
will	O
inhibit	O
the	O
hepatic	O
metabolic	O
clearance	O
of	O
drugs	O
metabolized	O
by	O
the	O
major	O
CYP	O
enzyme	O
3A4	O
,	O
as	O
well	O
as	O
the	O
CYP	O
enzymes	O
2D6	O
,	O
2C9	O
,	O
2C19	O
,	O
2E1	O
,	O
or	O
1A2	O
.	O

Alosetron	S-drug
does	O
not	O
appear	O
to	O
induce	O
the	O
major	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
drug	O
metabolizing	O
enzyme	O
3A	O
.	O

Alosetron	S-drug
also	O
does	O
not	O
appear	O
to	O
induce	O
CYP	O
enzymes	O
2E1	O
or	O
2C19	O
.	O

It	O
is	O
not	O
known	O
whether	O
alosetron	S-drug
might	O
induce	O
other	O
enzymes	O
.	O

The	O
benzodiazepines	S-group-EF-1
,	O
including	O
alprazolam	S-drug-EF-1
,	O
produce	O
additive	O
CNS	O
depressant	O
effects	O
when	O
co	O
-	O
administered	O
with	O
other	O
psychotropic	B-group-EF-2
medications	E-group-EF-2
,	O
anticonvulsants	S-group-EF-2
,	O
antihistaminics	S-group-EF-2
,	O
ethanol	S-drug-EF-2
,	O
and	O
other	O
drugs	O
which	O
themselves	O
produce	O
CNS	O
depression	O
.	O

The	O
steady	O
state	O
plasma	O
concentrations	O
of	O
imipramine	S-drug-ME-1
and	O
desipramine	S-drug-ME-1
have	O
been	O
reported	O
to	O
be	O
increased	O
an	O
average	O
of	O
31	O
%	O
and	O
20	O
%	O
,	O
respectively	O
,	O
by	O
the	O
concomitant	O
administration	O
of	O
alprazolam	S-drug-ME-2
tablets	O
in	O
doses	O
up	O
to	O
4	O
mg	O
/	O
day	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
changes	O
is	O
unknown	O
.	O

Drugs	O
That	O
Inhibit	O
Alprazolam	S-drug
Metabolism	O
Via	O
Cytochrome	O
P450	O
3A	O
:	O
The	O
initial	O
step	O
in	O
alprazolam	S-drug
metabolism	O
is	O
hydroxylation	O
catalyzed	O
by	O
cytochrome	O
P450	O
3A	O
(	O
CYP	O
3A	O
)	O
.	O

Drugs	O
which	O
inhibit	O
this	O
metabolic	O
pathway	O
may	O
have	O
a	O
profound	O
effect	O
on	O
the	O
clearance	O
of	O
alprazolam	S-drug
.	O

Drugs	O
Demonstrated	O
to	O
be	O
CYP	O
3A	O
Inhibitors	O
of	O
Possible	O
Clinical	O
Significance	O
on	O
the	O
Basis	O
of	O
Clinical	O
Studies	O
Involving	O
Alprazolam	S-drug
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	S-drug
)	O
:	O
Coadministration	O
of	O
fluoxetine	S-drug-ME-1
with	O
alprazolam	S-drug-ME-2
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	S-drug
by	O
46	O
%	O
,	O
decreased	O
clearance	O
by	O
21	O
%	O
,	O
increased	O
half	O
-	O
life	O
by	O
17	O
%	O
,	O
and	O
decreased	O
measured	O
psychomotor	O
performance	O
.	O

Coadministration	O
of	O
propoxyphene	S-drug-ME-1
decreased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	S-drug-ME-2
by	O
6	O
%	O
,	O
decreased	O
clearance	O
by	O
38	O
%	O
,	O
and	O
increased	O
half	O
-	O
life	O
by	O
58	O
%	O
.	O

Coadministration	O
of	O
oral	O
contraceptives	S-group-ME-1
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	S-drug-ME-2
by	O
18	O
%	O
,	O
decreased	O
clearance	O
by	O
22	O
%	O
,	O
and	O
increased	O
half	O
-	O
life	O
by	O
29	O
%	O
.	O

Drugs	O
and	O
other	O
substances	O
demonstrated	O
to	O
be	O
CYP	O
3A	O
inhibitors	O
on	O
the	O
basis	O
of	O
clinical	O
studies	O
involving	O
benzodiazepines	S-group
metabolized	O
similarly	O
to	O
alprazolam	S-drug
or	O
on	O
the	O
basis	O
of	O
in	O
vitro	O
studies	O
with	O
alprazolam	S-drug
or	O
other	O
benzodiazepines	S-group
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	S-drug
)	O
:	O
Available	O
data	O
from	O
clinical	O
studies	O
of	O
benzodiazepines	S-group
other	O
than	O
alprazolam	S-drug
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	S-drug-IN-1
for	O
the	O
following	O
:	O
diltiazem	S-drug-IN-2
,	O
isoniazid	S-drug-IN-2
,	O
macrolide	B-group-IN-2
antibiotics	E-group-IN-2
such	O
as	O
erythromycin	S-drug-IN-2
and	O
clarithromycin	S-drug-IN-2
,	O
and	O
grapefruit	O
juice	O
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
alprazolam	S-drug
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	S-drug-IN-1
for	O
the	O
following	O
:	O
sertraline	S-drug-IN-2
and	O
paroxetine	S-drug-IN-2
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
benzodiazepines	S-group-IN-1
other	O
than	O
alprazolam	S-drug-IN-1
suggest	O
a	O
possible	O
drug	O
interaction	O
for	O
the	O
following	O
:	O
ergotamine	S-drug-IN-2
,	O
cyclosporine	S-drug-IN-2
,	O
amiodarone	S-drug-IN-2
,	O
nicardipine	S-drug-IN-2
,	O
and	O
nifedipine	S-drug-IN-2
.	O

Caution	O
is	O
recommended	O
during	O
the	O
coadministration	O
of	O
any	O
of	O
these	O
with	O
alprazolam	S-drug
.	O

No	O
drug	O
interactions	O
have	O
been	O
reported	O
between	O
Prostin	B-brand
VR	I-brand
Pediatric	E-brand
and	O
the	O
therapy	O
standard	O
in	O
neonates	O
with	O
restricted	O
pulmonary	O
or	O
systemic	O
blood	O
flow	O
.	O

Standard	O
therapy	O
includes	O
antibiotics	S-group
,	O
such	O
as	O
penicillin	S-drug
and	O
gentamicin	S-drug
;	O

vasopressors	S-group
,	O
such	O
as	O
dopamine	S-drug
and	O
isoproterenol	S-drug
;	O

cardiac	B-group
glycosides	E-group
;	O

and	O
diuretics	S-group
,	O
such	O
as	O
furosemide	S-drug
.	O

Caverject	S-brand
:	O
The	O
potential	O
for	O
pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
alprostadil	S-drug
and	O
other	O
agents	O
has	O
not	O
been	O
formally	O
studied	O
.	O

The	O
interaction	O
of	O
Activase	S-brand
with	O
other	O
cardioactive	O
or	O
cerebroactive	O
drugs	O
has	O
not	O
been	O
studied	O
.	O

In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	S-drug-EF-1
and	O
vitamin	B-group-EF-1
K	I-group-EF-1
antagonists	E-group-EF-1
,	O
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B-drug-IN-1
acid	E-drug-IN-1
,	O
dipyridamole	S-drug-EF-1
and	O
Abciximab	S-drug-EF-1
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
,	O
during	O
,	O
or	O
after	O
Activase	S-brand-MU-2
therapy	O
.	O

Use	O
of	O
Antithrombotics	S-group
Aspirin	S-brand
and	O
heparin	S-drug
have	O
been	O
administered	O
concomitantly	O
with	O
and	O
following	O
infusions	O
of	O
Activase	S-brand
in	O
the	O
management	O
of	O
acute	O
myocardial	O
infarction	O
or	O
pulmonary	O
embolism	O
.	O

Because	O
heparin	S-drug
,	O
aspirin	S-brand
,	O
or	O
Activase	S-brand
may	O
cause	O
bleeding	O
complications	O
,	O
careful	O
monitoring	O
for	O
bleeding	O
is	O
advised	O
,	O
especially	O
at	O
arterial	O
puncture	O
sites	O
.	O

The	O
concomitant	O
use	O
of	O
heparin	S-drug
or	O
aspirin	S-brand
during	O
the	O
first	O
24	O
hours	O
following	O
symptom	O
onset	O
were	O
prohibited	O
in	O
The	O
NINDS	O
t	O
-	O
PA	O
Stroke	O
Trial	O
.	O

The	O
safety	O
of	O
such	O
concomitant	O
use	O
with	O
Activase	S-brand
for	O
the	O
management	O
of	O
acute	O
ischemic	O
stroke	O
is	O
unknown	O
.	O

Concurrent	O
administration	O
of	O
HEXALEN	S-brand-EF-1
and	O
antidepressants	B-group-EF-2
of	I-group-EF-2
the	I-group-EF-2
MAO	I-group-EF-2
inhibitor	I-group-EF-2
class	E-group-EF-2
may	O
cause	O
severe	O
orthostatic	O
hypotension.Cimetidine	O
,	O
an	O
inhibitor	O
of	O
microsomal	O
drug	O
metabolism	O
,	O
increased	O
altretamines	O
half	O
-	O
life	O
and	O
toxicity	O
in	O
a	O
rat	O
model	O
.	O

Data	O
from	O
a	O
randomized	O
trial	O
of	O
HEXALEN	S-brand-EF-1
and	O
cisplatin	S-drug-EF-2
plus	O
or	O
minus	O
pyridoxine	S-drug
in	O
ovarian	O
cancer	O
indicated	O
that	O
pyridoxine	S-drug
significantly	O
reduced	O
neurotoxicity	O
;	O

however	O
,	O
it	O
adversely	O
affected	O
response	O
duration	O
suggesting	O
that	O
pyridoxine	S-drug-AD-1
should	O
not	O
be	O
administered	O
with	O
HEXALEN	S-brand-AD-2
and	O
/	O
or	O
cisplatin.1	O

Careful	O
observation	O
is	O
required	O
when	O
amantadine	S-drug-AD-1
is	O
administered	O
concurrently	O
with	O
central	B-group-AD-2
nervous	I-group-AD-2
system	I-group-AD-2
stimulants	E-group-AD-2
.	O

Coadministration	O
of	O
thioridazine	S-drug
has	O
been	O
reported	O
to	O
worsen	O
the	O
tremor	O
in	O
elderly	O
patients	O
with	O
Parkinsons	O
disease	O
;	O

however	O
,	O
it	O
is	O
not	O
known	O
if	O
other	O
phenothiazines	S-group
produce	O
a	O
similar	O
response	O
.	O

Special	O
consideration	O
should	O
be	O
given	O
to	O
the	O
administration	O
of	O
ETHYOL	S-brand-AD-1
in	O
patients	O
receiving	O
antihypertensive	B-group-AD-2
medications	E-group-AD-2
or	O
other	O
drugs	O
that	O
could	O
cause	O
or	O
potentiate	O
hypotension	O
.	O

When	O
amiloride	S-drug-EF-1
HCl	O
is	O
administered	O
concomitantly	O
with	O
an	O
angiotensin	B-group-EF-2
-	I-group-EF-2
converting	I-group-EF-2
enzyme	I-group-EF-2
inhibitor	E-group-EF-2
,	O
the	O
risk	O
of	O
hyperkalemia	O
may	O
be	O
increased	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	O
.	O

Lithium	S-drug-AD-1
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	S-group-AD-2
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	O
toxicity	O
.	O

Read	O
circulars	O
for	O
lithium	S-drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	B-group-EF-1
-	I-group-EF-1
steroidal	I-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
agent	E-group-EF-1
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	S-group-EF-2
,	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	E-group-EF-2
and	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
.	O

Therefore	O
,	O
when	O
MIDAMOR	S-brand-AD-1
and	O
non	B-group-AD-2
-	I-group-AD-2
steroidal	I-group-AD-2
anti	I-group-AD-2
-	I-group-AD-2
inflammatory	I-group-AD-2
agents	E-group-AD-2
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	S-group
is	O
obtained	O
.	O

Since	O
indomethacin	S-drug-EF-1
and	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	I-group-EF-2
diuretics	E-group-EF-2
,	O
including	O
MIDAMOR	S-brand-EF-2
,	O
may	O
each	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
,	O
the	O
potential	O
effects	O
on	O
potassium	O
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Drug	O
Laboratory	O
Test	O
Interactions	O
:	O
Prolongation	O
of	O
the	O
template	O
bleeding	O
time	O
has	O
been	O
reported	O
during	O
continuous	O
intravenous	O
infusion	O
of	O
AMICAR	S-brand
at	O
dosages	O
exceeding	O
24	O
g	O
/	O
day	O
.	O

Platelet	O
function	O
studies	O
in	O
these	O
patients	O
have	O
not	O
demonstrated	O
any	O
significant	O
platelet	O
dysfunction	O
.	O

However	O
,	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
at	O
high	O
concentrations	O
(	O
7.4	O
mMol	O
/	O
L	O
or	O
0.97	O
mg	O
/	O
mL	O
and	O
greater	O
)	O
EACA	S-drug
inhibits	O
ADP	O
and	O
collagen	O
-	O
induced	O
platelet	O
aggregation	O
,	O
the	O
release	O
of	O
ATP	O
and	O
serotonin	O
,	O
and	O
the	O
binding	O
of	O
fibrinogen	O
to	O
the	O
platelets	O
in	O
a	O
concentration	O
-	O
response	O
manner	O
.	O

Following	O
a	O
10	O
g	O
bolus	O
of	O
AMICAR	S-brand
,	O
transient	O
peak	O
plasma	O
concentrations	O
of	O
4.6	O
mMol	O
/	O
L	O
or	O
0.60	O
mg	O
/	O
mL	O
have	O
been	O
obtained	O
.	O

The	O
concentration	O
of	O
AMICAR	S-brand
necessary	O
to	O
maintain	O
inhibition	O
of	O
fibrinolysis	O
is	O
0.99	O
mMol	O
/	O
L	O
or	O
0.13	O
mg	O
/	O
mL	O
.	O

Administration	O
of	O
a	O
5	O
g	O
bolus	O
followed	O
by	O
1	O
to	O
1.25	O
g	O
/	O
hr	O
should	O
achieve	O
and	O
sustain	O
plasma	O
levels	O
of	O
0.13	O
mg	O
/	O
mL	O
.	O

Thus	O
,	O
concentrations	O
which	O
have	O
been	O
obtained	O
in	O
vivo	O
clinically	O
in	O
patients	O
with	O
normal	O
renal	O
function	O
are	O
considerably	O
lower	O
than	O
the	O
in	O
vitro	O
concentrations	O
found	O
to	O
induce	O
abnormalities	O
in	O
platelet	O
function	O
tests	O
.	O

However	O
,	O
higher	O
plasma	O
concentrations	O
of	O
AMICAR	S-brand
may	O
occur	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
.	O

Cytadren	S-brand-ME-1
accelerates	O
the	O
metabolism	O
of	O
dexamethasone	S-drug-ME-2
;	O

therefore	O
,	O
if	O
glucocorticoid	S-group
replacement	O
is	O
needed	O
,	O
hydrocortisone	S-drug
should	O
be	O
prescribed	O
.	O

Aminoglutethimide	S-drug-EF-1
diminishes	O
the	O
effect	O
of	O
coumarin	S-group-EF-2
and	O
warfarin	S-drug-EF-2
.	O

Renal	O
clearance	O
measurements	O
of	O
PAH	S-drug-EF-1
can	O
not	O
be	O
made	O
with	O
any	O
significant	O
accuracy	O
in	O
patients	O
receiving	O
sulfonamides	S-group-EF-2
,	O
procaine	S-drug-EF-2
,	O
or	O
thiazolesulfone	S-drug-EF-2
.	O

These	O
compounds	O
interfere	O
with	O
chemical	O
color	O
development	O
essential	O
to	O
the	O
analytical	O
procedures	O
.	O

Probenecid	S-drug-ME-1
depresses	O
tubular	O
secretion	O
of	O
certain	O
weak	O
acids	O
such	O
as	O
PAH	S-drug-ME-2
.	O

Therefore	O
,	O
patients	O
receiving	O
probenecid	S-drug-EF-1
will	O
have	O
erroneously	O
low	O
ERPF	O
and	O
Tm	O
PAH	S-drug-EF-2
values	O
.	O

There	O
have	O
been	O
no	O
formal	O
studies	O
of	O
the	O
interaction	O
of	O
LEVULAN	B-brand
KERASTICK	E-brand
for	O
Topical	O
Solution	O
with	O
any	O
other	O
drugs	O
,	O
and	O
no	O
drug	O
-	O
specific	O
interactions	O
were	O
noted	O
during	O
any	O
of	O
the	O
controlled	O
clinical	O
trials	O
.	O

It	O
is	O
,	O
however	O
,	O
possible	O
that	O
concomitant	O
use	O
of	O
other	O
known	O
photosensitizing	B-group-EF-1
agents	E-group-EF-1
such	O
as	O
griseofulvin	S-drug-EF-1
,	O
thiazide	B-group-EF-1
diuretics	E-group-EF-1
,	O
sulfonylureas	S-group-EF-1
,	O
phenothiazines	S-group-EF-1
,	O
sulfonamides	S-group-EF-1
and	O
tetracyclines	S-group-EF-1
might	O
increase	O
the	O
photosensitivity	O
reaction	O
of	O
actinic	O
keratoses	O
treated	O
with	O
the	O
LEVULAN	B-brand-EF-2
KERASTICK	E-brand-EF-2
for	O
Topical	O
Solution	O
.	O

Aminosalicylic	B-drug-ME-1
acid	E-drug-ME-1
may	O
decrease	O
the	O
amount	O
of	O
digoxin	S-drug-ME-2
(	O
Lanoxin	S-brand-ME-2
,	O
Lanoxicaps	S-drug
)	O
that	O
gets	O
absorbed	O
into	O
your	O
body	O
.	O

In	O
the	O
case	O
that	O
you	O
are	O
taking	O
digoxin	S-drug-AD-1
while	O
taking	O
aminosalicylic	B-drug-AD-2
acid	E-drug-AD-2
,	O
higher	O
doses	O
of	O
digoxin	S-drug
may	O
be	O
needed	O
.	O

Aminosalicylic	B-drug-ME-1
acid	E-drug-ME-1
may	O
also	O
decrease	O
the	O
absorption	O
of	O
vitamin	B-drug-ME-2
B12	E-drug-ME-2
,	O
which	O
can	O
lead	O
to	O
a	O
deficiency	O
.	O

Therefore	O
you	O
may	O
need	O
to	O
take	O
a	O
vitamin	B-drug-AD-1
B12	E-drug-AD-1
supplement	O
while	O
taking	O
aminosalicylic	B-drug-AD-2
acid	E-drug-AD-2
.	O

Amiodarone	S-drug
is	O
metabolized	O
to	O
desethylamiodarone	S-drug
by	O
the	O
cytochrome	O
P450	O
(	O
CYP450	O
)	O
enzyme	O
group	O
,	O
specifically	O
cytochromes	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
and	O
CYP2C8	O
.	O

The	O
CYP3A4	O
isoenzyme	O
is	O
present	O
in	O
both	O
the	O
liver	O
and	O
intestines	O
.	O

Amiodarone	S-drug
is	O
also	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
CYP3A4	O
.	O

Therefore	O
,	O
amiodarone	S-drug
has	O
the	O
potential	O
for	O
interactions	O
with	O
drugs	O
or	O
substances	O
that	O
may	O
be	O
substrates	O
,	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	O
.	O

While	O
only	O
a	O
limited	O
number	O
of	O
in	O
vivo	O
drug	O
-	O
drug	O
interactions	O
with	O
amiodarone	S-drug
have	O
been	O
reported	O
,	O
chiefly	O
with	O
the	O
oral	O
formulation	O
,	O
the	O
potential	O
for	O
other	O
interactions	O
should	O
be	O
anticipated	O
.	O

This	O
is	O
especially	O
important	O
for	O
drugs	O
associated	O
with	O
serious	O
toxicity	O
,	O
such	O
as	O
other	O
antiarrhythmics	S-group
.	O

If	O
such	O
drugs	O
are	O
needed	O
,	O
their	O
dose	O
should	O
be	O
reassessed	O
and	O
,	O
where	O
appropriate	O
,	O
plasma	O
concentration	O
measured	O
.	O

In	O
view	O
of	O
the	O
long	O
and	O
variable	O
half	O
-	O
life	O
of	O
amiodarone	S-drug
,	O
potential	O
for	O
drug	O
interactions	O
exists	O
not	O
only	O
with	O
concomitant	O
medication	O
but	O
also	O
with	O
drugs	O
administered	O
after	O
discontinuation	O
of	O
amiodarone	S-drug
.	O

Since	O
amiodarone	S-drug
is	O
a	O
substrate	O
for	O
CYP3A4	O
and	O
CYP2C8	O
,	O
drugs	O
/	O
substances	O
that	O
inhibit	O
these	O
isoenzymes	O
may	O
decrease	O
the	O
metabolism	O
and	O
increase	O
serum	O
concentration	O
of	O
amiodarone	S-drug
.	O

Reported	O
examples	O
include	O
the	O
following	O
:	O
Protease	B-group
Inhibitors	E-group
:	O
Protease	B-group
inhibitors	E-group
are	O
known	O
to	O
inhibit	O
CYP3A4	O
to	O
varying	O
degrees	O
.	O

A	O
case	O
report	O
of	O
one	O
patient	O
taking	O
amiodarone	S-drug-ME-1
200	O
mg	O
and	O
indinavir	S-drug-ME-2
800	O
mg	O
three	O
times	O
a	O
day	O
resulted	O
in	O
increases	O
in	O
amiodarone	S-drug
concentrations	O
from	O
0.9	O
mg	O
/	O
L	O
to	O
1.3	O
mg	O
/	O
L	O
.	O

DEA	O
concentrations	O
were	O
not	O
affected	O
.	O

There	O
was	O
no	O
evidence	O
of	O
toxicity	O
.	O

Monitoring	O
for	O
amiodarone	S-drug
toxicity	O
and	O
serial	O
measurement	O
of	O
amiodarone	S-drug-AD-1
serum	O
concentration	O
during	O
concomitant	O
protease	B-group-AD-2
inhibitor	E-group-AD-2
therapy	O
should	O
be	O
considered	O
.	O

Histamine	B-group-ME-1
H2	I-group-ME-1
antagonists	E-group-ME-1
:	O
Cimetidine	S-drug-ME-2
inhibits	O
CYP3A4	O
and	O
can	O
increase	O
serum	O
amiodarone	S-drug
levels	O
.	O

Other	O
substances	O
:	O
Grapefruit	O
juice	O
given	O
to	O
healthy	O
volunteers	O
increased	O
amiodarone	S-drug
AUC	O
by	O
50	O
%	O
and	O
Cmax	O
by	O
84	O
%	O
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
amiodarone	S-drug
.	O

Grapefruit	O
juice	O
should	O
not	O
be	O
taken	O
during	O
treatment	O
with	O
oral	O
amiodarone	O
.	O

This	O
information	O
should	O
be	O
considered	O
when	O
changing	O
from	O
intravenous	O
amiodarone	S-drug
to	O
oral	O
amiodarone	S-drug
.	O

Amiodarone	S-drug
may	O
suppress	O
certain	O
CYP450	O
enzymes	O
,	O
including	O
CYP1A2	S-drug
,	O
CYP2C9	S-drug
,	O
CYP2D6	S-drug
,	O
and	O
CYP3A4	S-drug
.	O

This	O
inhibition	O
can	O
result	O
in	O
unexpectedly	O
high	O
plasma	O
levels	O
of	O
other	O
drugs	S-drug
which	O
are	O
metabolized	O
by	O
those	O
CYP450	O
enzymes	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Immunosuppressives	O
:	O
Cyclosporine	S-drug
(	O
CYP3A4	S-drug
substrate	O
)	O
administered	O
in	O
combination	O
with	O
oral	O
amiodarone	S-drug
has	O
been	O
reported	O
to	O
produce	O
persistently	O
elevated	O
plasma	O
concentrations	O
of	O
cyclosporine	S-drug
resulting	O
in	O
elevated	O
creatinine	O
,	O
despite	O
reduction	O
in	O
dose	O
of	O
cyclosporine	S-drug
.	O

HMG	B-drug
-	I-drug
CoA	I-drug
Reductase	I-drug
Inhibitors	E-drug
:	O
Simvastatin	S-drug
(	O
CYP3A4	S-drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	S-drug
has	O
been	O
associated	O
with	O
reports	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
.	O

Cardiovasculars	O
:	O
Cardiac	B-drug
glycosides	E-drug
:	O
In	O
patients	O
receiving	O
digoxin	S-drug
therapy	O
,	O
administration	O
of	O
oral	O
amiodarone	S-drug
regularly	O
results	O
in	O
an	O
increase	O
in	O
serum	O
digoxin	S-drug
concentration	O
that	O
may	O
reach	O
toxic	O
levels	O
with	O
resultant	O
clinical	O
toxicity	O
.	O

Amiodarone	S-drug
taken	O
concomitantly	O
with	O
digoxin	S-drug
increases	O
the	O
serum	O
digoxin	S-drug
concentration	O
by	O
70	O
%	O
after	O
one	O
day	O
.	O

On	O
administration	O
of	O
oral	O
amiodarone	S-drug-AD-1
,	O
the	O
need	O
for	O
digitalis	S-group-AD-2
therapy	O
should	O
be	O
reviewed	O
and	O
the	O
dose	O
reduced	O
by	O
approximately	O
50	O
%	O
or	O
discontinued	O
.	O

If	O
digitalis	S-drug
treatment	O
is	O
continued	O
,	O
serum	O
levels	O
should	O
be	O
closely	O
monitored	O
and	O
patients	O
observed	O
for	O
clinical	O
evidence	O
of	O
toxicity	O
.	O

These	O
precautions	O
probably	O
should	O
apply	O
to	O
digitoxin	S-drug
administration	O
as	O
well	O
.	O

Antiarrhythmics	S-drug
:	O
Other	O
antiarrhythmic	S-drug
drugs	O
,	O
such	O
as	O
quinidine	S-drug
,	O
procainamide	S-drug
,	O
disopyramide	S-drug
,	O
and	O
phenytoin	S-drug
,	O
have	O
been	O
used	O
concurrently	O
with	O
amiodarone	S-drug
.	O

There	O
have	O
been	O
case	O
reports	O
of	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
quinidine	S-drug
,	O
procainamide	S-drug
,	O
and	O
phenytoin	S-drug
during	O
concomitant	O
therapy	O
with	O
amiodarone	S-drug
.	O

Phenytoin	S-drug
decreases	O
serum	O
amiodarone	O
levels	O
.	O

Amiodarone	S-drug
taken	O
concomitantly	O
with	O
quinidine	S-drug
increases	O
quinidine	S-drug
serum	O
concentration	O
by	O
33	O
%	O
after	O
two	O
days	O
.	O

Amiodarone	S-drug
taken	O
concomitantly	O
with	O
procainamide	S-drug
for	O
less	O
than	O
seven	O
days	O
increases	O
plasma	O
concentrations	O
of	O
procainamide	S-drug
and	O
n	O
-	O
acetyl	O
procainamide	S-drug
by	O
55	O
%	O
and	O
33	O
%	O
,	O
respectively	O
.	O

Quinidine	S-drug
and	O
procainamide	O
doses	O
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
when	O
either	O
is	O
administered	O
with	O
amiodarone	S-drug
.	O

Plasma	O
levels	O
of	O
flecainide	S-drug
have	O
been	O
reported	O
to	O
increase	O
in	O
the	O
presence	O
of	O
oral	O
amiodarone	S-drug
;	O

because	O
of	O
this	O
,	O
the	O
dosage	O
of	O
flecainide	S-drug
should	O
be	O
adjusted	O
when	O
these	O
drugs	S-drug
are	O
administered	O
concomitantly	O
.	O

In	O
general	O
,	O
any	O
added	O
antiarrhythmic	B-drug
drug	E-drug
should	O
be	O
initiated	O
at	O
a	O
lower	O
than	O
usual	O
dose	O
with	O
careful	O
monitoring	O
.	O

Combination	O
of	O
amiodarone	S-drug
with	O
other	O
antiarrhythmic	S-drug
therapy	O
should	O
be	O
reserved	O
for	O
patients	O
with	O
life	O
-	O
threatening	O
ventricular	O
arrhythmias	O
who	O
are	O
incompletely	O
responsive	O
to	O
a	O
single	O
agent	O
or	O
incompletely	O
responsive	O
to	O
amiodarone	S-drug
.	O

During	O
transfer	O
to	O
oral	O
amiodarone	S-drug
,	O
the	O
dose	O
levels	O
of	O
previously	O
administered	O
agents	O
should	O
be	O
reduced	O
by	O
30	O
to	O
50	O
%	O
several	O
days	O
after	O
the	O
addition	O
of	O
oral	O
amiodarone	S-drug
.	O

The	O
continued	O
need	O
for	O
the	O
other	O
antiarrhythmic	S-drug
agent	O
should	O
be	O
reviewed	O
after	O
the	O
effects	O
of	O
amiodarone	S-drug
have	O
been	O
established	O
,	O
and	O
discontinuation	O
ordinarily	O
should	O
be	O
attempted	O
.	O

If	O
the	O
treatment	O
is	O
continued	O
,	O
these	O
patients	O
should	O
be	O
particularly	O
carefully	O
monitored	O
for	O
adverse	O
effects	O
,	O
especially	O
conduction	O
disturbances	O
and	O
exacerbation	O
of	O
tachyarrhythmias	O
,	O
as	O
amiodarone	S-drug
is	O
continued	O
.	O

In	O
amiodarone	S-drug
-	O
treated	O
patients	O
who	O
require	O
additional	O
antiarrhythmic	S-drug
therapy	O
,	O
the	O
initial	O
dose	O
of	O
such	O
agents	O
should	O
be	O
approximately	O
half	O
of	O
the	O
usual	O
recommended	O
dose	O
.	O

Antihypertensives	S-drug
:	O
Amiodarone	S-drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
-	O
receptor	S-drug
blocking	O
agents	O
(	O
e.g	O
.	O
,	O
propranolol	S-drug
,	O
a	O
CYP3A4	S-drug
inhibitor	O
)	O
or	O
calcium	B-drug
channel	E-drug
antagonists	O
(	O
e.g	O
.	O
,	O
verapamil	S-drug
,	O
a	O
CYP3A4	S-drug
substrate	O
,	O
and	O
diltiazem	S-drug
,	O
a	O
CYP3A4	S-drug
inhibitor	O
)	O
because	O
of	O
the	O
possible	O
potentiation	O
of	O
bradycardia	O
,	O
sinus	O
arrest	O
,	O
and	O
AV	O
block	O
;	O

if	O
necessary	O
,	O
amiodarone	S-drug
can	O
continue	O
to	O
be	O
used	O
after	O
insertion	O
of	O
a	O
pacemaker	O
in	O
patients	O
with	O
severe	O
bradycardia	O
or	O
sinus	O
arrest	O
.	O

Anticoagulants	S-drug
:	O
Potentiation	O
of	O
warfarin	S-drug
-	O
type	O
(	O
CYP2C9	S-drug
and	O
CYP3A4	S-drug
substrate	O
)	O
anticoagulant	S-drug
response	O
is	O
almost	O
always	O
seen	O
in	O
patients	O
receiving	O
amiodarone	S-drug
and	O
can	O
result	O
in	O
serious	O
or	O
fatal	O
bleeding	O
.	O

Since	O
the	O
concomitant	O
administration	O
of	O
warfarin	S-drug
with	O
amiodarone	S-drug
increases	O
the	O
prothrombin	O
time	O
by	O
100	O
%	O
after	O
3	O
to	O
4	O
days	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	S-drug
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
to	O
one	O
-	O
half	O
,	O
and	O
prothrombin	O
times	O
should	O
be	O
monitored	O
closely	O
.	O

Some	O
drugs	S-drug
/	O
substances	O
are	O
known	O
to	O
accelerate	O
the	O
metabolism	O
of	O
amiodarone	S-drug
by	O
stimulating	O
the	O
synthesis	O
of	O
CYP3A4	S-drug
(	O
enzyme	O
induction	O
)	O
.	O

This	O
may	O
lead	O
to	O
low	O
amiodarone	S-drug
serum	O
levels	O
and	O
potential	O
decrease	O
in	O
efficacy	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Antibiotics	S-drug
:	O
Rifampin	S-drug
is	O
a	O
potent	O
inducer	O
of	O
CYP3A4	S-drug
.	O

Administration	O
of	O
rifampin	S-drug
concomitantly	O
with	O
oral	O
amiodarone	S-drug
has	O
been	O
shown	O
to	O
result	O
in	O
decreases	O
in	O
serum	O
concentrations	O
of	O
amiodarone	S-drug
and	O
desethylamiodarone	S-drug
.	O

Other	O
substances	O
,	O
including	O
herbal	O
preparations	O
:	O
St.	O
John	O
s	O
Wort	O
(	O
Hypericum	O
perforatum	O
)	O
induces	O
CYP3A4	O
.	O

Since	O
amiodarone	S-drug
is	O
a	O
substrate	O
for	O
CYP3A4	S-drug
,	O
there	O
is	O
the	O
potential	O
that	O
the	O
use	O
of	O
St.	O
John	O
s	O
Wort	O
in	O
patients	O
receiving	O
amiodarone	S-drug
could	O
result	O
in	O
reduced	O
amiodarone	S-drug
levels	O
.	O

Other	O
reported	O
interactions	O
with	O
amiodarone	S-drug
:	O
Fentanyl	S-drug
(	O
CYP3A4	S-drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	S-drug
may	O
cause	O
hypotension	O
,	O
bradycardia	O
,	O
and	O
decreased	O
cardiac	O
output	O
.	O

Sinus	O
bradycardia	O
has	O
been	O
reported	O
with	O
oral	O
amiodarone	S-drug
in	O
combination	O
with	O
lidocaine	S-drug
(	O
CYP3A4	S-drug
substrate	O
)	O
given	O
for	O
local	O
anesthesia	S-drug
.	O

Seizure	O
,	O
associated	O
with	O
increased	O
lidocaine	S-drug
concentrations	O
,	O
has	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
intravenous	O
amiodarone	S-drug
.	O

Dextromethorphan	S-drug
is	O
a	O
substrate	O
for	O
both	O
CYP2D6	S-drug
and	O
CYP3A4	S-drug
.	O

Amiodarone	S-drug
inhibits	O
CYP2D6	S-drug
.	O

Cholestyramine	S-drug
increases	O
enterohepatic	O
elimination	O
of	O
amiodarone	S-drug
and	O
may	O
reduce	O
its	O
serum	O
levels	O
and	O
t1	S-drug
/	O
2	O
.	O

Disopyramide	S-drug
increases	O
QT	O
prolongation	O
which	O
could	O
cause	O
arrhythmia	O
.	O

Fluoroquinolones	S-drug
,	O
macrolide	B-drug
antibiotics	E-drug
,	O
and	O
azoles	O
are	O
known	O
to	O
cause	O
QTc	O
prolongation	O
.	O

There	O
have	O
been	O
reports	O
of	O
QTc	O
prolongation	O
,	O
with	O
or	O
without	O
TdP	O
,	O
in	O
patients	O
taking	O
amiodarone	S-drug
when	O
fluoroquinolones	S-drug
,	O
macrolide	B-drug
antibiotics	E-drug
,	O
or	O
azoles	O
were	O
administered	O
concomitantly	O
.	O

Hemodynamic	O
and	O
electrophysiologic	O
interactions	O
have	O
also	O
been	O
observed	O
after	O
concomitant	O
administration	O
with	O
propranolol	S-drug
,	O
diltiazem	S-drug
,	O
and	O
verapamil	S-drug
.	O

Volatile	O
Anesthetic	S-drug
Agents	O
:	O
.	O

In	O
addition	O
to	O
the	O
interactions	O
noted	O
above	O
,	O
chronic	O
(	O
2	O
weeks	O
)	O
oral	O
Cordarone	S-drug
administration	O
impairs	O
metabolism	O
of	O
phenytoin	S-drug
,	O
dextromethorphan	S-drug
,	O
and	O
methotrexate	S-drug
.	O

Electrolyte	O
Disturbances	O
Patients	O
with	O
hypokalemia	O
or	O
hypomagnesemia	O
should	O
have	O
the	O
condition	O
corrected	O
whenever	O
possible	O
before	O
being	O
treated	O
with	O
Cordarone	B-drug
I.V	I-drug
.	E-drug
,	O
as	O
these	O
disorders	O
can	O
exaggerate	O
the	O
degree	O
of	O
QTc	O
prolongation	O
and	O
increase	O
the	O
potential	O
for	O
TdP	O
.	O

Special	O
attention	O
should	O
be	O
given	O
to	O
electrolyte	O
and	O
acid	O
-	O
base	O
balance	O
in	O
patients	O
experiencing	O
severe	O
or	O
prolonged	O
diarrhea	O
or	O
in	O
patients	O
receiving	O
concomitant	O
diuretics	S-drug
.	O

Drugs	O
Metabolized	O
by	O
P450	O
2D6	O
-	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7	O
-	O
10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O

reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-group
antidepressants	E-group
(	O
TCAs	S-group
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
-	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	S-group
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	S-group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	S-drug
;	O

cimetidine	S-drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	S-group
,	O
phenothiazines	S-group
,	O
and	O
the	O
Type	B-group
1C	I-group
antiarrhythmics	E-group
propafenone	S-drug
and	O
flecainide	S-drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	B-group
reuptake	I-group
inhibitors	E-group
(	O
SSRIs	S-group
)	O
,	O
e.g	O
.	O
,	O
fluoxetine	S-drug
,	O
sertraline	S-drug
,	O
and	O
paroxetine	S-drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	S-group-EF-1
-	O
TCA	S-group-EF-2
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	S-group
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
TCAs	S-group-AD-1
with	O
any	O
of	O
the	O
SSRIs	S-group-AD-2
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	S-drug
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B-group
antidepressants	E-group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-group
antidepressant	E-group
or	O
the	O
other	O
drug	O
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-drug
antidepressant	E-drug
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	S-group
plasma	O
levels	O
whenever	O
a	O
TCA	S-group
is	O
going	O
to	O
be	O
coadministered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Monoamine	B-drug
Oxidase	I-drug
Inhibitors	E-drug
:	O
Guanethidine	S-drug
or	O
similarly	O
acting	O
compounds	O
;	O

thyroid	S-drug
medication	O
;	O

alcohol	S-drug
,	O
barbiturates	S-drug
and	O
other	O
CNS	B-drug
depressants	E-drug
;	O

and	O
disulfiram	S-drug
When	O
amitriptyline	B-drug
HCl	E-drug
is	O
given	O
with	O
anticholinergic	S-drug
agents	O
or	O
sympathomimetic	S-drug
drugs	O
,	O
including	O
epinephrine	S-drug
combined	O
with	O
local	O
anesthetics	S-drug
,	O
close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosages	O
are	O
required	O
.	O

Hyperpyrexia	O
has	O
been	O
reported	O
when	O
amitriptyline	B-drug-EF-1
HCl	E-drug-EF-1
is	O
administered	O
with	O
anticholinergic	S-drug-EF-2
agents	O
or	O
with	O
neuroleptic	S-drug
drugs	O
,	O
particularly	O
during	O
hot	O
weather	O
.	O

Paralytic	O
ileus	O
may	O
occur	O
in	O
patients	O
taking	O
tricyclic	B-drug-EF-1
antidepressants	E-drug-EF-1
in	O
combination	O
with	O
anticholinergic	S-drug-EF-2
-	O
type	O
drugs	O
.	O

Cimetidine	S-drug-ME-1
is	O
reported	O
to	O
reduce	O
hepatic	O
metabolism	O
of	O
certain	O
tricyclic	B-drug-ME-2
antidepressants	E-drug-ME-2
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
steady	O
-	O
state	O
concentrations	O
of	O
these	O
drugs	S-drug
.	O

Clinically	O
significant	O
effects	O
have	O
been	O
reported	O
with	O
the	O
tricyclic	B-drug-EF-1
antidepressants	E-drug-EF-1
when	O
used	O
concomitantly	O
with	O
cimetidine	S-drug-EF-2
.	O

Increases	O
in	O
plasma	O
levels	O
of	O
tricyclic	B-drug-ME-1
antidepressants	E-drug-ME-1
,	O
and	O
in	O
the	O
frequency	O
and	O
severity	O
of	O
side	O
effects	O
,	O
particularly	O
anticholinergic	S-drug
,	O
have	O
been	O
reported	O
when	O
cimetidine	S-drug-ME-2
was	O
added	O
to	O
the	O
drug	S-drug
regimen	O
.	O

Discontinuation	O
of	O
cimetidine	S-drug
in	O
well	O
-	O
controlled	O
patients	O
receiving	O
tricyclic	B-drug-ME-1
antidepressants	E-drug-ME-1
and	O
cimetidine	S-drug-ME-2
may	O
decrease	O
the	O
plasma	O
levels	O
and	O
efficacy	O
of	O
the	O
antidepressants	S-drug
.	O

Caution	O
is	O
advised	O
if	O
patients	O
receive	O
large	O
doses	O
of	O
ethchlorvynol	S-drug
concurrently	O
.	O

Transient	O
delirium	O
has	O
been	O
reported	O
in	O
patients	O
who	O
were	O
treated	O
with	O
one	O
gram	O
of	O
ethchlorvynol	S-drug-EF-1
and	O
75	O
-	O
150	O
mg	O
of	O
amitriptyline	B-drug-EF-2
HCl	E-drug-EF-2
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
amphotericin	B-drug-EF-1
B	E-drug-EF-1
:	O
Antineoplastic	B-group-EF-2
agents	E-group-EF-2
:	O
may	O
enhance	O
the	O
potential	O
for	O
renal	O
toxicity	O
,	O
bronchospasm	O
and	O
hypotension	O
.	O

Antineoplastic	B-group
agents	E-group
(	O
e.	O
g.	O
,	O
nitrogen	B-drug
mustard	E-drug
,	O
etc	O
.	O
)	O
should	O
be	O
given	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O

Corticosteroids	S-group-EF-1
and	O
Corticotropin	S-drug-EF-1
(	O
ACTH	S-group-EF-1
)	O
:	O
may	O
potentiate	O
amphotericin	B-drug-EF-2
B	E-drug-EF-2
-	O
induced	O
hypokalemia	O
which	O
may	O
predispose	O
the	O
patient	O
to	O
cardiac	O
dysfunction	O
.	O

Avoid	O
concomitant	O
use	O
unless	O
necessary	O
to	O
control	O
side	O
effects	O
of	O
amphotericin	B-drug
B	E-drug
.	O

If	O
used	O
concomitantly	O
,	O
closely	O
monitor	O
serum	O
electrolytes	O
and	O
cardiac	O
function	O
.	O

Digitalis	B-group
glycosides	E-group
:	O
amphotericin	B-drug-EF-1
B	E-drug-EF-1
-	O
induced	O
hypokalemia	O
may	O
potentiate	O
digitalis	S-group-EF-2
toxicity	O
.	O

Serum	O
potassium	O
levels	O
and	O
cardiac	O
function	O
should	O
be	O
closely	O
monitored	O
and	O
any	O
deficit	O
promptly	O
corrected	O
.	O

Flucytosine	S-drug
:	O
while	O
a	O
synergistic	O
relationship	O
with	O
amphotericin	B-drug-EF-1
B	E-drug-EF-1
has	O
been	O
reported	O
,	O
concomitant	O
use	O
may	O
increase	O
the	O
toxicity	O
of	O
flucytosine	S-drug-EF-2
by	O
possibly	O
increasing	O
its	O
cellular	O
uptake	O
and	O
/	O
or	O
impairing	O
its	O
renal	O
excretion	O
.	O

Imidazoles	S-group
(	O
e.	O
g.	O
,	O
ketoconazole	S-drug
,	O
miconazole	S-drug
,	O
clotrimazole	S-drug
,	O
fluconazole	S-drug
,	O
etc	O
.	O
)	O
:	O
in	O
vitro	O
and	O
animal	O
studies	O
with	O
the	O
combination	O
of	O
amphotericin	B-drug
B	E-drug
and	O
imidazoles	S-group
suggest	O
that	O
imidazoles	S-group-EF-1
may	O
induce	O
fungal	O
resistance	O
to	O
amphotericin	B-drug-EF-2
B	E-drug-EF-2
.	O

Combination	O
therapy	O
should	O
be	O
administered	O
with	O
caution	O
,	O
especially	O
in	O
immunocompromised	O
patients	O
.	O

Other	O
nephrotoxic	O
medications	O
:	O
agents	O
such	O
as	O
aminoglycosides	S-group
,	O
cyclosporine	S-drug
,	O
and	O
pentamidine	S-drug
may	O
enhance	O
the	O
potential	O
for	O
drug	O
-	O
induced	O
renal	O
toxicity	O
,	O
and	O
should	O
be	O
used	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O

Intensive	O
monitoring	O
of	O
renal	O
function	O
is	O
recommended	O
in	O
patients	O
requiring	O
any	O
combination	O
of	O
nephrotoxic	O
medications	O
.	O

Skeletal	B-group
muscle	I-group
relaxants	E-group
:	O
amphotericin	B-drug-EF-1
B	E-drug-EF-1
-	O
induced	O
hypokalemia	O
may	O
enhance	O
the	O
curariform	O
effect	O
of	O
skeletal	B-group-EF-2
muscle	I-group-EF-2
relaxants	E-group-EF-2
(	O
e.g	O
.	O
,	O
tubocurarine	S-drug-EF-2
)	O
.	O

Serum	O
potassium	O
levels	O
should	O
be	O
monitored	O
and	O
deficiencies	O
corrected	O
.	O

Leukocyte	B-drug_n
transfusions	E-drug_n
:	O
acute	O
pulmonary	O
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
intravenous	O
amphotericin	B-drug-EF-1
B	E-drug-EF-1
and	O
leukocyte	B-drug_n-EF-2
transfusions	E-drug_n-EF-2
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
ampicillin	S-drug
.	O

Allopurinol	S-drug
:	O
Increased	O
possibility	O
of	O
skin	O
rash	O
,	O
particularly	O
in	O
hyperuricemic	O
patients	O
may	O
occur	O
.	O

Bacteriostatic	B-group
Antibiotics	E-group
:	O
Chloramphenicol	S-drug-EF-1
,	O
erythromycins	S-drug-EF-1
,	O
sulfonamides	S-group-EF-1
,	O
or	O
tetracyclines	S-group-EF-1
may	O
interfere	O
with	O
the	O
bactericidal	O
effect	O
of	O
penicillins	S-group-EF-2
.	O

This	O
has	O
been	O
demonstrated	O
in	O
view	O
,	O
however	O
,	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
well	O
documented	O
.	O

Oral	O
Contraceptives	S-group
:	O
May	O
be	O
less	O
effective	O
and	O
increased	O
breakthrough	O
bleeding	O
may	O
occur	O
.	O

Probenecid	S-drug-ME-1
:	O
May	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
ampicillin	S-drug-ME-2
resulting	O
in	O
increased	O
blood	O
levels	O
and	O
/	O
or	O
ampicillin	S-drug
toxicity	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
After	O
treatment	O
with	O
ampicillin	S-drug
,	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	B-drug_n
sulfate	E-drug_n
tests	O
(	O
Benedicts	O
solution	O
,	O
Fehlings	O
solution	O
,	O
or	O
Clinitest	O
tablets	O
)	O
but	O
not	O
with	O
enzyme	O
based	O
tests	O
such	O
as	O
Clinistix	O
and	O
Glucose	O
Enzymatic	O
Test	O
Strip	O
USP	O
.	O

Amprenavir	S-drug
is	O
metabolized	O
in	O
the	O
liver	O
by	O
the	O
cytochrome	O
P450	O
enzyme	O
system	O
.	O

Amprenavir	S-drug
inhibits	O
CYP3A4	O
.	O

Caution	O
should	O
be	O
used	O
when	O
coadministering	O
medications	O
that	O
are	O
substrates	O
,	O
inhibitors	O
,	O
or	O
inducers	O
of	O
CYP3A4	O
,	O
or	O
potentially	O
toxic	O
medications	O
that	O
are	O
metabolized	O
by	O
CYP3A4	O
.	O

Amprenavir	S-drug
does	O
not	O
inhibit	O
CYP2D6	O
,	O
CYP1A2	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2E1	O
,	O
or	O
uridine	O
glucuronosyltransferase	O
(	O
UDPGT	O
)	O
.	O

HIV	B-group
Protease	I-group
Inhibitors	E-group
:	O
The	O
effect	O
of	O
amprenavir	S-drug
on	O
total	O
drug	O
concentrations	O
of	O
other	O
HIV	B-group
protease	I-group
inhibitors	E-group
in	O
subjects	O
receiving	O
both	O
agents	O
was	O
evaluated	O
using	O
comparisons	O
to	O
historical	O
data	O
.	O

Indinavir	S-drug-ME-1
steady	O
-	O
state	O
Cmax	O
,	O
A.C.	O
and	O
Cmin	O
were	O
decreased	O
by	O
22	O
%	O
,	O
38	O
%	O
,	O
and	O
27	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	S-drug-ME-2
.	O

Similar	O
decreases	O
in	O
Cmax	O
and	O
AUC	O
were	O
seen	O
after	O
the	O
first	O
dose	O
.	O

Saquinavir	S-drug-ME-1
steady	O
-	O
state	O
Cmax	O
,	O
A.C.	O
and	O
Cmin	O
were	O
increased	O
21	O
%	O
,	O
decreased	O
19	O
%	O
,	O
and	O
decreased	O
48	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	S-drug-ME-2
.	O

Nelfinavir	S-drug-ME-1
steady	O
-	O
state	O
Cmax	O
,	O
A.C.	O
and	O
Cmin	O
were	O
increased	O
by	O
12	O
%	O
,	O
15	O
%	O
,	O
and	O
14	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	S-drug-ME-2
.	O

Methadone	S-drug
:	O
Coadministration	O
of	O
amprenavir	S-drug-EF-1
and	O
methadone	S-drug-EF-2
can	O
decrease	O
plasma	O
levels	O
of	O
methadone	S-drug
.	O

Coadministration	O
of	O
amprenavir	S-drug-ME-1
and	O
methadone	S-drug-ME-2
as	O
compared	O
to	O
a	O
non	O
-	O
matched	O
historicalcontrol	O
group	O
resulted	O
in	O
a	O
30	O
%	O
,	O
27	O
%	O
,	O
and	O
25	O
%	O
decrease	O
in	O
serum	O
amprenavir	S-drug
AUC	O
,	O
Cmax	O
,	O
andCmin	O
,	O
respectively	O
.	O

Amprenavir	S-drug
is	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
C.P.A	O
.	O
metabolism	O
and	O
therefore	O
should	O
not	O
be	O
administered	O
concurrently	O
with	O
medications	O
with	O
narrow	O
therapeutic	O
windows	O
that	O
are	O
substrates	O
of	O
CYP3A4	O
.	O

There	O
are	O
other	O
agents	O
that	O
may	O
result	O
in	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
drug	O
interactions	O
.	O

Laboratory	O
Tests	O
:	O
The	O
combination	O
of	O
Amprenavir	S-drug-EF-1
and	O
low	O
-	O
dose	O
ritonavir	S-drug-EF-2
has	O
been	O
associated	O
with	O
elevations	O
of	O
cholesterol	O
and	O
triglycerides	O
,	O
SGOT	O
(	O
AST	O
)	O
,	O
and	O
SGPT	O
(	O
ALT	O
)	O
in	O
some	O
patients	O
.	O

Appropriate	O
laboratory	O
testing	O
should	O
be	O
considered	O
prior	O
to	O
initiating	O
combination	O
therapy	O
with	O
Amprenavir	S-drug-AD-1
and	O
ritonavir	S-drug-AD-2
and	O
at	O
periodic	O
intervals	O
or	O
if	O
any	O
clinical	O
signs	O
or	O
symptoms	O
of	O
hyperlipidemia	O
or	O
elevated	O
liver	O
function	O
tests	O
occur	O
during	O
therapy	O
.	O

For	O
comprehensive	O
information	O
concerning	O
laboratory	O
test	O
alterations	O
associated	O
with	O
ritonavir	S-drug
,	O
physicians	O
should	O
refer	O
to	O
the	O
complete	O
prescribing	O
information	O
for	O
NORVIR	S-brand
(	O
ritonavir	S-drug
)	O
.	O

Taking	O
amyl	B-drug-EF-1
nitrite	E-drug-EF-1
after	O
drinking	O
alcohol	S-drug-EF-2
may	O
worsen	O
side	O
effects	O
and	O
may	O
cause	O
severe	O
hypotension	O
and	O
cardiovascular	O
collapse	O
.	O

Limited	O
PK	O
and	O
/	O
or	O
PD	O
studies	O
investigating	O
possible	O
interactions	O
between	O
anagrelide	S-drug
and	O
other	O
medicinal	O
products	O
have	O
been	O
conducted	O
.	O

In	O
vivo	O
interaction	O
studies	O
in	O
humans	O
have	O
demonstrated	O
that	O
digoxin	S-drug
and	O
warfarin	S-drug
do	O
not	O
affect	O
the	O
PK	O
properties	O
of	O
anagrelide	S-drug
,	O
nor	O
does	O
anagrelide	S-drug
affect	O
the	O
PK	O
properties	O
of	O
digoxin	S-drug
or	O
warfarin	S-drug
.	O

Although	O
additional	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
,	O
the	O
most	O
common	O
medications	O
used	O
concomitantly	O
with	O
anagrelide	S-drug
in	O
clinical	O
trials	O
were	O
aspirin	S-brand
,	O
acetaminophen	S-drug
,	O
furosemide	S-drug
,	O
iron	S-drug
,	O
ranitidine	S-drug
,	O
hydroxyurea	S-drug
,	O
and	O
allopurinol	S-drug
.	O

There	O
is	O
no	O
clinical	O
evidence	O
to	O
suggest	O
that	O
anagrelide	S-drug
interacts	O
with	O
any	O
of	O
these	O
compounds	O
.	O

An	O
in	O
vivo	O
interaction	O
study	O
in	O
humans	O
demonstrated	O
that	O
a	O
single	O
1mg	O
dose	O
of	O
anagrelide	S-drug
administered	O
concomitantly	O
with	O
a	O
single	O
900	O
mg	O
dose	O
of	O
aspirin	S-brand
was	O
generally	O
well	O
tolerated	O
.	O

There	O
was	O
no	O
effect	O
on	O
bleeding	O
time	O
,	O
PT	O
or	O
aPTT	O
.	O

No	O
clinically	O
relevant	O
pharmacokinetic	O
interactions	O
between	O
anagrelide	S-drug
and	O
acetylsalicylic	B-drug
acid	E-drug
were	O
observed	O
.	O

In	O
that	O
same	O
study	O
,	O
aspirin	S-brand
alone	O
produced	O
a	O
marked	O
inhibition	O
in	O
platelet	O
aggregation	O
ex	O
vivo	O
.	O

Anagrelide	S-drug-EF-1
alone	O
had	O
no	O
effect	O
on	O
platelet	O
aggregation	O
,	O
but	O
did	O
slightly	O
enhance	O
the	O
inhibition	O
of	O
platelet	O
aggregation	O
by	O
aspirin	S-brand-EF-2
.	O

Anagrelide	S-drug
is	O
metabolized	O
at	O
least	O
in	O
part	O
by	O
CYP1A2	O
.	O

It	O
is	O
known	O
that	O
CYP1A2	O
is	O
inhibited	O
by	O
several	O
medicinal	O
products	O
,	O
including	O
fluvoxamine	S-drug-ME-1
,	O
and	O
such	O
medicinal	O
products	O
could	O
theoretically	O
adversely	O
influence	O
the	O
clearance	O
of	O
anagrelide	S-drug-ME-2
.	O

Anagrelide	S-drug
demonstrates	O
some	O
limited	O
inhibitory	O
activity	O
towards	O
CYP1A2	O
which	O
may	O
present	O
a	O
theoretical	O
potential	O
for	O
interaction	O
with	O
other	O
coadministered	O
medicinal	O
products	O
sharing	O
that	O
clearance	O
mechanism	O
e.g	O
.	O

Anagrelide	S-drug-ME-1
demonstrates	O
some	O
limited	O
inhibitory	O
activity	O
towards	O
CYP1A2	O
which	O
may	O
present	O
a	O
theoretical	O
potential	O
for	O
interaction	O
with	O
other	O
coadministered	O
medicinal	O
products	O
sharing	O
that	O
clearance	O
mechanism	O
e.g	O
.	O
theophylline	S-drug-ME-2
.	O

Anagrelide	S-drug
is	O
an	O
inhibitor	O
of	O
cyclic	O
AMP	O
PDE	O
III	O
.	O

The	O
effects	O
of	O
medicinal	O
products	O
with	O
similar	O
properties	O
such	O
as	O
inotropes	O
milrinone	S-drug-EF-1
,	O
enoximone	S-drug-EF-1
,	O
amrinone	S-drug-EF-1
,	O
olprinone	S-drug_n-EF-1
and	O
cilostazol	S-drug-EF-1
may	O
be	O
exacerbated	O
by	O
anagrelide	S-drug-EF-2
.	O

There	O
is	O
a	O
single	O
case	O
report	O
,	O
which	O
suggests	O
that	O
sucralfate	S-drug-ME-1
may	O
interfere	O
with	O
anagrelide	S-drug-ME-2
absorption	O
.	O

Food	O
has	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
anagrelide	S-drug
.	O

No	O
drug	O
-	O
drug	O
interaction	O
studies	O
in	O
human	O
subjects	O
have	O
been	O
conducted	O
.	O

Toxicologic	O
and	O
toxicokinetic	O
studies	O
in	O
rats	O
did	O
not	O
demonstrate	O
any	O
alterations	O
in	O
the	O
clearance	O
or	O
toxicologic	O
profile	O
of	O
either	O
methotrexate	S-drug
or	O
Kineret	S-brand
when	O
the	O
two	O
agents	O
were	O
administered	O
together	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
Kineret	S-brand-EF-1
and	O
etanercept	S-drug-EF-2
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
etanercept	S-drug
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
Kineret	S-brand-EF-1
and	O
etanercept	S-drug-EF-2
developed	O
neutropenia	O
(	O
ANC	O
1	O
x	O
109	O
/	O
L	O
)	O
.	O

Anastrozole	S-drug
inhibited	O
in	O
vitro	O
metabolic	O
reactions	O
catalyzed	O
by	O
cytochromes	O
P450	O
1A2	O
,	O
2C8	O
/	O
9	O
,	O
and	O
3A4	O
but	O
only	O
at	O
relatively	O
high	O
concentrations	O
.	O

Anastrozole	S-drug
did	O
not	O
inhibit	O
P450	O
2A6	O
or	O
the	O
polymorphic	O
P450	O
2D6	O
in	O
human	O
liver	O
microsomes	O
.	O

Anastrozole	S-drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
antipyrine	S-drug
.	O

Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
other	O
than	O
with	O
antipyrine	S-drug
,	O
based	O
on	O
these	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
,	O
it	O
is	O
unlikely	O
that	O
co	O
-	O
administration	O
of	O
a	O
1	O
mg	O
dose	O
of	O
ARIMIDEX	S-brand
with	O
other	O
drugs	O
will	O
result	O
in	O
clinically	O
significant	O
drug	O
inhibition	O
of	O
cytochrome	O
P450	O
-	O
mediated	O
metabolism	O
of	O
the	O
other	O
drugs	O
.	O

An	O
interaction	O
study	O
with	O
warfarin	S-drug
showed	O
no	O
clinically	O
significant	O
effect	O
of	O
anastrozole	S-drug
on	O
warfarin	S-drug
pharmacokinetics	O
or	O
anticoagulant	O
activity	O
.	O

At	O
a	O
median	O
follow	O
-	O
up	O
of	O
33	O
months	O
,	O
the	O
combination	O
of	O
ARIMIDEX	S-brand
and	O
tamoxifen	S-drug
did	O
not	O
demonstrate	O
any	O
efficacy	O
benefit	O
when	O
compared	O
with	O
tamoxifen	S-drug
in	O
all	O
patients	O
as	O
well	O
as	O
in	O
the	O
hormone	O
receptor	O
-	O
positive	O
subpopulation	O
.	O

This	O
treatment	O
arm	O
was	O
discontinued	O
from	O
the	O
trial	O
.	O

Based	O
on	O
clinical	O
and	O
pharmacokinetic	O
results	O
from	O
the	O
ATAC	O
trial	O
,	O
tamoxifen	S-drug-AD-1
should	O
not	O
be	O
administered	O
with	O
anastrozole	S-drug-AD-2
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
Drug	O
Interactions	O
and	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Clinical	O
Studies	O
-	O
Adjuvant	O
Treatment	O
of	O
Breast	O
Cancer	O
in	O
Postmenopausal	O
Women	O
subsections	O
)	O
.	O

Co	O
-	O
administration	O
of	O
anastrozole	S-drug-ME-1
and	O
tamoxifen	S-drug-ME-2
resulted	O
in	O
a	O
reduction	O
of	O
anastrozole	S-drug
plasma	O
levels	O
by	O
27	O
%	O
compared	O
with	O
those	O
achieved	O
with	O
anastrozole	S-drug
alone	O
.	O

Estrogen	S-group-AD-1
-	O
containing	O
therapies	O
should	O
not	O
be	O
used	O
with	O
ARIMIDEX	S-brand-AD-2
as	O
they	O
may	O
diminish	O
its	O
pharmacologic	O
action	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
No	O
clinically	O
significant	O
changes	O
in	O
the	O
results	O
of	O
clinical	O
laboratory	O
tests	O
have	O
been	O
observed	O

No	O
clinically	O
relevant	O
drug	O
-	O
drug	O
interactions	O
have	O
been	O
observed	O
with	O
drugs	O
likely	O
to	O
be	O
co	O
-	O
administered	O
with	O
anidulafungin	S-drug
.	O

Caution	O
should	O
be	O
observed	O
when	O
anileridine	S-drug-AD-1
is	O
coadministered	O
with	O
other	O
opioids	S-group-AD-2
,	O
sedatives	S-group-AD-2
,	O
phenothiazines	S-group-AD-2
,	O
or	O
anesthetics	S-group-AD-2
,	O
as	O
these	O
agents	O
may	O
increase	O
respiratory	O
and	O
circulatory	O
depression	O
.	O

Addition	O
or	O
deletion	O
of	O
any	O
drug	O
from	O
the	O
therapeutic	O
regimen	O
of	O
patients	O
receiving	O
oral	O
anticoagulants	S-group
may	O
affect	O
patient	O
response	O
to	O
the	O
anticoagulant	S-group
.	O

Frequent	O
determination	O
of	O
prothrombin	O
time	O
and	O
close	O
monitoring	O
of	O
the	O
patient	O
is	O
essential	O
to	O
ascertain	O
when	O
adjustment	O
of	O
dosage	O
of	O
anticoagulant	S-group
may	O
be	O
needed	O
.	O

Because	O
of	O
the	O
variability	O
of	O
individual	O
patient	O
response	O
,	O
multiple	O
interacting	O
mechanisms	O
with	O
some	O
drugs	O
,	O
the	O
dependency	O
of	O
the	O
extent	O
of	O
the	O
interaction	O
on	O
the	O
dosage	O
and	O
duration	O
of	O
therapy	O
,	O
and	O
the	O
possible	O
administration	O
of	O
several	O
interacting	O
drugs	O
simultaneously	O
,	O
it	O
is	O
difficult	O
to	O
predict	O
the	O
direction	O
and	O
degree	O
of	O
the	O
ultimate	O
effect	O
of	O
concomitant	O
medications	O
on	O
anticoagulant	S-group
response	O
.	O

For	O
example	O
,	O
since	O
cholestyramine	S-drug-ME-1
may	O
reduce	O
the	O
gastrointestinal	O
absorption	O
of	O
both	O
the	O
oral	O
anticoagulants	S-group-ME-2
and	O
vitamin	B-group-ME-2
K	E-group-ME-2
,	O
the	O
net	O
effects	O
are	O
unpredictable	O
.	O

Chloral	B-drug-ME-1
hydrate	E-drug-ME-1
may	O
cause	O
an	O
increased	O
prothrombin	O
response	O
by	O
displacing	O
the	O
anticoagulant	S-group-ME-2
from	O
protein	O
binding	O
sites	O
or	O
a	O
diminished	O
prothrombin	O
response	O
through	O
increased	O
metabolism	O
of	O
the	O
unbound	O
drug	O
by	O
hepatic	O
enzyme	O
induction	O
,	O
thus	O
leading	O
to	O
inter	O
-	O
patient	O
variation	O
in	O
ultimate	O
prothrombin	O
effect	O
.	O

An	O
interacting	O
drug	O
which	O
leads	O
to	O
a	O
decrease	O
in	O
prothrombin	O
time	O
necessitating	O
an	O
increased	O
dose	O
of	O
oral	O
anticoagulant	S-group
to	O
maintain	O
an	O
adequate	O
degree	O
of	O
anticoagulation	O
may	O
,	O
if	O
abruptly	O
discontinued	O
,	O
increase	O
the	O
risk	O
of	O
subsequent	O
bleeding	O
.	O

Drugs	O
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	S-group-EF-1
response	O
,	O
ie	O
,	O
decreased	O
prothrom	O
-	O
bin	O
time	O
response	O
,	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	B-group-EF-2
steroids	E-group-EF-2
;	O

alcohol	S-drug
*	O
;	O

antacids	S-group
;	O

antihistamines	S-group
;	O

barbiturates	S-group
;	O

carbamazepine	S-drug
;	O

chloral	B-drug
hydrate	E-drug
*	O
;	O

chlordiazepoxide	S-drug
;	O

cholestyramine	S-drug
;	O

diet	O
high	O
in	O
vitamin	B-group
K	E-group
;	O

diuretics	S-group
*	O
;	O

ethchlorvynol	S-drug
;	O

glutethimide	S-drug
;	O

griseofulvin	S-drug
;	O

haloperidol	S-drug
;	O

meprobamate	S-drug
;	O

oral	O
contraceptives	S-group
;	O

paraldehyde	S-drug
;	O

primidone	S-drug
;	O

ranitidine	S-drug
*	O
;	O

rifampin	S-drug
;	O

unreliable	O
prothrombin	O
time	O
determinations	O
;	O

vitamin	B-drug
C	E-drug
;	O

Drugs	O
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	S-group-EF-1
response	O
,	O
ie	O
,	O
decreased	O
prothrom	O
-	O
bin	O
time	O
response	O
,	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	B-group-EF-2
steroids	E-group-EF-2
;	O
alcohol	S-drug-EF-2
*	O
;	O
antacids	S-group-EF-2
;	O
antihistamines	S-group-EF-2
;	O
barbiturates	S-group-EF-2
;	O
carbamazepine	S-drug-EF-2
;	O
chloral	B-drug-EF-2
hydrate	E-drug-EF-2
*	O
;	O
chlordiazepoxide	S-drug-EF-2
;	O
cholestyramine	S-drug-EF-2
;	O
diet	O
high	O
in	O
vitamin	B-group-EF-2
K	E-group-EF-2
;	O
diuretics	S-group-EF-2
*	O
;	O
ethchlorvynol	S-drug-EF-2
;	O
glutethimide	S-drug-EF-2
;	O
griseofulvin	S-drug-EF-2
;	O
haloperidol	S-drug-EF-2
;	O
meprobamate	S-drug-EF-2
;	O
oral	O
contraceptives	S-group-EF-2
;	O
paraldehyde	S-drug-EF-2
;	O
primidone	S-drug-EF-2
;	O
ranitidine	S-drug-EF-2
*	O
;	O
rifampin	S-drug-EF-2
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
vitamin	B-drug-EF-2
C	E-drug-EF-2
;	O
warfarin	B-drug-EF-2
sodium	E-drug-EF-2
under	O
-	O
dosage	O
.	O

Drugs	O
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	S-group-EF-1
response	O
,	O
ie	O
,	O
increased	O
prothrombin	O
response	O
,	O
in	O
man	O
include	O
:	O
alcohol	S-drug-EF-2
*	O
;	O

allopurinol	S-drug
;	O

aminosalicylic	B-drug
acid	E-drug
;	O

amiodarone	S-drug
;	O

anabolic	B-group
steroids	E-group
;	O

antibiotics	S-group
;	O

bromelains	S-drug
;	O

chloral	B-drug
hydrate	E-drug
*	O
;	O

chlorpropamide	S-drug
;	O

chymotrypsin	S-drug
;	O

cimetidine	S-drug
;	O

cinchophen	S-drug
;	O

clofibrate	S-drug
;	O

dextran	S-drug
;	O

dextrothyroxine	S-drug
;	O

diazoxide	S-drug
;	O

dietary	O
deficiencies	O
;	O

diflunisal	S-drug
;	O

diuretics	S-group
*	O
;	O

disulfiram	S-drug
;	O

drugs	O
affecting	O
blood	O
elements	O
;	O

ethacrynic	B-drug
acid	E-drug
;	O

fenoprofen	S-drug
;	O

glucagon	S-drug
;	O

hepatotoxic	O
drugs	O
;	O

ibuprofen	S-drug
;	O

indomethacin	S-drug
;	O

influenza	B-group
virus	I-group
vaccine	E-group
;	O

inhalation	O
anesthetics	S-group
;	O

mefenamic	B-drug
acid	E-drug
;	O

methyldopa	S-drug
;	O

methylphenidate	S-drug
;	O

metronidazole	S-drug
;	O

miconazole	S-drug
;	O

monoamine	B-group
oxidase	I-group
inhibitors	E-group
;	O

nalidixic	B-drug
acid	E-drug
;	O

naproxen	S-drug
;	O

oxolinic	B-drug
acid	E-drug
;	O

oxyphenbutazone	S-drug
;	O

pentoxifylline	S-drug
;	O

phenylbutazone	S-drug
;	O

phenyramidol	S-drug_n
;	O

phenytoin	S-drug
;	O

prolonged	O
hot	O
weather	O
;	O

prolonged	B-group
narcotics	E-group
;	O

pyrazolones	S-group
;	O

quinidine	S-drug
;	O

quinine	S-drug
;	O

ranitidine	S-drug
*	O
;	O

salicylates	S-group
;	O
sulfinpyrazone	S-drug
;	O

sulfonamides	S-group
,	O
long	O
acting	O
;	O

sulindac	S-drug
;	O

thyroid	B-group
drugs	E-group
;	O

tolbutamide	S-drug
;	O

triclofos	B-drug
sodium	E-drug
;	O

trimethoprim	S-drug
/	O
sulfamethoxazole	S-drug
;	O

unreliable	O
prothrombin	O
time	O
determinations	O
;	O

Drugs	O
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	S-group-EF-1
response	O
,	O
ie	O
,	O
increased	O
prothrombin	O
response	O
,	O
in	O
man	O
include	O
:	O
alcohol	S-drug-EF-2
*	O
;	O
allopurinol	S-drug-EF-2
;	O
aminosalicylic	B-drug-EF-2
acid	E-drug-EF-2
;	O
amiodarone	S-drug-EF-2
;	O
anabolic	B-group-EF-2
steroids	E-group-EF-2
;	O
antibiotics	S-group-EF-2
;	O
bromelains	S-drug-EF-2
;	O
chloral	B-drug-EF-2
hydrate	E-drug-EF-2
*	O
;	O
chlorpropamide	S-drug-EF-2
;	O
chymotrypsin	S-drug-EF-2
;	O
cimetidine	S-drug-EF-2
;	O
cinchophen	S-drug-EF-2
;	O
clofibrate	S-drug-EF-2
;	O
dextran	S-drug-EF-2
;	O
dextrothyroxine	S-drug-EF-2
;	O
diazoxide	S-drug-EF-2
;	O
dietary	O
deficiencies	O
;	O
diflunisal	S-drug-EF-2
;	O
disulfiram	S-drug-EF-2
;	O
drugs	O
affecting	O
blood	O
elements	O
;	O
ethacrynic	B-drug-EF-2
acid	E-drug-EF-2
;	O
fenoprofen	S-drug-EF-2
;	O
glucagon	S-drug-EF-2
;	O
hepatotoxic	O
drugs	O
;	O
ibuprofen	S-drug-EF-2
;	O
indomethacin	S-drug-EF-2
;	O
influenza	B-group-EF-2
virus	I-group-EF-2
vaccine	E-group-EF-2
;	O
inhalation	O
anesthetics	S-group-EF-2
;	O
mefenamic	B-drug-EF-2
acid	E-drug-EF-2
;	O
methyldopa	S-drug-EF-2
;	O
methylphenidate	S-drug-EF-2
;	O
metronidazole	S-drug-EF-2
;	O
miconazole	S-drug-EF-2
;	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
;	O
nalidixic	B-drug-EF-2
acid	E-drug-EF-2
;	O
naproxen	S-drug-EF-2
;	O
oxolinic	B-drug-EF-2
acid	E-drug-EF-2
;	O
oxyphenbutazone	S-drug-EF-2
;	O
pentoxifylline	S-drug-EF-2
;	O
phenylbutazone	S-drug-EF-2
;	O
phenyramidol	S-drug_n-EF-2
;	O
phenytoin	S-drug-EF-2
;	O
prolonged	O
hot	O
weather	O
;	O
prolonged	B-group-EF-2
narcotics	E-group-EF-2
;	O
pyrazolones	S-group-EF-2
;	O
quinidine	S-drug-EF-2
;	O
quinine	S-drug-EF-2
;	O
ranitidine	S-drug-EF-2
*	O
;	O
salicylates	S-group-EF-2
;	O
sulfinpyrazone	S-drug-EF-2
;	O
sulfonamides	S-group-EF-2
,	O
long	O
acting	O
;	O
sulindac	S-drug-EF-2
;	O
thyroid	B-group-EF-2
drugs	E-group-EF-2
;	O
tolbutamide	S-drug-EF-2
;	O
triclofos	B-drug-EF-2
sodium	E-drug-EF-2
;	O
trimethoprim	S-drug-EF-2
/	O
sulfamethoxazole	S-drug-EF-2
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
warfarin	B-drug-EF-2
sodium	E-drug-EF-2
overdosage	O
.	O

Oral	O
anticoagulants	S-group-ME-1
may	O
potentiate	O
the	O
hypoglycemic	O
action	O
of	O
hypoglycemic	B-group-ME-2
agents	E-group-ME-2
,	O
eg	O
,	O
tolbutamide	S-drug-ME-2
and	O
chlorpropamide	S-drug-ME-2
,	O
by	O
inhibiting	O
their	O
metabolism	O
in	O
the	O
liver	O
.	O

Because	O
oral	O
anticoagulants	S-group-ME-1
may	O
interfere	O
with	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	S-drug-ME-2
,	O
toxic	O
levels	O
of	O
the	O
anticonvulsant	S-group
may	O
occur	O
when	O
an	O
oral	O
anticoagulant	S-group-ME-1
and	O
phenytoin	S-drug-ME-2
are	O
administered	O
concurrently	O
.	O

Drugs	O
that	O
reduce	O
the	O
number	O
of	O
blood	O
platelets	O
by	O
causing	O
bone	O
marrow	O
depression	O
(	O
such	O
as	O
antineoplastic	B-group-EF-1
agents	E-group-EF-1
)	O
or	O
drugs	O
which	O
inhibit	O
platelet	O
function	O
(	O
eg	O
,	O
aspirin	S-brand-EF-1
and	O
other	O
non	B-group-EF-1
-	I-group-EF-1
steroidal	I-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
,	O
dipyridamole	S-drug-EF-1
,	O
hydrochloroquine	S-drug-EF-1
,	O
clofibrate	S-drug-EF-1
,	O
dextran	S-drug-EF-1
)	O
may	O
increase	O
the	O
bleeding	O
tendency	O
produced	O
by	O
anticoagulants	S-group-EF-2
without	O
altering	O
prothrombin	O
time	O
determinations	O
.	O

The	O
beneficial	O
effects	O
on	O
arterial	O
thrombus	O
formation	O
from	O
combined	O
therapy	O
with	O
antiplatelet	S-group-AD-1
and	O
anticoagulant	B-group-AD-2
medication	E-group-AD-2
must	O
be	O
weighed	O
against	O
an	O
increased	O
risk	O
of	O
inducing	O
hemorrhage	O
.	O

*	O
Increased	O
and	O
decreased	O
prothrombin	O
time	O
responses	O
have	O
been	O
reported	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interferences	O
:	O
Dicumarol	S-drug
and	O
indanedione	B-group
anticoagulants	E-group
,	O
including	O
anisindione	S-drug
,	O
or	O
their	O
metabolites	O
may	O
color	O
alkaline	O
urine	O
red	O
-	O
orange	O
,	O
which	O
may	O
interfere	O
with	O
spectrophotometrically	O
determined	O
urinary	O
laboratory	O
tests	O
.	O

The	O
color	O
reverses	O
when	O
the	O
test	O
sample	O
is	O
acidified	O
in	O
vitro	O
to	O
a	O
pH	O
below	O
4	O
.	O

5HT3	B-group
Antagonists	E-group
:	O
Based	O
on	O
reports	O
of	O
profound	O
hypotension	O
and	O
loss	O
of	O
consciousness	O
when	O
apomorphine	S-drug-EF-1
was	O
administered	O
with	O
ondansetron	S-drug-EF-2
,	O
the	O
concomitant	O
use	O
of	O
apomorphine	S-drug-AD-1
with	O
drugs	O
of	O
the	O
5HT3	B-group-AD-2
antagonist	I-group-AD-2
class	E-group-AD-2
(	O
including	O
,	O
for	O
example	O
,	O
ondansetron	S-drug-AD-2
,	O
granisetron	S-drug-AD-2
,	O
dolasetron	S-drug-AD-2
,	O
palonosetron	S-drug-AD-2
,	O
and	O
alosetron	S-drug-AD-2
)	O
is	O
contraindicated	O
.	O

Antihypertensive	B-group
Medications	O
and	O
Vasodilators	S-group
:	O
The	O
following	O
adverse	O
events	O
were	O
experienced	O
more	O
commonly	O
in	O
patients	O
receiving	O
concomitant	O
antihypertensive	B-group-EF-1
medications	E-group-EF-1
or	O
vasodilators	S-group-EF-2
(	O
n	O
=	O
94	O
)	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
drugs	O
(	O
n	O
=	O
456	O
)	O
:	O
hypotension	O
10	O
%	O
vs	O
4	O
%	O
,	O
myocardial	O
infarction	O
3	O
%	O
vs	O
1	O
%	O
,	O
serious	O
pneumonia	O
5	O
%	O
vs	O
3	O
%	O
,	O
serious	O
falls	O
9	O
%	O
vs	O
3	O
%	O
,	O
and	O
bone	O
and	O
joint	O
injuries	O
6	O
%	O
vs	O
2	O
%	O
.	O

The	O
mechanism	O
underlying	O
many	O
of	O
these	O
events	O
is	O
unknown	O
,	O
but	O
may	O
represent	O
increased	O
hypotension	O
.	O

Dopamine	B-group
Antagonists	E-group
:	O
Since	O
apomorphine	S-drug
is	O
a	O
dopamine	B-group
agonist	E-group
,	O
it	O
is	O
possible	O
that	O
dopamine	B-group-EF-1
antagonists	E-group-EF-1
,	O
such	O
as	O
the	O
neuroleptics	S-group
(	O
phenothiazines	S-group-EF-1
,	O
butyrophenones	S-group-EF-1
,	O
thioxanthenes	S-group-EF-1
)	O
or	O
metoclopramide	S-drug-EF-M
,	O
may	O
diminish	O
the	O
effectiveness	O
of	O
APOKYN	S-brand-EF-2
.	O

Patients	O
with	O
major	O
psychotic	O
disorders	O
,	O
treated	O
with	O
neuroleptics	S-group-AD-1
,	O
should	O
be	O
treated	O
with	O
dopamine	B-group-AD-2
agonists	E-group-AD-2
only	O
if	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
.	O

Drugs	O
Prolonging	O
the	O
QT	O
/	O
QTc	O
Interval	O
Caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
apomorphine	S-drug
concomitantly	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
/	O
QTc	O
interval	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
APOKYN	S-brand
and	O
laboratory	O
tests	O
.	O

Apraclonidine	S-drug-AD-1
should	O
not	O
be	O
used	O
in	O
patients	O
receiving	O
MAO	B-group-AD-2
inhibitors..	O

Although	O
no	O
specific	O
drug	O
interactions	O
with	O
topical	O
glaucoma	O
drugs	O
or	O
systemic	O
medications	O
were	O
identified	O
in	O
clinical	O
studies	O
of	O
IOPIDINE	S-brand-AD-1
0.5	O
%	O
Ophthalmic	O
Solution	O
,	O
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	B-group-AD-2
depressants	E-group-AD-2
(	O
alcohol	S-drug-AD-2
,	O
barbiturates	S-group-AD-2
,	O
opiates	S-group-AD-2
,	O
sedatives	S-group-AD-2
,	O
anesthetics	S-group-AD-2
)	O
should	O
be	O
considered	O
.	O

Tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine	S-drug-EF-2
.	O

It	O
is	O
not	O
known	O
whether	O
the	O
concurrent	O
use	O
of	O
these	O
agents	O
with	O
apraclonidine	S-drug
can	O
lead	O
to	O
a	O
reduction	O
in	O
IOP	O
lowering	O
effect	O
.	O

No	O
data	O
on	O
the	O
level	O
of	O
circulating	O
catecholamines	O
after	O
apraclonidine	S-drug
withdrawal	O
are	O
available	O
.	O

Caution	O
,	O
however	O
,	O
is	O
advised	O
in	O
patients	O
taking	O
tricyclic	B-group
antidepressants	E-group
which	O
can	O
affect	O
the	O
metabolism	O
and	O
uptake	O
of	O
circulating	O
amines	O
.	O

An	O
additive	O
hypotensive	O
effect	O
has	O
been	O
reported	O
with	O
the	O
combination	O
of	O
systemic	O
clonidine	S-drug-EF-1
and	O
neuroleptic	S-group-EF-2
therapy	O
.	O

Systemic	O
clonidine	S-drug
may	O
inhibit	O
the	O
production	O
of	O
catecholamines	O
in	O
response	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
and	O
mask	O
the	O
signs	O
and	O
symptoms	O
of	O
hypoglycemia	O
.	O

Since	O
apraclonidine	S-drug-AD-1
may	O
reduce	O
pulse	O
and	O
blood	O
pressure	O
,	O
caution	O
in	O
using	O
drugs	O
such	O
as	O
beta	B-group-AD-2
-	I-group-AD-2
blockers	E-group-AD-2
(	O
ophthalmic	O
and	O
systemic	O
)	O
,	O
antihypertensives	S-group-AD-2
,	O
and	O
cardiac	B-group-AD-2
glycosides	E-group-AD-2
is	O
advised	O
.	O

Patients	O
using	O
cardiovascular	O
drugs	O
concurrently	O
with	O
IOPIDINE	S-brand
0.5	O
%	O
Ophthalmic	O
Solution	O
should	O
have	O
pulse	O
and	O
blood	O
pressures	O
frequently	O
monitored	O
.	O

Caution	O
should	O
be	O
exercised	O
with	O
simultaneous	O
use	O
of	O
clonidine	S-drug
and	O
other	O
similar	O
pharmacologic	O
agents	O

Aprepitant	S-drug
is	O
a	O
substrate	O
,	O
a	O
moderate	O
inhibitor	O
,	O
and	O
an	O
inducer	O
of	O
CYP3A4	O
.	O

Aprepitant	S-drug
is	O
also	O
an	O
inducer	O
of	O
CYP2C9	O
.	O

Effect	O
of	O
aprepitant	S-drug
on	O
the	O
pharmacokinetics	O
of	O
other	O
agents	O

As	O
a	O
moderate	O
inhibitor	O
of	O
CYP3A4	O
,	O
aprepitant	S-drug
can	O
increase	O
plasma	O
concentrations	O
of	O
coadministered	O
medicinal	O
products	O
that	O
are	O
metabolized	O
through	O
CYP3A4	O
.	O

Aprepitant	S-drug-ME-1
has	O
been	O
shown	O
to	O
induce	O
the	O
metabolism	O
of	O
S	B-drug-ME-2
(	I-drug-ME-2
-	I-drug-ME-2
)	I-drug-ME-2
warfarin	E-drug-ME-2
and	O
tolbutamide	S-drug-ME-2
,	O
which	O
are	O
metabolized	O
through	O
CYP2C9	O
.	O

Coadministration	O
of	O
Aprepitant	S-drug-ME-1
with	O
these	O
drugs	O
or	O
other	O
drugs	O
that	O
are	O
known	O
to	O
be	O
metabolized	O
by	O
CYP2C9	O
,	O
such	O
as	O
phenytoin	S-drug-ME-2
,	O
may	O
result	O
in	O
lower	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
.	O

Aprepitant	S-drug
is	O
unlikely	O
to	O
interact	O
with	O
drugs	O
that	O
are	O
substrates	O
for	O
the	O
P	O
-	O
glycoprotein	O
transporter	O
,	O
as	O
demonstrated	O
by	O
the	O
lack	O
of	O
interaction	O
of	O
Aprepitant	S-drug
with	O
digoxin	S-drug
in	O
a	O
clinical	O
drug	O
interaction	O
study	O
.	O

5	B-group
-	I-group
HT3	I-group
antagonists	E-group
:	O
In	O
clinical	O
drug	O
interaction	O
studies	O
,	O
aprepitant	S-drug
did	O
not	O
have	O
clinically	O
important	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
ondansetron	S-drug
or	O
granisetron	S-drug
.	O

No	O
clinical	O
or	O
drug	O
interaction	O
study	O
was	O
conducted	O
with	O
dolasetron	S-drug
.	O

Corticosteroids	S-group
:	O
Dexamethasone	S-drug
:	O
Aprepitant	S-drug-ME-1
,	O
when	O
given	O
as	O
a	O
regimen	O
of	O
125mg	O
with	O
dexamethasone	S-drug-ME-2
coadministered	O
orally	O
as	O
20	O
mg	O
on	O
Day	O
1	O
,	O
and	O
Aprepitant	S-drug-ME-1
when	O
given	O
as	O
80	O
mg	O
/	O
day	O
with	O
dexamethasone	S-drug-ME-2
coadministered	O
orally	O
as	O
8	O
mg	O
on	O
Days	O
2	O
through	O
5	O
,	O
increased	O
the	O
AUC	O
of	O
dexamethasone	S-drug
,	O
a	O
CYP3A4	O
substrate	O
by	O
2.2	O
-	O
fold	O
,	O
on	O
Days	O
1	O
and	O
5	O
.	O

The	O
oral	O
dexamethasone	S-drug-AD-1
doses	O
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
when	O
coadministered	O
with	O
Aprepitant	S-drug-AD-2
,	O
to	O
achieve	O
exposures	O
of	O
dexamethasone	S-drug
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	S-drug
.	O

The	O
daily	O
dose	O
of	O
dexamethasone	S-drug-ME-1
administered	O
in	O
clinical	O
studies	O
with	O
Aprepitant	S-drug-ME-2
reflects	O
an	O
approximate	O
50	O
%	O
reduction	O
of	O
the	O
dose	O
of	O
dexamethasone	S-drug
.	O

Aprepitant	S-drug-ME-1
,	O
when	O
given	O
as	O
a	O
regimen	O
of	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
,	O
increased	O
the	O
AUC	O
of	O
methylprednisolone	S-drug-ME-2
,	O
a	O
CYP3A4	O
substrate	O
,	O
by	O
1.34	O
-	O
fold	O
on	O
Day	O
1	O
and	O
by	O
2.5	O
-	O
fold	O
on	O
Day	O
3	O
,	O
when	O
methylprednisolone	S-drug
was	O
coadministered	O
intravenously	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
orally	O
as	O
40	O
mg	O
on	O
Days	O
2	O
and	O
3	O
.	O

The	O
IV	O
methylprednisolone	S-drug-AD-1
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
25	O
%	O
,	O
and	O
the	O
oral	O
methylprednisolone	S-drug-AD-1
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
when	O
coadministered	O
with	O
Aprepitant	S-drug-AD-2
to	O
achieve	O
exposures	O
of	O
methylprednisolone	S-drug
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	S-drug
.	O

Warfarin	S-drug
:	O
A	O
single	O
125	O
-	O
mg	O
dose	O
of	O
Aprepitant	S-drug
was	O
administered	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
to	O
healthy	O
subjects	O
who	O
were	O
stabilized	O
on	O
chronic	O
warfarin	S-drug
therapy	O
.	O

Although	O
there	O
was	O
no	O
effect	O
of	O
Aprepitant	S-drug
on	O
the	O
plasma	O
AUC	O
of	O
R	B-drug
(	I-drug
+	I-drug
)	E-drug
or	O
S	B-drug
(	I-drug
-	I-drug
)	I-drug
warfarin	E-drug
determined	O
on	O
Day	O
3	O
,	O
there	O
was	O
a	O
34	O
%	O
decrease	O
in	O
S	B-drug-ME-1
(	I-drug-ME-1
-	I-drug-ME-1
)	I-drug-ME-1
warfarin	E-drug-ME-1
(	O
a	O
CYP2C9	O
substrate	O
)	O
trough	O
concentration	O
accompanied	O
by	O
a	O
14	O
%	O
decrease	O
in	O
the	O
prothrombin	O
time	O
(	O
reported	O
as	O
International	O
Normalized	O
Ratio	O
or	O
INR	O
)	O
5	O
days	O
after	O
completion	O
of	O
dosing	O
with	O
Aprepitant	S-drug-ME-2
.	O

In	O
patients	O
on	O
chronic	O
warfarin	S-drug-AD-1
therapy	O
,	O
the	O
prothrombin	O
time	O
(	O
INR	O
)	O
should	O
be	O
closely	O
monitored	O
in	O
the	O
2	O
-	O
week	O
period	O
,	O
particularly	O
at	O
7	O
to	O
10	O
days	O
,	O
following	O
initiation	O
of	O
the	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	S-drug-AD-2
with	O
each	O
chemotherapy	O
cycle	O
.	O

Tolbutamide	S-drug
:	O
Aprepitant	S-drug
,	O
when	O
given	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
,	O
decreased	O
the	O
AUC	O
of	O
tolbutamide	S-drug
(	O
a	O
CYP2C9	O
substrate	O
)	O
by	O
23	O
%	O
on	O
Day	O
4	O
,	O
28	O
%	O
on	O
Day	O
8	O
,	O
and	O
15	O
%	O
on	O
Day	O
15	O
,	O
when	O
a	O
single	O
dose	O
of	O
tolbutamide	S-drug-ME-1
500	O
mg	O
was	O
admini	O
,	O
stered	O
orally	O
prior	O
to	O
the	O
administration	O
of	O
the	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	S-drug-ME-2
and	O
on	O
Days	O
4,8	O
,	O
and	O
15	O
.	O

Oral	O
contraceptives	S-group
:	O
Aprepitant	S-drug-ME-1
,	O
when	O
given	O
once	O
daily	O
for	O
14	O
days	O
as	O
a	O
100	O
-	O
mg	O
capsule	O
with	O
an	O
oral	O
contraceptive	S-group
containing	O
35	O
mcg	O
of	O
ethinyl	B-drug-ME-2
estradiol	E-drug-ME-2
and	O
1	O
mg	O
of	O
norethindrone	S-drug-ME-2
,	O
decreased	O
the	O
AUC	O
of	O
ethinyl	B-drug
estradiol	E-drug
by	O
43	O
%	O
,	O
and	O
decreased	O
the	O
AUC	O
of	O
norethindrone	S-drug
by	O
8	O
%	O
;	O

therefore	O
,	O
the	O
efficacy	O
of	O
oral	O
contraceptives	S-group-EF-1
during	O
administration	O
of	O
Aprepitant	S-drug-EF-2
may	O
be	O
reduced	O
.	O

Although	O
a	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	S-drug-AD-1
given	O
concomitantly	O
with	O
oral	O
contraceptives	S-group-AD-2
has	O
not	O
been	O
studied	O
,	O
alternative	O
or	O
back	O
-	O
up	O
methods	O
of	O
contraception	O
should	O
be	O
used	O
.	O

Midazolam	S-drug
:	O
Aprepitant	S-drug-ME-1
increased	O
the	O
AUC	O
of	O
midazolam	S-drug-ME-2
,	O
a	O
sensitive	O
CYP3A4	O
substrate	O
,	O
by	O
2.3	O
-	O
fold	O
on	O
Day	O
1	O
and	O
3.3	O
-	O
fold	O
on	O
Day	O
5	O
,	O
when	O
a	O
single	O
oral	O
dose	O
of	O
midazolam	S-drug
2	O
mg	O
was	O
coadministered	O
on	O
Day	O
1	O
and	O
Day	O
5	O
of	O
a	O
regimen	O
of	O
Aprepitant	S-drug
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
through	O
5	O
.	O

The	O
potential	O
effects	O
of	O
increased	O
plasma	O
concentrations	O
of	O
midazolam	S-drug-AD-1
or	O
other	O
benzodiazepines	S-group-AD-1
metabolized	O
via	O
CYP3A4	O
(	O
alprazolam	S-drug-AD-1
,	O
triazolam	S-drug-AD-1
)	O
should	O
be	O
considered	O
when	O
coadministering	O
these	O
agents	O
with	O
Aprepitant	S-drug-AD-2
.	O

In	O
another	O
study	O
with	O
intravenous	O
administration	O
of	O
midazolam	S-drug
,	O
Aprepitant	S-drug
was	O
given	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
,	O
and	O
midazolam	S-drug
2	O
mg	O
IV	O
was	O
given	O
prior	O
to	O
the	O
administration	O
of	O
the	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	S-drug
and	O
on	O
Days	O
4	O
,	O
8	O
,	O
and	O
15	O
.	O

Aprepitant	S-drug-ME-1
increased	O
the	O
AUC	O
of	O
midazolam	S-drug-ME-2
by	O
25	O
%	O
on	O
Day	O
4	O
and	O
decreased	O
the	O
AUC	O
of	O
midazolam	S-drug-ME-2
by	O
19	O
%	O
on	O
Day	O
8	O
relative	O
to	O
the	O
dosing	O
of	O
Aprepitant	S-drug
on	O
Days	O
1	O
through	O
3	O
.	O

These	O
effects	O
were	O
not	O
considered	O
clinically	O
important	O
.	O

The	O
AUC	O
of	O
midazolam	S-drug
on	O
Day	O
15	O
was	O
similar	O
to	O
that	O
observed	O
at	O
baseline	O
.	O

Effect	O
of	O
other	O
agents	O
on	O
the	O
pharmacokinefics	O
of	O
aprepitant	S-drug

Aprepitant	S-drug
is	O
a	O
substrate	O
for	O
CYP3A4	O
;	O

therefore	O
,	O
coadministration	O
of	O
Aprepitant	S-drug
with	O
drugs	O
that	O
inhibit	O
CYP3A4	O
activity	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
aprepitant	S-drug
.	O

Consequently	O
,	O
concomitant	O
administration	O
of	O
Aprepitant	S-drug-AD-1
with	O
strong	O
CYP3A4	O
inhibitors	O
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug-AD-2
,	O
itraconazole	S-drug-AD-2
,	O
nefazodone	S-drug-AD-2
,	O
troleandomycin	S-drug-AD-2
,	O
clarithromycin	S-drug-AD-2
,	O
ritonavir	S-drug-AD-2
,	O
nelfinavir	S-drug-AD-2
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Because	O
moderate	O
CYP3A4	O
inhibitors	O
(	O
e.g	O
.	O
,	O
diltiazem	S-drug-AD-1
)	O
result	O
in	O
2	O
-	O
fold	O
increase	O
in	O
plasma	O
concentrations	O
of	O
aprepitant	S-drug-AD-2
,	O
concomitant	O
administration	O
should	O
also	O
be	O
approached	O
with	O
caution	O
.	O

Aprepitant	S-drug
is	O
a	O
substrate	O
for	O
CYP3A4	O
;	O

therefore	O
,	O
coadministration	O
of	O
Aprepitant	S-drug-ME-1
with	O
drugs	O
that	O
strongly	O
induce	O
CYP3A4	O
activity	O
(	O
e.g	O
.	O
,	O
rifampin	S-drug-ME-2
,	O
carbamazepine	S-drug
,	O
phenytoin	S-drug-ME-2
)	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
of	O
aprepitant	S-drug-ME-2
that	O
may	O
result	O
in	O
decreased	O
efficacy	O
of	O
Aprepitant	S-drug
.	O

Ketoconazole	S-drug
:	O
When	O
a	O
single	O
125	O
-	O
mg	O
dose	O
of	O
Aprepitant	S-drug
was	O
administered	O
on	O
Day5	O
of	O
a	O

Ketoconazole	S-drug
:	O
When	O
a	O
single	O
125	O
-	O
mg	O
dose	O
of	O
Aprepitant	S-drug-ME-1
was	O
administered	O
on	O
Day5	O
of	O
a	O
10	O
-	O
day	O
regimen	O
of	O
400	O
mg	O
/	O
day	O
of	O
ketoconazole	S-drug-ME-2
,	O
a	O
strong	O
CYP3A4	O
inhibitor	O
,	O
the	O
AUC	O
of	O
aprepitant	S-drug
increased	O
approximately	O
5	O
-	O
fold	O
and	O
the	O
mean	O
terminal	O
half	O
-	O
life	O
of	O
aprepitant	S-drug
increased	O
approximately	O
3	O
-	O
fold	O
.	O

Concomitant	O
administration	O
of	O
Aprepitant	S-drug
with	O
strong	O
CYP3A4	O
inhibitors	O
should	O
be	O
approached	O
cautiously	O
.	O

Rifampin	S-drug
:	O
When	O
a	O
single	O
375	O
-	O
mg	O
dose	O
of	O
Aprepitant	S-drug-ME-1
was	O
administered	O
on	O
Day9	O
of	O
a	O
14	O
-	O
day	O
regimen	O
of	O
600	O
mg	O
/	O
day	O
of	O
rifampin	S-drug-ME-2
,	O
a	O
strong	O
CYP3A4	O
inducer	O
,	O
the	O
AUC	O
of	O
aprepitant	S-drug
decreased	O
approximately	O
11	O
-	O
fold	O
and	O
the	O
mean	O
terminal	O
half	O
-	O
life	O
decreased	O
approximately	O
3	O
-	O
fold	O
.	O

Coadministration	O
of	O
Aprepitant	S-drug
with	O
drugs	O
that	O
induce	O
CYP3A4	O
activity	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
and	O
decreased	O
efficacy	O
of	O
Aprepitant	S-drug
.	O

Additional	O
interactions	O

Diltiazem	S-drug
:	O
In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
,	O
administration	O
of	O
aprepitant	S-drug-ME-1
once	O
daily	O
,	O
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
230	O
mg	O
of	O
the	O
capsule	O
formulation	O
,	O
with	O
diltiazem	S-drug-ME-2
120	O
mg	O
3	O
times	O
daily	O
for	O
5	O
days	O
,	O
resulted	O
in	O
a	O
2	O
-	O
fold	O
increase	O
of	O
aprepitant	S-drug
AUC	O
and	O
a	O
simultaneous	O
1.7	O
-	O
fold	O
increase	O
of	O
diltiazem	S-drug
AUC	O
.	O

These	O
pharmacokinetic	O
effects	O
did	O
not	O
result	O
in	O
clinically	O
meaningful	O
changes	O
in	O
ECG	O
,	O
heart	O
rate	O
or	O
blood	O
pressure	O
beyond	O
those	O
changes	O
induced	O
by	O
diltiazem	S-drug
alone	O
.	O

Paroxetine	S-drug
:	O
Coadministration	O
of	O
once	O
daily	O
doses	O
of	O
aprepitant	S-drug-ME-1
,	O
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
85	O
mg	O
or	O
170	O
mg	O
of	O
the	O
capsule	O
formulation	O
,	O
with	O
paroxetine	S-drug-ME-2
20	O
mg	O
once	O
daily	O
,	O
resulted	O
in	O
a	O
decrease	O
in	O
AUC	O
by	O
approximately	O
25	O
%	O
and	O
Cmax	O
,	O
by	O
approximately	O
20	O
%	O
of	O
both	O
aprepitant	S-drug
and	O
paroxetine	S-drug
.	O

Beta	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
:	O
concurrent	O
use	O
may	O
blunt	O
the	O
response	O
to	O
arbutamine	S-drug
.	O

Beta	B-group-AD-1
-	I-group-AD-1
adrenergic	I-group-AD-1
blocking	I-group-AD-1
agents	E-group-AD-1
should	O
be	O
withdrawn	O
at	O
least	O
48	O
hours	O
before	O
conducting	O
an	O
arbutamine	S-drug-AD-2
-	O
mediated	O
stress	O
test	O
.	O

Antiarrhythmic	B-drug
agents	I-drug
,	I-drug
class	I-drug
I	E-drug
(	O
such	O
as	O
flecainide	S-drug
,	O
lidocaine	S-drug
,	O
or	O
quinidine	S-drug
)	O
:	O
concurrent	O
use	O
with	O
arbutamine	S-drug
may	O
have	O
a	O
proarrhythmic	O
effect	O
.	O

Antidepressants	S-group
(	O
tricyclic	S-group
)	O
,	O
atropine	S-drug
or	O
other	O
anticholinergic	B-group
agents	E-group
,	O
or	O
digitalis	B-group
glycosides	E-group
:	O
concurrent	O
use	O
with	O
arbutamine	S-drug
may	O
produce	O
additive	O
inotropic	O
and	O
/	O
or	O
chronotropic	O
effects	O
.	O

Anticoagulants	S-group-EF-1
including	O
coumarin	O
derivatives	O
,	O
indandione	O
derivatives	O
,	O
and	O
platelet	B-group-EF-1
aggregation	I-group-EF-1
inhibitors	E-group-EF-1
such	O
as	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
(	O
NSAIDs	S-group-EF-1
)	O
,	O
and	O
aspirin	S-brand-EF-1
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
when	O
administered	O
concomitantly	O
with	O
ardeparin	S-drug-EF-2
.	O

If	O
additional	O
adrenergic	B-group-AD-1
drugs	E-group-AD-1
are	O
to	O
be	O
administered	O
by	O
any	O
route	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
pharmacologically	O
predictable	O
sympathetic	O
effects	O
of	O
BROVANA	S-brand-AD-2
may	O
be	O
potentiated	O
.	O

When	O
paroxetine	S-drug
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
was	O
co	O
-	O
administered	O
with	O
BROVANA	S-brand
at	O
steady	O
-	O
state	O
,	O
exposure	O
to	O
either	O
drug	O
was	O
not	O
altered	O
.	O

Dosage	O
adjustments	O
of	O
BROVANA	S-brand
are	O
not	O
necessary	O
when	O
the	O
drug	O
is	O
given	O
concomitantly	O
with	O
potent	O
CYP2D6	O
inhibitors	O
.	O

Concomitant	O
treatment	O
with	O
methylxanthines	S-group-EF-1
(	O
aminophylline	S-drug-EF-1
,	O
theophylline	S-drug-EF-1
)	O
,	O
steroids	S-group-EF-1
,	O
or	O
diuretics	S-group-EF-1
may	O
potentiate	O
any	O
hypokalemic	O
effect	O
of	O
adrenergic	B-group-EF-2
agonists	E-group-EF-2
.	O

The	O
ECG	O
changes	O
and	O
/	O
or	O
hypokalemia	O
that	O
may	O
result	O
from	O
the	O
administration	O
of	O
non	B-group-EF-1
-	I-group-EF-1
potassium	I-group-EF-1
sparing	I-group-EF-1
diuretics	E-group-EF-1
(	O
such	O
as	O
loop	S-group-EF-1
or	O
thiazide	B-group-EF-1
diuretics	E-group-EF-1
)	O
can	O
be	O
acutely	O
worsened	O
by	O
beta	B-group-EF-2
-	I-group-EF-2
agonists	E-group-EF-2
,	O
especially	O
when	O
the	O
recommended	O
dose	O
of	O
the	O
beta	B-group
-	I-group
agonist	E-group
is	O
exceeded	O
.	O

Although	O
the	O
clinical	O
significance	O
of	O
these	O
effects	O
is	O
not	O
known	O
,	O
caution	O
is	O
advised	O
in	O
the	O
co	O
-	O
administration	O
of	O
beta	B-group-AD-1
-	I-group-AD-1
agonists	E-group-AD-1
with	O
non	B-group-AD-2
-	I-group-AD-2
potassium	I-group-AD-2
sparing	I-group-AD-2
diuretics	E-group-AD-2
.	O

BROVANA	S-brand-AD-1
,	O
as	O
with	O
other	O
beta2	B-group-AD-1
-	I-group-AD-1
agonists	E-group-AD-1
,	O
should	O
be	O
administered	O
with	O
extreme	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
monoamine	B-group-MU-M
oxidase	I-group-MU-M
inhibitors	E-group-MU-M
,	O
tricyclic	B-group-MU-M
antidepressants	E-group-MU-M
,	O
or	O
drugs	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
because	O
the	O
action	O
of	O
adrenergic	B-group-EF-2
agonists	E-group-EF-2
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O

Drugs	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
have	O
an	O
increased	O
risk	O
of	O
ventricular	O
arrhythmias	O
.	O

The	O
concurrent	O
use	O
of	O
intravenously	O
or	O
orally	O
administered	O
methylxanthines	S-group
(	O
e.g	O
.	O
,	O
aminophylline	S-drug
,	O
theophylline	S-drug
)	O
by	O
patients	O
receiving	O
BROVANA	S-brand
has	O
not	O
been	O
completely	O
evaluated	O
.	O

In	O
two	O
combined	O
12	O
-	O
week	O
placebo	O
controlled	O
trials	O
that	O
included	O
BROVANA	S-brand
doses	O
of	O
15	O
mcg	O
twice	O
daily	O
,	O
25	O
mcg	O
twice	O
daily	O
,	O
and	O
50	O
mcg	O
once	O
daily	O
,	O
54	O
of	O
873	O
BROVANA	S-brand
-	O
treated	O
subjects	O
received	O
concomitant	O
theophylline	S-drug
at	O
study	O
entry	O
.	O

In	O
a	O
12	O
-	O
month	O
controlled	O
trial	O
that	O
included	O
a	O
50	O
mcg	O
once	O
daily	O
BROVANA	S-brand
dose	O
,	O
30	O
of	O
the	O
528	O
BROVANA	S-brand
-	O
treated	O
subjects	O
received	O
concomitant	O
theophylline	S-drug
at	O
study	O
entry	O
.	O

In	O
these	O
trials	O
,	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
were	O
approximately	O
2	O
-	O
3	O
bpm	O
and	O
6	O
-	O
8	O
mm	O
Hg	O
higher	O
,	O
respectively	O
,	O
in	O
subjects	O
on	O
concomitant	O
theophylline	S-drug
compared	O
with	O
the	O
overall	O
population	O
.	O

Beta	B-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
receptor	I-group-EF-1
antagonists	E-group-EF-1
(	O
beta	B-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
)	O
and	O
BROVANA	S-brand-EF-2
may	O
interfere	O
with	O
the	O
effect	O
of	O
each	O
other	O
when	O
administered	O
concurrently	O
.	O

Beta	B-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
not	O
only	O
block	O
the	O
therapeutic	O
effects	O
of	O
beta	B-group-EF-2
-	I-group-EF-2
agonists	E-group-EF-2
,	O
but	O
may	O
produce	O
severe	O
bronchospasm	O
in	O
COPD	O
patients	O
.	O

Therefore	O
,	O
patients	O
with	O
COPD	O
should	O
not	O
normally	O
be	O
treated	O
with	O
beta	B-group
-	I-group
blockers	E-group
.	O

However	O
,	O
under	O
certain	O
circumstances	O
,	O
e.g	O
.	O
,	O
as	O
prophylaxis	O
after	O
myocardial	O
infarction	O
,	O
there	O
may	O
be	O
no	O
acceptable	O
alternatives	O
to	O
the	O
use	O
of	O
beta	B-group
-	I-group
blockers	E-group
in	O
patients	O
with	O
COPD	O
.	O

In	O
this	O
setting	O
,	O
cardioselective	B-group
beta	I-group
-	I-group
blockers	E-group
could	O
be	O
considered	O
,	O
although	O
they	O
should	O
be	O
administered	O
with	O
caution	O
.	O

Heparin	S-drug
:	O
Since	O
heparin	S-drug
is	O
contraindicated	O
in	O
patients	O
with	O
heparin	S-drug
-	O
induced	O
thrombocytopenia	O
,	O
the	O
co	O
-	O
administration	O
of	O
Argatroban	S-drug
and	O
heparin	S-drug
is	O
unlikely	O
for	O
this	O
indication	O
.	O

However	O
,	O
if	O
Argatroban	S-drug
is	O
to	O
be	O
initiated	O
after	O
cessation	O
of	O
heparin	S-drug
therapy	O
,	O
allow	O
sufficient	O
time	O
for	O
heparins	O
effect	O
on	O
the	O
aPTT	O
to	O
decrease	O
prior	O
to	O
initiation	O
of	O
Argatroban	S-drug
therapy	O
.	O

Aspirin	S-brand
/	O
Acetaminophen	S-drug
:	O
Pharmacokinetic	O
or	O
pharmacodynamic	O
drug	O
-	O
drug	O
interactions	O
have	O
not	O
been	O
demonstrated	O
between	O
Argatroban	S-drug
and	O
concomitantly	O
administered	O
aspirin	S-brand
(	O
162.5	O
mg	O
orally	O
given	O
26	O
and	O
2	O
hours	O
prior	O
to	O
initiation	O
of	O
Argatroban	S-drug
1	O
g	O
/	O
kg	O
/	O
min	O
.	O
over	O
4	O
hours	O
)	O
or	O
acetaminophen	S-drug
(	O
1000	O
mg	O
orally	O
given	O
12	O
,	O
6	O
and	O
0	O
hours	O
prior	O
to	O
,	O
and	O
6	O
and	O
12	O
hours	O
subsequent	O
to	O
,	O
initiation	O
of	O
Argatroban	S-drug
1.5	O
g	O
/	O
kg	O
/	O
min	O
.	O
over	O
18	O
hours	O
)	O
.	O

Oral	O
anticoagulant	B-group
agents	E-group
:	O
Pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
Argatroban	S-drug
and	O
warfarin	S-drug
(	O
7.5	O
mg	O
single	O
oral	O
dose	O
)	O
have	O
not	O
been	O
demonstrated	O
.	O

However	O
,	O
the	O
concomitant	O
use	O
of	O
Argatroban	S-drug-EF-1
and	O
warfarin	S-drug-EF-2
(	O
5	O
-	O
7.5	O
mg	O
initial	O
oral	O
dose	O
followed	O
by	O
2.5	O
-	O
6	O
mg	O
/	O
day	O
orally	O
for	O
6	O
-	O
10	O
days	O
)	O
results	O
in	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
.	O

Thrombolytic	B-group
agents	E-group
:	O
The	O
safety	O
and	O
effectiveness	O
of	O
Argatroban	S-drug
with	O
thrombolytic	B-group
agents	E-group
have	O
not	O
been	O
established	O
.	O

Co	O
-	O
administration	O
:	O
Concomitant	O
use	O
of	O
Argatroban	S-drug-EF-1
with	O
antiplatelet	B-group-EF-2
agents	E-group-EF-2
,	O
thrombolytics	S-group-EF-2
,	O
and	O
other	O
anticoagulants	S-group-EF-2
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

Drug	O
-	O
drug	O
interactions	O
have	O
not	O
been	O
observed	O
between	O
Argatroban	S-drug
and	O
digoxin	S-drug
or	O
erythromycin	S-drug
.	O

Drug	O
-	O
Drug	O
Interactions	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
aripiprazole	S-drug
,	O
caution	O
should	O
be	O
used	O
when	O
ABILIFY	S-brand-AD-1
is	O
taken	O
in	O
combination	O
with	O
other	O
centrally	B-group-AD-2
acting	I-group-AD-2
drugs	E-group-AD-2
and	O
alcohol	S-drug-AD-2
.	O

Due	O
to	O
its	O

1	O
-	O
adrenergic	O
receptor	O
antagonism	O
,	O
aripiprazole	S-drug-EF-1
has	O
the	O
potential	O
to	O
enhance	O
the	O
effect	O
of	O
certain	O
antihypertensive	B-group-EF-2
agents	E-group-EF-2
.	O

Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
ABILIFY	S-brand
Aripiprazole	S-brand
is	O
not	O
a	O
substrate	O
of	O
CYP1A1	O
,	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2B6	O
,	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
or	O
CYP2E1	O
enzymes	O
.	O

Aripiprazole	S-drug
also	O
does	O
not	O
undergo	O
direct	O
glucuronidation	O
.	O

This	O
suggests	O
that	O
an	O
interaction	O
of	O
aripiprazole	S-drug
with	O
inhibitors	O
or	O
inducers	O
of	O
these	O
enzymes	O
,	O
or	O
other	O
factors	O
,	O
like	O
smoking	O
,	O
is	O
unlikely	O
.	O

Both	O
CYP3A4	O
and	O
CYP2D6	O
are	O
responsible	O
for	O
aripiprazole	S-drug
metabolism	O
.	O

Agents	O
that	O
induce	O
CYP3A4	O
(	O
eg	O
,	O
carbamazepine	S-drug-ME-1
)	O
could	O
cause	O
an	O
increase	O
in	O
aripiprazole	S-drug-ME-2
clearance	O
and	O
lower	O
blood	O
levels	O
.	O

Inhibitors	O
of	O
CYP3A4	O
(	O
eg	O
,	O
ketoconazole	S-drug-ME-1
)	O
or	O
CYP2D6	O
(	O
eg	O
,	O
quinidine	S-drug-ME-1
,	O
fluoxetine	S-drug-ME-1
,	O
or	O
paroxetine	S-drug-ME-1
)	O
can	O
inhibit	O
aripiprazole	S-drug-ME-2
elimination	O
and	O
cause	O
increased	O
blood	O
levels	O
.	O

Ketoconazole	S-drug
:	O
Coadministration	O
of	O
ketoconazole	S-drug-ME-1
(	O
200	O
mg	O
/	O
day	O
for	O
14	O
days	O
)	O
with	O
a	O
15	O
-	O
mg	O
single	O
dose	O
of	O
aripiprazole	S-drug-ME-2
increased	O
the	O
AUC	O
of	O
aripiprazole	S-drug
and	O
its	O
active	O
metabolite	O
by	O
63	O
%	O
and	O
77	O
%	O
,	O
respectively	O
.	O

The	O
effect	O
of	O
a	O
higher	O
ketoconazole	S-drug
dose	O
(	O
400	O
mg	O
/	O
day	O
)	O
has	O
not	O
been	O
studied	O
.	O

When	O
concomitant	O
administration	O
of	O
ketoconazole	S-drug-AD-1
with	O
aripiprazole	S-drug-AD-2
occurs	O
,	O
aripiprazole	S-drug
dose	O
should	O
be	O
reduced	O
to	O
one	O
-	O
half	O
of	O
its	O
normal	O
dose	O
.	O

Other	O
strong	O
inhibitors	O
of	O
CYP3A4	O
(	O
itraconazole	S-drug
)	O
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
need	O
similar	O
dose	O
reductions	O
;	O

weaker	O
inhibitors	O
(	O
erythromycin	S-drug
,	O
grapefruit	O
juice	O
)	O
have	O
not	O
been	O
studied	O
.	O

When	O
the	O
CYP3A4	O
inhibitor	O
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
,	O
aripiprazole	S-drug
dose	O
should	O
then	O
be	O
increased	O
.	O

Quinidine	S-drug
:	O
Coadministration	O
of	O
a	O
10	O
-	O
mg	O
single	O
dose	O
of	O
aripiprazole	S-drug-ME-1
with	O
quinidine	S-drug-ME-2
(	O
166	O
mg	O
/	O
day	O
for	O
13	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
increased	O
the	O
AUC	O
of	O
aripiprazole	S-drug
by	O
112	O
%	O
but	O
decreased	O
the	O
AUC	O
of	O
its	O
active	O
metabolite	O
,	O
dehydroaripiprazole	S-drug_n
,	O
by	O
35	O
%	O
.	O

Aripiprazole	S-drug
dose	O
should	O
be	O
reduced	O
to	O
one	O
-	O
half	O
of	O
its	O
normal	O
dose	O
when	O
concomitant	O
administration	O
of	O
quinidine	S-drug-AD-1
with	O
aripiprazole	S-drug-AD-2
occurs	O
.	O

Other	O
significant	O
inhibitors	O
of	O
CYP2D6	O
,	O
such	O
as	O
fluoxetine	S-drug
or	O
paroxetine	S-drug
,	O
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
,	O
therefore	O
,	O
should	O
be	O
accompanied	O
by	O
similar	O
dose	O
reductions	O
.	O

When	O
the	O
CYP2D6	O
inhibitor	O
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
,	O
aripiprazole	S-drug
dose	O
should	O
then	O
be	O
increased	O
.	O

Carbamazepine	S-drug
:	O
Coadministration	O
of	O
carbamazepine	S-drug-ME-1
(	O
200	O
mg	O
BID	O
)	O
,	O
a	O
potent	O
CYP3A4	O
inducer	O
,	O
with	O
aripiprazole	S-drug-ME-2
(	O
30	O
mg	O
QD	O
)	O
resulted	O
in	O
an	O
approximate	O
70	O
%	O
decrease	O
in	O
Cmax	O
and	O
AUC	O
values	O
of	O
both	O
aripiprazole	S-drug
and	O
its	O
active	O
metabolite	O
,	O
dehydro	B-drug_n
-	I-drug_n
aripiprazole	E-drug_n
.	O

When	O
carbamazepine	S-drug-AD-1
is	O
added	O
to	O
aripiprazole	S-drug-AD-2
therapy	O
,	O
aripiprazole	S-drug
dose	O
should	O
be	O
doubled	O
.	O

Additional	O
dose	O
increases	O
should	O
be	O
based	O
on	O
clinical	O
evaluation	O
.	O

When	O
carbamazepine	S-drug-AD-1
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
,	O
aripiprazole	S-drug-AD-2
dose	O
should	O
then	O
be	O
reduced	O
.	O

No	O
clinically	O
significant	O
effect	O
of	O
famotidine	S-drug
,	O
valproate	S-drug
,	O
or	O
lithium	S-drug
was	O
seen	O
on	O
the	O
pharmacokinetics	O
of	O
aripiprazole	S-drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
-	O
Drug	O
Interactions	O
)	O
.	O

Potential	O
for	O
ABILIFY	S-brand
to	O
Affect	O
Other	O
Drugs	O
Aripiprazole	S-drug
is	O
unlikely	O
to	O
cause	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
enzymes	O
.	O

In	O
in	O
vivo	O
studies	O
,	O
10	O
-	O
to	O
30	O
-	O
mg	O
/	O
day	O
doses	O
of	O
aripiprazole	S-drug
had	O
no	O
significant	O
effect	O
on	O
metabolism	O
by	O
CYP2D6	O
(	O
dextromethorphan	S-drug
)	O
,	O
CYP2C9	O
(	O
warfarin	S-drug
)	O
,	O
CYP2C19	O
(	O
omeprazole	S-drug
,	O
warfarin	S-drug
)	O
,	O
and	O
CYP3A4	O
(	O
dextromethorphan	S-drug
)	O
substrates	O
.	O

Additionally	O
,	O
aripiprazole	S-drug
and	O
dehydroaripiprazole	S-drug_n
did	O
not	O
show	O
potential	O
for	O
altering	O
CYP1A2	O
-	O
mediated	O
metabolism	O
in	O
vitro	O
.	O

Alcohol	S-drug
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
aripiprazole	S-drug
coadministered	O
with	O
ethanol	S-drug
and	O
placebo	O
coadministered	O
with	O
ethanol	S-drug
on	O
performance	O
of	O
gross	O
motor	O
skills	O
or	O
stimulus	O
response	O
in	O
healthy	O
subjects	O
.	O

As	O
with	O
most	O
psychoactive	O
medications	O
,	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
alcohol	S-drug-AD-1
while	O
taking	O
ABILIFY	S-brand-AD-2

No	O
formal	O
assessments	O
of	O
pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
TRISENOX	S-brand
and	O
other	O
agents	O
have	O
been	O
conducted	O
.	O

Caution	O
is	O
advised	O
when	O
TRISENOX	S-brand-AD-1
is	O
coadministered	O
with	O
other	O
medications	O
that	O
can	O
prolong	O
the	O
QT	O
interval	O
(	O
e.g	O
.	O
certain	O
antiarrhythmics	S-group-AD-2
or	O
thioridazine	S-drug-AD-2
)	O
or	O
lead	O
to	O
electrolyte	O
abnormalities	O
(	O
such	O
as	O
diuretics	S-group-AD-2
or	O
amphotericin	B-drug-AD-2
B	E-drug-AD-2
)	O
.	O

Tissue	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
ELSPAR	S-brand-EF-1
can	O
diminish	O
or	O
abolish	O
the	O
effect	O
of	O
methotrexate	S-drug-EF-2
on	O
malignant	O
cells.14	O
This	O
effect	O
on	O
methotrexate	S-drug
activity	O
persists	O
as	O
long	O
as	O
plasma	O
asparagine	O
levels	O
are	O
suppressed	O
.	O

These	O
results	O
would	O
seem	O
to	O
dictate	O
against	O
the	O
clinical	O
use	O
of	O
methotrexate	S-drug-AD-1
with	O
ELSPAR	S-brand-AD-2
,	O
or	O
during	O
the	O
period	O
following	O
ELSPAR	S-brand
therapy	O
when	O
plasma	O
asparagine	O
levels	O
are	O
below	O
normal	O
.	O

Uricosuric	B-group
Agents	E-group
:	O
Aspirin	S-brand-EF-1
may	O
decrease	O
the	O
effects	O
of	O
probenecid	S-drug-EF-2
,	O
sulfinpyrazone	S-drug-EF-2
,	O
and	O
phenylbutazone	S-drug-EF-2
.	O

Alcohol	S-drug-EF-1
:	O
Has	O
a	O
synergistic	O
effect	O
with	O
aspirin	S-brand-EF-2
in	O
causing	O
gastrointestinal	O
bleeding	O
.	O

Corticosteroids	S-group-EF-1
:	O
Concomitant	O
administration	O
with	O
aspirin	S-brand-EF-2
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
and	O
may	O
reduce	O
serum	O
salicylate	O
levels	O
.	O

Pyrazolone	B-group-EF-1
Derivatives	E-group-EF-1
(	O
phenylbutazone	S-drug-EF-1
,	O
oxyphenbutazone	S-drug-EF-1
,	O
and	O
possibly	O
dipyrone	S-drug-EF-1
)	O
:	O
Concomitant	O
administration	O
with	O
aspirin	S-drug-EF-2
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
.	O

Nonsteroidal	B-drug
Antiinflammatory	E-drug
Agents	O
:	O
Aspirin	S-drug-AD-1
is	O
contraindicated	O
in	O
patients	O
who	O
are	O
hypersensitive	O
to	O
nonsteroidal	B-drug-AD-2
anti	I-drug-AD-2
-	I-drug-AD-2
inflammatory	E-drug-AD-2
agents	O
.	O

Urinary	O
Alkalinizers	O
:	O
Decrease	O
aspirin	S-brand
effectiveness	O
by	O
increasing	O
the	O
rate	O
of	O
salicylate	S-group
renal	O
excretion	O
.	O

Phenobarbital	S-drug-ME-1
:	O
Decreases	O
aspirin	S-brand-ME-2
effectiveness	O
by	O
enzyme	O
induction	O
.	O

Phenytoin	S-drug
:	O
Serum	O
phenytoin	S-drug-EF-1
levels	O
may	O
be	O
increased	O
by	O
aspirin	S-brand-EF-2
.	O

Propranolol	S-drug-EF-1
:	O
May	O
decrease	O
aspirins	S-brand-EF-2
anti	O
-	O
inflammatory	O
action	O
by	O
competing	O
for	O
the	O
same	O
receptors	O
.	O

Antacids	S-group
:	O
Enteric	O
Coated	O
Aspirin	S-brand-AD-1
should	O
not	O
be	O
given	O
concurrently	O
with	O
antacids	S-group-AD-2
,	O
since	O
an	O
increase	O
in	O
the	O
pH	O
of	O
the	O
stomach	O
may	O
effect	O
the	O
enteric	O
coating	O
of	O
the	O
tablets	O
.	O

Ketoconazole	S-drug
/	O
Itraconazole	S-drug
,	O
Macrolides	S-group
,	O
Including	O
Erythromycin	S-drug

Catecholamine	O
-	O
depleting	O
drugs	O
(	O
eg	O
,	O
reserpine	S-drug-EF-1
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agents	O
.	O

Patients	O
treated	O
with	O
TENORMIN	S-brand
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Calcium	B-group-EF-1
channel	I-group-EF-1
blockers	E-group-EF-1
may	O
also	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
TENORMIN	S-brand-EF-2
.	O

Beta	B-group-EF-1
blockers	E-group-EF-1
may	O
exacerbate	O
the	O
rebound	O
hypertension	O
which	O
can	O
follow	O
the	O
withdrawal	O
of	O
clonidine	S-drug-EF-2
.	O

If	O
the	O
two	O
drugs	O
are	O
coadministered	O
,	O
the	O
beta	B-group-AD-1
blocker	E-group-AD-1
should	O
be	O
withdrawn	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	S-drug-AD-2
.	O

If	O
replacing	O
clonidine	S-drug
by	O
beta	B-group
-	I-group
blocker	E-group
therapy	O
,	O
the	O
introduction	O
of	O
beta	B-group-AD-1
blockers	E-group-AD-1
should	O
be	O
delayed	O
for	O
several	O
days	O
after	O
clonidine	S-drug-AD-2
administration	O
has	O
stopped	O
.	O

Concomitant	O
use	O
of	O
prostaglandin	O
synthase	O
inhibiting	O
drugs	O
,	O
eg	O
,	O
indomethacin	S-drug-EF-1
,	O
may	O
decrease	O
the	O
hypotensive	O
effects	O
of	O
beta	B-group-EF-2
blockers	E-group-EF-2
.	O

Information	O
on	O
concurrent	O
usage	O
of	O
atenolol	S-drug
and	O
aspirin	S-brand
is	O
limited	O
.	O

Data	O
from	O
several	O
studies	O
,	O
ie	O
,	O
TIMI	O
-	O
II	O
,	O
ISIS	O
-	O
2	O
,	O
currently	O
do	O
not	O
suggest	O
any	O
clinical	O
interaction	O
between	O
aspirin	S-brand
and	O
beta	B-group
blockers	E-group
in	O
the	O
acute	O
myocardial	O
infarction	O
setting	O
.	O

While	O
taking	O
beta	B-group
blockers	E-group
,	O
patients	O
with	O
a	O
history	O
of	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
have	O
a	O
more	O
severe	O
reaction	O
on	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	S-drug
used	O
to	O
treat	O
the	O
allergic	O
reaction	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
Albuterol	S-drug
-	O
STRATTERA	S-brand-AD-1
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
systemically	O
-	O
administered	O
(	O
oral	O
or	O
intravenous	O
)	O
albuterol	S-drug-AD-2
(	O
or	O
other	O
beta2	B-group
agonists	E-group
)	O
because	O
the	O
action	O
of	O
albuterol	S-drug
on	O
the	O
cardiovascular	O
system	O
can	O
be	O
potentiated	O
resulting	O
in	O
increases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O

CYP2D6	O
inhibitors	O
-	O
Atomoxetine	S-drug
is	O
primarily	O
metabolized	O
by	O
the	O
CYP2D6	O
pathway	O
to	O
4	B-drug_n
-	I-drug_n
hydroxyatomoxetine	E-drug_n
.	O

In	O
EMs	O
,	O
selective	O
inhibitors	O
of	O
CYP2D6	O
increase	O
atomoxetine	S-drug
steady	O
-	O
state	O
plasma	O
concentrations	O
to	O
exposures	O
similar	O
to	O
those	O
observed	O
in	O
PMs	O
.	O

Dosage	O
adjustment	O
of	O
STRATTERA	S-brand-AD-1
may	O
be	O
necessary	O
when	O
coadministered	O
with	O
CYP2D6	O
inhibitors	O
,	O
e.g	O
.	O
,	O
paroxetine	S-drug-AD-2
,	O
fluoxetine	S-drug-AD-2
,	O
and	O
quinidine	S-drug-AD-2
.	O

In	O
EM	O
individuals	O
treated	O
with	O
paroxetine	S-drug-ME-1
or	O
fluoxetine	S-drug-ME-1
,	O
the	O
AUC	O
of	O
atomoxetine	S-drug-ME-2
is	O
approximately	O
6	O
-	O
to	O
8	O
-	O
fold	O
and	O
Css	O
,	O
max	O
is	O
about	O
3	O
-	O
to	O
4	O
-	O
fold	O
greater	O
than	O
atomoxetine	S-drug
alone	O
.	O

In	O
vitro	O
studies	O
suggest	O
that	O
coadministration	O
of	O
cytochrome	O
P450	O
inhibitors	O
to	O
PMs	O
will	O
not	O
increase	O
the	O
plasma	O
concentrations	O
of	O
atomoxetine	S-drug
.	O

Pressor	O
agents	O
-	O
Because	O
of	O
possible	O
effects	O
on	O
blood	O
pressure	O
,	O
STRATTERA	S-brand
should	O
be	O
used	O
cautiously	O
with	O
pressor	O
agents	O
.	O

The	O
risk	O
of	O
myopathy	O
during	O
treatment	O
with	O
drugs	O
of	O
this	O
class	O
is	O
increased	O
with	O
concurrent	O
administration	O
of	O
cyclosporine	S-drug
,	O
fibric	B-group
acid	I-group
derivatives	E-group
,	O
niacin	S-drug
(	O
nicotinic	B-drug
acid	E-drug
)	O
,	O
erythromycin	S-drug
,	O
azole	B-group
antifungals	E-group
.	O

Antacid	S-group
:	O
When	O
atorvastatin	S-drug-ME-1
and	O
Maalox	B-brand-ME-2
TC	E-brand-ME-2
suspension	O
were	O
coadministered	O
,	O
plasma	O
concentrations	O
of	O
atorvastatin	S-drug
decreased	O
approximately	O
35	O
%	O
.	O

However	O
,	O
LDL	O
-	O
C	O
reduction	O
was	O
not	O
altered	O
.	O

Antipyrine	S-drug
:	O
Because	O
atorvastatin	S-drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
antipyrine	S-drug
,	O
interactions	O
with	O
other	O
drugs	S-drug
metabolized	O
via	O
the	O
same	O
cytochrome	O
isozymes	O
are	O
not	O
expected	O
.	O

Colestipol	S-drug
:	O
Plasma	O
concentrations	O
of	O
atorvastatin	S-drug
decreased	O
approximately	O
25	O
%	O
when	O
colestipol	S-drug-ME-1
and	O
atorvastatin	S-drug-ME-2
were	O
coadministered	O
.	O

However	O
,	O
LDL	O
-	O
C	O
reduction	O
was	O
greater	O
when	O
atorvastatin	S-drug-EF-1
and	O
colestipol	S-drug-EF-2
were	O
coadministered	O
than	O
when	O
either	O
drug	O
was	O
given	O
alone	O
.	O

Cimetidine	S-drug
:	O
Atorvastatin	S-drug
plasma	O
concentrations	O
and	O
LDL	O
-	O
C	O
reduction	O
were	O
not	O
altered	O
by	O
coadministration	O
of	O
cimetidine	S-drug
.	O

Digoxin	S-drug
:	O
When	O
multiple	O
doses	O
of	O
atorvastatin	S-drug-ME-1
and	O
digoxin	S-drug-ME-2
were	O
coadministered	O
,	O
steady	O
-	O
state	O
plasma	O
digoxin	S-drug
concentrations	O
increased	O
by	O
approximately	O
20	O
%	O
.	O

Patients	O
taking	O
digoxin	S-drug
should	O
be	O
monitored	O
appropriately	O
.	O

Erythromycin	S-drug
:	O
In	O
healthy	O
individuals	O
,	O
plasma	O
concentrations	O
of	O
atorvastatin	S-drug
increased	O
approximately	O
40	O
%	O
with	O
coadministration	O
of	O
atorvastatin	S-drug-ME-1
and	O
erythromycin	S-drug-ME-2
,	O
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
.	O

Oral	O
Contraceptives	S-group
:	O
Coadministration	O
of	O
atorvastatin	S-drug-ME-1
and	O
an	O
oral	O
contraceptive	S-group-ME-2
increased	O
AUC	O
values	O
for	O
norethindrone	S-drug-ME-2
and	O
ethinyl	B-drug-ME-2
estradiol	E-drug-ME-2
by	O
approximately	O
30	O
%	O
and	O
20	O
%	O
.	O

These	O
increases	O
should	O
be	O
considered	O
when	O
selecting	O
an	O
oral	O
contraceptive	S-group-AD-1
for	O
a	O
woman	O
taking	O
atorvastatin	S-drug-AD-2
.	O

Warfarin	S-drug
:	O
Atorvastatin	S-drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
prothrombin	O
time	O
when	O
administered	O
to	O
patients	O
receiving	O
chronic	O
warfarin	S-drug
treatment	O
.	O

Endocrine	O
Function	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
interfere	O
with	O
cholesterol	O
synthesis	O
and	O
theoretically	O
might	O
blunt	O
adrenal	O
and	O
/	O
or	O
gonadal	O
steroid	O
production	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
atorvastatin	S-drug
does	O
not	O
reduce	O
basal	O
plasma	O
cortisol	O
concentration	O
or	O
impair	O
adrenal	O
reserve	O
.	O

The	O
effects	O
of	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
on	O
male	O
fertility	O
have	O
not	O
been	O
studied	O
in	O
adequate	O
numbers	O
of	O
patients	O
.	O

The	O
effects	O
,	O
if	O
any	O
,	O
on	O
the	O
pituitary	O
-	O
gonadal	O
axis	O
in	O
premenopausal	O
women	O
are	O
unknown	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
an	O
HMG	B-group-AD-1
-	I-group-AD-1
CoA	I-group-AD-1
reductase	I-group-AD-1
inhibitor	E-group-AD-1
is	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
may	O
decrease	O
the	O
levels	O
or	O
activity	O
of	O
endogenous	O
steroid	O
hormones	O
,	O
such	O
as	O
ketoconazole	S-drug-AD-2
,	O
spironolactone	S-drug-AD-2
,	O
and	O
cimetidine	S-drug-AD-2
.	O

CNS	O
Toxicity	O
Brain	O
hemorrhage	O
was	O
seen	O
in	O
a	O
female	O
dog	O
treated	O
for	O
3	O
months	O
at	O
120	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Brain	O
hemorrhage	O
and	O
optic	O
nerve	O
vacuolation	O
were	O
seen	O
in	O
another	O
female	O
dog	O
that	O
was	O
sacrificed	O
in	O
moribund	O
condition	O
after	O
11	O
weeks	O
of	O
escalating	O
doses	O
up	O
to	O
280	O
mg	O
/	O
kg	O
/	O
day	O
.	O

The	O
120	O
mg	O
/	O
kg	O
dose	O
resulted	O
in	O
a	O
systemic	O
exposure	O
approximately	O
16	O
times	O
the	O
human	O
plasma	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
(	O
AUC	O
,	O
0	O
-	O
24	O
hours	O
)	O
based	O
on	O
the	O
maximum	O
human	O
dose	O
of	O
80	O
mg	O
/	O
day	O
.	O

A	O
single	O
tonic	O
convulsion	O
was	O
seen	O
in	O
each	O
of	O
2	O
male	O
dogs	O
(	O
one	O
treated	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
and	O
one	O
at	O
120	O
mg	O
/	O
kg	O
/	O
day	O
)	O
in	O
a	O
2	O
-	O
year	O
study	O
.	O

No	O
CNS	O
lesions	O
have	O
been	O
observed	O
in	O
mice	O
after	O
chronic	O
treatment	O
for	O
up	O
to	O
2	O
years	O
at	O
doses	O
up	O
to	O
400	O
mg	O
/	O
kg	O
/	O
day	O
or	O
in	O
rats	O
at	O
doses	O
up	O
to	O
100	O
mg	O
/	O
kg	O
/	O
day	O
.	O

These	O
doses	O
were	O
6	O
to	O
11	O
times	O
(	O
mouse	O
)	O
and	O
8	O
to	O
16	O
times	O
(	O
rat	O
)	O
the	O
human	O
AUC	O
(	O
0	O
-	O
24	O
)	O
based	O
on	O
the	O
maximum	O
recommended	O
human	O
dose	O
of	O
80	O
mg	O
/	O
day	O
.	O

CNS	O
vascular	O
lesions	O
,	O
characterized	O
by	O
perivascular	O
hemorrhages	O
,	O
edema	O
,	O
and	O
mononuclear	O
cell	O
infiltration	O
of	O
perivascular	O
spaces	O
,	O
have	O
been	O
observed	O
in	O
dogs	O
treated	O
with	O
other	O
members	O
of	O
this	O
class	O
.	O

A	O
chemically	O
similar	O
drug	O
in	O
this	O
class	O
produced	O
optic	O
nerve	O
degeneration	O
(	O
Wallerian	O
degeneration	O
of	O
retinogeniculate	O
fibers	O
)	O
in	O
clinically	O
normal	O
dogs	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
at	O
a	O
dose	O
that	O
produced	O
plasma	O
drug	O
levels	O
about	O
30	O
times	O
higher	O
than	O
the	O
mean	O
drug	O
level	O
in	O
humans	O
taking	O
the	O
highest	O
recommended	O
dose	O
.	O

Atovaquone	S-drug
is	O
highly	O
bound	O
to	O
plasma	O
protein	O
(	O
99.9	O
%	O
)	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
MEPRON	S-brand
concurrently	O
with	O
other	O
highly	O
plasma	O
protein	O
-	O
bound	O
drugs	O
with	O
narrow	O
therapeutic	O
indices	O
,	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
.	O

The	O
extent	O
of	O
plasma	O
protein	O
binding	O
of	O
atovaquone	S-drug
in	O
human	O
plasma	O
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
therapeutic	O
concentrations	O
of	O
phenytoin	S-drug
(	O
15	O
mcg	O
/	O
mL	O
)	O
,	O
nor	O
is	O
the	O
binding	O
of	O
phenytoin	S-drug
affected	O
by	O
the	O
presence	O
of	O
atovaquone	S-drug
.	O

Rifampin	S-drug
:	O
Coadministration	O
of	O
rifampin	S-drug-ME-1
and	O
MEPRON	S-brand-ME-2
Suspension	O
results	O
in	O
a	O
significant	O
decrease	O
in	O
average	O
steady	O
-	O
state	O
plasma	O
atovaquone	S-drug
concentrations	O
.	O

Alternatives	O
to	O
rifampin	S-drug-AD-1
should	O
be	O
considered	O
during	O
the	O
course	O
of	O
PCP	O
treatment	O
with	O
MEPRON	S-brand-AD-2
.	O

Rifabutin	S-drug
,	O
another	O
rifamycin	S-drug
,	O
is	O
structurally	O
similar	O
to	O
rifampin	S-drug
and	O
may	O
possibly	O
have	O
some	O
of	O
the	O
same	O
drug	O
interactions	O
as	O
rifampin	S-drug
.	O

No	O
interaction	O
trials	O
have	O
been	O
conducted	O
with	O
MEPRON	S-brand
and	O
rifabutin	S-drug
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
It	O
is	O
not	O
known	O
if	O
MEPRON	S-brand
interferes	O
with	O
clinical	O
laboratory	O
test	O
or	O
assay	O
results	O
.	O

Drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	S-brand-EF-1
include	O
:	O
enflurane	S-drug-EF-2
;	O

isoflurane	S-drug
;	O

halothane	S-drug
;	O

certain	O
antibiotics	S-group
,	O
especially	O
the	O
aminoglycosides	S-group
and	O
polymyxins	S-group
;	O

lithium	S-drug
;	O

magnesium	S-drug
salts	O
;	O

procainamide	S-drug
;	O

Drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	S-brand-EF-1
include	O
:	O
enflurane	S-drug-EF-2
;	O
isoflurane	S-drug-EF-2
;	O
halothane	S-drug-EF-2
;	O
certain	O
antibiotics	S-group-EF-2
,	O
especially	O
the	O
aminoglycosides	S-group-EF-2
and	O
polymyxins	S-group-EF-2
;	O
lithium	S-drug-EF-2
;	O
magnesium	S-drug-EF-2
salts	O
;	O
procainamide	S-drug-EF-2
;	O
and	O
quinidine	S-drug-EF-2
.	O

If	O
other	O
muscle	B-group
relaxants	E-group
are	O
used	O
during	O
the	O
same	O
procedure	O
,	O
the	O
possibility	O
of	O
a	O
synergistic	O
or	O
antagonist	O
effect	O
should	O
be	O
considered	O
.	O

The	O
prior	O
administration	O
of	O
succinylcholine	S-drug-EF-1
does	O
not	O
enhance	O
the	O
duration	O
,	O
but	O
quickens	O
the	O
onset	O
and	O
may	O
increase	O
the	O
depth	O
,	O
of	O
neuromuscular	O
block	O
induced	O
by	O
TRACRIUM	S-brand-EF-2
.	O

TRACRIUM	S-brand-AD-1
should	O
not	O
be	O
administered	O
until	O
a	O
patient	O
has	O
recovered	O
from	O
succinylcholine	S-drug-AD-2
-	O
induced	O
neuromuscular	O
block	O
.	O

When	O
atropine	S-drug-EF-1
and	O
pralidoxime	S-drug-EF-2
are	O
used	O
together	O
,	O
the	O
signs	O
of	O
atropinization	O
(	O
flushing	O
,	O
mydriasis	O
,	O
tachycardia	O
,	O
dryness	O
of	O
the	O
mouth	O
and	O
nose	O
)	O
may	O
occur	O
earlier	O
than	O
might	O
be	O
expected	O
than	O
when	O
atropine	S-drug
is	O
used	O
alone	O
because	O
pralidoxime	S-drug-EF-1
may	O
potentiate	O
the	O
effect	O
of	O
atropine	S-drug-EF-2
.	O

The	O
following	O
precautions	O
should	O
be	O
kept	O
in	O
mind	O
in	O
the	O
treatment	O
of	O
anticholinesterase	O
poisoning	O
although	O
they	O
do	O
not	O
bear	O
directly	O
on	O
the	O
use	O
of	O
atropine	S-drug-AD-1
and	O
pralidoxime	S-drug-AD-2
.	O

Since	O
barbiturates	S-group-AD-1
are	O
potentiated	O
by	O
the	O
anticholinesterases	S-group-AD-2
,	O
they	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
convulsions	O
.	O

Auranofin	S-drug-AD-1
should	O
be	O
avoided	O
by	O
patients	O
with	O
a	O
history	O
of	O
serious	O
reaction	O
to	O
any	O
gold	B-group-AD-2
medication	E-group-AD-2
,	O
including	O
Solganal	S-brand-AD-2
and	O
Myochrysine	S-brand-AD-2
.	O

Auranofin	S-drug-AD-1
should	O
not	O
be	O
used	O
together	O
with	O
penicillamine	S-drug-AD-2
(	O
Depen	S-brand-AD-2
,	O
Cuprimine	S-brand-AD-2
)	O
,	O
another	O
arthritis	O
medication	O
.	O

It	O
should	O
also	O
be	O
avoided	O
in	O
patients	O
with	O
blood	O
,	O
liver	O
or	O
kidney	O
diseases	O
,	O
recent	O
radiation	O
treatment	O
,	O
or	O
uncontrolled	O
diabetes	O
.	O

Patients	O
should	O
report	O
to	O
their	O
practitioners	O
any	O
new	O
rashes	O
,	O
itching	O
,	O
mouth	O
sores	O
,	O
or	O
unusual	O
taste	O
while	O
taking	O
auranofin	S-drug
.	O

Gold	S-group
is	O
excreted	O
slowly	O
from	O
the	O
body	O
.	O

Safety	O
and	O
effectiveness	O
in	O
children	O
has	O
not	O
been	O
established	O
.	O

No	O
formal	O
assessments	O
of	O
drug	O
-	O
drug	O
interactions	O
between	O
Vidaza	S-brand
and	O
other	O
agents	O
have	O
been	O
conducted	O

MAO	B-group-EF-1
inhibitors	E-group-EF-1
prolong	O
and	O
intensify	O
the	O
effects	O
of	O
antihistamines	S-group-EF-2
.	O

Concomitant	O
use	O
of	O
antihistamines	S-group-EF-1
with	O
alcohol	S-drug-EF-2
,	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
barbiturates	S-group-EF-2
,	O
or	O
other	O
central	B-group-EF-2
nervous	I-group-EF-2
system	I-group-EF-2
depressants	E-group-EF-2
may	O
have	O
an	O
additive	O
effect	O
.	O

When	O
sympathomimetic	B-group-EF-1
drugs	E-group-EF-1
are	O
given	O
to	O
patients	O
receiving	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
,	O
hypertensive	O
reactions	O
,	O
including	O
hypertensive	O
crises	O
,	O
may	O
occur	O
.	O

The	O
antihypertensive	O
effects	O
of	O
methyldopa	S-drug-EF-1
,	O
mecamylamine	S-drug-EF-1
,	O
reserpine	S-drug-EF-1
,	O
and	O
veratrum	B-drug-EF-1
alkaloids	E-drug-EF-1
may	O
be	O
reduced	O
by	O
sympathomimetics	S-group-EF-2
.	O

Beta	B-group-IN-1
-	I-group-IN-1
adrenergic	I-group-IN-1
blocking	I-group-IN-1
agents	E-group-IN-1
may	O
also	O
interact	O
with	O
sympathomimetics	S-group-IN-2
.	O

Increased	O
ectopic	O
pacemaker	O
activity	O
can	O
occur	O
when	O
pseudoephedrine	S-drug-EF-1
is	O
used	O
concomitantly	O
with	O
digitalis	S-group-EF-2
.	O

Antacids	S-group-ME-1
increase	O
the	O
rate	O
of	O
absorption	O
of	O
pseudoephedrine	S-drug-ME-M
,	O
while	O
kaolin	S-drug-ME-2
decreases	O
it	O
.	O

Use	O
with	O
Allopurinol	S-drug
:	O
The	O
principal	O
pathway	O
for	O
detoxification	O
of	O
azathioprine	S-drug-ME-1
is	O
inhibited	O
by	O
allopurinol	S-drug-ME-2
.	O

Patients	O
receiving	O
azathioprine	S-drug-AD-1
and	O
allopurinol	S-drug-AD-2
concomitantly	O
should	O
have	O
a	O
dose	O
reduction	O
of	O
azathioprine	S-drug
,	O
to	O
approximately	O
1	O
/	O
3	O
to	O
1	O
/	O
4	O
the	O
usual	O
dose	O
.	O

Use	O
with	O
Other	O
Agents	O
Affecting	O
Myelopoesis	O
:	O
Drugs	O
which	O
may	O
affect	O
leukocyte	O
production	O
,	O
including	O
co	B-brand
-	I-brand
trimoxazole	E-brand
,	O
may	O
lead	O
to	O
exaggerated	O
leukopenia	O
,	O
especially	O
in	O
renal	O
transplant	O
recipients	O
.	O

Use	O
with	O
Angiotensln	B-group
Converting	I-group
Enzyme	I-group
Inhibitors	E-group
:	O
The	O
use	O
of	O
angiotensin	B-group-EF-1
converting	I-group-EF-1
enzyme	I-group-EF-1
inhibitors	E-group-EF-1
to	O
control	O
hypertension	O
in	O
patients	O
on	O
azathioprine	S-drug-EF-2
has	O
been	O
reported	O
to	O
induce	O
severe	O
leukopenia	O
.	O

No	O
information	O
provided	O

Co	O
-	O
administration	O
of	O
nelfinavir	S-drug
at	O
steady	O
-	O
state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	S-drug
.	O

Co	O
-	O
administration	O
of	O
nelfinavir	S-drug-EF-1
at	O
steady	O
-	O
state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	S-drug-EF-2
(	O
2	O
x	O
600	O
mg	O
tablets	O
)	O
results	O
in	O
increased	O
azithromycin	S-drug
serum	O
concentrations	O
.	O

Although	O
a	O
dose	O
adjustment	O
of	O
azithromycin	S-drug-AD-1
is	O
not	O
recommended	O
when	O
administered	O
in	O
combination	O
with	O
nelfinavir	S-drug-AD-2
,	O
close	O
monitoring	O
for	O
known	O
side	O
effects	O
of	O
azithromycin	S-drug
,	O
such	O
as	O
liver	O
enzyme	O
abnormalities	O
and	O
hearing	O
impairment	O
,	O
is	O
warranted	O
.	O

Azithromycin	S-drug
did	O
not	O
affect	O
the	O
prothrombin	O
time	O
response	O
to	O
a	O
single	O
dose	O
of	O
warfarin	S-drug
.	O

However	O
,	O
prudent	O
medical	O
practice	O
dictates	O
careful	O
monitoring	O
of	O
prothrombin	O
time	O
in	O
all	O
patients	O
treated	O
with	O
azithromycin	S-drug-AD-1
and	O
warfarin	S-drug-AD-2
concomitantly	O
.	O

Concurrent	O
use	O
of	O
macrolides	S-group-EF-1
and	O
warfarin	S-drug-EF-2
in	O
clinical	O
practice	O
has	O
been	O
associated	O
with	O
increased	O
anticoagulant	O
effects	O
.	O

Drug	O
interaction	O
studies	O
were	O
performed	O
with	O
azithromycin	S-drug
and	O
other	O
drugs	O
likely	O
to	O
be	O
co	O
-	O
administered	O
.	O

When	O
used	O
in	O
therapeutic	O
doses	O
,	O
azithromycin	S-drug-ME-1
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
atorvastatin	S-drug-ME-2
,	O
carbamazepine	S-drug-ME-2
,	O
cetirizine	S-drug-ME-2
,	O
didanosine	S-drug-ME-2
,	O
efavirenz	S-drug-ME-2
,	O
fluconazole	S-drug-ME-2
,	O
indinavir	S-drug-ME-2
,	O
midazolam	S-drug-ME-2
,	O
rifabutin	S-drug-ME-2
,	O
sildenafil	S-drug-ME-2
,	O
theophylline	S-drug-ME-2
(	O
intravenous	O
and	O
oral	O
)	O
,	O
triazolam	S-drug-ME-2
,	O
trimethoprim	S-drug-ME-2
/	O
sulfamethoxazole	S-drug-ME-2
or	O
zidovudine	S-drug-ME-2
.	O

Co	O
-	O
administration	O
with	O
efavirenz	S-drug-ME-1
or	O
fluconazole	S-drug-ME-1
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
azithromycin	S-drug-ME-2
.	O

No	O
dosage	O
adjustment	O
of	O
either	O
drug	O
is	O
recommended	O
when	O
azithromycin	S-drug
is	O
co	O
administered	O
with	O
any	O
of	O
the	O
above	O
agents	O
.	O

Interactions	O
with	O
the	O
drugs	O
listed	O
below	O
have	O
not	O
been	O
reported	O
in	O
clinical	O
trials	O
with	O
azithromycin	S-drug
;	O

however	O
,	O
no	O
specific	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
to	O
evaluate	O
potential	O
drug	O
-	O
drug	O
interaction	O
.	O

Nonetheless	O
,	O
they	O
have	O
been	O
observed	O
with	O
macrolide	B-group
products	E-group
.	O

Until	O
further	O
data	O
are	O
developed	O
regarding	O
drug	O
interactions	O
when	O
azithromycin	S-drug
and	O
these	O
drugs	O
are	O
used	O
concomitantly	O
,	O
careful	O
monitoring	O
of	O
patients	O
is	O
advised	O
:	O
Digoxin	S-drug
elevated	O
digoxin	S-drug
concentrations	O
.	O

Ergotamine	S-drug
or	O
dihydroergotamine	S-drug
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Cyclosporine	S-drug
,	O
hexobarbital	S-drug
and	O
phenytoin	S-drug
concentrations	O
.	O

Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
laboratory	O
test	O
interactions	O
.	O

Repeat	O
Treatment	O
Studies	O
evaluating	O
the	O
use	O
of	O
repeated	O
courses	O
of	O
Zmax	S-brand
have	O
not	O
been	O
conducted	O
.	O

Azlocillin	S-drug-AD-1
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
amikacin	S-drug-AD-2
,	O
ciprofloxacin	S-drug-AD-2
,	O
gentamicin	S-drug-AD-2
,	O
netilmicin	S-drug-AD-2
,	O
or	O
tobramycin	S-drug-AD-2
.	O

Injection	O
There	O
is	O
inadequate	O
systematic	O
experience	O
with	O
the	O
use	O
of	O
baclofen	S-drug
injection	O
in	O
combination	O
with	O
other	O
medications	O
to	O
predict	O
specific	O
drug	O
-	O
drug	O
interactions	O
.	O

Interactions	O
attributed	O
to	O
the	O
combined	O
use	O
of	O
baclofen	S-drug-EF-1
injection	O
and	O
epidural	O
morphine	S-drug-EF-2
include	O
hypotension	O
and	O
dyspnea	O
.	O

SIDE	O
EFFECTS	O
(	O
KEMSTRO	S-brand
)	O
The	O
most	O
common	O
adverse	O
reaction	O
during	O
treatment	O
with	O
baclofen	S-drug
is	O
transient	O
drowsiness	O
(	O
10	O
-	O
63	O
%	O
)	O
.	O

In	O
one	O
controlled	O
study	O
of	O
175	O
patients	O
,	O
transient	O
drowsiness	O
was	O
observed	O
in	O
63	O
%	O
of	O
those	O
receiving	O
baclofen	S-drug
tablets	O
compared	O
to	O
36	O
%	O
of	O
those	O
in	O
the	O
placebo	O
group	O
.	O

Other	O
common	O
adverse	O
reactions	O
are	O
dizziness	O
(	O
5	O
-	O
15	O
%	O
)	O
,	O
weakness	O
(	O
5	O
-	O
15	O
%	O
)	O
and	O
fatigue	O
(	O
2	O
-	O
4	O
%	O
)	O
.	O

Others	O
reported	O
:	O
Neuropsychiatric	O
:	O
Confusion	O
(	O
1	O
-	O
11	O
%	O
)	O
,	O
headache	O
(	O
4	O
-	O
8	O
%	O
)	O
,	O
insomnia	O
(	O
2	O
-	O
7	O
%	O
)	O
;	O

and	O
,	O
rarely	O
,	O
euphoria	O
,	O
excitement	O
,	O
depression	O
,	O
hallucinations	O
,	O
paresthesia	O
,	O
muscle	O
pain	O
,	O
tinnitus	O
,	O
slurred	O
speech	O
,	O
coordination	O
disorder	O
,	O
tremor	O
,	O
rigidity	O
,	O
dystonia	O
,	O
ataxia	O
,	O
blurred	O
vision	O
,	O
nystagmus	O
,	O
strabismus	O
,	O
miosis	O
,	O
mydriasis	O
,	O
diplopia	O
,	O
dysarthria	O
,	O
epileptic	O
seizure	O
.	O

Cardiovascular	O
:	O
Hypotension	O
(	O
0	O
-	O
9	O
%	O
)	O
.	O

Rare	O
instances	O
of	O
dyspnea	O
,	O
palpitation	O
,	O
chest	O
pain	O
,	O
syncope	O
.	O

Gastrointestinal	O
:	O
Nausea	O
(	O
4	O
-	O
12	O
%	O
)	O
,	O
constipation	O
(	O
2	O
-	O
6	O
%	O
)	O
;	O

and	O
,	O
rarely	O
,	O
dry	O
mouth	O
,	O
anorexia	O
,	O
taste	O
disorder	O
,	O
abdominal	O
pain	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
and	O
positive	O
test	O
for	O
occult	O
blood	O
in	O
stool	O
.	O

Genitourinary	O
:	O
Urinary	O
frequency	O
(	O
2	O
-	O
6	O
%	O
)	O
;	O

and	O
,	O
rarely	O
,	O
enuresis	O
,	O
urinary	O
retention	O
,	O
dysuria	O
,	O
impotence	O
,	O
inability	O
to	O
ejaculate	O
,	O
nocturia	O
,	O
hematuria	O
.	O

Other	O
:	O
Instances	O
of	O
rash	O
,	O
pruritus	O
,	O
ankle	O
edema	O
,	O
excessive	O
perspiration	O
,	O
weight	O
gain	O
,	O
nasal	O
congestion	O
.	O

Some	O
of	O
the	O
CNS	O
and	O
genitourinary	O
symptoms	O
may	O
be	O
related	O
to	O
the	O
underlying	O
disease	O
rather	O
than	O
to	O
drug	O
therapy	O
.	O

The	O
following	O
laboratory	O
tests	O
have	O
been	O
found	O
to	O
be	O
abnormal	O
in	O
a	O
few	O
patients	O
receiving	O
baclofen	S-drug
:	O
increased	O
SGOT	O
,	O
elevated	O
alkaline	O
phosphatase	O
,	O
and	O
elevation	O
of	O
blood	O
sugar	O
.	O

The	O
adverse	O
experience	O
profile	O
seen	O
with	O
KEMSTROTM	S-brand
was	O
similar	O
to	O
that	O
seen	O
with	O
baclofen	S-drug
tablets	O
.	O

No	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
for	O
COLAZAL	S-brand
,	O
however	O
the	O
use	O
of	O
orally	O
administered	O
antibiotics	S-group
could	O
,	O
theoretically	O
,	O
interfere	O
with	O
the	O
release	O
of	O
mesalamine	S-drug
in	O
the	O
colon	O
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
when	O
Simulect	S-brand
is	O
added	O
to	O
triple	O
-	O
immunosuppression	O
regimens	O
including	O
cyclosporine	S-drug
,	O
corticosteroids	S-group
,	O
and	O
either	O
azathioprine	S-drug
or	O
mycophenolate	B-drug
mofetil	E-drug
.	O

Three	O
clinical	O
trials	O
have	O
investigated	O
Simulect	S-brand
use	O
in	O
combination	O
with	O
triple	O
-	O
therapy	O
regimens	O
.	O

Pharmacokinetics	O
were	O
assessed	O
in	O
two	O
of	O
these	O
trials	O
.	O

Total	O
body	O
clearance	O
of	O
Simulect	S-brand-ME-1
was	O
reduced	O
by	O
an	O
average	O
22	O
%	O
and	O
51	O
%	O
when	O
azathioprine	S-drug-ME-2
and	O
mycophenolate	B-drug-ME-2
mofetil	E-drug-ME-2
,	O
respectively	O
,	O
were	O
added	O
to	O
a	O
regimen	O
consisting	O
of	O
cyclosporine	S-drug
,	O
USP	O
(	O
MODIFIED	O
)	O
and	O
corticosteroids	S-group
.	O

Nonetheless	O
,	O
the	O
range	O
of	O
individual	O
Simulect	S-brand
clearance	O
values	O
in	O
the	O
presence	O
of	O
azathioprine	S-drug
(	O
12	O
-	O
57	O
mL	O
/	O
h	O
)	O
or	O
mycophenolate	B-drug
mofetil	E-drug
(	O
7	O
-	O
54	O
mL	O
/	O
h	O
)	O
did	O
not	O
extend	O
outside	O
the	O
range	O
observed	O
with	O
dual	O
therapy	O
(	O
10	O
-	O
78	O
mL	O
/	O
h	O
)	O
.	O

The	O
following	O
medications	O
have	O
been	O
administered	O
in	O
clinical	O
trials	O
with	O
Simulect	S-brand
with	O
no	O
increase	O
in	O
adverse	O
reactions	O
:	O
ATG	O
/	O
ALG	O
,	O
azathioprine	S-drug
,	O
corticosteroids	S-group
,	O
cyclosporine	S-drug
,	O
mycophenolate	B-drug
mofetil	E-drug
,	O
and	O
muromonab	B-drug
-	I-drug
CD3	E-drug
.	O

It	O
is	O
not	O
known	O
if	O
REGRANEX	S-brand
Gel	O
interacts	O
with	O
other	O
topical	O
medications	O
applied	O
to	O
the	O
ulcer	O
site	O
.	O

The	O
use	O
of	O
REGRANEX	S-brand
Gel	O
with	O
other	O
topical	O
drugs	O
has	O
not	O
been	O
studied	O
.	O

Albuterol	S-drug
,	O
Antihistamines	S-group
,	O
antidiabetic	B-group
drugs	E-group
,	O
diuretics	S-group
,	O
digitalis	S-group
.	O

Diuretics	S-group
:	O
Patients	O
on	O
diuretics	S-group-EF-1
,	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
Lotensin	S-brand-EF-2
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
Lotensin	S-brand
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	S-group-AD-1
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
Lotensin	S-brand-AD-2
.	O

If	O
this	O
is	O
not	O
possible	O
,	O
the	O
starting	O
dose	O
should	O
be	O
reduced	O
.	O

Potassium	S-drug
Supplements	O
and	O
Potassium	B-group-EF-1
-	I-group-EF-1
Sparing	I-group-EF-1
Diuretics	E-group-EF-1
Lotensin	O
can	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
.	O

Potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
(	O
spironolactone	S-drug
,	O
amiloride	S-drug
,	O
triamterene	S-drug
,	O
and	O
others	O
)	O
or	O
potassium	S-drug
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
,	O
they	O
should	O
be	O
given	O
with	O
caution	O
,	O
and	O
the	O
patient	O
's	O
serum	O
potassium	O
should	O
be	O
monitored	O
frequently	O
.	O

Oral	O
Anticoagulants	S-group
Interaction	O
studies	O
with	O
warfarin	S-drug
and	O
acenocoumarol	S-drug
failed	O
to	O
identify	O
any	O
clinically	O
important	O
effects	O
on	O
the	O
serum	O
concentrations	O
or	O
clinical	O
effects	O
of	O
these	O
anticoagulants	S-group
.	O

Lithium	S-drug
:	O
Increased	O
serum	O
lithium	S-drug
levels	O
and	O
symptoms	O
of	O
lithium	S-drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B-group-ME-1
inhibitors	E-group-ME-1
during	O
therapy	O
with	O
lithium	S-drug-ME-2
.	O

These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
,	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	S-drug
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	S-group-EF-1
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	S-drug-EF-2
toxicity	O
may	O
be	O
increased	O
.	O

Other	O
No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
Lotensin	S-brand
was	O
administered	O
concomitantly	O
with	O
hydrochlorothiazide	S-drug
,	O
chlorthalidone	S-drug
,	O
furosemide	S-drug
,	O
digoxin	S-drug
,	O
propranolol	S-drug
,	O
atenolol	S-drug
,	O
naproxen	S-drug
,	O
or	O
cimetidine	S-drug
.	O

Lotensin	S-brand
has	O
been	O
used	O
concomitantly	O
with	O
beta	B-group
-	I-group
adrenergic	I-group
-	I-group
blocking	I-group
agents	E-group
,	O
calcium	B-group
-	I-group
channel	I-group
-	I-group
blocking	I-group
agents	E-group
,	O
diuretics	S-group
,	O
digoxin	S-drug
,	O
and	O
hydralazine	S-drug
,	O
without	O
evidence	O
of	O
clinically	O
important	O
adverse	O
interactions	O
.	O

Benazepril	S-drug-EF-1
,	O
like	O
other	O
ACE	B-group-EF-1
inhibitors	E-group-EF-1
,	O
has	O
had	O
less	O
than	O
additive	O
effects	O
with	O
beta	B-group-EF-2
-	I-group-EF-2
adrenergic	I-group-EF-2
blockers	E-group-EF-2
,	O
presumably	O
because	O
both	O
drugs	O
lower	O
blood	O
pressure	O
by	O
inhibiting	O
parts	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O

May	O
interact	O
with	O
the	O
following	O
:	O
cholestyramine	S-drug-EF-1
,	O
colestipol	S-drug-EF-1
(	O
use	O
with	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
may	O
prevent	O
the	O
diuretic	S-group
from	O
working	O
properly	O
;	O

Bentiromide	S-drug-IN-1
may	O
interact	O
with	O
acetaminophen	S-drug-IN-2
(	O
e.g	O
.	O
,	O
Tylenol	S-brand-IN-2
)	O
,	O
chloramphenicol	S-drug-IN-2
(	O
e.g	O
.	O
,	O
Chloromycetin	S-brand-IN-2
)	O
,	O
local	O
anesthetics	S-group-IN-2
(	O
e.g	O
.	O
,	O
benzocaine	S-drug-IN-2
and	O
lidocaine	S-drug-IN-2
)	O
,	O
para	B-drug_n-IN-2
-	I-drug_n-IN-2
aminobenzoic	I-drug_n-IN-2
acid	E-drug_n-IN-2
(	O
PABA	S-drug_n-IN-2
)	O
-	O
containing	O
preparations	O
(	O
e.g	O
.	O
,	O
sunscreens	O
and	O
some	O
multivitamins	S-group-IN-2
)	O
,	O
procainamide	S-drug-IN-2
(	O
e.g	O
.	O
,	O
Pronestyl	S-brand-IN-2
)	O
,	O
sulfonamides	S-group-IN-2
(	O
sulfa	O
medicines	O
)	O
,	O
thiazide	B-group-IN-2
diuretics	E-group-IN-2
(	O
use	O
of	O
these	O
medicines	O
during	O
the	O
test	O
period	O
will	O
affect	O
the	O
test	O
results	O
)	O
,	O
and	O
pancreatic	O
supplements	O
(	O
use	O
of	O
pancreatic	O
supplements	O
may	O
give	O
false	O
test	O
results	O
)	O
.	O

May	O
interact	O
with	O
other	O
creams	O
,	O
lotions	O
,	O
or	O
skin	O
medicines	O
when	O
placed	O
on	O
the	O
same	O
areas	O
of	O
your	O
skin	O
that	O
you	O
are	O
using	O
bentoquatam	S-drug_n
.	O

No	O
information	O
is	O
available	O
.	O

Hypertensive	O
crises	O
have	O
resulted	O
when	O
sympathomimetic	B-group-EF-1
amines	E-group-EF-1
have	O
been	O
used	O
concomitantly	O
within14	O
days	O
following	O
use	O
of	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
.	O

DIDREX	S-brand-AD-1
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
CNS	B-group-AD-2
stimulants	E-group-AD-2
.	O

Amphetamines	S-group-EF-1
may	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
antihypertensives	S-group-EF-2
.	O

Amphetamines	S-group-EF-1
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
.	O

Urinary	O
alkalinizing	O
agents	O
increase	O
blood	O
levels	O
and	O
decrease	O
excretion	O
of	O
amphetamines	S-group
.	O

Urinary	B-drug-ME-1
acidifying	E-drug-ME-1
agents	O
decrease	O
blood	O
levels	O
and	O
increase	O
excretion	O
of	O
amphetamines	S-group-ME-2
.	O

Benzthiazide	S-drug-IN-1
may	O
interact	O
with	O
alcohol	S-drug-IN-2
,	O
blood	B-group-IN-2
thinners	O
,	O
decongestant	B-group-IN-2
drugs	E-group-IN-2
(	O
allergy	O
,	O
cold	O
,	O
and	O
sinus	O
medicines	O
)	O
,	O
diabetic	O
drugs	O
,	O
lithium	S-drug-IN-2
,	O
norepinephrine	S-drug-IN-2
,	O
NSAIDs	S-group-IN-2
like	O
Aleve	S-brand-IN-2
or	O
Ibuprofen	S-drug-IN-2
,	O
and	O
high	O
blood	O
pressure	O
medications	O
.	O

Antipsychotic	B-group
drugs	E-group
such	O
as	O
phenothiazines	S-group
or	O
haloperidol	S-drug
;	O

tricyclic	B-group
antidepressants	E-group
.	O

Nitrates	S-group
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	S-drug
with	O
long	O
-	O
and	O
short	O
-	O
acting	O
nitrates	S-group
has	O
been	O
safely	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
pectoris	O
.	O

Sublingual	O
nitroglycerin	S-drug
may	O
be	O
taken	O
if	O
necessary	O
for	O
the	O
control	O
of	O
acute	O
angina	O
attacks	O
during	O
Bepridil	S-drug
therapy	O
.	O

Beta	B-group
-	I-group
blocking	I-group
Agents	E-group
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	S-drug
and	O
beta	B-group
-	I-group
blocking	I-group
agents	E-group
has	O
been	O
well	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
.	O

Available	O
data	O
are	O
not	O
sufficient	O
,	O
however	O
,	O
to	O
predict	O
the	O
effects	O
of	O
concomitant	O
medication	O
on	O
patients	O
with	O
impaired	O
ventricular	O
function	O
or	O
cardiac	O
conduction	O
abnormalities	O
.	O

Digoxin	S-drug
:	O
In	O
controlled	O
studies	O
in	O
healthy	O
volunteers	O
,	O
bepridil	B-drug-ME-1
hydrochloride	E-drug-ME-1
either	O
had	O
no	O
effect	O
(	O
one	O
study	O
)	O
or	O
was	O
associated	O
with	O
modest	O
increases	O
,	O
about	O
30	O
%	O
(	O
two	O
studies	O
)	O
in	O
steady	O
-	O
state	O
serum	O
digoxin	S-drug-ME-2
concentrations	O
.	O

Limited	O
clinical	O
data	O
in	O
angina	O
patients	O
receiving	O
concomitant	O
bepridil	B-drug
hydrochloride	E-drug
and	O
digoxin	S-drug
therapy	O
indicate	O
no	O
discernible	O
changes	O
in	O
serum	O
digoxin	O
levels	O
.	O

Available	O
data	O
are	O
neither	O
sufficient	O
to	O
rule	O
out	O
possible	O
increases	O
in	O
serum	O
digoxin	S-drug
with	O
concomitant	O
treatment	O
in	O
some	O
patients	O
,	O
nor	O
other	O
possible	O
interactions	O
,	O
particularly	O
in	O
patients	O
with	O
cardiac	O
conduction	O
abnormalities	O
(	O
Also	O
see	O
WARNINGS	O
Congestive	O
Heart	O
Failure	O
)	O
.	O

Oral	O
Hypoglycemics	S-group
:	O
Bepridil	S-drug
has	O
been	O
safely	O
used	O
in	O
diabetic	O
patients	O
without	O
significantly	O
lowering	O
their	O
blood	O
glucose	O
levels	O
or	O
altering	O
their	O
need	O
for	O
insulin	S-drug
or	O
oral	O
hypoglycemic	B-group
agents	E-group
.	O

General	O
Interactions	O
:	O
Certain	O
drugs	O
could	O
increase	O
the	O
likelihood	O
of	O
potentially	O
serious	O
adverse	O
effects	O
with	O
bepridil	B-drug
hydrochloride	E-drug
.	O

In	O
general	O
,	O
these	O
are	O
drugs	O
that	O
have	O
one	O
or	O
more	O
pharmacologic	O
activities	O
similar	O
to	O
bepridil	B-drug
hydrochloride	E-drug
,	O
including	O
anti	B-group
-	I-group
arrhythmic	I-group
agents	E-group
such	O
as	O
quinidine	S-drug
and	O
procainamide	S-drug
,	O
cardiac	B-group
glycosides	E-group
and	O
tricyclic	B-group
anti	I-group
-	I-group
depressants	E-group
.	O

Anti	B-group-EF-1
-	I-group-EF-1
arrhythmics	E-group-EF-1
and	O
tricyclic	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
depressants	E-group-EF-1
could	O
exaggerate	O
the	O
prolongation	O
of	O
the	O
QT	O
interval	O
observed	O
with	O
bepridil	B-drug-EF-2
hydrochloride	E-drug-EF-2
.	O

Cardiac	B-group-EF-1
glycosides	E-group-EF-1
could	O
exaggerate	O
the	O
depression	O
of	O
AV	O
nodal	O
conduction	O
observed	O
with	O
bepridil	B-drug-EF-2
hydrochloride	E-drug-EF-2
.	O

APRD00513_IN	O
,	O
txt	O

The	O
following	O
drugs	O
have	O
been	O
coadministered	O
with	O
Kerlone	S-brand
and	O
have	O
not	O
altered	O
its	O
pharmacokinetics	O
:	O
cimetidine	S-drug
,	O
nifedipine	S-drug
,	O
chlorthalidone	S-drug
,	O
and	O
hydrochlorothiazide	S-drug
.	O

Concomitant	O
administration	O
of	O
Kerlone	S-brand
with	O
the	O
oral	O
anticoagulant	S-group
warfarin	S-drug
has	O
been	O
shown	O
not	O
to	O
potentiate	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	S-drug
.	O

Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g	O
.	O
,	O
reserpine	S-drug-EF-1
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-drug-EF-2
-	I-drug-EF-2
blocking	E-drug-EF-2
agents	O
.	O

Patients	O
treated	O
with	O
a	O
beta	B-group
-	I-group
adrenergic	I-group
receptor	I-group
blocking	I-group
agent	E-group
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Should	O
it	O
be	O
decided	O
to	O
discontinue	O
therapy	O
in	O
patients	O
receiving	O
beta	B-group-AD-1
-	I-group-AD-1
blockers	E-group-AD-1
and	O
clonidine	S-drug-AD-2
concurrently	O
,	O
the	O
beta	B-group-AD-1
-	I-group-AD-1
blocker	E-group-AD-1
should	O
be	O
discontinued	O
slowly	O
over	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	S-drug-AD-2
.	O

Literature	O
reports	O
suggest	O
that	O
oral	O
calcium	B-group-AD-1
antagonists	E-group-AD-1
may	O
be	O
used	O
in	O
combination	O
with	O
beta	B-group-AD-2
-	I-group-AD-2
adrenergic	I-group-AD-2
blocking	I-group-AD-2
agents	E-group-AD-2
when	O
heart	O
function	O
is	O
normal	O
,	O
but	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
impaired	O
cardiac	O
function	O
.	O

Hypotension	O
,	O
AV	O
conduction	O
disturbances	O
,	O
and	O
left	O
ventricular	O
failure	O
have	O
been	O
reported	O
in	O
some	O
patients	O
receiving	O
beta	B-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
when	O
an	O
oral	O
calcium	B-group-EF-2
antagonist	E-group-EF-2
was	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Hypotension	O
was	O
more	O
likely	O
to	O
occur	O
if	O
the	O
calcium	B-group
antagonist	E-group
were	O
a	O
dihydropyridine	B-group
derivative	E-group
,	O
e.g	O
.	O
,	O
nifedipine	S-drug
,	O
while	O
left	O
ventricular	O
failure	O
and	O
AV	O
conduction	O
disturbances	O
,	O
including	O
complete	O
heart	O
block	O
,	O
were	O
more	O
likely	O
to	O
occur	O
with	O
either	O
verapamil	S-drug
or	O
diltiazem	S-drug
.	O

Risk	O
of	O
Anaphylactic	O
Reaction	O
:	O
Although	O
it	O
is	O
known	O
that	O
patients	O
on	O
beta	B-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
may	O
be	O
refractory	O
to	O
epinephrine	S-drug-EF-2
in	O
the	O
treatment	O
of	O
anaphylactic	O
shock	O
,	O
beta	B-group
-	I-group
blockers	E-group
can	O
,	O
in	O
addition	O
,	O
interfere	O
with	O
the	O
modulation	O
of	O
allergic	O
reaction	O
and	O
lead	O
to	O
an	O
increased	O
severity	O
and	O
/	O
or	O
frequency	O
of	O
attacks	O
.	O

Severe	O
allergic	O
reactions	O
including	O
anaphylaxis	O
have	O
been	O
reported	O
in	O
patients	O
exposed	O
to	O
a	O
variety	O
of	O
allergens	O
either	O
by	O
repeated	O
challenge	O
,	O
or	O
accidental	O
contact	O
,	O
and	O
with	O
diagnostic	O
or	O
therapeutic	O
agents	O
while	O
receiving	O
beta	B-group
-	I-group
blockers	E-group
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	S-drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

Special	O
care	O
is	O
required	O
if	O
this	O
drug	O
is	O
given	O
to	O
patients	O
receiving	O
ganglion	B-group
blocking	I-group
compounds	E-group
because	O
a	O
critical	O
fall	O
in	O
blood	O
pressure	O
may	O
occur	O
.	O

Usually	O
,	O
severe	O
abdominal	O
symptoms	O
appear	O
before	O
there	O
is	O
such	O
a	O
fall	O
in	O
the	O
blood	O
pressure	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
with	O
anti	B-group
-	I-group
neoplastic	I-group
agents	E-group
have	O
been	O
conducted	O
.	O

In	O
Study	O
1	O
,	O
patients	O
with	O
colorectal	O
cancer	O
were	O
given	O
irinotecan	S-drug
/	O
5	B-drug
-	I-drug
FU	E-drug
/	O
leucovorin	S-drug
(	O
bolus	O
-	O
IFL	O
)	O
with	O
or	O
without	O
AVASTIN	S-brand
.	O

Irinotecan	S-drug
concentrations	O
were	O
similar	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
alone	O
and	O
in	O
combination	O
with	O
AVASTIN	S-brand
.	O

The	O
concentrations	O
of	O
SN38	S-drug_n
,	O
the	O
active	O
metabolite	O
of	O
irinotecan	S-drug
,	O
were	O
on	O
average	O
33	O
%	O
higher	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
in	O
combination	O
with	O
AVASTIN	S-brand
when	O
compared	O
with	O
bolus	O
-	O
IFL	O
alone	O
.	O

In	O
Study	O
1	O
,	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
plus	O
AVASTIN	S-brand
had	O
a	O
higher	O
incidence	O
of	O
Grade	O
3	O
-	O
4	O
diarrhea	O
and	O
neutropenia	O
.	O

Due	O
to	O
high	O
inter	O
-	O
patient	O
variability	O
and	O
limited	O
sampling	O
,	O
the	O
extent	O
of	O
the	O
increase	O
in	O
SN38	S-drug_n
levels	O
in	O
patients	O
receiving	O
concurrent	O
irinotecan	S-drug
and	O
AVASTIN	S-brand
is	O
uncertain	O
.	O

No	O
formal	O
studies	O
to	O
evaluate	O
drug	O
interactions	O
with	O
bexarotene	S-drug
have	O
been	O
conducted	O
.	O

Bexarotene	S-drug
oxidative	O
metabolites	O
appear	O
to	O
be	O
formed	O
by	O
cytochrome	O
P450	O
3A4	O
.	O

On	O
the	O
basis	O
of	O
the	O
metabolism	O
of	O
bexarotene	S-drug
by	O
cytochrome	O
P450	O
3A4	O
,	O
ketoconazole	S-drug-ME-1
,	O
itraconazole	S-drug-ME-1
,	O
erythromycin	S-drug-ME-1
,	O
gemfibrozil	S-drug-ME-1
,	O
grapefruit	O
juice	O
,	O
and	O
other	O
inhibitors	O
of	O
cytochrome	O
P450	O
3A4	O
would	O
be	O
expected	O
to	O
lead	O
to	O
an	O
increase	O
in	O
plasma	O
bexarotene	S-drug-ME-2
concentrations	O
.	O

Furthermore	O
,	O
rifampin	S-drug-ME-1
,	O
phenytoin	S-drug-ME-1
,	O
phenobarbital	S-drug-ME-1
,	O
and	O
other	O
inducers	O
of	O
cytochrome	O
P450	O
3A4	O
may	O
cause	O
a	O
reduction	O
in	O
plasma	O
bexarotene	S-drug-ME-2
concentrations	O
.	O

Concomitant	O
administration	O
of	O
Targretin	S-brand-ME-1
capsules	O
and	O
gemfibrozil	S-drug-ME-2
resulted	O
in	O
substantial	O
increases	O
in	O
plasma	O
concentrations	O
of	O
bexarotene	S-drug
,	O
probably	O
at	O
least	O
partially	O
related	O
to	O
cytochrome	O
P450	O
3A4	O
inhibition	O
by	O
gemfibrozil	S-drug
.	O

Under	O
similar	O
conditions	O
,	O
bexarotene	S-drug
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
atorvastatin	S-drug
administration	O
.	O

Concomitant	O
administration	O
of	O
gemfibrozil	S-drug-AD-1
with	O
Targretin	S-brand-AD-2
capsules	O
is	O
not	O
recommended	O
.	O

When	O
Bezalip	S-brand
or	O
Bezalip	B-brand
retard	E-brand
is	O
used	O
at	O
the	O
same	O
time	O
as	O
other	O
medicines	O
or	O
substances	O
the	O
following	O
interactions	O
must	O
be	O
taken	O
into	O
account	O
:	O
-	O
Bezalip	S-brand-EF-1
and	O
Bezalip	B-brand-EF-1
retard	E-brand-EF-1
may	O
enhance	O
the	O
action	O
of	O
anticoagulants	B-group-EF-2
of	I-group-EF-2
the	I-group-EF-2
coumarin	I-group-EF-2
type	E-group-EF-2
.	O

For	O
this	O
reason	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	S-drug-AD-1
should	O
be	O
reduced	O
by	O
30	O
-	O
50	O
%	O
at	O
the	O
start	O
of	O
treatment	O
with	O
Bezalip	S-brand-AD-2
or	O
Bezalip	S-brand-AD-2
retard	O
and	O
then	O
titrated	O
according	O
to	O
the	O
blood	O
clotting	O
parameters	O

-	O
The	O
action	O
of	O
sulphonylureas	S-group-EF-1
and	O
insulin	S-drug-EF-1
may	O
be	O
enhanced	O
by	O
Bezalip	S-brand-EF-2
or	O
Bezalip	B-brand-EF-2
retard	E-brand-EF-2
.	O

This	O
may	O
be	O
due	O
to	O
an	O
improved	O
glucose	O
utilization	O
with	O
simultaneous	O
reduction	O
in	O
insulin	S-drug
requirement	O

-	O
In	O
isolated	O
cases	O
,	O
a	O
pronounced	O
though	O
reversible	O
,	O
impairment	O
of	O
renal	O
function	O
(	O
accompanied	O
by	O
a	O
corresponding	O
increase	O
in	O
the	O
serum	O
creatinine	O
level	O
)	O
has	O
been	O
reported	O
in	O
organ	O
transplant	O
patients	O
receiving	O
immuno	B-group-EF-1
-	I-group-EF-1
suppressant	E-group-EF-1
therapy	O
and	O
concomitant	O
bezafibrate	S-drug-EF-2
.	O

Accordingly	O
,	O
renal	O
function	O
should	O
be	O
closely	O
monitored	O
in	O
these	O
patients	O
and	O
,	O
in	O
the	O
event	O
of	O
relevant	O
significant	O
changes	O
in	O
laboratory	O
parameters	O
,	O
bezafibrate	S-drug
should	O
,	O
if	O
necessary	O
,	O
be	O
discontinued	O

-	O
When	O
Bezalip	S-brand-AD-1
or	O
Bezalip	B-brand-AD-1
retard	E-brand-AD-1
is	O
used	O
concurrently	O
with	O
anion	B-group-AD-2
-	I-group-AD-2
exchange	I-group-AD-2
resins	E-group-AD-2
(	O
e.g	O
.	O
cholestryramine	S-drug-AD-2
)	O
,	O
an	O
interval	O
of	O
at	O
least	O
2	O
hours	O
should	O
be	O
maintained	O
between	O
the	O
two	O
medicines	O
,	O
since	O
the	O
absorption	O
of	O
Bezalip	S-brand
or	O
Bezalip	B-brand
retard	E-brand
is	O
impaired	O

-	O
Perhexiline	B-drug-AD-1
hydrogen	I-drug-AD-1
maleate	E-drug-AD-1
or	O
MAO	B-group-AD-1
-	I-group-AD-1
inhibitors	E-group-AD-1
(	O
with	O
hepatotoxic	O
potential	O
)	O
must	O
not	O
be	O
administered	O
together	O
with	O
Bezalip	S-brand-AD-2
or	O
Bezalip	B-brand-AD-2
retard	E-brand-AD-2
.	O

In	O
vitro	O
studies	O
have	O
shown	O
CASODEX	S-brand-ME-1
can	O
displace	O
coumarin	B-group-ME-2
anticoagulants	O
,	O
such	O
as	O
warfarin	S-drug-ME-2
,	O
from	O
their	O
protein	O
-	O
binding	O
sites	O
.	O

It	O
is	O
recommended	O
that	O
if	O
CASODEX	S-brand-AD-1
is	O
started	O
in	O
patients	O
already	O
receiving	O
coumarin	B-group-AD-2
anticoagulants	E-group-AD-2
,	O
prothrombin	O
times	O
should	O
be	O
closely	O
monitored	O
and	O
adjustment	O
of	O
the	O
anticoagulant	S-group-AD-2
dose	O
may	O
be	O
necessary	O
.	O

No	O
Information	O
Provided	O

Drug	O
Interactions	O
:	O
The	O
central	O
anticholinergic	S-group-EF-1
syndrome	O
can	O
occur	O
when	O
anticholinergic	O
agents	O
such	O
as	O
AKINETON	S-brand-EF-1
are	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
have	O
secondary	O
anticholinergic	O
actions	O
,	O
e.g	O
.	O
,	O
certain	O
narcotic	B-group-EF-2
analgesics	E-group-EF-2
such	O
as	O
meperidine	S-drug-EF-2
,	O
the	O
phenothiazines	S-group-EF-2
and	O
other	O
antipsychotics	S-group-EF-2
,	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
certain	O
antiarrhythmics	S-group-EF-2
such	O
as	O
the	O
quinidine	S-drug-EF-2
salts	O
,	O
and	O
antihistamines	S-group-EF-2
.	O

ZEBETA	S-brand-AD-1
should	O
not	O
be	O
combined	O
with	O
other	O
beta	B-group-AD-2
-	I-group-AD-2
blocking	I-group-AD-2
agents	E-group-AD-2
.	O

Patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
,	O
such	O
as	O
reserpine	S-drug-EF-1
or	O
guanethidine	S-drug-EF-1
,	O
should	O
be	O
closely	O
monitored	O
,	O
because	O
the	O
added	O
beta	O
-	O
adrenergic	O
blocking	O
action	O
of	O
ZEBETA	S-brand-EF-2
may	O
produce	O
excessive	O
reduction	O
of	O
sympathetic	O
activity	O
.	O

In	O
patients	O
receiving	O
concurrent	O
therapy	O
with	O
clonidine	S-drug
,	O
if	O
therapy	O
is	O
to	O
be	O
discontinued	O
,	O
it	O
is	O
suggested	O
that	O
ZEBETA	S-brand-AD-1
be	O
discontinued	O
for	O
several	O
days	O
before	O
the	O
withdrawal	O
of	O
clonidine	S-drug-AD-2
.	O

ZEBETA	S-brand-AD-1
should	O
be	O
used	O
with	O
care	O
when	O
myocardial	B-group-AD-2
depressants	E-group-AD-2
or	O
inhibitors	O
of	O
AV	O
conduction	O
,	O
such	O
as	O
certain	O
calcium	B-group-AD-2
antagonists	E-group-AD-2
(	O
particularly	O
of	O
the	O
phenylalkylamine	S-group-AD-2
[	O
verapamil	S-drug-AD-2
]	O
and	O
benzothiazepine	S-group-AD-2
[	O
diltiazem	S-drug-AD-2
]	O
classes	O
)	O
,	O
or	O
antiarrhythmic	B-group-AD-2
agents	E-group-AD-2
,	O
such	O
as	O
disopyramide	S-drug-AD-2
,	O
are	O
used	O
concurrently	O
.	O

Concurrent	O
use	O
of	O
rifampin	S-drug-ME-1
increases	O
the	O
metabolic	O
clearance	O
of	O
ZEBETA	S-brand-ME-2
,	O
resulting	O
in	O
a	O
shortened	O
elimination	O
half	O
-	O
life	O
of	O
ZEBETA	S-brand
.	O

However	O
,	O
initial	O
dose	O
modification	O
is	O
generally	O
not	O
necessary	O
.	O

Pharmacokinetic	O
studies	O
document	O
no	O
clinically	O
relevant	O
interactions	O
with	O
other	O
agents	O
given	O
concomitantly	O
,	O
including	O
thiazide	B-group
diuretics	E-group
,	O
digoxin	S-drug
,	O
and	O
cimetidine	S-drug
.	O

There	O
was	O
no	O
effect	O
of	O
ZEBETA	S-brand
on	O
prothrombin	O
time	O
in	O
patients	O
on	O
stable	O
doses	O
of	O
warfarin	S-drug
.	O

Risk	O
of	O
Anaphylactic	O
Reaction	O
:	O
While	O
taking	O
beta	B-group
-	I-group
blockers	E-group
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	S-drug
used	O
to	O
treat	O
allergic	O
reactions	O
.	O

Use	O
of	O
MAO	B-group
inhibitors	E-group
may	O
cause	O
an	O
excessive	O
increase	O
in	O
blood	O
pressure	O
and	O
heart	O
stimulation	O
.	O

If	O
you	O
are	O
also	O
using	O
a	O
steroid	S-group-AD-1
inhaler	O
,	O
take	O
bitolterol	S-drug-AD-M
first	O
and	O
then	O
wait	O
about	O
15	O
minutes	O
before	O
using	O
the	O
steroid	S-group-AD-2
inhaler	O
.	O

This	O
allows	O
bitolterol	S-drug-EF-1
to	O
open	O
air	O
passages	O
,	O
increasing	O
the	O
effectiveness	O
of	O
the	O
steroid	S-group-EF-2
.	O

Angiomax	S-brand
does	O
not	O
exhibit	O
binding	O
to	O
plasma	O
proteins	O
(	O
other	O
than	O
thrombin	O
)	O
or	O
red	O
blood	O
cells	O
.	O

In	O
clinical	O
trials	O
in	O
patients	O
undergoing	O
PTCA	O
/	O
PCI	O
,	O
co	O
-	O
administration	O
of	O
Angiomax	S-brand-EF-1
with	O
heparin	S-drug-EF-2
,	O
warfarin	S-drug-EF-2
,	O
thrombolytics	S-group-EF-2
or	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibitors	O
was	O
associated	O
with	O
increased	O
risks	O
of	O
major	O
bleeding	O
events	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
medications	O
.	O

There	O
is	O
no	O
experience	O
with	O
co	O
-	O
administration	O
of	O
Angiomax	S-brand
and	O
plasma	O
expanders	O
such	O
as	O
dextran	S-drug
.	O

Angiomax	S-brand
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
disease	O
states	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bleeding	O
.	O

Immunogenicity	O
/	O
Re	O
-	O
exposure	O
:	O
In	O
in	O
vitro	O
studies	O
,	O
Angiomax	S-brand
exhibited	O
no	O
platelet	O
aggregation	O
response	O
against	O
sera	O
from	O
patients	O
with	O
a	O
history	O
of	O
HIT	O
/	O
HITTS	O
.	O

Among	O
494	O
subjects	O
who	O
received	O
Angiomax	S-brand
in	O
clinical	O
trials	O
and	O
were	O
tested	O
for	O
antibodies	O
,	O
2	O
subjects	O
had	O
treatment	O
-	O
emergent	O
positive	O
bivalirudin	S-drug
antibody	O
tests	O
.	O

Neither	O
subject	O
demonstrated	O
clinical	O
evidence	O
of	O
allergic	O
or	O
anaphylactic	O
reactions	O
and	O
repeat	O
testing	O
was	O
not	O
performed	O
.	O

Nine	O
additional	O
patients	O
who	O
had	O
initial	O
positive	O
tests	O
were	O
negative	O
on	O
repeat	O
testing	O
.	O

Certain	O
antibiotic	S-group
,	O
cisplatin	S-drug
,	O
cyclosporine	S-drug
,	O
diuretic	S-group
,	O
foscarnet	S-drug
,	O
and	O
vaccines	S-group
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
VELCADE	S-brand
.	O

In	O
vitro	O
studies	O
with	O
human	O
liver	O
microsomes	O
indicate	O
that	O
bortezomib	S-drug
is	O
primarily	O
a	O
substrate	O
for	O
cytochrome	O
P450	O
3A4	O
,	O
2C19	O
,	O
and	O
1A2	O
.	O

Patients	O
who	O
are	O
concomitantly	O
receiving	O
VELCADE	S-brand
and	O
drugs	O
that	O
are	O
inhibitors	O
or	O
inducers	O
of	O
cytochrome	O
P450	O
3A4	O
should	O
be	O
closely	O
monitored	O
for	O
either	O
toxicities	O
or	O
reduced	O
efficacy	O
.	O

During	O
clinical	O
trials	O
,	O
hypoglycemia	O
and	O
hyperglycemia	O
were	O
reported	O
in	O
diabetic	O
patients	O
receiving	O
oral	O
hypoglycemics	S-group
.	O

Patients	O
on	O
oral	O
antidiabetic	B-group-AD-1
agents	E-group-AD-1
receiving	O
VELCADE	S-brand-AD-2
treatment	O
may	O
require	O
close	O
monitoring	O
of	O
their	O
blood	O
glucose	O
levels	O
and	O
adjustment	O
of	O
the	O
dose	O
of	O
their	O
antidiabetic	B-group
medication	E-group
.	O

Drug	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

Bosentan	S-drug
is	O
metabolized	O
by	O
CYP2C9	O
and	O
CYP3A4	O
.	O

Inhibition	O
of	O
these	O
isoenzymes	O
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
bosentan	S-drug
.	O

Bosentan	S-drug
is	O
an	O
inducer	O
of	O
CYP3A4	O
and	O
CYP2C9	O
.	O

Consequently	O
,	O
plasma	O
concentrations	O
of	O
drugs	O
metabolized	O
by	O
these	O
two	O
isoenzymes	O
will	O
be	O
decreased	O
when	O
TRACLEER	S-brand
is	O
co	O
-	O
administered	O
.	O

Bosentan	S-drug
had	O
no	O
relevant	O
inhibitory	O
effect	O
on	O
any	O
CYP	O
isoenzymes	O
tested	O
(	O
CYP1A2	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP3A4	O
)	O
.	O

Consequently	O
,	O
TRACLEER	S-brand
is	O
not	O
expected	O
to	O
increase	O
the	O
plasma	O
concentrations	O
of	O
drugs	O
metabolized	O
by	O
these	O
enzymes	O
.	O

Hormonal	B-group
Contraceptives	E-group
,	O
Including	O
Oral	O
,	O
Injectable	O
,	O
Transdermal	O
,	O
and	O
Implantable	O
Contraceptives	S-group
:	O
An	O
interaction	O
study	O
demonstrated	O
that	O
co	O
-	O
administration	O
of	O
bosentan	S-drug-ME-1
and	O
the	O
oral	O
hormonal	B-group
contraceptive	E-group
Ortho	B-brand-ME-2
-	I-brand-ME-2
Novum	E-brand-ME-2
produced	O
average	O
decreases	O
of	O
norethindrone	S-drug
and	O
ethinyl	B-drug
estradiol	E-drug
levels	O
of	O
14	O
%	O
and	O
31	O
%	O
,	O
respectively	O
.	O

However	O
,	O
decreases	O
in	O
exposure	O
were	O
as	O
much	O
as	O
56	O
%	O
and	O
66	O
%	O
,	O
respectively	O
,	O
in	O
individual	O
subjects	O
.	O

Therefore	O
,	O
hormonal	B-group-EF-1
contraceptives	E-group-EF-1
,	O
including	O
oral	O
,	O
injectable	O
,	O
transdermal	O
,	O
and	O
implantable	O
forms	O
,	O
may	O
not	O
be	O
reliable	O
when	O
TRACLEER	S-brand-EF-2
is	O
co	O
-	O
administered	O
.	O

Women	O
should	O
practice	O
additional	O
methods	O
of	O
contraception	O
and	O
not	O
rely	O
on	O
hormonal	O
contraception	O
alone	O
when	O
taking	O
TRACLEER	S-brand
.	O

Specific	O
interaction	O
studies	O
have	O
demonstrated	O
the	O
following	O
:	O
Cyclosporine	B-drug
A	E-drug
:	O
During	O
the	O
first	O
day	O
of	O
concomitant	O
administration	O
,	O
trough	O
concentrations	O
of	O
bosentan	S-drug
were	O
increased	O
by	O
about	O
30	O
-	O
fold	O
.	O

Steady	O
-	O
state	O
bosentan	S-drug-ME-1
plasma	O
concentrations	O
were	O
3	O
-	O
to	O
4	O
-	O
fold	O
higher	O
than	O
in	O
the	O
absence	O
of	O
cyclosporine	B-drug-ME-2
A	E-drug-ME-2
.	O

The	O
concomitant	O
administration	O
of	O
bosentan	S-drug-AD-1
and	O
cyclosporine	B-drug-AD-2
A	E-drug-AD-2
is	O
contraindicated	O
.	O

Co	O
-	O
administration	O
of	O
bosentan	S-drug-ME-1
decreased	O
the	O
plasma	O
concentrations	O
of	O
cyclosporine	B-drug-ME-2
A	E-drug-ME-2
(	O
a	O
CYP3A4	O
substrate	O
)	O
by	O
approximately	O
50	O
%	O
.	O

Tacrolimus	S-drug
:	O
Co	O
-	O
administration	O
of	O
tacrolimus	S-drug
and	O
bosentan	S-drug
has	O
not	O
been	O
studied	O
in	O
man	O
.	O

Co	O
-	O
administration	O
of	O
tacrolimus	S-drug-ME-1
and	O
bosentan	S-drug-ME-2
resulted	O
in	O
markedly	O
increased	O
plasma	O
concentrations	O
of	O
bosentan	S-drug
in	O
animals	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
tacrolimus	S-drug-AD-1
and	O
bosentan	S-drug-AD-2
are	O
used	O
together	O
.	O

Glyburide	S-drug
:	O
An	O
increased	O
risk	O
of	O
elevated	O
liver	O
aminotransferases	O
was	O
observed	O
in	O
patients	O
receiving	O
concomitant	O
therapy	O
with	O
glyburide	S-drug
.	O

Therefore	O
,	O
the	O
concomitant	O
administration	O
of	O
TRACLEER	S-brand-AD-1
and	O
glyburide	S-drug-AD-2
is	O
contraindicated	O
,	O
and	O
alternative	O
hypoglycemic	B-group
agents	E-group
should	O
be	O
considered	O
.	O

Co	O
-	O
administration	O
of	O
bosentan	S-drug-ME-1
decreased	O
the	O
plasma	O
concentrations	O
of	O
glyburide	S-drug-ME-2
by	O
approximately	O
40	O
%	O
.	O

The	O
plasma	O
concentrations	O
of	O
bosentan	S-drug
were	O
also	O
decreased	O
by	O
approximately	O
30	O
%	O
.	O

Bosentan	S-drug-ME-1
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
oral	O
hypoglycemic	B-group-ME-2
agents	E-group-ME-2
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2C9	O
or	O
CYP3A4	O
.	O

The	O
possibility	O
of	O
worsened	O
glucose	O
control	O
in	O
patients	O
using	O
these	O
agents	O
should	O
be	O
considered	O
.	O

Ketoconazole	S-drug
:	O
Co	O
-	O
administration	O
of	O
bosentan	S-drug-ME-1
125	O
mg	O
b.i.d	O
.	O
and	O
ketoconazole	S-drug-ME-2
,	O
a	O
potent	O
CYP3A4	O
inhibitor	O
,	O
increased	O
the	O
plasma	O
concentrations	O
of	O
bosentan	S-drug
by	O
approximately	O
2	O
-	O
fold	O
.	O

No	O
dose	O
adjustment	O
of	O
bosentan	S-drug
is	O
necessary	O
,	O
but	O
increased	O
effects	O
of	O
bosentan	S-drug
should	O
be	O
considered	O
.	O

Simvastatin	S-drug
and	O
Other	O
Statins	S-group
:	O
Co	O
-	O
administration	O
of	O
bosentan	S-drug-ME-1
decreased	O
the	O
plasma	O
concentrations	O
of	O
simvastatin	S-drug-ME-2
(	O
a	O
CYP3A4	O
substrate	O
)	O
,	O
and	O
its	O
active	O
-	O
hydroxy	O
acid	O
metabolite	O
,	O
by	O
approximately	O
50	O
%	O
.	O

The	O
plasma	O
concentrations	O
of	O
bosentan	S-drug
were	O
not	O
affected	O
.	O

Bosentan	S-drug-ME-1
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
statins	S-group-ME-2
that	O
have	O
significant	O
metabolism	O
by	O
CYP3A4	O
,	O
such	O
as	O
lovastatin	S-drug-ME-2
and	O
atorvastatin	S-drug-ME-2
.	O

The	O
possibility	O
of	O
reduced	O
statin	S-group
efficacy	O
should	O
be	O
considered	O
.	O

Patients	O
using	O
CYP3A4	O
metabolized	O
statins	S-group-AD-1
should	O
have	O
cholesterol	O
levels	O
monitored	O
after	O
TRACLEER	S-brand-AD-2
is	O
initiated	O
to	O
see	O
whether	O
the	O
statin	S-group
dose	O
needs	O
adjustment	O
.	O

Warfarin	S-drug
:	O
Co	O
-	O
administration	O
of	O
bosentan	S-drug-ME-1
500	O
mg	O
b.i.d	O
.	O
for	O
6	O
days	O
decreased	O
the	O
plasma	O
concentrations	O
of	O
both	O
S	B-drug-ME-2
-	I-drug-ME-2
warfarin	E-drug-ME-2
(	O
a	O
CYP2C9	O
substrate	O
)	O
and	O
R	B-drug-ME-2
-	I-drug-ME-2
warfarin	E-drug-ME-2
(	O
a	O
CYP3A4	O
substrate	O
)	O
by	O
29	O
and	O
38	O
%	O
,	O
respectively	O
.	O

Clinical	O
experience	O
with	O
concomitant	O
administration	O
of	O
bosentan	S-drug
and	O
warfarin	S-drug
in	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
did	O
not	O
show	O
clinically	O
relevant	O
changes	O
in	O
INR	O
or	O
warfarin	S-drug
dose	O
(	O
baseline	O
vs.	O
end	O
of	O
the	O
clinical	O
studies	O
)	O
,	O
and	O
the	O
need	O
to	O
change	O
the	O
warfarin	S-drug
dose	O
during	O
the	O
trials	O
due	O
to	O
changes	O
in	O
INR	O
or	O
due	O
to	O
adverse	O
events	O
was	O
similar	O
among	O
bosentan	S-drug
-	O
and	O
placebo	O
-	O
treated	O
patients	O
.	O

Digoxin	S-drug
,	O
Nimodipine	S-drug
and	O
Losartan	S-drug
:	O
Bosentan	S-drug
has	O
no	O
significant	O
pharmacokinetic	O
interactions	O
with	O
digoxin	S-drug
and	O
nimodipine	S-drug
,	O
and	O
losartan	S-drug
has	O
no	O
significant	O
effect	O
on	O
plasma	O
levels	O
of	O
bosentan	S-drug
.	O

Co	O
-	O
administration	O
of	O
BOTOX	S-brand-AD-1
and	O
aminoglycosides	S-group-AD-2
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e.g	O
.	O
,	O
curare	B-group-AD-2
-	I-group-AD-2
like	I-group-AD-2
compounds	E-group-AD-2
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	S-drug
may	O
be	O
potentiated	O
.	O

The	O
effect	O
of	O
administering	O
different	O
botulinum	B-group
neurotoxin	E-group
serotypes	O
at	O
the	O
same	O
time	O
or	O
within	O
several	O
months	O
of	O
each	O
other	O
is	O
unknown	O
.	O

Excessive	O
neuromuscular	O
weakness	O
may	O
be	O
exacerbated	O
by	O
administration	O
of	O
another	O
botulinum	B-group-EF-1
toxin	E-group-EF-1
prior	O
to	O
the	O
resolution	O
of	O
the	O
effects	O
of	O
a	O
previously	O
administered	O
botulinum	B-group-EF-2
toxin	E-group-EF-2
.	O

Co	O
-	O
administration	O
of	O
MYOBLOC	S-brand-AD-1
and	O
aminoglycosides	S-group-AD-2
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e.g	O
.	O
,	O
curare	B-group-AD-2
-	I-group-AD-2
like	I-group-AD-2
compounds	E-group-AD-2
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	S-drug
may	O
be	O
potentiated	O
.	O

The	O
effect	O
of	O
administering	O
different	O
botulinum	B-group
neurotoxin	E-group
serotypes	O
at	O
the	O
same	O
time	O
or	O
within	O
less	O
than	O
4	O
months	O
of	O
each	O
other	O
is	O
unknown	O
.	O

However	O
,	O
neuromuscular	O
paralysis	O
may	O
be	O
potentiated	O
by	O
co	O
-	O
administration	O
or	O
overlapping	O
administration	O
of	O
different	O
botulinum	B-group
toxin	E-group
serotypes	O
.	O

Digitalis	S-group-EF-1
toxicity	O
may	O
be	O
aggravated	O
by	O
the	O
initial	O
release	O
of	O
norepinephrine	O
caused	O
by	O
Bretylium	B-drug-EF-2
Tosylate	E-drug-EF-2
Injection	O
.	O

The	O
pressor	O
effects	O
of	O
catecholamines	S-group-EF-1
such	O
as	O
dopamine	S-drug-EF-1
or	O
norepinephrine	S-drug-EF-1
are	O
enhanced	O
by	O
Bretylium	B-drug-EF-2
Tosylate	E-drug-EF-2
.	O

When	O
catecholamines	S-group
are	O
administered	O
,	O
dilute	O
solutions	O
should	O
be	O
used	O
and	O
blood	O
pressure	O
should	O
be	O
monitored	O
closely	O
.	O

Although	O
there	O
is	O
little	O
published	O
information	O
on	O
concomitant	O
administration	O
of	O
lidocaine	S-drug
and	O
Bretylium	B-drug
Tosylate	E-drug
,	O
these	O
drugs	O
are	O
often	O
administered	O
concurrently	O
without	O
any	O
evidence	O
of	O
interactions	O
resulting	O
in	O
adverse	O
effects	O
or	O
diminished	O
efficacy	O
.	O

Although	O
specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ALPHAGAN	B-brand-AD-1
P	E-brand-AD-1
,	O
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	B-group-AD-2
depressants	E-group-AD-2
(	O
alcohol	S-drug-AD-2
,	O
barbiturates	S-group-AD-2
,	O
opiates	S-group-AD-2
,	O
sedatives	S-group-AD-2
,	O
or	O
anesthetics	S-group-AD-2
)	O
should	O
be	O
considered	O
.	O

Alpha	B-group
-	I-group
agonists	E-group
,	O
as	O
a	O
class	O
,	O
may	O
reduce	O
pulse	O
and	O
blood	O
pressure	O
.	O

Caution	O
in	O
using	O
concomitant	O
drugs	O
such	O
as	O
beta	B-group
-	I-group
blockers	E-group
(	O
ophthalmic	O
and	O
systemic	O
)	O
,	O
anti	B-group
-	I-group
hypertensives	E-group
and	O
/	O
or	O
cardiac	B-group
glycosides	E-group
is	O
advised	O
.	O

Tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine.It	O
is	O
not	O
known	O
whether	O
the	O
concurrent	O
use	O
of	O
these	O
agents	O
with	O
ALPHAGAN	B-brand
P	E-brand
in	O
humans	O
can	O
lead	O
to	O
resulting	O
interference	O
with	O
the	O
IOP	O
lowering	O
effect	O
.	O

No	O
data	O
on	O
the	O
level	O
of	O
circulating	O
catecholamines	O
after	O
ALPHAGAN	B-brand
P	E-brand
administration	O
are	O
available	O
.	O

Caution	O
,	O
however	O
,	O
is	O
advised	O
in	O
patients	O
taking	O
tricyclic	B-group
antidepressants	E-group
which	O
can	O
affect	O
the	O
metabolism	O
and	O
uptake	O
of	O
circulating	O
amines	O
.	O

AZOPT	S-brand
(	O
brinzolamide	S-drug
ophthalmic	O
suspension	O
)	O
1	O
%	O
contains	O
a	O
carbonic	B-group
anhydrase	I-group
inhibitor	E-group
.	O

Acid	O
-	O
base	O
and	O
electrolyte	O
alterations	O
were	O
not	O
reported	O
in	O
the	O
clinical	O
trials	O
with	O
brinzolamide	S-drug
.	O

However	O
,	O
in	O
patients	O
treated	O
with	O
oral	O
carbonic	B-group-IN-1
anhydrase	I-group-IN-1
inhibitors	E-group-IN-1
,	O
rare	O
instances	O
of	O
drug	O
interactions	O
have	O
occurred	O
with	O
high	O
-	O
dose	O
salicylate	S-drug-IN-2
therapy	O
.	O

Therefore	O
,	O
the	O
potential	O
for	O
such	O
drug	O
interaction	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
AZOPT	S-brand
(	O
brinzolamide	S-drug
ophthalmic	O
suspension	O
)	O
1	O
%	O
.	O

The	O
risk	O
of	O
using	O
bromocriptine	B-drug
mesylate	E-drug
in	O
combination	O
with	O
other	O
drugs	O
has	O
not	O
been	O
systematically	O
evaluated	O
,	O
but	O
alcohol	S-drug-EF-1
may	O
potentiate	O
the	O
side	O
effects	O
of	O
bromocriptine	B-drug-EF-2
mesylate	E-drug-EF-2
.	O

Bromocriptine	B-drug-IN-1
mesylate	E-drug-IN-1
may	O
interact	O
with	O
dopamine	B-group-IN-2
antagonists	E-group-IN-2
,	O
butyrophenones	S-group-IN-2
,	O
and	O
certain	O
other	O
agents	O
.	O

Compounds	O
in	O
these	O
categories	O
result	O
in	O
a	O
decreased	O
efficacy	O
of	O
bromocriptine	B-drug-EF-1
mesylate	E-drug-EF-1
:	O
phenothiazines	S-group-EF-2
,	O
haloperidol	S-drug-EF-2
,	O
metoclopramide	S-drug-EF-2
,	O
pimozide	S-drug-EF-2
.	O

Concomitant	O
use	O
of	O
bromocriptine	B-drug-AD-1
mesylate	E-drug-AD-1
with	O
other	O
ergot	B-group-AD-2
alkaloids	E-group-AD-2
is	O
not	O
recommended	O
.	O

Dexbrompheniramine	S-drug-EF-1
can	O
interact	O
with	O
alcohol	S-drug-EF-2
or	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	S-group
)	O
,	O
anticholinergics	S-group-EF-2
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	S-group
)	O
,	O
and	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
(	I-group-EF-2
MAO	I-group-EF-2
)	I-group-EF-2
inhibitors	E-group-EF-2
(	O
concurrent	O
use	O
with	O
antihistamines	S-group
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	S-group
)	O
.	O

This	O
drug	O
may	O
interact	O
with	O
alcohol	S-drug
or	O
other	O
CNS	B-group
depressants	E-group
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	S-group
)	O
,	O
anticholinergics	S-group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	S-group
)	O
,	O
and	O
monoamine	B-group
oxidase	I-group
(	I-group
MAO	I-group
)	I-group
inhibitors	E-group
(	O
concurrent	O
use	O
with	O
antihistamines	S-group
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	S-group
)	O
.	O

Concomitant	O
oral	O
administration	O
of	O
ketoconazole	S-drug-ME-1
(	O
a	O
known	O
inhibitor	O
of	O
CYP3A4	O
activity	O
in	O
the	O
liver	O
and	O
in	O
the	O
intestinal	O
mucosa	O
)	O
caused	O
an	O
eight	O
-	O
fold	O
increase	O
of	O
the	O
systemic	O
exposure	O
to	O
oral	O
budesonide	S-drug-ME-2
.	O

If	O
treatment	O
with	O
inhibitors	O
of	O
CYP3A4	O
activity	O
(	O
such	O
as	O
ketoconazole	S-drug-AD-1
,	O
intraconazole	S-drug-AD-1
,	O
ritonavir	S-drug-AD-1
,	O
indinavir	S-drug-AD-1
,	O
saquinavir	S-drug-AD-1
,	O
erythromycin	S-drug-AD-1
,	O
etc	O
.	O
)	O
is	O
indicated	O
,	O
reduction	O
of	O
the	O
budesonide	S-drug-AD-2
dose	O
should	O
be	O
considered	O
.	O

After	O
extensive	O
intake	O
of	O
grapefruit	O
juice	O
(	O
which	O
inhibits	O
CYP3A4	O
activity	O
predominantly	O
in	O
the	O
intestinal	O
mucosa	O
)	O
,	O
the	O
systemic	O
exposure	O
for	O
oral	O
budesonide	S-drug
increased	O
about	O
two	O
times	O
.	O

As	O
with	O
other	O
drugs	O
primarily	O
being	O
metabolized	O
through	O
CYP3A4	O
,	O
ingestion	O
of	O
grapefruit	O
or	O
grapefruit	O
juice	O
should	O
be	O
avoided	O
in	O
connection	O
with	O
budesonide	S-drug
administration	O
.	O

-	O
Drugs	O
with	O
ototoxic	O
potential	O
:	O
Especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
,	O
the	O
use	O
of	O
parenterally	O
administered	O
bumetanide	S-drug-AD-1
in	O
patients	O
to	O
whom	O
aminoglycoside	B-group-AD-2
antibiotics	E-group-AD-2
are	O
also	O
being	O
given	O
should	O
be	O
avoided	O
,	O
except	O
in	O
life	O
-	O
threatening	O
conditions	O
.	O

-	O
Drugs	O
with	O
nephrotoxic	O
potential	O
:	O
There	O
has	O
been	O
no	O
experience	O
on	O
the	O
concurrent	O
use	O
of	O
bumetanide	S-drug
with	O
drugs	O
known	O
to	O
have	O
a	O
nephrotoxic	O
potential	O
.	O

Therefore	O
,	O
the	O
simultaneous	O
administration	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

-	O
Lithium	S-drug
:	O
Lithium	S-drug-AD-1
should	O
generally	O
not	O
be	O
given	O
with	O
diuretics	S-group-AD-2
(	O
such	O
as	O
bumetanide	S-drug-AD-2
)	O
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	S-drug
toxicity	O
.	O

-	O
Probenecid	S-drug
:	O
Pretreatment	O
with	O
probenecid	S-drug-EF-1
reduces	O
both	O
the	O
natriuresis	O
and	O
hyperreninemia	O
produced	O
by	O
bumetanide	S-drug-EF-2
.	O

This	O
antagonistic	O
effect	O
of	O
probenecid	S-drug-ME-1
on	O
bumetanide	S-drug-ME-2
natriuresis	O
is	O
not	O
due	O
to	O
a	O
direct	O
action	O
on	O
sodium	O
excretion	O
but	O
is	O
probably	O
secondary	O
to	O
its	O
inhibitory	O
effect	O
on	O
renal	O
tubular	O
secretion	O
of	O
bumetanide	S-drug
.	O

Thus	O
,	O
probenecid	S-drug-AD-1
should	O
not	O
be	O
administered	O
concurrently	O
with	O
bumetanide	S-drug-AD-2
.	O

-	O
Indomethacin	S-drug
:	O
Indomethacin	S-drug-MU-1
blunts	O
the	O
increases	O
in	O
urine	O
volume	O
and	O
sodium	O
excretion	O
seen	O
during	O
bumetanide	S-drug-ME-2
treatment	O
and	O
inhibits	O
the	O
bumetanide	S-drug-EF-2
-	O
induced	O
increase	O
in	O
plasma	O
renin	O
activity	O
.	O

Concurrent	O
therapy	O
with	O
bumetanide	S-drug
is	O
thus	O
not	O
recommended	O
.	O

-	O
Antihypertensives	S-group
:	O
Bumetanide	S-drug-EF-1
may	O
potentiate	O
the	O
effect	O
of	O
various	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
,	O
necessitating	O
a	O
reduction	O
in	O
the	O
dosage	O
of	O
these	O
drugs	O
.	O

-	O
Digoxin	S-drug
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
no	O
effect	O
on	O
digoxin	S-drug
blood	O
levels	O
.	O

-	O
Anticoagulants	S-group
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
bumetanide	S-drug
to	O
have	O
no	O
effect	O
on	O
warfarin	S-drug
metabolism	O
or	O
on	O
plasma	O
prothrombin	O
activity	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B-group
solutions	E-group
containing	O
epinephrine	S-drug-EF-1
or	O
norepinephrine	S-drug-EF-1
to	O
patients	O
receiving	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
or	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
may	O
produce	O
severe	O
,	O
prolonged	O
hypertension	O
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
in	O
which	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	B-group
drugs	E-group
and	O
of	O
ergot	B-group
-	I-group
type	I-group
oxytocic	I-group
drugs	E-group
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Phenothiazines	S-group-EF-1
and	O
butyrophenones	S-group-EF-1
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	S-drug-EF-2
.	O

Buprenorphine	S-drug
is	O
metabolized	O
to	O
norbuprenorphine	S-drug_n
by	O
cytochrome	O
CYP	O
3A4	O
.	O

Because	O
CYP	O
3A4	O
inhibitors	O
may	O
increase	O
plasma	O
concentrations	O
of	O
buprenorphine	S-drug
,	O
patients	O
already	O
on	O
CYP	O
3A4	O
inhibitors	O
such	O
as	O
azole	B-group
antifungals	E-group
(	O
e.g	O
.	O

ketoconazole	S-drug
)	O
,	O
macrolide	B-group
antibiotics	E-group
(	O
e.g	O
.	O
erythromycin	S-drug
)	O
,	O
and	O
HIV	B-group
protease	I-group
inhibitors	E-group
(	O
e.g	O
.	O
ritonavir	S-drug
,	O
indinavir	S-drug
and	O
saquinavir	S-drug
)	O
should	O
have	O
their	O
dose	O
of	O
SUBUTEX	S-brand
or	O
SUBOXONE	S-brand
adjusted	O
.	O

Based	O
on	O
anecdotal	O
reports	O
,	O
there	O
may	O
be	O
an	O
interaction	O
between	O
buprenorphine	S-drug-IN-1
and	O
benzodiazepines	S-group-IN-2
.	O

There	O
have	O
been	O
a	O
number	O
of	O
reports	O
in	O
the	O
post	O
-	O
marketing	O
experience	O
of	O
coma	O
and	O
death	O
associated	O
with	O
the	O
concomitant	O
intravenous	O
misuse	O
of	O
buprenorphine	S-drug-EF-1
and	O
benzodiazepines	S-drug-EF-2
by	O
addicts	O
.	O

In	O
many	O
of	O
these	O
cases	O
,	O
buprenorphine	S-drug
was	O
misused	O
by	O
self	O
-	O
injection	O
of	O
crushed	O
SUBUTEX	S-brand
tablets	O
.	O

SUBUTEX	S-brand-AD-1
and	O
SUBOXONE	S-brand-AD-1
should	O
be	O
prescribed	O
with	O
caution	O
to	O
patients	O
on	O
benzodiazepines	S-group-AD-2
or	O
other	O
drugs	O
that	O
act	O
on	O
the	O
central	O
nervous	O
system	O
,	O
regardless	O
of	O
whether	O
these	O
drugs	O
are	O
taken	O
on	O
the	O
advice	O
of	O
a	O
physician	O
or	O
are	O
taken	O
as	O
drugs	O
of	O
abuse	O
.	O

Patients	O
should	O
be	O
warned	O
of	O
the	O
potential	O
danger	O
of	O
the	O
intravenous	O
self	O
-	O
administration	O
of	O
benzodiazepines	S-group-AD-1
while	O
under	O
treatment	O
with	O
SUBOXONE	S-brand-AD-2
or	O
SUBUTEX	S-brand-AD-2
.	O

Few	O
systemic	O
data	O
have	O
been	O
collected	O
on	O
the	O
metabolism	O
of	O
WELLBUTRIN	S-brand
following	O
concomitant	O
administration	O
with	O
other	O
drugs	O
or	O
,	O
alternatively	O
,	O
the	O
effect	O
of	O
concomitant	O
administration	O
of	O
WELLBUTRIN	S-brand
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
.	O

Because	O
bupropion	S-drug
is	O
extensively	O
metabolized	O
,	O
the	O
coadministration	O
of	O
other	O
drugs	O
may	O
affect	O
its	O
clinical	O
activity	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
bupropion	S-drug
is	O
primarily	O
metabolized	O
to	O
hydroxybupropion	S-drug_n
by	O
the	O
CYP2B6	O
isoenzyme	O
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
a	O
drug	O
interaction	O
between	O
WELLBUTRIN	S-brand-IN-1
and	O
drugs	O
that	O
affect	O
the	O
CYP2B6	O
isoenzyme	O
(	O
e.g	O
.	O
,	O
orphenadrine	S-drug-IN-2
and	O
cyclophosphamide	S-drug-IN-2
)	O
.	O

The	O
threohydrobupropion	S-drug_n
metabolite	O
of	O
bupropion	S-drug
does	O
not	O
appear	O
to	O
be	O
produced	O
by	O
the	O
cytochrome	O
P450	O
isoenzymes	O
.	O

The	O
effects	O
of	O
concomitant	O
administration	O
of	O
cimetidine	S-drug
on	O
the	O
pharmacokinetics	O
of	O
bupropion	S-drug
and	O
its	O
active	O
metabolites	O
were	O
studied	O
in	O
24	O
healthy	O
young	O
male	O
volunteers	O
.	O

Following	O
oral	O
administration	O
of	O
two	O
150	O
-	O
mg	O
sustained	O
-	O
release	O
tablets	O
with	O
and	O
without	O
800	O
mg	O
of	O
cimetidine	S-drug
,	O
the	O
pharmacokinetics	O
of	O
bupropion	S-drug
and	O
hydroxybupropion	S-drug_n
were	O
unaffected	O
.	O

However	O
,	O
there	O
were	O
16	O
%	O
and	O
32	O
%	O
increases	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
respectively	O
,	O
of	O
the	O
combined	O
moieties	O
of	O
threohydrobupropion	S-drug_n
and	O
erythrohydrobupropion	S-drug_n
.	O

While	O
not	O
systematically	O
studied	O
,	O
certain	O
drugs	O
may	O
induce	O
the	O
metabolism	O
of	O
bupropion	S-drug-ME-1
(	O
e.g	O
.	O
,	O
carbamazepine	S-drug-ME-2
,	O
phenobarbital	S-drug-ME-2
,	O
phenytoin	S-drug-ME-2
)	O
.	O

Animal	O
data	O
indicated	O
that	O
bupropion	S-drug
may	O
be	O
an	O
inducer	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
in	O
humans	O
.	O

In	O
one	O
study	O
,	O
following	O
chronic	O
administration	O
of	O
bupropion	S-drug
,	O
100	O
mg	O
3	O
times	O
daily	O
to	O
8	O
healthy	O
male	O
volunteers	O
for	O
14	O
days	O
,	O
there	O
was	O
no	O
evidence	O
of	O
induction	O
of	O
its	O
own	O
metabolism	O
.	O

Nevertheless	O
,	O
there	O
may	O
be	O
the	O
potential	O
for	O
clinically	O
important	O
alterations	O
of	O
blood	O
levels	O
of	O
coadministered	O
drugs	O
.	O

Drugs	O
Metabolized	O
by	O
Cytochrome	O
P450IID6	O
(	O
CYP2D6	O
)	O
:	O
Many	O
drugs	O
,	O
including	O
most	O
antidepressants	S-group
(	O
SSRIs	O
,	O
many	O
tricyclics	S-group
)	O
,	O
beta	B-group
-	I-group
blockers	E-group
,	O
antiarrhythmics	S-drug
,	O
and	O
antipsychotics	S-group
are	O
metabolized	O
by	O
the	O
CYP2D6	O
isoenzyme	O
.	O

Although	O
bupropion	S-drug
is	O
not	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
bupropion	S-drug
and	O
hydroxybupropion	S-drug_n
are	O
inhibitors	O
of	O
the	O
CYP2D6	O
isoenzyme	O
in	O
vitro	O
.	O

In	O
a	O
study	O
of	O
15	O
male	O
subjects	O
(	O
ages	O
19	O
to	O
35	O
years	O
)	O
who	O
were	O
extensive	O
metabolizers	O
of	O
the	O
CYP2D6	O
isoenzyme	O
,	O
daily	O
doses	O
of	O
bupropion	S-drug-ME-1
given	O
as	O
150	O
mg	O
twice	O
daily	O
followed	O
by	O
a	O
single	O
dose	O
of	O
50	O
mg	O
desipramine	S-drug-ME-2
increased	O
the	O
Cmax	O
,	O
AUC	O
,	O
and	O
t1	O
/	O
2	O
of	O
desipramine	S-drug
by	O
an	O
average	O
of	O
approximately	O
2	O
-	O
,	O
5	O
-	O
and	O
2	O
-	O
fold	O
,	O
respectively	O
.	O

The	O
effect	O
was	O
present	O
for	O
at	O
least	O
7	O
days	O
after	O
the	O
last	O
dose	O
of	O
bupropion	S-drug
.	O

Concomitant	O
use	O
of	O
bupropion	S-drug
with	O
other	O
drugs	O
metabolized	O
by	O
CYP2D6	O
has	O
not	O
been	O
formally	O
studied	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
bupropion	S-drug-AD-1
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP2D6	O
isoenzyme	O
including	O
certain	O
antidepressants	S-group-AD-2
(	O
e.g	O
.	O
,	O
nortriptyline	S-drug-AD-2
,	O
imipramine	S-drug-AD-2
,	O
desipramine	S-drug-AD-2
,	O
paroxetine	S-drug-AD-2
,	O
fluoxetine	S-drug-AD-2
,	O
sertraline	S-drug-AD-2
)	O
,	O
antipsychotics	S-group-AD-2
(	O
e.g	O
.	O
,	O
haloperidol	S-drug-AD-2
,	O
risperidone	S-drug-AD-2
,	O
thioridazine	S-drug-AD-2
)	O
,	O
beta	B-group-AD-2
-	I-group-AD-2
blockers	E-group-AD-2
(	O
e.g	O
.	O
,	O
metoprolol	S-drug-AD-2
)	O
,	O
and	O
Type	B-group-AD-2
1C	I-group-AD-2
antiarrhythmics	E-group-AD-2
(	O
e.g	O
.	O
,	O
propafenone	S-drug-AD-2
,	O
flecainide	S-drug-AD-2
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
and	O
should	O
be	O
initiated	O
at	O
the	O
lower	O
end	O
of	O
the	O
dose	O
range	O
of	O
the	O
concomitant	O
medication	O
.	O

If	O
bupropion	S-drug
is	O
added	O
to	O
the	O
treatment	O
regimen	O
of	O
a	O
patient	O
already	O
receiving	O
a	O
drug	O
metabolized	O
by	O
CYP2D6	O
,	O
the	O
need	O
to	O
decrease	O
the	O
dose	O
of	O
the	O
original	O
medication	O
should	O
be	O
considered	O
,	O
particularly	O
for	O
those	O
concomitant	O
medications	O
with	O
a	O
narrow	O
therapeutic	O
index	O
.	O

MAO	B-group
Inhibitors	E-group
:	O
Studies	O
in	O
animals	O
demonstrate	O
that	O
the	O
acute	O
toxicity	O
of	O
bupropion	S-drug-EF-1
is	O
enhanced	O
by	O
the	O
MAO	B-group
inhibitor	E-group
phenelzine	S-drug-EF-2
.	O

Levodopa	S-drug
and	O
Amantadine	S-drug
:	O
Limited	O
clinical	O
data	O
suggest	O
a	O
higher	O
incidence	O
of	O
adverse	O
experiences	O
in	O
patients	O
receiving	O
bupropion	S-drug-EF-1
concurrently	O
with	O
either	O
levodopa	S-drug-EF-2
or	O
amantadine	S-drug-EF-2
.	O

Administration	O
of	O
WELLBUTRIN	S-brand-AD-1
Tablets	O
to	O
patients	O
receiving	O
either	O
levodopa	S-drug-AD-2
or	O
amantadine	S-drug-AD-2
concurrently	O
should	O
be	O
undertaken	O
with	O
caution	O
,	O
using	O
small	O
initial	O
doses	O
and	O
small	O
gradual	O
dose	O
increases	O
.	O

Drugs	O
that	O
Lower	O
Seizure	O
Threshold	O
:	O
Concurrent	O
administration	O
of	O
WELLBUTRIN	S-brand-AD-1
and	O
agents	O
(	O
e.g	O
.	O
,	O
antipsychotics	S-group-AD-2
,	O
other	O
antidepressants	S-group-AD-2
,	O
theophylline	S-drug-AD-2
,	O
systemic	O
steroids	S-group-AD-2
,	O
etc	O
.	O
)	O
that	O
lower	O
seizure	O
threshold	O
should	O
be	O
undertaken	O
only	O
with	O
extreme	O
caution	O
.	O

Low	O
initial	O
dosing	O
and	O
small	O
gradual	O
dose	O
increases	O
should	O
be	O
employed	O
.	O

Nicotine	S-drug
Transdermal	O
System	O
:	O
.	O

Alcohol	S-drug
:	O
In	O
post	O
-	O
marketing	O
experience	O
,	O
there	O
have	O
been	O
rare	O
reports	O
of	O
adverse	O
neuropsychiatric	O
events	O
or	O
reduced	O
alcohol	S-drug
tolerance	O
in	O
patients	O
who	O
were	O
drinking	O
alcohol	S-drug-EF-1
during	O
treatment	O
with	O
WELLBUTRIN	S-brand-EF-2
.	O

The	O
consumption	O
of	O
alcohol	S-drug-AD-1
during	O
treatment	O
with	O
WELLBUTRIN	S-brand-AD-2
should	O
be	O
minimized	O
or	O
avoided	O
(	O
also	O
see	O
a	O
href	O
=	O
bupropz_od.htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O

It	O
is	O
recommended	O
that	O
buspirone	B-drug-AD-1
hydrochloride	E-drug-AD-1
not	O
be	O
used	O
concomitantly	O
with	O
MAO	B-group-AD-2
inhibitors	E-group-AD-2
Because	O
the	O
effects	O
of	O
concomitant	O
administration	O
of	O
buspirone	B-drug
HCl	E-drug
with	O
most	O
other	O
psychotropic	B-group
drugs	E-group
have	O
not	O
been	O
studied	O
,	O
the	O
concomitant	O
use	O
of	O
buspirone	B-drug
HCl	E-drug
with	O
other	O
CNS	O
-	O
active	O
drugs	O
should	O
be	O
approached	O
with	O
caution	O
.	O

There	O
is	O
one	O
report	O
suggesting	O
that	O
the	O
concomitant	O
use	O
of	O
trazodone	B-drug-EF-1
hydrochloride	E-drug-EF-1
(	O
Desyrel	S-brand-EF-1
)	O
and	O
buspirone	B-drug-EF-2
HCl	E-drug-EF-2
may	O
have	O
caused	O
3	O
-	O
to	O
6	O
-	O
fold	O
elevations	O
on	O
SGPT	O
(	O
ALT	O
)	O
in	O
a	O
few	O
patients	O
.	O

In	O
a	O
similar	O
study	O
,	O
attempting	O
to	O
replicate	O
this	O
finding	O
,	O
no	O
interactive	O
effect	O
on	O
hepatic	O
transaminases	O
was	O
identified	O
.	O

In	O
a	O
study	O
in	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
buspirone	B-drug-ME-1
HCl	E-drug-ME-1
and	O
haloperidol	S-drug-ME-2
resulted	O
in	O
increased	O
serum	O
haloperidol	S-drug
concentrations	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
not	O
clear	O
.	O

In	O
vitro	O
,	O
buspirone	S-drug
does	O
not	O
displace	O
tightly	O
bound	O
drugs	O
like	O
phenytoin	S-drug
,	O
propranolol	S-drug
,	O
and	O
warfarin	S-drug
from	O
serum	O
proteins	O
.	O

However	O
,	O
there	O
has	O
been	O
one	O
report	O
of	O
prolonged	O
prothrombin	O
time	O
when	O
buspirone	S-drug-EF-1
was	O
added	O
to	O
the	O
regimen	O
of	O
a	O
patient	O
treated	O
with	O
warfarin	S-drug-EF-2
.	O

The	O
patient	O
was	O
also	O
chronically	O
receiving	O
phenytoin	S-drug
,	O
phenobarbital	S-drug
,	O
digoxin	S-drug
,	O
and	O
levothyroxine	B-drug
sodium	E-drug
.	O

In	O
vitro	O
,	O
buspirone	S-drug-ME-1
may	O
displace	O
less	O
firmly	O
bound	O
drugs	O
like	O
digoxin	S-drug-ME-2
.	O

The	O
clinical	O
significance	O
of	O
this	O
property	O
is	O
unknown	O
.	O

Itraconazole	S-drug-ME-1
decreases	O
busulfan	S-drug-ME-2
clearance	O
by	O
up	O
to	O
25	O
%	O
,	O
and	O
may	O
produce	O
AUCs	O
1500	O
M	O
min	O
in	O
some	O
patients	O
.	O

Fluconazole	S-drug
,	O
and	O
the	O
5	B-group
-	I-group
HT3	I-group
antiemetics	E-group
ondansetron	S-drug
(	O
Zofran	S-brand
)	O
and	O
granisetron	S-drug
(	O
Kytril	S-brand
)	O
have	O
all	O
been	O
used	O
with	O
BUSULFEX	S-brand
.	O

Phenytoin	S-drug-ME-1
increases	O
the	O
clearance	O
of	O
busulfan	S-drug-ME-2
by	O
15	O
%	O
or	O
more	O
,	O
possibly	O
due	O
to	O
the	O
induction	O
of	O
glutathione	O
-	O
S	O
-	O
transferase	O
.	O

Since	O
the	O
pharmacokinetics	O
of	O
BUSULFEX	S-brand-ME-1
were	O
studied	O
in	O
patients	O
treated	O
with	O
phenytoin	S-drug-ME-2
,	O
the	O
clearance	O
of	O
BUSULFEX	S-brand
at	O
the	O
recommended	O
dose	O
may	O
be	O
lower	O
and	O
exposure	O
(	O
AUC	O
)	O
higher	O
in	O
patients	O
not	O
treated	O
with	O
phenytoin	S-drug
.	O

Because	O
busulfan	S-drug
is	O
eliminated	O
from	O
the	O
body	O
via	O
conjugation	O
with	O
glutathione	O
,	O
use	O
of	O
acetaminophen	S-drug-ME-1
prior	O
to	O
(	O
72	O
hours	O
)	O
or	O
concurrent	O
with	O
BUSULFEX	S-brand-ME-2
may	O
result	O
in	O
reduced	O
busulfan	S-drug
clearance	O
based	O
upon	O
the	O
known	O
property	O
of	O
acetaminophen	S-drug
to	O
decrease	O
glutathione	O
levels	O
in	O
the	O
blood	O
and	O
tissues	O
.	O

Interactions	O
may	O
occur	O
with	O
the	O
following	O
:	O
adrenocorticoids	O
(	O
cortisone	O
-	O
like	O
medicine	O
)	O
,	O
anticoagulants	S-group
(	O
blood	B-group
thinners	O
)	O
,	O
carbamazepine	S-drug
,	O
corticotropin	S-drug
(	O
barbiturates	S-group
may	O
decrease	O
the	O
effects	O
of	O
these	O
medicines	O
)	O
,	O
central	B-group
nervous	I-group
system	I-group
(	I-group
CNS	I-group
)	I-group
depressants	E-group
(	O
using	O
these	O
medicines	O
with	O
barbiturates	S-group
may	O
result	O
in	O
increased	O
CNS	O
depressant	O
effects	O
)	O
,	O
divalproex	B-drug
sodium	E-drug
,	O
valproic	B-drug
acid	E-drug
(	O
using	O
these	O
medicines	O
with	O
barbiturates	S-group
may	O
change	O
the	O
amount	O
of	O
either	O
medicine	O
that	O
you	O
need	O
to	O
take	O
)	O
,	O
and	O
oral	O
contraceptives	S-group
containing	O
estrogens	S-group
(	O
barbiturates	S-group-EF-1
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
oral	O
contraceptives	S-group-EF-2
,	O
and	O
you	O
may	O
need	O
to	O
change	O
to	O
a	O
different	O
type	O
of	O
birth	O
control	O
)	O
.	O

The	O
CNS	O
effects	O
of	O
butalbital	S-drug-EF-1
may	O
be	O
enhanced	O
by	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
(	I-group-EF-2
MAO	I-group-EF-2
)	I-group-EF-2
inhibitors	E-group-EF-2
.	O

Butalbital	S-drug-EF-1
,	O
acetaminophen	S-drug-EF-1
and	O
caffeine	S-drug-EF-1
may	O
enhance	O
the	O
effects	O
of	O
:	O
other	O
narcotic	B-group-EF-2
analgesics	O
,	O
alcohol	S-drug-EF-2
,	O
general	O
anesthetics	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
such	O
as	O
chlordiazepoxide	S-drug-EF-2
,	O
sedative	B-group-EF-2
-	I-group-EF-2
hypnotics	E-group-EF-2
,	O
or	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
,	O
causing	O
increased	O
CNS	O
depression	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Acetaminophen	S-drug
may	O
produce	O
false	O
-	O
positive	O
test	O
results	O
for	O
urinary	O
5	O
-	O
hydroxyindoleacetic	O
acid	O
.	O

Potential	O
drug	O
interactions	O
between	O
Mentax	S-brand
(	O
butenafine	B-drug
HCl	E-drug
cream	O
)	O
Cream	O
,	O
1	O
%	O
,	O
and	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

Concurrent	O
use	O
of	O
butorphanol	S-drug-EF-1
with	O
central	B-group-EF-2
nervous	I-group-EF-2
system	I-group-EF-2
depressants	E-group-EF-2
(	O
e.g	O
.	O
,	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
,	O
and	O
antihistamines	S-group-EF-2
)	O
may	O
result	O
in	O
increased	O
central	B-group
nervous	I-group
system	I-group
depressant	E-group
effects	O
.	O

When	O
used	O
concurrently	O
with	O
such	O
drugs	O
,	O
the	O
dose	O
of	O
butorphanol	S-drug
should	O
be	O
the	O
smallest	O
effective	O
dose	O
and	O
the	O
frequency	O
of	O
dosing	O
reduced	O
as	O
much	O
as	O
possible	O
when	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
potentiate	O
the	O
action	O
of	O
opioids	S-group
.	O

In	O
healthy	O
volunteers	O
,	O
the	O
pharmacokinetics	O
of	O
a	O
1	O
-	O
mg	O
dose	O
of	O
butorphanol	S-drug
administered	O
as	O
STADOL	B-brand
NS	E-brand
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
a	O
single	O
6	O
-	O
mg	O
subcutaneous	O
dose	O
of	O
sumatriptan	S-drug
.	O

However	O
,	O
in	O
another	O
study	O
in	O
healthy	O
volunteers	O
,	O
the	O
pharmacokinetics	O
of	O
butorphanol	S-drug
were	O
significantly	O
altered	O
(	O
29	O
%	O
decrease	O
in	O
AUC	O
and	O
38	O
%	O
decrease	O
in	O
Cmax	O
)	O
when	O
a	O
1	O
-	O
mg	O
dose	O
of	O
STADOL	B-brand-ME-1
NS	E-brand-ME-1
was	O
administered	O
1	O
minute	O
after	O
a	O
20	O
-	O
mg	O
dose	O
of	O
sumatriptan	S-drug-ME-2
nasal	O
spray	O
.	O

(	O
The	O
two	O
drugs	O
were	O
administered	O
in	O
opposite	O
nostrils	O
.	O
)	O

When	O
the	O
STADOL	B-brand-ME-1
NS	E-brand-ME-1
was	O
administered	O
30	O
minutes	O
after	O
the	O
sumatriptan	S-drug-ME-2
nasal	O
spray	O
,	O
the	O
AUC	O
of	O
butorphanol	S-drug
increased	O
11	O
%	O
and	O
Cmax	O
decreased	O
18	O
%	O
.	O

In	O
neither	O
case	O
were	O
the	O
pharmacokinetics	O
of	O
sumatriptan	S-drug
affected	O
by	O
coadministration	O
with	O
STADOL	B-brand
NS	E-brand
.	O

These	O
results	O
suggest	O
that	O
the	O
analgesic	O
effect	O
of	O
STADOL	B-brand-EF-1
NS	E-brand-EF-1
may	O
be	O
diminished	O
when	O
it	O
is	O
administered	O
shortly	O
after	O
sumatriptan	S-drug-EF-2
nasal	O
spray	O
,	O
but	O
by	O
30	O
minutes	O
any	O
such	O
reduction	O
in	O
effect	O
should	O
be	O
minimal	O
.	O

The	O
safety	O
of	O
using	O
STADOL	B-brand
NS	E-brand
and	O
IMITREX	S-brand
(	O
sumatriptan	S-drug
)	O
Nasal	O
Spray	O
during	O
the	O
same	O
episode	O
of	O
migraine	O
has	O
not	O
been	O
established	O
.	O

However	O
,	O
it	O
should	O
be	O
noted	O
that	O
both	O
products	O
are	O
capable	O
of	O
producing	O
transient	O
increases	O
in	O
blood	O
pressure	O
.	O

The	O
pharmacokinetics	O
of	O
a	O
1	O
-	O
mg	O
dose	O
of	O
butorphanol	S-drug
administered	O
as	O
STADOL	B-brand
NS	E-brand
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
cimetidine	S-drug
(	O
300	O
mg	O
QID	O
)	O
.	O

Conversely	O
,	O
the	O
administration	O
of	O
STADOL	B-brand
NS	E-brand
(	O
1	O
mg	O
butorphanol	S-drug
QID	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
300	O
-	O
mg	O
dose	O
of	O
cimetidine	S-drug
.	O

It	O
is	O
not	O
known	O
if	O
the	O
effects	O
of	O
butorphanol	S-drug-AD-1
are	O
altered	O
by	O
concomitant	O
medications	O
that	O
affect	O
hepatic	O
metabolism	O
of	O
drugs	O
(	O
erythromycin	S-drug-AD-2
,	O
etc	O
.	O
)	O
,	O
but	O
physicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
that	O
a	O
smaller	O
initial	O
dose	O
and	O
longer	O
intervals	O
between	O
doses	O
may	O
be	O
needed	O
.	O

The	O
fraction	O
of	O
STADOL	B-brand
NS	E-brand
absorbed	O
is	O
unaffected	O
by	O
the	O
concomitant	O
administration	O
of	O
a	O
nasal	B-group
vasoconstrictor	E-group
(	O
oxymetazoline	S-drug
)	O
,	O
but	O
the	O
rate	O
of	O
absorption	O
is	O
decreased	O
.	O

Therefore	O
,	O
a	O
slower	O
onset	O
can	O
be	O
anticipated	O
if	O
STADOL	B-brand-EF-1
NS	E-brand-EF-1
is	O
administered	O
concomitantly	O
with	O
,	O
or	O
immediately	O
following	O
,	O
a	O
nasal	B-group-EF-2
vasoconstrictor	E-group-EF-2
.	O

No	O
information	O
is	O
available	O
about	O
the	O
use	O
of	O
butorphanol	S-drug
concurrently	O
with	O
MAO	B-group
inhibitors	E-group
.	O

DOSTINEX	S-brand-AD-1
should	O
not	O
be	O
administered	O
concurrently	O
with	O
D2	O
-	O
antagonists	O
,	O
such	O
as	O
phenothiazines	S-group-AD-2
,	O
butyrophenones	S-group-AD-2
,	O
thioxanthines	S-group-AD-2
,	O
or	O
metoclopramide	S-drug-AD-2
.	O

Cytochrome	O
P450	O
1A2	O
(	O
CYP1A2	O
)	O
is	O
known	O
to	O
be	O
the	O
major	O
enzyme	O
involved	O
in	O
the	O
metabolism	O
of	O
caffeine	S-drug
.	O

Therefore	O
,	O
caffeine	S-drug
has	O
the	O
potential	O
to	O
interact	O
with	O
drugs	O
that	O
are	O
substrates	O
for	O
CYP1A2	O
,	O
inhibit	O
CYP1A2	O
,	O
or	O
induce	O
CYP1A2	O
.	O

Few	O
data	O
exist	O
on	O
drug	O
interactions	O
with	O
caffeine	S-drug
in	O
preterm	O
neonates	O
.	O

Based	O
on	O
adult	O
data	O
,	O
lower	O
doses	O
of	O
caffeine	S-drug-AD-1
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	O
which	O
are	O
reported	O
to	O
decrease	O
caffeine	S-drug
elimination	O
(	O
e.g	O
.	O
,	O
cimetidine	S-drug-AD-2
and	O
ketoconazole	S-drug-AD-2
)	O
and	O
higher	O
caffeine	S-drug-AD-1
doses	O
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	O
that	O
increase	O
caffeine	S-drug
elimination	O
(	O
e.g	O
.	O
,	O
phenobarbital	S-drug-AD-2
and	O
phenytoin	S-drug-AD-2
)	O
.	O

Caffeine	S-drug-EF-1
administered	O
concurrently	O
with	O
ketoprofen	S-drug-EF-2
reduced	O
the	O
urine	O
volume	O
in	O
4	O
healthy	O
volunteers	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
interaction	O
in	O
preterm	O
neonates	O
is	O
not	O
known	O
.	O

Interconversion	O
between	O
caffeine	S-drug
and	O
theophylline	S-drug
has	O
been	O
reported	O
in	O
preterm	O
neonates	O
.	O

The	O
concurrent	O
use	O
of	O
these	O
drugs	O
is	O
not	O
recommended	O
.	O

Interactions	O
for	O
vitamin	B-group
D	I-group
analogues	E-group
(	O
Vitamin	B-drug
D2	E-drug
,	O
Vitamin	B-drug
D3	E-drug
,	O
Calcitriol	S-drug
,	O
and	O
Calcidiol	S-drug
)	O
:	O
Cholestyramine	S-drug
:	O
Cholestyramine	S-drug-ME-1
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B-group-ME-2
soluble	I-group-ME-2
vitamins	E-group-ME-2
;	O

as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	B-group
D	E-group
.	O

Phenytoin	S-drug
/	O
Phenobarbital	S-drug
:	O
The	O
coadministration	O
of	O
phenytoin	S-drug-ME-1
or	O
phenobarbital	S-drug-ME-1
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B-group
D	E-group
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	S-drug-ME-2
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol	S-drug
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	S-brand
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O

Thiazides	S-group
:	O
Thiazides	S-group
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	O
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	S-group-EF-1
with	O
vitamin	B-group-EF-2
D	E-group-EF-2
causes	O
hypercalcemia	O
.	O

Therefore	O
,	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O

Digitalis	S-group
:	O
Vitamin	B-group-AD-1
D	E-group-AD-1
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	S-group-AD-2
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	S-drug
:	O
Ketoconazole	S-drug-ME-1
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B-group-ME-2
D	E-group-ME-2
.	O

Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
300	O
mg	O
/	O
day	O
to	O
1200	O
mg	O
/	O
day	O
ketoconazole	S-drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O

However	O
,	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	S-drug
with	O
vitamin	B-group
D	E-group
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	S-group
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B-group-ME-1
D	I-group-ME-1
analogues	E-group-ME-1
,	O
which	O
promote	O
calcium	O
absorption	O
,	O
and	O
corticosteroids	S-group-ME-2
,	O
which	O
inhibit	O
calcium	O
absorption	O
.	O

Phosphate	O
-	O
Binding	O
Agents	O
:	O
Since	O
vitamin	B-group
D	E-group
also	O
has	O
an	O
effect	O
on	O
phosphate	O
transport	O
in	O
the	O
intestine	O
,	O
kidneys	O
and	O
bones	O
,	O
the	O
dosage	O
of	O
phosphate	O
-	O
binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	O
concentration	O
.	O

Vitamin	B-group
D	E-group
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B-group
D	I-group
analogues	E-group
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	S-drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	S-drug
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	S-drug
:	O
Magnesium	S-drug-AD-1
-	O
containing	O
preparations	O
(	O
eg	O
,	O
antacids	S-group-AD-1
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B-group-AD-2
D	E-group-AD-2
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Interactions	O
for	O
vitamin	B-group
D	I-group
analogues	E-group
(	O
Vitamin	B-drug
D2	E-drug
,	O
Vitamin	B-drug
D3	E-drug
,	O
Calcitriol	S-drug
,	O
and	O
Calcidiol	S-drug
)	O
:	O
Cholestyramine	S-drug
:	O
Cholestyramine	S-drug-ME-1
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B-group-ME-2
soluble	I-group-ME-2
vitamins	E-group-ME-2
;	O

as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	B-group
D	E-group
.	O

Phenytoin	S-drug
/	O
Phenobarbital	S-drug
:	O
The	O
coadministration	O
of	O
phenytoin	S-drug-ME-1
or	O
phenobarbital	S-drug-ME-1
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B-group
D	E-group
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	S-drug-ME-2
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol	S-drug
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	S-brand
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O

Thiazides	S-group
:	O
Thiazides	S-group
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	S-drug
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	S-group-EF-1
with	O
vitamin	B-group-EF-2
D	E-group-EF-2
causes	O
hypercalcemia	O
.	O

Therefore	O
,	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O

Digitalis	S-group
:	O
Vitamin	B-group-AD-1
D	E-group-AD-1
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	S-group-AD-2
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	S-drug
:	O
Ketoconazole	S-drug-ME-1
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B-group-ME-2
D	E-group-ME-2
.	O

Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
300	O
mg	O
/	O
day	O
to	O
1200	O
mg	O
/	O
day	O
ketoconazole	S-drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O

However	O
,	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	S-drug
with	O
vitamin	B-group
D	E-group
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	S-group
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B-group-ME-1
D	I-group-ME-1
analogues	E-group-ME-1
,	O
which	O
promote	O
calcium	O
absorption	O
,	O
and	O
corticosteroids	S-group-ME-2
,	O
which	O
inhibit	O
calcium	O
absorption	O
.	O

Phosphate	O
-	O
Binding	O
Agents	O
:	O
Since	O
vitamin	B-group
D	E-group
also	O
has	O
an	O
effect	O
on	O
phosphate	O
transport	O
in	O
the	O
intestine	O
,	O
kidneys	O
and	O
bones	O
,	O
the	O
dosage	O
of	O
phosphate	O
-	O
binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	O
concentration	O
.	O

Vitamin	B-group
D	E-group
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B-group
D	I-group
analogues	E-group
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	S-drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	S-drug
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	S-drug
:	O
Magnesium	S-drug-AD-1
-	O
containing	O
preparations	O
(	O
eg	O
,	O
antacids	S-group-AD-1
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B-group-AD-2
D	E-group-AD-2
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Concomitant	O
use	O
with	O
other	O
calcium	S-drug
-	O
containing	O
medicines	O
(	O
including	O
antacids	S-group
)	O
may	O
cause	O
too	O
much	O
calcium	S-drug
in	O
the	O
blood	O
or	O
urine	O
,	O
which	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O

Using	O
calcium	B-drug-EF-1
acetate	E-drug-EF-1
with	O
digitalis	B-group-EF-2
glycosides	E-group-EF-2
(	O
heart	O
medicine	O
)	O
may	O
cause	O
hypercalcemia	O
(	O
too	O
much	O
calcium	S-drug
in	O
the	O
blood	O
)	O
,	O
which	O
could	O
increase	O
the	O
chance	O
of	O
developing	O
an	O
irregular	O
heartbeat	O
.	O

May	O
interact	O
with	O
cefamandole	B-drug
naftate	E-drug
,	O
cephalothin	B-drug
sodium	E-drug
,	O
magnesium	B-drug
sulfate	E-drug
,	O
prednisolone	B-drug
sodium	I-drug
succinate	E-drug
,	O
and	O
prochlorperazine	B-drug
edisylate	E-drug
.	O

No	O
significant	O
drug	O
interactions	O
have	O
been	O
reported	O
in	O
studies	O
of	O
candesartan	B-drug
cilexetil	E-drug
given	O
with	O
other	O
drugs	O
such	O
as	O
glyburide	S-drug
,	O
nifedipine	S-drug
,	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
hydrochlorothiazide	S-drug
,	O
and	O
oral	O
contraceptives	S-group
in	O
healthy	O
volunteers	O
,	O
or	O
given	O
with	O
enalapril	S-drug
to	O
patients	O
with	O
heart	O
failure	O
(	O
NYHA	O
class	O
II	O
and	O
III	O
)	O
.	O

Because	O
candesartan	S-drug
is	O
not	O
significantly	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
and	O
at	O
therapeutic	O
concentrations	O
has	O
no	O
effects	O
on	O
P450	O
enzymes	O
,	O
interactions	O
with	O
drugs	O
that	O
inhibit	O
or	O
are	O
metabolized	O
by	O
those	O
enzymes	O
would	O
not	O
be	O
expected	O
.	O

Lithium	S-drug
Reversible	O
increases	O
in	O
serum	O
lithium	S-drug
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	S-drug-ME-1
with	O
ACE	B-group-ME-2
inhibitors	E-group-ME-2
,	O
and	O
with	O
some	O
angiotensin	B-group-ME-2
II	I-group-ME-2
receptor	I-group-ME-2
antagonists	E-group-ME-2
.	O

An	O
increase	O
in	O
serum	O
lithium	S-drug
concentration	O
has	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	S-drug-ME-1
with	O
ATACAND	S-brand-ME-2
,	O
so	O
careful	O
monitoring	O
of	O
serum	O
lithium	S-drug
levels	O
is	O
recommended	O
during	O
concomitant	O
use	O
.	O

Antacid	S-group
:	O
The	O
effect	O
of	O
an	O
aluminum	B-drug
hydroxide	E-drug
-	O
and	O
magnesium	B-drug
hydroxide	E-drug
-	O
containing	O
antacid	S-group
(	O
Maalox	S-brand
)	O
*	O
on	O
the	O
pharmacokinetics	O
of	O
capecitabine	S-drug
was	O
investigated	O
in	O
12	O
cancer	O
patients	O
.	O

There	O
was	O
a	O
small	O
increase	O
in	O
plasma	O
concentrations	O
of	O
capecitabine	S-drug
and	O
one	O
metabolite	O
(	O
5	B-drug_n
-	I-drug_n
DFCR	E-drug_n
)	O
;	O

there	O
was	O
no	O
effect	O
on	O
the	O
3	O
major	O
metabolites	O
(	O
5	B-drug_n
-	I-drug_n
DFUR	E-drug_n
,	O
5	B-drug_n
-	I-drug_n
FU	E-drug_n
and	O
FBAL	S-drug_n
)	O
.	O

Coumarin	B-group
Anticoagulants	E-group
Altered	O
coagulation	O
parameters	O
and	O
/	O
or	O
bleeding	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
capecitabine	S-drug-EF-1
concomitantly	O
with	O
coumarin	B-group-EF-2
-	I-group-EF-2
derivative	I-group-EF-2
anticoagulants	E-group-EF-2
such	O
as	O
warfarin	S-drug
and	O
phenprocoumon	S-drug-EF-2
.	O

Patients	O
taking	O
coumarin	B-group-AD-1
-	I-group-AD-1
derivative	I-group-AD-1
anticoagulants	E-group-AD-1
concomitantly	O
with	O
capecitabine	S-drug-AD-2
should	O
be	O
monitored	O
regularly	O
for	O
alterations	O
in	O
their	O
coagulation	O
parameters	O
(	O
PT	O
or	O
INR	O
)	O
.	O

Leucovorin	S-drug
:	O
The	O
concentration	O
of	O
5	B-drug-ME-1
-	I-drug-ME-1
fluorouracil	E-drug-ME-1
is	O
increased	O
and	O
its	O
toxicity	O
may	O
be	O
enhanced	O
by	O
leucovorin	S-drug-ME-2
.	O

Deaths	O
from	O
severe	O
enterocolitis	O
,	O
diarrhea	O
,	O
and	O
dehydration	O
have	O
been	O
reported	O
in	O
elderly	O
patients	O
receiving	O
weekly	O
leucovorin	S-drug-EF-1
and	O
fluorouracil	S-drug-EF-2
.	O

Hypotension	O
Patients	O
on	O
Diuretic	S-group
Therapy	O
:	O
Patients	O
on	O
diuretics	S-group-EF-1
and	O
especially	O
those	O
in	O
whom	O
diuretic	S-group
therapy	O
was	O
recently	O
instituted	O
,	O
as	O
well	O
as	O
those	O
on	O
severe	O
dietary	O
salt	O
restriction	O
or	O
dialysis	O
,	O
may	O
occasionally	O
experience	O
a	O
precipitous	O
reduction	O
of	O
blood	O
pressure	O
usually	O
within	O
the	O
first	O
hour	O
after	O
receiving	O
the	O
initial	O
dose	O
of	O
captopril	S-drug-EF-2
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
captopril	S-drug-EF-1
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	S-group-EF-2
or	O
increasing	O
the	O
salt	O
intake	O
approximately	O
one	O
week	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
captopril	S-drug
(	O
captopril	S-drug
tablets	O
,	O
USP	O
)	O
or	O
initiating	O
therapy	O
with	O
small	O
doses	O
(	O
6.25	O
or	O
12.5	O
mg	O
)	O
.	O

Alternatively	O
,	O
provide	O
medical	O
supervision	O
for	O
at	O
least	O
one	O
hour	O
after	O
the	O
initial	O
dose	O
.	O

If	O
hypotension	O
occurs	O
,	O
the	O
patient	O
should	O
be	O
placed	O
in	O
a	O
supine	O
position	O
and	O
,	O
if	O
necessary	O
,	O
receive	O
an	O
intravenous	O
infusion	O
of	O
normal	O
saline	O
.	O

This	O
transient	O
hypotensive	O
response	O
is	O
not	O
a	O
contraindication	O
to	O
further	O
doses	O
which	O
can	O
be	O
given	O
without	O
difficulty	O
once	O
the	O
blood	O
pressure	O
has	O
increased	O
after	O
volume	O
expansion	O
.	O

Agents	O
Having	O
Vasodilator	O
Activity	O
:	O
Data	O
on	O
the	O
effect	O
of	O
concomitant	O
use	O
of	O
other	O
vasodilators	S-group
in	O
patients	O
receiving	O
captopril	S-drug
for	O
heart	O
failure	O
are	O
not	O
available	O
;	O

therefore	O
,	O
nitroglycerin	S-drug-AD-1
or	O
other	O
nitrates	S-group-AD-1
(	O
as	O
used	O
for	O
management	O
of	O
angina	O
)	O
or	O
other	O
drugs	O
having	O
vasodilator	O
activity	O
should	O
,	O
if	O
possible	O
,	O
be	O
discontinued	O
before	O
starting	O
captopril	S-drug-AD-2
.	O

If	O
resumed	O
during	O
captopril	S-drug
therapy	O
,	O
such	O
agents	O
should	O
be	O
administered	O
cautiously	O
,	O
and	O
perhaps	O
at	O
lower	O
dosage	O
.	O

Agents	O
Causing	O
Renin	O
Release	O
Captopril	S-drug-EF-1
's	O
effect	O
will	O
be	O
augmented	O
by	O
antihypertensive	B-group-EF-2
agents	E-group-EF-2
that	O
cause	O
renin	O
release	O
.	O

For	O
example	O
,	O
diuretics	S-group
(	O
e.g	O
.	O
,	O
thiazides	S-group
)	O
may	O
activate	O
the	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
.	O

Agents	O
Affecting	O
Sympathetic	O
Activity	O
The	O
sympathetic	O
nervous	O
system	O
may	O
be	O
especially	O
important	O
in	O
supporting	O
blood	O
pressure	O
in	O
patients	O
receiving	O
captopril	S-drug
alone	O
or	O
with	O
diuretics	S-group
.	O

Therefore	O
,	O
agents	O
affecting	O
sympathetic	O
activity	O
(	O
e.g	O
.	O
,	O
ganglionic	B-group
blocking	I-group
agents	E-group
or	O
adrenergic	B-group
neuron	I-group
blocking	I-group
agents	E-group
)	O
should	O
be	O
used	O
with	O
caution	O
.	O

Beta	B-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
blocking	I-group-EF-1
drugs	E-group-EF-1
add	O
some	O
further	O
antihypertensive	O
effect	O
to	O
captopril	S-drug-EF-2
,	O
but	O
the	O
overall	O
response	O
is	O
less	O
than	O
additive	O
.	O

Agents	O
Increasing	O
Serum	O
Potassium	O
Since	O
captopril	S-drug
decreases	O
aldosterone	O
production	O
,	O
elevation	O
of	O
serum	O
potassium	O
may	O
occur	O
.	O

Potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
such	O
as	O
spironolactone	S-drug
,	O
triamterene	S-drug
,	O
or	O
amiloride	S-drug
,	O
or	O
potassium	S-drug
supplements	O
should	O
be	O
given	O
only	O
for	O
documented	O
hypokalemia	O
,	O
and	O
then	O
with	O
caution	O
,	O
since	O
they	O
may	O
lead	O
to	O
a	O
significant	O
increase	O
of	O
serum	O
potassium	O
.	O

Salt	O
substitutes	O
containing	O
potassium	S-drug
should	O
also	O
be	O
used	O
with	O
caution	O
.	O

Inhibitors	O
Of	O
Endogenous	O
Prostaglandin	O
Synthesis	O
It	O
has	O
been	O
reported	O
that	O
indomethacin	S-drug-EF-1
may	O
reduce	O
the	O
antihypertensive	O
effect	O
of	O
captopril	S-drug-EF-2
,	O
especially	O
in	O
cases	O
of	O
low	O
renin	O
hypertension	O
.	O

Other	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
agents	E-group
(	O
e.g	O
.	O
,	O
aspirin	S-brand
)	O
may	O
also	O
have	O
this	O
effect	O
.	O

Lithium	S-drug
:	O
Increased	O
serum	O
lithium	S-drug
levels	O
and	O
symptoms	O
of	O
lithium	S-drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	S-drug-EF-1
and	O
ACE	B-group-EF-2
inhibitor	E-group-EF-2
therapy	O
.	O

These	O
drugs	O
should	O
be	O
coad	O
-	O
ministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	S-drug
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	S-group-EF-1
is	O
also	O
used	O
,	O
it	O
may	O
increase	O
the	O
risk	O
of	O
lithium	S-drug-EF-2
toxicity	O
.	O

Cardiac	B-group
Glycosides	E-group
:	O
In	O
a	O
study	O
of	O
young	O
healthy	O
male	O
subjects	O
no	O
evidence	O
of	O
a	O
direct	O
pharmacokinetic	O
captopril	S-drug
-	O
digoxin	S-drug
interaction	O
could	O
be	O
found	O
.	O

Loop	B-group
Diuretics	E-group
:	O
Furosemide	S-drug
administered	O
concurrently	O
with	O
captopril	S-drug
does	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
captopril	S-drug
in	O
renally	O
impaired	O
hypertensive	O
patients	O
.	O

Allopurinol	S-drug
:	O
In	O
a	O
study	O
of	O
healthy	O
male	O
volunteers	O
no	O
significant	O
pharmacokinetic	O
interaction	O
occurred	O
when	O
captopril	S-drug
and	O
allopurinol	S-drug
were	O
administered	O
concomitantly	O
for	O
6	O
days	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Captopril	S-drug
may	O
cause	O
a	O
false	O
-	O
positive	O
urine	O
test	O
for	O
acetone	O
.	O

Clinically	O
meaningful	O
drug	O
interactions	O
have	O
occurred	O
with	O
concomitant	O
medications	O
and	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
the	O
following	O
:	O
Agents	O
Highly	O
Bound	O
to	O
Plasma	O
Protein	O
Carbamazepine	S-drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
;	O

therefore	O
,	O
administration	O
of	O
EQUETROTM	S-brand
to	O
a	O
patient	O
taking	O
another	O
drug	O
that	O
is	O
highly	O
protein	O
bound	O
should	O
not	O
cause	O
increased	O
free	O
concentrations	O
of	O
the	O
other	O
drug	O
.	O

Agents	O
that	O
Inhibit	O
Cytochrome	O
P450	O
Isoenzymes	O
and	O
/	O
or	O
Epoxide	O
Hydrolase	O
Carbamazepine	S-drug
is	O
metabolized	O
mainly	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A4	O
to	O
the	O
active	O
carbamazepine	B-drug
10,11	I-drug
-	I-drug
epoxide	E-drug
,	O
which	O
is	O
further	O
metabolized	O
to	O
the	O
trans	O
-	O
diol	O
by	O
epoxide	O
hydrolase	O
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	S-drug
and	O
any	O
agent	O
that	O
inhibits	O
CYP3A4	O
and	O
/	O
or	O
epoxide	O
hydrolase	O
.	O

Agents	O
that	O
are	O
CYP3A4	O
inhibitors	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
,	O
to	O
increase	O
plasma	O
levels	O
of	O
EQUETROTM	S-brand-ME-1
are	O
the	O
following	O
:	O
Acetazolamide	S-drug-ME-2
,	O
azole	B-group-ME-2
antifungals	E-group-ME-2
,	O
cimetidine	S-drug-ME-2
,	O
clarithromycin	S-drug-ME-2
(	O
1	O
)	O
,	O
dalfopristin	S-drug-ME-2
,	O
danazol	S-drug-ME-2
,	O
delavirdine	S-drug-ME-2
,	O
diltiazem	S-drug-ME-2
,	O
erythromycin	S-drug-ME-2
(	O
1	O
)	O
,	O
fluoxetine	S-drug-ME-2
,	O
fluvoxamine	S-drug-ME-2
,	O
grapefruit	O
juice	O
,	O
isoniazid	S-drug-ME-2
,	O
itraconazole	S-drug-ME-2
,	O
ketoconazole	S-drug-ME-2
,	O
loratadine	S-drug-ME-2
,	O
nefazodone	S-drug-ME-2
,	O
niacinamide	S-drug-ME-2
,	O
nicotinamide	S-drug-ME-2
,	O
protease	B-group-ME-2
inhibitors	E-group-ME-2
,	O
propoxyphene	S-drug-ME-2
,	O
quinine	S-drug-ME-2
,	O
quinupristin	S-drug-ME-2
,	O
troleandomycin	S-drug-ME-2
,	O
valproate	S-drug-ME-2
(	O
1	O
)	O
,	O
verapamil	S-drug-ME-2
,	O
zileuton	S-drug-ME-2
.	O

Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
of	O
EQUETROTM	S-brand
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP3A4	O
or	O
epoxide	O
hydrolase	O
inhibitors	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
reduction	O
for	O
EQUETROTM	S-brand
may	O
be	O
necessary	O
.	O

Agents	O
that	O
Induce	O
Cytochrome	O
P450	O
Isoenzymes	O
Carbamazepine	S-drug
is	O
metabolized	O
by	O
CYP3A4	O
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	S-drug
and	O
any	O
agent	O
that	O
induces	O
CYP3A4	O
.	O

Agents	O
that	O
are	O
CYP	O
inducers	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
,	O
to	O
decrease	O
plasma	O
levels	O
of	O
EQUETROTM	S-brand-ME-1
are	O
the	O
following	O
:	O
Cisplatin	S-drug-ME-2
,	O
doxorubicin	B-drug-ME-2
HCL	E-drug-ME-2
,	O
felbamate	S-drug-ME-2
,	O
rifampin	S-drug-ME-2
,	O
phenobarbital	S-drug-ME-2
,	O
Phenytoin	S-drug-ME-2
(	O
2	O
)	O
,	O
primidone	S-drug-ME-2
,	O
methsuximide	S-drug-ME-2
,	O
and	O
theophylline	S-drug-ME-2
Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
EQUETROTM	S-brand
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP3A4	O
inducers	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
increase	O
for	O
EQUETROTM	S-brand
may	O
be	O
necessary	O
.	O

Agents	O
with	O
Decreased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	S-drug
due	O
to	O
Induction	O
of	O
Cytochrome	O
P450	O
Enzymes	O
Carbamazepine	S-drug
is	O
known	O
to	O
induce	O
CYP1A2	O
and	O
CYP3A4	O
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	S-drug
and	O
any	O
agent	O
metabolized	O
by	O
one	O
(	O
or	O
more	O
)	O
of	O
these	O
enzymes	O
.	O

Agents	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
to	O
have	O
decreased	O
plasma	O
levels	O
in	O
the	O
presence	O
of	O
EQUETROTM	S-brand-ME-1
due	O
to	O
induction	O
of	O
CYP	O
enzymes	O
are	O
the	O
following	O
:	O
Acetaminophen	S-drug-ME-2
,	O
alprazolam	S-drug-ME-2
,	O
amitriptyline	S-drug-ME-2
,	O
bupropion	S-drug-ME-2
,	O
buspirone	S-drug-ME-2
,	O
citalopram	S-drug-ME-2
,	O
clobazam	S-drug-ME-2
,	O
clonazepam	S-drug-ME-2
,	O
clozapine	S-drug-ME-2
,	O
cyclosporin	S-drug-ME-2
,	O
delavirdine	S-drug-ME-2
,	O
desipramine	S-drug-ME-2
,	O
diazepam	S-drug-ME-2
,	O
dicumarol	S-drug-ME-2
,	O
doxycycline	S-drug-ME-2
,	O
ethosuximide	S-drug-ME-2
,	O
felbamate	S-drug-ME-2
,	O
felodipine	S-drug-ME-2
,	O
glucocorticoids	S-group-ME-2
,	O
haloperidol	S-drug-ME-2
,	O
itraconazole	S-drug-ME-2
,	O
lamotrigine	S-drug-ME-2
,	O
levothyroxine	S-drug-ME-2
,	O
lorazepam	S-drug-ME-2
,	O
methadone	S-drug-ME-2
,	O
midazolam	S-drug-ME-2
,	O
mirtazapine	S-drug-ME-2
,	O
nortriptyline	S-drug-ME-2
,	O
olanzapine	S-drug-ME-2
,	O
oral	O
contraceptives	S-group-ME-2
(	O
3	O
)	O
,	O
oxcarbazepine	S-drug-ME-2
,	O
Phenytoin	S-drug-ME-2
(	O
4	O
)	O
,	O
praziquantel	S-drug-ME-2
,	O
protease	B-group-ME-2
inhibitors	E-group-ME-2
,	O
quetiapine	S-drug-ME-2
,	O
risperidone	S-drug-ME-2
,	O
theophylline	S-drug-ME-2
,	O
topiramate	S-drug-ME-2
,	O
tiagabine	S-drug-ME-2
,	O
tramadol	S-drug-ME-2
,	O
triazolam	S-drug-ME-2
,	O
valproate	S-drug-ME-2
,	O
warfarin	S-drug-ME-2
(	O
5	O
)	O
,	O
ziprasidone	S-drug-ME-2
,	O
and	O
zonisamide	S-drug-ME-2
.	O

Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
EQUETROTM	S-brand
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
increase	O
for	O
the	O
concomitant	O
agent	O
may	O
be	O
necessary	O
.	O

Agents	O
with	O
Increased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	S-drug
:	O
EQUETROTM	S-brand-ME-1
increases	O
the	O
plasma	O
levels	O
of	O
the	O
following	O
agents	O
:	O
Clomipramine	B-drug-ME-2
HCl	E-drug-ME-2
,	O
Phenytoin	S-drug-ME-2
(	O
6	O
)	O
,	O
and	O
primidone	S-drug-ME-2
Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
the	O
treatment	O
with	O
EQUETROTM	S-brand
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
decrease	O
for	O
the	O
concomitant	O
agent	O
may	O
be	O
necessary	O
.	O

Pharmacological	O
/	O
Pharmacodynamic	O
Interactions	O
with	O
Carbamazepine	S-drug
Concomitant	O
administration	O
of	O
carbamazepine	S-drug-EF-1
and	O
lithium	S-drug-EF-2
may	O
increase	O
the	O
risk	O
of	O
neurotoxic	O
side	O
effects	O
.	O

Given	O
the	O
anticonvulsant	O
properties	O
of	O
carbamazepine	S-drug
,	O
EQUETROTM	S-brand
may	O
reduce	O
the	O
thyroid	O
function	O
as	O
has	O
been	O
reported	O
with	O
other	O
anticonvulsants	S-group
.	O

Additionally	O
,	O
anti	B-group-EF-1
-	I-group-EF-1
malarial	I-group-EF-1
drugs	E-group-EF-1
,	O
such	O
as	O
chloroquine	S-drug-EF-1
and	O
mefloquine	S-drug-EF-1
,	O
may	O
antagonize	O
the	O
activity	O
of	O
carbamazepine	S-drug-EF-2
.	O

Thus	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
EQUETROTM	S-brand
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
adjustment	O
may	O
be	O
necessary	O
.	O

Because	O
of	O
its	O
primary	O
CNS	O
effect	O
,	O
caution	O
should	O
be	O
used	O
when	O
EQUETROTM	S-brand-AD-1
is	O
taken	O
with	O
other	O
centrally	B-group-AD-2
acting	I-group-AD-2
drugs	E-group-AD-2
and	O
alcohol	S-drug-AD-2
.	O

Geocillin	S-brand-ME-1
(	O
carbenicillin	B-drug-ME-1
indanyl	I-drug-ME-1
sodium	E-drug-ME-1
)	O
blood	O
levels	O
may	O
be	O
increased	O
and	O
prolonged	O
by	O
concurrent	O
administration	O
of	O
probenecid	S-drug-ME-2
.	O

Caution	O
should	O
be	O
exercised	O
when	O
the	O
following	O
drugs	O
are	O
administered	O
concomitantly	O
with	O
LODOSYN	S-brand
(	O
Carbidopa	S-drug
)	O
given	O
with	O
levodopa	S-drug
or	O
carbidopa	S-drug
-	O
levodopa	S-drug
combination	O
products	O
.	O

For	O
patients	O
receiving	O
monoamine	B-group
oxidase	I-group
inhibitors	E-group
,	O
see	O
CONTRAINDICATIONS	O
.	O

Dopamine	B-group-EF-1
D2	I-group-EF-1
receptor	I-group-EF-1
antagonists	E-group-EF-1
(	O
e.g	O
.	O
,	O
phenothiazines	S-group-EF-1
,	O
butyrophenones	S-group-EF-1
,	O
risperidone	S-drug-EF-1
)	O
and	O
isoniazid	S-drug-EF-1
may	O
reduce	O
the	O
therapeutic	O
effects	O
of	O
levodopa	S-drug-EF-2
.	O

In	O
addition	O
,	O
the	O
beneficial	O
effects	O
of	O
levodopa	S-drug-EF-1
in	O
Parkinsons	O
disease	O
have	O
been	O
reported	O
to	O
be	O
reversed	O
by	O
phenytoin	S-drug-EF-2
and	O
papaverine	S-drug-EF-2
.	O

Patients	O
taking	O
these	O
drugs	O
with	O
LODOSYN	S-brand
and	O
levodopa	S-drug
or	O
carbidopa	S-drug
-	O
levodopa	S-drug
combination	O
products	O
should	O
be	O
carefully	O
observed	O
for	O
loss	O
of	O
therapeutic	O
response	O
.	O

Iron	S-drug-ME-1
salts	O
may	O
reduce	O
the	O
bioavailability	O
of	O
carbidopa	S-drug-ME-2
and	O
levodopa	S-drug-ME-2
.	O

The	O
clinical	O
relevance	O
is	O
unclear	O
.	O

Although	O
metoclopramide	S-drug-ME-1
may	O
increase	O
the	O
bioavailability	O
of	O
levodopa	S-drug-ME-2
by	O
increasing	O
gastric	O
emptying	O
,	O
metoclopramide	S-drug
may	O
also	O
adversely	O
affect	O
disease	O
control	O
by	O
its	O
dopamine	O
receptor	O
antagonistic	O
properties	O
.	O

Iodine	S-drug-EF-1
or	O
iodine	S-drug
excess	O
may	O
decrease	O
the	O
effect	O
of	O
Carbimazole	S-drug-EF-2
,	O
and	O
an	O
iodine	S-drug-EF-1
deficiency	O
can	O
increase	O
the	O
effect	O
of	O
Carbimazole	S-drug-EF-2
.	O

Serum	O
concentration	O
of	O
digoxin	S-drug-ME-1
and	O
digitoxin	S-drug-ME-1
may	O
increase	O
when	O
patients	O
take	O
antithyroid	B-group-ME-2
agents	E-group-ME-2
.	O

A	O
decrease	O
of	O
the	O
dosage	O
may	O
be	O
necessary	O
when	O
patient	O
becomes	O
euthyroid	O
.	O

Antithyroid	B-group-EF-1
agents	E-group-EF-1
may	O
decrease	O
thyroidal	O
uptake	O
of	O
sodium	B-drug-EF-2
iodide	I-drug-EF-2
I131	E-drug-EF-2
,	O
a	O
rebound	O
in	O
uptake	O
may	O
occur	O
up	O
to	O
5	O
days	O
after	O
sudden	O
withdrawal	O
of	O
Carbimazole	S-drug
.	O

Patients	O
response	O
to	O
oral	O
anticoagulants	S-group
may	O
be	O
affected	O
by	O
his	O
/	O
her	O
thyroid	O
and	O
metabolic	O
status	O
.	O

An	O
evaluation	O
of	O
prothrombin	O
time	O
and	O
an	O
adjustment	O
of	O
anticoagulant	S-group
dosage	O
are	O
recommended	O

Antihistamines	S-group-EF-1
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
barbiturates	S-group-EF-2
,	O
alcohol	S-drug-EF-2
,	O
and	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
.	O

MAO	B-group-EF-1
inhibitors	E-group-EF-1
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	S-group-EF-2
.	O

Sympathomimetic	B-group-EF-1
amines	E-group-EF-1
may	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
reserpine	S-drug-EF-2
,	O
veratrum	B-group-EF-2
alkaloids	E-group-EF-2
,	O
methyldopa	S-drug-EF-2
and	O
mecamylamine	S-drug-EF-2
.	O

Effects	O
of	O
sympathomimetics	S-group-EF-1
are	O
increased	O
with	O
MAO	B-group-EF-2
inhibitors	E-group-EF-2
and	O
beta	B-group-EF-2
adrenergic	I-group-EF-2
blockers	E-group-EF-2
.	O

The	O
renal	O
effects	O
of	O
nephrotoxic	O
compounds	O
may	O
be	O
potentiated	O
by	O
Carboplatin	S-drug
.	O

HEMABATE	S-brand-EF-1
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	B-group-EF-2
agents	E-group-EF-2
.	O

Concomitant	O
use	O
with	O
other	O
oxytocic	B-group
agents	E-group
is	O
not	O
recommended	O

Ocupress	S-brand-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
beta	B-group-AD-2
-	I-group-AD-2
adrenergic	I-group-AD-2
blocking	I-group-AD-2
agent	E-group-AD-2
orally	O
because	O
of	O
the	O
potential	O
for	O
additive	O
effects	O
on	O
systemic	O
beta	O
-	O
blockade	O
.	O

Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta	B-group-AD-1
-	I-group-AD-1
blocker	E-group-AD-1
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
such	O
as	O
reserpine	S-drug-AD-2
,	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Inhibitors	O
of	O
CYP2D6	O
;	O

poor	O
metabolizers	O
of	O
debrisoquin	S-drug
:	O
Interactions	O
of	O
carvedilol	S-drug
with	O
strong	O
inhibitors	O
of	O
CYP2D6	O
(	O
such	O
as	O
quinidine	S-drug-EF-1
,	O
fluoxetine	S-drug-EF-1
,	O
paroxetine	S-drug-EF-1
,	O
and	O
propafenone	S-drug-EF-1
)	O
have	O
not	O
been	O
studied	O
,	O
but	O
these	O
drugs	O
would	O
be	O
expected	O
to	O
increase	O
blood	O
levels	O
of	O
the	O
R	O
(	O
+	O
)	O
enantiomer	O
of	O
carvedilol	S-drug-EF-2
.	O

Retrospective	O
analysis	O
of	O
side	O
effects	O
in	O
clinical	O
trials	O
showed	O
that	O
poor	O
2D6	O
metabolizers	O
had	O
a	O
higher	O
rate	O
of	O
dizziness	O
during	O
up	O
-	O
titration	O
,	O
presumably	O
resulting	O
from	O
vasodilating	O
effects	O
of	O
the	O
higher	O
concentrations	O
of	O
the	O
a	O
-	O
blocking	O
R	O
(	O
+	O
)	O
enantiomer	O
.	O

Catecholamine	O
-	O
depleting	O
Agents	O
:	O
Patients	O
taking	O
both	O
agents	B-group-EF-1
with	I-group-EF-1
b	I-group-EF-1
-	I-group-EF-1
blocking	I-group-EF-1
properties	E-group-EF-1
and	O
a	O
drug	O
that	O
can	O
deplete	O
catecholamines	O
(	O
e.g	O
.	O
,	O
reserpine	S-drug-EF-2
and	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
)	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
hypotension	O
and	O
/	O
or	O
severe	O
bradycardia	O
.	O

Clonidine	S-drug
:	O
Concomitant	O
administration	O
of	O
clonidine	S-drug-EF-1
with	O
agents	B-group-EF-2
with	I-group-EF-2
b	I-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
properties	E-group-EF-2
may	O
potentiate	O
blood	O
-	O
pressure	O
-	O
and	O
heart	O
-	O
rate	O
-	O
lowering	O
effects	O
.	O

When	O
concomitant	O
treatment	O
with	O
agents	B-group-AD-1
with	I-group-AD-1
b	I-group-AD-1
-	I-group-AD-1
blocking	I-group-AD-1
properties	E-group-AD-1
and	O
clonidine	S-drug-AD-2
is	O
to	O
be	O
terminated	O
,	O
the	O
b	B-group
-	I-group
blocking	I-group
agent	E-group
should	O
be	O
discontinued	O
first	O
.	O

Clonidine	S-drug
therapy	O
can	O
then	O
be	O
discontinued	O
several	O
days	O
later	O
by	O
gradually	O
decreasing	O
the	O
dosage	O
.	O

Cyclosporine	S-drug
:	O
Modest	O
increases	O
in	O
mean	O
trough	O
cyclosporine	S-drug-ME-1
concentrations	O
were	O
observed	O
following	O
initiation	O
of	O
carvedilol	S-drug-ME-2
treatment	O
in	O
21	O
renal	O
transplant	O
patients	O
suffering	O
from	O
chronic	O
vascular	O
rejection	O
.	O

In	O
about	O
30	O
%	O
of	O
patients	O
,	O
the	O
dose	O
of	O
cyclosporine	S-drug
had	O
to	O
be	O
reduced	O
in	O
order	O
to	O
maintain	O
cyclosporine	S-drug
concentrations	O
within	O
the	O
therapeutic	O
range	O
,	O
while	O
in	O
the	O
remainder	O
no	O
adjustment	O
was	O
needed	O
.	O

On	O
the	O
average	O
for	O
the	O
group	O
,	O
the	O
dose	O
of	O
cyclosporine	S-drug
was	O
reduced	O
about	O
20	O
%	O
in	O
these	O
patients	O
.	O

Due	O
to	O
wide	O
interindividual	O
variability	O
in	O
the	O
dose	O
adjustment	O
required	O
,	O
it	O
is	O
recommended	O
that	O
cyclosporine	S-drug-AD-1
concentrations	O
be	O
monitored	O
closely	O
after	O
initiation	O
of	O
carvedilol	S-drug-AD-M
therapy	O
and	O
that	O
the	O
dose	O
of	O
cyclosporine	S-drug-AD-2
be	O
adjusted	O
as	O
appropriate	O
.	O

Digoxin	S-drug
:	O
Digoxin	S-drug
concentrations	O
are	O
increased	O
by	O
about	O
15	O
%	O
when	O
digoxin	S-drug-ME-1
and	O
carvedilol	S-drug-ME-2
are	O
administered	O
concomitantly	O
.	O

Both	O
digoxin	S-drug-EF-1
and	O
COREG	S-brand-EF-2
slow	O
AV	O
conduction	O
.	O

Therefore	O
,	O
increased	O
monitoring	O
of	O
digoxin	S-drug-AD-1
is	O
recommended	O
when	O
initiating	O
,	O
adjusting	O
,	O
or	O
discontinuing	O
COREG	S-brand-AD-2
.	O

Inducers	O
and	O
Inhibitors	O
of	O
Hepatic	O
Metabolism	O
:	O
Rifampin	S-drug-ME-1
reduced	O
plasma	O
concentrations	O
of	O
carvedilol	S-drug-ME-2
by	O
about	O
70	O
%	O
.	O

Cimetidine	S-drug
increased	O
AUC	O
by	O
about	O
30	O
%	O
but	O
caused	O
no	O
change	O
in	O
Cmax	O
.	O

Calcium	B-group
Channel	I-group
Blockers	E-group
:	O
Isolated	O
cases	O
of	O
conduction	O
disturbance	O
(	O
rarely	O
with	O
hemodynamic	O
compromise	O
)	O
have	O
been	O
observed	O
when	O
COREG	S-brand-EF-1
is	O
co	O
-	O
administered	O
with	O
diltiazem	S-drug-EF-2
.	O

As	O
with	O
other	O
agents	B-group
with	I-group
b	I-group
-	I-group
blocking	I-group
properties	E-group
,	O
if	O
COREG	S-brand-AD-1
is	O
to	O
be	O
administered	O
orally	O
with	O
calcium	B-group
channel	I-group
blockers	E-group
of	O
the	O
verapamil	S-drug-AD-2
or	O
diltiazem	S-drug-AD-2
type	O
,	O
it	O
is	O
recommended	O
that	O
ECG	O
and	O
blood	O
pressure	O
be	O
monitored	O
.	O

Insulin	S-drug
or	O
Oral	O
Hypoglycemics	S-group
:	O
Agents	B-group-EF-1
with	I-group-EF-1
b	I-group-EF-1
-	I-group-EF-1
blocking	I-group-EF-1
properties	E-group-EF-1
may	O
enhance	O
the	O
blood	O
-	O
sugar	O
-	O
reducing	O
effect	O
of	O
insulin	S-drug-EF-2
and	O
oral	O
hypoglycemics	S-group-EF-2
.	O

Therefore	O
,	O
in	O
patients	O
taking	O
insulin	S-drug
or	O
oral	O
hypoglycemics	S-group
,	O
regular	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
.	O

Studies	O
in	O
vitro	O
show	O
that	O
caspofungin	B-drug
acetate	E-drug
is	O
not	O
an	O
inhibitor	O
of	O
any	O
enzyme	O
in	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
system	O
.	O

In	O
clinical	O
studies	O
,	O
caspofungin	S-drug
did	O
not	O
induce	O
the	O
CYP3A4	O
metabolism	O
of	O
other	O
drugs	O
.	O

Caspofungin	S-drug
is	O
not	O
a	O
substrate	O
for	O
P	O
-	O
glycoprotein	O
and	O
is	O
a	O
poor	O
substrate	O
for	O
cytochrome	O
P450	O
enzymes	O
.	O

Clinical	O
studies	O
in	O
healthy	O
volunteers	O
show	O
that	O
the	O
pharmacokinetics	O
of	O
CANCIDAS	S-brand
are	O
not	O
altered	O
by	O
itraconazole	S-drug
,	O
amphotericin	B-drug
B	E-drug
,	O
mycophenolate	S-drug
,	O
nelfinavir	S-drug
,	O
or	O
tacrolimus	S-drug
.	O

CANCIDAS	S-brand
has	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
itraconazole	S-drug
,	O
amphotericin	B-drug
B	E-drug
,	O
or	O
the	O
active	O
metabolite	O
of	O
mycophenolate	O
.	O

CANCIDAS	S-brand-ME-1
reduced	O
the	O
blood	O
AUC0	O
-	O
12	O
of	O
tacrolimus	S-drug-ME-2
by	O
approximately	O
20	O
%	O
,	O
peak	O
blood	O
concentration	O
(	O
Cmax	O
)	O
by	O
16	O
%	O
,	O
and	O
12	O
-	O
hour	O
blood	O
concentration	O
(	O
C12hr	O
)	O
by	O
26	O
%	O
in	O
healthy	O
subjects	O
when	O
tacrolimus	S-drug
(	O
2	O
doses	O
of	O
0.1	O
mg	O
/	O
kg	O
12	O
hours	O
apart	O
)	O
was	O
administered	O
on	O
the	O
10th	O
day	O
of	O
CANCIDAS	S-brand
70	O
mg	O
daily	O
,	O
as	O
compared	O
to	O
results	O
from	O
a	O
control	O
period	O
in	O
which	O
tacrolimus	S-drug
was	O
administered	O
alone	O
.	O

For	O
patients	O
receiving	O
both	O
therapies	O
,	O
standard	O
monitoring	O
of	O
tacrolimus	S-drug
blood	O
concentrations	O
and	O
appropriate	O
tacrolimus	S-drug
dosage	O
adjustments	O
are	O
recommended	O
.	O

In	O
two	O
clinical	O
studies	O
,	O
cyclosporine	S-drug-ME-1
(	O
one	O
4	O
mg	O
/	O
kg	O
dose	O
or	O
two	O
3	O
mg	O
/	O
kg	O
doses	O
)	O
increased	O
the	O
AUC	O
of	O
caspofungin	S-drug-ME-2
by	O
approximately	O
35	O
%	O
.	O

CANCIDAS	S-brand
did	O
not	O
increase	O
the	O
plasma	O
levels	O
of	O
cyclosporine	S-drug
.	O

There	O
were	O
transient	O
increases	O
in	O
liver	O
ALT	O
and	O
AST	O
when	O
CANCIDAS	S-brand-EF-1
and	O
cyclosporine	S-drug-EF-2
were	O
co	O
-	O
administered	O
.	O

A	O
drug	O
-	O
drug	O
interaction	O
study	O
with	O
rifampin	S-drug-ME-1
in	O
healthy	O
volunteers	O
has	O
shown	O
a	O
30	O
%	O
decrease	O
in	O
caspofungin	S-drug-ME-2
trough	O
concentrations	O
.	O

Patients	O
on	O
rifampin	S-drug-AD-1
should	O
receive	O
70	O
mg	O
of	O
CANCIDAS	S-brand-AD-2
daily	O
.	O

In	O
addition	O
,	O
results	O
from	O
regression	O
analyses	O
of	O
patient	O
pharmacokinetic	O
data	O
suggest	O
that	O
co	O
-	O
administration	O
of	O
other	O
inducers	O
of	O
drug	O
clearance	O
(	O
efavirenz	S-drug-ME-1
,	O
nevirapine	S-drug-ME-1
,	O
phenytoin	S-drug-ME-1
,	O
dexamethasone	S-drug-ME-1
,	O
or	O
carbamazepine	S-drug-ME-1
)	O
with	O
CANCIDAS	S-brand-ME-2
may	O
result	O
in	O
clinically	O
meaningful	O
reductions	O
in	O
caspofungin	S-drug
concentrations	O
.	O

It	O
is	O
not	O
known	O
which	O
drug	O
clearance	O
mechanism	O
involved	O
in	O
caspofungin	S-drug
disposition	O
may	O
be	O
inducible	O
.	O

When	O
CANCIDAS	S-brand-AD-1
is	O
co	O
-	O
administered	O
with	O
inducers	O
of	O
drug	O
clearance	O
,	O
such	O
as	O
efavirenz	S-drug-AD-2
,	O
nevirapine	S-drug-AD-2
,	O
phenytoin	S-drug-AD-2
,	O
dexamethasone	S-drug-AD-2
,	O
or	O
carbamazepine	S-drug-AD-2
,	O
use	O
of	O
a	O
daily	O
dose	O
of	O
70	O
mg	O
of	O
CANCIDAS	S-brand
should	O
be	O
considered	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Positive	O
direct	O
Coombs	O
tests	O
have	O
been	O
reported	O
during	O
treatment	O
with	O
the	O
cephalosporin	B-group
antibiotics	E-group
.	O

In	O
hematologic	O
studies	O
or	O
in	O
transfusion	O
cross	O
-	O
matching	O
procedures	O
when	O
anti	O
-	O
globulin	O
tests	O
are	O
performed	O
on	O
the	O
minor	O
side	O
or	O
in	O
Coombs	O
testing	O
of	O
newborns	O
whose	O
mothers	O
have	O
received	O
cephalosporin	B-group
antibiotics	E-group
before	O
parturition	O
,	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
may	O
be	O
due	O
to	O
the	O
drug	O
.	O

Probenecid	S-drug-ME-1
may	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
cephalosporins	S-group-ME-2
when	O
used	O
concurrently	O
,	O
resulting	O
in	O
increased	O
and	O
more	O
prolonged	O
cephalosporin	S-group
blood	O
levels	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
Benedicts	O
solution	O
,	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
tablets	O
,	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
such	O
as	O
CLINISTIX	O
.	O

Positive	O
direct	O
and	O
indirect	O
antiglobulin	O
(	O
Coombs	O
)	O
tests	O
have	O
occurred	O
;	O

these	O
may	O
also	O
occur	O
in	O
neonates	O
whose	O
mothers	O
received	O
cephalosporins	S-group
before	O
delivery	O
.	O

Antacids	S-group
(	O
aluminum	S-drug
-	O
or	O
magnesium	S-drug
-	O
containing	O
)	O
:	O
Concomitant	O
administration	O
of	O
300	O
-	O
mg	O
cefdinir	S-drug-ME-1
capsules	O
with	O
30	O
mL	O
Maalox	B-brand-ME-2
TC	E-brand-ME-2
suspension	O
reduces	O
the	O
rate	O
(	O
Cmax	O
)	O
and	O
extent	O
(	O
AUC	O
)	O
of	O
absorption	O
by	O
approximately	O
40	O
%	O
.	O

Time	O
to	O
reach	O
Cmax	O
is	O
also	O
prolonged	O
by	O
1	O
hour	O
.	O

There	O
are	O
no	O
significant	O
effects	O
on	O
cefdinir	S-drug
pharmacokinetics	O
if	O
the	O
antacid	S-group
is	O
administered	O
2	O
hours	O
before	O
or	O
2	O
hours	O
after	O
cefdinir	S-drug
.	O

If	O
antacids	S-group
are	O
required	O
during	O
OMNICEF	S-brand
therapy	O
,	O
OMNICEF	S-brand-AD-1
should	O
be	O
taken	O
at	O
least	O
2	O
hours	O
before	O
or	O
after	O
the	O
antacid	S-group-AD-2
.	O

Probenecid	S-drug
:	O
As	O
with	O
other	O
b	B-group-ME-1
-	I-group-ME-1
lactam	I-group-ME-1
antibiotics	E-group-ME-1
,	O
probenecid	S-drug-ME-1
inhibits	O
the	O
renal	O
excretion	O
of	O
cefdinir	S-drug-ME-2
,	O
resulting	O
in	O
an	O
approximate	O
doubling	O
in	O
A.C.	O
a	O
54	O
%	O
increase	O
in	O
peak	O
cefdinir	S-drug
plasma	O
levels	O
,	O
and	O
a	O
50	O
%	O
prolongation	O
in	O
the	O
apparent	O
elimination	O
half	O
-	O
life	O
.	O

Iron	B-group
Supplements	E-group
and	O
Foods	O
Fortified	O
With	O
Iron	S-drug
Concomitant	O
administration	O
of	O
cefdinir	S-drug-ME-1
with	O
a	O
therapeutic	O
iron	B-group
supplement	E-group
containing	O
60	O
mg	O
of	O
elemental	O
iron	S-drug-ME-2
(	O
as	O
FeSO4	O
)	O
or	O
vitamins	S-group
supplemented	O
with	O
10	O
mg	O
of	O
elemental	O
iron	S-drug-ME-2
reduced	O
extent	O
of	O
absorption	O
by	O
80	O
%	O
and	O
31	O
%	O
,	O
respectively	O
.	O

If	O
iron	B-group-AD-1
supplements	E-group-AD-1
are	O
required	O
during	O
OMNICEF	S-brand
therapy	O
,	O
OMNICEF	S-brand-AD-2
should	O
be	O
taken	O
at	O
least	O
2	O
hours	O
before	O
or	O
after	O
the	O
supplement	O
.	O

The	O
effect	O
of	O
foods	O
highly	O
fortified	O
with	O
elemental	O
iron	S-drug_n
(	O
primarily	O
iron	S-drug_n
-	O
fortified	O
breakfast	O
cereals	O
)	O
on	O
cefdinir	S-drug
absorption	O
has	O
not	O
been	O
studied	O
.	O

Concomitantly	O
administered	O
iron	S-drug_n
-	O
fortified	O
infant	O
formula	O
(	O
2.2	O
mg	O
elemental	O
iron	S-drug_n
/	O
6	O
oz	O
)	O
has	O
no	O
significant	O
effect	O
on	O
cefdinir	S-drug
pharmacokinetics	O
.	O

Therefore	O
,	O
OMNICEF	S-brand
for	O
Oral	O
Suspension	O
can	O
be	O
administered	O
with	O
iron	S-drug_n
-	O
fortified	O
infant	O
formula	O
.	O

There	O
have	O
been	O
rare	O
reports	O
of	O
reddish	O
stools	O
in	O
patients	O
who	O
have	O
received	O
cefdinir	S-drug
in	O
Japan	O
.	O

The	O
reddish	O
color	O
is	O
due	O
to	O
the	O
formation	O
of	O
a	O
nonabsorbable	O
complex	O
between	O
cefdinir	S-drug-ME-1
or	O
its	O
breakdown	O
products	O
and	O
iron	S-drug-ME-2
in	O
the	O
gastrointestinal	O
tract	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	S-drug
,	O
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	S-drug
.	O

The	O
administration	O
of	O
cefdinir	S-drug
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
urine	O
using	O
Clinitest	O
,	O
Benedict	O
s	O
solution	O
,	O
or	O
Fehlings	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
or	O
Tes	O
-	O
Tape	O
)	O
be	O
used	O
.	O

Cephalosporins	S-group
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

Oral	O
Contraceptives	S-group
Multiple	O
doses	O
of	O
cefditoren	B-drug
pivoxil	E-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B-drug
estradiol	E-drug
,	O
the	O
estrogenic	O
component	O
in	O
most	O
oral	O
contraceptives	S-group
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-drug-AD-1
pivoxil	E-drug-AD-1
be	O
taken	O
concomitantly	O
with	O
antacids	S-group-AD-2
.	O

H2	B-group
-	I-group
Receptor	I-group
Antagonists	E-group
:	O
Co	O
-	O
administration	O
of	O
a	O
single	O
dose	O
of	O
intravenously	O
administered	O
famotidine	S-drug-ME-1
(	O
20	O
mg	O
)	O
reduced	O
the	O
oral	O
absorption	O
of	O
a	O
single	O
400	O
mg	O
dose	O
of	O
cefditoren	B-drug-ME-2
pivoxil	E-drug-ME-2
administered	O
following	O
a	O
meal	O
,	O
as	O
evidenced	O
by	O
a	O
27	O
%	O
decrease	O
in	O
mean	O
Cmax	O
and	O
a	O
22	O
%	O
decrease	O
in	O
mean	O
AUC	O
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-drug
pivoxil	E-drug
be	O
taken	O
concomitantly	O
with	O
H2	B-group
receptor	I-group
antagonists	E-group
.	O

Probenecid	S-drug
:	O
As	O
with	O
other	O
b	B-group-ME-1
-	I-group-ME-1
lactam	I-group-ME-1
antibiotics	E-group-ME-1
,	O
co	O
-	O
administration	O
of	O
probenecid	S-drug-ME-1
with	O
cefditoren	B-drug-ME-2
pivoxil	E-drug-ME-2
resulted	O
in	O
an	O
increase	O
in	O
the	O
plasma	O
exposure	O
of	O
cefditoren	S-drug
,	O
with	O
a	O
49	O
%	O
increase	O
in	O
mean	O
Cmax	O
,	O
a	O
122	O
%	O
increase	O
in	O
mean	O
AUC	O
,	O
and	O
a	O
53	O
%	O
increase	O
in	O
half	O
-	O
life	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Cephalosporins	S-group
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	O
reduction	O
tests	O
(	O
Benedicts	O
or	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
tablets	O
)	O
,	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
for	O
glycosuria	O
(	O
e.g	O
.	O
,	O
CLINISTIX	O
,	O
TES	O
-	O
TAPE	O
)	O
.	O

As	O
a	O
false	O
-	O
negative	O
result	O
may	O
occur	O
in	O
the	O
ferricyanide	O
test	O
,	O
it	O
is	O
recommended	O
that	O
either	O
the	O
glucose	O
oxidase	O
or	O
hexokinase	O
method	O
be	O
used	O
to	O
determine	O
blood	O
/	O
plasma	O
glucose	O
levels	O
in	O
patients	O
receiving	O
cefditoren	B-drug
pivoxil	E-drug
.	O

Renal	O
function	O
should	O
be	O
monitored	O
carefully	O
if	O
high	O
doses	O
of	O
aminoglycosides	S-group-AD-1
are	O
to	O
be	O
administered	O
with	O
MAXIPIME	S-brand-AD-2
because	O
of	O
the	O
increased	O
potential	O
of	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycoside	B-group
antibiotics	E-group
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	S-group-EF-1
with	O
potent	O
diuretics	S-group-EF-2
such	O
as	O
furosemide	S-drug-EF-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
administration	O
of	O
cefepime	S-drug
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
when	O
using	O
Clinitest	O
tablets	O
.	O

It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
or	O
Tes	O
-	O
Tape	O
)	O
be	O
used	O
.	O

Carbamazepine	S-drug
:	O
Elevated	O
carbamazepine	S-drug-ME-1
levels	O
have	O
been	O
reported	O
in	O
postmarketing	O
experience	O
when	O
SUPRAX	S-brand-ME-2
is	O
administered	O
concomitantly	O
.	O

Drug	O
monitoring	O
may	O
be	O
of	O
assistance	O
in	O
detecting	O
alterations	O
in	O
carbamazepine	S-drug
plasma	O
concentrations	O
.	O

Warfarin	S-drug-EF-1
and	O
Anticoagulants	S-group-EF-1
:	O
Increased	O
prothrombin	O
time	O
,	O
with	O
or	O
without	O
clinical	O
bleeding	O
,	O
has	O
been	O
reported	O
when	O
cefixime	S-drug-EF-2
is	O
administered	O
concomitantly	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	S-drug
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	S-drug
.	O

The	O
administration	O
of	O
SUPRAX	S-brand
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
using	O
Clinitest	O
*	O
*	O
,	O
Benedict	O
s	O
solution	O
,	O
or	O
Fehling	O
s	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
*	O
*	O
or	O
Tes	O
-	O
Tape	O
*	O
*	O
)	O
be	O
used	O
.	O

A	O
false	O
-	O
positive	O
direct	O
Coombs	O
test	O
has	O
been	O
reported	O
during	O
treatment	O
with	O
other	O
cephalosporin	B-group
antibiotics	E-group
;	O

therefore	O
,	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
may	O
be	O
due	O
to	O
the	O
drug	O
.	O

Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	S-group-EF-1
and	O
aminoglycoside	B-group-EF-2
antibiotics	E-group-EF-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Cephalosporins	S-group
,	O
including	O
cefotaxime	B-drug
sodium	E-drug
,	O
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

Increases	O
in	O
serum	O
creatinine	O
have	O
occurred	O
when	O
CEFOTAN	S-brand
was	O
given	O
alone	O
.	O

If	O
CEFOTAN	S-brand-EF-1
and	O
an	O
aminoglycoside	S-group-EF-2
are	O
used	O
concomitantly	O
,	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
,	O
because	O
nephrotoxicity	O
may	O
be	O
potentiated	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
The	O
administration	O
of	O
CEFOTAN	S-brand
may	O
result	O
in	O
a	O
false	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
using	O
Clinitest	O
,	O
Benedicts	O
solution	O
,	O
or	O
Fehlings	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
be	O
used	O
.	O

As	O
with	O
other	O
cephalosporins	S-group
,	O
high	O
concentrations	O
of	O
cefotetan	S-drug
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
Jaffe	O
reaction	O
and	O
produce	O
false	O
increases	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O

Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	S-group-EF-1
and	O
aminoglycoside	B-group-EF-2
antibiotics	E-group-EF-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
cephalothin	S-drug
,	O
high	O
concentrations	O
of	O
cefoxitin	S-drug
(	O
100	O
micrograms	O
/	O
mL	O
)	O
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
the	O
Jaff	O
reaction	O
,	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O

Serum	O
samples	O
from	O
patients	O
treated	O
with	O
cefoxitin	S-drug
should	O
not	O
be	O
analyzed	O
for	O
creatinine	O
if	O
withdrawn	O
within	O
2	O
hours	O
of	O
drug	O
administration	O
.	O

High	O
concentrations	O
of	O
cefoxitin	S-drug
in	O
the	O
urine	O
may	O
interfere	O
with	O
measurement	O
of	O
urinary	O
17	O
-	O
hydroxy	O
-	O
corticosteroids	O
by	O
the	O
Porter	O
-	O
Silber	O
reaction	O
,	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
reported	O
.	O

A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
.	O

This	O
has	O
been	O
observed	O
with	O
CLINITEST	O
reagent	O
tablets	O

Registered	O
trademark	O
of	O
Ames	O
Company	O
,	O
Division	O
of	O
Miles	O
Laboratories	O
,	O
Inc	O
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
aminoglycoside	B-group-EF-1
antibiotics	E-group-EF-1
and	O
cephalosporin	B-group-EF-2
antibiotics	E-group-EF-2
.	O

Concomitant	O
administration	O
of	O
probenecid	S-drug-ME-1
doubled	O
the	O
AUC	O
for	O
cefprozil	S-drug-ME-2
.	O

The	O
bioavailability	O
of	O
the	O
capsule	O
formulation	O
of	O
cefprozil	S-drug
was	O
not	O
affected	O
when	O
administered	O
5	O
minutes	O
following	O
an	O
antacid	S-group
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	S-group-EF-1
with	O
aminoglycoside	B-group-EF-2
antibiotics	E-group-EF-2
or	O
potent	O
diuretics	S-group-EF-2
such	O
as	O
furosemide	S-drug-EF-2
.	O

Renal	O
function	O
should	O
be	O
carefully	O
monitored	O
,	O
especially	O
if	O
higher	O
dosages	O
of	O
the	O
aminoglycosides	S-group
are	O
to	O
be	O
administered	O
or	O
if	O
therapy	O
is	O
prolonged	O
,	O
because	O
of	O
the	O
potential	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycosidic	B-group
antibiotics	E-group
.	O

Nephrotoxicity	O
and	O
ototoxicity	O
were	O
not	O
noted	O
when	O
ceftazidime	S-drug
was	O
given	O
alone	O
in	O
clinical	O
trials	O
.	O

Chloramphenicol	S-drug-EF-1
has	O
been	O
shown	O
to	O
be	O
antagonistic	O
to	O
beta	B-group-EF-2
-	I-group-EF-2
lactam	I-group-EF-2
antibiotics	E-group-EF-2
,	O
including	O
ceftazidime	S-drug-EF-2
,	O
based	O
on	O
in	O
vitro	O
studies	O
and	O
time	O
kill	O
curves	O
with	O
enteric	O
gram	O
-	O
negative	O
bacilli	O
.	O

Due	O
to	O
the	O
possibility	O
of	O
antagonism	O
in	O
vivo	O
,	O
particularly	O
when	O
bactericidal	O
activity	O
is	O
desired	O
,	O
this	O
drug	O
combination	O
should	O
be	O
avoided	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
administration	O
of	O
ceftazidime	S-drug
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
when	O
using	O
CLINITEST	O
tablets	O
,	O
Benedicts	O
solution	O
,	O
or	O
Fehlings	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
(	O
such	O
as	O
CLINISTIX	O
or	O
TES	O
-	O
TAPE	O
)	O
be	O
used	O
.	O

Theophylline	S-drug
:	O
Twelve	O
healthy	O
male	O
volunteers	O
were	O
administered	O
one	O
200	O
-	O
mg	O
ceftibuten	S-drug
capsule	O
twice	O
daily	O
for	O
6	O
days	O
.	O

With	O
the	O
morning	O
dose	O
of	O
ceftibuten	S-drug
on	O
day	O
6	O
,	O
each	O
volunteer	O
received	O
a	O
single	O
intravenous	O
infusion	O
of	O
theophylline	S-drug
(	O
4	O
mg	O
/	O
kg	O
)	O
.	O

The	O
pharmacokinetics	O
of	O
theophylline	S-drug
were	O
not	O
altered	O
.	O

The	O
effect	O
of	O
ceftibuten	S-drug
on	O
the	O
pharmacokinetics	O
of	O
theophylline	S-drug
administered	O
orally	O
has	O
not	O
been	O
investigated	O
.	O

Antacids	S-group
or	O
H	B-group
2	I-group
-	I-group
receptor	I-group
antagonists	E-group
:	O
The	O
effect	O
of	O
increased	O
gastric	O
pH	O
on	O
the	O
bioavailability	O
of	O
ceftibuten	S-drug
was	O
evaluated	O
in	O
18	O
healthy	O
adult	O
volunteers	O
.	O

Each	O
volunteer	O
was	O
administered	O
one	O
400	O
-	O
mg	O
ceftibuten	S-drug
capsule	O
.	O

A	O
single	O
dose	O
of	O
liquid	O
antacid	S-group
did	O
not	O
affect	O
the	O
C	O
max	O
or	O
AUC	O
of	O
ceftibuten	S-drug
;	O

however	O
,	O
150	O
mg	O
of	O
ranitidine	S-drug-ME-1
q12h	O
for	O
3	O
days	O
increased	O
the	O
ceftibuten	S-drug-ME-2
C	O
max	O
by	O
23	O
%	O
and	O
ceftibuten	S-drug-ME-2
AUC	O
by	O
16	O
%	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
increases	O
is	O
not	O
known	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
There	O
have	O
been	O
no	O
chemical	O
or	O
laboratory	O
test	O
interactions	O
with	O
ceftibuten	S-drug
noted	O
to	O
date	O
.	O

False	O
-	O
positive	O
direct	O
Coombs	O
tests	O
have	O
been	O
reported	O
during	O
treatment	O
with	O
other	O
cephalosporins	S-group
.	O

Therefore	O
,	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
could	O
be	O
due	O
to	O
the	O
drug	O
.	O

The	O
results	O
of	O
assays	O
using	O
red	O
cells	O
from	O
healthy	O
subjects	O
to	O
determine	O
whether	O
ceftibuten	S-drug
would	O
cause	O
direct	O
Coombs	O
reactions	O
in	O
vitro	O
showed	O
no	O
positive	O
reaction	O
at	O
ceftibuten	S-drug
concentrations	O
as	O
high	O
as	O
40	O
g	O
/	O
mL	O
.	O

Although	O
the	O
occurrence	O
has	O
not	O
been	O
reported	O
with	O
Cefizox	S-brand
,	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	S-group-EF-1
and	O
aminoglycosides	S-group-EF-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	O
reduction	O
tests	O
(	O
Benedict	O
s	O
or	O
Fehling	O
s	O
solution	O
or	O
with	O
Clinitest	O
tablets	O
)	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
for	O
glycosuria	O
.	O

As	O
a	O
false	O
-	O
negative	O
result	O
may	O
occur	O
in	O
the	O
ferricyanide	O
test	O
,	O
it	O
is	O
recommended	O
that	O
either	O
the	O
glucose	O
oxidase	O
or	O
hexokinase	O
method	O
be	O
used	O
to	O
determine	O
blood	O
plasma	O
glucose	O
levels	O
in	O
patients	O
receiving	O
cefuroxime	S-drug
.	O

Cefuroxime	S-drug
does	O
not	O
interfere	O
with	O
the	O
assay	O
of	O
serum	O
and	O
urine	O
creatinine	O
by	O
the	O
alkaline	O
picrate	O
method	O
.	O

General	O
:	O
Significant	O
interactions	O
may	O
occur	O
when	O
celecoxib	S-drug
is	O
administered	O
together	O
with	O
drugs	O
that	O
inhibit	O
P450	O
2C9	O
.	O

Celecoxib	S-drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
cytochrome	O
P450	O
2C9	O
in	O
the	O
liver	O
.	O

Co	O
-	O
administration	O
of	O
celecoxib	S-drug
with	O
drugs	O
that	O
are	O
known	O
to	O
inhibit	O
2C9	O
should	O
be	O
done	O
with	O
caution	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
celecoxib	S-drug
is	O
not	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
2C9	O
,	O
2C19	O
or	O
3A4	O
.	O

In	O
vitro	O
studies	O
also	O
indicate	O
that	O
celecoxib	S-drug
,	O
although	O
not	O
a	O
substrate	O
,	O
is	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
2D6	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
in	O
vivo	O
drug	O
interaction	O
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
P450	O
2D6	O
.	O

Clinical	O
studies	O
with	O
celecoxib	S-drug-IN-1
have	O
identified	O
potentially	O
significant	O
interactions	O
with	O
fluconazole	S-drug-IN-2
and	O
lithium	S-drug-IN-2
.	O

Experience	O
with	O
nonsteroidal	B-group-IN-1
anti	I-group-IN-1
-	I-group-IN-1
inflammatory	I-group-IN-1
drugs	E-group-IN-1
(	O
NSAIDs	S-group-IN-1
)	O
suggests	O
the	O
potential	O
for	O
interactions	O
with	O
furosemide	S-drug-IN-2
and	O
ACE	B-group-IN-2
inhibitors	E-group-IN-2
.	O

The	O
effects	O
celecoxib	S-drug
on	O
the	O
pharmacokinetics	O
and	O
/	O
or	O
pharmacodynamics	O
of	O
glyburide	S-drug
,	O
ketoconazole	S-drug
,	O
methotrexate	S-drug
,	O
phenytoin	S-drug
,	O
tolbutamide	S-drug
,	O
and	O
warfarin	S-drug
have	O
been	O
studied	O
in	O
vivo	O
and	O
clinically	O
important	O
interactions	O
have	O
not	O
been	O
found	O
.	O

ACE	B-group
inhibitors	E-group
:	O
Reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
Angiotensin	B-group-EF-2
Converting	I-group-EF-2
Enzyme	I-group-EF-2
(	I-group-EF-2
ACE	I-group-EF-2
)	I-group-EF-2
inhibitors	E-group-EF-2
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
CELEBREX	S-brand-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
-	I-group-AD-2
inhibitors	E-group-AD-2
.	O

Furosemide	S-drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	S-group-EF-1
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	S-drug-EF-2
and	O
thiazides	S-group-EF-2
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

Aspirin	S-brand
:	O
CELEBREX	S-brand-AD-1
can	O
be	O
used	O
with	O
low	O
dose	O
aspirin	S-brand-AD-2
.	O

However	O
,	O
concomitant	O
administration	O
of	O
aspirin	S-brand-EF-1
with	O
CELEBREX	S-brand-EF-2
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
,	O
compared	O
to	O
use	O
of	O
CELEBREX	S-brand
alone	O
.	O

Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
,	O
CELEBREX	S-brand
is	O
not	O
a	O
substitute	O
for	O
aspirin	S-brand
for	O
cardiovascular	O
prophylaxis	O
.	O

Fluconazole	S-drug
:	O
Concomitant	O
administration	O
of	O
fluconazole	S-drug-ME-1
at	O
200	O
mg	O
QD	O
resulted	O
in	O
a	O
two	O
-	O
fold	O
increase	O
in	O
celecoxib	S-drug-ME-2
plasma	O
concentration	O
.	O

This	O
increase	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
celecoxib	S-drug-ME-1
metabolism	O
via	O
P450	O
2C9	O
by	O
fluconazole	S-drug-ME-2
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
:	O
Metabolism	O
)	O
.	O

CELEBREX	S-brand-AD-1
should	O
be	O
introduced	O
at	O
the	O
lowest	O
recommended	O
dose	O
in	O
patients	O
receiving	O
fluconazole	S-drug-AD-2
.	O

Lithium	S-drug
:	O
In	O
a	O
study	O
conducted	O
in	O
healthy	O
subjects	O
,	O
mean	O
steady	O
-	O
state	O
lithium	S-drug
plasma	O
levels	O
increased	O
approximately	O
17	O
%	O
in	O
subjects	O
receiving	O
lithium	S-drug-ME-1
450	O
mg	O
BID	O
with	O
CELEBREX	S-brand-ME-2
200	O
mg	O
BID	O
as	O
compared	O
to	O
subjects	O
receiving	O
lithium	S-drug
alone	O
.	O

Patients	O
on	O
lithium	S-drug-AD-1
treatment	O
should	O
be	O
closely	O
monitored	O
when	O
CELEBREX	S-brand-AD-2
is	O
introduced	O
or	O
withdrawn	O
.	O

Methotrexate	S-drug
:	O
In	O
an	O
interaction	O
study	O
of	O
rheumatoid	O
arthritis	O
patients	O
taking	O
methotrexate	S-drug
,	O
CELEBREX	S-brand
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
methotrexate	S-drug
.	O

Warfarin	S-drug
:	O
The	O
effect	O
of	O
celecoxib	S-drug
on	O
the	O
anti	O
-	O
coagulant	O
effect	O
of	O
warfarin	S-drug
was	O
studied	O
in	O
a	O
group	O
of	O
healthy	O
subjects	O
receiving	O
daily	O
doses	O
of	O
2	O
-	O
5	O
mg	O
of	O
warfarin	S-drug
.	O

In	O
these	O
subjects	O
,	O
celecoxib	S-drug
did	O
not	O
alter	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	S-drug
as	O
determined	O
by	O
prothrombin	O
time	O
.	O

However	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CELEBREX	S-brand-AD-1
with	O
warfarin	S-drug-AD-2
since	O
these	O
patients	O
are	O
at	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O

Metformin	S-drug
:	O
In	O
healthy	O
subjects	O
given	O
single	O
500	O
mg	O
doses	O
of	O
cephalexin	S-drug-ME-1
and	O
metformin	S-drug-ME-2
,	O
plasma	O
metformin	S-drug
mean	O
cmax	O
and	O
AUC	O
increased	O
by	O
an	O
average	O
of	O
34	O
%	O
and	O
24	O
%	O
,	O
respectively	O
,	O
and	O
metformin	S-drug
mean	O
renal	O
clearance	O
decreased	O
by	O
14	O
%	O
.	O

No	O
information	O
is	O
available	O
about	O
the	O
interaction	O
of	O
cephalexin	S-drug
and	O
metformin	S-drug
following	O
multiple	O
doses	O
of	O
either	O
drug	O
.	O

Although	O
not	O
observed	O
in	O
this	O
study	O
,	O
adverse	O
effects	O
could	O
potentially	O
arise	O
from	O
co	O
-	O
administration	O
of	O
cephalexin	S-drug-ME-1
and	O
metformin	S-drug-ME-2
by	O
inhibition	O
of	O
tubular	O
secretion	O
via	O
organic	O
cationic	O
transporter	O
systems	O
.	O

Accordingly	O
,	O
careful	O
patient	O
monitoring	O
and	O
dose	O
adjustment	O
of	O
metformin	S-drug
is	O
recommended	O
in	O
patients	O
concomitantly	O
taking	O
cephalexin	S-drug-AD-1
and	O
metformin	S-drug-AD-2
.	O

Probenecid	S-drug
:	O
As	O
with	O
other	O
b	B-group
-	I-group
lactams	E-group
,	O
the	O
renal	O
excretion	O
of	O
cephalexin	S-drug-ME-1
is	O
inhibited	O
by	O
probenecid	S-drug-ME-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
a	O
result	O
of	O
administration	O
of	O
Keflex	S-brand
,	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
.	O

This	O
has	O
been	O
observed	O
with	O
Benedict	O
s	O
and	O
Fehling	O
s	O
solutions	O
and	O
also	O
with	O
Clinitest	O
tablets	O
.	O

Immunosuppressive	B-group
Drugs	E-group
,	O
Fibric	B-group
Acid	I-group
Derivatives	E-group
,	O
Niacin	S-drug
(	O
Nicotinic	B-drug
Acid	E-drug
,	O
Erythromycin	S-drug
,	O
Azole	B-group
Antifungals	E-group
:	O
Skeletal	O
Muscle	O
.	O

ANTACID	S-group
(	O
Magnesium	B-drug
-	I-drug
Aluminum	I-drug
Hydroxide	E-drug
)	O
:	O
Cerivastatin	S-drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
antacid	S-group
.	O

CIMETlDINE	S-drug
:	O
Cerivastatin	S-drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
cimetidine	S-drug
.	O

CHOLESTYRAMINE	S-drug
:	O
The	O
influence	O
of	O
the	O
bile	O
-	O
acidsequestering	O
agent	O
cholestyramine	S-drug
on	O
the	O
pharmacokinetits	O
of	O
cerivastatin	B-drug
sodium	E-drug
was	O
evaluated	O
in	O
12	O
healthy	O
males	O
in	O
2	O
separate	O
randomized	O
crossover	O
studies	O
.	O

In	O
the	O
first	O
study	O
,	O
concomitant	O
administration	O
of	O
0.2	O
mg	O
cerivastatin	B-drug-ME-1
sodium	E-drug-ME-1
and	O
12	O
g	O
cholestyramine	S-drug-ME-2
resulted	O
in	O
decreases	O
of	O
more	O
than	O
22	O
%	O
for	O
AUC	O
and	O
40	O
%	O
for	O
Cmax	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-drug
sodium	E-drug
alone	O
.	O

However	O
,	O
in	O
the	O
second	O
study	O
,	O
administration	O
of	O
12	O
g	O
cholestyramine	S-drug-ME-1
1	O
hour	O
before	O
the	O
evening	O
meal	O
and	O
0.3	O
mg	O
cerivastatin	B-drug-ME-2
sodium	E-drug-ME-2
approximately	O
4	O
hours	O
after	O
the	O
same	O
evening	O
meal	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
cerivastatin	S-drug
AUC	O
of	O
less	O
than	O
8	O
%	O
,	O
and	O
a	O
decrease	O
in	O
Cmax	O
of	O
about	O
30	O
%	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-drug
sodium	E-drug
alone	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
expected	O
that	O
a	O
dosing	O
schedule	O
of	O
cerivastatin	B-drug
sodium	E-drug
given	O
at	O
bedtime	O
and	O
cholestyramine	S-drug
given	O
before	O
the	O
evening	O
meal	O
would	O
not	O
result	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
clinical	O
effect	O
of	O
cerivastatin	B-drug
sodium	E-drug
.	O

DIGOXIN	S-drug
:	O
Plasma	O
digoxin	S-drug
levels	O
and	O
digoxin	S-drug
clearance	O
at	O
steady	O
-	O
state	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
0.2	O
mg	O
cerivastatin	B-drug
sodium	E-drug
.	O

Cerivastatin	S-drug
plasma	O
concentrations	O
were	O
also	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
digoxin	S-drug
.	O

WARFARIN	S-drug
:	O
Co	O
-	O
administration	O
of	O
warfarin	S-drug
and	O
cerivastatin	S-drug
to	O
healthy	O
volunteers	O
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
prothrombin	O
time	O
or	O
clotting	O
factor	O
VII	O
when	O
compared	O
to	O
co	O
-	O
administration	O
of	O
warfarin	S-drug
and	O
placebo	O
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
both	O
the	O
(	O
R	O
)	O
and	O
(	O
S	O
)	O
isomers	O
of	O
warfarin	S-drug
were	O
unaffected	O
by	O
concurrent	O
dosing	O
of	O
0.3	O
mg	O
cerivastatin	B-drug
sodium	E-drug
.	O

Co	O
-	O
administration	O
of	O
warfarin	S-drug
and	O
cerivastatin	S-drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
cerivastatin	B-drug
sodium	E-drug
.	O

ERYTHROMYCIN	S-drug
:	O
In	O
hypercholesterolemic	O
patients	O
,	O
steady	O
-	O
state	O
cerivastatin	S-drug-ME-1
AUC	O
and	O
Cmax	O
increased	O
approximately	O
50	O
%	O
and	O
24	O
%	O
respectively	O
after	O
10	O
days	O
with	O
co	O
-	O
administration	O
of	O
erythromycin	S-drug-ME-2
,	O
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
.	O

OTHER	O
CONCOMITANT	O
THERAPY	O
:	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
in	O
clinical	O
studies	O
,	O
cerivastatin	B-drug
sodium	E-drug
was	O
used	O
concomitantly	O
with	O
angiotensin	B-group
-	I-group
converting	I-group
enzyme	I-group
(	I-group
ACE	I-group
)	I-group
inhibitors	E-group
,	O
betablockers	S-group
,	O
calcium	B-group
-	I-group
channel	I-group
blockers	E-group
,	O
diuretics	S-group
,	O
and	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drugs	E-group
(	O
NSAIDs	S-group
)	O
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Pharmacokinetic	O
interaction	O
studies	O
with	O
cetirizine	S-drug
in	O
adults	O
were	O
conducted	O
with	O
pseudoephedrine	S-drug
,	O
antipyrine	S-drug
,	O
ketoconazole	S-drug
,	O
erythromycin	S-drug
and	O
azithromycin	S-drug
.	O

No	O
interactions	O
were	O
observed	O
.	O

In	O
a	O
multiple	O
dose	O
study	O
of	O
theophylline	S-drug-ME-1
(	O
400	O
mg	O
once	O
daily	O
for	O
3	O
days	O
)	O
and	O
cetirizine	S-drug-ME-2
(	O
20	O
mg	O
once	O
daily	O
for	O
3	O
days	O
)	O
,	O
a	O
16	O
%	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	S-drug
was	O
observed	O
.	O

The	O
disposition	O
of	O
theophylline	S-drug
was	O
not	O
altered	O
by	O
concomitant	O
cetirizine	S-drug
administration	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
:	O
No	O
clinically	O
significant	O
drug	O
interactions	O
have	O
been	O
found	O
with	O
theophylline	S-drug
at	O
a	O
low	O
dose	O
,	O
azithromycin	S-drug
,	O
pseudoephedrine	S-drug
,	O
ketoconazole	S-drug
,	O
or	O
erythromycin	S-drug
.	O

There	O
was	O
a	O
small	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	S-drug-ME-1
caused	O
by	O
a	O
400	O
-	O
mg	O
dose	O
of	O
theophylline	S-drug-ME-2
;	O

it	O
is	O
possible	O
that	O
larger	O
theophylline	S-drug
doses	O
could	O
have	O
a	O
greater	O
effect	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Cetrotide	S-brand
.	O

A	O
drug	O
interaction	O
study	O
was	O
performed	O
in	O
which	O
ERBITUX	S-brand
was	O
administered	O
in	O
combination	O
with	O
irinotecan	S-drug
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
pharmacokinetic	O
interactions	O
between	O
ERBITUX	S-brand
and	O
irinotecan	S-drug
.	O

Cevimeline	S-drug-AD-1
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
taking	O
beta	B-group-AD-2
adrenergic	I-group-AD-2
antagonists	E-group-AD-2
,	O
because	O
of	O
the	O
possibility	O
of	O
conduction	O
disturbances	O
.	O

Drugs	O
with	O
parasympathomimetic	O
effects	O
administered	O
concurrently	O
with	O
cevimeline	S-drug
can	O
be	O
expected	O
to	O
have	O
additive	O
effects	O
.	O

Cevimeline	S-drug
might	O
interfere	O
with	O
desirable	O
antimuscarinic	O
effects	O
of	O
drugs	O
used	O
concomitantly	O
.	O

Drugs	O
which	O
inhibit	O
CYP2D6	O
and	O
CYP3A3	O
/	O
4	O
also	O
inhibit	O
the	O
metabolism	O
of	O
cevimeline	S-drug
.	O

Cevimeline	S-drug
should	O
be	O
used	O
with	O
caution	O
in	O
individuals	O
known	O
or	O
suspected	O
to	O
be	O
deficient	O
in	O
CYP2D6	O
activity	O
,	O
based	O
on	O
previous	O
experience	O
,	O
as	O
they	O
may	O
be	O
at	O
a	O
higher	O
risk	O
of	O
adverse	O
events	O
.	O

In	O
an	O
in	O
vitro	O
study	O
,	O
cytochrome	O
P450	O
isozymes	O
1A2	O
,	O
2A6	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
were	O
not	O
inhibited	O
by	O
exposure	O
to	O
cevimeline	S-drug
.	O

There	O
are	O
no	O
known	O
drug	O
/	O
drug	O
interactions	O
with	O
chlorambucil	S-drug
.	O

Although	O
clinical	O
studies	O
have	O
not	O
established	O
a	O
cause	O
and	O
effect	O
relationship	O
,	O
physicians	O
should	O
be	O
aware	O
that	O
variable	O
effects	O
an	O
blood	O
coagulation	O
have	O
been	O
reported	O
very	O
rarely	O
in	O
patients	O
receiving	O
oral	O
anticoagulants	S-group-EF-1
and	O
chlordiazepoxide	S-drug-EF-2
.	O

The	O
concomitant	O
use	O
of	O
alcohol	S-drug
or	O
other	O
central	B-group
nervous	I-group
system	I-group
depressants	E-group
may	O
have	O
an	O
additive	O
effect	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B-group-EF-1
solutions	E-group-EF-1
containing	O
epinephrine	S-drug-EF-1
or	O
norepinephrine	S-drug-EF-1
to	O
patients	O
receiving	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
,	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
or	O
phenothiazines	S-group-EF-2
may	O
produce	O
severe	O
,	O
prolonged	O
hypotension	O
or	O
hypertension	O
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
when	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	B-group-EF-1
drugs	E-group-EF-1
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot	B-group-EF-2
-	I-group-EF-2
type	I-group-EF-2
oxytocic	I-group-EF-2
drugs	E-group-EF-2
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

The	O
para	O
-	O
aminobenzoic	O
acid	O
metabolite	O
of	O
chloroprocaine	O
inhibits	O
the	O
action	O
of	O
sulfonamides	S-group
.	O

Therefore	O
,	O
chloroprocaine	S-drug-AD-1
should	O
not	O
be	O
used	O
in	O
any	O
condition	O
in	O
which	O
a	O
sulfonamide	B-group-AD-2
drug	E-group-AD-2
is	O
being	O
employed	O
.	O

Antacids	S-group
and	O
kaolin	S-drug
:	O
Antacids	S-group-ME-1
and	O
kaolin	S-drug-ME-1
can	O
reduce	O
absorption	O
of	O
chloroquine	S-drug-ME-2
;	O

an	O
interval	O
of	O
at	O
least	O
4	O
hours	O
between	O
intake	O
of	O
these	O
agents	O
and	O
chloroquine	S-drug
should	O
be	O
observed	O
.	O

Cimetidine	S-drug
:	O
Cimetidine	S-drug-ME-1
can	O
inhibit	O
the	O
metabolism	O
of	O
chloroquine	S-drug-ME-2
,	O
increasing	O
its	O
plasma	O
level	O
.	O

Concomitant	O
use	O
of	O
cimetidine	S-drug
should	O
be	O
avoided	O
.	O

Ampicillin	S-drug
:	O
In	O
a	O
study	O
of	O
healthy	O
volunteers	O
,	O
chloroquine	S-drug-ME-1
significantly	O
reduced	O
the	O
bioavailability	O
of	O
ampicillin	S-drug-ME-2
.	O

An	O
interval	O
of	O
at	O
least	O
two	O
hours	O
between	O
intake	O
of	O
this	O
agent	O
and	O
chloroquine	S-drug
should	O
be	O
observed	O
.	O

Cyclosporin	S-drug
:	O
After	O
introduction	O
of	O
chloroquine	S-drug-ME-1
(	O
oral	O
form	O
)	O
,	O
a	O
sudden	O
increase	O
in	O
serum	O
cyclosporin	S-drug-ME-2
level	O
has	O
been	O
reported	O
.	O

Therefore	O
,	O
close	O
monitoring	O
of	O
serum	O
cyclosporin	S-drug
level	O
is	O
recommended	O
and	O
,	O
if	O
necessary	O
,	O
chloroquine	S-drug
should	O
be	O
discontinued	O
.	O

When	O
given	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
thiazide	B-group
diuretics	E-group
.	O

-	O
Alcohol	S-drug
,	O
barbiturates	S-group
,	O
or	O
narcotics	S-group
:	O
Potentiation	O
of	O
otthostatic	O
hypotension	O
may	O
occur	O

-	O
Antidiabetic	B-group
drugs	E-group
:	O
(	O
Oral	O
agents	O
and	O
insulin	S-drug
)	O
Dosage	O
adjustment	O
of	O
the	O
antidiabetic	B-group
drug	E-group
may	O
be	O
required	O

-	O
Other	O
antihypertensive	B-group
drugs	E-group
:	O
Additive	O
effect	O
or	O
potentiation	O

-	O
Cholestyramine	S-drug
and	O
colestipol	S-drug
resins	S-group
:	O
Cholestytamine	S-drug-ME-1
and	O
colestipol	S-drug-ME-1
resins	S-group
have	O
the	O
potential	O
of	O
binding	O
thiazide	B-group-ME-2
diuretics	E-group-ME-2
and	O
reducing	O
diuretic	S-group
absorption	O
from	O
the	O
gastrointestinal	O
tract	O

-	O
Corticosteroids	S-group
,	O
ACTH	S-drug
:	O
Intensified	O
electrolyte	O
depletion	O
,	O
particularly	O
hypokalemia	O

-	O
Pressor	O
amines	O
(	O
e.g	O
.	O
,	O
norepinephrine	S-drug
)	O
:	O
Possible	O
decreased	O
response	O
to	O
pressor	O
amines	O
but	O
not	O
sufficient	O
to	O
preclude	O
their	O
use	O

-	O
Skeletal	B-group
muscle	I-group
relaxants	E-group
,	O
nondepolarizing	O
(	O
e.g	O
.	O
,	O
tubocurarine	S-drug
)	O
:	O
Possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	B-group
relaxant	E-group

-	O
Lithium	S-drug-AD-1
:	O
Generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	S-group-AD-2
.	O

Diuretic	B-group-ME-1
agents	E-group-ME-1
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	S-drug-ME-2
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	S-drug-ME-2
toxicity	O
.	O

Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	S-drug-AD-1
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
chlorothiazide	S-drug-AD-2

-	O
Non	B-group
-	I-group
steroidal	I-group
Anti	I-group
-	I-group
inflammatory	I-group
Drugs	E-group
:	O
In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	B-group-EF-1
-	I-group-EF-1
steroidal	I-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
agent	E-group-EF-1
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	S-group-EF-2
,	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	E-group-EF-2
and	O
thiazide	B-drug-EF-2
diuretics	E-drug-EF-2
.	O

Therefore	O
,	O
when	O
chlorothiazide	S-drug-AD-1
and	O
non	B-group-AD-2
-	I-group-AD-2
steroidal	I-group-AD-2
anti	I-group-AD-2
-	I-group-AD-2
inflammatory	I-group-AD-2
agents	E-group-AD-2
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	S-group
is	O
obtained	O

-	O
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Thiazides	S-group
should	O
be	O
discontinued	O
before	O
carrying	O
out	O
tests	O
for	O
parathyroid	O
function	O
.	O

Chlorotrianisene	S-drug-IN-1
may	O
interact	O
with	O
antidepressants	S-group-IN-2
,	O
aspirin	S-brand-IN-2
,	O
barbiturates	S-group-IN-2
,	O
bromocriptine	S-drug-IN-2
,	O
calcium	S-drug-IN-2
supplements	O
,	O
corticosteroids	S-group-IN-2
,	O
corticotropin	S-drug-IN-2
,	O
cyclosporine	S-drug-IN-2
,	O
dantrolene	S-drug-IN-2
,	O
nicotine	S-drug-IN-2
,	O
somatropin	S-drug-IN-2
,	O
tamoxifen	S-drug-IN-2
,	O
and	O
warfarin	S-drug-IN-2
.	O

May	O
interact	O
with	O
skin	O
products	O
or	O
shampoos	O
for	O
dandruff	O
or	O
psoriasis	O
.	O

Substrate	O
of	O
CYP2D6	O
(	O
minor	O
)	O
,	O
3A4	O
(	O
major	O
)	O
;	O

Inhibits	O
CYP2D6	O
(	O
weak	O
)	O
.	O

Increased	O
toxicity	O
(	O
CNS	O
depression	O
)	O
:	O
CNS	B-group
depressants	E-group
,	O
MAO	B-group
inhibitors	E-group
,	O
tricyclic	B-group
antidepressants	E-group
,	O
phenothiazines	S-group
.	O

CYP3A4	O
inhibitors	O
:	O
May	O
increase	O
the	O
levels	O
/	O
effects	O
of	O
chlorpheniramine	S-drug
.	O

Example	O
inhibitors	O
include	O
azole	B-group
antifungals	E-group
,	O
ciprofloxacin	S-drug
,	O
clarithromycin	S-drug
,	O
diclofenac	S-drug
,	O
doxycycline	S-drug
,	O
erythromycin	S-drug
,	O
imatinib	S-drug
,	O
isoniazid	S-drug
,	O
nefazodone	S-drug
,	O
nicardipine	S-drug
,	O
propofol	S-drug
,	O
protease	B-group
inhibitors	E-group
,	O
quinidine	S-drug
,	O
and	O
verapamil	S-drug
.	O

The	O
concurrent	O
use	O
of	O
two	O
or	O
more	O
drugs	O
with	O
anticholinergic	O
activity	O
-	O
-	O
such	O
as	O
an	O
antipsychotic	B-group-EF-1
drug	E-group-EF-1
(	O
eg	O
,	O
chlorpromazine	S-drug-EF-1
)	O
,	O
an	O
antiparkinsonian	B-group-EF-M
drug	E-group-EF-M
(	O
eg	O
,	O
trihexyphenidyl	S-drug-EF-M
)	O
,	O
and	O
/	O
or	O
a	O
tricyclic	B-group-EF-2
antidepressant	E-group-EF-2
(	O
eg	O
,	O
amitriptyline	S-drug-EF-2
)	O
-	O
-	O
commonly	O
results	O
in	O
excessive	O
anticholinergic	O
effects	O
,	O
including	O
dry	O
mouth	O
and	O
associated	O
dental	O
complications	O
,	O
blurred	O
vision	O
,	O
and	O
,	O
in	O
patients	O
exposed	O
to	O
high	O
temperature	O
and	O
humidity	O
,	O
hyperpyrexia	O
.	O

Interactions	O
may	O
also	O
occur	O
with	O
the	O
following	O
:	O
anti	B-group
-	I-group
depressants	E-group
/	O
anti	B-group
-	I-group
anxiety	I-group
drugs	E-group
,	O
drugs	O
used	O
to	O
treat	O
an	O
overactive	O
thyroid	O
,	O
beta	B-group
-	I-group
blockers	E-group
(	O
e.g	O
.	O
,	O
propranolol	S-drug
)	O
,	O
sparfloxacin	S-drug
,	O
grepafloxacin	S-drug
,	O
guanethidine	S-drug
,	O
guanadrel	S-drug
,	O
metrizamide	S-drug
,	O
cabergoline	S-drug
,	O
lithium	S-drug
,	O
narcotic	S-group
pain	O
medication	O
(	O
e.g	O
.	O
,	O
codeine	S-drug
)	O
,	O
drugs	O
used	O
to	O
aid	O
sleep	O
,	O
drowsiness	O
-	O
causing	O
antihistamines	S-group
(	O
e.g	O
.	O
,	O
diphenhydramine	S-drug
)	O
,	O
any	O
other	O
drugs	O
that	O
may	O
make	O
you	O
drowsy	O
.	O

The	O
hypoglycemic	O
action	O
of	O
sulfonylurea	S-group-EF-1
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B-group-EF-2
anti	I-group-EF-2
-	I-group-EF-2
inflammatory	I-group-EF-2
agents	E-group-EF-2
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	S-group-EF-2
,	O
sulfonamides	S-group-EF-2
,	O
chloramphenicol	S-drug-EF-2
,	O
probenecid	S-drug-EF-2
,	O
coumarins	S-group-EF-2
,	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
,	O
and	O
beta	B-group-EF-2
adrenergic	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
DIABINESE	S-brand
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
DIABINESE	S-brand
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O

Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
control	O
.	O

These	O
drugs	O
include	O
the	O
thiazides	S-group
and	O
other	O
diuretics	S-group
,	O
corticosteroids	S-group
,	O
phenothiazines	S-group
,	O
thyroid	O
products	O
,	O
estrogens	S-group
,	O
oral	O
contraceptives	S-group
,	O
phenytoin	S-drug
,	O
nicotinic	B-drug
acid	E-drug
,	O
sympathomimetics	S-group
,	O
calcium	B-group
channel	I-group
blocking	I-group
drugs	E-group
,	O
and	O
isoniazid	S-drug
.	O

When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
DIABINESE	S-brand
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
DIABINESE	S-brand
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

Since	O
animal	O
studies	O
suggest	O
that	O
the	O
action	O
of	O
barbiturates	S-group-EF-1
may	O
be	O
prolonged	O
by	O
therapy	O
with	O
chlorpropamide	S-drug-EF-2
,	O
barbiturates	S-group
should	O
be	O
employed	O
with	O
caution	O
.	O

In	O
some	O
patients	O
,	O
a	O
disulfiram	S-drug
-	O
like	O
reaction	O
may	O
be	O
produced	O
by	O
the	O
ingestion	O
of	O
alcohol	S-drug
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	S-drug-EF-1
and	O
oral	O
hypoglycemic	B-group-EF-2
agents	E-group-EF-2
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
,	O
topical	O
,	O
or	O
vaginal	O
preparations	O
of	O
miconazole	S-drug
is	O
not	O
known	O
.	O

Chlorprothixene	S-drug-ME-1
may	O
increase	O
the	O
plasma	O
-	O
level	O
of	O
concomitantly	O
given	O
lithium	S-drug-ME-2
.	O

In	O
order	O
to	O
avoid	O
lithium	S-drug
intoxication	O
,	O
lithium	S-drug
plasma	O
levels	O
should	O
be	O
monitored	O
closely	O
.	O

If	O
chlorprothixene	S-drug-AD-1
is	O
given	O
concomitantly	O
with	O
opioids	S-group-AD-2
,	O
the	O
opioid	S-group
dose	O
should	O
be	O
reduced	O
(	O
by	O
approx	O
.	O
50	O
%	O
)	O
,	O
because	O
chlorprothixene	S-drug-EF-1
amplifies	O
the	O
therapeutic	O
actions	O
and	O
side	O
-	O
effects	O
of	O
opioids	S-group-EF-2
massively	O
.	O

Avoid	O
the	O
concomitant	O
use	O
of	O
chlorprothixene	S-drug-AD-1
and	O
tramadol	S-drug-AD-2
(	O
Ultram	S-brand-AD-2
)	O
.	O

Massive	O
seizures	O
may	O
be	O
encountered	O
with	O
this	O
combination	O
.	O

Consider	O
additive	O
sedative	O
effects	O
and	O
confusional	O
states	O
to	O
emerge	O
,	O
if	O
chlorprothixene	S-drug-EF-1
is	O
given	O
with	O
benzodiazepines	S-group-EF-2
or	O
barbituates	S-group-EF-2
.	O

Choose	O
particular	O
low	O
doses	O
of	O
these	O
drugs	O
.	O

Exert	O
particular	O
caution	O
in	O
combining	O
chlorprothixene	S-drug-AD-1
with	O
other	O
anticholinergic	B-group-AD-2
drugs	E-group-AD-2
(	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
and	O
antiparkinsonian	B-group-AD-2
agents	E-group-AD-2
)	O
:	O
Particularly	O
the	O
elderly	O
may	O
develop	O
delirium	O
,	O
high	O
fever	O
,	O
severe	O
obstipation	O
,	O
even	O
ileus	O
and	O
glaucoma	O
.	O

Chlorthalidone	S-drug-EF-1
may	O
add	O
to	O
or	O
potentiate	O
the	O
action	O
of	O
other	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
.	O

Potentiation	O
occurs	O
with	O
ganglionic	B-group
peripheral	I-group
adrenergic	I-group
blocking	I-group
drugs	E-group
.	O

Medication	O
such	O
as	O
digitalis	S-group
may	O
also	O
influence	O
serum	O
electrolytes	O
.	O

Warning	O
signs	O
,	O
irrespective	O
of	O
cause	O
,	O
are	O
:	O
dryness	O
of	O
mouth	O
,	O
thirst	O
,	O
weakness	O
,	O
lethargy	O
,	O
drowsiness	O
,	O
restlessness	O
,	O
muscle	O
pains	O
or	O
cramps	O
,	O
muscular	O
fatigue	O
,	O
hypotension	O
,	O
oliguria	O
,	O
tachycardia	O
,	O
and	O
gastrointestinal	O
disturbances	O
such	O
as	O
nausea	O
and	O
vomiting	O
.	O

Insulin	S-drug
requirements	O
in	O
diabetic	O
patients	O
may	O
be	O
increased	O
,	O
decreased	O
,	O
or	O
unchanged	O
.	O

Higher	O
dosage	O
of	O
oral	O
hypoglycemic	B-group
agents	E-group
may	O
be	O
required	O
.	O

Latent	O
diabetes	O
mellitus	O
may	O
become	O
manifest	O
during	O
chlorthalidone	S-drug
administration	O
.	O

Chlorthalidone	S-drug-EF-1
and	O
related	O
drugs	O
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	S-drug-EF-2
.	O

Chlorthalidone	S-drug-EF-1
and	O
related	O
drugs	O
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	S-drug-EF-2
.	O

This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O

The	O
concomitant	O
use	O
of	O
alcohol	S-drug
or	O
other	O
central	B-group
nervous	I-group
system	I-group
depressants	E-group
may	O
have	O
an	O
additive	O
effect	O
.	O

Interactions	O
for	O
vitamin	B-group
D	E-group
analogues	O
(	O
Vitamin	B-drug
D2	E-drug
,	O
Vitamin	B-drug
D3	E-drug
,	O
Calcitriol	S-drug
,	O
and	O
Calcidiol	S-drug
)	O
:	O
Cholestyramine	S-drug
:	O
Cholestyramine	S-drug-ME-1
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B-group-ME-2
soluble	I-group-ME-2
vitamins	E-group-ME-2
;	O

as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	B-group
D	E-group
.	O

Phenytoin	S-drug
/	O
Phenobarbital	S-drug
:	O
The	O
coadministration	O
of	O
phenytoin	S-drug
or	O
phenobarbital	S-drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B-group
D	E-group
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	S-drug
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol	S-drug
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	S-brand
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O

Thiazides	S-group
:	O
Thiazides	S-group
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	O
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	S-group-EF-1
with	O
vitamin	B-group-EF-2
D	E-group-EF-2
causes	O
hypercalcemia	O
.	O

Therefore	O
,	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O

Digitalis	S-group
:	O
Vitamin	B-group-AD-1
D	E-group-AD-1
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	S-group-AD-2
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	S-drug
:	O
Ketoconazole	S-drug-ME-1
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B-group-ME-2
D	E-group-ME-2
.	O

Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
300	O
mg	O
/	O
day	O
to	O
1200	O
mg	O
/	O
day	O
ketoconazole	S-drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O

However	O
,	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	S-drug
with	O
vitamin	B-group
D	E-group
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	S-group
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B-group-EF-1
D	E-group-EF-1
analogues	O
,	O
which	O
promote	O
calcium	O
absorption	O
,	O
and	O
corticosteroids	S-group-EF-2
,	O
which	O
inhibit	O
calcium	O
absorption	O
.	O

Phosphate	O
-	O
Binding	O
Agents	O
:	O
Since	O
vitamin	B-group
D	E-group
also	O
has	O
an	O
effect	O
on	O
phosphate	O
transport	O
in	O
the	O
intestine	O
,	O
kidneys	O
and	O
bones	O
,	O
the	O
dosage	O
of	O
phosphate	O
-	O
binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	O
concentration	O
.	O

Vitamin	B-group
D	E-group
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B-group
D	E-group
analogues	O
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	S-drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	S-drug
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	S-drug
:	O
Magnesium	S-drug-EF-1
-	O
containing	O
preparations	O
(	O
eg	O
,	O
antacids	S-group-EF-1
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B-group-EF-2
D	E-group-EF-2
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Cholestyramine	S-drug-ME-1
resin	S-group
may	O
delay	O
or	O
reduce	O
the	O
absorption	O
of	O
concomitant	O
oral	O
medication	O
such	O
as	O
phenylbutazone	S-group-ME-2
,	O
warfarin	S-drug-ME-2
,	O
thiazide	B-group-ME-2
diuretics	E-group-ME-2
(	O
acidic	O
)	O
or	O
propranolol	S-drug-ME-2
(	O
basic	O
)	O
,	O
as	O
well	O
as	O
tetracycline	S-drug-ME-2
penicillin	B-drug-ME-2
G	E-drug-ME-2
,	O
phenobarbital	S-drug-ME-2
,	O
thyroid	O
and	O
thyroxine	S-drug-ME-2
preparations	O
,	O
estrogens	S-group-ME-2
and	O
progestins	S-group-ME-2
,	O
and	O
digitalis	S-group-ME-2
.	O

Interference	O
with	O
the	O
absorption	O
of	O
oral	O
phosphate	S-drug_n
supplements	O
has	O
been	O
observed	O
with	O
another	O
positively	O
-	O
charged	O
bile	O
acid	O
sequestrant	O
.	O

Cholestyramine	S-drug
resin	S-group
may	O
interfere	O
with	O
the	O
pharmacokinetics	O
of	O
drugs	O
that	O
undergo	O
enterohepatic	O
circulation	O
,	O
The	O
discontinuance	O
of	O
cholestyramine	S-drug-ME-1
resin	S-group
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	O
such	O
as	O
digitalis	S-group-ME-2
has	O
been	O
filtrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
cholestyramine	S-drug
resin	S-group
.	O

Because	O
cholestyramine	S-drug
binds	O
bile	O
acids	O
,	O
cholestyramine	S-drug
resin	S-group
may	O
interfere	O
with	O
normal	O
fat	O
digestion	O
and	O
absorption	O
and	O
thus	O
may	O
prevent	O
absorption	O
of	O
fat	B-group
soluble	I-group
vitamins	E-group
such	O
as	O
A	O
,	O
D	O
,	O
E	O
,	O
and	O
K	O
.	O

When	O
cholestyramine	S-drug
resin	S-group
is	O
given	O
for	O
long	O
periods	O
of	O
time	O
,	O
concomitant	O
supplementation	O
with	O
water	O
-	O
miscible	O
(	O
or	O
parenteral	O
)	O
forms	O
of	O
fat	B-group
-	I-group
soluble	I-group
vitamins	E-group
should	O
be	O
considered	O
.	O

SINCE	O
CHOLESTYRAMINE	S-drug
RESIN	S-group
MAY	O
BIND	O
OTHER	O
DRUGS	O
GIVEN	O
CONCURRENTLY	O
,	O
IT	O
IS	O
RECOMMENDED	O
THAT	O
PATIENTS	O
TAKE	O
OTHER	O
DRUGS	O
AT	O
LEAST	O
1	O
HOUR	O
BEFORE	O
OR	O
4	O
TO	O
6	O
HOURS	O
AFTER	O
CHOLESTYRAMINE	S-drug
RESIN	S-group
(	O
OR	O
AT	O
AS	O
GREAT	O
AN	O
INTERVAL	O
AS	O
POSSIBLE	O
)	O
TO	O
AVOID	O
IMPEDING	O
THEIR	O
ABSORPTION	O
.	O

Based	O
on	O
in	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
,	O
des	B-drug
-	I-drug
ciclesonide	E-drug
appears	O
to	O
have	O
no	O
inhibitory	O
or	O
induction	O
potential	O
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
metabolized	O
by	O
CYP	O
450	O
enzymes	O
.	O

The	O
inhibitory	O
potential	O
of	O
ciclesonide	S-drug
on	O
CYP450	O
isoenzymes	O
has	O
not	O
been	O
studied	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
the	O
plasma	O
protein	O
binding	O
of	O
des	B-drug
-	I-drug
ciclesonide	E-drug
was	O
not	O
affected	O
by	O
warfarin	S-drug
or	O
salicylic	B-drug
acid	E-drug
,	O
indicating	O
no	O
potential	O
for	O
protein	O
binding	O
-	O
based	O
drug	O
interactions	O
.	O

In	O
a	O
drug	O
interaction	O
study	O
,	O
co	O
-	O
administration	O
of	O
orally	O
inhaled	O
ciclesonide	S-drug
and	O
oral	O
erythromycin	S-drug
,	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
,	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
des	B-drug
-	I-drug
ciclesonide	E-drug
or	O
erythromycin	S-drug
.	O

In	O
another	O
drug	O
interaction	O
study	O
,	O
co	O
-	O
administration	O
of	O
orally	O
inhaled	O
ciclesonide	S-drug-ME-1
and	O
oral	O
ketoconazole	S-drug-ME-2
,	O
a	O
potent	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
,	O
increased	O
the	O
exposure	O
(	O
AUC	O
)	O
of	O
des	B-drug
-	I-drug
ciclesonide	E-drug
by	O
approximately	O
3.6	O
-	O
fold	O
at	O
steady	O
state	O
,	O
while	O
levels	O
of	O
ciclesonide	S-drug
remained	O
unchanged	O
.	O

Therefore	O
,	O
ketoconazole	S-drug-AD-1
should	O
be	O
administered	O
with	O
caution	O
with	O
intranasal	O
ciclesonide	S-drug-AD-2
.	O

Probenecid	S-drug
:	O
Probenecid	S-drug-ME-1
is	O
known	O
to	O
interact	O
with	O
the	O
metabolism	O
or	O
renal	O
tubular	O
excretion	O
of	O
many	O
drugs	O
(	O
e.g	O
.	O
,	O
acetaminophen	S-drug-ME-2
,	O
acyclovir	S-drug-ME-2
,	O
angiotensin	B-group-ME-2
-	I-group-ME-2
converting	I-group-ME-2
enzyme	I-group-ME-2
inhibitors	E-group-ME-2
,	O
aminosalicylic	B-drug-ME-2
acid	E-drug-ME-2
,	O
barbiturates	S-group-ME-2
,	O
benzodiazepines	S-group-ME-2
,	O
bumetanide	S-drug-ME-2
,	O
clofibrate	S-drug-ME-2
,	O
methotrexate	S-drug-ME-2
,	O
famotidine	S-drug-ME-2
,	O
furosemide	S-drug-ME-2
,	O
nonsteroidal	B-group-ME-2
anti	I-group-ME-2
-	I-group-ME-2
inflammatory	E-group-ME-2
agents	O
,	O
theophylline	S-drug-ME-2
,	O
and	O
zidovudine	S-drug-ME-2
)	O
.	O

Concomitant	O
medications	O
should	O
be	O
carefully	O
assessed	O
.	O

Zidovudine	S-drug-AD-1
should	O
either	O
be	O
temporarily	O
discontinued	O
or	O
decreased	O
by	O
50	O
%	O
when	O
coadministered	O
with	O
probenecid	S-drug-AD-2
on	O
the	O
day	O
of	O
VISTIDE	S-brand
infusion	O
.	O

Nephrotoxic	O
agents	O
:	O
Concomitant	O
administration	O
of	O
VISTIDE	S-brand-AD-1
and	O
agents	O
with	O
nephrotoxic	O
potential	O
[	O
e.g	O
.	O
,	O
intravenous	O
aminoglycosides	S-group-AD-2
(	O
e.g	O
.	O
,	O
tobramycin	S-drug-AD-2
,	O
gentamicin	S-drug-AD-2
,	O
and	O
amikacin	S-drug-AD-2
)	O
,	O
amphotericin	B-drug-AD-2
B	E-drug-AD-2
,	O
foscarnet	S-drug-AD-2
,	O
intravenous	O
pentamidine	S-drug-AD-2
,	O
vancomycin	S-drug-AD-2
,	O
and	O
non	B-group-AD-2
-	I-group-AD-2
steroidal	I-group-AD-2
anti	I-group-AD-2
-	I-group-AD-2
inflammatory	I-group-AD-2
agents	E-group-AD-2
]	O
is	O
contraindicated	O
.	O

Such	O
agents	O
must	O
be	O
discontinued	O
at	O
least	O
seven	O
days	O
prior	O
to	O
starting	O
therapy	O
with	O
VISTIDE	S-brand
.	O

Since	O
PLETAL	S-brand
is	O
extensively	O
metabolized	O
by	O
cytochrome	O
P	O
-	O
450	O
isoenzymes	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
PLETAL	S-brand-AD-1
is	O
coadministered	O
with	O
inhibitors	O
of	O
C.P.A	O
.	O
such	O
as	O
ketoconazole	S-drug-AD-2
and	O
erythromycin	S-drug-AD-2
or	O
inhibitors	O
of	O
CYP2C19	O
such	O
as	O
omeprazole	S-drug-AD-2
.	O

Pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
omeprazole	S-drug-ME-1
and	O
erythromycin	S-drug-ME-1
significantly	O
increased	O
the	O
systemic	O
exposure	O
of	O
cilostazol	S-drug-ME-2
and	O
/	O
or	O
its	O
major	O
metabolites	O
.	O

Population	O
pharmacokinetic	O
studies	O
showed	O
higher	O
concentrations	O
of	O
cilostazol	S-drug-ME-1
among	O
patients	O
concurrently	O
treated	O
with	O
diltiazem	S-drug-ME-2
,	O
an	O
inhibitor	O
of	O
C.P.A..	O

Pletal	S-brand
does	O
not	O
,	O
however	O
,	O
appear	O
to	O
cause	O
increased	O
blood	O
levels	O
of	O
drugs	O
metabolized	O
by	O
CYP3A4	O
,	O
as	O
it	O
had	O
no	O
effect	O
on	O
lovastatin	S-drug
,	O
a	O
drug	O
with	O
metabolism	O
very	O
sensitive	O
to	O
C.P.A	O
.	O
inhibition	O
.	O

Tagamet	S-brand-ME-1
,	O
apparently	O
through	O
an	O
effect	O
on	O
certain	O
microsomal	O
enzyme	O
systems	O
,	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
hepatic	O
metabolism	O
of	O
warfarin	B-group-ME-2
-	I-group-ME-2
type	I-group-ME-2
anticoagulants	E-group-ME-2
,	O
phenytoin	S-drug-ME-2
,	O
propranolol	S-drug-ME-2
,	O
nifedipine	S-drug-ME-2
,	O
chlordiazepoxide	S-drug-ME-2
,	O
diazepam	S-drug-ME-2
,	O
certain	O
tricyclic	B-group-ME-2
antidepressants	E-group-ME-2
,	O
lidocaine	S-drug-ME-2
,	O
theophylline	S-drug-ME-2
and	O
metronidazole	S-drug-ME-2
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
blood	O
levels	O
of	O
these	O
drugs	O
.	O

Clinically	O
significant	O
effects	O
have	O
been	O
reported	O
with	O
the	O
warfarin	B-group
anticoagulants	E-group
;	O

therefore	O
,	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
,	O
and	O
adjustment	O
of	O
the	O
anticoagulant	S-group-AD-1
dose	O
may	O
be	O
necessary	O
when	O
Tagamet	S-brand-AD-2
is	O
administered	O
concomitantly	O
.	O

Interaction	O
with	O
phenytoin	S-drug
,	O
lidocaine	S-drug
and	O
theophylline	S-drug
has	O
also	O
been	O
reported	O
to	O
produce	O
adverse	O
clinical	O
effects	O
.	O

However	O
,	O
a	O
crossover	O
study	O
in	O
healthy	O
subjects	O
receiving	O
either	O
Tagamet	S-brand-ME-1
300	O
mg	O
q.i.d	O
.	O
or	O
800	O
mg	O
h.s	O
.	O
concomitantly	O
with	O
a	O
300	O
mg	O
b.i.d	O
.	O
dosage	O
of	O
theophylline	S-drug-ME-2
(	O
Theo	B-brand-ME-2
-	I-brand-ME-2
Dur	E-brand-ME-2
,	O
Key	O
Pharmaceuticals	O
,	O
Inc.	O
)	O
demonstrated	O
less	O
alteration	O
in	O
steady	O
-	O
state	O
theophylline	S-drug
peak	O
serum	O
levels	O
with	O
the	O
800	O
mg	O
h.s	O
.	O
regimen	O
,	O
particularly	O
in	O
subjects	O
aged	O
54	O
years	O
and	O
older	O
.	O

Data	O
beyond	O
10	O
days	O
are	O
not	O
available	O
.	O

(	O
Note	O
:	O
All	O
patients	O
receiving	O
theophylline	S-drug
should	O
be	O
monitored	O
appropriately	O
,	O
regardless	O
of	O
concomitant	O
drug	O
therapy	O
.	O
)	O

Dosage	O
of	O
the	O
drugs	O
mentioned	O
above	O
and	O
other	O
similarly	O
metabolized	O
drugs	O
,	O
particularly	O
those	O
of	O
low	O
therapeutic	O
ratio	O
or	O
in	O
patients	O
with	O
renal	O
and	O
/	O
or	O
hepatic	O
impairment	O
,	O
may	O
require	O
adjustment	O
when	O
starting	O
or	O
stopping	O
concomitantly	O
administered	O
Tagamet	S-brand
to	O
maintain	O
optimum	O
therapeutic	O
blood	O
levels	O
.	O

Alteration	O
of	O
pH	O
may	O
affect	O
absorption	O
of	O
certain	O
drugs	O
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug
)	O
.	O

If	O
these	O
products	O
are	O
needed	O
,	O
they	O
should	O
be	O
given	O
at	O
least	O
2	O
hours	O
before	O
cimetidine	S-drug
administration	O
.	O

Additional	O
clinical	O
experience	O
may	O
reveal	O
other	O
drugs	O
affected	O
by	O
the	O
concomitant	O
administration	O
of	O
Tagamet	S-brand
.	O

and	O
/	O
or	O
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
See	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Pharmacokinetics	O
and	O
Drug	O
Interactions	O
.	O

Effect	O
of	O
Sensipar	S-brand
on	O
other	O
drugs	O
:	O
Drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
2D6	O
(	O
CYP2D6	O
)	O
:	O
Sensipar	S-brand
is	O
a	O
strong	O
in	O
vitro	O
inhibitor	O
of	O
CYP2D6	O
.	O

Therefore	O
,	O
dose	O
adjustments	O
of	O
concomitant	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2D6	O
and	O
have	O
a	O
narrow	O
therapeutic	O
index	O
(	O
e.g	O
.	O
,	O
flecainide	S-drug
,	O
vinblastine	S-drug
,	O
thioridazine	S-drug
and	O
most	O
tricyclic	B-group
antidepressants	E-group
)	O
may	O
be	O
required	O
.	O

Amitriptyline	S-drug
:	O
Concurrent	O
administration	O
of	O
25	O
mg	O
or	O
100	O
mg	O
cinacalcet	S-drug-ME-1
with	O
50	O
mg	O
amitriptyline	S-drug-ME-2
increased	O
amitriptyline	S-drug
exposure	O
and	O
nortriptyline	S-drug_n
(	O
active	O
metabolite	O
)	O
exposure	O
by	O
approximately	O
20	O
%	O
in	O
CYP2D6	O
extensive	O
metabolizers	O
.	O

Effect	O
of	O
other	O
drugs	O
on	O
Sensipar	S-brand
:	O
Sensipar	S-brand
is	O
metabolized	O
by	O
multiple	O
cytochrome	O
P450	O
enzymes	O
,	O
primarily	O
CYP3A4	O
,	O
CYP2D6	O
,	O
and	O
CYP1A2	O
.	O

Ketoconazole	S-drug
:	O
Sensipar	S-brand
is	O
metabolized	O
in	O
part	O
by	O
CYP3A4	O
.	O

Co	O
-	O
administration	O
of	O
ketoconazole	S-drug-ME-1
,	O
a	O
strong	O
inhibitor	O
of	O
CYP3A4	O
,	O
increased	O
cinacalcet	S-drug-ME-2
exposure	O
following	O
a	O
single	O
90	O
mg	O
dose	O
of	O
Sensipar	S-brand
by	O
2.3	O
fold	O
.	O

Dose	O
adjustment	O
of	O
Sensipar	S-brand-AD-1
may	O
be	O
required	O
and	O
PTH	O
and	O
serum	O
calcium	O
concentrations	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
patient	O
initiates	O
or	O
discontinues	O
therapy	O
with	O
a	O
strong	O
CYP3A4	O
inhibitor	O
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug-AD-2
,	O
erythromycin	S-drug-AD-2
,	O
itraconazole	S-drug-AD-2
;	O

see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
)	O
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	S-drug-ME-1
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
some	O
quinolones	S-group-ME-2
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	S-drug
-	O
related	O
side	O
-	O
effects	O
in	O
patients	O
on	O
concomitant	O
theophylline	S-drug-EF-1
-	O
quinolone	S-group-EF-2
therapy	O
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	S-drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	S-drug
adjusted	O
as	O
required	O
.	O

Quinolones	S-group-ME-1
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	S-drug-ME-2
.	O

This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	S-drug
and	O
a	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O

Although	O
this	O
interaction	O
has	O
not	O
been	O
reported	O
with	O
cinoxacin	S-drug
,	O
caution	O
should	O
be	O
exercised	O
when	O
cinoxacin	S-drug-AD-1
is	O
given	O
concomitantly	O
with	O
caffeine	S-drug-AD-2
-	O
containing	O
products	O
.	O

Antacids	S-group-ME-1
or	O
sucralfate	S-drug-ME-1
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
some	O
quinolones	S-group-ME-2
,	O
resulting	O
in	O
low	O
urine	O
levels	O
.	O

Also	O
,	O
concomitant	O
administration	O
of	O
quinolones	S-group-ME-1
with	O
products	O
containing	O
iron	S-drug-ME-2
,	O
multivitamins	S-group
containing	O
zinc	S-drug-ME-2
,	O
or	O
Videx	S-brand-ME-2
(	O
didanosine	S-drug-ME-2
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
result	O
in	O
low	O
urine	O
levels	O
.	O

Quinolones	S-group-EF-1
,	O
including	O
cinoxacin	S-drug-EF-1
,	O
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	S-group-EF-2
,	O
such	O
as	O
warfarin	S-drug-EF-2
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
closely	O
monitored	O
.	O

Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
another	O
quinolone	B-group-EF-1
class	I-group-EF-1
antimicrobial	E-group-EF-1
and	O
the	O
nonsteroidal	B-group-EF-2
anti	I-group-EF-2
-	I-group-EF-2
inflammatory	I-group-EF-2
drug	E-group-EF-2
fenbufen	S-drug-EF-2
concurrently	O
.	O

Animal	O
studies	O
also	O
suggest	O
an	O
increased	O
potential	O
for	O
seizures	O
when	O
these	O
2	O
drugs	O
are	O
given	O
concomitantly	O
.	O

Fenbufen	S-drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
at	O
this	O
time	O
.	O

Physicians	O
are	O
provided	O
this	O
information	O
to	O
increase	O
awareness	O
of	O
the	O
potential	O
for	O
serious	O
interactions	O
when	O
cinoxacin	S-drug-AD-1
and	O
certain	O
nonsteroidal	B-group-AD-2
anti	I-group-AD-2
-	I-group-AD-2
inflammatory	I-group-AD-2
agents	E-group-AD-2
are	O
administered	O
concomitantly	O
.	O

Elevated	O
cyclosporine	S-drug
serum	O
levels	O
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
quinolones	S-group-ME-1
and	O
cyclosporine	S-drug-ME-2
.	O

Some	O
quinolones	S-group-ME-1
,	O
including	O
ciprofloxacin	S-drug-ME-1
,	O
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	S-drug-ME-2
.	O

This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	S-drug
and	O
a	O
prolongation	O
of	O
its	O
serum	O
half	O
-	O
life	O
.	O

Some	O
quinolones	S-group-EF-1
,	O
including	O
ciprofloxacin	S-drug-EF-1
,	O
have	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
cyclosporine	S-drug-EF-2
concomitantly	O
.	O

Glyburide	S-drug
:	O
The	O
concomitant	O
administration	O
of	O
ciprofloxacin	S-drug-EF-1
with	O
the	O
sulfonylurea	S-group-EF-2
glyburide	S-drug-EF-2
has	O
,	O
on	O
rare	O
occasions	O
,	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O

Histamine	B-group
H2	I-group
-	I-group
receptor	I-group
antagonists	E-group
:	O
Histamine	B-group
H2	I-group
-	I-group
receptor	I-group
antagonists	E-group
appear	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
ciprofloxacin	S-drug
.	O

Methotrexate	S-drug
Renal	O
tubular	O
transport	O
of	O
methotrexate	S-drug-ME-1
may	O
be	O
inhibited	O
by	O
concomitant	O
administration	O
of	O
ciprofloxacin	S-drug-ME-2
,	O
potentially	O
leading	O
to	O
increased	O
plasma	O
levels	O
of	O
methotrexate	S-drug
.	O

This	O
might	O
increase	O
the	O
risk	O
of	O
methotrexate	S-drug
toxic	O
reactions	O
.	O

Therefore	O
,	O
patients	O
under	O
methotrexate	S-drug-AD-1
therapy	O
should	O
be	O
carefully	O
monitored	O
when	O
concomitant	O
ciprofloxacin	S-drug-AD-2
therapy	O
is	O
indicated	O
.	O

Multivalent	O
Cation	O
-	O
Containing	O
Products	O
:	O
Concurrent	O
administration	O
of	O
a	O
quinolone	S-group-ME-1
,	O
including	O
ciprofloxacin	S-drug-ME-1
,	O
with	O
multivalent	O
cation	O
-	O
containing	O
products	O
such	O
as	O
magnesium	S-drug-ME-2
or	O
aluminum	S-drug-ME-2
antacids	S-group-ME-2
,	O
sucralfate	S-drug-ME-2
,	O
VIDEX	S-brand-ME-2
chewable	O
/	O
buffered	O
tablets	O
or	O
pediatric	O
powder	O
,	O
or	O
products	O
containing	O
calcium	S-drug-ME-2
,	O
iron	S-drug-ME-2
,	O
or	O
zinc	S-drug-ME-2
may	O
substantially	O
decrease	O
the	O
absorption	O
of	O
ciprofloxacin	S-drug-ME-2
,	O
resulting	O
in	O
serum	O
and	O
urine	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O

Proquin	B-brand
XR	E-brand
should	O
be	O
administered	O
at	O
least	O
4	O
hours	O
before	O
or	O
2	O
hours	O
after	O
these	O
products	O
.	O

This	O
time	O
window	O
is	O
different	O
than	O
for	O
other	O
oral	O
formulations	O
of	O
ciprofloxacin	S-drug-AD-1
,	O
which	O
are	O
usually	O
administered	O
2	O
hours	O
before	O
or	O
6	O
hours	O
after	O
antacids	S-group-AD-2
.	O

Non	B-group
-	I-group
steroidal	I-group
anti	I-group
-	I-group
inflammatory	I-group
drugs	E-group
(	O
but	O
not	O
aspirin	S-brand
)	O
:	O
These	O
drugs	O
in	O
combination	O
with	O
very	O
high	O
doses	O
of	O
quinolones	S-group
have	O
been	O
shown	O
to	O
provoke	O
convulsions	O
in	O
pre	O
-	O
clinical	O
studies	O
.	O

Omeprazole	S-drug
:	O
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
ciprofloxacin	S-drug
was	O
bioequivalent	O
when	O
Proquin	B-brand
XR	E-brand
was	O
given	O
alone	O
or	O
when	O
Proquin	B-brand
XR	E-brand
was	O
given	O
2	O
hours	O
after	O
omeprazole	S-drug
at	O
the	O
dose	O
that	O
maximally	O
suppresses	O
gastric	O
acid	O
secretion	O
.	O

Omeprazole	S-drug
should	O
be	O
taken	O
as	O
directed	O
and	O
Proquin	B-brand
XR	E-brand
should	O
be	O
taken	O
with	O
a	O
main	O
meal	O
of	O
the	O
day	O
,	O
preferably	O
the	O
evening	O
meal..	O

Phenytoin	S-drug
:	O
Altered	O
serum	O
levels	O
of	O
phenytoin	S-drug-ME-1
(	O
increased	O
and	O
decreased	O
)	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
ciprofloxacin	S-drug-ME-2
.	O

Probenecid	S-drug
:	O
Probenecid	S-drug-ME-1
interferes	O
with	O
renal	O
tubular	O
secretion	O
of	O
ciprofloxacin	S-drug-ME-2
and	O
produces	O
an	O
increase	O
in	O
the	O
level	O
of	O
ciprofloxacin	S-drug-ME-2
in	O
serum	O
.	O

Theophylline	S-drug
:	O
As	O
with	O
some	O
other	O
quinolones	S-group-ME-1
,	O
concurrent	O
administration	O
of	O
ciprofloxacin	S-drug-ME-1
with	O
theophylline	S-drug-ME-2
may	O
lead	O
to	O
elevated	O
serum	O
concentrations	O
of	O
theophylline	S-drug
and	O
prolongation	O
of	O
its	O
elimination	O
half	O
-	O
life	O
.	O

This	O
may	O
result	O
in	O
increased	O
risk	O
of	O
theophylline	S-drug
-	O
related	O
adverse	O
reactions	O
.	O

If	O
concomitant	O
use	O
can	O
not	O
be	O
avoided	O
,	O
serum	O
levels	O
of	O
theophylline	S-drug
should	O
be	O
monitored	O
and	O
dosage	O
adjustments	O
made	O
as	O
appropriate	O
.	O

Warfarin	S-drug
:	O
Quinolones	S-group-EF-1
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	S-group
warfarin	S-drug-EF-2
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
monitored	O
.	O

Cisapride	S-drug
is	O
metabolized	O
mainly	O
via	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
.	O

In	O
some	O
cases	O
where	O
serious	O
ventricular	O
arrhythmias	O
,	O
QT	O
prolongation	O
,	O
and	O
torsades	O
de	O
pointes	O
have	O
occurred	O
when	O
cisapride	S-drug
was	O
taken	O
in	O
conjunction	O
with	O
one	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
inhibitors	O
,	O
elevated	O
blood	O
cisapride	S-drug
levels	O
were	O
noted	O
at	O
the	O
time	O
of	O
the	O
QT	O
prolongation	O
.	O

Antibiotics	S-group
:	O
In	O
vitro	O
and	O
/	O
or	O
in	O
vivo	O
data	O
show	O
that	O
clarithromycin	S-drug-ME-1
,	O
erythromycin	S-drug-ME-1
,	O
and	O
troleandomycin	S-drug-ME-1
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	S-drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Anticholinergics	S-group
:	O
Concurrent	O
administration	O
of	O
certain	O
anticholinergic	B-group-EF-1
compounds	E-group-EF-1
,	O
such	O
as	O
belladonna	B-group-EF-1
alkaloids	E-group-EF-1
and	O
dicyclomine	S-drug-EF-1
,	O
would	O
be	O
expected	O
to	O
compromise	O
the	O
beneficial	O
effects	O
of	O
cisapride	S-drug-EF-2
.	O

Anticoagulants	S-group
(	O
Oral	O
)	O
:	O
In	O
patients	O
receiving	O
oral	O
anticoagulants	S-group
,	O
the	O
coagulation	O
times	O
were	O
increased	O
in	O
some	O
cases	O
.	O

It	O
is	O
advisable	O
to	O
check	O
coagulation	O
time	O
within	O
the	O
first	O
few	O
days	O
after	O
the	O
start	O
and	O
discontinuation	O
of	O
cisapride	S-drug-AD-1
therapy	O
,	O
with	O
an	O
appropriate	O
adjustment	O
of	O
the	O
anticoagulant	S-group-AD-2
dose	O
,	O
if	O
necessary	O
.	O

Antidepressants	S-group
:	O
In	O
vitro	O
data	O
indicate	O
that	O
nefazodone	S-drug-ME-1
inhibits	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	S-drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Antifungals	S-group
:	O
In	O
vitro	O
and	O
/	O
or	O
in	O
vivo	O
data	O
indicate	O
that	O
fluconazole	S-drug-ME-1
,	O
itraconazole	S-drug-ME-1
,	O
and	O
oral	O
ketoconazole	S-drug-ME-1
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	S-drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Human	O
pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	S-drug-ME-1
markedly	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
,	O
resulting	O
in	O
a	O
mean	O
eight	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
cisapride	S-drug
.	O

A	O
study	O
in	O
14	O
normal	O
male	O
and	O
female	O
volunteers	O
suggests	O
that	O
coadministration	O
of	O
cisapride	S-drug-EF-1
and	O
ketoconazole	S-drug-EF-2
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

H2	B-group
Receptor	I-group
Antagonists	E-group
:	O
Cimetidine	S-drug-ME-1
coadministration	O
leads	O
to	O
an	O
increased	O
peak	O
plasma	O
concentration	O
and	O
AUC	O
of	O
cisapride	S-drug-ME-2
,	O
there	O
is	O
no	O
effect	O
on	O
cisapride	S-drug
absorption	O
when	O
it	O
is	O
coadministered	O
with	O
ranitidine	S-drug
.	O

The	O
gastrointestinal	O
absorption	O
of	O
cimetidine	S-drug-ME-1
and	O
ranitidine	S-drug-ME-1
is	O
accelerated	O
when	O
they	O
are	O
coadministered	O
with	O
cisapride	S-drug-ME-2
.	O

Protease	B-group
Inhibitors	E-group
:	O
In	O
vitro	O
data	O
indicate	O
that	O
indinavir	S-drug-ME-1
and	O
ritonavir	S-drug-ME-1
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	S-drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Other	O
:	O
Coadministration	O
of	O
grapefruit	O
juice	O
with	O
cisapride	S-drug
increases	O
the	O
bioavailability	O
of	O
cisapride	S-drug
and	O
concomitant	O
use	O
should	O
be	O
avoided	O
.	O

Cisapride	S-drug-AD-1
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
drugs	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
:	O
certain	O
antiarrhythmics	S-group-AD-2
,	O
including	O
those	O
of	O
Class	O
IA	O
(	O
such	O
as	O
quinidine	S-drug-AD-2
and	O
procainamide	S-drug-AD-2
)	O
and	O
Class	O
III	O
(	O
such	O
as	O
sotalol	S-drug-AD-2
)	O
;	O

tricyclic	B-group
antidepressants	E-group
(	O
such	O
as	O
amitriptyline	S-drug
)	O
;	O

certain	O
tetracyclic	B-group
antidepressants	E-group
(	O
such	O
as	O
maprotiline	S-drug
)	O
;	O

certain	O
antipsychotic	B-group
medications	E-group
(	O
such	O
as	O
sertindole	S-drug
)	O
;	O

astemizole	S-drug
,	O
bepridil	S-drug
,	O
sparfloxacin	S-drug
,	O
and	O
terodiline	S-drug
.	O

The	O
preceding	O
lists	O
of	O
drugs	O
are	O
not	O
comprehensive	O
.	O

The	O
acceleration	O
of	O
gastric	O
emptying	O
by	O
cisapride	S-drug
could	O
affect	O
the	O
rate	O
of	O
absorption	O
of	O
other	O
drugs	O
.	O

Patients	O
receiving	O
narrow	O
therapeutic	O
ratio	O
drugs	O
or	O
other	O
drugs	O
that	O
require	O
careful	O
titration	O
should	O
be	O
followed	O
closely	O
;	O

if	O
plasma	O
levels	O
are	O
being	O
monitored	O
,	O
they	O
should	O
be	O
reassessed	O
.	O

Administration	O
of	O
0.1	O
-	O
mg	O
/	O
kg	O
(	O
2	O
x	O
ED95	O
)	O
NIMBEX	S-brand-EF-1
at	O
10	O
%	O
or	O
95	O
%	O
recovery	O
following	O
an	O
intubating	O
dose	O
of	O
succinylcholine	S-drug-EF-2
(	O
1	O
mg	O
/	O
kg	O
)	O
produced	O
95	O
%	O
neuromuscular	O
block	O
.	O

The	O
time	O
to	O
onset	O
of	O
maximum	O
block	O
following	O
NIMBEX	S-brand-EF-1
is	O
approximately	O
2	O
minutes	O
faster	O
with	O
prior	O
administration	O
of	O
succinylcholine	S-drug-EF-2
.	O

Prior	O
administration	O
of	O
succinylcholine	S-drug
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
neuromuscular	O
block	O
following	O
initial	O
or	O
maintenance	O
bolus	O
doses	O
of	O
NIMBEX	S-brand
.	O

Infusion	O
requirements	O
of	O
NIMBEX	S-brand
in	O
patients	O
administered	O
succinylcholine	S-drug-EF-1
prior	O
to	O
infusions	O
of	O
NIMBEX	S-brand-EF-2
were	O
comparable	O
to	O
or	O
slightly	O
greater	O
than	O
when	O
succinylcholine	S-drug
was	O
not	O
administered	O
.	O

The	O
use	O
of	O
NIMBEX	S-brand
before	O
succinylcholine	S-drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	S-drug
has	O
not	O
been	O
studied	O
.	O

Although	O
not	O
studied	O
systematically	O
in	O
clinical	O
trials	O
,	O
no	O
drug	O
interactions	O
were	O
observed	O
when	O
vecuronium	S-drug
,	O
pancuronium	S-drug
,	O
or	O
atracurium	S-drug
were	O
administered	O
following	O
varying	O
degrees	O
of	O
recovery	O
from	O
single	O
doses	O
or	O
infusions	O
of	O
NIMBEX	S-brand
.	O

Isoflurane	S-drug-EF-1
or	O
enflurane	S-drug-EF-1
administered	O
with	O
nitrous	B-drug-EF-1
oxide	E-drug-EF-1
/	O
oxygen	S-drug
to	O
achieve	O
1.25	O
MAC	O
[	O
Minimum	O
Alveolar	O
Concentration	O
]	O
may	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
of	O
initial	O
and	O
maintenance	O
doses	O
of	O
NIMBEX	S-brand-EF-2
and	O
decrease	O
the	O
required	O
infusion	O
rate	O
of	O
NIMBEX	S-brand-EF-2
.	O

The	O
magnitude	O
of	O
these	O
effects	O
may	O
depend	O
on	O
the	O
duration	O
of	O
administration	O
of	O
the	O
volatile	O
agents	O
.	O

Fifteen	O
to	O
30	O
minutes	O
of	O
exposure	O
to	O
1.25	O
MAC	O
isoflurane	S-drug
or	O
enflurane	S-drug
had	O
minimal	O
effects	O
on	O
the	O
duration	O
of	O
action	O
of	O
initial	O
doses	O
of	O
NIMBEX	S-brand
and	O
therefore	O
,	O
no	O
adjustment	O
to	O
the	O
initial	O
dose	O
should	O
be	O
necessary	O
when	O
NIMBEX	S-brand
is	O
administered	O
shortly	O
after	O
initiation	O
of	O
volatile	O
agents	O
.	O

In	O
long	O
surgical	O
procedures	O
during	O
enflurane	S-drug-AD-1
or	O
isoflurane	S-drug-AD-1
anesthesia	O
,	O
less	O
frequent	O
maintenance	O
dosing	O
,	O
lower	O
maintenance	O
doses	O
,	O
or	O
reduced	O
infusion	O
rates	O
of	O
NIMBEX	S-brand-AD-2
may	O
be	O
necessary	O
.	O

The	O
average	O
infusion	O
rate	O
requirement	O
may	O
be	O
decreased	O
by	O
as	O
much	O
as	O
30	O
%	O
to	O
40	O
%	O
.	O

In	O
clinical	O
studies	O
propofol	S-drug
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
action	O
or	O
dosing	O
requirements	O
for	O
NIMBEX	S-brand
.	O

Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B-group-EF-1
agents	E-group-EF-1
such	O
as	O
NIMBEX	S-brand-EF-M
include	O
certain	O
antibiotics	S-group-EF-2
(	O
e.	O
g.	O
,	O
aminoglycosides	S-group-EF-2
,	O
tetracyclines	S-group-EF-2
,	O
bacitracin	S-drug-EF-2
,	O
polymyxins	S-group-EF-2
,	O
lincomycin	S-drug-EF-2
,	O
clindamycin	S-drug-EF-2
,	O
colistin	S-drug-EF-2
,	O
and	O
sodium	B-drug-EF-2
colistemethate	E-drug-EF-2
)	O
,	O
magnesium	S-group-EF-2
salts	O
,	O
lithium	S-drug-EF-2
,	O
local	O
anesthetics	S-group-EF-2
,	O
procainamide	S-drug-EF-2
,	O
and	O
quinidine	S-drug-EF-2
.	O

Resistance	O
to	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B-group-EF-1
neuromuscular	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
has	O
been	O
demonstrated	O
in	O
patients	O
chronically	O
administered	O
phenytoin	S-drug-EF-2
or	O
carbamazepine	S-drug-EF-2
.	O

While	O
the	O
effects	O
of	O
chronic	O
phenytoin	S-drug-EF-1
or	O
carbamazepine	S-drug-EF-1
therapy	O
on	O
the	O
action	O
of	O
NIMBEX	S-brand-EF-2
are	O
unknown	O
,	O
slightly	O
shorter	O
durations	O
of	O
neuromuscular	O
block	O
may	O
be	O
anticipated	O
and	O
infusion	O
rate	O
requirements	O
may	O
be	O
higher	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

Plasma	O
levels	O
of	O
anticonvulsant	B-group-ME-1
agents	E-group-ME-1
may	O
become	O
subtherapeutic	O
during	O
cisplatin	S-drug-ME-2
therapy	O
.	O

Central	B-group
nervous	I-group
system	I-group
depressant	E-group
(	O
CNS	O
)	O
drugs	O
including	O
alcohol	S-drug
,	O
antidepressants	S-group
,	O
antihistamines	S-group
,	O
antipsychotics	S-group
,	O
blood	O
pressure	O
medications	O
(	O
reserpine	S-drug
,	O
methyldopa	S-drug
,	O
beta	B-group
-	I-group
blockers	E-group
)	O
,	O
motion	O
sickness	O
medications	O
,	O
muscle	B-group
relaxants	E-group
,	O
narcotics	S-group
,	O
sedatives	S-group
,	O
sleeping	O
pills	O
and	O
tranquilizers	S-group

There	O
are	O
no	O
known	O
drug	O
interactions	O
with	O
LEUSTATIN	S-brand
Injection	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
LEUSTATIN	S-brand
Injection	O
is	O
administered	O
before	O
,	O
after	O
,	O
or	O
in	O
conjunction	O
with	O
other	O
drugs	O
known	O
to	O
cause	O
immunosuppression	O
or	O
myelosuppression	O
.	O

The	O
concurrent	O
administration	O
of	O
allopurinol	S-drug-EF-1
and	O
ampicillin	S-drug-EF-2
increases	O
substantially	O
the	O
incidence	O
of	O
rashes	O
in	O
patients	O
receiving	O
both	O
drugs	O
as	O
compared	O
to	O
patients	O
receiving	O
ampicillin	S-drug
alone	O
.	O

It	O
is	O
not	O
known	O
whether	O
this	O
potentiation	O
of	O
ampicillin	S-drug-EF-1
rashes	O
is	O
due	O
to	O
allopurinol	S-drug-EF-2
or	O
the	O
hyperuricemia	O
present	O
in	O
these	O
patients	O
.	O

In	O
controlled	O
clinical	O
trials	O
of	O
AUGMENTIN	B-brand
XR	E-brand
,	O
22	O
patients	O
received	O
concomitant	O
allopurinol	S-drug
and	O
AUGMENTIN	B-brand
XR	E-brand
.	O

No	O
rashes	O
were	O
reported	O
in	O
these	O
patients	O
.	O

However	O
,	O
this	O
sample	O
size	O
is	O
too	O
small	O
to	O
allow	O
for	O
any	O
conclusions	O
to	O
be	O
drawn	O
regarding	O
the	O
risk	O
of	O
rashes	O
with	O
concomitant	O
AUGMENTIN	B-brand
XR	E-brand
and	O
allopurinol	S-drug
use	O
.	O

In	O
common	O
with	O
other	O
broad	B-group-EF-1
-	I-group-EF-1
spectrum	I-group-EF-1
antibiotics	E-group-EF-1
,	O
AUGMENTIN	B-brand-EF-1
XR	E-brand-EF-1
may	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	S-group-EF-2

Additive	O
CNS	O
depression	O
may	O
occur	O
when	O
antihistamines	S-group-EF-1
are	O
administered	O
concomitantly	O
with	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
including	O
barbiturates	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
,	O
and	O
alcohol	S-drug-EF-2
.	O

Patients	O
receiving	O
antihistamines	S-group-AD-1
should	O
be	O
advised	O
against	O
the	O
concurrent	O
use	O
of	O
other	O
CNS	B-group-AD-2
depressant	I-group-AD-2
drugs	E-group-AD-2
.	O

Monoamine	B-group-EF-1
oxidase	I-group-EF-1
(	I-group-EF-1
MAO	I-group-EF-1
)	I-group-EF-1
inhibitors	E-group-EF-1
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	S-group-EF-2
.	O

Amantadine	S-drug-EF-1
,	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
,	O
and	O
MAOIs	S-group-EF-1
may	O
increase	O
anticholinergic	O
effect	O
of	O
clidinium	S-drug-EF-2
.	O

Clidinium	S-drug-EF-1
may	O
decrease	O
the	O
effect	O
of	O
phenothiazines	S-group-EF-2
,	O
levodopa	S-drug-EF-2
,	O
and	O
ketoconazole	S-drug-EF-2
.	O

Clindamycin	S-drug-EF-1
has	O
been	O
shown	O
to	O
have	O
neuromuscular	O
blocking	O
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	B-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

Therefore	O
,	O
it	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
such	O
agents	O
.	O

Antagonism	O
has	O
been	O
demonstrated	O
between	O
clindamycin	S-drug-EF-1
and	O
erythromycin	S-drug-EF-2
in	O
vitro	O
.	O

Because	O
of	O
possible	O
clinical	O
significance	O
,	O
these	O
two	O
drugs	O
should	O
not	O
be	O
administered	O
concurrently	O
.	O

Alcohol	S-drug
(	O
increases	O
bioavailability	O
by	O
50	O
%	O
)	O
,	O
cimetidine	S-drug
,	O
and	O
valproates	O
.	O

No	O
separate	O
information	O
available	O

Although	O
no	O
clinical	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
to	O
date	O
,	O
on	O
the	O
basis	O
of	O
the	O
in	O
vitro	O
studies	O
,	O
cytochrome	O
p450	O
inhibitors	O
and	O
inducers	O
are	O
unlikely	O
to	O
affect	O
the	O
metabolism	O
of	O
clofarabine	S-drug
.	O

The	O
effect	O
of	O
clofarabine	S-drug
on	O
the	O
metabolism	O
of	O
cytochrome	O
p450	O
substrates	O
has	O
not	O
been	O
studied	O
.	O

Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
There	O
are	O
no	O
known	O
clinically	O
significant	O
interactions	O
of	O
CLOLAR	S-brand
with	O
other	O
medications	O
or	O
laboratory	O
tests	O
.	O

No	O
formal	O
drug	O
/	O
laboratory	O
test	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
CLOLAR	S-brand
.	O

Preliminary	O
data	O
which	O
suggest	O
that	O
dapsone	S-drug-EF-1
may	O
inhibit	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
Lamprene	S-brand-EF-2
have	O
not	O
been	O
confirmed	O
.	O

If	O
leprosy	O
-	O
associated	O
inflammatory	O
reactions	O
develop	O
in	O
patients	O
being	O
treated	O
with	O
dapsone	S-drug-AD-1
and	O
clofazimine	S-drug-AD-2
,	O
it	O
is	O
still	O
advisable	O
to	O
continue	O
treatment	O
with	O
both	O
drugs	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
anticoagulants	S-group-AD-1
are	O
given	O
in	O
conjunction	O
with	O
Atromid	B-brand-AD-2
-	I-brand-AD-2
S	E-brand-AD-2
.	O

Usually	O
,	O
the	O
dosage	O
of	O
the	O
anticoagulant	S-group
should	O
be	O
reduced	O
by	O
one	O
-	O
half	O
(	O
depending	O
on	O
the	O
individual	O
case	O
)	O
to	O
maintain	O
the	O
prothrombin	O
time	O
at	O
the	O
desired	O
level	O
to	O
prevent	O
bleeding	O
complications	O
.	O

Frequent	O
prothrombin	O
determinations	O
are	O
advisable	O
until	O
it	O
has	O
been	O
determined	O
definitely	O
that	O
the	O
prothrombin	O
level	O
has	O
been	O
stabilized	O
.	O

Atromid	B-brand-ME-1
-	I-brand-ME-1
S	E-brand-ME-1
may	O
displace	O
acidic	O
drugs	O
such	O
as	O
phenytoin	S-drug-ME-2
or	O
tolbutamide	S-drug-ME-2
from	O
their	O
binding	O
sites	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
treating	O
patients	O
with	O
either	O
of	O
these	O
drugs	O
or	O
other	O
highly	O
protein	O
-	O
bound	O
drugs	O
and	O
Atromid	B-brand
-	I-brand
S	E-brand
.	O

The	O
hypoglycemic	O
effect	O
of	O
tolbutamide	S-drug-EF-1
has	O
been	O
reported	O
to	O
increase	O
when	O
Atromid	B-brand-EF-2
-	I-brand-EF-2
S	E-brand-EF-2
is	O
given	O
concurrently	O
.	O

Fulminant	O
rhabdomyolysis	O
has	O
been	O
seen	O
as	O
early	O
as	O
three	O
weeks	O
after	O
initiation	O
of	O
combined	O
therapy	O
with	O
another	O
fibrate	S-group-EF-1
and	O
lovastatin	S-drug-EF-2
but	O
may	O
be	O
seen	O
after	O
several	O
months	O
.	O

For	O
these	O
reasons	O
,	O
it	O
is	O
felt	O
that	O
,	O
in	O
most	O
subjects	O
who	O
have	O
had	O
an	O
unsatisfactory	O
lipid	O
response	O
to	O
either	O
drug	O
alone	O
,	O
the	O
possible	O
benefits	O
of	O
combined	O
therapy	O
with	O
lovastatin	S-drug-EF-1
and	O
a	O
fibrate	S-group-EF-2
do	O
not	O
outweigh	O
the	O
risks	O
of	O
severe	O
myopathy	O
,	O
rhabdomyolysis	O
,	O
and	O
acute	O
renal	O
failure	O
.	O

While	O
it	O
is	O
not	O
known	O
whether	O
this	O
interaction	O
occurs	O
with	O
fibrates	S-group
other	O
than	O
gemfibrozil	S-drug
,	O
myopathy	O
and	O
rhabdomyolysis	O
have	O
occasionally	O
been	O
associated	O
with	O
the	O
use	O
of	O
fibrates	S-group
alone	O
,	O
including	O
clofibrate	S-drug
.	O

Therefore	O
,	O
the	O
combined	O
use	O
of	O
lovastatin	S-drug-AD-1
with	O
fibrates	S-group-AD-2
should	O
generally	O
be	O
avoided	O
.	O

Drug	O
interactions	O
with	O
clomiphene	B-drug
citrate	E-drug
tablets	O
USP	O
have	O
not	O
been	O
documented	O
.	O

The	O
risks	O
of	O
using	O
Anafranil	S-brand
in	O
combination	O
with	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Anafranil	S-brand
,	O
caution	O
is	O
advised	O
in	O
using	O
it	O
concomitantly	O
with	O
other	O
CNS	O
-	O
active	O
drugs	O
.	O

Anafranil	S-brand-AD-1
should	O
not	O
be	O
used	O
with	O
MAO	B-group-AD-2
inhibitors	E-group-AD-2
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
Anafranil	S-brand-AD-1
is	O
administered	O
with	O
anticholinergic	S-group-AD-2
or	O
sympathomimetic	B-group-AD-2
drugs	E-group-AD-2
.	O

Several	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
have	O
been	O
reported	O
to	O
block	O
the	O
pharmacologic	O
effects	O
of	O
guanethidine	S-drug-EF-2
,	O
clonidine	S-drug-EF-2
,	O
or	O
similar	O
agents	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	S-drug-EF-2
because	O
of	O
its	O
structural	O
similarity	O
to	O
other	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
.	O

The	O
plasma	O
concentration	O
of	O
CMI	S-drug-ME-1
has	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
haloperidol	S-drug-ME-2
;	O

plasma	O
levels	O
of	O
several	O
closely	O
related	O
tricyclic	B-group-ME-1
antidepressants	E-group-ME-1
have	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
methylphenidate	S-drug-ME-M
or	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e.g	O
.	O
,	O
cimetidine	S-drug-ME-M
,	O
fluoxetine	S-drug-ME-M
)	O
and	O
decreased	O
by	O
the	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e.g	O
.	O
,	O
barbiturates	S-group-ME-M
,	O
phenytoin	S-drug-ME-M
)	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	S-drug-ME-2
as	O
well	O
.	O

Administration	O
of	O
CMI	S-drug-ME-1
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
of	O
phenobarbital	S-drug-ME-2
,	O
if	O
given	O
concomitantly	O
.	O

Drugs	O
Metabolized	O
by	O
P450	O
2D6	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
aucasian	O
population	O
(	O
about	O
7	O
%	O
-	O
10	O
%	O
of	O
Caucasians	O
are	O
so	O
-	O
called	O
poor	O
metabolizers	O
)	O
;	O

reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
lasma	O
concentrations	O
of	O
tricyclic	B-group
antidepressants	E-group
(	O
TCAs	S-group
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	S-group
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCAmay	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	S-drug
;	O

cimetidine	S-drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	S-group
,	O
phenothiazines	S-group
,	O
and	O
the	O
Type	B-group
1C	I-group
antiarrhythmics	E-group
propafenone	S-drug
and	O
flecainide	S-drug
)	O
.	O

While	O
all	O
the	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
(	O
SSRIs	S-group
)	O
,	O
e.g	O
.	O
,	O
fluoxetine	S-drug
,	O
sertraline	S-drug
,	O
paroxetine	S-drug
,	O
and	O
fluvoxamine	S-drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

Fluvoxamine	S-drug-ME-1
has	O
also	O
been	O
shown	O
to	O
inhibit	O
P450	O
1A2	O
,	O
an	O
isoform	O
also	O
involved	O
in	O
TCAmetabolism	O
.	O

The	O
extent	O
to	O
which	O
SSRI	S-group-IN-1
-	O
TCAinteractions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	S-group
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCAs	S-group-AD-1
with	O
any	O
of	O
the	O
SSRIs	S-group-AD-2
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCAtreatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	S-drug-AD-2
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
agents	O
in	O
the	O
tricyclic	B-group
antidepressant	I-group
class	E-group
(	O
which	O
includes	O
Anafranil	S-brand
)	O
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-group
antidepressant	I-group
agent	E-group
or	O
the	O
other	O
drug	O
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-group
antidepressant	I-group
agent	E-group
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCAplasma	O
levels	O
whenever	O
an	O
agent	O
of	O
the	O
tricyclic	B-group
antidepressant	I-group
class	E-group
including	O
Anafranil	S-brand
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
(	O
and	O
/	O
or	O
P450	O
1A2	O
)	O
.	O

Because	O
Anafranil	S-brand
is	O
highly	O
bound	O
to	O
serum	O
protein	O
,	O
the	O
administration	O
of	O
Anafranil	S-brand-ME-1
to	O
patients	O
taking	O
other	O
drugs	O
that	O
are	O
highly	O
bound	O
to	O
protein	O
(	O
e.g	O
.	O
,	O
warfarin	S-drug-ME-2
,	O
digoxin	S-drug-ME-2
)	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Conversely	O
,	O
adverse	O
effects	O
may	O
result	O
from	O
displacement	O
of	O
protein	O
-	O
bound	O
Anafranil	S-brand
by	O
other	O
highly	O
bound	O
drugs	O
.	O

Effect	O
of	O
Clonazepam	S-drug
on	O
the	O
Pharmacokinetics	O
of	O
Other	O
Drugs	O
:	O
Clonazepam	S-drug
does	O
not	O
appear	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	S-drug
,	O
carbamazepine	S-drug
,	O
or	O
phenobarbital	S-drug
.	O

The	O
effect	O
of	O
clonazepam	S-drug
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
has	O
not	O
been	O
investigated	O
.	O

Effect	O
of	O
Other	O
Drugs	O
on	O
the	O
Pharmacokinetics	O
of	O
Clonazepam	S-drug
:	O
Literature	O
reports	O
suggest	O
that	O
ranitidine	S-drug
,	O
an	O
agent	O
that	O
decreases	O
stomach	O
acidity	O
,	O
does	O
not	O
greatly	O
alter	O
clonazepam	S-drug
pharmacokinetics	O
.	O

In	O
a	O
study	O
in	O
which	O
the	O
2	O
mg	O
clonazepam	S-drug-ME-1
orally	O
disintegrating	O
tablet	O
was	O
administered	O
with	O
and	O
without	O
propantheline	S-drug-ME-2
(	O
an	O
anticholinergic	B-group
agent	E-group
with	O
multiple	O
effects	O
on	O
the	O
GI	O
tract	O
)	O
to	O
healthy	O
volunteers	O
,	O
the	O
AUC	O
of	O
clonazepam	S-drug
was	O
10	O
%	O
lower	O
and	O
the	O
Cmax	O
of	O
clonazepam	S-drug-ME-1
was	O
20	O
%	O
lower	O
when	O
the	O
orally	O
disintegrating	O
tablet	O
was	O
given	O
with	O
propantheline	S-drug-ME-2
compared	O
to	O
when	O
it	O
was	O
given	O
alone	O
.	O

Fluoxetine	S-drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
clonazepam	S-drug
.	O

Cytochrome	O
P	O
-	O
450	O
inducers	O
,	O
such	O
as	O
phenytoin	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
and	O
phenobarbital	S-drug-ME-1
,	O
induce	O
clonazepam	S-drug-ME-2
metabolism	O
,	O
causing	O
an	O
approximately	O
30	O
%	O
decrease	O
in	O
plasma	O
clonazepam	S-drug
levels	O
.	O

Although	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
,	O
based	O
on	O
the	O
involvement	O
of	O
the	O
cytochrome	O
P	O
-	O
450	O
3A	O
family	O
in	O
clonazepam	S-drug
metabolism	O
,	O
inhibitors	O
of	O
this	O
enzyme	O
system	O
,	O
notably	O
oral	O
antifungal	B-group-AD-1
agents	E-group-AD-1
,	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
receiving	O
clonazepam	S-drug-AD-2
.	O

Pharmacodynamic	O
Interactions	O
:	O
The	O
CNS	O
-	O
depressant	O
action	O
of	O
the	O
benzodiazepine	B-group-EF-1
class	E-group-EF-1
of	O
drugs	O
may	O
be	O
potentiated	O
by	O
alcohol	S-drug-EF-2
,	O
narcotics	S-group-EF-2
,	O
barbiturates	S-group-EF-2
,	O
nonbarbiturate	B-group-EF-2
hypnotics	E-group-EF-2
,	O
antianxiety	B-group-EF-2
agents	E-group-EF-2
,	O
the	O
phenothiazines	S-group-EF-2
,	O
thioxanthene	S-group-EF-2
and	O
butyrophenone	B-group-EF-2
classes	I-group-EF-2
of	I-group-EF-2
antipsychotic	I-group-EF-2
agents	E-group-EF-2
,	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
and	O
the	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
and	O
by	O
other	O
anticonvulsant	B-group-EF-2
drugs	E-group-EF-2
.	O

Tablet	O
If	O
a	O
patient	O
receiving	O
clonidine	B-drug-EF-1
hydrochloride	E-drug-EF-1
is	O
also	O
taking	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
the	O
effect	O
of	O
clonidine	S-drug
may	O
be	O
reduced	O
,	O
thus	O
necessitating	O
an	O
increase	O
in	O
dosage	O
.	O

Clonidine	B-drug-EF-1
hydrochloride	E-drug-EF-1
may	O
enhance	O
the	O
CNS	O
-	O
depressive	O
effects	O
of	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
or	O
other	O
sedatives	S-group-EF-2
.	O

Amitriptyline	S-drug-EF-1
in	O
combination	O
with	O
clonidine	S-drug-EF-2
enhances	O
the	O
manifestation	O
of	O
corneal	O
lesions	O
in	O
rats	O
Epidural	O
Injection	O
Clonidine	S-drug-EF-1
may	O
potentiate	O
the	O
CNS	O
-	O
depressive	O
effect	O
of	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
or	O
other	O
sedating	B-group-EF-2
drugs	E-group-EF-2
.	O

Narcotic	B-group-EF-1
analgesics	E-group-EF-1
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
clonidine	S-drug-EF-2
.	O

Tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
clonidine	S-drug-EF-2
.	O

The	O
effects	O
of	O
tricyclic	B-group
antidepressants	E-group
on	O
clonidines	O
analgesic	O
actions	O
are	O
not	O
known	O
.	O

Beta	B-group-EF-1
blockers	E-group-EF-1
may	O
exacerbate	O
the	O
hypertensive	O
response	O
seen	O
with	O
clonidine	S-drug-EF-2
withdrawl	O
.	O

Also	O
,	O
due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
such	O
as	O
bradycardia	O
and	O
AV	O
block	O
,	O
caution	O
is	O
warranted	O
in	O
patients	O
receiving	O
clonidine	S-drug-AD-1
with	O
agents	O
known	O
to	O
affect	O
sinus	O
node	O
function	O
or	O
AV	O
nodal	O
conduction	O
(	O
e.g	O
.	O
,	O
digitalis	S-group-AD-2
,	O
calcium	B-group-AD-2
channel	I-group-AD-2
blockers	E-group-AD-2
,	O
and	O
beta	B-group-AD-2
-	I-group-AD-2
blockers	E-group-AD-2
.	O
)	O

There	O
is	O
one	O
reported	O
case	O
of	O
a	O
patient	O
with	O
acute	O
delirium	O
associated	O
with	O
the	O
simultaneous	O
use	O
of	O
fluphenazine	S-drug-EF-1
and	O
oral	O
clonidine	S-drug-EF-2
.	O

Symptoms	O
resolved	O
when	O
clonidine	S-drug
was	O
withdrawn	O
and	O
recurred	O
when	O
the	O
patient	O
was	O
rechallenged	O
with	O
clonidine	S-drug
.	O

Epidural	O
clonidine	S-drug-EF-1
may	O
prolong	O
the	O
duration	O
of	O
pharmacologic	O
effects	O
of	O
epidural	O
local	O
anesthetics	S-group-EF-2
,	O
including	O
both	O
sensory	O
and	O
motor	O
blockade	O
.	O

Aspirin	S-brand
,	O
warfarin	S-drug
,	O
heparin	S-drug
,	O
NSAIDs	S-group

If	O
TRANXENE	S-brand
is	O
to	O
be	O
combined	O
with	O
other	O
drugs	O
acting	O
on	O
the	O
central	O
nervous	O
system	O
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	O
to	O
be	O
employed	O
.	O

Animal	O
experience	O
indicates	O
that	O
clorazepate	B-drug-EF-1
dipotassium	E-drug-EF-1
prolongs	O
the	O
sleeping	O
time	O
after	O
hexobarbital	S-drug-EF-2
or	O
after	O
ethyl	B-drug-EF-2
alcohol	E-drug-EF-2
,	O
increases	O
the	O
inhibitory	O
effects	O
of	O
chlorpromazine	S-drug-EF-2
,	O
but	O
does	O
not	O
exhibit	O
monoamine	O
oxidase	O
inhibition	O
.	O

Clinical	O
studies	O
have	O
shown	O
increased	O
sedation	O
with	O
concurrent	O
hypnotic	B-group
medications	E-group
.	O

The	O
actions	O
of	O
the	O
benzodiazepines	S-group-EF-1
may	O
be	O
potentiated	O
by	O
barbiturates	S-group-EF-2
,	O
narcotics	S-group-EF-2
,	O
phenothiazines	S-group-EF-2
,	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
or	O
other	O
antidepressants	S-group-EF-2
.	O

If	O
TRANXENE	S-brand
tablets	O
are	O
used	O
to	O
treat	O
anxiety	O
associated	O
with	O
somatic	O
disease	O
states	O
,	O
careful	O
attention	O
must	O
be	O
paid	O
to	O
possible	O
drug	O
interaction	O
with	O
concomitant	O
medication	O
.	O

In	O
bioavailability	O
studies	O
with	O
normal	O
subjects	O
,	O
the	O
concurrent	O
administration	O
of	O
antacids	S-group
at	O
therapeutic	O
levels	O
did	O
not	O
significantly	O
influence	O
the	O
bioavailability	O
of	O
TRANXENE	S-brand
tablets	O
.	O

The	O
risks	O
of	O
using	O
Clozapine	S-drug
in	O
combination	O
with	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

Pharmacodynamic	O
-	O
related	O
Interactions	O
:	O
The	O
mechanism	O
of	O
Clozapine	S-drug
induced	O
agranulocytosis	O
is	O
unknown	O
;	O

nonetheless	O
,	O
the	O
possibility	O
that	O
causative	O
factors	O
may	O
interact	O
synergistically	O
to	O
increase	O
the	O
risk	O
and	O
/	O
or	O
severity	O
of	O
bone	O
marrow	O
suppression	O
warrants	O
consideration	O
.	O

Therefore	O
,	O
Clozapine	S-drug
should	O
not	O
be	O
used	O
with	O
other	O
agents	O
having	O
a	O
well	O
-	O
known	O
potential	O
to	O
suppress	O
bone	O
marrow	O
function	O
.	O

Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Clozapine	S-drug-EF-1
,	O
caution	O
is	O
advised	O
in	O
using	O
it	O
concomitantly	O
with	O
other	O
CNS	O
-	O
active	O
drugs	O
or	O
alcohol	S-drug-EF-2
.	O

Orthostatic	O
hypotension	O
in	O
patients	O
taking	O
clozapine	S-drug
can	O
,	O
in	O
rare	O
cases	O
(	O
approximately	O
1	O
case	O
per	O
3,000	O
patients	O
)	O
,	O
be	O
accompanied	O
by	O
profound	O
collapse	O
and	O
respiratory	O
and	O
/	O
or	O
cardiac	O
arrest	O
.	O

Some	O
of	O
the	O
cases	O
of	O
collapse	O
/	O
respiratory	O
arrest	O
/	O
cardiac	O
arrest	O
during	O
initial	O
treatment	O
occurred	O
in	O
patients	O
who	O
were	O
being	O
administered	O
benzodiazepines	S-group
;	O

similar	O
events	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
other	O
psychotropic	B-group
drugs	E-group
or	O
even	O
Clozapine	S-drug
by	O
itself	O
.	O

Although	O
it	O
has	O
not	O
been	O
established	O
that	O
there	O
is	O
an	O
interaction	O
between	O
Clozapine	S-drug
and	O
benzodiazepines	S-group
or	O
other	O
psychotropics	S-group
,	O
caution	O
is	O
advised	O
when	O
clozapine	S-drug-AD-1
is	O
initiated	O
in	O
patients	O
taking	O
a	O
benzodiazepine	S-group-AD-2
or	O
any	O
other	O
psychotropic	B-group-AD-2
drug	E-group-AD-2
.	O

Clozapine	S-drug-EF-1
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
and	O
the	O
anticholinergic	O
effects	O
of	O
atropine	S-drug-EF-2
-	O
type	O
drugs	O
.	O

The	O
administration	O
of	O
epinephrine	S-drug
should	O
be	O
avoided	O
in	O
the	O
treatment	O
of	O
drug	O
induced	O
hypotension	O
because	O
of	O
a	O
possible	O
reverse	O
epinephrine	S-drug
effect	O
.	O

Pharmacokinetic	O
-	O
related	O
Interactions	O
:	O
Clozapine	S-drug
is	O
a	O
substrate	O
for	O
many	O
CYP	O
450	O
isozymes	O
,	O
in	O
particular	O
1A2	O
,	O
2D6	O
,	O
and	O
3A4	O
.	O

The	O
risk	O
of	O
metabolic	O
interactions	O
caused	O
by	O
an	O
effect	O
on	O
an	O
individual	O
isoform	O
is	O
therefore	O
minimized	O
.	O

Nevertheless	O
,	O
caution	O
should	O
be	O
used	O
in	O
patients	O
receiving	O
concomitant	O
treatment	O
with	O
other	O
drugs	O
that	O
are	O
either	O
inhibitors	O
or	O
inducers	O
of	O
these	O
enzymes	O
.	O

Concomitant	O
administration	O
of	O
drugs	O
known	O
to	O
induce	O
cytochrome	O
P450	O
enzymes	O
may	O
decrease	O
the	O
plasma	O
levels	O
of	O
clozapine	S-drug
.	O

Phenytoin	S-drug-ME-1
,	O
nicotine	S-drug-ME-1
,	O
and	O
rifampin	S-drug-ME-1
may	O
decrease	O
Clozapine	S-drug-ME-2
plasma	O
levels	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
effectiveness	O
of	O
a	O
previously	O
effective	O
Clozapine	S-drug
dose	O
.	O

Concomitant	O
administration	O
of	O
drugs	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
cytochrome	O
P450	O
isozymes	O
may	O
increase	O
the	O
plasma	O
levels	O
of	O
clozapine	S-drug
.	O

Cimetidine	S-drug-ME-1
,	O
caffeine	S-drug-ME-1
,	O
and	O
erythromycin	S-drug-ME-1
may	O
increase	O
plasma	O
levels	O
of	O
Clozapine	S-drug-ME-2
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Although	O
concomitant	O
use	O
of	O
Clozapine	S-drug-AD-1
and	O
carbamazepine	S-drug-AD-2
is	O
not	O
recommended	O
,	O
it	O
should	O
be	O
noted	O
that	O
discontinuation	O
of	O
concomitant	O
carbamazepine	S-drug-ME-1
administration	O
may	O
result	O
in	O
an	O
increase	O
in	O
Clozapine	S-drug-ME-2
plasma	O
levels	O
.	O

In	O
a	O
study	O
of	O
schizophrenic	O
patients	O
who	O
received	O
clozapine	S-drug
under	O
steady	O
state	O
conditions	O
,	O
fluvoxamine	S-drug
or	O
paroxetine	S-drug
was	O
added	O
in	O
16	O
and	O
14	O
patients	O
,	O
respectively	O
.	O

After	O
14	O
days	O
of	O
co	O
-	O
administration	O
,	O
mean	O
trough	O
concentrations	O
of	O
clozapine	S-drug
and	O
its	O
metabolites	O
,	O
N	B-drug_n
-	I-drug_n
desmethylclozapine	E-drug_n
and	O
clozapine	B-drug_n
N	I-drug_n
-	I-drug_n
oxide	E-drug_n
,	O
were	O
elevated	O
with	O
fluvoxamine	S-drug
by	O
about	O
three	O
-	O
fold	O
compared	O
to	O
baseline	O
concentrations	O
.	O

Paroxetine	S-drug-ME-1
produced	O
only	O
minor	O
changes	O
in	O
the	O
levels	O
of	O
clozapine	S-drug-ME-2
and	O
its	O
metabolites	O
.	O

However	O
,	O
other	O
published	O
reports	O
describe	O
modest	O
elevations	O
(	O
less	O
than	O
two	O
-	O
fold	O
)	O
of	O
clozapine	S-drug
and	O
metabolite	O
concentrations	O
when	O
clozapine	S-drug-ME-1
was	O
taken	O
with	O
paroxetine	S-drug-ME-2
,	O
fluoxetine	S-drug-ME-2
,	O
and	O
sertraline	S-drug-ME-2
.	O

Therefore	O
,	O
such	O
combined	O
treatment	O
should	O
be	O
approached	O
with	O
caution	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
when	O
Clozapine	S-drug-AD-1
is	O
combined	O
with	O
these	O
drugs	O
,	O
particularly	O
with	O
fluvoxamine	S-drug-AD-2
.	O

A	O
reduced	O
Clozapine	S-drug
dose	O
should	O
be	O
considered	O
.	O

A	O
subset	O
(	O
3	O
%	O
-	O
10	O
%	O
)	O
of	O
the	O
population	O
has	O
reduced	O
activity	O
of	O
certain	O
drug	O
metabolizing	O
enzymes	O
such	O
as	O
the	O
cytochrome	O
P450	O
isozyme	O
P450	O
2D6	O
.	O

Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	O
such	O
as	O
debrisoquin	S-drug
,	O
dextromethorphan	S-drug
,	O
the	O
tricyclic	B-group
antidepressants	E-group
,	O
and	O
clozapine	S-drug
.	O

These	O
individuals	O
may	O
develop	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
clozapine	S-drug
when	O
given	O
usual	O
doses	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
,	O
including	O
many	O
antidepressants	S-group
(	O
clozapine	S-drug
,	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
,	O
and	O
others	O
)	O
,	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
,	O
and	O
thus	O
may	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
system	O
,	O
leading	O
to	O
drug	O
interaction	O
.	O

Concomitant	O
use	O
of	O
clozapine	S-drug
with	O
other	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
clozapine	S-drug
or	O
the	O
other	O
drug	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
clozapine	S-drug-AD-1
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
,	O
including	O
antidepressants	S-group-AD-2
,	O
phenothiazines	S-group-AD-2
,	O
carbamazepine	S-drug-AD-2
,	O
and	O
Type	B-group-AD-2
1C	I-group-AD-2
antiarrhythmics	E-group-AD-2
(	O
e.g	O
.	O
,	O
propafenone	S-drug-AD-2
,	O
flecainide	S-drug-AD-2
and	O
encainide	S-drug-AD-2
)	O
,	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
e.g	O
.	O
,	O
quinidine	S-drug-AD-2
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

The	O
risk	O
of	O
a	O
potential	O
interaction	O
between	O
NovoSeven	S-brand
and	O
coagulation	B-group
factor	E-group
concentrates	O
has	O
not	O
been	O
adequately	O
evaluated	O
in	O
preclinical	O
or	O
clinical	O
studies	O
.	O

Simultaneous	O
use	O
of	O
activated	B-group
prothrombin	I-group
complex	I-group
concentrates	E-group
or	O
prothrombin	B-group
complex	I-group
concentrates	E-group
should	O
be	O
avoided	O
.	O

Although	O
the	O
specific	O
drug	O
interaction	O
was	O
not	O
studied	O
in	O
a	O
clinical	O
trial	O
,	O
there	O
have	O
been	O
more	O
than	O
50	O
episodes	O
of	O
concomitant	O
use	O
of	O
antifibrinolytic	O
therapies	O
(	O
i.e	O
.	O
,	O
tranexamic	B-drug
acid	E-drug
,	O
aminocaproic	B-drug
acid	E-drug
)	O
and	O
NovoSeven	S-brand
.	O

NovoSeven	S-brand
should	O
not	O
be	O
mixed	O
with	O
infusion	O
solutions	O
until	O
clinical	O
data	O
are	O
available	O
to	O
direct	O
this	O
use	O
.	O

Codeine	S-drug-EF-1
in	O
combination	O
with	O
other	O
narcotic	B-group-EF-2
analgesics	E-group-EF-2
,	O
general	O
anesthetics	S-group-EF-2
,	O
phenothiazines	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
,	O
sedative	B-group-EF-2
-	I-group-EF-2
hypnotics	E-group-EF-2
,	O
or	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
(	O
including	O
alcohol	S-drug-EF-2
)	O
has	O
additive	O
depressant	O
effects	O
.	O

When	O
s.c	O
.	O

combination	O
therapy	O
is	O
contemplated	O
,	O
the	O
dosage	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

Colchicine	S-drug-ME-1
is	O
inhibited	O
by	O
acidifying	B-group-ME-2
agents	E-group-ME-2
.	O

The	O
action	O
of	O
colchicine	S-drug-ME-1
is	O
potentiated	O
by	O
alkalinizing	B-group-ME-2
agents	E-group-ME-2
.	O

Colchicine	S-drug-EF-1
may	O
increase	O
sensitivity	O
to	O
the	O
CNS	B-group-EF-2
depressants	E-group-EF-2
.	O

Response	O
to	O
sympathomimetic	B-group-EF-1
agents	E-group-EF-1
may	O
be	O
enhanced	O
by	O
colchicine	S-drug-EF-2
.	O

WelChol	S-brand
has	O
been	O
studied	O
in	O
several	O
human	O
drug	O
interaction	O
studies	O
in	O
which	O
it	O
was	O
administered	O
with	O
a	O
meal	O
and	O
the	O
test	O
drug	O
.	O

WelChol	S-brand
was	O
found	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
digoxin	S-drug
,	O
lovastatin	S-drug
,	O
metoprolol	S-drug
,	O
quinidine	S-drug
,	O
valproic	B-drug
acid	E-drug
,	O
and	O
warfarin	S-drug
.	O

WelChol	S-brand-ME-1
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
sustained	O
-	O
release	O
verapamil	S-drug-ME-2
(	O
Calan	B-brand-ME-2
SR	E-brand-ME-2
)	O
by	O
approximately	O
31	O
%	O
and	O
11	O
%	O
,	O
respectively	O
.	O

Since	O
there	O
is	O
a	O
high	O
degree	O
of	O
variability	O
in	O
the	O
bioavailability	O
of	O
verapamil	S-drug
,	O
the	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unclear	O
.	O

In	O
clinical	O
studies	O
,	O
coadministration	O
of	O
WelChol	S-brand
with	O
atorvastatin	S-drug
,	O
lovastatin	S-drug
,	O
or	O
simvastatin	S-drug
did	O
not	O
interfere	O
with	O
the	O
lipid	O
-	O
lowering	O
activity	O
of	O
the	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitor	E-group
.	O

Other	O
drugs	O
have	O
not	O
been	O
studied	O
.	O

When	O
administering	O
other	O
drugs	O
for	O
which	O
alterations	O
in	O
blood	O
levels	O
could	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
safety	O
or	O
efficacy	O
,	O
physicians	O
should	O
consider	O
monitoring	O
drug	O
levels	O
or	O
effects	O
.	O

Since	O
colestipol	B-drug
hydrochloride	E-drug
is	O
an	O
anion	B-group
exchange	I-group
resin	E-group
,	O
it	O
may	O
have	O
a	O
strong	O
affinity	O
for	O
anions	O
other	O
than	O
the	O
bile	O
acids	O
.	O

In	O
vitro	O
studies	O
have	O
indicated	O
that	O
colestipol	B-drug
hydrochloride	E-drug
binds	O
a	O
number	O
of	O
drugs	O
.	O

Therefore	O
,	O
COLESTlD	S-brand
Tablets	O
may	O
delay	O
or	O
reduce	O
the	O
absorption	O
of	O
concomitant	O
oral	O
medication	O
.	O

The	O
interval	O
between	O
the	O
administration	O
of	O
COLESTID	S-brand
Tablets	O
and	O
any	O
other	O
medication	O
should	O
be	O
as	O
long	O
as	O
possible	O
.	O

Patients	O
should	O
take	O
other	O
drugs	O
at	O
least	O
one	O
hour	O
before	O
or	O
four	O
hours	O
after	O
COLESTID	S-brand
Tablets	O
to	O
avoid	O
impeding	O
their	O
absorption	O
.	O

Repeated	O
doses	O
of	O
colestipol	B-drug-ME-1
hydrochloride	E-drug-ME-1
given	O
prior	O
to	O
a	O
single	O
dose	O
of	O
propranolol	S-drug-ME-2
in	O
human	O
trials	O
have	O
been	O
reported	O
to	O
decrease	O
propranolol	S-drug
absorption	O
.	O

However	O
,	O
in	O
a	O
follow	O
-	O
up	O
study	O
in	O
normal	O
subjects	O
,	O
single	O
-	O
dose	O
administration	O
of	O
colestipol	B-drug
hydrochloride	E-drug
and	O
propranolol	S-drug
and	O
twice	O
-	O
a	O
-	O
day	O
administration	O
for	O
5	O
days	O
of	O
both	O
agents	O
did	O
not	O
affect	O
the	O
extent	O
of	O
propranolol	S-drug
absorption	O
,	O
but	O
had	O
a	O
small	O
yet	O
statistically	O
significant	O
effect	O
on	O
its	O
rate	O
of	O
absorption	O
;	O

the	O
time	O
to	O
reach	O
maximum	O
concentration	O
was	O
delayed	O
approximately	O
30	O
minutes	O
.	O

Effects	O
on	O
the	O
absorption	O
of	O
other	O
beta	B-group
-	I-group
blockers	E-group
have	O
not	O
been	O
determined	O
.	O

Therefore	O
,	O
patients	O
on	O
propranolol	S-drug-AD-1
should	O
be	O
observed	O
when	O
COLESTID	S-brand-AD-2
Tablets	O
are	O
either	O
added	O
or	O
deleted	O
from	O
a	O
therapeutic	O
regimen	O
.	O

Studies	O
in	O
humans	O
show	O
that	O
the	O
absorption	O
of	O
chlorothiazide	S-drug-ME-1
as	O
reflected	O
in	O
urinary	O
excretion	O
is	O
markedly	O
decreased	O
even	O
when	O
administered	O
one	O
hour	O
before	O
colestipol	B-drug-ME-2
hydrochloride	E-drug-ME-2
.	O

The	O
absorption	O
of	O
tetracycline	S-drug-ME-1
,	O
furosemide	S-drug-ME-1
,	O
penicillin	B-drug-ME-1
G	E-drug-ME-1
,	O
hydrochlorothiazide	S-drug-ME-1
,	O
and	O
gemfibrozil	S-drug-ME-1
was	O
significantly	O
decreased	O
when	O
given	O
simultaneously	O
with	O
colestipol	B-drug-ME-2
hydrochloride	E-drug-ME-2
;	O

these	O
drugs	O
were	O
not	O
tested	O
to	O
determine	O
the	O
effect	O
of	O
administration	O
one	O
hour	O
before	O
colestipol	B-drug
hydrochloride	E-drug
.	O

No	O
depressant	O
effect	O
on	O
blood	O
levels	O
in	O
humans	O
was	O
noted	O
when	O
colestipol	B-drug
hydrochloride	E-drug
was	O
administered	O
with	O
any	O
of	O
the	O
following	O
drugs	O
:	O
aspirin	S-brand
,	O
clindamycin	S-brand
,	O
clofibrate	S-drug
,	O
methyldopa	S-drug
,	O
nicotinic	B-drug
acid	E-drug
(	O
niacin	S-drug
)	O
,	O
tolbutamide	S-drug
,	O
phenytoin	S-drug
or	O
warfarin	S-drug
.	O

Particular	O
caution	O
should	O
be	O
observed	O
with	O
digitalis	B-group-EF-1
preparations	E-group-EF-1
since	O
there	O
are	O
conflicting	O
results	O
for	O
the	O
effect	O
of	O
colestipol	B-drug-MU-M
hydrochloride	E-drug-MU-M
on	O
the	O
availability	O
of	O
digoxin	S-drug-ME-2
and	O
digitoxin	S-drug-ME-2
.	O

The	O
potential	O
for	O
binding	O
of	O
these	O
drugs	O
if	O
given	O
concomitantly	O
is	O
present	O
.	O

Discontinuing	O
colestipol	B-drug
hydrochloride	E-drug
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	O
that	O
is	O
significantly	O
bound	O
to	O
the	O
resin	S-group
has	O
been	O
titrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
colestipol	B-drug
hydrochloride	E-drug
.	O

Bile	B-group-ME-1
acid	I-group-ME-1
binding	I-group-ME-1
resins	E-group-ME-1
may	O
also	O
interfere	O
with	O
the	O
absorption	O
of	O
oral	O
phosphate	S-drug-ME-2
supplements	O
and	O
hydrocortisone	S-drug-ME-2
.	O

Certain	O
other	O
antibiotics	S-group
(	O
aminoglycosides	S-group
and	O
polymyxin	S-group
)	O
have	O
also	O
been	O
reported	O
to	O
interfere	O
with	O
the	O
nerve	O
transmission	O
at	O
the	O
neuromuscular	O
junction	O
.	O

Based	O
on	O
this	O
reported	O
activity	O
,	O
they	O
should	O
not	O
be	O
given	O
concomitantly	O
with	O
Coly	B-brand
-	I-brand
Mycin	I-brand
M	E-brand
Parenteral	O
except	O
with	O
the	O
greatest	O
caution	O
.	O

Curariform	B-brand-EF-1
muscle	I-brand-EF-1
relaxants	E-brand-EF-1
(	O
eg	O
,	O
tubocurarine	S-drug-EF-1
)	O
and	O
other	O
drugs	O
,	O
including	O
ether	O
,	O
succinylcholine	S-drug-EF-1
,	O
gallamine	S-drug-EF-1
,	O
decamethonium	S-drug-EF-1
and	O
sodium	B-drug-EF-1
citrate	E-drug-EF-1
,	O
potentiate	O
the	O
neuromuscular	O
blocking	O
effect	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
Coly	B-brand-EF-2
-	I-brand-EF-2
Mycin	I-brand-EF-2
M	E-brand-EF-2
Parenteral	O
.	O

Sodium	B-drug-EF-1
cephalothin	E-drug-EF-1
may	O
enhance	O
the	O
nephrotoxicity	O
of	O
Coly	B-brand-EF-2
-	I-brand-EF-2
Mycin	I-brand-EF-2
M	E-brand-EF-2
Parenteral	O
.	O

The	O
concomitant	O
use	O
of	O
sodium	B-drug-AD-1
cephalothin	E-drug-AD-1
and	O
Coly	B-brand-AD-2
-	I-brand-AD-2
Mycin	I-brand-AD-2
M	E-brand-AD-2
Parenteral	O
should	O
be	O
avoided	O
.	O

Digoxin	S-drug
:	O
Coadministration	O
of	O
digoxin	S-drug-ME-1
,	O
a	O
P	O
-	O
glycoprotein	O
substrate	O
,	O
with	O
oral	O
conivaptan	S-drug-ME-2
resulted	O
in	O
a	O
reduction	O
in	O
clearance	O
and	O
an	O
increase	O
in	O
digoxin	S-drug
Cmax	O
and	O
AUC	O
values	O
.	O

Therefore	O
,	O
if	O
digoxin	S-drug-ME-1
is	O
administered	O
with	O
VAPRISOL	S-brand-ME-2
,	O
the	O
clinician	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
increases	O
in	O
digoxin	S-drug
levels	O
.	O

DRUG	O
/	O
LABORATORY	O
TEST	O
INTERACTIONS	O
1	O
.	O

Accelerated	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
and	O
platelet	O
aggregation	O
time	O
;	O

increased	O
platelet	O
count	O
;	O

increased	O
factors	O
II	O
,	O
VII	O
antigen	O
,	O
VIII	O
antigen	O
,	O
VIII	O
coagulant	O
activity	O
,	O
IX	O
,	O
X	O
,	O
XII	O
,	O
VII	O
-	O
X	O
complex	O
,	O
II	O
-	O
VII	O
-	O
X	O
complex	O
,	O
and	O
beta	O
-	O
thromboglobulin	O
;	O

decreased	O
levels	O
of	O
anti	O
-	O
factor	O
Xa	O
and	O
antithrombin	B-drug
III	E-drug
,	O
decreased	O
antithrombin	B-drug
III	E-drug
activity	O
;	O

increased	O
levels	O
of	O
fibrinogen	S-drug
and	O
fibrinogen	S-drug
activity	O
;	O

increased	O
plasminogen	O
antigen	O
and	O
activity	O
.	O

2	O
.	O

Increased	O
thyroid	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
levels	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	O
hormone	O
levels	O
as	O
measured	O
by	O
protein	O
-	O
bound	O
iodine	S-drug
(	O
PBI	O
)	O
,	O
T4	O
levels	O
(	O
by	O
column	O
or	O
by	O
radioimmunoassay	O
)	O
or	O
T3	O
levels	O
by	O
radioimmunoassay	O
.	O

T3	O
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
.	O

Free	O
T4	O
and	O
free	O
T3	O
concentrations	O
are	O
unaltered	O
.	O

Patients	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	B-group
hormone	E-group
.	O

3	O
.	O

Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
,	O
(	O
i.e	O
.	O
,	O
corticosteroid	O
binding	O
globulin	O
(	O
CBG	O
)	O
,	O
sex	O
hormone	O
binding	O
globulin	O
(	O
SHBG	O
)	O
)	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	S-group
and	O
sex	B-group
steroids	E-group
,	O
respectively	O
.	O

Free	O
hormone	O
concentrations	O
may	O
be	O
decreased	O
.	O

Other	O
plasma	O
proteins	O
may	O
be	O
increased	O
(	O
angiotensinogen	O
/	O
renin	O
substrate	O
,	O
alpha	O
-	O
1	O
-	O
antitrypsin	O
,	O
ceruloplasmin	O
)	O
.	O

4	O
.	O

Increased	O
plasma	O
HDL	O
and	O
HDL2	O
cholesterol	O
subfraction	O
concentrations	O
,	O
reduced	O
LDL	O
cholesterol	O
concentration	O
,	O
increased	O
triglyceride	O
levels	O
.	O

5	O
.	O

Impaired	O
glucose	O
tolerance	O
.	O

6	O
.	O

Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O

Corticotropin	S-drug-EF-1
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	S-drug-EF-2
therapy	O
.	O

The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O

Drugs	O
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	S-drug-MU-1
,	O
phenytoin	S-drug-MU-1
and	O
rifampin	S-drug-MU-1
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	S-group-ME-2
and	O
may	O
require	O
increases	O
in	O
corticosteroid	S-group-AD-2
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Drugs	O
such	O
as	O
troleandomycin	S-drug-ME-1
and	O
ketoconazole	S-drug-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
corticosteroids	S-group-ME-2
and	O
thus	O
decrease	O
their	O
clearance	O
.	O

Therefore	O
,	O
the	O
dose	O
of	O
corticosteroid	S-group
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O

Corticosteroids	S-group-EF-1
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	S-brand-EF-2
.	O

This	O
could	O
lead	O
to	O
decreased	O
salicylate	S-group
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	S-group-EF-1
toxicity	O
when	O
corticosteroid	S-drug-EF-2
is	O
withdrawn	O
.	O

Aspirin	S-brand-AD-1
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
cortico	B-group-AD-2
-	I-group-AD-2
steroids	E-group-AD-2
in	O
patients	O
suffering	O
from	O
hypopro	O
-	O
thrombinemia	O
.	O

The	O
effect	O
of	O
corticosteroids	S-group-EF-1
on	O
oral	O
anticoagulants	S-group-EF-2
is	O
variable	O
.	O

There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulants	S-group-EF-1
when	O
given	O
concurrently	O
with	O
corticosteroids	S-group-EF-2
.	O

Therefore	O
,	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O

Corticotropin	S-drug-EF-1
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	S-group-EF-2
therapy	O
.	O

Drug	O
Interaction	O
During	O
Pregnancy	O
:	O
Cromolyn	B-drug
sodium	E-drug
and	O
isoproterenol	S-drug
were	O
studied	O
following	O
subcutaneous	O
injections	O
in	O
pregnant	O
mice	O
.	O

Cromolyn	B-drug
sodium	E-drug
alone	O
in	O
doses	O
up	O
to	O
540	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
340	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
did	O
not	O
cause	O
significant	O
increases	O
in	O
resorptions	O
or	O
major	O
malformations	O
.	O

Isoproterenol	S-drug
alone	O
at	O
a	O
dose	O
of	O
2.7	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
7	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
increased	O
both	O
resorptions	O
and	O
malformations	O
.	O

The	O
addition	O
of	O
540	O
mg	O
/	O
kg	O
/	O
day	O
of	O
cromolyn	B-drug-EF-1
sodium	E-drug-EF-1
(	O
approximately	O
340	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
to	O
2.7	O
mg	O
/	O
kg	O
/	O
day	O
of	O
isoproterenol	S-drug-EF-2
(	O
approximately	O
7	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
appears	O
to	O
have	O
increased	O
the	O
incidence	O
of	O
both	O
resorptions	O
and	O
malformations	O
.	O

None	O
known	O
.	O

Persons	O
taking	O
most	O
antibiotics	S-group
,	O
methotrexate	S-drug
and	O
pyrimethamine	S-drug
invalidate	O
folic	B-drug
acid	E-drug
and	O
vitamin	B-drug
B12	E-drug
diagnostic	O
blood	O
assays	O
.	O

Colchicine	S-drug-ME-1
para	B-drug-ME-1
-	I-drug-ME-1
aminosalicylic	I-drug-ME-1
acid	E-drug-ME-1
and	O
heavy	O
alcohol	S-drug-ME-1
intake	O
for	O
longer	O
than	O
2	O
weeks	O
may	O
produce	O
malabsorption	O
of	O
vitamin	B-drug-ME-2
B12	E-drug-ME-2
.	O

FLEXERIL	S-brand-IN-1
may	O
have	O
life	O
-	O
threatening	O
interactions	O
with	O
MAO	B-group-IN-2
inhibitors	E-group-IN-2
.	O

FLEXERIL	S-brand-EF-1
may	O
enhance	O
the	O
effects	O
of	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
,	O
and	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
.	O

Tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
block	O
the	O
antihypertensive	O
action	O
of	O
guanethidine	S-drug-EF-2
and	O
similarly	O
acting	O
compounds	O
.	O

Tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
enhance	O
the	O
seizure	O
risk	O
in	O
patients	O
taking	O
tramadol	S-drug-EF-2

Cyclopentolate	S-drug-EF-1
may	O
interfere	O
with	O
the	O
anti	O
-	O
glaucoma	O
action	O
of	O
carbachol	S-drug-EF-2
or	O
pilocarpine	S-drug-EF-2
;	O

also	O
,	O
concurrent	O
use	O
of	O
this	O
medication	O
may	O
antagonise	O
the	O
anti	O
-	O
glaucoma	O
and	O
miotic	O
actions	O
of	O
ophthalmic	O
cholinesterase	B-group
inhibitors	E-group
.	O

The	O
rate	O
of	O
metabolism	O
and	O
the	O
leukopenic	O
activity	O
of	O
cyclophosphamide	S-drug-ME-1
reportedly	O
are	O
increased	O
by	O
chronic	O
administration	O
of	O
high	O
doses	O
of	O
phenobarbital	S-drug-ME-2
.	O

The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	O
actions	O
,	O
desirable	O
or	O
undesirable	O
,	O
involving	O
cyclophosphamide	S-drug
even	O
though	O
cyclophosphamide	S-drug
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	O
,	O
including	O
other	O
cytotoxic	O
drugs	O
.	O

Cyclophosphamide	S-drug-EF-1
treatment	O
,	O
which	O
causes	O
a	O
marked	O
and	O
persistent	O
inhibition	O
of	O
cholinesterase	O
activity	O
,	O
potentiates	O
the	O
effect	O
of	O
succinylcholine	B-drug-EF-2
chloride	E-drug-EF-2
.	O

If	O
a	O
patient	O
has	O
been	O
treated	O
with	O
cyclophosphamide	S-drug
within	O
10	O
days	O
of	O
general	O
anesthesia	O
,	O
the	O
anesthesiologist	O
should	O
be	O
alerted	O
.	O

May	O
interact	O
with	O
wthionamide	O
(	O
Trecator	B-brand
-	I-brand
SC	E-brand
)	O
and	O
isoniazid	S-drug
(	O
Nydrazid	S-brand
)	O
.	O

MAO	B-group-EF-1
inhibitors	E-group-EF-1
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	S-group-EF-2
.	O

Antihistamines	S-group-EF-1
may	O
have	O
additive	O
effects	O
with	O
alcohol	S-drug-EF-2
and	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
,	O
e.g	O
.	O
,	O
hypnotics	S-group-EF-2
,	O
sedatives	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
,	O
antianxiety	B-group-EF-2
agents	E-group-EF-2
.	O

No	O
drug	O
interactions	O
have	O
been	O
reported	O
.	O

Steady	O
state	O
plasma	O
digitoxin	S-drug
concentrations	O
did	O
not	O
appear	O
to	O
change	O
.	O

Therefore	O
,	O
monitoring	O
of	O
plasma	O
digoxin	S-drug
levels	O
may	O
be	O
indicated	O
in	O
patients	O
receiving	O
similar	O
combination	O
chemotherapy	O
regimens	O
.	O

The	O
utilization	O
of	O
digitoxin	S-drug
for	O
such	O
patients	O
may	O
be	O
considered	O
as	O
an	O
alternative	O
.	O

Also	O
flucytosine	S-drug
.	O

Drug	O
/	O
LaboratoryTest	O
Interactions	O
Dactinomycin	S-drug
may	O
interfere	O
with	O
bioassay	O
procedures	O
for	O
the	O
determination	O
of	O
antibacterial	B-group
drug	E-group
levels	O
.	O

Dantrium	S-brand
is	O
metabolized	O
by	O
the	O
liver	O
,	O
and	O
it	O
is	O
theoretically	O
possible	O
that	O
its	O
metabolism	O
may	O
be	O
enhanced	O
by	O
drugs	O
known	O
to	O
induce	O
hepatic	O
microsomal	O
enzymes	O
.	O

However	O
,	O
neither	O
phenobarbital	S-drug
nor	O
diazepam	S-drug
appears	O
to	O
affect	O
Dantrium	S-brand
metabolism	O
.	O

Binding	O
to	O
plasma	O
protein	O
is	O
not	O
significantly	O
altered	O
by	O
diazepam	S-drug
,	O
diphenylhydantoin	S-drug
,	O
or	O
phenylbutazone	S-drug
.	O

Binding	O
to	O
plasma	O
proteins	O
is	O
reduced	O
by	O
warfarin	S-drug
and	O
clotibrate	O
and	O
increased	O
by	O
tolbutamide	S-drug
.	O

Cardiovascular	O
collapse	O
in	O
patients	O
treated	O
simultaneously	O
with	O
varapamil	O
and	O
dantrolene	B-drug
sodium	E-drug
is	O
rare	O
.	O

The	O
combination	O
of	O
therapeutic	O
doses	O
of	O
intravenous	O
dantrolene	B-drug
sodium	E-drug
and	O
verapamil	S-drug
in	O
halothane	S-drug
a	O
-	O
chloralose	O
anesthetized	O
swine	O
has	O
resulted	O
in	O
ventricular	O
fibrillation	O
and	O
cardiovascular	O
collapse	O
in	O
association	O
with	O
marked	O
hyperkalemia	O
.	O

It	O
is	O
recommended	O
that	O
the	O
combination	O
of	O
intravenous	O
dantrolene	B-drug-AD-1
sodium	E-drug-AD-1
and	O
calcium	B-group-AD-2
channel	I-group-AD-2
blockers	E-group-AD-2
,	O
such	O
as	O
verapamil	S-drug-AD-2
,	O
not	O
be	O
used	O
together	O
during	O
the	O
management	O
of	O
malignant	O
hyperthermia	O
crisis	O
until	O
the	O
relevance	O
of	O
these	O
findings	O
to	O
humans	O
is	O
established	O
.	O

Administration	O
of	O
dantrolene	S-drug-EF-1
may	O
potentiate	O
vecuronium	S-drug-EF-2
-	O
induced	O
neuromuscular	O
block	O
.	O

A	O
drug	O
-	O
drug	O
interaction	O
study	O
evaluated	O
the	O
effect	O
of	O
the	O
use	O
of	O
ACZONE	S-brand
Gel	O
,	O
5	O
%	O
,	O
in	O
combination	O
with	O
double	O
strength	O
(	O
160	O
mg	O
/	O
800	O
mg	O
)	O
trimethoprim	S-drug
/	O
sulfamethoxazole	S-drug
(	O
TMP	S-drug
/	O
SMX	S-drug
)	O
.	O

During	O
co	O
-	O
administration	O
,	O
systemic	O
levels	O
of	O
TMP	S-drug
and	O
SMX	S-drug
were	O
essentially	O
unchanged	O
.	O

Notably	O
,	O
systemic	O
exposure	O
(	O
AUC0	O
-	O
12	O
)	O
of	O
dapsone	B-drug_n
hydroxylamine	E-drug_n
(	O
DHA	S-drug_n
)	O
was	O
more	O
than	O
doubled	O
in	O
the	O
presence	O
of	O
TMP	S-drug
/	O
SMX	S-drug
.	O

Exposure	O
from	O
the	O
proposed	O
topical	O
dose	O
is	O
about	O
1	O
%	O
of	O
that	O
from	O
the	O
100	O
mg	O
oral	O
dose	O
,	O
even	O
when	O
co	O
-	O
administered	O
with	O
TMP	S-drug
/	O
SMX	S-drug
.	O

Certain	O
concomitant	O
medications	O
(	O
such	O
as	O
rifampin	S-drug
,	O
anticonvulsants	S-group
,	O
St	O
.	O

John	O
s	O
wort	O
)	O
may	O
increase	O
the	O
formation	O
of	O
dapsone	B-drug_n
hydroxylamine	E-drug_n
,	O
a	O
metabolite	O
of	O
dapsone	S-drug
associated	O
with	O
hemolysis	O
.	O

With	O
oral	O
dapsone	S-drug-EF-1
treatment	O
,	O
folic	B-group-EF-2
acid	I-group-EF-2
antagonists	E-group-EF-2
such	O
as	O
pyrimethamine	S-drug-EF-2
have	O
been	O
noted	O
to	O
possibly	O
increase	O
the	O
likelihood	O
of	O
hematologic	O
reactions	O

Warfarin	S-drug
:	O
Concomitant	O
administration	O
of	O
daptomycin	S-drug
(	O
6	O
mg	O
/	O
kg	O
once	O
every	O
24	O
hours	O
for	O
5	O
days	O
)	O
and	O
warfarin	S-drug
(	O
25	O
mg	O
single	O
oral	O
dose	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
,	O
and	O
the	O
INR	O
was	O
not	O
significantly	O
altered	O
.	O

HMG	B-group
-	I-group
CoA	I-group
Reductase	I-group
Inhibitors	E-group
:	O
Inhibitors	B-group
of	I-group
HMG	I-group
-	I-group
CoA	I-group
reductase	E-group
may	O
cause	O
myopathy	O
,	O
which	O
is	O
manifested	O
as	O
muscle	O
pain	O
or	O
weakness	O
associated	O
with	O
elevated	O
levels	O
of	O
CPK	O
.	O

There	O
were	O
no	O
reports	O
of	O
skeletal	O
myopathy	O
in	O
a	O
placebo	O
-	O
controlled	O
Phase	O
I	O
trial	O
in	O
which	O
10	O
healthy	O
subjects	O
on	O
stable	O
simvastatin	S-drug
therapy	O
were	O
treated	O
concurrently	O
with	O
daptomycin	S-drug
(	O
4	O
mg	O
/	O
kg	O
once	O
every	O
24	O
hours	O
)	O
for	O
14	O
days	O
.	O

Experience	O
with	O
co	O
-	O
administration	O
of	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
and	O
Fentanyl	S-drug
in	O
patients	O
is	O
limited	O
,	O
therefore	O
,	O
consideration	O
should	O
be	O
given	O
to	O
temporarily	O
suspending	O
use	O
of	O
HMG	B-group-AD-1
-	I-group-AD-1
CoA	I-group-AD-1
reductase	I-group-AD-1
inhibitors	E-group-AD-1
in	O
patients	O
receiving	O
Fentanyl	S-drug-AD-2
.	O

Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
:	O
There	O
are	O
no	O
reported	O
drug	O
-	O
laboratory	O
test	O
interactions	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
of	O
Aranesp	S-brand
have	O
been	O
performed	O
.	O

The	O
daily	O
dose	O
of	O
ENABLEX	S-brand-AD-1
should	O
not	O
exceed	O
7.5	O
mg	O
when	O
coadministered	O
with	O
potent	O
CYP3A4	O
inhibitors	O
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug-AD-2
,	O
itraconazole	S-drug-AD-2
,	O
ritonavir	S-drug-AD-2
,	O
nelfinavir	S-drug-AD-2
,	O
clarithromycin	S-drug-AD-2
and	O
nefazadone	O
)	O
.	O

Caution	O
should	O
be	O
taken	O
when	O
ENABLEX	S-brand-AD-1
is	O
used	O
concomitantly	O
with	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2D6	O
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
window	O
,	O
such	O
as	O
flecainide	S-drug-AD-2
,	O
thioridazine	S-drug-AD-2
and	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
)	O
.	O

The	O
concomitant	O
use	O
of	O
ENABLEX	S-brand-EF-1
with	O
other	O
anticholinergic	B-group-EF-2
agents	E-group-EF-2
may	O
increase	O
the	O
frequency	O
and	O
/	O
or	O
severity	O
of	O
dry	O
mouth	O
,	O
constipation	O
,	O
blurred	O
vision	O
and	O
other	O
anticholinergic	O
pharmacological	O
effects	O
.	O

Anticholinergic	B-group
agents	E-group
may	O
potentially	O
alter	O
the	O
absorption	O
of	O
some	O
concomitantly	O
administered	O
drugs	O
due	O
to	O
effects	O
on	O
gastrointestinal	O
motility	O
.	O

Drug	O
Laboratory	O
Test	O
Interactions	O
Interactions	O
between	O
darifenacin	S-drug
and	O
laboratory	O
tests	O
have	O
not	O
been	O
studied	O
.	O

Drugs	O
that	O
may	O
increase	O
dasatinib	S-drug
plasma	O
concentrations	O
CYP3A4	O
Inhibitors	O
:	O
Dasatinib	S-drug
is	O
a	O
CYP3A4	O
substrate	O
.	O

Concomitant	O
use	O
of	O
SPRYCEL	S-brand-ME-1
and	O
drugs	O
that	O
inhibit	O
CYP3A4	O
(	O
eg	O
,	O
ketoconazole	S-drug-ME-2
,	O
itraconazole	S-drug-ME-2
,	O
erythromycin	S-drug-ME-2
,	O
clarithromycin	S-drug-ME-2
,	O
ritonavir	S-drug-ME-2
,	O
atazanavir	S-drug-ME-2
,	O
indinavir	S-drug-ME-2
,	O
nefazodone	S-drug-ME-2
,	O
nelfinavir	S-drug-ME-2
,	O
saquinavir	S-drug-ME-2
,	O
telithromycin	S-drug-ME-2
)	O
may	O
increase	O
exposure	O
to	O
dasatinib	S-drug
and	O
should	O
be	O
avoided	O
.	O

In	O
patients	O
receiving	O
treatment	O
with	O
SPRYCEL	S-brand
,	O
close	O
monitoring	O
for	O
toxicity	O
and	O
a	O
SPRYCEL	S-brand
dose	O
reduction	O
should	O
be	O
considered	O
if	O
systemic	O
administration	O
of	O
a	O
potent	O
CYP3A4	O
inhibitor	O
can	O
not	O
be	O
avoided	O
.	O

Drugs	O
that	O
may	O
decrease	O
dasatinib	S-drug
plasma	O
concentrations	O
CYP3A4	O
Inducers	O
:	O
Drugs	O
that	O
induce	O
CYP3A4	O
activity	O
may	O
decrease	O
dasatinib	S-drug
plasma	O
concentrations	O
.	O

In	O
patients	O
in	O
whom	O
CYP3A4	O
inducers	O
(	O
eg	O
,	O
dexamethasone	S-drug
,	O
phenytoin	S-drug
,	O
carbamazepine	S-drug
,	O
rifampicin	S-drug
,	O
phenobarbital	S-drug
)	O
are	O
indicated	O
,	O
alternative	O
agents	O
with	O
less	O
enzyme	O
induction	O
potential	O
should	O
be	O
used	O
.	O

If	O
SPRYCEL	S-brand
must	O
be	O
administered	O
with	O
a	O
CYP3A4	O
inducer	O
,	O
a	O
dose	O
increase	O
in	O
SPRYCEL	S-brand
should	O
be	O
considered	O
.	O

St.	O
Johns	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
may	O
decrease	O
SPRYCEL	S-brand
plasma	O
concentrations	O
unpredictably	O
.	O

Patients	O
receiving	O
SPRYCEL	S-brand
should	O
not	O
take	O
St.	O
Johns	O
wort	O
.	O

Antacids	S-group
:	O
Nonclinical	O
data	O
demonstrate	O
that	O
the	O
solubility	O
of	O
dasatinib	S-drug
is	O
pH	O
dependent	O
.	O

Simultaneous	O
administration	O
of	O
SPRYCEL	S-brand-AD-1
with	O
antacids	S-group-AD-2
should	O
be	O
avoided	O
.	O

If	O
antacid	S-group-AD-1
therapy	O
is	O
needed	O
,	O
the	O
antacid	O
dose	O
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
prior	O
to	O
or	O
2	O
hours	O
after	O
the	O
dose	O
of	O
SPRYCEL	S-brand-AD-2
.	O

H2	B-group
Blockers	E-group
/	O
Proton	B-group
Pump	I-group
Inhibitors	E-group
:	O
Long	O
-	O
term	O
suppression	O
of	O
gastric	O
acid	O
secretion	O
by	O
H2	B-group-EF-1
blockers	E-group-EF-1
or	O
proton	B-group-EF-1
pump	I-group-EF-1
inhibitors	E-group-EF-1
(	O
eg	O
,	O
famotidine	S-drug-EF-1
and	O
omeprazole	S-drug-EF-1
)	O
is	O
likely	O
to	O
reduce	O
dasatinib	S-drug-EF-2
exposure	O
.	O

The	O
concomitant	O
use	O
of	O
H2	B-group-AD-1
blockers	E-group-AD-1
or	O
proton	B-group-AD-1
pump	I-group-AD-1
inhibitors	E-group-AD-1
with	O
SPRYCEL	S-brand-AD-2
is	O
not	O
recommended	O
.	O

The	O
use	O
of	O
antacids	S-group
should	O
be	O
considered	O
in	O
place	O
of	O
H2	B-group-AD-1
blockers	E-group-AD-1
or	O
proton	B-group-AD-1
pump	I-group-AD-1
inhibitors	E-group-AD-1
in	O
patients	O
receiving	O
SPRYCEL	S-brand-AD-2
therapy	O
.	O

Drugs	O
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
dasatinib	S-drug
CYP3A4	O
Substrates	O
:	O
Dasatinib	S-drug
is	O
a	O
time	O
-	O
dependent	O
inhibitor	O
of	O
CYP3A4	O
.	O

Therefore	O
,	O
CYP3A4	O
substrates	O
known	O
to	O
have	O
a	O
narrow	O
therapeutic	O
index	O
such	O
as	O
alfentanil	S-drug-AD-1
,	O
astemizole	S-drug-AD-1
,	O
terfenadine	S-drug-AD-1
,	O
cisapride	S-drug-AD-1
,	O
cyclosporine	S-drug-AD-1
,	O
fentanyl	S-drug-AD-1
,	O
pimozide	S-drug-AD-1
,	O
quinidine	S-drug-AD-1
,	O
sirolimus	S-drug-AD-1
,	O
tacrolimus	S-drug-AD-1
,	O
or	O
ergot	B-group-AD-1
alkaloids	E-group-AD-1
(	O
ergotamine	S-drug-AD-1
,	O
dihydroergotamine	S-drug-AD-1
)	O
should	O
be	O
administered	O
with	O
caution	O
in	O
patients	O
receiving	O
SPRYCEL	S-brand-AD-2
.	O

Hepatic	O
Impairment	O
There	O
are	O
currently	O
no	O
clinical	O
studies	O
with	O
SPRYCEL	S-brand
in	O
patients	O
with	O
impaired	O
liver	O
function	O
(	O
clinical	O
studies	O
have	O
excluded	O
patients	O
with	O
ALT	O
and	O
/	O
or	O
AST	O
2.5	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
and	O
/	O
or	O
total	O
bilirubin	O
2	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
)	O
.	O

Metabolism	O
of	O
dasatinib	S-drug
is	O
mainly	O
hepatic	O
.	O

Caution	O
is	O
recommended	O
in	O
patients	O
with	O
hepatic	O
impairment	O
.	O

Renal	O
Impairment	O
There	O
are	O
currently	O
no	O
clinical	O
studies	O
with	O
SPRYCEL	S-brand
in	O
patients	O
with	O
impaired	O
renal	O
function	O
(	O
clinical	O
studies	O
have	O
excluded	O
patients	O
with	O
serum	O
creatinine	O
concentration	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
)	O
.	O

Dasatinib	S-drug
and	O
its	O
metabolites	O
are	O
minimally	O
excreted	O
via	O
the	O
kidney	O
.	O

Since	O
the	O
renal	O
excretion	O
of	O
unchanged	O
dasatinib	S-drug
and	O
its	O
metabolites	O
is	O
4	O
%	O
,	O
a	O
decrease	O
in	O
total	O
body	O
clearance	O
is	O
not	O
expected	O
in	O
patients	O
with	O
renal	O
insufficiency	O
.	O

Use	O
of	O
Cerubidine	S-brand-EF-1
in	O
a	O
patient	O
who	O
has	O
previously	O
received	O
doxorubicin	S-drug-EF-2
increases	O
the	O
risk	O
of	O
cardiotoxicity	O
.	O

Cerubidine	S-brand-AD-1
should	O
not	O
be	O
used	O
in	O
patients	O
who	O
have	O
previously	O
received	O
the	O
recommended	O
maximum	O
cumulative	O
doses	O
of	O
doxorubicin	S-drug-AD-2
or	O
Cerubidine	S-brand
.	O

Cyclophosphamide	S-drug-EF-1
used	O
concurrently	O
with	O
Cerubidine	S-brand-EF-2
may	O
also	O
result	O
in	O
increased	O
cardiotoxicity	O
.	O

Dosage	O
reduction	O
of	O
Cerubidine	S-brand
may	O
be	O
required	O
when	O
used	O
concurrently	O
with	O
other	O
myelosuppressive	O
agents	O
.	O

Hepatotoxic	O
medications	O
,	O
such	O
as	O
high	O
-	O
dose	O
methotrexate	S-drug
,	O
may	O
impair	O
liver	O
function	O
and	O
increase	O
the	O
risk	O
of	O
toxicity	O
.	O

Potentially	O
fatal	O
drug	O
interactions	O
may	O
occur	O
when	O
coadministered	O
with	O
digoxin	S-drug
,	O
as	O
this	O
may	O
enhance	O
cardiovascular	O
depression	O
and	O
bradyarrhythmias	O
may	O
occur	O
.	O

Anticholinesterases	S-group
(	O
neostgmine	O
,	O
physostigmine	S-drug
)	O
,	O
lignocaine	S-drug
,	O
quinine	S-drug
,	O
procainamide	S-drug
can	O
enhance	O
toxicity	O
and	O
cause	O
cardio	O
respiratory	O
depression	O
.	O

In	O
addition	O
,	O
neuromuscular	O
blocking	O
action	O
is	O
enhanced	O
by	O
general	O
anesthetics	S-group
,	O
local	O
anesthetics	S-group
like	O
lidocaine	S-drug
,	O
procaine	S-drug
,	O
beta	B-group
-	I-group
blockers	E-group
,	O
metaclopramide	S-drug
,	O
lithium	B-drug
carbonate	E-drug
,	O
and	O
terbutaline	S-drug
.	O

Drug	O
interaction	O
studies	O
with	O
decitabine	S-drug
have	O
not	O
been	O
conducted	O
.	O

In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
suggest	O
that	O
decitabine	S-drug
is	O
unlikely	O
to	O
inhibit	O
or	O
induce	O
cytochrome	O
P450	O
enzymes	O
.	O

In	O
vitro	O
metabolism	O
studies	O
have	O
suggested	O
that	O
decitabine	S-drug
is	O
not	O
a	O
substrate	O
for	O
the	O
human	O
liver	O
cytochrome	O
P450	O
enzymes	O
.	O

As	O
plasma	O
protein	O
binding	O
of	O
decitabine	S-drug
is	O
negligible	O
(	O
1	O
%	O
)	O
,	O
interactions	O
due	O
to	O
displacement	O
of	O
more	O
highly	O
protein	O
bound	O
drugs	O
from	O
plasma	O
proteins	O
are	O
not	O
expected	O
.	O

The	O
concomitant	O
administration	O
of	O
Exjade	S-brand
and	O
aluminum	S-drug
-	O
containing	O
antacid	B-group
preparations	E-group
has	O
not	O
been	O
formally	O
studied	O
.	O

Although	O
deferasirox	S-drug
has	O
a	O
lower	O
affinity	O
for	O
aluminum	S-drug
than	O
for	O
iron	S-drug
,	O
Exjade	S-brand-AD-1
should	O
not	O
be	O
taken	O
with	O
aluminum	S-drug-AD-2
-	O
containing	O
antacid	B-group
preparations	E-group
.	O

In	O
healthy	O
volunteers	O
,	O
Exjade	S-brand
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
.	O

The	O
effect	O
of	O
digoxin	S-drug
on	O
Exjade	S-brand
pharmacokinetics	O
has	O
not	O
been	O
studied	O
.	O

The	O
concomitant	O
administration	O
of	O
Exjade	S-brand
and	O
vitamin	B-drug
C	E-drug
has	O
not	O
been	O
formally	O
studied	O
.	O

Doses	O
of	O
vitamin	B-drug
C	E-drug
up	O
to	O
200	O
mg	O
were	O
allowed	O
in	O
clinical	O
studies	O
without	O
negative	O
consequences	O
.	O

The	O
interaction	O
of	O
Exjade	S-brand
with	O
hydroxyurea	S-drug
has	O
not	O
been	O
formally	O
studied	O
.	O

No	O
inhibition	O
of	O
deferasirox	S-drug
metabolism	O
by	O
hydroxyurea	S-drug
is	O
expected	O
based	O
on	O
the	O
results	O
of	O
an	O
in	O
vitro	O
study	O
.	O

Exjade	S-brand
should	O
not	O
be	O
combined	O
with	O
other	O
iron	O
chelator	O
therapies	O
,	O
as	O
safety	O
of	O
such	O
combinations	O
has	O
not	O
been	O
established	O
.	O

Drug	O
/	O
Food	O
Interactions	O
The	O
bioavailability	O
(	O
AUC	O
)	O
of	O
deferasirox	S-drug
was	O
variably	O
increased	O
when	O
taken	O
with	O
a	O
meal	O
.	O

Deferasirox	S-drug
should	O
be	O
taken	O
on	O
an	O
empty	O
stomach	O
30	O
minutes	O
before	O
eating	O
.	O

Exjade	S-brand
tablets	O
for	O
oral	O
suspension	O
can	O
be	O
dispersed	O
in	O
water	O
,	O
orange	O
juice	O
,	O
or	O
apple	O
juice	O
.	O

Antiacid	O
,	O
clarithromycin	S-drug
,	O
Didanosine	S-drug
,	O
Fluconazole	S-drug
,	O
Fluoxetine	S-drug
,	O
Indanavir	O
,	O
Ketoconazole	S-drug
,	O
Phenytoin	S-drug
,	O
Phenobarbitol	O
,	O
carbamazepine	S-drug
,	O
Rifabutin	S-drug
,	O
Rifampin	S-drug
,	O
Ritanovir	O
,	O
Saquinavir	S-drug
.	O

Possible	O
drug	O
interactions	O
of	O
HUMORSOL	S-brand-IN-1
with	O
succinylcholine	S-drug-IN-2
or	O
with	O
other	O
anticholinesterase	B-group-IN-2
agents	E-group-IN-2
.	O

Because	O
the	O
tetracyclines	S-group-AD-1
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	S-group-AD-2
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	S-group
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	O
,	O
such	O
as	O
the	O
tetracycline	B-group-EF-1
class	E-group-EF-1
of	O
antibiotics	S-group
,	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillins	S-group-EF-2
,	O
it	O
is	O
not	O
advisable	O
to	O
administer	O
these	O
drugs	O
concomitantly	O
.	O

Concurrent	O
use	O
of	O
tetracyclines	S-group-EF-1
with	O
oral	O
contraceptives	S-group-EF-2
may	O
render	O
oral	O
contraceptives	S-group
less	O
effective	O
.	O

Breakthrough	O
bleeding	O
has	O
been	O
reported	O

No	O
clinical	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

However	O
,	O
in	O
a	O
single	O
in	O
vivo	O
rodent	O
study	O
denileukin	B-drug
diftitox	E-drug
had	O
no	O
effect	O
on	O
P450	O
levels	O
.	O

Taking	O
a	O
rauwolfia	B-group-EF-1
alkaloid	E-group-EF-1
while	O
you	O
are	O
taking	O
or	O
within	O
2	O
weeks	O
of	O
taking	O
MAO	B-group-EF-2
inhibitors	E-group-EF-2
may	O
increase	O
the	O
risk	O
of	O
central	O
nervous	O
system	O
depression	O
or	O
may	O
cause	O
a	O
severe	O
high	O
blood	O
pressure	O
reaction	O
.	O

No	O
clinically	O
significant	O
adverse	O
interactions	O
with	O
commonly	O
used	O
preanesthetic	O
drugs	O
,	O
or	O
drugs	O
used	O
during	O
anesthesia	O
(	O
muscle	B-group
relaxants	E-group
,	O
intravenous	O
agents	O
,	O
and	O
local	O
anesthetic	B-group
agents	E-group
)	O
were	O
reported	O
in	O
clinical	O
trials	O
.	O

The	O
effect	O
of	O
desflurane	S-drug
on	O
the	O
disposition	O
of	O
other	O
drugs	O
has	O
not	O
been	O
determined	O
.	O

Like	O
isoflurane	S-drug
,	O
desflurane	S-drug
does	O
not	O
predispose	O
to	O
premature	O
ventricular	O
arrhythmias	O
in	O
the	O
presence	O
of	O
exogenously	O
infused	O
epinephrine	S-drug
in	O
swine	O
.	O

1	O
.	O

Drugs	O
Metabolized	O
by	O
P450	O
2D6	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7	O
to	O
10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O

reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-group
antidepressants	E-group
(	O
TCAs	S-group
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
traction	O
of	O
drug	O
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	S-group
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O

metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	S-group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	S-drug
;	O

cimetidine	S-drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	S-group
,	O
phenothiazines	S-group
,	O
and	O
the	O
Type	O
1C	O
antiarrhythrnics	O
propatenone	O
and	O
flecainide	S-drug
)	O
.	O

While	O
all	O
the	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
(	O
SSRIs	S-group
)	O
,	O
e.g	O
.	O
,	O
fluoxetine	S-drug
,	O
seriraline	O
,	O
and	O
paroxetine	S-drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	S-group-IN-1
-	O
TCA	S-group-IN-2
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	S-group
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
T.A	B-group-AD-1
.	E-group-AD-1
with	O
any	O
of	O
the	O
SSRIs	S-group-AD-2
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	S-drug
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B-group
antidepressants	E-group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-group
antidepressant	E-group
or	O
the	O
other	O
drug	O
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-group
antidepressant	E-group
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	S-group
plasma	O
levels	O
whenever	O
a	O
TCA	S-group
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

2	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
this	O
drug	O
is	O
given	O
concomitantly	O
with	O
anticholinergic	S-group
or	O
sympathomimetic	B-group
drugs	E-group
.	O

3	O
.	O

Clinical	O
experience	O
in	O
the	O
concurrent	O
administration	O
of	O
ECT	O
and	O
antidepressant	B-group
drugs	E-group
is	O
limited	O
.	O

Thus	O
,	O
if	O
such	O
treatment	O
is	O
essential	O
,	O
the	O
possibility	O
of	O
increased	O
risk	O
relative	O
to	O
benefits	O
should	O
be	O
considered	O
.	O

4	O
.	O

If	O
desipramine	B-drug-EF-1
hydrochloride	E-drug-EF-1
is	O
to	O
be	O
combined	O
with	O
other	O
psychotropic	B-group-EF-2
agents	E-group-EF-2
such	O
as	O
tranquilizers	S-group-EF-2
or	O
sedative	S-group-EF-2
/	O
hypnotics	S-group-EF-2
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	O
employed	O
since	O
the	O
sedative	O
effects	O
of	O
desipramine	S-drug-EF-1
and	O
benzodiazepines	S-group-EF-2
(	O
e.g	O
.	O
,	O
chlordiazepoxide	S-drug-EF-2
or	O
diazepam	S-drug-EF-2
)	O
are	O
additive	O
.	O

Both	O
the	O
sedative	O
and	O
anticholinergic	O
effects	O
of	O
the	O
major	B-group-EF-1
tranquilizers	E-group-EF-1
are	O
also	O
additive	O
to	O
those	O
of	O
desipramine	S-drug-EF-2
.	O

5	O
.	O

Concurrent	O
administration	O
of	O
cimetidine	S-drug-ME-1
and	O
tricyclic	B-group-ME-2
antidepressants	E-group-ME-2
can	O
produce	O
clinically	O
significant	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
the	O
tricyclic	B-group
antidepressants	E-group
.	O

Conversely	O
,	O
decreases	O
in	O
plasma	O
levels	O
of	O
the	O
tricyclic	B-group-ME-1
antidepressants	E-group-ME-1
have	O
been	O
reported	O
upon	O
discontinuation	O
of	O
cimetidine	S-drug-ME-2
which	O
may	O
result	O
in	O
the	O
loss	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
tricyclic	B-group
antidepressant	E-group
6	O
.	O

There	O
have	O
been	O
greater	O
than	O
two	O
-	O
fold	O
increases	O
of	O
previously	O
stable	O
plasma	O
levels	O
of	O
tricyclic	B-group-ME-1
antidepressants	E-group-ME-1
when	O
fluoxetine	S-drug-ME-2
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O

In	O
two	O
controlled	O
crossover	O
clinical	O
pharmacology	O
studies	O
in	O
healthy	O
male	O
(	O
n	O
=	O
12	O
in	O
each	O
study	O
)	O
a	O
nd	O
female	O
(	O
n	O
=	O
12	O
in	O
each	O
study	O
)	O
volunteers	O
,	O
desloratadine	S-drug
7.5	O
mg	O
(	O
1.5	O
times	O
the	O
daily	O
dose	O
)	O
once	O
daily	O
was	O
coadministered	O
with	O
erythromycin	S-drug
500	O
mg	O
every	O
8	O
hours	O
or	O
ketoconazole	S-drug
200	O
mg	O
every	O
12	O
hours	O
for	O
10	O
days	O
.	O

In	O
three	O
separate	O
controlled	O
,	O
parallel	O
group	O
clinical	O
pharmacology	O
studies	O
,	O
desloratadine	S-drug
at	O
the	O
clinical	O
dose	O
of	O
5	O
mg	O
has	O
been	O
coadministered	O
with	O
azithromycin	S-drug
500	O
mg	O
followed	O
by	O
250	O
mg	O
once	O
daily	O
for	O
4	O
days	O
(	O
n	O
=	O
18	O
)	O
or	O
with	O
fluoxetine	S-drug
20	O
mg	O
once	O
daily	O
for	O
7	O
days	O
after	O
a	O
23	O
day	O
pretreatment	O
period	O
with	O
fluoxetine	S-drug
(	O
n	O
=	O
18	O
)	O
or	O
with	O
cimetidine	S-drug
600	O
mg	O
every	O
12	O
hours	O
for	O
14	O
days	O
(	O
n	O
=	O
18	O
)	O
under	O
steady	O
state	O
conditions	O
to	O
normal	O
healthy	O
male	O
and	O
female	O
volunteers	O
.	O

Although	O
increased	O
plasma	O
concentrations	O
(	O
C	O
max	O
and	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
desloratadine	S-drug
and	O
3	B-drug_n
-	I-drug_n
hydroxydesloratadine	E-drug_n
were	O
observed	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
desloratadine	S-drug
,	O
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
(	O
including	O
the	O
corrected	O
QT	O
interval	O
)	O
,	O
clinical	O
laboratory	O
tests	O
,	O
vital	O
signs	O
,	O
and	O
adverse	O
events	O
.	O

Table	O
1	O
Changes	O
in	O
Desloratadine	S-drug
and	O
3	B-drug_n
-	I-drug_n
Hydroxydesloratadine	E-drug_n
Pharmacokinetics	O
in	O
Healthy	O
Male	O
and	O
Female	O
Volunteers	O

Desloratadine	S-drug
3	B-drug_n
-	I-drug_n
Hydroxydesloratadine	E-drug_n

C	O
max	O
AUC	O
0	O
-	O
24	O
hrs	O
C	O
max	O
AUC	O
0	O
-	O
24	O
hrs	O

(	O
500	O
mg	O
Q8h	O
)	O

+	O
24	O
%	O
+	O
14	O
%	O
+	O
43	O
%	O
+	O
40	O
%	O

(	O
200	O
mg	O
Q12h	O
)	O

+	O
45	O
%	O
+	O
39	O
%	O
+	O
43	O
%	O
+	O
72	O
%	O

(	O
500	O
mg	O
day	O
1	O
,	O
250	O
mg	O
QD	O
4	O
days	O
)	O

+	O
15	O
%	O
+	O
5	O
%	O
+	O
15	O
%	O
+	O
4	O
%	O

(	O
20	O
mg	O
QD	O
)	O

+	O
15	O
%	O
+	O
0	O
%	O
+	O
17	O
%	O
+	O
13	O
%	O

(	O
600	O
mg	O
Q12h	O
)	O

+	O
12	O
%	O
+	O
19	O
%	O
-	O
11	O
%	O
-	O
3	O
%	O

Although	O
the	O
pressor	O
activity	O
of	O
Desmopressin	S-drug
is	O
very	O
low	O
compared	O
to	O
its	O
antidiuretic	O
activity	O
,	O
large	O
doses	O
of	O
Desmopressin	S-drug
Tablets	O
should	O
be	O
used	O
with	O
other	O
pressor	O
agents	O
only	O
with	O
careful	O
patient	O
monitoring	O
.	O

Reduced	O
efficacy	O
and	O
increased	O
incidence	O
of	O
breakthrough	O
bleeding	O
and	O
menstrual	O
irregularities	O
have	O
been	O
associated	O
with	O
concomitant	O
use	O
of	O
rifampin	S-drug
.	O

A	O
similar	O
association	O
,	O
though	O
less	O
marked	O
,	O
has	O
been	O
suggested	O
with	O
barbiturates	S-group
,	O
phenyl	O
-	O
butazone	O
,	O
phenytoin	B-drug
sodium	E-drug
,	O
carbamazepine	S-drug
and	O
possibly	O
with	O
griseofulvin	S-drug
,	O
ampicillin	S-drug
,	O
and	O
tetracyclines	S-group
(	O
72	O
)	O

No	O
specific	O
information	O
available	O

Aminoglutethimide	S-drug
:	O
Aminoglutethimide	S-drug-EF-1
may	O
diminish	O
adrenal	O
suppression	O
by	O
corticosteroids	S-group-EF-2
.	O

Amphotericin	B-drug
B	E-drug
injection	O
and	O
potassium	O
-	O
depleting	O
agents	O
:	O
When	O
corticosteroids	S-group-AD-1
are	O
administered	O
concomitantly	O
with	O
potassium	O
-	O
depleting	O
agents	O
(	O
e.g	O
.	O
,	O
amphotericin	B-drug-AD-2
B	E-drug-AD-2
,	O
diuretics	S-group-AD-2
)	O
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
development	O
of	O
hypokalemia	O
.	O

In	O
addition	O
,	O
there	O
have	O
been	O
cases	O
reported	O
in	O
which	O
concomitant	O
use	O
of	O
amphotericin	B-drug-EF-1
B	E-drug-EF-1
and	O
hydrocortisone	S-drug-EF-2
was	O
followed	O
by	O
cardiac	O
enlargement	O
and	O
congestive	O
heart	O
failure	O
.	O

Antibiotics	S-group
:	O
Macrolide	B-group-ME-1
antibiotics	E-group-ME-1
have	O
been	O
reported	O
to	O
cause	O
a	O
significant	O
decrease	O
in	O
corticosteroid	S-group-ME-2
clearance	O
.	O

Anticholinesterases	S-group
:	O
Concomitant	O
use	O
of	O
anticholinesterase	B-group-EF-1
agents	E-group-EF-1
and	O
corticosteroids	S-group-EF-2
may	O
produce	O
severe	O
weakness	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
.	O

If	O
possible	O
,	O
anticholinesterase	B-group-AD-1
agents	E-group-AD-1
should	O
be	O
withdrawn	O
at	O
least	O
24	O
hours	O
before	O
initiating	O
corticosteroid	S-group-AD-2
therapy	O
.	O

Anticoagulants	S-group
,	O
oral	O
:	O
Co	O
-	O
administration	O
of	O
corticosteroids	S-group-EF-1
and	O
warfarin	S-drug-EF-2
usually	O
results	O
in	O
inhibition	O
of	O
response	O
to	O
warfarin	S-drug
,	O
although	O
there	O
have	O
been	O
some	O
conflicting	O
reports	O
.	O

Therefore	O
,	O
coagulation	O
indices	O
should	O
be	O
monitored	O
frequently	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O

Antidiabetics	S-group
:	O
Because	O
corticosteroids	S-group-EF-1
may	O
increase	O
blood	O
glucose	O
concentrations	O
,	O
dosage	O
adjustments	O
of	O
antidiabetic	B-group-EF-2
agents	E-group-EF-2
may	O
be	O
required	O
.	O

Antitubercular	O
drugs	O
:	O
Serum	O
concentrations	O
of	O
isoniazid	S-drug
may	O
be	O
decreased	O
.	O

Cholestyramine	S-drug
:	O
Cholestyramine	S-drug-ME-1
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	S-group-ME-2
.	O

Cyclosporine	S-drug
:	O
Increased	O
activity	O
of	O
both	O
cyclosporine	S-drug-EF-1
and	O
corticosteroids	S-group-EF-2
may	O
occur	O
when	O
the	O
two	O
are	O
used	O
concurrently	O
.	O

Convulsions	O
have	O
been	O
reported	O
with	O
this	O
concurrent	O
use	O
.	O

Dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
:	O
False	O
-	O
negative	O
results	O
in	O
the	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
in	O
patients	O
being	O
treated	O
with	O
indomethacin	S-drug
have	O
been	O
reported	O
.	O

Thus	O
,	O
results	O
of	O
the	O
DST	O
should	O
be	O
interpreted	O
with	O
caution	O
in	O
these	O
patients	O
.	O

Digitalis	B-group
glycosides	E-group
:	O
Patients	O
on	O
digitalis	B-group
glycosides	E-group
may	O
be	O
at	O
increased	O
risk	O
of	O
arrhythmias	O
due	O
to	O
hypokalemia	O
.	O

Ephedrine	S-drug
:	O
Ephedrine	S-drug-ME-1
may	O
enhance	O
the	O
metabolic	O
clearance	O
of	O
corticosteroids	S-group-ME-2
,	O
resulting	O
in	O
decreased	O
blood	O
levels	O
and	O
lessened	O
physiologic	O
activity	O
,	O
thus	O
requiring	O
an	O
increase	O
in	O
corticosteroid	S-group
dosage	O
.	O

Estrogens	S-group
,	O
including	O
oral	O
contraceptives	S-group
:	O
Estrogens	S-group-ME-1
may	O
decrease	O
the	O
hepatic	O
metabolism	O
of	O
certain	O
corticosteroids	S-group-ME-2
,	O
thereby	O
increasing	O
their	O
effect	O
.	O

Hepatic	O
Enzyme	O
Inducers	O
,	O
Inhibitors	O
and	O
Substrates	O
:	O
Drugs	O
which	O
induce	O
cytochrome	O
P450	O
3A4	O
(	O
CYP	O
3A4	O
)	O
enzyme	O
activity	O
(	O
e.g	O
.	O
,	O
barbiturates	S-group-ME-1
,	O
phenytoin	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
,	O
rifampin	S-drug-ME-1
)	O
may	O
enhance	O
the	O
metabolism	O
of	O
corticosteroids	S-group-ME-2
and	O
require	O
that	O
the	O
dosage	O
of	O
the	O
corticosteroid	S-group
be	O
increased	O
.	O

Drugs	O
which	O
inhibit	O
CYP	O
3A4	O
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug-ME-1
,	O
macrolide	B-group-ME-1
antibiotics	E-group-ME-1
such	O
as	O
erythromycin	S-drug-ME-1
)	O
have	O
the	O
potential	O
to	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
corticosteroids	S-group-ME-2
.	O

Dexamethasone	S-drug
is	O
a	O
moderate	O
inducer	O
of	O
CYP	O
3A4	O
.	O

Co	O
-	O
administration	O
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP	O
3A4	O
(	O
e.g	O
.	O
,	O
indinavir	S-drug
,	O
erythromycin	S-drug
)	O
may	O
increase	O
their	O
clearance	O
,	O
resulting	O
in	O
decreased	O
plasma	O
concentration	O
.	O

Ketoconazole	S-drug
:	O
Ketoconazole	S-drug-ME-1
has	O
been	O
reported	O
to	O
decrease	O
the	O
metabolism	O
of	O
certain	O
corticosteroids	S-group-ME-2
by	O
up	O
to	O
60	O
%	O
,	O
leading	O
to	O
increased	O
risk	O
of	O
corticosteroid	S-group
side	O
effects	O
.	O

In	O
addition	O
,	O
ketoconazole	S-drug-EF-1
alone	O
can	O
inhibit	O
adrenal	O
corticosteroid	S-drug-EF-2
synthesis	O
and	O
may	O
cause	O
adrenal	O
insufficiency	O
during	O
corticosteroid	O
withdrawal	O
.	O

Nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
agents	E-group
(	O
NSAIDS	S-group
)	O
:	O
Concomitant	O
use	O
of	O
aspirin	S-brand-EF-1
(	O
or	O
other	O
nonsteroidal	B-group-EF-1
antiinflammatory	I-group-EF-1
agents	E-group-EF-1
)	O
and	O
corticosteroids	S-group-EF-2
increases	O
the	O
risk	O
of	O
gastrointestinal	O
side	O
effects	O
.	O

Aspirin	S-brand-AD-1
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	S-group-AD-2
in	O
hypoprothrombinemia	O
.	O

The	O
clearance	O
of	O
salicylates	S-group-ME-1
may	O
be	O
increased	O
with	O
concurrent	O
use	O
of	O
corticosteroids	S-group-ME-2
.	O

Phenytoin	S-drug
:	O
In	O
post	O
-	O
marketing	O
experience	O
,	O
there	O
have	O
been	O
reports	O
of	O
both	O
increases	O
and	O
decreases	O
in	O
phenytoin	S-drug-ME-1
levels	O
with	O
dexamethasone	S-drug-ME-2
co	O
-	O
administration	O
,	O
leading	O
to	O
alterations	O
in	O
seizure	O
control	O
.	O

Skin	O
tests	O
:	O
Corticosteroids	S-group
may	O
suppress	O
reactions	O
to	O
skin	O
tests	O
.	O

Thalidomide	S-drug
:	O
Co	O
-	O
administration	O
with	O
thalidomide	S-drug
should	O
be	O
employed	O
cautiously	O
,	O
as	O
toxic	O
epidermal	O
necrolysis	O
has	O
been	O
reported	O
with	O
concomitant	O
use	O
.	O

Vaccines	S-group
:	O
Patients	O
on	O
corticosteroid	S-group-EF-1
therapy	O
may	O
exhibit	O
a	O
diminished	O
response	O
to	O
toxoids	O
and	O
live	S-group-EF-2
or	O
inactivated	B-group-EF-2
vaccines	E-group-EF-2
due	O
to	O
inhibition	O
of	O
antibody	O
response	O
.	O

Corticosteroids	S-group-EF-1
may	O
also	O
potentiate	O
the	O
replication	O
of	O
some	O
organisms	O
contained	O
in	O
live	B-group-EF-2
attenuated	I-group-EF-2
vaccines	E-group-EF-2
.	O

Routine	O
administration	O
of	O
vaccines	S-group-AD-1
or	O
toxoids	O
should	O
be	O
deferred	O
until	O
corticosteroid	S-group-AD-2
therapy	O
is	O
discontinued	O
if	O
possible	O
.	O

Dexbrompheniramine	S-drug-IN-1
can	O
interact	O
with	O
alcohol	S-drug-IN-2
or	O
other	O
CNS	B-group-IN-2
depressants	E-group-IN-2
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	S-group
)	O
,	O
anticholinergics	S-group-IN-2
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	S-group
)	O
,	O
and	O
monoamine	B-group-IN-2
oxidase	I-group-IN-2
(	I-group-IN-2
MAO	I-group-IN-2
)	I-group-IN-2
inhibitors	E-group-IN-2
(	O
concurrent	O
use	O
with	O
antihistamines	S-group
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	S-group
)	O
.	O

In	O
patients	O
receiving	O
nonselective	O
monoamine	B-group-EF-1
oxidase	I-group-EF-1
inhibitors	E-group-EF-1
(	O
MAOIs	S-group-EF-1
)	O
(	O
e.g	O
.	O
,	O
selegiline	B-drug-EF-1
hydrochloride	E-drug-EF-1
)	O
in	O
combination	O
with	O
serotoninergic	B-group-EF-2
agents	E-group-EF-2
(	O
e.g	O
.	O
,	O
fluoxetine	S-drug-EF-2
,	O
fluvoxamine	S-drug-EF-2
,	O
paroxetine	S-drug-EF-2
,	O
sertraline	S-drug-EF-2
,	O
venlafaxine	S-drug-EF-2
)	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
,	O
sometimes	O
fatal	O
,	O
reactions	O
.	O

Because	O
dexfenfluramine	S-drug
is	O
a	O
serotonin	O
releaser	O
and	O
reuptake	O
inhibitor	O
,	O
dexfenfluramine	S-drug-AD-1
should	O
not	O
be	O
used	O
concomitantly	O
with	O
a	O
MAO	B-group-AD-2
inhibitor	E-group-AD-2
.	O

At	O
least	O
14	O
days	O
should	O
elapse	O
between	O
discontinuation	O
of	O
a	O
MAO	B-group-AD-1
inhibitor	E-group-AD-1
and	O
initiation	O
of	O
treatment	O
with	O
dexfenfluramine	S-drug-AD-2
.	O

At	O
least	O
3	O
weeks	O
should	O
elapse	O
between	O
discontinuation	O
of	O
dexfenfluramine	S-drug-AD-1
and	O
initiation	O
of	O
treatment	O
with	O
a	O
MAO	B-group-AD-2
inhibitor	E-group-AD-2
.	O

A	O
rare	O
,	O
but	O
serious	O
,	O
constellation	O
of	O
symptoms	O
,	O
termed	O
serotonin	O
syndrome	O
,	O
has	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
selective	B-group-EF-1
serotonin	I-group-EF-1
reuptake	I-group-EF-1
inhibitors	E-group-EF-1
(	O
SSRIs	S-group-EF-1
)	O
and	O
agents	O
for	O
migraine	O
therapy	O
,	O
such	O
as	O
Imitrex	S-brand-EF-2
(	O
sumatriptan	B-drug-EF-2
succinate	E-drug-EF-2
)	O
and	O
dihydroergotamine	S-drug-EF-2
.	O

The	O
syndrome	O
requires	O
immediate	O
medical	O
attention	O
and	O
may	O
include	O
one	O
or	O
more	O
of	O
the	O
following	O
symptoms	O
:	O
excitement	O
,	O
hypomania	O
,	O
restlessness	O
,	O
loss	O
of	O
consciousness	O
,	O
confusion	O
,	O
disorientation	O
,	O
anxiety	O
,	O
agitation	O
,	O
motor	O
weakness	O
,	O
myoclonus	O
,	O
tremor	O
,	O
hemiballismus	O
,	O
hyperreflexia	O
,	O
ataxia	O
,	O
dysarthria	O
,	O
incoordination	O
,	O
hyperthermia	O
,	O
shivering	O
,	O
pupillary	O
dilation	O
,	O
diaphoresis	O
,	O
emesis	O
,	O
and	O
tachycardia	O
.	O

Dexfenfluramine	S-drug-AD-1
should	O
not	O
be	O
administered	O
with	O
other	O
serotoninergic	B-group-AD-2
agents	E-group-AD-2
.	O

The	O
appropriate	O
interval	O
between	O
administration	O
of	O
these	O
agents	O
and	O
dexfenfluramine	S-drug
has	O
not	O
been	O
established	O
.	O

The	O
use	O
of	O
dexfenfluramine	S-drug
with	O
other	O
CNS	O
-	O
active	O
drugs	O
has	O
not	O
been	O
systematically	O
evaluated	O
;	O

consequently	O
,	O
caution	O
is	O
advised	O
if	O
dexfenfluramine	S-drug
and	O
such	O
drugs	O
are	O
prescribed	O
concurrently	O
.	O

General	O
In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
demonstrated	O
no	O
evidence	O
of	O
cytochrome	O
P450	O
-	O
mediated	O
drug	O
interactions	O
that	O
are	O
likely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O

Anesthetics	S-group
/	O
Sedatives	S-group
/	O
Hypnotics	S-group
/	O
Opioids	S-group
:	O
Co	O
-	O
administration	O
of	O
PRECEDEX	S-brand-EF-1
with	O
anesthetics	S-group-EF-2
,	O
sedatives	S-group-EF-2
,	O
hypnotics	S-group-EF-2
,	O
and	O
opioids	S-group-EF-2
is	O
likely	O
to	O
lead	O
to	O
an	O
enhancement	O
of	O
effects	O
.	O

Specific	O
studies	O
have	O
confirmed	O
these	O
effects	O
with	O
sevoflurane	S-drug
,	O
isoflurane	S-drug
,	O
propofol	S-drug
,	O
alfentanil	S-drug
,	O
and	O
midazolam	S-drug
.	O

No	O
pharmacokinetic	O
interactions	O
between	O
dexmedetomidine	S-drug
and	O
isoflurane	S-drug
,	O
propofol	S-drug
,	O
alfentanil	S-drug
,	O
and	O
midazolam	S-drug
have	O
been	O
demonstrated	O
.	O

However	O
,	O
due	O
to	O
possible	O
pharmacodynamic	O
interactions	O
,	O
when	O
co	O
-	O
administered	O
with	O
PRECEDEX	S-brand
,	O
a	O
reduction	O
in	O
dosage	O
of	O
PRECEDEX	S-brand-AD-1
on	O
the	O
concomitant	O
anesthetic	S-group-AD-2
,	O
sedative	S-group-AD-2
,	O
hypnotic	S-group-AD-2
or	O
opioid	S-group-AD-2
may	O
be	O
required	O
.	O

Neuromuscular	B-group
Blockers	E-group
:	O
In	O
one	O
study	O
of	O
10	O
healthy	O
volunteers	O
,	O
administration	O
of	O
PRECEDEX	S-brand
for	O
45	O
minutes	O
at	O
a	O
plasma	O
concentration	O
of	O
1	O
(	O
one	O
)	O
ng	O
/	O
mL	O
resulted	O
in	O
no	O
clinically	O
meaningful	O
increases	O
in	O
the	O
magnitude	O
or	O
neuromuscular	O
blockade	O
associated	O
with	O
rocuronium	S-drug
administration	O
.	O

ZINECARD	S-brand
does	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
doxorubicin	S-drug
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
Impairment	O
of	O
Fertility	O
No	O
long	O
-	O
term	O
carcinogenicity	O
studies	O
have	O
been	O
carried	O
out	O
with	O
dexrazoxane	S-drug
in	O
animals	O
.	O

Dexrazoxane	S-drug
was	O
not	O
mutagenic	O
in	O
the	O
Ames	O
test	O
but	O
was	O
found	O
to	O
be	O
clastogenic	O
to	O
human	O
lymphocytes	O
in	O
vitro	O
and	O
to	O
mouse	O
bone	O
marrow	O
erythrocytes	O
in	O
vivo	O
(	O
micronucleus	O
test	O
)	O
.	O

The	O
possible	O
adverse	O
effects	O
of	O
ZINECARD	S-brand
on	O
the	O
fertility	O
of	O
humans	O
and	O
experimental	O
animals	O
,	O
male	O
or	O
female	O
,	O
have	O
not	O
been	O
adequately	O
studied	O
.	O

Testicular	O
atrophy	O
was	O
seen	O
with	O
dexrazoxane	S-drug
administration	O
at	O
doses	O
as	O
low	O
as	O
30	O
mg	O
/	O
kg	O
weekly	O
for	O
6	O
weeks	O
in	O
rats	O
(	O
1	O
/	O
3	O
the	O
human	O
dose	O
on	O
a	O
mg	O
/	O
m	O
2	O
basis	O
)	O
and	O
as	O
low	O
as	O
20	O
mg	O
/	O
kg	O
weekly	O
for	O
13	O
weeks	O
in	O
dogs	O
(	O
approximately	O
equal	O
to	O
the	O
human	O
dose	O
on	O
a	O
mg	O
/	O
m	O
2	O
basis	O
)	O
.	O

Acidifying	B-group
agents	E-group
:	O
Gastrointestinal	B-group-ME-1
acidifying	I-group-ME-1
agents	E-group-ME-1
(	O
guanethidine	S-drug-ME-1
,	O
reserpine	S-drug-ME-1
,	O
glutamic	B-drug-ME-1
acid	I-drug-ME-1
HCl	E-drug-ME-1
,	O
ascorbic	B-drug-ME-1
acid	E-drug-ME-1
,	O
fruit	O
juices	O
,	O
etc	O
.	O
)	O
lower	O
absorption	O
of	O
amphetamines	S-group-ME-2
.	O

Urinary	B-group-ME-1
acidifying	I-group-ME-1
agents	E-group-ME-1
(	O
ammonium	B-drug-ME-1
chloride	E-drug-ME-1
,	O
sodium	B-drug-ME-1
acid	I-drug-ME-1
phosphate	E-drug-ME-1
,	O
etc	O
.	O
)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	S-drug-ME-2
molecule	O
,	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O

Both	O
groups	O
of	O
agents	O
lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	S-group
.	O

Adrenergic	B-group
blockers	E-group
:	O
Adrenergic	B-group-EF-1
blockers	E-group-EF-1
are	O
inhibited	O
by	O
amphetamines	S-group-EF-2
.	O

Alkalinizing	O
agents	O
:	O
Gastrointestinal	O
alkalinizing	O
agents	O
(	O
sodium	B-drug-ME-1
bicarbonate	E-drug-ME-1
,	O
etc	O
.	O
)	O
increase	O
absorption	O
of	O
amphetamines	S-drug-ME-2
.	O

Urinary	O
alkalinizing	O
agents	O
(	O
acetazolamide	S-drug-ME-1
,	O
some	O
thiazides	S-group-ME-1
)	O
increase	O
the	O
concentration	O
of	O
the	O
non	O
-	O
ionized	O
species	O
of	O
the	O
amphetamine	S-drug-ME-2
molecule	O
,	O
thereby	O
decreasing	O
urinary	O
excretion	O
.	O

Both	O
groups	O
of	O
agents	O
increase	O
blood	O
levels	O
and	O
therefore	O
potentiate	O
the	O
actions	O
of	O
amphetamines	S-group
.	O

Antidepressants	S-group
,	O
tricyclic	S-group
:	O
Amphetamines	S-group-EF-1
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	S-group-EF-2
or	O
sympathomimetic	B-group-EF-2
agents	E-group-EF-2
;	O

d	B-drug-ME-1
-	I-drug-ME-1
amphetamine	E-drug-ME-1
with	O
desipramine	S-drug-ME-2
or	O
protriptyline	S-drug-ME-2
and	O
possibly	O
other	O
tricyclics	S-group-ME-2
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d	B-drug
-	I-drug
amphetamine	E-drug
in	O
the	O
brain	O
;	O

cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O

MAO	B-group
inhibitors	E-group
:	O
MAOI	B-group-ME-1
antidepressants	E-group-ME-1
,	O
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	S-drug-ME-1
,	O
slow	O
amphetamine	S-group-ME-2
metabolism	O
.	O

This	O
slowing	O
potentiates	O
amphetamines	S-group
,	O
increasing	O
their	O
effect	O
on	O
the	O
release	O
of	O
norepinephrine	O
and	O
other	O
monoamines	O
from	O
adrenergic	O
nerve	O
endings	O
;	O

this	O
can	O
cause	O
headaches	O
and	O
other	O
signs	O
of	O
hypertensive	O
crisis	O
.	O

A	O
variety	O
of	O
neurological	O
toxic	O
effects	O
and	O
malignant	O
hyperpyrexia	O
can	O
occur	O
,	O
sometimes	O
with	O
fatal	O
results	O
.	O

Antihistamines	S-group
:	O
Amphetamines	S-group-EF-1
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	S-group-EF-2
.	O

Antihypertensives	S-group
:	O
Amphetamines	S-group-EF-1
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	S-group-EF-2
.	O

Chlorpromazine	S-drug
:	O
Chlorpromazine	S-drug-EF-1
blocks	O
dopamine	O
and	O
norepinephrine	O
reuptake	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	S-group-EF-2
,	O
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	S-group
poisoning	O
.	O

Ethosuximide	S-drug
:	O
Amphetamines	S-group-ME-1
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	S-drug-ME-2
.	O

Haloperidol	S-drug
:	O
Haloperidol	S-drug-EF-1
blocks	O
dopamine	O
and	O
norepinephrine	O
reuptake	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	S-group-EF-2
.	O

Lithium	B-drug
carbonate	E-drug
:	O
The	O
stimulatory	O
effects	O
of	O
amphetamines	S-group-EF-1
may	O
be	O
inhibited	O
by	O
lithium	B-drug-EF-2
carbonate	E-drug-EF-2
.	O

Meperidine	S-drug
:	O
Amphetamines	S-group-EF-1
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	S-drug-EF-2
.	O

Methenamine	S-drug
therapy	O
:	O
Urinary	O
excretion	O
of	O
amphetamines	S-group-ME-1
is	O
increased	O
,	O
and	O
efficacy	O
is	O
reduced	O
,	O
by	O
acidifying	B-group-ME-2
agents	E-group-ME-2
used	O
in	O
methenamine	S-drug
therapy	O
.	O

Norepinephrine	S-drug
:	O
Amphetamines	S-group-EF-1
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	S-drug-EF-2
.	O

Phenobarbital	S-drug
:	O
Amphetamines	S-group-ME-1
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	S-drug-ME-2
;	O

co	O
-	O
administration	O
of	O
phenobarbital	S-drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Phenytoin	S-drug
:	O
Amphetamines	S-group-ME-1
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	S-drug-ME-2
;	O

co	O
-	O
administration	O
of	O
phenytoin	S-drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Propoxyphene	S-drug
:	O
In	O
cases	O
of	O
propoxyphene	S-drug-EF-1
overdosage	O
,	O
amphetamine	S-group-EF-2
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O

Veratrum	B-group
alkaloids	E-group
:	O
Amphetamines	S-group-EF-1
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	B-group-EF-2
alkaloids	E-group-EF-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Amphetamines	S-group-EF-1
can	O
cause	O
a	O
significant	O
elevation	O
in	O
plasma	O
corticosteroid	S-group-EF-2
levels	O
.	O

This	O
increase	O
is	O
greatest	O
in	O
the	O
evening	O
.	O

Amphetamines	S-group
may	O
interfere	O
with	O
urinary	O
steroid	O
determinations	O
.	O

Additive	O
depressant	O
effect	O
when	O
used	O
with	O
general	O
anesthetics	S-group
,	O
sedatives	S-group
,	O
antianxiety	B-group
drugs	E-group
,	O
hypnotics	S-group
,	O
alcohol	S-drug
,	O
and	O
other	O
opiate	B-group
analgesics	E-group
.	O

May	O
interact	O
with	O
thyroid	O
medication	O
(	O
e.g	O
.	O
,	O
levothyroxine	S-drug
)	O
,	O
iodine	S-drug
-	O
containing	O
products	O
,	O
antacids	S-group
,	O
H2	B-group
-	I-group
antagonists	E-group
(	O
e.g	O
.	O
,	O
famotidine	S-drug
,	O
ranitidine	S-drug
)	O
,	O
and	O
proton	B-group
pump	I-group
inhibitors	E-group
(	O
e.g	O
.	O
,	O
lansoprazole	S-drug
,	O
omeprazole	S-drug
)	O
.	O

This	O
product	O
can	O
affect	O
the	O
results	O
of	O
certain	O
lab	O
tests	O
.	O

Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
concomitant	O
high	O
-	O
dose	O
aspirin	S-brand-AD-1
and	O
carbonic	B-group-AD-2
anhydrase	I-group-AD-2
inhibitors	E-group-AD-2
,	O
as	O
anorexia	O
,	O
tachypnea	O
,	O
lethargy	O
and	O
coma	O
have	O
been	O
rarely	O
reported	O
due	O
to	O
a	O
possible	O
drug	O
interaction	O
.	O

Aspirin	S-brand
:	O
Concomitant	O
administration	O
of	O
diclofenac	S-drug-AD-1
and	O
aspirin	S-brand-AD-2
is	O
not	O
recommended	O
because	O
diclofenac	S-drug-ME-1
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	S-brand-ME-2
,	O
resulting	O
in	O
lower	O
plasma	O
concentrations	O
,	O
peak	O
plasma	O
levels	O
,	O
and	O
AUC	O
values	O
.	O

Anticoagulants	S-group
:	O
While	O
studies	O
have	O
not	O
shown	O
diclofenac	S-drug-AD-1
to	O
interact	O
with	O
anticoagulants	B-group
of	I-group
the	I-group
warfarin	I-group
type	E-group
,	O
caution	O
should	O
be	O
exercised	O
,	O
nonetheless	O
,	O
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	S-group-AD-2
.	O

Because	O
prostaglandins	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
,	O
and	O
NSAIDs	S-group
affect	O
platelet	O
function	O
as	O
well	O
,	O
concurrent	O
therapy	O
with	O
all	O
NSAIDs	S-group-AD-1
,	O
including	O
diclofenac	S-drug-AD-1
,	O
and	O
warfarin	S-drug-AD-2
requires	O
close	O
monitoring	O
of	O
patients	O
to	O
be	O
certain	O
that	O
no	O
change	O
in	O
their	O
anticoagulant	S-group
dosage	O
is	O
required	O
.	O

Digoxin	S-drug
,	O
Methotrexate	S-drug
,	O
Cyclosporine	S-drug
:	O
Diclofenac	S-drug
,	O
like	O
other	O
NSAIDs	S-group
,	O
may	O
affect	O
renal	O
prostaglandins	O
and	O
increase	O
the	O
toxicity	O
of	O
certain	O
drugs	O
.	O

Ingestion	O
of	O
diclofenac	S-drug-MU-1
may	O
increase	O
serum	O
concentrations	O
of	O
digoxin	S-drug-ME-2
and	O
methotrexate	S-drug-ME-2
and	O
increase	O
cyclosporine	S-drug-EF-2
s	O
nephrotoxicity	O
.	O

Patients	O
who	O
begin	O
taking	O
diclofenac	S-drug-EF-1
or	O
who	O
increase	O
their	O
diclofenac	S-drug
dose	O
or	O
any	O
other	O
NSAID	S-group-EF-1
while	O
taking	O
digoxin	S-drug-EF-2
,	O
methotrexate	S-drug-EF-2
,	O
or	O
cyclosporine	S-drug-EF-2
may	O
develop	O
toxicity	O
characteristics	O
for	O
these	O
drugs	O
.	O

They	O
should	O
be	O
observed	O
closely	O
,	O
particularly	O
if	O
renal	O
function	O
is	O
impaired	O
.	O

In	O
the	O
case	O
of	O
digoxin	S-drug
,	O
serum	O
levels	O
should	O
be	O
monitored	O
.	O

Lithium	S-drug
:	O
Diclofenac	S-drug-ME-1
decreases	O
lithium	S-drug-ME-2
renal	O
clearance	O
and	O
increases	O
lithium	S-drug-ME-2
plasma	O
levels	O
.	O

In	O
patients	O
taking	O
diclofenac	S-drug-EF-1
and	O
lithium	S-drug-EF-2
concomitantly	O
,	O
lithium	S-drug
toxicity	O
may	O
develop	O
.	O

Oral	O
Hypoglycemics	S-group
:	O
Diclofenac	S-drug
does	O
not	O
alter	O
glucose	O
metabolism	O
in	O
normal	O
subjects	O
nor	O
does	O
it	O
alter	O
the	O
effects	O
of	O
oral	O
hypoglycemic	B-group
agents	E-group
.	O

There	O
are	O
rare	O
reports	O
,	O
however	O
,	O
from	O
marketing	O
experiences	O
,	O
of	O
changes	O
in	O
effects	O
of	O
insulin	S-drug-EF-1
or	O
oral	O
hypoglycemic	B-group-EF-1
agents	E-group-EF-1
in	O
the	O
presence	O
of	O
diclofenac	S-drug-EF-2
that	O
necessitated	O
changes	O
in	O
the	O
doses	O
of	O
such	O
agents	O
.	O

Both	O
hypo	O
-	O
and	O
hyperglycemic	O
effects	O
have	O
been	O
reported	O
.	O

A	O
direct	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
,	O
but	O
physicians	O
should	O
consider	O
the	O
possibility	O
that	O
diclofenac	S-drug-EF-1
may	O
alter	O
a	O
diabetic	O
patient	O
s	O
response	O
to	O
insulin	S-drug-EF-2
or	O
oral	O
hypoglycemic	B-group-EF-2
agents	E-group-EF-2
.	O

Diuretics	S-group
:	O
Diclofenac	S-drug-EF-1
and	O
other	O
NSAIDs	S-group-EF-1
can	O
inhibit	O
the	O
activity	O
of	O
diuretics	S-group-EF-2
.	O

Concomitant	O
treatment	O
with	O
potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
.	O

Other	O
Drugs	O
:	O
In	O
small	O
groups	O
of	O
patients	O
(	O
7	O
-	O
10	O
/	O
interaction	O
study	O
)	O
,	O
the	O
concomitant	O
administration	O
of	O
azathioprine	S-drug
,	O
gold	S-group
,	O
chloroquine	S-drug
,	O
D	B-drug
-	I-drug
penicillamine	E-drug
,	O
prednisolone	S-drug
,	O
doxycycline	S-drug
,	O
or	O
digitoxin	S-drug
did	O
not	O
significantly	O
affect	O
the	O
peak	O
levels	O
and	O
AUC	O
values	O
of	O
diclofenac	S-drug
.	O

Phenobarbital	S-drug
toxicity	O
has	O
been	O
reported	O
to	O
have	O
occurred	O
in	O
a	O
patient	O
on	O
chronic	O
phenobarbital	S-drug-EF-1
treatment	O
following	O
the	O
initiation	O
of	O
diclofenac	S-drug-EF-2
therapy	O
.	O

Protein	O
Binding	O
In	O
vitro	O
,	O
diclofenac	S-drug-ME-1
interferes	O
minimally	O
or	O
not	O
at	O
all	O
with	O
the	O
protein	O
binding	O
of	O
salicylic	B-drug-ME-2
acid	E-drug-ME-2
(	O
20	O
%	O
decrease	O
in	O
binding	O
)	O
,	O
tolbutamide	S-drug-ME-2
,	O
prednisolone	S-drug-ME-2
(	O
10	O
%	O
decrease	O
in	O
binding	O
)	O
,	O
or	O
warfarin	S-drug-ME-2
.	O

Benzylpenicillin	S-drug
,	O
ampicillin	S-drug
,	O
oxacillin	S-drug
,	O
chlortetracycline	S-drug
,	O
doxycycline	S-drug
,	O
cephalothin	S-drug
,	O
erythromycin	S-drug
,	O
and	O
sulfamethoxazole	S-drug
have	O
no	O
influence	O
in	O
vitro	O
on	O
the	O
protein	O
binding	O
of	O
diclofenac	S-drug
in	O
human	O
serum	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Effect	O
on	O
Blood	O
Coagulation	O
:	O
Diclofenac	S-drug
increases	O
platelet	O
aggregation	O
time	O
but	O
does	O
not	O
affect	O
bleeding	O
time	O
,	O
plasma	O
thrombin	O
clotting	O
time	O
,	O
plasma	O
fibrinogen	O
,	O
or	O
factors	O
V	O
and	O
VII	O
to	O
XII	O
.	O

Statistically	O
significant	O
changes	O
in	O
prothrombin	O
and	O
partial	O
thromboplastin	O
times	O
have	O
been	O
reported	O
in	O
normal	O
volunteers	O
.	O

The	O
mean	O
changes	O
were	O
observed	O
to	O
be	O
less	O
than	O
1	O
second	O
in	O
both	O
instances	O
,	O
however	O
,	O
and	O
are	O
unlikely	O
to	O
be	O
clinically	O
important	O
.	O

Diclofenac	S-drug
is	O
a	O
prostaglandin	O
synthetase	O
inhibitor	O
,	O
however	O
,	O
and	O
all	O
drugs	O
that	O
inhibit	O
prostaglandin	O
synthesis	O
interfere	O
with	O
platelet	O
function	O
to	O
some	O
degree	O
;	O

therefore	O
,	O
patients	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
such	O
an	O
action	O
should	O
be	O
carefully	O
observed	O
.	O

Tetracycline	S-drug-EF-1
,	O
a	O
bacteriostatic	B-group
antibiotic	E-group
,	O
may	O
antagonize	O
the	O
bactercidal	O
effect	O
of	O
penicillin	S-drug-EF-2
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

The	O
following	O
agents	O
may	O
increase	O
certain	O
actions	O
or	O
side	O
effects	O
of	O
anticholinergic	B-group
drugs	E-group
.	O
amantadine	S-drug
antiarrhythmic	B-group
agents	E-group
of	O
class	O
(	O
e.g	O
.	O
quinidine	S-drug
)	O
,	O
antihistamines	S-group
antipsychotic	B-group
agents	E-group
(	O
e.g	O
.	O
phenothiazines	S-group
)	O
,	O
benzodiazepines	S-group
.	O

MAO	B-group
inhibitors	E-group
,	O
narcotic	B-group
analgesics	E-group
(	O
e.g	O
.	O
,	O
meperidine	S-drug
)	O
,	O
nitrates	S-group
and	O
nitrites	S-group
,	O
sympathomimetic	B-group
agents	E-group
,	O
tricyclic	B-group
antidepressants	E-group
,	O
and	O
other	O
drugs	O
having	O
anticholinergic	O
activity	O
.	O

Anticholinergics	S-group
antagonize	O
the	O
effects	O
of	O
antiglaucoma	B-group
agents	E-group
.	O

Anticholinergic	B-group
drugs	E-group
in	O
the	O
presence	O
of	O
increased	O
intraocular	O
pressure	O
may	O
be	O
hazardous	O
when	O
taken	O
concurrently	O
with	O
agents	O
such	O
as	O
corti	O
costeroids..	O

Anticholinergic	B-group-ME-1
agents	E-group-ME-1
may	O
affect	O
gastrointestinal	O
absorption	O
of	O
various	O
drugs	O
,	O
such	O
as	O
slowly	O
dissolving	O
dosage	O
forms	O
of	O
digoxin	S-drug-ME-2
;	O

increased	O
serum	O
digoxin	S-drug
concentrations	O
may	O
result	O
.	O

Anticholinergic	B-group-ME-1
drugs	E-group-ME-1
may	O
antagonize	O
the	O
effects	O
of	O
the	O
drugs	O
that	O
alter	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
metoclopramide	S-drug-ME-2
.	O

Because	O
antacids	S-group-ME-1
may	O
interfere	O
with	O
the	O
absorption	O
of	O
anticholinergic	B-group-ME-2
agents	E-group-ME-2
,	O
simultaneous	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

The	O
inhibiting	O
effects	O
of	O
anticholinergic	B-group
drugs	E-group
on	O
gastric	O
hydrochloric	O
acid	O
secretion	O
are	O
antagonized	O
by	O
agents	O
used	O
to	O
treat	O
achlorhydria	O
and	O
those	O
used	O
to	O
test	O
gastric	O
secretion	O
.	O

Coadministration	O
of	O
VIDEX	S-brand
with	O
drugs	O
that	O
are	O
known	O
to	O
cause	O
pancreatitis	O
may	O
increase	O
the	O
risk	O
of	O
this	O
toxicity	O
(	O
see	O
WARNINGS	O
)	O
and	O
should	O
be	O
done	O
with	O
extreme	O
caution	O
,	O
only	O
if	O
other	O
alternatives	O
are	O
not	O
available	O
,	O
and	O
only	O
if	O
clearly	O
indicated	O
.	O

Neuropathy	O
has	O
occurred	O
more	O
frequently	O
in	O
patients	O
with	O
a	O
history	O
of	O
neuropathy	O
or	O
neurotoxic	O
drug	O
therapy	O
,	O
including	O
stavudine	S-drug
,	O
and	O
these	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
neuropathy	O
during	O
VIDEX	S-brand
therapy	O
(	O
see	O
ADVERSE	O
REACTIONS	O
)	O
.	O

Allopurinol	S-drug
:	O
The	O
AUC	O
of	O
didanosine	S-drug
was	O
increased	O
about	O
4	O
-	O
fold	O
when	O
allopurinol	S-drug-ME-1
at	O
300	O
mg	O
/	O
day	O
was	O
coadministered	O
with	O
a	O
single	O
200	O
-	O
mg	O
dose	O
of	O
VIDEX	S-brand-ME-2
to	O
two	O
patients	O
with	O
renal	O
impairment	O
(	O
CLcr	O
=	O
15	O
and	O
18	O
mL	O
/	O
min	O
)	O
.	O

The	O
effects	O
of	O
allopurinol	S-drug
on	O
didanosine	S-drug
pharmacokinetics	O
in	O
subjects	O
with	O
normal	O
renal	O
function	O
are	O
not	O
known	O
.	O

Antacids	S-group
:	O
Concomitant	O
administration	O
of	O
antacids	S-group-EF-1
containing	O
magnesium	S-drug-EF-1
or	O
aluminum	S-drug-EF-1
with	O
VIDEX	S-brand-EF-2
Chewable	O
/	O
Dispersible	O
Buffered	O
Tablets	O
or	O
Pediatric	O
Powder	O
for	O
Oral	O
Solution	O
may	O
potentiate	O
adverse	O
events	O
associated	O
with	O
the	O
antacid	S-group
components	O
.	O

Drugs	O
Whose	O
Absorption	O
Can	O
Be	O
Affected	O
by	O
the	O
Level	O
of	O
Acidity	O
in	O
the	O
Stomach	O
:	O
Drugs	O
such	O
as	O
ketoconazole	S-drug-AD-1
and	O
itraconazole	S-drug-AD-1
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
prior	O
to	O
dosing	O
with	O
VIDEX	S-brand-AD-2
.	O

Ganciclovir	S-drug
:	O
Administration	O
of	O
VIDEX	S-brand-ME-1
2	O
hours	O
prior	O
to	O
or	O
concurrent	O
with	O
oral	O
ganciclovir	S-drug-ME-2
was	O
associated	O
with	O
a	O
111	O
(	O
114	O
)	O
%	O
increase	O
in	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
didanosine	S-drug
(	O
n	O
=	O
12	O
)	O
.	O

A	O
21	O
(	O
17	O
)	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
ganciclovir	S-drug
was	O
observed	O
when	O
VIDEX	S-brand-ME-1
was	O
administered	O
2	O
hours	O
prior	O
to	O
ganciclovir	S-drug-ME-2
,	O
but	O
not	O
when	O
the	O
two	O
drugs	O
were	O
administered	O
simultaneously	O
(	O
n	O
=	O
12	O
)	O
.	O

Quinolone	B-group
Antibiotics	O
:	O
VIDEX	S-brand-AD-1
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
after	O
or	O
6	O
hours	O
before	O
dosing	O
with	O
ciprofloxacin	S-drug-AD-2
because	O
plasma	O
concentrations	O
of	O
ciprofloxacin	S-drug-ME-1
are	O
decreased	O
when	O
administered	O
with	O
antacids	S-group
containing	O
magnesium	S-drug-ME-2
,	O
calcium	S-drug-ME-2
,	O
or	O
aluminum	S-drug-ME-2
.	O

In	O
eight	O
HIV	O
-	O
infected	O
patients	O
,	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
ciprofloxacin	S-drug
was	O
decreased	O
an	O
average	O
of	O
26	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
%	O
,	O
37	O
%	O
)	O
when	O
ciprofloxacin	S-drug-ME-1
was	O
administered	O
2	O
hours	O
prior	O
to	O
a	O
marketed	O
chewable	O
/	O
dispersible	O
tablet	O
formulation	O
of	O
VIDEX	S-brand-ME-2
.	O

The	O
AUC	O
of	O
ciprofloxacin	S-drug
was	O
decreased	O
an	O
average	O
of	O
15	O
-	O
fold	O
in	O
12	O
healthy	O
subjects	O
given	O
ciprofloxacin	S-drug-ME-1
and	O
didanosine	S-drug-ME-2
-	O
placebo	O
tablets	O
concurrently	O
.	O

In	O
a	O
single	O
subject	O
given	O
one	O
dose	O
of	O
ciprofloxacin	S-drug-ME-1
2	O
hours	O
after	O
a	O
dose	O
of	O
didanosine	S-drug-ME-2
-	O
placebo	O
tablets	O
,	O
a	O
greater	O
than	O
50	O
%	O
reduction	O
in	O
the	O
AUC	O
of	O
ciprofloxacin	S-drug
was	O
observed	O
.	O

Plasma	O
concentrations	O
of	O
quinolone	B-group-ME-1
antibiotics	E-group-ME-1
are	O
decreased	O
when	O
administered	O
with	O
antacids	S-group
containing	O
magnesium	S-drug-ME-2
,	O
calcium	S-drug-ME-2
,	O
or	O
aluminum	S-drug-ME-2
.	O

The	O
optimal	O
dosing	O
interval	O
for	O
coadministration	O
with	O
VIDEX	S-brand
should	O
be	O
determined	O
by	O
consulting	O
the	O
appropriate	O
quinolone	S-group
package	O
insert	O
.	O

Interactions	O
with	O
Other	O
Antiretroviral	B-group
Drugs	E-group
:	O
Significant	O
decreases	O
in	O
the	O
AUC	O
of	O
delavirdine	S-drug-ME-1
(	O
20	O
%	O
)	O
and	O
indinavir	S-drug-ME-1
(	O
84	O
%	O
)	O
occurred	O
following	O
simultaneous	O
administration	O
of	O
these	O
agents	O
with	O
VIDEX	S-brand-ME-2
.	O

To	O
avoid	O
this	O
interaction	O
,	O
delavirdine	S-drug-AD-1
or	O
indinavir	S-drug-AD-1
should	O
be	O
given	O
1	O
hour	O
prior	O
to	O
dosing	O
with	O
VIDEX	S-brand-AD-2
.	O

The	O
pharmacokinetics	O
of	O
nelfinavir	S-drug
are	O
not	O
altered	O
to	O
a	O
clinically	O
significant	O
degree	O
when	O
it	O
is	O
administered	O
with	O
a	O
light	O
meal	O
1	O
hour	O
after	O
VIDEX	S-brand
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen	S-group
-	O
containing	O
oral	O
contraceptives	S-group
.	O

The	O
following	O
similar	O
changes	O
may	O
be	O
expected	O
with	O
larger	O
doses	O
of	O
estrogen	S-group
:	O
-	O
Increased	O
sulfobromophthalein	O
retention	O

-	O
Increased	O
prothrombin	O
and	O
factors	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
;	O

decreased	O
antithrombin	B-drug
3	E-drug
;	O

increased	O
norepinephrine	O
-	O
induced	O
platelet	O
aggregability	O

-	O
Increased	O
thyroid	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
in	O
-	O
creased	O
circulating	O
total	O
thyroid	O
hormone	O
;	O

as	O
measured	O
by	O
PBI	O
,	O
T4	O
by	O
column	O
,	O
or	O
T4	O
by	O
radioimmunoassay	O
.	O

Free	O
T3	O
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
;	O

free	O
T4	O
concentration	O
is	O
unaltered	O

-	O
Impaired	O
glucose	O
tolerance	O

-	O
Decreased	O
pregnanediol	O
excretion	O

-	O
Reduced	O
response	O
to	O
metyrapone	O
test	O

-	O
Reduced	O
serum	O
folate	O
concentration	O

-	O
Increased	O
serum	O
triglyceride	O
and	O
phospholipid	O
concentration	O
.	O

Antidiabetic	B-group
drug	E-group
requirements	O
(	O
i.e	O
.	O
,	O
insulin	S-drug
)	O
may	O
be	O
altered	O
.	O

Concurrent	O
use	O
with	O
general	O
anesthetics	S-group
may	O
result	O
in	O
arrhythmias	O
.	O

The	O
pressor	O
effects	O
of	O
diethylpropion	S-drug
and	O
those	O
of	O
other	O
drugs	O
may	O
be	O
additive	O
when	O
the	O
drugs	O
are	O
used	O
concomitantly	O
;	O

conversely	O
,	O
diethylpropion	S-drug-IN-1
may	O
interfere	O
with	O
antihypertensive	B-group-IN-2
drugs	E-group-IN-2
(	O
i.e	O
.	O
,	O
guanethidine	S-drug-IN-2
,	O
a	B-drug-IN-2
-	I-drug-IN-2
methyldopa	E-drug-IN-2
)	O
.	O

Concurrent	O
use	O
of	O
phenothiazines	S-group-EF-1
may	O
antagonize	O
the	O
anorectic	O
effect	O
of	O
diethylpropion	S-drug-EF-2
.	O

May	O
interact	O
anticoagulants	S-group
(	O
altered	O
hypo	O
-	O
prothrombinemic	O
effect	O
)	O
,	O
barbiturates	S-group
,	O
rifampin	S-drug
and	O
other	O
inducers	O
of	O
hepatic	O
microsomal	O
enzyme	O
oxidation	O
system	O
(	O
decreased	O
effect	O
of	O
diethylstilbestrol	S-drug
)	O
,	O
corticosteroids	S-group
(	O
increased	O
effect	O
of	O
corticosteroids	S-group
)	O
.	O

Oral	O
Anticoagulants	S-group
:	O
In	O
some	O
normal	O
volunteers	O
,	O
the	O
concomitant	O
administration	O
of	O
diflunisal	S-drug-EF-1
and	O
warfarin	S-drug-EF-2
,	O
acenocoumarol	S-drug-EF-2
,	O
or	O
phenprocoumon	S-drug-EF-2
resulted	O
in	O
prolongation	O
of	O
prothrombin	O
time	O
.	O

This	O
may	O
occur	O
because	O
diflunisal	S-drug-ME-1
competitively	O
displaces	O
coumarins	S-group-ME-2
from	O
protein	O
binding	O
sites	O
.	O

Accordingly	O
,	O
when	O
diflunisal	S-drug-AD-1
is	O
administered	O
with	O
oral	O
anticoagulants	S-group-AD-2
,	O
the	O
prothrombin	O
time	O
should	O
be	O
closely	O
monitored	O
during	O
and	O
for	O
several	O
days	O
after	O
concomitant	O
drug	O
administration	O
.	O

Adjustment	O
of	O
dosage	O
of	O
oral	O
anticoagulants	S-group
may	O
be	O
required	O
.	O

Tolbutamide	S-drug
:	O
In	O
diabetic	O
patients	O
receiving	O
diflunisal	S-drug
and	O
tolbutamide	S-drug
,	O
no	O
significant	O
effects	O
were	O
seen	O
on	O
tolbutamide	S-drug
plasma	O
levels	O
or	O
fasting	O
blood	O
glucose	O
.	O

Hydrochlorothiazide	S-drug
:	O
In	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
diflunisal	S-drug-ME-1
and	O
hydrochlorothiazide	S-drug-ME-2
resulted	O
in	O
significantly	O
increased	O
plasma	O
levels	O
of	O
hydrochlorothiazide	S-drug
.	O

Diflunisal	S-drug-EF-1
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
hydrochlorothiazide	S-drug-EF-2
.	O

Furosemide	S-drug
:	O
In	O
normal	O
volunteers	O
,	O
the	O
concomitant	O
administration	O
of	O
diflunisal	S-drug
and	O
furosemide	S-drug
had	O
no	O
effect	O
on	O
the	O
diuretic	O
activity	O
of	O
furosemide	S-drug
.	O

Diflunisal	S-drug-EF-1
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
furosemide	S-drug-EF-2
.	O

Antacids	S-group
:	O
Concomitant	O
administration	O
of	O
antacids	S-group-ME-1
may	O
reduce	O
plasma	O
levels	O
of	O
diflunisal	S-drug-ME-2
.	O

This	O
effect	O
is	O
small	O
with	O
occasional	O
doses	O
of	O
antacids	S-group
,	O
but	O
may	O
be	O
clinically	O
significant	O
when	O
antacids	S-group
are	O
used	O
on	O
a	O
continuous	O
schedule	O
.	O

Acetaminophen	S-drug
:	O
In	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
diflunisal	S-drug-ME-1
and	O
acetaminophen	S-drug-ME-2
resulted	O
in	O
an	O
approximate	O
50	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
acetaminophen	S-drug
.	O

Acetaminophen	S-drug
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	S-drug
.	O

Since	O
acetaminophen	S-drug
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
hepatotoxicity	O
,	O
concomitant	O
administration	O
of	O
diflunisal	S-drug-AD-1
and	O
acetaminophen	S-drug-AD-2
should	O
be	O
used	O
cautiously	O
,	O
with	O
careful	O
monitoring	O
of	O
patients	O
.	O

Concomitant	O
administration	O
of	O
diflunisal	S-drug-EF-1
and	O
acetaminophen	S-drug-EF-2
in	O
dogs	O
,	O
but	O
not	O
in	O
rats	O
,	O
at	O
approximately	O
2	O
times	O
the	O
recommended	O
maximum	O
human	O
therapeutic	O
dose	O
of	O
each	O
(	O
40	O
to	O
52	O
mg	O
/	O
kg	O
/	O
day	O
of	O
diflunisal	S-drug
/	O
acetaminophen	S-drug
)	O
resulted	O
in	O
greater	O
gastrointestinal	O
toxicity	O
than	O
when	O
either	O
drug	O
was	O
administered	O
alone	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
has	O
not	O
been	O
established	O
.	O

Methotrexate	S-drug
:	O
Caution	O
should	O
be	O
used	O
if	O
diflunisal	S-drug-AD-1
is	O
administered	O
concomitantly	O
with	O
methotrexate	S-drug-AD-2
.	O

Nonsteroidal	B-group-ME-1
anti	I-group-ME-1
-	I-group-ME-1
inflammatory	I-group-ME-1
drugs	E-group-ME-1
have	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	S-drug-ME-2
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O

Cyclosporine	S-drug
:	O
Administration	O
of	O
nonsteroial	B-group-ME-1
anti	I-group-ME-1
-	I-group-ME-1
inflammatory	I-group-ME-1
drugs	E-group-ME-1
concomitantly	O
with	O
cyclosporine	S-drug-ME-2
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine	S-drug
-	O
induced	O
toxicity	O
,	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O

NSAIDs	S-group-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	S-drug-AD-2
,	O
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O

Nonsteroidal	B-group
Anti	I-group
-	I-group
Inflammatory	I-group
Drugs	E-group
:	O
The	O
administration	O
of	O
diflunisal	S-drug-ME-1
to	O
normal	O
volunteers	O
receiving	O
indomethacin	S-drug-ME-2
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	S-drug
.	O

In	O
some	O
patients	O
the	O
combined	O
use	O
of	O
indomethacin	S-drug-EF-1
and	O
diflunisal	S-drug-EF-2
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O

Therefore	O
,	O
indomethacin	S-drug-AD-1
and	O
diflunisal	S-drug-AD-2
should	O
not	O
be	O
used	O
concomitantly	O
.	O

The	O
concomitant	O
use	O
of	O
diflunisal	S-drug-EF-1
tablets	O
and	O
other	O
NSAIDs	S-group-EF-2
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
,	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O

The	O
following	O
information	O
was	O
obtained	O
from	O
studies	O
in	O
normal	O
volunteers	O
.	O

Aspirin	S-brand
:	O
In	O
normal	O
volunteers	O
,	O
a	O
small	O
decrease	O
in	O
diflunisal	S-drug
levels	O
was	O
observed	O
when	O
multiple	O
doses	O
of	O
diflunisal	S-drug-ME-1
and	O
aspirin	S-brand-ME-2
were	O
administered	O
concomitantly	O
.	O

Sulindac	S-drug
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	S-drug-ME-1
and	O
sulindac	S-drug-ME-2
in	O
normal	O
volunteers	O
resulted	O
in	O
lowering	O
of	O
the	O
plasma	O
levels	O
of	O
the	O
active	O
sulindac	O
sulfide	O
metabolite	O
by	O
approximately	O
one	O
-	O
third	O
.	O

Naproxen	S-drug
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	S-drug-ME-1
and	O
naproxen	S-drug-ME-2
in	O
normal	O
volunteers	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
levels	O
of	O
naproxen	S-drug
,	O
but	O
significantly	O
decreased	O
the	O
urinary	O
excretion	O
of	O
naproxen	S-drug
and	O
its	O
glucuronide	O
metabolite	O
.	O

Naproxen	S-drug
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	S-drug
.	O

Drug	O
laboratory	O
Test	O
Interactions	O
Serum	O
Salicylate	O
Assays	O
:	O
Caution	O
should	O
be	O
used	O
in	O
interpreting	O
the	O
results	O
of	O
serum	O
salicylate	O
assays	O
when	O
diflunisal	S-drug
is	O
present	O
.	O

Salicylate	S-group
levels	O
have	O
been	O
found	O
to	O
be	O
falsely	O
elevated	O
with	O
some	O
assay	O
methods	O
.	O

Potassium	B-group-EF-1
-	I-group-EF-1
depleting	I-group-EF-1
diuretics	E-group-EF-1
are	O
a	O
major	O
contributing	O
factor	O
to	O
digitalis	S-group-EF-2
toxicity	O
.	O

Calcium	S-drug
,	O
particularly	O
if	O
administered	O
rapidly	O
by	O
the	O
intravenous	O
route	O
,	O
may	O
produce	O
serious	O
arrhythmias	O
in	O
digitalized	O
patients	O
.	O

Quinidine	S-drug-ME-1
,	O
verapamil	S-drug-ME-1
,	O
amiodarone	S-drug-ME-1
,	O
propafenone	S-drug-ME-1
,	O
indomethacin	S-drug-ME-1
,	O
itraconazole	S-drug-ME-1
,	O
alprazolam	S-drug-ME-1
,	O
and	O
spironolactone	S-drug-ME-1
raise	O
the	O
serum	O
digoxin	S-drug-ME-2
concentration	O
due	O
to	O
a	O
reduction	O
in	O
clearance	O
and	O
/	O
or	O
in	O
volume	O
of	O
distribution	O
of	O
the	O
drug	O
,	O
with	O
the	O
implication	O
that	O
digitalis	S-group
intoxication	O
may	O
result	O
.	O

Erythromycin	S-drug-ME-1
and	O
clarithromycin	S-drug-ME-1
(	O
and	O
possibly	O
other	O
macrolide	B-group-ME-1
antibiotics	E-group-ME-1
)	O
and	O
tetracycline	S-drug-ME-1
may	O
increase	O
digoxin	S-drug-ME-2
absorption	O
in	O
patients	O
who	O
inactivate	O
digoxin	S-drug
by	O
bacterial	O
metabolism	O
in	O
the	O
lower	O
intestine	O
,	O
so	O
that	O
digitalis	S-group
intoxication	O
may	O
result	O
.	O

The	O
risk	O
of	O
this	O
interaction	O
may	O
be	O
reduced	O
if	O
digoxin	S-drug
is	O
given	O
as	O
capsules	O
.	O

Propantheline	S-drug-ME-1
and	O
diphenoxylate	S-drug-ME-1
,	O
by	O
decreasing	O
gut	O
motility	O
,	O
may	O
increase	O
digoxin	S-drug-ME-2
absorption	O
.	O

Antacids	S-group-ME-1
,	O
kaolin	S-drug-ME-1
-	O
pectin	O
,	O
sulfasalazine	S-drug-ME-1
,	O
neomycin	S-drug-ME-1
,	O
cholestyramine	S-drug-ME-1
,	O
certain	O
anticancer	O
drugs	O
,	O
and	O
metoclopramide	S-drug-ME-1
may	O
interfere	O
with	O
intestinal	O
digoxin	S-drug-ME-2
absorption	O
,	O
resulting	O
in	O
unexpectedly	O
low	O
serum	O
concentrations	O
.	O

Rifampin	S-drug-ME-1
may	O
decrease	O
serum	O
digoxin	S-drug-ME-2
concentration	O
,	O
especially	O
in	O
patients	O
with	O
renal	O
dysfunction	O
,	O
by	O
increasing	O
the	O
non	O
-	O
renal	O
clearance	O
of	O
digoxin	S-drug
.	O

There	O
have	O
been	O
inconsistent	O
reports	O
regarding	O
the	O
effects	O
of	O
other	O
drugs	O
(	O
e.g	O
.	O
,	O
quinine	S-drug
,	O
penicillamine	S-drug
)	O
on	O
serum	O
digoxin	S-drug
concentration	O
.	O

Thyroid	S-group-AD-1
administration	O
to	O
a	O
digitalized	O
,	O
hypothyroid	O
patient	O
may	O
increase	O
the	O
dose	O
requirement	O
of	O
digoxin	S-drug-AD-2
.	O

Concomitant	O
use	O
of	O
digoxin	S-drug-EF-1
and	O
sympathomimetics	S-group-EF-2
increases	O
the	O
risk	O
of	O
cardiac	O
arrhythmias	O
.	O

Succinylcholine	S-drug
may	O
cause	O
a	O
sudden	O
extrusion	O
of	O
potassium	O
from	O
muscle	O
cells	O
,	O
and	O
may	O
thereby	O
cause	O
arrhythmias	O
in	O
digitalized	O
patients	O
.	O

Although	O
beta	B-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
blockers	E-group-EF-1
or	O
calcium	B-group-EF-1
channel	I-group-EF-1
blockers	E-group-EF-1
and	O
digoxin	S-drug-EF-2
may	O
be	O
useful	O
in	O
combination	O
to	O
control	O
atrial	O
fibrillation	O
,	O
their	O
additive	O
effects	O
on	O
AV	O
node	O
conduction	O
can	O
result	O
in	O
advanced	O
or	O
complete	O
heart	O
block	O
.	O

Due	O
to	O
the	O
considerable	O
variability	O
of	O
these	O
interactions	O
,	O
the	O
dosage	O
of	O
digoxin	S-drug
should	O
be	O
individualized	O
when	O
patients	O
receive	O
these	O
medications	O
concurrently	O
.	O

Furthermore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
combining	O
digoxin	S-drug
with	O
any	O
drug	O
that	O
may	O
cause	O
a	O
significant	O
deterioration	O
in	O
renal	O
function	O
,	O
since	O
a	O
decline	O
in	O
glomerular	O
filtration	O
or	O
tubular	O
secretion	O
may	O
impair	O
the	O
excretion	O
of	O
digoxin	S-drug
.	O

Vasoconstrictors	S-group
:	O
D.H.E	B-brand-EF-1
.	I-brand-EF-1
45	E-brand-EF-1
(	O
dihydroergotamine	B-drug-EF-1
mesylate	E-drug-EF-1
)	O
Injection	O
,	O
USP	O
should	O
not	O
be	O
used	O
with	O
peripheral	B-group-EF-2
vasoconstrictors	E-group-EF-2
because	O
the	O
combination	O
may	O
cause	O
synergistic	O
elevation	O
of	O
blood	O
pressure	O
.	O

Sumatriptan	S-drug
:	O
Sumatriptan	S-drug-EF-1
has	O
been	O
reported	O
to	O
cause	O
coronary	O
artery	O
vasospasm	O
,	O
and	O
its	O
effect	O
could	O
be	O
additive	O
with	O
D.H.E	B-brand-EF-2
.	I-brand-EF-2
45	E-brand-EF-2
(	O
dihydroergotamine	B-drug-EF-2
mesylate	E-drug-EF-2
)	O
Injection	O
,	O
USP	O
.	O

Sumatriptan	S-drug-AD-1
and	O
D.H.E	B-brand-AD-2
.	I-brand-AD-2
45	E-brand-AD-2
(	O
dihydroergotamine	B-drug-AD-2
mesylate	E-drug-AD-2
)	O
Injection	O
,	O
USP	O
should	O
not	O
be	O
taken	O
within	O
24	O
hours	O
of	O
each	O
other..	O

Beta	B-group
Blockers	E-group
:	O
Although	O
the	O
results	O
of	O
a	O
clinical	O
study	O
did	O
not	O
indicate	O
a	O
safe	O
problem	O
associated	O
with	O
the	O
administration	O
of	O
D.H.E	B-brand
.	I-brand
45	E-brand
(	O
dihydroergotamine	B-drug
mesylate	E-drug
)	O
Injection	O
,	O
USP	O
to	O
subjects	O
already	O
receiving	O
propranolol	S-drug
,	O
there	O
have	O
been	O
reports	O
that	O
propranolol	S-drug-EF-1
may	O
potentiate	O
the	O
vasoconstrictive	O
action	O
of	O
ergotamine	S-drug-EF-2
by	O
blocking	O
the	O
vasodilating	O
property	O
of	O
epinephrine	O
.	O

Nicotine	S-drug
:	O
Nicotine	S-drug-EF-1
may	O
provoke	O
vasoconstriction	O
in	O
some	O
patients	O
,	O
predisposing	O
to	O
a	O
greater	O
ischemic	O
response	O
to	O
ergot	S-drug-EF-2
therapy	O
.	O

Macrolide	B-group
Antibiotics	E-group
(	O
e.	O
g.	O
erythromycin	S-drug
and	O
troleandomycin	S-drug
)	O
:	O
Agents	O
of	O
the	O
ergot	B-group-ME-1
alkaloid	I-group-ME-1
class	E-group-ME-1
,	O
of	O
which	O
D.H.E	B-brand-ME-1
.	I-brand-ME-1
45	E-brand-ME-1
(	O
dihydroergotamine	B-drug-ME-1
mesylate	E-drug-ME-1
)	O
Injection	O
,	O
USP	O
is	O
a	O
member	O
,	O
have	O
been	O
shown	O
to	O
interact	O
with	O
antibiotics	S-group
of	O
the	O
macrolide	B-group-ME-2
class	E-group-ME-2
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
unchanged	O
alkaloids	O
and	O
peripheral	O
vasoconstriction	O
.	O

Vasospastic	O
reactions	O
have	O
been	O
reported	O
with	O
therapeutic	O
doses	O
of	O
ergotamine	S-drug-EF-1
-	O
containing	O
drugs	O
when	O
co	O
-	O
administered	O
with	O
these	O
antibiotics	S-group-EF-2
.	O

SSRIs	S-group
:	O
Weakness	O
hyperreflexia	O
,	O
and	O
incoordination	O
have	O
been	O
reported	O
rarely	O
when	O
5	B-group-EF-1
-	I-group-EF-1
HT1	I-group-EF-1
agonists	E-group-EF-1
have	O
been	O
co	O
-	O
administered	O
with	O
SSRIs	S-group-EF-2
(	O
e.	O
g	O
.	O

fluoxetine	S-drug
,	O
fluvoxamine	S-drug
,	O
paroxetine	S-drug
,	O
sertraline	S-drug
)	O
.	O

There	O
have	O
been	O
no	O
reported	O
cases	O
from	O
spontaneous	O
reports	O
of	O
drug	O
interaction	O
between	O
SSRIs	S-group
and	O
D.H.E	B-brand
.	I-brand
45	E-brand
(	O
dihydroergotamine	B-drug
mesylate	E-drug
)	O
Injection	O
,	O
USP	O
.	O

Oral	O
Contraceptives	S-group
:	O
The	O
effect	O
of	O
oral	O
contraceptives	S-group
on	O
the	O
pharmacokinetics	O
of	O
D.H.E	B-brand
.	I-brand
45	E-brand
(	O
dihydroergotamine	B-drug
mesylate	E-drug
)	O
Injection	O
,	O
USP	O
has	O
not	O
been	O
studied	O
.	O

Administration	O
of	O
thiazide	B-group-EF-1
diuretics	E-group-EF-1
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
dihydrotachysterol	S-drug-EF-2
may	O
cause	O
hypercalcemia	O
.	O

Due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
,	O
caution	O
and	O
careful	O
titration	O
are	O
warranted	O
in	O
patients	O
receiving	O
diltiazem	B-drug
hydrochloride	E-drug
concomitantly	O
with	O
other	O
agents	O
known	O
to	O
affect	O
cardiac	O
contractility	O
and	O
/	O
or	O
conduction	O
.	O

Pharmacologic	O
studies	O
indicate	O
that	O
there	O
may	O
be	O
additive	O
effects	O
in	O
prolonging	O
AV	O
conduction	O
when	O
using	O
beta	B-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
or	O
digitalis	S-group-EF-1
concomitantly	O
with	O
Tiazac	S-brand-EF-2
.	O

As	O
with	O
all	O
drugs	O
,	O
care	O
should	O
be	O
exercised	O
when	O
treating	O
patients	O
with	O
multiple	O
medications	O
.	O

Diltiazem	S-drug
is	O
both	O
a	O
substrate	O
and	O
an	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
450	O
3A4	O
enzyme	O
system	O
.	O

Other	O
drugs	O
that	O
are	O
specific	O
substrates	O
,	O
inhibitors	O
,	O
or	O
inducers	O
of	O
the	O
enzyme	O
system	O
may	O
have	O
a	O
significant	O
impact	O
on	O
the	O
efficacy	O
and	O
side	O
effect	O
profile	O
of	O
diltiazem	S-drug
.	O

Patients	O
taking	O
other	O
drugs	O
that	O
are	O
substrates	O
of	O
CYP450	O
3A4	O
,	O
especially	O
patients	O
with	O
renal	O
and	O
/	O
or	O
hepatic	O
impairment	O
,	O
may	O
require	O
dosage	O
adjustment	O
when	O
starting	O
or	O
stopping	O
concomitantly	O
administered	O
diltiazem	S-drug
in	O
order	O
to	O
maintain	O
optimum	O
therapeutic	O
blood	O
levels	O
.	O

Beta	B-group
Blockers	E-group

Controlled	O
and	O
uncontrolled	O
domestic	O
studies	O
suggest	O
that	O
concomitant	O
use	O
of	O
diltiazem	B-drug
hydrochloride	E-drug
and	O
beta	B-group
-	I-group
blockers	E-group
is	O
usually	O
well	O
tolerated	O
,	O
but	O
available	O
data	O
are	O
not	O
sufficient	O
to	O
predict	O
the	O
effects	O
of	O
concomitant	O
treatment	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
or	O
cardiac	O
conduction	O
abnormalities	O
.	O

Administration	O
of	O
diltiazem	B-drug-ME-1
hydrochloride	E-drug-ME-1
concomitantly	O
with	O
propranolol	S-drug-ME-2
in	O
five	O
normal	O
volunteers	O
resulted	O
in	O
increased	O
propranolol	S-drug
levels	O
in	O
all	O
subjects	O
and	O
bioavailability	O
of	O
propranolol	S-drug
was	O
increased	O
approximately	O
50	O
%	O
.	O

In	O
vitro	O
,	O
propranolol	S-drug-ME-1
appears	O
to	O
be	O
displaced	O
from	O
its	O
binding	O
sites	O
by	O
diltiazem	S-drug-ME-2
.	O

If	O
combination	O
therapy	O
is	O
initiated	O
or	O
withdrawn	O
in	O
conjunction	O
with	O
propranolol	S-drug
,	O
an	O
adjustment	O
in	O
the	O
propranolol	S-drug
dose	O
may	O
be	O
warranted	O
.	O

A	O
study	O
in	O
six	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
diltiazem	S-drug
plasma	O
levels	O
(	O
58	O
%	O
)	O
and	O
AUC	O
(	O
53	O
%	O
)	O
after	O
a	O
1	O
-	O
week	O
course	O
of	O
cimetidine	S-drug-ME-1
1200	O
mg	O
/	O
day	O
and	O
a	O
single	O
dose	O
of	O
diltiazem	S-drug-ME-2
60mg	O
.	O

Ranitidine	S-drug
produced	O
smaller	O
,	O
nonsignificant	O
increases	O
.	O

The	O
effect	O
may	O
be	O
mediated	O
by	O
cimetidines	O
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P	O
-	O
450	O
,	O
the	O
enzyme	O
system	O
responsible	O
for	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
diltiazem	S-drug-ME-2
.	O

Patients	O
currently	O
receiving	O
diltiazem	S-drug-AD-1
therapy	O
should	O
be	O
carefully	O
monitored	O
for	O
a	O
change	O
in	O
pharmacological	O
effect	O
when	O
initiating	O
and	O
discontinuing	O
therapy	O
with	O
cimetidine	S-drug-AD-2
.	O

An	O
adjustment	O
in	O
the	O
diltiazem	S-drug
dose	O
may	O
be	O
warranted	O
.	O

Administration	O
of	O
diltiazem	B-drug-ME-1
hydrochloride	E-drug-ME-1
with	O
digoxin	S-drug-ME-2
in	O
24	O
healthy	O
male	O
subjects	O
increased	O
plasma	O
digoxin	S-drug
concentrations	O
approximately	O
20	O
%	O
.	O

Another	O
investigator	O
found	O
no	O
increase	O
in	O
digoxin	S-drug
levels	O
in	O
12	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

Since	O
there	O
have	O
been	O
conflicting	O
results	O
regarding	O
the	O
effect	O
of	O
digoxin	S-drug
levels	O
,	O
it	O
is	O
recommended	O
that	O
digoxin	S-drug-AD-1
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
diltiazem	B-drug-AD-2
hydrochloride	E-drug-AD-2
therapy	O
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O

The	O
depression	O
of	O
cardiac	O
contractility	O
,	O
conductivity	O
,	O
and	O
automaticity	O
as	O
well	O
as	O
the	O
vascular	O
dilation	O
associated	O
with	O
anesthetics	S-group-EF-1
may	O
be	O
potentiated	O
by	O
calcium	B-group-EF-2
channel	I-group-EF-2
blockers	E-group-EF-2
.	O

When	O
used	O
concomitantly	O
,	O
anesthetics	S-group-AD-1
and	O
calcium	B-group-AD-2
channel	I-group-AD-2
blockers	E-group-AD-2
should	O
be	O
titrated	O
carefully	O
.	O

A	O
pharmacokinetic	O
interaction	O
between	O
diltiazem	S-drug-IN-1
and	O
cyclosporine	S-drug-IN-2
has	O
been	O
observed	O
during	O
studies	O
involving	O
renal	O
and	O
cardiac	O
transplant	O
patients	O
.	O

In	O
renal	O
and	O
cardiac	O
transplant	O
recipients	O
,	O
a	O
reduction	O
of	O
cyclosporine	S-drug-ME-1
dose	O
ranging	O
from	O
15	O
%	O
to	O
48	O
%	O
was	O
necessary	O
to	O
maintain	O
cyclosporine	S-drug
trough	O
concentrations	O
similar	O
to	O
those	O
seen	O
prior	O
to	O
the	O
addition	O
of	O
diltiazem	S-drug-ME-2
.	O

If	O
these	O
agents	O
are	O
to	O
be	O
administered	O
concurrently	O
,	O
cyclosporine	S-drug-AD-1
concentrations	O
should	O
be	O
monitored	O
,	O
especially	O
when	O
diltiazem	S-drug-AD-2
therapy	O
is	O
initiated	O
,	O
adjusted	O
,	O
or	O
discontinued	O
.	O

The	O
effect	O
of	O
cyclosporine	S-drug
on	O
diltiazem	S-drug
plasma	O
concentrations	O
has	O
not	O
been	O
evaluated	O
.	O

Concomitant	O
administration	O
of	O
diltiazem	S-drug-ME-1
with	O
carbamazepine	S-drug-ME-2
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
carbamazepine	S-drug
(	O
40	O
%	O
to	O
72	O
%	O
increase	O
)	O
,	O
resulting	O
in	O
toxicity	O
in	O
some	O
cases	O
.	O

Patients	O
receiving	O
these	O
drugs	O
concurrently	O
should	O
be	O
monitored	O
for	O
a	O
potential	O
drug	O
interaction	O
.	O

Studies	O
showed	O
that	O
diltiazem	S-drug-ME-1
increased	O
the	O
AUC	O
of	O
midazolam	S-drug-ME-2
and	O
triazolam	S-drug-ME-2
by	O
3	O
-	O
4	O
fold	O
and	O
the	O
Cmax	O
by	O
2	O
-	O
fold	O
,	O
compared	O
to	O
placebo	O
.	O

The	O
elimination	O
half	O
life	O
of	O
midazolam	S-drug-ME-1
and	O
triazolam	S-drug-ME-1
also	O
increased	O
(	O
1.5	O
-	O
2.5	O
fold	O
)	O
during	O
coadministration	O
with	O
diltiazem	S-drug-ME-2
.	O

These	O
pharmacokinetic	O
effects	O
seen	O
during	O
diltiazem	S-drug-EF-1
coadministration	O
can	O
result	O
in	O
increased	O
clinical	O
effects	O
(	O
e.g	O
.	O
,	O
prolonged	O
sodation	O
)	O
of	O
both	O
midazolam	S-drug-EF-2
and	O
triazolam	S-drug-EF-2
.	O

In	O
a	O
ten	O
-	O
subject	O
study	O
,	O
coadministration	O
of	O
diltiazem	S-drug-ME-1
(	O
120	O
mg	O
bid	O
)	O
with	O
lovastatin	S-drug-ME-2
resulted	O
in	O
a	O
3	O
-	O
4	O
times	O
increase	O
in	O
mean	O
lovastatin	S-drug
AUC	O
and	O
Cmax	O
vs.	O
lovastatin	S-drug
alone	O
;	O

no	O
change	O
in	O
pravastatin	S-drug
AUC	O
and	O
Cmax	O
was	O
observed	O
during	O
diltiazem	S-drug
coadministration	O
.	O

Diltiazem	S-drug
plasma	O
levels	O
were	O
not	O
significantly	O
affected	O
by	O
lovastatin	S-drug
or	O
pravastatin	S-drug
.	O

Coadministration	O
of	O
rifampin	S-drug-ME-1
with	O
diltiazem	S-drug-ME-2
lowered	O
the	O
diltiazem	S-drug
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Coadministration	O
of	O
diltiazem	S-drug-AD-1
with	O
rifampin	S-drug-AD-2
or	O
any	O
known	O
CYP3A4	O
inducer	O
should	O
be	O
avoided	O
when	O
possible	O
,	O
and	O
alternative	O
therapy	O
considered	O
.	O

Dimenhydrinate	S-drug-EF-1
may	O
decrease	O
emetic	S-group
response	O
to	O
apomorphine	S-drug-EF-2
.	O

Oxytocin	S-drug-EF-1
or	O
other	O
oxytocics	S-group-EF-1
(	O
concurrent	O
use	O
with	O
dinoprost	S-drug-EF-2
may	O
result	O
in	O
uterine	O
hypertonus	O
,	O
possibly	O
causing	O
uterine	O
rupture	O
or	O
cervical	O
laceration	O
,	O
especially	O
in	O
the	O
absence	O
of	O
adequate	O
cervical	O
dilatation	O
;	O

although	O
combinations	O
are	O
sometimes	O
used	O
for	O
therapeutic	O
advantage	O
,	O
when	O
used	O
concurrently	O
,	O
patient	O
should	O
be	O
closely	O
monitored	O
.	O

PROSTIN	B-brand-EF-1
E2	E-brand-EF-1
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	B-group-EF-2
drugs	E-group-EF-2
.	O

Concomitant	O
use	O
with	O
other	O
oxytocic	B-group
agents	E-group
is	O
not	O
recommended	O
.	O

Diphenhydramine	B-drug-EF-1
hydrochloride	E-drug-EF-1
has	O
additive	O
effects	O
with	O
alcohol	S-drug-EF-2
and	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
(	O
hypnotics	S-group-EF-2
,	O
sedatives	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
,	O
etc	O
)	O
.	O

MAO	B-group-EF-1
inhibitors	E-group-EF-1
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
(	O
drying	O
)	O
effects	O
of	O
antihistamines	S-group-EF-2
.	O

CNS	O
depression	O
producing	O
medications	O
-	O
concurrent	O
use	O
may	O
potentiate	O
the	O
effects	O
of	O
either	O
these	O
medications	O
or	O
diphenidol	S-drug
;	O

anticholinergics	S-group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
-	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
diphenidol	S-drug
;	O

apomorphine	S-drug
-	O
prior	O
ingestion	O
of	O
diphenidol	S-drug-EF-1
may	O
decrease	O
the	O
emetic	S-group
response	O
to	O
apomorphine	S-drug-EF-2
in	O
the	O
treatment	O
of	O
poisoning	O
.	O

Known	O
drug	O
interactions	O
include	O
barbiturates	S-group
,	O
tranquilizers	S-group
,	O
and	O
alcohol	S-drug
.	O

Diphenoxylate	B-drug-IN-1
HCl	E-drug-IN-1
and	O
atropine	B-drug-IN-1
sulfate	E-drug-IN-1
may	O
interact	O
with	O
MAO	B-group-IN-2
inhibitors	E-group-IN-2
In	O
studies	O
with	O
male	O
rats	O
,	O
diphenoxylate	B-drug
hydrochloride	E-drug
was	O
found	O
to	O
inhibit	O
the	O
hepatic	O
microsomal	O
enzyme	O
system	O
at	O
a	O
dose	O
of	O
2	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Therefore	O
,	O
diphenoxylate	S-drug
has	O
the	O
potential	O
to	O
prolong	O
the	O
biological	O
half	O
-	O
lives	O
of	O
drugs	O
for	O
which	O
the	O
rate	O
of	O
elimination	O
is	O
dependent	O
on	O
the	O
microsomal	O
drug	O
metabolizing	O
enzyme	O
system	O
.	O

This	O
drug	O
may	O
interact	O
with	O
alcohol	S-drug
or	O
other	O
CNS	B-group
depressants	E-group
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	S-group
)	O
,	O
anticholinergics	S-group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	S-group
)	O
,	O
and	O
monoamine	B-group
oxidase	I-group
(	I-group
MAO	I-group
)	I-group
inhibitors	E-group
(	O
concurrent	O
use	O
with	O
antihistamines	S-drug
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	S-drug
)	O
.	O

No	O
pharmacokinetic	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
with	O
PERSANTINE	S-brand
(	O
dipyridamole	S-drug
USP	O
)	O
Tablets	O
.	O

The	O
following	O
information	O
was	O
obtained	O
from	O
the	O
literature	O
.	O

Adenosine	S-drug
:	O
Dipyridamole	S-drug-ME-1
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
and	O
cardiovascular	O
effects	O
of	O
adenosine	S-drug-ME-2
.	O

Adjustment	O
of	O
adenosine	S-drug
dosage	O
may	O
be	O
necessary	O
.	O

Cholinesterase	B-group
Inhibitors	E-group
:	O
Dipyridamole	S-drug-EF-1
may	O
counteract	O
the	O
anticholinesterase	O
effect	O
of	O
cholinesterase	B-group-EF-2
inhibitors	E-group-EF-2
,	O
thereby	O
potentially	O
aggravating	O
myasthenia	O
gravis	O
.	O

Terfenadine	S-drug
:	O
In	O
a	O
prospective	O
study	O
involving	O
six	O
-	O
healthy	O
-	O
male	O
volunteers	O
,	O
dirithromycin	S-drug
did	O
not	O
affect	O
the	O
metabolism	O
of	O
terfenadine	S-drug
.	O

These	O
six	O
volunteers	O
received	O
terfenadine	S-drug
alone	O
(	O
60	O
mg	O
twice	O
daily	O
)	O
for	O
8	O
days	O
,	O
followed	O
by	O
terfenadine	S-drug
in	O
combination	O
with	O
dirithromycin	S-drug
(	O
500	O
mg	O
once	O
daily	O
)	O
for	O
10	O
days	O
.	O

(	O
Both	O
drugs	O
were	O
thus	O
dosed	O
to	O
steady	O
state	O
.	O
)	O

The	O
pharmacokinetics	O
of	O
terfenadine	S-drug
and	O
its	O
acid	O
metabolite	O
and	O
the	O
electrocardiographic	O
QT	O
c	O
interval	O
were	O
measured	O
during	O
both	O
periods	O
:	O
with	O
terfenadine	S-drug
alone	O
,	O
and	O
with	O
terfenadine	S-drug
plus	O
dirithromycin	S-drug
.	O

In	O
five	O
men	O
,	O
terfenadine	S-drug
levels	O
were	O
undetectable	O
(	O
5	O
ng	O
/	O
mL	O
)	O
throughout	O
the	O
study	O
;	O

in	O
one	O
man	O
,	O
the	O
C	O
max	O
of	O
terfenadine	S-drug
was	O
8.1	O
ng	O
/	O
mL	O
with	O
terfenadine	S-drug
alone	O
and	O
7.2	O
ng	O
/	O
mL	O
with	O
terfenadine	S-drug-ME-1
plus	O
dirithromycin	S-drug-ME-2
.	O

The	O
mean	O
C	O
max	O
,	O
T	O
max	O
,	O
and	O
AUC	O
of	O
the	O
acid	O
metabolite	O
of	O
terfenadine	S-drug
were	O
not	O
significantly	O
changed	O
.	O

The	O
mean	O
QT	O
c	O
interval	O
(	O
msec	O
)	O
was	O
369	O
with	O
terfenadine	S-drug
alone	O
and	O
367	O
with	O
terfenadine	S-drug-EF-1
plus	O
dirithromycin	S-drug-EF-2
.	O

Also	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
lack	O
of	O
interaction	O
between	O
dirithromycin	S-drug
and	O
terfenadine	S-drug
.	O

Thus	O
,	O
the	O
interaction	O
observed	O
between	O
erythromycin	S-drug-IN-1
and	O
terfenadine	S-drug-IN-2
is	O
not	O
expected	O
for	O
dirithromycin	S-drug
.	O

Serious	O
cardiac	O
dysrhythmias	O
,	O
some	O
resulting	O
in	O
death	O
,	O
have	O
occurred	O
in	O
patients	O
receiving	O
terfenadine	S-drug-EF-1
concomitantly	O
with	O
other	O
macrolide	B-group-EF-2
antibiotics	E-group-EF-2
.	O

In	O
addition	O
,	O
most	O
macrolides	S-group-AD-1
are	O
contraindicated	O
in	O
patients	O
receiving	O
terfenadine	S-drug-AD-2
therapy	O
who	O
have	O
pre	O
-	O
existing	O
cardiac	O
abnormalities	O
(	O
arrhythmia	O
,	O
bradycardia	O
,	O
QT	O
c	O
interval	O
prolongation	O
,	O
ischemic	O
heart	O
disease	O
,	O
congestive	O
heart	O
failure	O
,	O
etc	O
.	O
)	O
or	O
electrolyte	O
disturbances	O
.	O

Theophylline	S-drug
:	O
Following	O
co	O
-	O
administration	O
of	O
two	O
250	O
-	O
mg	O
dirithromycin	S-drug
tablets	O
administered	O
once	O
daily	O
with	O
200	O
-	O
mg	O
theophylline	S-drug
tablets	O
administered	O
twice	O
daily	O
for	O
10	O
days	O
to	O
14	O
healthy	O
subjects	O
,	O
the	O
steady	O
-	O
state	O
plasma	O
concentration	O
of	O
theophylline	S-drug
was	O
not	O
significantly	O
altered	O
.	O

In	O
general	O
,	O
most	O
patients	O
treated	O
with	O
dirithromycin	S-drug
who	O
are	O
receiving	O
concomitant	O
theophylline	S-drug
therapy	O
may	O
not	O
require	O
empiric	O
adjustment	O
of	O
theophylline	S-drug
dosage	O
or	O
monitoring	O
of	O
theophylline	S-drug
plasma	O
concentrations	O
.	O

However	O
,	O
theophylline	S-drug
plasma	O
concentrations	O
should	O
be	O
monitored	O
,	O
with	O
dosage	O
adjustment	O
as	O
appropriate	O
,	O
in	O
patients	O
whose	O
pulmonary	O
disease	O
requires	O
maintaining	O
a	O
given	O
theophylline	S-drug
plasma	O
concentration	O
for	O
optimal	O
pulmonary	O
function	O
or	O
in	O
patients	O
with	O
theophylline	S-drug
concentrations	O
at	O
the	O
higher	O
end	O
of	O
the	O
therapeutic	O
range	O
.	O

Antacids	S-group
or	O
H	B-group
2	I-group
receptor	I-group
antagonists	E-group
:	O
When	O
dirithromycin	S-drug-ME-1
is	O
administered	O
immediately	O
following	O
antacids	S-group-ME-2
or	O
H	B-group-ME-2
2	I-group-ME-2
-	I-group-ME-2
receptor	I-group-ME-2
antagonists	E-group-ME-2
,	O
the	O
absorption	O
of	O
dirithromycin	S-drug
is	O
slightly	O
enhanced	O
.	O

The	O
following	O
drug	O
interactions	O
have	O
been	O
reported	O
with	O
erythromycin	S-drug
products	O
.	O

It	O
is	O
presently	O
not	O
known	O
whether	O
these	O
same	O
drug	O
interactions	O
occur	O
with	O
dirithromycin	S-drug
.	O

Until	O
further	O
data	O
are	O
available	O
regarding	O
the	O
potential	O
interaction	O
of	O
dirithromycin	S-drug
with	O
these	O
compounds	O
,	O
caution	O
should	O
be	O
used	O
during	O
coadministration	O
.	O

Triazolam	S-drug
:	O
Erythromycin	S-drug-MU-1
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	S-drug-ME-2
and	O
,	O
thus	O
,	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
triazolam	S-drug-EF-2
.	O

Digoxin	S-drug
:	O
Concomitant	O
administration	O
of	O
erythromycin	S-drug-ME-1
and	O
digoxin	S-drug-ME-2
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	S-drug
serum	O
levels	O
.	O

Anticoagulants	S-group
:	O
There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	O
effects	O
when	O
erythromycin	S-drug-EF-1
and	O
oral	O
anticoagulants	S-group-EF-2
were	O
used	O
concomitantly	O
.	O

Increased	O
anticoagulation	O
effects	O
due	O
to	O
a	O
drug	O
interaction	O
with	O
erythromycin	S-drug
may	O
be	O
more	O
pronounced	O
in	O
the	O
elderly	O
.	O

Ergotamine	S-drug
:	O
Concurrent	O
use	O
of	O
erythromycin	S-drug-EF-1
and	O
ergotamine	S-drug-EF-2
or	O
dihydroergotamine	S-drug-EF-2
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Other	O
drugs	O
Drug	O
interactions	O
have	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
erythromycin	S-drug-IN-1
and	O
other	O
medications	O
,	O
including	O
cyclosporine	S-drug-IN-2
,	O
hexobarbital	S-drug-IN-2
,	O
carbamazepine	S-drug-IN-2
,	O
alfentanil	S-drug-IN-2
,	O
disopyramide	S-drug-IN-2
,	O
phenytoin	S-drug-IN-2
,	O
bromocriptine	S-drug-IN-2
,	O
valproate	S-drug-IN-2
,	O
astemizole	S-drug-IN-2
,	O
and	O
lovastatin	S-drug-IN-2
.	O

If	O
phenytoin	S-drug-ME-1
or	O
other	O
hepatic	O
enzyme	O
inducers	O
are	O
taken	O
concurrently	O
with	O
Norpace	S-brand-ME-2
or	O
Norpace	B-brand-ME-2
CR	E-brand-ME-2
,	O
lower	O
plasma	O
levels	O
of	O
disopyramide	S-drug
may	O
occur	O
.	O

Monitoring	O
of	O
disopyramide	S-drug
plasma	O
levels	O
is	O
recommended	O
in	O
such	O
concurrent	O
use	O
to	O
avoid	O
ineffective	O
therapy	O
.	O

Other	O
antiarrhythmic	B-group
drugs	E-group
(	O
eg	O
,	O
quinidine	S-drug
,	O
procainamide	S-drug
,	O
lidocaine	S-drug
,	O
propranolol	S-drug
)	O
have	O
occasionally	O
been	O
used	O
concurrently	O
with	O
Norpace	S-brand
.	O

Excessive	O
widening	O
of	O
the	O
QRS	O
complex	O
and	O
/	O
or	O
prolongation	O
of	O
the	O
Q	O
-	O
T	O
interval	O
may	O
occur	O
in	O
these	O
situations	O
.	O

In	O
healthy	O
subjects	O
,	O
no	O
significant	O
drug	O
-	O
drug	O
interaction	O
was	O
observed	O
when	O
Norpace	S-brand
was	O
coadministered	O
with	O
either	O
propranolol	S-drug
or	O
diazepam	S-drug
.	O

Concomitant	O
administration	O
of	O
Norpace	S-brand-ME-1
and	O
quinidine	S-drug-ME-2
resulted	O
in	O
slight	O
increases	O
in	O
plasma	O
disopyramide	S-drug
levels	O
and	O
slight	O
decreases	O
in	O
plasma	O
quinidine	S-drug
levels	O
.	O

Norpace	S-brand
does	O
not	O
increase	O
serum	O
digoxin	S-drug
levels	O
.	O

Patients	O
taking	O
disopyramide	B-drug-ME-1
phosphate	E-drug-ME-1
and	O
erythromycin	S-drug-ME-2
concomitantly	O
may	O
develop	O
increased	O
serum	O
concentrations	O
of	O
disopyramide	S-drug
resulting	O
in	O
excessive	O
widening	O
of	O
the	O
QRS	O
complex	O
and	O
/	O
or	O
prolongation	O
of	O
the	O
Q	O
-	O
T	O
interval	O
.	O

Patients	O
taking	O
disopyramide	B-drug
phosphate	E-drug
and	O
hepatic	O
enzyme	O
inhibitors	O
concomitantly	O
should	O
be	O
closely	O
monitored	O
.	O

Until	O
data	O
on	O
possible	O
interactions	O
between	O
verapamil	S-drug
and	O
disopyramide	B-drug
phosphate	E-drug
are	O
obtained	O
,	O
disopyramide	S-drug-AD-1
should	O
not	O
be	O
administered	O
within	O
48	O
hours	O
before	O
or	O
24	O
hours	O
after	O
verapamil	S-drug-AD-2
administration	O
.	O

Disulfiram	S-drug
appears	O
to	O
decrease	O
the	O
rate	O
at	O
which	O
certain	O
drugs	O
are	O
metabolized	O
and	O
therefore	O
may	O
increase	O
the	O
blood	O
levels	O
and	O
the	O
possibility	O
of	O
clinical	O
toxicity	O
of	O
drugs	O
given	O
concomitantly	O
.	O

DISULFIRAM	S-drug-AD-1
SHOULD	O
BE	O
USED	O
WITH	O
CAUTION	O
IN	O
THOSE	O
PATIENTS	O
REVEIVING	O
PHENYTOIN	S-drug-AD-2
AND	O
ITS	O
CONGENERS	O
.	O

SINCE	O
THE	O
CONCOMITANT	O
ADMINISTRATION	O
OF	O
THESE	O
TWO	O
DRUGS	O
CAN	O
LEAD	O
TO	O
PHENYTOIN	S-drug
INTOXICATION	O
,	O
PRIOR	O
TO	O
ADMINISTERING	O
DISULFIRAM	S-drug-EF-1
TO	O
A	O
PATIENT	O
ON	O
PHENYTOIN	S-drug-EF-2
THERAPY	O
,	O
A	O
BASELINE	O
PHENYTOIN	S-drug
SERUM	O
LEVEL	O
SHOULD	O
BE	O
OBTAINED	O
.	O

SUBSEQUENT	O
TO	O
INITIATION	O
OF	O
DISULFIRAM	S-drug
THERAPY	O
.	O

SERUM	O
LEVELS	O
OF	O
PHENYTOIN	S-drug
SHOULD	O
BE	O
DETERMINED	O
ON	O
DIFFERENT	O
DAYS	O
FOR	O
EVIDENCE	O
OF	O
AN	O
INCREASE	O
OR	O
FOR	O
A	O
CONTINUING	O
RISE	O
IN	O
LEVELS	O
.	O

INCREASED	O
PHENYTOIN	S-drug
LEVELS	O
SHOULD	O
BE	O
TREATED	O
WITH	O
APPROPRIATE	O
DOSAGE	O
ADJUSTMENT	O
.	O

It	O
may	O
be	O
necessary	O
to	O
adjust	O
the	O
dosage	O
of	O
oral	O
anticoagulants	S-group-AD-1
upon	O
beginning	O
or	O
stopping	O
disulfiram	S-drug-AD-2
.	O
since	O
disulfiram	S-drug
may	O
prolong	O
prothrombin	O
time	O
.	O

Patients	O
taking	O
isoniazid	S-drug-AD-1
when	O
disulfiram	S-drug-AD-2
is	O
given	O
should	O
be	O
observed	O
for	O
the	O
appearance	O
of	O
unsteady	O
gait	O
or	O
marked	O
changes	O
in	O
mental	O
status	O
;	O

the	O
disulfiram	S-drug
should	O
be	O
discontinued	O
if	O
such	O
signs	O
appear	O
.	O

In	O
rats	O
,	O
simultaneous	O
ingestion	O
of	O
disulfiram	S-drug-EF-1
and	O
nitrite	S-drug-EF-2
in	O
the	O
diet	O
for	O
78	O
weeks	O
has	O
been	O
reported	O
to	O
cause	O
tumors	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
disulfiram	S-drug-EF-1
may	O
react	O
with	O
nitrites	S-group-EF-2
in	O
the	O
rat	O
stomach	O
to	O
form	O
a	O
nitrosamine	O
,	O
which	O
is	O
tumorigenic	O
.	O

Disulfiram	S-drug
alone	O
in	O
the	O
rat	O
s	O
diet	O
did	O
not	O
lead	O
to	O
such	O
tumors	O
.	O

The	O
relevance	O
of	O
this	O
finding	O
to	O
humans	O
is	O
not	O
known	O
at	O
this	O
time	O
.	O

Animal	O
studies	O
indicate	O
that	O
dobutamine	S-drug-EF-1
may	O
be	O
ineffective	O
if	O
the	O
patient	O
has	O
recently	O
received	O
a	O
b	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
drug	E-group-EF-2
.	O

In	O
such	O
a	O
case	O
,	O
the	O
peripheral	O
vascular	O
resistance	O
may	O
increase	O
.	O

Preliminary	O
studies	O
indicate	O
that	O
the	O
concomitant	O
use	O
of	O
dobutamine	S-drug-EF-1
and	O
nitroprusside	S-drug-EF-2
results	O
in	O
a	O
higher	O
cardiac	O
output	O
and	O
,	O
usually	O
,	O
a	O
lower	O
pulmonary	O
wedge	O
pressure	O
than	O
when	O
either	O
drug	O
is	O
used	O
alone	O
.	O

There	O
was	O
no	O
evidence	O
of	O
drug	O
interactions	O
in	O
clinical	O
studies	O
in	O
which	O
dobutamine	S-drug
was	O
administered	O
concurrently	O
with	O
other	O
drugs	O
,	O
including	O
digitalis	B-group
preparations	E-group
,	O
furosemide	S-drug
,	O
spironolactone	S-drug
,	O
lidocaine	S-drug
,	O
glyceryl	B-drug
trinitrate	E-drug
,	O
isosorbide	B-drug
dinitrate	E-drug
,	O
morphine	S-drug
,	O
atropine	S-drug
,	O
heparin	S-drug
,	O
protamine	S-drug
,	O
potassium	B-drug
chloride	E-drug
,	O
folic	B-drug
acid	E-drug
,	O
and	O
acetaminophen	S-drug
.	O

There	O
have	O
been	O
no	O
formal	O
clinical	O
studies	O
to	O
evaluate	O
the	O
drug	O
interactions	O
of	O
TAXOTERE	S-brand
with	O
other	O
medications	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
metabolism	O
of	O
docetaxel	S-drug-ME-1
may	O
be	O
modified	O
by	O
the	O
concomitant	O
administration	O
of	O
compounds	O
that	O
induce	O
,	O
inhibit	O
,	O
or	O
are	O
metabolized	O
by	O
cytochrome	O
P450	O
3A4	O
,	O
such	O
as	O
cyclosporine	S-drug-ME-2
,	O
terfenadine	S-drug-ME-2
,	O
ketoconazole	S-drug-ME-2
,	O
erythromycin	S-drug-ME-2
,	O
and	O
troleandomycin	S-drug-ME-2
.	O

Caution	O
should	O
be	O
exercised	O
with	O
these	O
drugs	O
when	O
treating	O
patients	O
receiving	O
TAXOTERE	S-brand
as	O
there	O
is	O
a	O
potential	O
for	O
a	O
significant	O
interaction	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
Cimetidine	S-drug
:	O
Concomitant	O
use	O
of	O
cimetidine	S-drug
is	O
contraindicated	O
.	O

Cimetidine	S-drug-ME-1
at	O
400	O
mg	O
BID	O
(	O
the	O
usual	O
prescription	O
dose	O
)	O
co	O
-	O
administered	O
with	O
TIKOSYN	S-brand-ME-2
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	S-drug
plasma	O
levels	O
by	O
58	O
%	O
.	O

Cimetidine	S-drug-ME-1
at	O
doses	O
of	O
100	O
mg	O
BID	O
(	O
OTC	O
dose	O
)	O
resulted	O
in	O
a	O
13	O
%	O
increase	O
in	O
dofetilide	S-drug-ME-2
plasma	O
levels	O
(	O
500	O
mcg	O
single	O
dose	O
)	O
.	O

No	O
studies	O
have	O
been	O
conducted	O
at	O
intermediate	O
doses	O
of	O
cimetidine	S-drug
.	O

If	O
a	O
patient	O
requires	O
TIKOSYN	S-brand-AD-1
and	O
anti	B-group
-	I-group
ulcer	E-group
therapy	O
,	O
it	O
is	O
suggested	O
that	O
omeprazole	S-drug
,	O
ranitidine	S-drug
,	O
or	O
antacids	S-group
(	O
aluminum	S-drug
and	O
magnesium	B-drug
hydroxides	O
)	O
be	O
used	O
as	O
alternatives	O
to	O
cimetidine	S-drug-AD-2
,	O
as	O
these	O
agents	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
profile	O
of	O
TIKOSYN	S-brand
.	O

Verapamil	S-drug
:	O
Concomitant	O
use	O
of	O
verapamil	S-drug
is	O
contraindicated	O
.	O

Co	O
-	O
administration	O
of	O
TIKOSYN	S-brand-ME-1
with	O
verapamil	S-drug-ME-2
resulted	O
in	O
increases	O
in	O
dofetilide	S-drug
peak	O
plasma	O
levels	O
of	O
42	O
%	O
,	O
although	O
overall	O
exposure	O
to	O
dofetilide	S-drug
was	O
not	O
significantly	O
increased	O
.	O

In	O
an	O
analysis	O
of	O
the	O
supraventricular	O
arrhythmia	O
and	O
DIAMOND	O
patient	O
populations	O
,	O
the	O
concomitant	O
administration	O
of	O
verapamil	S-drug-EF-1
with	O
dofetilide	S-drug-EF-2
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O

Ketoconazole	S-drug
:	O
Concomitant	O
use	O
of	O
ketoconazole	S-drug
is	O
contraindicated	O
.	O

Ketoconazole	S-drug-ME-1
at	O
400	O
mg	O
daily	O
(	O
the	O
maximum	O
approved	O
prescription	O
dose	O
)	O
co	O
-	O
administered	O
with	O
TIKOSYN	S-brand-ME-2
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	S-drug
Cmax	O
by	O
53	O
%	O
in	O
males	O
and	O
97	O
%	O
in	O
females	O
,	O
and	O
AUC	O
by	O
41	O
%	O
in	O
males	O
and	O
69	O
%	O
in	O
females	O
.	O

Trimethoprim	S-drug
Alone	O
or	O
in	O
Combination	O
with	O
Sulfamethoxazole	S-drug
:	O
Concomitant	O
use	O
of	O
trimethoprim	S-drug
alone	O
or	O
in	O
combination	O
with	O
sulfamethoxazole	S-drug
is	O
contraindicated	O
.	O

Hydrochlorothiazide	S-drug
(	O
HCTZ	S-drug
)	O
Alone	O
or	O
in	O
Combination	O
with	O
Triamterene	S-drug
:	O
Concomitant	O
use	O
of	O
HCTZ	S-drug
alone	O
or	O
in	O
combination	O
with	O
triamterene	S-drug
is	O
contraindicated	O
.	O

HCTZ	S-drug
50	O
mg	O
QD	O
or	O
HCTZ	S-drug
/	O
triamterene	S-drug
50	O
/	O
100	O
mg	O
QD	O
was	O
co	O
-	O
administered	O
with	O
TIKOSYN	S-brand
(	O
500	O
mcg	O
BID	O
)	O
for	O
5	O
days	O
(	O
following	O
2	O
days	O
of	O
diuretic	S-group
use	O
at	O
half	O
dose	O
)	O
.	O

In	O
patients	O
receiving	O
HCTZ	S-drug-ME-1
alone	O
,	O
dofetilide	S-drug-ME-2
AUC	O
increased	O
by	O
27	O
%	O
and	O
Cmax	O
by	O
21	O
%	O
.	O

However	O
,	O
the	O
pharmacodynamic	O
effect	O
increased	O
by	O
197	O
%	O
(	O
QTc	O
increase	O
over	O
time	O
)	O
and	O
by	O
95	O
%	O
(	O
maximum	O
QTc	O
increase	O
)	O
.	O

However	O
,	O
the	O
pharmacodynamic	O
effect	O
increased	O
by	O
190	O
%	O
(	O
QTc	O
increase	O
over	O
time	O
)	O
and	O
by	O
84	O
%	O
(	O
Maximum	O
QTc	O
increase	O
)	O
.	O

The	O
pharmacodynamic	O
effects	O
can	O
be	O
explained	O
by	O
a	O
combination	O
of	O
the	O
increase	O
in	O
dofetilide	S-drug
exposure	O
and	O
the	O
reductions	O
in	O
serum	O
potassium	O
.	O

In	O
the	O
DIAMOND	O
trials	O
,	O
1252	O
patients	O
were	O
treated	O
with	O
TIKOSYN	S-brand
and	O
diuretics	S-group
concomitantly	O
of	O
whom	O
493	O
died	O
compared	O
to	O
508	O
deaths	O
among	O
the	O
1248	O
patients	O
receiving	O
placebo	O
and	O
diuretics	S-group
.	O

Of	O
the	O
229	O
patients	O
who	O
had	O
potassium	B-group
depleting	I-group
diuretics	E-group
added	O
to	O
their	O
concomitant	O
medications	O
in	O
the	O
DIAMOND	O
trials	O
,	O
the	O
patients	O
on	O
TIKOSYN	S-brand
had	O
a	O
non	O
-	O
significantly	O
reduced	O
relative	O
risk	O
for	O
death	O
of	O
0.68	O
(	O
95	O
%	O
CI	O
0.376	O
,	O
1.230	O
)	O
.	O

Potential	O
Drug	O
Interactions	O
Dofetilide	S-drug
is	O
eliminated	O
in	O
the	O
kidney	O
by	O
cationic	O
secretion	O
.	O

Inhibitors	O
of	O
renal	O
cationic	O
secretion	O
are	O
contraindicated	O
with	O
TIKOSYN	S-brand
.	O

In	O
addition	O
,	O
drugs	O
that	O
are	O
actively	O
secreted	O
via	O
this	O
route	O
(	O
e.g	O
.	O
,	O
triamterene	S-drug-AD-1
,	O
metformin	S-drug-AD-1
and	O
amiloride	S-drug-AD-1
)	O
should	O
be	O
co	O
-	O
administered	O
with	O
care	O
as	O
they	O
might	O
increase	O
dofetilide	S-drug-AD-2
levels	O
.	O

Dofetilide	S-drug
is	O
metabolized	O
to	O
a	O
small	O
extent	O
by	O
the	O
CYP3A4	O
isoenzyme	O
of	O
the	O
cytochrome	O
P450	O
system	O
.	O

Inhibitors	O
of	O
the	O
CYP3A4	O
isoenzyme	O
could	O
increase	O
systemic	O
dofetilide	S-drug
exposure	O
.	O

Inhibitors	O
of	O
this	O
isoenzyme	O
(	O
e.g	O
.	O
,	O
macrolide	B-group-AD-1
antibiotics	E-group-AD-1
,	O
azole	B-group-AD-1
antifungal	I-group-AD-1
agents	E-group-AD-1
,	O
protease	B-group-AD-1
inhibitors	E-group-AD-1
,	O
serotonin	B-group-AD-1
reuptake	I-group-AD-1
inhibitors	E-group-AD-1
,	O
amiodarone	S-drug-AD-1
,	O
cannabinoids	S-group-AD-1
,	O
diltiazem	S-drug-AD-1
,	O
grapefruit	O
juice	O
,	O
nefazadone	S-drug-AD-1
,	O
norfloxacin	S-drug-AD-1
,	O
quinine	S-drug-AD-1
,	O
zafirlukast	S-drug-AD-1
)	O
should	O
be	O
cautiously	O
coadministered	O
with	O
TIKOSYN	S-brand-AD-2
as	O
they	O
can	O
potentially	O
increase	O
dofetilide	S-drug
levels	O
.	O

Dofetilide	S-drug
is	O
not	O
an	O
inhibitor	O
of	O
CYP3A4	O
nor	O
of	O
other	O
cytochrome	O
P450	O
isoenzymes	O
(	O
e.g	O
.	O
,	O
CYP2C9	O
,	O
CYP2D6	O
)	O
and	O
is	O
not	O
expected	O
to	O
increase	O
levels	O
of	O
drugs	O
metabolized	O
by	O
CYP3A4	O
.	O

Other	O
Drug	O
Interaction	O
Information	O
Digoxin	S-drug
:	O
Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	S-brand
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
.	O

In	O
patients	O
,	O
the	O
concomitant	O
administration	O
of	O
digoxin	S-drug-EF-1
with	O
dofetilide	S-drug-EF-2
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O

It	O
is	O
not	O
clear	O
whether	O
this	O
represents	O
an	O
interaction	O
with	O
TIKOSYN	S-brand
or	O
the	O
presence	O
of	O
more	O
severe	O
structural	O
heart	O
disease	O
in	O
patients	O
on	O
digoxin	S-drug
;	O

structural	O
heart	O
disease	O
is	O
a	O
known	O
risk	O
factor	O
for	O
arrhythmia	O
.	O

No	O
increase	O
in	O
mortality	O
was	O
observed	O
in	O
patients	O
taking	O
digoxin	S-drug
as	O
concomitant	O
medication	O
.	O

Other	O
Drugs	O
:	O
In	O
healthy	O
volunteers	O
,	O
amlodipine	S-drug
,	O
phenytoin	S-drug
,	O
glyburide	S-drug
,	O
ranitidine	S-drug
,	O
omeprazole	S-drug
,	O
hormone	O
replacement	O
therapy	O
(	O
a	O
combination	O
of	O
conjugated	O
estrogens	S-group
and	O
medroxyprogesterone	S-drug
)	O
,	O
antacid	S-group
(	O
aluminum	S-drug
and	O
magnesium	B-drug
hydroxides	O
)	O
and	O
theophylline	S-drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
TIKOSYN	S-brand
.	O

In	O
addition	O
,	O
studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	S-brand
does	O
not	O
affect	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	S-drug
,	O
or	O
the	O
pharmacokinetics	O
of	O
propranolol	S-drug
(	O
40	O
mg	O
twice	O
daily	O
)	O
,	O
phenytoin	S-drug
,	O
theophylline	S-drug
,	O
or	O
oral	O
contraceptives	S-group
.	O

Population	O
pharmacokinetic	O
analyses	O
were	O
conducted	O
on	O
plasma	O
concentration	O
data	O
from	O
1445	O
patients	O
in	O
clinical	O
trials	O
to	O
examine	O
the	O
effects	O
of	O
concomitant	O
medications	O
on	O
clearance	O
or	O
volume	O
of	O
distribution	O
of	O
dofetilide	S-drug
.	O

Concomitant	O
medications	O
were	O
grouped	O
as	O
ACE	B-group
inhibitors	E-group
,	O
oral	O
anticoagulants	S-group
,	O
calcium	B-group
channel	I-group
blockers	E-group
,	O
beta	B-group
blockers	E-group
,	O
cardiac	B-group
glycosides	E-group
,	O
inducers	O
of	O
CYP3A4	O
,	O
substrates	O
and	O
inhibitors	O
of	O
CYP3A4	O
,	O
substrates	O
and	O
inhibitors	O
of	O
P	O
-	O
glycoprotein	O
,	O
nitrates	S-group
,	O
sulphonylureas	S-group
,	O
loop	B-group
diuretics	E-group
,	O
potassium	B-group
sparing	I-group
diuretics	E-group
,	O
thiazide	B-group
diuretics	E-group
,	O
substrates	O
and	O
inhibitors	O
of	O
tubular	O
organic	O
cation	O
transport	O
,	O
and	O
QTc	O
-	O
prolonging	O
drugs	O
.	O

Differences	O
in	O
clearance	O
between	O
patients	O
on	O
these	O
medications	O
(	O
at	O
any	O
occasion	O
in	O
the	O
study	O
)	O
and	O
those	O
off	O
medications	O
varied	O
between	O
-	O
16	O
%	O
and	O
+	O
3	O
%	O
.	O

The	O
mean	O
clearances	O
of	O
dofetilide	S-drug-ME-1
were	O
16	O
%	O
and	O
15	O
%	O
lower	O
in	O
patients	O
on	O
thiazide	B-group-ME-2
diuretics	E-group-ME-2
and	O
inhibitors	O
of	O
tubular	O
organic	O
cation	O
transport	O
,	O
respectively	O
.	O

The	O
potential	O
for	O
clinically	O
significant	O
drug	O
-	O
drug	O
interactions	O
posed	O
by	O
dolasetron	S-drug
and	O
hydrodolasetron	S-drug_n
appears	O
to	O
be	O
low	O
for	O
drugs	O
commonly	O
used	O
in	O
chemotherapy	O
or	O
surgery	O
,	O
because	O
hydrodolasetron	S-drug_n
is	O
eliminated	O
by	O
multiple	O
routes	O
.	O

Blood	O
levels	O
of	O
hydrodolasetron	S-drug_n
increased	O
24	O
%	O
when	O
dolasetron	S-drug-ME-1
was	O
coadministered	O
with	O
cimetidine	S-drug-ME-2
(	O
nonselective	O
inhibitor	O
of	O
cytochrome	O
P	O
-	O
450	O
)	O
for	O
7	O
days	O
,	O
and	O
decreased	O
28	O
%	O
with	O
coadministration	O
of	O
rifampin	S-drug-ME-2
(	O
potent	O
inducer	O
of	O
cytochrome	O
P	O
-	O
450	O
)	O
for	O
7	O
days	O
.	O

Dolasetron	S-drug
has	O
been	O
safely	O
coadministered	O
with	O
drugs	O
used	O
in	O
chemotherapy	O
and	O
surgery	O
.	O

As	O
with	O
other	O
agents	O
which	O
prolong	O
ECG	O
intervals	O
,	O
caution	O
should	O
be	O
exercised	O
in	O
patients	O
taking	O
drugs	O
which	O
prolong	O
ECG	O
intervals	O
,	O
particularly	O
QTc	O
.	O

In	O
patients	O
taking	O
furosemide	S-drug
,	O
nifedipine	S-drug
,	O
diltiazem	S-drug
,	O
ACE	B-group
inhibitors	E-group
,	O
verapamil	S-drug
,	O
glyburide	S-drug
,	O
propranolol	S-drug
,	O
and	O
various	O
chemotherapy	O
agents	O
,	O
no	O
effect	O
was	O
shown	O
on	O
the	O
clearance	O
of	O
hydrodolasetron	S-drug_n
.	O

Clearance	O
of	O
hydrodolasetron	S-drug_n
decreased	O
by	O
about	O
27	O
%	O
when	O
dolasetron	B-drug-ME-1
mesylate	E-drug-ME-1
was	O
administered	O
intravenously	O
concomitantly	O
with	O
atenolol	S-drug-ME-2
.	O

Dolasetron	S-drug
does	O
not	O
influence	O
anesthesia	O
recovery	O
time	O
in	O
patients	O
.	O

Dolasetron	B-drug
mesylate	E-drug
did	O
not	O
inhibit	O
the	O
antitumor	O
activity	O
of	O
four	O
chemotherapeutic	B-group
agents	E-group
(	O
cisplatin	S-drug
,	O
5	B-drug
-	I-drug
fluorouracil	E-drug
,	O
doxorubicin	S-drug
,	O
cyclophosphamide	S-drug
)	O
in	O
four	O
murine	O
models	O
.	O

Drugs	O
that	O
inhibit	O
or	O
Induce	O
CYP	O
2D6	O
and	O
CYP	O
3A4	O
may	O
affect	O
the	O
concentration	O
on	O
Aricept	S-brand
.	O

Because	O
dopamine	S-drug
is	O
metabolized	O
by	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
,	O
inhibition	O
of	O
this	O
enzyme	O
prolongs	O
and	O
potentiates	O
the	O
effect	O
of	O
dopamine	S-drug
.	O

Patients	O
who	O
have	O
been	O
treated	O
with	O
MAO	B-group-AD-1
inhibitors	E-group-AD-1
within	O
two	O
to	O
three	O
weeks	O
prior	O
to	O
the	O
administration	O
of	O
dopamine	B-drug-AD-2
HCl	E-drug-AD-2
should	O
receive	O
initial	O
doses	O
of	O
dopamine	B-drug
HCl	E-drug
no	O
greater	O
than	O
one	O
-	O
tenth	O
(	O
1	O
/	O
10	O
)	O
of	O
the	O
usual	O
dose	O
.	O

Concurrent	O
administration	O
of	O
low	O
-	O
dose	O
dopamine	B-drug-EF-1
HCl	E-drug-EF-1
and	O
diuretic	B-group-EF-2
agents	E-group-EF-2
may	O
produce	O
an	O
additive	O
or	O
potentiating	O
effect	O
on	O
urine	O
flow	O
.	O

Tricyclic	B-group
antidepressants	E-group
may	O
potentiate	O
the	O
cardiovascular	O
effects	O
of	O
adreneric	O
agents	O
.	O

Cardiac	O
effects	O
of	O
dopamine	S-drug-EF-1
are	O
antagonized	O
by	O
beta	B-group-EF-2
-	I-group-EF-2
adrenergic	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
,	O
such	O
as	O
propranolol	S-drug-EF-2
and	O
metoprolol	S-drug-EF-2
.	O

The	O
peripheral	O
vasoconstriction	O
caused	O
by	O
high	O
doses	O
of	O
dopamine	B-drug-EF-1
HCl	E-drug-EF-1
is	O
antagonized	O
by	O
alpha	B-group-EF-2
-	I-group-EF-2
adrenergic	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

Dopamine	S-drug
-	O
induced	O
renal	O
and	O
mesenteric	O
vasodilation	O
is	O
not	O
antagonized	O
by	O
either	O
alpha	B-group
-	E-group
or	O
beta	B-drug
-	I-drug
adrenergic	I-drug
blocking	I-drug
agents	E-drug
.	O

Butyrophenones	S-group-EF-1
(	O
such	O
as	O
haloperidol	S-drug-EF-1
)	O
and	O
phenothiazines	S-group-EF-1
can	O
suppress	O
the	O
dopaminergic	O
renal	O
and	O
mesenteric	O
vasodilation	O
induced	O
with	O
low	O
dose	O
dopamine	O
infusion	O
.	O

Cyclopropane	S-drug-EF-1
or	O
halogenated	B-group-EF-1
hydrocarbon	I-group-EF-1
anesthetics	E-group-EF-1
increase	O
cardiac	O
autonomic	O
irritability	O
and	O
may	O
sensitize	O
the	O
myocardium	O
to	O
the	O
action	O
of	O
certain	O
intravenously	O
administered	O
catecholamines	S-group-EF-2
,	O
such	O
as	O
dopamine	S-drug-EF-2
.	O

This	O
interaction	O
appears	O
to	O
be	O
related	O
both	O
to	O
pressor	O
activity	O
and	O
to	O
beta	O
-	O
adrenergic	O
stimulating	O
properties	O
of	O
these	O
catecholamines	S-group
and	O
may	O
produce	O
ventricular	O
arrhythmias	O
and	O
hypertension	O
.	O

Therefore	O
,	O
EXTREME	O
CAUTION	O
should	O
be	O
exercised	O
when	O
administering	O
dopamine	B-drug-AD-1
HCl	E-drug-AD-1
to	O
patients	O
receiving	O
cyclopropane	S-drug-AD-2
or	O
halogenated	B-group-AD-2
hydrocarbon	I-group-AD-2
anesthetics	E-group-AD-2
.	O

It	O
has	O
been	O
reported	O
that	O
results	O
of	O
studies	O
in	O
animals	O
indicate	O
that	O
dopamine	S-drug-EF-1
-	O
induced	O
ventricular	O
arrhythmias	O
during	O
anesthesia	O
can	O
be	O
reversed	O
by	O
propranolol	S-drug-EF-2
.	O

The	O
concomitant	O
use	O
of	O
vasopressors	O
,	O
vasoconstricting	O
agents	O
(	O
such	O
as	O
ergonovine	S-drug-EF-1
)	O
and	O
some	O
oxytocic	B-group-EF-2
drugs	E-group-EF-2
may	O
result	O
in	O
severe	O
hypertension	O
.	O

Administration	O
of	O
phenytoin	S-drug-EF-1
to	O
patients	O
receiving	O
dopamine	B-drug-EF-2
HCl	E-drug-EF-2
has	O
been	O
reported	O
to	O
lead	O
to	O
hypotension	O
and	O
bradycardia	O
.	O

It	O
is	O
suggested	O
that	O
in	O
patients	O
receiving	O
dopamine	B-drug-AD-1
HCl	E-drug-AD-1
,	O
alternatives	O
to	O
phenytoin	S-drug-AD-2
should	O
be	O
used	O
if	O
anticonvulsant	S-group
therapy	O
is	O
needed	O
.	O

Clinical	O
trials	O
have	O
indicated	O
that	O
Pulmozyme	S-brand
can	O
be	O
effectively	O
and	O
safely	O
used	O
in	O
conjunction	O
with	O
standard	O
cystic	O
fibrosis	O
therapies	O
including	O
oral	O
,	O
inhaled	O
and	O
/	O
or	O
parenteral	O
antibiotics	S-group
,	O
bronchodilators	S-group
,	O
enzyme	O
supplements	O
,	O
vitamins	S-group
,	O
oral	O
or	O
inhaled	O
corticosteroids	S-group
,	O
and	O
analgesics	S-group
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Although	O
acid	O
-	O
base	O
and	O
electrolyte	O
disturbances	O
were	O
not	O
reported	O
in	O
the	O
clinical	O
trials	O
with	O
dorzolamide	S-drug-EF-1
,	O
these	O
disturbances	O
have	O
been	O
reported	O
with	O
oral	O
carbonic	B-group-EF-2
anhydrase	I-group-EF-2
inhibitors	E-group-EF-2
and	O
have	O
,	O
in	O
some	O
instances	O
,	O
resulted	O
in	O
drug	O
interactions	O
(	O
e.g	O
.	O
,	O
toxicity	O
associated	O
with	O
high	O
-	O
dose	O
salicylate	S-group
therapy	O
)	O
.	O

Therefore	O
,	O
the	O
potential	O
for	O
such	O
drug	O
interactions	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
dorzolamide	S-drug
.	O

Prior	O
administration	O
of	O
succinylcholine	S-drug
has	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
NUROMAX	S-brand
.	O

The	O
use	O
of	O
NUROMAX	S-brand
before	O
succinylcholine	S-drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	S-drug
has	O
not	O
been	O
studied	O
.	O

There	O
are	O
no	O
clinical	O
data	O
on	O
concomitant	O
use	O
of	O
NUROMAX	S-brand
and	O
other	O
nondepolarizing	O
neuromuscular	B-group
blocking	I-group
agents	E-group
.	O

Isoflurane	S-drug-ME-1
,	O
enflurane	S-drug-ME-1
,	O
and	O
halothane	S-drug-ME-1
decrease	O
the	O
ED50	O
of	O
NUROMAX	S-brand-ME-2
by	O
30	O
%	O
to	O
45	O
%	O
.	O

These	O
agents	O
may	O
also	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
by	O
up	O
to	O
25	O
%	O
.	O

Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
agents	O
such	O
as	O
NUROMAX	S-brand-EF-1
include	O
certain	O
antibiotics	S-group-EF-2
(	O
e.	O
g.	O
,	O
aminoglycosides	S-group-EF-2
,	O
tetracyclines	S-group-EF-2
,	O
bacitracin	S-group-EF-2
,	O
polymyxins	S-group-EF-2
,	O
lincomycin	S-drug-EF-2
,	O
clindamycin	S-drug-EF-2
,	O
colistin	S-drug-EF-2
,	O
and	O
sodium	B-drug-EF-2
colistimethate	E-drug-EF-2
)	O
,	O
magnesium	S-drug-EF-2
salts	O
,	O
lithium	S-drug-EF-2
,	O
local	O
anesthetics	S-group-EF-2
,	O
procainamide	S-drug-EF-2
,	O
and	O
quinidine	S-drug-EF-2
.	O

As	O
with	O
some	O
other	O
nondepolarizing	B-group-EF-1
neuromuscular	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
,	O
the	O
time	O
of	O
onset	O
of	O
neuromuscular	O
block	O
induced	O
by	O
NUROMAX	S-brand-EF-1
is	O
lengthened	O
and	O
the	O
duration	O
of	O
block	O
is	O
shortened	O
in	O
patients	O
receiving	O
phenytoin	S-drug-EF-2
or	O
carbamazepine	S-drug-EF-2
.	O

Administration	O
of	O
doxapram	S-drug-EF-1
to	O
patients	O
who	O
are	O
receiving	O
sympathomimetic	S-group-EF-2
or	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibiting	I-group-EF-2
drugs	E-group-EF-2
may	O
result	O
in	O
an	O
additive	O
pressor	O
effect	O
.	O

In	O
patients	O
who	O
have	O
received	O
muscle	B-group
relaxants	E-group
,	O
doxapram	S-drug-EF-1
may	O
temporarily	O
mask	O
the	O
residual	O
effects	O
of	O
muscle	B-group-EF-2
relaxant	I-group-EF-2
drugs	E-group-EF-2
.	O

In	O
patients	O
who	O
have	O
received	O
general	O
anesthesia	O
utilizing	O
a	O
volatile	O
agent	O
known	O
to	O
sensitize	O
the	O
myocardium	O
to	O
catecholamines	O
,	O
administration	O
of	O
doxapram	S-drug
should	O
be	O
delayed	O
until	O
the	O
volatile	O
agent	O
has	O
been	O
excreted	O
in	O
order	O
to	O
lessen	O
the	O
potential	O
for	O
arrhythmias	O
,	O
including	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
.	O

Most	O
(	O
98	O
%	O
)	O
of	O
plasma	O
doxazosin	S-drug
is	O
protein	O
bound	O
.	O

In	O
vitro	O
data	O
in	O
human	O
plasma	O
indicate	O
that	O
doxazosin	B-drug
mesylate	E-drug
has	O
no	O
effect	O
on	O
protein	O
binding	O
of	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
phenytoin	S-drug
or	O
indomethacin	S-drug
.	O

There	O
is	O
no	O
information	O
on	O
the	O
effect	O
of	O
other	O
highly	O
plasma	O
protein	O
bound	O
drugs	O
on	O
doxazosin	S-drug
binding	O
.	O

Doxazosin	B-drug
mesylate	E-drug
has	O
been	O
administered	O
without	O
any	O
evidence	O
of	O
an	O
adverse	O
drug	O
interaction	O
to	O
patients	O
receiving	O
thiazide	B-group
diuretics	E-group
,	O
beta	B-group
-	I-group
blocking	I-group
agents	O
,	O
and	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drugs	E-group
.	O

In	O
a	O
placebo	O
-	O
controlled	O
trial	O
in	O
normal	O
volunteers	O
,	O
the	O
administration	O
of	O
a	O
single	O
1	O
mg	O
dose	O
of	O
doxazosin	S-drug-ME-1
on	O
day	O
1	O
of	O
a	O
four	O
-	O
day	O
regimen	O
of	O
oral	O
cimetidine	S-drug-ME-2
(	O
400	O
mg	O
twice	O
daily	O
)	O
resulted	O
in	O
a	O
10	O
%	O
increase	O
in	O
mean	O
AUC	O
of	O
doxazosin	S-drug
(	O
p	O
=	O
0.006	O
)	O
,	O
and	O
a	O
slight	O
but	O
not	O
statistically	O
significant	O
increase	O
in	O
mean	O
Cmax	O
and	O
mean	O
half	O
-	O
life	O
of	O
doxazosin	S-drug
.	O

The	O
clinical	O
significance	O
of	O
this	O
increase	O
in	O
doxazosin	S-drug
AUC	O
is	O
unknown	O
.	O

In	O
clinical	O
trials	O
,	O
doxazosin	B-drug
mesylate	E-drug
tablets	O
have	O
been	O
administered	O
to	O
patients	O
on	O
a	O
variety	O
of	O
concomitant	O
medications	O
;	O

while	O
no	O
formal	O
interaction	O
studies	O
have	O
been	O
conducted	O
,	O
no	O
interactions	O
were	O
observed	O
.	O

Doxazosin	B-drug
mesylate	E-drug
tablets	O
have	O
been	O
used	O
with	O
the	O
following	O
drugs	O
or	O
drug	O
classes	O
:	O
1	O
.	O

Analgesic	S-group
/	O
anti	B-group
-	I-group
inflammatory	E-group
(	O
e.g	O
.	O
,	O
acetaminophen	S-drug
,	O
aspirin	S-brand
,	O
codeine	S-drug
and	O
codeine	S-drug
combinations	O
,	O
ibuprofen	S-drug
,	O
indomethacin	S-drug
)	O
.	O

2	O
.	O

Antibiotics	S-group
(	O
e.g	O
.	O
,	O
erythromycin	S-drug
,	O
trimethoprim	S-drug
and	O
sulfamethoxazole	S-drug
,	O
amoxicillin	S-drug
)	O
.	O

3	O
.	O

Antihistamines	S-group
(	O
e.g	O
.	O
,	O
chlorpheniramine	S-group
)	O
.	O

4	O
.	O

Cardiovascular	O
agents	O
(	O
e.g	O
.	O
,	O
atenolol	S-drug
,	O
hydrochlorothiazide	S-drug
,	O
propranolol	S-drug
)	O
.	O

5	O
.	O

Corticosteroids	S-group
.	O

6	O
.	O

Gastrointestinal	O
agents	O
(	O
e.g	O
.	O
,	O
antacids	S-group
)	O
.	O

7	O
.	O

Hypoglycemics	S-group
and	O
endocrine	O
drugs	O
.	O

8	O
.	O

Sedatives	S-group
and	O
tranquilizers	S-group
(	O
e.g	O
.	O
,	O
diazepam	S-drug
)	O
.	O

9	O
.	O

Cold	O
and	O
flu	O
remedies	O
.	O

Drugs	O
Metabolized	O
by	O
P450	O
2D6	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
Caucasian	O
population	O
(	O
about	O
7	O
-	O
10	O
%	O
of	O
Caucasians	O
are	O
so	O
-	O
called	O
poor	O
metabolizers	O
)	O
;	O

reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-group
antidepressants	E-group
(	O
TCAs	S-group
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
-	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	S-group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	S-drug
;	O

cimetidine	S-drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	S-group
,	O
phenothiazines	S-group
,	O
and	O
the	O
Type	B-group
1C	I-group
antiarrhythmics	E-group
propafenone	S-drug
and	O
flecainide	S-drug
)	O
.	O

While	O
all	O
the	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
(	O
SSRIs	S-group
)	O
,	O
e.g	O
.	O
,	O
citalopram	S-drug
,	O
escitalopram	S-drug
,	O
fluoxetine	S-drug
,	O
sertraline	S-drug
,	O
and	O
paroxetine	S-drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	S-group-IN-1
-	O
TCA	S-group-IN-2
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	S-group
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCAs	S-group-AD-1
with	O
any	O
of	O
the	O
SSRIs	S-group-AD-2
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	S-drug
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B-group
antidepressants	E-group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-group
antidepressant	E-group
or	O
the	O
other	O
drug	O
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-group
antidepressant	E-group
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	S-group
plasma	O
levels	O
whenever	O
a	O
TCA	S-group
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Doxepin	S-drug
is	O
primarily	O
metabolized	O
by	O
CYP2D6	O
(	O
with	O
CYP1A2	O
and	O
CYP3A4	O
as	O
minor	O
pathways	O
)	O
.	O

Inhibitors	O
or	O
substrates	O
of	O
CYP2D6	O
(	O
i.e	O
.	O
,	O
quinidine	S-drug-ME-1
,	O
selective	B-group-ME-1
serotonin	I-group-ME-1
reuptake	I-group-ME-1
inhibitors	E-group-ME-1
[	O
SSRIs	S-group-ME-1
]	O
)	O
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
doxepin	S-drug-ME-2
when	O
administered	O
concomitantly	O
.	O

The	O
extent	O
of	O
interaction	O
depends	O
on	O
the	O
variability	O
of	O
effect	O
on	O
CYP2D6	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
interaction	O
with	O
doxepin	S-drug
has	O
not	O
been	O
systematically	O
evaluated	O
.	O

MAO	B-group
Inhibitors	E-group
:	O
Serious	O
side	O
effects	O
and	O
even	O
death	O
have	O
been	O
reported	O
following	O
the	O
concomitant	O
use	O
of	O
certain	O
drugs	O
with	O
MAO	B-group
inhibitors	E-group
.	O

Therefore	O
,	O
MAO	B-group-AD-1
inhibitors	E-group-AD-1
should	O
be	O
discontinued	O
at	O
least	O
two	O
weeks	O
prior	O
to	O
the	O
cautious	O
initiation	O
of	O
therapy	O
with	O
SINEQUAN	S-brand-AD-2
.	O

The	O
exact	O
length	O
of	O
time	O
may	O
vary	O
and	O
is	O
dependent	O
upon	O
the	O
particular	O
MAO	B-group
inhibitor	E-group
being	O
used	O
,	O
the	O
length	O
of	O
time	O
it	O
has	O
been	O
administered	O
,	O
and	O
the	O
dosage	O
involved	O
.	O

Cimetidine	S-drug
:	O
Cimetidine	S-drug-ME-1
has	O
been	O
reported	O
to	O
produce	O
clinically	O
significant	O
fluctuations	O
in	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
various	O
tricyclic	B-group-ME-2
antidepressants	E-group-ME-2
.	O

Serious	O
anticholinergic	O
symptoms	O
(	O
i.e	O
.	O
,	O
severe	O
dry	O
mouth	O
,	O
urinary	O
retention	O
and	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	B-group-EF-1
antidepressant	E-group-EF-1
when	O
cimetidine	S-drug-EF-2
therapy	O
is	O
initiated	O
.	O

Additionally	O
,	O
higher	O
than	O
expected	O
tricyclic	B-group-ME-1
antidepressant	E-group-ME-1
levels	O
have	O
been	O
observed	O
when	O
they	O
are	O
begun	O
in	O
patients	O
already	O
taking	O
cimetidine	S-drug-ME-2
.	O

In	O
patients	O
who	O
have	O
been	O
reported	O
to	O
be	O
well	O
controlled	O
on	O
tricyclic	B-group
antidepressants	E-group
receiving	O
concurrent	O
cimetidine	S-drug
therapy	O
,	O
discontinuation	O
of	O
cimetidine	S-drug-ME-1
has	O
been	O
reported	O
to	O
decrease	O
established	O
steady	O
-	O
state	O
serum	O
tricyclic	B-group-ME-2
antidepressant	E-group-ME-2
levels	O
and	O
compromise	O
their	O
therapeutic	O
effects	O
.	O

Alcohol	S-drug
:	O
It	O
should	O
be	O
borne	O
in	O
mind	O
that	O
alcohol	S-drug-ME-1
ingestion	O
may	O
increase	O
the	O
danger	O
inherent	O
in	O
any	O
intentional	O
or	O
unintentional	O
SINEQUAN	S-brand-ME-2
overdosage	O
.	O

This	O
is	O
especially	O
important	O
in	O
patients	O
who	O
may	O
use	O
alcohol	S-drug
excessively	O
.	O

Tolazamide	S-drug
:	O
A	O
case	O
of	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
a	O
type	O
II	O
diabetic	O
patient	O
maintained	O
on	O
tolazamide	S-drug-EF-1
(	O
1	O
gm	O
/	O
day	O
)	O
11	O
days	O
after	O
the	O
addition	O
of	O
doxepin	S-drug-EF-2
(	O
75	O
mg	O
/	O
day	O
)	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
DOXIL	S-brand
.	O

Until	O
specific	O
compatibility	O
data	O
are	O
available	O
,	O
it	O
is	O
not	O
recommended	O
that	O
DOXIL	S-brand
be	O
mixed	O
with	O
other	O
drugs	O
.	O

DOXIL	S-brand
may	O
interact	O
with	O
drugs	O
known	O
to	O
interact	O
with	O
the	O
conventional	O
formulation	O
of	O
doxorubicin	B-drug
HCl	E-drug
.	O

Because	O
tetracyclines	S-group-AD-1
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	S-group-AD-2
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	S-group
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillin	S-drug
,	O
it	O
is	O
advisable	O
to	O
avoid	O
giving	O
tetracyclines	S-group-AD-1
in	O
conjunction	O
with	O
penicillin	S-group-AD-2
.	O

Absorption	O
of	O
tetracyclines	S-group-ME-1
is	O
impaired	O
by	O
antacids	S-group
containing	O
aluminum	S-drug-ME-2
,	O
calcium	S-drug-ME-2
,	O
or	O
magnesium	S-drug-ME-2
,	O
and	O
iron	S-drug-ME-2
-	O
containing	O
preparations	O
.	O

Absorption	O
of	O
tetracycline	S-drug-ME-1
is	O
impaired	O
by	O
bismuth	B-drug-ME-2
subsalicylate	E-drug-ME-2
.	O

Barbiturates	S-group-ME-1
,	O
carbamazepine	S-drug-ME-1
,	O
and	O
phenytoin	S-drug-ME-1
decrease	O
the	O
half	O
-	O
life	O
of	O
doxycycline	S-drug-ME-2
.	O

The	O
concurrent	O
use	O
of	O
tetracycline	S-drug-EF-1
and	O
Penthrane	S-brand-EF-2
(	O
methoxyflurane	S-drug-EF-2
)	O
has	O
been	O
reported	O
to	O
result	O
in	O
fatal	O
renal	O
toxicity	O
.	O

Concurrent	O
use	O
of	O
tetracycline	S-drug-EF-1
may	O
render	O
oral	O
contraceptives	S-group-EF-2
less	O
effective	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
False	O
elevations	O
of	O
urinary	O
catecholamine	O
levels	O
may	O
occur	O
due	O
to	O
interference	O
with	O
the	O
fluorescence	O
test	O
.	O

Potential	O
drug	O
interactions	O
for	O
doxylamine	S-drug
include	O
,	O
increased	O
sedation	O
if	O
doxylamine	S-drug-EF-1
is	O
combined	O
with	O
other	O
CNS	B-group-EF-2
depressant	I-group-EF-2
drugs	E-group-EF-2
.	O

Antihistamines	S-group-EF-1
may	O
partially	O
counteract	O
the	O
anticoagulation	O
effects	O
of	O
heparin	S-drug-EF-2
or	O
warfarin	S-drug-EF-2
.	O

Doxylamine	S-drug-EF-1
may	O
enhance	O
the	O
effects	O
of	O
epinephrine	S-drug-EF-2
.	O

Androgens	S-group
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulahts	O
.	O

Dosage	O
of	O
the	O
anticoagulant	S-group
may	O
require	O
reduction	O
in	O
order	O
to	O
maintain	O
satisfactory	O
therapeutic	O
hypoprothrombinemia	O
.	O

Concurrent	O
administration	O
of	O
oxyphenbutazone	S-drug-ME-1
and	O
androgens	S-group-ME-2
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	S-drug
.	O

In	O
diabetic	O
patients	O
,	O
the	O
metabolic	O
effects	O
of	O
androgens	S-group-EF-1
may	O
decrease	O
blood	O
glucose	O
and	O
therefore	O
,	O
insulin	S-drug-EF-2
requirements	O
.	O

Other	O
CNS	B-group-EF-1
depressant	I-group-EF-1
drugs	E-group-EF-1
(	O
e.g	O
.	O
barbiturates	S-group-EF-1
,	O
tranquilizers	S-group-EF-1
,	O
opioids	S-group-EF-1
and	O
general	O
anesthetics	S-group-EF-1
)	O
have	O
additive	O
or	O
potentiating	O
effects	O
with	O
INAPSINE	S-brand-EF-2
.	O

When	O
patients	O
have	O
received	O
such	O
drugs	O
,	O
the	O
dose	O
of	O
INAPSINE	S-brand
required	O
will	O
be	O
less	O
than	O
usual	O
.	O

Following	O
the	O
administration	O
of	O
INAPSINE	S-brand-AD-1
,	O
the	O
dose	O
of	O
other	O
CNS	B-group-AD-2
depressant	I-group-AD-2
drugs	E-group-AD-2
should	O
be	O
reduced	O
.	O

Drug	O
interaction	O
studies	O
with	O
Xigris	S-brand
have	O
not	O
been	O
performed	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

However	O
,	O
since	O
there	O
is	O
an	O
increased	O
risk	O
of	O
bleeding	O
with	O
Xigris	S-brand
,	O
caution	O
should	O
be	O
employed	O
when	O
Xigris	S-brand
is	O
used	O
with	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
.	O

Approximately	O
2	O
/	O
3	O
of	O
the	O
patients	O
in	O
the	O
Phase	O
3	O
study	O
received	O
either	O
prophylactic	O
low	O
dose	O
heparin	S-drug
(	O
unfractionated	B-drug
heparin	E-drug
up	O
to	O
15,000	O
units	O
/	O
day	O
)	O
or	O
prophylactic	O
doses	O
of	O
low	B-group
molecular	I-group
weight	I-group
heparins	E-group
as	O
indicated	O
in	O
the	O
prescribing	O
information	O
for	O
the	O
specific	O
products	O
.	O

Concomitant	O
use	O
of	O
prophylactic	O
low	O
dose	O
heparin	S-drug
did	O
not	O
appear	O
to	O
affect	O
safety	O
,	O
however	O
,	O
its	O
effects	O
on	O
the	O
efficacy	O
of	O
Xigris	S-brand
have	O
not	O
been	O
evaluated	O
in	O
an	O
adequate	O
and	O
well	O
-	O
controlled	O
clinical	O
trial	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Because	O
Xigris	S-brand
may	O
affect	O
the	O
APTT	O
assay	O
,	O
Xigris	S-brand
present	O
in	O
plasma	O
samples	O
may	O
interfere	O
with	O
one	O
-	O
stage	O
coagulation	O
assays	O
based	O
on	O
the	O
APTT	O
(	O
such	O
as	O
factor	O
VIII	O
,	O
IX	O
,	O
and	O
XI	O
assays	O
)	O
.	O

This	O
interference	O
may	O
result	O
in	O
an	O
apparent	O
factor	O
concentration	O
that	O
is	O
lower	O
than	O
the	O
true	O
concentration	O
.	O

Xigris	S-brand
present	O
in	O
plasma	O
samples	O
does	O
not	O
interfere	O
with	O
one	O
-	O
stage	O
factor	O
assays	O
based	O
on	O
the	O
PT	O
(	O
such	O
as	O
factor	O
II	O
,	O
V	O
,	O
VII	O
,	O
and	O
X	O
assays	O
)	O
.	O

Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
Duloxetine	S-drug
:	O
Both	O
CYP1A2	O
and	O
CYP2D6	O
are	O
responsible	O
for	O
duloxetine	S-drug
metabolism	O
.	O

Inhibitors	O
of	O
CYP1A2	O
:	O
Concomitant	O
use	O
of	O
duloxetine	S-drug-ME-1
with	O
fluvoxamine	S-drug-ME-2
,	O
an	O
inhibitor	O
of	O
CYP1A2	O
,	O
results	O
in	O
approximately	O
a	O
6	O
-	O
fold	O
increase	O
in	O
AUC	O
and	O
about	O
a	O
2.5	O
-	O
fold	O
increase	O
in	O
Cmax	O
of	O
duloxetine	S-drug
.	O

Some	O
quinolone	B-group
antibiotics	E-group
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
these	O
combinations	O
should	O
be	O
avoided	O
.	O

Inhibitors	O
of	O
CYP2D6	O
:	O
Because	O
CYP2D6	O
is	O
involved	O
in	O
duloxetine	S-drug
metabolism	O
,	O
concomitant	O
use	O
of	O
duloxetine	S-drug
with	O
potent	O
inhibitors	O
of	O
CYP2D6	O
may	O
result	O
in	O
higher	O
concentrations	O
of	O
duloxetine	S-drug
.	O

Paroxetine	S-drug-ME-1
(	O
20	O
mg	O
QD	O
)	O
increased	O
the	O
concentration	O
of	O
duloxetine	S-drug-ME-2
(	O
40	O
mg	O
QD	O
)	O
by	O
about	O
60	O
%	O
,	O
and	O
greater	O
degrees	O
of	O
inhibition	O
are	O
expected	O
with	O
higher	O
doses	O
of	O
paroxetine	S-drug
.	O

Similar	O
effects	O
would	O
be	O
expected	O
with	O
other	O
potent	O
CYP2D6	O
inhibitors	O
(	O
e.g	O
.	O
,	O
fluoxetine	S-drug
,	O
quinidine	S-drug
)	O
.	O

Potential	O
for	O
Duloxetine	S-drug
to	O
Affect	O
Other	O
Drugs	O
:	O
Drugs	O
Metabolized	O
by	O
CYP1A2	O
:	O
In	O
vitro	O
drug	O
interaction	O
studies	O
demonstrate	O
that	O
duloxetine	S-drug
does	O
not	O
induce	O
CYP1A2	O
activity	O
,	O
and	O
it	O
is	O
unlikely	O
to	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
the	O
metabolism	O
of	O
CYP1A2	O
substrates	O
.	O

Drugs	O
Metabolized	O
by	O
CYP2D6	O
:	O
Duloxetine	S-drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP2D6	O
.	O

When	O
duloxetine	S-drug-ME-1
was	O
administered	O
(	O
at	O
a	O
dose	O
of	O
60	O
mg	O
BID	O
)	O
in	O
conjunction	O
with	O
a	O
single	O
50	O
-	O
mg	O
dose	O
of	O
desipramine	S-drug-ME-2
,	O
a	O
CYP2D6	O
substrate	O
,	O
the	O
AUC	O
of	O
desipramine	S-drug
increased	O
3	O
-	O
fold	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
Duloxetine	S-drug-AD-1
with	O
other	O
drugs	O
that	O
are	O
extensively	O
metabolized	O
by	O
this	O
isozyme	O
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
index	O
,	O
including	O
certain	O
antidepressants	S-group-AD-2
(	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
[	O
TCAs	S-group-AD-2
]	O
,	O
such	O
as	O
nortriptyline	S-drug-AD-2
,	O
amitriptyline	S-drug-AD-2
,	O
and	O
imipramine	S-drug-AD-2
)	O
,	O
phenothiazines	S-group-AD-2
and	O
Type	B-group-AD-2
1C	I-group-AD-2
antiarrhythmics	E-group-AD-2
(	O
e.g	O
.	O
,	O
propafenone	S-drug-AD-2
,	O
flecainide	S-drug-AD-2
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Plasma	O
TCA	S-group
concentrations	O
may	O
need	O
to	O
be	O
monitored	O
and	O
the	O
dose	O
of	O
the	O
TCA	S-group
may	O
need	O
to	O
be	O
reduced	O
if	O
a	O
TCA	S-group-AD-1
is	O
co	O
-	O
administered	O
with	O
Duloxetine	S-drug-AD-2
.	O

Because	O
of	O
the	O
risk	O
of	O
serious	O
ventricular	O
arrhythmias	O
and	O
sudden	O
death	O
potentially	O
associated	O
with	O
elevated	O
plasma	O
levels	O
of	O
thioridazine	S-drug
,	O
Duloxetine	S-drug-AD-1
and	O
thioridazine	S-drug-AD-2
should	O
not	O
be	O
co	O
-	O
administered	O
.	O

Drugs	O
Metabolized	O
by	O
CYP3A	O
:	O
Results	O
of	O
in	O
vitro	O
studies	O
demonstrate	O
that	O
duloxetine	S-drug
does	O
not	O
inhibit	O
or	O
induce	O
CYP3A	O
activity	O
.	O

Duloxetine	S-drug
May	O
Have	O
a	O
Clinically	O
Important	O
Interaction	O
with	O
the	O
Following	O
Other	O
Drugs	O
:	O
Alcohol	S-drug
:	O
When	O
Duloxetine	S-drug
and	O
ethanol	S-drug
were	O
administered	O
several	O
hours	O
apart	O
so	O
that	O
peak	O
concentrations	O
of	O
each	O
would	O
coincide	O
,	O
Duloxetine	S-drug
did	O
not	O
increase	O
the	O
impairment	O
of	O
mental	O
and	O
motor	O
skills	O
caused	O
by	O
alcohol	S-drug
.	O

In	O
the	O
Duloxetine	S-drug
clinical	O
trials	O
database	O
,	O
three	O
Duloxetine	S-drug
-	O
treated	O
patients	O
had	O
liver	O
injury	O
as	O
manifested	O
by	O
ALT	O
and	O
total	O
bilirubin	O
elevations	O
,	O
with	O
evidence	O
of	O
obstruction	O
.	O

Substantial	O
intercurrent	O
ethanol	S-drug
use	O
was	O
present	O
in	O
each	O
of	O
these	O
cases	O
,	O
and	O
this	O
may	O
have	O
contributed	O
to	O
the	O
abnormalities	O
seen	O
.	O

CNS	O
Acting	O
Drugs	O
:	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Duloxetine	S-drug
,	O
it	O
should	O
be	O
used	O
with	O
caution	O
when	O
it	O
is	O
taken	O
in	O
combination	O
with	O
or	O
substituted	O
for	O
other	O
centrally	O
acting	O
drugs	O
,	O
including	O
those	O
with	O
a	O
similar	O
mechanism	O
of	O
action	O
.	O

Potential	O
for	O
Interaction	O
with	O
Drugs	O
that	O
Affect	O
Gastric	O
Acidity	O
:	O
Duloxetine	S-drug
has	O
an	O
enteric	O
coating	O
that	O
resists	O
dissolution	O
until	O
reaching	O
a	O
segment	O
of	O
the	O
gastrointestinal	O
tract	O
where	O
the	O
pH	O
exceeds	O
5.5	O
.	O

In	O
extremely	O
acidic	O
conditions	O
,	O
Duloxetine	S-drug
,	O
unprotected	O
by	O
the	O
enteric	O
coating	O
,	O
may	O
undergo	O
hydrolysis	O
to	O
form	O
naphthol	O
.	O

Caution	O
is	O
advised	O
in	O
using	O
Duloxetine	S-drug
in	O
patients	O
with	O
conditions	O
that	O
may	O
slow	O
gastric	O
emptying	O
(	O
e.g	O
.	O
,	O
some	O
diabetics	O
)	O
.	O

Drugs	O
that	O
raise	O
the	O
gastrointestinal	O
pH	O
may	O
lead	O
to	O
an	O
earlier	O
release	O
of	O
duloxetine	S-drug
.	O

However	O
,	O
co	O
-	O
administration	O
of	O
Duloxetine	S-drug
with	O
aluminum	S-drug
-	O
and	O
magnesium	S-drug
-	O
containing	O
antacids	S-group
(	O
51	O
mEq	O
)	O
or	O
Duloxetine	S-drug
with	O
famotidine	S-drug
,	O
had	O
no	O
significant	O
effect	O
on	O
the	O
rate	O
or	O
extent	O
of	O
duloxetine	S-drug
absorption	O
after	O
administration	O
of	O
a	O
40	O
-	O
mg	O
oral	O
dose	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
concomitant	O
administration	O
of	O
proton	B-group
pump	I-group
inhibitors	E-group
affects	O
duloxetine	S-drug
absorption	O
.	O

Synergism	O
between	O
xanthine	B-group-EF-1
bronchodilators	E-group-EF-1
(	O
e.g	O
.	O
,	O
theophylline	S-drug-EF-1
)	O
,	O
ephedrine	S-drug-EF-1
,	O
and	O
other	O
sympathomimetic	B-group-EF-2
bronchodilators	E-group-EF-2
has	O
been	O
reported	O
.	O

This	O
should	O
be	O
considered	O
whenever	O
these	O
agents	O
are	O
prescribed	O
concomitantly	O
.	O

Concurrent	O
administration	O
of	O
dyphylline	S-drug-ME-1
and	O
probenecid	S-drug-ME-2
,	O
which	O
competes	O
for	O
tubular	O
secretion	O
,	O
has	O
been	O
shown	O
to	O
increase	O
the	O
plasma	O
half	O
-	O
life	O
of	O
dyphylline	S-drug
.	O

Phospholine	B-drug-EF-1
Iodide	E-drug-EF-1
potentiates	O
other	O
cholinesterase	B-group-EF-2
inhibitors	E-group-EF-2
such	O
as	O
succinylcholine	S-drug-EF-2
or	O
organophosphate	S-drug_n-EF-2
and	O
carbamate	B-drug_n-EF-2
insecticides	O
.	O

Patients	O
undergoing	O
systemic	O
anticholinesterase	O
treatment	O
should	O
be	O
warned	O
of	O
the	O
possible	O
additive	O
effects	O
of	O
Phospholine	B-drug
Iodide	E-drug
.	O

Drug	O
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
Soliris	S-brand
.	O

There	O
is	O
no	O
known	O
drug	O
interference	O
with	O
standard	O
clinical	O
laboratory	O
tests	O
.	O

Steroids	S-group-EF-1
enhance	O
the	O
renal	O
toxicity	O
of	O
edetate	B-drug-EF-2
calcium	I-drug-EF-2
disodium	E-drug-EF-2
in	O
animals	O
.	O
7	O
Edetate	B-drug-ME-1
calcium	I-drug-ME-1
disodium	E-drug-ME-1
interferes	O
with	O
the	O
action	O
of	O
zinc	B-drug-ME-2
insulin	E-drug-ME-2
preparations	O
by	O
chelating	O
the	O
zinc	S-drug
.	O
7	O

Care	O
should	O
be	O
given	O
when	O
administering	O
this	O
drug	O
to	O
patients	O
with	O
symptoms	O
of	O
myasthenic	O
weakness	O
who	O
are	O
also	O
on	O
anticholinesterase	B-group
drugs	E-group
.	O

Since	O
symptoms	O
of	O
anticholinesterase	O
overdose	O
(	O
cholinergic	O
crisis	O
)	O
may	O
mimic	O
underdosage	O
(	O
myasthenic	O
weakness	O
)	O
,	O
their	O
condition	O
may	O
be	O
worsened	O
by	O
the	O
use	O
of	O
this	O
drug	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
RAPTIVA	S-brand
.	O

RAPTIVA	S-brand-AD-1
should	O
not	O
be	O
used	O
with	O
other	O
immunosuppressive	B-group-AD-2
drugs	E-group-AD-2
.	O

Acellular	S-group-AD-1
,	O
live	S-group-AD-1
and	O
live	B-group-AD-1
-	I-group-AD-1
attenuated	I-group-AD-1
vaccines	E-group-AD-1
should	O
not	O
be	O
administered	O
during	O
RAPTIVA	S-brand-AD-2
treatment	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Increases	O
in	O
lymphocyte	O
counts	O
related	O
to	O
the	O
pharmacologic	O
mechanism	O
of	O
action	O
are	O
frequently	O
observed	O
during	O
RAPTIVA	S-brand
treatment	O
.	O

Efavirenz	S-drug
has	O
been	O
shown	O
in	O
vivo	O
to	O
induce	O
CYP3A4	O
.	O

Other	O
compounds	O
that	O
are	O
substrates	O
of	O
CYP3A4	O
may	O
have	O
decreased	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
SUSTIVA	S-brand
(	O
efavirenz	S-drug
)	O
.	O

In	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
efavirenz	S-drug
inhibits	O
2C9	O
,	O
2C19	O
,	O
and	O
3A4	O
isozymes	O
in	O
the	O
range	O
of	O
observed	O
efavirenz	S-drug
plasma	O
concentrations	O
.	O

Coadministration	O
of	O
efavirenz	S-drug
with	O
drugs	O
primarily	O
metabolized	O
by	O
these	O
isozymes	O
may	O
result	O
in	O
altered	O
plasma	O
concentrations	O
of	O
the	O
coadministered	O
drug	O
.	O

Therefore	O
,	O
appropriate	O
dose	O
adjustments	O
may	O
be	O
necessary	O
for	O
these	O
drugs	O
.	O

Drugs	O
which	O
induce	O
CYP3A4	O
activity	O
(	O
eg	O
,	O
phenobarbital	S-drug-ME-1
,	O
rifampin	S-drug-ME-1
,	O
rifabutin	S-drug-ME-1
)	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
efavirenz	S-drug-ME-2
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
.	O

Drug	O
interactions	O
with	O
SUSTIVA	S-brand
are	O
summarized	O
in	O
Table	O
5	O
.	O

Table	O
5a	O
:	O
Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
SUSTIVA	S-brand

Drug	O
Class	O

Drugs	O
Within	O
Class	O
Not	O
To	O
Be	O
Coadministered	O
With	O
SUSTIVA	S-brand

Antihistamines	S-group
:	O
Benzodiazepines	S-group
GI	O
Motility	O
Agents	O
Anti	B-group
-	I-group
Migraine	E-group
Antifungal	S-group

astemizole	S-drug
midazolam	S-drug
,	O
triazolam	S-drug
cisapride	S-drug
ergot	O
derivatives	O
voriconazole	S-drug

Established	O
Drug	O
Interactions	O

Drug	O
Name	O

Clinical	O
Comment	O

When	O
coadministered	O
with	O
SUSTIVA	S-brand
in	O
treatment	O
-	O
naive	O
patients	O
,	O
the	O
recommended	O
dose	O
of	O
atazanavir	S-drug
is	O
300	O
mg	O
with	O
ritonavir	S-drug
100	O
mg	O
and	O
SUSTIVA	S-brand
600	O
mg	O
(	O
all	O
once	O
daily	O
)	O
.	O

Dosing	O
recommendations	O
for	O
SUSTIVA	S-brand
and	O
atazanavir	S-drug
in	O
treatment	O
-	O
experienced	O
patients	O
have	O
not	O
been	O
established	O
.	O

Established	O
Drug	O
Interactions	O
(	O
continued	O
)	O

Drug	O
Name	O

Clinical	O
Comment	O

clarithromycin	S-drug
concentration	O

Plasma	O
concentrations	O
decreased	O
by	O
SUSTIVA	S-brand
;	O

clinical	O
significance	O
unknown	O
.	O

In	O
uninfected	O
volunteers	O
,	O
46	O
%	O
developed	O
rash	O
while	O
receiving	O
SUSTIVA	S-brand-EF-1
and	O
clarithromycin	S-drug-EF-2
.	O

No	O
dose	O
adjustment	O
of	O
SUSTIVA	S-brand
is	O
recommended	O
when	O
given	O
with	O
clarithromycin	S-drug
.	O

Alternatives	O
to	O
clarithromycin	S-drug
,	O
such	O
as	O
azithromycin	S-drug
,	O
should	O
be	O
considered	O
.	O

Other	O
macrolide	B-group
antibiotics	E-group
,	O
such	O
as	O
erythromycin	S-drug
,	O
have	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	S-brand
.	O

14	O
-	O
OH	O
metabolite	O
concentration	O

indinavir	S-drug
concentration	O

The	O
optimal	O
dose	O
of	O
indinavir	S-drug
,	O
when	O
given	O
in	O
combination	O
with	O
SUSTIVA	S-brand
,	O
is	O
not	O
known	O
.	O

Increasing	O
the	O
indinavir	S-drug
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	S-drug-ME-1
metabolism	O
due	O
to	O
SUSTIVA	S-brand-ME-2
.	O

When	O
indinavir	S-drug-ME-1
at	O
an	O
increased	O
dose	O
(	O
1000	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
with	O
SUSTIVA	S-brand-ME-2
(	O
600	O
mg	O
once	O
daily	O
)	O
,	O
the	O
indinavir	S-drug
AUC	O
and	O
Cmin	O
were	O
decreased	O
on	O
average	O
by	O
33	O
-	O
46	O
%	O
and	O
39	O
-	O
57	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
when	O
indinavir	S-drug
(	O
800	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
alone	O
.	O

Lopinavir	S-drug
/	O
ritonavir	S-drug

lopinavir	S-drug
concentration	O

A	O
dose	O
increase	O
of	O
lopinavir	S-drug-AD-1
/	O
ritonavir	S-drug-AD-1
to	O
533	O
/	O
133	O
mg	O
(	O
4	O
capsules	O
or	O
6.5	O
mL	O
)	O
twice	O
daily	O
taken	O
with	O
food	O
is	O
recommended	O
when	O
used	O
in	O
combination	O
with	O
SUSTIVA	S-brand-AD-2
.	O

methadone	S-drug
concentration	O

Coadministration	O
in	O
HIV	O
-	O
infected	O
individuals	O
with	O
a	O
history	O
of	O
injection	O
drug	O
use	O
resulted	O
in	O
decreased	O
plasma	O
levels	O
of	O
methadone	S-drug
and	O
signs	O
of	O
opiate	S-group
withdrawal	O
.	O

Methadone	S-drug
dose	O
was	O
increased	O
by	O
a	O
mean	O
of	O
22	O
%	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O

Patients	O
should	O
be	O
monitored	O
for	O
signs	O
of	O
withdrawal	O
and	O
their	O
methadone	S-drug
dose	O
increased	O
as	O
required	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O

Ethinyl	B-drug
estradiol	E-drug

ethinyl	B-drug
estradiol	E-drug
concentration	O

Plasma	O
concentrations	O
increased	O
by	O
SUSTIVA	S-brand
(	O
efavirenz	S-drug
)	O
;	O

clinical	O
significance	O
unknown	O
.	O

Because	O
the	O
potential	O
interaction	O
of	O
efavirenz	S-drug-AD-1
with	O
oral	O
contraceptives	S-group-AD-2
has	O
not	O
been	O
fully	O
characterized	O
,	O
a	O
reliable	O
method	O
of	O
barrier	O
contraception	O
should	O
be	O
used	O
in	O
addition	O
to	O
oral	O
contraceptives	S-group
.	O

rifabutin	S-drug
concentration	O

Increase	O
daily	O
dose	O
of	O
rifabutin	S-drug
by	O
50	O
%	O
.	O

Consider	O
doubling	O
the	O
rifabutin	S-drug
dose	O
in	O
regimens	O
where	O
rifabutin	S-drug
is	O
given	O
2	O
or	O
3	O
times	O
a	O
week	O
.	O

efavirenz	S-drug
concentration	O

Clinical	O
significance	O
of	O
reduced	O
efavirenz	S-drug
concentrations	O
unknown	O
.	O

ritonavir	S-drug
concentration	O

Combination	O
was	O
associated	O
with	O
a	O
higher	O
frequency	O
of	O
adverse	O
clinical	O
experiences	O
(	O
eg	O
,	O
dizziness	O
,	O
nausea	O
,	O
paresthesia	O
)	O
and	O
laboratory	O
abnormalities	O
(	O
elevated	O
liver	O
enzymes	O
)	O
.	O

Monitoring	O
of	O
liver	O
enzymes	O
is	O
recommended	O
when	O
SUSTIVA	S-brand-AD-1
is	O
used	O
in	O
combination	O
with	O
ritonavir	S-drug-AD-2
.	O

efavirenz	S-drug
concentration	O

saquinavir	S-drug
concentration	O

Should	O
not	O
be	O
used	O
as	O
sole	O
protease	B-group
inhibitor	E-group
in	O
combination	O
with	O
SUSTIVA	S-brand
.	O

sertraline	S-drug
concentration	O

Increases	O
in	O
sertraline	S-drug
dose	O
should	O
be	O
guided	O
by	O
clinical	O
response	O
.	O

Other	O
Potentially	O
Clinically	O
Significant	O
Drug	O
or	O
Herbal	O
Product	O
Interactions	O
With	O
SUSTIVAb	O

Anticoagulants	S-group
:	O
Warfarin	S-drug

Plasma	O
concentrations	O
and	O
effects	O
potentially	O
increased	O
or	O
decreased	O
by	O
SUSTIVA	S-brand
.	O

Anticonvulsants	S-group
:	O
Phenytoin	S-drug
Phenobarbital	S-drug
Carbamazepine	S-drug

Potential	O
for	O
reduction	O
in	O
anticonvulsant	S-group-ME-1
and	O
/	O
or	O
efavirenz	S-drug-ME-2
plasma	O
levels	O
;	O

periodic	O
monitoring	O
of	O
anticonvulsant	S-group
plasma	O
levels	O
should	O
be	O
conducted	O
.	O

Antifungals	S-group
:	O
Itraconazole	S-drug
Ketoconazole	S-drug

Drug	O
interaction	O
studies	O
with	O
SUSTIVA	S-brand
and	O
these	O
imidazole	S-group
and	O
triazole	B-group
antifungals	E-group
have	O
not	O
been	O
conducted	O
.	O

SUSTIVA	S-brand-ME-1
has	O
the	O
potential	O
to	O
decrease	O
plasma	O
concentrations	O
of	O
itraconazole	S-drug-ME-2
and	O
ketoconazole	S-drug-ME-2
.	O

Anti	B-group
-	I-group
HIV	I-group
protease	I-group
inhibitors	E-group
:	O
Saquinavir	S-drug
/	O
ritonavir	S-drug
combination	O

No	O
pharmacokinetic	O
data	O
are	O
available	O
.	O

SUSTIVAhas	O
the	O
potential	O
to	O
decrease	O
serum	O
concentrations	O
of	O
amprenavir	S-drug
.	O

Non	B-group
-	I-group
nucleoside	I-group
reverse	I-group
transcriptase	I-group
inhibitors	E-group

No	O
studies	O
have	O
been	O
performed	O
with	O
other	O
NNRTIs	S-group
.	O

St.	O
John	O
s	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O

Expected	O
to	O
substantially	O
decrease	O
plasma	O
levels	O
of	O
efavirenz	S-drug
;	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	S-brand
.	O

a	O
See	O
Tables	O
1	O
and	O
2	O
.	O

b	O
This	O
table	O
is	O
not	O
all	O
-	O
inclusive	O
.	O

Other	O
Drugs	O
:	O
Based	O
on	O
the	O
results	O
of	O
drug	O
interaction	O
studies	O
,	O
no	O
dosage	O
adjustment	O
is	O
recommended	O
when	O
SUSTIVA	S-brand
(	O
efavirenz	S-drug
)	O
is	O
given	O
with	O
the	O
following	O
:	O
aluminum	B-group
/	I-group
magnesium	I-group
hydroxide	I-group
antacids	E-group
,	O
azithromycin	S-drug
,	O
cetirizine	S-drug
,	O
famotidine	S-drug
,	O
fluconazole	S-drug
,	O
lamivudine	S-drug
,	O
lorazepam	S-drug
,	O
nelfinavir	S-drug
,	O
paroxetine	S-drug
,	O
and	O
zidovudine	S-drug
.	O

Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
SUSTIVA	S-brand
and	O
NRTIs	S-group
other	O
than	O
lamivudine	S-drug
and	O
zidovudine	S-drug
.	O

Clinically	O
significant	O
interactions	O
would	O
not	O
be	O
expected	O
since	O
the	O
NRTIs	S-group
are	O
metabolized	O
via	O
a	O
different	O
route	O
than	O
efavirenz	S-drug
and	O
would	O
be	O
unlikely	O
to	O
compete	O
for	O
the	O
same	O
metabolic	O
enzymes	O
and	O
elimination	O
pathways	O
.	O

The	O
potential	O
for	O
drug	O
interactions	O
with	O
EMTRIVA	S-brand
has	O
been	O
studied	O
in	O
combination	O
with	O
indinavir	S-drug
,	O
stavudine	S-drug
,	O
famciclovir	S-drug
,	O
and	O
tenofovir	B-drug
disoproxil	I-drug
fumarate	E-drug
.	O

There	O
were	O
no	O
clinically	O
significant	O
drug	O
interactions	O
for	O
any	O
of	O
these	O
drugs	O

Hypotension	O
:	O
Patients	O
on	O
Diuretic	O
Therapy	O
:	O
Patients	O
on	O
diuretics	S-drug-EF-1
and	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
enalapril	S-drug-EF-2
or	O
enalaprilat	S-drug-EF-2
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
enalapril	S-drug-EF-1
or	O
enalaprilat	S-drug-EF-1
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	S-drug-EF-2
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
enalapril	S-drug
or	O
enalaprilat	S-drug
.	O

If	O
it	O
is	O
necessary	O
to	O
continue	O
the	O
diuretic	S-group
,	O
provide	O
close	O
medical	O
supervision	O
after	O
the	O
initial	O
dose	O
for	O
at	O
least	O
two	O
hours	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
for	O
at	O
least	O
an	O
additional	O
hour..	O

Agents	O
Causing	O
Renin	O
Release	O
:	O
The	O
antihypertensive	O
effect	O
of	O
enalapril	S-drug-EF-1
and	O
enalapril	S-drug-EF-1
IV	O
is	O
augmented	O
by	O
antihypertensive	B-group-EF-2
agents	E-group-EF-2
that	O
cause	O
renin	O
release	O
(	O
e.g	O
.	O
,	O
diuretics	S-group-EF-2
)	O
.	O

Non	B-group
-	I-group
steroidal	I-group
Anti	I-group
-	I-group
inflammatory	I-group
Agents	E-group
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
,	O
the	O
co	O
-	O
administration	O
of	O
enalapril	S-drug-EF-2
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O

These	O
effects	O
are	O
usually	O
reversible	O
.	O

In	O
a	O
clinical	O
pharmacology	O
study	O
,	O
indomethacin	S-drug
or	O
sulindac	S-drug
was	O
administered	O
to	O
hypertensive	O
patients	O
receiving	O
VASOTEC	S-brand
.	O

In	O
this	O
study	O
there	O
was	O
no	O
evidence	O
of	O
a	O
blunting	O
of	O
the	O
antihypertensive	O
action	O
of	O
VASOTEC	S-brand
.	O

However	O
,	O
reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	S-group-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
inhibitors	E-group-AD-2
.	O

Other	O
Cardiovascular	O
Agents	O
:	O
Enalapril	S-drug
and	O
enalapril	S-drug
IV	O
have	O
been	O
used	O
concomitantly	O
with	O
beta	B-group
adrenergic	I-group
-	I-group
blocking	I-group
agents	E-group
,	O
methyldopa	S-drug
,	O
nitrates	S-group
,	O
calcium	B-group
-	I-group
blocking	I-group
agents	E-group
,	O
hydralazine	S-drug
,	O
prazosin	S-drug
and	O
digoxin	S-drug
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Enalapril	S-drug
IV	O
has	O
been	O
used	O
concomitantly	O
with	O
digitalis	S-group
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
reactions	O
.	O

Agents	O
Increasing	O
Serum	O
Potassium	O
:	O
Enalapril	S-drug-EF-1
and	O
enalapril	S-drug-EF-1
IV	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-group-EF-2
-	I-group-EF-2
type	I-group-EF-2
diuretics	E-group-EF-2
.	O

Potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
(	O
e.g	O
.	O
,	O
spironolactone	S-drug
,	O
triamterene	S-drug
,	O
or	O
amiloride	S-drug
)	O
,	O
potassium	S-drug
supplements	O
,	O
or	O
potassium	S-drug
-	O
containing	O
salt	O
substitutes	O
may	O
lead	O
to	O
significant	O
increases	O
in	O
serum	O
potassium	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	O
.	O

Potassium	O
sparing	O
agents	O
should	O
generally	O
not	O
be	O
used	O
in	O
patients	O
with	O
heart	O
failure	O
receiving	O
enalapril	S-drug
.	O

Lithium	S-drug
:	O
Lithium	S-drug
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	S-drug-EF-1
concomitantly	O
with	O
drugs	O
which	O
cause	O
elimination	O
of	O
sodium	O
,	O
including	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
.	O

It	O
is	O
recommended	O
that	O
serum	O
lithium	S-drug
levels	O
be	O
monitored	O
frequently	O
if	O
enalapril	S-drug-AD-1
is	O
administered	O
concomitantly	O
with	O
lithium	S-drug-AD-2
.	O

The	O
action	O
of	O
nondepolarizing	O
relaxants	O
is	O
augmented	O
by	O
Enflurane	S-drug
.	O

Less	O
than	O
the	O
usual	O
amounts	O
of	O
these	O
medicines	O
should	O
be	O
used	O
.	O

If	O
the	O
usual	O
amounts	O
of	O
nondepolarizing	O
relaxants	O
are	O
given	O
,	O
the	O
time	O
for	O
recovery	O
from	O
neuromuscular	O
blockade	O
will	O
be	O
longer	O
in	O
the	O
presence	O
of	O
Enflurane	S-drug
than	O
when	O
halothane	S-drug
or	O
nitrous	B-drug
oxide	E-drug
with	O
a	O
balanced	O
technique	O
are	O
used	O
.	O

CYP450	O
Metabolized	O
Drugs	O
Results	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
suggest	O
that	O
enfuvirtide	S-drug
is	O
unlikely	O
to	O
have	O
significant	O
drug	O
interactions	O
with	O
concomitantly	O
administered	O
drugs	O
metabolized	O
by	O
CYP450	O
enzymes	O
.	O

Antiretroviral	B-group
Agents	E-group
:	O
No	O
drug	O
interactions	O
with	O
other	O
antiretroviral	B-group
medications	E-group
have	O
been	O
identified	O
that	O
would	O
warrant	O
alteration	O
of	O
either	O
the	O
enfuvirtide	S-drug
dose	O
or	O
the	O
dose	O
of	O
the	O
other	O
antiretroviral	B-group
medication	E-group
.	O

Bismuth	S-drug
:	O
Bismuth	B-drug-ME-1
subsalicylate	E-drug-ME-1
,	O
given	O
concomitantly	O
with	O
enoxacin	S-drug-ME-2
or	O
60	O
minutes	O
following	O
enoxacin	S-drug
administration	O
,	O
decreased	O
enoxacin	S-drug
bioavailability	O
by	O
approximately	O
25	O
%	O
.	O

Thus	O
,	O
concomitant	O
administration	O
of	O
enoxacin	S-drug-AD-1
and	O
bismuth	B-drug-AD-2
subsalicylate	E-drug-AD-2
should	O
be	O
avoided	O
.	O

Caffeine	S-drug
:	O
Enoxacin	S-drug-ME-1
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
450	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	S-group-ME-2
.	O

In	O
a	O
multiple	O
-	O
dose	O
study	O
,	O
enoxacin	S-drug-ME-1
caused	O
a	O
dose	O
-	O
related	O
increase	O
in	O
the	O
mean	O
elimination	O
half	O
-	O
life	O
of	O
caffeine	S-drug-ME-2
,	O
thereby	O
decreasing	O
the	O
clearance	O
of	O
caffeine	S-drug
by	O
up	O
to	O
80	O
%	O
and	O
leading	O
to	O
a	O
five	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
the	O
half	O
-	O
life	O
of	O
caffeine	S-drug
.	O

Trough	O
plasma	O
enoxacin	S-drug
levels	O
were	O
also	O
20	O
%	O
higher	O
when	O
caffeine	S-drug-ME-1
and	O
enoxacin	S-drug-ME-2
were	O
administered	O
concomitantly	O
.	O

Caffeine	S-drug
-	O
related	O
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
consuming	O
caffeine	S-drug-EF-1
while	O
on	O
therapy	O
with	O
enoxacin	S-drug-EF-2
.	O

Cyclosporine	S-drug
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	S-drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	S-drug-ME-1
with	O
other	O
members	O
of	O
the	O
quinolone	B-group-ME-2
class	E-group-ME-2
.	O

Digoxin	S-drug
:	O
Enoxacin	S-drug-ME-1
may	O
raise	O
serum	O
digoxin	S-drug-ME-2
levels	O
in	O
some	O
individuals	O
.	O

If	O
signs	O
and	O
symptoms	O
suggestive	O
of	O
digoxin	S-drug
toxicity	O
occur	O
when	O
enoxacin	S-drug-EF-1
and	O
digoxin	S-drug-EF-2
are	O
given	O
concomitantly	O
,	O
physicians	O
are	O
advised	O
to	O
obtain	O
serum	O
digoxin	S-drug
levels	O
and	O
adjust	O
digoxin	S-drug
doses	O
appropriately	O
.	O

Non	B-group
-	I-group
steroidal	I-group
anti	I-group
-	I-group
inflammatory	I-group
agents	E-group
:	O
Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
enoxacin	S-drug-EF-1
concomitantly	O
with	O
the	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drug	E-group
fenbufen	S-drug-EF-2
.	O

Animal	O
studies	O
also	O
suggest	O
an	O
increased	O
potential	O
for	O
seizures	O
when	O
these	O
two	O
drugs	O
are	O
given	O
concomitantly	O
.	O

Fenbufen	S-drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
at	O
this	O
time	O
.	O

Sucralfate	S-drug
and	O
antacids	S-group
:	O
Quinolones	S-group
form	O
chelates	O
with	O
metal	O
cations	O
.	O

Therefore	O
,	O
administration	O
of	O
quinolones	S-group
with	O
antacids	S-group
containing	O
calcium	S-drug
,	O
magnesium	S-drug
,	O
or	O
aluminum	S-drug
;	O

with	O
sucralfate	S-drug
;	O

with	O
divalent	O
or	O
trivalent	O
cations	O
such	O
as	O
iron	S-drug
;	O

or	O
with	O
multivitamins	S-group
containing	O
zinc	S-drug-ME-1
may	O
substantially	O
interfere	O
with	O
drug	O
absorption	O
and	O
result	O
in	O
insufficient	O
plasma	O
and	O
tissue	O
quinolone	S-group-ME-2
concentrations	O
.	O

Antacids	S-group
containing	O
aluminum	B-drug-ME-1
hydroxide	E-drug-ME-1
and	O
magnesium	B-drug-ME-1
hydroxide	E-drug-ME-1
reduce	O
the	O
oral	O
absorption	O
of	O
enoxacin	S-drug-ME-2
by	O
75	O
%	O
.	O

The	O
oral	O
bioavailability	O
of	O
enoxacin	S-drug-ME-1
is	O
reduced	O
by	O
60	O
%	O
with	O
coadministration	O
of	O
ranitidine	S-drug-ME-2
.	O

These	O
agents	O
should	O
not	O
be	O
taken	O
for	O
8	O
hours	O
before	O
or	O
for	O
2	O
hours	O
after	O
enoxacin	S-drug
administration	O
.	O

Theophylline	S-drug
:	O
Enoxacin	S-drug-ME-1
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
450	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	S-group-ME-2
.	O

Enoxacin	S-drug-ME-1
interferes	O
with	O
the	O
metabolism	O
of	O
theophylline	S-drug-ME-2
resulting	O
in	O
a	O
42	O
%	O
to	O
74	O
%	O
dose	O
-	O
related	O
decrease	O
in	O
theophylline	S-drug
clearance	O
and	O
a	O
subsequent	O
260	O
%	O
to	O
350	O
%	O
increase	O
in	O
serum	O
theophylline	O
levels	O
.	O

Theophylline	S-drug
-	O
related	O
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
when	O
theophylline	S-drug-EF-1
and	O
enoxacin	S-drug-EF-2
were	O
coadministered	O
.	O

Warfarin	S-drug
:	O
Quinolones	S-group-ME-1
,	O
including	O
enoxacin	S-drug-ME-1
,	O
decrease	O
the	O
clearance	O
of	O
R	B-drug-ME-2
-	I-drug-ME-2
warfarin	E-drug-ME-2
,	O
the	O
less	O
active	O
isomer	O
of	O
racemic	O
warfarin	S-drug
.	O

Enoxacin	S-drug
does	O
not	O
affect	O
the	O
clearance	O
of	O
the	O
active	O
S	O
-	O
isomer	O
,	O
and	O
changes	O
in	O
clotting	O
time	O
have	O
not	O
been	O
observed	O
when	O
enoxacin	S-drug
and	O
warfarin	S-drug
were	O
coadministered	O
.	O

Nevertheless	O
,	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
monitored	O
when	O
warfarin	S-drug-AD-1
or	O
its	O
derivatives	O
and	O
enoxacin	S-drug-AD-2
are	O
given	O
concomitantly	O
.	O

Unless	O
really	O
needed	O
,	O
agents	O
which	O
may	O
enhance	O
the	O
risk	O
of	O
hemorrhage	O
should	O
be	O
discontinued	O
prior	O
to	O
initiation	O
of	O
Lovenox	S-brand
Injection	O
therapy	O
.	O

These	O
agents	O
include	O
medications	O
such	O
as	O
:	O
anticoagulants	S-group
,	O
platelet	B-group
inhibitors	E-group
including	O
acetylsalicylic	B-drug
acid	E-drug
,	O
sali	O
-	O
cylates	O
,	O
NSAIDs	S-group
(	O
including	O
ketorolac	B-drug
tromethamine	E-drug
)	O
,	O
dipyridamole	S-drug
,	O
or	O
sulfinpyrazone	S-drug
.	O

If	O
co	O
-	O
administration	O
is	O
essential	O
,	O
conduct	O
close	O
clinical	O
and	O
laboratory	O
monitoring	O

In	O
vitro	O
studies	O
of	O
human	O
CYP	O
enzymes	O
showed	O
that	O
entacapone	S-drug
inhibited	O
the	O
CYP	O
enzymes	O
1A2	O
,	O
2A6	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
and	O
3A	O
only	O
at	O
very	O
high	O
concentrations	O
(	O
IC50	O
from	O
200	O
to	O
over	O
1000	O
uM	O
;	O

an	O
oral	O
200	O
mg	O
dose	O
achieves	O
a	O
highest	O
level	O
of	O
approximately	O
5	O
uM	O
in	O
people	O
)	O
;	O

these	O
enzymes	O
would	O
therefore	O
not	O
be	O
expected	O
to	O
be	O
inhibited	O
in	O
clinical	O
use	O
.	O

Protein	O
Binding	O
:	O
Entacapone	S-drug
is	O
highly	O
protein	O
bound	O
(	O
98	O
%	O
)	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
no	O
binding	O
displacement	O
between	O
entacapone	S-drug
and	O
other	O
highly	O
bound	O
drugs	O
,	O
such	O
as	O
warfarin	S-drug
,	O
salicylic	B-drug
acid	E-drug
,	O
phenylbutazone	S-drug
,	O
and	O
diazepam	S-drug
.	O

Drugs	O
Metabolized	O
by	O
Catechol	O
-	O
O	O
-	O
methyltransferase	O
(	O
COMT	O
)	O
:	O
Hormone	O
levels	O
:	O
Levodopa	S-drug
is	O
known	O
to	O
depress	O
prolactin	O
secretion	O
and	O
increase	O
growth	O
hormone	O
levels	O
.	O

Treatment	O
with	O
entacapone	S-drug
coadministered	O
with	O
levodopa	S-drug
/	O
dopa	B-group
decarboxylase	I-group
inhibitor	E-group
does	O
not	O
change	O
these	O
effects	O
.	O

No	O
interaction	O
was	O
noted	O
with	O
the	O
MAO	B-group
-	I-group
B	I-group
inhibitor	E-group
selegiline	S-drug
in	O
two	O
multiple	O
-	O
dose	O
interaction	O
studies	O
when	O
entacapone	S-drug
was	O
coadministered	O
with	O
a	O
levodopa	S-drug
/	O
dopa	B-group
decarboxylase	I-group
inhibitor	E-group
(	O
n	O
=	O
29	O
)	O
.	O

More	O
than	O
600	O
Parkinsons	O
disease	O
patients	O
in	O
clinical	O
trials	O
have	O
used	O
selegiline	S-drug
in	O
combination	O
with	O
entacapone	S-drug
and	O
levodopa	S-drug
/	O
dopa	B-group
decarboxylase	I-group
inhibitor	E-group
.	O

As	O
most	O
entacapone	S-drug
excretion	O
is	O
via	O
the	O
bile	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
drugs	O
known	O
to	O
interfere	O
with	O
biliary	O
excretion	O
,	O
glucuronidation	O
,	O
and	O
intestinal	O
beta	O
-	O
glucuronidase	O
are	O
given	O
concurrently	O
with	O
entacapone	S-drug
.	O

These	O
include	O
probenecid	S-drug
,	O
cholestyramine	S-drug
,	O
and	O
some	O
antibiotics	S-group
(	O
e.g	O
.	O
erythromycin	S-drug
,	O
rifamipicin	O
,	O
ampicillin	S-drug
and	O
chloramphenicol	S-drug
)	O
.	O

No	O
interaction	O
with	O
the	O
tricyclic	B-group
antidepressant	E-group
imipramine	S-drug
was	O
shown	O
in	O
a	O
single	O
-	O
dose	O
study	O
with	O
entacapone	S-drug
without	O
coadministered	O
levodopa	S-drug
/	O
dopa	B-group
-	I-group
decarboxylase	I-group
inhibitor	E-group
.	O

Since	O
entecavir	S-drug
is	O
primarily	O
eliminated	O
by	O
the	O
kidneys	O
,	O
coadministration	O
of	O
BARACLUDE	S-brand
with	O
drugs	O
that	O
reduce	O
renal	O
function	O
or	O
compete	O
for	O
active	O
tubular	O
secretion	O
may	O
increase	O
serum	O
concentrations	O
of	O
either	O
entecavir	S-drug
or	O
the	O
coadministered	O
drug	O
.	O

Coadministration	O
of	O
entecavir	S-drug
with	O
lamivudine	S-drug
,	O
adefovir	B-drug
dipivoxil	E-drug
,	O
or	O
tenofovir	B-drug
disoproxil	I-drug
fumarate	E-drug
did	O
not	O
result	O
in	O
significant	O
drug	O
interactions	O
.	O

The	O
effects	O
of	O
coadministration	O
of	O
BARACLUDE	S-brand
with	O
other	O
drugs	O
that	O
are	O
renally	O
eliminated	O
or	O
are	O
known	O
to	O
affect	O
renal	O
function	O
have	O
not	O
been	O
evaluated	O
,	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
adverse	O
events	O
when	O
BARACLUDE	S-brand
is	O
coadministered	O
with	O
such	O
drugs	O
.	O

None	O
Reported	O

Epinephrine	S-drug
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
hyperthyroidism	O
,	O
hypertension	O
and	O
cardiac	O
arrhythmias	O
.	O

All	O
vasopressors	S-group-AD-1
should	O
be	O
used	O
cautiously	O
in	O
patients	O
taking	O
monoamine	B-group-AD-2
oxidase	I-group-AD-2
(	I-group-AD-2
MAO	I-group-AD-2
)	I-group-AD-2
inhibitors	E-group-AD-2
.	O

Epinephrine	S-drug-AD-1
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
other	O
sympathomimetic	B-group-AD-2
drugs	E-group-AD-2
(	O
such	O
as	O
isoproterenol	S-drug-AD-2
)	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
increased	O
toxicity	O
.	O

Combined	O
effects	O
may	O
induce	O
serious	O
cardiac	O
arrhythmias	O
.	O

They	O
may	O
be	O
administered	O
alternately	O
when	O
the	O
preceding	O
effect	O
of	O
other	O
such	O
drug	O
has	O
subsided	O
.	O

Administration	O
of	O
epinephrine	S-drug-EF-1
to	O
patients	O
receiving	O
cyclopropane	S-drug-EF-2
or	O
halogenated	B-group-EF-2
hydrocarbon	I-group-EF-2
general	I-group-EF-2
anesthetics	E-group-EF-2
such	O
as	O
halothane	S-drug-EF-2
which	O
sensitize	O
the	O
myocardium	O
,	O
may	O
induce	O
cardiac	O
arrhythmia..	O

When	O
encountered	O
,	O
such	O
arrhythmias	O
may	O
respond	O
to	O
administration	O
of	O
a	O
beta	B-group
-	I-group
adrenergic	I-group
blocking	I-group
drug	E-group
.	O

Epinephrine	S-drug-AD-1
also	O
should	O
be	O
used	O
cautiously	O
with	O
other	O
drugs	O
(	O
e.g	O
.	O
,	O
digitalis	S-group-AD-2
,	O
glycosides	S-group-AD-2
)	O
that	O
sensitize	O
the	O
myocardium	O
to	O
the	O
actions	O
of	O
sympathomimetic	B-group
drugs	E-group
.	O

Diuretic	B-group-EF-1
agents	E-group-EF-1
may	O
decrease	O
vascular	O
response	O
to	O
pressor	O
drugs	O
such	O
as	O
epinephrine	S-drug-EF-2
.	O

Epinephrine	S-drug-EF-1
may	O
antagonize	O
the	O
neuron	O
blockade	O
produced	O
by	O
guanethidine	S-drug-EF-2
resulting	O
in	O
decreased	O
antihypertensive	O
effect	O
and	O
requiring	O
increased	O
dosage	O
of	O
the	O
latter	O
.	O

ELLENCE	S-brand
when	O
used	O
in	O
combination	O
with	O
other	O
cytotoxic	O
drugs	O
may	O
show	O
on	O
-	O
treatment	O
additive	O
toxicity	O
,	O
especially	O
hematologic	O
and	O
gastrointestinal	O
effects	O
.	O

Concomitant	O
use	O
of	O
ELLENCE	S-brand-AD-1
with	O
other	O
cardioactive	O
compounds	O
that	O
could	O
cause	O
heart	O
failure	O
(	O
e.g	O
.	O
,	O
calcium	B-group-AD-2
channel	I-group-AD-2
blockers	E-group-AD-2
)	O
,	O
requires	O
close	O
monitoring	O
of	O
cardiac	O
function	O
throughout	O
treatment	O
.	O

There	O
are	O
few	O
data	O
regarding	O
the	O
coadministration	O
of	O
radiation	O
therapy	O
and	O
epirubicin	S-drug
.	O

In	O
adjuvant	O
trials	O
of	O
epirubicin	S-drug
-	O
containing	O
CEF	O
-	O
120	O
or	O
FEC	O
-	O
100	O
chemotherapies	O
,	O
breast	O
irradiation	O
was	O
delayed	O
until	O
after	O
chemotherapy	O
was	O
completed	O
.	O

This	O
practice	O
resulted	O
in	O
no	O
apparent	O
increase	O
in	O
local	O
breast	O
cancer	O
recurrence	O
relative	O
to	O
published	O
accounts	O
in	O
the	O
literature	O
.	O

A	O
small	O
number	O
of	O
patients	O
received	O
epirubicin	S-drug
-	O
based	O
chemotherapy	O
concomitantly	O
with	O
radiation	O
therapy	O
but	O
had	O
chemotherapy	O
interrupted	O
in	O
order	O
to	O
avoid	O
potential	O
overlapping	O
toxicities	O
.	O

It	O
is	O
likely	O
that	O
use	O
of	O
epirubicin	S-drug
with	O
radiotherapy	O
may	O
sensitize	O
tissues	O
to	O
the	O
cytotoxic	O
actions	O
of	O
irradiation	O
.	O

Administration	O
of	O
ELLENCE	S-brand
after	O
previous	O
radiation	O
therapy	O
may	O
induce	O
an	O
inflammatory	O
recall	O
reaction	O
at	O
the	O
site	O
of	O
the	O
irradiation	O
.	O

Epirubicin	S-drug
is	O
extensively	O
metabolized	O
by	O
the	O
liver	O
.	O

Changes	O
in	O
hepatic	O
function	O
induced	O
by	O
concomitant	O
therapies	O
may	O
affect	O
epirubicin	S-drug
metabolism	O
,	O
pharmacokinetics	O
,	O
therapeutic	O
efficacy	O
,	O
and	O
/	O
or	O
toxicity	O
.	O

Cimetidine	S-drug-ME-1
increased	O
the	O
AUC	O
of	O
epirubicin	S-drug-ME-2
by	O
50	O
%	O
.	O

Cimetidine	S-drug-AD-1
treatment	O
should	O
be	O
stopped	O
during	O
treatment	O
with	O
ELLENCE	S-brand-AD-2
.	O

Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
ELLENCE	S-brand
and	O
laboratory	O
tests	O
.	O

Inhibitors	O
of	O
CYP3A4	O
-	O
Eplerenone	S-drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
CYP3A4	O
.	O

A	O
pharmacokinetic	O
study	O
evaluating	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
INSPRA	S-brand-ME-1
100	O
mg	O
with	O
ketoconazole	S-drug-ME-2
200	O
mg	O
BID	O
,	O
a	O
potent	O
inhibitor	O
of	O
the	O
CYP3A4	O
pathway	O
,	O
showed	O
a	O
1.7	O
-	O
fold	O
increase	O
in	O
Cmax	O
of	O
eplerenone	S-drug
and	O
a	O
5.4	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
eplerenone	S-drug
.	O

INSPRA	S-brand
should	O
not	O
be	O
used	O
with	O
drugs	O
described	O
as	O
strong	O
inhibitors	O
of	O
CYP3A4	O
in	O
their	O
labeling	O
.	O

Administration	O
of	O
eplerenone	S-drug-ME-1
with	O
other	O
CYP3A4	O
inhibitors	O
(	O
e.g	O
.	O
,	O
erythromycin	S-drug-ME-2
500	O
mg	O
BID	O
,	O
verapamil	S-drug-ME-2
240	O
mg	O
QD	O
,	O
saquinavir	S-drug-ME-2
1200	O
mg	O
TID	O
,	O
fluconazole	S-drug-ME-2
200	O
mg	O
QD	O
)	O
resulted	O
in	O
increases	O
in	O
Cmax	O
of	O
eplerenone	S-drug
ranging	O
from	O
1.4	O
-	O
to	O
1.6	O
-	O
fold	O
and	O
AUC	O
from	O
2.0	O
-	O
to	O
2.9	O
-	O
fold	O
.	O

ACE	B-group
Inhibitors	E-group
and	O
Angiotensin	B-group
II	I-group
Receptor	I-group
Antagonists	E-group
(	O
Congestive	O
Heart	O
Failure	O
Post	O
-	O
Myocardial	O
Infarction	O
)	O
-	O
In	O
EPHESUS	O
,	O
3020	O
(	O
91	O
%	O
)	O
patients	O
receiving	O
INSPRA	S-brand
25	O
to	O
50	O
mg	O
also	O
received	O
ACE	B-group
inhibitors	E-group
or	O
angiotensin	B-group
II	I-group
receptor	I-group
antagonists	E-group
(	O
ACEI	S-group
/	O
ARB	S-group
)	O
.	O

Rates	O
of	O
patients	O
with	O
maximum	O
potassium	O
levels	O
5.5	O
mEq	O
/	O
L	O
were	O
similar	O
regardless	O
of	O
the	O
use	O
of	O
ACEI	S-group
/	O
ARB	S-group
.	O

ACE	B-group
Inhibitors	E-group
and	O
Angiotensin	B-group
II	I-group
Receptor	I-group
Antagonists	E-group
(	O
Hypertension	O
)	O
-	O
In	O
clinical	O
studies	O
of	O
patients	O
with	O
hypertension	O
,	O
the	O
addition	O
of	O
INSPRA	S-brand-EF-1
50	O
to	O
100	O
mg	O
to	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
and	O
angiotensin	B-group-EF-2
II	I-group-EF-2
receptor	I-group-EF-2
antagonists	E-group-EF-2
increased	O
mean	O
serum	O
potassium	O
slightly	O
(	O
about	O
0.09	O
-	O
0.13	O
mEq	O
/	O
L	O
)	O
.	O

In	O
a	O
study	O
in	O
diabetics	O
with	O
microalbuminuria	O
INSPRA	S-brand-EF-1
200	O
mg	O
combined	O
with	O
the	O
ACE	B-group
inhibitor	E-group
enalapril	S-drug-EF-2
10	O
mg	O
increased	O
the	O
frequency	O
of	O
hyperkalemia	O
(	O
serum	O
potassium	O
5.5	O
mEq	O
/	O
L	O
)	O
from	O
17	O
%	O
on	O
enalapril	S-drug
alone	O
to	O
38	O
%	O
.	O

Lithium	S-drug
-	O
A	O
drug	O
interaction	O
study	O
of	O
eplerenone	S-drug
with	O
lithium	S-drug
has	O
not	O
been	O
conducted	O
.	O

Serum	O
lithium	S-drug
levels	O
should	O
be	O
monitored	O
frequently	O
if	O
INSPRA	S-brand-AD-1
is	O
administered	O
concomitantly	O
with	O
lithium	S-drug-AD-2
.	O

Nonsteroidal	B-group
Anti	I-group
-	I-group
Inflammatory	I-group
Drugs	E-group
(	O
NSAIDs	S-group
)	O
-	O
A	O
drug	O
interaction	O
study	O
of	O
eplerenone	S-drug
with	O
an	O
NSAID	S-group
has	O
not	O
been	O
conducted	O
.	O

The	O
administration	O
of	O
other	O
potassium	B-group-EF-1
-	I-group-EF-1
sparing	I-group-EF-1
antihypertensives	E-group-EF-1
with	O
NSAIDs	S-group-EF-2
has	O
been	O
shown	O
to	O
reduce	O
the	O
antihypertensive	O
effect	O
in	O
some	O
patients	O
and	O
result	O
in	O
severe	O
hyperkalemia	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O

Therefore	O
,	O
when	O
INSPRA	S-brand-AD-1
and	O
NSAIDs	S-group-AD-2
are	O
used	O
concomitantly	O
,	O
patients	O
should	O
be	O
observed	O
to	O
determine	O
whether	O
the	O
desired	O
effect	O
on	O
blood	O
pressure	O
is	O
obtained	O
.	O

No	O
evidence	O
of	O
interaction	O
of	O
PROCRIT	S-brand
with	O
other	O
drugs	O
was	O
observed	O
in	O
the	O
course	O
of	O
clinical	O
trials	O
.	O

Additional	O
reductions	O
in	O
blood	O
pressure	O
may	O
occur	O
when	O
FLOLAN	S-brand-EF-1
is	O
administered	O
with	O
diuretics	S-group-EF-2
,	O
antihypertensive	B-group-EF-2
agents	E-group-EF-2
,	O
or	O
other	O
vasodilators	S-group-EF-2
.	O

When	O
other	O
antiplatelet	B-group-EF-1
agents	E-group-EF-1
or	O
anticoagulants	S-group-EF-1
are	O
used	O
concomitantly	O
,	O
there	O
is	O
the	O
potential	O
for	O
FLOLAN	S-brand-EF-2
to	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

However	O
,	O
patients	O
receiving	O
infusions	O
of	O
FLOLAN	S-brand
in	O
clinical	O
trials	O
were	O
maintained	O
on	O
anticoagulants	S-group
without	O
evidence	O
of	O
increased	O
bleeding	O
.	O

In	O
clinical	O
trials	O
,	O
FLOLAN	S-brand
was	O
used	O
with	O
digoxin	S-drug
,	O
diuretics	S-group
,	O
anticoagulants	S-group
,	O
oral	O
vasodilators	S-group
,	O
and	O
supplemental	O
oxygen.In	O
a	O
pharmacokinetic	O
substudy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
receiving	O
furosemide	S-drug-ME-1
or	O
digoxin	S-drug-ME-1
in	O
whom	O
therapy	O
with	O
FLOLAN	S-brand-ME-2
was	O
initiated	O
,	O
apparent	O
oral	O
clearance	O
values	O
for	O
furosemide	S-drug
(	O
n	O
=	O
23	O
)	O
and	O
digoxin	S-drug
(	O
n	O
=	O
30	O
)	O
were	O
decreased	O
by	O
13	O
%	O
and	O
15	O
%	O
,	O
respectively	O
,	O
on	O
the	O
second	O
day	O
of	O
therapy	O
and	O
had	O
returned	O
to	O
baseline	O
values	O
by	O
day	O
87	O
.	O

The	O
change	O
in	O
furosemide	S-drug
clearance	O
value	O
is	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O

However	O
,	O
patients	O
on	O
digoxin	S-drug-ME-1
may	O
show	O
elevations	O
of	O
digoxin	S-drug
concentrations	O
after	O
initiation	O
of	O
therapy	O
with	O
FLOLAN	S-brand-ME-2
,	O
which	O
may	O
be	O
clinically	O
significant	O
in	O
patients	O
prone	O
to	O
digoxin	S-drug
toxicity	O
.	O

Eprosartan	S-drug
has	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
and	O
the	O
pharmacodynamics	O
of	O
warfarin	S-drug
and	O
glyburide	S-drug
.	O

Thus	O
no	O
dosing	O
adjustments	O
are	O
necessary	O
during	O
concomitant	O
use	O
with	O
these	O
agents	O
.	O

Because	O
eprosartan	S-drug
is	O
not	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
,	O
inhibitors	O
of	O
CYP450	O
enzyme	O
would	O
not	O
be	O
expected	O
to	O
affect	O
its	O
metabolism	O
,	O
and	O
ketoconazole	S-drug
and	O
fluconazole	S-drug
,	O
potent	O
inhibitors	O
of	O
CYP3A	O
and	O
2C9	O
,	O
respectively	O
,	O
have	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
eprosartan	S-drug
pharmacokinetics	O
.	O

Ranitidine	S-drug
also	O
has	O
no	O
effect	O
on	O
eprosartan	S-drug
pharmacokinetics	O
.	O

Eprosartan	S-drug
(	O
up	O
to	O
400	O
mg	O
b.i.d	O
.	O
or	O
800	O
mg	O
q.d	O
.	O
)	O
doses	O
have	O
been	O
safely	O
used	O
concomitantly	O
with	O
a	O
thiazide	B-group
diuretic	E-group
(	O
hydrochlorothiazide	S-drug
)	O
.	O

Eprosartan	S-drug
doses	O
of	O
up	O
to	O
300	O
mg	O
b.i.d	O
.	O
have	O
been	O
safely	O
used	O
concomitantly	O
with	O
sustained	O
-	O
release	O
calcium	B-group
channel	I-group
blockers	E-group
(	O
sustained	O
-	O
release	O
nifedipine	S-drug
)	O
with	O
no	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Enoxaparin	S-drug
dosed	O
as	O
a	O
1.0	O
mg	O
/	O
kg	O
subcutaneous	O
injection	O
q12h	O
for	O
four	O
doses	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
eptifibatide	S-drug
or	O
the	O
level	O
of	O
platelet	O
aggregation	O
in	O
healthy	O
adults	O
.	O

Mineral	B-drug-ME-1
oil	E-drug-ME-1
interferes	O
with	O
the	O
absorption	O
of	O
fat	B-group-ME-2
-	I-group-ME-2
soluble	I-group-ME-2
vitamins	E-group-ME-2
,	O
including	O
vitamin	B-group-ME-2
D	I-group-ME-2
preparations	E-group-ME-2
.	O

Administration	O
of	O
thiazide	B-group-EF-1
diuretics	E-group-EF-1
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
ergocalciferol	S-drug-EF-2
may	O
cause	O
hypercalcemia	O
.	O

No	O
reported	O
interactions	O
.	O

The	O
effects	O
of	O
ERGOMAR	S-brand-ME-1
may	O
be	O
potentiated	O
by	O
triacetyloleandomycin	S-drug-ME-M
which	O
inhibits	O
the	O
metabolism	O
of	O
ergotamine	S-drug-ME-2
.	O

The	O
pressor	O
effects	O
of	O
ERGOMAR	S-brand-EF-1
and	O
other	O
vasoconstrictor	B-group-EF-2
drugs	E-group-EF-2
can	O
combine	O
to	O
cause	O
dangerous	O
hypertension	O
.	O

Co	O
-	O
treatment	O
with	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	S-drug-ME-1
increases	O
erlotinib	S-drug-ME-2
AUC	O
by	O
2	O
/	O
3	O
.	O

Caution	O
should	O
be	O
used	O
when	O
administering	O
or	O
taking	O
TARCEVA	S-brand-AD-1
with	O
ketoconazole	S-drug-AD-2
and	O
other	O
strong	O
CYP3A4	O
inhibitors	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
atazanavir	S-drug-AD-2
,	O
clarithromycin	S-drug-AD-2
,	O
indinavir	S-drug-AD-2
,	O
itraconazole	S-drug-AD-2
,	O
nefazodone	S-drug-AD-2
,	O
nelfinavir	S-drug-AD-2
,	O
ritonavir	S-drug-AD-2
,	O
saquinavir	S-drug-AD-2
,	O
telithromycin	S-drug-AD-2
,	O
troleandomycin	S-drug-AD-2
(	O
TAO	S-drug-AD-2
)	O
,	O
and	O
voriconazole	S-drug-AD-2
.	O

Pre	O
-	O
treatment	O
with	O
the	O
CYP3A4	O
inducer	O
rifampicin	S-drug-ME-1
decreased	O
erlotinib	S-drug-ME-2
AUC	O
by	O
about	O
2	O
/	O
3	O
.	O

Alternate	O
treatments	O
lacking	O
CYP3A4	O
inducing	O
activity	O
should	O
be	O
considered	O
.	O

If	O
an	O
alternative	O
treatment	O
is	O
unavailable	O
,	O
a	O
TARCEVA	S-brand
dose	O
greater	O
than	O
150	O
mg	O
should	O
be	O
considered	O
for	O
NSCLC	O
patients	O
,	O
and	O
greater	O
than	O
100	O
mg	O
considered	O
for	O
pancreatic	O
cancer	O
patients	O
.	O

If	O
the	O
TARCEVA	S-brand-AD-1
dose	O
is	O
adjusted	O
upward	O
,	O
the	O
dose	O
will	O
need	O
to	O
be	O
reduced	O
upon	O
discontinuation	O
of	O
rifampicin	S-drug-AD-2
or	O
other	O
inducers	O
.	O

Other	O
CYP3A4	O
inducers	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
rifabutin	S-drug
,	O
rifapentine	S-drug
,	O
phenytoin	S-drug
,	O
carbamazepine	S-drug
,	O
phenobarbital	S-drug
and	O
St.	O
Johns	O
Wort	O
.	O

Hepatotoxicity	O
Asymptomatic	O
increases	O
in	O
liver	O
transaminases	O
have	O
been	O
observed	O
in	O
TARCEVA	S-brand
treated	O
patients	O
;	O

therefore	O
,	O
periodic	O
liver	O
function	O
testing	O
(	O
transaminases	O
,	O
bilirubin	O
,	O
and	O
alkaline	O
phosphatase	O
)	O
should	O
be	O
considered	O
.	O

Dose	O
reduction	O
or	O
interruption	O
of	O
TARCEVA	S-brand
should	O
be	O
considered	O
if	O
changes	O
in	O
liver	O
function	O
are	O
severe	O
.	O

Patients	O
with	O
Hepatic	O
Impairment	O
In	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
erlotinib	S-drug
is	O
cleared	O
primarily	O
by	O
the	O
liver	O
.	O

Therefore	O
,	O
erlotinib	S-drug
exposure	O
may	O
be	O
increased	O
in	O
patients	O
with	O
hepatic	O
dysfunction	O
.	O

Elevated	O
International	O
Normalized	O
Ratio	O
and	O
Potential	O
Bleeding	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and	O
infrequent	O
reports	O
of	O
bleeding	O
events	O
including	O
gastrointestinal	O
and	O
non	O
-	O
gastrointestinal	O
bleedings	O
have	O
been	O
reported	O
in	O
clinical	O
studies	O
,	O
some	O
associated	O
with	O
concomitant	O
warfarin	S-drug
administration	O
.	O

Patients	O
taking	O
warfarin	S-drug
or	O
other	O
coumarin	B-group
-	I-group
derivative	I-group
anticoagulants	E-group
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O

When	O
ertapenem	S-drug
is	O
co	O
-	O
administered	O
with	O
probenecid	S-drug
(	O
500	O
mg	O
p.o	O
.	O
every	O
6	O
hours	O
)	O
,	O
probenecid	S-drug-ME-1
competes	O
for	O
active	O
tubular	O
secretion	O
and	O
reduces	O
the	O
renal	O
clearance	O
of	O
ertapenem	S-drug-ME-2
.	O

Based	O
on	O
total	O
ertapenem	S-drug-ME-1
concentrations	O
,	O
probenecid	S-drug-ME-2
increased	O
the	O
AUC	O
by	O
25	O
%	O
and	O
reduced	O
the	O
plasma	O
and	O
renal	O
clearances	O
by	O
20	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

The	O
half	O
-	O
life	O
increased	O
from	O
4.0	O
to	O
4.8	O
hours	O
.	O

Because	O
of	O
the	O
small	O
effect	O
on	O
half	O
-	O
life	O
,	O
the	O
coadministration	O
with	O
probenecid	S-drug-AD-1
to	O
extend	O
the	O
half	O
-	O
life	O
of	O
ertapenem	S-drug-AD-2
is	O
not	O
recommended	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
ertapenem	S-drug
does	O
not	O
inhibit	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
of	O
digoxin	S-drug
or	O
vinblastine	S-drug
and	O
that	O
ertapenem	S-drug
is	O
not	O
a	O
substrate	O
for	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
.	O

In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
indicate	O
that	O
ertapenem	S-drug
does	O
not	O
inhibit	O
metabolism	O
mediated	O
by	O
any	O
of	O
the	O
following	O
six	O
cytochrome	O
p450	O
(	O
CYP	O
)	O
isoforms	O
:	O
1A2	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
and	O
3A4	O
.	O

Drug	O
interactions	O
caused	O
by	O
inhibition	O
of	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
drug	O
clearance	O
or	O
CYP	O
-	O
mediated	O
drug	O
clearance	O
with	O
the	O
listed	O
isoforms	O
are	O
unlikely	O
.	O

Other	O
than	O
with	O
probenecid	S-drug
,	O
no	O
specific	O
clinical	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O

Erythromycin	S-drug-EF-1
use	O
in	O
patients	O
who	O
are	O
receiving	O
high	O
doses	O
of	O
theophylline	S-drug-EF-2
may	O
be	O
associated	O
with	O
an	O
increase	O
in	O
serum	O
theophylline	S-drug
levels	O
and	O
potential	O
theophylline	S-drug
toxicity	O
.	O

In	O
case	O
of	O
theophylline	S-drug
toxicity	O
and	O
/	O
or	O
elevated	O
serum	O
theophylline	S-drug
levels	O
,	O
the	O
dose	O
of	O
theophylline	S-drug-AD-1
should	O
be	O
reduced	O
while	O
the	O
patient	O
is	O
receiving	O
concomitant	O
erythromycin	S-drug-AD-2
therapy	O
.	O

Concomitant	O
administration	O
of	O
erythromycin	S-drug-ME-1
and	O
digoxin	S-drug-ME-2
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	S-drug
serum	O
levels	O
.	O

There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	O
effects	O
when	O
erythromycin	S-drug-EF-1
and	O
oral	O
anticoagulants	S-group-EF-2
were	O
used	O
concomitantly	O
.	O

Increased	O
anticoagulation	O
effects	O
due	O
to	O
interactions	O
of	O
erythromycin	S-drug
with	O
various	O
oral	O
anticoagulents	O
may	O
be	O
more	O
pronounced	O
in	O
the	O
elderly	O
.	O

Concurrent	O
use	O
of	O
erythromycin	S-drug-EF-1
and	O
ergotamine	S-drug-EF-2
or	O
dihydroergotamine	S-drug-EF-2
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Erythromycin	S-drug-MU-1
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	S-drug-ME-2
and	O
midazolam	S-drug-ME-2
and	O
thus	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
these	O
benzodiazepines	S-group-EF-2
.	O

The	O
use	O
of	O
erythromycin	S-drug
in	O
patients	O
concurrently	O
taking	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
may	O
be	O
associated	O
with	O
elevations	O
in	O
serum	O
levels	O
of	O
these	O
other	O
drugs	O
.	O

There	O
have	O
been	O
reports	O
of	O
interactions	O
of	O
erythromycin	S-drug-IN-1
with	O
carbamazepine	S-drug-IN-2
,	O
cyclosporine	S-drug-IN-2
,	O
tacrolimus	S-drug-IN-2
,	O
hexobarbital	S-drug-IN-2
,	O
phenytoin	S-drug-IN-2
,	O
alfentanil	S-drug-IN-2
,	O
cisapride	S-drug-IN-2
,	O
disopyramide	S-drug-IN-2
,	O
lovastatin	S-drug-IN-2
,	O
bromocriptine	S-drug-IN-2
,	O
valproate	S-drug-IN-2
,	O
terfenadine	S-drug-IN-2
,	O
and	O
astemizole	S-drug-IN-2
.	O

Serum	O
concentrations	O
of	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
should	O
be	O
monitored	O
closely	O
in	O
patients	O
concurrently	O
receiving	O
erythromycin	S-drug
.	O

Erythromycin	S-drug-ME-1
has	O
been	O
reported	O
to	O
significantly	O
alter	O
the	O
metabolism	O
of	O
nonsedating	O
antihistamines	S-group
terfenadine	S-drug-ME-2
and	O
astemizole	S-drug-ME-2
when	O
taken	O
concomitantly	O
.	O

Rare	O
cases	O
of	O
serious	O
cardiovascular	O
adverse	O
events	O
,	O
including	O
electrocardiographic	O
QT	O
/	O
QTc	O
interval	O
prolongation	O
,	O
cardiac	O
arrest	O
,	O
torsades	O
de	O
pointes	O
,	O
and	O
other	O
ventricular	O
arrhythmias	O
have	O
been	O
observed	O
.	O

In	O
addition	O
,	O
deaths	O
have	O
been	O
reported	O
rarely	O
with	O
concomitant	O
administration	O
of	O
terfenadine	S-drug-EF-1
and	O
erythromycin	S-drug-EF-2
.	O

There	O
have	O
been	O
postmarketing	O
reports	O
of	O
drug	O
interactions	O
when	O
erythromycin	S-drug-EF-1
is	O
coadministered	O
with	O
cisapride	S-drug-EF-2
,	O
resulting	O
in	O
QT	O
prolongation	O
,	O
cardiac	O
arrythmias	O
,	O
ventricular	O
tachycardia	O
,	O
ventricular	O
fibrulation	O
,	O
and	O
torsades	O
de	O
pointes	O
,	O
most	O
like	O
due	O
to	O
inhibition	O
of	O
hepatic	O
metabolism	O
of	O
cisapride	S-drug-ME-1
by	O
erythromycin	S-drug-ME-2
.	O

Fatalities	O
have	O
been	O
reported	O
.	O

Patients	O
receiving	O
concomitant	O
lovastatin	S-drug-AD-1
and	O
erythromycin	S-drug-AD-2
should	O
be	O
carefully	O
monitored	O
;	O

cases	O
of	O
rhabdomyolysis	O
have	O
been	O
reported	O
in	O
seriously	O
ill	O
patients	O
.	O

CNS	O
Drugs	O
-	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
escitalopram	S-drug
,	O
caution	O
should	O
be	O
used	O
when	O
it	O
is	O
taken	O
in	O
combination	O
with	O
other	O
centrally	O
acting	O
drugs	O
.	O

Alcohol	S-drug
-	O
Although	O
LEXAPRO	S-brand
did	O
not	O
potentiate	O
the	O
cognitive	O
and	O
motor	O
effects	O
of	O
alcohol	S-drug
in	O
a	O
clinical	O
trial	O
,	O
as	O
with	O
other	O
psychotropic	B-group-AD-1
medications	E-group-AD-1
,	O
the	O
use	O
of	O
alcohol	S-drug-AD-1
by	O
patients	O
taking	O
LEXAPRO	S-brand-AD-2
is	O
not	O
recommended	O
.	O

Monoamine	B-group
Oxidase	I-group
Inhibitors	E-group
(	O
MAOIs	S-group
)	O

Drugs	O
That	O
Interfere	O
With	O
Hemostasis	O
(	O
NSAIDs	S-group
,	O
Aspirin	S-brand
,	O
Warfarin	S-drug
,	O
etc	O
.	O
)	O

Serotonin	O
release	O
by	O
platelets	O
plays	O
an	O
important	O
role	O
in	O
hemostasis	O
.	O

Epidemiological	O
studies	O
of	O
the	O
case	O
-	O
control	O
and	O
cohort	O
design	O
that	O
have	O
demonstrated	O
an	O
association	O
between	O
use	O
of	O
psychotropic	B-group-EF-1
drugs	E-group-EF-1
that	O
interfere	O
with	O
serotonin	O
reuptake	O
and	O
the	O
occurrence	O
of	O
upper	O
gastrointestinal	O
bleeding	O
have	O
also	O
shown	O
that	O
concurrent	O
use	O
of	O
an	O
NSAID	S-group-EF-2
or	O
aspirin	S-brand-EF-2
potentiated	O
the	O
risk	O
of	O
bleeding	O
.	O

Thus	O
,	O
patients	O
should	O
be	O
cautioned	O
about	O
the	O
use	O
of	O
such	O
drugs	O
concurrently	O
with	O
LEXAPRO	S-brand
.	O

Cimetidine	S-drug
-	O
In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg	O
/	O
day	O
racemic	O
citalopram	S-drug-ME-1
,	O
combined	O
administration	O
of	O
400	O
mg	O
/	O
day	O
cimetidine	S-drug-ME-2
for	O
8	O
days	O
resulted	O
in	O
an	O
increase	O
in	O
citalopram	S-drug
AUC	O
and	O
Cmax	O
of	O
43	O
%	O
and	O
39	O
%	O
,	O
respectively	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O

Digoxin	S-drug
-	O
In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg	O
/	O
day	O
racemic	O
citalopram	S-drug
,	O
combined	O
administration	O
of	O
citalopram	S-drug
and	O
digoxin	S-drug
(	O
single	O
dose	O
of	O
1	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	S-drug
or	O
digoxin	S-drug
.	O

Lithium	S-drug
-	O
Coadministration	O
of	O
racemic	O
citalopram	S-drug
(	O
40	O
mg	O
/	O
day	O
for	O
10	O
days	O
)	O
and	O
lithium	S-drug
(	O
30	O
mmol	O
/	O
day	O
for	O
5	O
days	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
citalopram	S-drug
or	O
lithium	S-drug
.	O

Nevertheless	O
,	O
plasma	O
lithium	S-drug
levels	O
should	O
be	O
monitored	O
with	O
appropriate	O
adjustment	O
to	O
the	O
lithium	S-drug
dose	O
in	O
accordance	O
with	O
standard	O
clinical	O
practice	O
.	O

Because	O
lithium	S-drug-EF-1
may	O
enhance	O
the	O
serotonergic	O
effects	O
of	O
escitalopram	S-drug-EF-2
,	O
caution	O
should	O
be	O
exercised	O
when	O
LEXAPRO	S-brand-AD-1
and	O
lithium	S-drug-AD-2
are	O
coadministered	O
.	O

Pimozide	S-drug
and	O
Celexa	S-brand
-	O
In	O
a	O
controlled	O
study	O
,	O
a	O
single	O
dose	O
of	O
pimozide	S-drug-EF-1
2	O
mg	O
co	O
-	O
administered	O
with	O
racemic	O
citalopram	S-drug-EF-2
40	O
mg	O
given	O
once	O
daily	O
for	O
11	O
days	O
was	O
associated	O
with	O
a	O
mean	O
increase	O
in	O
QTc	O
values	O
of	O
approximately	O
10	O
msec	O
compared	O
to	O
pimozide	S-drug
given	O
alone	O
.	O

Racemic	O
citalopram	S-drug
did	O
not	O
alter	O
the	O
mean	O
AUC	O
or	O
Cmax	O
of	O
pimozide	S-drug
.	O

The	O
mechanism	O
of	O
this	O
pharmacodynamic	O
interaction	O
is	O
not	O
known	O
.	O

Sumatriptan	S-drug
-	O
There	O
have	O
been	O
rare	O
postmarketing	O
reports	O
describing	O
patients	O
with	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
following	O
the	O
use	O
of	O
a	O
selective	B-group-EF-1
serotonin	I-group-EF-1
reuptake	I-group-EF-1
inhibitor	E-group-EF-1
(	O
SSRI	S-group-EF-1
)	O
and	O
sumatriptan	S-drug-EF-2
.	O

If	O
concomitant	O
treatment	O
with	O
sumatriptan	S-drug-AD-1
and	O
an	O
SSRI	S-group-AD-2
(	O
e.g	O
.	O
,	O
fluoxetine	S-drug-AD-2
,	O
fluvoxamine	S-drug-AD-2
,	O
paroxetine	S-drug-AD-2
,	O
sertraline	S-drug-AD-2
,	O
citalopram	S-drug-AD-2
,	O
escitalopram	S-drug-AD-2
)	O
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Theophylline	S-drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	S-drug
(	O
40	O
mg	O
/	O
day	O
for	O
21	O
days	O
)	O
and	O
the	O
CYP1A2	O
substrate	O
theophylline	S-drug
(	O
single	O
dose	O
of	O
300	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	S-drug
.	O

The	O
effect	O
of	O
theophylline	S-drug
on	O
the	O
pharmacokinetics	O
of	O
citalopram	S-drug
was	O
not	O
evaluated	O
.	O

Warfarin	S-drug
-	O
Administration	O
of	O
40	O
mg	O
/	O
day	O
racemic	O
citalopram	S-drug
for	O
21	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	S-drug
,	O
a	O
CYP3A4	O
substrate	O
.	O

Prothrombin	O
time	O
was	O
increased	O
by	O
5	O
%	O
,	O
the	O
clinical	O
significance	O
of	O
which	O
is	O
unknown	O
.	O

Carbamazepine	S-drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	S-drug
(	O
40	O
mg	O
/	O
day	O
for	O
14	O
days	O
)	O
and	O
carbamazepine	S-drug
(	O
titrated	O
to	O
400	O
mg	O
/	O
day	O
for	O
35	O
days	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
carbamazepine	S-drug
,	O
a	O
CYP3A4	O
substrate	O
.	O

Although	O
trough	O
citalopram	S-drug
plasma	O
levels	O
were	O
unaffected	O
,	O
given	O
the	O
enzyme	O
-	O
inducing	O
properties	O
of	O
carbamazepine	S-drug
,	O
the	O
possibility	O
that	O
carbamazepine	S-drug-ME-1
might	O
increase	O
the	O
clearance	O
of	O
escitalopram	S-drug-ME-2
should	O
be	O
considered	O
if	O
the	O
two	O
drugs	O
are	O
coadministered	O
.	O

Triazolam	S-drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	S-drug
(	O
titrated	O
to	O
40	O
mg	O
/	O
day	O
for	O
28	O
days	O
)	O
and	O
the	O
CYP3A4	O
substrate	O
triazolam	S-drug
(	O
single	O
dose	O
of	O
0.25	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	S-drug
or	O
triazolam	S-drug
.	O

Ketoconazole	S-drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	S-drug-ME-1
(	O
40	O
mg	O
)	O
and	O
ketoconazole	S-drug-ME-2
(	O
200	O
mg	O
)	O
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
ketoconazole	S-drug
by	O
21	O
%	O
and	O
10	O
%	O
,	O
respectively	O
,	O
and	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
citalopram	S-drug
.	O

Ritonavir	S-drug
-	O
Combined	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ritonavir	S-drug
(	O
600	O
mg	O
)	O
,	O
both	O
a	O
CYP3A4	O
substrate	O
and	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
and	O
escitalopram	S-drug
(	O
20	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
ritonavir	S-drug
or	O
escitalopram	S-drug
.	O

CYP3A4	O
and	O
-	O
2C19	O
Inhibitors	O
-	O
In	O
vitro	O
studies	O
indicated	O
that	O
CYP3A4	O
and	O
-	O
2C19	O
are	O
the	O
primary	O
enzymes	O
involved	O
in	O
the	O
metabolism	O
of	O
escitalopram	S-drug
.	O

However	O
,	O
coadministration	O
of	O
escitalopram	S-drug
(	O
20	O
mg	O
)	O
and	O
ritonavir	S-drug
(	O
600	O
mg	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
escitalopram	S-drug
.	O

Because	O
escitalopram	S-drug
is	O
metabolized	O
by	O
multiple	O
enzyme	O
systems	O
,	O
inhibition	O
of	O
a	O
single	O
enzyme	O
may	O
not	O
appreciably	O
decrease	O
escitalopram	S-drug
clearance	O
.	O

Drugs	O
Metabolized	O
by	O
Cytochrome	O
P4502D6	O
-	O
In	O
vitro	O
studies	O
did	O
not	O
reveal	O
an	O
inhibitory	O
effect	O
of	O
escitalopram	S-drug
on	O
CYP2D6	O
.	O

In	O
addition	O
,	O
steady	O
state	O
levels	O
of	O
racemic	O
citalopram	S-drug
were	O
not	O
significantly	O
different	O
in	O
poor	O
metabolizers	O
and	O
extensive	O
CYP2D6	O
metabolizers	O
after	O
multiple	O
-	O
dose	O
administration	O
of	O
citalopram	S-drug
,	O
suggesting	O
that	O
coadministration	O
,	O
with	O
escitalopram	S-drug
,	O
of	O
a	O
drug	O
that	O
inhibits	O
CYP2D6	O
,	O
is	O
unlikely	O
to	O
have	O
clinically	O
significant	O
effects	O
on	O
escitalopram	S-drug
metabolism	O
.	O

However	O
,	O
there	O
are	O
limited	O
in	O
vivo	O
data	O
suggesting	O
a	O
modest	O
CYP2D6	O
inhibitory	O
effect	O
for	O
escitalopram	S-drug
,	O
i.e	O
.	O
,	O
coadministration	O
of	O
escitalopram	S-drug-ME-1
(	O
20	O
mg	O
/	O
day	O
for	O
21	O
days	O
)	O
with	O
the	O
tricyclic	B-group
antidepressant	E-group
desipramine	S-drug-ME-2
(	O
single	O
dose	O
of	O
50	O
mg	O
)	O
,	O
a	O
substrate	O
for	O
CYP2D6	O
,	O
resulted	O
in	O
a	O
40	O
%	O
increase	O
in	O
Cmax	O
and	O
a	O
100	O
%	O
increase	O
in	O
AUC	O
of	O
desipramine	S-drug
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
escitalopram	S-drug
and	O
drugs	O
metabolized	O
by	O
CYP2D6	O
.	O

Metoprolol	S-drug
-	O
Administration	O
of	O
20	O
mg	O
/	O
day	O
LEXAPRO	S-brand-ME-1
for	O
21	O
days	O
in	O
healthy	O
volunteers	O
resulted	O
in	O
a	O
50	O
%	O
increase	O
in	O
Cmax	O
and	O
82	O
%	O
increase	O
in	O
AUC	O
of	O
the	O
beta	B-group
-	I-group
adrenergic	I-group
blocker	E-group
metoprolol	S-drug-ME-2
(	O
given	O
in	O
a	O
single	O
dose	O
of	O
100	O
mg	O
)	O
.	O

Increased	O
metoprolol	S-drug
plasma	O
levels	O
have	O
been	O
associated	O
with	O
decreased	O
cardioselectivity	O
.	O

Coadministration	O
of	O
LEXAPRO	S-brand
and	O
metoprolol	S-drug
had	O
no	O
clinically	O
significant	O
effects	O
on	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

Electroconvulsive	O
Therapy	O
(	O
ECT	O
)	O
-	O
There	O
are	O
no	O
clinical	O
studies	O
of	O
the	O
combined	O
use	O
of	O
ECT	O
and	O
escitalopram	S-drug
.	O

Concomitant	O
Administration	O
with	O
Racemic	O
Citalopram	S-drug
Citalopram	S-drug
-	O
Since	O
escitalopram	S-drug-AD-1
is	O
the	O
active	O
isomer	O
of	O
racemic	O
citalopram	S-drug-AD-2
(	O
Celexa	S-brand-AD-2
)	O
,	O
the	O
two	O
agents	O
should	O
not	O
be	O
coadministered	O
.	O

Catecholamine	O
-	O
depleting	O
drugs	O
,	O
e.g	O
.	O
,	O
reserpine	S-drug-EF-1
,	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

Patients	O
treated	O
concurrently	O
with	O
BREVIBLOC	S-brand
(	O
esmolol	B-drug
HCl	E-drug
)	O
and	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
result	O
in	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

A	O
study	O
of	O
interaction	O
between	O
BREVIBLOC	S-brand
and	O
warfarin	S-drug
showed	O
that	O
concomitant	O
administration	O
of	O
BREVIBLOC	S-brand
and	O
warfarin	S-drug
does	O
not	O
alter	O
warfarin	S-drug
plasma	O
levels	O
.	O

BREVIBLOC	S-brand-ME-1
concentrations	O
were	O
equivocally	O
higher	O
when	O
given	O
with	O
warfarin	S-drug-ME-2
,	O
but	O
this	O
is	O
not	O
likely	O
to	O
be	O
clinically	O
important	O
.	O

When	O
digoxin	S-drug-ME-1
and	O
BREVIBLOC	S-brand-ME-2
were	O
concomitantly	O
administered	O
intravenously	O
to	O
normal	O
volunteers	O
,	O
there	O
was	O
a	O
10	O
-	O
20	O
%	O
increase	O
in	O
digoxin	S-drug
blood	O
levels	O
at	O
some	O
time	O
points	O
.	O

Digoxin	S-drug
did	O
not	O
affect	O
BREVIBLOC	S-brand
pharmacokinetics	O
.	O

When	O
intravenous	O
morphine	S-drug
and	O
BREVIBLOC	S-brand
were	O
concomitantly	O
administered	O
in	O
normal	O
subjects	O
,	O
no	O
effect	O
on	O
morphine	S-drug
blood	O
levels	O
was	O
seen	O
,	O
but	O
BREVIBLOC	S-brand-ME-1
steady	O
-	O
state	O
blood	O
levels	O
were	O
increased	O
by	O
46	O
%	O
in	O
the	O
presence	O
of	O
morphine	S-drug-ME-2
.	O

No	O
other	O
pharmacokinetic	O
parameters	O
were	O
changed	O
.	O

The	O
effect	O
of	O
BREVIBLOC	S-drug
on	O
the	O
duration	O
of	O
succinylcholine	S-drug
-	O
induced	O
neuromuscular	O
blockade	O
was	O
studied	O
in	O
patients	O
undergoing	O
surgery	O
.	O

The	O
onset	O
of	O
neuromuscular	O
blockade	O
by	O
succinylcholine	S-drug-EF-1
was	O
unaffected	O
by	O
BREVIBLOC	S-brand-EF-2
,	O
but	O
the	O
duration	O
of	O
neuromuscular	O
blockade	O
was	O
prolonged	O
from	O
5	O
minutes	O
to	O
8	O
minutes	O
.	O

Although	O
the	O
interactions	O
observed	O
in	O
these	O
studies	O
do	O
not	O
appear	O
to	O
be	O
of	O
major	O
clinical	O
importance	O
,	O
BREVIBLOC	S-brand-AD-1
should	O
be	O
titrated	O
with	O
caution	O
in	O
patients	O
being	O
treated	O
concurrently	O
with	O
digoxin	S-drug-AD-2
,	O
morphine	S-drug-AD-2
,	O
succinylcholine	S-drug-AD-2
or	O
warfarin	S-drug-AD-2
.	O

While	O
taking	O
beta	B-group
blockers	E-group
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	S-drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
use	O
of	O
BREVIBLOC	S-brand-AD-1
and	O
verapamil	S-drug-AD-2
in	O
patients	O
with	O
depressed	O
myocardial	O
function	O
.	O

Fatal	O
cardiac	O
arrests	O
have	O
occurred	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O

Additionally	O
,	O
BREVIBLOC	S-brand-AD-1
should	O
not	O
be	O
used	O
to	O
control	O
supraventricular	O
tachycardia	O
in	O
the	O
presence	O
of	O
agents	O
which	O
are	O
vasoconstrictive	O
and	O
inotropic	O
such	O
as	O
dopamine	S-drug-AD-2
,	O
epinephrine	S-drug-AD-2
,	O
and	O
norepinephrine	S-drug-AD-2
because	O
of	O
the	O
danger	O
of	O
blocking	O
cardiac	O
contractility	O
when	O
systemic	O
vascular	O
resistance	O
is	O
high	O
.	O

Esomeprazole	S-drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver	O
by	O
CYP2C19	O
and	O
CYP3A4	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
esomeprazole	S-drug
is	O
not	O
likely	O
to	O
inhibit	O
CYPs	O
1A2	O
,	O
2A6	O
,	O
2C9	O
,	O
2D6	O
,	O
2E1	O
and	O
3A4	O
.	O

No	O
clinically	O
relevant	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
these	O
CYP	O
enzymes	O
would	O
be	O
expected	O
.	O

Drug	O
interaction	O
studies	O
have	O
shown	O
that	O
esomeprazole	S-drug
does	O
not	O
have	O
any	O
clinically	O
significant	O
interactions	O
with	O
phenytoin	S-drug
,	O
warfarin	S-drug
,	O
quinidine	S-drug
,	O
clarithromycin	S-drug
or	O
amoxicillin	S-drug
.	O

Post	O
-	O
marketing	O
reports	O
of	O
changes	O
in	O
prothrombin	O
measures	O
have	O
been	O
received	O
among	O
patients	O
on	O
concomitant	O
warfarin	S-drug
and	O
esomeprazole	S-drug
therapy	O
.	O

Increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
may	O
lead	O
to	O
abnormal	O
bleeding	O
and	O
even	O
death	O
.	O

Patients	O
treated	O
with	O
proton	B-group-EF-1
pump	I-group-EF-1
inhibitors	E-group-EF-1
and	O
warfarin	S-drug-EF-2
concomitantly	O
may	O
need	O
to	O
be	O
monitored	O
for	O
increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
.	O

Esomeprazole	S-drug
may	O
potentially	O
interfere	O
with	O
CYP2C19	O
,	O
the	O
major	O
esomeprazole	S-drug
metabolizing	O
enzyme	O
.	O

Coadministration	O
of	O
esomeprazole	S-drug-ME-1
30	O
mg	O
and	O
diazepam	S-drug-ME-2
,	O
a	O
CYP2C19	O
substrate	O
,	O
resulted	O
in	O
a	O
45	O
%	O
decrease	O
in	O
clearance	O
of	O
diazepam	S-drug
.	O

Increased	O
plasma	O
levels	O
of	O
diazepam	S-drug
were	O
observed	O
12	O
hours	O
after	O
dosing	O
and	O
onwards	O
.	O

However	O
,	O
at	O
that	O
time	O
,	O
the	O
plasma	O
levels	O
of	O
diazepam	S-drug
were	O
below	O
the	O
therapeutic	O
interval	O
,	O
and	O
thus	O
this	O
interaction	O
is	O
unlikely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O

Esomeprazole	S-drug
inhibits	O
gastric	O
acid	O
secretion	O
.	O

Therefore	O
,	O
esomeprazole	S-drug-ME-1
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
eg	O
,	O
ketoconazole	S-drug-ME-2
,	O
iron	S-drug-ME-2
salts	O
and	O
digoxin	S-drug-ME-2
)	O
.	O

Coadministration	O
of	O
oral	O
contraceptives	S-group
,	O
diazepam	S-drug
,	O
phenytoin	S-drug
,	O
or	O
quinidine	S-drug
did	O
not	O
seem	O
to	O
change	O
the	O
pharmacokinetic	O
profile	O
of	O
esomeprazole	S-drug
.	O

Concomitant	O
administration	O
of	O
clarithromycin	S-drug-AD-1
with	O
pimozide	S-drug-AD-2
is	O
contraindicated	O
.	O

If	O
ProSom	S-brand
is	O
given	O
concomitantly	O
with	O
other	O
drugs	O
acting	O
on	O
the	O
central	O
nervous	O
system	O
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
all	O
agents	O
.	O

The	O
action	O
of	O
the	O
benzodiazepines	S-group-EF-1
may	O
be	O
potentiated	O
by	O
anticonvulsants	S-group-EF-2
,	O
antihistamines	S-group-EF-2
,	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
,	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
,	O
narcotics	S-group-EF-2
,	O
phenothiazines	S-group-EF-2
,	O
psychotropic	B-group-EF-2
medications	E-group-EF-2
,	O
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O

Smokers	O
have	O
an	O
increased	O
clearance	O
of	O
benzodiazepines	S-group
as	O
compared	O
to	O
nonsmokers	O
;	O

this	O
was	O
seen	O
in	O
studies	O
with	O
estazolam	S-drug
.	O

While	O
no	O
in	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
between	O
estazolam	S-drug-ME-1
and	O
inducers	O
of	O
CYP3A	O
,	O
compounds	O
that	O
are	O
potent	O
CYP3A	O
inducers	O
(	O
such	O
as	O
carbamazepine	S-drug-ME-2
,	O
phenytoin	S-drug-ME-2
,	O
rifampin	S-drug-ME-2
,	O
and	O
barbiturates	S-group-ME-2
)	O
would	O
be	O
expected	O
to	O
decrease	O
estazolam	S-drug-ME-2
concentrations	O
.	O

Estazolam	S-drug
:	O
Interaction	O
with	O
Drugs	O
that	O
Inhibit	O
Metabolism	O
via	O
Cytochrome	O
P450	O
3A	O
(	O
CYP3A	O
)	O
:	O
The	O
metabolism	O
of	O
estazolam	S-drug
to	O
the	O
major	O
circulating	O
metabolite	O
4	B-drug_n
-	I-drug_n
hydroxy	I-drug_n
-	I-drug_n
estazolam	E-drug_n
and	O
the	O
metabolism	O
of	O
other	O
triazolobenzodiazepines	S-group
is	O
catalyzed	O
by	O
CYP3A	O
.	O

Consequently	O
,	O
estazolam	S-drug-AD-1
should	O
be	O
avoided	O
in	O
patients	O
receiving	O
ketoconazole	S-drug-AD-2
and	O
itraconazole	S-drug-AD-2
,	O
which	O
are	O
very	O
potent	O
inhibitors	O
of	O
CYP3A	O
.	O

With	O
drugs	O
inhibiting	O
CYP3A	O
to	O
a	O
lesser	O
,	O
but	O
still	O
significant	O
degree	O
,	O
estazolam	S-drug
should	O
be	O
used	O
only	O
with	O
caution	O
and	O
consideration	O
of	O
appropriate	O
dosage	O
reduction	O
.	O

The	O
following	O
are	O
examples	O
of	O
drugs	O
known	O
to	O
inhibit	O
the	O
metabolism	O
of	O
other	O
related	O
benzodiazepines	S-group-ME-1
,	O
presumably	O
through	O
inhibition	O
of	O
CYP3A	O
:	O
nefazodone	S-drug-ME-2
,	O
fluvoxamine	S-drug-ME-2
,	O
cimetidine	S-drug-ME-2
,	O
diltiazem	S-drug-ME-2
,	O
isoniazide	S-drug-ME-2
,	O
and	O
some	O
macrolide	B-group-ME-2
antibiotics	E-group-ME-2
.	O

Drug	O
Interaction	O
with	O
Fluoxetine	S-drug
:	O
A	O
multiple	O
-	O
dose	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effect	O
of	O
fluoxetine	S-drug
20	O
mg	O
BID	O
on	O
the	O
pharmacokinetics	O
of	O
estazolam	S-drug
2	O
mg	O
QHS	O
after	O
seven	O
days	O
.	O

The	O
pharmacokinetics	O
of	O
estazolam	S-drug
(	O
Cmax	O
and	O
AUC	O
)	O
were	O
not	O
affected	O
during	O
multiple	O
-	O
dose	O
fluoxetine	S-drug
,	O
suggesting	O
no	O
clinically	O
significant	O
pharmacokinetic	O
interaction	O
.	O

Estazolam	S-drug
:	O
Interaction	O
with	O
Other	O
Drugs	O
that	O
are	O
Metabolized	O
by	O
Cytochrome	O
P450	O
(	O
CYP	O
)	O
:	O
At	O
clinically	O
relevant	O
concentrations	O
,	O
in	O
vitro	O
studies	O
indicate	O
that	O
estazolam	S-drug
(	O
0.6	O
M	O
)	O
was	O
not	O
inhibitory	O
towards	O
the	O
major	O
cytochrome	O
P450	O
isoforms	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
and	O
CYP3A	O
.	O

Therefore	O
,	O
based	O
on	O
these	O
in	O
vitro	O
data	O
,	O
estazolam	S-drug
is	O
very	O
unlikely	O
to	O
inhibit	O
the	O
biotransformation	O
of	O
other	O
drugs	O
metabolized	O
by	O
these	O
CYP	O
isoforms	O

D	O
.	O

Drug	O
and	O
Laboratory	O
Test	O
Interactions	O
1	O
.	O

Accelerated	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
and	O
platelet	O
aggregation	O
time	O
;	O

increased	O
platelet	O
count	O
;	O

increased	O
factors	O
II	O
,	O
VII	O
antigen	O
,	O
VIII	O
antigen	O
,	O
VIII	O
coagulant	O
activity	O
,	O
IX	O
,	O
X	O
,	O
XII	O
,	O
VII	O
-	O
X	O
complex	O
,	O
II	O
-	O
VII	O
-	O
X	O
complex	O
,	O
and	O
beta	O
-	O
thromboglobulin	O
;	O

decreased	O
levels	O
of	O
anti	O
-	O
factor	O
Xa	O
and	O
antithrombin	O
III	O
,	O
decreased	O
antithrombin	O
III	O
activity	O
;	O

increased	O
levels	O
of	O
fibrinogen	O
and	O
fibrinogen	O
activity	O
;	O

increased	O
plasminogen	O
antigen	O
and	O
activity	O
.	O

2	O
.	O

Increased	O
thyroid	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	O
hormone	O
levels	O
,	O
as	O
measured	O
by	O
protein	O
-	O
bound	O
iodine	O
(	O
PBI	O
)	O
,	O
T4	O
levels	O
(	O
by	O
column	O
or	O
by	O
radioimmunoassay	O
)	O
or	O
T3	O
levels	O
by	O
radioimmunoassay	O
.	O

T3	O
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
.	O

Free	O
T4	O
and	O
T3	O
concentrations	O
are	O
unaltered	O
.	O

Patients	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	B-group
hormone	E-group
.	O

3	O
.	O

Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
,	O
i.e	O
.	O
,	O
corticosteroid	O
binding	O
globulin	O
(	O
CBG	O
)	O
,	O
sex	O
hormone	O
-	O
binding	O
globulin	O
(	O
SHBG	O
)	O
,	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	S-group
and	O
sex	B-group
steroids	E-group
,	O
respectively	O
.	O

Free	O
hormone	O
concentrations	O
may	O
be	O
decreased	O
.	O

Other	O
plasma	O
proteins	O
may	O
be	O
increased	O
(	O
angiotensinogen	O
/	O
renin	O
substrate	O
,	O
alpha	O
-	O
1	O
-	O
antitrypsin	O
,	O
ceruloplasmin	O
)	O
.	O

4	O
.	O

Increased	O
plasma	O
HDL	O
and	O
HDL2	O
cholesterol	O
subfraction	O
concentrations	O
,	O
reduced	O
LDL	O
cholesterol	O
concentration	O
,	O
increased	O
triglyceride	O
levels	O
.	O

5	O
.	O

Impaired	O
glucose	O
tolerance	O
.	O

6	O
.	O

Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O

Milk	O
,	O
milk	O
products	O
,	O
and	O
calcium	S-drug-ME-1
-	O
rich	O
foods	O
or	O
drugs	O
may	O
impair	O
the	O
absorption	O
of	O
EMCYT	S-brand-ME-2
.	O

CNS	O
-	O
Active	O
Drugs	O
Ethanol	S-drug
An	O
additive	O
effect	O
on	O
psychomotor	O
performance	O
was	O
seen	O
with	O
coadministration	O
of	O
eszopiclone	S-drug-EF-1
and	O
ethanol	S-drug-EF-2
0.70	O
g	O
/	O
kg	O
for	O
up	O
to	O
4	O
hours	O
after	O
ethanol	S-drug
administration	O
.	O

Paroxetine	S-drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	S-drug
3	O
mg	O
and	O
paroxetine	S-drug
20	O
mg	O
daily	O
for	O
7	O
days	O
produced	O
no	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
.	O

Lorazepam	S-drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	S-drug
3	O
mg	O
and	O
lorazepam	S-drug
2	O
mg	O
did	O
not	O
have	O
clinically	O
relevant	O
effects	O
on	O
the	O
pharmacodynamics	O
or	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O

Olanzapine	S-drug
:	O
Coadministration	O
of	O
eszopiclone	S-drug-EF-1
3	O
mg	O
and	O
olanzapine	S-drug-EF-2
10	O
mg	O
produced	O
a	O
decrease	O
in	O
DSST	O
scores	O
.	O

The	O
interaction	O
was	O
pharmacodynamic	O
;	O

there	O
was	O
no	O
alteration	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O

Drugs	O
That	O
Inhibit	O
CYP3A4	O
(	O
Ketoconazole	S-drug
)	O
CYP3A4	O
is	O
a	O
major	O
metabolic	O
pathway	O
for	O
elimination	O
of	O
eszopiclone	S-drug
.	O

The	O
AUC	O
of	O
eszopiclone	S-drug-ME-1
was	O
increased	O
2.2	O
-	O
fold	O
by	O
coadministration	O
of	O
ketoconazole	S-drug-ME-2
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
400	O
mg	O
daily	O
for	O
5	O
days	O
.	O

Cmax	O
and	O
t1	O
/	O
2	O
were	O
increased	O
1.4	O
-	O
fold	O
and	O
1.3	O
-	O
fold	O
,	O
respectively	O
.	O

Other	O
strong	O
inhibitors	O
of	O
CYP3A4	O
(	O
e.g	O
.	O
,	O
itraconazole	S-drug
,	O
clarithromycin	S-drug
,	O
nefazodone	S-drug
,	O
troleandomycin	S-drug
,	O
ritonavir	S-drug
,	O
nelfinavir	S-drug
)	O
would	O
be	O
expected	O
to	O
behave	O
similarly	O
.	O

Drugs	O
That	O
Induce	O
CYP3A4	O
(	O
Rifampicin	S-drug
)	O
Racemic	O
zopiclone	S-drug-ME-1
exposure	O
was	O
decreased	O
80	O
%	O
by	O
concomitant	O
useof	O
rifampicin	S-drug-ME-2
,	O
a	O
potent	O
inducer	O
of	O
CYP3A4	O
.	O

A	O
similar	O
effect	O
would	O
be	O
expected	O
with	O
eszopiclone	S-drug
.	O

Drugs	O
Highly	O
Bound	O
To	O
Plasma	O
Protein	O
Eszopiclone	S-drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
52	O
-	O
59	O
%	O
bound	O
)	O
;	O

therefore	O
,	O
the	O
disposition	O
of	O
eszopiclone	S-drug
is	O
not	O
expected	O
to	O
be	O
sensitive	O
to	O
alterations	O
in	O
protein	O
binding	O
.	O

Administration	O
of	O
eszopiclone	S-drug
3	O
mg	O
to	O
a	O
patient	O
taking	O
another	O
drug	O
that	O
is	O
highly	O
protein	O
-	O
bound	O
would	O
not	O
be	O
expected	O
to	O
cause	O
an	O
alteration	O
in	O
the	O
free	O
concentration	O
of	O
either	O
drug	O
.	O

Drugs	O
With	O
A	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	S-drug
A	O
single	O
dose	O
of	O
eszopiclone	S-drug
3	O
mg	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
measured	O
at	O
steady	O
state	O
following	O
dosing	O
of	O
0.5	O
mg	O
twice	O
daily	O
for	O
one	O
day	O
and	O
0.25	O
mg	O
daily	O
for	O
the	O
next	O
6	O
days	O
.	O

Warfarin	S-drug
:	O
Eszopiclone	S-drug
3	O
mg	O
administered	O
daily	O
for	O
5	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
(	B-drug
R	I-drug
)	I-drug
-	E-drug
or	O
(	B-drug
S	I-drug
)	I-drug
-	I-drug
warfarin	E-drug
,	O
nor	O
were	O
there	O
any	O
changes	O
in	O
the	O
pharmacodynamic	O
profile	O
(	O
prothrombin	O
time	O
)	O
following	O
a	O
single	O
25	O
mg	O
oral	O
dose	O
of	O
warfarin	S-drug

Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ENBREL	S-brand
.	O

However	O
,	O
it	O
was	O
observed	O
that	O
the	O
pharmacokinetics	O
of	O
ENBREL	S-brand
was	O
unaltered	O
by	O
concomitant	O
methotrexate	S-drug
in	O
rheumatoid	O
arthritis	O
patients	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
ENBREL	S-brand-EF-1
and	O
anakinra	S-drug-EF-2
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
ENBREL	S-brand
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
ENBREL	S-brand-EF-1
and	O
anakinra	S-drug-EF-2
developed	O
neutropenia	O
(	O
ANC	O
1	O
x	O
109	O
/	O
L	O
)	O
.	O

Patients	O
in	O
a	O
clinical	O
study	O
who	O
were	O
on	O
established	O
therapy	O
with	O
sulfasalazine	S-drug-EF-1
,	O
to	O
which	O
ENBREL	S-brand-EF-2
was	O
added	O
,	O
were	O
noted	O
to	O
develop	O
a	O
mild	O
decrease	O
in	O
mean	O
neutrophil	O
counts	O
in	O
comparison	O
to	O
groups	O
treated	O
with	O
either	O
ENBREL	S-brand
CI	O
or	O
sulfasalazine	S-drug
alone	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
observation	O
is	O
unknown	O
.	O

Lithium	S-drug-ME-1
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	S-group-ME-2
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	S-drug
toxicity	O
.	O

Read	O
circulars	O
for	O
lithium	S-drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O

EDECRIN	S-brand-EF-1
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
other	O
drugs	O
such	O
as	O
aminoglycoside	S-group-EF-2
and	O
some	O
cephalosporin	B-group-EF-2
antibiotics	E-group-EF-2
.	O

Their	O
concurrent	O
use	O
should	O
be	O
avoided	O
.	O

A	O
number	O
of	O
drugs	O
,	O
including	O
ethacrynic	B-drug-ME-1
acid	E-drug-ME-1
,	O
have	O
been	O
shown	O
to	O
displace	O
warfarin	S-drug-ME-2
from	O
plasma	O
protein	O
;	O

a	O
reduction	O
in	O
the	O
usual	O
anticoagulant	S-group
dosage	O
may	O
be	O
required	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	B-group-EF-1
-	I-group-EF-1
steroidal	I-group-EF-1
antiinflammatory	I-group-EF-1
agent	E-group-EF-1
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	S-group-EF-2
,	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	E-group-EF-2
and	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
.	O

Therefore	O
,	O
when	O
EDECRIN	S-brand-EF-1
and	O
non	B-group-EF-2
-	I-group-EF-2
steroidal	I-group-EF-2
anti	I-group-EF-2
-	I-group-EF-2
inflammatory	I-group-EF-2
agents	E-group-EF-2
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	S-group
is	O
obtained	O
.	O

The	O
results	O
of	O
a	O
study	O
of	O
coadministration	O
of	O
ethambutol	S-drug-ME-1
(	O
50	O
mg	O
/	O
kg	O
)	O
with	O
an	O
aluminum	B-drug-ME-2
hydroxide	E-drug-ME-2
containing	O
antacid	S-group
to	O
13	O
patients	O
with	O
tuberculosis	O
showed	O
a	O
reduction	O
of	O
mean	O
serum	O
concentrations	O
and	O
urinary	O
excretion	O
of	O
ethambutol	S-drug
of	O
approximately	O
20	O
%	O
and	O
13	O
%	O
,	O
respectively	O
,	O
suggesting	O
that	O
the	O
oral	O
absorption	O
of	O
ethambutol	S-drug
may	O
be	O
reduced	O
by	O
these	O
antacid	B-group
products	E-group
.	O

It	O
is	O
recommended	O
to	O
avoid	O
concurrent	O
administration	O
of	O
ethambutol	S-drug-AD-1
with	O
aluminum	B-drug-AD-2
hydroxide	E-drug-AD-2
containing	O
antacids	S-group
for	O
at	O
least	O
4	O
hours	O
following	O
ethambutol	S-drug
administration	O
.	O

Dicumarol	S-drug
and	O
warfarin	S-drug
may	O
decrease	O
hypoprothrombinemic	O
effect	O
.	O

Other	O
depressasnts	O
such	O
as	O
alcohol	S-drug-EF-1
,	O
barbiturates	S-group-EF-1
,	O
and	O
MAOIs	S-group-EF-1
may	O
enhance	O
CNS	O
depression	O
when	O
administered	O
with	O
ethchlorvynol	S-drug-EF-2
.	O

May	O
interact	O
with	O
addictive	O
medications	O
,	O
especially	O
central	B-group
nervous	I-group
system	I-group
(	I-group
CNS	I-group
)	I-group
depressants	E-group
with	O
habituating	O
potential	O
(	O
prolonged	O
concurrent	O
use	O
may	O
increase	O
the	O
risk	O
of	O
habituation	O
)	O
,	O
alcohol	S-drug
or	O
CNS	O
depression	O
producing	O
medications	O
(	O
concurrent	O
use	O
may	O
increase	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
ethinamate	S-drug
)	O
.	O

Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen	S-group
-	O
containing	O
oral	O
contraceptives	S-group
.	O

The	O
following	O
similar	O
changes	O
may	O
be	O
expected	O
with	O
larger	O
doses	O
of	O
estrogen	S-group
:	O
Increased	O
sulfobromophthalein	O
retention	O
;	O

increased	O
prothrombin	O
and	O
factors	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
;	O

decreased	O
antithrombin	O
3	O
;	O

increased	O
norepinephrine	O
-	O
induced	O
platel	O
et	O
aggregation	O
;	O

increased	O
thyroid	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	O
hormone	O
,	O
as	O
measured	O
by	O
PBI	O
,	O
T4	O
by	O
column	O
,	O
or	O
T4	O
by	O
radioimmunoassay	O
.	O

Free	O
T3	O
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
;	O

free	O
T4	O
concentration	O
is	O
unaltered	O
:	O
impaired	O
glucose	O
tolerance	O
;	O

decreased	O
pregnanediol	O
excretion	O
;	O

reduced	O
response	O
to	O
metyrapone	O
test	O
;	O

reduced	O
serum	O
folate	O
concentration	O
;	O

increased	O
serum	O
triglyceride	O
and	O
phospholipid	O
concentration	O
.	O

Trecator	S-brand-ME-1
has	O
been	O
found	O
to	O
temporarily	O
raise	O
serum	O
concentrations	O
of	O
isoniazid	S-drug-ME-2
.	O

Trecator	S-brand-EF-1
may	O
potentiate	O
the	O
adverse	O
effects	O
of	O
other	O
antituberculous	B-group-EF-2
drugs	E-group-EF-2
administered	O
concomitantly	O
.	O

In	O
particular	O
,	O
convulsions	O
have	O
been	O
reported	O
when	O
ethionamide	S-drug-EF-1
is	O
administered	O
with	O
cycloserine	S-drug-EF-2
and	O
special	O
care	O
should	O
be	O
taken	O
when	O
the	O
treatment	O
regimen	O
includes	O
both	O
of	O
these	O
drugs	O
.	O

Excessive	O
ethanol	S-drug
ingestion	O
should	O
be	O
avoided	O
because	O
a	O
psychotic	O
reaction	O
has	O
been	O
reported	O
.	O

Ethopropazine	S-drug-EF-1
may	O
interact	O
with	O
alcohol	S-drug-EF-2
or	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
,	O
causing	O
increased	O
sedative	O
effects	O
.	O

It	O
may	O
also	O
interact	O
with	O
amantadine	S-drug
or	O
other	O
anticholinergic	B-group
drugs	E-group
or	O
MAOIs	S-group
,	O
which	O
may	O
intensify	O
the	O
anticholinergic	O
action	O
.	O

Ethopropazine	S-drug-ME-1
can	O
interact	O
with	O
chlorpromazine	S-drug-ME-2
,	O
increasing	O
the	O
metabolism	O
of	O
chlorpromazine	S-drug
.	O

Since	O
Zarontin	S-brand-IN-1
(	O
ethosuximide	S-drug-IN-1
)	O
may	O
interact	O
with	O
concurrently	O
administered	O
antiepileptic	B-group-IN-2
drugs	E-group-IN-2
,	O
periodic	O
serum	O
level	O
determinations	O
of	O
these	O
drugs	O
may	O
be	O
necessary	O
(	O
eg	O
,	O
ethosuximide	S-drug-ME-1
may	O
elevate	O
phenytoin	S-drug-ME-2
serum	O
levels	O
and	O
valproic	B-drug-ME-1
acid	E-drug-ME-1
has	O
been	O
reported	O
to	O
both	O
increase	O
and	O
decrease	O
ethosuximide	S-drug-ME-2
levels	O
)	O
.	O

PEGANONE	S-brand
used	O
in	O
combination	O
with	O
other	O
drugs	O
known	O
to	O
adversely	O
affect	O
the	O
hematopoietic	O
system	O
should	O
be	O
avoided	O
if	O
possible	O
.	O

Considerable	O
caution	O
should	O
be	O
exercised	O
if	O
PEGANONE	S-brand-AD-1
is	O
administered	O
concurrently	O
with	O
Phenurone	S-brand-AD-2
(	O
phenacemide	S-drug-AD-2
)	O
since	O
paranoid	O
symptoms	O
have	O
been	O
reported	O
during	O
therapy	O
with	O
this	O
combination	O
.	O

A	O
two	O
-	O
way	O
interaction	O
between	O
the	O
hydantoin	B-group-IN-1
antiepileptic	E-group-IN-1
,	O
phenytoin	S-drug-IN-2
,	O
and	O
the	O
coumarin	B-group-IN-2
anticoagulants	O
has	O
been	O
suggested	O
.	O

Presumably	O
,	O
phenytoin	S-drug-ME-1
acts	O
as	O
a	O
stimulator	O
of	O
coumarin	S-group-ME-2
metabolism	O
and	O
has	O
been	O
reported	O
to	O
cause	O
decreased	O
serum	O
levels	O
of	O
the	O
coumarin	B-group-ME-2
anticoagulants	E-group-ME-2
and	O
increased	O
prothrombin	O
-	O
proconvertin	O
concentrations	O
.	O

Conversely	O
,	O
the	O
coumarin	B-group-ME-1
anticoagulants	E-group-ME-1
have	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
levels	O
and	O
prolong	O
the	O
serum	O
half	O
-	O
life	O
of	O
phenytoin	S-drug-ME-2
by	O
inhibiting	O
its	O
metabolism	O
.	O

Although	O
there	O
is	O
no	O
documentation	O
of	O
such	O
,	O
a	O
similar	O
interaction	O
between	O
ethotoin	S-drug
and	O
the	O
coumarin	B-group
anticoagulants	E-group
may	O
occur	O
.	O

Caution	O
is	O
therefore	O
advised	O
when	O
administering	O
PEGANONE	S-brand-AD-1
to	O
patients	O
receiving	O
coumarin	B-group-AD-2
anticoagulants	E-group-AD-2
.	O

Ethoxzolamide	S-drug-EF-1
may	O
increase	O
the	O
action	O
of	O
tricyclics	S-group-EF-2
,	O
amphetamines	S-group-EF-2
,	O
procainamide	S-drug-EF-2
,	O
and	O
quinidine	S-drug-EF-2
.	O

It	O
may	O
increase	O
excretion	O
of	O
barbiturates	S-group
,	O
lithium	S-drug
,	O
and	O
ASA	S-drug
and	O
may	O
also	O
increase	O
the	O
toxicity	O
of	O
salicylates	S-group
.	O

Coadministration	O
of	O
ethoxzolamide	S-drug-EF-1
with	O
other	O
diuretics	S-group-EF-2
,	O
amphotericin	B-drug-EF-2
B	E-drug-EF-2
,	O
and	O
corticosteroids	S-group-EF-2
may	O
cause	O
hypokalemia	O
.	O

Ethinyl	B-drug
estradiol	E-drug
:	O
Substrate	O
of	O
CYP3A4	O
(	O
major	O
)	O
,	O
3A5	O
-	O
7	O
(	O
minor	O
)	O
;	O

Inhibits	O
CYP1A2	O
(	O
weak	O
)	O
,	O
2B6	O
(	O
weak	O
)	O
,	O
2C19	O
(	O
weak	O
)	O
,	O
3A4	O
(	O
weak	O
)	O
.	O

Acetaminophen	S-drug-ME-1
:	O
May	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B-group-ME-2
estrogens	E-group-ME-2
,	O
possibly	O
by	O
inhibiting	O
conjugation	O
.	O

Combination	O
hormonal	B-group-ME-1
contraceptives	E-group-ME-1
may	O
also	O
decrease	O
the	O
plasma	O
concentration	O
of	O
acetaminophen	S-drug-ME-2
.	O

Acitretin	S-drug-EF-1
:	O
Interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin	S-group-EF-2
-	O
containing	O
minipill	O
preparations	O
.	O

The	O
effect	O
on	O
other	O
progestational	B-group
contraceptives	E-group
(	O
eg	O
,	O
implants	O
,	O
injectables	O
)	O
is	O
unknown	O
.	O

Aminoglutethimide	S-drug-ME-1
:	O
May	O
increase	O
CYP	O
metabolism	O
of	O
progestins	S-group-ME-2
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O

Use	O
of	O
a	O
nonhormonal	B-group
contraceptive	I-group
product	E-group
is	O
recommended	O
.	O

Antibiotics	S-group
(	O
ampicillin	S-drug
,	O
tetracycline	S-drug
)	O
:	O
Pregnancy	O
has	O
been	O
reported	O
following	O
concomitant	O
use	O
,	O
however	O
,	O
pharmacokinetic	O
studies	O
have	O
not	O
shown	O
consistent	O
effects	O
with	O
these	O
antibiotics	S-group
on	O
plasma	O
concentrations	O
of	O
synthetic	B-group
steroids	E-group
.	O

Use	O
of	O
a	O
nonhormonal	B-group
contraceptive	I-group
product	E-group
is	O
recommended	O
.	O

Anticoagulants	S-group
:	O
Combination	O
hormonal	B-group-EF-1
contraceptives	E-group-EF-1
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
coumarin	B-group-EF-2
derivatives	E-group-EF-2
.	O

Combination	O
hormonal	B-group
contraceptives	E-group
may	O
also	O
increase	O
risk	O
of	O
thromboembolic	O
disorders	O
.	O

Anticonvulsants	S-group-ME-1
(	O
carbamazepine	S-drug-ME-1
,	O
felbamate	S-drug-ME-1
,	O
phenobarbital	S-drug-ME-1
,	O
phenytoin	S-drug-ME-1
,	O
topiramate	S-drug-ME-1
)	O
:	O
Increase	O
the	O
metabolism	O
of	O
ethinyl	B-drug-ME-2
estradiol	E-drug-ME-2
and	O
/	O
or	O
some	O
progestins	S-group-ME-2
,	O
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O

Use	O
of	O
a	O
nonhormonal	B-group
contraceptive	I-group
product	E-group
is	O
recommended	O
.	O

Ascorbic	B-drug
acid	E-drug
:	O
Doses	O
of	O
ascorbic	B-drug-ME-1
acid	E-drug-ME-1
(	O
vitamin	B-drug-ME-1
C	E-drug-ME-1
)	O
1	O
g	O
/	O
day	O
have	O
been	O
reported	O
to	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B-group-ME-2
estrogens	E-group-ME-2
by	O
~	O
47	O
%	O
,	O
possibly	O
by	O
inhibiting	O
conjugation	O
;	O

clinical	O
implications	O
are	O
unclear	O
.	O

Atorvastatin	S-drug
:	O
Atorvastatin	S-drug-ME-1
increases	O
the	O
AUC	O
for	O
norethindrone	S-drug-ME-2
and	O
ethinyl	B-drug-ME-2
estradiol	E-drug-ME-2
.	O

Benzodiazepines	S-group
:	O
Combination	O
hormonal	B-group-ME-1
contraceptives	E-group-ME-1
may	O
decrease	O
the	O
clearance	O
of	O
some	O
benzodiazepines	S-group-ME-2
(	O
alprazolam	S-drug-ME-2
,	O
chlordiazepoxide	S-drug-ME-2
,	O
diazepam	S-drug-ME-2
)	O
and	O
increase	O
the	O
clearance	O
of	O
others	O
(	O
lorazepam	S-drug-ME-2
,	O
oxazepam	S-drug-ME-2
,	O
temazepam	S-drug-ME-2
)	O
.	O

Clofibric	B-drug_n
acid	E-drug_n
:	O
Combination	O
hormonal	B-group-ME-1
contraceptives	E-group-ME-1
may	O
increase	O
the	O
clearance	O
of	O
clofibric	B-drug_n-ME-2
acid	E-drug_n-ME-2
.	O

Cyclosporine	S-drug
:	O
Combination	O
hormonal	B-group-ME-1
contraceptives	E-group-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
cyclosporine	S-drug-ME-2
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
;	O

monitor	O
cyclosporine	S-drug
levels	O
.	O

CYP3A4	O
inducers	O
:	O
CYP3A4	O
inducers	O
may	O
decrease	O
the	O
levels	O
/	O
effects	O
of	O
ethinyl	B-drug
estradiol	E-drug
.	O

Example	O
inducers	O
include	O
aminoglutethimide	S-drug
,	O
carbamazepine	S-drug
,	O
nafcillin	S-drug
,	O
nevirapine	S-drug
,	O
phenobarbital	S-drug
,	O
phenytoin	S-drug
,	O
and	O
rifamycins	S-group
.	O

Griseofulvin	S-drug
:	O
Griseofulvin	S-drug-ME-1
may	O
induce	O
the	O
metabolism	O
of	O
combination	B-group-ME-2
hormonal	I-group-ME-2
contraceptives	E-group-ME-2
causing	O
menstrual	O
changes	O
;	O

pregnancies	O
have	O
been	O
reported	O
.	O

Use	O
of	O
barrier	O
form	O
of	O
contraception	O
is	O
suggested	O
while	O
on	O
griseofulvin	S-drug
therapy	O
.	O

Morphine	S-drug
:	O
Combination	O
hormonal	B-group-ME-1
contraceptives	E-group-ME-1
may	O
increase	O
the	O
clearance	O
of	O
morphine	S-drug-ME-2
.	O

Non	B-group
-	I-group
nucleoside	I-group
reverse	I-group
transcriptase	I-group
inhibitors	E-group
(	O
NNRTIs	S-group
)	O
:	O
Nevirapine	S-drug-ME-1
may	O
decrease	O
plasma	O
levels	O
of	O
combination	B-group-ME-2
hormonal	I-group-ME-2
contraceptives	E-group-ME-2
;	O

use	O
of	O
a	O
nonhormonal	B-group
contraceptive	I-group
product	E-group
is	O
recommended	O
.	O

No	O
data	O
for	O
delavirdine	S-drug
;	O

incomplete	O
data	O
for	O
efavirenz	S-drug
.	O

Prednisolone	S-drug
:	O
Ethinyl	B-drug-ME-1
estradiol	E-drug-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
prednisolone	S-drug-ME-2
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Protease	B-group
inhibitors	E-group
:	O
Amprenavir	S-drug-ME-1
,	O
lopinavir	S-drug-ME-1
,	O
nelfinavir	S-drug-ME-1
,	O
and	O
ritonavir	S-drug-ME-1
have	O
been	O
shown	O
to	O
decrease	O
plasma	O
levels	O
of	O
combination	B-group-ME-2
hormonal	I-group-ME-2
contraceptives	E-group-ME-2
;	O

use	O
of	O
a	O
nonhormonal	B-group
contraceptive	I-group
product	E-group
is	O
recommended	O
.	O

Indinavir	S-drug-ME-1
has	O
been	O
shown	O
to	O
increase	O
plasma	O
levels	O
of	O
combination	B-group-ME-2
hormonal	I-group-ME-2
contraceptives	E-group-ME-2
.	O

No	O
data	O
for	O
saquinavir	S-drug
.	O

Rifampin	S-drug
:	O
Rifampin	S-drug-ME-1
increases	O
the	O
metabolism	O
of	O
ethinyl	B-drug-ME-2
estradiol	E-drug-ME-2
and	O
some	O
progestins	S-group-ME-2
(	O
norethindrone	S-drug-ME-2
)	O
resulting	O
in	O
decreased	O
contraceptive	O
effectiveness	O
and	O
increased	O
menstrual	O
irregularities	O
.	O

Use	O
of	O
a	O
nonhormonal	B-group
contraceptive	I-group
product	E-group
is	O
recommended	O
.	O

Salicylic	B-drug
acid	E-drug
:	O
Combination	O
hormonal	B-group-ME-1
contraceptives	E-group-ME-1
may	O
increase	O
the	O
clearance	O
of	O
salicylic	B-drug-ME-2
acid	E-drug-ME-2
.	O

Selegiline	S-drug
:	O
Combination	B-group-ME-1
hormonal	I-group-ME-1
contraceptives	E-group-ME-1
may	O
increase	O
the	O
serum	O
concentration	O
of	O
selegiline	S-drug-ME-2
.	O

Theophylline	S-drug
:	O
Ethinyl	B-drug-ME-1
estradiol	E-drug-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
theophylline	S-drug-ME-2
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Tricyclic	B-group-ME-1
antidepressants	E-group-ME-1
(	O
amitriptyline	S-drug-ME-1
,	O
imipramine	S-drug-ME-1
,	O
nortriptyline	S-drug-ME-1
)	O
:	O
Metabolism	O
may	O
be	O
inhibited	O
by	O
combination	B-group-ME-2
hormonal	I-group-ME-2
contraceptives	E-group-ME-2
,	O
increasing	O
plasma	O
levels	O
of	O
antidepressant	S-group
;	O

use	O
caution	O
.	O

ETHANOL	S-drug
/	O
NUTRITION	O
/	O
HERB	O
INTERACTIONS	O
:	O
Food	O
:	O
CNS	O
effects	O
of	O
caffeine	S-drug
may	O
be	O
enhanced	O
if	O
combination	B-group-EF-1
hormonal	I-group-EF-1
contraceptives	E-group-EF-1
are	O
used	O
concurrently	O
with	O
caffeine	S-drug-EF-2
.	O

Grapefruit	O
juice	O
increases	O
ethinyl	B-drug
estradiol	E-drug
concentrations	O
and	O
would	O
be	O
expected	O
to	O
increase	O
progesterone	S-drug
serum	O
levels	O
as	O
well	O
;	O

clinical	O
implications	O
are	O
unclear	O
.	O

Herb	O
/	O
Nutraceutical	O
:	O
St	O
Johns	O
wort	O
may	O
decrease	O
the	O
effectiveness	O
of	O
combination	B-group
hormonal	I-group
contraceptives	E-group
by	O
inducing	O
hepatic	O
enzymes	O
.	O

Avoid	O
dong	O
quai	O
and	O
black	O
cohosh	O
(	O
have	O
estrogen	O
activity	O
)	O
.	O

Avoid	O
saw	O
palmetto	O
,	O
red	O
clover	O
,	O
ginseng	O
.	O

There	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
experiencing	O
increases	O
in	O
their	O
prothrombin	O
times	O
when	O
etidronate	S-drug-EF-1
was	O
added	O
to	O
warfarin	S-drug-EF-2
therapy	O
.	O

The	O
majority	O
of	O
these	O
reports	O
concerned	O
variable	O
elevations	O
in	O
prothrombin	O
times	O
without	O
clinically	O
significant	O
sequelae	O
.	O

Although	O
the	O
relevance	O
of	O
these	O
reports	O
and	O
any	O
mechanism	O
of	O
coagulation	O
alterations	O
is	O
unclear	O
,	O
patients	O
on	O
warfarin	S-drug
should	O
have	O
their	O
prothrombin	O
time	O
monitored	O
.	O

ACE	B-group
-	I-group
inhibitors	E-group
Reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-group-EF-2
-	I-group-EF-2
inhibitors	E-group-EF-2
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	S-group-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
-	I-group-AD-2
inhibitors	E-group-AD-2
.	O

Antacids	S-group
:	O
The	O
concomitant	O
administration	O
of	O
antacids	S-group
has	O
no	O
apparent	O
effect	O
on	O
the	O
extent	O
of	O
absorption	O
of	O
Lodine	S-brand
.	O

However	O
,	O
antacids	S-group
can	O
decrease	O
the	O
peak	O
concentration	O
reached	O
by	O
15	O
%	O
to	O
20	O
%	O
but	O
have	O
no	O
detectable	O
effect	O
on	O
the	O
time	O
-	O
to	O
-	O
peak	O
.	O

Aspirin	S-brand
:	O
When	O
Lodine	S-brand-ME-1
is	O
administered	O
with	O
aspirin	S-brand-ME-2
,	O
its	O
protein	O
binding	O
is	O
reduced	O
,	O
although	O
the	O
clearance	O
of	O
free	O
etodolac	S-drug
is	O
not	O
altered	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
known	O
;	O

however	O
,	O
as	O
with	O
other	O
NSAIDs	S-group
,	O
concomitant	O
administration	O
of	O
Lodine	S-brand-AD-1
and	O
aspirin	S-brand-AD-2
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O

Cyclosporine	O
,	O
Digoxin	O
,	O
Methotrexate	O
Lodine	S-brand-ME-1
,	O
like	O
other	O
NSAIDs	S-group-ME-1
,	O
through	O
effects	O
on	O
renal	O
prostaglandins	O
,	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
these	O
drugs	O
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
cyclosporine	S-drug-ME-2
,	O
digoxin	S-drug-ME-2
,	O
methotrexate	S-drug-ME-2
,	O
and	O
increased	O
toxicity	O
.	O

Nephrotoxicity	O
associated	O
with	O
cyclosporine	S-drug
may	O
also	O
be	O
enhanced	O
.	O

Patients	O
receiving	O
these	O
drugs	O
who	O
are	O
given	O
Lodine	S-brand
,	O
or	O
any	O
other	O
NSAID	S-group
,	O
and	O
particularly	O
those	O
patients	O
with	O
altered	O
renal	O
function	O
,	O
should	O
be	O
observed	O
for	O
the	O
development	O
of	O
the	O
specific	O
toxicities	O
of	O
these	O
drugs	O
.	O

Diuretics	S-group
:	O
Etodolac	O
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
furosemide	S-drug
or	O
hydrochlorothiazide	S-drug
.	O

Nevertheless	O
,	O
clinical	O
studies	O
,	O
as	O
well	O
as	O
postmarketing	O
observations	O
have	O
shown	O
that	O
Lodine	S-brand-EF-1
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	S-drug-EF-2
and	O
thiazides	S-group-EF-2
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

During	O
concomitant	O
therapy	O
with	O
NSAIDs	S-group
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	O
efficacy	O
.	O

Glyburide	S-drug
:	O
Etodolac	S-drug
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
glyburide	S-drug
.	O

Lithium	S-drug
:	O
NSAIDs	S-group-ME-1
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	S-drug-ME-2
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	S-drug
clearance	O
.	O

The	O
mean	O
minimum	O
lithium	S-drug
concentration	O
increased	O
15	O
%	O
and	O
the	O
renal	O
clearance	O
was	O
decreased	O
by	O
approximately	O
20	O
%	O
.	O

These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
the	O
NSAID	S-group
.	O

Thus	O
,	O
when	O
NSAIDs	S-group-EF-1
and	O
lithium	S-drug-EF-2
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	S-drug
toxicity	O
.	O

Phenylbutazone	S-drug
:	O
Phenylbutazone	S-drug-ME-1
causes	O
increase	O
(	O
by	O
about	O
80	O
%	O
)	O
in	O
the	O
free	O
fraction	O
of	O
etodolac	S-drug-ME-2
.	O

Although	O
in	O
vivo	O
studies	O
have	O
not	O
been	O
done	O
to	O
see	O
if	O
etodolac	S-drug-AD-1
clearance	O
is	O
changed	O
by	O
coadministration	O
of	O
phenylbutazone	S-drug-AD-2
,	O
it	O
is	O
not	O
recommended	O
that	O
they	O
be	O
coadministered	O
.	O

Phenytoin	S-drug
:	O
Etodolac	S-drug
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
phenytoin	S-drug
.	O

Warfarin	S-drug
:	O
The	O
effects	O
of	O
warfarin	S-drug-EF-1
and	O
NSAIDs	S-group-EF-2
on	O
GI	O
bleeding	O
are	O
synergistic	O
,	O
such	O
that	O
users	O
of	O
both	O
drugs	O
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
that	O
of	O
users	O
of	O
either	O
drug	O
alone	O
.	O

Short	O
-	O
term	O
pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
administration	O
of	O
warfarin	S-drug-ME-1
and	O
Lodine	S-brand-ME-2
(	O
etodolac	S-drug-ME-2
capsules	O
and	O
tablets	O
)	O
results	O
in	O
reduced	O
protein	O
binding	O
of	O
warfarin	S-drug
,	O
but	O
there	O
was	O
no	O
change	O
in	O
the	O
clearance	O
of	O
free	O
warfarin	S-drug
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
pharmacodynamic	O
effect	O
of	O
warfarin	S-drug
administered	O
alone	O
and	O
warfarin	S-drug
administered	O
with	O
Lodine	S-brand
as	O
measured	O
by	O
prothrombin	O
time	O
.	O

Thus	O
,	O
concomitant	O
therapy	O
with	O
warfarin	S-drug
and	O
Lodine	S-brand
should	O
not	O
require	O
dosage	O
adjustment	O
of	O
either	O
drug	O
.	O

However	O
,	O
caution	O
should	O
be	O
exercised	O
because	O
there	O
have	O
been	O
a	O
few	O
spontaneous	O
reports	O
of	O
prolonged	O
prothrombin	O
times	O
,	O
with	O
or	O
without	O
bleeding	O
,	O
in	O
etodolac	S-drug-EF-1
-	O
treated	O
patients	O
receiving	O
concomitant	O
warfarin	S-drug-EF-2
therapy	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
urine	O
of	O
patients	O
who	O
take	O
Lodine	S-brand
can	O
give	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
urinary	O
bilirubin	O
(	O
urobilin	O
)	O
due	O
to	O
the	O
presence	O
of	O
phenolic	O
metabolites	O
of	O
etodolac	S-drug
.	O

Diagnostic	O
dip	O
-	O
stick	O
methodology	O
,	O
used	O
to	O
detect	O
ketone	O
bodies	O
in	O
urine	O
,	O
has	O
resulted	O
in	O
false	O
-	O
positive	O
findings	O
in	O
some	O
patients	O
treated	O
with	O
Lodine	S-brand
.	O

Generally	O
,	O
this	O
phenomenon	O
has	O
not	O
been	O
associated	O
with	O
other	O
clinically	O
significant	O
events	O
.	O

No	O
dose	O
relationship	O
has	O
been	O
observed	O
.	O

Lodine	S-brand
treatment	O
is	O
associated	O
with	O
a	O
small	O
decrease	O
in	O
serum	O
uric	O
acid	O
levels	O
.	O

In	O
clinical	O
trials	O
,	O
mean	O
decreases	O
of	O
1	O
to	O
2	O
mg	O
/	O
dL	O
were	O
observed	O
in	O
arthritic	O
patients	O
receiving	O
etodolac	S-drug
(	O
600	O
mg	O
to	O
1000	O
mg	O
/	O
day	O
)	O
after	O
4	O
weeks	O
of	O
therapy	O
.	O

These	O
levels	O
then	O
remained	O
stable	O
for	O
up	O
to	O
1	O
year	O
of	O
therapy	O
.	O

The	O
following	O
drug	O
interactions	O
have	O
been	O
reported	O
with	O
etomidate	S-drug
.	O

Drug	O
Effect	O

Probenecid	S-drug
Prolonged	O
action	O
of	O
etomidate	S-drug

Diazoxide	S-drug
Hypotension	O

Zimelidine	S-drug_n
etomidate	S-drug
antagonism	O

Opioid	B-group
analgesics	E-group
Decreased	O
antinociceptive	O
action	O

Aminophylline	S-drug
Etomidate	S-drug
antagonism	O

Midazolam	S-drug
Synergism	O

Etonogestrel	S-drug-IN-1
may	O
interact	O
with	O
the	O
following	O
medications	O
:	O
acetaminophen	S-drug-IN-2
(	O
Tylenol	S-brand-IN-2
)	O
,	O
antibiotics	S-group-IN-2
such	O
as	O
ampicillin	S-drug-IN-2
and	O
tetracycline	S-drug-IN-2
,	O
anticonvulsants	S-group-IN-2
(	O
Dilantin	S-brand-IN-2
,	O
Phenobarbital	S-drug-IN-2
,	O
Tegretol	S-brand-IN-2
,	O
Trileptal	S-brand-IN-2
,	O
Topamax	S-brand-IN-2
,	O
Felbatol	S-brand-IN-2
)	O
,	O
antifungals	S-group-IN-2
(	O
Gris	B-brand-IN-2
-	I-brand-IN-2
PEG	E-brand-IN-2
,	O
Nizoral	S-brand-IN-2
,	O
Sporanox	S-brand-IN-2
)	O
,	O
atorvastatin	S-drug-IN-2
(	O
Lipitor	S-brand-IN-2
)	O
,	O
clofibrate	S-drug-IN-2
(	O
Atromid	B-brand-IN-2
-	I-brand-IN-2
S	E-brand-IN-2
)	O
,	O
cyclosporine	S-drug-IN-2
(	O
Neoral	S-brand-IN-2
,	O
Sandimmune	S-brand-IN-2
)	O
,	O
HIV	O
drugs	O
classified	O
as	O
protease	B-group-IN-2
inhibitors	E-group-IN-2
(	O
Agenerase	S-brand-IN-2
,	O
Crixivan	S-brand-IN-2
,	O
Fortovase	S-brand-IN-2
,	O
Invirase	S-brand-IN-2
,	O
Kaletra	S-brand-IN-2
,	O
Norvir	S-brand-IN-2
,	O
Viracept	S-brand-IN-2
)	O
,	O
morphine	S-drug-IN-2
(	O
Astramorph	S-brand-IN-2
,	O
Kadian	S-brand-IN-2
,	O
MS	B-brand-IN-2
Contin	E-brand-IN-2
)	O
,	O
phenylbutazone	S-drug-IN-2
,	O
prednisolone	S-drug-IN-2
(	O
Prelone	S-brand-IN-2
)	O
,	O
rifadin	S-brand-IN-2
(	O
rifampin	S-drug-IN-2
)	O
,	O
St.	O
Johns	O
wort	O
,	O
temazepam	S-drug-IN-2
,	O
theophylline	S-drug-IN-2
(	O
Theo	B-brand-IN-2
-	I-brand-IN-2
Dur	E-brand-IN-2
)	O
,	O
and	O
vitamin	B-drug-IN-2
C	E-drug-IN-2
.	O

Caution	O
should	O
be	O
exercised	O
when	O
administering	O
ETOPOPHOS	S-brand-AD-1
with	O
drugs	O
that	O
are	O
known	O
to	O
inhibit	O
phosphatase	O
activities	O
(	O
e.g	O
.	O
,	O
levamisole	B-drug-AD-2
hydrochloride	E-drug-AD-2
)	O
.	O

High	O
-	O
dose	O
cyclosporin	B-drug-ME-1
A	E-drug-ME-1
resulting	O
in	O
concentrations	O
above	O
2000	O
ng	O
/	O
mL	O
administered	O
with	O
oral	O
etoposide	S-drug-ME-2
has	O
led	O
to	O
an	O
80	O
%	O
increase	O
in	O
etoposide	S-drug
exposure	O
with	O
a	O
38	O
%	O
decrease	O
in	O
total	O
body	O
clearance	O
of	O
etoposide	S-drug
compared	O
to	O
etoposide	S-drug
alone	O
.	O

Exemestane	S-drug
is	O
extensively	O
metabolized	O
by	O
CYP	O
3A4	O
,	O
but	O
coadministration	O
of	O
ketoconazole	S-drug
,	O
a	O
potent	O
inhibitor	O
of	O
CYP	O
3A4	O
,	O
has	O
no	O
significant	O
effect	O
on	O
exemestane	S-drug
pharmacokinetics	O
.	O

Significant	O
pharmacokinetic	O
interactions	O
mediated	O
by	O
inhibition	O
of	O
CYP	O
isoenzymes	O
therefore	O
appear	O
unlikely	O
.	O

Co	O
-	O
medications	O
that	O
induce	O
CYP	O
3A4	O
(	O
e.g	O
.	O
,	O
rifampicin	S-drug-ME-1
,	O
phenytoin	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
,	O
phenobarbital	S-drug-ME-1
,	O
or	O
St.	O
John	O
s	O
wort	O
)	O
may	O
significantly	O
decrease	O
exposure	O
to	O
exemestane	S-drug-ME-2
.	O

Dose	O
modification	O
is	O
recommended	O
for	O
patients	O
who	O
are	O
also	O
receiving	O
a	O
potent	O
CYP	O
3A4	O
inducer	O
.	O

Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
No	O
clinically	O
relevant	O
changes	O
in	O
the	O
results	O
of	O
clinical	O
laboratory	O
tests	O
have	O
been	O
observed	O
.	O

Concurrent	O
use	O
with	O
probenecid	S-drug-ME-1
or	O
other	O
drugs	O
significantly	O
eliminated	O
by	O
active	O
renal	O
tubular	O
secretion	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
penciclovir	S-drug-ME-2
.	O

The	O
conversion	O
of	O
6	B-drug_n
-	I-drug_n
deoxy	I-drug_n
penciclovir	E-drug_n
to	O
penciclovir	S-drug
is	O
catalyzed	O
by	O
aldehyde	O
oxidase	O
.	O

Interactions	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
could	O
potentially	O
occur	O
.	O

No	O
drug	O
interactions	O
have	O
been	O
identified	O
.	O

Studies	O
with	O
famotidine	S-drug
in	O
man	O
,	O
in	O
animal	O
models	O
,	O
and	O
in	O
vitro	O
have	O
shown	O
no	O
significant	O
interference	O
with	O
the	O
disposition	O
of	O
compounds	O
metabolized	O
by	O
the	O
hepatic	O
microsomal	O
enzymes	O
,	O
e.g	O
.	O
,	O
cytochrome	O
P450	O
system	O
.	O

Compounds	O
tested	O
in	O
man	O
include	O
warfarin	S-drug
,	O
theophylline	S-drug
,	O
phenytoin	S-drug
,	O
diazepam	S-drug
,	O
aminopyrine	S-drug
and	O
antipyrine	S-drug
.	O

Indocyanine	B-drug_n
green	E-drug_n
as	O
an	O
index	O
of	O
hepatic	O
drug	O
extraction	O
has	O
been	O
tested	O
and	O
no	O
significant	O
effects	O
have	O
been	O
found	O
.	O

The	O
drug	O
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
controlled	O
clinical	O
trials	O
and	O
studies	O
involving	O
otherwise	O
healthy	O
adults	O
with	O
epilepsy	O
.	O

Use	O
in	O
Conjunction	O
with	O
Other	O
Antiepileptic	B-group
Drugs	E-group
:	O
The	O
addition	O
of	O
Felbatol	S-brand-ME-1
to	O
antiepileptic	B-group-ME-2
drugs	E-group-ME-2
(	O
AEDs	S-group-ME-2
)	O
affects	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
AEDs	S-group
.	O

The	O
net	O
effect	O
of	O
these	O
interactions	O
is	O
summarized	O
in	O
the	O
following	O
table	O
:	O
AED	S-group
AED	S-group
Felbatol	S-brand

Coadministered	O
Concentration	O
Concentration	O

Valproate	S-drug
*	O
*	O

Carbamazepine	S-drug
(	O
CBZ	S-drug
)	O

*	O
CBZ	O
epoxide	O

*	O
Not	O
administered	O
,	O
but	O
an	O
active	O
metabolite	O
of	O
carbamazepine	S-drug
.	O

*	O
*	O
No	O
significant	O
effect	O
.	O

Specific	O
Effects	O
of	O
Felbatol	S-brand
on	O
Other	O
Antiepileptic	B-group
Drugs	E-group
Phenytoin	S-drug
:	O
Felbatol	S-brand-ME-1
causes	O
an	O
increase	O
in	O
steady	O
-	O
state	O
phenytoin	S-drug-ME-2
plasma	O
concentrations	O
.	O

In	O
10	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
phenytoin	S-drug
,	O
the	O
steadystate	O
trough	O
(	O
Cmin	O
)	O
phenytoin	S-drug
plasma	O
concentration	O
was	O
17	O
5	O
micrograms	O
/	O
mL	O
.	O

The	O
steady	O
-	O
state	O
Cmin	O
increased	O
to	O
21	O
5	O
micrograms	O
/	O
mL	O
when	O
1200	O
mg	O
/	O
day	O
of	O
felbamate	S-drug
was	O
coadministered	O
.	O

Increasing	O
the	O
felbamate	S-drug-ME-1
dose	O
to	O
1800	O
mg	O
/	O
day	O
in	O
six	O
of	O
these	O
subjects	O
increased	O
the	O
steady	O
-	O
state	O
phenytoin	S-drug-ME-2
Cmin	O
to	O
25	O
7	O
micrograms	O
/	O
mL	O
.	O

In	O
order	O
to	O
maintain	O
phenytoin	S-drug
levels	O
,	O
limit	O
adverse	O
experiences	O
,	O
and	O
achieve	O
the	O
felbamate	S-drug-AD-1
dose	O
of	O
3600	O
mg	O
/	O
day	O
,	O
a	O
phenytoin	S-drug-AD-2
dose	O
reduction	O
of	O
approximately	O
40	O
%	O
was	O
necessary	O
for	O
eight	O
of	O
these	O
10	O
subjects	O
.	O

In	O
a	O
controlled	O
clinical	O
trial	O
,	O
a	O
20	O
%	O
reduction	O
of	O
the	O
phenytoin	S-drug
dose	O
at	O
the	O
initiation	O
of	O
Felbatol	S-brand
therapy	O
resulted	O
in	O
phenytoin	S-drug
levels	O
comparable	O
to	O
those	O
prior	O
to	O
Felbatol	S-brand
administration	O
.	O

Carbamazepine	S-drug
:	O
Felbatol	S-brand-ME-1
causes	O
a	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
carbamazepine	S-drug-ME-2
plasma	O
concentrations	O
and	O
an	O
increase	O
in	O
the	O
steady	O
-	O
state	O
carbamazepine	B-drug_n
epoxide	E-drug_n
plasma	O
concentration	O
.	O

In	O
nine	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
carbamazepine	S-drug
,	O
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
carbamazepine	S-drug
concentration	O
was	O
8	O
2	O
micrograms	O
/	O
mL	O
.	O

The	O
carbamazepine	S-drug-ME-1
steady	O
-	O
state	O
Cmin	O
decreased	O
31	O
%	O
to	O
5	O
1	O
micrograms	O
/	O
mL	O
when	O
felbamate	S-drug-ME-2
(	O
3000	O
mg	O
/	O
day	O
,	O
divided	O
into	O
three	O
doses	O
)	O
was	O
coadministered	O
.	O

Carbamazepine	B-drug_n
epoxide	E-drug_n
steady	O
-	O
state	O
Cmin	O
concentrations	O
increased	O
57	O
%	O
from	O
1.0	O
0.3	O
to	O
1.6	O
0.4	O
micrograms	O
/	O
mL	O
with	O
the	O
addition	O
of	O
felbamate	S-drug
.	O

In	O
clinical	O
trials	O
,	O
similar	O
changes	O
in	O
carbamazepine	S-drug
and	O
carbamazepine	B-drug_n
epoxide	E-drug_n
were	O
seen	O
.	O

Valproate	S-drug
:	O
Felbatol	S-brand-ME-1
causes	O
an	O
increase	O
in	O
steady	O
-	O
state	O
valproate	S-drug-ME-2
concentrations	O
.	O

In	O
four	O
subjects	O
with	O
epilepsy	O
ingesting	O
valproate	S-drug
,	O
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
valproate	S-drug
plasma	O
concentration	O
was	O
63	O
16	O
micrograms	O
/	O
mL	O
.	O

The	O
steady	O
-	O
state	O
Cmin	O
increased	O
to	O
78	O
14	O
micrograms	O
/	O
mL	O
when	O
1200	O
mg	O
/	O
day	O
of	O
felbamate	S-drug
was	O
coadministered	O
.	O

Increasing	O
the	O
felbamate	S-drug-ME-1
dose	O
to	O
2400	O
mg	O
/	O
day	O
increased	O
the	O
steadystate	O
valproate	S-drug-ME-2
Cmin	O
to	O
96	O
25	O
micrograms	O
/	O
mL	O
.	O

Corresponding	O
values	O
for	O
free	O
valproate	S-drug
Cmin	O
concentrations	O
were	O
7	O
3	O
,	O
9	O
4	O
,	O
and	O
11	O
6	O
micrograms	O
/	O
mL	O
for	O
0	O
,	O
1200	O
,	O
and	O
2400	O
mg	O
/	O
day	O
Felbatol	S-brand
,	O
respectively	O
.	O

The	O
ratios	O
of	O
the	O
AUCs	O
of	O
unbound	O
valproate	S-drug
to	O
the	O
AUCs	O
of	O
the	O
total	O
valproate	S-drug
were	O
11.1	O
%	O
,	O
13.0	O
%	O
,	O
and	O
11.5	O
%	O
,	O
with	O
coadministration	O
of	O
0	O
,	O
1200	O
,	O
and	O
2400	O
mg	O
/	O
day	O
of	O
Felbatol	S-brand
,	O
respectively	O
.	O

Phenobarbital	S-drug
:	O
Coadministration	O
of	O
felbamate	S-drug-ME-1
with	O
phenobarbital	S-drug-ME-2
causes	O
an	O
increase	O
in	O
phenobarbital	S-drug
plasma	O
concentrations	O
,	O
In	O
12	O
otherwise	O
healthy	O
male	O
volunteers	O
ingesting	O
phenobarbital	S-drug
,	O
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
phenobarbital	S-drug
concentration	O
was	O
14.2	O
micrograms	O
/	O
mL	O
.	O

The	O
steady	O
-	O
state	O
Cmin	O
concentration	O
increased	O
to	O
17.8	O
micrograms	O
/	O
mL	O
when	O
2400	O
mg	O
/	O
day	O
of	O
felbamate	S-drug
was	O
coadministered	O
for	O
one	O
week	O
.	O

Effects	O
of	O
Other	O
Antiepileptic	B-group
Drugs	E-group
on	O
Felbatol	S-brand
Phenytoin	S-drug
:	O
Phenytoin	S-drug-ME-1
causes	O
an	O
approximate	O
doubling	O
of	O
the	O
clearance	O
of	O
Felbatol	S-brand-ME-2
(	O
felbamate	S-drug-ME-2
)	O
at	O
steady	O
state	O
and	O
,	O
therefore	O
,	O
the	O
addition	O
of	O
phenytoin	S-drug-ME-1
causes	O
an	O
approximate	O
45	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
trough	O
concentrations	O
of	O
Felbatol	S-brand-ME-2
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	S-brand
given	O
as	O
monotherapy	O
.	O

Carbamazepine	S-drug
:	O
Carbamazepine	S-drug-ME-1
causes	O
an	O
approximate	O
50	O
%	O
increase	O
in	O
the	O
clearance	O
of	O
Felbatol	S-brand-ME-2
at	O
steady	O
state	O
and	O
,	O
therefore	O
,	O
the	O
addition	O
of	O
carbamazepine	S-drug-ME-1
results	O
in	O
an	O
approximate	O
40	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
trough	O
concentrations	O
of	O
Felbatol	S-brand-ME-2
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	S-brand
given	O
as	O
monotherapy	O
.	O

Valproate	S-drug
:	O
Available	O
data	O
suggest	O
that	O
there	O
is	O
no	O
significant	O
effect	O
of	O
valproate	S-drug
on	O
the	O
clearance	O
of	O
Felbatol	S-brand
at	O
steady	O
state	O
,	O
Therefore	O
,	O
the	O
addition	O
of	O
valproate	S-drug
is	O
not	O
expected	O
to	O
cause	O
a	O
clinically	O
important	O
effect	O
on	O
Felbatol	S-brand
(	O
felbamate	S-drug
)	O
plasma	O
concentrations	O
.	O

Phenobarbital	S-drug
:	O
It	O
appears	O
that	O
phenobarbital	S-drug-ME-1
may	O
reduce	O
plasma	O
felbamate	S-drug-ME-2
concentrations	O
.	O

Steady	O
-	O
state	O
plasma	O
felbamate	S-drug
concentrations	O
were	O
found	O
to	O
be	O
29	O
%	O
lower	O
than	O
the	O
mean	O
concentrations	O
of	O
a	O
group	O
of	O
newly	O
diagnosed	O
subjects	O
with	O
epilepsy	O
also	O
receiving	O
2400	O
mg	O
of	O
felbamate	S-drug
a	O
day	O
.	O

Effects	O
of	O
Antacids	S-group
on	O
Felbatol	S-brand
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
a	O
2400	O
mg	O
dose	O
of	O
Felbatol	S-brand
as	O
monotherapy	O
given	O
as	O
tablets	O
was	O
not	O
affected	O
when	O
coadministered	O
with	O
antacids	S-group
.	O

Effects	O
of	O
Erythromycin	S-drug
on	O
Felbatol	S-brand
The	O
coadministration	O
of	O
erythromycin	S-drug
(	O
1000	O
mg	O
/	O
day	O
)	O
for	O
10	O
days	O
did	O
not	O
alter	O
the	O
pharmacokinetic	O
parameters	O
of	O
Cmax	O
,	O
Cmin	O
,	O
AUC	O
,	O
CI	O
/	O
kg	O
or	O
tmax	O
at	O
felbamate	S-drug
daily	O
doses	O
of	O
3000	O
or	O
3600	O
mg	O
/	O
day	O
in	O
10	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
.	O

Effects	O
of	O
Felbatol	S-brand
on	O
Low	O
-	O
Dose	O
Combination	B-group
Oral	I-group
Contraceptives	E-group
A	O
group	O
of	O
24	O
nonsmoking	O
,	O
healthy	O
white	O
female	O
volunteers	O
established	O
on	O
an	O
oral	O
contraceptive	S-group
regimen	O
containing	O
30	O
mg	O
ethinyl	B-drug
estradiol	E-drug
and	O
75	O
mg	O
gestodene	S-drug
for	O
at	O
least	O
3	O
months	O
received	O
2400	O
mg	O
/	O
day	O
of	O
felbamate	S-drug
from	O
midcycle	O
(	O
day	O
15	O
)	O
to	O
midcycle	O
(	O
day	O
14	O
)	O
of	O
two	O
consecutive	O
oral	O
contraceptive	S-group
cycles	O
.	O

Felbamate	S-drug-ME-1
treatment	O
resulted	O
in	O
a	O
42	O
%	O
decrease	O
in	O
the	O
gestodene	S-drug-ME-2
AUC	O
0	O
-	O
24	O
,	O
but	O
no	O
clinically	O
relevant	O
effect	O
was	O
observed	O
on	O
the	O
pharmacokinetic	O
parameters	O
of	O
ethinyl	B-drug
estradiol	E-drug
.	O

No	O
volunteer	O
showed	O
hormonal	O
evidence	O
of	O
ovulation	O
,	O
but	O
one	O
volunteer	O
reported	O
intermenstrual	O
bleeding	O
during	O
felbamate	S-drug
treatment	O
.	O

CYP3A4	S-drug
Inhibitors	O
Felodipine	O
is	O
metabolized	O
by	O
CYP3A4	S-drug
.	O

Co	O
-	O
administration	O
of	O
CYP3A4	O
inhibitors	O
(	O
eg	O
,	O
ketoconazole	S-drug
,	O
itraconazole	S-drug
,	O
erythromycin	S-drug
,	O
grapefruit	O
juice	O
,	O
cimetidine	S-drug
)	O
with	O
felodipine	S-drug
may	O
lead	O
to	O
several	O
-	O
fold	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
felodipine	S-drug
,	O
either	O
due	O
to	O
an	O
increase	O
in	O
bioavailability	O
or	O
due	O
to	O
a	O
decrease	O
in	O
metabolism	O
.	O

These	O
increases	O
in	O
concentration	O
may	O
lead	O
to	O
increased	O
effects	O
,	O
(	O
lower	O
blood	O
pressure	O
and	O
increased	O
heart	O
rate	O
)	O
.	O

These	O
effects	O
have	O
been	O
observed	O
with	O
co	O
-	O
administration	O
of	O
itraconazole	S-drug
(	O
a	O
potent	O
CYP3A4	S-drug
inhibitor	O
)	O
.	O

Caution	O
should	O
be	O
used	O
when	O
CYP3A4	S-drug
inhibitors	O
are	O
co	O
-	O
administered	O
with	O
felodipine	S-drug
.	O

A	O
conservative	O
approach	O
to	O
dosing	O
felodipine	S-drug
should	O
be	O
taken	O
.	O

The	O
following	O
specific	O
interactions	O
have	O
been	O
reported	O
:	O
Itraconazole	O
Co	O
-	O
administration	O
of	O
another	O
extended	O
release	O
formulation	O
of	O
felodipine	S-drug
with	O
itraconazole	S-drug
resulted	O
in	O
approximately	O
8	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
,	O
more	O
than	O
6	O
-	O
fold	O
increase	O
in	O
the	O
Cmax	O
,	O
and	O
2	O
-	O
fold	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	S-drug
.	O

Erythromycin	O
Co	O
-	O
administration	O
of	O
felodipine	S-drug
(	O
PLENDIL	S-drug
)	O
with	O
erythromycin	S-drug
resulted	O
in	O
approximately	O
2.5	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
and	O
about	O
2	O
-	O
fold	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	S-drug
.	O

Grapefruit	O
juice	O
Co	O
-	O
administration	O
of	O
felodipine	S-drug
with	O
grapefruit	O
juice	O
resulted	O
in	O
more	O
than	O
2	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
but	O
no	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	S-drug
.	O

Cimetidine	O
Co	O
-	O
administration	O
of	O
felodipine	S-drug
with	O
cimetidine	S-drug
(	O
a	O
non	O
-	O
specific	O
CYP	O
-	O
450	O
inhibitor	O
)	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
50	O
%	O
in	O
the	O
AUC	O
and	O
the	O
Cmax	O
,	O
of	O
felodipine	S-drug
.	O

Beta	O
-	O
Blocking	O
Agents	O
A	O
pharmacokinetic	O
study	O
of	O
felodipine	S-drug
in	O
conjunction	O
with	O
metoprolol	S-drug
demonstrated	O
no	O
significant	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
felodipine	S-drug
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
metoprolol	S-drug
,	O
however	O
,	O
were	O
increased	O
approximately	O
31	O
and	O
38	O
%	O
,	O
respectively	O
.	O

In	O
controlled	O
clinical	O
trials	O
,	O
however	O
,	O
beta	B-drug
blockers	E-drug
including	O
metoprolol	S-drug
were	O
concurrently	O
administered	O
with	O
felodipine	S-drug
and	O
were	O
well	O
tolerated	O
.	O

Digoxin	O
When	O
given	O
concomitantly	O
with	O
PLENDIL	S-drug
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
in	O
patients	O
with	O
heart	O
failure	O
were	O
not	O
significantly	O
altered	O
.	O

Anticonvulsants	S-group
:	O
In	O
a	O
pharmacokinetic	O
study	O
,	O
maximum	O
plasma	O
concentrations	O
of	O
felodipine	S-drug-ME-1
were	O
considerably	O
lower	O
in	O
epileptic	O
patients	O
on	O
long	O
-	O
term	O
anticonvulsant	S-group-ME-2
therapy	O
(	O
eg	O
,	O
phenytoin	S-drug-ME-2
,	O
carbamazepine	S-drug-ME-2
,	O
or	O
phenobarbital	S-drug-ME-2
)	O
than	O
in	O
healthy	O
volunteers	O
.	O

In	O
such	O
patients	O
,	O
the	O
mean	O
area	O
under	O
the	O
felodipine	S-drug
plasma	O
concentration	O
-	O
time	O
curve	O
was	O
also	O
reduced	O
to	O
approximately	O
6	O
%	O
of	O
that	O
observed	O
in	O
healthy	O
volunteers	O
.	O

Since	O
a	O
clinically	O
significant	O
interaction	O
may	O
be	O
anticipated	O
,	O
alternative	O
antihypertensive	S-drug
therapy	O
should	O
be	O
considered	O
in	O
these	O
patients	O
.	O

Tacrolimus	O
Felodipine	S-drug
may	O
increase	O
the	O
blood	O
concentration	O
of	O
tacrolimus	S-drug
.	O

When	O
given	O
concomitantly	O
with	O
felodipine	S-drug
,	O
the	O
tacrolimus	S-drug
blood	O
concentration	O
should	O
be	O
followed	O
and	O
the	O
tacrolimus	O
dose	O
may	O
need	O
to	O
be	O
adjusted	O
.	O

Other	O
Concomitant	O
Therapy	O
In	O
healthy	O
subjects	O
there	O
were	O
no	O
clinically	O
significant	O
interactions	O
when	O
felodipine	S-drug
was	O
given	O
concomitantly	O
with	O
indomethacin	S-drug
or	O
spironolactone	S-drug
.	O

Interaction	O
with	O
Food	O
See	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Pharmacokinetics	O
and	O
Metabolism	O
.	O

Fenfluramine	S-drug-EF-1
may	O
increase	O
slightly	O
the	O
effect	O
of	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
,	O
e.g	O
.	O
,	O
guanethidine	S-drug-EF-2
,	O
methyldopa	S-drug-EF-2
,	O
reserpine	S-drug-EF-2
.	O

Other	O
CNS	B-group-AD-1
depressant	I-group-AD-1
drugs	E-group-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
fenfluramine	S-drug-AD-2
,	O
since	O
the	O
effects	O
may	O
be	O
additive	O
.	O

Oral	O
Anticoagulants	S-group
CAUTION	O
SHOULD	O
BE	O
EXERCISED	O
WHEN	O
COUMARIN	B-group-AD-1
ANTICOAGULANTS	E-group-AD-1
ARE	O
GIVEN	O
IN	O
CONJUNCTION	O
WITH	O
TRICOR	S-brand-AD-2
.	O

THE	O
DOSAGE	O
OF	O
THE	O
ANTICOAGULANTS	S-group
SHOULD	O
BE	O
REDUCED	O
TO	O
MAINTAIN	O
THE	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
AT	O
THE	O
DESIRED	O
LEVEL	O
TO	O
PREVENT	O
BLEEDING	O
COMPLICATIONS	O
.	O

FREQUENT	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
DETERMINATIONS	O
ARE	O
ADVISABLE	O
UNTIL	O
IT	O
HAS	O
BEEN	O
DEFINITELY	O
DETERMINED	O
THAT	O
THE	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
HAS	O
STABILIZED	O
.	O

HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
:	O
The	O
combined	O
use	O
of	O
TRICOR	S-brand-AD-1
and	O
HMG	B-group-AD-2
-	I-group-AD-2
CoA	I-group-AD-2
reductase	I-group-AD-2
inhibitors	E-group-AD-2
should	O
be	O
avoided	O
unless	O
the	O
benefit	O
of	O
further	O
alterations	O
in	O
lipid	O
levels	O
is	O
likely	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
this	O
drug	O
combination	O
.	O

Resins	S-group
:	O
Since	O
bile	B-group
acid	I-group
sequestrants	E-group
may	O
bind	O
other	O
drugs	O
given	O
concurrently	O
,	O
patients	O
should	O
take	O
TRICOR	S-brand-ME-1
at	O
least	O
1	O
hour	O
before	O
or	O
4	O
-	O
6	O
hours	O
after	O
a	O
bile	B-group-ME-2
acid	I-group-ME-2
binding	I-group-ME-2
resin	E-group-ME-2
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Cyclosporine	S-drug
:	O
Because	O
cyclosporine	S-drug-EF-1
can	O
produce	O
nephrotoxicity	O
with	O
decreases	O
in	O
creatinine	O
clearance	O
and	O
rises	O
in	O
serum	O
creatinine	O
,	O
and	O
because	O
renal	O
excretion	O
is	O
the	O
primary	O
elimination	O
route	O
of	O
fibrate	B-group-EF-2
drugs	E-group-EF-2
including	O
TRICOR	S-brand-EF-2
,	O
there	O
is	O
a	O
risk	O
that	O
an	O
interaction	O
will	O
lead	O
to	O
deterioration	O
.	O

The	O
benefits	O
and	O
risks	O
of	O
using	O
TRICOR	S-brand-AD-1
with	O
immunosuppressants	S-group-AD-2
and	O
other	O
potentially	O
nephrotoxic	O
agents	O
should	O
be	O
carefully	O
considered	O
,	O
and	O
the	O
lowest	O
effective	O
dose	O
employed	O

Drug	O
-	O
drug	O
interactions	O
In	O
vitro	O
studies	O
using	O
human	O
liver	O
microsomes	O
indicate	O
that	O
fenofibrate	S-drug
and	O
fenofibric	B-drug_n
acid	E-drug_n
are	O
not	O
inhibitors	O
of	O
cytochrome	O
(	O
CYP	O
)	O
P450	O
isoforms	O
CYP3A4	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
or	O
CYP1A2	O
.	O

They	O
are	O
weak	O
inhibitors	O
of	O
CYP2C19	O
and	O
CYP2A6	O
,	O
and	O
mild	O
-	O
to	O
-	O
moderate	O
inhibitors	O
of	O
CYP2C9	O
at	O
therapeutic	O
concentrations	O
.	O

Potentiation	O
of	O
coumarin	B-group
-	I-group
type	I-group
anticoagulants	E-group
has	O
been	O
observed	O
with	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
/	O
INR	O
.	O

Bile	B-group
acid	I-group
sequestrants	E-group
have	O
been	O
shown	O
to	O
bind	O
other	O
drugs	O
given	O
concurrently	O
.	O

Therefore	O
,	O
fenofibrate	S-drug-AD-1
should	O
be	O
taken	O
at	O
least	O
1	O
hour	O
before	O
or	O
4	O
-	O
6	O
hours	O
after	O
a	O
bile	B-group-AD-2
acid	I-group-AD-2
binding	I-group-AD-2
resin	E-group-AD-2
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Concomitant	O
administration	O
of	O
fenofibrate	S-drug-ME-1
(	O
equivalent	O
to	O
145mg	O
TRICOR	S-brand-ME-1
)	O
with	O
pravastatin	S-drug-ME-2
(	O
40	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
Cmax	O
and	O
AUC	O
values	O
for	O
pravastatin	S-drug
by	O
36	O
%	O
(	O
range	O
from	O
69	O
%	O
decrease	O
to	O
321	O
%	O
increase	O
)	O
and	O
28	O
%	O
(	O
range	O
from	O
54	O
%	O
decrease	O
to	O
128	O
%	O
increase	O
)	O
,	O
respectively	O
,	O
and	O
for	O
3	O
-	O
hydroxy	O
-	O
iso	O
-	O
pravastatin	O
by	O
55	O
%	O
(	O
range	O
from	O
32	O
%	O
decrease	O
to	O
314	O
%	O
increase	O
)	O
and	O
39	O
%	O
(	O
range	O
from	O
24	O
%	O
decrease	O
to	O
261	O
%	O
increase	O
)	O
,	O
respectively	O
in	O
23	O
healthy	O
adults	O
.	O

A	O
single	O
dose	O
of	O
pravastatin	S-drug
had	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
fenofibric	B-drug_n
acid	E-drug_n
.	O

Concomitant	O
administration	O
of	O
fenofibrate	S-drug-ME-1
(	O
equivalent	O
to	O
145	O
mg	O
TRICOR	S-brand-ME-1
)	O
with	O
atorvastatin	S-drug-ME-2
(	O
20	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
resulted	O
in	O
approximately	O
17	O
%	O
decrease	O
(	O
range	O
from	O
67	O
%	O
decrease	O
to	O
44	O
%	O
increase	O
)	O
in	O
atorvastatin	S-drug
AUC	O
values	O
in	O
22	O
healthy	O
males	O
.	O

The	O
atorvastatin	S-drug
Cmax	O
values	O
were	O
not	O
significantly	O
affected	O
by	O
fenofibrate	S-drug
.	O

The	O
pharmacokinetics	O
of	O
fenofibric	B-drug_n
acid	E-drug_n
were	O
not	O
significantly	O
affected	O
by	O
atorvastatin	S-drug

Drug	O
Interactions	O
with	O
Beta	B-group
-	I-group
Blockers	E-group
:	O
Concomitant	O
use	O
of	O
fenoldopam	S-drug-AD-1
with	O
beta	B-group-AD-2
-	I-group-AD-2
blockers	E-group-AD-2
should	O
be	O
avoided	O
.	O

If	O
the	O
drugs	O
are	O
used	O
together	O
,	O
caution	O
should	O
be	O
exercised	O
because	O
unexpected	O
hypotension	O
could	O
result	O
from	O
beta	O
-	O
blocker	O
inhibition	O
of	O
the	O
sympathetic	O
reflex	O
response	O
to	O
fenoldopam	S-drug
.	O

Drug	O
Interactions	O
,	O
General	O
:	O
Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
,	O
intravenous	O
fenoldopam	S-drug
has	O
been	O
administered	O
safely	O
with	O
drugs	O
such	O
as	O
digitalis	S-group
and	O
sublingual	O
nitroglycerin	S-drug
.	O

There	O
is	O
limited	O
experience	O
with	O
concomitant	O
antihypertensive	B-group
agents	E-group
such	O
as	O
alpha	B-group
-	I-group
blockers	E-group
,	O
calcium	B-group
channel	I-group
-	I-group
blockers	E-group
,	O
ACE	B-group
inhibitors	E-group
,	O
and	O
diuretics	S-group
(	O
both	O
thiazide	S-group
-	O
like	O
and	O
loop	O
)	O
.	O

The	O
coadministration	O
of	O
aspirin	S-brand-ME-1
decreases	O
the	O
biologic	O
half	O
-	O
life	O
of	O
fenoprofen	S-drug-ME-2
because	O
of	O
an	O
increase	O
in	O
metabolic	O
clearance	O
that	O
results	O
in	O
a	O
greater	O
amount	O
of	O
hydroxylated	B-drug_n
fenoprofen	E-drug_n
in	O
the	O
urine	O
.	O

Although	O
the	O
mechanism	O
of	O
interaction	O
between	O
fenoprofen	S-drug-ME-1
and	O
aspirin	S-brand-ME-2
is	O
not	O
totally	O
known	O
,	O
enzyme	O
induction	O
and	O
displacement	O
of	O
fenoprofen	S-drug
from	O
plasma	O
albumin	O
binding	O
sites	O
are	O
possibilities	O
.	O

Because	O
Nalfon	S-brand
has	O
not	O
been	O
shown	O
to	O
produce	O
any	O
additional	O
effect	O
beyond	O
that	O
obtained	O
with	O
aspirin	S-brand
alone	O
and	O
because	O
aspirin	S-brand-ME-1
increases	O
the	O
rate	O
of	O
excretion	O
of	O
Nalfon	S-brand-ME-2
,	O
the	O
concomitant	O
use	O
of	O
Nalfon	S-brand-AD-1
and	O
salicylates	S-group-AD-2
is	O
not	O
recommended	O
.	O

Chronic	O
administration	O
of	O
phenobarbital	S-drug-ME-1
,	O
a	O
known	O
enzyme	O
inducer	O
,	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
plasma	O
half	O
-	O
life	O
of	O
fenoprofen	S-drug-ME-2
.	O

When	O
phenobarbital	S-drug-AD-1
is	O
added	O
to	O
or	O
withdrawn	O
from	O
treatment	O
,	O
dosage	O
adjustment	O
of	O
Nalfon	S-brand-AD-2
may	O
be	O
required	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
fenoprofen	S-drug
,	O
because	O
of	O
its	O
affinity	O
for	O
albumin	O
,	O
may	O
displace	O
from	O
their	O
binding	O
sites	O
other	O
drugs	O
that	O
are	O
also	O
albumin	O
bound	O
,	O
and	O
this	O
may	O
lead	O
to	O
drug	O
interaction	O
.	O

Theoretically	O
,	O
fenoprofen	S-drug
could	O
likewise	O
be	O
displaced	O
.	O

Patients	O
receiving	O
hydantoins	S-group
,	O
sulfonamides	S-group
,	O
or	O
sulfonylureas	S-group
should	O
be	O
observed	O
for	O
increased	O
activity	O
of	O
these	O
drugs	O
and	O
,	O
therefore	O
,	O
signs	O
of	O
toxicity	O
from	O
these	O
drugs	O
.	O

In	O
patients	O
receiving	O
coumarin	B-group-EF-1
-	I-group-EF-1
type	I-group-EF-1
anticoagulants	E-group-EF-1
,	O
the	O
addition	O
of	O
Nalfon	S-brand-EF-2
to	O
therapy	O
could	O
prolong	O
the	O
prothrombin	O
time	O
.	O

Patients	O
receiving	O
both	O
drugs	O
should	O
be	O
under	O
careful	O
observation	O
.	O

Patients	O
treated	O
with	O
Nalfon	S-brand-EF-1
may	O
be	O
resistant	O
to	O
the	O
effects	O
of	O
loop	B-group-EF-2
diuretics	E-group-EF-2
.	O

In	O
patients	O
receiving	O
Nalfon	S-brand-AD-1
and	O
a	O
steroid	S-group-AD-2
concomitantly	O
,	O
any	O
reduction	O
in	O
steroid	S-group
dosage	O
should	O
be	O
gradual	O
in	O
order	O
to	O
avoid	O
the	O
possible	O
complications	O
of	O
sudden	O
steroid	S-group
withdrawal	O
.	O

Agents	O
Affecting	O
Cytochrome	O
P450	O
3A4	O
Isoenzyme	O
System	O
Fentanyl	S-drug
is	O
metabolized	O
mainly	O
via	O
the	O
human	O
cytochrome	O
P450	O
3A4	O
isoenzyme	O
system	O
(	O
CYP3A4	O
)	O
,	O
therefore	O
potential	O
interactions	O
may	O
occur	O
when	O
DURAGESIC	S-brand
is	O
given	O
concurrently	O
with	O
agents	O
that	O
affect	O
CYP3A4	O
activity	O
.	O

Coadminstration	O
with	O
agents	O
that	O
induce	O
3A4	O
activity	O
may	O
reduce	O
the	O
efficacy	O
of	O
DURAGESIC	S-brand
.	O

The	O
concomitant	O
use	O
of	O
transdermal	O
fentanyl	S-drug-ME-1
with	O
ritonavir	S-drug-ME-2
or	O
other	O
potent	O
3A4	O
inhibitors	O
such	O
as	O
ketoconazole	S-drug-ME-2
,	O
itraconazole	S-drug-ME-2
,	O
troleandomycin	S-drug-ME-2
,	O
clarithromycin	S-drug-ME-2
,	O
nelfinavir	S-drug-ME-2
,	O
and	O
nefazadone	O
may	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	S-drug
plasma	O
concentrations	O
.	O

The	O
concomitant	O
use	O
of	O
other	O
CYP3A4	O
inhibitors	O
such	O
as	O
diltiazem	S-drug-ME-1
and	O
erythromycin	S-drug-ME-1
with	O
transdermal	O
fentanyl	S-drug-ME-2
may	O
also	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	S-drug
plasma	O
concentrations	O
,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
drug	O
effects	O
and	O
may	O
cause	O
serious	O
respiratory	O
depression	O
.	O

In	O
this	O
situation	O
,	O
special	O
patient	O
care	O
and	O
observation	O
are	O
appropriate	O
.	O

Central	B-group
Nervous	I-group
System	I-group
Depressants	E-group
:	O
The	O
concomitant	O
use	O
of	O
DURAGESIC	S-brand-EF-1
(	O
fentanyl	S-drug-EF-1
transdermal	O
system	O
)	O
with	O
other	O
central	B-group-EF-2
nervous	I-group-EF-2
system	I-group-EF-2
depressants	E-group-EF-2
,	O
including	O
but	O
not	O
limited	O
to	O
other	O
opioids	S-group-EF-2
,	O
sedatives	S-group-EF-2
,	O
hypnotics	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
(	O
e.g	O
.	O
,	O
benzodiazepines	S-group-EF-2
)	O
,	O
general	O
anesthetics	S-group-EF-2
,	O
phenothiazines	S-group-EF-2
,	O
skeletal	B-group-EF-2
muscle	I-group-EF-2
relaxants	E-group-EF-2
,	O
and	O
alcohol	S-drug-EF-2
,	O
may	O
cause	O
respiratory	O
depression	O
,	O
hypotension	O
,	O
and	O
profound	O
sedation	O
,	O
or	O
potentially	O
result	O
in	O
coma	O
or	O
death	O
.	O

When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
significantly	O
reduced	O
.	O

MAO	B-group
Inhibitors	E-group
:	O
DURAGESIC	S-brand-AD-1
is	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
who	O
have	O
received	O
MAOI	S-group-AD-2
within	O
14	O
days	O
because	O
severe	O
and	O
unpredictable	O
potentiation	O
by	O
MAO	B-group-AD-1
inhibitors	E-group-AD-1
has	O
been	O
reported	O
with	O
opioid	B-group-AD-2
analgesics	E-group-AD-2

Drug	O
Interaction	O
with	O
Erythromycin	S-drug
and	O
Ketoconazole	S-drug
Fexofenadine	S-drug
has	O
been	O
shown	O
to	O
exhibit	O
minimal	O
(	O
ca	O
.	O
5	O
%	O
)	O
metabolism	O
.	O

However	O
,	O
co	O
administration	O
of	O
fexofenadine	B-drug-ME-1
hydrochloride	E-drug-ME-1
with	O
either	O
ketoconazole	S-drug-ME-2
or	O
erythromycin	S-drug-ME-2
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
fexofenadine	S-drug
.	O

Fexofenadine	S-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
erythromycin	S-drug
or	O
ketoconazole	S-drug
.	O

In	O
2	O
separate	O
studies	O
,	O
fexofenadine	B-drug
hydrochloride	E-drug
120	O
mg	O
twice	O
daily	O
(	O
240	O
mg	O
total	O
daily	O
dose	O
)	O
was	O
co	O
-	O
administered	O
with	O
either	O
erythromycin	S-drug
500	O
mg	O
every	O
8	O
hours	O
or	O
ketoconazole	S-drug
400	O
mg	O
once	O
daily	O
under	O
steady	O
-	O
state	O
conditions	O
to	O
healthy	O
volunteers	O
(	O
n	O
=	O
24	O
,	O
each	O
study	O
)	O
.	O

No	O
differences	O
in	O
adverse	O
events	O
or	O
QTc	O
interval	O
were	O
observed	O
when	O
subjects	O
were	O
administered	O
fexofenadine	B-drug
hydrochloride	E-drug
alone	O
or	O
in	O
combination	O
with	O
either	O
erythromycin	S-drug
or	O
ketoconazole	S-drug
.	O

The	O
findings	O
of	O
these	O
studies	O
are	O
summarized	O
in	O
the	O
following	O
table	O
:	O
Effects	O
on	O
steady	O
-	O
state	O
fexofenadine	S-drug
pharmacokinetics	O
after	O
7	O
days	O
of	O
co	O
-	O
administration	O
with	O
fexofenadine	B-drug
hydrochloride	E-drug
120	O
mg	O
every	O
12	O
hours	O
(	O
two	O
times	O
the	O
recommended	O
twice	O
daily	O
dose	O
)	O
in	O
healthy	O
volunteers	O
(	O
n	O
=	O
24	O
)	O

Concomitant	O
Drug	O

cmaxSS	O
(	O
Peak	O
plasma	O
concentration	O
)	O

AUCss	O
(	O
0	O
-	O
12h	O
)	O
(	O
Extent	O
of	O
systemic	O
exposure	O
)	O

Erythromycin	S-drug
(	O
500	O
mg	O
every	O
8	O
hrs	O
)	O

+	O
82	O
%	O

+	O
109	O
%	O

Ketoconazole	S-drug
(	O
400	O
mg	O
once	O
daily	O
)	O

+	O
135	O
%	O

+	O
164	O
%	O

The	O
changes	O
in	O
plasma	O
levels	O
were	O
within	O
the	O
range	O
of	O
plasma	O
levels	O
achieved	O
in	O
adequate	O
and	O
well	O
-	O
controlled	O
clinical	O
trials	O
.	O

The	O
mechanism	O
of	O
these	O
interactions	O
has	O
been	O
evaluated	O
in	O
in	O
vitro	O
,	O
in	O
situ	O
,	O
and	O
in	O
vivo	O
animal	O
models	O
.	O

These	O
studies	O
indicate	O
that	O
ketoconazole	S-drug-ME-1
or	O
erythromycin	S-drug-ME-1
co	O
-	O
administration	O
enhances	O
fexofenadine	S-drug-ME-2
gastrointestinal	O
absorption	O
.	O

This	O
observed	O
increase	O
in	O
the	O
bioavailability	O
of	O
fexofenadine	S-drug
may	O
be	O
due	O
to	O
transport	O
-	O
related	O
effects	O
,	O
such	O
as	O
p	O
-	O
glycoprotein	O
.	O
in	O
vivo	O
animal	O
studies	O
also	O
suggest	O
that	O
in	O
addition	O
to	O
enhancing	O
absorption	O
,	O
ketoconazole	S-drug-ME-1
decreases	O
fexofenadine	S-drug-ME-2
gastrointestinal	O
secretion	O
,	O
while	O
erythromycin	S-drug
may	O
also	O
decrease	O
biliary	O
excretion	O
.	O

Drug	O
Interactions	O
with	O
Antacids	S-group
Administration	O
of	O
120	O
mg	O
of	O
fexofenadine	B-drug-ME-1
hydrochloride	E-drug-ME-1
(	O
2	O
x	O
60	O
mg	O
capsule	O
)	O
within	O
15	O
minutes	O
of	O
an	O
aluminum	S-drug-ME-2
and	O
magnesium	S-drug-ME-2
containing	O
antacid	S-group-ME-2
(	O
Maalox	S-brand-ME-2
)	O
decreased	O
fexofenadine	S-drug
AUC	O
by	O
41	O
%	O
and	O
cmax	O
by	O
43	O
%	O
.	O

ALLEGRA	S-brand-AD-1
should	O
not	O
be	O
taken	O
closely	O
in	O
time	O
with	O
aluminum	S-drug-AD-2
and	O
magnesium	S-drug-AD-2
containing	O
antacids	S-group
.	O

Interactions	O
with	O
Fruit	O
Juices	O
Fruit	O
juices	O
such	O
as	O
grapefruit	O
,	O
orange	O
and	O
apple	O
may	O
reduce	O
the	O
bioavailability	O
and	O
exposure	O
of	O
fexofenadine	S-drug
.	O

This	O
is	O
based	O
on	O
the	O
results	O
from	O
3	O
clinical	O
studies	O
using	O
histamine	S-drug
induced	O
skin	O
wheals	O
and	O
flares	O
coupled	O
with	O
population	O
pharmacokinetic	O
analysis	O
.	O

The	O
size	O
of	O
wheal	O
and	O
flare	O
were	O
significantly	O
larger	O
when	O
fexofenadine	B-drug
hydrochloride	E-drug
was	O
administered	O
with	O
either	O
grapefruit	O
or	O
orange	O
juices	O
compared	O
to	O
water	O
.	O

Based	O
on	O
the	O
literature	O
reports	O
,	O
the	O
same	O
effects	O
may	O
be	O
extrapolated	O
to	O
other	O
fruit	O
juices	O
such	O
as	O
apple	O
juice	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
observations	O
is	O
unknown	O
.	O

In	O
addition	O
,	O
based	O
on	O
the	O
population	O
pharmacokinetics	O
analysis	O
of	O
the	O
combined	O
data	O
from	O
grapefruit	O
and	O
orange	O
juices	O
studies	O
with	O
the	O
data	O
from	O
a	O
bioequivalence	O
study	O
,	O
the	O
bioavailability	O
of	O
fexofenadine	S-drug
was	O
reduced	O
by	O
36	O
%	O
.	O

Therefore	O
,	O
to	O
maximize	O
the	O
effects	O
of	O
fexofenadine	S-drug
,	O
it	O
is	O
recommended	O
that	O
ALLEGRA	S-brand
should	O
be	O
taken	O
with	O
water	O

Drug	O
interactions	O
between	O
NEUPOGEN	S-brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Drugs	O
which	O
may	O
potentiate	O
the	O
release	O
of	O
neutrophils	O
,	O
such	O
as	O
lithium	S-drug
,	O
should	O
be	O
used	O
with	O
caution	O
.	O

No	O
drug	O
interactions	O
of	O
clinical	O
importance	O
have	O
been	O
identified	O
.	O

Finasteride	S-drug
does	O
not	O
appear	O
to	O
affect	O
the	O
cytochrome	O
P450	O
-	O
linked	O
drug	O
-	O
metabolizing	O
enzyme	O
system	O
.	O

Compounds	O
that	O
have	O
been	O
tested	O
in	O
man	O
include	O
antipyrine	S-drug
,	O
digoxin	S-drug
,	O
propranolol	S-drug
,	O
theophylline	S-drug
,	O
and	O
warfarin	S-drug
and	O
no	O
clinically	O
meaningful	O
interactions	O
were	O
found	O
.	O

Other	O
concomitant	O
therapy	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
finasteride	S-drug
doses	O
of	O
1	O
mg	O
or	O
more	O
were	O
concomitantly	O
used	O
in	O
clinical	O
studies	O
with	O
acetaminophen	S-drug
,	O
acetylsalicylic	B-drug
acid	E-drug
,	O
a	O
-	O
blockers	O
,	O
analgesics	S-group
,	O
angiotensin	B-group
-	I-group
converting	I-group
enzyme	I-group
(	I-group
ACE	I-group
)	I-group
inhibitors	E-group
,	O
anticonvulsants	S-group
,	O
benzodiazepines	S-group
,	O
beta	B-group
blockers	E-group
,	O
calcium	B-group
-	I-group
channel	I-group
blockers	E-group
,	O
cardiac	O
nitrates	S-group
,	O
diuretics	S-group
,	O
H2	B-group
antagonists	E-group
,	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
,	O
prostaglandin	B-group
synthetase	I-group
inhibitors	E-group
(	O
also	O
referred	O
to	O
as	O
NSAIDs	S-group
)	O
,	O
and	O
quinolone	B-group
anti	I-group
-	I-group
infectives	E-group
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Finasteride	S-drug
had	O
no	O
effect	O
on	O
circulating	O
levels	O
of	O
cortisol	O
,	O
thyroid	O
-	O
stimulating	O
hormone	O
,	O
or	O
thyroxine	O
,	O
nor	O
did	O
it	O
affect	O
the	O
plasma	O
lipid	O
profile	O
(	O
e.g	O
.	O
,	O
total	O
cholesterol	O
,	O
low	O
-	O
density	O
lipoproteins	O
,	O
high	O
-	O
density	O
lipoproteins	O
and	O
triglycerides	O
)	O
or	O
bone	O
mineral	O
density	O
.	O

In	O
studies	O
with	O
finasteride	S-drug
,	O
no	O
clinically	O
meaningful	O
changes	O
in	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
or	O
prolactin	O
were	O
detected	O
.	O

In	O
healthy	O
volunteers	O
,	O
treatment	O
with	O
finasteride	S-drug
did	O
not	O
alter	O
the	O
response	O
of	O
LH	O
and	O
FSH	O
to	O
gonadotropin	O
-	O
releasing	O
hormone	O
indicating	O
that	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
testicular	O
axis	O
was	O
not	O
affected	O
.	O

In	O
clinical	O
studies	O
with	O
PROPECIA	S-brand
(	O
finasteride	S-drug
,	O
1	O
mg	O
)	O
in	O
men	O
18	O
-	O
41	O
years	O
of	O
age	O
,	O
the	O
mean	O
value	O
of	O
serum	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
decreased	O
from	O
0.7	O
ng	O
/	O
mL	O
at	O
baseline	O
to	O
0.5	O
ng	O
/	O
mL	O
at	O
Month	O
12	O
.	O

Further	O
,	O
in	O
clinical	O
studies	O
with	O
PROSCAR	S-brand
(	O
finasteride	S-drug
,	O
5	O
mg	O
)	O
when	O
used	O
in	O
older	O
men	O
who	O
have	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
PSA	O
levels	O
are	O
decreased	O
by	O
approximately	O
50	O
%	O
.	O

These	O
findings	O
should	O
be	O
taken	O
into	O
account	O
for	O
proper	O
interpretation	O
of	O
serum	O
PSA	O
when	O
evaluating	O
men	O
treated	O
with	O
finasteride	S-drug
.	O

Drug	O
Interactions	O
.	O

TAMBOCOR	S-brand
has	O
been	O
administered	O
to	O
patients	O
receiving	O
digitalis	B-group
preparations	E-group
or	O
beta	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
without	O
adverse	O
effects	O
.	O

During	O
administration	O
of	O
multiple	O
oral	O
doses	O
of	O
TAMBOCOR	S-brand-ME-1
to	O
healthy	O
subjects	O
stabilized	O
on	O
a	O
maintenance	O
dose	O
of	O
digoxin	S-drug-ME-2
,	O
a	O
13	O
%	O
-	O
19	O
%	O
increase	O
in	O
plasma	O
digoxin	S-drug
levels	O
occurred	O
at	O
six	O
hours	O
postdose	O
.	O

In	O
a	O
study	O
involving	O
healthy	O
subjects	O
receiving	O
TAMBOCOR	S-brand-ME-1
and	O
propranolol	S-drug-ME-2
concurrently	O
,	O
plasma	O
flecainide	S-drug
levels	O
were	O
increased	O
about	O
20	O
%	O
and	O
propranolol	S-drug
levels	O
were	O
increased	O
about	O
30	O
%	O
compared	O
to	O
control	O
values	O
.	O

In	O
this	O
formal	O
interaction	O
study	O
,	O
TAMBOCOR	S-brand
and	O
propranolol	S-drug
were	O
each	O
found	O
to	O
have	O
negative	O
inotropic	O
effects	O
;	O

when	O
the	O
drugs	O
were	O
administered	O
together	O
,	O
the	O
effects	O
were	O
additive	O
.	O

The	O
effects	O
of	O
concomitant	O
administration	O
of	O
TAMBOCOR	S-brand-EF-1
and	O
propranolol	S-drug-EF-2
on	O
the	O
PR	O
interval	O
were	O
less	O
than	O
additive	O
.	O

In	O
TAMBOCOR	S-brand
clinical	O
trials	O
,	O
patients	O
who	O
were	O
receiving	O
beta	B-group
blockers	E-group
concurrently	O
did	O
not	O
experience	O
an	O
increased	O
incidence	O
of	O
side	O
effects	O
.	O

Nevertheless	O
,	O
the	O
possibility	O
of	O
additive	O
negative	O
inotropic	O
effects	O
of	O
beta	B-group-EF-1
blockers	E-group-EF-1
and	O
flecainide	S-drug-EF-2
should	O
be	O
recognized	O
.	O

Flecainide	S-drug
is	O
not	O
extensively	O
bound	O
to	O
plasma	O
proteins	O
.	O

In	O
vitro	O
studies	O
with	O
several	O
drugs	O
which	O
may	O
be	O
administered	O
concomitantly	O
showed	O
that	O
the	O
extent	O
of	O
flecainide	S-drug
binding	O
to	O
human	O
plasma	O
proteins	O
is	O
either	O
unchanged	O
or	O
only	O
slightly	O
less	O
.	O

Consequently	O
,	O
interactions	O
with	O
other	O
drugs	O
which	O
are	O
highly	O
protein	O
bound	O
(	O
e.g	O
.	O
,	O
anticoagulants	S-group
)	O
would	O
not	O
be	O
expected	O
.	O

TAMBOCOR	S-brand
has	O
been	O
used	O
in	O
a	O
large	O
number	O
of	O
patients	O
receiving	O
diuretics	S-group
without	O
apparent	O
interaction	O
.	O

Limited	O
data	O
in	O
patients	O
receiving	O
known	O
enzyme	O
inducers	O
(	O
phenytoin	S-drug-ME-1
,	O
phenobarbital	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
)	O
indicate	O
only	O
a	O
30	O
%	O
increase	O
in	O
the	O
rate	O
of	O
flecainide	S-drug-ME-2
elimination	O
.	O

In	O
healthy	O
subjects	O
receiving	O
cimetidine	S-drug-ME-1
(	O
1	O
gm	O
daily	O
)	O
for	O
one	O
week	O
,	O
plasma	O
flecainide	S-drug-ME-2
levels	O
increased	O
by	O
about	O
30	O
%	O
and	O
half	O
-	O
life	O
increased	O
by	O
about	O
10	O
%	O
.	O

When	O
amiodarone	S-drug-ME-1
is	O
added	O
to	O
flecainide	S-drug-ME-2
therapy	O
,	O
plasma	O
flecainide	S-drug
levels	O
may	O
increase	O
two	O
-	O
fold	O
or	O
more	O
in	O
some	O
patients	O
,	O
if	O
flecainide	S-drug
dosage	O
is	O
not	O
reduced	O
.	O

Drugs	O
that	O
inhibit	O
cytochrome	O
P450IID6	O
,	O
such	O
as	O
quinidine	S-drug-ME-1
,	O
might	O
increase	O
the	O
plasma	O
concentrations	O
of	O
flecainide	S-drug-ME-2
in	O
patients	O
that	O
are	O
on	O
chronic	O
flecainide	S-drug
therapy	O
;	O

especially	O
if	O
these	O
patients	O
are	O
extensive	O
metabolizers	O
.	O

There	O
has	O
been	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	S-brand
and	O
either	O
disopyramide	S-drug
or	O
verapamil	S-drug
.	O

Because	O
both	O
of	O
these	O
drugs	O
have	O
negative	O
inotropic	O
properties	O
and	O
the	O
effects	O
of	O
coadministration	O
with	O
TAMBOCOR	S-brand
are	O
unknown	O
,	O
neither	O
disopyramide	S-drug-AD-1
nor	O
verapamil	S-drug-AD-1
should	O
be	O
administered	O
concurrently	O
with	O
TAMBOCOR	S-brand-AD-2
unless	O
,	O
in	O
the	O
judgment	O
of	O
the	O
physician	O
,	O
the	O
benefits	O
of	O
this	O
combination	O
outweigh	O
the	O
risks	O
.	O

There	O
has	O
been	O
too	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	S-brand
with	O
nifedipine	S-drug
or	O
diltiazem	S-drug
to	O
recommend	O
concomitant	O
use	O
.	O

Combination	O
Therapy	O
:	O
Any	O
form	O
of	O
therapy	O
which	O
adds	O
to	O
the	O
stress	O
of	O
the	O
patient	O
,	O
interferes	O
with	O
nutrition	O
or	O
depresses	O
bone	O
marrow	O
function	O
will	O
increase	O
the	O
toxicity	O
of	O
Floxuridine	S-drug
.	O

Cytosine	B-drug-EF-1
arabinoside	E-drug-EF-1
,	O
a	O
cytostatic	B-group
agent	E-group
,	O
has	O
been	O
reported	O
to	O
inactivate	O
the	O
antifungal	O
activity	O
of	O
flucytosine	S-drug-EF-2
by	O
competitive	O
inhibition	O
.	O

Drugs	O
which	O
impair	O
glomerular	O
filtration	O
may	O
prolong	O
the	O
biological	O
half	O
-	O
life	O
of	O
flucytosine	S-drug
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Measurement	O
of	O
serum	O
creatinine	O
levels	O
should	O
be	O
determined	O
by	O
the	O
Jaffe	O
reaction	O
,	O
since	O
Ancobon	S-brand
does	O
not	O
interfere	O
with	O
the	O
determination	O
of	O
creatinine	O
values	O
by	O
this	O
method	O
.	O

Most	O
automated	O
equipment	O
for	O
measurement	O
of	O
creatinine	O
makes	O
use	O
of	O
the	O
Jaffe	O
reaction	O
.	O

The	O
use	O
of	O
FLUDARA	S-brand-AD-1
FOR	O
INJECTION	O
in	O
combination	O
with	O
pentostatin	S-drug-AD-2
is	O
not	O
recommended	O
due	O
to	O
the	O
risk	O
of	O
severe	O
pulmonary	O
toxicity	O
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
adrenal	B-group
corticosteroids	E-group
.	O

Amphotericin	B-drug
B	E-drug
or	O
potassium	B-group
-	I-group
depleting	I-group
diuretics	E-group
(	O
benzothiadiazines	S-group
and	O
related	O
drugs	O
,	O
ethacrynic	B-drug
acid	E-drug
and	O
furosemide	S-drug
)	O
enhanced	O
hypokalemia	O
.	O

Check	O
serum	O
potassium	O
levels	O
at	O
frequent	O
intervals	O
;	O

use	O
potassium	S-drug
supplements	O
if	O
necessary	O
.	O

Digitalis	B-group
glycosides	E-group
enhanced	O
possibility	O
of	O
arrhythmias	O
or	O
digitalis	S-group
toxicity	O
associated	O
with	O
hypokalemia	O
.	O

Monitor	O
serum	O
potassium	O
levels	O
;	O

use	O
potassium	S-drug
supplements	O
if	O
necessary	O
.	O

Oral	O
anticoagulants	S-group
decreased	O
prothrombin	O
time	O
response	O
.	O

Monitor	O
prothrombin	O
levels	O
and	O
adjust	O
anticoagulant	S-group
dosage	O
accordingly	O
.	O

Antidiabetic	B-group
drugs	E-group
(	O
oral	O
agents	O
and	O
insulin	S-drug
)	O
diminished	O
antidiabetic	O
effect	O
.	O

Monitor	O
for	O
symptoms	O
of	O
hyperglycemia	O
;	O

adjust	O
dosage	O
of	O
antidiabetic	B-group
drug	E-group
upward	O
if	O
necessary	O
.	O

Aspirin	S-brand
increased	O
ulcerogenic	O
effect	O
;	O

decreased	O
pharmacologic	O
effect	O
of	O
aspirin	S-brand
.	O

Rarely	O
salicylate	S-group
toxicity	O
may	O
occur	O
in	O
patients	O
who	O
discontinue	O
steroids	S-group-EF-1
after	O
concurrent	O
high	O
-	O
dose	O
aspirin	S-brand-EF-2
therapy	O
.	O

Monitor	O
salicylate	S-group
levels	O
or	O
the	O
therapeutic	O
effect	O
for	O
which	O
aspirin	S-brand
is	O
given	O
;	O

adjust	O
salicylate	S-group
dosage	O
accordingly	O
if	O
effect	O
is	O
altered	O
.	O

Barbiturates	S-group-ME-1
,	O
phenytoin	S-drug-ME-1
,	O
or	O
rifampin	S-drug-ME-1
increased	O
metabolic	O
clearance	O
of	O
fludrocortisone	B-drug-ME-2
acetate	E-drug-ME-2
because	O
of	O
the	O
induction	O
of	O
hepatic	O
enzymes	O
.	O

Observe	O
the	O
patient	O
for	O
possible	O
diminished	O
effect	O
of	O
steroid	S-group
and	O
increase	O
the	O
steroid	S-group
dosage	O
accordingly	O
.	O

Anabolic	B-group
steroids	E-group
(	O
particularly	O
C	O
-	O
17	O
alkylated	O
androgens	S-group
such	O
as	O
oxymetholone	S-drug
,	O
methandrostenolone	S-drug
,	O
norethandrolone	S-drug
,	O
and	O
similar	O
compounds	O
)	O
enhanced	O
tendency	O
toward	O
edema	O
.	O

Use	O
caution	O
when	O
giving	O
these	O
drugs	O
together	O
,	O
especially	O
in	O
patients	O
with	O
hepatic	O
or	O
cardiac	O
disease	O
.	O

Vaccines	S-group
neurological	O
complications	O
and	O
lack	O
of	O
antibody	O
response	O
.	O

Estrogen	S-group
increased	O
levels	O
of	O
corticosteroid	O
-	O
binding	O
globulin	O
,	O
thereby	O
increasing	O
the	O
bound	O
(	O
inactive	O
)	O
fraction	O
;	O

this	O
effect	O
is	O
at	O
least	O
balanced	O
by	O
decreased	O
metabolism	O
of	O
corticosteroids	S-group
.	O

When	O
estrogen	S-group
therapy	O
is	O
initiated	O
,	O
a	O
reduction	O
in	O
corticosteroid	S-group
dosage	O
may	O
be	O
required	O
,	O
and	O
increased	O
amounts	O
may	O
be	O
required	O
when	O
estrogen	S-group
is	O
terminated	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Corticosteroids	S-group
may	O
affect	O
the	O
nitrobluetetrazolium	O
test	O
for	O
bacterial	O
infection	O
and	O
produce	O
false	O
-	O
negative	O
results	O

Interaction	O
with	O
central	B-group
nervous	I-group
system	I-group
depressants	E-group
other	O
than	O
benzodiazepines	S-group
has	O
not	O
been	O
specifically	O
studied	O
;	O

however	O
,	O
no	O
deleterious	O
interactions	O
were	O
seen	O
when	O
ROMAZICON	S-brand
was	O
administered	O
after	O
narcotics	S-group
,	O
inhalational	O
anesthetics	S-group
,	O
muscle	B-group
relaxants	E-group
and	O
muscle	O
relaxant	O
antagonists	O
administered	O
in	O
conjunction	O
with	O
sedation	O
or	O
anesthesia	O
.	O

Particular	O
caution	O
is	O
necessary	O
when	O
using	O
ROMAZICON	S-brand-EF-1
in	O
cases	O
of	O
mixed	O
drug	O
overdosage	O
since	O
the	O
toxic	O
effects	O
(	O
such	O
as	O
convulsions	O
and	O
cardiac	O
dysrhythmias	O
)	O
of	O
other	O
drugs	O
taken	O
in	O
overdose	O
(	O
especially	O
cyclic	B-group-EF-2
antidepressants	E-group-EF-2
)	O
may	O
emerge	O
with	O
the	O
reversal	O
of	O
the	O
benzodiazepine	S-group
effect	O
by	O
flumazenil	S-drug
.	O

The	O
use	O
of	O
ROMAZICON	S-brand
is	O
not	O
recommended	O
in	O
epileptic	O
patients	O
who	O
have	O
been	O
receiving	O
benzodiazepine	O
treatment	O
for	O
a	O
prolonged	O
period	O
.	O

Although	O
ROMAZICON	S-brand-EF-1
exerts	O
a	O
slight	O
intrinsic	O
anticonvulsant	O
effect	O
,	O
its	O
abrupt	O
suppression	O
of	O
the	O
protective	O
effect	O
of	O
a	O
benzodiazepine	S-group-EF-2
agonist	O
can	O
give	O
rise	O
to	O
convulsions	O
in	O
epileptic	O
patients	O
.	O

ROMAZICON	S-brand-EF-1
blocks	O
the	O
central	O
effects	O
of	O
benzodiazepines	S-group-EF-2
by	O
competitive	O
interaction	O
at	O
the	O
receptor	O
level	O
.	O

The	O
effects	O
of	O
nonbenzodiazepine	O
agonists	O
at	O
benzodiazepine	O
receptors	O
,	O
such	O
as	O
zopiclone	S-drug-EF-1
,	O
triazolopyridazines	O
and	O
others	O
,	O
are	O
also	O
blocked	O
by	O
ROMAZICON	S-brand-EF-2
.	O

The	O
pharmacokinetics	O
of	O
benzodiazepines	S-group
are	O
unaltered	O
in	O
the	O
presence	O
of	O
flumazenil	S-drug
and	O
vice	O
versa	O
.	O

There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
ethanol	S-drug
and	O
flumazenil	S-drug
.	O

Use	O
in	O
Ambulatory	O
Patients	O
The	O
effects	O
of	O
ROMAZICON	S-brand
may	O
wear	O
off	O
before	O
a	O
long	B-group
-	I-group
acting	I-group
benzodiazepine	E-group
is	O
completely	O
cleared	O
from	O
the	O
body	O
.	O

In	O
general	O
,	O
if	O
a	O
patient	O
shows	O
no	O
signs	O
of	O
sedation	O
within	O
2	O
hours	O
after	O
a	O
1	O
-	O
mg	O
dose	O
of	O
flumazenil	S-drug
,	O
serious	O
resedation	O
at	O
a	O
later	O
time	O
is	O
unlikely	O
.	O

An	O
adequate	O
period	O
of	O
observation	O
must	O
be	O
provided	O
for	O
any	O
patient	O
in	O
whom	O
either	O
long	B-group
-	I-group
acting	I-group
benzodiazepines	E-group
(	O
such	O
as	O
diazepam	S-drug
)	O
or	O
large	O
doses	O
of	O
short	B-group
-	I-group
acting	I-group
benzodiazepines	E-group
(	O
such	O
as	O
10	O
mg	O
of	O
midazolam	S-drug
)	O
have	O
been	O
used	O
.	O

Because	O
of	O
the	O
increased	O
risk	O
of	O
adverse	O
reactions	O
in	O
patients	O
who	O
have	O
been	O
taking	O
benzodiazepines	S-group
on	O
a	O
regular	O
basis	O
,	O
it	O
is	O
particularly	O
important	O
that	O
physicians	O
query	O
patients	O
or	O
their	O
guardians	O
carefully	O
about	O
benzodiazepine	S-group
,	O
alcohol	S-drug
and	O
sedative	S-group
use	O
as	O
part	O
of	O
the	O
history	O
prior	O
to	O
any	O
procedure	O
in	O
which	O
the	O
use	O
of	O
ROMAZICON	S-brand
is	O
planned	O
.	O

No	O
information	O
available	O
.	O

Do	O
not	O
take	O
this	O
medicine	O
with	O
thioridizine	O
,	O
or	O
within	O
5	O
weeks	O
of	O
taking	O
fluoxetine	S-drug
.	O

Talk	O
to	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
certain	O
antibiotics	S-group
such	O
as	O
erythromycin	S-drug
,	O
clarithromycin	S-drug
or	O
azithromycin	S-drug
.	O

This	O
medicine	O
should	O
not	O
be	O
taken	O
with	O
MAO	B-group
inhibitors	E-group
.	O

Caution	O
should	O
be	O
exercised	O
when	O
taking	O
this	O
medicine	O
certain	O
antibiotics	S-group
,	O
such	O
as	O
erythromycin	S-drug
,	O
clarithromycin	S-drug
,	O
or	O
azithromycin	S-drug
.	O

This	O
medicine	O
should	O
not	O
be	O
taken	O
with	O
MAO	B-group
inhibitors	E-group
.	O

If	O
you	O
think	O
you	O
are	O
taking	O
an	O
MAO	B-group
inhibitor	E-group
talk	O
to	O
your	O
doctor	O
or	O
pharmacist	O
.	O

Do	O
not	O
take	O
this	O
medicine	O
with	O
St.	O
Johns	O
Wort	O
because	O
of	O
the	O
additive	O
effects	O
of	O
sertonin	O
.	O

This	O
medication	O
should	O
not	O
be	O
taken	O
with	O
MAO	B-group
inhibitors	E-group
.	O

Your	O
doctor	O
or	O
pharmacist	O
can	O
give	O
you	O
more	O
information	O
on	O
MAO	B-group
inhibitors	E-group
.	O

Wait	O
5	O
weeks	O
after	O
stopping	O
escitalopram	S-drug-AD-1
before	O
starting	O
a	O
non	B-group-AD-2
-	I-group-AD-2
selective	I-group-AD-2
MAO	I-group-AD-2
inhibitor	E-group-AD-2
.	O

Wait	O
2	O
weeks	O
after	O
stopping	O
an	O
MAO	B-group-AD-1
inhibitor	E-group-AD-1
before	O
starting	O
escitalopram	S-drug-AD-2
.	O

If	O
you	O
are	O
taking	O
medications	O
for	O
migraines	O
such	O
as	O
Imitrex	S-brand
,	O
talk	O
to	O
your	O
doctor	O
before	O
starting	O
this	O
medicine	O
.	O

If	O
you	O
are	O
taking	O
a	O
tricyclic	B-group
antidepressant	E-group
,	O
talk	O
to	O
your	O
doctor	O
before	O
taking	O
this	O
medicine	O
.	O

St.	O
John	O
s	O
Wort	O
should	O
be	O
avoided	O
while	O
taking	O
this	O
medicine	O
due	O
to	O
the	O
additive	O
effects	O
of	O
serotonin	O
.	O

Tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
drugs	O
:	O
blood	B-group
thinners	O
(	O
Coumadin	S-brand
)	O
other	O
antidepressants	S-group
metoprolol	S-drug
antihistamines	S-group
carbamazepine	S-drug
(	O
Tegretol	S-brand
)	O
cimetidine	S-drug
(	O
Tagamet	S-brand
)	O
estrogens	S-group
fluoxetine	S-drug
(	O
Prozac	S-brand
)	O
intraconazole	O
(	O
Sporanox	S-brand
)	O
ketoconazole	S-drug
(	O
Nizoral	S-brand
)	O
levodopa	S-drug
lithium	S-drug
muscle	B-group
relaxants	E-group
birth	O
control	O
pills	O
sleeping	O
pills	O
thyroid	O
medications	O

Androgens	S-group
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulahts	O
.	O

Dosage	O
of	O
the	O
anticoagulant	S-group
may	O
require	O
reduction	O
in	O
order	O
to	O
maintain	O
satisfactory	O
therapeutic	O
hypoprothrombinemia	O
.	O

Concurrent	O
administration	O
of	O
oxyphenbutazone	S-drug-ME-1
and	O
androgens	S-group-ME-2
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	S-drug
.	O

In	O
diabetic	O
patients	O
,	O
the	O
metabolic	O
effects	O
of	O
androgens	S-group-EF-1
may	O
decrease	O
blood	O
glucose	O
and	O
therefore	O
,	O
insulin	S-drug-EF-2
requirements	O
.	O

Drug	O
Interactions	O
:	O
Flupenthixol	S-drug-IN-1
may	O
interact	O
with	O
some	O
drugs	O
,	O
like	O
Monoamine	B-group-IN-2
oxidase	I-group-IN-2
inhibitors	E-group-IN-2
(	O
MAOI	S-group-IN-2
)	O
:	O
MAOI	S-group-EF-1
could	O
theoretically	O
affect	O
flupenthixol	S-drug-EF-2
pharmacodynamics	O
-	O
Arecoline	S-drug_n
-	O
Eproxindine	O
-	O
Ethanol	S-drug
:	O
Flupenthixol	S-drug-EF-1
and	O
Ethanol	S-drug-EF-2
cause	O
additive	O
CNS	O
depression	O
-	O
Tricyclic	B-group
antidepressants	E-group
:	O
Flupenthixol	S-drug-EF-1
increases	O
the	O
effect	O
of	O
Tricyclic	B-group-EF-2
antidepressants	E-group-EF-2

Antacids	S-group
:	O
Administration	O
of	O
flurbiprofen	S-drug
to	O
volunteers	O
under	O
fasting	O
conditions	O
,	O
or	O
with	O
antacid	S-group
suspension	O
yielded	O
similar	O
serum	O
flurbiprofen	S-drug
time	O
profiles	O
in	O
young	O
subjects	O
(	O
n	O
=	O
12	O
)	O
.	O

In	O
geriatric	O
subjects	O
(	O
n	O
=	O
7	O
)	O
there	O
was	O
a	O
reduction	O
in	O
the	O
rate	O
but	O
not	O
the	O
extent	O
of	O
flurbiprofen	S-drug
absorption	O
.	O

Anticoagulants	S-group
:	O
Flurbiprofen	S-drug-EF-1
like	O
other	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
,	O
has	O
been	O
shown	O
to	O
affect	O
bleeding	O
parameters	O
in	O
patients	O
receiving	O
anti	B-group-EF-2
-	I-group-EF-2
coagulants	E-group-EF-2
,	O
and	O
serious	O
clinical	O
bleeding	O
has	O
been	O
reported	O
.	O

The	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
flurbiprofen	S-drug-AD-1
to	O
patients	O
taking	O
anticoagulants	S-group-AD-2
.	O

Aspirin	S-brand
:	O
Concurrent	O
administration	O
of	O
aspirin	S-brand-ME-1
and	O
flurbiprofen	S-drug-ME-2
resulted	O
in	O
50	O
%	O
lower	O
serum	O
flurbiprofen	S-drug
concentrations	O
.	O

This	O
effect	O
of	O
aspirin	S-brand
(	O
which	O
also	O
lowers	O
serum	O
concentrations	O
of	O
other	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drugs	E-group
given	O
with	O
it	O
)	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
n	O
=	O
15	O
)	O
as	O
well	O
as	O
normal	O
volunteers	O
(	O
n	O
=	O
16	O
)	O
.	O

Concurrent	O
use	O
of	O
flurbiprofen	S-drug-AD-1
and	O
aspirin	S-brand-AD-2
is	O
therefore	O
not	O
recommended	O
.	O

Beta	B-group
-	I-group
adrenergic	I-group
Blocking	I-group
Agents	E-group
:	O
The	O
effect	O
of	O
flurbiprofen	S-drug
on	O
blood	O
pressure	O
response	O
to	O
propranolol	S-drug
and	O
atenolol	S-drug
was	O
evaluated	O
in	O
men	O
with	O
mild	O
uncomplicated	O
hypertension	O
(	O
n	O
=	O
10	O
)	O
.	O

Flurbiprofen	S-drug-EF-1
pretreatment	O
attenuated	O
the	O
hypotensive	O
effect	O
of	O
a	O
single	O
dose	O
of	O
propranolol	S-drug-EF-2
but	O
not	O
atenolol	S-drug
.	O

Flurbiprofen	S-drug
did	O
not	O
appear	O
to	O
affect	O
the	O
beta	O
-	O
blocker	O
-	O
mediated	O
reduction	O
in	O
heart	O
rate	O
.	O

Flurbiprofen	S-drug-IN-1
did	O
not	O
affect	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	O
,	O
and	O
the	O
mechanism	O
under	O
lying	O
the	O
interference	O
with	O
propranolols	O
hypotensive	O
effect	O
is	O
unknown	O
.	O

Patients	O
taking	O
both	O
flurbiprofen	S-drug-AD-1
and	O
a	O
beta	B-group-AD-2
-	I-group-AD-2
blocker	E-group-AD-2
should	O
be	O
monitored	O
to	O
ensure	O
that	O
a	O
satisfactory	O
hypotensive	O
effect	O
is	O
achieved	O
.	O

Cimetidine	S-drug
,	O
Ranitidine	S-drug
:	O
In	O
normal	O
volunteers	O
(	O
n	O
=	O
9	O
)	O
,	O
pretreatment	O
with	O
cimetidine	S-drug
or	O
ranitidine	S-drug
did	O
not	O
affect	O
flurbiprofen	S-drug
pharmacokinetics	O
except	O
that	O
a	O
small	O
(	O
13	O
%	O
)	O
but	O
statistically	O
significant	O
increase	O
in	O
the	O
area	O
under	O
the	O
serum	O
concentration	O
curve	O
of	O
flurbiprofen	S-drug-ME-1
resulted	O
with	O
cimetidine	S-drug-ME-2
.	O

Digoxin	S-drug
:	O
Studies	O
of	O
concomitant	O
administration	O
of	O
flurbiprofen	S-drug
and	O
digoxin	S-drug
to	O
healthy	O
men	O
(	O
n	O
=	O
14	O
)	O
did	O
not	O
show	O
a	O
change	O
in	O
the	O
steady	O
state	O
serum	O
levels	O
of	O
either	O
drug	O
.	O

Diuretics	S-group
:	O
Studies	O
in	O
normal	O
volunteers	O
have	O
shown	O
that	O
flurbiprofen	S-drug-EF-1
like	O
other	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
,	O
can	O
interfere	O
with	O
the	O
effects	O
of	O
furosemide	S-drug-EF-2
.	O

Although	O
results	O
have	O
varied	O
from	O
study	O
to	O
study	O
,	O
effects	O
have	O
been	O
shown	O
on	O
furosemide	S-drug
-	O
stimulated	O
diuresis	O
,	O
natriuresis	O
,	O
and	O
kaliuresis	O
.	O

Other	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
that	O
inhibit	O
prostaglandin	O
synthesis	O
have	O
been	O
shown	O
to	O
interfere	O
with	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
in	O
some	O
studies	O
and	O
with	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	I-group-EF-2
diuretics	E-group-EF-2
.	O

Patients	O
receiving	O
flurbiprofen	S-drug-AD-1
and	O
furosemide	S-drug-AD-2
or	O
other	O
diuretics	S-group-AD-2
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
is	O
obtained	O
.	O

Oral	O
Hypoglycemic	B-group
Agents	E-group
:	O
In	O
one	O
study	O
,	O
flurbiprofen	S-drug
was	O
given	O
to	O
adult	O
diabetics	O
who	O
were	O
already	O
receiving	O
glyburide	S-drug
(	O
n	O
=	O
4	O
)	O
,	O
metformin	S-drug
(	O
n	O
=	O
2	O
)	O
chlorpropamide	S-drug
with	O
phenformin	S-drug
(	O
n	O
=	O
3	O
)	O
or	O
glyburide	S-drug
with	O
phenformin	S-drug
(	O
n	O
=	O
6	O
)	O
.	O

Although	O
there	O
was	O
a	O
slight	O
reduction	O
in	O
blood	O
sugar	O
concentrations	O
during	O
concomitant	O
administration	O
of	O
flurbiprofen	S-drug-EF-1
and	O
hypoglycemic	B-group-EF-2
agents	E-group-EF-2
,	O
there	O
were	O
no	O
signs	O
or	O
symptoms	O
of	O
hypoglycemia	O
.	O

Increases	O
in	O
prothrombin	O
time	O
have	O
been	O
noted	O
in	O
patients	O
receiving	O
long	O
-	O
term	O
warfarin	S-drug-EF-1
therapy	O
after	O
flutamide	S-drug-EF-2
was	O
initiated	O
.	O

Therefore	O
,	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
and	O
adjustment	O
of	O
the	O
anticoagulant	S-group
dose	O
may	O
be	O
necessary	O
when	O
EULEXIN	S-brand-AD-1
Capsules	O
are	O
administered	O
concomitantly	O
with	O
warfarin	S-drug-AD-2
.	O

Potential	O
for	O
Interaction	O
with	O
Monoamine	B-group
Oxidase	I-group
Inhibitors	E-group

In	O
patients	O
receiving	O
another	O
serotonin	B-group-EF-1
reuptake	I-group-EF-1
inhibitor	I-group-EF-1
drug	E-group-EF-1
in	O
combination	O
with	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
(	O
MAOI	S-group-EF-2
)	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
,	O
sometimes	O
fatal	O
,	O
reactions	O
including	O
hyperthermia	O
,	O
rigidity	O
,	O
myoclonus	O
,	O
autonomic	O
instability	O
with	O
possible	O
rapid	O
fluctuations	O
of	O
vital	O
signs	O
,	O
and	O
mental	O
status	O
changes	O
that	O
include	O
extreme	O
agitation	O
progressing	O
to	O
delirium	O
and	O
coma	O
.	O

These	O
reactions	O
have	O
also	O
been	O
reported	O
in	O
patients	O
who	O
have	O
discontinued	O
that	O
drug	O
and	O
have	O
been	O
started	O
on	O
a	O
MAOI	S-group
.	O

Some	O
cases	O
presented	O
with	O
features	O
resembling	O
neuroleptic	O
malignant	O
syndrome	O
.	O

Therefore	O
,	O
it	O
is	O
recommended	O
that	O
Fluvoxamine	S-drug-AD-1
Tablets	O
not	O
be	O
used	O
in	O
combination	O
with	O
MAOIs	S-group-AD-2
,	O
or	O
within	O
14	O
days	O
of	O
discontinuing	O
treatment	O
with	O
a	O
MAOI	S-group-AD-2
.	O

After	O
stopping	O
Fluvoxamine	S-drug-AD-1
Tablets	O
,	O
at	O
least	O
2	O
weeks	O
should	O
be	O
allowed	O
before	O
starting	O
a	O
MAOI	S-group-AD-2
.	O

Potential	O
Terfenadine	S-drug
,	O
Astemizole	S-drug
,	O
and	O
Cisapride	S-drug
Interactions	O

Terfenadine	S-drug-ME-1
,	O
astemizole	S-drug-ME-1
and	O
cisapride	S-drug-ME-1
are	O
all	O
metabolized	O
by	O
the	O
cytochrome	O
P450IIIA4	O
isozyme	O
,	O
and	O
it	O
has	O
been	O
demonstrated	O
that	O
ketoconazole	S-drug-ME-2
,	O
a	O
potent	O
inhibitor	O
of	O
IIIA4	O
,	O
blocks	O
the	O
metabolism	O
of	O
these	O
drugs	O
,	O
resulting	O
in	O
increased	O
plasma	O
concentrations	O
of	O
parent	O
drug	O
.	O

Increased	O
plasma	O
concentrations	O
of	O
terfenadine	S-drug
,	O
astemizole	S-drug
,	O
and	O
cisapride	S-drug
cause	O
QT	O
prolongation	O
and	O
have	O
been	O
associated	O
with	O
torsades	O
de	O
pointes	O
-	O
type	O
ventricular	O
tachycardia	O
,	O
sometimes	O
fatal	O
.	O

As	O
noted	O
below	O
,	O
a	O
sub	O
-	O
for	O
fluvoxamine	S-drug
in	O
combination	O
with	O
alprazolam	S-drug
,	O
a	O
drug	O
that	O
is	O
known	O
to	O
be	O
metabolized	O
by	O
the	O
IIIA4	O
isozyme	O
.	O

Although	O
it	O
has	O
not	O
been	O
definitively	O
demonstrated	O
that	O
fluvoxamine	S-drug
is	O
a	O
potent	O
IIIA4	O
inhibitor	O
,	O
it	O
is	O
likely	O
to	O
be	O
,	O
given	O
the	O
substantial	O
interaction	O
of	O
fluvoxamine	S-drug-IN-1
with	O
alprazolam	S-drug-IN-2
.	O

Consequently	O
,	O
it	O
is	O
recommended	O
that	O
fluvoxamine	S-drug-AD-1
not	O
be	O
used	O
in	O
combination	O
with	O
either	O
terbinafine	S-drug-AD-2
,	O
astemizole	S-drug-AD-2
,	O
or	O
cisapride	S-drug-AD-2
.	O

Other	O
Potentially	O
Important	O
Drug	O
Interactions	O
:	O
Benzodiazepines	S-group
:	O
Benzodiazepines	S-group-ME-1
metabolized	O
by	O
hepatic	O
oxidation	O
(	O
e.g	O
.	O
,	O
alprazolam	S-drug-ME-1
,	O
midazolam	S-drug-ME-1
,	O
triazolam	S-drug-ME-1
elc	O
.	O
)	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
clearance	O
of	O
these	O
drugs	O
is	O
likely	O
to	O
be	O
reduced	O
by	O
fluvoxamine	S-drug-ME-2
.	O

The	O
clearance	O
of	O
benzodiazepines	S-group
metabolized	O
by	O
glucuronidation	O
(	O
e.	O
g.	O
,	O
lorazepam	S-drug
,	O
oxazepam	S-drug
,	O
temazepam	S-drug
)	O
is	O
unlikely	O
to	O
be	O
affected	O
by	O
fluvoxamine	S-drug
.	O

Alprazolam	S-drug
:	O
When	O
fluvoxamine	B-drug-ME-1
maleate	E-drug-ME-1
(	O
100	O
mg	O
qd	O
)	O
and	O
alprazolam	S-drug-ME-2
(	O
1	O
mg	O
q.d	O
.	O
were	O
co	O
-	O
administered	O
to	O
steady	O
state	O
,	O
plasma	O
concentration	O
and	O
other	O
pharmacokinetics	O
parameters	O
(	O
AUC	O
,	O
Cmax	O
,	O
T1	O
/	O
2	O
,	O
)	O
of	O
alprazolam	S-drug
were	O
approximately	O
twice	O
those	O
observed	O
when	O
alprazolam	S-drug
was	O
administered	O
alone	O
;	O

oral	O
clearance	O
was	O
reduced	O
by	O
about	O
50	O
%	O
.	O

The	O
elevated	O
plasma	O
alprazolam	S-drug
concentrations	O
resulted	O
in	O
decreased	O
psychomotor	O
performance	O
and	O
memory	O
.	O

This	O
interaction	O
,	O
which	O
has	O
not	O
been	O
investigated	O
using	O
higher	O
doses	O
of	O
fluvoxamine	S-drug
,	O
may	O
be	O
more	O
pronounced	O
if	O
a	O
300	O
mg	O
daily	O
dose	O
is	O
co	O
-	O
administered	O
,	O
particularly	O
since	O
fluvoxamine	S-drug
exhibits	O
non	O
-	O
linear	O
pharmacokinetics	O
over	O
the	O
dosage	O
range	O
100	O
-	O
300	O
mg	O
.	O
If	O
alprazolam	S-drug-AD-1
is	O
co	O
-	O
administered	O
with	O
Fluvoxamine	S-drug-AD-2
Tablets	O
,	O
the	O
initial	O
alprazolam	S-drug
dosage	O
should	O
be	O
at	O
least	O
halved	O
and	O
titration	O
to	O
the	O
lowest	O
effective	O
dose	O
is	O
recommended	O
.	O

No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	S-drug
Tablets	O
.	O

Diazepam	S-drug
:	O
The	O
co	O
-	O
administration	O
of	O
Fluvoxamine	S-drug-AD-1
Tablets	O
and	O
diazepam	S-drug-AD-2
is	O
generally	O
not	O
advisable	O
.	O

Because	O
fluvoxamine	S-drug-ME-1
reduces	O
the	O
clearance	O
of	O
both	O
diazepam	S-drug-ME-2
and	O
its	O
active	O
metabolite	O
,	O
N	B-drug_n-ME-2
-	I-drug_n-ME-2
desmethyldiazepam	E-drug_n-ME-2
,	O
there	O
is	O
a	O
strong	O
likelihood	O
of	O
substantial	O
accumulation	O
of	O
both	O
species	O
during	O
chronic	O
co	O
-	O
administration	O
.	O

Evidence	O
supporting	O
the	O
conclusion	O
that	O
it	O
is	O
inadvisable	O
to	O
co	O
-	O
administer	O
fluvoxamine	S-drug-AD-1
and	O
diazepam	S-drug-AD-2
is	O
derived	O
from	O
a	O
study	O
in	O
which	O
healthy	O
volunteers	O
taking	O
150	O
mg	O
/	O
day	O
of	O
fluvoxamine	S-drug
were	O
administered	O
a	O
single	O
oral	O
dose	O
of	O
10	O
mg	O
of	O
diazepam	S-drug
.	O

In	O
these	O
subjects	O
(	O
R	O
=	O
B	O
)	O
,	O
the	O
clearance	O
of	O
diazepam	S-drug
was	O
reduced	O
by	O
65	O
%	O
and	O
that	O
of	O
N	B-drug_n
-	I-drug_n
desmethyldiazepam	E-drug_n
to	O
a	O
level	O
that	O
was	O
too	O
low	O
to	O
measure	O
over	O
the	O
course	O
of	O
the	O
2	O
week	O
long	O
study	O
.	O

It	O
is	O
likely	O
that	O
experience	O
significantly	O
underestimates	O
the	O
degree	O
of	O
accumulation	O
that	O
might	O
occur	O
with	O
repealed	O
diazepam	S-drug
administration	O
.	O

Moreover	O
,	O
as	O
noted	O
with	O
alprazolam	S-drug-EF-1
,	O
the	O
effect	O
of	O
fluvoxamine	S-drug-EF-2
may	O
even	O
be	O
more	O
pronounced	O
when	O
it	O
is	O
administered	O
at	O
higher	O
doses	O
.	O

Accordingly	O
,	O
diazepam	S-drug-AD-1
and	O
fluvoxamine	S-drug-AD-2
should	O
not	O
ordinarily	O
be	O
co	O
-	O
administered	O
.	O

Theophylline	S-drug
:	O
The	O
effect	O
of	O
steady	O
-	O
state	O
fluvoxamine	S-drug
l50	O
mg	O
bid	O
on	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
dose	O
of	O
Theophylline	S-drug
(	O
375	O
mg	O
)	O
as	O
442	O
mg	O
aminophylline	S-drug
was	O
evaluated	O
in	O
12	O
healthy	O
non	O
-	O
smoking	O
,	O
male	O
volunteers	O
.	O

The	O
clearance	O
of	O
theophylline	S-drug
was	O
decreased	O
approximately	O
3	O
-	O
fold	O
.	O

Therefore	O
,	O
if	O
theophylline	S-drug-AD-1
is	O
co	O
-	O
administered	O
with	O
fluvoxamine	B-drug-AD-2
maleate	E-drug-AD-2
,	O
its	O
dose	O
should	O
be	O
reduced	O
to	O
one	O
third	O
of	O
the	O
usual	O
daily	O
maintenance	O
dose	O
and	O
plasma	O
concentrations	O
of	O
theophylline	S-drug
should	O
to	O
monitored	O
.	O

No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	S-drug
Tablets	O
.	O

Warfarin	S-drug
:	O
When	O
fluvoxamine	B-drug-ME-1
maleate	E-drug-ME-1
(	O
50	O
mg	O
tid	O
)	O
was	O
administered	O
concomitantly	O
with	O
warfarin	S-drug-ME-2
for	O
two	O
weeks	O
,	O
warfarin	S-drug
plasma	O
concentrations	O
increased	O
by	O
98	O
%	O
and	O
prothrombin	O
times	O
were	O
prolonged	O
.	O

Thus	O
patients	O
receiving	O
oral	O
anticoagulants	S-group-AD-1
and	O
Fluvoxamine	S-drug-AD-2
Tablets	O
should	O
have	O
their	O
prothrombin	O
time	O
monitored	O
and	O
their	O
anticoagulant	S-group
dose	O
adjusted	O
accordingly	O
.	O

No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	S-drug
Tablets	O
.	O

Medications	O
that	O
interfere	O
with	O
your	O
bodys	O
ability	O
to	O
use	O
folate	O
may	O
also	O
increase	O
the	O
need	O
for	O
this	O
vitamin	S-group
.	O

Medications	O
can	O
interfere	O
with	O
folate	O
utilization	O
,	O
including	O
:	O
anticonvulsant	B-group
medications	E-group
(	O
such	O
as	O
phenytoin	S-drug
,	O
and	O
primidone	S-drug
)	O
metformin	S-drug
(	O
sometimes	O
prescribed	O
to	O
control	O
blood	O
sugar	O
in	O
type	O
2	O
diabetes	O
)	O
sulfasalazine	S-drug
(	O
used	O
to	O
control	O
inflammation	O
associated	O
with	O
Crohns	O
disease	O
and	O
ulcerative	O
colitis	O
)	O
triamterene	S-drug
(	O
a	O
diuretic	S-group
)	O
Methotrexate	S-drug
There	O
has	O
been	O
concern	O
about	O
the	O
interaction	O
between	O
vitamin	B-drug-IN-1
B12	E-drug-IN-1
and	O
folic	B-drug-IN-2
acid	E-drug-IN-2
.	O

Folic	B-drug
acid	E-drug
supplements	O
can	O
correct	O
the	O
anemia	O
associated	O
with	O
vitamin	O
B12	O
deficiency	O
.	O

Unfortunately	O
,	O
folic	B-drug
acid	E-drug
will	O
not	O
correct	O
changes	O
in	O
the	O
nervous	O
system	O
that	O
result	O
from	O
vitamin	O
B12	O
deficiency	O
.	O

Permanent	O
nerve	O
damage	O
could	O
theoretically	O
occur	O
if	O
vitamin	O
B12	O
deficiency	O
is	O
not	O
treated	O
.	O

Therefore	O
,	O
intake	O
of	O
supplemental	O
folic	B-drug
acid	E-drug
should	O
not	O
exceed	O
1000	O
micrograms	O
(	O
g	O
,	O
sometimes	O
mcg	O
)	O
per	O
day	O
to	O
prevent	O
folic	B-drug
acid	E-drug
from	O
masking	O
symptoms	O
of	O
vitamin	O
B12	O
deficiency	O
.	O

It	O
is	O
important	O
for	O
older	O
adults	O
to	O
be	O
aware	O
of	O
the	O
relationship	O
between	O
folic	B-drug
acid	E-drug
and	O
vitamin	B-drug
B12	E-drug
because	O
they	O
are	O
at	O
greater	O
risk	O
of	O
having	O
a	O
vitamin	O
B12	O
deficiency	O
.	O

If	O
you	O
are	O
50	O
years	O
of	O
age	O
or	O
older	O
,	O
ask	O
your	O
physician	O
to	O
check	O
your	O
B12	O
status	O
before	O
you	O
take	O
a	O
supplement	O
that	O
contains	O
folic	B-drug
acid	E-drug
.	O

No	O
drug	O
/	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Oral	O
doses	O
of	O
Antizol	S-brand-ME-1
(	O
10	O
-	O
20	O
mg	O
/	O
kg	O
)	O
,	O
via	O
alcohol	O
dehydrogenase	O
inhibition	O
,	O
significantly	O
reduced	O
the	O
rate	O
of	O
elimination	O
of	O
ethanol	S-drug-ME-2
(	O
by	O
approximately	O
40	O
%	O
)	O
given	O
to	O
healthy	O
volunteers	O
in	O
moderate	O
doses	O
.	O

Similarly	O
,	O
ethanol	S-drug-ME-1
decreased	O
the	O
rate	O
of	O
elimination	O
of	O
Antizol	S-brand-ME-2
(	O
by	O
approximately	O
50	O
%	O
)	O
by	O
the	O
same	O
mechanism	O
.	O

Reciprocal	O
interactions	O
may	O
occur	O
with	O
concomitant	O
use	O
of	O
Antizol	S-brand-ME-1
and	O
drugs	O
that	O
increase	O
or	O
inhibit	O
the	O
cytochrome	O
P450	O
system	O
(	O
e.g	O
.	O
,	O
phenytoin	S-drug-ME-2
,	O
carbamazepine	S-drug-ME-2
,	O
cimetidine	S-drug-ME-2
,	O
ketoconazole	S-drug-ME-2
)	O
,	O
though	O
this	O
has	O
not	O
been	O
studied	O

In	O
clinical	O
studies	O
performed	O
with	O
Fondaparinux	S-drug
,	O
the	O
concomitant	O
use	O
of	O
oral	O
anticoagulants	S-group
(	O
warfarin	S-drug
)	O
,	O
platelet	B-group
inhibitors	E-group
(	O
acetylsalicylic	B-drug
acid	E-drug
)	O
,	O
NSAIDs	S-group
(	O
piroxicam	S-drug
)	O
,	O
and	O
digoxin	S-drug
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
/	O
pharmacodynamics	O
of	O
fondaparinux	B-drug
sodium	E-drug
.	O

In	O
addition	O
,	O
Fondaparinux	S-drug
neither	O
influenced	O
the	O
pharmacodynamics	O
of	O
warfarin	S-drug
,	O
acetylsalicylic	B-drug
acid	E-drug
,	O
piroxicam	S-drug
,	O
and	O
digoxin	S-drug
,	O
nor	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
at	O
steady	O
state	O
.	O

Agents	O
that	O
may	O
enhance	O
the	O
risk	O
of	O
hemorrhage	O
should	O
be	O
discontinued	O
prior	O
to	O
initiation	O
of	O
Fondaparinux	S-drug
therapy	O
.	O

If	O
co	O
-	O
administration	O
is	O
essential	O
,	O
close	O
monitoring	O
may	O
be	O
appropriate	O
.	O

In	O
an	O
in	O
vitro	O
study	O
in	O
human	O
liver	O
microsomes	O
,	O
inhibition	O
of	O
CYP2A6	O
hydroxylation	O
of	O
coumarin	S-group-ME-1
by	O
fondaparinux	S-drug-ME-2
(	O
200	O
m	O
m	O
M	O
i.e	O
.	O
,	O
350	O
mg	O
/	O
L	O
)	O
was	O
17	O
-	O
28	O
%	O
.	O

Inhibition	O
of	O
the	O
other	O
isozymes	O
evaluated	O
(	O
CYPs	O
2A1	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
3A4	O
,	O
and	O
3E1	O
)	O
was	O
0	O
-	O
16	O
%	O
.	O

Since	O
fondaparinux	S-drug
does	O
not	O
markedly	O
inhibit	O
CYP450s	O
(	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
or	O
CYP3A4	O
)	O
in	O
vitro	O
,	O
fondaparinux	B-drug
sodium	E-drug
is	O
not	O
expected	O
to	O
significantly	O
interact	O
with	O
other	O
drugs	O
in	O
vivo	O
by	O
inhibition	O
of	O
metabolism	O
mediated	O
by	O
these	O
isozymes	O
.	O

Since	O
fondaparinux	B-drug
sodium	E-drug
does	O
not	O
bind	O
significantly	O
to	O
plasma	O
proteins	O
other	O
than	O
ATIII	O
,	O
no	O
drug	O
interactions	O
by	O
protein	O
-	O
binding	O
displacement	O
are	O
expected	O
.	O

Short	B-group
-	I-group
Acting	I-group
beta2	I-group
-	I-group
agonists	E-group
:	O
Aerosol	O
bronchodilators	S-group
of	O
the	O
short	O
-	O
acting	O
adrenergic	O
stimulant	O
type	O
may	O
be	O
used	O
for	O
relief	O
of	O
breakthrough	O
symptoms	O
while	O
using	O
formoterol	S-drug
.	O

However	O
,	O
increasing	O
use	O
of	O
such	O
preparations	O
to	O
control	O
symptoms	O
indicates	O
deterioration	O
of	O
asthma	O
control	O
and	O
the	O
need	O
to	O
reassess	O
the	O
patient	O
s	O
therapy	O
.	O

Concomitant	O
administration	O
of	O
other	O
sympathomimetic	B-group-EF-1
agents	E-group-EF-1
may	O
potentiate	O
the	O
undesirable	O
effects	O
of	O
FORADIL	S-brand-EF-2
.	O

Monoamine	B-group
Oxidase	I-group
Inhibitors	E-group
and	O
Tricyclic	B-group
Antidepressants	E-group
:	O
FORADIL	S-brand-AD-1
should	O
be	O
administered	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
monoamine	B-group-AD-2
oxidase	I-group-AD-2
inhibitors	E-group-AD-2
or	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
because	O
the	O
action	O
of	O
formoterol	S-drug
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O

Corticosteroids	S-group
,	O
Methylxanthines	S-group
and	O
Diuretics	S-group
:	O
Concomitant	O
treatment	O
with	O
xanthine	B-group-EF-1
derivatives	E-group-EF-1
,	O
steroids	S-group-EF-1
,	O
or	O
diuretics	S-group-EF-1
may	O
potentiate	O
a	O
possible	O
hypokalemic	O
effect	O
of	O
beta2	B-group-EF-2
-	I-group-EF-2
agonists	I-group-EF-2
.	E-group-EF-2

Hypokalemia	O
may	O
increase	O
susceptibility	O
to	O
cardiac	O
arrhythmias	O
in	O
patients	O
treated	O
with	O
digitalis	S-group
.	O

-	O
adrenergic	O
Blockers	O
:	O
-	O
adrenergic	O
blockers	O
may	O
weaken	O
or	O
antagonise	O
the	O
effect	O
of	O
FORADIL	S-brand
.	O

Therefore	O
FORADIL	S-brand
should	O
not	O
be	O
given	O
together	O
with	O
-	O
adrenergic	O
blockers	O
(	O
including	O
eye	O
drops	O
)	O
unless	O
there	O
are	O
compelling	O
reasons	O
for	O
their	O
use	O
.	O

Other	O
Drugs	O
:	O
Drugs	O
such	O
as	O
quinidine	S-drug
,	O
disopyramide	S-drug
,	O
procainamide	S-drug
,	O
phenothiazines	S-group
,	O
antihistamines	S-group
,	O
and	O
tricyclic	B-group
antidepressants	E-group
may	O
be	O
associated	O
with	O
QT	O
-	O
interval	O
prolongation	O
and	O
an	O
increased	O
risk	O
of	O
ventricular	O
arrhythmia	O
.	O

INFORMATION	O
TO	O
BE	O
PROVIDED	O
TO	O
THE	O
PATIENT	O
OR	O
GUARDIAN	O
See	O
illustrated	O
Information	O
For	O
The	O
Patient	O
or	O
Guardian	O
section	O
.	O

It	O
is	O
important	O
that	O
patients	O
understand	O
how	O
to	O
use	O
FORADIL	S-brand
(	O
formoterol	B-drug
fumarate	E-drug
)	O
capsules	O
with	O
the	O
supplied	O
AerolizerTM	O
inhalation	O
device	O
and	O
how	O
it	O
should	O
be	O
used	O
in	O
relation	O
to	O
other	O
asthma	O
or	O
COPD	O
medications	O
they	O
are	O
taking	O
.	O

Patients	O
/	O
Guardians	O
should	O
be	O
given	O
the	O
following	O
information	O
:	O
i	O
.	O

The	O
recommended	O
dosage	O
(	O
one	O
or	O
two	O
capsules	O
twice	O
daily	O
,	O
morning	O
and	O
evening	O
)	O
should	O
not	O
be	O
exceeded	O
.	O

ii	O
.	O

FORADIL	S-brand
is	O
not	O
meant	O
to	O
relieve	O
acute	O
asthma	O
or	O
COPD	O
symptoms	O
and	O
extra	O
doses	O
should	O
not	O
be	O
used	O
for	O
that	O
purpose	O
.	O

Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
a	O
short	O
-	O
acting	O
,	O
inhaled	O
beta2	B-group
-	I-group
agonist	E-group
such	O
as	O
salbutamol	S-drug
(	O
the	O
physician	O
should	O
provide	O
the	O
patient	O
with	O
such	O
medication	O
and	O
instruct	O
the	O
patient	O
in	O
how	O
it	O
should	O
be	O
used	O
)	O
.	O

iii	O
.	O

The	O
physician	O
should	O
be	O
notified	O
immediately	O
if	O
any	O
of	O
the	O
following	O
situations	O
occur	O
,	O
which	O
may	O
be	O
a	O
sign	O
of	O
seriously	O
worsening	O
asthma	O
:	O
Decreased	O
effectiveness	O
of	O
short	B-group
-	I-group
acting	I-group
,	I-group
inhaled	I-group
beta2	I-group
-	I-group
agonists	E-group
;	O

Need	O
for	O
more	O
inhalations	O
than	O
usual	O
of	O
short	B-group
-	I-group
acting	I-group
,	I-group
inhaled	I-group
beta2	I-group
-	I-group
agonists	E-group
.	O

iv	O
.	O

FORADIL	S-brand
should	O
not	O
be	O
used	O
as	O
a	O
substitute	O
for	O
oral	O
or	O
inhaled	O
corticosteroids	S-group
.	O

The	O
dosage	O
of	O
these	O
medications	O
should	O
not	O
be	O
changed	O
and	O
they	O
should	O
not	O
be	O
stopped	O
without	O
consulting	O
the	O
physician	O
,	O
even	O
if	O
the	O
patient	O
feels	O
better	O
after	O
initiating	O
treatment	O
with	O
FORADIL	S-brand
.	O

v.	O
Patients	O
should	O
be	O
cautioned	O
regarding	O
potential	O
adverse	O
cardiovascular	O
effects	O
,	O
such	O
as	O
palpitations	O
or	O
chest	O
pain	O
.	O

vi	O
.	O

In	O
patients	O
receiving	O
FORADIL	S-brand
,	O
other	O
inhaled	O
medications	O
should	O
be	O
used	O
only	O
as	O
directed	O
by	O
the	O
physician	O
.	O

vii	O
.	O

Guardians	O
of	O
children	O
who	O
have	O
been	O
prescribed	O
FORADIL	S-brand
should	O
be	O
alerted	O
to	O
the	O
general	O
concern	O
regarding	O
asthma	O
therapy	O
compliance	O
,	O
especially	O
neglect	O
of	O
anti	O
-	O
inflammatory	O
therapy	O
and	O
overuse	O
of	O
short	B-group
-	I-group
acting	I-group
beta2	I-group
-	I-group
agonists	E-group
.	O

A	O
possible	O
drug	O
interaction	O
of	O
FOSCAVIR	S-brand-IN-1
and	O
intravenous	O
pentamidine	S-drug-IN-2
has	O
been	O
described	O
.	O

Concomitant	O
treatment	O
of	O
four	O
patients	O
in	O
the	O
United	O
Kingdom	O
with	O
FOSCAVIR	S-brand-EF-1
and	O
intravenous	O
pentamidine	S-drug-EF-2
may	O
have	O
caused	O
hypocalcemia	O
;	O

one	O
patient	O
died	O
with	O
severe	O
hypocalcemia	O
.	O

Toxicity	O
associated	O
with	O
concomitant	O
use	O
of	O
aerosolized	O
pentamidine	S-drug
has	O
not	O
been	O
reported	O
.	O

Because	O
of	O
foscarnets	O
tendency	O
to	O
cause	O
renal	O
impairment	O
,	O
the	O
use	O
of	O
FOSCAVIR	S-brand-AD-1
should	O
be	O
avoided	O
in	O
combination	O
with	O
potentially	O
nephrotoxic	O
drugs	O
such	O
as	O
aminoglycosides	S-group-AD-2
,	O
amphotericin	B-drug-AD-2
B	E-drug-AD-2
and	O
intravenous	O
pentamidine	S-drug-AD-2
unless	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
to	O
the	O
patient	O
.	O

Since	O
FOSCAVIR	S-brand
decreases	O
serum	O
concentrations	O
of	O
ionized	O
calcium	O
,	O
concurrent	O
treatment	O
with	O
other	O
drugs	O
known	O
to	O
influence	O
serum	O
calcium	O
concentrations	O
should	O
be	O
used	O
with	O
particular	O
caution	O
.	O

Ganciclovir	S-drug
:	O
The	O
pharmacokinetics	O
of	O
foscarnet	S-drug
and	O
ganciclovir	S-drug
were	O
not	O
altered	O
in	O
13	O
patients	O
receiving	O
either	O
concomitant	O
therapy	O
or	O
daily	O
alternating	O
therapy	O
for	O
maintenance	O
of	O
CMV	O
disease	O
.	O

Metoclopramide	S-drug
:	O
When	O
coadministered	O
with	O
MONUROL	S-brand-ME-1
,	O
metoclopramide	S-drug-ME-2
,	O
a	O
drug	O
which	O
increases	O
gastrointestinal	O
motility	O
,	O
lowers	O
the	O
serum	O
concentration	O
and	O
urinary	O
excretion	O
of	O
fosfomycin	S-drug
.	O

Other	O
drugs	O
that	O
increase	O
gastrointestinal	O
motility	O
may	O
produce	O
similar	O
effects	O
.	O

Cimetidine	S-drug
:	O
Cimetidine	S-drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
fosfomycin	S-drug
when	O
coadministered	O
with	O
MONUROL	S-brand
.	O

Diuretics	S-group
:	O
Patients	O
on	O
diuretics	S-group-EF-1
,	O
especially	O
those	O
with	O
intravascular	O
volume	O
depletion	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
fosinopril	B-drug-EF-2
sodium	E-drug-EF-2
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	S-group-EF-1
or	O
increasing	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
fosinopril	B-drug-EF-2
sodium	E-drug-EF-2
.	O

If	O
this	O
is	O
not	O
possible	O
,	O
the	O
starting	O
dose	O
should	O
be	O
reduced	O
and	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
several	O
hours	O
following	O
an	O
initial	O
dose	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
(	O
see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
.	O
)	O

Potassium	S-drug
Supplements	O
and	O
Potassium	B-group
-	I-group
Sparing	I-group
Diuretics	E-group
:	O
Fosinopril	B-drug-EF-1
sodium	E-drug-EF-1
can	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
.	O

Potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
(	O
spironolactone	S-drug
,	O
amiloride	S-drug
,	O
triamterene	S-drug
,	O
and	O
others	O
)	O
or	O
potassium	S-drug
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
,	O
they	O
should	O
be	O
given	O
with	O
caution	O
,	O
and	O
the	O
patients	O
serum	O
potassium	O
should	O
be	O
monitored	O
frequently	O
.	O

Lithium	S-drug
:	O
Increased	O
serum	O
lithium	S-drug
levels	O
and	O
symptoms	O
of	O
lithium	S-drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B-group-EF-1
inhibitors	E-group-EF-1
during	O
therapy	O
with	O
lithium	S-drug-EF-2
.	O

These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
,	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	S-drug
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	S-group
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	O
toxicity	O
may	O
be	O
increased	O
.	O

Antacids	S-group
:	O
In	O
a	O
clinical	O
pharmacology	O
study	O
,	O
coadministration	O
of	O
an	O
antacid	S-group-ME-1
(	O
aluminum	B-drug-ME-1
hydroxide	E-drug-ME-1
,	O
magnesium	B-drug-ME-1
hydroxide	E-drug-ME-1
,	O
and	O
simethicone	S-drug-ME-1
)	O
with	O
fosinopril	S-drug-ME-2
reduced	O
serum	O
levels	O
and	O
urinary	O
excretion	O
of	O
fosinoprilat	S-drug_n
as	O
compared	O
with	O
fosinopril	S-drug
administered	O
alone	O
,	O
suggesting	O
that	O
antacids	S-group-ME-1
may	O
impair	O
absorption	O
of	O
fosinopril	S-drug-ME-2
.	O

Therefore	O
,	O
if	O
concomitant	O
administration	O
of	O
these	O
agents	O
is	O
indicated	O
,	O
dosing	O
should	O
be	O
separated	O
by	O
2	O
hours	O
.	O

Other	O
:	O
Neither	O
fosinopril	B-drug
sodium	E-drug
nor	O
its	O
metabolites	O
have	O
been	O
found	O
to	O
interact	O
with	O
food	O
.	O

In	O
separate	O
single	O
or	O
multiple	O
dose	O
pharmacokinetic	O
interaction	O
studies	O
with	O
chlorthalidone	S-drug
,	O
nifedipine	S-drug
,	O
propanolol	S-drug
,	O
hydrochlorothiazide	S-drug
,	O
cimetidine	S-drug
,	O
metoclopramide	S-drug
,	O
propantheline	S-drug
,	O
digoxin	S-drug
,	O
and	O
warfarin	S-drug
,	O
the	O
bioavailability	O
of	O
fosinoprilat	S-drug_n
was	O
not	O
altered	O
by	O
coadministration	O
of	O
fosinopril	S-drug
with	O
any	O
one	O
of	O
these	O
drugs	O
.	O

In	O
a	O
study	O
with	O
concomitant	O
administration	O
of	O
aspirin	S-brand
and	O
fosinopril	B-drug
sodium	E-drug
,	O
the	O
bioavailability	O
of	O
unbound	O
fosinoprilat	S-drug_n
was	O
not	O
altered	O
.	O

In	O
a	O
pharmacokinetic	O
interaction	O
study	O
with	O
warfarin	S-drug
,	O
bioavailability	O
parameters	O
,	O
the	O
degree	O
of	O
protein	O
binding	O
,	O
and	O
the	O
anticoagulant	O
effect	O
(	O
measured	O
by	O
prothrombin	O
time	O
)	O
of	O
warfarin	S-drug
were	O
not	O
significantly	O
changed	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Fosinopril	S-drug
may	O
cause	O
a	O
false	O
low	O
measurement	O
of	O
serum	O
digoxin	S-drug
levels	O
with	O
the	O
Digi	O
-	O
Tab	O
RIA	O
Kit	O
for	O
Digoxin	S-drug
.	O

Other	O
kits	O
,	O
such	O
as	O
the	O
Coat	O
-	O
A	O
-	O
Count	O
RIA	O
Kit	O
,	O
may	O
be	O
used	O
.	O

No	O
drugs	O
are	O
known	O
to	O
interfere	O
with	O
the	O
conversion	O
of	O
fosphenytoin	S-drug
to	O
phenytoin	S-drug
.	O

Conversion	O
could	O
be	O
affected	O
by	O
alterations	O
in	O
the	O
level	O
of	O
phosphatase	O
activity	O
,	O
but	O
given	O
the	O
abundance	O
and	O
wide	O
distribution	O
of	O
phosphatases	O
in	O
the	O
body	O
it	O
is	O
unlikely	O
that	O
drugs	O
would	O
affect	O
this	O
activity	O
enough	O
to	O
affect	O
conversion	O
of	O
fosphenytoin	S-drug
to	O
phenytoin	S-drug
.	O

Drugs	O
highly	O
bound	O
to	O
albumin	O
could	O
increase	O
the	O
unbound	O
fraction	O
of	O
fosphenytoin	S-drug
.	O

Although	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
could	O
result	O
in	O
clinically	O
significant	O
effects	O
,	O
caution	O
is	O
advised	O
when	O
administering	O
Cerebyx	S-brand
with	O
other	O
drugs	O
that	O
significantly	O
bind	O
to	O
serum	O
albumin	O
.	O

The	O
pharmacokinetics	O
and	O
protein	O
binding	O
of	O
fosphenytoin	S-drug
,	O
phenytoin	S-drug
,	O
and	O
diazepam	S-drug
were	O
not	O
altered	O
when	O
diazepam	S-drug
and	O
Cerebyx	S-brand
were	O
concurrently	O
administered	O
in	O
single	O
submaximal	O
doses	O
.	O

The	O
most	O
significant	O
drug	O
interactions	O
following	O
administration	O
of	O
Cerebyx	S-brand
are	O
expected	O
to	O
occur	O
with	O
drugs	O
that	O
interact	O
with	O
phenytoin	S-drug
.	O

Phenytoin	S-drug
is	O
extensively	O
bound	O
to	O
serum	O
plasma	O
proteins	O
and	O
is	O
prone	O
to	O
competitive	O
displacement	O
.	O

Phenytoin	S-drug
is	O
metabolized	O
by	O
hepatic	O
cytochrome	O
P450	O
enzymes	O
and	O
is	O
particularly	O
susceptible	O
to	O
inhibitory	O
drug	O
interactions	O
because	O
it	O
is	O
subject	O
to	O
saturable	O
metabolism	O
.	O

Inhibition	O
of	O
metabolism	O
may	O
produce	O
significant	O
increases	O
in	O
circulating	O
phenytoin	S-drug
concentrations	O
and	O
enhance	O
the	O
risk	O
of	O
drug	O
toxicity	O
.	O

Phenytoin	S-drug
is	O
a	O
potent	O
inducer	O
of	O
hepatic	O
drug	O
-	O
metabolizing	O
enzymes	O
.	O

The	O
most	O
commonly	O
occurring	O
drug	O
interactions	O
are	O
listed	O
below	O
:	O
-	O
Drugs	O
that	O
may	O
increase	O
plasma	O
phenytoin	S-drug-ME-1
concentrations	O
include	O
:	O
acute	O
alcohol	S-drug-ME-2
intake	O
,	O
amiodarone	S-drug-ME-2
,	O
chboramphenicol	O
,	O
chlordiazepoxide	S-drug-ME-2
,	O
cimetidine	S-drug-ME-2
,	O
diazepam	S-drug-ME-2
,	O
dicumarol	S-drug-ME-2
,	O
disulfiram	S-drug-ME-2
,	O
estrogens	S-group-ME-2
,	O
ethosuximide	S-drug-ME-2
,	O
fluoxetine	S-drug-ME-2
,	O
H2	B-group-ME-2
-	I-group-ME-2
antagonists	E-group-ME-2
,	O
halothane	S-drug-ME-2
,	O
isoniazid	S-drug-ME-2
,	O
methylphenidate	S-drug-ME-2
,	O
phenothiazines	S-group-ME-2
,	O
phenylbutazone	S-drug-ME-2
,	O
salicylates	S-group-ME-2
,	O
succinimides	S-group-ME-2
,	O
sulfonamides	S-group-ME-2
,	O
tolbutamide	S-drug-ME-2
,	O
trazodone	S-drug-ME-2

-	O
Drugs	O
that	O
may	O
decrease	O
plasma	O
phenytoin	S-drug-ME-1
concentrations	O
include	O
:	O
carbamazepine	S-drug-ME-2
,	O
chronic	O
alcohol	S-drug-ME-2
abuse	O
,	O
reserpine	S-drug-ME-2

-	O
Drugs	O
that	O
may	O
either	O
increase	O
or	O
decrease	O
plasma	O
phenytoin	S-drug-ME-1
concentrations	O
include	O
:	O
phenobarbital	S-drug-ME-2
,	O
vaiproic	O
acid	O
,	O
and	O
sodium	B-drug-ME-2
valproate	E-drug-ME-2
.	O

Similarly	O
,	O
the	O
effects	O
of	O
phenytoin	S-drug-EF-1
on	O
phenobarbital	S-drug-EF-2
,	O
valproic	B-drug-EF-2
acid	E-drug-EF-2
and	O
sodium	O
plasma	O
valproate	S-drug-EF-2
concentrations	O
are	O
unpredictable	O

-	O
Although	O
not	O
a	O
true	O
drug	O
interaction	O
,	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
precipitate	O
seizures	O
in	O
susceptible	O
patients	O
and	O
Cerebyx	S-brand-EF-2
dosage	O
may	O
need	O
to	O
be	O
adjusted	O

-	O
Drugs	O
whose	O
efficacy	O
is	O
impaired	O
by	O
phenytoin	S-drug-EF-1
include	O
:	O
anticoagulants	S-group-EF-2
,	O
corticosteroids	S-group-EF-2
,	O
coumarin	S-group-EF-2
,	O
digitoxin	S-drug-EF-2
,	O
doxycycline	S-drug-EF-2
,	O
estrogens	S-group-EF-2
,	O
furosemide	S-drug-EF-2
,	O
oral	O
contraceptives	S-group-EF-2
,	O
rifampin	S-drug-EF-2
,	O
quinidine	S-drug-EF-2
,	O
theophylline	S-drug-EF-2
,	O
vitamin	B-group-EF-2
D	E-group-EF-2
.	O

Monitoring	O
of	O
plasma	O
phenytoin	S-drug
concentrations	O
may	O
be	O
helpful	O
when	O
possible	O
drug	O
interactions	O
are	O
suspected	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Phenytoin	S-drug
may	O
decrease	O
serum	O
concentrations	O
of	O
14	O
.	O

It	O
may	O
also	O
produce	O
artifactually	O
low	O
results	O
in	O
dexamethasone	O
or	O
metyrapone	O
tests	O
.	O

Phenytoin	S-drug
may	O
also	O
cause	O
increased	O
serum	O
concentrations	O
of	O
glucose	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
gamma	O
glutamyl	O
transpeptidase	O
(	O
GGT	O
)	O
.	O

Care	O
should	O
be	O
taken	O
when	O
using	O
immunoanalytical	O
methods	O
to	O
measure	O
plasma	O
phenytoin	S-drug
concentrations	O
following	O
Cerebyx	S-brand
administration	O
.	O

Ergot	O
-	O
containing	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Due	O
to	O
a	O
theoretical	O
risk	O
of	O
a	O
pharmacodynamic	O
interaction	O
,	O
use	O
of	O
ergotamine	S-drug-AD-1
-	O
containing	O
or	O
ergot	B-group-AD-1
-	I-group-AD-1
type	I-group-AD-1
medications	E-group-AD-1
(	O
like	O
dihydroergotamine	S-drug-AD-1
or	O
methysergide	S-drug-AD-1
)	O
and	O
FROVA	S-brand-AD-2
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
(	O
see	O
a	O
href	O
=	O
frova_od.htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O
.	O

Concomitant	O
use	O
of	O
other	O
5	O
-	O
HT1B	O
/	O
1D	O
agonists	O
within	O
24	O
hours	O
of	O
FROVA	S-brand
treatment	O
is	O
not	O
recommended	O
.	O

Selective	B-group-EF-1
serotonin	I-group-EF-1
reuptake	I-group-EF-1
inhibitors	E-group-EF-1
(	O
SSRIs	S-group-EF-1
)	O
(	O
e.g	O
.	O
,	O
fluoxetine	S-drug-EF-1
,	O
fluvoxamine	S-drug-EF-1
,	O
paroxetine	S-drug-EF-1
,	O
sertraline	S-drug-EF-1
)	O
have	O
been	O
reported	O
,	O
rarely	O
,	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5	B-group-EF-2
-	I-group-EF-2
HT1	I-group-EF-2
agonists	E-group-EF-2
.	O

If	O
concomitant	O
treatment	O
with	O
frovatriptan	S-drug-AD-1
and	O
an	O
SSRI	S-group-AD-2
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
FROVA	S-brand
is	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O

Fulvestrant	S-drug
is	O
metabolized	O
by	O
CYP	O
3A4	O
in	O
vitro	O
.	O

Clinical	O
studies	O
of	O
the	O
effect	O
of	O
strong	O
CYP	O
3A4	O
inhibitors	O
on	O
the	O
pharmacokinetics	O
of	O
fulvestrant	S-drug
have	O
not	O
been	O
performed	O
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
and	O
Impairment	O
of	O
Fertility	O
A	O
two	O
-	O
year	O
carcinogenesis	O
study	O
was	O
conducted	O
in	O
female	O
and	O
male	O
rats	O
,	O
at	O
intramuscular	O
doses	O
of	O
15	O
mg	O
/	O
kg	O
/	O
30	O
days	O
,	O
10	O
mg	O
/	O
rat	O
/	O
30	O
days	O
and	O
10	O
mg	O
/	O
rat	O
/	O
15	O
days	O
.	O

These	O
doses	O
correspond	O
to	O
approximately	O
1	O
-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
fold	O
(	O
in	O
females	O
)	O
and	O
1.3	O
-	O
,	O
1.3	O
-	O
,	O
and	O
1.6	O
-	O
fold	O
(	O
in	O
males	O
)	O
the	O
systemic	O
exposure	O
[	O
AUC0	O
-	O
30	O
days	O
]	O
]	O
achieved	O
in	O
women	O
receiving	O
the	O
recommended	O
dose	O
of	O
250	O
mg	O
/	O
month	O
.	O

An	O
increased	O
incidence	O
of	O
benign	O
ovarian	O
granulosa	O
cell	O
tumors	O
and	O
testicular	O
Leydig	O
cell	O
tumors	O
was	O
evident	O
,	O
in	O
females	O
dosed	O
at	O
10	O
mg	O
/	O
rat	O
/	O
15	O
days	O
and	O
males	O
dosed	O
at	O
15	O
mg	O
/	O
rat	O
/	O
30	O
days	O
,	O
respectively	O
.	O

Induction	O
of	O
such	O
tumors	O
is	O
consistent	O
with	O
the	O
pharmacology	O
-	O
related	O
endocrine	O
feedback	O
alterations	O
in	O
gonadotropin	O
levels	O
caused	O
by	O
an	O
antiestrogen	S-group
.	O

Fulvestrant	S-drug
was	O
not	O
mutagenic	O
or	O
clastogenic	O
in	O
multiple	O
in	O
vitro	O
tests	O
with	O
and	O
without	O
the	O
addition	O
of	O
a	O
mammalian	O
liver	O
metabolic	O
activation	O
factor	O
(	O
bacterial	O
mutation	O
assay	O
in	O
strains	O
of	O
Salmonella	O
typhimurium	O
and	O
Escherichia	O
coli	O
,	O
in	O
vitro	O
cytogenetics	O
study	O
in	O
human	O
lymphocytes	O
,	O
mammalian	O
cell	O
mutation	O
assay	O
in	O
mouse	O
lymphoma	O
cells	O
and	O
in	O
vivo	O
micronucleus	O
test	O
in	O
rat	O
.	O

In	O
female	O
rats	O
,	O
fulvestrant	S-drug
administered	O
at	O
doses	O
0.01	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
one	O
-	O
hundredth	O
of	O
the	O
human	O
recommended	O
dose	O
based	O
on	O
body	O
surface	O
area	O
[	O
BSA	O
]	O
,	O
for	O
2	O
weeks	O
prior	O
to	O
and	O
for	O
1	O
week	O
following	O
mating	O
,	O
caused	O
a	O
reduction	O
in	O
fertility	O
and	O
embryonic	O
survival	O
.	O

No	O
adverse	O
effects	O
on	O
female	O
fertility	O
and	O
embryonic	O
survival	O
were	O
evident	O
in	O
female	O
animals	O
dosed	O
at	O
0.001	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
one	O
-	O
thousandth	O
of	O
the	O
human	O
dose	O
based	O
on	O
BSA	O
)	O
.	O

Restoration	O
of	O
female	O
fertility	O
to	O
values	O
similar	O
to	O
controls	O
was	O
evident	O
following	O
a	O
29	O
-	O
day	O
withdrawal	O
period	O
after	O
dosing	O
at	O
2	O
mg	O
/	O
kg	O
/	O
day	O
(	O
twice	O
the	O
human	O
dose	O
based	O
on	O
BSA	O
)	O
.	O

The	O
effects	O
of	O
fulvestrant	S-drug
on	O
the	O
fertility	O
of	O
female	O
rats	O
appear	O
to	O
be	O
consistent	O
with	O
its	O
anti	O
-	O
estrogenic	O
activity	O
.	O

The	O
potential	O
effects	O
of	O
fulvestrant	S-drug
on	O
the	O
fertility	O
of	O
male	O
animals	O
were	O
not	O
studied	O
but	O
in	O
a	O
6	O
-	O
month	O
toxicology	O
study	O
,	O
male	O
rats	O
treated	O
with	O
intramuscular	O
doses	O
of	O
15	O
mg	O
/	O
kg	O
/	O
30	O
days	O
,	O
10	O
mg	O
/	O
rat	O
/	O
30	O
days	O
,	O
or	O
10	O
mg	O
/	O
rat	O
/	O
15	O
days	O
fulvestrant	S-drug
showed	O
a	O
loss	O
of	O
spermatozoa	O
from	O
the	O
seminiferous	O
tubules	O
,	O
seminiferous	O
tubular	O
atrophy	O
,	O
and	O
degenerative	O
changes	O
in	O
the	O
epididymides	O
.	O

Changes	O
in	O
the	O
testes	O
and	O
epididymides	O
had	O
not	O
recovered	O
20	O
weeks	O
after	O
cessation	O
of	O
dosing	O
.	O

These	O
fulvestrant	S-drug
doses	O
correspond	O
to	O
approximately	O
2	O
-	O
,	O
3	O
-	O
,	O
and	O
3	O
-	O
fold	O
the	O
systemic	O
exposure	O
[	O
AUC0	O
-	O
30	O
days	O
]	O
achieved	O
in	O
women	O
.	O

Pregnancy	O
Pregnancy	O
Category	O
D	O
:	O
.	O

In	O
studies	O
in	O
female	O
rats	O
at	O
doses	O
0.01	O
mg	O
/	O
kg	O
/	O
day	O
(	O
IM	O
;	O

approximately	O
one	O
-	O
hundredth	O
of	O
the	O
human	O
recommended	O
dose	O
based	O
on	O
body	O
surface	O
area	O
[	O
BSA	O
]	O
)	O
,	O
fulvestrant	S-drug
caused	O
a	O
reversible	O
reduction	O
in	O
female	O
fertility	O
,	O
as	O
well	O
as	O
effects	O
on	O
embryo	O
/	O
fetal	O
development	O
consistent	O
with	O
its	O
anti	O
-	O
estrogenic	O
activity	O
.	O

Fulvestrant	S-drug
caused	O
an	O
increased	O
incidence	O
of	O
fetal	O
abnormalities	O
in	O
rats	O
(	O
tarsal	O
flexure	O
of	O
the	O
hind	O
paw	O
at	O
2	O
mg	O
/	O
kg	O
/	O
day	O
IM	O
;	O

twice	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
and	O
non	O
-	O
ossification	O
of	O
the	O
odontoid	O
and	O
ventral	O
tubercle	O
of	O
the	O
first	O
cervical	O
vertebra	O
at	O
doses	O
0.1	O
mg	O
/	O
kg	O
/	O
day	O
IM	O
(	O
approximately	O
one	O
-	O
tenth	O
of	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
when	O
administered	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O

Rabbits	O
failed	O
to	O
maintain	O
pregnancy	O
when	O
dosed	O
with	O
1	O
mg	O
/	O
kg	O
/	O
day	O
fulvestrant	S-drug
IM	O
(	O
twice	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O

Further	O
,	O
in	O
rabbits	O
dosed	O
at	O
0.25	O
mg	O
/	O
kg	O
/	O
day	O
(	O
about	O
one	O
-	O
half	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
,	O
increases	O
in	O
placental	O
weight	O
and	O
post	O
-	O
implantation	O
loss	O
were	O
observed	O
but	O
,	O
there	O
were	O
no	O
observed	O
effects	O
on	O
fetal	O
development	O
.	O

Fulvestrant	S-drug
was	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
fetal	O
variations	O
in	O
rabbits	O
(	O
backwards	O
displacement	O
of	O
the	O
pelvic	O
girdle	O
,	O
and	O
27	O
pre	O
-	O
sacral	O
vertebrae	O
at	O
0.25	O
mg	O
/	O
kg	O
/	O
day	O
IM	O
;	O

one	O
-	O
half	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
when	O
administered	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O

Because	O
pregnancy	O
could	O
not	O
be	O
maintained	O
in	O
the	O
rabbit	O
following	O
doses	O
of	O
fulvestrant	S-drug
of	O
1	O
mg	O
/	O
kg	O
/	O
day	O
and	O
above	O
,	O
this	O
study	O
was	O
inadequate	O
to	O
fully	O
define	O
the	O
possible	O
adverse	O
effects	O
on	O
fetal	O
development	O
at	O
clinically	O
relevant	O
exposures	O
.	O

Nursing	O
Mothers	O
Fulvestrant	S-drug
is	O
found	O
in	O
rat	O
milk	O
at	O
levels	O
significantly	O
higher	O
(	O
approximately	O
12	O
-	O
fold	O
)	O
than	O
plasma	O
after	O
administration	O
of	O
2	O
mg	O
/	O
kg	O
.	O

Drug	O
exposure	O
in	O
rodent	O
pups	O
from	O
fulvestrant	S-drug
-	O
treated	O
lactating	O
dams	O
was	O
estimated	O
as	O
10	O
%	O
of	O
the	O
administered	O
dose	O
.	O

It	O
is	O
not	O
known	O
if	O
fulvestrant	S-drug
is	O
excreted	O
in	O
human	O
milk	O
.	O

Because	O
many	O
drugs	O
are	O
excreted	O
in	O
human	O
milk	O
,	O
and	O
because	O
of	O
the	O
potential	O
for	O
serious	O
adverse	O
reactions	O
from	O
FASLODEX	S-brand
in	O
nursing	O
infants	O
,	O
a	O
decision	O
should	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
or	O
to	O
discontinue	O
the	O
drug	O
taking	O
into	O
account	O
the	O
importance	O
of	O
the	O
drug	O
to	O
the	O
mother	O
.	O

Pediatric	O
Use	O
The	O
safety	O
and	O
efficacy	O
of	O
FASLODEX	S-brand
in	O
pediatric	O
patients	O
have	O
not	O
been	O
established	O
.	O

Geriatric	O
Use	O
When	O
tumor	O
response	O
was	O
considered	O
by	O
age	O
,	O
objective	O
responses	O
were	O
seen	O
in	O
24	O
%	O
and	O
22	O
%	O
of	O
patients	O
under	O
65	O
years	O
of	O
age	O
and	O
in	O
16	O
%	O
and	O
11	O
%	O
of	O
patients	O
65	O
years	O
of	O
age	O
and	O
older	O
,	O
who	O
were	O
treated	O
with	O
FASLODEX	S-brand
in	O
the	O
European	O
and	O
North	O
American	O
trials	O
,	O
respectively	O
.	O

Furosemide	S-drug-EF-1
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
aminoglycoside	B-group-EF-2
antibiotics	E-group-EF-2
,	O
especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
.	O

Except	O
in	O
life	O
-	O
threatening	O
situations	O
,	O
avoid	O
this	O
combination	O
.	O

Furosemide	S-drug-AD-1
should	O
not	O
be	O
used	O
concomitantly	O
with	O
ethacrynic	B-drug-AD-2
acid	E-drug-AD-2
because	O
of	O
the	O
possibility	O
of	O
ototoxicity	O
.	O

Patients	O
receiving	O
high	O
doses	O
of	O
salicylates	S-group-EF-1
concomitantly	O
with	O
furosemide	S-drug-EF-2
,	O
as	O
in	O
rheumatic	O
disease	O
,	O
may	O
experience	O
salicylate	S-group
toxicity	O
at	O
lower	O
doses	O
because	O
of	O
competitive	O
renal	O
excretory	O
sites	O
.	O

Furosemide	S-drug-EF-1
has	O
a	O
tendency	O
to	O
antagonize	O
the	O
skeletal	O
muscle	O
relaxing	O
effect	O
of	O
tubocurarine	S-drug-EF-2
and	O
may	O
potentiate	O
the	O
action	O
of	O
succinylcholine	S-drug-EF-2
.	O

Lithium	S-drug-AD-1
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	S-group-AD-2
because	O
they	O
reduce	O
lithiums	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	S-drug
toxicity	O
.	O

Furosemide	S-drug-EF-1
may	O
add	O
to	O
or	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
other	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
.	O

Potentiation	O
occurs	O
with	O
ganglionic	S-group
or	O
peripheral	B-group
adrenergic	I-group
blocking	I-group
drugs	E-group
.	O

Furosemide	S-drug-EF-1
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	S-drug-EF-2
.	O

However	O
,	O
norepinephrine	S-drug
may	O
still	O
be	O
used	O
effectively	O
.	O

Tablets	O
Simultaneous	O
administration	O
of	O
sucralfate	S-drug-EF-1
and	O
furosemide	S-drug-EF-2
tablets	O
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
furosemide	S-drug
.	O

Patients	O
receiving	O
both	O
drugs	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
diuretic	O
and	O
/	O
or	O
antihypertensive	O
effect	O
of	O
furosemide	S-drug
is	O
achieved	O
.	O

The	O
intake	O
of	O
furosemide	S-drug-AD-1
and	O
sucralfate	S-drug-AD-2
should	O
be	O
separated	O
by	O
at	O
least	O
two	O
hours	O
.	O

Tablets	O
,	O
Injection	O
,	O
and	O
Oral	O
Solution	O
One	O
study	O
in	O
six	O
subjects	O
demonstrated	O
that	O
the	O
combination	O
of	O
furosemide	S-drug-EF-1
and	O
acetylsalicylic	B-drug-EF-2
acid	E-drug-EF-2
temporarily	O
reduced	O
creatinine	O
clearance	O
in	O
patients	O
with	O
chronic	O
renal	O
insufficiency	O
.	O

There	O
are	O
case	O
reports	O
of	O
patients	O
who	O
developed	O
increased	O
BUN	O
,	O
serum	O
creatinine	O
and	O
serum	O
potassium	O
levels	O
,	O
and	O
weight	O
gain	O
when	O
furosemide	S-drug-EF-1
was	O
used	O
in	O
conjunction	O
with	O
NSAIDs	S-group-EF-2
.	O

Literature	O
reports	O
indicate	O
that	O
coadministration	O
of	O
indomethacin	S-drug-EF-1
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
furosemide	S-drug-EF-2
in	O
some	O
patients	O
by	O
inhibiting	O
prostaglandin	O
synthesis	O
.	O

Indomethacin	S-drug
may	O
also	O
affect	O
plasma	O
renin	O
levels	O
,	O
aldosterone	O
excretion	O
,	O
and	O
renin	O
profile	O
evaluation	O
.	O

Patients	O
receiving	O
both	O
indomethacin	S-drug-AD-1
and	O
furosemide	S-drug-AD-2
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
diuretic	O
and	O
/	O
or	O
antihypertensive	O
effect	O
of	O
furosemide	S-drug
is	O
achieved	O
.	O

In	O
vitro	O
studies	O
were	O
conducted	O
to	O
investigate	O
the	O
potential	O
of	O
gabapentin	S-drug
to	O
inhibit	O
the	O
major	O
cytochrome	O
P450	O
enzymes	O
(	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
and	O
CYP3A4	O
)	O
that	O
mediate	O
drug	O
and	O
xenobiotic	O
metabolism	O
using	O
isoform	O
selective	O
marker	O
substrates	O
and	O
human	O
liver	O
microsomal	O
preparations	O
.	O

Only	O
at	O
the	O
highest	O
concentration	O
tested	O
(	O
171	O

g	O
/	O
mL	O
;	O

1	O
mM	O
)	O
was	O
a	O
slight	O
degree	O
of	O
inhibition	O
(	O
14	O
%	O
-	O
30	O
%	O
)	O
of	O
isoform	O
CYP2A6	O
observed	O
.	O

No	O
inhibition	O
of	O
any	O
of	O
the	O
other	O
isoforms	O
tested	O
was	O
observed	O
at	O
gabapentin	S-drug
concentrations	O
up	O
to	O
171	O
mg	O
/	O
mL	O
(	O
approximately	O
15	O
times	O
the	O
Cmax	O
at	O
3600	O
mg	O
/	O
day	O
)	O
.	O

Gabapentin	S-drug
is	O
not	O
appreciably	O
metabolized	O
nor	O
does	O
it	O
interfere	O
with	O
the	O
metabolism	O
of	O
commonly	O
coadministered	O
antiepileptic	B-group
drugs	E-group
.	O

The	O
drug	O
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
studies	O
involving	O
healthy	O
adults	O
and	O
adult	O
patients	O
with	O
epilepsy	O
.	O

Phenytoin	S-drug
:	O
In	O
a	O
single	O
(	O
400	O
mg	O
)	O
and	O
multiple	O
dose	O
(	O
400	O
mg	O
TID	O
)	O
study	O
of	O
Neurontin	S-brand
in	O
epileptic	O
patients	O
(	O
N	O
=	O
8	O
)	O
maintained	O
on	O
phenytoin	S-drug
monotherapy	O
for	O
at	O
least	O
2	O
months	O
,	O
gabapentin	S-drug
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
trough	O
plasma	O
concentrations	O
of	O
phenytoin	S-drug
and	O
phenytoin	S-drug
had	O
no	O
effect	O
on	O
gabapentin	S-drug
pharmacokinetics	O
.	O

Carbamazepine	S-drug
:	O
Steady	O
-	O
state	O
trough	O
plasma	O
carbamazepine	S-drug
and	O
carbamazepine	B-drug_n
10	I-drug_n
,	I-drug_n
11	I-drug_n
epoxide	E-drug_n
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
gabapentin	S-drug
(	O
400	O
mg	O
TID	O
;	O

N	O
=	O
12	O
)	O
administration	O
.	O

Likewise	O
,	O
gabapentin	S-drug
pharmacokinetics	O
were	O
unaltered	O
by	O
carbamazepine	S-drug
administration	O
.	O

Valproic	B-drug
Acid	E-drug
:	O
The	O
mean	O
steady	O
-	O
state	O
trough	O
serum	O
valproic	B-drug
acid	E-drug
concentrations	O
prior	O
to	O
and	O
during	O
concomitant	O
gabapentin	S-drug
administration	O
(	O
400	O
mg	O
TID	O
;	O

N	O
=	O
17	O
)	O
were	O
not	O
different	O
and	O
neither	O
were	O
gabapentin	S-drug
pharmacokinetic	O
parameters	O
affected	O
by	O
valproic	B-drug
acid	E-drug
.	O

Phenobarbital	S-drug
:	O
Estimates	O
of	O
steady	O
-	O
state	O
pharmacokinetic	O
parameters	O
for	O
phenobarbital	S-drug
or	O
gabapentin	S-drug
(	O
300	O
mg	O
TID	O
;	O

N	O
=	O
12	O
)	O
are	O
identical	O
whether	O
the	O
drugs	O
are	O
administered	O
alone	O
or	O
together	O
.	O

Naproxen	S-drug
:	O
Coadministration	O
(	O
N	O
=	O
18	O
)	O
of	O
naproxen	B-drug-ME-1
sodium	E-drug-ME-1
capsules	O
(	O
250	O
mg	O
)	O
with	O
Neurontin	S-brand-ME-2
(	O
125	O
mg	O
)	O
appears	O
to	O
increase	O
the	O
amount	O
of	O
gabapentin	S-drug
absorbed	O
by	O
12	O
%	O
to	O
15	O
%	O
.	O

Gabapentin	S-drug
had	O
no	O
effect	O
on	O
naproxen	S-drug
pharmacokinetic	O
parameters	O
.	O

These	O
doses	O
are	O
lower	O
than	O
the	O
therapeutic	O
doses	O
for	O
both	O
drugs	O
.	O

The	O
magnitude	O
of	O
interaction	O
within	O
the	O
recommended	O
dose	O
ranges	O
of	O
either	O
drug	O
is	O
not	O
known	O
.	O

Hydrocodone	S-drug
:	O
Coadministration	O
of	O
Neurontin	S-brand
(	O
125	O
to	O
500	O
mg	O
;	O

N	O
=	O
48	O
)	O
decreases	O
hydrocodone	S-drug
(	O
10	O
mg	O
;	O

N	O
=	O
50	O
)	O
Cmax	O
and	O
AUC	O
values	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
relative	O
to	O
administration	O
of	O
hydrocodone	S-drug
alone	O
;	O

Cmax	O
and	O
AUC	O
values	O
are	O
3	O
%	O
to	O
4	O
%	O
lower	O
,	O
respectively	O
,	O
after	O
administration	O
of	O
125	O
mg	O
Neurontin	S-brand
and	O
21	O
%	O
to	O
22	O
%	O
lower	O
,	O
respectively	O
,	O
after	O
administration	O
of	O
500	O
mg	O
Neurontin	S-brand
.	O

The	O
mechanism	O
for	O
this	O
interaction	O
is	O
unknown	O
.	O

Hydrocodone	S-drug-ME-1
increases	O
gabapentin	S-drug-ME-2
AUC	O
values	O
by	O
14	O
%	O
.	O

The	O
magnitude	O
of	O
interaction	O
at	O
other	O
doses	O
is	O
not	O
known	O
.	O

Morphine	S-drug
:	O
A	O
literature	O
article	O
reported	O
that	O
when	O
a	O
60	O
-	O
mg	O
controlled	O
-	O
release	O
morphine	S-drug-ME-1
capsule	O
was	O
administered	O
2	O
hours	O
prior	O
to	O
a	O
600	O
-	O
mg	O
Neurontin	S-brand-ME-2
capsule	O
(	O
N	O
=	O
12	O
)	O
,	O
mean	O
gabapentin	S-drug
AUC	O
increased	O
by	O
44	O
%	O
compared	O
to	O
gabapentin	S-drug
administered	O
without	O
morphine	S-drug
.	O

Morphine	S-drug
pharmacokinetic	O
parameter	O
values	O
were	O
not	O
affected	O
by	O
administration	O
of	O
Neurontin	S-brand
2	O
hours	O
after	O
morphine	S-drug
.	O

The	O
magnitude	O
of	O
interaction	O
at	O
other	O
doses	O
is	O
not	O
known	O
.	O

Cimetidine	S-drug
:	O
In	O
the	O
presence	O
of	O
cimetidine	S-drug-ME-1
at	O
300	O
mg	O
QID	O
(	O
N	O
=	O
12	O
)	O
the	O
mean	O
apparent	O
oral	O
clearance	O
of	O
gabapentin	S-drug-ME-2
fell	O
by	O
14	O
%	O
and	O
creatinine	O
clearance	O
fell	O
by	O
10	O
%	O
.	O

Thus	O
cimetidine	S-drug-ME-1
appeared	O
to	O
alter	O
the	O
renal	O
excretion	O
of	O
both	O
gabapentin	S-drug-ME-2
and	O
creatinine	O
,	O
an	O
endogenous	O
marker	O
of	O
renal	O
function	O
.	O

This	O
small	O
decrease	O
in	O
excretion	O
of	O
gabapentin	S-drug-ME-1
by	O
cimetidine	S-drug-ME-2
is	O
not	O
expected	O
to	O
be	O
of	O
clinical	O
importance	O
.	O

The	O
effect	O
of	O
gabapentin	S-drug
on	O
cimetidine	S-drug
was	O
not	O
evaluated	O
.	O

Oral	O
Contraceptive	S-group
:	O
Based	O
on	O
AUC	O
and	O
half	O
-	O
life	O
,	O
multiple	O
-	O
dose	O
pharmacokinetic	O
profiles	O
of	O
norethindrone	S-drug
and	O
ethinyl	B-drug
estradiol	E-drug
following	O
administration	O
of	O
tablets	O
containing	O
2.5	O
mg	O
of	O
norethindrone	B-drug
acetate	E-drug
and	O
50	O
mcg	O
of	O
ethinyl	B-drug
estradiol	E-drug
were	O
similar	O
with	O
and	O
without	O
coadministration	O
of	O
gabapentin	S-drug
(	O
400	O
mg	O
TID	O
;	O

N	O
=	O
13	O
)	O
.	O

The	O
Cmax	O
of	O
norethindrone	S-drug-ME-1
was	O
13	O
%	O
higher	O
when	O
it	O
was	O
coadministered	O
with	O
gabapentin	S-drug-ME-2
;	O

this	O
interaction	O
is	O
not	O
expected	O
to	O
be	O
of	O
clinical	O
importance	O
.	O

Antacid	S-group
(	O
Maalox	S-brand
)	O
:	O
Maalox	S-brand-ME-1
reduced	O
the	O
bioavailability	O
of	O
gabapentin	S-drug-ME-2
(	O
N	O
=	O
16	O
)	O
by	O
about	O
20	O
%	O
.	O

This	O
decrease	O
in	O
bioavailability	O
was	O
about	O
5	O
%	O
when	O
gabapentin	S-drug-ME-1
was	O
administered	O
2	O
hours	O
after	O
Maalox	S-brand-ME-2
.	O

It	O
is	O
recommended	O
that	O
gabapentin	S-drug-AD-1
be	O
taken	O
at	O
least	O
2	O
hours	O
following	O
Maalox	S-brand-AD-2
administration	O
.	O

Effect	O
of	O
Probenecid	S-drug
:	O
Probenecid	S-drug
is	O
a	O
blocker	O
of	O
renal	O
tubular	O
secretion	O
.	O

Gabapentin	S-drug
pharmacokinetic	O
parameters	O
without	O
and	O
with	O
probenecid	S-drug
were	O
comparable	O
.	O

This	O
indicates	O
that	O
gabapentin	S-drug
does	O
not	O
undergo	O
renal	O
tubular	O
secretion	O
by	O
the	O
pathway	O
that	O
is	O
blocked	O
by	O
probenecid	S-drug
.	O

Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
Because	O
false	O
positive	O
readings	O
were	O
reported	O
with	O
the	O
Ames	O
N	O
-	O
Multistix	O
SG	O
dipstick	O
test	O
for	O
urinary	O
protein	O
when	O
gabapentin	S-drug
was	O
added	O
to	O
other	O
antiepileptic	B-group
drugs	E-group
,	O
the	O
more	O
specific	O
sulfosalicylic	O
acid	O
precipitation	O
procedure	O
is	O
recommended	O
to	O
determine	O
the	O
presence	O
of	O
urine	O
protein	O

LABORATORY	O
TEST	O
FINDINGS	O
Asymptomatic	O
,	O
transitory	O
changes	O
in	O
serum	O
iron	O
have	O
been	O
observed	O
.	O

The	O
clinical	O
significance	O
is	O
unknown	O
.	O

Omniscan	S-brand
interferes	O
with	O
serum	O
calcium	O
measurements	O
with	O
some	O
colorimetric	O
(	O
complexometric	O
)	O
methods	O
commonly	O
used	O
in	O
hospitals	O
,	O
resulting	O
in	O
serum	O
calcium	O
concentrations	O
lower	O
than	O
the	O
true	O
values	O
.	O

Thus	O
,	O
it	O
is	O
recommended	O
not	O
to	O
use	O
such	O
methods	O
for	O
12	O
-	O
24	O
hours	O
after	O
administration	O
of	O
Omniscan	S-brand
.	O

If	O
such	O
measurements	O
are	O
necessary	O
,	O
the	O
use	O
of	O
other	O
methods	O
is	O
recommended	O
.	O

All	O
patients	O
in	O
whom	O
this	O
effect	O
was	O
observed	O
remained	O
asymptomatic	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

No	O
drug	O
interactions	O
have	O
been	O
observed	O
with	O
the	O
Vitrasert	S-brand
Implant	O
.	O

There	O
is	O
limited	O
experience	O
with	O
use	O
of	O
retinal	O
tamponades	O
in	O
conjunction	O
with	O
the	O
Vitrasert	S-brand
Implant	O
.	O

Substances	O
that	O
are	O
inducers	O
of	O
CYP3A4	O
activity	O
increase	O
the	O
metabolism	O
of	O
gefitinib	S-drug
and	O
decrease	O
its	O
plasma	O
concentrations	O
.	O

In	O
patients	O
receiving	O
a	O
potent	O
CYP3A4	O
inducer	O
such	O
as	O
rifampicin	S-drug
or	O
phenytoin	S-drug
,	O
a	O
dose	O
increase	O
to	O
500	O
mg	O
daily	O
should	O
be	O
considered	O
in	O
the	O
absence	O
of	O
severe	O
adverse	O
drug	O
reaction	O
,	O
and	O
clinical	O
response	O
and	O
adverse	O
events	O
should	O
be	O
carefully	O
monitored	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
-	O
Drug	O
-	O
Drug	O
Interactions	O
and	O
DOSAGE	O
AND	O
ADMINISTRATION	O
-	O
Dosage	O
Adjustment	O
sections	O
)	O
.	O

International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and	O
/	O
or	O
bleeding	O
events	O
have	O
been	O
reported	O
in	O
some	O
patients	O
taking	O
warfarin	S-drug-EF-1
while	O
on	O
IRESSA	S-brand-EF-2
therapy	O
.	O

Patients	O
taking	O
warfarin	S-drug
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O
.	O

Substances	O
that	O
are	O
potent	O
inhibitors	O
of	O
CYP3A4	O
activity	O
(	O
eg	O
,	O
ketoconazole	S-drug-ME-1
and	O
itraconazole	S-drug-ME-1
)	O
decrease	O
gefitinib	S-drug-ME-2
metabolism	O
and	O
increase	O
gefitinib	S-drug-ME-2
plasma	O
concentrations	O
.	O

This	O
increase	O
may	O
be	O
clinically	O
relevant	O
as	O
adverse	O
experiences	O
are	O
related	O
to	O
dose	O
and	O
exposure	O
;	O

therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CYP3A4	O
inhibitors	O
with	O
IRESSA	S-brand
.	O

Drugs	O
that	O
cause	O
significant	O
sustained	O
elevation	O
in	O
gastric	O
pH	O
(	O
histamine	B-group-ME-1
H2	I-group-ME-1
-	I-group-ME-1
receptor	I-group-ME-1
antagonists	E-group-ME-1
such	O
as	O
ranitidine	S-drug-ME-1
or	O
cimetidine	S-drug-ME-1
)	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
IRESSA	S-brand-ME-2
and	O
therefore	O
potentially	O
may	O
reduce	O
efficacy	O
.	O

Phase	O
II	O
clinical	O
trial	O
data	O
,	O
where	O
IRESSA	S-brand
and	O
vinorelbine	S-drug
have	O
been	O
used	O
concomitantly	O
,	O
indicate	O
that	O
IRESSA	S-brand-EF-1
may	O
exacerbate	O
the	O
neutropenic	O
effect	O
of	O
vinorelbine	S-drug-EF-2
.	O

No	O
specific	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

For	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
Gemzar	S-brand
and	O
cisplatin	S-drug
in	O
combination	O
,	O
see	O
Drug	O
Interactions	O
under	O
CLINICAL	O
PHARMACOLOGY	O
section	O
.	O

Clinical	O
Laboratory	O

increased	O
creatine	O

positive	O
antinuclear	O

increased	O
bilirubin	O

increased	O
liver	O

transaminases	O
(	O
AST	O

(	O
SGOT	O
)	O
,	O
ALT	O
(	O
SGPT	O
)	O

increased	O
alkaline	O

bone	O
marrow	O
hypoplasia	O

laryngeal	O
edema	O

Lupus	O
-	O
like	O
syndrome	O

exfoliative	O
dermatitis	O

Administration	O
of	O
repeat	O
doses	O
of	O
FACTIVE	S-brand
had	O
no	O
effect	O
on	O
the	O
repeat	O
dose	O
pharmacokinetics	O
of	O
theophylline	S-drug
,	O
digoxin	S-drug
or	O
an	O
ethinylestradiol	S-drug
/	O
levonorgestrol	O
oral	O
contraceptive	B-group
product	E-group
in	O
healthy	O
subjects	O
.	O

Concomitant	O
administration	O
of	O
FACTIVE	S-brand-ME-1
and	O
calcium	B-drug-ME-2
carbonate	E-drug-ME-2
,	O
cimetidine	S-drug-ME-2
,	O
omeprazole	S-drug-ME-2
,	O
or	O
an	O
estrogen	S-group-ME-2
/	O
progesterone	S-drug-ME-2
oral	O
contraceptive	S-group-ME-2
produced	O
minor	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
gemifloxacin	S-drug
,	O
which	O
were	O
considered	O
to	O
be	O
without	O
clinical	O
significance	O
.	O

Concomitant	O
administration	O
of	O
FACTIVE	S-brand-ME-1
with	O
probenecid	S-drug-ME-2
resulted	O
in	O
a	O
45	O
%	O
increase	O
in	O
systemic	O
exposure	O
to	O
gemifloxacin	S-drug
.	O

FACTIVE	S-brand
had	O
no	O
significant	O
effect	O
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	S-drug
in	O
healthy	O
subjects	O
on	O
stable	O
warfarin	S-drug
therapy	O
.	O

However	O
,	O
because	O
some	O
quinolones	S-group-EF-1
have	O
been	O
reported	O
to	O
enhance	O
the	O
anticoagulant	O
effects	O
of	O
warfarin	S-drug-EF-2
or	O
its	O
derivatives	O
in	O
patients	O
,	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
quinolone	B-group-AD-1
antimicrobial	E-group-AD-1
is	O
administered	O
concomitantly	O
with	O
warfarin	S-drug-AD-2
or	O
its	O
derivatives	O
.	O

Quinolones	S-group
form	O
chelates	O
with	O
alkaline	O
earth	O
and	O
transition	O
metals	O
.	O

The	O
absorption	O
of	O
oral	O
gemifloxacin	S-drug-ME-1
is	O
significantly	O
reduced	O
by	O
the	O
concomitant	O
administration	O
of	O
an	O
antacid	S-group
containing	O
aluminum	S-drug-ME-2
and	O
magnesium	S-drug-ME-2
.	O

Magnesium	S-drug-AD-1
-	O
and	O
/	O
or	O
aluminum	S-drug-AD-1
-	O
containing	O
antacids	S-group
,	O
products	O
containing	O
ferrous	B-drug-AD-1
sulfate	E-drug-AD-1
(	O
iron	S-drug-AD-1
)	O
,	O
multivitamin	B-group-AD-1
preparations	E-group-AD-1
containing	O
zinc	S-drug-AD-1
or	O
other	O
metal	O
cations	O
,	O
or	O
Videx	S-brand-AD-1
(	O
didanosine	S-drug-AD-1
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
taken	O
within	O
3	O
hours	O
before	O
or	O
2	O
hours	O
after	O
FACTIVE	S-brand-AD-2
.	O

Sucralfate	S-drug-AD-1
should	O
not	O
be	O
taken	O
within	O
2	O
hours	O
of	O
FACTIVE	S-brand-AD-2
.	O

There	O
have	O
been	O
no	O
formal	O
drug	O
-	O
interaction	O
studies	O
performed	O
with	O
Mylotarg	S-brand
.	O

The	O
potential	O
for	O
drug	O
-	O
drug	O
interaction	O
with	O
drugs	O
affected	O
by	O
cytochrome	O
P450	O
enzymes	O
may	O
not	O
be	O
ruled	O
out	O
.	O

Laboratory	O
Test	O
Interactions	O

Mylotarg	S-brand
is	O
not	O
known	O
to	O
interfere	O
with	O
any	O
routine	O
diagnostic	O
tests	O
.	O

Interactions	O
between	O
COPAXONE	S-brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Results	O
from	O
existing	O
clinical	O
trials	O
suggest	O
no	O
significant	O
interactions	O
between	O
COPAXONE	S-brand
and	O
other	O
therapies	O
commonly	O
used	O
in	O
MS	O
patients	O
,	O
including	O
the	O
concurrent	O
use	O
of	O
corticosteroids	S-group
for	O
up	O
to	O
28	O
days	O
.	O

COPAXONE	S-brand
has	O
not	O
been	O
formally	O
evaluated	O
in	O
combination	O
with	O
Interferon	B-drug
beta	E-drug
.	O

However	O
,	O
10	O
patients	O
who	O
switched	O
from	O
therapy	O
with	O
Interferon	B-drug
beta	E-drug
to	O
COPAXONE	S-brand
did	O
not	O
report	O
any	O
serious	O
and	O
unexpected	O
adverse	O
reactions	O
thought	O
to	O
be	O
related	O
to	O
treatment	O
.	O

The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	S-group-EF-1
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B-group-EF-2
anti	I-group-EF-2
-	I-group-EF-2
inflammatory	I-group-EF-2
agents	E-group-EF-2
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	S-group-EF-2
,	O
sulfonamides	S-group-EF-2
,	O
chloramphenicol	S-drug-EF-2
,	O
probenecid	S-drug-EF-2
,	O
coumarins	S-group-EF-2
,	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
,	O
and	O
beta	B-group-EF-2
adrenergic	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
MICRONASE	S-brand
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
MICRONASE	S-brand
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O

Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
control	O
.	O

These	O
drugs	O
include	O
the	O
thiazides	S-group
and	O
other	O
diuretics	S-group
,	O
corticosteroids	S-group
,	O
phe	O
-	O
nothiazines	O
,	O
thyroid	B-group
products	E-group
,	O
estrogens	S-group
,	O
oral	O
contraceptives	S-group
,	O
phenytoin	S-drug
,	O
nicotinic	B-drug
acid	E-drug
,	O
sympathomimet	O
-	O
ics	O
,	O
calcium	B-group
channel	I-group
blocking	I-group
drugs	E-group
,	O
and	O
isoniazid	S-drug
.	O

When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
MICRONASE	S-brand
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
MICRONASE	S-brand
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

A	O
possible	O
interaction	O
between	O
glyburide	S-drug-IN-1
and	O
ciprofloxacin	S-drug-IN-2
,	O
a	O
fluoroquinolone	B-group
antibiotic	E-group
,	O
has	O
been	O
reported	O
,	O
resulting	O
in	O
a	O
potentiation	O
of	O
the	O
hypoglycemic	O
action	O
of	O
glyburide	S-drug
.	O

The	O
mechanism	O
for	O
this	O
interaction	O
is	O
not	O
known	O
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	S-drug-EF-1
and	O
oral	O
hypoglycemic	B-group-EF-2
agents	E-group-EF-2
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
,	O
topical	O
or	O
vaginal	O
preparations	O
of	O
miconazole	S-drug
is	O
not	O
known	O
.	O

Metformin	S-drug
:	O
In	O
a	O
single	O
-	O
dose	O
interaction	O
study	O
in	O
NIDDM	O
subjects	O
,	O
decreases	O
in	O
glyburide	S-drug
AUC	O
and	O
Cmax	O
were	O
observed	O
,	O
but	O
were	O
highly	O
variable	O
.	O

The	O
single	O
-	O
dose	O
nature	O
of	O
this	O
study	O
and	O
the	O
lack	O
of	O
correlation	O
between	O
glyburide	S-drug
blood	O
levels	O
and	O
pharmaco	O
-	O
dynamic	O
effects	O
,	O
makes	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
uncertain	O
.	O

Coadministration	O
of	O
gly	O
-	O
buride	O
and	O
metformin	S-drug
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
either	O
metformin	S-drug
pharmacokinetics	O
or	O
pharmaco	O
-	O
dynamics	O
.	O

Many	O
other	O
medicines	O
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
glimepiride	S-drug
or	O
affect	O
your	O
condition	O
.	O

Before	O
taking	O
glimepiride	S-drug-AD-1
,	O
tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
medicines	O
:	O
-	O
aspirin	S-brand-AD-2
or	O
another	O
salicylate	S-group-AD-2
such	O
as	O
magnesium	B-drug-AD-2
/	I-drug-AD-2
choline	I-drug-AD-2
salicylate	E-drug-AD-2
(	O
Trilisate	S-brand-AD-2
)	O
,	O
salsalate	S-drug-AD-2
(	O
Disalcid	S-brand-AD-2
,	O
others	O
)	O
,	O
choline	B-drug-AD-2
salicylate	E-drug-AD-2
(	O
Arthropan	S-drug-AD-2
)	O
,	O
magnesium	B-drug-AD-2
salicylate	E-drug-AD-2
(	O
Magan	S-brand-AD-2
)	O
,	O
or	O
bismuth	B-drug-AD-2
subsalicylate	E-drug-AD-2
(	O
Pepto	B-brand-AD-2
-	I-brand-AD-2
Bismol	E-brand-AD-2
)	O
;	O

-	O
a	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drug	E-group
(	O
NSAID	S-group
)	O
such	O
as	O
ibuprofen	S-drug
(	O
Motrin	S-brand
,	O
Advil	S-brand
,	O
Nuprin	S-brand
,	O
others	O
)	O
,	O
ketoprofen	S-drug
(	O
Orudis	S-brand
,	O
Orudis	B-brand
KT	E-brand
,	O
Oruvail	S-brand
)	O
,	O
diclofenac	S-drug
(	O
Voltaren	S-brand
,	O
Cataflam	S-brand
)	O
,	O
etodolac	S-drug
(	O
Lodine	S-brand
)	O
,	O
indomethacin	S-drug
(	O
Indocin	S-brand
)	O
,	O
nabumetone	S-drug
(	O
Relafen	S-brand
)	O
,	O
oxaprozin	S-drug
(	O
Daypro	S-brand
)	O
,	O
and	O
naproxen	S-drug
(	O
Anaprox	S-brand
,	O
Naprosyn	S-brand
,	O
Aleve	S-brand
)	O
;	O

-	O
a	O
sulfa	O
-	O
based	O
drug	O
such	O
as	O
sulfamethoxazole	S-drug
-	O
trimethoprim	S-drug
(	O
Bactrim	S-brand
,	O
Septra	S-brand
)	O
,	O
sulfisoxazole	S-drug
(	O
Gantrisin	S-brand
)	O
,	O
or	O
sulfasalazine	S-drug
(	O
Azulfidine	S-brand
)	O
;	O

-	O
a	O
monoamine	B-group
oxidase	I-group
inhibitor	E-group
(	O
MAOI	S-group
)	O
such	O
as	O
isocarboxazid	S-drug
(	O
Marplan	S-brand
)	O
,	O
tranylcypromine	S-drug
(	O
Parnate	S-brand
)	O
,	O
or	O
phenelzine	S-drug
(	O
Nardil	S-brand
)	O
;	O

-	O
a	O
beta	B-group
-	I-group
blocker	E-group
such	O
as	O
propranolol	S-drug
(	O
Inderal	S-brand
)	O
,	O
atenolol	S-drug
(	O
Tenormin	S-brand
)	O
,	O
acebutolol	S-drug
(	O
Sectral	S-brand
)	O
,	O
metoprolol	S-drug
(	O
Lopressor	S-brand
)	O
,	O
and	O
others	O
;	O

-	O
a	O
diuretic	S-group
(	O
water	O
pill	O
)	O
such	O
as	O
hydrochlorothiazide	S-drug
(	O
HCTZ	S-drug
,	O
Hydrodiuril	S-brand
)	O
,	O
chlorothiazide	S-drug
(	O
Diuril	S-brand
)	O
,	O
and	O
others	O
;	O

-	O
a	O
steroid	B-group
medicine	E-group
such	O
as	O
prednisone	S-drug
(	O
Deltasone	S-brand
,	O
Orasone	S-brand
,	O
others	O
)	O
,	O
methylprednisolone	S-drug
(	O
Medrol	S-brand
,	O
others	O
)	O
,	O
prednisolone	S-drug
(	O
Prelone	S-brand
,	O
Pediapred	S-brand
,	O
others	O
)	O
,	O
and	O
others	O
;	O

-	O
a	O
phenothiazine	S-group
such	O
as	O
chlorpromazine	S-drug
(	O
Thorazine	S-brand
)	O
,	O
fluphenazine	S-drug
(	O
Prolixin	S-brand
,	O
Permitil	S-brand
)	O
,	O
prochlorperazine	S-drug
(	O
Compazine	S-brand
)	O
,	O
promethazine	S-drug
(	O
Phenergan	S-brand
)	O
,	O
and	O
others	O
;	O

-	O
phenytoin	S-drug
(	O
Dilantin	S-brand
)	O
;	O

-	O
isoniazid	S-drug
(	O
Nydrazid	S-brand
)	O
;	O

-	O
rifampin	S-drug
(	O
Rifadin	S-brand
,	O
Rifamate	S-brand
)	O
;	O

or	O
-	O
over	O
-	O
the	O
-	O
counter	O
cough	O
,	O
cold	O
,	O
allergy	O
,	O
or	O
weight	O
loss	O
medications	O
.	O

You	O
may	O
require	O
a	O
dosage	O
adjustment	O
or	O
special	O
monitoring	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
medicines	O
listed	O
above	O
.	O

Drugs	O
other	O
than	O
those	O
listed	O
here	O
may	O
also	O
interact	O
with	O
glimepiride	S-drug
or	O
affect	O
your	O
condition	O
.	O

Talk	O
to	O
your	O
doctor	O
and	O
pharmacist	O
before	O
taking	O
any	O
prescription	O
or	O
over	O
-	O
the	O
-	O
counter	O
medicines	O
,	O
including	O
herbal	O
products	O
.	O

Immediate	O
and	O
Extended	O
Release	O
Tablets	O
The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	S-group-EF-1
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B-group-EF-2
anti	I-group-EF-2
-	I-group-EF-2
inflammatory	I-group-EF-2
agents	E-group-EF-2
,	O
some	O
azoles	S-group-EF-2
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	S-group-EF-2
,	O
sulfonamides	S-group-EF-2
,	O
chloramphenicol	S-drug-EF-2
,	O
probenecid	S-drug-EF-2
,	O
coumarins	S-group-EF-2
,	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
,	O
and	O
beta	B-group-EF-2
adrenergic	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
glipizide	S-drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
glipizide	S-drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O

In	O
vitro	O
binding	O
studies	O
with	O
human	O
serum	O
proteins	O
indicate	O
that	O
glipizide	S-drug
binds	O
differently	O
than	O
tolbutamide	S-drug
and	O
does	O
not	O
interact	O
with	O
salicylate	S-group
or	O
dicumarol	S-drug
.	O

However	O
,	O
caution	O
must	O
be	O
exercised	O
in	O
extrapolating	O
these	O
findings	O
to	O
the	O
clinical	O
situation	O
and	O
in	O
the	O
use	O
of	O
glipizide	S-drug
with	O
these	O
drugs	O
.	O

Certain	O
drugs	O
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
control	O
.	O

These	O
drugs	O
include	O
the	O
thiazides	S-group
and	O
other	O
diuretics	S-group
,	O
corticosteroids	S-group
,	O
phenothiazines	S-group
,	O
thyroid	B-group
products	E-group
,	O
estrogens	S-group
,	O
oral	O
contraceptives	S-group
,	O
phenytoin	S-drug
,	O
nicotinic	B-drug
acid	E-drug
,	O
sympathomimetics	S-group
,	O
calcium	B-group
channel	I-group
blocking	I-group
drugs	E-group
,	O
and	O
isoniazid	S-drug
.	O

When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
glipizide	S-drug
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
glipizide	S-drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	S-drug-IN-1
and	O
oral	O
hypoglycemic	B-group-IN-2
agents	E-group-IN-2
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
,	O
topical	O
,	O
or	O
vaginal	O
preparations	O
of	O
miconazole	S-drug
is	O
not	O
known	O
.	O

The	O
effect	O
of	O
concomitant	O
administration	O
of	O
fluconazole	S-drug-IN-1
and	O
glipizide	S-drug-IN-2
has	O
been	O
demonstrated	O
in	O
a	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
normal	O
volunteers	O
.	O

All	O
subjects	O
received	O
glipizide	S-drug
alone	O
and	O
following	O
treatment	O
with	O
100	O
mg	O
of	O
fluconazole	S-drug
as	O
a	O
single	O
daily	O
oral	O
dose	O
for	O
seven	O
days	O
.	O

The	O
mean	O
percentage	O
increase	O
in	O
the	O
glipizide	S-drug-ME-1
AUC	O
after	O
fluconazole	S-drug-ME-2
administration	O
was	O
56.9	O
%	O
(	O
range	O
:	O
35	O
to	O
81	O
)	O
.	O

The	O
concurrent	O
use	O
of	O
Robinul	S-brand-EF-1
Injection	O
with	O
other	O
anticholinergics	S-group-EF-2
or	O
medications	O
with	O
anticholinergic	O
activity	O
,	O
such	O
as	O
phenothiazines	S-group-EF-2
,	O
antiparkinson	B-group-EF-2
drugs	E-group-EF-2
,	O
or	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
may	O
intensify	O
the	O
antimuscarinic	O
effects	O
and	O
may	O
result	O
in	O
an	O
increase	O
in	O
anticholinergic	O
side	O
effects	O
.	O

Concomitant	O
administration	O
of	O
Robinul	S-brand-ME-1
Injection	O
and	O
potassium	B-drug-ME-2
chloride	E-drug-ME-2
in	O
a	O
wax	O
matrix	O
may	O
increase	O
the	O
severity	O
of	O
potassium	O
chloride	O
-	O
induced	O
gastrointestinal	O
lesions	O
as	O
a	O
result	O
of	O
a	O
slower	O
gastrointestinal	O
transit	O
time	O
.	O

The	O
Factrel	S-brand
test	O
should	O
be	O
conducted	O
in	O
the	O
absence	O
of	O
other	O
drugs	O
which	O
directly	O
affect	O
the	O
pituitary	O
secretion	O
of	O
the	O
gonadotropins	O
.	O

These	O
would	O
include	O
a	O
variety	O
of	O
preparations	O
which	O
contain	O
androgens	S-group
,	O
estrogens	S-group
,	O
progestins	S-group
,	O
or	O
glucocorticoids	S-group
.	O

The	O
gonadotropin	O
levels	O
may	O
be	O
transiently	O
elevated	O
by	O
spironolactone	S-drug
,	O
minimally	O
elevated	O
by	O
levodopa	S-drug
,	O
and	O
suppressed	O
by	O
oral	O
contraceptives	S-group
and	O
digoxin	S-drug
.	O

The	O
response	O
to	O
Factrel	S-brand-EF-1
may	O
be	O
blunted	O
by	O
phenothiazines	S-group-EF-2
and	O
dopamine	B-group-EF-2
antagonists	E-group-EF-2
which	O
cause	O
a	O
rise	O
in	O
prolactin	O
.	O

No	O
formal	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

No	O
confirmed	O
interactions	O
have	O
been	O
reported	O
between	O
ZOLADEX	S-brand
and	O
other	O
drugs	O

Antacids	S-group
,	O
Sucralfate	S-drug
,	O
Metal	O
Cations	O
,	O
Multivitamins	S-group
Quinolones	S-group
form	O
chelates	O
with	O
alkaline	O
earth	O
and	O
transition	O
metal	O
cations	O
.	O

Administration	O
of	O
quinolones	S-group-ME-1
with	O
antacids	S-group
containing	O
aluminum	S-drug-ME-2
,	O
magnesium	S-drug-ME-2
,	O
or	O
calcium	S-drug-ME-2
,	O
with	O
sucralfate	S-drug-ME-2
,	O
with	O
metal	O
cations	O
such	O
as	O
iron	S-drug-ME-2
,	O
or	O
with	O
multivitamins	S-group-ME-2
containing	O
iron	S-drug-ME-2
or	O
zinc	S-drug-ME-2
,	O
or	O
with	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
VIDEX	S-brand-ME-2
(	O
didanosine	S-drug-ME-2
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
,	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	S-group
,	O
resulting	O
in	O
systemic	O
concentrations	O
considerably	O
lower	O
than	O
desired	O
.	O

These	O
agents	O
should	O
not	O
be	O
taken	O
within	O
4	O
hours	O
before	O
or	O
4	O
hours	O
after	O
grepafloxacin	S-drug
administration	O
.	O

Caffeine	S-drug
Theobromine	S-drug
Grepafloxacin	S-drug-ME-1
,	O
like	O
other	O
quinolones	S-group-ME-1
,	O
may	O
inhibit	O
the	O
metabolism	O
of	O
caffeine	S-drug-ME-2
and	O
theobromine	S-drug-ME-2
.	O

These	O
stimulants	O
are	O
commonly	O
found	O
in	O
coffee	O
and	O
tea	O
,	O
respectively	O
.	O

In	O
some	O
patients	O
,	O
this	O
may	O
lead	O
to	O
reduced	O
clearance	O
,	O
prolongation	O
of	O
plasma	O
half	O
-	O
life	O
,	O
and	O
enhanced	O
effects	O
of	O
caffeine	S-drug
and	O
theobromine	S-drug
.	O

Theophylline	S-drug
:	O
Grepafloxacin	S-drug-ME-1
is	O
a	O
competitive	O
inhibitor	O
of	O
the	O
metabolism	O
of	O
theophylline	S-drug-ME-2
.	O

Serum	O
theophylline	S-drug
concentrations	O
increase	O
when	O
grepafloxacin	S-drug-ME-1
is	O
initiated	O
in	O
a	O
patient	O
maintained	O
on	O
theophylline	S-drug-ME-2
.	O

When	O
initiating	O
a	O
multi	O
-	O
day	O
course	O
of	O
grepafloxacin	S-drug
in	O
a	O
patient	O
maintained	O
on	O
theophylline	S-drug
,	O
the	O
theophylline	S-drug-AD-1
maintenance	O
dose	O
should	O
be	O
halved	O
for	O
the	O
period	O
of	O
concurrent	O
use	O
of	O
grepafloxacin	S-drug-AD-2
and	O
monitoring	O
of	O
serum	O
theophylline	S-drug
concentrations	O
should	O
be	O
initiated	O
as	O
a	O
guide	O
to	O
further	O
dosage	O
adjustments	O
.	O

Warfarin	S-drug
:	O
In	O
subjects	O
receiving	O
warfarin	S-drug
,	O
no	O
significant	O
change	O
in	O
clotting	O
time	O
was	O
observed	O
when	O
grepafloxacin	S-drug
was	O
coadministered	O
.	O

However	O
,	O
because	O
some	O
quinolones	S-group-EF-1
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
warfarin	S-drug-EF-2
or	O
its	O
derivatives	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
anticoagulation	O
test	O
should	O
be	O
monitored	O
closely	O
if	O
a	O
quinolone	B-group-AD-1
antimicrobial	E-group-AD-1
is	O
administered	O
with	O
warfarin	S-drug-AD-2
or	O
its	O
derivatives	O
.	O

Drugs	O
Metabolized	O
by	O
Cytochrome	O
P450	O
Enzymes	O
The	O
drug	O
interaction	O
study	O
evaluating	O
the	O
effect	O
of	O
grepafloxacin	S-drug
on	O
theophylline	S-drug
indicates	O
that	O
grepafloxacin	S-drug-ME-1
inhibits	O
theophylline	S-drug-ME-2
metabolism	O
,	O
which	O
is	O
mediated	O
by	O
CYP1A2	O
.	O

While	O
no	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
grepafloxacin	S-drug
on	O
the	O
metabolism	O
of	O
C.P.A	O
.	O

substrates	O
,	O
in	O
vitro	O
data	O
suggest	O
similar	O
effects	O
of	O
grepafloxacin	S-drug
in	O
CYP3A4	O
mediated	O
metabolism	O
and	O
theophylline	S-drug
metabolism	O
.	O

In	O
addition	O
,	O
other	O
quinolones	S-group-ME-1
have	O
been	O
reported	O
to	O
decrease	O
the	O
CYP3A4	O
-	O
mediated	O
metabolism	O
of	O
cyclosporine	S-drug-ME-2
.	O

Other	O
drugs	O
metabolized	O
by	O
C.P.A	O
.	O

include	O
terfenadine	S-drug
,	O
astemizole	S-drug
,	O
cisapride	S-drug
,	O
midazolam	S-drug
,	O
and	O
triazolam	S-drug
.	O

The	O
clinical	O
relevance	O
of	O
the	O
potential	O
effect	O
of	O
grepafloxacin	S-drug
on	O
the	O
metabolism	O
of	O
C.P.A	O
.	O
substrates	O
is	O
not	O
known	O
.	O

Patients	O
receiving	O
concurrent	O
administration	O
of	O
substrates	O
of	O
C.P.A	O
.	O
were	O
not	O
excluded	O
from	O
clinical	O
trials	O
of	O
grepafloxacin	S-drug
.	O

Nonsteroidal	B-group
Anti	I-group
-	I-group
inflammatory	I-group
Drugs	E-group
(	O
NSAIDs	S-group
)	O
:	O
The	O
concomitant	O
administration	O
of	O
a	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
inflammatory	I-group-EF-1
drug	E-group-EF-1
with	O
a	O
quinolone	S-group-EF-2
may	O
increase	O
the	O
risks	O
of	O
CNS	O
stimulation	O
and	O
convulsions	O
.	O

Antidiabetic	B-group
Agents	E-group
:	O
Disturbances	O
of	O
blood	O
glucose	O
,	O
including	O
hyperglycemia	O
and	O
hypoglycemia	O
,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
concomitantly	O
with	O
quinolones	S-group-EF-1
and	O
an	O
antidiabetic	B-group-EF-2
agent	E-group-EF-2
.	O

Therefore	O
,	O
careful	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
when	O
these	O
agents	O
are	O
coadministered	O
.	O

Patients	O
on	O
warfarin	B-group-AD-1
-	I-group-AD-1
type	I-group-AD-1
anticoagulant	E-group-AD-1
therapy	O
may	O
require	O
dosage	O
adjustment	O
of	O
the	O
anticoagulant	O
during	O
and	O
after	O
griseofulvin	S-drug-AD-2
therapy	O
.	O

Concomitant	O
use	O
of	O
barbiturates	S-group-EF-1
usually	O
depresses	O
griseofulvin	S-drug-EF-2
activity	O
and	O
may	O
necessitate	O
raising	O
the	O
dosage	O
.	O

The	O
concomitant	O
administration	O
of	O
griseofulvin	S-drug-EF-1
has	O
been	O
reported	O
to	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	S-group-EF-2
and	O
to	O
increase	O
the	O
incidence	O
of	O
breakthrough	O
bleeding	O
.	O

The	O
use	O
of	O
codeine	S-drug-EF-1
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	S-drug-EF-2
,	O
antihistamines	S-group-EF-2
,	O
psychotropics	S-group-EF-2
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O

Serious	O
toxicity	O
may	O
result	O
if	O
dextromethorphan	S-drug-EF-1
is	O
coadministered	O
with	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
(	O
MAOIs	S-group-EF-2
)	O
.	O

The	O
use	O
of	O
dextromethorphan	B-drug-EF-1
hydrobromide	E-drug-EF-1
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	S-drug-EF-2
,	O
antihistamines	S-group-EF-2
,	O
psychotropics	S-group-EF-2
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O

http	O
:	O
/	O
/	O
www.rxlist.com	O
/	O
cgi	O
/	O
generic3	O
/	O
guanethidine_od.htm	O

The	O
potential	O
for	O
increased	O
sedation	O
when	O
guanfacine	S-drug-EF-1
is	O
given	O
with	O
other	O
CNS	B-group-EF-2
-	I-group-EF-2
depressant	I-group-EF-2
drug	E-group-EF-2
should	O
be	O
appreciated	O
.	O

The	O
administration	O
of	O
guanfacine	S-drug-ME-1
concomitantly	O
with	O
known	O
microsomal	O
enzyme	O
inducer	O
(	O
phenobarbital	S-drug-ME-2
or	O
phenytoin	S-drug-ME-2
)	O
to	O
two	O
patients	O
with	O
renal	O
impairment	O
reportedly	O
resulted	O
in	O
significant	O
reductions	O
in	O
elimination	O
half	O
-	O
life	O
and	O
plasma	O
concentration	O
.	O

In	O
such	O
cases	O
,	O
therefore	O
,	O
more	O
frequent	O
dosing	O
may	O
be	O
required	O
to	O
achieve	O
or	O
maintain	O
the	O
desired	O
hypotensive	O
response	O
.	O

Further	O
,	O
if	O
guanfacine	S-drug
is	O
to	O
be	O
discontinued	O
in	O
such	O
patients	O
,	O
careful	O
tapering	O
of	O
the	O
dosage	O
may	O
be	O
necessary	O
in	O
order	O
to	O
avoid	O
rebound	O
phenomena	O
.	O

TCAs	S-group-EF-1
decrease	O
the	O
hypotensive	O
effect	O
of	O
guanfacine	S-drug-EF-2
.	O

Noncardioselective	B-group-EF-1
beta	I-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
(	O
nadolol	S-drug-EF-1
,	O
porpranolol	O
,	O
timolol	S-drug-EF-1
)	O
may	O
exacerbate	O
rebound	O
hypertension	O
when	O
guanfacine	S-drug-EF-2
is	O
withdrawn	O
.	O

The	O
beta	B-group
-	I-group
blocker	E-group
should	O
be	O
withdrawn	O
first	O
.	O

The	O
gradual	O
withdrawal	O
of	O
guafacine	S-drug
or	O
a	O
cardioselective	B-group
beta	I-group
-	I-group
blocker	E-group
could	O
be	O
substituted	O
.	O

Anticoagulants	S-group
:	O
Ten	O
patients	O
who	O
were	O
stabilized	O
on	O
oral	O
anticoagulants	S-group
were	O
given	O
guanfacine	S-drug
,	O
1	O
-	O
2	O
mg	O
/	O
day	O
,	O
for	O
4	O
weeks	O
.	O

No	O
changes	O
were	O
observed	O
in	O
the	O
degree	O
of	O
anticoagulation	O
.	O

In	O
several	O
well	O
-	O
controlled	O
studies	O
,	O
guanfacine	S-drug
was	O
administered	O
together	O
with	O
diuretics	S-group
with	O
no	O
drug	O
interactions	O
reported	O
.	O

In	O
the	O
long	O
-	O
term	O
safety	O
studies	O
,	O
guanfacine	S-drug
was	O
given	O
concomitantly	O
with	O
many	O
drugs	O
without	O
evidence	O
of	O
any	O
interactions	O
.	O

The	O
principal	O
drugs	O
given	O
(	O
number	O
of	O
patients	O
in	O
parentheses	O
)	O
were	O
:	O
cardiac	B-group
glycosides	E-group
(	O
115	O
)	O
,	O
sedatives	S-group
and	O
hypnotics	S-group
(	O
103	O
)	O
,	O
coronary	B-group
vasodilators	E-group
(	O
52	O
)	O
,	O
oral	O
hypoglycemics	S-group
(	O
45	O
)	O
,	O
cough	O
and	O
cold	O
preparations	O
(	O
45	O
)	O
,	O
NSAIDs	S-group
(	O
38	O
)	O
,	O
antihyperlipidemics	S-group
(	O
29	O
)	O
,	O
antigout	B-group
drugs	E-group
(	O
24	O
)	O
,	O
oral	O
contraceptives	S-group
(	O
18	O
)	O
,	O
bronchodilators	S-group
(	O
13	O
)	O
,	O
insulin	S-drug
(	O
10	O
)	O
,	O
and	O
beta	B-group
blockers	E-group
(	O
10	O
)	O
.	O

Laboratory	O
Test	O
In	O
clinical	O
trials	O
,	O
no	O
clinically	O
relevant	O
laboratory	O
test	O
abnormalities	O
were	O
identified	O
as	O
causally	O
related	O
to	O
drug	O
during	O
short	O
-	O
term	O
treatment	O
with	O
guanfacine	S-drug
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
No	O
laboratory	O
test	O
abnormalities	O
related	O
to	O
the	O
use	O
of	O
guanfacine	S-drug
have	O
been	O
identified	O
.	O

An	O
encephalopathic	O
syndrome	O
(	O
characterized	O
by	O
weakness	O
,	O
lethargy	O
,	O
fever	O
,	O
tremulousness	O
and	O
confusion	O
,	O
extrapyramidal	O
symptoms	O
,	O
leukocytosis	O
,	O
elevated	O
serum	O
enzymes	O
,	O
BUN	O
,	O
and	O
FBS	O
)	O
followed	O
by	O
irreversible	O
brain	O
damage	O
has	O
occurred	O
in	O
a	O
few	O
patients	O
treated	O
with	O
lithium	S-drug-EF-1
plus	O
HALDOL	S-brand-EF-2
.	O

A	O
causal	O
relationship	O
between	O
these	O
events	O
and	O
the	O
concomitant	O
administration	O
of	O
lithium	S-drug
and	O
HALDOL	S-brand
has	O
not	O
been	O
established	O
;	O

however	O
,	O
patients	O
receiving	O
such	O
combined	O
therapy	O
should	O
be	O
monitored	O
closely	O
for	O
early	O
evidence	O
of	O
neurological	O
toxicity	O
and	O
treatment	O
discontinued	O
promptly	O
if	O
such	O
signs	O
appear	O
.	O

As	O
with	O
other	O
antipsychotic	B-group-EF-1
agents	E-group-EF-1
,	O
it	O
should	O
be	O
noted	O
that	O
HALDOL	S-brand-EF-1
may	O
be	O
capable	O
of	O
potentiating	O
CNS	B-group-EF-2
depressants	E-group-EF-2
such	O
as	O
anesthetics	S-group-EF-2
,	O
opiates	S-group-EF-2
,	O
and	O
alcohol	S-drug-EF-2
.	O

In	O
a	O
study	O
of	O
12	O
schizophrenic	O
patients	O
coadministered	O
oral	O
haloperidol	S-drug-ME-1
and	O
rifampin	S-drug-ME-2
,	O
plasma	O
haloperidol	S-drug
levels	O
were	O
decreased	O
by	O
a	O
mean	O
of	O
70	O
%	O
and	O
mean	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
were	O
increased	O
from	O
baseline	O
.	O

In	O
5	O
other	O
schizophrenic	O
patients	O
treated	O
with	O
oral	O
haloperidol	S-drug
and	O
rifampin	S-drug
,	O
discontinuation	O
of	O
rifampin	S-drug-ME-1
produced	O
a	O
mean	O
3.3	O
-	O
fold	O
increase	O
in	O
haloperidol	S-drug-ME-2
concentrations	O
.	O

Thus	O
,	O
careful	O
monitoring	O
of	O
clinical	O
status	O
is	O
warranted	O
when	O
rifampin	S-drug-AD-1
is	O
administered	O
or	O
discontinued	O
in	O
haloperidol	S-drug-AD-2
-	O
treated	O
patients	O
.	O

FLUOTHANE	S-brand-EF-1
augments	O
the	O
action	O
of	O
non	B-group-EF-2
-	I-group-EF-2
depolarising	I-group-EF-2
muscle	I-group-EF-2
relaxants	O
and	O
the	O
muscle	O
relaxant	O
effects	O
of	O
aminoglycosides	S-group-EF-2
.	O

FLUOTHANE	S-brand-EF-1
may	O
augment	O
the	O
hypotension	O
caused	O
by	O
the	O
ganglionic	O
-	O
blocking	O
effect	O
of	O
tubocurarine	S-drug-EF-2
.	O

Caution	O
should	O
be	O
exercised	O
during	O
the	O
administration	O
of	O
adrenaline	S-drug-AD-1
to	O
patients	O
anaesthetised	O
with	O
FLUOTHANE	S-brand-AD-2
as	O
arrhythmias	O
may	O
be	O
precipitated	O
.	O

For	O
this	O
reason	O
the	O
dose	O
of	O
adrenaline	S-drug
should	O
be	O
restricted	O
and	O
an	O
antiarrhythmic	B-group
agent	E-group
administered	O
as	O
appropriate	O
.	O

Caution	O
should	O
also	O
be	O
applied	O
for	O
other	O
sympathomimetics	S-group
,	O
and	O
for	O
aminophylline	S-drug
and	O
theophylline	S-drug
and	O
tricyclic	B-group
antidepressants	E-group
,	O
which	O
may	O
also	O
precipitate	O
arrhythmias	O
.	O

Drug	O
Interactions	O
:	O
a	O
.	O
Drugs	O
Enhancing	O
Heparin	S-drug
Effect	O
:	O
Oral	O
anticoagulants	S-group
:	O
Heparin	B-drug
sodium	E-drug
may	O
prolong	O
the	O
one	O
-	O
stage	O
prothrombin	O
time	O
.	O

Therefore	O
,	O
when	O
heparin	B-drug-AD-1
sodium	E-drug-AD-1
is	O
given	O
with	O
dicumarol	S-drug-AD-2
or	O
warfarin	B-drug-AD-2
sodium	E-drug-AD-2
,	O
a	O
period	O
of	O
at	O
least	O
5	O
hours	O
after	O
the	O
last	O
intravenous	O
dose	O
or	O
24	O
hours	O
after	O
the	O
last	O
subcutaneous	O
dose	O
should	O
elapse	O
before	O
blood	O
is	O
drawn	O
if	O
a	O
valid	O
prothrombin	O
time	O
is	O
to	O
be	O
obtained	O
.	O

Platelet	B-group
inhibitors	E-group
:	O
Drugs	O
such	O
as	O
acetylsalicylic	B-drug-EF-1
acid	E-drug-EF-1
,	O
dextran	S-drug-EF-1
,	O
phenylbutazone	S-drug-EF-1
,	O
ibuprofen	S-drug-EF-1
,	O
indomethacin	S-drug-EF-1
,	O
dipyridamole	S-drug-EF-1
,	O
hydroxychloroquine	S-drug-EF-1
and	O
others	O
that	O
interfere	O
with	O
platelet	O
-	O
aggregation	O
reactions	O
(	O
the	O
main	O
hemostatic	O
defense	O
of	O
heparinized	O
patients	O
)	O
may	O
induce	O
bleeding	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
heparin	B-drug-EF-2
sodium	E-drug-EF-2
.	O

The	O
anticoagulant	O
effect	O
of	O
heparin	S-drug-EF-1
is	O
enhanced	O
by	O
concurrent	O
treatment	O
with	O
antithrombin	B-drug-EF-2
III	E-drug-EF-2
(	O
human	O
)	O
in	O
patients	O
with	O
hereditary	O
antithrombin	O
III	O
deficiency	O
.	O

Thus	O
in	O
order	O
to	O
avoid	O
bleeding	O
,	O
reduced	O
dosage	O
of	O
heparin	S-drug-AD-1
is	O
recommended	O
during	O
treatment	O
with	O
antithrombin	B-drug-AD-2
III	E-drug-AD-2
(	O
human	O
)	O
.	O

b	O
.	O

Drugs	O
Decreasing	O
Heparin	S-drug
Effect	O
:	O
Digitalis	S-group-EF-1
,	O
tetracyclines	S-group-EF-1
,	O
nicotine	S-drug-EF-1
,	O
or	O
antihistamines	S-group-EF-1
may	O
partially	O
counteract	O
the	O
anticoagulant	O
action	O
of	O
heparin	B-drug-EF-2
sodium	E-drug-EF-2
.	O

Heparin	B-drug
Sodium	E-drug
Injection	O
should	O
not	O
be	O
mixed	O
with	O
doxorubicin	S-drug
,	O
droperidol	S-drug
,	O
ciprofloxacin	S-drug
,	O
or	O
mitoxantrone	S-drug
,	O
since	O
it	O
has	O
been	O
reported	O
that	O
these	O
drugs	O
are	O
incompatible	O
with	O
heparin	S-drug
and	O
a	O
precipitate	O
may	O
form	O
.	O

Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
Hyperaminotransferasemia	O
:	O
Significant	O
elevations	O
of	O
aminotransferase	O
(	O
SGOT	O
[	O
S	O
-	O
AST	O
]	O
and	O
SGPT	O
[	O
S	O
-	O
ALT	O
]	O
)	O
levels	O
have	O
occurred	O
in	O
a	O
high	O
percentage	O
of	O
patients	O
(	O
and	O
healthy	O
subjects	O
)	O
who	O
have	O
received	O
heparin	B-drug
sodium	E-drug
.	O

Since	O
aminotransferase	O
determinations	O
are	O
important	O
in	O
the	O
differential	O
diagnosis	O
of	O
myocardial	O
infarction	O
,	O
liver	O
disease	O
and	O
pulmonary	O
emboli	O
,	O
rises	O
that	O
might	O
be	O
caused	O
by	O
drugs	O
(	O
heparin	B-drug
sodium	E-drug
)	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

Opioids	S-group
are	O
strong	O
central	B-group
nervous	I-group
system	I-group
depressants	E-group
,	O
but	O
regular	O
users	O
develop	O
physiological	O
tolerance	O
allowing	O
gradually	O
increased	O
dosages	O
.	O

In	O
combination	O
with	O
other	O
central	B-group-EF-1
nervous	I-group-EF-1
system	I-group-EF-1
depressants	E-group-EF-1
,	O
heroin	S-drug_n-EF-2
may	O
still	O
kill	O
even	O
experienced	O
users	O
,	O
particularly	O
if	O
their	O
tolerance	O
to	O
the	O
drug	O
has	O
reduced	O
or	O
the	O
strength	O
of	O
their	O
usual	O
dose	O
has	O
increased	O
.	O

Toxicology	O
studies	O
of	O
heroin	S-drug_n-EF-1
-	O
related	O
deaths	O
reveal	O
frequent	O
involvement	O
of	O
other	O
central	B-group-EF-2
nervous	I-group-EF-2
system	I-group-EF-2
depressants	E-group-EF-2
,	O
including	O
alcohol	S-drug-EF-2
,	O
benzodiazepines	S-group-EF-2
such	O
as	O
diazepam	S-drug-EF-2
(	O
Valium	S-brand-EF-2
)	O
,	O
and	O
,	O
to	O
a	O
rising	O
degree	O
,	O
methadone	S-drug-EF-2
.	O

Ironically	O
,	O
benzodiazepines	S-group
are	O
often	O
used	O
in	O
the	O
treatment	O
of	O
heroin	S-drug
addiction	O
while	O
they	O
cause	O
much	O
more	O
severe	O
withdrawal	O
symptoms	O
.	O

Cocaine	S-drug-EF-1
sometimes	O
proves	O
to	O
be	O
fatal	O
when	O
used	O
in	O
combination	O
with	O
heroin	S-drug_n-EF-2
.	O

No	O
information	O
available	O
.	O

Barbiturates	S-group-EF-1
may	O
decrease	O
the	O
effectiveness	O
of	O
oral	O
contraceptives	S-group-EF-2
,	O
certain	O
antibiotics	S-group-EF-2
,	O
quinidine	S-drug-EF-2
,	O
theophylline	S-drug-EF-2
,	O
corticosteroids	S-group-EF-2
,	O
anticoagulants	S-group-EF-2
,	O
and	O
beta	B-group-EF-2
blockers	E-group-EF-2
.	O

MAO	B-group-AD-1
inhibitors	E-group-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
hydralazine	S-drug-AD-2
.	O

When	O
other	O
potent	O
parental	O
antihypertensive	B-group-EF-1
drugs	E-group-EF-1
,	O
such	O
as	O
diazoxide	S-drug-EF-2
,	O
are	O
used	O
in	O
combination	O
with	O
hydralazine	S-drug-EF-2
,	O
patients	O
should	O
be	O
continuously	O
observed	O
for	O
several	O
hours	O
for	O
any	O
excessive	O
fall	O
in	O
blood	O
pressure	O
.	O

Profound	O
hypotensive	O
episodes	O
may	O
occur	O
when	O
diazoxide	S-drug-EF-1
infection	O
and	O
hydralazine	S-drug-EF-2
are	O
used	O
concomitantly	O
.	O

Beta	B-group
-	I-group
blockers	E-group
(	O
metoprolol	S-drug
,	O
propranolol	S-drug
)	O
serum	O
concentrations	O
and	O
pharmacologic	O
effects	O
may	O
be	O
increased	O
.	O

Monitor	O
cardiovascular	O
status	O
.	O

Propranolol	S-drug-ME-1
increases	O
hydralazines	O
serum	O
concentrations	O
.	O

Acebutolol	S-drug
,	O
atenolol	S-drug
,	O
and	O
nadolol	S-drug
(	O
low	O
hepatic	O
clearance	O
or	O
no	O
first	O
-	O
pass	O
metabolism	O
)	O
are	O
unlikely	O
to	O
be	O
affected	O
.	O

NSAIDs	S-group-EF-1
may	O
decrease	O
the	O
hemodynamic	O
effects	O
of	O
hydralazine	S-drug-EF-2
;	O

avoid	O
use	O
if	O
possible	O
or	O
closely	O
monitor	O
cardiovascular	O
status	O
at	O
the	O
end	O
of	O
drug	O
interactions	O

When	O
given	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
thiazide	B-group
diuretics	E-group
.	O

Alcohol	S-drug
,	O
barbiturates	S-group
,	O
or	O
narcotics	S-group
:	O
potentiation	O
of	O
orthostatic	O
hypotension	O
may	O
occur	O
.	O

Antidiabetic	B-group
drugs	E-group
:	O
(	O
oral	O
agents	O
and	O
insulin	S-drug
)	O
-	O
dosage	O
adjustment	O
of	O
the	O
antidiabetic	B-group
drug	E-group
may	O
be	O
required	O
.	O

Other	O
antihypertensive	B-group
drugs	E-group
:	O
additive	O
effect	O
or	O
potentiation	O
.	O

Cholestyramine	S-drug
and	O
colestipol	S-drug
resins	S-group
:	O
Absorption	O
of	O
hydrochlorothiazide	S-drug-ME-1
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	B-group-ME-2
exchange	I-group-ME-2
resins	E-group-ME-2
.	O

Single	O
doses	O
of	O
either	O
cholestyramine	S-drug-ME-1
or	O
colestipol	S-drug-ME-1
resins	S-group
bind	O
the	O
hydrochlorothiazide	S-drug-ME-2
and	O
reduce	O
its	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
85	O
and	O
43	O
percent	O
,	O
respectively	O
.	O

Corticosteroids	S-group
,	O
ACTH	S-drug
:	O
intensified	O
electrolyte	O
depletion	O
,	O
particularly	O
hypokalemia	O
.	O

Pressor	O
amines	O
(	O
e.g	O
.	O
,	O
norepinephrine	S-drug
)	O
:	O
possible	O
decreased	O
response	O
to	O
pressor	O
amines	O
but	O
not	O
sufficient	O
to	O
preclude	O
their	O
use	O
.	O

Skeletal	B-group
muscle	I-group
relaxants	E-group
,	O
nondepolarizing	O
(	O
e.g	O
.	O
,	O
tubocurarine	S-drug
)	O
:	O
possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	B-group
relaxant	E-group
.	O

Lithium	S-drug-AD-1
:	O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	S-group-AD-2
.	O

Diuretic	B-group-MU-1
agents	E-group-MU-1
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	S-drug-ME-2
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	S-drug-EF-2
toxicity	O
.	O

Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	S-drug-AD-1
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
Hydrochlorothiazide	S-drug-AD-2
.	O

Non	B-group
-	I-group
steroidal	I-group
Anti	I-group
-	I-group
inflammatory	I-group
Drugs	E-group
:	O
In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	B-group-EF-1
-	I-group-EF-1
steroidal	I-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
agent	E-group-EF-1
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	S-group-EF-2
,	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	E-group-EF-2
and	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
.	O

Therefore	O
,	O
when	O
Hydrochlorothiazide	S-drug-AD-1
and	O
non	B-group-AD-2
-	I-group-AD-2
steroidal	I-group-AD-2
anti	I-group-AD-2
-	I-group-AD-2
inflammatory	I-group-AD-2
agents	E-group-AD-2
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	S-group
is	O
obtained	O
.	O

Patients	O
receiving	O
other	O
narcotic	B-group-EF-1
analgesics	E-group-EF-1
,	O
antipsychotics	S-group-EF-1
,	O
antianxiety	B-group-EF-1
agents	E-group-EF-1
,	O
or	O
other	O
CNS	B-group-EF-1
depressants	E-group-EF-1
(	O
including	O
alcohol	S-drug-EF-1
)	O
concomitantly	O
with	O
hydrocodone	S-drug-EF-2
and	O
acetaminophen	S-drug
tablets	O
may	O
exhibit	O
an	O
additive	O
CNS	O
depression	O
.	O

When	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

The	O
use	O
of	O
MAO	B-group-EF-1
inhibitors	E-group-EF-1
or	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
with	O
hydrocodone	S-drug-EF-2
preparations	O
may	O
increase	O
the	O
effect	O
of	O
either	O
the	O
antidepressant	S-group
or	O
hydrocodone	S-drug
.	O

The	O
concurrent	O
use	O
of	O
anticholinergics	S-group-EF-1
with	O
hydrocodone	S-drug-EF-2
may	O
produce	O
paralytic	O
ileus	O
.	O

No	O
information	O
available	O
.	O

Anticoagulants	S-group
,	O
oral	O

(	O
Effects	O
may	O
be	O
decreased	O
when	O
used	O
concurrently	O
with	O
thiazide	B-group
diuretics	E-group
;	O

dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
)	O

Antigout	B-group
medications	E-group

(	O
Thiazide	B-group
diuretics	E-group
may	O
raise	O
the	O
level	O
of	O
blood	O
uric	O
acid	O
;	O

dosage	O
adjustment	O
of	O
antigout	B-group
medications	E-group
may	O
be	O
necessary	O
to	O
control	O
hyperuricemia	O
and	O
gout	O
.	O
)	O

Antihypertensive	B-group
medications	E-group
,	O
other	O
,	O
especially	O
diazoxide	S-drug
,	O
or	O
preanesthetic	O
and	O
anesthetic	O
agents	O
used	O
in	O
surgery	O
or	O
skeletal	B-group
-	I-group
muscle	I-group
relaxants	E-group
,	O
nondepolarizing	O
,	O
used	O
in	O
surgery	O

(	O
Effects	O
may	O
be	O
potentiated	O
when	O
used	O
concurrently	O
with	O
thiazide	B-group
diuretics	E-group
;	O

dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O
)	O

Amphotericin	B-drug
B	E-drug
or	O
Corticosteroids	S-group
or	O
Corticotropin	S-drug
(	O
ACTH	S-drug
)	O

(	O
Concurrent	O
use	O
with	O
thiazide	B-group
diuretics	E-group
may	O
intensify	O
electrolyte	O
imbalance	O
,	O
particularly	O
hypokalemia	O
.	O
)	O

Cardiac	B-group
glycosides	E-group

(	O
Concurrent	O
use	O
with	O
thiazide	B-group-EF-1
diuretics	E-group-EF-1
may	O
enhance	O
the	O
possibility	O
of	O
digitalis	S-group-EF-2
toxicity	O
associated	O
with	O
hypokalemia	O
.	O
)	O

(	O
May	O
inhibit	O
gastrointestinal	O
absorption	O
of	O
the	O
thiazide	B-group
diuretics	E-group
;	O

administration	O
1	O
hour	O
before	O
or	O
4	O
hours	O
after	O
colestipol	S-drug
is	O
recommended	O
.	O
)	O

(	O
Thiazide	B-group
diuretics	E-group
may	O
raise	O
blood	O
glucose	O
levels	O
;	O

for	O
adult	O
-	O
onset	O
diabetics	O
,	O
dosage	O
adjustment	O
of	O
hypoglycemic	B-group-AD-1
medications	E-group-AD-1
may	O
be	O
necessary	O
during	O
and	O
after	O
thiazide	B-group-AD-2
diuretic	E-group-AD-2
therapy	O
;	O

insulin	S-drug
requirements	O
may	O
be	O
increased	O
,	O
decreased	O
,	O
or	O
unchanged	O
.	O
)	O

Lithium	S-drug
salts	O

(	O
Concurrent	O
use	O
with	O
thiazide	B-group
diuretics	E-group
is	O
not	O
recommended	O
,	O
as	O
they	O
may	O
provoke	O
lithium	S-drug
toxicity	O
because	O
of	O
reduced	O
renal	O
clearance	O
.	O
)	O

(	O
Effectiveness	O
may	O
be	O
decreased	O
when	O
used	O
concurrently	O
with	O
thiazide	B-group
diuretics	E-group
because	O
of	O
alkalinization	O
of	O
the	O
urine	O
.	O
)	O

Nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
agents	E-group

(	O
In	O
some	O
patients	O
,	O
the	O
steroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
agent	E-group-EF-1
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	S-group-EF-2
,	O
potassium	B-group-EF-2
sparing	E-group-EF-2
,	O
and	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
.	O

Therefore	O
,	O
when	O
hydroflumethiazide	S-drug-AD-1
and	O
nonsteroidal	B-group-AD-2
anti	I-group-AD-2
-	I-group-AD-2
inflammatory	I-group-AD-2
agents	E-group-AD-2
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	S-group
is	O
obtained	O
.	O
)	O

(	O
Thiazides	S-group-EF-1
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	S-drug-EF-2
.	O

This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O
)	O

(	O
Thiazide	B-group-EF-1
drugs	E-group-EF-1
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	S-drug-EF-2
.	O
)	O

DIAGNOSTIC	O
INTERFERENCE	O
With	O
expected	O
physiologic	O
effects	O
:	O
Blood	O
and	O
urine	O
glucose	O
levels	O
(	O
usually	O
only	O
in	O
patients	O
with	O
a	O
predisposition	O
for	O
glucose	O
intolerance	O
)	O
and	O
Serum	O
bilirubin	O
levels	O
(	O
by	O
displacement	O
from	O
albumin	O
binding	O
)	O
and	O
Serum	O
calcium	O
levels	O
(	O
thiazide	B-group
diuretics	E-group
should	O
be	O
discontinued	O
before	O
parathyroid	O
-	O
function	O
tests	O
are	O
carried	O
out	O
)	O
and	O
Serum	O
uric	O
acid	O
levels	O
(	O
may	O
be	O
increased	O
)	O
Serum	O
magnesium	O
,	O
potassium	O
,	O
and	O
sodium	O
levels	O
(	O
may	O
be	O
decreased	O
;	O

serum	O
magnesium	O
levels	O
may	O
increase	O
in	O
uremic	O
patients	O
)	O
Serum	O
protein	O
-	O
bound	O
iodine	O
(	O
PBI	O
)	O
levels	O
(	O
may	O
be	O
decreased	O
)	O
Thiazides	S-group
should	O
be	O
discontinued	O
before	O
carrying	O
out	O
tests	O
for	O
parathyroid	O
function	O
.	O

Patients	O
receiving	O
other	O
narcotic	B-group-EF-1
analgesics	O
,	O
general	O
anesthetics	S-group-EF-1
,	O
phenothiazines	S-group-EF-1
,	O
tranquilizers	S-group-EF-1
,	O
sedative	B-group-EF-1
-	I-group-EF-1
hypnotics	E-group-EF-1
,	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
or	O
other	O
CNS	B-group-EF-1
depressants	E-group-EF-1
(	O
including	O
alcohol	S-drug-EF-1
)	O
concomitantly	O
with	O
DILAUDID	S-brand-EF-2
may	O
exhibit	O
an	O
additive	O
CNS	O
depression	O
.	O

When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Cyanokit	S-brand
.	O

Prospective	O
studies	O
on	O
the	O
potential	O
for	O
hydroxyurea	S-drug
to	O
interact	O
with	O
other	O
drugs	O
have	O
not	O
been	O
performed	O
.	O

Concurrent	O
use	O
of	O
hydroxyurea	S-drug
and	O
other	O
myelosuppressive	O
agents	O
or	O
radiation	O
therapy	O
may	O
increase	O
the	O
likelihood	O
of	O
bone	O
marrow	O
depression	O
or	O
other	O
adverse	O
events	O
.	O

Since	O
hydroxyurea	S-drug-EF-1
may	O
raise	O
the	O
serum	O
uric	O
acid	O
level	O
,	O
dosage	O
adjustment	O
of	O
uricosuric	B-group-EF-2
medication	E-group-EF-2
may	O
be	O
necessary	O

THE	O
POTENTIATING	O
ACTION	O
OF	O
HYDROXYZINE	S-drug-EF-1
MUST	O
BE	O
CONSIDERED	O
WHEN	O
THE	O
DRUG	O
IS	O
USED	O
IN	O
CONJUNCTION	O
WITH	O
CENTRAL	B-group-EF-2
NERVOUS	I-group-EF-2
SYSTEM	I-group-EF-2
DEPRESSANTS	E-group-EF-2
SUCH	O
AS	O
NARCOTICS	S-group-EF-2
,	O
NON	B-group-EF-2
-	I-group-EF-2
NARCOTIC	I-group-EF-2
ANALGESICS	E-group-EF-2
AND	O
BARBITURATES	S-group-EF-2
.	O

Therefore	O
when	O
central	B-group-AD-1
nervous	I-group-AD-1
system	I-group-AD-1
depressants	E-group-AD-1
are	O
administered	O
concomitantly	O
with	O
hydroxyzine	S-drug-AD-2
their	O
dosage	O
should	O
be	O
reduced	O
.	O

Since	O
drowsiness	O
may	O
occur	O
with	O
use	O
of	O
this	O
drug	O
,	O
patients	O
should	O
be	O
warned	O
of	O
this	O
possibility	O
and	O
cautioned	O
against	O
driving	O
a	O
car	O
or	O
operating	O
dangerous	O
machinery	O
while	O
taking	O
Atarax	S-brand
.	O

Patients	O
should	O
be	O
advised	O
against	O
the	O
simultaneous	O
use	O
of	O
other	O
CNS	B-group
depressant	I-group
drugs	E-group
,	O
and	O
cautioned	O
that	O
the	O
effect	O
of	O
alcohol	S-drug
may	O
be	O
increased	O
.	O

Additive	O
adverse	O
effects	O
resulting	O
from	O
cholinergic	O
blockade	O
may	O
occur	O
when	O
LEVSIN	S-brand-EF-1
is	O
administered	O
concomitantly	O
with	O
other	O
antimuscarinics	S-group-EF-2
,	O
amantadine	S-drug-EF-2
,	O
haloperidol	S-drug-EF-2
,	O
phenothiazines	S-group-EF-2
,	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
(	I-group-EF-2
MAO	I-group-EF-2
)	I-group-EF-2
inhibitors	E-group-EF-2
,	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
or	O
some	O
antihistamines	S-group-EF-2
.	O

Antacids	S-group-ME-1
may	O
interfere	O
with	O
the	O
absorption	O
of	O
LEVSIN	S-brand-ME-2
.	O

Administer	O
LEVSIN	S-brand
before	O
meals	O
;	O

antacids	S-group
after	O
meals	O
.	O

Calcium	S-drug
Supplements	O
/	O
Antacids	S-group

Products	O
containing	O
calcium	S-drug-ME-1
and	O
other	O
multivalent	O
cations	O
(	O
such	O
as	O
aluminum	S-drug-ME-1
,	O
magnesium	S-drug-ME-1
,	O
iron	S-drug-ME-1
)	O
are	O
likely	O
to	O
interfere	O
with	O
absorption	O
of	O
Ibandronate	S-drug-ME-2
.	O

Ibandronate	S-drug-AD-1
should	O
be	O
taken	O
at	O
least	O
60	O
minutes	O
before	O
any	O
oral	O
medications	O
containing	O
multivalent	O
cations	O
(	O
including	O
antacids	S-group-AD-2
,	O
supplements	O
or	O
vitamins	S-group-AD-2
)	O
.	O

H2	B-group
Blockers	E-group
and	O
Proton	B-group
Pump	I-group
Inhibitors	E-group
(	O
PPIs	S-group
)	O

Of	O
over	O
3500	O
patients	O
enrolled	O
in	O
the	O
Ibandronate	S-drug
osteoporosis	O
Treatment	O
and	O
Prevention	O
Studies	O
,	O
15	O
%	O
used	O
anti	O
-	O
peptic	O
agents	O
(	O
primarily	O
H2	B-group
blockers	E-group
and	O
PPIs	S-group
)	O
.	O

Among	O
these	O
patients	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	S-drug
was	O
similar	O
to	O
that	O
in	O
placebo	O
-	O
treated	O
patients	O
.	O

Similarly	O
,	O
of	O
over	O
1600	O
patients	O
enrolled	O
in	O
a	O
study	O
comparing	O
once	O
-	O
monthly	O
with	O
daily	O
dosing	O
regimens	O
of	O
ibandronate	S-drug
,	O
14	O
%	O
of	O
patients	O
used	O
anti	O
-	O
peptic	O
agents	O
.	O

Among	O
these	O
patients	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	S-drug
150	O
mg	O
once	O
monthly	O
was	O
similar	O
to	O
that	O
in	O
patients	O
treated	O
with	O
Ibandronate	S-drug
2.5	O
mg	O
once	O
daily	O
.	O

Aspirin	S-brand
/	O
Nonsteroidal	B-group
Antiinflammatory	I-group
Drugs	O
(	O
NSAIDs	S-group
)	O

In	O
the	O
large	O
,	O
placebo	O
-	O
controlled	O
osteoporosis	O
Treatment	O
Study	O
,	O
aspirin	S-brand
and	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drugs	E-group
were	O
taken	O
by	O
62	O
%	O
of	O
the	O
2946	O
patients	O
.	O

Among	O
aspirin	S-brand
or	O
NSAID	S-group
users	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
ibandronate	S-drug
2.5	O
mg	O
daily	O
(	O
28.9	O
%	O
)	O
was	O
similar	O
to	O
that	O
in	O
placebo	O
-	O
treated	O
patients	O
(	O
30.7	O
%	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
1	O
-	O
year	O
monthly	O
comparison	O
study	O
,	O
aspirin	S-brand
and	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drugs	E-group
were	O
taken	O
by	O
39	O
%	O
of	O
the	O
1602	O
patients	O
.	O

The	O
incidence	O
of	O
upper	O
gastrointestinal	O
events	O
in	O
patients	O
concomitantly	O
taking	O
aspirin	S-brand
or	O
NSAIDs	S-group
was	O
similar	O
in	O
patients	O
taking	O
ibandronate	S-drug
2.5	O
mg	O
daily	O
(	O
21.7	O
%	O
)	O
and	O
150	O
mg	O
once	O
monthly	O
(	O
22.0	O
%	O
)	O
.	O

However	O
,	O
since	O
aspirin	S-brand
,	O
NSAIDs	S-group
,	O
and	O
bisphosphonates	S-group
are	O
all	O
associated	O
with	O
gastrointestinal	O
irritation	O
,	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
concomitant	O
use	O
of	O
aspirin	S-brand-AD-1
or	O
NSAIDs	S-group-AD-1
with	O
Ibandronate	S-drug-AD-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O

Bisphosphonates	S-group
are	O
known	O
to	O
interfere	O
with	O
the	O
use	O
of	O
bone	O
-	O
imaging	O
agents	O
.	O

Specific	O
studies	O
with	O
ibandronate	S-drug
have	O
not	O
been	O
performed	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
ZEVALIN	S-brand
.	O

Due	O
to	O
the	O
frequent	O
occurrence	O
of	O
severe	O
and	O
prolonged	O
thrombocytopenia	O
,	O
the	O
potential	O
benefits	O
of	O
medications	O
which	O
interfere	O
with	O
platelet	O
function	O
and	O
/	O
or	O
anticoagulation	O
should	O
be	O
weighed	O
against	O
the	O
potential	O
increased	O
risks	O
of	O
bleeding	O
and	O
hemorrhage	O
.	O

Patients	O
receiving	O
medications	O
that	O
interfere	O
with	O
platelet	O
function	O
or	O
coagulation	O
should	O
have	O
more	O
frequent	O
laboratory	O
monitoring	O
for	O
thrombocytopenia	O
.	O

In	O
addition	O
,	O
the	O
transfusion	O
practices	O
for	O
such	O
patients	O
may	O
need	O
to	O
be	O
modified	O
given	O
the	O
increased	O
risk	O
of	O
bleeding	O
.	O

Patients	O
in	O
clinical	O
studies	O
were	O
prohibited	O
from	O
receiving	O
growth	O
factor	O
treatment	O
for	O
2	O
weeks	O
prior	O
to	O
the	O
ZEVALIN	S-brand
therapeutic	O
regimen	O
as	O
well	O
as	O
for	O
2	O
weeks	O
following	O
completion	O
of	O
the	O
regimen	O
.	O

Coumarin	B-group
-	I-group
Type	I-group
Anticoagulants	E-group
:	O
Several	O
short	O
-	O
term	O
controlled	O
studies	O
failed	O
to	O
wshow	O
that	O
ibuprofen	S-drug
significantly	O
affected	O
prothrombin	O
times	O
or	O
a	O
variety	O
of	O
other	O
clotting	O
factors	O
when	O
administered	O
to	O
individuals	O
on	O
coumarin	B-group
-	I-group
type	I-group
anticoagulants	E-group
.	O

However	O
,	O
because	O
bleeding	O
has	O
been	O
reported	O
when	O
ibuprofen	S-drug-EF-1
and	O
other	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
agents	E-group-EF-1
have	O
been	O
administered	O
to	O
patients	O
on	O
coumarin	B-group-EF-2
-	I-group-EF-2
type	I-group-EF-2
anticoagulants	E-group-EF-2
,	O
the	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
ibuprofen	S-drug-AD-1
to	O
patients	O
on	O
anticoagulants	S-group-AD-2
.	O

Aspirin	S-brand
:	O
Animal	O
studies	O
wshow	O
that	O
aspirin	S-brand-EF-1
given	O
with	O
nonsteroidal	B-group-EF-2
anti	I-group-EF-2
-	I-group-EF-2
inflammatory	I-group-EF-2
agents	E-group-EF-2
,	O
including	O
ibuprofen	S-drug-EF-2
,	O
yields	O
a	O
net	O
decrease	O
in	O
anti	O
-	O
inflammatory	O
activity	O
with	O
lowered	O
blood	O
levels	O
of	O
the	O
non	O
-	O
aspirin	O
drug	O
.	O

Single	O
dose	O
bioavailability	O
studies	O
in	O
normal	O
volunteers	O
have	O
failed	O
to	O
wshow	O
an	O
effect	O
of	O
aspirin	S-brand
on	O
ibuprofen	S-drug
blood	O
levels	O
.	O

Correlative	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
.	O

Methotrexate	S-drug
:	O
Ibuprofen	S-drug-ME-1
,	O
as	O
well	O
as	O
other	O
nonsteroidal	B-group-ME-1
anti	I-group-ME-1
-	I-group-ME-1
inflammatory	I-group-ME-1
drugs	E-group-ME-1
,	O
probably	O
reduces	O
the	O
tubular	O
secretion	O
of	O
methotrexate	S-drug-ME-2
based	O
on	O
in	O
vitro	O
studies	O
in	O
rabbit	O
kidney	O
slices	O
.	O

This	O
may	O
indicate	O
that	O
ibuprofen	S-drug-EF-1
could	O
enhance	O
the	O
toxicity	O
of	O
methotrexate	S-drug-EF-2
.	O

Caution	O
should	O
be	O
used	O
if	O
ibuprofen	S-drug-AD-1
is	O
administered	O
concomitantly	O
with	O
methotrexate	S-drug-AD-2
.	O

H	O
-	O
2	O
Antagonists	O
:	O
In	O
studies	O
with	O
human	O
volunteers	O
,	O
co	O
-	O
administration	O
of	O
cimetidine	S-drug
or	O
ranitidine	S-drug
with	O
ibuprofen	S-drug
had	O
no	O
substantive	O
effect	O
on	O
ibuprofen	S-drug
serum	O
concentrations	O
.	O

Furosemide	S-drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
random	O
observations	O
,	O
have	O
shown	O
that	O
ibuprofen	S-drug-EF-1
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	S-drug-EF-2
and	O
thiazides	S-group-EF-2
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

During	O
concomitant	O
therapy	O
with	O
ibuprofen	S-drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	S-group
efficacy	O
.	O

Lithium	S-drug
:	O
Ibuprofen	S-drug-ME-1
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	S-drug-ME-2
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	S-drug
clearance	O
in	O
a	O
study	O
of	O
eleven	O
normal	O
volunteers	O
.	O

The	O
mean	O
minimum	O
lithium	S-drug
concentration	O
increased	O
15	O
%	O
and	O
the	O
renal	O
clearance	O
of	O
lithium	S-drug
was	O
decreased	O
by	O
19	O
%	O
during	O
this	O
period	O
of	O
concomitant	O
drug	O
administration	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
ibuprofen	S-drug
.	O

Thus	O
,	O
when	O
ibuprofen	S-drug-AD-1
and	O
lithium	S-drug-AD-2
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	S-drug
toxicity	O
.	O

(	O
Read	O
circulars	O
for	O
lithium	S-drug
preparation	O
before	O
use	O
of	O
such	O
concurrent	O
therapy	O
)	O
.	O

No	O
specific	O
pharmacokinetic	O
or	O
other	O
formal	O
drug	O
interaction	O
studies	O
were	O
conducted	O
.	O

Digoxin	S-drug
:	O
Supraventricular	O
arrhythmias	O
may	O
mask	O
the	O
cardiotoxicity	O
associated	O
with	O
excessive	O
digoxin	S-drug
levels	O
.	O

Therefore	O
,	O
it	O
is	O
advisable	O
to	O
be	O
particularly	O
cautious	O
in	O
patients	O
whose	O
plasma	O
digoxin	S-drug
levels	O
are	O
above	O
or	O
suspected	O
to	O
be	O
above	O
the	O
usual	O
therapeutic	O
range	O
.	O

Coadministration	O
of	O
digoxin	S-drug
did	O
not	O
have	O
effects	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	S-drug
in	O
the	O
clinical	O
trials	O
.	O

Calcium	B-group
channel	I-group
blocking	I-group
agents	E-group
:	O
Coadministration	O
of	O
calcium	B-group
channel	I-group
blockers	E-group
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	S-drug
in	O
the	O
clinical	O
trials	O
.	O

Beta	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
:	O
Coadministration	O
of	O
beta	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	S-drug
in	O
the	O
clinical	O
trials	O
.	O

General	O
No	O
clinical	O
drug	O
interaction	O
studies	O
were	O
performed	O
.	O

No	O
evaluation	O
of	O
EXTRANEALs	O
effects	O
on	O
the	O
cytochrome	O
P450	O
system	O
was	O
conducted	O
.	O

As	O
with	O
other	O
dialysis	B-group
solutions	E-group
,	O
blood	O
concentrations	O
of	O
dialyzable	O
drugs	O
may	O
be	O
reduced	O
by	O
dialysis	O
.	O

Dosage	O
adjustment	O
of	O
concomitant	O
medications	O
may	O
be	O
necessary	O
.	O

In	O
patients	O
using	O
cardiac	B-group
glycosides	E-group
(	O
digoxin	S-drug
and	O
others	O
)	O
,	O
plasma	O
levels	O
of	O
calcium	O
,	O
potassium	O
and	O
magnesium	O
must	O
be	O
carefully	O
monitored	O
.	O

Insulin	S-drug
:	O
A	O
clinical	O
study	O
in	O
6	O
insulin	O
-	O
dependent	O
diabetic	O
patients	O
demonstrated	O
no	O
effect	O
of	O
EXTRANEAL	S-brand
on	O
insulin	S-drug
absorption	O
from	O
the	O
peritoneal	O
cavity	O
or	O
on	O
insulins	O
ability	O
to	O
control	O
blood	O
glucose	O
when	O
insulin	S-drug
was	O
administered	O
intraperitoneally	O
with	O
EXTRANEAL	S-brand
.	O

However	O
,	O
appropriate	O
monitoring	O
of	O
blood	O
glucose	O
should	O
be	O
performed	O
when	O
initiating	O
EXTRANEAL	S-brand-AD-1
in	O
diabetic	O
patients	O
and	O
insulin	S-drug-AD-2
dosage	O
should	O
be	O
adjusted	O
if	O
needed	O
.	O

Heparin	S-drug
:	O
No	O
human	O
drug	O
interaction	O
studies	O
with	O
heparin	S-drug
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
heparin	S-drug
with	O
EXTRANEAL	S-brand
.	O

Antibiotics	S-group
:	O
No	O
human	O
drug	O
interaction	O
studies	O
with	O
antibiotics	S-group
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
evaluating	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
vancomycin	S-drug
,	O
cefazolin	S-drug
,	O
ampicillin	S-drug
,	O
ampicillin	S-drug
/	O
flucoxacillin	O
,	O
ceftazidime	S-drug
,	O
gentamicin	S-drug
,	O
and	O
amphotericin	S-drug
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
these	O
antibiotics	S-group
with	O
EXTRANEAL	S-brand
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Blood	O
Glucose	O
Blood	O
glucose	O
measurement	O
must	O
be	O
done	O
with	O
a	O
glucose	O
-	O
specific	O
method	O
to	O
prevent	O
maltose	O
interference	O
with	O
test	O
results	O
.	O

Since	O
falsely	O
elevated	O
glucose	O
levels	O
have	O
been	O
observed	O
with	O
blood	O
glucose	O
monitoring	O
devices	O
and	O
test	O
strips	O
that	O
use	O
glucose	O
dehydrogenase	O
pyrroloquinolinequinone	O
(	O
GDH	O
PQQ	O
)	O
-	O
based	O
methods	O
,	O
GDH	O
PQQ	O
-	O
based	O
methods	O
should	O
not	O
be	O
used	O
to	O
measure	O
glucose	O
levels	O
in	O
patients	O
administered	O
EXTRANEAL..	O

Serum	O
Amylase	O
An	O
apparent	O
decrease	O
in	O
serum	O
amylase	O
activity	O
has	O
been	O
observed	O
in	O
patients	O
administered	O
EXTRANEAL	S-brand
.	O

Preliminary	O
investigations	O
indicate	O
that	O
icodextrin	S-drug
and	O
its	O
metabolites	O
interfere	O
with	O
enzymatic	O
-	O
based	O
amylase	O
assays	O
,	O
resulting	O
in	O
inaccurately	O
low	O
values	O
.	O

This	O
should	O
be	O
taken	O
into	O
account	O
when	O
evaluating	O
serum	O
amylase	O
levels	O
for	O
diagnosis	O
or	O
monitoring	O
of	O
pancreatitis	O
in	O
patients	O
using	O
EXTRANEAL	S-brand
.	O

Interactions	O
may	O
occur	O
between	O
EPA	S-drug-IN-1
supplements	O
and	O
aspirin	S-brand-IN-2
and	O
other	O
non	B-group-IN-2
-	I-group-IN-2
steroidal	I-group-IN-2
anti	I-group-IN-2
-	I-group-IN-2
inflammatory	I-group-IN-2
drugs	E-group-IN-2
and	O
herbs	O
such	O
as	O
garlic	O
(	O
Allium	O
sativum	O
)	O
and	O
ginkgo	S-drug-IN-2
(	O
Ginkgo	B-drug-IN-2
biloba	E-drug-IN-2
)	O
.	O

Such	O
interactions	O
might	O
be	O
manifested	O
by	O
increased	O
susceptibility	O
to	O
bruising	O
,	O
nosebleeds	O
,	O
hemoptysis	O
,	O
hematemesis	O
,	O
hematuria	O
and	O
blood	O
in	O
the	O
stool	O
.	O

Most	O
who	O
take	O
EPA	S-drug
supplements	O
and	O
the	O
above	O
drugs	O
or	O
herbs	O
do	O
not	O
suffer	O
from	O
these	O
problems	O
and	O
if	O
they	O
occur	O
,	O
they	O
are	O
rare	O
.	O

If	O
they	O
do	O
occur	O
,	O
the	O
EPA	S-drug
dose	O
should	O
be	O
lowered	O
or	O
discontinued	O
.	O

Conflicting	O
results	O
have	O
been	O
reported	O
regarding	O
the	O
effects	O
of	O
EPA	S-drug
supplements	O
on	O
glycemic	O
control	O
in	O
non	O
-	O
diabetics	O
with	O
glucose	O
intolerance	O
,	O
and	O
those	O
with	O
type	O
2	O
diabetes	O
.	O

Some	O
early	O
studies	O
indicated	O
that	O
EPA	S-drug
supplements	O
might	O
have	O
detrimental	O
effects	O
in	O
those	O
groups	O
.	O

Recent	O
,	O
better	O
designed	O
studies	O
have	O
not	O
reported	O
these	O
adverse	O
effects	O
.	O

There	O
is	O
no	O
evidence	O
that	O
EPA	S-drug
supplements	O
have	O
detrimental	O
effects	O
on	O
glucose	O
tolerance	O
,	O
insulin	O
secretion	O
or	O
insulin	O
resistance	O
in	O
non	O
-	O
diabetic	O
subjects	O
.	O

Diabetics	O
should	O
discuss	O
the	O
use	O
of	O
these	O
supplements	O
with	O
their	O
physicians	O
and	O
note	O
if	O
the	O
supplements	O
affect	O
their	O
glycemic	O
control	O
.	O

Diabetics	O
who	O
take	O
EPA	S-drug
supplements	O
should	O
be	O
monitored	O
by	O
their	O
physicians	O
.	O

Other	O
medicines	O
-	O
Although	O
certain	O
medicines	O
should	O
not	O
be	O
used	O
together	O
at	O
all	O
,	O
in	O
other	O
cases	O
two	O
different	O
medicines	O
may	O
be	O
used	O
together	O
even	O
if	O
an	O
interaction	O
might	O
occur	O
.	O

In	O
these	O
cases	O
,	O
your	O
doctor	O
may	O
want	O
to	O
change	O
the	O
dose	O
,	O
or	O
other	O
precautions	O
may	O
be	O
necessary	O
.	O

When	O
you	O
are	O
using	O
idoxuridine	S-drug-AD-1
,	O
it	O
is	O
especially	O
important	O
that	O
your	O
health	O
care	O
professional	O
know	O
if	O
you	O
are	O
using	O
the	O
following	O
:	O
Eye	O
product	O
containing	O
boric	B-drug-AD-2
acid	E-drug-AD-2
.	O

Boric	B-drug-ME-1
acid	E-drug-ME-1
may	O
interact	O
with	O
the	O
idoxuridine	S-drug-ME-2
preparation	O
causing	O
a	O
gritty	O
substance	O
to	O
form	O
or	O
may	O
interact	O
with	O
the	O
preservative	O
in	O
the	O
idoxuridine	S-drug
preparation	O
causing	O
a	O
toxic	O
effect	O
in	O
the	O
eye	O
.	O

The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	O
actions	O
,	O
desirable	O
or	O
undesirable	O
,	O
involving	O
ifosfamide	S-drug
even	O
though	O
ifosfamide	S-drug
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	O
,	O
including	O
other	O
cytotoxic	O
drugs	O
.	O

In	O
studies	O
in	O
normal	O
volunteers	O
,	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
between	O
intravenous	O
iloprost	S-drug
and	O
either	O
nifedipine	S-drug
,	O
diltiazem	S-drug
,	O
or	O
captopril	S-drug
.	O

However	O
,	O
iloprost	S-drug-EF-1
has	O
the	O
potential	O
to	O
increase	O
the	O
hypotensive	O
effect	O
of	O
vasodilators	S-group-EF-2
and	O
antihypertensive	B-group-EF-2
agents	E-group-EF-2
.	O

Since	O
iloprost	S-drug-EF-1
inhibits	O
platelet	O
function	O
,	O
there	O
is	O
a	O
potential	O
for	O
increased	O
risk	O
of	O
bleeding	O
,	O
particularly	O
in	O
patients	O
maintained	O
on	O
anticoagulants	S-group-EF-2
.	O

During	O
clinical	O
trials	O
,	O
iloprost	S-drug
was	O
used	O
concurrently	O
with	O
anticoagulants	S-group
,	O
diuretics	S-group
,	O
cardiac	B-group
glycosides	E-group
,	O
calcium	B-group
channel	I-group
blockers	E-group
,	O
analgesics	S-group
,	O
antipyretics	S-group
,	O
nonsteroidal	B-group
antiinflammatories	E-group
,	O
corticosteroids	S-group
,	O
and	O
other	O
medications	O
.	O

Intravenous	O
infusion	O
of	O
iloprost	S-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
.	O

Acetylsalicylic	B-drug
acid	E-drug
did	O
not	O
alter	O
the	O
clearance	O
(	O
pharmacokinetics	O
)	O
of	O
iloprost	S-drug
.	O

Although	O
clinical	O
studies	O
have	O
not	O
been	O
conducted	O
,	O
in	O
vitro	O
studies	O
of	O
iloprost	S-drug
indicate	O
that	O
no	O
relevant	O
inhibition	O
of	O
cytochrome	O
P450	O
drug	O
metabolism	O
would	O
be	O
expected	O
.	O

Drugs	O
that	O
may	O
alter	O
imatinib	S-drug
plasma	O
concentrations	O
Drugs	O
that	O
may	O
increase	O
imatinib	S-drug
plasma	O
concentrations	O
:	O
Caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	S-brand-AD-1
with	O
inhibitors	O
of	O
the	O
CYP3A4	O
family	O
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug-AD-2
,	O
itraconazole	S-drug-AD-2
,	O
erythromycin	S-drug-AD-2
,	O
clarithromycin	S-drug-AD-2
)	O
.	O

Substances	O
that	O
inhibit	O
the	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP3A4	O
)	O
activity	O
may	O
decrease	O
metabolism	O
and	O
increase	O
imatinib	S-drug
concentrations	O
.	O

There	O
is	O
a	O
significant	O
increase	O
in	O
exposure	O
to	O
imatinib	S-drug
when	O
Gleevec	S-brand-ME-1
is	O
coadministered	O
with	O
ketoconazole	S-drug-ME-2
(	O
CYP3A4	O
inhibitor	O
)	O
.	O

Drugs	O
that	O
may	O
decrease	O
imatinib	S-drug
plasma	O
concentrations	O
:	O
Substances	O
that	O
are	O
inducers	O
of	O
CYP3A4	O
activity	O
may	O
increase	O
metabolism	O
and	O
decrease	O
imatinib	S-drug
plasma	O
concentrations	O
.	O

Co	O
-	O
medications	O
that	O
induce	O
CYP3A4	O
(	O
e.g	O
.	O
,	O
dexamethasone	S-drug
,	O
phenytoin	S-drug
,	O
carbamazepine	S-drug
,	O
rifampin	S-drug
,	O
phenobarbital	S-drug
or	O
St	O
.	O

Johns	O
Wort	O
)	O
may	O
significantly	O
reduce	O
exposure	O
to	O
Gleevec	S-brand
.	O

Pretreatment	O
of	O
healthy	O
volunteers	O
with	O
multiple	O
doses	O
of	O
rifampin	S-drug-ME-1
followed	O
by	O
a	O
single	O
dose	O
of	O
Gleevec	S-brand-ME-2
,	O
increased	O
Gleevec	S-brand
oral	O
-	O
dose	O
clearance	O
by	O
3.8	O
-	O
fold	O
,	O
which	O
significantly	O
(	O
p	O
0.05	O
)	O
decreased	O
mean	O
cmax	O
and	O
AUC	O
(	O
0	O
-	O
8	O
)	O
.	O

In	O
patients	O
where	O
rifampin	S-drug
or	O
other	O
CYP3A4	O
inducers	O
are	O
indicated	O
,	O
alternative	O
therapeutic	O
agents	O
with	O
less	O
enzyme	O
induction	O
potential	O
should	O
be	O
considered	O
.	O

Drugs	O
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
Gleevec	S-brand
Gleevec	S-brand-ME-1
increases	O
the	O
mean	O
cmax	O
and	O
AUC	O
of	O
simvastatin	S-drug-ME-2
(	O
CYP3A4	O
substrate	O
)	O
2	O
-	O
and	O
3.5	O
-	O
fold	O
,	O
respectively	O
,	O
suggesting	O
an	O
inhibition	O
of	O
the	O
CYP3A4	O
by	O
Gleevec	S-brand
.	O

Particular	O
caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	S-brand-AD-1
with	O
CYP3A4	O
substrates	O
that	O
have	O
a	O
narrow	O
therapeutic	O
window	O
(	O
e.g	O
.	O
,	O
cyclosporine	S-drug-AD-2
or	O
pimozide	S-drug-AD-2
)	O
.	O

Gleevec	S-brand-ME-1
will	O
increase	O
plasmaconcentration	O
of	O
other	O
CYP3A4	O
metabolized	O
drugs	O
(	O
e.g	O
.	O
,	O
triazolo	O
-	O
benzodiazepines	S-group-ME-2
,	O
dihydropyridine	B-group-ME-2
calcium	I-group-ME-2
channel	I-group-ME-2
blockers	E-group-ME-2
,	O
certain	O
HMG	B-group-ME-2
-	I-group-ME-2
CoA	I-group-ME-2
reductase	I-group-ME-2
inhibitors	E-group-ME-2
,	O
etc	O
.	O
)	O
.	O

Because	O
warfarin	S-drug
is	O
metabolized	O
by	O
CYP2C9	O
and	O
CYP3A4	O
,	O
patients	O
who	O
require	O
anticoagulation	O
should	O
receive	O
low	O
-	O
molecular	O
weight	O
or	O
standard	O
heparin	S-drug
.	O

in	O
vitro	O
,	O
Gleevec	S-brand
inhibits	O
the	O
cytochrome	O
P450	O
isoenzyme	O
CYP2D6	O
activity	O
at	O
similar	O
concentrations	O
that	O
affect	O
CYP3A4	O
activity	O
.	O

Systemic	O
exposure	O
to	O
substrates	O
of	O
CYP2D6	O
is	O
expected	O
to	O
be	O
increased	O
when	O
coadministered	O
with	O
Gleevec	O
.	O

No	O
specific	O
studies	O
have	O
been	O
performed	O
and	O
caution	O
is	O
recommended	O
.	O

in	O
vitro	O
,	O
Gleevec	S-brand
inhibits	O
acetaminophen	O
O	O
-	O
glucuronidation	O
(	O
Ki	O
value	O
of	O
58.5	O
M	O
)	O
at	O
therapeutic	O
levels	O
.	O

Systemic	O
exposure	O
to	O
acetaminophen	S-drug-ME-1
is	O
expected	O
to	O
be	O
increased	O
when	O
coadministered	O
with	O
Gleevec	S-brand-ME-2
.	O

No	O
specific	O
studies	O
in	O
humans	O
have	O
been	O
performed	O
and	O
caution	O
is	O
recommended	O
.	O

In	O
occasional	O
susceptible	O
patients	O
or	O
in	O
those	O
receiving	O
anticholinergic	B-group
drugs	E-group
(	O
including	O
antiparkinsonism	O
agents	O
)	O
in	O
addition	O
,	O
the	O
atropine	O
-	O
like	O
effects	O
may	O
become	O
more	O
pronounced	O
(	O
e.g	O
.	O
,	O
paralytic	O
ileus	O
)	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
is	O
required	O
when	O
this	O
drug	O
is	O
administered	O
concomitantly	O
with	O
anticholinergic	B-group
drugs	E-group
.	O

Avoid	O
the	O
use	O
of	O
preparations	O
such	O
as	O
decongestants	S-group-AD-1
and	O
local	O
anesthetics	S-group-AD-1
which	O
contain	O
any	O
sympathomimetic	B-group-AD-1
amine	E-group-AD-1
(	O
e.g	O
.	O
,	O
epinephrine	S-drug-AD-1
,	O
norepinephrine	S-drug-AD-1
)	O
,	O
since	O
it	O
has	O
been	O
reported	O
that	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
can	O
potentiate	O
the	O
effects	O
of	O
catecholamines	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
imipramine	B-drug
hydrochloride	E-drug
is	O
used	O
with	O
agents	O
that	O
lower	O
blood	O
pressure	O
.	O

Imipramine	B-drug-EF-1
hydrochloride	E-drug-EF-1
may	O
potentiate	O
the	O
effects	O
of	O
CNS	B-group-EF-2
depressant	I-group-EF-2
drugs	E-group-EF-2
.	O

The	O
plasma	O
concentration	O
of	O
imipramine	S-drug-ME-1
may	O
increase	O
when	O
the	O
drug	O
is	O
given	O
concomitantly	O
with	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e.g	O
.	O
,	O
cimetidine	S-drug-ME-2
,	O
fluoxetine	S-drug-ME-2
)	O
and	O
decrease	O
by	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e.g	O
.	O
,	O
barbiturates	S-group-ME-2
,	O
phenytoin	S-drug-ME-2
)	O
,	O
and	O
adjustment	O
of	O
the	O
dosage	O
of	O
imipramine	S-drug
may	O
therefore	O
be	O
necessary	O
.	O

Drugs	O
Metabolized	O
by	O
P450	O
2D6	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7	O
to	O
10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O

reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-group
antidepressants	E-group
(	O
TCAs	S-group
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
-	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	S-group
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O

metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	S-group
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	S-drug
;	O

cimetidine	S-drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	S-group
,	O
phenothiazines	S-group
,	O
and	O
the	O
Type	B-group
1C	I-group
antiarrhythmics	E-group
propafenone	S-drug
and	O
flecainide	S-drug
)	O
.	O

While	O
all	O
the	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
(	O
SSRIs	S-group
)	O
,	O
e.	O
g.	O
,	O
fluoxetine	S-drug
,	O
sertraline	S-drug
,	O
and	O
paroxetine	S-drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	S-group-IN-1
-	O
TCA	S-group-IN-2
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
,	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	S-group
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCA5	O
with	O
any	O
of	O
the	O
SSRIs	S-group
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	S-drug
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B-group
antidepressants	E-group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-group
antidepressant	E-group
or	O
the	O
other	O
drug	O
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	O
is	O
withdrawn	O
from	O
cotherapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-group
antidepressant	E-group
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	S-group
plasma	O
levels	O
whenever	O
a	O
TCA	S-group
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

No	O
information	O
available	O

Indinavir	S-drug
is	O
an	O
inhibitor	O
of	O
the	O
cytochrome	O
P450	O
isoform	O
CYP3A4	O
.	O

Coadministration	O
of	O
CRIXIVAN	S-brand
and	O
drugs	O
primarily	O
metabolized	O
by	O
CYP3A4	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
other	O
drug	O
,	O
which	O
could	O
increase	O
or	O
prolong	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Indinavir	S-drug
is	O
metabolized	O
by	O
CYP3A4	O
.	O

Drugs	O
that	O
induce	O
CYP3A4	O
activity	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
indinavir	S-drug
,	O
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
of	O
indinavir	S-drug
.	O

Coadministration	O
of	O
CRIXIVAN	S-brand
and	O
other	O
drugs	O
that	O
inhibit	O
CYP3A4	O
may	O
decrease	O
the	O
clearance	O
of	O
indinavir	S-drug
and	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
indinavir	S-drug
.	O

Table	O
8	O

Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
with	O
CRIXIVAN	S-brand

Drug	O
Class	O
:	O
Drug	O
Name	O
Clinical	O
Comment	O

Antiarrhythmics	S-group
:	O
amiodarone	S-drug

CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Ergot	O
derivatives	O
:	O
dihydroergotamine	S-drug
,	O
ergonovine	S-drug
,	O
ergotamine	S-drug
,	O
methylergonovine	S-drug

CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
peripheral	O
vasospasm	O
and	O
ischemia	O
of	O
the	O
extremities	O
and	O
other	O
tissues	O
.	O

Sedative	S-group
/	O
hypnotics	S-group
:	O
midazolam	S-drug
,	O
triazolam	S-drug

CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
prolonged	O
or	O
increased	O
sedation	O
or	O
respiratory	O
depression	O
.	O

GI	O
motility	O
agents	O
:	O
cisapride	S-drug

CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Neuroleptic	S-group
:	O
pimozide	S-drug

CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Herbal	O
products	O
:	O
St.	O
John	O
s	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O

May	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	S-brand
or	O
to	O
the	O
class	O
of	O
protease	B-group
inhibitors	E-group
.	O

Antimycobacterial	S-group
:	O
rifampin	S-drug

May	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	S-brand
or	O
to	O
the	O
class	O
of	O
protease	B-group
inhibitors	E-group
or	O
other	O
coadministered	O
antiretroviral	B-group
agents	E-group
.	O

HMG	B-group
-	I-group
CoA	I-group
Reductase	I-group
inhibitors	E-group
:	O
lovastatin	S-drug
,	O
simvastatin	S-drug

Potential	O
for	O
serious	O
reactions	O
such	O
as	O
risk	O
of	O
myopathy	O
including	O
rhabdomyolysis	O
.	O

Protease	B-group
inhibitor	E-group
:	O
atazanavir	S-drug

Both	O
CRIXIVAN	S-brand
and	O
atazanavir	S-drug
are	O
associated	O
with	O
indirect	O
(	O
unconjugated	O
)	O
hyperbilirubinemia	O
.	O

Combinations	O
of	O
these	O
drugs	O
have	O
not	O
been	O
studied	O
and	O
coadministration	O
of	O
CRIXIVAN	S-brand-AD-1
and	O
atazanavir	S-drug-AD-2
is	O
not	O
recommended	O
.	O

Table	O
9	O

Established	O
and	O
Other	O
Potentially	O
Significant	O
Drug	O
Interactions	O
:	O
Alteration	O
in	O
Dose	O
or	O
Regimen	O
May	O
Be	O
Recommended	O
Based	O
on	O
Drug	O
Interaction	O
Studies	O
or	O
Predicted	O
Interaction	O

Drug	O
Name	O

Clinical	O
Comment	O

HIV	B-group
Antiviral	I-group
Agents	E-group

indinavir	S-drug
concentration	O

Dose	O
reduction	O
of	O
CRIXIVAN	S-brand-AD-1
to	O
600	O
mg	O
every	O
8	O
hours	O
should	O
be	O
considered	O
when	O
taking	O
delavirdine	S-drug-AD-2
400	O
mg	O
three	O
times	O
a	O
day	O
.	O

Indinavir	S-drug-AD-1
and	O
didanosine	S-drug-AD-2
formulations	O
containing	O
buffer	O
should	O
be	O
administered	O
at	O
least	O
one	O
hour	O
apart	O
on	O
an	O
empty	O
stomach	O
.	O

indinavir	S-drug
concentration	O

The	O
optimal	O
dose	O
of	O
indinavir	S-drug
,	O
when	O
given	O
in	O
combination	O
with	O
efavirenz	S-drug
,	O
is	O
not	O
known	O
.	O

Increasing	O
the	O
indinavir	S-drug
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	S-drug-ME-1
metabolism	O
due	O
to	O
efavirenz	S-drug-ME-2
.	O

indinavir	S-drug
concentration	O

The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

indinavir	S-drug
concentration	O

Indinavir	S-drug-ME-1
concentrations	O
may	O
be	O
decreased	O
in	O
the	O
presence	O
of	O
nevirapine	S-drug-ME-2
.	O

The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

indinavir	S-drug
concentration	O
ritonavir	S-drug
concentration	O

The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

Preliminary	O
clinical	O
data	O
suggest	O
that	O
the	O
incidence	O
of	O
nephrolithiasis	O
is	O
higher	O
in	O
patients	O
receiving	O
indinavir	S-drug-EF-1
in	O
combination	O
with	O
ritonavir	S-drug-EF-2
than	O
those	O
receiving	O
CRIXIVAN	S-brand
800	O
mg	O
q8h	O
.	O

saquinavir	S-drug
concentration	O

The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

Other	O
Agents	O

Antiarrhythmics	S-group
:	O
bepridil	S-drug
,	O
lidocaine	S-drug
(	O
systemic	O
)	O
and	O
quinidine	S-drug

antiarrhythmic	B-group
agents	E-group
concentration	O

Caution	O
is	O
warranted	O
and	O
therapeutic	O
concentration	O
monitoring	O
is	O
recommended	O
for	O
antiarrhythmics	S-group-AD-1
when	O
coadministered	O
with	O
CRIXIVAN	S-brand-AD-2
.	O

Anticonvulsants	S-group
:	O
carbamazepine	S-drug
,	O
phenobarbital	S-drug
,	O
phenytoin	S-drug

indinavir	S-drug
concentration	O

Use	O
with	O
caution	O
.	O

CRIXIVAN	S-brand-EF-1
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
indinavir	S-drug-EF-2
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O
.	O

Calcium	B-group
Channel	I-group
Blockers	E-group
,	O
Dihydropyridine	S-group
:	O
e.g	O
.	O
,	O
felodipine	S-drug
,	O
nifedipine	S-drug
,	O
nicardipine	S-drug

dihydropyridine	B-group
calcium	I-group
channel	I-group
blockers	E-group
concentration	O

Caution	O
is	O
warranted	O
and	O
clinical	O
monitoring	O
of	O
patients	O
is	O
recommended	O
.	O

clarithromycin	S-drug
concentration	O
indinavir	S-drug
concentration	O

The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

HMG	B-group
-	I-group
CoA	I-group
Reductase	I-group
Inhibitor	E-group
:	O
atorvastatin	S-drug

atorvastatin	S-drug
concentration	O

Use	O
lowest	O
possible	O
dose	O
of	O
atorvastatin	S-drug-AD-1
with	O
careful	O
monitoring	O
,	O
or	O
consider	O
HMG	B-group-AD-1
-	I-group-AD-1
CoA	I-group-AD-1
reductase	I-group-AD-1
inhibitors	E-group-AD-1
that	O
are	O
not	O
primarily	O
metabolized	O
by	O
CYP3A4	O
,	O
such	O
as	O
pravastatin	S-drug
,	O
fluvastatin	S-drug
,	O
or	O
rosuvastatin	S-drug
in	O
combination	O
with	O
CRIXIVAN	S-brand-AD-2
.	O

Immunosuppressants	S-group
:	O
cyclosporine	S-drug
,	O
tacrolimus	S-drug
,	O
sirolimus	S-drug

immunosuppressant	B-group
agents	E-group
concentration	O

Plasma	O
concentrations	O
may	O
be	O
increased	O
by	O
CRIXIVAN	S-brand
.	O

indinavir	S-drug
concentration	O

Dose	O
reduction	O
of	O
CRIXIVAN	S-brand-AD-1
to	O
600	O
mg	O
every	O
8	O
hours	O
is	O
recommended	O
when	O
administering	O
itraconazole	S-drug-AD-2
concurrently	O
.	O

indinavir	S-drug
concentration	O

Dose	O
reduction	O
of	O
CRIXIVAN	S-brand
to	O
600	O
mg	O
every	O
8	O
hours	O
should	O
be	O
considered	O
.	O

indinavir	S-drug
concentration	O
rifabutin	S-drug
concentration	O

Dose	O
reduction	O
of	O
rifabutin	S-drug
to	O
half	O
the	O
standard	O
dose	O
and	O
a	O
dose	O
increase	O
of	O
CRIXIVAN	S-brand
to	O
1000	O
mg	O
(	O
three	O
333	O
-	O
mg	O
capsules	O
)	O
every	O
8	O
hours	O
are	O
recommended	O
when	O
rifabutin	S-drug-AD-1
and	O
CRIXIVAN	S-brand-AD-2
are	O
coadministered	O
.	O

sildenafil	S-drug
concentration	O

Sildenafil	S-drug-AD-1
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
25	O
mg	O
in	O
a	O
48	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	S-drug-AD-2
therapy	O
.	O

tadalafil	S-drug
concentration	O

Tadalafil	S-drug-AD-1
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
10	O
mg	O
in	O
a	O
72	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	S-drug-AD-2
therapy	O
.	O

vardenafil	S-drug
concentration	O

Vardenafil	S-drug-AD-1
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
2.5	O
mg	O
in	O
a	O
24	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	S-drug-AD-2
therapy	O
.	O

Note	O
:	O

=	O
increase	O
;	O

=	O
decrease	O

In	O
normal	O
volunteers	O
receiving	O
indomethacin	S-drug
,	O
the	O
administration	O
of	O
diflunisal	S-drug-ME-1
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	S-drug-ME-2
.	O

In	O
some	O
patients	O
,	O
combined	O
use	O
of	O
INDOCIN	S-brand-EF-1
and	O
diflunisal	S-drug-EF-2
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O

Therefore	O
,	O
diflunisal	S-drug-AD-1
and	O
INDOCIN	S-brand-AD-2
should	O
not	O
be	O
used	O
concomitantly	O
.	O

In	O
a	O
study	O
in	O
normal	O
volunteers	O
,	O
it	O
was	O
found	O
that	O
chronic	O
concurrent	O
administration	O
of	O
3.6	O
g	O
of	O
aspirin	S-brand-ME-1
per	O
day	O
decreases	O
indomethacin	S-drug-ME-2
blood	O
levels	O
approximately	O
20	O
%	O
.	O

The	O
concomitant	O
use	O
of	O
INDOCIN	S-brand-AD-1
with	O
other	O
NSAIDs	S-group-AD-2
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
,	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
INDOCIN	S-brand
does	O
not	O
influence	O
the	O
hypoprothrombinemia	O
produced	O
by	O
anticoagulants	S-group
.	O

However	O
,	O
when	O
any	O
additional	O
drug	O
,	O
including	O
INDOCIN	S-brand-AD-1
,	O
is	O
added	O
to	O
the	O
treatment	O
of	O
patients	O
on	O
anticoagulant	S-group-AD-2
therapy	O
,	O
the	O
patients	O
should	O
be	O
observed	O
for	O
alterations	O
of	O
the	O
prothrombin	O
time	O
.	O

In	O
post	O
-	O
marketing	O
experience	O
,	O
bleeding	O
has	O
been	O
reported	O
in	O
patients	O
on	O
concomitant	O
treatment	O
with	O
anticoagulants	S-group-EF-1
and	O
INDOCIN	S-brand-EF-2
.	O

Caution	O
should	O
be	O
exercised	O
when	O
INDOCIN	S-brand-AD-1
and	O
anticoagulants	S-group-AD-2
are	O
administered	O
concomitantly	O
.	O

When	O
INDOCIN	S-brand-ME-1
is	O
given	O
to	O
patients	O
receiving	O
probenecid	S-drug-ME-2
,	O
the	O
plasma	O
levels	O
of	O
indomethacin	S-drug
are	O
likely	O
to	O
be	O
increased	O
.	O

Therefore	O
,	O
a	O
lower	O
total	O
daily	O
dosage	O
of	O
INDOCIN	S-brand
may	O
produce	O
a	O
satisfactory	O
therapeutic	O
effect	O
.	O

When	O
increases	O
in	O
the	O
dose	O
of	O
INDOCIN	S-brand
are	O
made	O
,	O
they	O
should	O
be	O
made	O
carefully	O
and	O
in	O
small	O
increments	O
.	O

Caution	O
should	O
be	O
used	O
if	O
INDOCIN	S-brand-AD-1
is	O
administered	O
simultaneously	O
with	O
methotrexate	S-drug-AD-2
.	O

INDOCIN	S-brand-ME-1
has	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	S-drug-ME-2
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O

Administration	O
of	O
non	B-group-EF-1
-	I-group-EF-1
steroidal	I-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
concomitantly	O
with	O
cyclosporine	S-drug-EF-2
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine	S-drug
-	O
induced	O
toxicity	O
,	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O

NSAIDs	S-group-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	S-drug-AD-2
,	O
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O

Capsules	O
INDOCIN	S-brand-ME-1
50	O
mg	O
t.i.d	O
.	O
produced	O
a	O
clinically	O
relevant	O
elevation	O
of	O
plasma	O
lithium	S-drug-ME-2
and	O
reduction	O
in	O
renal	O
lithium	S-drug
clearance	O
in	O
psychiatric	O
patients	O
and	O
normal	O
subjects	O
with	O
steady	O
state	O
plasma	O
lithium	S-drug
concentrations	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
.	O

As	O
a	O
consequence	O
,	O
when	O
INDOCIN	S-brand-AD-1
and	O
lithium	S-drug-AD-2
are	O
given	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
carefully	O
observed	O
for	O
signs	O
of	O
lithium	S-drug
toxicity	O
.	O

(	O
Read	O
circulars	O
for	O
lithium	S-drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O
)	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
monitoring	O
serum	O
lithium	S-drug
concentration	O
should	O
be	O
increased	O
at	O
the	O
outset	O
of	O
such	O
combination	O
drug	O
treatment	O
.	O

INDOCIN	S-brand-ME-1
given	O
concomitantly	O
with	O
digoxin	S-drug-ME-2
has	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
concentration	O
and	O
prolong	O
the	O
half	O
-	O
life	O
of	O
digoxin	S-drug
.	O

Therefore	O
,	O
when	O
INDOCIN	S-brand-AD-1
and	O
digoxin	S-drug-AD-2
are	O
used	O
concomitantly	O
,	O
serum	O
digoxin	S-drug
levels	O
should	O
be	O
closely	O
monitored	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
INDOCIN	S-brand-EF-1
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	S-group-EF-2
,	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	E-group-EF-2
,	O
and	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
.	O

Therefore	O
,	O
when	O
INDOCIN	S-brand
and	O
INDOCIN	S-brand
.	O

(	O
Indomethacin	S-drug
)	O
diuretics	S-group
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	S-group
is	O
obtained	O
.	O

INDOCIN	S-brand
reduces	O
basal	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
,	O
as	O
well	O
as	O
those	O
elevations	O
of	O
PRA	O
induced	O
by	O
furosemide	S-drug
administration	O
,	O
or	O
salt	O
or	O
volume	O
depletion	O
.	O

These	O
facts	O
should	O
be	O
considered	O
when	O
evaluating	O
plasma	O
renin	O
activity	O
in	O
hypertensive	O
patients	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
triamterene	S-drug-EF-1
to	O
a	O
maintenance	O
schedule	O
of	O
INDOCIN	S-brand-EF-2
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	O
volunteers	O
.	O

INDOCIN	S-brand-AD-1
and	O
triamterene	S-drug-AD-2
should	O
not	O
be	O
administered	O
together	O
.	O

INDOCIN	S-brand
and	O
potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
each	O
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
.	O

The	O
potential	O
effects	O
of	O
INDOCIN	S-brand-EF-1
and	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	I-group-EF-2
diuretics	E-group-EF-2
on	O
potassium	O
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Most	O
of	O
the	O
above	O
effects	O
concerning	O
diuretics	S-group-EF-1
have	O
been	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
mechanisms	O
involving	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
by	O
INDOCIN	S-brand-EF-2
.	O

Blunting	O
of	O
the	O
antihypertensive	O
effect	O
of	O
beta	B-group-EF-1
-	I-group-EF-1
adrenoceptor	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
by	O
non	B-group-EF-2
-	I-group-EF-2
steroidal	I-group-EF-2
antiinflammatory	I-group-EF-2
drugs	E-group-EF-2
including	O
INDOCIN	S-brand-EF-2
has	O
been	O
reported	O
.	O

Therefore	O
,	O
when	O
using	O
these	O
blocking	O
agents	O
to	O
treat	O
hypertension	O
,	O
patients	O
should	O
be	O
observed	O
carefully	O
in	O
order	O
to	O
confirm	O
that	O
the	O
desired	O
therapeutic	O
effect	O
has	O
been	O
obtained	O
.	O

INDOCIN	S-brand-EF-1
can	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
captopril	S-drug-EF-2
and	O
losartan	S-drug-EF-2
.	O

False	O
-	O
negative	O
results	O
in	O
the	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
in	O
patients	O
being	O
treated	O
with	O
INDOCIN	S-brand
have	O
been	O
reported	O
.	O

Thus	O
,	O
results	O
of	O
the	O
DST	O
should	O
be	O
interpreted	O
with	O
caution	O
in	O
these	O
patients	O
.	O

Concurrent	O
administration	O
of	O
etanercept	S-drug-EF-1
(	O
another	O
TNF	O
-	O
blocking	O
agent	O
)	O
and	O
anakinra	S-drug-EF-2
(	O
an	O
interleukin	B-group
-	I-group
1	I-group
antagonist	E-group
)	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
,	O
and	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O

Other	O
TNFa	B-group-EF-1
-	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
(	O
including	O
REMICADE	S-brand-EF-1
)	O
used	O
in	O
combination	O
with	O
anakinra	S-drug-EF-2
may	O
also	O
result	O
in	O
similar	O
toxicities	O
.	O

Specific	O
drug	O
interaction	O
studies	O
,	O
including	O
interactions	O
with	O
MTX	S-drug
,	O
have	O
not	O
been	O
conducted	O
.	O

The	O
majority	O
of	O
patients	O
in	O
rheumatoid	O
arthritis	O
or	O
Crohn	O
s	O
disease	O
clinical	O
studies	O
received	O
one	O
or	O
more	O
concomitant	O
medications	O
.	O

In	O
rheumatoid	O
arthritis	O
,	O
concomitant	O
medications	O
besides	O
MTX	S-drug
were	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
agents	E-group
,	O
folic	B-drug
acid	E-drug
,	O
corticosteroids	S-group
and	O
/	O
or	O
narcotics	S-group
.	O

Concomitant	O
Crohn	O
s	O
disease	O
medications	O
were	O
antibiotics	S-group
,	O
antivirals	S-group
,	O
corticosteroids	S-group
,	O
6	B-drug
-	I-drug
MP	E-drug
/	O
AZA	S-drug
and	O
aminosalicylates	O
.	O

In	O
psoriatic	O
arthritis	O
clinical	O
trials	O
,	O
concomitant	O
medications	O
included	O
MTX	S-drug
in	O
approximately	O
half	O
of	O
the	O
patients	O
as	O
well	O
as	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
agents	E-group
,	O
folic	B-drug
acid	E-drug
and	O
corticosteroids	S-group
.	O

Patients	O
with	O
Crohn	O
s	O
disease	O
who	O
received	O
immunosuppressants	S-group
tended	O
to	O
experience	O
fewer	O
infusion	O
reactions	O
compared	O
to	O
patients	O
on	O
no	O
immunosuppressants	S-group
.	O

Serum	O
infliximab	S-drug
concentrations	O
appeared	O
to	O
be	O
unaffected	O
by	O
baseline	O
use	O
of	O
medications	O
for	O
the	O
treatment	O
of	O
Crohn	O
s	O
disease	O
including	O
corticosteroids	S-group
,	O
antibiotics	S-group
(	O
metronidazole	S-drug
or	O
ciprofloxacin	S-drug
)	O
and	O
aminosalicylates	O
.	O

A	O
number	O
of	O
substances	O
affect	O
glucose	O
metabolism	O
and	O
may	O
require	O
insulin	S-drug
dose	O
adjustment	O
and	O
particularly	O
close	O
monitoring	O
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetes	O
products	O
,	O
ACE	B-group
inhibitors	E-group
,	O
disopyramide	S-drug
,	O
fibrates	S-group
,	O
fluoxetine	S-drug
,	O
MAO	B-group
inhibitors	E-group
,	O
propoxyphene	S-drug
,	O
salicylates	S-group
,	O
somatostatin	B-group
analog	E-group
(	O
e.g	O
.	O
,	O
octreotide	S-drug
)	O
,	O
sulfonamide	B-group
antibiotics	E-group
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	S-drug
:	O
corticosteroids	S-group
,	O
danazol	S-drug
,	O
diuretics	S-group
,	O
sympathomimetic	B-group
agents	E-group
(	O
e.g	O
.	O
,	O
epinephrine	S-drug
,	O
albuterol	S-drug
,	O
terbutaline	S-drug
)	O
,	O
isoniazid	S-drug
,	O
phenothiazine	B-group
derivatives	E-group
,	O
somatropin	S-drug
,	O
thyroid	B-group
hormones	E-group
,	O
estrogens	S-group
,	O
progestogens	S-group
(	O
e.g	O
.	O
,	O
in	O
oral	O
contraceptives	S-group
)	O
.	O

Beta	B-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
,	O
clonidine	S-drug-EF-1
,	O
lithium	S-drug-EF-1
salts	O
,	O
and	O
alcohol	S-drug-EF-1
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	S-drug-EF-2
.	O

Pentamidine	S-drug
may	O
cause	O
hypoglycemia	O
,	O
which	O
may	O
sometimes	O
be	O
followed	O
by	O
hyperglycemia	O
.	O

In	O
addition	O
,	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta	B-group
-	I-group
blockers	E-group
,	O
clonidine	S-drug
,	O
guanethidine	S-drug
,	O
and	O
reserpine	S-drug
,	O
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O

A	O
number	O
of	O
substances	O
affect	O
glucose	O
metabolism	O
and	O
may	O
require	O
insulin	S-drug
dose	O
adjustment	O
and	O
particularly	O
close	O
monitoring	O
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetic	B-group
products	E-group
,	O
ACE	B-group
inhibitors	E-group
,	O
disopyramide	S-drug
,	O
fibrates	S-group
,	O
fluoxetine	S-drug
,	O
monoamine	B-group
oxidase	I-group
(	I-group
MAO	I-group
)	I-group
inhibitors	E-group
,	O
propoxyphene	S-drug
,	O
salicylates	S-group
,	O
somatostatin	B-group
analog	E-group
(	O
e.g	O
.	O
,	O
octreotide	S-drug
)	O
,	O
sulfonamide	B-group
antibiotics	E-group
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
:	O
corticosteroids	S-group
,	O
niacin	S-drug
,	O
danazol	S-drug
,	O
diuretics	S-group
,	O
sympathomimetic	B-group
agents	E-group
(	O
e.g	O
.	O
,	O
epinephrine	S-drug
,	O
salbutamol	S-drug
,	O
terbutaline	S-drug
)	O
,	O
isoniazid	S-drug
,	O
phenothiazine	B-group
derivatives	E-group
,	O
somatropin	S-drug
,	O
thyroid	B-group
hormones	E-group
,	O
estrogens	S-group
,	O
progestogens	S-group
(	O
e.g	O
.	O
,	O
in	O
oral	O
contraceptives	S-group
)	O
.	O

Beta	B-group-EF-1
-	I-group-EF-1
blockers	E-group-EF-1
,	O
clonidine	S-drug-EF-1
,	O
lithium	S-drug-EF-1
salts	O
,	O
and	O
alcohol	S-drug-EF-1
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	S-drug-EF-2
.	O

Pentamidine	S-drug
may	O
cause	O
hypoglycemia	O
,	O
which	O
may	O
sometimes	O
be	O
followed	O
by	O
hyperglycemia	O
.	O

In	O
addition	O
,	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta	B-group
-	I-group
blockers	E-group
,	O
clonidine	S-drug
,	O
guanethidine	S-drug
,	O
and	O
reserpine	S-drug
,	O
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O

Mixing	O
of	O
Insulins	S-group

A	O
clinical	O
study	O
in	O
healthy	O
male	O
volunteers	O
(	O
n	O
=	O
24	O
)	O
demonstrated	O
that	O
mixing	O
NovoLog	S-brand
with	O
NPH	B-drug
human	I-drug
insulin	E-drug
immediately	O
before	O
injection	O
produced	O
some	O
attenuation	O
in	O
the	O
peak	O
concentration	O
of	O
NovoLog	S-brand
,	O
but	O
that	O
the	O
time	O
to	O
peak	O
and	O
the	O
total	O
bioavailability	O
of	O
NovoLog	S-brand
were	O
not	O
significantly	O
affected	O
.	O

If	O
NovoLog	S-brand
is	O
mixed	O
with	O
NPH	B-drug
human	I-drug
insulin	E-drug
,	O
NovoLog	S-brand
should	O
be	O
drawn	O
into	O
the	O
syringe	O
first	O
.	O

The	O
injection	O
should	O
be	O
made	O
immediately	O
after	O
mixing	O
.	O

Because	O
there	O
are	O
no	O
data	O
on	O
the	O
compatibility	O
of	O
NovoLog	S-brand
and	O
crystalline	O
zinc	B-drug
insulin	E-drug
preparations	O
,	O
NovoLog	S-brand
should	O
not	O
be	O
mixed	O
with	O
these	O
preparations	O
.	O

The	O
effects	O
of	O
mixing	O
NovoLog	S-brand
with	O
insulins	S-group
of	O
animal	O
source	O
or	O
insulin	S-drug
preparations	O
produced	O
by	O
other	O
manufacturers	O
have	O
not	O
been	O
studied	O
.	O

Mixtures	O
should	O
not	O
be	O
administered	O
intravenously	O
.	O

When	O
used	O
in	O
external	O
subcutaneous	O
infusion	O
pumps	O
for	O
insulin	S-drug
,	O
NovoLog	S-brand
should	O
not	O
be	O
mixed	O
with	O
any	O
other	O
insulins	S-group
or	O
diluent	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Rebif	S-brand
.	O

Due	O
to	O
its	O
potential	O
to	O
cause	O
neutropenia	O
and	O
lymphopenia	O
,	O
proper	O
monitoring	O
of	O
patients	O
is	O
required	O
if	O
Rebif	S-brand
is	O
given	O
in	O
combination	O
with	O
myelosuppressive	O
agents	O
.	O

Also	O
,	O
the	O
potential	O
for	O
hepatic	O
injury	O
should	O
be	O
considered	O
when	O
Rebif	S-brand
is	O
used	O
in	O
combination	O
with	O
other	O
products	O
associated	O
with	O
hepatic	O
injury	O
,	O
or	O
when	O
new	O
agents	O
are	O
added	O
to	O
the	O
regimen	O
of	O
patients	O
already	O
on	O
Rebif	S-brand
.	O

Interactions	O
between	O
Betaseron	S-brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Although	O
studies	O
designed	O
to	O
examine	O
drug	O
interactions	O
have	O
not	O
been	O
done	O
,	O
it	O
was	O
noted	O
that	O
corticosteroid	S-group
or	O
ACTH	S-drug
treatment	O
of	O
relapses	O
for	O
periods	O
of	O
up	O
to	O
28	O
days	O
has	O
been	O
administered	O
to	O
patients	O
(	O
N	O
=	O
180	O
)	O
receiving	O
Betaseron	S-brand
.	O

Betaseron	S-brand-ME-1
administration	O
to	O
three	O
cancer	O
patients	O
over	O
a	O
dose	O
range	O
of	O
0.025	O
mg	O
to	O
2.2	O
mg	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
antipyrine	S-drug-ME-2
elimination.14	O
The	O
effect	O
of	O
alternate	O
-	O
day	O
administration	O
of	O
0.25	O
mg	O
of	O
Betaseron	S-brand
on	O
drug	O
metabolism	O
in	O
MS	O
patients	O
is	O
unknown	O
.	O

ATROVENT	S-brand
Inhalation	O
Aerosol	O
has	O
been	O
used	O
concomitantly	O
with	O
other	O
drugs	O
,	O
including	O
sympathomimetic	B-group
bronchodilators	E-group
,	O
methylxanthines	S-group
,	O
and	O
steroids	S-group
,	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

With	O
the	O
exception	O
of	O
albuterol	S-drug
,	O
there	O
are	O
no	O
formal	O
studies	O
fully	O
evaluating	O
the	O
interaction	O
effects	O
of	O
ATROVENT	S-brand
Inhalation	O
Aerosol	O
and	O
these	O
drugs	O
with	O
respect	O
to	O
effectiveness	O
.	O

Anticholinergic	B-group
agents	E-group
:	O
Although	O
ipratropium	B-drug-EF-1
bromide	E-drug-EF-1
is	O
minimally	O
absorbed	O
into	O
the	O
systemic	O
circulation	O
,	O
there	O
is	O
some	O
potential	O
for	O
an	O
additive	O
interaction	O
with	O
concomitantly	O
used	O
anticholinergic	B-group-EF-2
medications	E-group-EF-2
.	O

Caution	O
is	O
therefore	O
advised	O
in	O
the	O
coadministration	O
of	O
ATROVENT	S-brand-AD-1
Inhalation	O
Aerosol	O
with	O
other	O
anticholinergic	S-group-AD-2
-	O
containing	O
drugs	O
.	O

No	O
significant	O
drug	O
-	O
drug	O
pharmacokinetic	O
(	O
or	O
pharmacodynamic	O
)	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	S-drug
,	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
and	O
nifedipine	S-drug
.	O

In	O
vitro	O
studies	O
show	O
significant	O
inhibition	O
of	O
the	O
formation	O
of	O
oxidized	O
irbesartan	O
metabolites	O
with	O
the	O
known	O
cytochrome	O
CYP	O
2C9	O
substrates	O
/	O
inhibitors	O
sulphenazole	S-drug
,	O
tolbutamide	S-drug
and	O
nifedipine	S-drug
.	O

However	O
,	O
in	O
clinical	O
studies	O
the	O
consequences	O
of	O
concomitant	O
irbesartan	S-drug
on	O
the	O
pharmacodynamics	O
of	O
warfarin	S-drug
were	O
negligible	O
.	O

Based	O
on	O
in	O
vitro	O
data	O
,	O
no	O
interaction	O
would	O
be	O
expected	O
with	O
drugs	O
whose	O
metabolism	O
is	O
dependent	O
upon	O
cytochrome	O
P450	O
isozymes	O
1A1	O
,	O
1A2,2A6,2B6,2D6,2E1	O
,	O
or	O
3A4	O
.	O

In	O
separate	O
studies	O
of	O
patients	O
receiving	O
maintenance	O
doses	O
of	O
warfarin	S-drug
,	O
hydrochlorothiazide	S-drug
,	O
or	O
digoxin	S-drug
,	O
irbesartan	S-drug
administration	O
for	O
7	O
days	O
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
warfarin	S-drug
(	O
prothrombin	O
time	O
)	O
or	O
pharmacokinetics	O
of	O
digoxin	S-drug
.	O

The	O
pharmacokinetics	O
of	O
irbesartan	S-drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
nifedipine	S-drug
or	O
hydrochlorothiazide	S-drug

The	O
adverse	O
effects	O
of	O
CAMPTOSAR	S-brand-EF-1
,	O
such	O
as	O
myelosuppression	O
and	O
diarrhea	O
,	O
would	O
be	O
expected	O
to	O
be	O
exacerbated	O
by	O
other	O
antineoplastic	B-group-EF-2
agents	E-group-EF-2
having	O
similar	O
adverse	O
effects	O
.	O

Patients	O
who	O
have	O
previously	O
received	O
pelvic	O
/	O
abdominal	O
irradiation	O
are	O
at	O
increased	O
risk	O
of	O
severe	O
myelosuppression	O
following	O
the	O
administration	O
of	O
CAMPTOSAR	S-brand
.	O

The	O
concurrent	O
administration	O
of	O
CAMPTOSAR	S-brand
with	O
irradiation	O
has	O
not	O
been	O
adequately	O
studied	O
and	O
is	O
not	O
recommended	O
.	O

Lymphocytopenia	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	S-brand-EF-1
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
administration	O
of	O
dexamethasone	S-drug-EF-2
as	O
antiemetic	O
prophylaxis	O
may	O
have	O
enhanced	O
the	O
likelihood	O
of	O
this	O
effect	O
.	O

However	O
,	O
serious	O
opportunistic	O
infections	O
have	O
not	O
been	O
observed	O
,	O
and	O
no	O
complications	O
have	O
specifically	O
been	O
attributed	O
to	O
lymphocytopenia	O
.	O

Hyperglycemia	O
has	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	S-brand
.	O

Usually	O
,	O
this	O
has	O
been	O
observed	O
in	O
patients	O
with	O
a	O
history	O
of	O
diabetes	O
mellitus	O
or	O
evidence	O
of	O
glucose	O
intolerance	O
prior	O
to	O
administration	O
of	O
CAMPTOSAR	S-brand
.	O

It	O
is	O
probable	O
that	O
dexamethasone	S-drug
,	O
given	O
as	O
antiemetic	O
prophylaxis	O
,	O
contributed	O
to	O
hyperglycemia	O
in	O
some	O
patients	O
.	O

The	O
incidence	O
of	O
akathisia	O
in	O
clinical	O
trials	O
of	O
the	O
weekly	O
dosage	O
schedule	O
was	O
greater	O
(	O
8.5	O
%	O
,	O
4	O
/	O
47	O
patients	O
)	O
when	O
prochlorperazine	S-drug-EF-1
was	O
administered	O
on	O
the	O
same	O
day	O
as	O
CAMPTOSAR	S-brand-EF-2
than	O
when	O
these	O
drugs	O
were	O
given	O
on	O
separate	O
days	O
(	O
1.3	O
%	O
,	O
1	O
/	O
80	O
patients	O
)	O
.	O

The	O
8.5	O
%	O
incidence	O
of	O
akathisia	O
,	O
however	O
,	O
is	O
within	O
the	O
range	O
reported	O
for	O
use	O
of	O
prochlorperazine	S-drug
when	O
given	O
as	O
a	O
premedication	O
for	O
other	O
chemotherapies	O
.	O

It	O
would	O
be	O
expected	O
that	O
laxative	S-group-EF-1
use	O
during	O
therapy	O
with	O
CAMPTOSAR	S-brand-EF-2
would	O
worsen	O
the	O
incidence	O
or	O
severity	O
of	O
diarrhea	O
,	O
but	O
this	O
has	O
not	O
been	O
studied	O
.	O

In	O
view	O
of	O
the	O
potential	O
risk	O
of	O
dehydration	O
secondary	O
to	O
vomiting	O
and	O
/	O
or	O
diarrhea	O
induced	O
by	O
CAMPTOSAR	S-brand
,	O
the	O
physician	O
may	O
wish	O
to	O
withhold	O
diuretics	S-group-EF-1
during	O
dosing	O
with	O
CAMPTOSAR	S-brand-EF-2
and	O
,	O
certainly	O
,	O
during	O
periods	O
of	O
active	O
vomiting	O
or	O
diarrhea	O
.	O

Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
CAMPTOSAR	S-brand
and	O
laboratory	O
tests	O
.	O

Isocarboxazid	S-drug-AD-1
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
receiving	O
Antabuse	S-brand-AD-2
(	O
disulfiram	S-drug-AD-2
,	O
Wyeth	O
-	O
Ayerst	O
Laboratories	O
)	O
.	O

In	O
a	O
single	O
study	O
,	O
rats	O
given	O
high	O
intraperitoneal	O
doses	O
of	O
an	O
MAO	B-group-EF-1
inhibitor	E-group-EF-1
plus	O
disulfiram	S-drug-EF-2
experienced	O
severe	O
toxicity	O
,	O
including	O
convulsions	O
and	O
death	O
.	O

Concomitant	O
use	O
of	O
Isocarboxazid	S-drug-AD-1
and	O
other	O
psychotropic	B-group-AD-2
agents	E-group-AD-2
is	O
generally	O
not	O
recommended	O
because	O
of	O
possible	O
potentiating	O
effects	O
.	O

This	O
is	O
especially	O
true	O
in	O
patients	O
who	O
may	O
subject	O
themselves	O
to	O
an	O
overdosage	O
of	O
drugs	O
.	O

If	O
combination	O
therapy	O
is	O
needed	O
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
all	O
agents	O
to	O
be	O
used	O
.	O

The	O
monoamine	O
oxidase	O
inhibitory	O
effects	O
of	O
Isocarboxazid	S-drug
may	O
persist	O
for	O
a	O
substantial	O
period	O
after	O
discontinuation	O
of	O
the	O
drug	O
,	O
and	O
this	O
should	O
be	O
borne	O
in	O
mind	O
when	O
another	O
drug	O
is	O
prescribed	O
following	O
Isocarboxazid	S-drug
.	O

To	O
avoid	O
potentiation	O
,	O
the	O
physician	O
wishing	O
to	O
terminate	O
treatment	O
with	O
Isocarboxazid	S-drug
and	O
begin	O
therapy	O
with	O
another	O
agent	O
should	O
allow	O
for	O
an	O
interval	O
of	O
10	O
days	O
.	O

May	O
interact	O
with	O
the	O
following	O
:	O
beta	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
(	O
these	O
medicines	O
may	O
make	O
your	O
condition	O
worse	O
and	O
prevent	O
the	O
adrenergic	B-group
bronchodilators	E-group
from	O
working	O
properly	O
)	O
and	O
disopyramide	S-drug
,	O
quinidine	S-drug
,	O
phenothiazines	S-group
,	O
and	O
procainamide	S-drug
(	O
these	O
medicines	O
may	O
increase	O
the	O
risk	O
of	O
heart	O
problems	O
)	O
.	O

Isoflurane	S-drug-EF-1
potentiates	O
the	O
muscle	O
relaxant	O
effect	O
of	O
all	O
muscle	B-group-EF-2
relaxants	E-group-EF-2
,	O
most	O
notably	O
nondepolarizing	B-group-EF-2
muscle	I-group-EF-2
relaxants	E-group-EF-2
,	O
and	O
MAC	O
(	O
minimum	O
alveolar	O
concentration	O
)	O
is	O
reduced	O
by	O
concomitant	O
administration	O
of	O
N	O
2O	O
.	O

See	O
CLINICAL	O
PHARMACOLOGY	O
.	O

Food	O
:	O
Isoniazid	S-drug
should	O
not	O
be	O
administered	O
with	O
food	O
.	O

Studies	O
have	O
shown	O
that	O
the	O
bioavailability	O
of	O
isoniazid	S-drug
is	O
reduced	O
significantly	O
when	O
administered	O
with	O
food	O
.	O

Acetaminophen	S-drug
:	O
A	O
report	O
of	O
severe	O
acetaminophen	S-drug-EF-1
toxicity	O
was	O
reported	O
in	O
a	O
patient	O
receiving	O
Isoniazid	S-drug-EF-2
.	O

It	O
is	O
believed	O
that	O
the	O
toxicity	O
may	O
have	O
resulted	O
from	O
a	O
previously	O
unrecognized	O
interaction	O
between	O
isoniazid	S-drug-EF-1
and	O
acetaminophen	S-drug-EF-2
and	O
a	O
molecular	O
basis	O
for	O
this	O
interaction	O
has	O
been	O
proposed	O
.	O

However	O
,	O
current	O
evidence	O
suggests	O
that	O
isoniazid	S-drug
does	O
induce	O
P	O
-	O
450IIE1	O
,	O
a	O
mixed	O
-	O
function	O
oxidase	O
enzyme	O
that	O
appears	O
to	O
generate	O
the	O
toxic	O
metabolites	O
,	O
in	O
the	O
liver	O
.	O

Furthermore	O
it	O
has	O
been	O
proposed	O
that	O
isoniazid	S-drug-ME-1
resulted	O
In	O
induction	O
of	O
P	O
-	O
450IIE1	O
in	O
the	O
patients	O
liver	O
which	O
,	O
in	O
turn	O
,	O
resulted	O
in	O
a	O
greater	O
proportion	O
of	O
the	O
ingested	O
acetaminophen	S-drug-ME-2
being	O
converted	O
to	O
the	O
toxic	O
metabolites	O
.	O

Studies	O
have	O
demonstrated	O
that	O
pretreatment	O
with	O
isoniazid	S-drug
potentiates	O
a	O
cetaminophen	O
hepatoxicity	O
in	O
rats	O
.	O

Carbamazepine	S-drug
:	O
Isoniazid	S-drug-ME-1
is	O
known	O
to	O
slow	O
the	O
metabolism	O
of	O
carbamazepine	S-drug-ME-2
and	O
increase	O
its	O
serum	O
levels	O
Carbamazepine	S-drug-AD-1
levels	O
should	O
be	O
determined	O
prior	O
to	O
concurrent	O
administration	O
with	O
isoniazid	S-drug-AD-2
,	O
signs	O
and	O
symptoms	O
of	O
carbamazepine	S-drug
toxicity	O
should	O
be	O
monitored	O
closely	O
,	O
and	O
appropriate	O
dosage	O
adjustment	O
of	O
the	O
anticonvulsant	S-group
should	O
be	O
made	O
.	O

Ketoconazole	S-drug
:	O
Potential	O
interaction	O
of	O
Ketoconazole	S-drug-IN-1
and	O
Isoniazid	S-drug-IN-2
may	O
exist	O
.	O

Phenytoin	S-drug
:	O
Isoniazid	S-drug-ME-1
may	O
increase	O
serum	O
levels	O
of	O
phenytoin	S-drug-ME-2
.	O

To	O
avoid	O
phenytoin	S-drug
intoxication	O
,	O
appropriate	O
adjustment	O
of	O
the	O
anticonvulsant	S-group
should	O
be	O
made	O
.	O

Therophylline	O
:	O
A	O
recent	O
study	O
has	O
shown	O
that	O
concomitan	O
administration	O
of	O
isoniazid	S-drug-ME-1
and	O
theophylline	S-drug-ME-2
may	O
cause	O
elevated	O
plasma	O
levels	O
of	O
theophylline	S-drug
,	O
and	O
in	O
some	O
instances	O
a	O
slight	O
decrease	O
in	O
the	O
elimination	O
of	O
isoniazid	S-drug
.	O

Since	O
the	O
therapeutic	O
range	O
of	O
theophylline	S-drug
is	O
narrow	O
theophylline	S-drug
serum	O
levels	O
should	O
be	O
monitored	O
closely	O
,	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
theophylline	S-drug
should	O
be	O
made	O
.	O

Valproate	S-drug
:	O
A	O
recent	O
case	O
study	O
has	O
shown	O
a	O
possible	O
increase	O
in	O
the	O
plasma	O
level	O
of	O
valproate	S-drug-ME-1
when	O
co	O
administered	O
with	O
isoniazid	S-drug-ME-2
.	O

Plasma	O
valproate	S-drug
concentration	O
should	O
be	O
monitored	O
when	O
isoniazid	S-drug-AD-1
and	O
valproate	S-drug-AD-2
are	O
co	O
administered	O
,	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
valproate	S-drug
should	O
be	O
made	O
.	O

Isoproterenol	B-drug-AD-1
hydrochloride	E-drug-AD-1
injection	O
and	O
epinephrine	S-drug-AD-2
should	O
not	O
be	O
administered	O
simultaneously	O
because	O
both	O
drugs	O
are	O
direct	O
cardiac	O
stimulants	O
and	O
their	O
combined	O
effects	O
may	O
induce	O
serious	O
arrhythmias	O
.	O

The	O
drugs	O
may	O
,	O
however	O
,	O
be	O
administered	O
alternately	O
provided	O
a	O
proper	O
interval	O
has	O
elapsed	O
between	O
doses	O
.	O

ISUPREL	S-brand-AD-1
should	O
be	O
used	O
with	O
caution	O
,	O
if	O
at	O
all	O
,	O
when	O
potent	O
inhalational	O
anesthetics	S-group-AD-2
such	O
as	O
halothane	S-drug-AD-2
are	O
employed	O
because	O
of	O
potential	O
to	O
sensitize	O
the	O
myocardium	O
to	O
effects	O
of	O
sympathomimetic	B-group
amines	E-group
.	O

The	O
vasodilating	O
effects	O
of	O
isosorbide	B-drug-EF-1
dinitrate	E-drug-EF-1
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	S-group-EF-2
.	O

Alcohol	S-drug
,	O
in	O
particular	O
,	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O

The	O
vasodilating	O
effects	O
of	O
isosorbide	B-drug-EF-1
mononitrate	E-drug-EF-1
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	S-group-EF-2
.	O

Alcohol	S-drug
,	O
in	O
particular	O
,	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O

Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B-group-EF-1
channel	I-group-EF-1
blockers	E-group-EF-1
and	O
organic	B-group-EF-2
nitrates	E-group-EF-2
were	O
used	O
in	O
combination	O
.	O

Dose	O
adjustments	O
of	O
either	O
class	O
of	O
agents	O
may	O
be	O
necessary	O
.	O

Vitamin	B-group
A	E-group
:	O
Because	O
of	O
the	O
relationship	O
of	O
Accutane	S-brand-EF-1
to	O
vitamin	B-group-EF-2
A	E-group-EF-2
,	O
patients	O
should	O
be	O
advised	O
against	O
taking	O
vitamin	B-group
supplements	E-group
containing	O
vitamin	B-group
A	E-group
to	O
avoid	O
additive	O
toxic	O
effects	O

Tetracyclines	S-group
:	O
Concomitant	O
treatment	O
with	O
Accutane	S-brand-AD-1
and	O
tetracyclines	S-group-AD-2
should	O
be	O
avoided	O
because	O
Accutane	S-brand-EF-1
use	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
cases	O
of	O
pseudotumor	O
cerebri	O
(	O
benign	O
intracranial	O
hypertension	O
)	O
,	O
some	O
of	O
which	O
involved	O
concomitant	O
use	O
of	O
tetracyclines	S-group-EF-2

Micro	O
-	O
dosed	O
Progesterone	S-drug
Preparations	O
:	O
Micro	O
-	O
dosed	O
progesterone	S-drug-EF-1
preparations	O
(	O
minipills	O
that	O
do	O
not	O
contain	O
an	O
estrogen	S-group
)	O
may	O
be	O
an	O
inadequate	O
method	O
of	O
contraception	O
during	O
Accutane	S-brand-EF-2
therapy	O
.	O

Although	O
other	O
hormonal	B-group
contraceptives	E-group
are	O
highly	O
effective	O
,	O
there	O
have	O
been	O
reports	O
of	O
pregnancy	O
from	O
women	O
who	O
have	O
used	O
combined	B-group
oral	I-group
contraceptives	E-group
,	O
as	O
well	O
as	O
topical	O
/	O
injectable	O
/	O
implantable	O
/	O
insertable	O
hormonal	O
birth	O
control	O
products	O
.	O

These	O
reports	O
are	O
more	O
frequent	O
for	O
women	O
who	O
use	O
only	O
a	O
single	O
method	O
of	O
contraception	O
.	O

It	O
is	O
not	O
known	O
if	O
hormonal	B-group
contraceptives	E-group
differ	O
in	O
their	O
effectiveness	O
when	O
used	O
with	O
Accutane	S-brand
.	O

Therefore	O
,	O
it	O
is	O
critically	O
important	O
for	O
women	O
of	O
childbearing	O
potential	O
to	O
select	O
and	O
commit	O
to	O
use	O
2	O
forms	O
of	O
effective	O
contraception	O
simultaneously	O
,	O
at	O
least	O
1	O
of	O
which	O
must	O
be	O
a	O
primary	O
form	O
,	O
unless	O
absolute	O
abstinence	O
is	O
the	O
chosen	O
method	O
,	O
or	O
the	O
patient	O
has	O
undergone	O
a	O
hysterectomy	O

Phenytoin	S-drug
:	O
Accutane	S-brand
has	O
not	O
been	O
shown	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	S-drug
in	O
a	O
study	O
in	O
seven	O
healthy	O
volunteers	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
in	O
vitro	O
finding	O
that	O
neither	O
isotretinoin	S-drug
nor	O
its	O
metabolites	O
induce	O
or	O
inhibit	O
the	O
activity	O
of	O
the	O
CYP	O
2C9	O
human	O
hepatic	O
P450	O
enzyme	O
.	O

Phenytoin	S-drug
is	O
known	O
to	O
cause	O
osteomalacia	O
.	O

No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
phenytoin	S-drug
and	O
Accutane	S-brand
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
using	O
these	O
drugs	O
together	O

Systemic	B-group
Corticosteroids	E-group
:	O
Systemic	B-group
corticosteroids	E-group
are	O
known	O
to	O
cause	O
osteoporosis	O
.	O

No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
systemic	B-group
corticosteroids	E-group
and	O
Accutane	S-brand
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
using	O
these	O
drugs	O
together	O
.	O

Prescribers	O
are	O
advised	O
to	O
consult	O
the	O
package	O
insert	O
of	O
medication	O
administered	O
concomitantly	O
with	O
hormonal	B-group
contraceptives	E-group
,	O
since	O
some	O
medications	O
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
birth	O
control	O
products	O
.	O

Accutane	S-brand
use	O
is	O
associated	O
with	O
depression	O
in	O
some	O
patients	O
.	O

Pregnancies	O
have	O
been	O
reported	O
by	O
users	O
of	O
combined	B-group
hormonal	I-group
contraceptives	E-group
who	O
also	O
used	O
some	O
form	O
of	O
St.	O
Johns	O
Wort	O
.	O

Laboratory	O
Tests	O
Pregnancy	O
Test	O
Female	O
patients	O
of	O
childbearing	O
potential	O
must	O
have	O
negative	O
results	O
from	O
2	O
urine	O
or	O
serum	O
pregnancy	O
tests	O
with	O
a	O
sensitivity	O
of	O
at	O
least	O
25	O
mIU	O
/	O
mL	O
before	O
receiving	O
the	O
initial	O
Accutane	S-brand
prescription	O
.	O

The	O
first	O
test	O
is	O
obtained	O
by	O
the	O
prescriber	O
when	O
the	O
decision	O
is	O
made	O
to	O
pursue	O
qualification	O
of	O
the	O
patient	O
for	O
Accutane	S-brand
(	O
a	O
screening	O
test	O
)	O
.	O

The	O
second	O
pregnancy	O
test	O
(	O
a	O
confirmation	O
test	O
)	O
should	O
be	O
done	O
during	O
the	O
first	O
5	O
days	O
of	O
the	O
menstrual	O
period	O
immediately	O
preceding	O
the	O
beginning	O
of	O
Accutane	S-brand
therapy	O
.	O

For	O
patients	O
with	O
amenorrhea	O
,	O
the	O
second	O
test	O
should	O
be	O
done	O
at	O
least	O
11	O
days	O
after	O
the	O
last	O
act	O
of	O
unprotected	O
sexual	O
intercourse	O
(	O
without	O
using	O
2	O
effective	O
forms	O
of	O
contraception	O
)	O
.	O

Each	O
month	O
of	O
therapy	O
,	O
the	O
patient	O
must	O
have	O
a	O
negative	O
result	O
from	O
a	O
urine	O
or	O
serum	O
pregnancy	O
test	O
.	O

A	O
pregnancy	O
test	O
must	O
be	O
repeated	O
each	O
month	O
prior	O
to	O
the	O
female	O
patient	O
receiving	O
each	O
prescription	O

Lipids	O
:	O
Pretreatment	O
and	O
follow	O
-	O
up	O
blood	O
lipids	O
should	O
be	O
obtained	O
under	O
fasting	O
conditions	O
.	O

After	O
consumption	O
of	O
alcohol	S-drug
,	O
at	O
least	O
36	O
hours	O
should	O
elapse	O
before	O
these	O
determinations	O
are	O
made	O
.	O

It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
at	O
weekly	O
or	O
biweekly	O
intervals	O
until	O
the	O
lipid	O
response	O
to	O
Accutane	S-brand
is	O
established	O
.	O

The	O
incidence	O
of	O
hypertriglyceridemia	O
is	O
1	O
patient	O
in	O
4	O
on	O
Accutane	S-brand
therapy	O

Liver	O
Function	O
Tests	O
:	O
Since	O
elevations	O
of	O
liver	O
enzymes	O
have	O
been	O
observed	O
during	O
clinical	O
trials	O
,	O
and	O
hepatitis	O
has	O
been	O
reported	O
,	O
pretreatment	O
and	O
follow	O
-	O
up	O
liver	O
function	O
tests	O
should	O
be	O
performed	O
at	O
weekly	O
or	O
biweekly	O
intervals	O
until	O
the	O
response	O
to	O
Accutane	S-brand
has	O
been	O
established	O

Glucose	O
:	O
Some	O
patients	O
receiving	O
Accutane	S-brand
have	O
experienced	O
problems	O
in	O
the	O
control	O
of	O
their	O
blood	O
sugar	O
.	O

In	O
addition	O
,	O
new	O
cases	O
of	O
diabetes	O
have	O
been	O
diagnosed	O
during	O
Accutane	S-brand
therapy	O
,	O
although	O
no	O
causal	O
relationship	O
has	O
been	O
established	O

CPK	O
:	O
Some	O
patients	O
undergoing	O
vigorous	O
physical	O
activity	O
while	O
on	O
Accutane	S-brand
therapy	O
have	O
experienced	O
elevated	O
CPK	O
levels	O
;	O

however	O
,	O
the	O
clinical	O
significance	O
is	O
unknown	O
.	O

There	O
have	O
been	O
rare	O
postmarketing	O
reports	O
of	O
rhabdomyolysis	O
,	O
some	O
associated	O
with	O
strenuous	O
physical	O
activity	O
.	O

In	O
a	O
clinical	O
trial	O
of	O
217	O
pediatric	O
patients	O
(	O
12	O
to	O
17	O
years	O
)	O
with	O
severe	O
recalcitrant	O
nodular	O
acne	O
,	O
transient	O
elevations	O
in	O
CPK	O
were	O
observed	O
in	O
12	O
%	O
of	O
patients	O
,	O
including	O
those	O
undergoing	O
strenuous	O
physical	O
activity	O
in	O
association	O
with	O
reported	O
musculoskeletal	O
adverse	O
events	O
such	O
as	O
back	O
pain	O
,	O
arthralgia	O
,	O
limb	O
injury	O
,	O
or	O
muscle	O
sprain	O
.	O

In	O
these	O
patients	O
,	O
approximately	O
half	O
of	O
the	O
CPK	O
elevations	O
returned	O
to	O
normal	O
within	O
2	O
weeks	O
and	O
half	O
returned	O
to	O
normal	O
within	O
4	O
weeks	O
.	O

No	O
cases	O
of	O
rhabdomyolysis	O
were	O
reported	O
in	O
this	O
trial	O
.	O

Nitroglycerin	S-drug
:	O
DynaCirc	S-brand
(	O
isradipine	S-drug
)	O
has	O
been	O
safely	O
coadministered	O
with	O
nitroglycerin	S-drug
.	O

Hydrochlorothiazide	S-drug
:	O
A	O
study	O
in	O
normal	O
healthy	O
volunteers	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
DynaCirc	S-brand
(	O
isradipine	S-drug
)	O
and	O
hydrochlorothiazide	S-drug
does	O
not	O
result	O
in	O
altered	O
pharmacoktnetics	O
of	O
either	O
drug	O
.	O

In	O
a	O
study	O
in	O
hypertensive	O
patients	O
,	O
addition	O
of	O
isradipine	S-drug
to	O
existing	O
hydrochlorothiazide	S-drug
therapy	O
did	O
not	O
result	O
in	O
any	O
unexpected	O
adverse	O
effects	O
,	O
and	O
isradipine	S-drug
had	O
an	O
additional	O
antihypertensive	O
effect	O
.	O

Propranolol	S-drug
:	O
In	O
a	O
single	O
dose	O
study	O
in	O
normal	O
volunteers	O
,	O
coadministration	O
of	O
propranolol	S-drug
had	O
a	O
small	O
effect	O
on	O
the	O
rate	O
but	O
no	O
effect	O
on	O
the	O
extent	O
of	O
isradipine	S-drug
bioavailability	O
.	O

Significant	O
increases	O
In	O
AUC	O
(	O
27	O
%	O
)	O
and	O
Cmax	O
(	O
58	O
%	O
)	O
and	O
decreases	O
in	O
tmax	O
(	O
23	O
%	O
)	O
of	O
propranolol	S-drug
were	O
noted	O
in	O
this	O
study	O
.	O

However	O
,	O
concomitant	O
administration	O
of	O
5	O
mg	O
b.i.d	O
.	O
isradipine	S-drug
and	O
40	O
mg	O
b.i.d	O
.	O

propranolol	S-drug
to	O
healthy	O
volunteers	O
under	O
steady	O
-	O
state	O
conditions	O
had	O
no	O
relevant	O
effect	O
on	O
either	O
drug	O
s	O
bioavailability	O
,	O
AUC	O
and	O
Cmax	O
,	O
differences	O
were	O
20	O
%	O
between	O
isradipine	S-drug
given	O
singly	O
and	O
in	O
combination	O
with	O
propranolol	S-drug
,	O
and	O
between	O
propranolol	S-drug
given	O
singly	O
and	O
in	O
combination	O
with	O
isradipine	S-drug
.	O

Cimetidine	S-drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
a	O
one	O
-	O
week	O
course	O
of	O
cimetidine	S-drug-ME-1
at	O
400	O
mg	O
b.i.d	O
.	O
with	O
a	O
single	O
5	O
mg	O
dose	O
of	O
isradipine	S-drug-ME-2
on	O
the	O
sixth	O
day	O
showed	O
an	O
increase	O
in	O
isradipine	S-drug
mean	O
peak	O
plasma	O
concentrations	O
(	O
36	O
%	O
)	O
and	O
significant	O
increase	O
in	O
area	O
under	O
the	O
curve	O
(	O
50	O
%	O
)	O
.	O

If	O
isradipine	S-drug-AD-1
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	S-drug-AD-2
careful	O
monitoring	O
for	O
adverse	O
reactions	O
is	O
advised	O
and	O
downward	O
dose	O
adjustment	O
may	O
be	O
required	O
.	O

Rifampicin	S-drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
a	O
six	O
-	O
day	O
course	O
of	O
rifampicin	S-drug-ME-1
at	O
600	O
mg	O
/	O
day	O
followed	O
by	O
a	O
single	O
5	O
mg	O
dose	O
of	O
isradipine	S-drug-ME-2
resulted	O
in	O
a	O
reduction	O
in	O
isradipine	S-drug
levels	O
to	O
below	O
detectable	O
limits	O
.	O

If	O
rifampicin	S-drug-ME-1
therapy	O
is	O
required	O
,	O
isradipine	S-drug-ME-2
concentrations	O
and	O
therapeutic	O
effects	O
are	O
likely	O
to	O
be	O
markedly	O
reduced	O
or	O
abolished	O
as	O
a	O
consequence	O
of	O
increased	O
metabolism	O
and	O
higher	O
clearance	O
of	O
isradipine	S-drug
.	O

Warfarin	S-drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
no	O
clinically	O
relevant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
between	O
isradipine	S-drug
and	O
racemic	O
warfarin	S-drug
was	O
seen	O
when	O
two	O
single	O
oral	O
doses	O
of	O
warfarin	S-drug
(	O
0.7	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
were	O
administered	O
during	O
11	O
days	O
of	O
multipledose	O
treatment	O
with	O
5	O
mg	O
b.i.d	O
.	O
isradipine	S-drug
.	O

Neither	O
racemic	O
warfarin	S-drug
nor	O
isradipine	S-drug
binding	O
to	O
plasma	O
proteins	O
in	O
vitro	O
was	O
altered	O
by	O
the	O
addition	O
of	O
the	O
other	O
drug	O
.	O

Digoxin	S-drug
:	O
The	O
concomitant	O
administration	O
of	O
DynaCirc	S-brand
(	O
isradipine	S-drug
)	O
and	O
digoxin	S-drug
in	O
a	O
single	O
-	O
dose	O
pharmacokinetic	O
study	O
did	O
not	O
affect	O
renal	O
,	O
nonrenal	O
and	O
total	O
body	O
clearance	O
of	O
digoxin	S-drug
.	O

Fentanyl	S-drug
Anesthesia	O
:	O
Severe	O
hypotension	O
has	O
been	O
reported	O
during	O
fentanyl	S-drug-EF-1
anesthesia	O
with	O
concomitant	O
use	O
of	O
a	O
beta	B-group-EF-2
blocker	E-group-EF-2
and	O
a	O
calcium	B-group-EF-2
channel	I-group-EF-2
blocker	E-group-EF-2
.	O

Even	O
though	O
such	O
interactions	O
have	O
not	O
been	O
seen	O
in	O
clinical	O
studies	O
with	O
DynaCirc	S-brand
(	O
isradipine	S-drug
)	O
,	O
an	O
increased	O
volume	O
of	O
circulating	O
fluids	O
might	O
be	O
required	O
if	O
such	O
an	O
interaction	O
were	O
to	O
occur	O
.	O

Both	O
itraconazole	S-drug
and	O
its	O
major	O
metabolite	O
,	O
hydroxyitraconazole	S-drug_n
,	O
are	O
inhibitors	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
.	O

Coadministration	O
of	O
Itraconazole	S-drug
and	O
drugs	O
primarily	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
drugs	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Therefore	O
,	O
unless	O
otherwise	O
specified	O
,	O
appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

Coadministration	O
of	O
terfenadine	S-drug-ME-1
with	O
Itraconazole	S-drug-ME-2
has	O
led	O
to	O
elevated	O
plasma	O
concentrations	O
of	O
terfenadine	S-drug
,	O
resulting	O
in	O
rare	O
instances	O
of	O
life	O
-	O
threatening	O
cardiac	O
dysrhythmias	O
and	O
one	O
death	O
.	O

Another	O
oral	O
azole	B-group
antifungal	E-group
,	O
ketoconazole	S-drug-ME-1
,	O
inhibits	O
the	O
metabolism	O
of	O
astemizole	S-drug-ME-2
,	O
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
astemizole	S-drug
and	O
its	O
active	O
metabolite	O
desmethylastermizole	S-drug_n
which	O
may	O
prolong	O
QT	O
intervals	O
.	O

In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	S-drug-ME-1
,	O
when	O
compared	O
to	O
ketoconazole	S-drug
,	O
has	O
a	O
less	O
pronounced	O
effect	O
on	O
the	O
biotransformation	O
system	O
responsible	O
for	O
the	O
metabolism	O
of	O
astemizole	S-drug-ME-2
.	O

Based	O
on	O
the	O
chemical	O
resemblance	O
of	O
itraconazole	S-drug
and	O
ketoconazole	S-drug
,	O
coadministration	O
of	O
astemizole	S-drug-AD-1
with	O
itraconazole	S-drug-AD-2
is	O
contraindicated	O
.	O

Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	S-drug-ME-1
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
resulting	O
in	O
an	O
eight	O
-	O
fold	O
increase	O
in	O
the	O
mean	O
AUC	O
of	O
cisapride	S-drug
.	O

Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	S-drug-EF-1
and	O
cisapride	S-drug-EF-2
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	S-drug-ME-1
also	O
markedly	O
inhibits	O
the	O
biotransformation	O
system	O
mainly	O
responsible	O
for	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
;	O

therefore	O
concomitant	O
administration	O
of	O
Itraconazole	S-drug-AD-1
with	O
cisapride	S-drug-AD-2
is	O
contraindicated	O
.	O

Coadministration	O
of	O
Itraconazole	S-drug-ME-1
with	O
oral	O
midazolam	S-drug-ME-2
or	O
triazolam	S-drug-ME-2
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	O
.	O

This	O
may	O
potentiate	O
and	O
prolong	O
hypnotic	O
and	O
sedative	O
effects	O
.	O

These	O
agents	O
should	O
not	O
be	O
used	O
in	O
patients	O
treated	O
with	O
Itraconazole	S-drug
.	O

If	O
midazolam	S-drug
is	O
administered	O
parenterally	O
,	O
special	O
precaution	O
is	O
required	O
since	O
the	O
sedative	O
effect	O
may	O
be	O
prolonged	O
.	O

Coadministration	O
of	O
Itraconazole	S-drug-ME-1
and	O
cyclosporine	S-drug-ME-2
,	O
tacrolimus	S-drug-ME-2
or	O
digoxin	S-drug-ME-2
has	O
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
the	O
latter	O
three	O
drugs	O
.	O

Cyclosporine	S-drug-AD-1
,	O
tacrolimus	S-drug-AD-1
and	O
digoxin	S-drug-AD-1
concentrations	O
should	O
be	O
monitored	O
at	O
the	O
initiation	O
of	O
Itraconazole	S-drug-AD-2
therapy	O
and	O
frequently	O
thereafter	O
,	O
and	O
the	O
dose	O
of	O
these	O
three	O
drug	O
products	O
adjusted	O
appropriately	O
.	O

Rhabdomyolysis	O
has	O
been	O
observed	O
in	O
patients	O
receiving	O
HMG	B-group-EF-1
-	I-group-EF-1
CoA	I-group-EF-1
reductase	I-group-EF-1
inhibitors	E-group-EF-1
administered	O
alone	O
(	O
at	O
recommended	O
dosages	O
)	O
or	O
concomitantly	O
with	O
immunosuppressive	B-group-EF-2
drugs	E-group-EF-2
including	O
cyclosporine	S-drug-EF-2
.	O

When	O
Itraconazole	S-drug-ME-1
was	O
coadministered	O
with	O
phenytoin	S-drug-ME-2
,	O
rifampin	S-drug-ME-2
,	O
or	O
H2antagonists	O
,	O
reduced	O
plasma	O
concentrations	O
of	O
itraconazole	S-drug
were	O
reported	O
.	O

The	O
physician	O
is	O
advised	O
to	O
monitor	O
the	O
plasma	O
concentrations	O
of	O
itraconazole	S-drug
when	O
any	O
of	O
these	O
drugs	O
is	O
taken	O
concurrently	O
,	O
and	O
to	O
increase	O
the	O
dose	O
of	O
Itraconazole	S-drug
if	O
necessary	O
.	O

Although	O
no	O
studies	O
have	O
been	O
conducted	O
,	O
concomitant	O
administration	O
of	O
Itraconazole	S-drug-ME-1
and	O
phenytoin	S-drug-ME-2
may	O
alter	O
the	O
metabolism	O
of	O
phenytoin	S-drug
;	O

therefore	O
,	O
plasma	O
concentrations	O
of	O
phenytoin	S-drug-AD-1
should	O
also	O
be	O
monitored	O
when	O
it	O
is	O
given	O
concurrently	O
with	O
Itraconazole	S-drug-AD-2
.	O

It	O
has	O
been	O
reported	O
that	O
Itraconazole	S-drug-EF-1
enhances	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	S-group-EF-2
-	O
like	O
drugs	O
.	O

Therefore	O
,	O
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
in	O
patients	O
receiving	O
Itraconazole	S-drug-AD-1
and	O
coumarin	S-group-AD-2
-	O
like	O
drugs	O
simultaneously	O
.	O

Plasma	O
concentrations	O
of	O
azole	B-group-ME-1
antifungal	I-group-ME-1
agents	E-group-ME-1
are	O
reduced	O
when	O
given	O
concurrently	O
with	O
isoniazid	S-drug-ME-2
.	O

Itraconazole	S-drug
plasma	O
concentrations	O
should	O
be	O
monitored	O
when	O
Itraconazole	S-drug-AD-1
and	O
isoniazid	S-drug-AD-2
are	O
coadministered	O
.	O

Severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
azole	B-group-EF-1
antifungal	I-group-EF-1
agents	E-group-EF-1
and	O
oral	O
hypoglycemic	B-group-EF-2
agents	E-group-EF-2
.	O

Blood	O
glucose	O
concentrations	O
should	O
be	O
carefully	O
monitored	O
when	O
Itraconazole	S-drug-AD-1
and	O
oral	O
hypoglycemic	B-group-AD-2
agents	E-group-AD-2
are	O
coadministered	O
.	O

Tinnitus	O
and	O
decreased	O
hearing	O
have	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	S-drug-EF-1
and	O
quinidine	S-drug-EF-2
.	O

Edema	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	S-drug-EF-1
and	O
dihydropyridine	B-group-EF-2
calcium	I-group-EF-2
channel	I-group-EF-2
blockers	E-group-EF-2
.	O

Appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

The	O
results	O
from	O
a	O
study	O
in	O
which	O
eight	O
HIV	O
-	O
infected	O
individuals	O
were	O
treated	O
with	O
zidovudine	S-drug
,	O
8	O
+	O
/	O
-	O
0.4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
showed	O
that	O
the	O
pharmacokinetics	O
of	O
zidovudine	S-drug
were	O
not	O
affected	O
during	O
concomitant	O
administration	O
of	O
Itraconazole	S-drug
,	O
100	O
mg	O
b.i.d	O
.	O

In	O
vitro	O
mixing	O
of	O
an	O
aminoglycoside	S-group-EF-1
with	O
beta	O
-	O
lactamtype	O
antibiotics	S-group-EF-2
(	O
penicillins	S-group-EF-2
or	O
cephalosporins	S-group-EF-2
)	O
may	O
result	O
in	O
a	O
significant	O
mutual	O
inactivation	O
.	O

Even	O
when	O
an	O
aminoglycoside	S-group-ME-1
and	O
a	O
penicillin	S-group-ME-2
-	O
type	O
drug	O
are	O
administered	O
separately	O
by	O
different	O
routes	O
,	O
a	O
reduction	O
in	O
aminoglycoside	S-group
serum	O
half	O
-	O
life	O
or	O
serum	O
levels	O
has	O
been	O
reported	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
and	O
in	O
some	O
patients	O
with	O
normal	O
renal	O
function	O
.	O

Usually	O
,	O
such	O
inactivation	O
of	O
the	O
aminoglycoside	S-group
is	O
clinically	O
significant	O
only	O
in	O
patients	O
with	O
severely	O
impaired	O
renal	O
function..	O

Prolonged	O
recovery	O
time	O
may	O
occur	O
if	O
barbiturates	S-group-EF-1
and	O
/	O
or	O
narcotics	S-group-EF-1
are	O
used	O
concurrently	O
with	O
ketamine	S-drug-EF-2
.	O

Ketamine	S-drug
is	O
clinically	O
compatible	O
with	O
the	O
commonly	O
used	O
general	O
and	O
local	O
anesthetic	B-group
agents	E-group
when	O
an	O
adequate	O
respiratory	O
exchange	O
is	O
maintained	O
.	O

Ketoconazole	S-drug
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
.	O

Coadministration	O
of	O
NIZORAL	S-brand
Tablets	O
and	O
drugs	O
primarily	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
drugs	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Therefore	O
,	O
unless	O
otherwise	O
specified	O
,	O
appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

The	O
following	O
drug	O
interactions	O
have	O
been	O
identified	O
involving	O
NIZORAL	S-brand
Tablets	O
and	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
:	O
Ketoconazole	S-drug-ME-1
tablets	O
inhibit	O
the	O
metabolism	O
of	O
terfenadine	S-drug-ME-2
,	O
resulting	O
in	O
an	O
increased	O
plasma	O
concentration	O
of	O
terfenadine	S-drug
and	O
a	O
delay	O
in	O
the	O
elimination	O
of	O
its	O
acid	O
metabolite	O
.	O

The	O
increased	O
plasma	O
concentration	O
of	O
terfenadine	S-drug
or	O
its	O
metabolite	O
may	O
result	O
in	O
prolonged	O
QT	O
intervals	O
.	O

Pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	S-drug-EF-1
inhibits	O
the	O
metabolism	O
of	O
astemizole	S-drug-EF-2
,	O
resulting	O
in	O
elevated	O
plasma	O
levels	O
of	O
astemizole	S-drug
and	O
its	O
active	O
metabolite	O
desmethylastemizole	S-drug_n
which	O
may	O
prolong	O
QT	O
intervals	O
.	O

Coadministration	O
of	O
astemizole	S-drug-AD-1
with	O
ketoconazole	S-drug-AD-2
tablets	O
is	O
therefore	O
contraindicated	O
.	O

Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	S-drug-ME-1
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	S-drug-ME-2
resulting	O
in	O
a	O
mean	O
eight	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
cisapride	S-drug
.	O

Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	S-drug-EF-1
and	O
cisapride	S-drug-EF-2
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Therefore	O
concomitant	O
administration	O
of	O
ketoconazole	S-drug-AD-1
tablets	O
with	O
cisapride	S-drug-AD-2
is	O
contraindicated	O
.	O

Ketoconazole	S-drug-ME-1
tablets	O
may	O
alter	O
the	O
metabolism	O
of	O
cyclosporine	S-drug-ME-2
,	O
tacrolimus	S-drug-ME-2
,	O
and	O
methylprednisolone	S-drug-ME-2
,	O
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
drugs	O
.	O

Dosage	O
adjustment	O
may	O
be	O
required	O
if	O
cyclosporine	S-drug
,	O
tacrolimus	S-drug
,	O
or	O
methylprednisolone	S-drug
are	O
given	O
concomitantly	O
with	O
NIZORAL	S-brand
Tablets	O
.	O

Coadministration	O
of	O
NIZORAL	S-brand-ME-1
Tablets	O
with	O
midazolam	S-drug-ME-2
or	O
triazolam	S-drug-ME-2
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	O
.	O

This	O
may	O
potentiate	O
and	O
prolong	O
hypnotic	O
and	O
sedative	O
effects	O
,	O
especially	O
with	O
repeated	O
dosing	O
or	O
chronic	O
administration	O
of	O
these	O
agents	O
.	O

These	O
agents	O
should	O
not	O
be	O
used	O
in	O
patients	O
treated	O
with	O
NIZORAL	S-brand
Tablets	O
.	O

If	O
midazolam	S-drug
is	O
administered	O
parenterally	O
,	O
special	O
precaution	O
is	O
required	O
since	O
the	O
sedative	O
effect	O
may	O
be	O
prolonged	O
.	O

Rare	O
cases	O
of	O
elevated	O
plasma	O
concentrations	O
of	O
digoxin	S-drug
have	O
been	O
reported	O
.	O

It	O
is	O
not	O
clear	O
whether	O
this	O
was	O
due	O
to	O
the	O
combination	O
of	O
therapy	O
.	O

It	O
is	O
,	O
therefore	O
,	O
advisable	O
to	O
monitor	O
digoxin	S-drug-AD-1
concentrations	O
in	O
patients	O
receiving	O
ketoconazole	S-drug-AD-2
.	O

When	O
taken	O
orally	O
,	O
imidazole	B-group-EF-1
compounds	E-group-EF-1
like	O
ketoconazole	S-drug-EF-1
may	O
enhance	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	S-group-EF-2
-	O
like	O
drugs	O
.	O

In	O
simultaneous	O
treatment	O
with	O
imidazole	B-group-AD-1
drugs	E-group-AD-1
and	O
coumarin	B-group-AD-2
drugs	E-group-AD-2
,	O
the	O
anticoagulant	O
effect	O
should	O
be	O
carefully	O
titrated	O
and	O
monitored	O
.	O

Because	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
oral	O
miconazole	S-drug-EF-1
(	O
an	O
imidazole	S-group
)	O
and	O
oral	O
hypoglycemic	B-group-EF-2
agents	E-group-EF-2
,	O
such	O
a	O
potential	O
interaction	O
involving	O
the	O
latter	O
agents	O
when	O
used	O
concomitantly	O
with	O
ketoconazole	S-drug
tablets	O
(	O
an	O
imidazole	S-group
)	O
can	O
not	O
be	O
ruled	O
out	O
.	O

Concomitant	O
administration	O
of	O
ketoconazole	S-drug-ME-1
tablets	O
with	O
phenytoin	S-drug-ME-2
may	O
alter	O
the	O
metabolism	O
of	O
one	O
or	O
both	O
of	O
the	O
drugs	O
.	O

It	O
is	O
suggested	O
to	O
monitor	O
both	O
ketoconazole	S-drug-AD-1
and	O
phenytoin	S-drug-AD-2
.	O

Concomitant	O
administration	O
of	O
rifampin	S-drug-ME-1
with	O
ketoconazole	S-drug-ME-2
tablets	O
reduces	O
the	O
blood	O
levels	O
of	O
the	O
latter	O
.	O

INH	S-drug-ME-1
(	O
Isoniazid	S-drug-ME-1
)	O
is	O
also	O
reported	O
to	O
affect	O
ketoconazole	S-drug-ME-2
concentrations	O
adversely	O
.	O

These	O
drugs	O
should	O
not	O
be	O
given	O
concomitantly	O
.	O

After	O
the	O
coadministration	O
of	O
200	O
mg	O
oral	O
ketoconazole	S-drug-ME-1
twice	O
daily	O
and	O
one	O
20	O
mg	O
dose	O
of	O
loratadine	S-drug-ME-2
to	O
11	O
subjects	O
,	O
the	O
AUC	O
and	O
Cmax	O
of	O
loratadine	S-drug
averaged	O
302	O
%	O
(	O
142	O
S.D	O
.	O
)	O
and	O
251	O
%	O
(	O
68	O
S.D	O
.	O
)	O
,	O
respectively	O
,	O
of	O
those	O
obtained	O
after	O
co	O
-	O
treatment	O
with	O
placebo	O
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
descarboethoxyloratadine	S-drug_n
,	O
an	O
active	O
metabolite	O
,	O
averaged	O
155	O
%	O
(	O
27	O
S.D	O
.	O
)	O
and	O
141	O
%	O
(	O
35	O
S.D	O
.	O
)	O
,	O
respectively	O
.	O

However	O
,	O
no	O
related	O
changes	O
were	O
noted	O
in	O
the	O
QT0	O
on	O
ECG	O
taken	O
at	O
2	O
,	O
6	O
,	O
and	O
24	O
hours	O
after	O
the	O
coadministration	O
.	O

Also	O
,	O
there	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
adverse	O
events	O
when	O
loratadine	S-drug
was	O
administered	O
with	O
or	O
without	O
ketoconazole	S-drug
.	O

Rare	O
cases	O
of	O
a	O
disulfiram	O
-	O
like	O
reaction	O
to	O
alcohol	S-drug
have	O
been	O
reported	O
.	O

These	O
experiences	O
have	O
been	O
characterized	O
by	O
flushing	O
,	O
rash	O
,	O
peripheral	O
edema	O
,	O
nausea	O
,	O
and	O
headache	O
.	O

Symptoms	O
resolved	O
within	O
a	O
few	O
hours	O
.	O

The	O
following	O
drug	O
interactions	O
were	O
studied	O
with	O
ketoprofen	S-drug
doses	O
of	O
200	O
mg	O
/	O
day	O
.	O

The	O
possibility	O
of	O
increased	O
interaction	O
should	O
be	O
kept	O
in	O
mind	O
when	O
Orudis	S-brand
doses	O
greater	O
than	O
50	O
mg	O
as	O
a	O
single	O
dose	O
or	O
200	O
mg	O
of	O
ketoprofen	S-drug
per	O
day	O
are	O
used	O
concomitantly	O
with	O
highly	O
bound	O
drugs	O
.	O

1	O
.	O

Antacids	S-group
:	O
Concomitant	O
administration	O
of	O
magnesium	B-drug
hydroxide	E-drug
and	O
aluminum	B-drug
hydroxide	E-drug
does	O
not	O
interfere	O
with	O
the	O
rate	O
or	O
extent	O
of	O
the	O
absorption	O
of	O
ketoprofen	S-drug
administered	O
as	O
Orudis	S-brand
.	O

2	O
.	O

Aspirin	S-brand
:	O
Ketoprofen	S-drug
does	O
not	O
alter	O
aspirin	S-brand
absorption	O
;	O

however	O
,	O
in	O
a	O
study	O
of	O
12	O
normal	O
subjects	O
,	O
concurrent	O
administration	O
of	O
aspirin	S-brand-ME-1
decreased	O
ketoprofen	S-drug-ME-2
protein	O
binding	O
and	O
increased	O
ketoprofen	S-drug-ME-2
plasma	O
clearance	O
from	O
0.07	O
L	O
/	O
kg	O
/	O
h	O
without	O
aspirin	S-brand
to	O
0.11	O
L	O
/	O
kg	O
/	O
h	O
with	O
aspirin	S-brand
.	O

The	O
clinical	O
significance	O
of	O
these	O
changes	O
has	O
not	O
been	O
adequately	O
studied	O
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
aspirin	S-brand-AD-1
and	O
ketoprofen	S-drug-AD-2
is	O
not	O
recommended	O
.	O

3	O
.	O

Diuretic	S-group
:	O
Hydrochlorothiazide	S-drug-EF-1
,	O
given	O
concomitantly	O
with	O
ketoprofen	S-drug-EF-2
,	O
produces	O
a	O
reduction	O
in	O
urinary	O
potassium	O
and	O
chloride	O
excretion	O
compared	O
to	O
hydrochlorothiazide	S-drug
alone	O
.	O

Patients	O
taking	O
diuretics	S-group
are	O
at	O
a	O
greater	O
risk	O
of	O
developing	O
renal	O
failure	O
secondary	O
to	O
a	O
decrease	O
in	O
renal	O
blood	O
flow	O
caused	O
by	O
prostaglandin	O
inhibition	O
.	O

4	O
.	O

Digoxin	S-drug
:	O
In	O
a	O
study	O
in	O
12	O
patients	O
with	O
congestive	O
heart	O
failure	O
where	O
ketoprofen	S-drug
and	O
digoxin	S-drug
were	O
concomitantly	O
administered	O
,	O
ketoprofen	S-drug
did	O
not	O
alter	O
the	O
serum	O
levels	O
of	O
digoxin	S-drug
.	O

5	O
.	O

Warfarin	S-drug
:	O
In	O
a	O
short	O
-	O
term	O
controlled	O
study	O
in	O
14	O
normal	O
volunteers	O
,	O
ketoprofen	S-drug
did	O
not	O
significantly	O
interfere	O
with	O
the	O
effect	O
of	O
warfarin	S-drug
on	O
prothrombin	O
time	O
.	O

Bleeding	O
from	O
a	O
number	O
of	O
sites	O
may	O
be	O
a	O
complication	O
of	O
warfarin	S-drug
treatment	O
and	O
GI	O
bleeding	O
a	O
complication	O
of	O
ketoprofen	S-drug
treatment	O
.	O

Because	O
prostaglandina	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
and	O
ketoprofen	S-drug
has	O
an	O
effect	O
on	O
platelet	O
function	O
as	O
well	O
,	O
concurent	O
therapy	O
with	O
ketoprofen	S-drug-AD-1
and	O
warfarin	S-drug-AD-2
requires	O
close	O
monitoring	O
of	O
patients	O
on	O
both	O
drugs	O
.	O

6	O
.	O

Probenecid	S-drug
:	O
Probenecid	S-drug-ME-1
increases	O
both	O
free	O
and	O
bound	O
ketoprofen	S-drug-ME-2
by	O
reducing	O
the	O
plasma	O
clearance	O
of	O
ketoprofen	S-drug
to	O
about	O
one	O
-	O
third	O
,	O
as	O
well	O
as	O
decreasing	O
its	O
protein	O
binding	O
.	O

Therefore	O
,	O
the	O
combination	O
of	O
ketoprofen	S-drug-AD-1
and	O
probenecid	S-drug-AD-2
is	O
not	O
recommended	O
.	O

7	O
.	O

Methotrexate	S-drug
:	O
Ketoprofen	S-drug-ME-1
,	O
like	O
other	O
NSAIDs	S-group-ME-1
,	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
methotrexate	S-drug-ME-2
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
the	O
drug	O
and	O
increased	O
toxicity	O
.	O

8	O
.	O

Lithium	S-drug
:	O
Nonsteroidal	B-group-ME-1
anti	I-group-ME-1
-	I-group-ME-1
inflammatory	I-group-ME-1
agents	E-group-ME-1
have	O
been	O
reported	O
to	O
increase	O
steadystate	O
plasma	O
lithium	S-drug-ME-2
levels	O
.	O

It	O
is	O
recommended	O
that	O
plasma	O
lithium	S-drug
levels	O
be	O
monitored	O
when	O
ketoprofen	S-drug-AD-1
is	O
coadministered	O
with	O
lithium	S-drug-AD-2
.	O

DRUG	O
/	O
LABORATORY	O
TEST	O
INTERACTIONS	O
:	O
EFFECT	O
ON	O
BLOOD	O
COAGULATION	O
Ketoprofen	S-drug
decreases	O
platelet	O
adhesion	O
and	O
aggregation	O
.	O

Therefore	O
,	O
it	O
can	O
prolong	O
bleeding	O
time	O
by	O
approximately	O
3	O
to	O
4	O
minutes	O
from	O
baseline	O
values	O
.	O

There	O
is	O
no	O
significant	O
change	O
in	O
platelet	O
count	O
,	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
or	O
thrombin	O
time	O
.	O

Ketorolac	S-drug
is	O
highly	O
bound	O
to	O
human	O
plasma	O
protein	O
(	O
mean	O
99.2	O
%	O
)	O
.	O

Warfarin	S-drug
,	O
Digoxin	S-drug
,	O
Salicylate	S-group
,	O
and	O
Heparin	S-drug
The	O
in	O
vitro	O
binding	O
of	O
warfarin	S-drug-ME-1
to	O
plasma	O
proteins	O
is	O
only	O
slightly	O
reduced	O
by	O
ketorolac	B-drug-ME-2
tromethamine	E-drug-ME-2
(	O
99.5	O
%	O
control	O
vs	O
99.3	O
%	O
)	O
when	O
ketorolac	S-drug
plasma	O
concentrations	O
reach	O
5	O
to10	O
m	O
g	O
/	O
mL	O
.	O

Ketorolac	S-drug
does	O
not	O
alter	O
digoxin	S-drug
protein	O
binding	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
,	O
at	O
therapeutic	O
concentrations	O
of	O
salicylate	S-group-ME-1
(	O
300	O
m	O
g	O
/	O
mL	O
)	O
,	O
the	O
binding	O
of	O
ketorolac	S-drug-ME-2
was	O
reduced	O
from	O
approximately	O
99.2	O
%	O
to	O
97.5	O
%	O
,	O
representing	O
a	O
potential	O
twofold	O
increase	O
in	O
unbound	O
ketorolac	S-drug
plasma	O
levels	O
.	O

Therapeutic	O
concentrations	O
of	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
ibuprofen	S-drug
,	O
naproxen	S-drug
,	O
piroxicam	S-drug
,	O
acetaminophen	S-drug
,	O
phenytoin	S-drug
andtolbutamide	O
did	O
not	O
alter	O
ketorolac	B-drug
tromethamine	E-drug
protein	O
binding	O
.	O

In	O
a	O
study	O
involving	O
12	O
adult	O
volunteers	O
,	O
TORADOLORAL	O
was	O
coadministered	O
with	O
a	O
single	O
dose	O
of	O
25	O
mg	O
warfarin	S-drug
,	O
causing	O
no	O
significant	O
changes	O
in	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	S-drug
.	O

In	O
another	O
study	O
,	O
TORADOLIV	O
/	O
IM	O
was	O
given	O
with	O
two	O
doses	O
of	O
5000	O
U	O
of	O
heparin	S-drug
to	O
11	O
healthy	O
volunteers	O
,	O
resulting	O
in	O
a	O
mean	O
template	O
bleeding	O
time	O
of	O
6.4	O
minutes	O
(	O
3.2	O
to	O
11.4	O
min	O
)	O
compared	O
to	O
a	O
mean	O
of	O
6.0	O
minutes	O
(	O
3.4	O
to	O
7.5	O
min	O
)	O
for	O
heparin	S-drug
alone	O
and	O
5.1	O
minutes	O
(	O
3.5	O
to	O
8.5	O
min	O
)	O
for	O
placebo	O
.	O

Although	O
these	O
results	O
do	O
not	O
indicate	O
a	O
significant	O
interaction	O
between	O
TORADOL	S-brand
and	O
warfarin	S-drug
or	O
heparin	S-drug
,	O
the	O
administration	O
of	O
TORADOL	S-brand-AD-1
to	O
patients	O
taking	O
anticoagulants	S-group-AD-2
should	O
be	O
done	O
extremely	O
cautiously	O
,	O
and	O
patients	O
should	O
be	O
closely	O
monitored	O
.	O

Furosemide	S-drug
:	O
TORADOL	S-brand-EF-1
IV	O
/	O
IM	O
reduced	O
the	O
diuretic	S-group
response	O
to	O
furosemide	S-drug-EF-2
in	O
normovolemic	O
healthy	O
subjects	O
by	O
approximately	O
20	O
%	O
(	O
mean	O
sodium	O
and	O
urinary	O
output	O
decreased	O
17	O
%	O
)	O
.	O

Probenecid	S-drug
:	O
Concomitant	O
administration	O
of	O
TORADOL	S-brand-ME-1
ORAL	O
and	O
probenecid	S-drug-ME-2
resulted	O
in	O
decreased	O
clearance	O
of	O
ketorolac	S-drug
and	O
significant	O
increases	O
in	O
ketorolac	S-drug
plasma	O
levels	O
(	O
total	O
AUC	O
increased	O
approximately	O
threefold	O
from	O
5.4	O
to	O
17.8	O
m	O
g	O
/	O
h	O
/	O
mL	O
)	O
and	O
terminal	O
half	O
-	O
life	O
increased	O
approximately	O
twofold	O
from	O
6.6	O
to	O
15.1	O
hours	O
.	O

Therefore	O
,	O
concomitant	O
use	O
of	O
TORADOL	S-brand-AD-1
and	O
probenecid	S-drug-AD-2
is	O
contraindicated	O
.	O

Lithium	S-drug
:	O
Inhibition	O
of	O
renal	O
lithium	S-drug
clearance	O
,	O
leading	O
to	O
an	O
increase	O
in	O
plasma	O
lithium	S-drug
concentration	O
,	O
has	O
been	O
reported	O
with	O
some	O
prostaglandin	O
synthesis	O
-	O
inhibiting	O
drugs	O
.	O

The	O
effect	O
of	O
TORADOL	S-brand
on	O
plasma	O
lithium	S-drug
has	O
not	O
been	O
studied	O
,	O
but	O
cases	O
of	O
increased	O
lithium	S-drug-ME-1
plasma	O
levels	O
during	O
TORADOL	S-brand-ME-2
therapy	O
have	O
been	O
reported	O
.	O

Methotrexate	S-drug
:	O
Concomitant	O
administration	O
of	O
methotrexate	S-drug-ME-1
and	O
some	O
NSAIDs	S-group-ME-2
has	O
been	O
reported	O
to	O
reduce	O
the	O
clearance	O
of	O
methotrexate	S-drug
,	O
enhancing	O
the	O
toxicity	O
of	O
methotrexate	S-drug
.	O

The	O
effect	O
of	O
TORADOL	S-brand
on	O
methotrexate	S-drug
clearance	O
has	O
not	O
been	O
studied	O
.	O

Nondepolarizing	B-group
Muscle	I-group
Relaxants	E-group
:	O
In	O
postmarketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
a	O
possible	O
interaction	O
between	O
TORADOLIV	O
/	O
IM	O
and	O
nondepolarizing	B-group
muscle	I-group
relaxants	E-group
that	O
resulted	O
in	O
apnea	O
.	O

The	O
concurrent	O
use	O
of	O
TORADOL	S-brand
with	O
muscle	B-group
relaxants	E-group
has	O
not	O
been	O
formally	O
studied	O
.	O

ACE	B-group
Inhibitors	E-group
:	O
Concomitant	O
use	O
of	O
ACE	B-group
inhibitors	E-group
may	O
increase	O
the	O
risk	O
of	O
renal	O
impairment	O
,	O
particularly	O
in	O
volume	O
-	O
depleted	O
patients	O
.	O

Antiepileptic	B-group
Drugs	E-group
:	O
Sporadic	O
cases	O
of	O
seizures	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
TORADOL	S-brand-EF-1
and	O
antiepileptic	B-group-EF-2
drugs	E-group-EF-2
(	O
phenytoin	S-drug-EF-2
,	O
carbamazepine	S-drug-EF-2
)	O
.	O

Psychoactive	B-group
Drugs	E-group
:	O
Hallucinations	O
have	O
been	O
reported	O
when	O
TORADOL	S-brand-EF-1
was	O
used	O
in	O
patients	O
taking	O
psychoactive	B-group-EF-2
drugs	E-group-EF-2
(	O
fluoxetine	S-drug-EF-2
,	O
thiothixene	S-drug-EF-2
,	O
alprazolam	S-drug-EF-2
)	O
.	O

Morphine	S-drug
:	O
TORADOLIV	O
/	O
IM	O
has	O
been	O
administered	O
concurrently	O
with	O
morphine	S-drug
in	O
several	O
clinical	O
trials	O
of	O
postoperative	O
pain	O
without	O
evidence	O
of	O
adverse	O
interactions	O
.	O

Do	O
not	O
mix	O
TORADOL	S-brand
and	O
morphine	S-drug
in	O
the	O
same	O
syringe	O
.	O

There	O
is	O
no	O
evidence	O
in	O
animal	O
or	O
human	O
studies	O
that	O
TORADOL	S-brand
induces	O
or	O
inhibits	O
hepatic	O
enzymes	O
capable	O
of	O
metabolizing	O
itself	O
or	O
other	O
drugs	O

Cyclosporine	S-drug
-	O
L	B-drug-EF-1
-	I-drug-EF-1
arginine	E-drug-EF-1
may	O
counteract	O
the	O
antinaturetic	O
effect	O
of	O
cyclosporin	S-drug-EF-2
.	O

Ibuprofen	S-drug
-	O
L	B-drug-ME-1
-	I-drug-ME-1
arginine	E-drug-ME-1
may	O
increase	O
the	O
absorption	O
of	O
ibuprofen	S-drug-ME-2
if	O
taken	O
concomitantly	O
.	O

Organic	O
nitrates	S-group
-	O
L	B-drug-EF-1
-	I-drug-EF-1
arginine	E-drug-EF-1
supplements	O
theoretically	O
may	O
potentiate	O
the	O
effects	O
of	O
organic	O
nitrates	S-drug-EF-2
if	O
taken	O
concomitantly	O
.	O

Sildenafil	B-drug
citrate	E-drug
-	O
Theoretically	O
,	O
L	B-drug-EF-1
-	I-drug-EF-1
arginine	E-drug-EF-1
supplements	O
taken	O
concomitantly	O
with	O
sildenafil	B-drug-EF-2
citrate	E-drug-EF-2
,	O
may	O
potentiate	O
the	O
effects	O
of	O
the	O
drug	O
.	O

No	O
drug	O
,	O
nutritional	O
supplement	O
,	O
food	O
or	O
herb	O
interactions	O
are	O
known	O
.	O

Interacts	O
with	O
valproic	B-drug
acid	E-drug

No	O
well	O
-	O
known	O
drug	O
interactions	O
with	O
glutamic	B-drug
acid	E-drug

Human	B-drug
growth	I-drug
hormone	E-drug
-	O
Concomitant	O
use	O
of	O
L	B-drug-ME-1
-	I-drug-ME-1
glutamine	E-drug-ME-1
and	O
human	B-drug-ME-2
growth	I-drug-ME-2
hormone	E-drug-ME-2
may	O
enhance	O
nutrient	O
absorption	O
in	O
those	O
with	O
severe	O
short	O
bowel	O
syndrome	O
.	O

L	B-drug
-	I-drug
glutamine	E-drug
has	O
orphan	O
drug	O
status	O
for	O
this	O
indication	O
.	O

Indomethacin	S-drug
-	O
Concomitant	O
use	O
of	O
L	B-drug-EF-1
-	I-drug-EF-1
glutamine	E-drug-EF-1
and	O
indomethacin	S-drug-EF-2
may	O
ameliorate	O
increased	O
intestinal	O
permeability	O
caused	O
by	O
indomethacin	S-drug
.	O

The	O
reported	O
dose	O
used	O
for	O
L	B-drug
-	I-drug
glutamine	E-drug
was	O
21	O
grams	O
daily	O
taken	O
in	O
divided	O
doses	O
three	O
times	O
a	O
day	O
.	O

Further	O
,	O
misoprostol	S-drug
is	O
reported	O
to	O
have	O
a	O
synergistic	O
effect	O
with	O
this	O
combination	O
in	O
ameliorating	O
intestinal	O
permeability	O
.	O

Methotrexate	S-drug
-	O
There	O
is	O
one	O
report	O
that	O
methotrexate	S-drug-EF-1
may	O
decrease	O
the	O
possible	O
effectiveness	O
of	O
supplemental	O
L	B-drug-EF-2
-	I-drug-EF-2
glutamine	E-drug-EF-2
for	O
chemotherapy	O
-	O
induced	O
mucositis	O
.	O

In	O
another	O
report	O
,	O
nine	O
patients	O
with	O
breast	O
cancer	O
were	O
reported	O
to	O
have	O
decreased	O
symptoms	O
of	O
methotrexate	S-drug-EF-1
-	O
related	O
toxicity	O
when	O
given	O
supplemental	O
L	B-drug-EF-2
-	I-drug-EF-2
glutamine	E-drug-EF-2
at	O
a	O
dose	O
of	O
0.5	O
gram	O
/	O
kilogram	O
/	O
day	O
.	O

Paclitaxel	S-drug
-	O
In	O
one	O
report	O
,	O
L	B-drug-EF-1
-	I-drug-EF-1
glutamine	E-drug-EF-1
at	O
a	O
dose	O
of	O
10	O
grams	O
three	O
times	O
daily	O
,	O
given	O
24	O
hours	O
after	O
receiving	O
paclitaxel	S-drug-EF-2
,	O
appeared	O
to	O
prevent	O
the	O
development	O
of	O
myalgia	O
and	O
arthralgia	O
,	O
adverse	O
reactions	O
of	O
paclitaxel	S-drug
.	O

Medroxyprogesterone	B-drug
Acetate	E-drug
-	O
L	B-drug-EF-1
-	I-drug-EF-1
histidine	E-drug-EF-1
was	O
observed	O
to	O
enhance	O
(	O
in	O
tissue	O
culture	O
)	O
the	O
effect	O
of	O
medroxyprogesterone	B-drug-EF-2
acetate	E-drug-EF-2
in	O
reducing	O
the	O
number	O
of	O
human	O
breast	O
cancer	O
cells	O
that	O
were	O
in	O
the	O
S	O
phase	O
.	O

H1	S-group
and	O
H2	B-group
Blockers	E-group
-	O
Although	O
not	O
reported	O
,	O
L	B-drug-EF-1
-	I-drug-EF-1
histidine	E-drug-EF-1
,	O
via	O
its	O
metabolism	O
to	O
histamine	O
,	O
might	O
decrease	O
the	O
efficacy	O
of	O
H1	S-group-EF-2
and	O
H2	B-group-EF-2
blockers	E-group-EF-2
.	O

Concomitant	O
use	O
of	O
calcium	S-drug-ME-1
supplements	O
and	O
L	B-drug-ME-2
-	I-drug-ME-2
lysine	E-drug-ME-2
may	O
increase	O
calcium	S-drug
absorption	O

Acetaminophen	S-drug
and	O
methotrexate	S-drug
-	O
L	B-drug-EF-1
-	I-drug-EF-1
methionine	E-drug-EF-1
may	O
decrease	O
hepatic	O
toxicity	O
in	O
those	O
with	O
acetaminophen	S-drug-EF-2
overdosage	O
or	O
in	O
those	O
taking	O
methotrexate	S-drug-EF-2
.	O

Theoretically	O
,	O
it	O
may	O
decrease	O
hepatic	O
toxicity	O
in	O
the	O
case	O
of	O
other	O
potential	O
hepatotoxic	O
drugs	O
,	O
as	O
well	O
.	O

Gentamicin	S-drug
-	O
Methionine	S-drug-EF-1
may	O
protect	O
against	O
the	O
ototoxic	O
effects	O
of	O
gentamicin	S-drug-EF-2
.	O

Non	B-group
-	I-group
selective	I-group
monoamine	I-group
oxidase	I-group
(	I-group
MAO	I-group
)	I-group
inhibitors	E-group
-	O
including	O
phenelzine	B-drug
sulfate	E-drug
,	O
tranylcypromine	B-drug
sulfate	E-drug
and	O
pargyline	S-drug
HC1	O
.	O

Concomitant	O
use	O
of	O
L	B-drug-EF-1
-	I-drug-EF-1
phenylalanine	E-drug-EF-1
and	O
non	B-group-EF-2
-	I-group-EF-2
selective	I-group-EF-2
MAO	I-group-EF-2
inhibitors	E-group-EF-2
may	O
cause	O
hypertension	O
.	O

Selegiline	S-drug
-	O
L	B-drug-EF-1
-	I-drug-EF-1
phenylalanine	E-drug-EF-1
and	O
the	O
selective	B-group
MAO	I-group
inhibitor	E-group
selegiline	S-drug-EF-2
may	O
have	O
synergistic	O
antidepressant	O
activity	O
if	O
used	O
concomitantly	O
.	O

Neuroleptic	B-group-EF-1
Drugs	E-group-EF-1
-	O
L	B-drug-EF-2
-	I-drug-EF-2
phenylalanine	E-drug-EF-2
may	O
potentiate	O
the	O
tardive	O
dyskinesia	O
side	O
reactions	O
of	O
neuroleptic	B-group
drugs	E-group
if	O
used	O
concomitantly	O
with	O
them	O
.	O

Monoamine	B-group
oxidase	I-group
(	I-group
MAO	I-group
)	I-group
inhibitors	E-group
such	O
as	O
isocarboxazid	S-drug
(	O
e.g	O
.	O
,	O
Marplan	S-brand
)	O
,	O
phenelzine	S-drug
(	O
e.g	O
.	O
,	O
Nardil	S-brand
)	O
,	O
procarbazine	S-drug
(	O
e.g	O
.	O
,	O
Matulane	S-brand
)	O
,	O
selegiline	S-drug
(	O
e.g	O
.	O
,	O
Eldepryl	S-brand
)	O
,	O
and	O
tranylcypromine	S-drug
(	O
e.g	O
.	O
,	O
Parnate	S-brand
)	O
:	O
Using	O
these	O
medicines	O
with	O
L	B-drug
-	I-drug
tryptophan	E-drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O

Non	B-group
-	I-group
selective	I-group
MAO	I-group
inhibitors	E-group
including	O
tranylcypromine	B-drug
sulfate	E-drug
,	O
phenelzine	B-drug
sulfate	E-drug
,	O
and	O
pargyline	S-drug
HC1	O
:	O
Concomitant	O
use	O
of	O
L	B-drug-EF-1
-	I-drug-EF-1
tyrosine	E-drug-EF-1
and	O
non	O
-	O
selective	O
MAO	B-group-EF-2
inhibitors	E-group-EF-2
may	O
cause	O
hypertension	O
.	O

In	O
one	O
survey	O
,	O
2.3	O
%	O
of	O
patients	O
taking	O
labetalol	B-drug-EF-1
HCl	E-drug-EF-1
in	O
combination	O
with	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
experienced	O
tremor	O
,	O
as	O
compared	O
to	O
0.7	O
%	O
reported	O
to	O
occur	O
with	O
labetalol	B-drug
HCl	E-drug
alone	O
.	O

The	O
contribution	O
of	O
each	O
of	O
the	O
treatments	O
to	O
this	O
adverse	O
reaction	O
is	O
unknown	O
but	O
the	O
possibility	O
of	O
a	O
drug	O
interaction	O
can	O
not	O
be	O
excluded	O
.	O

Drugs	O
possessing	O
beta	O
-	O
blocking	O
properties	O
can	O
blunt	O
the	O
bronchodilator	O
effect	O
of	O
beta	B-group
-	I-group
receptor	I-group
agonist	I-group
drugs	E-group
in	O
patients	O
with	O
bronchospasm	O
;	O

therefore	O
,	O
doses	O
greater	O
than	O
the	O
normal	O
antiasthmatic	O
dose	O
of	O
beta	B-group
-	I-group
agonist	I-group
bronchodilator	I-group
drugs	E-group
may	O
be	O
required	O
.	O

Cimetidine	S-drug-ME-1
has	O
been	O
shown	O
to	O
increase	O
the	O
bioavailability	O
of	O
labetalol	B-drug-ME-2
HCl	E-drug-ME-2
.	O

Since	O
this	O
could	O
be	O
explained	O
either	O
by	O
enhanced	O
absorption	O
or	O
by	O
an	O
alteration	O
of	O
hepatic	O
metabolism	O
of	O
labetalol	B-drug
HCl	E-drug
,	O
special	O
care	O
should	O
be	O
used	O
in	O
establishing	O
the	O
dose	O
required	O
for	O
blood	O
pressure	O
control	O
in	O
such	O
patients	O
.	O

Synergism	O
has	O
been	O
shown	O
between	O
halothane	S-drug-EF-1
anesthesia	O
and	O
intravenously	O
administered	O
labetalol	B-drug-EF-2
HCl	E-drug-EF-2
.	O

During	O
controlled	O
hypotensive	O
anesthesia	O
using	O
labetalol	B-drug-EF-1
HCl	E-drug-EF-1
in	O
association	O
with	O
halothane	S-drug-EF-2
,	O
high	O
concentrations	O
(	O
3	O
%	O
or	O
above	O
)	O
of	O
halothane	S-drug
should	O
not	O
be	O
used	O
because	O
the	O
degree	O
of	O
hypotension	O
will	O
be	O
increased	O
and	O
because	O
of	O
the	O
possibility	O
of	O
a	O
large	O
reduction	O
in	O
cardiac	O
output	O
and	O
an	O
increase	O
in	O
central	O
venous	O
pressure	O
.	O

The	O
anesthesiologist	O
should	O
be	O
informed	O
when	O
a	O
patient	O
is	O
receiving	O
labetalol	B-drug
HCl	E-drug
.	O

Labetalol	B-drug-EF-1
HCl	E-drug-EF-1
blunts	O
the	O
reflex	O
tachycardia	O
produced	O
by	O
nitroglycerin	S-drug-EF-2
without	O
preventing	O
its	O
hypotensive	O
effect	O
.	O

If	O
labetalol	B-drug-EF-1
HCl	E-drug-EF-1
is	O
used	O
with	O
nitroglycerin	S-drug-EF-2
in	O
patients	O
with	O
angina	O
pectoris	O
,	O
additional	O
antihypertensive	O
effects	O
may	O
occur	O
.	O

Care	O
should	O
be	O
taken	O
if	O
labetalol	S-drug-AD-1
is	O
used	O
concomitantly	O
with	O
calcium	B-group-AD-2
antagonists	O
of	O
the	O
verapamil	S-drug
type	O
.	O

Risk	O
of	O
Anaphylactic	O
Reaction	O
While	O
taking	O
beta	B-group
-	I-group
blockers	E-group
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	S-drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
presence	O
of	O
labetalol	O
metabolites	O
in	O
the	O
urine	O
may	O
result	O
in	O
falsely	O
elevated	O
levels	O
of	O
urinary	O
catecholamines	O
,	O
metanephrine	O
,	O
normetanephrine	O
and	O
vanillylmandelic	O
acid	O
when	O
measured	O
by	O
fluorimetric	O
or	O
photometric	O
methods	O
.	O

In	O
screening	O
patients	O
suspected	O
of	O
having	O
a	O
pheochromocytoma	O
and	O
being	O
treated	O
with	O
labetalol	B-drug
HCl	E-drug
,	O
a	O
specific	O
method	O
,	O
such	O
as	O
a	O
high	O
performance	O
liquid	O
chromatographic	O
assay	O
with	O
solid	O
phase	O
extraction	O
(	O
e.g	O
.	O
,	O
J	O
Chromatogr	O
385	O
:	O
241,1987	O
)	O
should	O
be	O
employed	O
in	O
determining	O
levels	O
of	O
catecholamines	O
.	O

Labetalol	B-drug
HCl	E-drug
has	O
also	O
been	O
reported	O
to	O
produce	O
a	O
false	O
positive	O
test	O
for	O
amphetamine	S-drug
when	O
screening	O
urine	O
for	O
the	O
presence	O
of	O
drugs	O
using	O
the	O
commercially	O
available	O
assay	O
methods	O
Toxi	O
-	O
Lab	O
A	O
(	O
thin	O
-	O
layer	O
chromatographic	O
assay	O
)	O
and	O
Emit	O
-	O
d.a.u	O
.	O
(	O
radioenzymatic	O
assay	O
)	O
.	O

When	O
patients	O
being	O
treated	O
with	O
labetalol	S-drug
have	O
a	O
positive	O
urine	O
test	O
for	O
amphetamine	S-drug
using	O
these	O
techniques	O
confirmation	O
should	O
be	O
made	O
by	O
using	O
more	O
specific	O
methods	O
such	O
as	O
a	O
gas	O
chromatographic	O
-	O
mass	O
spectrometer	O
technique	O
.	O

Results	O
of	O
preliminary	O
studies	O
in	O
humans	O
and	O
rats	O
suggest	O
that	O
nonabsorbable	O
antacids	S-group-ME-1
given	O
concurrently	O
with	O
lactulose	S-drug-ME-2
may	O
inhibit	O
the	O
desired	O
lactulose	S-drug
-	O
induced	O
drop	O
in	O
colonic	O
pH	O
.	O

Therefore	O
,	O
a	O
possible	O
lack	O
of	O
desired	O
effect	O
of	O
treatment	O
should	O
be	O
taken	O
into	O
consideration	O
before	O
such	O
drugs	O
are	O
given	O
concomitantly	O
with	O
lactulose	S-drug
.	O

Lamivudine	S-drug
is	O
predominantly	O
eliminated	O
in	O
the	O
urine	O
by	O
active	O
organic	O
cationic	O
secretion	O
.	O

The	O
possibility	O
of	O
interactions	O
with	O
other	O
drugs	O
administered	O
concurrently	O
should	O
be	O
considered	O
,	O
particularly	O
when	O
their	O
main	O
route	O
of	O
elimination	O
is	O
active	O
renal	O
secretion	O
via	O
the	O
organic	O
cationic	O
transport	O
system	O
(	O
e.g	O
.	O
,	O
trimethoprim	S-drug
)	O
.	O

No	O
change	O
in	O
dose	O
of	O
either	O
drug	O
is	O
recommended	O
.	O

There	O
is	O
no	O
information	O
regarding	O
the	O
effect	O
on	O
lamivudine	S-drug
pharmacokinetics	O
of	O
higher	O
doses	O
of	O
TMP	S-drug
/	O
SMX	S-drug
such	O
as	O
those	O
used	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
.	O

No	O
data	O
are	O
available	O
regarding	O
interactions	O
with	O
other	O
drugs	O
that	O
have	O
renal	O
clearance	O
mechanisms	O
similar	O
to	O
that	O
of	O
lamivudine	S-drug
.	O

Lamivudine	S-drug-EF-1
and	O
zalcitabine	S-drug-EF-2
may	O
inhibit	O
the	O
intracellular	O
phosphorylation	O
of	O
one	O
another	O
.	O

Therefore	O
,	O
use	O
of	O
lamivudine	S-drug-AD-1
in	O
combination	O
with	O
zalcitabine	S-drug-AD-2
is	O
not	O
recommended	O

Lansoprazole	S-drug
is	O
metabolized	O
through	O
the	O
cytochrome	O
P450	O
system	O
,	O
specifically	O
through	O
the	O
CYP3A	O
and	O
CYP2C19	O
isozymes	O
.	O

Studies	O
have	O
shown	O
that	O
lansoprazole	S-drug
does	O
not	O
have	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
,	O
such	O
as	O
warfarin	S-drug
,	O
antipyrine	S-drug
,	O
indomethacin	S-drug
,	O
ibuprofen	S-drug
,	O
phenytoin	S-drug
,	O
propranolol	S-drug
,	O
prednisone	S-drug
,	O
diazepam	S-drug
,	O
clarithromycin	S-drug
,	O
or	O
terfenadine	S-drug
in	O
healthy	O
subjects	O
.	O

These	O
compounds	O
are	O
metabolized	O
through	O
various	O
cytochrome	O
P450	O
isozymes	O
including	O
CYP1A2	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
and	O
CYP3A	O
.	O

When	O
lansoprazole	S-drug-ME-1
was	O
administered	O
concomitantly	O
with	O
theophylline	S-drug-ME-2
(	O
CYP1A2	O
,	O
CYP3A	O
)	O
,	O
a	O
minor	O
increase	O
(	O
10	O
%	O
)	O
in	O
the	O
clearance	O
of	O
theophylline	S-drug
was	O
seen	O
.	O

Because	O
the	O
small	O
magnitude	O
and	O
the	O
direction	O
of	O
the	O
effect	O
on	O
theophylline	S-drug
clearance	O
,	O
this	O
interaction	O
is	O
unlikely	O
to	O
be	O
clinical	O
concern	O
.	O

Nonetheless	O
,	O
individual	O
patients	O
may	O
require	O
additional	O
titration	O
of	O
their	O
theophylline	S-drug-AD-1
dosage	O
when	O
lansoprazole	S-drug-AD-2
is	O
started	O
or	O
stopped	O
to	O
ensure	O
clinically	O
effective	O
blood	O
levels	O
.	O

Lansoprazole	S-drug
has	O
also	O
been	O
shown	O
to	O
have	O
no	O
clinically	O
significant	O
interaction	O
with	O
amoxicillin	S-drug
.	O

In	O
a	O
single	O
-	O
dose	O
crossover	O
study	O
examining	O
lansoprazole	S-drug
30	O
mg	O
and	O
omeprazole	S-drug
20	O
mg	O
each	O
administered	O
alone	O
and	O
concomitantly	O
with	O
sucralfate	S-drug
1	O
gram	O
,	O
absorption	O
of	O
the	O
proton	B-group-ME-1
pump	I-group-ME-1
inhibitors	E-group-ME-1
was	O
delayed	O
and	O
their	O
bioavailability	O
was	O
reduced	O
by	O
17	O
%	O
and	O
16	O
%	O
,	O
respectively	O
,	O
when	O
administered	O
concomitantly	O
with	O
sucralfate	S-drug-ME-2
.	O

Therefore	O
,	O
proton	B-group-AD-1
pump	I-group-AD-1
inhibitors	E-group-AD-1
should	O
be	O
taken	O
at	O
least	O
30	O
minutes	O
prior	O
to	O
sucralfate	S-drug-AD-2
.	O

In	O
clinical	O
trials	O
,	O
antacids	S-group
were	O
administered	O
concomitantly	O
with	O
lansoprazole	S-drug
delayed	O
-	O
release	O
capsules	O
;	O

this	O
did	O
not	O
interfere	O
with	O
its	O
effect	O
.	O

Lansoprazole	S-drug
causes	O
a	O
profound	O
and	O
long	O
lasting	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
;	O

therefore	O
,	O
it	O
is	O
theoretically	O
possible	O
that	O
lansoprazole	S-drug-ME-1
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
e.g	O
.	O
ketoconazole	S-drug-ME-2
,	O
ampicillin	S-drug-ME-2
esters	O
,	O
iron	S-drug-ME-2
salts	O
,	O
digoxin	S-drug-ME-2
)	O
.	O

Effects	O
of	O
Lapatinib	S-drug
on	O
Drug	O
Metabolizing	O
Enzymes	O
and	O
Drug	O
Transport	O
Systems	O
Lapatinib	S-drug
inhibits	O
CYP3A4	O
and	O
CYP2C8	O
in	O
vitro	O
at	O
clinically	O
relevant	O
concentrations	O
.	O

Caution	O
should	O
be	O
exercised	O
and	O
dose	O
reduction	O
of	O
the	O
concomitant	O
substrate	O
drug	O
should	O
be	O
considered	O
when	O
dosing	O
lapatinib	S-drug
concurrently	O
with	O
medications	O
with	O
narrow	O
therapeutic	O
windows	O
that	O
are	O
substrates	O
of	O
CYP3A4	O
or	O
CYP2C8	O
.	O

Lapatinib	S-drug
did	O
not	O
significantly	O
inhibit	O
the	O
following	O
enzymes	O
in	O
human	O
liver	O
microsomes	O
:	O
CYP1A2	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
and	O
CYP2D6	O
or	O
UGT	O
enzymes	O
in	O
vitro	O
,	O
however	O
,	O
the	O
clinical	O
significance	O
is	O
unknown	O
.	O

Lapatinib	S-drug
inhibits	O
human	O
P	O
-	O
glycoprotein	O
.	O

If	O
TYKERB	S-brand
is	O
administered	O
with	O
drugs	O
that	O
are	O
substrates	O
of	O
Pgp	O
,	O
increased	O
concentrations	O
of	O
the	O
substrate	O
drug	O
are	O
likely	O
,	O
and	O
caution	O
should	O
be	O
exercised	O
.	O

Drugs	O
that	O
Inhibit	O
or	O
Induce	O
Cytochrome	O
P450	O
3A4	O
Enzymes	O
Lapatinib	S-drug
undergoes	O
extensive	O
metabolism	O
by	O
CYP3A4	O
,	O
and	O
concomitant	O
administration	O
of	O
strong	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	O
alter	O
lapatinib	S-drug
concentrations	O
significantly	O
.	O

Dose	O
adjustment	O
of	O
lapatinib	S-drug
should	O
be	O
considered	O
for	O
patients	O
who	O
must	O
receive	O
concomitant	O
strong	O
inhibitors	O
or	O
concomitant	O
strong	O
inducers	O
of	O
CYP3A4	O
enzymes	O
.	O

Ketoconazole	S-drug
:	O
In	O
healthy	O
subjects	O
receiving	O
ketoconazole	S-drug-ME-1
,	O
a	O
CYP3A4	O
inhibitor	O
,	O
at	O
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	S-drug-ME-2
was	O
increased	O
to	O
approximately	O
3.6	O
-	O
fold	O
of	O
control	O
and	O
half	O
-	O
life	O
increased	O
to	O
1.7	O
-	O
fold	O
of	O
control	O
.	O

Carbamazepine	S-drug
:	O
In	O
healthy	O
subjects	O
receiving	O
the	O
CYP3A4	O
inducer	O
,	O
carbamazepine	S-drug-ME-1
,	O
at	O
100	O
mg	O
twice	O
daily	O
for	O
3	O
days	O
and	O
200	O
mg	O
twice	O
daily	O
for	O
17	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	S-drug-ME-2
was	O
decreased	O
approximately	O
72	O
%	O
.	O

Drugs	O
that	O
Inhibit	O
Drug	O
Transport	O
Systems	O
Lapatinib	S-drug
is	O
a	O
substrate	O
of	O
the	O
efflux	O
transporter	O
P	O
-	O
glycoprotein	O
(	O
Pgp	O
,	O
ABCB1	O
)	O
.	O

If	O
TYKERB	S-brand
is	O
administered	O
with	O
drugs	O
that	O
inhibit	O
Pgp	O
,	O
increased	O
concentrations	O
of	O
lapatinib	S-drug
are	O
likely	O
,	O
and	O
caution	O
should	O
be	O
exercised	O
.	O

Other	O
Chemotherapy	O
Agents	O
In	O
a	O
separate	O
study	O
,	O
concomitant	O
administration	O
of	O
lapatinib	S-drug
with	O
capecitabine	S-drug
did	O
not	O
meaningfully	O
alter	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
(	O
or	O
the	O
metabolites	O
of	O
capecitabine	S-drug
)	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
precipitation	O
occurs	O
when	O
eye	O
drops	O
containing	O
thimerosal	S-drug_n
are	O
mixed	O
with	O
latanoprost	S-drug
.	O

If	O
such	O
drugs	O
are	O
used	O
they	O
should	O
be	O
administered	O
with	O
an	O
interval	O
of	O
at	O
least	O
5	O
minutes	O
between	O
applications	O
.	O

Cholestyramine	S-drug
and	O
Charcoal	S-drug
Administration	O
of	O
cholestyramine	S-drug-ME-1
or	O
activated	B-drug-ME-1
charcoal	E-drug-ME-1
in	O
patients	O
(	O
n	O
=	O
13	O
)	O
and	O
volunteers	O
(	O
n	O
=	O
96	O
)	O
resulted	O
in	O
a	O
rapid	O
and	O
significant	O
decrease	O
in	O
plasma	O
M1	O
(	O
the	O
active	O
metabolite	O
of	O
leflunomide	S-drug-ME-2
)	O
concentration	O
.	O

Hepatotoxic	O
Drugs	O
Increased	O
side	O
effects	O
may	O
occur	O
when	O
leflunomide	S-drug
is	O
given	O
concomitantly	O
with	O
hepatotoxic	O
substances	O
.	O

This	O
is	O
also	O
to	O
be	O
considered	O
when	O
leflunomide	S-drug
treatment	O
is	O
followed	O
by	O
such	O
drugs	O
without	O
a	O
drug	O
elimination	O
procedure	O
.	O

In	O
a	O
small	O
(	O
n	O
=	O
30	O
)	O
combination	O
study	O
of	O
ARAVA	S-brand-EF-1
with	O
methotrexate	S-drug-EF-2
,	O
a	O
2	O
-	O
to	O
3	O
-	O
fold	O
elevation	O
in	O
liver	O
enzymes	O
was	O
seen	O
in	O
5	O
of	O
30	O
patients	O
.	O

All	O
elevations	O
resolved	O
,	O
2	O
with	O
continuation	O
of	O
both	O
drugs	O
and	O
3	O
after	O
discontinuation	O
of	O
leflunomide	S-drug
.	O

A	O
3	O
-	O
fold	O
increase	O
was	O
seen	O
in	O
another	O
5	O
patients	O
.	O

All	O
of	O
these	O
also	O
resolved	O
,	O
2	O
with	O
continuation	O
of	O
both	O
drugs	O
and	O
3	O
after	O
discontinuation	O
of	O
leflunomide	S-drug
.	O

Three	O
patients	O
met	O
ACR	O
criteria	O
for	O
liver	O
biopsy	O
(	O
1	O
:	O
Roegnik	O
Grade	O
I	O
,	O
2	O
:	O
Roegnik	O
Grade	O
IIIa	O
)	O
.	O

No	O
pharmacokinetic	O
interaction	O
was	O
identified	O
.	O

NSAIDs	S-group
:	O
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
diclofenac	S-drug
and	O
ibuprofen	S-drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
;	O

however	O
,	O
there	O
was	O
extensive	O
concomitant	O
use	O
of	O
NSAIDs	S-group
in	O
clinical	O
studies	O
and	O
no	O
differential	O
effect	O
was	O
observed	O
.	O

Tolbutamide	S-drug
:	O
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
tolbutamide	S-drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O

Rifampin	S-drug
:	O
Following	O
concomitant	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ARAVA	S-brand-ME-1
to	O
subjects	O
receiving	O
multiple	O
doses	O
of	O
rifampin	S-drug-ME-2
,	O
M1	O
peak	O
levels	O
were	O
increased	O
(	O
~	O
40	O
%	O
)	O
over	O
those	O
seen	O
when	O
ARAVA	S-brand
was	O
given	O
alone	O
.	O

Because	O
of	O
the	O
potential	O
for	O
ARAVA	S-brand
levels	O
to	O
continue	O
to	O
increase	O
with	O
multiple	O
dosing	O
,	O
caution	O
should	O
be	O
used	O
if	O
patients	O
are	O
to	O
be	O
receiving	O
both	O
ARAVA	S-brand-AD-1
and	O
rifampin	S-drug-AD-2
.	O

Warfarin	S-drug
:	O
Increased	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
when	O
ARAVA	S-brand-EF-1
and	O
warfarin	S-drug-EF-2
were	O
co	O
-	O
administered	O
has	O
been	O
rarely	O
reported	O
.	O

Results	O
from	O
human	O
in	O
vitro	O
metabolism	O
studies	O
and	O
nonclinical	O
studies	O
show	O
that	O
REVLIMID	S-brand
(	O
lenalidomide	S-drug
)	O
is	O
neither	O
metabolized	O
by	O
nor	O
inhibits	O
or	O
induces	O
the	O
cytochrome	O
P450	O
pathway	O
suggesting	O
that	O
lenalidomide	S-drug
is	O
not	O
likely	O
to	O
cause	O
or	O
be	O
subject	O
to	O
P450	O
-	O
based	O
metabolic	O
drug	O
interactions	O
in	O
man	O
.	O

Co	O
-	O
administration	O
of	O
multiple	O
doses	O
of	O
10	O
mg	O
of	O
lenalidomide	S-drug
had	O
no	O
effect	O
on	O
the	O
single	O
dose	O
pharmacokinetics	O
of	O
R	B-drug
-	E-drug
and	O
S	B-drug
-	I-drug
warfarin	E-drug
.	O

Co	O
-	O
administration	O
of	O
single	O
25	O
-	O
mg	O
dose	O
warfarin	S-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
total	O
lenalidomide	S-drug
.	O

Expected	O
changes	O
in	O
laboratory	O
assessments	O
of	O
PT	O
and	O
INR	O
were	O
observed	O
after	O
warfarin	S-drug
administration	O
,	O
but	O
these	O
changes	O
were	O
not	O
affected	O
by	O
concomitant	O
lenalidomide	S-drug
administration	O
.	O

Concomitant	O
treatment	O
with	O
thrombolytics	S-group
(	O
eg	O
,	O
rt	O
-	O
PA	O
or	O
streptokinase	S-drug
)	O
may	O
:	O
-	O
increase	O
the	O
risk	O
of	O
bleeding	O
complications	O
-	O
considerably	O
enhance	O
the	O
effect	O
of	O
REFLUDAN	S-brand
on	O
aPTT	O
prolongation	O

Concomitant	O
treatment	O
with	O
coumarin	B-group
derivatives	E-group
(	O
vitamin	B-group
K	I-group
antagonists	E-group
)	O
and	O
drugs	O
that	O
affect	O
platelet	O
function	O
may	O
also	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

Clinical	O
interaction	O
studies	O
with	O
cimetidine	S-drug
and	O
warfarin	S-drug
indicated	O
that	O
the	O
coadministration	O
of	O
Femara	S-brand
with	O
these	O
drugs	O
does	O
not	O
result	O
in	O
clinically	O
-	O
significant	O
drug	O
interactions	O
.	O

(	O
See	O
CLINICAL	O
PHARMACOLOGY	O
)	O
Coadministration	O
of	O
Femara	S-brand-ME-1
and	O
tamoxifen	S-drug-ME-2
20	O
mg	O
daily	O
resulted	O
in	O
a	O
reduction	O
of	O
letrozole	S-drug
plasma	O
levels	O
by	O
38	O
%	O
on	O
average	O
.	O

There	O
is	O
no	O
clinical	O
experience	O
to	O
date	O
on	O
the	O
use	O
of	O
Femara	S-brand
in	O
combination	O
with	O
other	O
anticancer	O
agents	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
-	O
Interactions	O
None	O
observed	O
.	O

Folic	B-drug-EF-1
acid	E-drug-EF-1
in	O
large	O
amounts	O
may	O
counteract	O
the	O
antiepileptic	O
effect	O
of	O
phenobarbital	S-drug-EF-2
,	O
phenytoin	S-drug-EF-2
and	O
primidone	S-drug-EF-2
,	O
and	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
susceptible	O
pediatric	O
patients	O
.	O

Preliminary	O
animal	O
and	O
human	O
studies	O
have	O
shown	O
that	O
small	O
quantities	O
of	O
systemically	O
administered	O
leucovorin	S-drug
enter	O
the	O
CSF	O
primarily	O
as	O
5	O
-	O
methyltetrahydro	O
-	O
folate	O
and	O
,	O
in	O
humans	O
,	O
remain	O
1	O
to	O
3	O
orders	O
of	O
magnitude	O
lower	O
than	O
the	O
usual	O
methotrexate	S-drug
concentrations	O
following	O
intrathecal	O
administration	O
.	O

However	O
,	O
high	O
doses	O
of	O
leucovorin	S-drug-EF-1
may	O
reduce	O
the	O
efficacy	O
of	O
intrathecally	O
administered	O
methotrexate	S-drug-EF-2
.	O

Leucovorin	S-drug-EF-1
may	O
enhance	O
the	O
toxicity	O
of	O
5	B-drug-EF-2
-	I-drug-EF-2
fluorouracil	E-drug-EF-2
.	O

ERGAMISOL	S-brand-EF-1
(	O
levamisole	B-drug-EF-1
hydrochloride	E-drug-EF-1
)	O
has	O
been	O
reported	O
to	O
produce	O
ANTABUSE	O
-	O
like	O
side	O
effects	O
when	O
given	O
concomitantly	O
with	O
alcohol	S-drug-EF-2
.	O

The	O
physician	O
is	O
advised	O
to	O
monitor	O
plasma	O
levels	O
of	O
phenytoin	S-drug
and	O
to	O
decrease	O
the	O
dose	O
if	O
necessary	O
.	O

Because	O
of	O
reports	O
of	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
beyond	O
the	O
therapeutic	O
range	O
in	O
patients	O
taking	O
concurrent	O
levamisole	S-drug-AD-1
and	O
warfarin	B-drug-AD-2
sodium	E-drug-AD-2
,	O
it	O
is	O
suggested	O
that	O
the	O
prothrombin	O
time	O
be	O
monitored	O
carefully	O
,	O
and	O
the	O
dose	O
of	O
warfarin	B-drug
sodium	E-drug
or	O
other	O
coumarin	S-group
-	O
like	O
drugs	O
should	O
be	O
adjusted	O
accordingly	O
,	O
in	O
patients	O
taking	O
both	O
drugs	O
.	O

in	O
vitro	O
data	O
on	O
metabolic	O
interactions	O
indicate	O
that	O
Keppra	S-brand
is	O
unlikely	O
to	O
produce	O
,	O
or	O
be	O
subject	O
to	O
,	O
pharmacokinetic	O
interactions	O
.	O

Levetiracetam	S-drug
and	O
its	O
major	O
metabolite	O
,	O
at	O
concentrations	O
well	O
above	O
cmax	O
levels	O
achieved	O
within	O
the	O
therapeutic	O
dose	O
range	O
,	O
are	O
neither	O
inhibitors	O
of	O
nor	O
high	O
affinity	O
substrates	O
for	O
human	O
liver	O
cytochrome	O
P450	O
isoforms	O
,	O
epoxide	O
hydrolase	O
or	O
UDP	O
-	O
glucuronidation	O
enzymes	O
.	O

In	O
addition	O
,	O
levetiracetam	S-drug
does	O
not	O
affect	O
the	O
in	O
vitro	O
glucuronidation	O
of	O
valproic	B-drug
acid	E-drug
.	O

Levetiracetam	S-drug
circulates	O
largely	O
unbound	O
(	O
10	O
%	O
bound	O
)	O
to	O
plasma	O
proteins	O
;	O

clinically	O
significant	O
interactions	O
with	O
other	O
drugs	O
through	O
competition	O
for	O
protein	O
binding	O
sites	O
are	O
therefore	O
unlikely	O
.	O

Potential	O
pharmacokinetic	O
interactions	O
were	O
assessed	O
in	O
clinical	O
pharmacokinetic	O
studies	O
(	O
phenytoin	S-drug
,	O
valproate	S-drug
,	O
oral	O
contraceptive	S-group
,	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
probenecid	S-drug
)	O
and	O
through	O
pharmacokinetic	O
screening	O
in	O
the	O
placebo	O
-	O
controlled	O
clinical	O
studies	O
in	O
epilepsy	O
patients	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
Between	O
Keppra	S-brand
And	O
Other	O
Antiepileptic	B-group
Drugs	E-group
(	O
AEDs	S-group
)	O
Phenytoin	S-drug
Keppra	S-brand
(	O
3000	O
mg	O
daily	O
)	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
disposition	O
of	O
phenytoin	S-drug
in	O
patients	O
with	O
refractory	O
epilepsy	O
.	O

Pharmacokinetics	O
of	O
levetiracetam	S-drug
were	O
also	O
not	O
affected	O
by	O
phenytoin	S-drug
.	O

Valproate	S-drug
Keppra	S-brand
(	O
1500	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
valproate	S-drug
in	O
healthy	O
volunteers	O
.	O

Valproate	S-drug
500	O
mg	O
twice	O
daily	O
did	O
not	O
modify	O
the	O
rate	O
or	O
extent	O
of	O
levetiracetam	S-drug
absorption	O
or	O
its	O
plasma	O
clearance	O
or	O
urinary	O
excretion	O
.	O

There	O
also	O
was	O
no	O
effect	O
on	O
exposure	O
to	O
and	O
the	O
excretion	O
of	O
the	O
primary	O
metabolite	O
,	O
ucb	O
L057	O
.	O

Potential	O
drug	O
interactions	O
between	O
Keppra	S-brand
and	O
other	O
AEDs	S-group
(	O
carbamazepine	S-drug
,	O
gabapentin	S-drug
,	O
lamotrigine	S-drug
,	O
phenobarbital	S-drug
,	O
phenytoin	S-drug
,	O
primidone	S-drug
and	O
valproate	S-drug
)	O
were	O
also	O
assessed	O
by	O
evaluating	O
the	O
serum	O
concentrations	O
of	O
levetiracetam	S-drug
and	O
these	O
AEDs	S-group
during	O
placebo	O
-	O
controlled	O
clinical	O
studies	O
.	O

These	O
data	O
indicate	O
that	O
levetiracetam	S-drug
does	O
not	O
influence	O
the	O
plasma	O
concentration	O
of	O
other	O
AEDs	S-group
and	O
that	O
these	O
AEDs	S-group
do	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	S-drug
.	O

Effect	O
of	O
AEDs	S-group
in	O
Pediatric	O
Patients	O
There	O
was	O
about	O
a	O
22	O
%	O
increase	O
of	O
apparent	O
total	O
body	O
clearance	O
of	O
levetiracetam	S-drug-ME-1
when	O
it	O
was	O
co	O
-	O
administered	O
with	O
enzyme	O
-	O
inducing	O
AEDs	S-group-ME-2
.	O

Dose	O
adjustment	O
is	O
not	O
recommended.Levetiracetam	O
had	O
no	O
effect	O
on	O
plasma	O
concentrations	O
of	O
carbamazepine	S-drug
,	O
valproate	S-drug
,	O
topiramate	S-drug
,	O
or	O
lamotrigine	S-drug
.	O

Other	O
Drug	O
Interactions	O
Oral	O
Contraceptives	S-group
Keppra	S-brand
(	O
500	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
an	O
oral	O
contraceptive	S-group
containing	O
0.03	O
mg	O
ethinyl	B-drug
estradiol	E-drug
and	O
0.15	O
mg	O
levonorgestrel	S-drug
,	O
or	O
of	O
the	O
luteinizing	O
hormone	O
and	O
progesterone	O
levels	O
,	O
indicating	O
that	O
impairment	O
of	O
contraceptive	O
efficacy	O
is	O
unlikely	O
.	O

Coadministration	O
of	O
this	O
oral	O
contraceptive	S-group
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	S-drug
.	O

Digoxin	S-drug
Keppra	S-brand
(	O
1000	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
(	O
ECG	O
)	O
of	O
digoxin	S-drug
given	O
as	O
a	O
0.25	O
mg	O
dose	O
every	O
day	O
.	O

Coadministration	O
of	O
digoxin	S-drug
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	S-drug
.	O

Warfarin	S-drug
Keppra	S-brand
(	O
1000	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
R	S-drug
and	O
S	B-drug
warfarin	E-drug
.	O

Prothrombin	O
time	O
was	O
not	O
affected	O
by	O
levetiracetam	S-drug
.	O

Coadministration	O
of	O
warfarin	S-drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
levetiracetam	S-drug
.	O

Probenecid	S-drug
:	O
Probenecid	S-drug
,	O
a	O
renal	O
tubular	O
secretion	O
blocking	O
agent	O
,	O
administered	O
at	O
a	O
dose	O
of	O
500	O
mg	O
four	O
times	O
a	O
day	O
,	O
did	O
not	O
change	O
the	O
pharmacokinetics	O
of	O
levetiracetam	S-drug
1000	O
mg	O
twice	O
daily	O
.	O

Cssmax	O
of	O
the	O
metabolite	O
,	O
ucb	O
L057	O
,	O
was	O
approximately	O
doubled	O
in	O
the	O
presence	O
of	O
probenecid	S-drug
while	O
the	O
fraction	O
of	O
drug	O
excreted	O
unchanged	O
in	O
the	O
urine	O
remained	O
the	O
same	O
.	O

Renal	O
clearance	O
of	O
ucb	O
L057	O
in	O
the	O
presence	O
of	O
probenecid	S-drug
decreased	O
60	O
%	O
,	O
probably	O
related	O
to	O
competitive	O
inhibition	O
of	O
tubular	O
secretion	O
of	O
ucb	O
L057	O
.	O

The	O
effect	O
of	O
Keppra	S-brand
on	O
probenecid	S-drug
was	O
not	O
studied	O
.	O

Although	O
BETAGAN	S-brand
used	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
pupil	O
size	O
,	O
mydriasis	O
resulting	O
from	O
concomitant	O
therapy	O
with	O
BETAGAN	S-brand-EF-1
and	O
epinephrine	S-drug-EF-2
may	O
occur	O
.	O

Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta	B-group-AD-1
-	I-group-AD-1
blocker	E-group-AD-1
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
such	O
as	O
reserpine	S-drug-AD-2
,	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
or	O
postural	O
hypotension	O
.	O

Patients	O
receiving	O
beta	B-group-AD-1
-	I-group-AD-1
adrenergic	I-group-AD-1
blocking	I-group-AD-1
agents	E-group-AD-1
along	O
with	O
either	O
oral	O
or	O
intravenous	O
calcium	B-group-AD-2
antagonists	E-group-AD-2
should	O
be	O
monitored	O
for	O
possible	O
atrioventricular	O
conduction	O
disturbances	O
,	O
left	O
ventricular	O
failure	O
and	O
hypotension	O
.	O

In	O
patients	O
with	O
impaired	O
cardiac	O
function	O
,	O
simultaneous	O
use	O
should	O
be	O
avoided	O
altogether	O
.	O

The	O
concomitant	O
use	O
of	O
beta	B-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
with	O
digitalis	S-group-EF-2
and	O
calcium	B-group-EF-2
antagonists	O
may	O
have	O
additive	O
effects	O
on	O
prolonging	O
atrioventricular	O
conduction	O
time	O
.	O

Phenothiazine	B-group-ME-1
-	I-group-ME-1
related	I-group-ME-1
compounds	E-group-ME-1
and	O
beta	B-group-ME-2
-	I-group-ME-2
adrenergic	I-group-ME-2
blocking	I-group-ME-2
agents	E-group-ME-2
may	O
have	O
additive	O
hypotensite	O
effects	O
due	O
to	O
the	O
inhibition	O
of	O
each	O
other	O
s	O
metabolism	O
.	O

Chirocaine	S-brand-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
other	O
local	O
anesthetics	S-group-AD-2
or	O
agents	O
structurally	O
related	O
to	O
amide	O
-	O
type	O
local	O
anesthetics	O
since	O
the	O
toxic	O
effects	O
of	O
these	O
drugs	O
could	O
be	O
additive	O
.	O

In	O
vitro	O
studies	O
indicate	O
CYP3A4	O
isoform	O
and	O
CYP1A2	O
isoform	O
mediate	O
the	O
metabolism	O
of	O
levobupivacaine	S-drug
to	O
desbutyl	B-drug_n
levobupivacaine	E-drug_n
and	O
3	B-drug_n
-	I-drug_n
hydroxy	I-drug_n
levobupivacaine	E-drug_n
,	O
respectively	O
.	O

Thus	O
agents	O
likely	O
to	O
be	O
concomitantly	O
administered	O
with	O
Chirocaine	S-brand
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
family	O
may	O
potentially	O
interact	O
with	O
Chirocaine	S-brand
.	O

Although	O
no	O
clinical	O
studies	O
have	O
been	O
conducted	O
,	O
it	O
is	O
likely	O
that	O
the	O
metabolism	O
of	O
levobupivacaine	S-drug-ME-1
may	O
be	O
affected	O
by	O
the	O
known	O
CYP3A4	O
inducers	O
(	O
such	O
as	O
phenytoin	S-drug-ME-2
,	O
phenobarbital	S-drug-ME-2
,	O
rifampin	S-drug-ME-2
)	O
,	O
CYP3A4	O
inhibitors	O
(	O
azole	O
antimycotics	O
e.g	O
.	O
,	O
ketoconazole	S-drug-ME-2
;	O

certain	O
protease	B-group
inhibitors	E-group
e.g	O
.	O
,	O
ritanovir	O
;	O

macrolide	B-group
antibiotics	E-group
e.g	O
.	O
,	O
erythromycin	S-drug
;	O

and	O
calcium	B-group
channel	I-group
antagonists	E-group
e.g	O
.	O
,	O
verapamil	S-drug
)	O
,	O
CYP1A2	O
inducers	O
(	O
omeprazole	S-drug
)	O
and	O
CYP1A2	O
inhibitors	O
(	O
furafylline	S-drug
and	O
clarithromycin	S-drug
)	O
.	O

Dosage	O
adjustment	O
may	O
be	O
warranted	O
when	O
levobupivacaine	S-drug
is	O
concurrently	O
administered	O
with	O
CYP3A4	O
inhibitors	O
and	O
CYP1A2	O
inhibitors	O
as	O
systemic	O
levobupivacaine	S-drug
levels	O
may	O
rise	O
resulting	O
in	O
toxicity	O
.	O

Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
Levofloxacin	S-drug
.	O

However	O
,	O
the	O
systemic	O
administration	O
of	O
some	O
quinolones	S-group-MU-1
has	O
been	O
shown	O
to	O
elevate	O
plasma	O
concentrations	O
of	O
theophylline	S-drug-ME-2
,	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	S-drug-ME-2
,	O
and	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	S-group
warfarin	S-drug-EF-2
and	O
its	O
derivatives	O
,	O
and	O
has	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
systemic	O
cyclosporine	S-drug-EF-2
concomitantly	O
.	O

Interactions	O
with	O
Other	O
CNS	O
Agents	O
:	O
Concurrent	O
use	O
of	O
Levo	B-brand-EF-1
-	I-brand-EF-1
Dromoran	E-brand-EF-1
with	O
all	O
central	B-group-EF-2
nervous	I-group-EF-2
system	I-group-EF-2
depressants	E-group-EF-2
(	O
eg	O
,	O
alcohol	S-drug-EF-2
,	O
sedatives	S-group-EF-2
,	O
hypnotics	S-group-EF-2
,	O
other	O
opioids	S-group-EF-2
,	O
general	O
anesthetics	S-group-EF-2
,	O
barbiturates	S-group-EF-2
,	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
phenothiazines	S-group-EF-2
,	O
tranquilizers	S-group-EF-2
,	O
skeletal	B-group-EF-2
muscle	I-group-EF-2
relaxants	E-group-EF-2
and	O
antihistamines	S-group-EF-2
)	O
may	O
result	O
in	O
additive	O
central	O
nervous	O
system	O
depressant	O
effects	O
.	O

Respiratory	O
depression	O
,	O
hypotension	O
,	O
and	O
profound	O
sedation	O
or	O
coma	O
may	O
occur	O
.	O

When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

Although	O
no	O
interaction	O
between	O
MAO	B-group
inhibitors	E-group
and	O
Levo	B-brand-AD-1
-	I-brand-AD-1
Dromoran	E-brand-AD-1
has	O
been	O
observed	O
,	O
it	O
is	O
not	O
recommended	O
for	O
use	O
with	O
MAO	B-group-AD-2
inhibitors	E-group-AD-2
.	O

Most	O
cases	O
of	O
serious	O
or	O
fatal	O
adverse	O
events	O
involving	O
Levo	B-brand
-	I-brand
Dromoran	E-brand
reported	O
to	O
the	O
manufacturer	O
or	O
the	O
FDA	O
have	O
involved	O
either	O
the	O
administration	O
of	O
large	O
initial	O
doses	O
or	O
too	O
frequent	O
doses	O
of	O
the	O
drug	O
to	O
nonopioid	O
tolerant	O
patients	O
,	O
or	O
the	O
simultaneous	O
administration	O
of	O
levorphanol	S-drug
with	O
other	O
drugs	O
affecting	O
respiration	O
.	O

The	O
initial	O
dose	O
of	O
levorphanol	S-drug
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
or	O
more	O
when	O
it	O
is	O
given	O
to	O
patients	O
along	O
with	O
another	O
drug	O
affecting	O
respiration	O
.	O

Interactions	O
with	O
Mixed	B-group
Agonist	I-group
/	I-group
Antagonist	I-group
Opioid	I-group
Analgesics	E-group
:	O
Agonist	B-group-AD-1
/	I-group-AD-1
antagonist	I-group-AD-1
analgesics	E-group-AD-1
(	O
eg	O
,	O
pentazocine	S-drug-AD-1
,	O
nalbuphine	S-drug-AD-1
,	O
butorphanol	S-drug-AD-1
,	O
dezocine	S-drug-AD-1
and	O
buprenorphine	S-drug-AD-1
)	O
should	O
NOT	O
be	O
administered	O
to	O
a	O
patient	O
who	O
has	O
received	O
or	O
is	O
receiving	O
a	O
course	O
of	O
therapy	O
with	O
a	O
pure	B-group-AD-1
agonist	I-group-AD-1
opioid	I-group-AD-1
analgesic	E-group-AD-1
such	O
as	O
Levo	B-brand-AD-2
-	I-brand-AD-2
Dromoran	E-brand-AD-2
.	O

In	O
opioid	S-group
-	O
dependent	O
patients	O
,	O
mixed	B-group
agonist	I-group
/	I-group
antagonist	I-group
analgesics	E-group
may	O
precipitate	O
withdrawal	O
symptoms	O
.	O

No	O
Important	O
Interactions	O
To	O
Date	O
Levosimendan	S-drug
does	O
not	O
have	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
captopril	S-drug
,	O
beta	B-group
-	I-group
blockers	E-group
,	O
felodipine	S-drug
,	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
isosorbide	B-drug
mononitrate	E-drug
,	O
carvedilol	S-drug
,	O
ethanol	S-drug
or	O
itraconazole	S-drug
.	O

The	O
magnitude	O
and	O
relative	O
importance	O
of	O
the	O
effects	O
noted	O
below	O
are	O
likely	O
to	O
be	O
patient	O
specific	O
and	O
may	O
vary	O
by	O
such	O
factors	O
as	O
age	O
,	O
gender	O
,	O
race	O
,	O
intercurrent	O
illnesses	O
,	O
dose	O
of	O
either	O
agent	O
,	O
additional	O
concomitant	O
medications	O
,	O
and	O
timing	O
of	O
drug	O
administration	O
.	O

Any	O
agent	O
that	O
alters	O
thyroid	O
hormone	O
synthesis	O
,	O
secretion	O
,	O
distribution	O
,	O
effect	O
on	O
target	O
tissues	O
,	O
metabolism	O
,	O
or	O
elimination	O
may	O
alter	O
the	O
optimal	O
therapeutic	O
dose	O
of	O
levothyroxine	S-drug
sodium	O
.	O

Levothyroxine	B-drug
Sodium	E-drug
Absorption	O
:	O
The	O
following	O
agents	O
may	O
bind	O
and	O
decrease	O
absorption	O
of	O
levothyroxine	B-drug-ME-1
sodium	E-drug-ME-1
from	O
the	O
gastrointestinal	O
tract	O
:	O
aluminum	B-drug-ME-2
hydoxide	E-drug-ME-2
,	O
cholestyramine	S-drug-ME-2
resin	O
,	O
colestipol	B-drug-ME-2
hydrochloride	E-drug-ME-2
,	O
ferrous	B-drug-ME-2
sulfate	E-drug-ME-2
,	O
sodium	B-drug-ME-2
polystyrene	I-drug-ME-2
sulfonate	E-drug-ME-2
,	O
soybean	O
flour	O
(	O
e.g	O
.	O
,	O
infant	O
formula	O
)	O
,	O
sucralfate	S-drug-ME-2
.	O

Binding	O
to	O
Serum	O
Proteins	O
:	O
The	O
following	O
agents	O
may	O
either	O
inhibit	O
levothyroxine	B-drug-ME-1
sodium	E-drug-ME-1
binding	O
to	O
serum	O
proteins	O
or	O
alter	O
the	O
concentrations	O
of	O
serum	O
binding	O
proteins	O
:	O
androgens	S-group-ME-2
and	O
related	O
anabolic	B-group-ME-2
hormones	E-group-ME-2
,	O
asparaginase	S-drug-ME-2
,	O
clofibrate	S-drug-ME-2
,	O
estrogens	S-group-ME-2
and	O
estrogen	B-group-ME-2
-	I-group-ME-2
containing	I-group-ME-2
compounds	E-group-ME-2
,	O
5	B-drug-ME-2
-	I-drug-ME-2
fluorouracil	E-drug-ME-2
,	O
furosemide	S-drug-ME-2
,	O
glucocorticoids	S-group-ME-2
,	O
meclofenamic	B-drug-ME-2
acid	E-drug-ME-2
,	O
mefenamic	B-drug-ME-2
acid	E-drug-ME-2
,	O
methadone	S-drug-ME-2
,	O
perphenazine	S-drug-ME-2
,	O
phenylbutazone	S-drug-ME-2
,	O
phenytoin	S-drug-ME-2
,	O
salicylates	S-group-ME-2
,	O
tamoxifen	S-drug-ME-2
.	O

Thyroid	O
Physiology	O
:	O
The	O
following	O
agents	O
may	O
alter	O
thyroid	O
hormone	O
or	O
TSH	O
levels	O
,	O
generally	O
by	O
effects	O
on	O
thyroid	O
hormone	O
synthesis	O
,	O
secretion	O
,	O
distribution	O
,	O
metabolism	O
,	O
hormone	O
action	O
,	O
or	O
elimination	O
,	O
or	O
altered	O
TSH	O
secretion	O
:	O
aminoglutethimide	S-drug
,	O
p	B-drug
-	I-drug
aminosalicylic	I-drug
acid	E-drug
,	O
amiodarone	S-drug
,	O
androgens	S-group
and	O
related	O
anabolic	O
hormones	O
,	O
complex	O
anions	O
(	O
thiocyanate	S-drug
,	O
perchlorate	S-drug
,	O
pertechnetate	S-drug
)	O
,	O
antithyroid	B-group
drugs	E-group
,	O
b	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
,	O
carbamazepine	S-drug
,	O
chloral	B-drug
hydrate	E-drug
,	O
diazepam	S-drug
,	O
dopamine	S-drug
and	O
dopamine	B-group
agonists	E-group
,	O
ethionamide	S-drug
,	O
glucocorticoids	S-group
,	O
heparin	S-drug
,	O
hepatic	O
enzyme	O
inducers	O
,	O
insulin	S-drug
,	O
iodinated	O
cholestographic	O
agents	O
,	O
iodine	B-group
-	I-group
containing	I-group
compounds	E-group
,	O
levodopa	S-drug
,	O
lovastatin	S-drug
,	O
lithium	S-drug
,	O
6	B-drug
-	I-drug
mercaptopurine	E-drug
,	O
metoclopramide	S-drug
,	O
mitotane	S-drug
,	O
nitroprusside	S-drug
,	O
phenobarbital	S-drug
,	O
phenytoin	S-drug
,	O
resorcinol	S-drug
,	O
rifampin	S-drug
,	O
somatostatin	B-group
analogs	E-group
,	O
sulfonamides	S-group
,	O
sulfonylureas	S-group
,	O
thiazide	B-group
diuretics	E-group
.	O

Adrenocorticoids	O
:	O
Metabolic	O
clearance	O
of	O
adrenocorticoids	O
is	O
decreased	O
in	O
hypothyroid	O
patients	O
and	O
increased	O
in	O
hyperthyroid	O
patients	O
,	O
and	O
may	O
therefore	O
change	O
with	O
changing	O
thyroid	O
status	O
.	O

Amiodarone	S-drug
:	O
Amiodarone	S-drug
therapy	O
alone	O
can	O
cause	O
hypothyroidism	O
or	O
hyperthyroidism	O
.	O

Anticoagulants	S-group
(	O
Oral	O
)	O
:	O
The	O
hypoprothrombinemic	O
effect	O
of	O
anticoagulants	S-group
may	O
be	O
potentiated	O
,	O
apparently	O
by	O
increased	O
catabloism	O
of	O
vitamin	O
K	O
-	O
dependent	O
clotting	O
factors	O
.	O

Antidiabetic	B-group
Agents	E-group
(	O
Insulin	S-drug
,	O
Sulfonylureas	S-group
)	O
:	O
Requirements	O
for	O
insulin	S-drug
or	O
oral	O
antidiabetic	B-group
agents	E-group
may	O
be	O
reduced	O
in	O
hypothyroid	O
patients	O
with	O
diabetes	O
mellitus	O
and	O
may	O
subsequently	O
increase	O
with	O
the	O
initiation	O
of	O
thyroid	O
hormone	O
replacement	O
therapy	O
.	O

b	B-group
-	I-group
Adrenergic	I-group
Blocking	I-group
Agents	E-group
:	O
Actions	O
of	O
some	O
of	O
beta	B-group
-	I-group
blocking	I-group
agents	E-group
may	O
be	O
impaired	O
when	O
hypothyroid	O
patients	O
become	O
euthyroid	O
.	O

Cytokines	S-group
(	O
interferon	S-group
,	O
interleukin	S-group
)	O
:	O
Cytokines	S-group
have	O
been	O
reported	O
to	O
induce	O
both	O
hyperthyroidism	O
and	O
hypothyroidism	O
.	O

Digitalis	B-group
Glycosides	E-group
:	O
Therapeutic	O
effects	O
of	O
digitalis	B-group
glycosides	E-group
may	O
be	O
reduced	O
.	O

Serum	O
digitalis	S-group
levels	O
may	O
be	O
decreased	O
in	O
hyperthyroidism	O
or	O
when	O
a	O
hypothyroid	O
patient	O
becomes	O
euthyroid	O
.	O

Ketamine	S-drug
:	O
Marked	O
hypertension	O
and	O
tachycardia	O
have	O
been	O
reported	O
in	O
association	O
with	O
concomitant	O
administration	O
of	O
levothyroxine	B-drug-EF-1
sodium	E-drug-EF-1
and	O
ketamine	S-drug-EF-2
.	O

Maprotiline	S-drug
:	O
Risk	O
of	O
cardiac	O
arrhythmias	O
may	O
increase	O
.	O

Sodium	B-drug
Iodide	E-drug
(	O
123I	O
and	O
131I	O
)	O
,	O
Sodium	B-drug
Pertechnetate	I-drug
Tc99m	E-drug
:	O
Uptake	O
of	O
radiolabeled	O
ions	O
may	O
be	O
decreased	O
.	O

Somatrem	S-drug
/	O
Somatropin	S-drug
:	O
Excessive	O
concurrent	O
use	O
of	O
thyroid	B-group
hormone	E-group
may	O
accelerate	O
epiphyseal	O
closure	O
.	O

Untreated	O
hypothyroidism	O
may	O
interfere	O
with	O
the	O
growth	O
response	O
to	O
somatrem	S-drug
or	O
somatropin	S-drug
.	O

Theophylline	S-drug
:	O
Theophylline	S-drug
clearance	O
may	O
decrease	O
in	O
hypothyroid	O
patients	O
and	O
return	O
toward	O
normal	O
when	O
a	O
euthyroid	O
state	O
is	O
achieved	O
.	O

Tricyclic	B-group
Antidepressants	E-group
:	O
Concurrent	O
use	O
may	O
increase	O
the	O
therapeutic	O
and	O
toxic	O
effects	O
of	O
both	O
drugs	O
,	O
possibly	O
due	O
to	O
increased	O
catecholamine	O
sensitivity	O
.	O

Onset	O
of	O
action	O
of	O
tricyclics	S-group
may	O
be	O
accelerated	O
.	O

Sympathomimetic	B-group
Agents	E-group
:	O
Possible	O
increased	O
risk	O
of	O
coronary	O
insufficiency	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B-group
solutions	E-group
containing	O
epinephrine	S-drug-EF-1
or	O
norepinephrine	S-drug-EF-1
to	O
patients	O
receiving	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
or	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
may	O
produce	O
severe	O
,	O
prolonged	O
hypertension	O
.	O

Phenothiazines	S-group-EF-1
and	O
butyrophenones	S-group-EF-1
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	S-drug-EF-2
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
when	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	B-group
drugs	E-group
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot	B-group
-	I-group
type	I-group
oxytocic	I-group
drugs	E-group
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Lincomycin	S-drug-EF-1
has	O
been	O
shown	O
to	O
have	O
neuromuscular	O
blocking	O
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	B-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

Therefore	O
,	O
it	O
should	O
be	O
used	O
in	O
caution	O
in	O
patients	O
receiving	O
such	O
agents	O
.	O

Antagonism	O
between	O
lincomycin	S-drug-EF-1
and	O
erythromycin	S-drug-EF-2
in	O
vitro	O
has	O
been	O
demonstrated	O
.	O

Because	O
of	O
possible	O
clinical	O
significance	O
,	O
the	O
two	O
drugs	O
should	O
not	O
be	O
administered	O
concurrently	O
.	O

Oils	O
may	O
enhance	O
absorption	O
.	O

Therefore	O
,	O
simultaneous	O
use	O
of	O
creams	O
,	O
ointments	O
or	O
oils	O
should	O
be	O
avoided	O
.	O

Monoamine	O
Oxidase	O
Inhibition	O
:	O
Linezolid	S-drug
is	O
a	O
reversible	O
,	O
nonselective	O
inhibitor	O
of	O
monoamine	O
oxidase	O
.	O

Therefore	O
,	O
linezolid	S-drug-IN-1
has	O
the	O
potential	O
for	O
interaction	O
with	O
adrenergic	S-group-IN-2
and	O
serotonergic	B-group-IN-2
agents	E-group-IN-2
.	O

Adrenergic	B-group
Agents	E-group
:	O
Some	O
individuals	O
receiving	O
ZYVOX	S-brand-EF-1
may	O
experience	O
a	O
reversible	O
enhancement	O
of	O
the	O
pressor	O
response	O
to	O
indirect	O
-	O
acting	O
sympathomimetic	B-group-EF-2
agents	E-group-EF-2
,	O
vasopressor	S-group-EF-2
or	O
dopaminergic	B-group-EF-2
agents	E-group-EF-2
.	O

Commonly	O
used	O
drugs	O
such	O
as	O
phenylpropanolamine	S-drug
and	O
pseudoephedrine	S-drug
have	O
been	O
specifically	O
studied	O
.	O

Initial	O
doses	O
of	O
adrenergic	B-group
agents	E-group
,	O
such	O
as	O
dopamine	S-drug
or	O
epinephrine	S-drug
,	O
should	O
be	O
reduced	O
and	O
titrated	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Serotonergic	B-group
Agents	E-group
:	O
Co	O
-	O
administration	O
of	O
linezolid	S-drug
and	O
serotonergic	B-group
agents	E-group
was	O
not	O
associated	O
with	O
serotonin	O
syndrome	O
in	O
Phase	O
1	O
,	O
2	O
or	O
3	O
studies	O
.	O

Spontaneous	O
reports	O
of	O
serotonin	O
syndrome	O
associated	O
with	O
co	O
-	O
administration	O
of	O
ZYVOX	S-brand-EF-1
and	O
serotonergic	B-group-EF-2
agents	E-group-EF-2
,	O
including	O
antidepressants	S-group-EF-2
such	O
as	O
selective	B-group-EF-2
serotonin	I-group-EF-2
reuptake	I-group-EF-2
inhibitors	E-group-EF-2
(	O
SSRIs	S-group-EF-2
)	O
,	O
have	O
been	O
reported	O
.	O

Patients	O
who	O
are	O
treated	O
with	O
ZYVOX	S-brand-EF-1
and	O
concomitant	O
serotonergic	B-group-EF-2
agents	E-group-EF-2
should	O
be	O
closely	O
observed	O
for	O
signs	O
and	O
symptoms	O
of	O
serotonin	O
syndrome	O
(	O
e.g	O
.	O
,	O
cognitive	O
dysfunction	O
,	O
hyperpyrexia	O
,	O
hyperreflexia	O
,	O
incoordination	O
)	O
.	O

If	O
any	O
signs	O
or	O
symptoms	O
occur	O
physicians	O
should	O
consider	O
discontinuation	O
of	O
either	O
one	O
or	O
both	O
agents	O
(	O
ZYVOX	S-brand-AD-1
or	O
concomitant	O
serotonergic	B-group-AD-2
agents	E-group-AD-2
)	O
.	O

Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
drug	O
-	O
laboratory	O
test	O
interactions	O
.	O

Oral	O
Anticoagulants	S-group
:	O
Thyroid	B-group
hormones	E-group
appear	O
to	O
increase	O
catabolism	O
of	O
vitamin	O
K	O
-	O
dependent	O
clotting	O
factors	O
.	O

If	O
oral	O
anticoagulants	S-group
are	O
also	O
being	O
given	O
,	O
compensatory	O
increases	O
in	O
clotting	O
factor	O
synthesis	O
are	O
impaired	O
.	O

Patients	O
stabilized	O
on	O
oral	O
anticoagulants	S-group-AD-1
who	O
are	O
found	O
to	O
require	O
thyroid	S-group-AD-2
replacement	O
therapy	O
should	O
be	O
watched	O
very	O
closely	O
when	O
thyroid	O
is	O
started	O
.	O

If	O
a	O
patient	O
is	O
truly	O
hypothyroid	O
,	O
it	O
is	O
likely	O
that	O
a	O
reduction	O
in	O
anticoagulant	S-group
dosage	O
will	O
be	O
required	O
.	O

No	O
special	O
precautions	O
appear	O
to	O
be	O
necessary	O
when	O
oral	O
anticoagulant	O
therapy	O
is	O
begun	O
in	O
a	O
patient	O
already	O
stabilized	O
on	O
maintenance	O
thyroid	O
replacement	O
therapy	O
.	O

Insulin	S-drug
or	O
Oral	O
Hypoglycemics	S-group
:	O
Initiating	O
thyroid	O
replacement	O
therapy	O
may	O
cause	O
increases	O
in	O
insulin	S-drug
or	O
oral	O
hypoglycemic	S-group
requirements	O
.	O

The	O
effects	O
seen	O
are	O
poorly	O
understood	O
and	O
depend	O
upon	O
a	O
variety	O
of	O
factors	O
such	O
as	O
dose	O
and	O
type	O
of	O
thyroid	B-group
preparations	E-group
and	O
endocrine	O
status	O
of	O
the	O
patient	O
.	O

Patients	O
receiving	O
insulin	S-drug
or	O
oral	O
hypoglycemics	S-group
should	O
be	O
closely	O
watched	O
during	O
initiation	O
of	O
thyroid	O
replacement	O
therapy	O
.	O

Cholestyramine	S-drug
:	O
Cholestyramine	S-drug-ME-1
binds	O
both	O
T4	S-drug-ME-2
and	O
T3	S-drug-ME-2
in	O
the	O
intestine	O
,	O
thus	O
impairing	O
absorption	O
of	O
these	O
thyroid	B-group
hormones	E-group
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
the	O
binding	O
is	O
not	O
easily	O
removed	O
.	O

Therefore	O
,	O
4	O
to	O
5	O
hours	O
should	O
elapse	O
between	O
administration	O
of	O
cholestyramine	S-drug-AD-1
and	O
thyroid	B-group-AD-2
hormones	E-group-AD-2
.	O

Estrogen	S-group
,	O
Oral	O
Contraceptives	S-group
:	O
Estrogens	S-group
tend	O
to	O
increase	O
serum	O
thyroxine	O
-	O
binding	O
globulin	O
(	O
TBg	O
)	O
.	O

In	O
a	O
patient	O
with	O
a	O
nonfunctioning	O
thyroid	O
gland	O
who	O
is	O
receiving	O
thyroid	O
replacement	O
therapy	O
,	O
free	O
levothyroxine	S-drug-ME-1
may	O
be	O
decreased	O
when	O
estrogens	S-group-ME-2
are	O
started	O
thus	O
increasing	O
thyroid	S-group
requirements	O
.	O

However	O
,	O
if	O
the	O
patients	O
thyroid	O
gland	O
has	O
sufficient	O
function	O
,	O
the	O
decreased	O
free	O
thyroxine	O
will	O
result	O
in	O
a	O
compensatory	O
increase	O
in	O
thyroxine	O
output	O
by	O
the	O
thyroid	O
.	O

Therefore	O
,	O
patients	O
without	O
a	O
functioning	O
thyroid	S-group-AD-1
gland	O
who	O
are	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
need	O
to	O
increase	O
their	O
thyroid	O
dose	O
if	O
estrogens	S-group-AD-2
or	O
estrogen	S-group
-	O
containing	O
oral	O
contraceptives	S-group-AD-2
are	O
given	O
.	O

Tricyclic	B-group
Antidepressants	E-group
:	O
Use	O
of	O
thyroid	B-group-EF-1
products	E-group-EF-1
with	O
imipramine	S-drug-EF-2
and	O
other	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
may	O
increase	O
receptor	O
sensitivity	O
and	O
enhance	O
antidepressant	O
activity	O
transient	O
cardiac	O
arrhythmias	O
have	O
been	O
observed	O
.	O

Thyroid	B-group
hormone	E-group
activity	O
may	O
also	O
be	O
enhanced	O
.	O

Digitalis	S-group
:	O
Thyroid	B-group-EF-1
preparations	E-group-EF-1
may	O
potentiate	O
the	O
toxic	O
effects	O
of	O
digitalis	S-group-EF-2
.	O

Thyroid	O
hormonal	O
replacement	O
increases	O
metabolic	O
rate	O
,	O
which	O
requires	O
an	O
increase	O
in	O
digitalis	S-group
dosage	O
.	O

Ketamine	S-drug
:	O
When	O
administered	O
to	O
patients	O
on	O
a	O
thyroid	B-group-EF-1
preparation	E-group-EF-1
,	O
this	O
parenteral	O
anesthetic	S-group-EF-2
may	O
cause	O
hypertension	O
and	O
tachycardia	O
.	O

Use	O
with	O
caution	O
and	O
be	O
prepared	O
to	O
treat	O
hypertension	O
,	O
if	O
necessary	O
.	O

Vasopressors	O
:	O
Thyroxine	S-drug-EF-1
increases	O
the	O
adrenergic	O
effect	O
of	O
catecholamines	O
such	O
as	O
epinephrine	S-drug-EF-2
and	O
norepinephrine	S-drug-EF-2
.	O

Therefore	O
,	O
injection	O
of	O
these	O
agents	O
into	O
patients	O
receiving	O
thyroid	B-group
preparations	E-group
increases	O
the	O
risk	O
of	O
precipitating	O
coronary	O
insufficiency	O
especially	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

Careful	O
observation	O
is	O
required	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
following	O
drugs	O
or	O
moieties	O
are	O
known	O
to	O
interfere	O
with	O
laboratory	O
tests	O
performed	O
in	O
patients	O
on	O
thyroid	B-group
hormone	E-group
therapy	O
:	O
androgens	S-group
,	O
corticosteroids	S-group
,	O
estrogens	S-group
,	O
oral	O
contraceptives	S-group
containing	O
estrogens	S-group
,	O
iodine	S-group
-	O
containing	O
preparations	O
and	O
the	O
numerous	O
preparations	O
containing	O
salicylates	S-group
.	O

-	O
Changes	O
in	O
TBg	O
concentration	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
the	O
interpretation	O
of	O
T4	O
and	O
T3	O
values	O
.	O

In	O
such	O
cases	O
,	O
the	O
unbound	O
(	O
free	O
)	O
hormone	O
should	O
be	O
measured	O
.	O

Pregnancy	O
estrogens	S-group
and	O
estrogen	S-group
-	O
containing	O
oral	O
contraceptives	S-group
increase	O
TBg	O
concentrations	O
.	O

TBg	O
may	O
also	O
be	O
increased	O
during	O
infectious	O
hepatitis	O
.	O

Decreases	O
in	O
TBg	O
concentrations	O
are	O
observed	O
in	O
nephrosis	O
,	O
acromegaly	O
and	O
after	O
androgen	S-group
or	O
corticosteroid	S-group
therapy	O
.	O

Familial	O
hyper	O
-	O
or	O
hypo	O
-	O
thyroxine	O
-	O
binding	O
-	O
globulinemias	O
have	O
been	O
described	O
.	O

The	O
incidence	O
of	O
TBg	O
deficiency	O
approximates	O
1	O
in	O
9000	O
.	O

The	O
binding	O
of	O
thyroxine	O
by	O
thyroxine	O
-	O
binding	O
prealbumin	O
(	O
TBPA	O
)	O
is	O
inhibited	O
by	O
salicylates	S-group

-	O
Medicinal	O
or	O
dietary	O
iodine	S-group
interferes	O
with	O
all	O
in	O
vivo	O
tests	O
of	O
radio	O
-	O
iodine	O
uptake	O
producing	O
low	O
uptakes	O
which	O
may	O
not	O
be	O
reflective	O
of	O
a	O
true	O
decrease	O
in	O
hormone	O
synthesis	O

-	O
The	O
persistence	O
of	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
hypothyroidism	O
in	O
spite	O
of	O
adequate	O
dosage	O
replacement	O
indicates	O
either	O
poor	O
patient	O
compliance	O
,	O
poor	O
absorption	O
,	O
excessive	O
fecal	O
loss	O
,	O
or	O
inactivity	O
of	O
the	O
preparation	O
.	O

Intracellular	O
resistance	O
to	O
thyroid	B-group
hormone	E-group
is	O
quite	O
rare	O
.	O

Urinary	O
acidifying	O
agents	O
These	O
agents	O
(	O
ammonium	B-drug-ME-1
chloride	E-drug-ME-1
,	O
sodium	B-drug-ME-1
acid	I-drug-ME-1
phosphate	E-drug-ME-1
,	O
etc	O
.	O
)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	S-drug-ME-2
molecule	O
,	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O

Both	O
groups	O
of	O
agents	O
lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	S-group
.	O

Adrenergic	B-group
blockers	E-group
Adrenergic	B-group-EF-1
blockers	E-group-EF-1
are	O
inhibited	O
by	O
amphetamines	S-group-EF-2
.	O

Antidepressants	S-group
,	O
tricyclic	S-group
Amphetamines	S-group-EF-1
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	B-drug-EF-2
antidepressants	E-drug-EF-2
or	O
sympathomimetic	B-group-EF-2
agents	E-group-EF-2
;	O

d	B-drug-ME-1
-	I-drug-ME-1
amphetamine	E-drug-ME-1
with	O
desipramine	S-drug-ME-2
or	O
protriptyline	S-drug-ME-2
and	O
possibly	O
other	O
tricyclics	S-group-ME-2
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d	B-drug
-	I-drug
amphetamine	E-drug
in	O
the	O
brain	O
;	O

cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O

MAO	B-group
inhibitors	E-group
MAOI	B-group-ME-1
antidepressants	E-group-ME-1
,	O
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	S-drug-ME-1
,	O
slow	O
amphetamine	S-drug-ME-2
metabolism	O
.	O

This	O
slowing	O
potentiates	O
amphetamines	S-group
,	O
increasing	O
their	O
effect	O
on	O
the	O
release	O
of	O
norepinephrine	O
and	O
other	O
monoamines	O
from	O
adrenergic	O
nerve	O
endings	O
;	O

this	O
can	O
cause	O
headaches	O
and	O
other	O
signs	O
of	O
hypertensive	O
crisis	O
.	O

A	O
variety	O
of	O
toxic	O
neurological	O
effects	O
and	O
malignant	O
hyperpyrexia	O
can	O
occur	O
,	O
sometimes	O
with	O
fatal	O
results	O
.	O

Antihistamines	S-group
:	O
Amphetamines	S-group-EF-1
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	S-group-EF-2
.	O

Antihypertensives	S-group
:	O
Amphetamines	S-group-EF-1
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	S-drug-EF-2
.	O

Chlorpromazine	S-drug
:	O
Chlorpromazine	S-drug-EF-1
blocks	O
dopamine	O
and	O
norepinephrine	O
receptors	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	S-group-EF-2
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	S-group
poisoning	O
.	O

Ethosuximide	S-drug
:	O
Amphetamines	S-group-ME-1
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	S-drug-ME-2
.	O

Haloperidol	S-drug
:	O
Haloperidol	S-drug-EF-1
blocks	O
dopamine	O
receptors	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	S-group-EF-2
.	O

Lithium	B-drug
carbonate	E-drug
:	O
The	O
anorectic	O
and	O
stimulatory	O
effects	O
of	O
amphetamines	S-group-EF-1
may	O
be	O
inhibited	O
by	O
lithium	B-drug-EF-2
carbonate	E-drug-EF-2
.	O

Meperidine	S-drug
:	O
Amphetamines	S-group-EF-1
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	S-drug-EF-2
.	O

Methenamine	S-drug
therapy	O
Urinary	O
excretion	O
of	O
amphetamines	S-group-ME-1
is	O
increased	O
,	O
and	O
efficacy	O
is	O
reduced	O
by	O
acidifying	O
agents	O
used	O
in	O
methenamine	S-drug-ME-2
therapy	O
.	O

Norepinephrine	S-drug
:	O
Amphetamines	S-group-EF-1
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	S-drug-EF-2
.	O

Phenobarbital	S-drug
:	O
Amphetamines	S-group-ME-1
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	S-drug-ME-2
;	O

co	O
-	O
administration	O
of	O
phenobarbital	S-drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Phenytoin	S-drug
:	O
Amphetamines	S-group-ME-1
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	S-drug-ME-2
;	O

co	O
-	O
administration	O
of	O
phenytoin	S-drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Propoxyphene	S-drug
:	O
In	O
cases	O
of	O
propoxyphene	S-drug-EF-1
overdosage	O
,	O
amphetamine	S-drug-EF-2
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O

Veratrum	B-group
alkaloids	E-group
:	O
Amphetamines	S-group-EF-1
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	B-group-EF-2
alkaloids	E-group-EF-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Amphetamines	S-group
can	O
cause	O
a	O
significant	O
elevation	O
in	O
plasma	O
corticosteroid	O
levels	O
.	O

This	O
increase	O
is	O
greatest	O
in	O
the	O
evening	O
.	O

Amphetamines	S-group
may	O
interfere	O
with	O
urinary	O
steroid	O
determinations	O
.	O

Hypotension	O
-	O
Patients	O
on	O
Diuretic	O
Therapy	O
:	O
Patients	O
on	O
diuretics	S-group-EF-1
,	O
and	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
PRINIVIL	S-brand-EF-2
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
PRINIVIL	S-brand
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	S-group-EF-1
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
PRINIVIL	S-brand-EF-2
.	O

If	O
it	O
is	O
necessary	O
to	O
continue	O
the	O
diuretic	S-group-AD-1
,	O
initiate	O
therapy	O
with	O
PRINIVIL	S-brand-AD-2
at	O
a	O
dose	O
of	O
5	O
mg	O
daily	O
,	O
and	O
provide	O
close	O
medical	O
supervision	O
after	O
the	O
initial	O
dose	O
until	O
blood	O
pressure	O
has	O
stabilized	O
.	O

When	O
a	O
diuretic	S-group-EF-1
is	O
added	O
to	O
the	O
therapy	O
of	O
a	O
patient	O
receiving	O
PRINIVIL	S-brand-EF-2
,	O
an	O
additional	O
antihypertensive	O
effect	O
is	O
usually	O
observed	O
.	O

Studies	O
with	O
ACE	B-group
inhibitors	E-group
in	O
combination	O
with	O
diuretics	S-group
indicate	O
that	O
the	O
dose	O
of	O
the	O
ACE	B-group-AD-1
inhibitor	E-group-AD-1
can	O
be	O
reduced	O
when	O
it	O
is	O
given	O
with	O
a	O
diuretic	S-group-AD-2
.	O

Non	B-group
-	I-group
steroidal	I-group
Anti	I-group
-	I-group
inflammatory	I-group
Agents	E-group
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
non	B-group-EF-1
-	I-group-EF-1
steroidal	I-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
drugs	E-group-EF-1
,	O
the	O
co	O
-	O
administration	O
of	O
lisinopril	S-drug-EF-2
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O

These	O
effects	O
are	O
usually	O
reversible	O
.	O

Reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
,	O
including	O
lisinopril	S-drug-EF-2
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	S-group-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
inhibitors	E-group-AD-2
.	O

In	O
a	O
study	O
in	O
36	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
where	O
the	O
antihypertensive	O
effects	O
of	O
PRINIVIL	S-brand
alone	O
were	O
compared	O
to	O
PRINIVIL	S-brand
given	O
concomitantly	O
with	O
indomethacin	S-drug
,	O
the	O
use	O
of	O
indomethacin	S-drug
was	O
associated	O
with	O
a	O
reduced	O
antihypertensive	O
effect	O
,	O
although	O
the	O
difference	O
between	O
the	O
two	O
regimens	O
was	O
not	O
significant	O
.	O

Other	O
Agents	O
:	O
PRINIVIL	S-brand
has	O
been	O
used	O
concomitantly	O
with	O
nitrates	S-group
and	O
/	O
or	O
digoxin	S-drug
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

This	O
included	O
post	O
myocardial	O
infarction	O
patients	O
who	O
were	O
receiving	O
intravenous	O
or	O
transdermal	O
nitroglycerin	S-drug
.	O

No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
PRINIVIL	S-brand
was	O
used	O
concomitantly	O
with	O
propranolol	S-drug
or	O
hydrochlorothiazide	S-drug
.	O

The	O
presence	O
of	O
food	O
in	O
the	O
stomach	O
does	O
not	O
alter	O
the	O
bioavailability	O
of	O
PRINIVIL	S-brand
.	O

Agents	O
Increasing	O
Serum	O
Potassium	O
:	O
PRINIVIL	S-brand-EF-1
attenuates	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-group-EF-2
-	I-group-EF-2
type	I-group-EF-2
diuretics	E-group-EF-2
.	O

Use	O
of	O
PRINIVIL	S-brand-EF-1
with	O
potassium	B-group-EF-2
-	I-group-EF-2
sparing	I-group-EF-2
diuretics	E-group-EF-2
(	O
e.g	O
.	O
,	O
spironolactone	S-drug-EF-2
,	O
triamterene	S-drug-EF-2
,	O
or	O
amiloride	S-drug-EF-2
)	O
,	O
potassium	S-drug-EF-2
supplements	O
,	O
or	O
potassium	O
-	O
containing	O
salt	O
substitutes	O
may	O
lead	O
to	O
significant	O
increases	O
in	O
serum	O
potassium	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	O
.	O

Potassium	O
sparing	O
agents	O
should	O
generally	O
not	O
be	O
used	O
in	O
patients	O
with	O
heart	O
failure	O
who	O
are	O
receiving	O
PRINIVIL	S-brand
.	O

Lithium	S-drug
:	O
Lithium	S-drug
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	S-drug-EF-1
concomitantly	O
with	O
drugs	O
which	O
cause	O
elimination	O
of	O
sodium	O
,	O
including	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
.	O

Lithium	S-drug
toxicity	O
was	O
usually	O
reversible	O
upon	O
discontinuation	O
of	O
lithium	S-drug-EF-1
and	O
the	O
ACE	B-group-EF-2
inhibitor	E-group-EF-2
.	O

It	O
is	O
recommended	O
that	O
serum	O
lithium	S-drug
levels	O
be	O
monitored	O
frequently	O
if	O
PRINIVIL	S-brand-AD-1
is	O
administered	O
concomitantly	O
with	O
lithium	S-drug-AD-2
.	O

-	O
Lofexidine	S-drug-EF-1
may	O
enhance	O
the	O
CNS	O
depressive	O
effects	O
of	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
and	O
other	O
sedatives	S-group-EF-2

-	O
Lofexidine	S-drug-EF-1
may	O
enhance	O
the	O
effects	O
of	O
anti	B-group-EF-2
-	I-group-EF-2
hypertensive	I-group-EF-2
drug	E-group-EF-2
therapy	O

-	O
Concomitant	O
use	O
of	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
reduce	O
the	O
efficacy	O
of	O
lofexidine	S-drug-EF-2
.	O

Theophylline	S-drug
:	O
In	O
three	O
pharmacokinetic	O
studies	O
including	O
46	O
normal	O
,	O
healthy	O
subjects	O
,	O
theophylline	S-drug
clearance	O
and	O
concentration	O
were	O
not	O
significantly	O
altered	O
by	O
the	O
addition	O
of	O
lomefloxacin	S-drug
.	O

In	O
clinical	O
studies	O
where	O
patients	O
were	O
on	O
chronic	O
theophylline	S-drug
therapy	O
,	O
lomefloxacin	S-drug
had	O
no	O
measurable	O
effect	O
on	O
the	O
mean	O
distribution	O
of	O
theophylline	S-drug
concentrations	O
or	O
the	O
mean	O
estimates	O
of	O
theophylline	S-drug
clearance	O
.	O

Though	O
individual	O
theophylline	S-drug
levels	O
fluctuated	O
,	O
there	O
were	O
no	O
clinically	O
significant	O
symptoms	O
of	O
drug	O
inter	O
-	O
action	O
.	O

Antacids	S-group
and	O
sucralfate	S-drug
:	O
Sucralfate	S-drug-ME-1
and	O
antacids	S-group
containing	O
magnesium	S-drug-ME-1
or	O
aluminum	S-drug-ME-1
,	O
as	O
well	O
as	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
Videx	S-brand-ME-1
(	O
didanosine	S-drug-ME-1
)	O
,	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
can	O
form	O
chelation	O
complexes	O
with	O
lomefloxacin	S-drug-ME-2
and	O
interfere	O
with	O
its	O
bioavailability	O
.	O

Sucralfate	S-drug-ME-1
administered	O
2	O
hours	O
before	O
lomefloxacin	S-drug-ME-2
resulted	O
in	O
a	O
slower	O
absorption	O
(	O
mean	O
C	O
max	O
decreased	O
by	O
30	O
%	O
and	O
mean	O
T	O
max	O
increased	O
by	O
1	O
hour	O
)	O
and	O
a	O
lesser	O
extent	O
of	O
absorption	O
(	O
mean	O
AUC	O
decreased	O
by	O
approximately	O
25	O
%	O
)	O
.	O

Magnesium	S-drug-ME-1
-	O
and	O
aluminum	S-drug-ME-1
-	O
containing	O
antacids	S-group-ME-1
,	O
administered	O
concomitantly	O
with	O
lomefloxacin	S-drug-ME-2
,	O
significantly	O
decreased	O
the	O
bioavailability	O
(	O
48	O
%	O
)	O
of	O
lomefloxacin	S-drug
.	O

Separating	O
the	O
doses	O
of	O
antacid	S-group-ME-1
and	O
lomefloxacin	S-drug-ME-2
minimizes	O
this	O
decrease	O
in	O
bioavailability	O
;	O

therefore	O
,	O
administration	O
of	O
these	O
agents	O
should	O
precede	O
lomefloxacin	S-drug
dosing	O
by	O
4	O
hours	O
or	O
follow	O
lomefloxacin	S-drug
dosing	O
by	O
at	O
least	O
2	O
hours	O
.	O

Caffeine	S-drug
:	O
Two	O
hundred	O
mg	O
of	O
caffeine	S-drug
(	O
equivalent	O
to	O
1	O
to	O
3	O
cups	O
of	O
American	O
coffee	O
)	O
was	O
administered	O
to	O
16	O
normal	O
,	O
healthy	O
volunteers	O
who	O
had	O
achieved	O
steady	O
-	O
state	O
blood	O
concentrations	O
of	O
lomefloxacin	S-drug
after	O
being	O
dosed	O
at	O
400	O
mg	O
qd	O
.	O

This	O
did	O
not	O
result	O
in	O
any	O
statistically	O
or	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetic	O
parameters	O
of	O
either	O
caffeine	S-drug
or	O
its	O
major	O
metabolite	O
,	O
paraxanthine	S-drug_n
.	O

No	O
data	O
are	O
available	O
on	O
potential	O
interactions	O
in	O
individuals	O
who	O
consume	O
greater	O
than	O
200	O
mg	O
of	O
caffeine	S-drug
per	O
day	O
or	O
in	O
those	O
,	O
such	O
as	O
the	O
geriatric	O
population	O
,	O
who	O
are	O
generally	O
believed	O
to	O
be	O
more	O
susceptible	O
to	O
the	O
development	O
of	O
drug	O
-	O
induced	O
CNS	O
-	O
related	O
adverse	O
effects	O
.	O

Other	O
quinolones	S-group-ME-1
have	O
demonstrated	O
moderate	O
to	O
marked	O
interference	O
with	O
the	O
metabolism	O
of	O
caffeine	S-drug-ME-2
,	O
resulting	O
in	O
a	O
reduced	O
clearance	O
,	O
a	O
prolongation	O
of	O
plasma	O
half	O
-	O
life	O
,	O
and	O
an	O
increase	O
in	O
symptoms	O
that	O
accompany	O
high	O
levels	O
of	O
caffeine	S-drug
.	O

Cimetidine	S-drug
:	O
Cimetidine	S-drug-ME-1
has	O
been	O
demonstrated	O
to	O
interfere	O
with	O
the	O
elimination	O
of	O
other	O
quinolones	S-group-ME-2
.	O

This	O
interference	O
has	O
resulted	O
in	O
significant	O
increases	O
in	O
half	O
-	O
life	O
and	O
AUC	O
.	O

The	O
interaction	O
between	O
lomefloxacin	S-drug
and	O
cimetidine	S-drug
has	O
not	O
been	O
studied	O
.	O

Cyclosporine	S-drug
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	S-drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	S-drug-ME-1
with	O
other	O
members	O
of	O
the	O
quinolone	B-group-ME-2
class	E-group-ME-2
.	O

Interaction	O
between	O
lomefloxacin	S-drug
and	O
cyclosporine	S-drug
has	O
not	O
been	O
studied	O
.	O

Omeprazole	S-drug
:	O
No	O
clinically	O
significant	O
changes	O
in	O
lomefloxacin	S-drug
pharmacokinetics	O
(	O
AUC	O
,	O
C	O
max	O
,	O
or	O
T	O
max	O
)	O
were	O
observed	O
when	O
a	O
single	O
dose	O
of	O
lomefloxacin	S-drug
400	O
mg	O
was	O
given	O
after	O
multiple	O
doses	O
of	O
omeprazole	S-drug
(	O
20	O
mg	O
qd	O
)	O
in	O
13	O
healthy	O
volunteers	O
.	O

Changes	O
in	O
omeprazole	S-drug
pharmacokinetics	O
were	O
not	O
studied	O
.	O

Phenytoin	S-drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
mean	O
phenytoin	S-drug
AUC	O
,	O
C	O
max	O
,	O
C	O
min	O
or	O
T	O
max	O
(	O
although	O
C	O
max	O
increased	O
by	O
11	O
%	O
)	O
when	O
extended	O
phenytoin	B-drug
sodium	E-drug
capsules	O
(	O
100	O
mg	O
tid	O
)	O
were	O
coadministered	O
with	O
lomefloxacin	S-drug
(	O
400	O
mg	O
qd	O
)	O
for	O
five	O
days	O
in	O
15	O
healthy	O
males	O
.	O

Lomefloxacin	S-drug
is	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
phenytoin	S-drug
metabolism	O
.	O

Probenecid	S-drug
:	O
Probenecid	S-drug
slows	O
the	O
renal	O
elimination	O
of	O
lome	O
-	O
floxacin	O
.	O

An	O
increase	O
of	O
63	O
%	O
in	O
the	O
mean	O
AUC	O
and	O
increases	O
of	O
50	O
%	O
and	O
4	O
%	O
,	O
respectively	O
,	O
in	O
the	O
mean	O
T	O
max	O
and	O
mean	O
C	O
max	O
were	O
noted	O
in	O
1	O
study	O
of	O
6	O
individuals	O
.	O

Terfenadine	S-drug
:	O
No	O
clinically	O
significant	O
changes	O
occurred	O
in	O
heart	O
rate	O
or	O
corrected	O
QT	O
intervals	O
,	O
or	O
in	O
terfenadine	S-drug
metabolite	O
or	O
lomefloxacin	S-drug
pharmacokinetics	O
,	O
during	O
concurrent	O
administration	O
of	O
lomefloxacin	S-drug
and	O
terfenadine	S-drug
at	O
steady	O
-	O
state	O
in	O
28	O
healthy	O
males	O
.	O

Warfarin	S-drug
:	O
Quinolones	S-group-EF-1
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	S-group-EF-2
,	O
warfarin	S-drug-EF-2
,	O
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
monitored	O
closely	O
.	O

However	O
,	O
no	O
clinically	O
or	O
statistically	O
significant	O
differences	O
in	O
prothrombin	O
time	O
ratio	O
or	O
warfarin	S-drug
enantiomer	O
pharmacokinetics	O
were	O
observed	O
in	O
a	O
small	O
study	O
of	O
7	O
healthy	O
males	O
who	O
received	O
both	O
warfarin	S-drug
and	O
lomefloxacin	S-drug
under	O
steady	O
-	O
state	O
conditions	O
.	O

There	O
was	O
no	O
evidence	O
in	O
clinical	O
trials	O
of	O
drug	O
interactions	O
with	O
concurrent	O
medications	O
.	O

Probenecid	S-drug
:	O
As	O
with	O
other	O
b	B-group-ME-1
-	I-group-ME-1
lactam	I-group-ME-1
antibiotics	E-group-ME-1
,	O
renal	O
excretion	O
of	O
loracarbef	S-drug-ME-1
is	O
inhibited	O
by	O
probenecid	S-drug-ME-2
and	O
resulted	O
in	O
an	O
approximate	O
80	O
%	O
increase	O
in	O
the	O
AUC	O
for	O
loracarbef	S-drug
.	O

Loratadine	S-drug
(	O
10	O
mg	O
once	O
daily	O
)	O
has	O
been	O
coadministered	O
with	O
therapeutic	O
doses	O
of	O
erythromycin	S-drug
,	O
cimetidine	S-drug
,	O
and	O
ketoconazole	S-drug
in	O
controlled	O
clinical	O
pharmacology	O
studies	O
in	O
adult	O
volunteers	O
.	O

Although	O
increased	O
plasma	O
concentrations	O
(	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
loratadine	S-drug
and	O
/	O
or	O
descarboethoxyloratadine	S-drug
were	O
observed	O
following	O
coadministration	O
of	O
loratadine	S-drug
with	O
each	O
of	O
these	O
drugs	O
in	O
normal	O
volunteers	O
(	O
n	O
=	O
24	O
in	O
each	O
study	O
)	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
loratadine	S-drug
,	O
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
,	O
clinical	O
laboratory	O
tests	O
,	O
vital	O
signs	O
,	O
and	O
adverse	O
events	O
.	O

There	O
were	O
no	O
significant	O
effects	O
on	O
QTc	O
intervals	O
,	O
and	O
no	O
reports	O
of	O
sedation	O
or	O
syncope	O
.	O

No	O
effects	O
on	O
plasma	O
concentrations	O
of	O
cimetidine	S-drug
or	O
ketoconazole	S-drug
were	O
observed	O
.	O

Plasma	O
concentrations	O
(	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
erythromycin	S-drug-ME-1
decreased	O
15	O
%	O
with	O
coadministration	O
of	O
loratadine	S-drug-ME-2
relative	O
to	O
that	O
observed	O
with	O
erythromycin	S-drug
alone	O
.	O

The	O
clinical	O
relevance	O
of	O
this	O
difference	O
is	O
unknown	O
.	O

These	O
above	O
findings	O
are	O
summarized	O
in	O
TABLE	O
1	O
.	O

TABLE	O
1	O
Effects	O
on	O
Plasma	O
Concentrations	O
(	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
Loratadine	S-drug
and	O
Descarboethoxyloratadine	S-drug
After	O
10	O
Days	O
of	O
Coadministration	O
(	O
Loratadine	S-drug
10	O
mg	O
)	O
in	O
Normal	O
Volunteers	O

Loratadine	S-drug
Descarboethoxyloratadine	S-drug

Erythromycin	S-drug
(	O
500	O
mg	O
q8h	O
)	O
+	O
40	O
%	O
+	O
46	O
%	O

Cimetidine	S-drug
(	O
300	O
mg	O
qid	O
)	O
+	O
103	O
%	O
+	O
6	O
%	O

Ketoconazole	S-drug
(	O
200	O
mg	O
q12h	O
)	O
+	O
307	O
%	O
+	O
73	O
%	O

There	O
does	O
not	O
appear	O
to	O
be	O
an	O
increase	O
in	O
adverse	O
events	O
in	O
subjects	O
who	O
received	O
oral	O
contraceptives	S-group
and	O
loratadine	S-drug
.	O

Tablets	O
:	O
The	O
benzodiazepines	S-group-EF-1
,	O
including	O
lorazepam	S-drug-EF-1
,	O
produce	O
CNS	O
-	O
depressant	O
effects	O
when	O
administered	O
with	O
such	O
medications	O
as	O
barbiturates	S-group-EF-2
or	O
alcohol	S-drug-EF-2
.	O

Injection	O
:	O
Lorazepam	S-drug-EF-1
injection	O
,	O
like	O
other	O
injectable	O
benzodiazepines	S-group-EF-1
,	O
produces	O
depression	O
of	O
the	O
central	O
nervous	O
system	O
when	O
administered	O
with	O
ethyl	B-drug-EF-2
alcohol	E-drug-EF-2
,	O
phenothiazines	S-group-EF-2
,	O
barbiturates	S-group-EF-2
,	O
MAO	B-group-EF-2
inhibitors	E-group-EF-2
,	O
and	O
other	O
antidepressants.When	O
scopolamine	S-drug-EF-1
is	O
used	O
concomitantly	O
with	O
injectable	O
lorazepam	S-drug-EF-2
,	O
an	O
increased	O
incidence	O
of	O
sedation	O
,	O
hallucinations	O
,	O
and	O
irrational	O
behavior	O
has	O
been	O
observed	O
.	O

No	O
significant	O
drug	O
-	O
drug	O
pharmacokinetic	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	S-drug
,	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
cimetidine	S-drug
and	O
phenobarbital	S-drug
.	O

Rifampin	S-drug-ME-1
,	O
an	O
inducer	O
of	O
drug	O
metabolism	O
,	O
decreased	O
the	O
concentrations	O
of	O
losartan	S-drug-ME-2
and	O
its	O
active	O
metabolite	O
.	O

In	O
humans	O
,	O
two	O
inhibitors	O
of	O
P450	O
3A4	O
have	O
been	O
studied	O
.	O

Ketoconazole	S-drug
did	O
not	O
affect	O
the	O
conversion	O
of	O
losartan	S-drug
to	O
the	O
active	O
metabolite	O
after	O
intravenous	O
administration	O
of	O
losartan	S-drug
,	O
and	O
erythromycin	S-drug
had	O
no	O
clinically	O
significant	O
effect	O
after	O
oral	O
administration	O
.	O

Fluconazole	S-drug-ME-1
,	O
an	O
inhibitor	O
of	O
P450	O
2C9	O
,	O
decreased	O
active	O
metabolite	O
concentration	O
and	O
increased	O
losartan	S-drug-ME-2
concentration	O
.	O

The	O
pharmacodynamic	O
consequences	O
of	O
concomitant	O
use	O
of	O
losartan	S-drug
and	O
inhibitors	O
of	O
P450	O
2C9	O
have	O
not	O
been	O
examined	O
.	O

Subjects	O
who	O
do	O
not	O
metabolize	O
losartan	S-drug
to	O
active	O
metabolite	O
have	O
been	O
shown	O
to	O
have	O
a	O
specific	O
,	O
rare	O
defect	O
in	O
cytochrome	O
P450	O
2C9	O
.	O

These	O
data	O
suggest	O
that	O
the	O
conversion	O
of	O
losartan	S-drug
to	O
its	O
active	O
metabolite	O
is	O
mediated	O
primarily	O
by	O
P450	O
2C9	O
and	O
not	O
P450	O
3A4	O
.	O

As	O
with	O
other	O
drugs	O
that	O
block	O
angiotensin	O
II	O
or	O
its	O
effects	O
,	O
concomitant	O
use	O
of	O
potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
(	O
e.g	O
.	O
,	O
spironolactone	S-drug
,	O
triamterene	S-drug
,	O
amiloride	S-drug
)	O
,	O
potassium	S-drug
supplements	O
,	O
or	O
salt	O
substitutes	O
containing	O
potassium	O
may	O
lead	O
to	O
increases	O
in	O
serum	O
potassium	O
.	O

As	O
with	O
other	O
antihypertensive	B-group
agents	E-group
,	O
the	O
antihypertensive	O
effect	O
of	O
losartan	S-drug-EF-1
may	O
be	O
blunted	O
by	O
the	O
non	B-group
-	I-group
steroidal	I-group
anti	I-group
-	I-group
inflammatory	I-group
drug	E-group
indomethacin	S-drug-EF-2

CYP3A4	O
Interactions	O

Lovastatin	S-drug
is	O
metabolized	O
by	O
CYP3A4	O
but	O
has	O
no	O
CYP3A4	O
inhibitory	O
activity	O
;	O

therefore	O
it	O
is	O
not	O
expected	O
to	O
affect	O
the	O
plasma	O
concentrations	O
of	O
other	O
drugs	O
metabolized	O
by	O
CYP3A4	O
.	O

Potent	O
inhibitors	O
of	O
CYP3A4	O
(	O
below	O
)	O
increase	O
the	O
risk	O
of	O
myopathy	O
by	O
reducing	O
the	O
elimination	O
of	O
lovastatin	S-drug
.	O

Pharmacokinetics	O
.	O

Itraconazole	S-drug
Ketoconazole	S-drug
Erythromycin	S-drug
Clarithromycin	S-drug
Telithromycin	S-drug
HIV	B-group
protease	I-group
inhibitors	E-group
Nefazodone	S-drug
Cyclosporine	S-drug
Large	O
quantities	O
of	O
grapefruit	O
juice	O
(	O
1	O
quart	O
daily	O
)	O

Interactions	O
with	O
lipid	O
-	O
lowering	O
drugs	O
that	O
can	O
cause	O
myopathy	O
when	O
given	O
alone	O
.	O

The	O
risk	O
of	O
myopathy	O
is	O
also	O
increased	O
by	O
the	O
following	O
lipid	O
-	O
lowering	O
drugs	O
that	O
are	O
not	O
potent	O
CYP3A4	O
inhibitors	O
,	O
but	O
which	O
can	O
cause	O
myopathy	O
when	O
given	O
alone	O
.	O

See	O
WARNINGS	O
,	O
Myopathy	O
/	O
Rhabdomyolysis	O
.	O

Gemfibrozil	S-drug
Other	O
fibrates	S-group
Niacin	S-drug
(	O
nicotinic	B-drug
acid	E-drug
)	O
(	O
=	O
1	O
g	O
/	O
day	O
)	O

Other	O
drug	O
interactions	O

Danazol	S-drug
:	O
The	O
risk	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
is	O
increased	O
by	O
concomitant	O
administration	O
of	O
danazol	S-drug-EF-1
particularly	O
with	O
higher	O
doses	O
of	O
lovastatin	S-drug-EF-2
(	O
see	O
WARNINGS	O
,	O
Myopathy	O
/	O
Rhabdomyolysis	O
)	O
.	O

Amiodarone	S-drug
or	O
Verapamil	S-drug
:	O
The	O
risk	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
is	O
increased	O
when	O
either	O
amiodarone	S-drug-EF-1
or	O
verapamil	S-drug-EF-1
is	O
used	O
concomitantly	O
with	O
a	O
closely	O
related	O
member	O
of	O
the	O
HMG	B-group-EF-2
-	I-group-EF-2
CoA	I-group-EF-2
reductase	I-group-EF-2
inhibitor	I-group-EF-2
class	E-group-EF-2
(	O
see	O
WARNINGS	O
,	O
Myopathy	O
/	O
Rhabdomyolysis	O
)	O
.	O

Coumarin	B-group
Anticoagulants	O
:	O
In	O
a	O
small	O
clinical	O
trial	O
in	O
which	O
lovastatin	S-drug
was	O
administered	O
to	O
warfarin	S-drug
treated	O
patients	O
,	O
no	O
effect	O
on	O
prothrombin	O
time	O
was	O
detected	O
.	O

However	O
,	O
another	O
HMG	B-group-EF-1
-	I-group-EF-1
CoA	I-group-EF-1
reductase	I-group-EF-1
inhibitor	E-group-EF-1
has	O
been	O
found	O
to	O
produce	O
a	O
less	O
than	O
two	O
-	O
second	O
increase	O
in	O
prothrombin	O
time	O
in	O
healthy	O
volunteers	O
receiving	O
low	O
doses	O
of	O
warfarin	S-drug-EF-2
.	O

Also	O
,	O
bleeding	O
and	O
/	O
or	O
increased	O
prothrombin	O
time	O
have	O
been	O
reported	O
in	O
a	O
few	O
patients	O
taking	O
coumarin	B-group-EF-1
anticoagulants	O
concomitantly	O
with	O
lovastatin	S-drug-EF-2
.	O

It	O
is	O
recommended	O
that	O
in	O
patients	O
taking	O
anticoagulants	S-group-AD-1
,	O
prothrombin	O
time	O
be	O
determined	O
before	O
starting	O
lovastatin	S-drug-AD-2
and	O
frequently	O
enough	O
during	O
early	O
therapy	O
to	O
insure	O
that	O
no	O
significant	O
alteration	O
of	O
prothrombin	O
time	O
occurs	O
.	O

Once	O
a	O
stable	O
prothrombin	O
time	O
has	O
been	O
documented	O
,	O
prothrombin	O
times	O
can	O
be	O
monitored	O
at	O
the	O
intervals	O
usually	O
recommended	O
for	O
patients	O
on	O
coumarin	B-group
anticoagulants	E-group
.	O

If	O
the	O
dose	O
of	O
lovastatin	S-drug
is	O
changed	O
,	O
the	O
same	O
procedure	O
should	O
be	O
repeated	O
.	O

Lovastatin	S-drug
therapy	O
has	O
not	O
been	O
associated	O
with	O
bleeding	O
or	O
with	O
changes	O
in	O
prothrombin	O
time	O
in	O
patients	O
not	O
taking	O
anticoagulants	S-group
.	O

Propranolol	S-drug
:	O
In	O
normal	O
volunteers	O
,	O
there	O
was	O
no	O
clinically	O
significant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
with	O
concomitant	O
administration	O
of	O
single	O
doses	O
of	O
lovastatin	S-drug
and	O
propranolol	S-drug
.	O

Digoxin	S-drug
:	O
In	O
patients	O
with	O
hypercholesterolemia	O
,	O
concomitant	O
administration	O
of	O
lovastatin	S-drug
and	O
digoxin	S-drug
resulted	O
in	O
no	O
effect	O
on	O
digoxin	S-drug
plasma	O
concentrations	O
.	O

Oral	O
Hypoglycemic	B-group
Agents	E-group
:	O
In	O
pharmacokinetic	O
studies	O
of	O
MEVACOR	S-brand
in	O
hypercholesterolemic	O
noninsulin	O
dependent	O
diabetic	O
patients	O
,	O
there	O
was	O
no	O
drug	O
interaction	O
with	O
glipizide	S-drug
or	O
with	O
chlorpropamide	S-drug

There	O
have	O
been	O
rare	O
reports	O
of	O
significant	O
respiratory	O
depression	O
,	O
stupor	O
and	O
/	O
or	O
hypotension	O
with	O
the	O
concomitant	O
use	O
of	O
loxapine	S-drug-EF-1
and	O
lorazepam	S-drug-EF-2
.	O

The	O
risk	O
of	O
using	O
loxapine	S-drug
in	O
combination	O
with	O
CNS	O
-	O
active	O
drugs	O
has	O
not	O
been	O
systematically	O
evaluated	O
.	O

Therefore	O
,	O
caution	O
is	O
advised	O
if	O
the	O
concomitant	O
administration	O
of	O
loxapine	S-drug
and	O
CNS	O
-	O
active	O
drugs	O
is	O
required	O
.	O

The	O
absorption	O
of	O
lymecycline	S-drug-ME-1
may	O
be	O
affected	O
by	O
the	O
simultaneous	O
administration	O
of	O
indigestion	O
remedies	O
,	O
iron	S-drug-ME-2
or	O
zinc	S-drug-ME-2
supplements	O
.	O

Oral	O
contraceptives	S-group-EF-1
may	O
be	O
less	O
effective	O
while	O
you	O
are	O
taking	O
lymecycline	S-drug-EF-2
.	O

Warfarin	S-drug-EF-1
:	O
Meclofenamate	B-drug-EF-2
sodium	E-drug-EF-2
enhances	O
the	O
effect	O
of	O
warfarin	S-drug
.	O

Therefore	O
,	O
when	O
meclofenamate	B-drug-AD-1
sodium	E-drug-AD-1
is	O
given	O
to	O
a	O
patient	O
receiving	O
warfarin	S-drug-AD-2
,	O
the	O
dosage	O
of	O
warfarin	S-drug
should	O
be	O
reduced	O
to	O
prevent	O
excessive	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
.	O

Aspirin	S-brand
:	O
Concurrent	O
administration	O
of	O
aspirin	S-brand-ME-1
may	O
lower	O
meclofenamate	B-drug-ME-2
sodium	E-drug-ME-2
plasma	O
levels	O
,	O
possibly	O
by	O
competing	O
for	O
protein	O
-	O
binding	O
sites	O
.	O

The	O
urinary	O
excretion	O
of	O
meclofenamate	B-drug
sodium	E-drug
is	O
unaffected	O
by	O
aspirin	S-brand
,	O
indicating	O
no	O
change	O
in	O
meclofenamate	B-drug
sodium	E-drug
absorption	O
.	O

Meclofenamate	B-drug
sodium	E-drug
does	O
not	O
affect	O
serum	O
salicylate	S-group
levels	O
.	O

Greater	O
fecal	O
blood	O
loss	O
results	O
from	O
concomitant	O
administration	O
of	O
both	O
drugs	O
than	O
from	O
either	O
drug	O
alone	O
.	O

Propoxyphene	S-drug
:	O
The	O
concurrent	O
administration	O
of	O
propoxyphene	B-drug
hydrochloride	E-drug
does	O
not	O
affect	O
the	O
bioavailability	O
of	O
meclofenamate	B-drug
sodium	E-drug
.	O

Antacids	S-group
:	O
Concomitant	O
administration	O
of	O
aluminum	S-drug
and	O
magnesium	B-drug
hydroxides	O
does	O
not	O
interfere	O
with	O
absorption	O
of	O
meclofenamate	B-drug
sodium	E-drug
.	O

Aspirin	S-brand
:	O
As	O
with	O
other	O
NSAIDs	S-group-AD-1
,	O
concomitant	O
administration	O
of	O
Ponstel	S-brand-AD-1
and	O
aspirin	S-brand-AD-2
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O

Methotrexate	S-drug
:	O
NSAIDs	S-group-ME-1
have	O
been	O
reported	O
to	O
competitively	O
inhibit	O
methotrexate	S-drug-ME-2
accumulation	O
in	O
rabbit	O
kidney	O
slices	O
.	O

This	O
may	O
indicate	O
that	O
they	O
could	O
enhance	O
the	O
toxicity	O
of	O
methotrexate	S-drug
.	O

Caution	O
should	O
be	O
used	O
when	O
NSAIDs	S-group-AD-1
are	O
administered	O
concomitantly	O
with	O
methotrexate	S-drug-AD-2
.	O

ACE	B-group
inhibitors	E-group
:	O
Reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	S-group-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
inhibitors	E-group-AD-2
.	O

Furosemide	S-drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	S-group-EF-1
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	S-drug-EF-2
and	O
thiazides	S-group-EF-2
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

During	O
concomitant	O
therapy	O
of	O
Ponstel	S-brand-AD-1
with	O
furosemide	S-drug-AD-2
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	O
efficacy	O
.	O

Lithium	S-drug
:	O
NSAIDs	S-group-ME-1
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	S-drug-ME-2
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	S-drug-ME-2
clearance	O
.	O

The	O
mean	O
minimum	O
lithium	S-drug
concentration	O
increased	O
15	O
%	O
and	O
the	O
renal	O
clearance	O
was	O
decreased	O
by	O
approximately	O
20	O
%	O
.	O

These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
the	O
NSAID	S-group
.	O

Thus	O
,	O
when	O
NSAIDs	S-group-AD-1
and	O
lithium	S-drug-AD-2
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	S-drug
toxicity	O
.	O

Warfarin	S-drug
:	O
The	O
effects	O
of	O
warfarin	S-drug-EF-1
and	O
NSAIDs	S-group-EF-2
on	O
GI	O
bleeding	O
are	O
synergistic	O
,	O
such	O
that	O
users	O
of	O
both	O
drugs	O
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
users	O
of	O
either	O
drug	O
alone	O
.	O

Antacids	S-group
:	O
In	O
a	O
single	O
dose	O
study	O
(	O
n	O
=	O
6	O
)	O
,	O
ingestion	O
of	O
an	O
antacid	S-group
containing	O
1.7	O
-	O
gram	O
of	O
magnesium	B-drug-ME-1
hydroxide	E-drug-ME-1
with	O
500	O
-	O
mg	O
of	O
mefenamic	B-drug-ME-2
acid	E-drug-ME-2
increased	O
the	O
Cmax	O
and	O
AUC	O
of	O
mefenamic	B-drug
acid	E-drug
by	O
125	O
%	O
and	O
36	O
%	O
,	O
respectively	O
.	O
A	O
number	O
of	O
compounds	O
are	O
inhibitors	O
of	O
CYP2C9	O
including	O
fluconazole	S-drug
,	O
lovastatin	S-drug
and	O
trimethoprim	S-drug
.	O

Drug	O
interaction	O
studies	O
of	O
mefenamic	B-drug
acid	E-drug
and	O
these	O
compounds	O
have	O
not	O
been	O
conducted	O
.	O

The	O
possibility	O
of	O
altered	O
safety	O
and	O
efficacy	O
should	O
be	O
considered	O
when	O
Ponstel	S-brand
is	O
used	O
concomitantly	O
with	O
these	O
drugs	O
.	O

Drug	O
-	O
drug	O
interactions	O
with	O
Mefloquine	S-drug
have	O
not	O
been	O
explored	O
in	O
detail	O
.	O

There	O
is	O
one	O
report	O
of	O
cardiopulmonary	O
arrest	O
,	O
with	O
full	O
recovery	O
,	O
in	O
a	O
patient	O
who	O
was	O
taking	O
a	O
beta	B-group
blocker	E-group
(	O
propranolol	S-drug
)	O
.	O

The	O
effects	O
of	O
Mefloquineuine	O
on	O
the	O
compromised	O
cardiovascular	O
system	O
have	O
not	O
been	O
evaluated	O
.	O

The	O
benefits	O
of	O
Mefloquine	S-drug
therapy	O
should	O
be	O
weighed	O
against	O
the	O
possibility	O
of	O
adverse	O
effects	O
in	O
patients	O
with	O
cardiac	O
disease	O
.	O

Because	O
of	O
the	O
danger	O
of	O
a	O
potentially	O
fatal	O
prolongation	O
of	O
the	O
QTc	O
interval	O
,	O
halofantrine	S-drug-AD-1
must	O
not	O
be	O
given	O
simultaneously	O
with	O
or	O
subsequent	O
to	O
Mefloquine	S-drug-AD-2
.	O

Concomitant	O
administration	O
of	O
Mefloquine	S-drug-EF-1
and	O
other	O
related	O
compounds	O
(	O
eg	O
,	O
quinine	S-drug-EF-2
,	O
quinidine	S-drug-EF-2
and	O
chloroquine	S-drug-EF-2
)	O
may	O
produce	O
electrocardiographic	O
abnormalities	O
and	O
increase	O
the	O
risk	O
of	O
convulsions	O
.	O

If	O
these	O
drugs	O
are	O
to	O
be	O
used	O
in	O
the	O
initial	O
treatment	O
of	O
severe	O
malaria	O
,	O
Mefloquine	S-drug
administration	O
should	O
be	O
delayed	O
at	O
least	O
12	O
hours	O
after	O
the	O
last	O
dose	O
.	O

There	O
is	O
evidence	O
that	O
the	O
use	O
of	O
halofantrine	S-drug
after	O
Mefloquineuine	O
causes	O
a	O
significant	O
lengthening	O
of	O
the	O
QTc	O
interval	O
.	O

Clinically	O
significant	O
QTc	O
prolongation	O
has	O
not	O
been	O
found	O
with	O
Mefloquineuine	O
alone	O
.	O

This	O
appears	O
to	O
be	O
the	O
only	O
clinically	O
relevant	O
interaction	O
of	O
this	O
kind	O
with	O
Mefloquine	S-drug-EF-1
,	O
although	O
theoretically	O
,	O
coadministration	O
of	O
other	O
drugs	O
known	O
to	O
alter	O
cardiac	O
conduction	O
(	O
eg	O
,	O
anti	B-drug-EF-2
-	I-drug-EF-2
arrhythmic	E-drug-EF-2
or	O
beta	B-group-EF-2
-	I-group-EF-2
adrenergic	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
,	O
calcium	B-group-EF-2
channel	I-group-EF-2
blockers	E-group-EF-2
,	O
antihistamines	S-group-EF-2
or	O
H1	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
,	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
and	O
phenothiazines	S-group-EF-2
)	O
might	O
also	O
contribute	O
to	O
a	O
prolongation	O
of	O
the	O
QTc	O
interval	O
.	O

There	O
are	O
no	O
data	O
that	O
conclusively	O
establish	O
whether	O
the	O
concomitant	O
administration	O
of	O
Mefloquineuine	O
and	O
the	O
above	O
listed	O
agents	O
has	O
an	O
effect	O
on	O
cardiac	O
function	O
.	O

In	O
patients	O
taking	O
an	O
anticonvulsant	S-group-EF-1
(	O
eg	O
,	O
valproic	B-drug-EF-1
acid	E-drug-EF-1
,	O
carbamazepine	S-drug-EF-1
,	O
phenobarbital	S-drug-EF-1
or	O
phenytoin	S-drug-EF-1
)	O
,	O
the	O
concomitant	O
use	O
of	O
Mefloquine	S-drug-EF-2
may	O
reduce	O
seizure	O
control	O
by	O
lowering	O
the	O
plasma	O
levels	O
of	O
the	O
anticonvulsant	S-group
.	O

Therefore	O
,	O
patients	O
concurrently	O
taking	O
antiseizure	O
medication	O
and	O
Mefloquine	S-drug
should	O
have	O
the	O
blood	O
level	O
of	O
their	O
antiseizure	O
medication	O
monitored	O
and	O
the	O
dosage	O
adjusted	O
appropriately	O
.	O

When	O
Mefloquine	S-drug-EF-1
is	O
taken	O
concurrently	O
with	O
oral	O
live	B-group-EF-2
typhoid	I-group-EF-2
vaccines	E-group-EF-2
,	O
attenuation	O
of	O
immunization	O
can	O
not	O
be	O
excluded	O
.	O

Vaccinations	O
with	O
attenuated	O
live	O
bacteria	O
should	O
therefore	O
be	O
completed	O
at	O
least	O
3	O
days	O
before	O
the	O
first	O
dose	O
of	O
Mefloquine	S-drug
.	O

No	O
other	O
drug	O
interactions	O
are	O
known	O
.	O

Nevertheless	O
,	O
the	O
effects	O
of	O
Mefloquine	S-drug-AD-1
on	O
travelers	O
receiving	O
comedication	O
,	O
particularly	O
diabetics	O
or	O
patients	O
using	O
anticoagulants	S-group-AD-2
,	O
should	O
be	O
checked	O
before	O
departure	O
.	O

In	O
clinical	O
trials	O
,	O
the	O
concomitant	O
administration	O
of	O
sulfadoxine	S-drug
and	O
pyrimethamine	S-drug
did	O
not	O
alter	O
the	O
adverse	O
reaction	O
profile	O
.	O

Broad	B-group
-	I-group
Spectrum	I-group
Antibiotics	E-group
-	O
Broad	B-group
-	I-group
spectrum	I-group
antibiotics	E-group
may	O
sterilize	O
the	O
bowel	O
and	O
decrease	O
the	O
vitamin	B-group
K	E-group
contribution	O
to	O
the	O
body	O
by	O
the	O
intestinal	O
microflora	O
.	O

Cephalosporins	S-group
-	O
Cephalosporins	S-group
containing	O
side	O
chains	O
of	O
N	O
-	O
methylthiotetrazole	O
(	O
cefmenoxime	S-drug
,	O
cefoperazone	S-drug
,	O
cefotetan	S-drug
,	O
cefamandole	S-drug
,	O
latamoxef	S-drug
)	O
or	O
methylthiadiazole	O
(	O
cefazolin	S-drug
)	O
can	O
cause	O
vitamin	O
K	O
deficiency	O
and	O
hypoprothrombinemia	O
.	O

These	O
cephalosporins	S-group
are	O
inhibitors	O
of	O
hepatic	O
vitamin	O
K	O
epoxide	O
reductase	O
.	O

Cholestyramine	S-drug
-	O
Concomitant	O
intake	O
of	O
cholestyramine	S-drug-ME-1
and	O
vitamin	B-group-ME-2
K	E-group-ME-2
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B-group
K	E-group
.	O

Colestipol	S-drug
-	O
Concomitant	O
intake	O
of	O
colestipol	S-drug-ME-1
and	O
vitamin	B-group-ME-2
K	E-group-ME-2
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B-group
K	E-group
.	O

Mineral	B-drug_n
Oil	E-drug_n
-	O
Concomitant	O
intake	O
of	O
mineral	B-drug_n-ME-1
oil	E-drug_n-ME-1
and	O
vitamin	B-group-ME-2
K	E-group-ME-2
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B-group
K	E-group
.	O

Orlistat	S-drug
-	O
Orlistat	S-drug-ME-1
may	O
decrease	O
the	O
absorption	O
of	O
vitamin	B-group-ME-2
K	E-group-ME-2
.	O

Salicylates	S-group
-	O
Salicylates	S-group
in	O
large	O
doses	O
may	O
inhibit	O
vitamin	O
K	O
epoxide	O
reductase	O
resulting	O
in	O
vitamin	O
K	O
deficiency	O
.	O

Warfarin	S-drug
-	O
Vitamin	B-group-EF-1
K	E-group-EF-1
can	O
antagonize	O
the	O
effect	O
of	O
warfarin	S-drug-EF-2

Nabilone	S-drug-AD-1
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
who	O
are	O
taking	O
other	O
psychoactive	B-group-AD-2
drugs	E-group-AD-2
or	O
CNS	B-group-AD-2
depressants	E-group-AD-2
,	O
including	O
alcohol	S-drug-AD-2
,	O
barbiturates	S-group-AD-2
and	O
narcotic	B-group-AD-2
analgesics	E-group-AD-2
,	O
or	O
to	O
those	O
with	O
a	O
history	O
of	O
psychiatric	O
disorder	O
(	O
including	O
manic	O
-	O
depressive	O
illness	O
and	O
schizophrenia	O
)	O
.	O

Nabilone	S-drug-EF-1
has	O
been	O
shown	O
to	O
have	O
an	O
additive	O
CNS	O
depressant	O
effect	O
when	O
given	O
with	O
either	O
diazepam	S-drug-EF-2
,	O
secobarbitone	B-brand-EF-2
sodium	E-brand-EF-2
,	O
alcohol	S-drug-EF-2
or	O
codeine	S-drug-EF-2
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
,	O
because	O
of	O
its	O
affinity	O
for	O
protein	O
,	O
6MNA	S-drug_n
may	O
displace	O
other	O
protein	O
-	O
bound	O
drugs	O
from	O
their	O
binding	O
site	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
administering	O
nabumetone	S-drug-AD-1
with	O
warfarin	S-drug-MU-M
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	S-group-IN-2
.	O

Concomitant	O
administration	O
of	O
an	O
aluminum	S-drug
-	O
containing	O
antacid	S-group
had	O
no	O
significant	O
effect	O
in	O
the	O
bioavailability	O
of	O
6MNA	S-drug_n
.	O

When	O
administered	O
with	O
food	O
or	O
milk	O
,	O
there	O
is	O
more	O
rapid	O
absorption	O
;	O

however	O
,	O
the	O
total	O
amount	O
of	O
6MNA	S-drug_n
in	O
the	O
plasma	O
is	O
unchanged	O
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
beta	B-group-IN-1
-	I-group-IN-1
adrenergic	I-group-IN-1
receptor	I-group-IN-1
blocking	I-group-IN-1
agents	E-group-IN-1
:	O
Anesthetics	S-group-IN-2
,	O
general	O
:	O
exaggeration	O
of	O
the	O
hypotension	O
induced	O
by	O
general	O
anesthetics	S-group
.	O

Antidiabetic	B-group
drugs	E-group
(	O
oral	O
agents	O
and	O
insulin	S-drug
)	O
:	O
hypoglycemia	O
or	O
hyperglycemia	O
;	O

adjust	O
dosage	O
of	O
antidiabetic	B-group
drug	E-group
accordingly	O
.	O

Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g	O
.	O
,	O
reserpine	S-drug
)	O
:	O
additive	O
effect	O
;	O

monitor	O
closely	O
for	O
evidence	O
of	O
hypotension	O
and	O
/	O
or	O
excessive	O
bradycardia	O
(	O
e.g	O
.	O
,	O
vertigo	O
,	O
syncope	O
,	O
postural	O
hypotension	O
)	O
.	O

Response	O
to	O
Treatment	O
for	O
Anaphylactic	O
Reaction	O
:	O
While	O
taking	O
beta	B-group
-	I-group
blockers	E-group
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	S-drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

No	O
pharmacokinetic	O
-	O
based	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
SYNAREL	S-brand
.	O

However	O
,	O
because	O
nafarelin	B-drug
acetate	E-drug
is	O
a	O
peptide	O
that	O
is	O
primarily	O
degraded	O
by	O
peptidase	O
and	O
not	O
by	O
cytochrome	O
P	O
-	O
450	O
enzymes	O
,	O
and	O
the	O
drug	O
is	O
only	O
about	O
80	O
%	O
bound	O
to	O
plasma	O
proteins	O
at	O
4	O
C	O
,	O
drug	O
interactions	O
would	O
not	O
be	O
expected	O
to	O
occur	O
.	O

Tetracycline	S-drug-EF-1
,	O
a	O
bacteriostatic	B-group
antibiotic	E-group
,	O
may	O
antagonize	O
the	O
bactericidal	O
effect	O
of	O
penicillin	S-drug-EF-2
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

No	O
specific	O
information	O
available	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	S-drug-ME-1
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	S-group-ME-2
use	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	S-drug
-	O
related	O
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
quinolones	S-group-EF-1
and	O
theophylline	S-drug-EF-2
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	S-drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	S-drug
adjusted	O
,	O
as	O
required	O
.	O

Quinolones	S-group-ME-1
have	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	S-drug-ME-2
.	O

This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	S-drug
and	O
the	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O

Quinolones	S-group-EF-1
,	O
including	O
nalidixic	B-drug-EF-1
acid	E-drug-EF-1
,	O
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	S-group
warfarin	S-drug-EF-2
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
.	O

Nitrofurantoin	S-drug-EF-1
interferes	O
with	O
the	O
therapeutic	O
action	O
of	O
nalidixic	B-drug-EF-2
acid	E-drug-EF-2
.	O

Antacids	S-group
containing	O
magnesium	S-drug
,	O
aluminum	S-drug
,	O
or	O
calcium	S-drug
;	O

sucralfate	S-drug
or	O
divalent	O
or	O
trivalent	O
cations	O
such	O
as	O
iron	S-drug
;	O

multivitamins	S-group
containing	O
zinc	S-drug
;	O

and	O
Videx	S-brand-ME-1
,	O
(	O
Didanosine	S-drug-ME-1
)	O
,	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	S-group-ME-2
,	O
resulting	O
in	O
systemic	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O

These	O
agents	O
should	O
not	O
be	O
taken	O
within	O
the	O
two	O
hour	O
period	O
before	O
or	O
within	O
the	O
two	O
-	O
hour	O
period	O
after	O
nalidixic	B-drug
acid	E-drug
administration	O
.	O

Elevated	O
serum	O
levels	O
of	O
cyclosporine	S-drug
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
some	O
quinolones	S-group-ME-1
and	O
cyclosporine	S-drug-ME-2
.	O

Therefore	O
,	O
cyclosporine	S-drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	S-drug
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	O
are	O
used	O
concomitantly	O
.	O

Studies	O
to	O
evaluate	O
possible	O
interactions	O
between	O
REVIA	S-brand
and	O
drugs	O
other	O
than	O
opiates	S-group
have	O
not	O
been	O
performed	O
.	O

Consequently	O
,	O
caution	O
is	O
advised	O
if	O
the	O
concomitant	O
administration	O
of	O
REVIA	S-brand
and	O
other	O
drugs	O
is	O
required	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
concomitant	O
use	O
of	O
REVIA	S-brand-EF-1
and	O
disulfiram	S-drug-EF-2
is	O
unknown	O
,	O
and	O
the	O
concomitant	O
use	O
of	O
two	O
potentially	O
hepatotoxic	O
medications	O
is	O
not	O
ordinarily	O
recommended	O
unless	O
the	O
probable	O
benefits	O
outweigh	O
the	O
known	O
risks	O
.	O

Lethargy	O
and	O
somnolence	O
have	O
been	O
reported	O
following	O
doses	O
of	O
REVIA	S-brand-EF-1
and	O
thioridazine	S-drug-EF-2
.	O

Patients	O
taking	O
REVIA	S-brand-EF-1
may	O
not	O
benefit	O
from	O
opioid	S-group-EF-2
containing	O
medicines	O
,	O
such	O
as	O
cough	O
and	O
cold	O
preparations	O
,	O
antidiarrheal	O
preparations	O
,	O
and	O
opioid	B-group-EF-2
analgesics	E-group-EF-2
.	O

In	O
an	O
emergency	O
situation	O
when	O
opioid	O
analgesia	O
must	O
be	O
administered	O
to	O
a	O
patient	O
receiving	O
REVIA	S-brand-EF-1
,	O
the	O
amount	O
of	O
opioid	S-group-EF-2
required	O
may	O
be	O
greater	O
than	O
usual	O
,	O
and	O
the	O
resulting	O
respiratory	O
depression	O
may	O
be	O
deeper	O
and	O
more	O
prolonged	O
.	O

The	O
use	O
of	O
NSAIDs	S-group-EF-1
in	O
patients	O
who	O
are	O
receiving	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
may	O
potentiate	O
renal	O
disease	O
states	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
naproxen	S-drug
anion	O
,	O
because	O
of	O
its	O
affinity	O
for	O
protein	O
,	O
may	O
displace	O
from	O
their	O
binding	O
sites	O
other	O
drugs	O
which	O
are	O
also	O
albumin	O
-	O
bound	O
.	O

Theoretically	O
,	O
the	O
naproxen	S-drug
anion	O
itself	O
could	O
likewise	O
be	O
displaced	O
.	O

Short	O
-	O
term	O
controlled	O
studies	O
failed	O
to	O
show	O
that	O
taking	O
the	O
drug	O
significantly	O
affects	O
prothrombin	O
times	O
when	O
administered	O
to	O
individuals	O
on	O
coumarin	B-group
-	I-group
type	I-group
anticoagulants	E-group
.	O

Caution	O
is	O
advised	O
nonetheless	O
,	O
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
nonsteroidal	O
agents	O
of	O
this	O
class	O
.	O

Similarly	O
,	O
patients	O
receiving	O
the	O
drug	O
and	O
a	O
hydantoin	S-group
,	O
sulfonamide	S-group
or	O
sulfonylurea	S-group
should	O
be	O
observed	O
for	O
signs	O
of	O
toxicity	O
to	O
these	O
drugs	O
.	O

Concomitant	O
administration	O
of	O
naproxen	S-drug-AD-1
and	O
aspirin	S-brand-AD-2
is	O
not	O
recommended	O
because	O
naproxen	S-drug-AD-1
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	S-brand-AD-2
,	O
resulting	O
in	O
lower	O
plasma	O
concentrations	O
and	O
peak	O
plasma	O
levels	O
.	O

The	O
natriuretic	O
effect	O
of	O
furosemide	S-drug
has	O
been	O
reported	O
to	O
be	O
inhibited	O
by	O
some	O
drugs	O
of	O
this	O
class	O
.	O

Inhibition	O
of	O
renal	O
lithium	S-drug
clearance	O
leading	O
to	O
increases	O
in	O
plasma	O
lithium	S-drug
concentrations	O
has	O
also	O
been	O
reported	O
.	O

Naproxen	S-drug-EF-1
and	O
other	O
NSAIDs	S-group-EF-1
can	O
reduce	O
the	O
antihypertensive	O
effect	O
of	O
propranolol	S-drug-EF-2
and	O
other	O
beta	B-group-EF-2
-	I-group-EF-2
blockers	E-group-EF-2
.	O

Probenecid	S-drug-ME-1
given	O
concurrently	O
increases	O
naproxen	S-drug-ME-2
anion	O
plasma	O
levels	O
and	O
extends	O
its	O
plasma	O
half	O
-	O
life	O
significantly	O
.	O

Caution	O
should	O
be	O
used	O
if	O
naproxen	S-drug-AD-1
is	O
administered	O
concomitantly	O
with	O
methotrexate	S-drug-AD-2
.	O

Naproxen	S-drug-ME-1
,	O
naproxen	B-drug-ME-1
sodium	E-drug-ME-1
and	O
other	O
NSAIDs	S-group-ME-1
have	O
been	O
reported	O
to	O
reduce	O
the	O
tubular	O
secretion	O
of	O
methotrexate	S-drug-ME-2
in	O
an	O
animal	O
model	O
,	O
possibly	O
increasing	O
the	O
toxicity	O
of	O
methotrexate	S-drug
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Naproxen	S-drug
may	O
decrease	O
platelet	O
aggregation	O
and	O
prolong	O
bleeding	O
time	O
.	O

This	O
effect	O
should	O
be	O
kept	O
in	O
mind	O
when	O
bleeding	O
times	O
are	O
determined	O
.	O

The	O
administration	O
of	O
naproxen	S-drug
may	O
result	O
in	O
increased	O
urinary	O
values	O
for	O
17	O
-	O
ketogenic	O
steroids	O
because	O
of	O
an	O
interaction	O
between	O
the	O
drug	O
and	O
/	O
or	O
its	O
metabolites	O
with	O
m	O
-	O
dinitrobenzene	O
used	O
in	O
this	O
assay	O
.	O

Although	O
17	O
-	O
hydroxy	O
-	O
corticosteroid	O
measurements	O
(	O
Porter	O
-	O
Silber	O
test	O
)	O
do	O
not	O
appear	O
to	O
be	O
artifactually	O
altered	O
,	O
it	O
is	O
suggested	O
that	O
therapy	O
with	O
naproxen	S-drug
be	O
temporarily	O
discontinued	O
72	O
hours	O
before	O
adrenal	O
function	O
tests	O
are	O
performed	O
if	O
the	O
Porter	O
-	O
Silber	O
test	O
is	O
to	O
be	O
used	O
.	O

Naproxen	S-drug
may	O
interfere	O
with	O
some	O
urinary	O
assays	O
of	O
5	O
-	O
hydroxy	O
indoleacetic	O
acid	O
(	O
5HIAA	O
)	O
.	O

Ergot	S-group
-	O
containing	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine	S-drug-AD-1
-	O
containing	O
or	O
ergot	B-group-AD-1
-	I-group-AD-1
type	I-group-AD-1
medications	E-group-AD-1
(	O
like	O
dihydroergotamine	S-drug-AD-1
or	O
methysergide	S-drug-AD-1
)	O
and	O
naratriptan	S-drug-AD-2
within	O
24	O
hours	O
is	O
contraindicated	O
.	O

The	O
administration	O
of	O
naratriptan	S-drug
with	O
other	O
5	B-group
-	I-group
HT1	I-group
agonists	E-group
has	O
not	O
been	O
evaluated	O
in	O
migraine	O
patients	O
.	O

Because	O
their	O
vasospastic	O
effects	O
may	O
be	O
additive	O
,	O
coadministration	O
of	O
naratriptan	S-drug-AD-1
and	O
other	O
5	B-group-AD-2
-	I-group-AD-2
HT1	I-group-AD-2
agonists	E-group-AD-2
within	O
24	O
hours	O
of	O
each	O
other	O
is	O
not	O
recommended	O
.	O

Selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
(	O
SSRIs	S-group
)	O
(	O
e.g	O
.	O
,	O
fluoxetine	S-drug
,	O
fluvoxamine	S-drug
,	O
paroxetine	S-drug
,	O
sertraline	S-drug
)	O
have	O
been	O
reported	O
,	O
rarely	O
,	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5	O
-	O
HTv	O
agonists	O
.	O

If	O
concomitant	O
treatment	O
with	O
naratriptan	S-drug-AD-1
and	O
an	O
SSRI	S-group-AD-2
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
AMERGE	S-brand
Tablets	O
are	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O

After	O
multiple	O
dosing	O
,	O
interferon	B-drug-ME-1
beta	I-drug-ME-1
-	I-drug-ME-1
1a	E-drug-ME-1
(	O
AVONEX	S-brand-ME-1
30	O
mcg	O
IM	O
once	O
weekly	O
)	O
reduced	O
TYSABRI	S-brand-ME-2
clearance	O
by	O
approximately	O
30	O
%	O
.	O

The	O
similarity	O
of	O
the	O
TYSABRI	S-brand
-	O
associated	O
adverse	O
event	O
profile	O
between	O
Study	O
1	O
(	O
without	O
co	O
-	O
administered	O
AVONEX	S-brand
)	O
and	O
Study	O
2	O
(	O
with	O
co	O
-	O
administered	O
AVONEX	S-brand
)	O
indicates	O
that	O
this	O
alteration	O
in	O
clearance	O
does	O
not	O
necessitate	O
reduction	O
of	O
the	O
TYSABRI	S-brand
dose	O
to	O
maintain	O
safety	O
,	O
General	O
)	O
.	O

Results	O
of	O
studies	O
in	O
multiple	O
sclerosis	O
patients	O
taking	O
TYSABRI	S-brand
and	O
concomitant	O
interferon	B-drug
beta	I-drug
-	I-drug
1a	E-drug
(	O
AVONEX	S-brand
30	O
mcg	O
IM	O
once	O
weekly	O
)	O
or	O
glatiramer	B-drug
acetate	E-drug
were	O
inconclusive	O
with	O
regard	O
to	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
the	O
beta	B-drug
-	I-drug
interferon	E-drug
or	O
glatiramer	B-drug
acetate	E-drug
.	O

In	O
vitro	O
drug	O
metabolism	O
studies	O
indicate	O
that	O
Starlix	S-brand
is	O
predominantly	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
isozyme	O
CYP2C9	O
(	O
70	O
%	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
CYP3A4	O
(	O
30	O
%	O
)	O
.	O

Starlix	S-brand-ME-1
is	O
a	O
potential	O
inhibitor	O
of	O
the	O
CYP2C9	O
isoenzyme	O
in	O
vivo	O
as	O
indicated	O
by	O
its	O
ability	O
to	O
inhibit	O
the	O
in	O
vitro	O
metabolism	O
of	O
tolbutamide	S-drug-ME-2
.	O

Inhibition	O
of	O
CYP3A4	O
metabolic	O
reactions	O
was	O
not	O
detected	O
in	O
in	O
vitro	O
experiments	O
.	O

Glyburide	S-drug
:	O
In	O
a	O
randomized	O
,	O
multiple	O
-	O
dose	O
crossover	O
study	O
,	O
patients	O
with	O
Type	O
2	O
diabetes	O
were	O
administered	O
120	O
mg	O
Starlix	S-brand
three	O
times	O
a	O
day	O
before	O
meals	O
for	O
1	O
day	O
in	O
combination	O
with	O
glyburide	S-drug
10	O
mg	O
daily	O
.	O

There	O
were	O
no	O
clinically	O
relevant	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Metformin	S-drug
:	O
When	O
Starlix	S-brand
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
metformin	S-drug
500	O
mg	O
three	O
times	O
daily	O
to	O
patients	O
with	O
Type	O
2	O
diabetes	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Digoxin	S-drug
:	O
When	O
Starlix	S-brand
120	O
mg	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
a	O
single	O
1	O
-	O
mg	O
dose	O
of	O
digoxin	S-drug
to	O
healthy	O
volunteers	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Warfarin	S-drug
:	O
When	O
healthy	O
subjects	O
were	O
administered	O
Starlix	S-brand
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
for	O
four	O
days	O
in	O
combination	O
with	O
a	O
single	O
dose	O
of	O
warfarin	S-drug
30	O
mg	O
on	O
day	O
2	O
,	O
there	O
were	O
no	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Prothrombin	O
time	O
was	O
not	O
affected	O
.	O

Diclofenac	S-drug
:	O
Administration	O
of	O
morning	O
and	O
lunch	O
doses	O
of	O
Starlix	S-brand
120	O
mg	O
in	O
combination	O
with	O
a	O
single	O
75	O
-	O
mg	O
dose	O
of	O
diclofenac	S-drug
in	O
healthy	O
volunteers	O
resulted	O
in	O
no	O
significant	O
changes	O
to	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Nateglinide	S-drug
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
98	O
%	O
)	O
,	O
mainly	O
albumin	O
.	O

In	O
vitro	O
displacement	O
studies	O
with	O
highly	O
protein	O
-	O
bound	O
drugs	O
such	O
as	O
furosemide	S-drug
,	O
propranolol	S-drug
,	O
captopril	S-drug
,	O
nicardipine	S-drug
,	O
pravastatin	S-drug
,	O
glyburide	S-drug
,	O
warfarin	S-drug
,	O
phenytoin	S-drug
,	O
acetylsalicylic	B-drug
acid	E-drug
,	O
tolbutamide	S-drug
,	O
and	O
metformin	S-drug
showed	O
no	O
influence	O
on	O
the	O
extent	O
of	O
nateglinide	S-drug
protein	O
binding	O
.	O

Similarly	O
,	O
nateglinide	S-drug
had	O
no	O
influence	O
on	O
the	O
serum	O
protein	O
binding	O
of	O
propranolol	S-drug
,	O
glyburide	S-drug
,	O
nicardipine	S-drug
,	O
warfarin	S-drug
,	O
phenytoin	S-drug
,	O
acetylsalicylic	B-drug
acid	E-drug
,	O
and	O
tolbutamide	S-drug
in	O
vitro	O
.	O

However	O
,	O
prudent	O
evaluation	O
of	O
individual	O
cases	O
is	O
warranted	O
in	O
the	O
clinical	O
setting	O
.	O

Certain	O
drugs	O
,	O
including	O
nonsteroidal	B-group-EF-1
anti	I-group-EF-1
-	I-group-EF-1
inflammatory	I-group-EF-1
agents	E-group-EF-1
(	O
NSAIDs	S-group-EF-1
)	O
,	O
salicylates	S-group-EF-1
,	O
monoamine	B-group-EF-1
oxidase	I-group-EF-1
inhibitors	E-group-EF-1
,	O
and	O
non	B-group-EF-1
-	I-group-EF-1
selective	I-group-EF-1
beta	I-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
-	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
may	O
potentiate	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	S-brand-EF-2
and	O
other	O
oral	O
antidiabetic	B-group-EF-2
drugs	E-group-EF-2
.	O

Certain	O
drugs	O
including	O
thiazides	S-group-EF-1
,	O
corticosteroids	S-group-EF-1
,	O
thyroid	B-group-EF-1
products	E-group-EF-1
,	O
and	O
sympathomimetics	S-group-EF-1
may	O
reduce	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	S-brand-EF-2
and	O
other	O
oral	O
antidiabetic	B-group-EF-2
drugs	E-group-EF-2
.	O

When	O
these	O
drugs	O
are	O
administered	O
to	O
or	O
withdrawn	O
from	O
patients	O
receiving	O
Starlix	S-brand
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
changes	O
in	O
glycemic	O
control	O
.	O

In	O
clinical	O
studies	O
,	O
Tilade	S-brand
has	O
been	O
co	O
-	O
administered	O
with	O
other	O
anti	O
-	O
asthma	O
medications	O
,	O
including	O
inhaled	O
and	O
oral	O
bronchodilators	S-group
,	O
and	O
inhaled	O
corticosteroids	S-group
,	O
with	O
no	O
evidence	O
of	O
increased	O
frequency	O
of	O
adverse	O
events	O
or	O
laboratory	O
abnormalities	O
.	O

No	O
formal	O
drug	O
-	O
drug	O
interaction	O
studies	O
,	O
however	O
,	O
have	O
been	O
conducted	O
.	O

Nelfinavir	S-drug
is	O
an	O
inhibitor	O
of	O
CYP3A	O
(	O
cytochrome	O
P450	O
3A	O
)	O
.	O

Coadministration	O
of	O
VIRACEPT	S-brand
and	O
drugs	O
primarily	O
metabolized	O
by	O
CYP3A	O
(	O
e.g	O
.	O
,	O
dihydropyridine	B-group
calcium	I-group
channel	I-group
blockers	E-group
)	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
other	O
drug	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Nelfinavir	S-drug
is	O
metabolized	O
in	O
proof	O
by	O
C.P.A	O
.	O

Coadministration	O
of	O
VIRACEPT	S-brand
and	O
drugs	O
that	O
induce	O
CYP3A	O
may	O
decrease	O
nelfinavir	S-drug
plasma	O
concentrations	O
and	O
reduce	O
its	O
therapeutic	O
effect	O
.	O

Coadministration	O
of	O
VIRACEPT	S-brand
and	O
drugs	O
that	O
inhibit	O
CYP3A	O
may	O
increase	O
nelfinavir	S-drug
plasma	O
concentrations	O
.	O

Based	O
on	O
known	O
metabolic	O
profiles	O
,	O
clinically	O
significant	O
drug	O
interactions	O
are	O
not	O
expected	O
between	O
VIRACEPT	S-brand
and	O
dapsone	S-drug
,	O
trimethoprim	S-drug
/	O
sulfamethoxazole	S-drug
,	O
clarithromycin	S-drug
,	O
erythromycin	S-drug
,	O
itraconazole	S-drug
or	O
fluconazole	S-drug
.	O

Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
VIRACEPT	S-brand-AD-1
Antiarrhythmics	S-group-AD-2
:	O
amiodarone	S-drug-AD-2
,	O
quinidine	S-drug-AD-2
Antihistamines	S-group-AD-2
:	O
astemizole	S-drug-AD-2
,	O
terfenadine	S-drug-AD-2
Antimigraine	O
:	O
ergot	B-group-AD-2
derivatives	E-group-AD-2
Antimycobacterial	B-group-AD-2
agents	E-group-AD-2
:	O
rifampin	S-drug-AD-2
Benzodiazepines	S-group-AD-2
midazolam	S-drug-AD-2
,	O
triazolam	S-drug-AD-2
GI	O
motility	O
agents	O
:	O
cisapride	S-drug-AD-2

Drugs	O
Which	O
Require	O
a	O
Dose	O
Reduction	O
When	O
Coadminstered	O
With	O
VIRACEPT	S-brand-AD-1
Antimycobacterial	B-group-AD-2
agents	E-group-AD-2
:	O
rifabutin	S-drug-AD-2

*	O
This	O
table	O
is	O
not	O
all	O
inclusive	O
*	O
*	O
VIRACEPT	S-brand
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
nelfinavir	S-drug
plasma	O
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O

Terfenadine	S-drug
:	O
Administration	O
of	O
terfenadine	S-drug
with	O
VIRACEPT	S-brand
resulted	O
in	O
the	O
appearance	O
of	O
unchanged	O
terfenadine	S-drug
in	O
plasma	O
;	O

therefore	O
,	O
VIRACEPT	S-brand-AD-1
should	O
not	O
be	O
administered	O
concurrently	O
with	O
terfenadine	S-drug-AD-2
because	O
of	O
the	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
cardiac	O
arrhythmias	O
.	O

Because	O
a	O
similar	O
interaction	O
is	O
likely	O
,	O
VIRACEPT	S-brand-AD-1
should	O
also	O
not	O
be	O
administered	O
concurrently	O
with	O
astemizole	S-drug-AD-2
.	O

Anti	B-group
-	I-group
HIV	I-group
Protease	I-group
Inhibitors	E-group

Indinavir	S-drug
:	O
Coadministration	O
of	O
indinavir	S-drug-ME-1
with	O
VIRACEPT	S-brand-ME-2
resulted	O
in	O
an	O
83	O
%	O
increase	O
in	O
nelfinavir	S-drug
plasma	O
AUC	O
and	O
a	O
51	O
%	O
increase	O
in	O
indinavir	S-drug
plasma	O
A.C	O
.	O

Currently	O
,	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O

Ritonavir	S-drug
:	O
Coadministration	O
of	O
ritonavir	S-drug-ME-1
with	O
VIRACEPT	S-brand-ME-2
resulted	O
in	O
a	O
152	O
%	O
increase	O
in	O
nelfinavir	S-drug
plasma	O
AUC	O
and	O
very	O
little	O
change	O
in	O
ritonavir	S-drug
plasma	O
A.C	O
.	O

Currently	O
,	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O

Saquinavir	S-drug
:	O
Coadministration	O
of	O
saquinavir	S-drug-ME-1
(	O
using	O
an	O
experimental	O
soft	O
-	O
gelatin	O
capsule	O
formulation	O
of	O
saquinavir	S-drug
1200mg	O
)	O
with	O
VIRACEPT	S-brand-ME-2
resulted	O
in	O
an	O
18	O
%	O
increase	O
in	O
nelfinavir	S-drug
plasma	O
AUC	O
and	O
a	O
4	O
-	O
fold	O
increase	O
in	O
saquinavir	S-drug
plasma	O
A.C	O
.	O

If	O
used	O
in	O
combination	O
with	O
saquinavir	S-drug
hard	O
gelatin	O
capsules	O
at	O
the	O
recommended	O
dose	O
of	O
600	O
mg	O
tid	O
,	O
no	O
dose	O
adjustments	O
are	O
needed	O
.	O

Currently	O
,	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O

Antifungal	B-group
Agents	E-group

Ketoconazole	S-drug
:	O
Coadministration	O
of	O
ketoconazole	S-drug-ME-1
with	O
VIRACEPT	S-brand-ME-2
resulted	O
in	O
a	O
35	O
%	O
increase	O
in	O
nelfinavir	S-drug
plasma	O
A.C	O
.	O

This	O
change	O
was	O
not	O
considered	O
clinically	O
significant	O
and	O
no	O
dose	O
adjustment	O
is	O
needed	O
when	O
ketoconazole	S-drug
and	O
VIRACEPT	S-brand
are	O
coadministered	O
.	O

Anti	B-group
-	I-group
HIV	I-group
Reverse	I-group
Transcriptase	I-group
Inhibitors	E-group

Didanosine	S-drug
:	O
It	O
is	O
recommended	O
that	O
didanosine	S-drug
be	O
administered	O
on	O
an	O
empty	O
stomach	O
;	O

therefore	O
,	O
nelfinavir	S-drug-AD-1
should	O
be	O
administered	O
(	O
with	O
food	O
)	O
one	O
hour	O
after	O
or	O
more	O
than	O
two	O
hours	O
before	O
didanosine	S-drug-AD-2
.	O

A	O
dose	O
adjustment	O
is	O
not	O
needed	O
when	O
zidovudine	S-drug-AD-1
is	O
administered	O
with	O
VIRACEPT	S-brand-AD-2
.	O

Little	O
or	O
no	O
change	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
was	O
observed	O
when	O
VIRACEPT	S-brand
was	O
coadministered	O
with	O
lamivudine	S-drug
or	O
stavudine	S-drug
.	O

Antimycobacterial	B-group
Agents	E-group

Rifabutin	S-drug
:	O
Coadministration	O
of	O
rifabutin	S-drug-ME-1
and	O
VIRACEPT	S-brand-ME-2
resulted	O
in	O
a	O
32	O
%	O
decrease	O
in	O
nelfinavir	S-drug
plasma	O
AUC	O
and	O
a	O
207	O
%	O
increase	O
in	O
rifabutin	S-drug
plasma	O
A.C	O
.	O

It	O
is	O
recommended	O
that	O
the	O
dose	O
of	O
rifabutin	S-drug-AD-1
be	O
reduced	O
to	O
one	O
-	O
half	O
the	O
usual	O
dose	O
when	O
administered	O
with	O
VIRACEPT	S-brand-AD-2
.	O

Rifampin	S-drug
:	O
Coadministration	O
of	O
rifampin	S-drug-ME-1
and	O
VIRACEPT	S-brand-ME-2
resulted	O
in	O
an	O
82	O
%	O
decrease	O
in	O
nelfinavir	S-drug
plasma	O
A.C	O
.	O

VIRACEPT	S-brand-AD-1
and	O
rifampin	S-drug-AD-2
should	O
not	O
be	O
coadministered	O
.	O

Oral	O
Contraceptives	S-group

Ethinyl	B-drug
Estradiol	E-drug
and	O
Norethindrone	S-drug
:	O
Coadministration	O
of	O
VIRACEPT	S-brand-ME-1
with	O
OVCON	B-brand-ME-2
-	I-brand-ME-2
35	E-brand-ME-2
resulted	O
in	O
a	O
47	O
%	O
decrease	O
in	O
ethinyl	B-drug
estradiol	E-drug
and	O
an	O
18	O
%	O
decrease	O
in	O
norethindrone	S-drug
plasma	O
concentrations	O
.	O

Alternate	O
or	O
additional	O
contraceptive	O
measures	O
should	O
be	O
used	O
during	O
therapy	O
with	O
VIRACEPT	S-brand

Caution	O
should	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
neurotoxic	O
and	O
/	O
or	O
nephrotoxic	O
drugs	O
because	O
of	O
possible	O
enhancement	O
of	O
the	O
nephrotoxicity	O
and	O
/	O
or	O
ototoxicity	O
of	O
neomycin	S-drug
.	O

Caution	O
should	O
also	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
aminoglycosides	S-group
and	O
polymyxins	S-group
because	O
they	O
may	O
enhance	O
neomycin	O
s	O
nephrotoxicity	O
and	O
/	O
or	O
ototoxicity	O
and	O
potentiate	O
neomycin	B-drug
sulfate	E-drug
neuromuscular	O
blocking	O
effects	O
.	O

Oral	O
neomycin	S-drug-ME-1
inhibits	O
the	O
gastrointestinal	O
absorption	O
of	O
penicillin	B-drug-ME-2
V	E-drug-ME-2
,	O
oral	O
vitamin	B-drug-ME-2
B	I-drug-ME-2
-	I-drug-ME-2
12	E-drug-ME-2
,	O
methotrexate	S-drug-ME-2
and	O
5	B-drug-ME-2
-	I-drug-ME-2
fluorouracil	E-drug-ME-2
.	O

The	O
gastrointestinal	O
absorption	O
of	O
digoxin	S-drug
also	O
appears	O
to	O
be	O
inhibited	O
.	O

Therefore	O
,	O
digoxin	S-drug
serum	O
levels	O
should	O
be	O
monitored	O
.	O

Oral	O
neomycin	B-drug-EF-1
sulfate	E-drug-EF-1
may	O
enhance	O
the	O
effect	O
of	O
coumarin	S-group-EF-2
in	O
anticoagulants	S-group-EF-2
by	O
decreasing	O
vitamin	O
K	O
availability	O
.	O

Certain	O
antibiotics	S-group
,	O
especially	O
neomycin	S-drug
,	O
streptomycin	S-drug
and	O
kanamycin	S-drug
,	O
have	O
a	O
mild	O
but	O
definite	O
nondepolarizing	O
blocking	O
action	O
which	O
may	O
accentuate	O
neuromuscular	O
block	O
.	O

These	O
antibiotics	S-group-AD-1
should	O
be	O
used	O
in	O
the	O
myasthenic	O
patient	O
only	O
where	O
definitely	O
indicated	O
,	O
and	O
then	O
careful	O
adjustment	O
should	O
be	O
made	O
of	O
adjunctive	O
anticholinesterase	S-group-AD-2
dosage	O
.	O

Local	O
and	O
some	O
general	O
anesthetics	S-group
,	O
antiarrhythmic	B-group
agents	E-group
and	O
other	O
drugs	O
that	O
interfere	O
with	O
neuromuscular	O
transmission	O
should	O
be	O
used	O
cautiously	O
,	O
if	O
at	O
all	O
,	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
;	O

the	O
dose	O
of	O
Prostigmin	S-brand
may	O
have	O
to	O
be	O
increased	O
accordingly	O
.	O

No	O
trials	O
specifically	O
examining	O
potential	O
drug	O
interactions	O
with	O
Natrecor	S-brand
were	O
conducted	O
,	O
although	O
many	O
concomitant	O
drugs	O
were	O
used	O
in	O
clinical	O
trials	O
.	O

No	O
drug	O
interactions	O
were	O
detected	O
except	O
for	O
an	O
increase	O
in	O
symptomatic	O
hypotension	O
in	O
patients	O
receiving	O
oral	O
ACE	B-group
inhibitors	E-group
.	O

The	O
co	O
-	O
administration	O
of	O
Natrecor	S-brand
with	O
IV	O
vasodilators	S-group
such	O
as	O
nitroglycerin	S-drug
,	O
nitroprusside	S-drug
,	O
milrinone	S-drug
,	O
or	O
IV	O
ACE	B-group
inhibitors	E-group
has	O
not	O
been	O
evaluated	O
(	O
these	O
drugs	O
were	O
not	O
co	O
-	O
administered	O
with	O
Natrecor	S-brand
in	O
clinical	O
trials	O
)	O
.	O

Netilmicin	S-drug-AD-1
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
potent	O
loop	B-group-AD-2
diuretics	E-group-AD-2
such	O
as	O
furosemide	S-drug-AD-2
and	O
ethacrynic	B-drug-AD-2
acid	E-drug-AD-2
as	O
the	O
potential	O
for	O
ototoxicity	O
is	O
enhanced	O
by	O
the	O
combination	O
.	O

Nevirapine	S-drug
is	O
principally	O
metabolized	O
by	O
the	O
liver	O
via	O
the	O
cytochrome	O
P450	O
isoenzymes	O
,	O
3A4	O
and	O
2B6	O
.	O

Nevirapine	S-drug
is	O
known	O
to	O
be	O
an	O
inducer	O
of	O
these	O
enzymes	O
.	O

As	O
a	O
result	O
,	O
drugs	O
that	O
are	O
metabolized	O
by	O
these	O
enzyme	O
systems	O
may	O
have	O
lower	O
than	O
expected	O
plasma	O
levels	O
when	O
coadministered	O
with	O
nevirapine	S-drug
.	O

The	O
specific	O
pharmacokinetic	O
changes	O
that	O
occur	O
with	O
co	O
-	O
administration	O
of	O
nevirapine	S-drug
and	O
other	O
drugs	O
are	O
listed	O
in	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Table	O
1	O
.	O

Clinical	O
comments	O
about	O
possible	O
dosage	O
modifications	O
based	O
on	O
these	O
pharmacokinetic	O
changes	O
are	O
listed	O
in	O
Table	O
3	O
.	O

The	O
data	O
inTables	O
1	O
and	O
3	O
are	O
based	O
on	O
the	O
results	O
of	O
drug	O
interaction	O
studies	O
conducted	O
in	O
HIV	O
-	O
1	O
seropositive	O
subjects	O
unless	O
otherwise	O
indicated	O
.	O

In	O
addition	O
to	O
established	O
drug	O
interactions	O
,	O
there	O
may	O
be	O
potential	O
pharmacokinetic	O
interactions	O
between	O
nevirapine	S-drug
and	O
other	O
drug	O
classes	O
that	O
are	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
.	O

These	O
potential	O
drug	O
interactions	O
are	O
listed	O
in	O
Table	O
4	O
.	O

Although	O
specific	O
drug	O
interaction	O
studies	O
in	O
HIV	O
-	O
1	O
seropositive	O
subjects	O
have	O
not	O
been	O
conducted	O
for	O
the	O
classes	O
of	O
drugs	O
listed	O
in	O
Table	O
4	O
,	O
additional	O
clinical	O
monitoring	O
may	O
be	O
warranted	O
when	O
co	O
-	O
administering	O
these	O
drugs	O
.	O

The	O
in	O
vitro	O
interaction	O
between	O
nevirapine	S-drug-IN-1
and	O
the	O
antithrombotic	B-group
agent	E-group
warfarin	S-drug-IN-2
is	O
complex	O
.	O

As	O
a	O
result	O
,	O
when	O
giving	O
these	O
drugs	O
concomitantly	O
,	O
plasma	O
warfarin	S-drug
levels	O
may	O
change	O
with	O
the	O
potential	O
for	O
increases	O
in	O
coagulation	O
time	O
.	O

When	O
warfarin	S-drug-AD-1
is	O
co	O
-	O
administered	O
with	O
nevirapine	S-drug-AD-2
,	O
anticoagulation	O
levels	O
should	O
be	O
monitored	O
frequently	O
.	O

Table	O
3	O
Established	O
Drug	O
Interactions	O
:	O
Alteration	O
in	O
Dose	O
or	O
Regimen	O
May	O
Be	O
Recommended	O
Based	O
on	O
Drug	O
Interaction	O
Studies	O

Drug	O
Name	O

Effect	O
on	O
Concentration	O
of	O
Nevirapine	S-drug
or	O
Concomitant	O
Drug	O

Clinical	O
Comment	O

Clarithromycin	S-drug
14OH	O
-	O
clarithromycin	O

Clarithromycin	S-drug-ME-1
exposure	O
was	O
significantly	O
decreased	O
by	O
nevirapine	S-drug-ME-2
;	O

however	O
,	O
14	O
-	O
OH	O
metabolite	O
concentrations	O
were	O
increased.Because	O
clarithromycin	S-drug
active	O
metabolite	O
has	O
reduced	O
activity	O
against	O
Mycobacteriumavium	O
-	O
intracellulare	O
complex	O
,	O
overallactivity	O
against	O
this	O
pathogen	O
may	O
bealtered	O
.	O

Alternatives	O
to	O
clarithromycin	S-drug
,	O
such	O
as	O
azithromycin	S-drug
,	O
should	O
be	O
considered	O
.	O

Appropriate	O
doses	O
for	O
this	O
combination	O
are	O
not	O
established	O
.	O

Ethinyl	B-drug
estradiol	E-drug
and	O
Norethindrone	S-drug

Ethinyl	B-drug
estradiol	E-drug
Norethindrone	S-drug

Oral	O
contraceptives	S-group-AD-1
and	O
other	O
hormonalmethods	O
of	O
birth	O
control	O
should	O
not	O
be	O
usedas	O
the	O
sole	O
method	O
of	O
contraception	O
inwomen	O
taking	O
nevirapine	S-drug-AD-2
,	O
since	O
nevirapinemay	O
lower	O
the	O
plasma	O
levels	O
of	O
thesemedications	O
.	O

An	O
alternative	O
or	O
additional	O
method	O
of	O
contraception	O
is	O
recommended	O
.	O

Because	O
of	O
the	O
risk	O
of	O
increased	O
exposure	O
tonevirapine	O
,	O
caution	O
should	O
be	O
used	O
inconcomitant	O
administration	O
,	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
nevirapine	O
-	O
associated	O
adverse	O
events	O
.	O

Appropriate	O
doses	O
for	O
this	O
combination	O
arenot	O
established	O
,	O
but	O
an	O
increase	O
in	O
thedosage	O
of	O
indinavir	S-drug
may	O
be	O
required	O
.	O

Nevirapine	S-drug-AD-1
and	O
ketoconazole	S-drug-AD-2
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
ketoconazole	S-drug
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
of	O
the	O
drug	O
.	O

Lopinavir	S-drug
/	O
Ritonavir	S-drug

A	O
dose	O
increase	O
of	O
lopinavir	S-drug-AD-1
/	O
ritonavir	S-drug-AD-1
to	O
533	O
/	O
133	O
mg	O
twice	O
daily	O
with	O
food	O
isrecommended	O
in	O
combination	O
with	O
nevirapine	S-drug-AD-2
.	O

Methadone	S-drug
levels	O
may	O
be	O
decreased	O
;	O
increased	O
dosages	O
may	O
be	O
required	O
to	O
prevent	O
symptoms	O
of	O
opiate	S-group
withdrawal	O
.	O
Methadone	S-drug-AD-1
maintained	O
patients	O
beginning	O
nevirapine	S-drug-AD-2
therapy	O
should	O
be	O
monitored	O
forevidence	O
of	O
withdrawal	O
and	O
methadone	S-drug
dose	O
should	O
be	O
adjusted	O
accordingly	O
.	O

Nelfinavir	S-drug
M8	O

The	O
appropriate	O
dose	O
for	O
nelfinavir	S-drug
incombination	O
with	O
nevirapine	S-drug
,	O
with	O
respectto	O
safety	O
and	O
efficacy	O
,	O
has	O
not	O
been	O
established	O
.	O

Rifabutin	S-drug
and	O
its	O
metabolite	O
concentrationswere	O
moderately	O
increased	O
.	O

Due	O
to	O
highintersubject	O
variability	O
,	O
however	O
,	O
somepatients	O
may	O
experience	O
large	O
increases	O
inrifabutin	O
exposure	O
and	O
may	O
be	O
at	O
higher	O
riskfor	O
rifabutin	O
toxicity	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
in	O
concomitant	O
administration	O
.	O

Nevirapine	S-drug-AD-1
and	O
rifampin	S-drug-AD-2
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
nevirapine	S-drug
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
ofthe	O
drug	O
.	O

Physicians	O
needing	O
to	O
treatpatients	O
co	O
-	O
infected	O
with	O
tuberculosis	O
andusing	O
a	O
nevirapine	S-drug
containing	O
regimen	O
mayuse	O
rifabutin	S-drug
instead	O
.	O

Appropriate	O
doses	O
for	O
this	O
combination	O
arenot	O
established	O
,	O
but	O
an	O
increase	O
in	O
thedosage	O
of	O
saquinavir	S-drug
may	O
be	O
required	O
.	O

aBased	O
on	O
reports	O
of	O
narcotic	O
withdrawal	O
syndrome	O
in	O
patients	O
treated	O
with	O
nevirapine	S-drug-EF-1
and	O
methadone	S-drug-EF-2
concurrently	O
,	O
and	O
evidence	O
of	O
decreased	O
plasma	O
concentrations	O
of	O
methadone	S-drug
.	O

Table	O
4	O
Potential	O
Drug	O
Interactions	O
:	O
Use	O
With	O
Caution	O
,	O
Dose	O
Adjustment	O
of	O
Co	O
-	O
administered	O
Drug	O
May	O
Be	O
Needed	O
due	O
to	O
Possible	O
Decrease	O
in	O
Clinical	O
Effect	O

Examples	O
of	O
Drugs	O
in	O
Which	O
Plasma	O
Concentrations	O
May	O
Be	O
Decreased	O
By	O
Co	O
-	O
administration	O
With	O
Nevirapine	S-drug

Drug	O
Class	O
Examples	O
of	O
Drugs	O

Amiodarone	S-drug
,	O
disopyramide	S-drug
,	O
lidocaine	S-drug

Carbamazepine	S-drug
,	O
clonazepam	S-drug
,	O
ethosuximide	S-drug

Calcium	B-group
channel	I-group
blockers	E-group

Diltiazem	S-drug
,	O
nifedipine	S-drug
,	O
verapamil	S-drug

Cancer	O
chemotherapy	O

Ergot	B-group
alkaloids	E-group

Cyclosporin	S-drug
,	O
tacrolimus	S-drug
,	O
sirolimus	S-drug

Motility	O
agents	O

Opiate	B-group
agonists	E-group

Examples	O
of	O
Drugs	O
in	O
Which	O
Plasma	O
Concentrations	O
May	O
Be	O
Increased	O
By	O
Co	O
-	O
administration	O
With	O
Nevirapine	S-drug

Potential	O
effect	O
on	O
anticoagulation	O
.	O

Monitoring	O
of	O
anticoagulation	O
levels	O
is	O
recommended	O
.	O

Fat	O
redistribution	O
:	O
Redistribution	O
/	O
accumulation	O
of	O
body	O
fat	O
including	O
central	O
obesity	O
,	O
dorsocervical	O
fat	O
enlargement	O
(	O
buffalo	O
hump	O
)	O
,	O
peripheral	O
wasting	O
,	O
facial	O
wasting	O
,	O
breast	O
enlargement	O
,	O
and	O
cushingoid	O
appearance	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	S-group
therapy	O
.	O

The	O
mechanism	O
and	O
long	O
-	O
term	O
consequences	O
of	O
these	O
events	O
are	O
currently	O
unknown	O
.	O

A	O
causal	O
relationship	O
has	O
not	O
been	O
established	O

Interactions	O
for	O
Vitamin	B-drug
B3	E-drug
(	O
Niacin	S-drug
)	O
:	O
Antihypertensive	S-group
Therapy	O
:	O
Nicotinic	B-drug-EF-1
acid	E-drug-EF-1
may	O
potentiate	O
the	O
effects	O
of	O
ganglionic	B-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
and	O
vasoactive	O
drugs	O
resulting	O
in	O
postural	O
hypotension	O
.	O

Aspirin	S-brand
:	O
Concomitant	O
aspirin	S-brand-ME-1
may	O
decrease	O
the	O
metabolic	O
clearance	O
of	O
nicotinic	B-drug-ME-2
acid	E-drug-ME-2
.	O

The	O
clinical	O
relevance	O
of	O
this	O
finding	O
is	O
unclear	O
.	O

Other	O
:	O
Concomitant	O
alcohol	S-drug
or	O
hot	O
drinks	O
may	O
increase	O
the	O
side	O
effects	O
of	O
flushing	O
and	O
pruritus	O
and	O
should	O
be	O
avoided	O
at	O
the	O
time	O
of	O
drug	O
ingestion	O
.	O

Beta	B-group
-	I-group
Blockers	E-group
:	O
In	O
controlled	O
clinical	O
studies	O
,	O
adrenergic	B-group
beta	I-group
-	I-group
receptor	I-group
blockers	E-group
have	O
been	O
frequently	O
administered	O
concomitantly	O
with	O
nicardipine	B-drug
HCl	E-drug
.	O

The	O
combination	O
is	O
well	O
tolerated	O
.	O

Cimetidine	S-drug
:	O
Cimetidine	S-drug-ME-1
increases	O
nicardipine	B-drug-ME-2
HCl	E-drug-ME-2
plasma	O
levels	O
.	O

Patients	O
receiving	O
the	O
two	O
drugs	O
concomitantly	O
should	O
be	O
carefully	O
monitored	O
.	O

Digoxin	S-drug
:	O
Some	O
calcium	B-group-ME-1
blockers	E-group-ME-1
may	O
increase	O
the	O
concentration	O
of	O
digitalis	B-group-ME-2
preparations	E-group-ME-2
in	O
the	O
blood	O
.	O

Nicardipine	B-drug
HCl	E-drug
usually	O
does	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
digoxin	S-drug
,	O
however	O
,	O
serum	O
digoxin	S-drug-AD-1
levels	O
should	O
be	O
evaluated	O
after	O
concomitant	O
therapy	O
with	O
nicardipine	B-drug-AD-2
HCl	E-drug-AD-2
is	O
initiated	O
.	O

Maalox	S-brand
*	O
Coadministration	O
of	O
Maalox	B-brand
TC	E-brand
had	O
no	O
effect	O
on	O
nicardipine	B-drug
HCl	E-drug
absorption	O
.	O

Even	O
though	O
such	O
interactions	O
were	O
not	O
seen	O
during	O
clinical	O
studies	O
with	O
nicardipine	B-drug
HCl	E-drug
,	O
an	O
increased	O
volume	O
of	O
circulating	O
fluids	O
might	O
be	O
required	O
if	O
such	O
an	O
interaction	O
were	O
to	O
occur	O
.	O

Cyclosporine	S-drug
:	O
Concomitant	O
administration	O
of	O
nicardipine	S-drug
and	O
cyclosporine	S-drug
levels	O
.	O

Plasma	O
concentrations	O
of	O
cyclosporine	S-drug-AD-1
should	O
therefore	O
be	O
closely	O
monitored	O
,	O
and	O
its	O
dosage	O
reduced	O
accordingly	O
,	O
in	O
patients	O
treated	O
with	O
nicardipine	S-drug-AD-2
.	O

When	O
therapeutic	O
concentrations	O
of	O
furosemide	S-drug
,	O
propranolol	S-drug
,	O
dipyridamole	S-drug
,	O
warfarin	S-drug
,	O
quinidine	S-drug
,	O
or	O
naproxen	S-drug
were	O
added	O
to	O
human	O
plasma	O
(	O
in	O
vitro	O
)	O
,	O
the	O
plasma	O
protein	O
binding	O
of	O
nicardipine	B-drug
HCl	E-drug
was	O
not	O
altered	O
.	O

Physiological	O
changes	O
resulting	O
from	O
smoking	O
cessation	O
,	O
with	O
or	O
without	O
nicotine	S-drug
replacement	O
,	O
may	O
alter	O
the	O
pharmacokinetics	O
of	O
certain	O
concomitant	O
medications	O
,	O
such	O
as	O
tricyclic	B-group
antidepressants	E-group
and	O
theophylline	S-drug
.	O

Doses	O
of	O
these	O
and	O
perhaps	O
other	O
medications	O
may	O
need	O
to	O
be	O
adjusted	O
in	O
patients	O
who	O
successfully	O
quit	O
smoking	O
.	O

Beta	B-group
-	I-group
adrenergic	I-group
Blocking	I-group
Agents	E-group
:	O
Experience	O
in	O
over	O
1400	O
patients	O
in	O
a	O
non	O
-	O
comparative	O
clinical	O
trial	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
nifedipine	S-drug-EF-1
and	O
beta	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
is	O
usually	O
well	O
tolerated	O
,	O
but	O
there	O
have	O
been	O
occasional	O
literature	O
reports	O
suggesting	O
that	O
the	O
combination	O
may	O
increase	O
the	O
likelihood	O
of	O
congestive	O
heart	O
failure	O
,	O
severe	O
hypotension	O
or	O
exacerbation	O
of	O
angina	O
.	O

Long	O
Acting	O
Nitrates	S-group
:	O
Nifedipine	S-drug
may	O
be	O
safely	O
co	O
-	O
administered	O
with	O
nitrates	S-group
,	O
but	O
there	O
have	O
been	O
no	O
controlled	O
studies	O
to	O
evaluate	O
the	O
antianginal	O
effectiveness	O
of	O
this	O
combination	O
.	O

Digitalis	S-group
:	O
Immediate	O
Release	O
Capsules	O
:	O
Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	S-drug
levels	O
,	O
and	O
there	O
is	O
a	O
possible	O
interaction	O
between	O
digoxin	S-drug-IN-1
and	O
nifedipine	S-drug-IN-2
,	O
it	O
is	O
recommended	O
that	O
digoxin	S-drug-AD-1
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	S-drug-AD-2
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O

Extended	O
Release	O
Tablets	O
:	O
Administration	O
of	O
nifedipine	S-drug
with	O
digoxin	S-drug-ME-1
increased	O
digoxin	S-drug-ME-2
levels	O
in	O
9	O
of	O
12	O
normal	O
volunteers	O
.	O

The	O
average	O
increase	O
was	O
45	O
%	O
.	O

Another	O
investigator	O
found	O
no	O
increase	O
in	O
digoxin	S-drug
levels	O
in	O
13	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

In	O
an	O
uncontrolled	O
study	O
of	O
over	O
200	O
patients	O
with	O
congestive	O
heart	O
failure	O
during	O
which	O
digoxin	S-drug
blood	O
levels	O
were	O
not	O
measured	O
,	O
digitalis	O
toxicity	O
was	O
not	O
observed	O
.	O

Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	S-drug
levels	O
,	O
it	O
is	O
recommended	O
that	O
digoxin	S-drug-AD-1
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	S-drug-AD-2
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O

Quinidine	S-drug
:	O
Immediate	O
Release	O
Capsules	O
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
an	O
interaction	O
between	O
quinidine	S-drug-ME-1
and	O
nifedipine	S-drug-ME-2
(	O
with	O
a	O
decreased	O
plasma	O
level	O
of	O
quinidine	S-drug
)	O
.	O

Coumarin	B-group
Anticoagulants	E-group
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
increased	O
prothrombin	O
time	O
in	O
patients	O
taking	O
coumarin	B-group-EF-1
anticoagulants	E-group-EF-1
to	O
whom	O
nifedipine	S-drug-EF-2
was	O
administered	O
.	O

However	O
,	O
the	O
relationship	O
to	O
nifedipine	S-drug
therapy	O
is	O
uncertain	O
.	O

Cimetidine	S-drug
:	O
A	O
study	O
in	O
6	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
nifedipine	S-drug
plasma	O
levels	O
(	O
80	O
%	O
)	O
and	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
(	O
74	O
%	O
)	O
after	O
a	O
1	O
week	O
course	O
of	O
cimetidine	S-drug-ME-1
at	O
1000	O
mg	O
per	O
day	O
and	O
nifedipine	S-drug-ME-2
at	O
40	O
mg	O
per	O
day	O
.	O

Ranitidine	S-drug
produced	O
smaller	O
,	O
non	O
-	O
significant	O
increases	O
.	O

The	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
cimetidine	S-drug
on	O
hepatic	O
cytochrome	O
P	O
-	O
450	O
,	O
the	O
enzyme	O
system	O
probably	O
responsible	O
for	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
nifedipine	S-drug
.	O

If	O
nifedipine	S-drug-AD-1
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	S-drug-AD-2
,	O
cautious	O
titration	O
is	O
advised	O
.	O

In	O
vitro	O
,	O
nilutamide	S-drug
has	O
been	O
shown	O
to	O
inhibit	O
the	O
activity	O
of	O
liver	O
cytochrome	O
P	O
-	O
450	O
isoenzymes	O
and	O
therefore	O
,	O
may	O
reduce	O
the	O
metabolism	O
of	O
compounds	O
requiring	O
these	O
systems	O
.	O

Consequently	O
,	O
drugs	O
with	O
a	O
low	O
therapeutic	O
margin	O
,	O
such	O
as	O
vitamin	B-group
K	I-group
antagonists	E-group
,	O
phenytoin	S-drug
,	O
and	O
theophylline	S-drug
,	O
could	O
have	O
a	O
delayed	O
elimination	O
and	O
increases	O
in	O
their	O
serum	O
half	O
-	O
life	O
leading	O
to	O
a	O
toxic	O
level	O
.	O

The	O
dosage	O
of	O
these	O
drugs	O
or	O
others	O
with	O
a	O
similar	O
metabolism	O
may	O
need	O
to	O
be	O
modified	O
if	O
they	O
are	O
administered	O
concomitantly	O
with	O
nilutamide	S-drug
.	O

For	O
example	O
,	O
when	O
vitamin	B-group-AD-1
K	I-group-AD-1
antagonists	E-group-AD-1
are	O
administered	O
concomitantly	O
with	O
nilutamide	S-drug-AD-2
,	O
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
and	O
if	O
necessary	O
,	O
the	O
dosage	O
of	O
vitamin	B-group
K	I-group
antagonists	E-group
should	O
be	O
reduced	O
.	O

It	O
is	O
possible	O
that	O
the	O
cardiovascular	O
action	O
of	O
other	O
calcium	B-group-EF-1
channel	I-group-EF-1
blockers	E-group-EF-1
could	O
be	O
enhanced	O
by	O
the	O
addition	O
of	O
Nimotop	S-brand-EF-2
.	O

In	O
Europe	O
,	O
Nimotop	S-brand-EF-1
was	O
observed	O
to	O
occasionally	O
intensify	O
the	O
effect	O
of	O
antihypertensive	B-group-EF-2
compounds	E-group-EF-2
taken	O
concomitantly	O
by	O
patients	O
suffering	O
from	O
hypertension	O
;	O

this	O
phenomenon	O
was	O
not	O
observed	O
in	O
North	O
American	O
clinical	O
trials	O
.	O

A	O
study	O
in	O
eight	O
healthy	O
volunteers	O
has	O
shown	O
a	O
50	O
%	O
increase	O
in	O
mean	O
peak	O
nimodipine	S-drug
plasma	O
concentrations	O
and	O
a	O
90	O
%	O
increase	O
in	O
mean	O
area	O
under	O
the	O
curve	O
,	O
after	O
a	O
one	O
week	O
course	O
of	O
cimetidine	S-drug-ME-1
at	O
1,000	O
mg	O
/	O
day	O
and	O
nimodipine	S-drug-ME-2
at	O
90	O
mg	O
/	O
day	O
.	O

This	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P	O
-	O
450	O
by	O
cimetidine	S-drug
,	O
which	O
could	O
decrease	O
first	O
pass	O
metabolism	O
of	O
nimodipine	S-drug
.	O

A	O
30	O
to	O
45	O
%	O
increase	O
in	O
AUC	O
and	O
Cmax	O
of	O
nisoldipine	S-drug-ME-1
was	O
observed	O
with	O
concomitant	O
administration	O
of	O
cimetidine	B-drug-ME-2
400	I-drug-ME-2
mg	E-drug-ME-2
twice	O
daily	O
.	O

Ranitidine	S-drug
150	O
mg	O
twice	O
daily	O
did	O
not	O
interact	O
significantly	O
with	O
nisoldipine	S-drug
(	O
AUC	O
was	O
decreased	O
by	O
15	O
-	O
20	O
%	O
)	O
.	O

No	O
pharmacodynamic	O
effects	O
of	O
either	O
histamine	B-group
H2	I-group
receptor	I-group
antagonist	E-group
were	O
observed	O
.	O

Coadministration	O
of	O
phenytoin	S-drug-ME-1
with	O
40	O
mg	O
SULAR	S-brand-ME-2
tablets	O
in	O
epileptic	O
patients	O
lowered	O
the	O
nisoldipine	S-drug
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Coadministration	O
of	O
SULAR	S-brand-AD-1
with	O
phenytoin	S-drug-AD-2
or	O
any	O
known	O
CYP3A4	O
inducer	O
should	O
be	O
avoided	O
and	O
alternative	O
antihypertensive	S-group
therapy	O
should	O
be	O
considered	O
.	O

Pharmacokinetic	O
interactions	O
between	O
nisoldipine	S-drug
and	O
beta	B-group
-	I-group
blockers	E-group
(	O
atenolol	S-drug
,	O
propranolol	S-drug
)	O
were	O
variable	O
and	O
not	O
significant	O
.	O

Propranolol	S-drug-EF-1
attenuated	O
the	O
heart	O
rate	O
increase	O
following	O
administration	O
of	O
immediate	O
release	O
nisoldipine	S-drug-EF-2
.	O

The	O
blood	O
pressure	O
effect	O
of	O
SULAR	S-brand-EF-1
tended	O
to	O
be	O
greater	O
in	O
patients	O
on	O
atenolol	S-drug-EF-2
than	O
in	O
patients	O
on	O
no	O
other	O
antihypertensive	S-group
therapy	O
.	O

Quinidine	S-drug-ME-1
at	O
648	O
mg	O
bid	O
decreased	O
the	O
bioavailability	O
(	O
AUC	O
)	O
of	O
nisoldipine	S-drug-ME-2
by	O
26	O
%	O
,	O
but	O
not	O
the	O
peak	O
concentration	O
.	O

The	O
immediate	O
release	O
,	O
but	O
not	O
the	O
coat	O
-	O
core	O
formulation	O
of	O
nisoldipine	S-drug-ME-1
increased	O
plasma	O
quinidine	S-drug-ME-2
concentrations	O
by	O
about	O
20	O
%	O
.	O

This	O
interaction	O
was	O
not	O
accompanied	O
by	O
ECG	O
changes	O
and	O
its	O
clinical	O
significance	O
is	O
not	O
known	O
.	O

No	O
significant	O
interactions	O
were	O
found	O
between	O
nisoldipine	S-drug
and	O
warfarin	S-drug
or	O
digoxin	S-drug
.	O

Tizoxanide	S-drug
is	O
highly	O
bound	O
to	O
plasma	O
protein	O
(	O
99.9	O
%	O
)	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
nitazoxanide	S-drug-ME-1
concurrently	O
with	O
other	O
highly	O
plasma	O
protein	O
-	O
bound	O
drugs	O
with	O
narrow	O
therapeutic	O
indices	O
,	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
(	O
e.g	O
.	O
,	O
warfarin	S-drug-ME-2
)	O
.	O

In	O
vitro	O
metabolism	O
studies	O
have	O
demonstrated	O
that	O
tizoxanide	S-drug
has	O
no	O
significant	O
inhibitory	O
effect	O
on	O
cytochrome	O
P450	O
enzymes	O
.	O

Although	O
no	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
in	O
vivo	O
,	O
it	O
is	O
expected	O
that	O
no	O
significant	O
interaction	O
would	O
occur	O
when	O
nitazoxanide	S-drug
is	O
co	O
-	O
administered	O
with	O
drugs	O
that	O
either	O
are	O
metabolized	O
by	O
or	O
inhibit	O
cytochrome	O
P450	O
enzymes	O
.	O

No	O
formal	O
drug	O
-	O
interaction	O
studies	O
have	O
been	O
performed	O
,	O
and	O
a	O
clinically	O
significant	O
interaction	O
with	O
other	O
medications	O
used	O
in	O
the	O
treatment	O
of	O
hypoxic	O
respiratory	O
failure	O
can	O
not	O
be	O
excluded	O
based	O
on	O
the	O
available	O
data	O
.	O

INOmax	S-brand
has	O
been	O
administered	O
with	O
tolazoline	S-drug
,	O
dopamine	S-drug
,	O
dobutamine	S-drug
,	O
steroids	S-group
,	O
surfactant	S-drug
,	O
and	O
high	O
-	O
frequency	O
ventilation	O
.	O

Although	O
there	O
are	O
no	O
study	O
data	O
to	O
evaluate	O
the	O
possibility	O
,	O
nitric	B-group-EF-1
oxide	I-group-EF-1
donor	I-group-EF-1
compounds	E-group-EF-1
,	O
including	O
sodium	B-drug-EF-1
nitroprusside	E-drug-EF-1
and	O
nitroglycerin	S-drug-EF-1
,	O
may	O
have	O
an	O
additive	O
effect	O
with	O
INOmax	S-brand-EF-2
on	O
the	O
risk	O
of	O
developing	O
methemoglobinemia	O
.	O

An	O
association	O
between	O
prilocaine	S-drug
and	O
an	O
increased	O
risk	O
of	O
methaemoglobinaemia	O
,	O
particularly	O
in	O
infants	O
,	O
has	O
specifically	O
been	O
described	O
in	O
a	O
literature	O
case	O
report	O
.	O

This	O
risk	O
is	O
present	O
whether	O
the	O
drugs	O
are	O
administered	O
as	O
oral	O
,	O
parenteral	O
,	O
or	O
topical	O
formulations	O
.	O

Antacids	S-group
containing	O
magnesium	B-drug-ME-1
trisilicate	E-drug-ME-1
,	O
when	O
administered	O
concomitantly	O
with	O
nitrofurantoin	S-drug-ME-2
,	O
reduce	O
both	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
.	O

The	O
mechanism	O
for	O
this	O
interaction	O
probably	O
is	O
adsorption	O
of	O
nitrofurantoin	S-drug-ME-1
onto	O
the	O
surface	O
of	O
magnesium	B-drug-ME-2
trisilicate	E-drug-ME-2
.	O

Uricosuric	B-group-ME-1
drugs	E-group-ME-1
,	O
such	O
as	O
probenecid	S-drug-ME-1
and	O
sulfinpyrazone	S-drug-ME-1
,	O
can	O
inhibit	O
renal	O
tubular	O
secretion	O
of	O
nitrofurantoin	S-drug-ME-2
.	O

The	O
resulting	O
increase	O
in	O
nitrofurantoin	S-drug
serum	O
levels	O
may	O
increase	O
toxicity	O
,	O
and	O
the	O
decreased	O
urinary	O
levels	O
could	O
lessen	O
its	O
efficacy	O
as	O
a	O
urinary	O
tract	O
antibacterial	S-group
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
a	O
result	O
of	O
the	O
presence	O
of	O
nitrofurantoin	S-drug
,	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
.	O

This	O
has	O
been	O
observed	O
with	O
Benedict	O
s	O
and	O
Fehling	O
s	O
solutions	O
but	O
not	O
with	O
the	O
glucose	O
enzymatic	O
test	O
.	O

The	O
vasodilating	O
effects	O
of	O
nitroglycerin	S-drug-EF-1
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	S-group-EF-2
.	O

Alcohol	S-drug
,	O
in	O
particular	O
,	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O

Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B-group-EF-1
channel	I-group-EF-1
blockers	E-group-EF-1
and	O
organic	O
nitrates	S-group-EF-2
were	O
used	O
in	O
combination	O
.	O

Dose	O
adjustments	O
of	O
either	O
class	O
of	O
agents	O
may	O
be	O
necessary	O
.	O

The	O
hypotensive	O
effect	O
of	O
sodium	B-drug-EF-1
nitroprusside	E-drug-EF-1
is	O
augmented	O
by	O
that	O
of	O
most	O
other	O
hypotensive	B-group-EF-2
drugs	E-group-EF-2
,	O
including	O
ganglionic	B-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
,	O
negative	O
inotropic	O
agents	O
,	O
and	O
inhaled	O
anesthetics	S-group-EF-2
.	O

No	O
interactions	O
have	O
been	O
observed	O
between	O
nizatidine	S-drug
and	O
theophylline	S-drug
,	O
chlordiazepoxide	S-drug
,	O
lorazepam	S-drug
,	O
lidocaine	S-drug
,	O
phenytoin	S-drug
,	O
and	O
warfarin	S-drug
.	O

Nizatidine	S-drug
does	O
not	O
inhibit	O
the	O
cytochrome	O
P	O
-	O
450	O
-	O
linked	O
drug	O
-	O
metabolizing	O
enzyme	O
system	O
;	O

therefore	O
,	O
drug	O
interactions	O
mediated	O
by	O
inhibition	O
of	O
hepatic	O
metabolism	O
are	O
not	O
expected	O
to	O
occur	O
.	O

In	O
patients	O
given	O
very	O
high	O
doses	O
(	O
3900	O
mg	O
)	O
of	O
aspirin	S-brand-ME-1
daily	O
,	O
increases	O
in	O
serum	O
salicylate	S-group
levels	O
were	O
seen	O
when	O
nizatidine	S-drug-ME-2
,	O
150	O
mg	O
b.i.d	O
.	O
,	O
was	O
administered	O
concurrently	O
.	O

The	O
effectiveness	O
of	O
progestin	S-group-EF-1
-	O
only	O
pills	O
is	O
reduced	O
by	O
hepatic	O
enzyme	O
-	O
inducing	O
drugs	O
such	O
as	O
the	O
anticonvulsants	S-group
phenytoin	S-drug-EF-2
,	O
carbamazepine	S-drug-EF-2
,	O
and	O
barbiturates	S-group-EF-2
,	O
and	O
the	O
antituberculosis	B-group
drug	E-group
rifampin	S-drug-EF-2
.	O

No	O
significant	O
interaction	O
has	O
been	O
found	O
with	O
broad	O
-	O
spectrum	O
antibiotics	S-group
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	S-drug-ME-1
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	S-group-ME-2
use	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	S-drug
-	O
related	O
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
norfloxacin	S-drug-EF-1
and	O
theophylline	S-drug-EF-2
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	S-drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	S-drug
adjusted	O
as	O
required	O
.	O

Elevated	O
serum	O
levels	O
of	O
cyclosporine	S-drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	S-drug-ME-1
with	O
norfloxacin	S-drug-ME-2
.	O

Therefore	O
,	O
cyclosporine	S-drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	S-drug
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	O
are	O
used	O
concomitantly	O
.	O

Quinolones	S-group-EF-1
,	O
including	O
norfloxacin	S-drug-EF-1
,	O
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	S-group-EF-2
,	O
including	O
warfarin	S-drug-EF-2
or	O
its	O
derivatives	O
or	O
similar	O
agents	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
closely	O
monitored	O
.	O

The	O
concomitant	O
administration	O
of	O
quinolones	S-group-EF-1
including	O
norfloxacin	S-drug-EF-1
with	O
glyburide	S-drug-EF-2
(	O
a	O
sulfonylurea	B-group
agent	E-group
)	O
has	O
,	O
on	O
rare	O
occasions	O
,	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O

Therefore	O
,	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
when	O
these	O
agents	O
are	O
co	O
-	O
administered	O
.	O

Diminished	O
urinary	O
excretion	O
of	O
norfloxacin	S-drug
has	O
been	O
reported	O
during	O
the	O
concomitant	O
administration	O
of	O
probenecid	S-drug-ME-1
and	O
norfloxacin	S-drug-ME-2
.	O

The	O
concomitant	O
use	O
of	O
nitrofurantoin	S-drug
is	O
not	O
recommended	O
since	O
nitrofurantoin	S-drug-EF-1
may	O
antagonize	O
the	O
antibacterial	O
effect	O
of	O
Norfloxacin	S-drug-EF-2
in	O
the	O
urinary	O
tract	O
.	O

Multivitamins	S-group-AD-1
,	O
or	O
other	O
products	O
containing	O
iron	S-drug-AD-1
or	O
zinc	S-drug-AD-1
,	O
antacids	S-group-AD-1
or	O
sucralfate	S-drug-AD-1
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
,	O
or	O
within	O
2	O
hours	O
of	O
,	O
the	O
administration	O
of	O
norfloxacin	S-drug-AD-2
,	O
because	O
they	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	S-drug
.	O

Videx	S-brand-AD-1
(	O
Didanosine	S-drug-AD-1
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
,	O
or	O
within	O
2	O
hours	O
of	O
,	O
the	O
administration	O
of	O
norfloxacin	S-drug-AD-2
,	O
because	O
these	O
products	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	S-drug
.	O

Some	O
quinolones	S-group-ME-1
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	S-drug-ME-2
.	O

This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	S-drug
and	O
a	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O

Reduced	O
efficacy	O
and	O
increased	O
incidence	O
of	O
breakthrough	O
bleeding	O
and	O
menstrual	O
irregularities	O
have	O
been	O
associated	O
with	O
concomitant	O
use	O
of	O
rifampin	S-drug
.	O

A	O
similar	O
association	O
,	O
though	O
less	O
marked	O
,	O
has	O
been	O
suggested	O
with	O
barbiturates	S-group
,	O
phenylbutazone	S-drug
,	O
phenytoin	B-drug
sodium	E-drug
,	O
carbamazepine	S-drug
,	O
griseofulvin	S-drug
,	O
topiramate	S-drug
,	O
and	O
possibly	O
with	O
ampicillin	S-drug
and	O
tetracyclines	S-group
72	O
.	O

A	O
possible	O
interaction	O
has	O
been	O
suggested	O
with	O
hormonal	B-group
contraceptives	E-group
and	O
the	O
herbal	O
supplement	O
St.	O
Johns	O
Wort	O
based	O
on	O
some	O
reports	O
of	O
oral	O
contraceptive	S-group
users	O
experiencing	O
breakthrough	O
bleeding	O
shortly	O
after	O
starting	O
St.	O
Johns	O
Wort	O
.	O

Pregnancies	O
have	O
been	O
reported	O
by	O
users	O
of	O
combined	B-group
hormonal	I-group
contraceptives	E-group
who	O
also	O
used	O
some	O
form	O
of	O
St.	O
Johns	O
Wort	O
.	O

Healthcare	O
prescribers	O
are	O
advised	O
to	O
consult	O
the	O
package	O
inserts	O
of	O
medication	O
administered	O
concomitantly	O
with	O
oral	O
contraceptives	S-group
.	O

Steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B-group-ME-1
antidepressants	E-group-ME-1
are	O
reported	O
to	O
fluctuate	O
significantly	O
when	O
cimetidine	S-drug-ME-2
is	O
either	O
added	O
or	O
deleted	O
from	O
the	O
drug	O
regimen	O
.	O

Serious	O
anticholinergic	O
symptoms	O
(	O
severe	O
dry	O
mouth	O
,	O
urinary	O
retention	O
,	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
when	O
cimetidine	S-drug-EF-2
is	O
added	O
to	O
the	O
drug	O
regimen	O
.	O

In	O
addition	O
,	O
higher	O
-	O
than	O
expected	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B-group-ME-1
antidepressants	E-group-ME-1
have	O
been	O
observed	O
when	O
therapy	O
is	O
initiated	O
in	O
patients	O
already	O
taking	O
cimetidine	S-drug-ME-2
.	O

In	O
well	O
-	O
controlled	O
patients	O
undergoing	O
concurrent	O
therapy	O
with	O
cimetidine	S-drug-ME-1
,	O
a	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B-group-ME-2
antidepressants	E-group-ME-2
may	O
occur	O
when	O
cime	O
-	O
tidine	O
therapy	O
is	O
discontinued	O
.	O

The	O
therapeutic	O
efficacy	O
of	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
be	O
compromised	O
in	O
these	O
patients	O
when	O
cimetidine	S-drug-EF-2
is	O
discontinued	O
.	O

Several	O
of	O
the	O
tricyclic	B-group
antidepressants	E-group
have	O
been	O
cited	O
in	O
these	O
reports	O
.	O

There	O
have	O
been	O
greater	O
than	O
2	O
-	O
fold	O
increases	O
in	O
previously	O
stable	O
plasma	O
levels	O
of	O
other	O
antidepressants	S-group-ME-1
,	O
including	O
nortriptyline	S-drug-ME-1
,	O
when	O
fluoxetine	B-drug-ME-2
hydrochloride	E-drug-ME-2
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O

Fluoxetine	S-drug
and	O
its	O
active	O
metabolite	O
,	O
norfluoxe	O
-	O
tine	O
,	O
have	O
long	O
half	O
-	O
lives	O
(	O
4	O
to	O
16	O
days	O
for	O
norfluoxetine	S-drug_n
)	O
,	O
that	O
may	O
affect	O
strategies	O
during	O
conversion	O
from	O
one	O
drug	O
to	O
the	O
other	O
.	O

Administration	O
of	O
reserpine	S-drug-EF-1
during	O
therapy	O
with	O
a	O
tricyclic	B-group-EF-2
antidepressant	E-group-EF-2
has	O
been	O
shown	O
to	O
produce	O
a	O
stimulating	O
effect	O
in	O
some	O
depressed	O
patients	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
the	O
dosage	O
are	O
required	O
when	O
nortriptyline	B-drug-AD-1
hydrochloride	E-drug-AD-1
is	O
used	O
with	O
other	O
anticholinergic	B-group-AD-2
drugs	E-group-AD-2
or	O
sympathomimetic	B-group-AD-2
drugs	E-group-AD-2
.	O

The	O
patient	O
should	O
be	O
informed	O
that	O
the	O
response	O
to	O
alcohol	S-drug
may	O
be	O
exaggerated	O
.	O

Drugs	O
Metabolized	O
by	O
P450IID6	O
A	O
subset	O
(	O
3	O
%	O
to	O
10	O
%	O
)	O
of	O
the	O
population	O
has	O
reduced	O
activity	O
of	O
certain	O
drug	O
metabolizing	O
enzymes	O
such	O
as	O
the	O
cytochrome	O
P450	O
isoenzyme	O
P450IID6	O
.	O

Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	O
such	O
as	O
debrisoquin	S-drug
,	O
dextromethorphan	S-drug
,	O
and	O
the	O
tricyclic	B-group
antidepressants	E-group
.	O

These	O
individuals	O
may	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-group
antidepressants	E-group
when	O
given	O
usual	O
doses	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
including	O
many	O
antidepressants	S-group
(	O
tricyclic	B-group
antidepressants	E-group
,	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
,	O
and	O
others	O
)	O
,	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isoenzyme	O
,	O
and	O
thus	O
may	O
make	O
normal	O
metab	O
-	O
olizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
system	O
,	O
leading	O
to	O
drug	O
interactions	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B-group
antidepressants	E-group
with	O
other	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450IID6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-group
antidepressant	E-group
or	O
the	O
other	O
drug	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
tricyclic	B-group-AD-1
antidepressants	E-group-AD-1
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
including	O
other	O
antidepressants	S-group-AD-2
,	O
phenothiazines	S-group-AD-2
,	O
carbamazepine	S-drug-AD-2
,	O
and	O
Type	B-group-AD-2
1C	I-group-AD-2
antiarrhythmics	E-group-AD-2
(	O
eg	O
,	O
propafenone	S-drug-AD-2
,	O
flecainide	S-drug-AD-2
,	O
and	O
encainide	S-drug-AD-2
)	O
,	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
eg	O
,	O
quinidine	S-drug-AD-2
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Oxcarbazepine	S-drug
can	O
inhibit	O
CYP2C19	O
and	O
induce	O
CYP3A4	O
/	O
5	O
with	O
potentially	O
important	O
effects	O
on	O
plasma	O
concentrations	O
of	O
other	O
drugs	O
.	O

In	O
addition	O
,	O
several	O
AED	S-group-ME-1
s	O
that	O
are	O
cytochrome	O
P450	O
inducers	O
can	O
decrease	O
plasma	O
concentrations	O
of	O
oxcarbazepine	S-drug-ME-2
and	O
MHD	S-drug_n
.	O

Oxcarbazepine	S-drug
was	O
evaluated	O
in	O
human	O
liver	O
microsomes	O
to	O
determine	O
its	O
capacity	O
to	O
inhibit	O
the	O
major	O
cytochrome	O
P450	O
enzymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
other	O
drugs	O
.	O

Results	O
demonstrate	O
that	O
oxcarbazepine	S-drug
and	O
its	O
pharmacologically	O
active	O
10	O
-	O
monohydroxy	O
metabolite	O
(	O
MHD	S-drug_n
)	O
have	O
little	O
or	O
no	O
capacity	O
to	O
function	O
as	O
inhibitors	O
for	O
most	O
of	O
the	O
human	O
cytochrome	O
P450	O
enzymes	O
evaluated	O
(	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
CYP4A9	O
and	O
CYP4A11	O
)	O
with	O
the	O
exception	O
of	O
CYP2C19	O
and	O
CYP3A4	O
/	O
5	O
.	O

Although	O
inhibition	O
of	O
CYP	O
3A4	O
/	O
5	O
by	O
OXC	S-drug
and	O
MHD	S-drug_n
did	O
occur	O
at	O
high	O
concentrations	O
,	O
it	O
is	O
not	O
likely	O
to	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
inhibition	O
of	O
CYP	O
-	O
2C19	O
by	O
OXC	S-drug
and	O
MHD	S-drug_n
,	O
however	O
,	O
is	O
clinically	O
relevant	O
.	O

In	O
vitro	O
,	O
the	O
UDP	O
-	O
glucuronyl	O
transferase	O
level	O
was	O
increased	O
,	O
indicating	O
induction	O
of	O
this	O
enzyme	O
.	O

Increases	O
of	O
22	O
%	O
with	O
MHD	S-drug_n
and	O
47	O
%	O
with	O
oxcarbazepine	S-drug
were	O
observed	O
.	O

As	O
MHD	S-drug_n
,	O
the	O
predominant	O
plasma	O
substrate	O
,	O
is	O
only	O
a	O
weak	O
inducer	O
of	O
UDP	O
-	O
glucuronyl	O
transferase	O
,	O
it	O
is	O
unlikely	O
to	O
have	O
an	O
effect	O
on	O
drugs	O
that	O
are	O
mainly	O
eliminated	O
by	O
conjugation	O
through	O
UDP	O
-	O
glucuronyl	O
transferase	O
(	O
e.g	O
.	O
,	O
valproic	B-drug
acid	E-drug
,	O
lamotrigine	S-drug
)	O
.	O

In	O
addition	O
,	O
oxcarbazepine	S-drug
and	O
MHD	S-drug_n
induce	O
a	O
subgroup	O
of	O
the	O
cytochrome	O
P450	O
3A	O
family	O
(	O
CYP3A4	O
and	O
CYP3A5	O
)	O
responsible	O
for	O
the	O
metabolism	O
of	O
dihydropyridine	B-group
calcium	I-group
antagonists	E-group
and	O
oral	O
contraceptives	S-group
,	O
resulting	O
in	O
a	O
lower	O
plasma	O
concentration	O
of	O
these	O
drugs	O
.	O

As	O
binding	O
of	O
MHD	S-drug_n
to	O
plasma	O
proteins	O
is	O
low	O
(	O
40	O
%	O
)	O
,	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	O
through	O
competition	O
for	O
protein	O
binding	O
sites	O
are	O
unlikely	O
.	O

Antiepileptic	B-group
drugs	E-group
:	O
Potential	O
interactions	O
between	O
Trileptal	S-brand
and	O
other	O
AEDs	S-group
were	O
assessed	O
in	O
clinical	O
studies	O
.	O

The	O
effect	O
of	O
these	O
interactions	O
on	O
mean	O
AUCs	O
and	O
Cmin	O
are	O
summarized	O
in	O
Table	O
2	O
:	O
Table	O
2	O
:	O
Summary	O
of	O
AED	O
interactions	O
with	O
Trileptal	S-brand

AED	S-group
Co	O
-	O
administered	O

Dose	O
of	O
AED	S-group
(	O
mg	O
/	O
day	O
)	O

Trileptal	S-brand
dose	O
(	O
mg	O
/	O
day	O
)	O

Influence	O
of	O
Trileptal	S-brand
on	O
AED	S-group
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O

Influence	O
of	O
AED	S-group
On	O
MHD	S-drug_n
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O

400	O
-	O
2000	O

nc1	O
40	O
%	O
decrease	O
[	O
CI	O
:	O
17	O
%	O
decrease	O
,	O
57	O
%	O
decrease	O
]	O

100	O
-	O
150	O

600	O
-	O
1800	O

14	O
%	O
increase	O
[	O
CI	O
:	O
2	O
%	O
increase	O
,	O
24	O
%	O
increase	O
]	O
25	O
%	O
decrease	O
[	O
CI	O
:	O
12	O
%	O
decrease	O
,	O
51	O
%	O
decrease	O
]	O

250	O
-	O
500	O

600	O
-	O
1800	O

nc1,2	O
30	O
%	O
decrease	O
[	O
CI	O
:	O
3	O
%	O
decrease	O
,	O
48	O
%	O
decrease	O
]	O

1200	O
-	O
2400	O
up	O
to	O
40	O
%	O
increase3	O
[	O
CI	O
:	O
12	O
%	O
increase	O
,	O
60	O
%	O
increase	O
]	O

Valproic	B-drug
acid	E-drug

400	O
-	O
2800	O

600	O
-	O
1800	O

nc1	O
18	O
%	O
decrease	O
[	O
CI	O
:	O
13	O
%	O
decrease	O
,	O
40	O
%	O
decrease	O
]	O

1	O
-	O
nc	O
denotes	O
a	O
mean	O
change	O
of	O
less	O
than	O
10	O
%	O
2	O
-	O
Pediatrics	O
3	O
-	O
Mean	O
increase	O
in	O
adults	O
at	O
high	O
Trileptal	S-brand
doses	O
In	O
vivo	O
,	O
the	O
plasma	O
levels	O
of	O
phenytoin	S-drug-ME-1
increased	O
by	O
up	O
to	O
40	O
%	O
,	O
when	O
Trileptal	S-brand-ME-2
was	O
given	O
at	O
doses	O
above	O
1200	O
mg	O
/	O
day	O
.	O

Therefore	O
,	O
when	O
using	O
doses	O
of	O
Trileptal	S-brand-AD-1
greater	O
than	O
1200	O
mg	O
/	O
day	O
during	O
adjunctive	O
therapy	O
,	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
phenytoin	S-drug-AD-2
may	O
be	O
required	O
.	O

The	O
increase	O
of	O
phenobarbital	S-drug-ME-1
level	O
,	O
however	O
,	O
is	O
small	O
(	O
15	O
%	O
)	O
when	O
given	O
with	O
Trileptal	S-brand-ME-2
.	O

Strong	O
inducers	O
of	O
cytochrome	O
P450	O
enzymes	O
(	O
i.e	O
.	O
carbamazepine	S-drug
,	O
phenytoin	S-drug
and	O
phenobarbital	S-drug
)	O
have	O
been	O
shown	O
to	O
decrease	O
the	O
plasma	O
levels	O
of	O
MHD	S-drug_n
(	O
29	O
-	O
40	O
%	O
)	O
.	O

No	O
autoinduction	O
has	O
been	O
observed	O
with	O
Trileptal	S-brand
.	O

Hormonal	O
contraceptives	S-group
Co	O
-	O
administration	O
of	O
Trileptal	S-brand-ME-1
with	O
an	O
oral	O
contraceptive	S-group-ME-2
has	O
been	O
shown	O
to	O
influence	O
the	O
plasma	O
concentrations	O
of	O
the	O
two	O
hormonal	O
components	O
,	O
ethinylestradiol	S-drug
(	O
EE	O
)	O
and	O
levonorgestrel	S-drug
(	O
LNG	O
)	O
.	O

The	O
mean	O
AUC	O
values	O
of	O
EE	O
were	O
decreased	O
by	O
48	O
%	O
[	O
90	O
%	O
CI	O
:	O
22	O
-	O
65	O
]	O
in	O
one	O
study	O
and	O
52	O
%	O
[	O
90	O
%	O
CI	O
:	O
38	O
-	O
52	O
]	O
in	O
another	O
study	O
[	O
1,2	O
]	O
.	O

The	O
mean	O
AUC	O
values	O
of	O
LNG	O
were	O
decreased	O
by	O
32	O
%	O
[	O
90	O
%	O
CI	O
:	O
20	O
-	O
45	O
]	O
in	O
one	O
study	O
and	O
52	O
%	O
[	O
90	O
%	O
CI	O
:	O
42	O
-	O
52	O
]	O
in	O
another	O
study	O
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
Trileptal	S-brand-EF-1
with	O
hormonal	B-group-EF-2
contraceptives	E-group-EF-2
may	O
render	O
these	O
contraceptives	S-group
less	O
effective	O
.	O

Studies	O
with	O
other	O
oral	O
or	O
implant	O
contraceptives	S-group
have	O
not	O
been	O
conducted	O
.	O

Calcium	B-group
Antagonists	O
:	O
After	O
repeated	O
co	O
-	O
administration	O
of	O
Trileptal	S-brand-ME-1
,	O
the	O
AUC	O
of	O
felodipine	S-drug-ME-2
was	O
lowered	O
by	O
28	O
%	O
[	O
90	O
%	O
CI	O
:	O
20	O
-	O
33	O
]	O
.	O

Verapamil	S-drug
produced	O
a	O
decrease	O
of	O
20	O
%	O
[	O
90	O
%	O
CI	O
:	O
18	O
-	O
27	O
]	O
of	O
the	O
plasma	O
levels	O
of	O
MHD	S-drug_n
.	O

Other	O
drug	O
interactions	O
Cimetidine	S-drug
,	O
erythromycin	S-drug
and	O
dextropropoxyphene	S-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
MHD	S-drug_n
.	O

Results	O
with	O
warfarin	S-drug
wshow	O
no	O
evidence	O
of	O
interaction	O
with	O
either	O
single	O
or	O
repeated	O
doses	O
of	O
Trileptal	S-brand
.	O

In	O
a	O
Phase	O
I	O
trial	O
using	O
escalating	O
doses	O
of	O
TAXOL	S-brand
(	O
110	O
-	O
200	O
mg	O
/	O
m2	O
)	O
and	O
cisplatin	S-drug
(	O
50	O
or	O
75	O
mg	O
/	O
m2	O
)	O
given	O
as	O
sequential	O
infusions	O
,	O
myelosuppression	O
was	O
more	O
profound	O
when	O
TAXOL	S-brand-EF-1
was	O
given	O
after	O
cisplatin	S-drug-EF-2
than	O
with	O
the	O
alternate	O
sequence	O
(	O
ie	O
,	O
TAXOL	S-brand
before	O
cisplatin	S-drug
)	O
.	O

Pharmacokinetic	O
data	O
from	O
these	O
patients	O
demonstrated	O
a	O
decrease	O
in	O
paclitaxel	S-drug
clearance	O
of	O
approximately	O
33	O
%	O
when	O
TAXOL	S-brand-ME-1
was	O
administered	O
following	O
cisplatin	S-drug-ME-2
.	O

The	O
metabolism	O
of	O
TAXOL	S-brand
is	O
catalyzed	O
by	O
cytochrome	O
P450	O
isoen	O
-	O
zymes	O
CYP2C8	O
and	O
CYP3A4	O
.	O

In	O
the	O
absence	O
of	O
formal	O
clinical	O
drug	O
interaction	O
studies	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	S-brand
concomitantly	O
with	O
known	O
substrates	O
or	O
inhibitors	O
of	O
the	O
cytochrome	O
P450	O
isoenzymes	O
CYP2C8	O
and	O
CYP3A4	O
.	O

Potential	O
interactions	O
between	O
TAXOL	S-brand
,	O
a	O
substrate	O
of	O
CYP3A4	O
,	O
and	O
protease	B-group
inhibitors	E-group
(	O
ritonavir	S-drug
,	O
saquinavir	S-drug
,	O
indinavir	S-drug
,	O
and	O
nelfinavir	S-drug
)	O
,	O
which	O
are	O
substrates	O
and	O
/	O
or	O
inhibitors	O
of	O
CYP3A4	O
,	O
have	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	O
.	O

Reports	O
in	O
the	O
literature	O
suggest	O
that	O
plasma	O
levels	O
of	O
doxorubicin	S-drug
(	O
and	O
its	O
active	O
metabolite	O
doxorubicinol	S-drug_n
)	O
may	O
be	O
increased	O
when	O
paclitaxel	S-drug-ME-1
and	O
doxorubicin	S-drug-ME-2
are	O
used	O
in	O
combination	O
.	O

Hematology	O
:	O
TAXOL	S-brand
therapy	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
baseline	O
neutrophil	O
counts	O
of	O
less	O
than	O
1,500	O
cells	O
/	O
mm3	O
.	O

In	O
order	O
to	O
monitor	O
the	O
occurrence	O
of	O
myelotoxicity	O
,	O
it	O
is	O
recommended	O
that	O
frequent	O
peripheral	O
blood	O
cell	O
counts	O
be	O
performed	O
on	O
all	O
patients	O
receiving	O
TAXOL	S-brand
.	O

Patients	O
should	O
not	O
be	O
re	O
-	O
treated	O
with	O
subsequent	O
cycles	O
of	O
TAXOL	S-brand
until	O
neutrophils	O
recover	O
to	O
a	O
level	O
1500	O
cells	O
/	O
mm3	O
and	O
platelets	O
recover	O
to	O
a	O
level	O
100,000	O
cells	O
/	O
mm3	O
.	O

In	O
the	O
case	O
of	O
severe	O
neutropenia	O
(	O
500	O
cells	O
/	O
mm3	O
for	O
seven	O
days	O
or	O
more	O
)	O
during	O
a	O
course	O
of	O
TAXOL	S-brand
therapy	O
,	O
a	O
20	O
%	O
reduction	O
in	O
dose	O
for	O
subsequent	O
courses	O
of	O
therapy	O
is	O
recommended	O
.	O

For	O
patients	O
with	O
advanced	O
HIV	O
disease	O
and	O
poor	O
-	O
risk	O
AIDS	O
-	O
related	O
Kaposi	O
s	O
sarcoma	O
,	O
TAXOL	S-brand
,	O
at	O
the	O
recommended	O
dose	O
for	O
this	O
disease	O
,	O
can	O
be	O
initiated	O
and	O
repeated	O
if	O
the	O
neutrophil	O
count	O
is	O
at	O
least	O
1000	O
cells	O
/	O
mm3	O
.	O

Hypersensitivity	O
Reactions	O
:	O
Patients	O
with	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
products	O
containing	O
Cremophor	O
EL	O
(	O
eg	O
,	O
cyclosporin	S-drug-AD-1
for	O
injection	O
concentrate	O
and	O
teniposide	S-drug-AD-1
for	O
injection	O
concentrate	O
)	O
should	O
not	O
be	O
treated	O
with	O
TAXOL	S-brand-AD-2
.	O

In	O
order	O
to	O
avoid	O
the	O
occurrence	O
of	O
severe	O
hypersensitivity	O
reactions	O
,	O
all	O
patients	O
treated	O
with	O
TAXOL	S-brand
should	O
be	O
premedicated	O
with	O
corticosteroids	S-group
(	O
such	O
as	O
dexamethasone	S-drug
)	O
,	O
diphen	O
-	O
hydramine	O
and	O
H2	B-group
antagonists	E-group
(	O
such	O
as	O
cimetidine	S-drug
or	O
ranitidine	S-drug
)	O
.	O

Minor	O
symptoms	O
such	O
as	O
flushing	O
,	O
skin	O
reactions	O
,	O
dyspnea	O
,	O
hypotension	O
,	O
or	O
tachycardia	O
do	O
not	O
require	O
interruption	O
of	O
therapy	O
.	O

However	O
,	O
severe	O
reactions	O
,	O
such	O
as	O
hypotension	O
requiring	O
treatment	O
,	O
dyspnea	O
requiring	O
bronchodilators	S-group
,	O
angioedema	O
,	O
or	O
generalized	O
urticaria	O
require	O
immediate	O
discontinuation	O
of	O
TAXOL	S-brand
and	O
aggressive	O
symptomatic	O
therapy	O
.	O

Patients	O
who	O
have	O
developed	O
severe	O
hypersensitivity	O
reactions	O
should	O
not	O
be	O
rechallenged	O
with	O
TAXOL	S-brand
.	O

Cardiovascular	O
:	O
Hypotension	O
,	O
bradycardia	O
,	O
and	O
hypertension	O
have	O
been	O
observed	O
during	O
administration	O
of	O
TAXOL	S-brand
,	O
but	O
generally	O
do	O
not	O
require	O
treatment	O
.	O

Occasionally	O
TAXOL	S-brand
infusions	O
must	O
be	O
interrupted	O
or	O
discontinued	O
because	O
of	O
initial	O
or	O
recurrent	O
hypertension	O
.	O

Frequent	O
vital	O
sign	O
monitoring	O
,	O
particularly	O
during	O
the	O
first	O
hour	O
of	O
TAXOL	S-brand
infusion	O
,	O
is	O
recommended	O
.	O

Continuous	O
cardiac	O
monitoring	O
is	O
not	O
required	O
except	O
for	O
patients	O
with	O
serious	O
conduction	O
abnormalities	O
.	O

Nervous	O
System	O
:	O
Although	O
the	O
occurrence	O
of	O
peripheral	O
neuropathy	O
is	O
frequent	O
,	O
the	O
development	O
of	O
severe	O
symptomatology	O
is	O
unusual	O
and	O
requires	O
a	O
dose	O
reduction	O
of	O
20	O
%	O
for	O
all	O
subsequentcourses	O
of	O
TAXOL	S-brand
.	O

TAXOL	S-brand
contains	O
dehydrated	O
alcohol	O
USP	O
,	O
396	O
mg	O
/	O
mL	O
;	O

consideration	O
should	O
be	O
given	O
to	O
possible	O
CNS	O
and	O
other	O
effects	O
of	O
alcohol	S-drug
.	O

Hepatic	O
:	O
There	O
is	O
limited	O
evidence	O
that	O
the	O
myelotoxicity	O
of	O
TAXOL	S-brand
may	O
be	O
exacerbated	O
in	O
patients	O
with	O
serum	O
total	O
bilirubin	O
2	O
times	O
ULN	O
.	O

Extreme	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	S-brand
to	O
such	O
patients	O
,	O
with	O
dose	O
reduction	O
as	O
recommended	O
in	O
DOSAGE	O
AND	O
ADMINISTRATION	O
,	O
Table	O
17	O
.	O

InjectionSite	O
Reaction	O
:	O
Injection	O
site	O
reactions	O
,	O
including	O
reactions	O
secondary	O
to	O
extravasation	O
,	O
were	O
usually	O
mild	O
and	O
consisted	O
of	O
erythema	O
,	O
tenderness	O
,	O
skin	O
discoloration	O
,	O
or	O
swelling	O
at	O
the	O
injection	O
site	O
.	O

These	O
reactions	O
have	O
been	O
observed	O
more	O
frequently	O
with	O
the	O
24	O
-	O
hour	O
infusion	O
than	O
with	O
the	O
3	O
-	O
hour	O
infusion	O
.	O

Recurrence	O
of	O
skin	O
reactions	O
at	O
a	O
site	O
of	O
previous	O
extravasation	O
following	O
administration	O
of	O
TAXOL	S-brand
at	O
a	O
different	O
site	O
,	O
ie	O
,	O
recall	O
,	O
has	O
been	O
reported	O
rarely	O
.	O

Rare	O
reports	O
of	O
more	O
severe	O
events	O
such	O
as	O
phlebitis	O
,	O
cellulitis	O
,	O
induration	O
,	O
skin	O
exfoliation	O
,	O
necrosis	O
,	O
and	O
fibrosis	O
have	O
been	O
received	O
as	O
part	O
of	O
the	O
continuing	O
surveillance	O
of	O
TAXOL	S-brand
safety	O
.	O

In	O
some	O
cases	O
the	O
onset	O
of	O
the	O
injection	O
site	O
reaction	O
either	O
occurred	O
during	O
a	O
prolonged	O
infusion	O
or	O
was	O
delayed	O
by	O
a	O
week	O
to	O
ten	O
days	O
.	O

A	O
specific	O
treatment	O
for	O
extravasation	O
reactions	O
is	O
unknown	O
at	O
this	O
time	O
.	O

Given	O
the	O
possibility	O
of	O
extravasation	O
,	O
it	O
is	O
advisable	O
to	O
closely	O
monitor	O
the	O
infusion	O
site	O
for	O
possible	O
infiltration	O
during	O
drug	O
administration	O
.	O

Treatment	O
with	O
PEGASYS	S-brand-ME-1
once	O
weekly	O
for	O
4	O
weeks	O
in	O
healthy	O
subjects	O
was	O
associated	O
with	O
an	O
inhibition	O
of	O
P450	O
1A2	O
and	O
a	O
25	O
%	O
increase	O
in	O
theophylline	S-drug-ME-2
AUC	O
.	O

Theophylline	S-drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
dose	O
adjustments	O
considered	O
for	O
patients	O
given	O
both	O
theophylline	S-drug-AD-1
and	O
PEGASYS	S-brand-AD-2
.	O

There	O
was	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
representative	O
drugs	O
metabolized	O
by	O
CYP	O
2C9	O
,	O
CYP	O
2C19	O
,	O
CYP	O
2D6	O
or	O
CYP	O
3A4	O
.	O

In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
treated	O
with	O
PEGASYS	S-brand
in	O
combination	O
with	O
COPEGUS	S-brand
,	O
PEGASYS	S-brand
treatment	O
did	O
not	O
affect	O
ribavirin	S-drug
distribution	O
or	O
clearance	O
.	O

Nucleoside	O
Analogues	O
Didanosine	S-drug
Co	O
-	O
administration	O
of	O
COPEGUS	S-brand-AD-1
and	O
didanosine	S-drug-AD-2
is	O
not	O
recommended	O
.	O

Reports	O
of	O
fatal	O
hepatic	O
failure	O
,	O
as	O
well	O
as	O
peripheral	O
neuropathy	O
,	O
pancreatitis	O
,	O
and	O
symptomatic	O
hyperlactatemia	O
/	O
lactic	O
acidosis	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O

Stavudine	S-drug
and	O
Zidovudine	S-drug
Ribavirin	S-drug-EF-1
can	O
antagonize	O
the	O
in	O
vitro	O
antiviral	O
activity	O
of	O
stavudine	S-drug-EF-2
and	O
zidovudine	S-drug-EF-2
against	O
HIV	O
.	O

Therefore	O
,	O
concomitant	O
use	O
of	O
ribavirin	S-drug
with	O
either	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
Impairment	O
of	O
Fertility	O
Carcinogenesis	O
PEGASYS	S-brand
has	O
not	O
been	O
tested	O
for	O
its	O
carcinogenic	O
potential	O
.	O

Mutagenesis	O
PEGASYS	S-brand
did	O
not	O
cause	O
DNA	O
damage	O
when	O
tested	O
in	O
the	O
Ames	O
bacterial	O
mutagenicity	O
assay	O
and	O
in	O
the	O
in	O
vitro	O
chromosomal	O
aberration	O
assay	O
in	O
human	O
lymphocytes	O
,	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
metabolic	O
activation	O
.	O

Use	O
With	O
Ribavirin	S-drug
Ribavirin	S-drug
is	O
genotoxic	O
and	O
mutagenic	O
.	O

The	O
carcinogenic	O
potential	O
of	O
ribavirin	S-drug
has	O
not	O
been	O
fully	O
determined	O
.	O

In	O
a	O
p53	O
(	O
+	O
/	O
-	O
)	O
mouse	O
carcinogenicity	O
study	O
at	O
doses	O
up	O
to	O
the	O
maximum	O
tolerated	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
/	O
day	O
ribavirin	S-drug
was	O
not	O
oncogenic	O
.	O

However	O
,	O
on	O
a	O
body	O
surface	O
area	O
basis	O
,	O
this	O
dose	O
was	O
0.5	O
times	O
maximum	O
recommended	O
human	O
24	O
-	O
hour	O
dose	O
of	O
ribavirin	S-drug
.	O

A	O
study	O
in	O
rats	O
to	O
assess	O
the	O
carcinogenic	O
potential	O
of	O
ribavirin	S-drug
is	O
ongoing	O
.	O

Mutagenesis	O
Impairment	O
of	O
Fertility	O
PEGASYS	S-brand
may	O
impair	O
fertility	O
in	O
women	O
.	O

Prolonged	O
menstrual	O
cycles	O
and	O
/	O
or	O
amenorrhea	O
were	O
observed	O
in	O
female	O
cynomolgus	O
monkeys	O
given	O
sc	O
injections	O
of	O
600	O
m	O
g	O
/	O
kg	O
/	O
dose	O
(	O
7200	O
m	O
g	O
/	O
m2	O
/	O
dose	O
)	O
of	O
PEGASYS	S-brand
every	O
other	O
day	O
for	O
one	O
month	O
,	O
at	O
approximately	O
180	O
times	O
the	O
recommended	O
weekly	O
human	O
dose	O
for	O
a	O
60	O
kg	O
person	O
(	O
based	O
on	O
body	O
surface	O
area	O
)	O
.	O

Menstrual	O
cycle	O
irregularities	O
were	O
accompanied	O
by	O
both	O
a	O
decrease	O
and	O
delay	O
in	O
the	O
peak	O
17b	O
-	O
estradiol	O
and	O
progesterone	O
levels	O
following	O
administration	O
of	O
PEGASYS	S-brand
to	O
female	O
monkeys	O
.	O

A	O
return	O
to	O
normal	O
menstrual	O
rhythm	O
followed	O
cessation	O
of	O
treatment	O
.	O

Every	O
other	O
day	O
dosing	O
with	O
100m	O
g	O
/	O
kg	O
(	O
1200m	O
g	O
/	O
m2	O
)	O
PEGASYS	S-brand
(	O
equivalent	O
to	O
approximately	O
30	O
times	O
the	O
recommended	O
human	O
dose	O
)	O
had	O
no	O
effects	O
on	O
cycle	O
duration	O
or	O
reproductive	O
hormone	O
status	O
.	O

The	O
effects	O
of	O
PEGASYS	S-brand
on	O
male	O
fertility	O
have	O
not	O
been	O
studied	O
.	O

However	O
,	O
no	O
adverse	O
effects	O
on	O
fertility	O
were	O
observed	O
in	O
male	O
Rhesus	O
monkeys	O
treated	O
with	O
non	O
-	O
pegylated	B-drug
interferon	I-drug
alfa	I-drug
-	I-drug
2a	E-drug
for	O
5	O
months	O
at	O
doses	O
up	O
to	O
25	O
x	O
106	O
IU	O
/	O
kg	O
/	O
day	O
.	O

Pregnancy	O
Pregnancy	O
:	O
Category	O
C	O
PEGASYS	S-brand
has	O
not	O
been	O
studied	O
for	O
its	O
teratogenic	O
effect	O
.	O

Non	B-drug
-	I-drug
pegylated	I-drug
interferon	I-drug
alfa	I-drug
-	I-drug
2a	E-drug
treatment	O
of	O
pregnant	O
Rhesus	O
monkeys	O
at	O
approximately	O
20	O
to	O
500	O
times	O
the	O
human	O
weekly	O
dose	O
resulted	O
in	O
a	O
statistically	O
significant	O
increase	O
in	O
abortions	O
.	O

No	O
teratogenic	O
effects	O
were	O
seen	O
in	O
the	O
offspring	O
delivered	O
at	O
term	O
.	O

PEGASYS	S-brand
should	O
be	O
assumed	O
to	O
have	O
abortifacient	O
potential	O
.	O

There	O
are	O
no	O
adequate	O
and	O
well	O
-	O
controlled	O
studies	O
of	O
PEGASYS	S-brand
in	O
pregnant	O
women	O
.	O

PEGASYS	S-brand
is	O
to	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
the	O
potential	O
benefit	O
justifies	O
the	O
potential	O
risk	O
to	O
the	O
fetus	O
.	O

PEGASYS	S-brand
is	O
recommended	O
for	O
use	O
in	O
women	O
of	O
childbearing	O
potential	O
only	O
when	O
they	O
are	O
using	O
effective	O
contraception	O
during	O
therapy	O
.	O

Pregnancy	O
:	O
Category	O
X	O
:	O
Use	O
With	O
Ribavirin	S-drug
(	O
see	O
CONTRAINDICATIONS	O
)	O
Significant	O
teratogenic	O
and	O
/	O
or	O
embryocidal	O
effects	O
have	O
been	O
demonstrated	O
in	O
all	O
animal	O
species	O
exposed	O
to	O
ribavirin	S-drug
.	O

COPEGUS	S-brand
therapy	O
is	O
contraindicated	O
in	O
women	O
who	O
are	O
pregnant	O
and	O
in	O
the	O
male	O
partners	O
of	O
women	O
who	O
are	O
pregnant	O
.	O

If	O
pregnancy	O
occurs	O
in	O
a	O
patient	O
or	O
partner	O
of	O
a	O
patient	O
during	O
treatment	O
or	O
during	O
the	O
6	O
months	O
after	O
treatment	O
cessation	O
,	O
such	O
cases	O
should	O
be	O
reported	O
to	O
the	O
COPEGUS	S-brand
Pregnancy	O
Registry	O
at	O
1	O
-	O
800	O
-	O
526	O
-	O
6367	O
.	O

Nursing	O
Mothers	O
It	O
is	O
not	O
known	O
whether	O
peginterferon	S-drug
or	O
ribavirin	S-drug
or	O
its	O
components	O
are	O
excreted	O
in	O
human	O
milk	O
.	O

The	O
effect	O
of	O
orally	O
ingested	O
peginterferon	S-drug
or	O
ribavirin	S-drug
from	O
breast	O
milk	O
on	O
the	O
nursing	O
infant	O
has	O
not	O
been	O
evaluated	O
.	O

Because	O
of	O
the	O
potential	O
for	O
adverse	O
reactions	O
from	O
the	O
drugs	O
in	O
nursing	O
infants	O
,	O
a	O
decision	O
must	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
or	O
discontinue	O
PEGASYS	S-brand
and	O
COPEGUS	S-brand
treatment	O
.	O

Pediatric	O
Use	O
The	O
safety	O
and	O
effectiveness	O
of	O
PEGASYS	S-brand
,	O
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	S-brand
in	O
patients	O
below	O
the	O
age	O
of	O
18	O
years	O
have	O
not	O
been	O
established	O
.	O

PEGASYS	S-brand
contains	O
benzyl	B-drug_n
alcohol	E-drug_n
.	O

Benzyl	B-drug_n
alcohol	E-drug_n
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
neurological	O
and	O
other	O
complications	O
in	O
neonates	O
and	O
infants	O
,	O
which	O
are	O
sometimes	O
fatal	O
.	O

Geriatric	O
Use	O
Younger	O
patients	O
have	O
higher	O
virologic	O
response	O
rates	O
than	O
older	O
patients	O
.	O

Clinical	O
studies	O
of	O
PEGASYS	S-brand
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	S-brand
did	O
not	O
include	O
sufficient	O
numbers	O
of	O
subjects	O
aged	O
65	O
or	O
over	O
to	O
determine	O
whether	O
they	O
respond	O
differently	O
from	O
younger	O
subjects	O
.	O

Adverse	O
reactions	O
related	O
to	O
alpha	B-drug
interferons	O
,	O
such	O
as	O
CNS	O
,	O
cardiac	O
,	O
and	O
systemic	O
(	O
eg	O
,	O
flu	O
-	O
like	O
)	O
effects	O
may	O
be	O
more	O
severe	O
in	O
the	O
elderly	O
and	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
use	O
of	O
PEGASYS	S-brand
in	O
this	O
population	O
.	O

PEGASYS	S-brand
and	O
COPEGUS	S-brand
are	O
excreted	O
by	O
the	O
kidney	O
,	O
and	O
the	O
risk	O
of	O
toxic	O
reactions	O
to	O
this	O
therapy	O
may	O
be	O
greater	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O

Because	O
elderly	O
patients	O
are	O
more	O
likely	O
to	O
have	O
decreased	O
renal	O
function	O
,	O
care	O
should	O
be	O
taken	O
in	O
dose	O
selection	O
and	O
it	O
may	O
be	O
useful	O
to	O
monitor	O
renal	O
function	O
.	O

PEGASYS	S-brand
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
creatinine	O
clearance	O
50	O
mL	O
/	O
min	O
and	O
COPEGUS	S-brand
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
creatinine	O
clearance	O
50	O
mL	O
/	O
min	O

Aminoglycosides	S-group
:	O
The	O
mixing	O
of	O
piperacillin	S-drug-EF-1
with	O
an	O
aminoglycoside	S-group-EF-2
in	O
vitro	O
can	O
result	O
in	O
substantial	O
inactivation	O
of	O
the	O
aminoglycoside	S-group
.	O

Vecuronium	S-drug
:	O
When	O
used	O
in	O
the	O
perioperative	O
period	O
,	O
piperacillin	S-drug-EF-1
has	O
been	O
implicated	O
in	O
the	O
prolongation	O
of	O
the	O
neuromuscular	O
blockade	O
of	O
vecuronium	S-drug-EF-2
.	O

Caution	O
is	O
indicated	O
when	O
piperacillin	S-drug
is	O
used	O
perioperatively	O
.	O

In	O
one	O
controlled	O
clinical	O
study	O
,	O
the	O
ureidopenicillins	O
,	O
including	O
piperacillin	S-drug-EF-1
,	O
were	O
reported	O
to	O
prolong	O
the	O
action	O
of	O
vecuronium	S-drug-EF-2
.	O

Due	O
to	O
their	O
similar	O
mechanism	O
of	O
action	O
,	O
it	O
is	O
expected	O
that	O
the	O
neuromuscular	O
blockade	O
produced	O
by	O
any	O
of	O
the	O
non	B-group-EF-1
-	I-group-EF-1
depolarizing	I-group-EF-1
muscle	I-group-EF-1
relaxants	E-group-EF-1
could	O
be	O
prolonged	O
in	O
the	O
presence	O
of	O
piperacillin	S-drug-EF-2
.	O

Probenecid	S-drug
:	O
The	O
oral	O
combination	O
of	O
probenecid	S-drug-ME-1
before	O
intramuscular	O
injection	O
of	O
PIPRACIL	S-brand-ME-2
produces	O
an	O
increase	O
in	O
piperacillin	S-drug
peak	O
serum	O
level	O
of	O
about	O
30	O
%	O
.	O

Anticoagulants	S-group
:	O
Coagulation	O
parameters	O
should	O
be	O
tested	O
more	O
frequently	O
and	O
monitored	O
regularly	O
during	O
simultaneous	O
administration	O
of	O
high	O
doses	O
of	O
heparin	S-drug
,	O
oral	O
anticoagulants	S-group
,	O
or	O
other	O
drugs	O
that	O
may	O
affect	O
the	O
blood	O
coagulation	O
system	O
or	O
the	O
thrombocyte	O
function	O
.	O

Methotrexate	S-drug
:	O
Piperacillin	B-drug-ME-1
sodium	E-drug-ME-1
may	O
reduce	O
the	O
excretion	O
of	O
methotrexate	S-drug-ME-2
.	O

Therefore	O
,	O
serum	O
levels	O
of	O
methotrexate	S-drug
should	O
be	O
monitored	O
in	O
patients	O
to	O
avoid	O
drug	O
toxicity	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
other	O
penicillins	S-drug
,	O
the	O
administration	O
of	O
PIPRACIL	S-brand
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
using	O
a	O
copper	O
-	O
reduction	O
method	O
.	O

It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
be	O
used	O
.	O

There	O
have	O
been	O
reports	O
of	O
positive	O
test	O
results	O
using	O
the	O
Bio	O
-	O
Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
in	O
patients	O
receiving	O
piperacillin	S-drug
/	O
tazobactam	S-drug
injection	O
who	O
were	O
subsequently	O
found	O
to	O
be	O
free	O
of	O
Aspergillus	O
infection	O
.	O

Cross	O
-	O
reactions	O
with	O
non	O
-	O
Aspergillus	O
polysaccharides	O
and	O
polyfuranoses	O
with	O
the	O
Bio	O
-	O
Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
have	O
been	O
reported	O
.	O

Therefore	O
,	O
positive	O
test	O
results	O
in	O
patients	O
receiving	O
piperacillin	S-drug
should	O
be	O
interpreted	O
cautiously	O
and	O
confirmed	O
by	O
other	O
diagnostic	O
methods	O
.	O

Phenothiazines	S-group
-	O
Taking	O
piperazine	S-drug-EF-1
and	O
a	O
phenothiazine	S-group-EF-2
together	O
may	O
increase	O
the	O
risk	O
of	O
convulsions	O
(	O
seizures	O
)	O
.	O

Pyrantel	S-drug
(	O
e.g	O
.	O
,	O
Antiminth	S-drug
)	O
-	O
Taking	O
piperazine	S-drug-EF-1
and	O
pyrantel	S-drug-EF-2
together	O
may	O
decrease	O
the	O
effects	O
of	O
piperazine	S-drug
.	O

ACE	B-group
inhibitors	E-group
:	O
Reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
Angiotensin	B-group-EF-2
Converting	I-group-EF-2
Enzyme	I-group-EF-2
(	I-group-EF-2
ACE	I-group-EF-2
)	I-group-EF-2
inhibitors	E-group-EF-2
.	O

In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
,	O
administration	O
of	O
25	O
mg	O
daily	O
of	O
VIOXX	S-brand-EF-1
with	O
the	O
ACE	B-group
inhibitor	E-group
benazepril	S-drug-EF-2
,	O
10	O
to	O
40	O
mg	O
for	O
4	O
weeks	O
,	O
was	O
associated	O
with	O
an	O
average	O
increase	O
in	O
mean	O
arterial	O
pressure	O
of	O
about	O
3	O
mm	O
Hg	O
compared	O
to	O
ACE	B-group
inhibitor	E-group
alone	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
VIOXX	S-brand-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
inhibitors	E-group-AD-2
.	O

Aspirin	S-brand
:	O
Concomitant	O
administration	O
of	O
low	O
-	O
dose	O
aspirin	S-brand-EF-1
with	O
VIOXX	S-brand-EF-2
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
,	O
compared	O
to	O
use	O
of	O
VIOXX	S-brand
alone	O
.	O

In	O
a	O
12	O
-	O
week	O
endoscopy	O
study	O
conducted	O
in	O
OA	O
patients	O
there	O
was	O
no	O
difference	O
in	O
the	O
cumulative	O
incidence	O
of	O
endoscopic	O
gastroduodenal	O
ulcers	O
in	O
patients	O
taking	O
low	O
-	O
dose	O
(	O
81	O
mg	O
)	O
enteric	O
coated	O
aspirin	S-brand
plus	O
VIOXX	S-brand
25	O
mg	O
daily	O
,	O
as	O
compared	O
to	O
those	O
taking	O
ibuprofen	S-drug
2400	O
mg	O
daily	O
alone	O
.	O

Patients	O
taking	O
low	O
-	O
dose	O
aspirin	S-brand
plus	O
ibuprofen	S-drug
were	O
not	O
studied	O
.	O

At	O
steady	O
state	O
,	O
VIOXX	S-brand
50	O
mg	O
once	O
daily	O
had	O
no	O
effect	O
on	O
the	O
anti	O
-	O
platelet	O
activity	O
of	O
low	O
-	O
dose	O
(	O
81	O
mg	O
once	O
daily	O
)	O
aspirin	S-brand
,	O
as	O
assessed	O
by	O
ex	O
vivo	O
platelet	O
aggregation	O
and	O
serum	O
TXB2	O
generation	O
in	O
clotting	O
blood	O
.	O

Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
,	O
VIOXX	S-brand
is	O
not	O
a	O
substitute	O
for	O
aspirin	S-brand
for	O
cardiovascular	O
prophylaxis	O
.	O

Therefore	O
,	O
in	O
patients	O
taking	O
VIOXX	S-brand
,	O
antiplatelet	O
therapies	O
should	O
not	O
be	O
discontinued	O
and	O
should	O
be	O
considered	O
in	O
patients	O
with	O
an	O
indication	O
for	O
cardiovascular	O
prophylaxis	O
.	O

Prospective	O
,	O
long	O
-	O
term	O
studies	O
on	O
concomitant	O
administration	O
of	O
VIOXX	S-brand
and	O
aspirin	S-brand
have	O
not	O
been	O
conducted	O
.	O

Cimetidine	S-drug
:	O
Co	O
-	O
administration	O
with	O
high	O
doses	O
of	O
cimetidine	S-drug-ME-1
[	O
800	O
mg	O
twice	O
daily	O
]	O
increased	O
the	O
Cmax	O
of	O
rofecoxib	S-drug-ME-2
by	O
21	O
%	O
,	O
the	O
AUC0	O
-	O
120hr	O
by	O
23	O
%	O
and	O
the	O
t1	O
/	O
2	O
by	O
15	O
%	O
.	O

These	O
small	O
changes	O
are	O
not	O
clinically	O
significant	O
and	O
no	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Digoxin	S-drug
:	O
Rofecoxib	S-drug
75	O
mg	O
once	O
daily	O
for	O
11	O
days	O
does	O
not	O
alter	O
the	O
plasma	O
concentration	O
profile	O
or	O
renal	O
elimination	O
of	O
digoxin	S-drug
after	O
a	O
single	O
0.5	O
mg	O
oral	O
dose	O
.	O

Furosemide	S-drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	S-group-EF-1
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	S-drug-EF-2
and	O
thiazides	S-group-EF-2
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

Ketoconazole	S-drug
:	O
Ketoconazole	S-drug
400	O
mg	O
daily	O
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
rofecoxib	S-drug
.	O

Lithium	S-drug
:	O
NSAIDs	S-group-ME-1
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	S-drug-ME-2
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	S-drug
clearance	O
.	O

In	O
post	O
-	O
marketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
increases	O
in	O
plasma	O
lithium	S-drug
levels	O
.	O

Thus	O
,	O
when	O
VIOXX	S-brand-AD-1
and	O
lithium	S-drug-AD-2
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	S-drug
toxicity	O
.	O

Methotrexate	S-drug
VIOXX	S-brand
12.5	O
,	O
25	O
,	O
and	O
50	O
mg	O
,	O
each	O
dose	O
administered	O
once	O
daily	O
for	O
7	O
days	O
,	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
concentration	O
of	O
methotrexate	S-drug
as	O
measured	O
by	O
AUC0	O
-	O
24hr	O
in	O
patients	O
receiving	O
single	O
weekly	O
methotrexate	S-drug
doses	O
of	O
7.5	O
to	O
20	O
mg	O
for	O
rheumatoid	O
arthritis	O
.	O

At	O
higher	O
than	O
recommended	O
doses	O
,	O
VIOXX	S-brand-ME-1
75	O
mg	O
administered	O
once	O
daily	O
for	O
10	O
days	O
increased	O
plasma	O
concentrations	O
by	O
23	O
%	O
as	O
measured	O
by	O
AUC0	O
-	O
24hr	O
in	O
patients	O
receiving	O
methotrexate	S-drug-ME-2
7.5	O
to	O
15	O
mg	O
/	O
week	O
for	O
rheumatoid	O
arthritis	O
.	O

At	O
24	O
hours	O
postdose	O
,	O
a	O
similar	O
proportion	O
of	O
patients	O
treated	O
with	O
methotrexate	S-drug
alone	O
(	O
94	O
%	O
)	O
and	O
subsequently	O
treated	O
with	O
methotrexate	S-drug-ME-1
co	O
-	O
administered	O
with	O
75	O
mg	O
of	O
rofecoxib	S-drug-ME-2
(	O
88	O
%	O
)	O
had	O
methotrexate	S-drug
plasma	O
concentrations	O
below	O
the	O
measurable	O
limit	O
(	O
5	O
ng	O
/	O
mL	O
)	O
.	O

Standard	O
monitoring	O
of	O
methotrexate	S-drug
-	O
related	O
toxicity	O
should	O
be	O
continued	O
if	O
VIOXX	S-brand-AD-1
and	O
methotrexate	S-drug-AD-2
are	O
administered	O
concomitantly	O
.	O

Oral	O
Contraceptives	S-group
Rofecoxib	S-drug
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B-drug
estradiol	E-drug
and	O
norethindrone	S-drug
.	O

Prednisone	S-drug
/	O
prednisolone	S-drug
:	O
Rofecoxib	S-drug
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
prednisolone	S-drug
or	O
prednisone	S-drug
.	O

Rifampin	S-drug
:	O
Co	O
-	O
administration	O
of	O
VIOXX	S-brand-ME-1
with	O
rifampin	S-drug-ME-2
600	O
mg	O
daily	O
,	O
a	O
potent	O
inducer	O
of	O
hepatic	O
metabolism	O
,	O
produced	O
an	O
approximate	O
50	O
%	O
decrease	O
in	O
rofecoxib	S-drug
plasma	O
concentrations	O
.	O

Therefore	O
,	O
a	O
starting	O
daily	O
dose	O
of	O
25	O
mg	O
of	O
VIOXX	S-brand
should	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
when	O
VIOXX	S-brand
is	O
co	O
-	O
administered	O
with	O
potent	O
inducers	O
of	O
hepatic	O
metabolism	O
.	O

Theophylline	S-drug
VIOXX	S-brand-ME-1
12.5	O
,	O
25	O
,	O
and	O
50	O
mg	O
administered	O
once	O
daily	O
for	O
7	O
days	O
increased	O
plasma	O
theophylline	S-drug-ME-2
concentrations	O
(	O
AUC	O
(	O
0	O
-	O
)	O
)	O
by	O
38	O
to	O
60	O
%	O
in	O
healthy	O
subjects	O
administered	O
a	O
single	O
300	O
-	O
mg	O
dose	O
of	O
theophylline	S-drug
.	O

Adequate	O
monitoring	O
of	O
theophylline	S-drug
plasma	O
concentrations	O
should	O
be	O
considered	O
when	O
therapy	O
with	O
VIOXX	S-brand-AD-1
is	O
initiated	O
or	O
changed	O
in	O
patients	O
receiving	O
theophylline	S-drug-AD-2
.	O

These	O
data	O
suggest	O
that	O
rofecoxib	S-drug
may	O
produce	O
a	O
modest	O
inhibition	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
1A2	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
interaction	O
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP	O
1A2	O
(	O
e.g	O
.	O
,	O
amitriptyline	S-drug
,	O
tacrine	S-drug
,	O
and	O
zileuton	S-drug
)	O
.	O

Warfarin	S-drug
:	O
Anticoagulant	O
activity	O
should	O
be	O
monitored	O
,	O
particularly	O
in	O
the	O
first	O
few	O
days	O
after	O
initiating	O
or	O
changing	O
VIOXX	S-brand-AD-1
therapy	O
in	O
patients	O
receiving	O
warfarin	S-drug-AD-2
or	O
similar	O
agents	O
,	O
since	O
these	O
patients	O
are	O
at	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O

In	O
single	O
and	O
multiple	O
dose	O
studies	O
in	O
healthy	O
subjects	O
receiving	O
both	O
warfarin	S-drug-EF-1
and	O
rofecoxib	S-drug-EF-2
,	O
prothrombin	O
time	O
(	O
measured	O
as	O
INR	O
)	O
was	O
increased	O
by	O
approximately	O
8	O
%	O
to	O
11	O
%	O
.	O

In	O
post	O
-	O
marketing	O
experience	O
,	O
bleeding	O
events	O
have	O
been	O
reported	O
,	O
predominantly	O
in	O
the	O
elderly	O
,	O
in	O
association	O
with	O
increases	O
in	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
VIOXX	S-brand-EF-1
concurrently	O
with	O
warfarin	S-drug-EF-2
.	O

DRUG	O
INTERACTIONS	O

Several	O
drug	O
interaction	O
studies	O
have	O
been	O
completed	O
with	O
both	O
INVIRASE	S-brand
and	O
FORTOVASE	S-brand
.	O

Observations	O
from	O
drug	O
interaction	O
studies	O
with	O
FORTOVASE	S-brand
may	O
not	O
be	O
predictive	O
for	O
INVIRASE	S-brand
.	O

Because	O
ritonavir	S-drug
is	O
coadministered	O
,	O
prescribers	O
should	O
also	O
refer	O
to	O
the	O
prescribing	O
information	O
for	O
ritonavir	S-drug
regarding	O
drug	O
interactions	O
associated	O
with	O
this	O
agent	O
.	O

The	O
metabolism	O
of	O
saquinavir	S-drug
is	O
mediated	O
by	O
cytochrome	O
P450	O
,	O
with	O
the	O
specific	O
isoenzyme	O
CYP3A4	O
responsible	O
for	O
90	O
%	O
of	O
the	O
hepatic	O
metabolism	O
.	O

Additionally	O
,	O
saquinavir	S-drug
is	O
a	O
substrate	O
for	O
P	O
-	O
Glycoprotein	O
(	O
Pgp	O
)	O
.	O

Therefore	O
,	O
drugs	O
that	O
affect	O
CYP3A4	O
and	O
/	O
or	O
Pgp	O
,	O
may	O
modify	O
the	O
pharmacokinetics	O
of	O
saquinavir	S-drug
.	O

Similarly	O
,	O
saquinavir	S-drug
might	O
also	O
modify	O
the	O
pharmacokinetics	O
of	O
other	O
drugs	O
that	O
are	O
substrates	O
for	O
CYP3A4	O
or	O
Pgp	O
.	O

Drugs	O
that	O
are	O
contraindicated	O
specifically	O
due	O
to	O
the	O
expected	O
magnitude	O
of	O
interaction	O
and	O
potential	O
for	O
serious	O
adverse	O
events	O
are	O
listed	O
CONTRAINDICATIONS	O
.	O

Additional	O
drugs	O
that	O
are	O
not	O
recommended	O
for	O
coadministration	O
with	O
INVIRASE	S-brand
and	O
ritonavir	S-drug
are	O
included	O
below	O
.	O

These	O
recommendations	O
are	O
based	O
on	O
either	O
drug	O
interaction	O
studies	O
or	O
predicted	O
interactions	O
due	O
to	O
the	O
expected	O
magnitude	O
of	O
interaction	O
and	O
potential	O
for	O
serious	O
events	O
or	O
loss	O
of	O
efficacy	O
.	O

With	O
some	O
agents	O
,	O
the	O
metabolism	O
may	O
be	O
induced	O
,	O
resulting	O
in	O
decreased	O
concentrations	O
.	O

Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
INVIRASE	S-brand
/	O
Ritonavir	S-drug

Drug	O
Class	O
:	O
Drug	O
Name	O
Clinical	O
Comment	O

Antiarrhythmics	S-group
:	O
Amiodarone	S-drug
,	O
bepridil	S-drug
,	O
flecainide	S-drug
,	O
propafenone	S-drug
,	O
quinidine	S-drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
.	O

Antihistamines	S-drug
:	O
astemizole	S-drug
*	O
,	O
terfenadine	S-drug
*	O
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
cardiac	O
arrhythmias	O
.	O

Ergot	B-group
Derivatives	E-group
:	O
Dihydroergotamine	S-drug
,	O
ergonovine	S-drug
,	O
ergotamine	S-drug
,	O
methylergonovine	S-drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
acute	O
ergot	S-group
toxicity	O
characterized	O
by	O
peripheral	O
vasospasm	O
and	O
ischemia	O
of	O
the	O
extremities	O
and	O
other	O
tissues	O
.	O

Antimycobacterial	B-group
Agents	E-group
:	O
rifampin	S-drug
CONTRAINDICATED	O
since	O
the	O
coadministration	O
of	O
this	O
product	O
with	O
saquinavir	S-drug
in	O
an	O
antiretroviral	S-group
regimen	O
reduces	O
the	O
plasma	O
concentrations	O
of	O
saquinavir	S-drug
.	O

Garlic	O
Capsules	O
Garlic	O
capsules	O
should	O
not	O
be	O
used	O
while	O
taking	O
saquinavir	S-drug
(	O
FORTOVASE	S-brand
)	O
as	O
the	O
sole	O
protease	B-group
inhibitor	E-group
due	O
to	O
the	O
risk	O
of	O
decreased	O
saquinavir	S-drug
plasma	O
concentrations	O
.	O

No	O
data	O
are	O
available	O
for	O
the	O
coadministration	O
of	O
INVIRASE	S-brand
/	O
ritonavir	S-drug
or	O
FORTOVASE	S-brand
/	O
ritonavir	S-drug
and	O
garlic	O
capsules	O
.	O

GI	O
Motility	O
Agent	O
:	O
cisapride	S-drug
*	O
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Herbal	O
Products	O
:	O
St.	O
John	O
s	O
wort	O
(	O
hypericum	O
perforatum	O
)	O
WARNING	O
coadministration	O
may	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
INVIRASE	S-brand
or	O
to	O
the	O
class	O
of	O
protease	O
inhibitors	O
.	O

HMG	B-group
-	I-group
CoA	I-group
Reductase	I-group
Inhibitors	E-group
:	O
lovastatin	S-drug
,	O
simvastatin	S-drug
WARNING	O
potential	O
for	O
serious	O
reactions	O
such	O
as	O
risk	O
of	O
myopathy	O
including	O
rhabdomyolysis	O
.	O

Sedatives	S-group
/	O
Hypnotics	S-group
:	O
triazolam	S-drug
,	O
midazolam	S-drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
prolonged	O
or	O
increased	O
sedation	O
or	O
respiratory	O
depression	O
.	O

*	O
No	O
longer	O
marketed	O
in	O
the	O
US	O
.	O

Drugs	O
That	O
Are	O
Mainly	O
Metabolized	O
by	O
CYP3A4	O

Although	O
specific	O
studies	O
have	O
not	O
been	O
performed	O
,	O
coadministration	O
with	O
drugs	O
that	O
are	O
mainly	O
metabolized	O
by	O
CYP3A4	O
(	O
eg	O
,	O
calcium	B-group-ME-1
channel	I-group-ME-1
blockers	E-group-ME-1
,	O
dapsone	S-drug-ME-1
,	O
disopyramide	S-drug-ME-1
,	O
quinine	S-drug-ME-1
,	O
amiodarone	S-drug-ME-1
,	O
quinidine	S-drug-ME-1
,	O
warfarin	S-drug-ME-1
,	O
tacrolimus	S-drug-ME-1
,	O
cyclosporine	S-drug-ME-1
,	O
ergot	B-group-ME-1
derivatives	E-group-ME-1
,	O
pimozide	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
,	O
fentanyl	S-drug-ME-1
,	O
alfentanyl	S-drug-ME-1
,	O
alprazolam	S-drug-ME-1
,	O
and	O
triazolam	S-drug-ME-1
)	O
may	O
have	O
elevated	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
saquinavir	S-drug-ME-2
;	O

therefore	O
,	O
these	O
combinations	O
should	O
be	O
used	O
with	O
caution	O
.	O

Since	O
INVIRASE	S-brand-AD-1
is	O
coadministered	O
with	O
ritonavir	S-drug-AD-2
,	O
the	O
ritonavir	S-drug
label	O
should	O
be	O
reviewed	O
for	O
additional	O
drugs	O
that	O
should	O
not	O
be	O
coadministered	O
.	O

Inducers	O
of	O
CYP3A4	O

Coadministration	O
with	O
compounds	O
that	O
are	O
potent	O
inducers	O
of	O
CYP3A4	O
(	O
eg	O
,	O
phenobarbital	S-drug-ME-1
,	O
phenytoin	S-drug-ME-1
,	O
dexamethasone	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
)	O
may	O
result	O
in	O
decreased	O
plasma	O
levels	O
of	O
saquinavir	S-drug-ME-2
.	O

Sulfacetamide	S-drug-IN-1
preparations	O
are	O
incompatible	O
with	O
silver	S-drug-IN-2
preparations	O
.	O

Sulfapyridine	S-drug-IN-1
may	O
interact	O
with	O
any	O
of	O
the	O
following	O
:	O
-	O
Acetaminophen	S-drug-IN-2
(	O
e.g	O
.	O
,	O
Tylenol	S-brand-IN-2
)	O
(	O
with	O
long	O
-	O
term	O
,	O
high	O
-	O
dose	O
use	O
)	O
or	O

-	O
Amiodarone	S-drug
(	O
e.g	O
.	O
,	O
Cordarone	S-brand
)	O
or	O

-	O
Anabolic	B-group
steroids	E-group
(	O
nandrolone	S-drug
[	O
e.g	O
.	O
,	O
Anabolin	S-brand
]	O
,	O
oxandrolone	S-drug
[	O
e.g	O
.	O
,	O
Anavar	S-brand
]	O
,	O
oxymetholone	S-drug
[	O
e.g	O
.	O
,	O
Anadrol	S-brand
]	O
,	O
stanozolol	S-drug
[	O
e.g	O
.	O
,	O
Winstrol	S-brand
]	O
)	O
or	O

-	O
Androgens	S-group
(	O
male	O
hormones	O
)	O
or	O

-	O
Antithyroid	B-group
agents	E-group
(	O
medicine	O
for	O
overactive	O
thyroid	O
)	O
or	O

-	O
Carbamazepine	S-drug
(	O
e.g	O
.	O
,	O
Tegretol	S-brand
)	O
or	O

-	O
Carmustine	S-drug
(	O
e.g	O
.	O
,	O
BiCNU	S-brand
)	O
or	O

-	O
Chloroquine	S-drug
(	O
e.g	O
.	O
,	O
Aralen	S-brand
)	O
or	O

-	O
Dantrolene	S-drug
(	O
e.g	O
.	O
,	O
Dantrium	S-brand
)	O
or	O

-	O
Daunorubicin	S-drug
(	O
e.g	O
.	O
,	O
Cerubidine	S-brand
)	O
or	O

-	O
Disulfiram	S-drug
(	O
e.g	O
.	O
,	O
Antabuse	S-brand
)	O
or	O

-	O
Divalproex	S-drug
(	O
e.g	O
.	O
,	O
Depakote	S-brand
)	O
or	O

-	O
Estrogens	S-group
(	O
female	O
hormones	O
)	O
or	O

-	O
Etretinate	S-drug
(	O
e.g	O
.	O
,	O
Tegison	S-brand
)	O
or	O

-	O
Gold	S-drug
salts	O
(	O
medicine	O
for	O
arthritis	O
)	O
or	O

-	O
Hydroxychloroquine	S-drug
(	O
e.g	O
.	O
,	O
Plaquenil	S-brand
)	O
or	O

-	O
Mercaptopurine	S-drug
(	O
e.g	O
.	O
,	O
Purinethol	S-brand
)	O
or	O

-	O
Naltrexone	S-drug
(	O
e.g	O
.	O
,	O
Trexan	S-brand
)	O
(	O
with	O
long	O
-	O
term	O
,	O
high	O
-	O
dose	O
use	O
)	O
or	O

-	O
Oral	O
contraceptives	S-group
(	O
birth	O
control	O
pills	O
)	O
containing	O
estrogen	S-group
or	O

-	O
Other	O
anti	B-group
-	I-group
infectives	E-group
by	O
mouth	O
or	O
by	O
injection	O
(	O
medicine	O
for	O
infection	O
)	O
or	O

-	O
Phenothiazines	S-group
(	O
acetophenazine	S-drug
[	O
e.g	O
.	O
,	O
Tindal	S-brand
]	O
,	O
chlorpromazine	S-drug
[	O
e.g	O
.	O
,	O
Thorazine	S-brand
]	O
,	O
fluphenazine	S-drug
[	O
e.g	O
.	O
,	O
Prolixin	S-brand
]	O
,	O
mesoridazine	S-brand
[	O
e.g	O
.	O
,	O
Serentil	S-brand
]	O
,	O
perphenazine	S-drug
[	O
e.g	O
.	O
,	O
Trilafon	S-brand
]	O
,	O
prochlorperazine	S-drug
[	O
e.g	O
.	O
,	O
Compazine	S-brand
]	O
,	O
promazine	S-drug
[	O
e.g	O
.	O
,	O
Sparine	S-brand
]	O
,	O
promethazine	S-drug
[	O
e.g	O
.	O
,	O
Phenergan	S-brand
]	O
,	O
thioridazine	S-drug
[	O
e.g	O
.	O
,	O
Mellaril	S-brand
]	O
,	O
trifluoperazine	S-drug
[	O
e.g	O
.	O
,	O
Stelazine	S-brand
]	O
,	O
triflupromazine	S-drug
[	O
e.g	O
.	O
,	O
Vesprin	S-brand
]	O
,	O
trimeprazine	S-drug
[	O
e.g	O
.	O
,	O
Temaril	S-brand
]	O
)	O
or	O

-	O
Plicamycin	S-drug
(	O
e.g	O
.	O
,	O
Mithracin	S-brand
)	O
or	O

-	O
Valproic	B-drug
acid	E-drug
(	O
e.g	O
.	O
,	O
Depakene	S-brand
)	O
Use	O
of	O
sulfapyridine	S-drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O

-	O
Acetohydroxamic	B-drug
acid	E-drug
(	O
e.g	O
.	O
,	O
Lithostat	S-brand
)	O
or	O

-	O
Dapsone	S-drug
or	O

-	O
Furazolidone	S-drug
(	O
e.g	O
.	O
,	O
Furoxone	S-brand
)	O
or	O

-	O
Nitrofurantoin	S-drug
(	O
e.g	O
.	O
,	O
Furadantin	S-brand
)	O
or	O

-	O
Primaquine	S-drug
or	O

-	O
Procainamide	S-drug
(	O
e.g	O
.	O
,	O
Pronestyl	S-brand
)	O
or	O

-	O
Quinidine	S-drug
(	O
e.g	O
.	O
,	O
Quinidex	S-brand
)	O
or	O

-	O
Quinine	S-drug
(	O
e.g	O
.	O
,	O
Quinamm	S-brand
)	O
or	O

-	O
Sulfoxone	S-drug
(	O
e.g	O
.	O
,	O
Diasone	S-brand
)	O
or	O

-	O
Vitamin	B-group
K	E-group
(	O
e.g	O
.	O
,	O
AquaMEPHYTON	S-brand
,	O
Synkayvite	S-brand
)	O
Use	O
of	O
sulfapyridine	S-drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O

-	O
Anticoagulants	S-group
(	O
blood	B-group
thinners	O
)	O
or	O

-	O
Ethotoin	S-drug
(	O
e.g	O
.	O
,	O
Peganone	S-brand
)	O
or	O

-	O
Mephenytoin	S-drug
(	O
e.g	O
.	O
,	O
Mesantoin	S-brand
)	O
Use	O
of	O
sulfapyridine	S-drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
of	O
these	O
medicines	O

-	O
Antidiabetics	S-group
,	O
oral	O
(	O
diabetes	O
medicine	O
you	O
take	O
by	O
mouth	O
)	O
Use	O
of	O
oral	O
antidiabetics	S-group-EF-1
with	O
sulfapyridine	S-drug-EF-2
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O
and	O
/	O
or	O
the	O
side	O
effects	O
or	O
oral	O
antidiabetics	S-group

-	O
Methotrexate	S-drug
(	O
e.g	O
.	O
,	O
Mexate	S-brand
)	O
Use	O
of	O
methotrexate	S-drug-EF-1
with	O
sulfapyridine	S-drug-EF-2
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
side	O
effects	O
of	O
methotrexate	S-drug

-	O
Methyldopa	S-drug
(	O
e.g	O
.	O
,	O
Aldomet	S-brand
)	O
Use	O
of	O
methyldopa	S-drug-EF-1
with	O
sulfapyridine	S-drug-EF-2
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
blood	O

-	O
Phenytoin	S-drug
(	O
e.g	O
.	O
,	O
Dilantin	S-brand
)	O
Use	O
of	O
phenytoin	S-drug-EF-1
with	O
sulfapyridine	S-drug-EF-2
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
side	O
effects	O
of	O
phenytoin	S-drug

In	O
evaluating	O
the	O
potential	O
for	O
interactions	O
among	O
co	O
-	O
administered	O
antiepilepsy	O
drugs	O
(	O
AEDs	S-group
)	O
,	O
whether	O
or	O
not	O
an	O
AED	S-group
induces	O
or	O
does	O
not	O
induce	O
metabolic	O
enzymes	O
is	O
an	O
important	O
consideration	O
.	O

Phenytoin	S-drug
,	O
phenobarbital	S-drug
and	O
carbamazepine	S-drug
are	O
ge	O
nerally	O
classified	O
as	O
enzyme	O
inducers	O
;	O

valproate	S-drug
and	O
gabapentin	S-drug
are	O
not	O
.	O

GABITRIL	S-brand
is	O
considered	O
to	O
be	O
a	O
non	O
-	O
enzyme	O
inducing	O
AED	S-group
.	O

The	O
drug	O
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
studies	O
involving	O
either	O
healthy	O
subjects	O
or	O
patients	O
with	O
epilepsy	O
.	O

Effects	O
of	O
GABITRIL	S-brand
on	O
other	O
Antiepilepsy	O
Drugs	O
(	O
AEDs	S-group
)	O
:	O
Phenytoin	S-drug
:	O
Tiagabine	S-drug
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
phenytoin	S-drug
in	O
patients	O
with	O
epilepsy	O
.	O

Carbamazepine	S-drug
:	O
Tiagabine	S-drug
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
carbamazepine	S-drug
or	O
its	O
epoxide	O
metabolite	O
in	O
patients	O
with	O
epilepsy	O
.	O

Valproate	S-drug
:	O
Tiagabine	S-drug-ME-1
causes	O
a	O
slight	O
decrease	O
(	O
about	O
10	O
%	O
)	O
in	O
steady	O
-	O
state	O
valproate	S-drug-ME-2
concentrations	O
.	O

Phenobarbital	S-drug
or	O
Primidone	S-drug
:	O
No	O
formal	O
pharmacokinetic	O
studies	O
have	O
been	O
performed	O
examining	O
the	O
addition	O
of	O
tiagabine	S-drug
to	O
regimens	O
containing	O
phenobarbital	S-drug
or	O
primidone	S-drug
.	O

The	O
addition	O
of	O
tiagabine	S-drug
in	O
a	O
limited	O
number	O
of	O
patients	O
in	O
three	O
well	O
-	O
controlled	O
studies	O
caused	O
no	O
systematic	O
changes	O
in	O
phenobarbital	S-drug
or	O
primidone	S-drug
concentrations	O
when	O
compared	O
to	O
placebo	O
.	O

Effects	O
of	O
other	O
Antiepilepsy	O
Drugs	O
(	O
AEDs	S-group
)	O
on	O
GABITRIL	S-brand
:	O
Carbamazepine	S-drug
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	S-drug-ME-1
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
carbamazepine	S-drug-ME-2
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	S-group
.	O

Phenytoin	S-drug
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	S-drug-ME-1
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
phenytoin	S-drug-ME-2
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	S-group
.	O

Phenobarbital	S-drug
(	O
Primidone	S-drug
)	O
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	S-drug-ME-1
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
phenobarbital	S-drug-ME-2
(	O
primidone	S-drug-ME-2
)	O
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	S-group
.	O

Valproate	S-drug
:	O
The	O
addition	O
of	O
tiagabine	S-drug
to	O
patients	O
taking	O
valproate	S-drug
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	S-drug
pharmacokinetics	O
,	O
but	O
valproate	S-drug-ME-1
significantly	O
decreased	O
tiagabine	S-drug-ME-2
binding	O
in	O
vitro	O
from	O
96.3	O
to	O
94.8	O
%	O
,	O
which	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
40	O
%	O
in	O
the	O
free	O
tiagabine	O
concentration	O
.	O

The	O
clinical	O
relevance	O
of	O
this	O
in	O
vitro	O
finding	O
is	O
unknown	O
.	O

Interaction	O
of	O
GABITRIL	S-brand
with	O
Other	O
Drugs	O
:	O
Cimetidine	S-drug
:	O
Co	O
-	O
administration	O
of	O
cimetidine	S-drug
(	O
800	O
mg	O
/	O
day	O
)	O
to	O
patients	O
taking	O
tiagabine	S-drug
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	S-drug
pharmacokinetics	O
.	O

Theophylline	S-drug
:	O
A	O
single	O
10	O
mg	O
dose	O
of	O
tiagabine	S-drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	S-drug
at	O
steady	O
state	O
.	O

Warfarin	S-drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
R	B-drug
-	I-drug
warfarin	E-drug
or	O
S	B-drug
-	I-drug
warfarin	E-drug
with	O
the	O
addition	O
of	O
tiagabine	S-drug
given	O
as	O
a	O
single	O
dose	O
.	O

Prothrombin	O
times	O
were	O
not	O
affected	O
by	O
tiagabine	S-drug
.	O

Digoxin	S-drug
:	O
Concomitant	O
administration	O
of	O
tiagabine	S-drug
did	O
not	O
affect	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
digoxin	S-drug
or	O
the	O
mean	O
daily	O
trough	O
serum	O
level	O
of	O
digoxin	S-drug
.	O

Ethanol	S-drug
or	O
Triazolam	S-drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
pharmacokinetics	O
of	O
triazolam	S-drug
(	O
0.125	O
mg	O
)	O
and	O
tiagabine	S-drug
(	O
10	O
mg	O
)	O
when	O
given	O
together	O
as	O
a	O
single	O
dose	O
.	O

The	O
pharmacokinetics	O
of	O
ethanol	S-drug
were	O
not	O
affected	O
by	O
multiple	O
-	O
dose	O
administration	O
of	O
tiagabine	S-drug
.	O

Tiagabine	S-drug
has	O
shown	O
no	O
clinically	O
important	O
potentiation	O
of	O
the	O
pharmacodynamic	O
effects	O
of	O
triazo	O
lam	O
or	O
alcohol	S-drug
.	O

Because	O
of	O
the	O
possible	O
additive	O
effects	O
of	O
drugs	O
that	O
may	O
depress	O
the	O
nervous	O
system	O
,	O
ethanol	S-drug-AD-1
or	O
triazolam	S-drug-AD-1
should	O
be	O
used	O
cautiously	O
in	O
combination	O
with	O
tiagabine	S-drug-AD-2
.	O

Oral	O
Contraceptives	S-group
:	O
Multiple	O
dose	O
administration	O
of	O
tiagabine	S-drug
(	O
8	O
mg	O
/	O
day	O
monotherapy	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
oral	O
contraceptives	S-group
in	O
healthy	O
women	O
of	O
childbearing	O
age	O
.	O

Antipyrine	S-drug
:	O
Antipyrine	S-drug
pharmacokinetics	O
were	O
not	O
significantly	O
different	O
before	O
and	O
after	O
tiagabine	S-drug
multiple	O
-	O
dose	O
regimens	O
.	O

This	O
indicates	O
that	O
tiagabine	S-drug
does	O
not	O
cause	O
induction	O
or	O
inhibition	O
of	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
responsible	O
for	O
the	O
metabolism	O
of	O
antipyrine	S-drug
.	O

Interaction	O
of	O
GABITRIL	S-brand
with	O
Highly	O
Protein	O
Bound	O
Drugs	O
:	O
In	O
vitro	O
data	O
showed	O
that	O
tiagabine	S-drug
is	O
96	O
%	O
bound	O
to	O
human	O
plasma	O
protein	O
and	O
therefore	O
has	O
the	O
potential	O
to	O
interact	O
with	O
other	O
highly	O
protein	O
bound	O
compounds	O
.	O

Such	O
an	O
interaction	O
can	O
potentially	O
lead	O
to	O
higher	O
free	O
fractions	O
of	O
either	O
tiagabine	S-drug
or	O
the	O
competing	O
drug	O
.	O

The	O
drug	O
interaction	O
studies	O
with	O
valdecoxib	S-drug
were	O
performed	O
both	O
with	O
valdecoxib	S-drug
and	O
a	O
rapidly	O
hydrolyzed	O
intravenous	O
prodrug	O
form	O
.	O

The	O
results	O
from	O
trials	O
using	O
the	O
intravenous	O
prodrug	O
are	O
reported	O
in	O
this	O
section	O
as	O
they	O
relate	O
to	O
the	O
role	O
of	O
valdecoxib	S-drug
in	O
drug	O
interactions	O
.	O

General	O
:	O
In	O
humans	O
,	O
valdecoxib	S-drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
CYP	O
3A4	O
and	O
2C9	O
with	O
glucuronidation	O
being	O
a	O
further	O
(	O
20	O
%	O
)	O
route	O
of	O
metabolism	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
valdecoxib	S-drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP	O
2C19	O
(	O
IC50	O
=	O
6	O
g	O
/	O
mL	O
or	O
19	O
M	O
)	O
and	O
2C9	O
(	O
IC50	O
=	O
13	O
g	O
/	O
mL	O
or	O
41	O
M	O
)	O
,	O
and	O
a	O
weak	O
inhibitor	O
of	O
CYP	O
2D6	O
(	O
IC50	O
=	O
31	O
g	O
/	O
mL	O
or	O
100	O
M	O
)	O
and	O
3A4	O
(	O
IC50	O
=	O
44	O
g	O
/	O
mL	O
or	O
141	O
M	O
)	O
..	O

Aspirin	S-brand
:	O
Concomitant	O
administration	O
of	O
aspirin	S-brand-EF-1
with	O
valdecoxib	S-drug-EF-2
may	O
result	O
in	O
an	O
increased	O
risk	O
of	O
GI	O
ulceration	O
and	O
complications	O
compared	O
to	O
valdecoxib	S-drug
alone	O
.	O

Because	O
of	O
its	O
lack	O
of	O
anti	O
-	O
platelet	O
effect	O
valdecoxib	S-drug
is	O
not	O
a	O
substitute	O
for	O
aspirin	S-brand
for	O
cardiovascular	O
prophylaxis	O
.	O

In	O
a	O
parallel	O
group	O
drug	O
interaction	O
study	O
comparing	O
the	O
intravenous	O
prodrug	O
form	O
of	O
valdecoxib	S-drug
at	O
40	O
mg	O
BID	O
(	O
n	O
=	O
10	O
)	O
vs	O
placebo	O
(	O
n	O
=	O
9	O
)	O
,	O
valdecoxib	S-drug
had	O
no	O
effect	O
on	O
in	O
vitro	O
aspirin	S-brand
-	O
mediated	O
inhibition	O
of	O
arachidonate	O
-	O
or	O
collagen	O
-	O
stimulated	O
platelet	O
aggregation	O
.	O

Methotrexate	S-drug
:	O
Valdecoxib	B-drug
10	I-drug
mg	E-drug
BID	O
did	O
not	O
show	O
a	O
significant	O
effect	O
on	O
the	O
plasma	O
exposure	O
or	O
renal	O
clearance	O
of	O
methotrexate	S-drug
.	O

ACE	B-group
-	I-group
inhibitors	E-group
:	O
Reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-group-EF-2
-	I-group-EF-2
inhibitors	E-group-EF-2
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
BEXTRA	S-brand-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
-	I-group-AD-2
inhibitors	E-group-AD-2
.	O

Furosemide	S-drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	S-group-EF-1
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	S-drug-EF-2
and	O
thiazides	S-group-EF-2
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

Anticonvulsants	S-group
(	O
Phenytoin	S-drug
)	O
:	O
Steady	O
state	O
plasma	O
exposure	O
(	O
AUC	O
)	O
of	O
valdecoxib	S-drug-ME-1
(	O
40	O
mg	O
BID	O
for	O
12	O
days	O
)	O
was	O
decreased	O
by	O
27	O
%	O
when	O
co	O
-	O
administered	O
with	O
multiple	O
doses	O
(	O
300	O
mg	O
QD	O
for	O
12	O
days	O
)	O
of	O
phenytoin	S-drug-ME-2
(	O
a	O
CYP	O
3A4	O
inducer	O
)	O
.	O

Patients	O
already	O
stabilized	O
on	O
valdecoxib	S-drug-AD-1
should	O
be	O
closely	O
monitored	O
for	O
loss	O
of	O
symptom	O
control	O
with	O
phenytoin	S-drug-AD-2
coadministration	O
.	O

Valdecoxib	S-drug
did	O
not	O
have	O
a	O
statistically	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
phenytoin	S-drug
(	O
a	O
CYP	O
2C9	O
and	O
CYP	O
2C19	O
substrate	O
)	O
.	O

Drug	O
interaction	O
studies	O
with	O
other	O
anticonvulsants	S-group
have	O
not	O
been	O
conducted	O
.	O

Routine	O
monitoring	O
should	O
be	O
performed	O
when	O
therapy	O
with	O
BEXTRA	S-brand
is	O
either	O
initiated	O
or	O
discontinued	O
in	O
patients	O
on	O
anticonvulsant	O
therapy	O
.	O

Dextromethorphan	S-drug
:	O
Dextromethorphan	S-drug
is	O
primarily	O
metabolized	O
by	O
CYP	O
2D6	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
3A4	O
.	O

Coadministration	O
with	O
valdecoxib	S-drug-ME-1
(	O
40	O
mg	O
BID	O
for	O
7	O
days	O
)	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
dextromethorphan	S-drug-ME-2
plasma	O
levels	O
suggesting	O
that	O
,	O
at	O
these	O
doses	O
,	O
valdecoxib	S-drug
is	O
a	O
weak	O
inhibitor	O
of	O
2D6	O
.	O

Even	O
so	O
dextromethorphan	S-drug-ME-1
plasma	O
concentrations	O
in	O
the	O
presence	O
of	O
high	O
doses	O
of	O
valdecoxib	S-drug-ME-2
were	O
almost	O
5	O
-	O
fold	O
lower	O
than	O
those	O
seen	O
in	O
CYP	O
2D6	O
poor	O
metabolizers	O
suggesting	O
that	O
dose	O
adjustment	O
is	O
not	O
necessary	O
.	O

Lithium	S-drug
:	O
Valdecoxib	S-drug-ME-1
40	O
mg	O
BID	O
for	O
7	O
days	O
produced	O
significant	O
decreases	O
in	O
lithium	S-drug-ME-2
serum	O
clearance	O
(	O
25	O
%	O
)	O
and	O
renal	O
clearance	O
(	O
30	O
%	O
)	O
with	O
a	O
34	O
%	O
higher	O
serum	O
exposure	O
compared	O
to	O
lithium	S-drug
alone	O
.	O

Lithium	S-drug
serum	O
concentrations	O
should	O
be	O
monitored	O
closely	O
when	O
initiating	O
or	O
changing	O
therapy	O
with	O
BEXTRA	S-brand-AD-1
in	O
patients	O
receiving	O
lithium	S-drug-AD-2
.	O

Lithium	B-drug
carbonate	E-drug
(	O
450	O
mg	O
BID	O
for	O
7	O
days	O
)	O
had	O
no	O
effect	O
on	O
valdecoxib	S-drug
pharmacokinetics	O
.	O

Warfarin	S-drug
:	O
The	O
effect	O
of	O
valdecoxib	S-drug
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	S-drug
(	O
1	O
-	O
8	O
mg	O
/	O
day	O
)	O
was	O
studied	O
in	O
healthy	O
subjects	O
by	O
coadministration	O
of	O
BEXTRA	S-brand
40	O
mg	O
BID	O
for	O
7	O
days	O
.	O

Valdecoxib	S-drug-MU-1
caused	O
a	O
statistically	O
significant	O
increase	O
in	O
plasma	O
exposures	O
of	O
R	B-drug-ME-2
-	I-drug-ME-2
warfarin	E-drug-ME-2
and	O
S	B-drug-ME-2
-	I-drug-ME-2
warfarin	E-drug-ME-2
(	O
12	O
%	O
and	O
15	O
%	O
,	O
respectively	O
)	O
,	O
and	O
in	O
the	O
pharmacodynamic	O
effects	O
(	O
prothrombin	O
time	O
,	O
measured	O
as	O
INR	O
)	O
of	O
warfarin	S-drug-EF-2
.	O

While	O
mean	O
INR	O
values	O
were	O
only	O
slightly	O
increased	O
with	O
coadministration	O
of	O
valdecoxib	S-drug
,	O
the	O
day	O
-	O
to	O
-	O
day	O
variability	O
in	O
individual	O
INR	O
values	O
was	O
increased	O
.	O

Anticoagulant	S-brand
therapy	O
should	O
be	O
monitored	O
,	O
particularly	O
during	O
the	O
first	O
few	O
weeks	O
,	O
after	O
initiating	O
therapy	O
with	O
BEXTRA	S-brand-AD-1
in	O
patients	O
receiving	O
warfarin	S-drug-AD-2
or	O
similar	O
agents	O
.	O

Fluconazole	S-drug
and	O
Ketoconazole	S-drug
:	O
Ketoconazole	S-drug
and	O
fluconazole	S-drug
are	O
predominantly	O
CYP	O
3A4	O
and	O
2C9	O
inhibitors	O
,	O
respectively	O
.	O

Concomitant	O
single	O
dose	O
administration	O
of	O
valdecoxib	S-drug-ME-1
20	O
mg	O
with	O
multiple	O
doses	O
of	O
ketoconazole	S-drug-ME-2
and	O
fluconazole	S-drug-ME-2
produced	O
a	O
significant	O
increase	O
in	O
exposure	O
of	O
valdecoxib	S-drug
.	O

Plasma	O
exposure	O
(	O
AUC	O
)	O
to	O
valdecoxib	S-drug-ME-1
was	O
increased	O
62	O
%	O
when	O
coadministered	O
with	O
fluconazole	S-drug-ME-2
and	O
38	O
%	O
when	O
coadministered	O
with	O
ketoconazole	S-drug-ME-2
.	O

Glyburide	S-drug
:	O
Glyburide	S-drug
is	O
a	O
CYP	O
2C9	O
substrate	O
.	O

Coadministration	O
of	O
valdecoxib	S-drug
(	O
10	O
mg	O
BID	O
for	O
7	O
days	O
)	O
with	O
glyburide	S-drug
(	O
5	O
mg	O
QD	O
or	O
10	O
mg	O
BID	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
of	O
glyburide	S-drug
.	O

Coadministration	O
of	O
valdecoxib	S-drug
(	O
40	O
mg	O
BID	O
(	O
day	O
1	O
)	O
and	O
40	O
mg	O
QD	O
(	O
days	O
2	O
-	O
7	O
)	O
)	O
with	O
glyburide	S-drug
(	O
5	O
mg	O
QD	O
)	O
did	O
not	O
affect	O
either	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
or	O
the	O
pharmacodynamics	O
(	O
blood	O
glucose	O
and	O
insulin	O
levels	O
)	O
of	O
glyburide	S-drug
.	O

Coadministration	O
of	O
valdecoxib	S-drug-ME-1
(	O
40	O
mg	O
BID	O
(	O
day	O
1	O
)	O
and	O
40	O
mg	O
QD	O
(	O
days	O
2	O
-	O
7	O
)	O
)	O
with	O
glyburide	S-drug-ME-2
(	O
10	O
mg	O
glyburide	S-drug
BID	O
)	O
resulted	O
in	O
21	O
%	O
increase	O
in	O
glyburide	S-drug
AUC0	O
-	O
12	O
and	O
a	O
16	O
%	O
increase	O
in	O
glyburide	S-drug
Cmax	O
leading	O
to	O
a	O
16	O
%	O
decrease	O
in	O
glucose	O
AUC0	O
-	O
24	O
.	O

Insulin	O
parameters	O
were	O
not	O
affected	O
.	O

Because	O
changes	O
in	O
glucose	O
concentrations	O
with	O
valdecoxib	S-drug
coadministration	O
were	O
within	O
the	O
normal	O
variability	O
and	O
individual	O
glucose	O
concentrations	O
were	O
above	O
or	O
near	O
70	O
mg	O
/	O
dL	O
,	O
dose	O
adjustment	O
for	O
glyburide	S-drug-AD-1
(	O
5	O
mg	O
QD	O
and	O
10	O
mg	O
BID	O
)	O
with	O
valdecoxib	S-drug-AD-2
coadministration	O
(	O
up	O
to	O
40	O
mg	O
QD	O
)	O
is	O
not	O
indicated	O
.	O

Coadministration	O
of	O
glyburide	S-drug
with	O
doses	O
higher	O
than	O
40	O
mg	O
valdecoxib	S-drug
(	O
e.g	O
.	O
,	O
40	O
mg	O
BID	O
)	O
have	O
not	O
been	O
studied	O
.	O

Omeprazole	S-drug
:	O
Omeprazole	S-drug
is	O
a	O
CYP	O
3A4	O
substrate	O
and	O
CYP	O
2C19	O
substrate	O
and	O
inhibitor	O
.	O

Valdecoxib	S-drug
steady	O
state	O
plasma	O
concentrations	O
(	O
40	O
mg	O
BID	O
)	O
were	O
not	O
affected	O
significantly	O
with	O
multiple	O
doses	O
of	O
omeprazole	S-drug
(	O
40	O
mg	O
QD	O
)	O
.	O

Coadministration	O
with	O
valdecoxib	S-drug-ME-1
increased	O
exposure	O
of	O
omeprazole	S-drug-ME-2
(	O
AUC	O
)	O
by	O
46	O
%	O
.	O

Drugs	O
whose	O
absorption	O
is	O
sensitive	O
to	O
pH	O
may	O
be	O
negatively	O
impacted	O
by	O
concomitant	O
administration	O
of	O
omeprazole	S-drug
and	O
valdecoxib	S-drug
.	O

However	O
,	O
because	O
higher	O
doses	O
(	O
up	O
to	O
360	O
mg	O
QD	O
)	O
of	O
omeprazole	S-drug
are	O
tolerated	O
in	O
Zollinger	O
-	O
Ellison	O
(	O
ZE	O
)	O
patients	O
,	O
no	O
dose	O
adjustment	O
for	O
omeprazole	S-drug
is	O
recommended	O
at	O
current	O
doses	O
.	O

Coadministration	O
of	O
valdecoxib	S-drug
with	O
doses	O
higher	O
than	O
40	O
mg	O
QD	O
omeprazole	S-drug
has	O
not	O
been	O
studied	O
.	O

Oral	O
Contraceptives	S-group
:	O
Valdecoxib	S-drug
(	O
40	O
mg	O
BID	O
)	O
did	O
not	O
induce	O
the	O
metabolism	O
of	O
the	O
combination	O
oral	O
contraceptive	S-group
norethindrone	S-drug
/	O
ethinyl	B-drug
estradiol	E-drug
(	O
1	O
mg	O
/	O
35	O
mcg	O
combination	O
,	O
Ortho	B-brand
-	I-brand
Novum	E-brand
1	O
/	O
35	O
)	O
.	O

Coadministration	O
of	O
valdecoxib	S-drug-ME-1
and	O
Ortho	B-brand-ME-2
-	I-brand-ME-2
Novum	E-brand-ME-2
1	O
/	O
35	O
increased	O
the	O
exposure	O
of	O
norethindrone	S-drug
and	O
ethinyl	B-drug
estradiol	E-drug
by	O
20	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

Although	O
there	O
is	O
little	O
risk	O
for	O
loss	O
of	O
contraceptive	O
efficacy	O
,	O
the	O
clinical	O
significance	O
of	O
these	O
increased	O
exposures	O
in	O
terms	O
of	O
safety	O
is	O
not	O
known	O
.	O

These	O
increased	O
exposures	O
of	O
norethindrone	S-drug
and	O
ethinyl	B-drug
estradiol	E-drug
should	O
be	O
taken	O
into	O
consideration	O
when	O
selecting	O
an	O
oral	O
contraceptive	S-group-AD-1
for	O
women	O
taking	O
valdecoxib	S-drug-AD-2
.	O

Diazepam	S-drug
:	O
Diazepam	S-drug
(	O
Valium	S-brand
)	O
is	O
a	O
CYP	O
3A4	O
and	O
CYP	O
2C19	O
substrate	O
.	O

Plasma	O
exposure	O
of	O
diazepam	S-drug-ME-1
(	O
10	O
mg	O
BID	O
)	O
was	O
increased	O
by	O
28	O
%	O
following	O
administration	O
of	O
valdecoxib	S-drug-ME-2
(	O
40	O
mg	O
BID	O
)	O
for	O
12	O
days	O
,	O
while	O
plasma	O
exposure	O
of	O
valdecoxib	S-drug
(	O
40	O
mg	O
BID	O
)	O
was	O
not	O
substantially	O
increased	O
following	O
administration	O
of	O
diazepam	S-drug
(	O
10	O
mg	O
BID	O
)	O
for	O
12	O
days	O
.	O

Although	O
the	O
magnitude	O
of	O
changes	O
in	O
diazepam	S-drug
plasma	O
exposure	O
when	O
coadministered	O
with	O
valdecoxib	S-drug-EF-1
were	O
not	O
sufficient	O
to	O
warrant	O
dosage	O
adjustments	O
,	O
patients	O
may	O
experience	O
enhanced	O
sedative	O
side	O
effects	O
caused	O
by	O
increased	O
exposure	O
of	O
diazepam	S-drug-EF-2
under	O
this	O
circumstance	O
.	O

Patients	O
should	O
be	O
cautioned	O
against	O
engaging	O
in	O
hazardous	O
activities	O
requiring	O
complete	O
mental	O
alertness	O
such	O
as	O
operating	O
machinery	O
or	O
driving	O
a	O
motor	O
vehicle	O
.	O

Effect	O
of	O
other	O
drugs	O
on	O
Vardenafil	S-drug

In	O
vitro	O
studies	O
:	O
Studies	O
in	O
human	O
liver	O
microsomes	O
showed	O
that	O
vardenafil	S-drug
is	O
metabolized	O
primarily	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
isoforms	O
3A4	O
/	O
5	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
by	O
CYP2C9	O
.	O

Therefore	O
,	O
inhibitors	O
of	O
these	O
enzymes	O
are	O
expected	O
to	O
reduce	O
vardenafil	S-drug
clearance	O
.	O

In	O
vivo	O
studies	O
:	O
Cytochrome	O
P450	O
Inhibitors	O

Cimetidine	S-drug
(	O
400	O
mg	O
b.i.d	O
.	O
)	O
had	O
no	O
effect	O
on	O
vardenafil	S-drug
bioavailability	O
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
vardenafil	S-drug
when	O
co	O
-	O
administered	O
with	O
20	O
mg	O
Vardenafil	S-drug
in	O
healthy	O
volunteers	O
.	O

Erythromycin	S-drug-ME-1
(	O
500	O
mg	O
t.i.d	O
)	O
produced	O
a	O
4	O
-	O
fold	O
increase	O
in	O
vardenafil	S-drug-ME-2
AUC	O
and	O
a	O
3	O
-	O
fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	S-drug
5	O
mg	O
in	O
healthy	O
volunteers	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
5	O
mg	O
dose	O
of	O
Vardenafil	S-drug-AD-1
in	O
a	O
24	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
erythromycin	S-drug-AD-2
.	O

Ketoconazole	S-drug-ME-1
(	O
200	O
mg	O
once	O
daily	O
)	O
produced	O
a	O
10	O
-	O
fold	O
increase	O
in	O
vardenafil	S-drug-ME-2
AUC	O
and	O
a	O
4	O
-	O
fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	S-drug
(	O
5	O
mg	O
)	O
in	O
healthy	O
volunteers	O
.	O

A	O
5	O
-	O
mg	O
Vardenafil	S-drug-AD-1
dose	O
should	O
not	O
be	O
exceeded	O
when	O
used	O
in	O
combination	O
with	O
200	O
mg	O
once	O
daily	O
ketoconazole	S-drug-AD-2
.	O

Since	O
higher	O
doses	O
of	O
ketoconazole	S-drug
(	O
400	O
mg	O
daily	O
)	O
may	O
result	O
in	O
higher	O
increases	O
in	O
Cmax	O
and	O
AUC	O
,	O
a	O
single	O
2.5	O
mg	O
dose	O
of	O
Vardenafil	S-drug-AD-1
should	O
not	O
be	O
exceeded	O
in	O
a	O
24	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ketoconazole	S-drug-AD-2
400	O
mg	O
daily	O
.	O

HIV	B-group
Protease	I-group
Inhibitors	E-group
:	O
Indinavir	S-drug-ME-1
(	O
800	O
mg	O
t.i.d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	S-drug-ME-2
10	O
mg	O
resulted	O
in	O
a	O
16	O
-	O
fold	O
increase	O
in	O
vardenafil	S-drug
AUC	O
,	O
a	O
7	O
-	O
fold	O
increase	O
in	O
vardenafil	S-drug
Cmax	O
and	O
a	O
2	O
-	O
fold	O
increase	O
in	O
vardenafil	S-drug
half	O
-	O
life	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2.5	O
mg	O
Vardenafil	S-drug-AD-1
dose	O
in	O
a	O
24	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
indinavir	S-drug-AD-2
.	O

Ritonavir	S-drug-ME-1
(	O
600	O
mg	O
b.i.d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	S-drug-ME-2
5	O
mg	O
resulted	O
in	O
a	O
49	O
-	O
fold	O
increase	O
in	O
vardenafil	S-drug
AUC	O
and	O
a	O
13	O
-	O
fold	O
increase	O
in	O
vardenafil	S-drug
Cmax	O
.	O

The	O
interaction	O
is	O
a	O
consequence	O
of	O
blocking	O
hepatic	O
metabolism	O
of	O
vardenafil	S-drug-ME-1
by	O
ritonavir	S-drug-ME-2
,	O
a	O
highly	O
potent	O
CYP3A4	O
inhibitor	O
,	O
which	O
also	O
inhibits	O
CYP2C9	O
.	O

Ritonavir	S-drug-ME-1
significantly	O
prolonged	O
the	O
half	O
-	O
life	O
of	O
vardenafil	S-drug-ME-2
to	O
26	O
hours	O
.	O

Consequently	O
,	O
it	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2.5	O
mg	O
Vardenafil	S-drug-AD-1
dose	O
in	O
a	O
72	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ritonavir	S-drug-AD-2
.	O

Other	O
Drug	O
Interactions	O
:	O
No	O
pharmacokinetic	O
interactions	O
were	O
observed	O
between	O
vardenafil	S-drug
and	O
the	O
following	O
drugs	O
:	O
glyburide	S-drug
,	O
warfarin	S-drug
,	O
digoxin	S-drug
,	O
Maalox	S-brand
,	O
and	O
ranitidine	S-drug
.	O

In	O
the	O
warfarin	S-drug
study	O
,	O
vardenafil	S-drug
had	O
no	O
effect	O
on	O
the	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
.	O

Effects	O
of	O
Vardenafil	S-drug
on	O
other	O
drugs	O

In	O
vitro	O
studies	O
:	O
Vardenafil	S-drug
and	O
its	O
metabolites	O
had	O
no	O
effect	O
on	O
CYP1A2	O
,	O
2A6	O
,	O
and	O
2E1	O
(	O
Ki	O
100uM	O
)	O
.	O

Weak	O
inhibitory	O
effects	O
toward	O
other	O
isoforms	O
(	O
CYP2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
3A4	O
)	O
were	O
found	O
,	O
but	O
Ki	O
values	O
were	O
in	O
excess	O
of	O
plasma	O
concentrations	O
achieved	O
following	O
dosing	O
.	O

The	O
most	O
potent	O
inhibitory	O
activity	O
was	O
observed	O
for	O
vardenafil	O
metabolite	O
M1	O
,	O
which	O
had	O
a	O
Ki	O
of	O
1.4	O
uM	O
toward	O
CYP3A4	O
,	O
which	O
is	O
about	O
20	O
times	O
higher	O
than	O
the	O
M1	O
Cmax	O
values	O
after	O
an	O
80	O
mg	O
Vardenafil	S-drug
dose	O
.	O

In	O
vivo	O
studies	O
:	O
Nitrates	S-group
:	O
The	O
blood	O
pressure	O
lowering	O
effects	O
of	O
sublingual	O
nitrates	S-group-ME-1
(	O
0.4	O
mg	O
)	O
taken	O
1	O
and	O
4	O
hours	O
after	O
vardenafil	S-drug-ME-2
and	O
increases	O
in	O
heart	O
rate	O
when	O
taken	O
at	O
1	O
,	O
4	O
and	O
8	O
hours	O
were	O
potentiated	O
by	O
a	O
20	O
mg	O
dose	O
of	O
Vardenafil	S-drug
in	O
healthy	O
middle	O
-	O
aged	O
subjects	O
.	O

These	O
effects	O
were	O
not	O
observed	O
when	O
Vardenafil	S-drug
20	O
mg	O
was	O
taken	O
24	O
hours	O
before	O
the	O
NTG	S-drug
.	O

Potentiation	O
of	O
the	O
hypotensive	O
effects	O
of	O
nitrates	S-group
for	O
patients	O
with	O
ischemic	O
heart	O
disease	O
has	O
not	O
been	O
evaluated	O
,	O
and	O
concomitant	O
use	O
of	O
Vardenafil	S-drug-AD-1
and	O
nitrates	S-group-AD-2
is	O
contraindicated	O
.	O

Nifedipine	S-drug
:	O
Vardenafil	S-drug
20	O
mg	O
,	O
when	O
co	O
-	O
administered	O
with	O
slow	O
-	O
release	O
nifedipine	S-drug
30	O
mg	O
or	O
60	O
mg	O
once	O
daily	O
,	O
did	O
not	O
affect	O
the	O
relative	O
bioavailability	O
(	O
AUC	O
)	O
or	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
nifedipine	S-drug
,	O
a	O
drug	O
that	O
is	O
metabolized	O
via	O
CYP3A4	O
.	O

Nifedipine	S-drug
did	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
Vardenafil	S-drug
when	O
taken	O
in	O
combination	O
.	O

In	O
these	O
patients	O
whose	O
hypertension	O
was	O
controlled	O
with	O
nifedipine	S-drug-EF-1
,	O
Vardenafil	S-drug-EF-2
20	O
mg	O
produced	O
mean	O
additional	O
supine	O
systolic	O
/	O
diastolic	O
blood	O
pressure	O
reductions	O
of	O
6	O
/	O
5	O
mm	O
Hg	O
compared	O
to	O
placebo	O
.	O

Alpha	B-group
-	I-group
blockers	E-group
:	O
When	O
Vardenafil	S-drug-EF-1
10	O
or	O
20	O
mg	O
was	O
given	O
to	O
healthy	O
volunteers	O
either	O
simultaneously	O
or	O
6	O
hours	O
after	O
a	O
10	O
mg	O
dose	O
of	O
terazosin	S-drug-EF-2
,	O
significant	O
hypotension	O
developed	O
in	O
a	O
substantial	O
number	O
of	O
subjects	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	S-drug-EF-1
10	O
mg	O
and	O
terazosin	S-drug-EF-2
10	O
mg	O
,	O
6	O
of	O
8	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	S-drug-EF-1
20	O
mg	O
and	O
terazosin	S-drug-EF-2
10	O
mg	O
,	O
2	O
of	O
9	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

When	O
Vardenafil	S-drug-EF-1
dosing	O
was	O
separated	O
from	O
terazosin	S-drug-EF-2
10	O
mg	O
by	O
6	O
hours	O
,	O
7	O
of	O
28	O
subjects	O
who	O
received	O
20	O
mg	O
of	O
Vardenafil	S-drug
experienced	O
a	O
decrease	O
in	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

In	O
a	O
similar	O
study	O
with	O
tamsulosin	S-drug
in	O
healthy	O
volunteers	O
,	O
1	O
of	O
24	O
subjects	O
dosed	O
with	O
Vardenafil	S-drug-EF-1
20	O
mg	O
and	O
tamsulosin	S-drug-EF-2
0.4	O
mg	O
separated	O
by	O
6	O
hours	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

Two	O
of	O
16	O
subjects	O
dosed	O
simultaneously	O
with	O
Vardenafil	S-drug-EF-1
10	O
mg	O
and	O
tamsulosin	S-drug-EF-2
0.4	O
mg	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

The	O
administration	O
of	O
lower	O
doses	O
of	O
Vardenafil	S-drug
with	O
alpha	B-group
-	I-group
blockers	E-group
has	O
not	O
been	O
completely	O
evaluated	O
to	O
determine	O
if	O
they	O
can	O
be	O
safely	O
administered	O
together	O
.	O

Based	O
on	O
these	O
data	O
,	O
Vardenafil	S-drug-AD-1
should	O
not	O
be	O
used	O
in	O
patients	O
on	O
alpha	B-group-AD-2
-	I-group-AD-2
blocker	E-group-AD-2
therapy	O
.	O

Ritonavir	S-drug
and	O
indinavir	S-drug
:	O
Upon	O
concomitant	O
administration	O
of	O
5	O
mg	O
of	O
Vardenafil	S-drug-ME-1
with	O
600	O
mg	O
BID	O
ritonavir	S-drug-ME-2
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
ritonavir	S-drug
were	O
reduced	O
by	O
approximately	O
20	O
%	O
.	O

Upon	O
administration	O
of	O
10	O
mg	O
of	O
Vardenafil	S-drug-ME-1
with	O
800	O
mg	O
TID	O
indinavir	S-drug-ME-2
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
indinavir	S-drug
were	O
reduced	O
by	O
40	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O

Alcohol	S-drug
:	O
Alcohol	S-drug
(	O
0.5	O
g	O
/	O
kg	O
body	O
weight	O
:	O
approximately	O
40	O
mL	O
of	O
absolute	O
alcohol	O
in	O
a	O
70	O
kg	O
person	O
)	O
and	O
vardenafil	S-drug
plasma	O
levels	O
were	O
not	O
altered	O
when	O
dosed	O
simultaneously	O
.	O

Vardenafil	S-drug
(	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
alcohol	S-drug
during	O
the	O
4	O
-	O
hour	O
observation	O
period	O
in	O
healthy	O
volunteers	O
when	O
administered	O
with	O
alcohol	S-drug
(	O
0.5	O
g	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Aspirin	S-brand
:	O
Vardenafil	S-drug
(	O
10	O
mg	O
and	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
increase	O
in	O
bleeding	O
time	O
caused	O
by	O
aspirin	S-brand
(	O
two	O
81	O
mg	O
tablets	O
)	O
.	O

Other	O
interactions	O
:	O
Vardenafil	S-drug
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
glyburide	S-drug
(	O
glucose	O
and	O
insulin	O
concentrations	O
)	O
and	O
warfarin	S-drug
(	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
)	O
.	O

Zidovudine	S-drug
:	O
There	O
is	O
no	O
significant	O
pharmacokinetic	O
interaction	O
between	O
ZDV	S-drug
and	O
zalcitabine	S-drug
which	O
has	O
been	O
confirmed	O
clinically	O
.	O

Zalcitabine	S-drug-EF-1
also	O
has	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
ZDV	S-drug-EF-2
,	O
as	O
shown	O
in	O
vitro	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
in	O
two	O
other	O
cell	O
lines	O
(	O
U937	O
and	O
Molt	O
-	O
4	O
)	O
.	O

In	O
the	O
same	O
study	O
it	O
was	O
shown	O
that	O
didanosine	S-drug
and	O
stavudine	S-drug
had	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	S-drug
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Lamivudine	S-drug
:	O
In	O
vitro	O
studies	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
U937	O
and	O
Molt	O
-	O
4	O
cells	O
revealed	O
that	O
lamivudine	S-drug-EF-1
significantly	O
inhibited	O
zalcitabine	S-drug-EF-2
phosphorylation	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

Effects	O
were	O
already	O
seen	O
with	O
doses	O
corresponding	O
to	O
relevant	O
plasma	O
levels	O
in	O
humans	O
,	O
and	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	S-drug
to	O
its	O
three	O
metabolites	O
(	O
including	O
the	O
active	O
zalcitabine	O
triphosphate	O
metabolite	O
)	O
was	O
significantly	O
inhibited	O
.	O

Zalcitabine	S-drug-EF-1
inhibited	O
lamivudine	S-drug-EF-2
phosphorylation	O
at	O
high	O
concentration	O
ratios	O
(	O
10	O
and	O
100	O
)	O
;	O

however	O
,	O
it	O
is	O
considered	O
to	O
be	O
unlikely	O
that	O
this	O
decrease	O
of	O
phosphorylated	O
lamivudine	S-drug
concentration	O
is	O
of	O
clinical	O
significance	O
,	O
as	O
lamivudine	S-drug
is	O
a	O
more	O
efficient	O
substrate	O
for	O
deoxycytidine	O
kinase	O
than	O
zalcitabine	S-drug
.	O

These	O
in	O
vitro	O
studies	O
suggest	O
that	O
concomitant	O
administration	O
of	O
zalcitabine	S-drug-EF-1
and	O
lamivudine	S-drug-EF-2
in	O
humans	O
may	O
result	O
in	O
sub	O
-	O
therapeutic	O
concentrations	O
of	O
active	O
phosphorylated	O
zalcitabine	S-drug
,	O
which	O
may	O
lead	O
to	O
a	O
decreased	O
antiretroviral	S-group
effect	O
of	O
zalcitabine	S-drug
.	O

It	O
is	O
unknown	O
how	O
the	O
effect	O
seen	O
in	O
these	O
in	O
vitro	O
studies	O
translates	O
into	O
clinical	O
consequences	O
.	O

Concomitant	O
use	O
of	O
zalcitabine	S-drug-AD-1
and	O
lamivudine	S-drug-AD-2
is	O
not	O
recommended	O
.	O

Saquinavir	S-drug
:	O
The	O
combination	O
of	O
HIVID	S-drug
,	O
saquinavir	S-drug
,	O
and	O
ZDV	S-drug
has	O
been	O
studied	O
(	O
as	O
triple	O
combination	O
)	O
in	O
adults	O
.	O

Pharmacokinetic	O
data	O
suggest	O
that	O
absorption	O
,	O
metabolism	O
,	O
and	O
elimination	O
of	O
each	O
of	O
these	O
drugs	O
are	O
unchanged	O
when	O
they	O
are	O
used	O
together	O
.	O

Drugs	O
Associated	O
With	O
Peripheral	O
Neuropathy	O
:	O
The	O
concomitant	O
use	O
of	O
HIVID	S-drug
with	O
drugs	O
that	O
have	O
the	O
potential	O
to	O
cause	O
peripheral	O
neuropathy	O
should	O
be	O
avoided	O
where	O
possible	O
.	O

Drugs	O
that	O
have	O
been	O
associated	O
with	O
peripheral	O
neuropathy	O
include	O
antiretroviral	B-drug
nucleoside	I-drug
analogues	E-drug
,	O
chloramphenicol	S-drug
,	O
cisplatin	S-drug
,	O
dapsone	S-drug
,	O
disulfiram	S-drug
,	O
ethionamide	S-drug
,	O
glutethimide	S-drug
,	O
gold	S-drug
,	O
hydralazine	S-drug
,	O
iodoquinol	S-drug
,	O
isoniazid	S-drug
,	O
metronidazole	S-drug
,	O
nitrofurantoin	S-drug
,	O
phenytoin	S-drug
,	O
ribavirin	S-drug
,	O
and	O
vincristine	S-drug
.	O

Concomitant	O
use	O
of	O
HIVID	S-drug-AD-1
with	O
didanosine	S-drug-AD-2
is	O
not	O
recommended	O
.	O

Intravenous	O
Pentamidine	S-drug
:	O
Treatment	O
with	O
HIVID	S-drug
should	O
be	O
interrupted	O
when	O
the	O
use	O
of	O
a	O
drug	O
that	O
has	O
the	O
potential	O
to	O
cause	O
pancreatitis	O
is	O
required	O
.	O

Death	O
due	O
to	O
fulminant	O
pancreatitis	O
possibly	O
related	O
to	O
intravenous	O
pentamidine	S-drug-EF-1
and	O
HIVID	S-drug-EF-2
has	O
been	O
reported	O
.	O

If	O
intravenous	O
pentamidine	S-drug-AD-1
is	O
required	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
,	O
treatment	O
with	O
HIVID	S-drug-AD-2
should	O
be	O
interrupted	O
.	O

Amphotericin	S-drug
,	O
Foscarnet	S-drug
,	O
and	O
Aminoglycosides	S-group
:	O
Drugs	O
such	O
as	O
amphotericin	S-drug-MU-1
,	O
foscarnet	S-drug-MU-1
,	O
and	O
aminoglycosides	S-group-MU-1
may	O
increase	O
the	O
risk	O
of	O
developing	O
peripheral	O
neuropathy	O
or	O
other	O
HIVID	S-drug-EF-2
-	O
associated	O
adverse	O
events	O
by	O
interfering	O
with	O
the	O
renal	O
clearance	O
of	O
zalcitabine	S-drug-ME-2
(	O
thereby	O
raising	O
systemic	O
exposure	O
)	O
.	O

Patients	O
who	O
require	O
the	O
use	O
of	O
one	O
of	O
these	O
drugs	O
with	O
HIVID	S-drug
should	O
have	O
frequent	O
clinical	O
and	O
laboratory	O
monitoring	O
with	O
dosage	O
adjustment	O
for	O
any	O
significant	O
change	O
in	O
renal	O
function	O
.	O

Probenecid	S-drug
or	O
Cimetidine	S-drug
:	O
Concomitant	O
administration	O
of	O
probenecid	S-drug-ME-1
or	O
cimetidine	S-drug-ME-1
decreases	O
the	O
elimination	O
of	O
zalcitabine	S-drug-ME-2
,	O
most	O
likely	O
by	O
inhibition	O
of	O
renal	O
tubular	O
secretion	O
of	O
zalcitabine	S-drug
.	O

Patients	O
receiving	O
these	O
drugs	O
in	O
combination	O
with	O
zalcitabine	S-drug
should	O
be	O
monitored	O
for	O
signs	O
of	O
toxicity	O
and	O
the	O
dose	O
of	O
zalcitabine	S-drug
reduced	O
if	O
warranted	O
.	O

Magnesium	S-drug
/	O
Aluminum	S-drug
-	O
containing	O
Antacid	B-group
Products	E-group
:	O
Absorption	O
of	O
zalcitabine	S-drug
is	O
moderately	O
reduced	O
(	O
approximately	O
25	O
%	O
)	O
when	O
coadministered	O
with	O
magnesium	S-drug
/	O
aluminum	S-drug
-	O
containing	O
antacid	B-group
products	E-group
.	O

The	O
clinical	O
significance	O
of	O
this	O
reduction	O
is	O
not	O
known	O
,	O
hence	O
zalcitabine	S-drug-AD-1
is	O
not	O
recommended	O
to	O
be	O
ingested	O
simultaneously	O
with	O
magnesium	S-drug-AD-2
/	O
aluminum	S-drug-AD-2
-	O
containing	O
antacids	S-group-AD-2
.	O

Metoclopramide	S-drug
:	O
Bioavailability	O
is	O
mildly	O
reduced	O
(	O
approximately	O
10	O
%	O
)	O
when	O
zalcitabine	S-drug-ME-1
and	O
metoclopramide	S-drug-ME-2
are	O
coadministered	O
.	O

Doxorubicin	S-drug
:	O
Doxorubicin	S-drug-EF-1
caused	O
a	O
decrease	O
in	O
zalcitabine	S-drug-EF-2
phosphorylation	O
(	O
50	O
%	O
inhibition	O
of	O
total	O
phosphate	O
formation	O
)	O
in	O
U937	O
/	O
Molt	O
4	O
cells	O
.	O

Although	O
there	O
may	O
be	O
decreased	O
zalcitabine	S-drug
activity	O
because	O
of	O
lessened	O
active	O
metabolite	O
formation	O
,	O
the	O
clinical	O
relevance	O
of	O
these	O
in	O
vitro	O
results	O
are	O
not	O
known	O
.	O

As	O
with	O
all	O
drugs	O
,	O
the	O
potential	O
exists	O
for	O
interaction	O
with	O
other	O
drugs	O
by	O
a	O
variety	O
of	O
mechanisms	O
.	O

CNS	O
-	O
Active	O
Drugs	O
Ethanol	S-drug
:	O
Sonata	S-brand-EF-1
10	O
mg	O
potentiated	O
the	O
CNS	O
-	O
impairing	O
effects	O
of	O
ethanol	S-drug-EF-2
0.75	O
g	O
/	O
kg	O
on	O
balance	O
testing	O
and	O
reaction	O
time	O
for	O
1	O
hour	O
after	O
ethanol	S-drug
administration	O
and	O
on	O
the	O
digit	O
symbol	O
substitution	O
test	O
(	O
DSST	O
)	O
,	O
symbol	O
copying	O
test	O
,	O
and	O
the	O
variability	O
component	O
of	O
the	O
divided	O
attention	O
test	O
for	O
2.5	O
hours	O
after	O
ethanol	S-drug
administration	O
.	O

The	O
potentiation	O
resulted	O
from	O
a	O
CNS	O
pharmacodynamic	O
interaction	O
;	O

zaleplon	S-drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
ethanol	S-drug
.	O

Imipramine	S-drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	S-brand-EF-1
20	O
mg	O
and	O
imipramine	S-drug-EF-2
75	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
2	O
to	O
4	O
hours	O
after	O
administration	O
.	O

The	O
interaction	O
was	O
pharmacodynamic	O
with	O
no	O
alteration	O
of	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O

Paroxetine	S-drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
Sonata	S-brand
20	O
mg	O
and	O
paroxetine	S-drug
20	O
mg	O
daily	O
for	O
7	O
days	O
did	O
not	O
produce	O
any	O
interaction	O
on	O
psychomotor	O
performance	O
.	O

Additionally	O
,	O
paroxetine	S-drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
Sonata	S-brand
,	O
reflecting	O
the	O
absence	O
of	O
a	O
role	O
of	O
CYP2D6	O
in	O
zaleplon	S-drug
s	O
metabolism	O
.	O

Thioridazine	S-drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	S-brand-EF-1
20	O
mg	O
and	O
thioridazine	S-drug-EF-2
50	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
2	O
to	O
4	O
hours	O
after	O
administration	O
.	O

The	O
interaction	O
was	O
pharmacodynamic	O
with	O
no	O
alteration	O
of	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O

Venlafaxine	S-drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	S-drug
10	O
mg	O
and	O
multiple	O
doses	O
of	O
venlafaxine	S-drug
ER	O
(	O
extended	O
release	O
)	O
150	O
mg	O
did	O
not	O
result	O
in	O
any	O
significant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
zaleplon	S-drug
or	O
venlafaxine	S-drug
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
as	O
a	O
result	O
of	O
coadministration	O
of	O
zaleplon	S-drug
and	O
venlafaxine	S-drug
ER	O
.	O

Promethazine	S-drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	S-drug-ME-1
and	O
promethazine	S-drug-ME-2
(	O
10	O
and	O
25	O
mg	O
,	O
respectively	O
)	O
resulted	O
in	O
a	O
15	O
%	O
decrease	O
in	O
maximal	O
plasma	O
concentrations	O
of	O
zaleplon	S-drug
,	O
but	O
no	O
change	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
.	O

However	O
,	O
the	O
pharmacodynamics	O
of	O
coadministration	O
of	O
zaleplon	S-drug
and	O
promethazine	S-drug
have	O
not	O
been	O
evaluated	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
these	O
2	O
agents	O
are	O
coadministered	O
.	O

Drugs	O
That	O
Induce	O
CYP3A4	O
Rifampin	S-drug
:	O
CYP3A4	O
is	O
ordinarily	O
a	O
minor	O
metabolizing	O
enzyme	O
of	O
zaleplon	S-drug
.	O

Multiple	O
-	O
dose	O
administration	O
of	O
the	O
potent	O
CYP3A4	O
inducer	O
rifampin	S-drug-ME-1
(	O
600	O
mg	O
every	O
24	O
hours	O
,	O
q24h	O
,	O
for	O
14	O
days	O
)	O
,	O
however	O
,	O
reduced	O
zaleplon	S-drug-ME-2
Cmax	O
and	O
AUC	O
by	O
approximately	O
80	O
%	O
.	O

The	O
coadministration	O
of	O
a	O
potent	O
CYP3A4	O
enzyme	O
inducer	O
,	O
although	O
not	O
posing	O
a	O
safety	O
concern	O
,	O
thus	O
could	O
lead	O
to	O
ineffectiveness	O
of	O
zaleplon	S-drug
.	O

An	O
alternative	O
non	O
-	O
CYP3A4	O
substrate	O
hypnotic	B-group
agent	E-group
may	O
be	O
considered	O
in	O
patients	O
taking	O
CYP3A4	O
inducers	O
such	O
as	O
rifampin	S-drug
,	O
phenytoin	S-drug
,	O
carbamazepine	S-drug
,	O
and	O
phenobarbital	S-drug
.	O

Drugs	O
That	O
Inhibit	O
CYP3A4	O
CYP3A4	O
is	O
a	O
minor	O
metabolic	O
pathway	O
for	O
the	O
elimination	O
of	O
zaleplon	S-drug
because	O
the	O
sum	O
of	O
desethylzaleplon	O
(	O
formed	O
via	O
CYP3A4	O
in	O
vitro	O
)	O
and	O
its	O
metabolites	O
,	O
5	B-drug_n
-	I-drug_n
oxo	I-drug_n
-	I-drug_n
desethylzaleplon	E-drug_n
and	O
5	B-drug_n
-	I-drug_n
oxo	I-drug_n
-	I-drug_n
desethylzaleplon	I-drug_n
glucuronide	E-drug_n
,	O
account	O
for	O
only	O
9	O
%	O
of	O
the	O
urinary	O
recovery	O
of	O
a	O
zaleplon	S-drug
dose	O
.	O

Coadministration	O
of	O
single	O
,	O
oral	O
doses	O
of	O
zaleplon	S-drug-ME-1
with	O
erythromycin	S-drug-ME-2
(	O
10	O
mg	O
and	O
800	O
mg	O
,	O
respectively	O
)	O
,	O
a	O
strong	O
,	O
selective	O
CYP3A4	O
inhibitor	O
produced	O
a	O
34	O
%	O
increase	O
in	O
zaleplons	O
maximal	O
plasma	O
concentrations	O
and	O
a	O
20	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
.	O

The	O
magnitude	O
of	O
interaction	O
with	O
multiple	O
doses	O
of	O
erythromycin	S-drug
is	O
unknown	O
.	O

Other	O
strong	O
selective	O
CYP3A4	O
inhibitors	O
such	O
as	O
ketoconazole	S-drug-ME-1
can	O
also	O
be	O
expected	O
to	O
increase	O
the	O
exposure	O
of	O
zaleplon	S-drug-ME-2
.	O

A	O
routine	O
dosage	O
adjustment	O
of	O
zaleplon	S-drug
is	O
not	O
considered	O
necessary	O
.	O

Drugs	O
That	O
Inhibit	O
Aldehyde	O
Oxidase	O
The	O
aldehyde	O
oxidase	O
enzyme	O
system	O
is	O
less	O
well	O
studied	O
than	O
the	O
cytochrome	O
P450	O
enzyme	O
system	O
.	O

Diphenhydramine	S-drug
:	O
Diphenhydramine	S-drug
is	O
reported	O
to	O
be	O
a	O
weak	O
inhibitor	O
of	O
aldehyde	O
oxidase	O
in	O
rat	O
liver	O
,	O
but	O
its	O
inhibitory	O
effects	O
in	O
human	O
liver	O
are	O
not	O
known	O
.	O

There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	S-drug
and	O
diphenhydramine	S-drug
following	O
the	O
administration	O
of	O
a	O
single	O
dose	O
(	O
10	O
mg	O
and	O
50	O
mg	O
,	O
respectively	O
)	O
of	O
each	O
drug	O
.	O

However	O
,	O
because	O
both	O
of	O
these	O
compounds	O
have	O
CNS	O
effects	O
,	O
an	O
additive	O
pharmacodynamic	O
effect	O
is	O
possible	O
.	O

Drugs	O
That	O
Inhibit	O
Both	O
Aldehyde	O
Oxidase	O
and	O
CYP3A4	O
Cimetidine	S-drug
:	O
Cimetidine	S-drug-ME-1
inhibits	O
both	O
aldehyde	O
oxidase	O
(	O
in	O
vitro	O
)	O
and	O
CYP3A4	O
(	O
in	O
vitro	O
and	O
in	O
vivo	O
)	O
,	O
the	O
primary	O
and	O
secondary	O
enzymes	O
,	O
respectively	O
,	O
responsible	O
for	O
zaleplon	S-drug-ME-2
metabolism	O
.	O

Concomitant	O
administration	O
of	O
Sonata	S-brand-ME-1
(	O
10	O
mg	O
)	O
and	O
cimetidine	S-drug-ME-2
(	O
800	O
mg	O
)	O
produced	O
an	O
85	O
%	O
increase	O
in	O
the	O
mean	O
Cmax	O
and	O
AUC	O
of	O
zaleplon	S-drug
.	O

An	O
initial	O
dose	O
of	O
5	O
mg	O
should	O
be	O
given	O
to	O
patients	O
who	O
are	O
concomitantly	O
being	O
treated	O
with	O
cimetidine	S-drug
.	O

Drugs	O
Highly	O
Bound	O
to	O
Plasma	O
Protein	O
Zaleplon	S-drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
fraction	O
bound	O
60	O
%	O
15	O
%	O
)	O
;	O

therefore	O
,	O
the	O
disposition	O
of	O
zaleplon	S-drug
is	O
not	O
expected	O
to	O
be	O
sensitive	O
to	O
alterations	O
in	O
protein	O
binding	O
.	O

In	O
addition	O
,	O
administration	O
of	O
Sonata	S-brand
to	O
a	O
patient	O
taking	O
another	O
drug	O
that	O
is	O
highly	O
protein	O
bound	O
should	O
not	O
cause	O
transient	O
increase	O
in	O
free	O
concentrations	O
of	O
the	O
other	O
drug	O
.	O

Drugs	O
with	O
a	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	S-drug
:	O
Sonata	S-brand
(	O
10	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetic	O
or	O
pharmacodynamic	O
profile	O
of	O
digoxin	S-drug
(	O
0.375	O
mg	O
q24h	O
for	O
8	O
days	O
)	O
.	O

Warfarin	S-drug
:	O
Multiple	O
oral	O
doses	O
of	O
Sonata	S-brand
(	O
20	O
mg	O
q24h	O
for	O
13	O
days	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	S-drug
(	O
R	O
+	O
)	O
-	O
or	O
(	O
S	O
-	O
)	O
-	O
enantiomers	O
or	O
the	O
pharmacodynamics	O
(	O
prothrombin	O
time	O
)	O
following	O
a	O
single	O
25	O
-	O
mg	O
oral	O
dose	O
of	O
warfarin	S-drug
.	O

Drugs	O
That	O
Alter	O
Renal	O
Excretion	O
Ibuprofen	S-drug
:	O
Ibuprofen	S-drug
is	O
known	O
to	O
affect	O
renal	O
function	O
and	O
,	O
consequently	O
,	O
alter	O
the	O
renal	O
excretion	O
of	O
other	O
drugs	O
.	O

There	O
was	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	S-drug
and	O
ibuprofen	S-drug
following	O
single	O
dose	O
administration	O
(	O
10	O
mg	O
and	O
600	O
mg	O
,	O
respectively	O
)	O
of	O
each	O
drug	O
.	O

This	O
was	O
expected	O
because	O
zaleplon	S-drug
is	O
primarily	O
metabolized	O
and	O
renal	O
excretion	O
of	O
unchanged	O
zaleplon	S-drug
accounts	O
for	O
less	O
than	O
1	O
%	O
of	O
the	O
administered	O
dose	O
.	O

The	O
fluoroquinolones	S-group
for	O
urinary	O
tract	O
infections	O
:	O
a	O
review	O
.	O

The	O
fluoroquinolones	S-group
are	O
a	O
rapidly	O
growing	O
class	O
of	O
antibiotics	S-group
with	O
a	O
broad	O
spectrum	O
of	O
activity	O
against	O
gram	O
-	O
negative	O
and	O
some	O
gram	O
-	O
positive	O
aerobic	O
bacteria	O
.	O

These	O
agents	O
,	O
including	O
norfloxacin	S-drug
,	O
ciprofloxacin	S-drug
,	O
ofloxacin	S-drug
,	O
enoxacin	S-drug
,	O
and	O
lomefloxacin	S-drug
,	O
have	O
been	O
extensively	O
studied	O
and	O
have	O
demonstrated	O
efficacy	O
and	O
safety	O
profiles	O
comparable	O
to	O
those	O
of	O
other	O
traditional	O
agents	O
for	O
the	O
treatment	O
of	O
complicated	O
or	O
uncomplicated	O
urinary	O
tract	O
infections	O
and	O
prostatitis	O
.	O

Advantages	O
offered	O
by	O
this	O
class	O
of	O
antibiotics	S-group
include	O
optimal	O
pharmacokinetics	O
,	O
effectiveness	O
against	O
multidrug	O
-	O
resistant	O
organisms	O
,	O
and	O
oral	O
administration	O
even	O
when	O
parenteral	O
antibiotics	S-drug
are	O
generally	O
used	O
.	O

The	O
fluoroquinolones	S-group
are	O
also	O
extensively	O
used	O
in	O
urologic	O
surgery	O
.	O

Progestin	O
-	O
only	O
oral	O
contraception	O
:	O
a	O
comprehensive	O
review	O
.	O

In	O
order	O
to	O
provide	O
information	O
for	O
the	O
appropriate	O
package	O
insert	O
labeling	O
of	O
progestin	B-group
-	I-group
only	I-group
oral	I-group
contraceptives	E-group
(	O
POC	S-group
)	O
in	O
the	O
US	O
,	O
a	O
comprehensive	O
review	O
was	O
made	O
of	O
norgestrel	S-drug
(	O
0.075	O
mg	O
)	O
and	O
norethindrone	S-drug
(	O
0.35	O
mg	O
)	O
,	O
with	O
the	O
clinical	O
differences	O
indicated	O
where	O
applicable	O
.	O

The	O
goal	O
of	O
this	O
review	O
was	O
to	O
cite	O
primary	O
sources	O
for	O
virtually	O
all	O
research	O
specific	O
to	O
POPs	O
since	O
1975	O
.	O

Conclusions	O
and	O
the	O
types	O
of	O
studies	O
which	O
support	O
these	O
conclusions	O
are	O
given	O
for	O
each	O
major	O
section	O
.	O

The	O
introductory	O
chapter	O
discusses	O
the	O
advantages	O
and	O
disadvantages	O
of	O
POCs	S-group
and	O
the	O
magnitude	O
and	O
prevalence	O
of	O
their	O
use	O
.	O

Future	O
trends	O
are	O
also	O
predicted	O
.	O

Chapter	O
2	O
considers	O
the	O
mode	O
of	O
action	O
,	O
including	O
ovulation	O
prevention	O
;	O

suppression	O
of	O
midcycle	O
gonadotropin	O
peaks	O
;	O

changes	O
in	O
cervical	O
mucus	O
,	O
the	O
endometrium	O
,	O
and	O
the	O
fallopian	O
tubes	O
;	O

and	O
clinical	O
implications	O
.	O

Chapter	O
3	O
covers	O
pharmacology	O
(	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
potency	O
,	O
and	O
clinical	O
implications	O
)	O
.	O

The	O
next	O
chapter	O
presents	O
information	O
on	O
efficacy	O
and	O
pregnancy	O
outcomes	O
in	O
terms	O
of	O
pregnancy	O
rates	O
,	O
compliance	O
and	O
efficacy	O
,	O
ectopic	O
pregnancies	O
,	O
the	O
outcome	O
of	O
pregnancies	O
conceived	O
while	O
using	O
POCs	S-group
,	O
and	O
fertility	O
following	O
discontinuation	O
.	O

Chapter	O
5	O
focuses	O
on	O
metabolic	O
effects	O
,	O
specifically	O
lipid	O
metabolism	O
,	O
carbohydrate	O
metabolism	O
and	O
diabetes	O
,	O
coagulation	O
factors	O
,	O
and	O
blood	O
pressure	O
.	O

Cardiovascular	O
disease	O
is	O
considered	O
in	O
the	O
next	O
chapter	O
,	O
and	O
chapter	O
7	O
presents	O
findings	O
on	O
endometrial	O
,	O
ovarian	O
,	O
cervical	O
,	O
breast	O
,	O
and	O
other	O
cancers	O
.	O

A	O
host	O
of	O
other	O
medical	O
considerations	O
are	O
discussed	O
in	O
chapter	O
8	O
,	O
including	O
persistent	O
ovarian	O
follicles	O
;	O

reproductive	O
tract	O
infections	O
;	O

abnormal	O
vaginal	O
bleeding	O
;	O

uterine	O
fibroids	O
;	O

gestational	O
trophoblastic	O
disease	O
;	O

benign	O
breast	O
disease	O
;	O

diseases	O
of	O
the	O
liver	O
,	O
gallbladder	O
,	O
and	O
bowel	O
;	O

endocrine	O
dysfunction	O
;	O

epilepsy	O
;	O

bone	O
density	O
;	O

sickle	O
cell	O
disease	O
;	O

ocular	O
effects	O
;	O

surgery	O
;	O

and	O
overdose	O
.	O

The	O
last	O
4	O
chapters	O
cover	O
interactions	O
with	O
drugs	O
and	O
laboratory	O
tests	O
,	O
common	O
side	O
effects	O
,	O
breast	O
feeding	O
,	O
and	O
effective	O
use	O
of	O
POCs	S-group
.	O

Information	O
on	O
precautions	O
and	O
contraindications	O
,	O
indications	O
,	O
use	O
instructions	O
,	O
and	O
instructions	O
for	O
appropriate	O
actions	O
after	O
missing	O
a	O
pill	O
is	O
appended	O
.	O

Antimicrobial	O
activity	O
of	O
Ganoderma	B-drug_n
lucidum	I-drug_n
extract	E-drug_n
alone	O
and	O
in	O
combination	O
with	O
some	O
antibiotics	S-group
.	O

Antimicrobial	O
activity	O
of	O
GL	S-drug_n
(	O
the	O
aqueous	O
extract	O
from	O
the	O
carpophores	O
of	O
Ganoderma	O
lucidum	O
(	O
FR	O
)	O
KARST	O
)	O
was	O
tested	O
in	O
vitro	O
against	O
Gram	O
positive	O
and	O
Gram	O
negative	O
bacteria	O
by	O
serial	O
broth	O
dilution	O
method	O
,	O
and	O
the	O
antimicrobial	O
activity	O
was	O
expressed	O
by	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
.	O

Among	O
fifteen	O
species	O
of	O
bacteria	O
tested	O
,	O
the	O
antimicrobial	O
activity	O
of	O
GL	S-drug_n
was	O
the	O
most	O
potent	O
against	O
Micrococcus	O
luteus	O
(	O
MIC	O
,	O
0.75	O
mg	O
/	O
ml	O
)	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
antimicrobial	O
combinations	O
of	O
GL	S-drug_n
with	O
four	O
kinds	O
of	O
antibiotics	S-group
(	O
ampicillin	S-drug
,	O
cefazolin	S-drug
,	O
oxytetracycline	S-drug
and	O
chloramphenicol	S-drug
)	O
,	O
the	O
fractional	O
inhibitory	O
concentration	O
index	O
(	O
FICI	O
)	O
was	O
determined	O
by	O
checkerboard	O
assay	O
for	O
each	O
strain	O
.	O

The	O
antimicrobial	O
combinations	O
of	O
GL	S-drug_n-EF-1
with	O
four	O
antibiotics	S-group-EF-2
resulted	O
in	O
additive	O
effect	O
in	O
most	O
instances	O
,	O
synergism	O
in	O
two	O
instances	O
,	O
and	O
antagonism	O
in	O
two	O
instances	O
.	O

Synergism	O
was	O
observed	O
when	O
GL	S-drug_n-EF-1
was	O
combined	O
with	O
cefazolin	S-drug-EF-2
against	O
Bacillus	O
subtilis	O
and	O
Klebsiella	O
oxytoca	O
.	O

Death	O
in	O
amphetamine	S-drug
users	O
:	O
causes	O
and	O
rates	O
.	O

The	O
world	O
medical	O
literature	O
contains	O
43	O
reports	O
of	O
deaths	O
associated	O
with	O
amphetamines	S-drug
in	O
a	O
35	O
-	O
year	O
period	O
.	O

These	O
included	O
seven	O
cerebrovascular	O
accidents	O
,	O
six	O
sudden	O
cardiac	O
deaths	O
,	O
three	O
cases	O
of	O
hyperpyrexia	O
,	O
eight	O
poisonings	O
of	O
uncertain	O
mechanism	O
and	O
seven	O
cases	O
of	O
medical	O
complications	O
of	O
intravenous	O
injection	O
;	O

the	O
remainder	O
were	O
of	O
uncertain	O
cause	O
.	O

In	O
contrast	O
,	O
in	O
Ontario	O
alone	O
,	O
in	O
1972	O
and	O
1973	O
there	O
were	O
26	O
deaths	O
in	O
amphetamine	S-drug
users	O
,	O
of	O
which	O
16	O
were	O
due	O
to	O
accident	O
suicide	O
or	O
homicide	O
.	O

Of	O
the	O
remaining	O
cases	O
,	O
two	O
were	O
cardiac	O
,	O
two	O
hepatic	O
and	O
the	O
rest	O
were	O
mixed	O
drug	O
overdose	O
.	O

Pulmonary	O
granulomata	O
,	O
subacute	O
hepatitis	O
and	O
other	O
lesions	O
resulting	O
from	O
intravenous	O
drug	O
use	O
were	O
common	O
findings	O
at	O
autopsy	O
.	O

On	O
the	O
basis	O
of	O
the	O
estimated	O
number	O
of	O
regular	O
users	O
of	O
intravenous	O
amphetamine	S-drug
in	O
Ontario	O
,	O
the	O
mortality	O
rate	O
in	O
such	O
users	O
is	O
at	O
least	O
four	O
times	O
as	O
high	O
as	O
in	O
the	O
general	O
population	O
of	O
the	O
same	O
age	O
,	O
and	O
is	O
comparable	O
to	O
that	O
in	O
alcoholics	O
and	O
heroin	S-drug_n
addicts	O
.	O

However	O
,	O
the	O
absolute	O
number	O
of	O
alcohol	S-drug
-	O
related	O
deaths	O
is	O
far	O
greater	O
than	O
the	O
number	O
of	O
deaths	O
in	O
amphetamine	S-drug
or	O
heroin	S-drug_n
users	O
.	O

Ascorbic	B-drug
acid	E-drug
and	O
the	O
common	O
cold	O
.	O

Evaluation	O
of	O
its	O
efficacy	O
and	O
toxicity	O
.	O

We	O
reviewed	O
the	O
clinical	O
data	O
relating	O
to	O
the	O
efficacy	O
and	O
safety	O
of	O
pharmacologic	O
doses	O
of	O
ascorbic	B-drug
acid	E-drug
in	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
common	O
cold	O
.	O

Although	O
one	O
study	O
tentatively	O
supports	O
the	O
hypothesis	O
that	O
such	O
doses	O
of	O
ascorbic	B-drug
acid	E-drug
may	O
be	O
efficacious	O
,	O
a	O
second	O
study	O
by	O
the	O
same	O
group	O
did	O
not	O
confirm	O
the	O
significant	O
findings	O
,	O
and	O
no	O
clear	O
,	O
reproducible	O
pattern	O
of	O
efficacy	O
has	O
emerged	O
from	O
the	O
review	O
of	O
all	O
the	O
evidence	O
.	O

Similarly	O
,	O
there	O
is	O
currently	O
little	O
adequate	O
evidence	O
on	O
either	O
the	O
presence	O
or	O
the	O
absence	O
of	O
serious	O
adverse	O
reactions	O
to	O
such	O
doses	O
of	O
ascorbic	B-drug
acid	E-drug
,	O
although	O
many	O
such	O
reactions	O
have	O
been	O
hypothesized	O
.	O

The	O
unrestricted	O
use	O
of	O
ascorbic	B-drug
acid	E-drug
for	O
these	O
purposes	O
can	O
not	O
be	O
advocated	O
on	O
the	O
basis	O
of	O
the	O
evidence	O
currently	O
available	O
.	O

Optimal	O
designs	O
for	O
the	O
individual	O
and	O
joint	O
exposure	O
general	O
logistic	O
regression	O
models	O
.	O

Interest	O
in	O
administering	O
compounds	O
in	O
combination	O
lies	O
both	O
in	O
enhancing	O
efficacious	O
effects	O
and	O
in	O
limiting	O
adverse	O
effects	O
.	O

Although	O
much	O
statistical	O
work	O
has	O
focused	O
on	O
developing	O
mathematical	O
functions	O
to	O
model	O
the	O
joint	O
dose	O
-	O
response	O
curves	O
,	O
relatively	O
little	O
work	O
exists	O
in	O
regard	O
to	O
designing	O
experiments	O
for	O
assessing	O
joint	O
action	O
.	O

A	O
variety	O
of	O
parametric	O
dose	O
-	O
response	O
models	O
based	O
on	O
either	O
the	O
normal	O
or	O
logistic	O
probability	O
distribution	O
have	O
been	O
proposed	O
in	O
the	O
literature	O
.	O

These	O
models	O
are	O
typically	O
nonlinear	O
in	O
the	O
parameters	O
,	O
and	O
as	O
such	O
,	O
a	O
nonlinear	O
weighted	O
least	O
squares	O
approach	O
can	O
be	O
employed	O
for	O
the	O
purpose	O
of	O
designing	O
experiments	O
.	O

The	O
approach	O
is	O
applicable	O
across	O
a	O
wide	O
variety	O
of	O
settings	O
commonly	O
associated	O
with	O
joint	O
action	O
data	O
,	O
including	O
continuous	O
and	O
discrete	O
responses	O
,	O
alternative	O
error	O
structures	O
,	O
and	O
nonzero	O
background	O
response	O
.	O

Further	O
,	O
designs	O
can	O
be	O
expressed	O
in	O
terms	O
of	O
proportionate	O
responses	O
associated	O
with	O
the	O
individual	O
compounds	O
rather	O
than	O
dose	O
levels	O
,	O
thereby	O
providing	O
for	O
results	O
that	O
are	O
applicable	O
across	O
compounds	O
.	O

As	O
a	O
precursor	O
to	O
this	O
effort	O
,	O
optimal	O
and	O
minimal	O
experimental	O
designs	O
for	O
the	O
case	O
in	O
which	O
a	O
single	O
compound	O
is	O
administered	O
have	O
also	O
been	O
developed	O
.	O

Although	O
the	O
proposed	O
methodology	O
for	O
deriving	O
experimental	O
designs	O
can	O
be	O
applied	O
to	O
any	O
nonlinear	O
regression	O
model	O
,	O
primary	O
focus	O
is	O
given	O
to	O
the	O
additive	O
and	O
nonadditive	O
independent	O
joint	O
action	O
(	O
IJA	O
)	O
models	O
for	O
individual	O
and	O
combined	O
exposures	O
proposed	O
by	O
Barton	O
,	O
Braunberg	O
,	O
and	O
Friedman	O
(	O
1	O
)	O
.	O

Differential	O
regulation	O
of	O
tyrosine	O
phosphorylation	O
in	O
tumor	O
cells	O
by	O
contortrostatin	S-drug_n
,	O
a	O
homodimeric	O
disintegrin	O
,	O
and	O
monomeric	O
disintegrins	O
echistatin	S-drug_n
and	O
flavoridin	S-drug_n
.	O

The	O
homodimeric	O
disintegrin	O
contortrostatin	S-drug_n
was	O
compared	O
directly	O
to	O
the	O
monomeric	O
disintegrins	O
echistatin	S-drug_n
and	O
flavoridin	S-drug_n
for	O
the	O
ability	O
to	O
affect	O
protein	O
tyrosine	O
phosphorylation	O
in	O
tumor	O
cells	O
.	O

It	O
was	O
observed	O
that	O
contortrostatin	S-drug_n
had	O
a	O
dramatic	O
effect	O
on	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
several	O
proteins	O
in	O
T24	O
human	O
bladder	O
cancer	O
cells	O
,	O
including	O
robust	O
induction	O
of	O
phosphorylation	O
of	O
proteins	O
in	O
the	O
range	O
of	O
120	O
-	O
140	O
kDa	O
.	O

Echistatin	S-drug_n-EF-1
alone	O
had	O
no	O
effect	O
on	O
tyrosine	O
phosphorylation	O
in	O
T24	O
cells	O
,	O
but	O
dose	O
-	O
dependently	O
inhibits	O
the	O
effects	O
of	O
contortrostatin	S-drug_n-EF-2
when	O
both	O
are	O
added	O
simultaneously	O
.	O

Among	O
the	O
proteins	O
that	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
contortrostatin	S-drug_n
treatment	O
is	O
CAS	O
,	O
a	O
130	O
kDa	O
adapter	O
protein	O
involved	O
in	O
integrin	O
signaling	O
.	O

Flavoridin	S-drug_n-EF-1
alone	O
was	O
found	O
to	O
have	O
no	O
effect	O
on	O
CAS	O
,	O
but	O
can	O
completely	O
block	O
contortrostatin	S-drug_n-EF-2
-	O
induced	O
phosphorylation	O
of	O
this	O
protein	O
in	O
MDA	O
-	O
MB	O
-	O
435	O
cells	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
homodimeric	O
structure	O
of	O
contortrostatin	S-drug_n
functionally	O
distinguishes	O
it	O
from	O
other	O
monomeric	O
members	O
of	O
the	O
disintegrin	O
family	O
.	O

Modification	O
of	O
surface	O
histidine	O
residues	O
abolishes	O
the	O
cytotoxic	O
activity	O
of	O
Clostridium	B-drug_n
difficile	I-drug_n
toxin	I-drug_n
A	E-drug_n
.	O

Clostridium	B-drug_n
difficile	I-drug_n
toxin	I-drug_n
A	E-drug_n
displays	O
both	O
cytotoxic	O
and	O
enterotoxic	O
activities	O
.	O

It	O
has	O
recently	O
been	O
demonstrated	O
that	O
toxin	B-drug_n
A	E-drug_n
exerts	O
its	O
cytotoxic	O
effect	O
by	O
the	O
glucosylation	O
of	O
the	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
the	O
Rho	O
family	O
.	O

Diethyl	B-drug_n
pyrocarbonate	E-drug_n
,	O
at	O
pH	O
7.0	O
,	O
was	O
used	O
to	O
chemically	O
modify	O
exposed	O
histidine	O
residues	O
on	O
toxin	B-drug_n
A	E-drug_n
.	O

Modification	O
of	O
toxin	B-drug_n
A	E-drug_n
with	O
diethyl	B-drug_n
pyrocarbonate	E-drug_n
abolished	O
both	O
its	O
cytotoxic	O
activity	O
and	O
the	O
ability	O
of	O
the	O
toxin	O
to	O
bind	O
Zn	O
-	O
Sepharose	O
gel	O
.	O

Treatment	O
of	O
toxin	B-drug_n
A	E-drug_n
with	O
[	O
(	O
14	O
)	O
C	O
]	O
-	O
diethyl	B-drug_n
pyrocarbonate	E-drug_n
revealed	O
concentration	O
dependent	O
labelling	O
of	O
histidine	O
residues	O
on	O
the	O
toxin	O
molecules	O
.	O

The	O
effects	O
of	O
diethyl	B-drug_n
pyrocarbonate	E-drug_n
could	O
be	O
reversed	O
by	O
hydroxylamine	S-drug_n
treatment	O
.	O

These	O
data	O
suggest	O
the	O
modified	O
histidine	O
residues	O
on	O
toxin	B-drug_n
A	E-drug_n
are	O
critical	O
to	O
its	O
cytotoxic	O
activity	O
.	O

Histidine	O
modification	O
had	O
no	O
effect	O
on	O
the	O
glucosyl	O
transferase	O
enzyme	O
activity	O
of	O
toxin	B-drug_n
A	E-drug_n
.	O

However	O
,	O
modification	O
abolished	O
the	O
'	O
cold	O
'	O
binding	O
of	O
toxin	O
to	O
bovine	O
thyroglobulin	O
in	O
an	O
ELISA	O
and	O
reduced	O
ligand	O
binding	O
activity	O
in	O
a	O
rabbit	O
erythrocyte	O
haemagglutination	O
assay	O
.	O

The	O
data	O
suggest	O
that	O
the	O
histidine	O
residues	O
may	O
be	O
crucial	O
to	O
the	O
receptor	O
-	O
binding	O
activity	O
of	O
toxin	B-drug_n
A	E-drug_n
.	O

Exposed	O
histidines	O
on	O
toxin	B-drug_n
A	E-drug_n
are	O
available	O
for	O
zinc	S-drug
chelation	O
,	O
and	O
these	O
have	O
been	O
exploited	O
in	O
the	O
development	O
of	O
a	O
novel	O
purification	O
protocol	O
for	O
toxin	B-drug_n
A	E-drug_n
using	O
zinc	S-drug
-	O
chelating	O
chromatography	O
.	O

Note	O
:	O
dissolution	O
of	O
aerosol	O
particles	O
of	O
budesonide	S-drug
in	O
Survanta	S-brand
,	O
a	O
model	O
lung	B-group
surfactant	E-group
.	O

The	O
effect	O
of	O
a	O
pulmonary	B-group
surfactant	E-group
extract	O
from	O
bovine	O
lung	O
,	O
Survanta	S-brand
,	O
on	O
the	O
dissolution	O
rate	O
of	O
aerosol	O
particles	O
of	O
budesonide	S-drug
was	O
determined	O
.	O

Aerosol	O
particles	O
of	O
budesonide	S-drug
were	O
generated	O
from	O
an	O
ethanol	S-drug
solution	O
,	O
dried	O
,	O
and	O
collected	O
by	O
a	O
cascade	O
impactor	O
for	O
characterization	O
or	O
by	O
a	O
liquid	O
impinger	O
for	O
dissolution	O
experiments	O
.	O

Powder	O
x	O
-	O
ray	O
diffraction	O
,	O
differential	O
scanning	O
calorimetry	O
,	O
differential	O
thermal	O
analysis	O
,	O
and	O
scanning	O
electron	O
microscopy	O
were	O
used	O
to	O
characterize	O
the	O
aerosol	O
particles	O
and	O
starting	O
material	O
.	O

No	O
change	O
in	O
phase	O
was	O
detected	O
,	O
although	O
the	O
aerosol	O
particles	O
appeared	O
to	O
contain	O
residual	O
solvent	S-group
.	O

The	O
dissolution	O
rate	O
of	O
the	O
aerosol	O
particles	O
in	O
saline	O
was	O
low	O
and	O
variable	O
.	O

Survanta	S-brand
increased	O
the	O
extent	O
of	O
dissolution	O
of	O
budesonide	S-drug
in	O
proportion	O
to	O
the	O
added	O
concentration	O
,	O
which	O
was	O
also	O
verified	O
by	O
equilibrium	O
solubilization	O
studies	O
.	O

Survanta	S-brand
also	O
increased	O
rate	O
of	O
dissolution	O
,	O
in	O
a	O
manner	O
similar	O
to	O
sodium	B-drug_n
dodecyl	I-drug_n
sulfate	E-drug_n
.	O

Analysis	O
of	O
the	O
concentration	O
of	O
budesonide	S-drug
following	O
ultracentrifugation	O
indicated	O
that	O
there	O
is	O
rapid	O
equilibration	O
of	O
budesonide	S-drug
between	O
the	O
Survanta	S-brand
and	O
aqueous	O
phase	O
.	O

These	O
results	O
show	O
that	O
lung	B-group
surfactant	E-group
has	O
the	O
potential	O
of	O
enhancing	O
the	O
rate	O
and	O
extent	O
of	O
dissolution	O
of	O
drugs	O
administered	O
to	O
the	O
lung	O
.	O

Activation	O
of	O
an	O
effector	O
immediate	O
-	O
early	O
gene	O
arc	O
by	O
methamphetamine	S-drug
.	O

As	O
immediate	O
-	O
early	O
genes	O
(	O
IEGs	O
)	O
are	O
thought	O
to	O
play	O
a	O
critical	O
role	O
in	O
mediating	O
stimulus	O
-	O
induced	O
neural	O
plasticity	O
,	O
IEG	O
response	O
induced	O
by	O
methamphetamine	S-drug
(	O
METH	S-drug
)	O
has	O
been	O
characterized	O
to	O
define	O
the	O
changes	O
in	O
gene	O
expression	O
that	O
may	O
underlie	O
its	O
long	O
-	O
lasting	O
behavioral	O
effects	O
.	O

Although	O
activation	O
of	O
several	O
transcription	O
factor	O
IEGs	O
has	O
been	O
described	O
,	O
little	O
is	O
known	O
about	O
effector	O
IEGs	O
.	O

Here	O
,	O
we	O
have	O
examined	O
whether	O
METH	S-drug
administration	O
affects	O
expression	O
of	O
an	O
effector	O
IEG	O
arc	O
(	O
activity	O
-	O
regulated	O
,	O
cytoskeleton	O
-	O
associated	O
)	O
that	O
encodes	O
a	O
protein	O
with	O
homology	O
to	O
spectrin	O
.	O

Using	O
in	O
situ	O
hybridization	O
,	O
we	O
observed	O
that	O
METH	S-drug-EF-1
caused	O
a	O
rapid	O
and	O
transient	O
dose	O
-	O
dependent	O
increase	O
in	O
arc	O
mRNA	O
level	O
in	O
the	O
striatum	O
and	O
cortex	O
that	O
was	O
abolished	O
by	O
pretreatment	O
with	O
the	O
specific	O
dopamine	O
D1	O
receptor	O
antagonist	O
SCH	B-drug_n-EF-2
-	I-drug_n-EF-2
23390	E-drug_n-EF-2
but	O
not	O
by	O
an	O
atypical	B-group
neuroleptic	E-group
clozapine	S-drug
.	O

METH	S-drug
induced	O
arc	O
mRNA	O
in	O
layers	O
IV	O
and	O
VI	O
of	O
the	O
cortex	O
which	O
dopamine	O
receptor	O
are	O
localized	O
to	O
.	O

These	O
results	O
suggest	O
that	O
D1	O
receptors	O
are	O
coupled	O
to	O
activation	O
of	O
arc	O
gene	O
,	O
which	O
may	O
be	O
involved	O
in	O
functional	O
or	O
structural	O
alterations	O
underlying	O
neural	O
plasticity	O
triggered	O
by	O
METH	S-drug
.	O

The	O
effects	O
of	O
DCG	B-drug_n
-	I-drug_n
IV	E-drug_n
and	O
L	B-drug_n
-	I-drug_n
CCG	I-drug_n
-	I-drug_n
1	E-drug_n
upon	O
phencyclidine	S-drug_n
(	O
PCP	S-drug_n
)	O
-	O
induced	O
locomotion	O
and	O
behavioral	O
changes	O
in	O
mice	O
.	O

The	O
behavioral	O
changes	O
of	O
mice	O
induced	O
by	O
acute	O
and	O
repeated	O
i.p	O
.	O

injection	O
of	O
phencyclidine	S-drug_n
(	O
PCP	S-drug_n
)	O
were	O
observed	O
by	O
measuring	O
locomotor	O
activity	O
and	O
stereotyped	O
behavior	O
.	O

Then	O
,	O
the	O
effects	O
of	O
metabotropic	O
glutamate	O
receptor	O
(	O
mGluR	O
)	O
agonists	O
,	O
DCG	B-drug_n
-	I-drug_n
IV	E-drug_n
and	O
L	B-drug_n
-	I-drug_n
CCG	I-drug_n
-	I-drug_n
1	E-drug_n
,	O
on	O
the	O
above	O
behavioral	O
changes	O
induced	O
by	O
PCP	S-drug_n
were	O
found	O
.	O

The	O
effects	O
of	O
DCG	B-drug_n-EF-1
-	I-drug_n-EF-1
IV	E-drug_n-EF-1
were	O
very	O
strong	O
and	O
completely	O
depressed	O
the	O
PCP	S-drug_n-EF-2
-	O
induced	O
hyperlocomotion	O
.	O

The	O
effects	O
of	O
L	B-drug_n
-	I-drug_n
CCG	I-drug_n
-	I-drug_n
1	E-drug_n
were	O
not	O
so	O
strong	O
.	O

Repeated	O
injection	O
of	O
PCP	S-drug_n
for	O
20	O
days	O
into	O
mice	O
induced	O
lower	O
locomotor	O
activity	O
than	O
that	O
in	O
acutely	O
injected	O
mice	O
.	O

These	O
behavioral	O
changes	O
may	O
be	O
related	O
with	O
the	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

In	O
order	O
to	O
examine	O
some	O
molecular	O
mechanisms	O
of	O
PCP	S-drug_n
-	O
induced	O
behavioral	O
changes	O
,	O
Northern	O
blot	O
analysis	O
of	O
total	O
RNA	O
from	O
prefrontal	O
cortical	O
tissues	O
of	O
mice	O
treated	O
with	O
PCP	S-drug_n
,	O
DCG	B-drug_n
-	I-drug_n
IV	E-drug_n
,	O
and	O
L	B-drug_n
-	I-drug_n
CCG	I-drug_n
-	I-drug_n
1	E-drug_n
was	O
carried	O
out	O
.	O

Behavioral	O
responses	O
to	O
repeated	O
cocaine	S-drug
exposure	O
in	O
mice	O
selectively	O
bred	O
for	O
differential	O
sensitivity	O
to	O
pentobarbital	S-drug
.	O

Mice	O
from	O
the	O
20th	O
generation	O
of	O
three	O
lines	O
divergently	O
selected	O
for	O
response	O
to	O
pentobarbital	S-drug
-	O
induced	O
sedation	O
times	O
[	O
long	O
-	O
sedation	O
time	O
(	O
LST	O
)	O
,	O
short	O
sedation	O
time	O
(	O
SST	O
)	O
,	O
and	O
randomly	O
bred	O
control	O
(	O
RBC	O
)	O
]	O
were	O
used	O
to	O
study	O
cocaine	S-drug
-	O
induced	O
behavioral	O
sensitization	O
.	O

These	O
lines	O
showed	O
variable	O
degrees	O
of	O
locomotor	O
activities	O
in	O
response	O
to	O
cocaine	S-drug
.	O

At	O
a	O
low	O
cocaine	S-drug
dose	O
and	O
long	O
withdrawal	O
period	O
(	O
10	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
day	O
for	O
5	O
days	O
followed	O
by	O
a	O
14	O
-	O
day	O
withdrawal	O
)	O
,	O
the	O
LST	O
mice	O
showed	O
tolerance	O
development	O
.	O

In	O
response	O
to	O
cocaine	S-drug
,	O
the	O
locomotor	O
activities	O
of	O
the	O
SST	O
were	O
not	O
significantly	O
different	O
from	O
the	O
RBC	O
group	O
.	O

At	O
a	O
higher	O
dose	O
and	O
a	O
shorter	O
withdrawal	O
period	O
(	O
20	O
mg	O
/	O
kg	O
,	O
daily	O
for	O
7	O
days	O
followed	O
by	O
a	O
3	O
-	O
day	O
withdrawal	O
)	O
,	O
the	O
SST	O
mice	O
showed	O
behavioral	O
sensitization	O
similar	O
to	O
the	O
RBC	O
mice	O
,	O
but	O
the	O
LST	O
mice	O
did	O
not	O
develop	O
sensitization	O
.	O

The	O
different	O
responses	O
in	O
locomotor	O
activity	O
induced	O
by	O
cocaine	S-drug
suggest	O
that	O
genetic	O
factors	O
may	O
play	O
a	O
role	O
in	O
determining	O
the	O
magnitude	O
of	O
response	O
to	O
this	O
drug	O
.	O

Dopamine	O
(	O
DA	O
)	O
levels	O
did	O
not	O
differ	O
significantly	O
in	O
either	O
striatum	O
(	O
STR	O
)	O
or	O
nucleus	O
accumbens	O
(	O
NAC	O
)	O
for	O
the	O
cocaine	S-drug
-	O
treated	O
animals	O
to	O
their	O
corresponding	O
saline	O
-	O
treated	O
controls	O
.	O

The	O
affinity	O
(	O
Kd	O
)	O
of	O
D2	O
in	O
the	O
NAC	O
decreased	O
significantly	O
,	O
without	O
changes	O
in	O
density	O
(	O
Bmax	O
)	O
,	O
in	O
the	O
cocaine	S-drug
-	O
treated	O
SST	O
and	O
RBC	O
mice	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
density	O
of	O
D2	O
binding	O
sites	O
in	O
the	O
SST	O
and	O
the	O
RBC	O
mice	O
in	O
the	O
STR	O
was	O
significantly	O
increased	O
in	O
cocaine	S-drug
-	O
treated	O
groups	O
without	O
change	O
in	O
Kd	O
.	O

The	O
LST	O
mice	O
did	O
not	O
show	O
any	O
changes	O
in	O
the	O
Kd	O
and	O
Bmax	O
in	O
either	O
the	O
STR	O
or	O
the	O
NAC	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
changes	O
in	O
the	O
Kd	O
of	O
D2	O
in	O
the	O
NAC	O
and	O
the	O
Bmax	O
of	O
D2	O
in	O
the	O
STR	O
may	O
contribute	O
to	O
the	O
differences	O
in	O
locomotor	O
responses	O
to	O
cocaine	S-drug
exposure	O
in	O
these	O
mouse	O
lines	O
.	O

18	B-drug_n
-	I-drug_n
Methoxycoronaridine	E-drug_n
(	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
)	O
and	O
ibogaine	S-drug_n
:	O
comparison	O
of	O
antiaddictive	O
efficacy	O
,	O
toxicity	O
,	O
and	O
mechanisms	O
of	O
action	O
.	O

18	B-drug_n
-	I-drug_n
MC	E-drug_n
,	O
a	O
novel	O
iboga	O
alkaloid	O
congener	O
,	O
is	O
being	O
developed	O
as	O
a	O
potential	O
treatment	O
for	O
multiple	O
forms	O
of	O
drug	O
abuse	O
.	O

Like	O
ibogaine	S-drug_n
(	O
40	O
mg	O
/	O
kg	O
)	O
,	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
(	O
40	O
mg	O
/	O
kg	O
)	O
decreases	O
the	O
intravenous	O
self	O
-	O
administration	O
of	O
morphine	S-drug
and	O
cocaine	S-drug
and	O
the	O
oral	O
self	O
-	O
administration	O
of	O
ethanol	S-drug
and	O
nicotine	S-drug
in	O
rats	O
;	O

unlike	O
ibogaine	S-drug_n
,	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
does	O
not	O
affect	O
responding	O
for	O
a	O
nondrug	O
reinforcer	O
(	O
water	O
)	O
.	O

Both	O
ibogaine	S-drug_n
and	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
ameliorate	O
opioid	S-group
withdrawal	O
signs	O
.	O

Both	O
ibogaine	S-drug_n
and	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
decrease	O
extracellular	O
levels	O
of	O
dopamine	O
in	O
the	O
nucleus	O
accumbens	O
,	O
but	O
only	O
ibogaine	S-drug_n
increases	O
extracellular	O
levels	O
of	O
serotonin	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Both	O
ibogaine	S-drug_n-EF-1
and	O
18	B-drug_n-EF-1
-	I-drug_n-EF-1
MC	E-drug_n-EF-1
block	O
morphine	S-drug-EF-2
-	O
induced	O
and	O
nicotine	S-drug-EF-2
-	O
induced	O
dopamine	O
release	O
in	O
the	O
nucleus	O
accumbens	O
;	O

only	O
ibogaine	S-drug_n-EF-1
enhances	O
cocaine	S-drug-EF-2
-	O
induced	O
increases	O
in	O
accumbal	O
dopamine	O
.	O

Both	O
ibogaine	S-drug_n
and	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
enhance	O
the	O
locomotor	O
and	O
/	O
or	O
stereotypic	O
effects	O
of	O
stimulants	O
.	O

Ibogaine	S-drug_n-EF-1
attenuates	O
,	O
but	O
18	B-drug_n-EF-1
-	I-drug_n-EF-1
MC	E-drug_n-EF-1
potentiates	O
,	O
the	O
acute	O
locomotor	O
effects	O
of	O
morphine	S-drug-EF-2
;	O

both	O
compounds	O
attenuate	O
morphine	S-drug
-	O
induced	O
locomotion	O
in	O
morphine	S-drug
-	O
experienced	O
rats	O
.	O

Ibogaine	S-drug_n
produces	O
whole	O
body	O
tremors	O
and	O
,	O
at	O
high	O
doses	O
(	O
>	O
or	O
=	O
100	O
mg	O
/	O
kg	O
)	O
,	O
cerebellar	O
damage	O
;	O

18	B-drug_n
-	I-drug_n
MC	E-drug_n
does	O
not	O
produce	O
these	O
effects	O
.	O

Ibogaine	S-drug_n
,	O
but	O
not	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
,	O
decreases	O
heart	O
rate	O
at	O
high	O
doses	O
.	O

While	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
and	O
ibogaine	S-drug_n
have	O
similar	O
affinities	O
for	O
kappa	O
opioid	O
and	O
possibly	O
nicotinic	O
receptors	O
,	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
has	O
much	O
lower	O
affinities	O
than	O
ibogaine	S-drug_n
for	O
NMDA	O
and	O
sigma	O
-	O
2	O
receptors	O
,	O
sodium	O
channels	O
,	O
and	O
the	O
5	O
-	O
HT	O
transporter	O
.	O

Both	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
and	O
ibogaine	S-drug_n
are	O
sequestered	O
in	O
fat	O
and	O
,	O
like	O
ibogaine	S-drug_n
,	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
probably	O
has	O
an	O
active	O
metabolite	O
.	O

The	O
data	O
suggest	O
that	O
18	B-drug_n
-	I-drug_n
MC	E-drug_n
has	O
a	O
narrower	O
spectrum	O
of	O
actions	O
and	O
will	O
have	O
a	O
substantially	O
greater	O
therapeutic	O
index	O
than	O
ibogaine	S-drug_n
.	O

Clinical	O
implications	O
of	O
warfarin	S-drug-IN-1
interactions	O
with	O
five	O
sedatives	S-group-IN-2
.	O

The	O
intensity	O
,	O
uniformity	O
and	O
time	O
course	O
of	O
anticoagulant	S-group
interference	O
by	O
phenobarbital	S-drug
,	O
secobarbital	S-drug
,	O
glutethimide	S-drug
,	O
chloral	B-drug
hydrate	E-drug
and	O
methaqualone	S-drug
were	O
systematically	O
investigated	O
in	O
16	O
patients	O
receiving	O
coumarin	S-group
therapy	O
.	O

Each	O
subject	O
received	O
an	O
individualized	O
fixed	O
daily	O
dose	O
of	O
warfarin	S-drug
and	O
served	O
as	O
his	O
own	O
pre	O
-	O
and	O
postsedative	O
treatment	O
control	O
.	O

Prothrombin	O
times	O
were	O
measured	O
four	O
times	O
weekly	O
during	O
five	O
long	O
-	O
term	O
experiments	O
.	O

Anticoagulant	O
inhibition	O
was	O
observed	O
during	O
the	O
administration	O
of	O
phenobarbital	S-drug
,	O
secobarbital	S-drug
and	O
glutethimide	S-drug
;	O

there	O
was	O
no	O
significant	O
change	O
in	O
prothrombin	O
test	O
results	O
during	O
the	O
trials	O
of	O
chloral	B-drug
hydrate	E-drug
and	O
methaqualone	S-drug
.	O

Barbiturates	S-group-AD-1
and	O
glutethimide	S-drug-AD-1
should	O
not	O
be	O
administered	O
to	O
patients	O
receiving	O
coumarin	B-group-AD-2
drugs	E-group-AD-2
.	O

The	O
concurrent	O
use	O
of	O
drugs	O
from	O
these	O
groups	O
is	O
decreasing	O
according	O
to	O
a	O
survey	O
of	O
200	O
hospital	O
medical	O
records	O
.	O

Chloral	B-drug-IN-1
hydrate	E-drug-IN-1
and	O
methaqualone	S-drug-IN-1
interact	O
pharmacologically	O
with	O
orally	O
administered	O
anticoagulant	B-group-IN-2
agents	E-group-IN-2
,	O
but	O
the	O
effect	O
is	O
not	O
clinically	O
significant	O
.	O

It	O
is	O
concluded	O
that	O
chloral	B-drug
hydrate	E-drug
and	O
methaqualone	S-drug
may	O
be	O
administered	O
safely	O
without	O
additional	O
caution	O
in	O
prothrombin	O
test	O
monitoring	O
during	O
oral	O
anticoagulant	S-group
therapy	O
.	O

Effects	O
of	O
low	O
temperatures	O
on	O
microtubules	O
in	O
the	O
non	O
-	O
myelinated	O
axons	O
of	O
post	O
-	O
ganglionic	O
sympathetic	O
nerves	O
.	O

The	O
effect	O
of	O
temperature	O
changes	O
on	O
the	O
number	O
of	O
microtubules	O
in	O
non	O
-	O
myelinated	O
axons	O
has	O
been	O
studied	O
in	O
cat	O
inferior	O
mesenteric	O
ganglion	O
/	O
hypogastric	O
nerve	O
preparations	O
incubated	O
at	O
various	O
temperatures	O
in	O
Eagles	O
minimal	O
essential	O
tissue	O
culture	O
medium	O
in	O
vitro	O
.	O

At	O
37	O
degrees	O
C	O
the	O
non	O
-	O
myelinated	O
axons	O
contained	O
28.4	O
plus	O
or	O
minus	O
0.8	O
S.E.M	O
.	O

(	O
54	O
)	O
microtubules	O
per	O
axon	O
.	O

After	O
incubation	O
at	O
0	O
degrees	O
C	O
for	O
4	O
h	O
this	O
number	O
fell	O
to	O
2.3	O
plus	O
or	O
minus	O
0.1	O
S.E.M	O
.	O

(	O
41	O
)	O
but	O
returned	O
to	O
normal	O
levels	O
when	O
the	O
nerves	O
were	O
rewarmed	O
.	O

This	O
loss	O
of	O
microtubules	O
on	O
cooling	O
the	O
nerves	O
and	O
their	O
reappearance	O
on	O
rewarming	O
was	O
a	O
rapid	O
process	O
;	O

it	O
was	O
independent	O
of	O
the	O
influence	O
of	O
the	O
nueronal	O
cell	O
body	O
and	O
of	O
protein	O
synthesis	O
within	O
the	O
axon	O
.	O

The	O
preservation	O
of	O
the	O
microtubules	O
was	O
improved	O
when	O
D2O	O
was	O
present	O
in	O
the	O
incubation	O
medium	O
.	O

Reformed	O
microtubules	O
appeared	O
to	O
function	O
normally	O
with	O
respect	O
to	O
their	O
possible	O
role	O
in	O
the	O
transport	O
of	O
noradrenaline	O
storage	O
vesicles	O
along	O
the	O
axons	O
.	O

Serum	O
digoxin	S-drug
levels	O
using	O
an	O
125I	O
-	O
labelled	O
antigen	O
:	O
Validation	O
of	O
method	O
and	O
observations	O
on	O
cardiac	O
patients	O
.	O

1	O
.	O

Determinations	O
of	O
serum	O
digoxin	S-drug
levels	O
utilizing	O
commercially	O
available	O
kits	O
with	O
an	O
125I	O
-	O
labelled	O
antigen	O
were	O
precise	O
and	O
not	O
materially	O
different	O
from	O
results	O
obtained	O
with	O
a	O
3H	O
-	O
labelled	O
antigen	O
.	O

2	O
.	O

In	O
order	O
to	O
approximate	O
the	O
steady	O
state	O
level	O
,	O
serum	O
digoxin	S-drug
levels	O
should	O
be	O
drawn	O
either	O
before	O
or	O
at	O
least	O
six	O
hours	O
following	O
the	O
administration	O
of	O
an	O
oral	O
tablet	O
.	O

3	O
.	O

Concomitantly	O
given	O
thiazide	B-group
diuretics	E-group
did	O
not	O
interfere	O
with	O
the	O
absorption	O
of	O
a	O
tablet	O
of	O
digoxin	S-drug
.	O

4	O
.	O

In	O
the	O
digitalized	O
patient	O
,	O
slow	O
alterations	O
in	O
serum	O
levels	O
after	O
oral	O
administration	O
appeared	O
well	O
correlated	O
with	O
,	O
at	O
least	O
,	O
the	O
negative	O
chronotropic	O
effects	O
of	O
the	O
drug	O
.	O

5	O
.	O

Maximal	O
exercise	O
testing	O
,	O
a	O
maneuver	O
often	O
applied	O
to	O
cardiac	O
patients	O
,	O
does	O
not	O
significantly	O
alter	O
the	O
serum	O
digoxin	S-drug
level	O
.	O

Combinations	O
of	O
clozapine	S-drug
and	O
phencyclidine	S-drug_n
:	O
effects	O
on	O
drug	O
discrimination	O
and	O
behavioral	O
inhibition	O
in	O
rats	O
.	O

Phencyclidine	S-drug_n
(	O
PCP	S-drug_n
)	O
produces	O
psychotomimetic	O
effects	O
in	O
humans	O
that	O
resemble	O
schizophrenia	O
symptoms	O
.	O

In	O
an	O
effort	O
to	O
screen	O
compounds	O
for	O
antipsychotic	O
activity	O
,	O
preclinical	O
researchers	O
have	O
investigated	O
whether	O
these	O
compounds	O
block	O
PCP	S-drug_n
-	O
induced	O
behaviors	O
in	O
animals	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
atypical	B-group
antipsychotic	E-group
clozapine	S-drug
was	O
tested	O
in	O
combination	O
with	O
an	O
active	O
dose	O
of	O
PCP	S-drug_n
in	O
two	O
-	O
lever	O
drug	O
discrimination	O
and	O
mixed	O
signalled	O
-	O
unsignalled	O
differential	O
-	O
reinforcement	O
-	O
of	O
-	O
low	O
-	O
rates	O
(	O
DRL	O
)	O
procedures	O
.	O

PCP	S-drug_n
produced	O
distinctive	O
effects	O
in	O
each	O
task	O
:	O
it	O
substituted	O
for	O
the	O
training	O
dose	O
in	O
PCP	S-drug_n
discrimination	O
and	O
it	O
increased	O
the	O
number	O
of	O
responses	O
with	O
short	O
(	O
<	O
3	O
s	O
)	O
interresponse	O
times	O
as	O
well	O
as	O
increasing	O
overall	O
response	O
rates	O
in	O
the	O
DRL	O
schedule	O
.	O

Acute	O
dosing	O
with	O
clozapine	S-drug
failed	O
to	O
alter	O
the	O
behavioral	O
effects	O
of	O
PCP	S-drug_n
in	O
either	O
procedure	O
even	O
when	O
tested	O
up	O
to	O
doses	O
that	O
produced	O
pharmacological	O
effects	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
acute	O
dosing	O
with	O
clozapine	S-drug
would	O
not	O
affect	O
behaviors	O
most	O
closely	O
associated	O
with	O
PCP	S-drug_n
intoxication	O
.	O

Further	O
,	O
they	O
bring	O
into	O
question	O
the	O
utility	O
of	O
using	O
PCP	S-drug_n
combination	O
procedures	O
in	O
animals	O
to	O
screen	O
for	O
antipsychotic	O
potential	O
.	O

Since	O
chronic	O
dosing	O
is	O
required	O
for	O
therapeutic	O
efficacy	O
of	O
antipsychotics	S-group
,	O
future	O
studies	O
should	O
focus	O
on	O
investigation	O
of	O
chronic	O
dosing	O
effects	O
of	O
these	O
drugs	O
in	O
combination	O
with	O
PCP	S-drug_n
.	O

The	O
mechanism	O
of	O
resveratrol	S-drug_n
-	O
induced	O
vasorelaxation	O
differs	O
in	O
the	O
mesenteric	O
resistance	O
arteries	O
of	O
lean	O
and	O
obese	O
rats	O
.	O

Resveratrol	S-drug_n
has	O
been	O
shown	O
to	O
induce	O
vasorelaxation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
resveratrol	S-drug_n
-	O
induced	O
vasorelaxation	O
in	O
resistance	O
mesenteric	O
arteries	O
from	O
male	O
lean	O
and	O
dietary	O
-	O
induced	O
obese	O
rats	O
.	O

Compared	O
with	O
lean	O
rats	O
,	O
arteries	O
from	O
dietary	O
-	O
obese	O
rats	O
showed	O
significant	O
(	O
P	O
<	O
0.001	O
)	O
endothelial	O
dysfunction	O
,	O
as	O
indicated	O
by	O
a	O
decrease	O
(	O
>	O
20	O
%	O
)	O
in	O
maximal	O
acetylcholine	O
-	O
induced	O
vasorelaxation	O
.	O

Resveratrol	S-drug_n
(	O
5	O
-	O
35	O
micromol	O
/	O
l	O
)	O
induced	O
concentration	O
-	O
dependent	O
relaxation	O
of	O
mesenteric	O
arteries	O
preconstricted	O
with	O
noradrenaline	S-drug
(	O
8	O
micromol	O
/	O
l	O
)	O
or	O
KCl	S-drug
(	O
125	O
mmol	O
/	O
l	O
)	O
from	O
both	O
lean	O
and	O
dietary	O
-	O
obese	O
rats	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
achieving	O
a	O
maximum	O
relaxation	O
of	O
>	O
95	O
%	O
at	O
a	O
concentration	O
of	O
35	O
micromol	O
/	O
l	O
.	O

However	O
,	O
L	B-drug_n
-	I-drug_n
NAME	E-drug_n
(	O
100	O
and	O
300	O
micromol	O
/	O
l	O
)	O
did	O
not	O
alter	O
the	O
effects	O
of	O
reseveratrol	S-drug_n
on	O
arteries	O
from	O
dietary	O
-	O
obese	O
rats	O
,	O
giving	O
superimposed	O
concentration	O
-	O
responses	O
curves	O
.	O

Indomethacin	S-drug
was	O
also	O
ineffective	O
in	O
altering	O
resveratrol	S-drug_n
activity	O
in	O
arteries	O
from	O
both	O
lean	O
and	O
dietary	O
-	O
obese	O
rats	O
.	O

In	O
noradrenaline	S-drug
-	O
precontracted	O
arteries	O
from	O
dietary	O
-	O
obese	O
rats	O
,	O
responses	O
to	O
resveratrol	S-drug_n
were	O
not	O
attenuated	O
by	O
endothelial	O
denudation	O
,	O
indicating	O
an	O
action	O
independent	O
of	O
the	O
endothelium	O
.	O

This	O
study	O
indicates	O
that	O
:	O
(	O
a	O
)	O
the	O
maximal	O
effects	O
of	O
resveratrol	S-drug_n
on	O
resistance	O
arteries	O
from	O
lean	O
and	O
dietary	O
-	O
obese	O
rats	O
are	O
not	O
effected	O
by	O
endothelial	O
dysfunction	O
,	O
and	O
(	O
b	O
)	O
the	O
effects	O
of	O
resveratrol	S-drug_n
in	O
lean	O
animals	O
(	O
where	O
endothelial	O
function	O
is	O
not	O
impaired	O
)	O
,	O
but	O
not	O
in	O
dietary	O
-	O
obese	O
rats	O
,	O
are	O
mediated	O
via	O
NO	O
.	O

If	O
taken	O
1	O
hour	O
before	O
indinavir	S-drug
(	O
IDV	S-drug
)	O
,	O
didanosine	S-drug
does	O
not	O
affect	O
IDV	S-drug
exposure	O
,	O
despite	O
persistent	O
buffering	O
effects	O
.	O

Concurrent	O
administration	O
of	O
indinavir	S-drug-ME-1
and	O
didanosine	S-drug-ME-2
significantly	O
reduces	O
the	O
level	O
of	O
exposure	O
to	O
indinavir	S-drug
,	O
but	O
it	O
is	O
unclear	O
how	O
soon	O
after	O
didanosine	S-drug
administration	O
indinavir	S-drug
may	O
be	O
given	O
safely	O
.	O

We	O
compared	O
indinavir	S-drug
pharmacokinetics	O
and	O
gastric	O
pH	O
in	O
12	O
human	O
immunodeficiency	O
virus	O
-	O
positive	O
patients	O
by	O
use	O
of	O
800	O
mg	O
of	O
indinavir	S-drug
alone	O
versus	O
800	O
mg	O
of	O
indinavir	S-drug
administered	O
1	O
h	O
after	O
didanosine	S-drug
administration	O
.	O

Median	O
gastric	O
pH	O
was	O
significantly	O
higher	O
when	O
indinavir	S-drug-ME-1
was	O
taken	O
after	O
didanosine	S-drug-ME-2
administration	O
;	O

however	O
,	O
no	O
significant	O
difference	O
in	O
the	O
maximum	O
concentration	O
in	O
plasma	O
or	O
the	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
from	O
time	O
zero	O
to	O
8	O
h	O
was	O
observed	O
.	O

Indinavir	S-drug-AD-1
may	O
be	O
taken	O
with	O
a	O
light	O
meal	O
1	O
h	O
following	O
the	O
administration	O
of	O
400	O
mg	O
of	O
didanosine	S-drug-AD-2
.	O

A	O
proposed	O
mechanism	O
for	O
the	O
potentiation	O
of	O
cAMP	O
-	O
mediated	O
acid	O
secretion	O
by	O
carbachol	S-drug
.	O

Acid	O
secretion	O
in	O
isolated	O
rabbit	O
gastric	O
glands	O
was	O
monitored	O
by	O
the	O
accumulation	O
of	O
[	O
(	O
14	O
)	O
C	O
]	O
aminopyrine	S-drug
.	O

Stimulation	O
of	O
the	O
glands	O
with	O
carbachol	S-drug
synergistically	O
augmented	O
the	O
response	O
to	O
dibutyryl	O
cAMP	O
.	O

The	O
augmentation	O
persisted	O
even	O
after	O
carbachol	S-drug
was	O
washed	O
out	O
and	O
was	O
resistant	O
to	O
chelated	O
extracellular	O
Ca	O
(	O
2	O
+	O
)	O
and	O
to	O
inhibitors	O
of	O
either	O
protein	O
kinase	O
C	O
or	O
calmodulin	O
kinase	O
II	O
.	O

Cytochalasin	B-drug_n-EF-1
D	E-drug_n-EF-1
at	O
10	O
microM	O
preferentially	O
blocked	O
the	O
secretory	O
effect	O
of	O
carbachol	S-drug-EF-2
and	O
its	O
synergism	O
with	O
cAMP	O
,	O
whereas	O
it	O
had	O
no	O
effect	O
on	O
histamine	O
-	O
or	O
cAMP	O
-	O
stimulated	O
acid	O
secretion	O
within	O
15	O
min	O
.	O

Cytochalasin	B-drug_n-EF-1
D	E-drug_n-EF-1
inhibited	O
the	O
carbachol	S-drug-EF-2
-	O
stimulated	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
concentration	O
(	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
)	O
increase	O
due	O
to	O
release	O
from	O
the	O
Ca	O
(	O
2	O
+	O
)	O
store	O
.	O

Treatment	O
of	O
the	O
glands	O
with	O
cytochalasin	B-drug_n
D	E-drug_n
redistributed	O
type	O
3	O
inositol	O
1,4,5	O
-	O
trisphosphate	O
receptor	O
(	O
the	O
major	O
subtype	O
in	O
the	O
parietal	O
cell	O
)	O
from	O
the	O
fraction	O
containing	O
membranes	O
of	O
large	O
size	O
to	O
the	O
microsomal	O
fraction	O
,	O
suggesting	O
a	O
dissociation	O
of	O
the	O
store	O
from	O
the	O
plasma	O
membrane	O
.	O

These	O
findings	O
suggest	O
that	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
release	O
by	O
cholinergic	O
stimulation	O
is	O
critical	O
for	O
determining	O
synergism	O
with	O
cAMP	O
in	O
parietal	O
cell	O
activation	O
and	O
that	O
functional	O
coupling	O
between	O
the	O
Ca	O
(	O
2	O
+	O
)	O
store	O
and	O
the	O
receptor	O
is	O
maintained	O
by	O
actin	O
microfilaments	O
.	O

Interference	O
of	O
biocytin	O
with	O
opioid	S-group
-	O
evoked	O
hyperpolarization	O
and	O
membrane	O
properties	O
of	O
rat	O
spinal	O
substantia	O
gelatinosa	O
neurons	O
.	O

In	O
our	O
laboratory	O
,	O
preliminary	O
whole	O
-	O
cell	O
,	O
tight	O
seal	O
recordings	O
of	O
rat	O
spinal	O
substantia	O
gelatinosa	O
neurons	O
including	O
biocytin	O
in	O
the	O
patch	O
pipette	O
yielded	O
a	O
significantly	O
smaller	O
proportion	O
of	O
neurons	O
hyperpolarized	O
by	O
selective	B-group
opioid	I-group
agonists	E-group
compared	O
with	O
recordings	O
without	O
biocytin	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
biocytin	O
inclusion	O
on	O
opioid	S-group
responses	O
and	O
other	O
membrane	O
properties	O
during	O
whole	O
-	O
cell	O
,	O
tight	O
seal	O
recordings	O
of	O
these	O
neurons	O
.	O

The	O
percentage	O
of	O
neurons	O
hyperpolarized	O
by	O
mu	B-group
-	E-group
,	O
delta	B-group
(	I-group
1	I-group
)	I-group
-	E-group
,	O
and	O
kappa	B-group
-	I-group
selective	I-group
opioids	E-group
was	O
significantly	O
reduced	O
when	O
1	O
%	O
but	O
not	O
<	O

or	O
=	O
0.2	O
%	O
biocytin	O
was	O
included	O
in	O
the	O
recording	O
pipette	O
,	O
compared	O
with	O
neurons	O
recorded	O
without	O
biocytin	O
.	O

However	O
,	O
a	O
significantly	O
higher	O
proportion	O
of	O
neurons	O
fired	O
spontaneous	O
action	O
potentials	O
with	O
either	O
0.05	O
-	O
0.2	O
or	O
1	O
%	O
biocytin	O
compared	O
to	O
no	O
biocytin	O
.	O

Resting	O
membrane	O
potential	O
,	O
input	O
impedance	O
and	O
the	O
proportion	O
of	O
neurons	O
displaying	O
transient	O
outward	O
rectification	O
were	O
each	O
significantly	O
altered	O
for	O
neurons	O
recorded	O
with	O
1	O
%	O
but	O
not	O
0.05	O
-	O
0.2	O
%	O
biocytin	O
.	O

These	O
effects	O
may	O
be	O
due	O
to	O
a	O
relatively	O
specific	O
blockade	O
of	O
diverse	O
potassium	O
channel	O
types	O
.	O

Because	O
efficient	O
labeling	O
can	O
be	O
achieved	O
with	O
0.1	O
%	O
biocytin	O
with	O
whole	O
-	O
cell	O
recording	O
,	O
higher	O
concentrations	O
are	O
contraindicated	O
.	O

Increased	O
stability	O
of	O
nucleophosmin	O
/	O
B23	O
in	O
anti	O
-	O
apoptotic	O
effect	O
of	O
ras	O
during	O
serum	O
deprivation	O
.	O

We	O
obtained	O
evidence	O
that	O
increased	O
stability	O
of	O
nucleophosmin	O
/	O
B23	O
is	O
involved	O
in	O
antiapoptotic	O
effect	O
of	O
ras	O
during	O
serum	O
deprivation	O
.	O

Nucleophosmin	O
/	O
B23	O
in	O
serum	O
-	O
deprived	O
(	O
0	O
%	O
serum	O
)	O
NIH	O
-	O
3T3	O
cells	O
was	O
found	O
to	O
be	O
highly	O
unstable	O
with	O
a	O
half	O
-	O
life	O
less	O
than	O
4	O
h	O
.	O

In	O
contrast	O
,	O
nucleophosmin	O
/	O
B23	O
in	O
serum	O
-	O
deprived	O
ras	O
-	O
transformed	O
(	O
RAS	O
-	O
3T3	O
)	O
cells	O
was	O
as	O
stable	O
as	O
that	O
in	O
serum	O
-	O
supplemented	O
NIH	O
-	O
3T3	O
or	O
RAS	O
-	O
3T3	O
cells	O
.	O

Treatment	O
of	O
RAS	O
-	O
3T3	O
cells	O
with	O
nucleophosmin	O
/	O
B23	O
antisense	O
oligomer	O
significantly	O
potentiated	O
the	O
apoptosis	O
induced	O
by	O
serum	O
deprivation	O
.	O

Much	O
less	O
caspase	O
-	O
3	O
activity	O
was	O
noted	O
in	O
the	O
lysate	O
derived	O
from	O
serum	O
-	O
deprived	O
RAS	O
-	O
3T3	O
cells	O
compared	O
with	O
that	O
in	O
the	O
lysate	O
of	O
serum	O
-	O
deprived	O
NIH	O
-	O
3T3	O
cells	O
.	O

Cell	O
permeable	O
caspase	O
-	O
3	O
inhibitor	O
added	O
in	O
the	O
medium	O
blocked	O
the	O
decrease	O
of	O
nucleophosmin	O
/	O
B23	O
and	O
apoptosis	O
induced	O
by	O
serum	O
deprivation	O
in	O
NIH	O
-	O
3T3	O
cells	O
.	O

The	O
inhibitor	O
,	O
on	O
the	O
other	O
hand	O
,	O
promoted	O
significant	O
decrease	O
of	O
nucleolin	O
/	O
C23	O
in	O
NIH	O
-	O
3T3	O
cells	O
during	O
serum	O
deprivation	O
.	O

Unlike	O
nucleolin	O
/	O
C23	O
,	O
down	O
-	O
regulation	O
of	O
nucleophosmin	O
/	O
B23	O
was	O
thus	O
not	O
proliferation	O
-	O
dependent	O
but	O
caspase	O
-	O
3	O
-	O
and	O
apoptosis	O
-	O
dependent	O
.	O

Our	O
results	O
indicate	O
important	O
relationships	O
among	O
ras	O
,	O
nucleophosmin	O
/	O
B23	O
,	O
activation	O
of	O
caspase	O
-	O
3	O
,	O
and	O
induction	O
of	O
apoptosis	O
.	O

Suppression	O
by	O
verapamil	S-drug-EF-1
of	O
bombesin	S-drug_n-EF-2
-	O
enhanced	O
peritoneal	O
metastasis	O
of	O
intestinal	O
adenocarcinomas	O
induced	O
by	O
azoxymethane	S-drug_n
in	O
wistar	O
rats	O
.	O

BACKGROUND	O
:	O
The	O
effects	O
of	O
combined	O
administration	O
of	O
bombesin	S-drug_n
and	O
verapamil	B-drug
hydrochloride	E-drug
(	O
verapamil	S-drug
)	O
,	O
a	O
calcium	B-group
channel	I-group
blocker	E-group
,	O
on	O
the	O
incidence	O
of	O
peritoneal	O
metastasis	O
of	O
intestinal	O
adenocarcinomas	O
induced	O
by	O
azoxymethane	S-drug_n
(	O
AOM	S-drug_n
)	O
and	O
the	O
labeling	O
index	O
of	O
intestinal	O
cancers	O
were	O
investigated	O
in	O
male	O
Wistar	O
rats	O
.	O

METHODS	O
:	O
From	O
the	O
beginning	O
of	O
the	O
experiment	O
,	O
rats	O
were	O
given	O
10	O
weekly	O
subcutaneous	O
injections	O
of	O
AOM	S-drug_n
(	O
7.4	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
and	O
subcutaneous	O
injections	O
of	O
bombesin	S-drug_n
(	O
40	O
microg	O
/	O
kg	O
body	O
weight	O
)	O
every	O
other	O
day	O
,	O
and	O
from	O
week	O
16	O
,	O
intraperitoneal	O
injections	O
of	O
verapamil	S-drug
(	O
10	O
or	O
20	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
every	O
other	O
day	O
until	O
the	O
end	O
fo	O
the	O
experiment	O
in	O
week	O
45	O
.	O

RESULTS	O
:	O
Bombesin	S-drug_n
significantly	O
increased	O
the	O
incidence	O
of	O
intestinal	O
tumors	O
and	O
cancer	O
metastasis	O
to	O
the	O
peritoneum	O
.	O

Although	O
verapamil	S-drug
administered	O
at	O
either	O
dose	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
enhancement	O
of	O
intestinal	O
carcinogenesis	O
by	O
bombesin	S-drug_n
or	O
on	O
the	O
location	O
,	O
histologic	O
type	O
,	O
depth	O
of	O
involvement	O
,	O
labeling	O
index	O
,	O
apoptotic	O
index	O
or	O
tumor	O
vascularity	O
of	O
intestinal	O
cancers	O
,	O
it	O
significantly	O
decreased	O
the	O
incidence	O
of	O
cancer	O
metastasis	O
.	O

Verapamil	S-drug-EF-1
also	O
significantly	O
decreased	O
the	O
incidence	O
of	O
lymphatic	O
invasion	O
of	O
adenocarcinomas	O
,	O
which	O
was	O
enhanced	O
by	O
bombesin	S-drug_n-EF-2
.	O

CONCLUSION	O
:	O
These	O
findings	O
indicate	O
that	O
verapamil	S-drug
inhibits	O
cancer	O
metastasis	O
through	O
actions	O
that	O
do	O
not	O
affect	O
the	O
growth	O
of	O
intestinal	O
cancers	O
.	O

In	O
vitro	O
interaction	O
of	O
prostaglandin	B-drug-IN-1
F2alpha	E-drug-IN-1
and	O
oxytocin	S-drug-IN-2
in	O
placental	O
vessels	O
.	O

The	O
interaction	O
of	O
prostaglandin	B-drug
F2alpha	E-drug
and	O
synthetic	O
oxytocin	S-drug
on	O
placental	O
vessels	O
was	O
studied	O
in	O
vitro	O
.	O

Resistance	O
was	O
measured	O
near	O
the	O
placental	O
margin	O
after	O
spontaneous	O
term	O
delivery	O
.	O

In	O
seven	O
experiments	O
reactions	O
to	O
norepinephrine	S-drug
and	O
oxytocin	S-drug
were	O
PGF2alpha	S-drug
.	O

PGF2alpha	S-drug-EF-1
produced	O
significantly	O
increased	O
vasoconstriction	O
after	O
a	O
single	O
administration	O
of	O
oxytocin	S-drug-EF-2
.	O

In	O
eight	O
experiments	O
the	O
perfusion	O
medium	O
contained	O
oxytocin	S-drug
.	O

There	O
was	O
no	O
change	O
after	O
a	O
single	O
dose	O
of	O
PGF2alpha	S-drug
.	O

The	O
reaction	O
after	O
norepinephrine	S-drug
remained	O
the	O
same	O
in	O
both	O
groups	O
of	O
experiments	O
.	O

There	O
is	O
thus	O
an	O
enhancement	O
effect	O

There	O
is	O
thus	O
an	O
enhancement	O
effect	O
of	O
PGF2alpha	S-drug-EF-1
upon	O
the	O
reaction	O
of	O
placental	O
vessels	O
to	O
oxytocin	S-drug-EF-2
in	O
vitro	O
.	O

Carbamazepine	S-drug
overdose	O
recognized	O
by	O
a	O
tricyclic	B-group
antidepressant	E-group
assay	O
.	O

Altered	O
mental	O
status	O
in	O
an	O
adolescent	O
presents	O
a	O
diagnostic	O
challenge	O
,	O
and	O
the	O
clinician	O
depends	O
on	O
clinical	O
evaluation	O
and	O
laboratory	O
studies	O
to	O
determine	O
therapy	O
and	O
prognosis	O
.	O

We	O
report	O
the	O
case	O
of	O
an	O
adolescent	O
with	O
altered	O
consciousness	O
caused	O
by	O
carbamazepine	S-drug-EF-1
overdose	O
with	O
a	O
positive	O
tricyclic	B-group-EF-2
antidepressant	E-group-EF-2
level	O
to	O
alert	O
clinicians	O
to	O
the	O
cross	O
-	O
reactivity	O
of	O
carbamazepine	S-drug-AD-1
with	O
a	O
toxicology	O
screen	O
for	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
.	O

Cypermethrin	S-drug-EF-1
-	O
induced	O
oxidative	O
stress	O
in	O
rat	O
brain	O
and	O
liver	O
is	O
prevented	O
by	O
vitamin	B-drug-EF-2
E	E-drug-EF-2
or	O
allopurinol	S-drug-EF-2
.	O

Considering	O
that	O
the	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
has	O
been	O
implicated	O
in	O
the	O
toxicity	O
of	O
various	O
pesticides	O
,	O
this	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
possibility	O
of	O
oxidative	O
stress	O
induction	O
by	O
cypermethrin	S-drug
,	O
a	O
Type	B-drug_n
II	I-drug_n
pyrethroid	E-drug_n
.	O

Either	O
single	O
(	O
170	O
mg	O
/	O
kg	O
)	O
or	O
repeated	O
(	O
75	O
mg	O
/	O
kg	O
per	O
day	O
for	O
5	O
days	O
)	O
oral	O
administration	O
of	O
cypermethrin	S-drug
was	O
found	O
to	O
produce	O
significant	O
oxidative	O
stress	O
in	O
cerebral	O
and	O
hepatic	O
tissues	O
of	O
rats	O
,	O
as	O
was	O
evident	O
by	O
the	O
elevation	O
of	O
the	O
level	O
of	O
thiobarbituric	O
acid	O
reactive	O
substances	O
(	O
TBARS	O
)	O
in	O
both	O
tissues	O
,	O
either	O
4	O
or	O
24	O
h	O
after	O
treatment	O
.	O

Much	O
higher	O
changes	O
were	O
observed	O
in	O
liver	O
,	O
increasing	O
from	O
a	O
level	O
of	O
60	O
%	O
at	O
4	O
h	O
up	O
to	O
nearly	O
4	O
times	O
the	O
control	O
at	O
24	O
h	O
for	O
single	O
dose	O
.	O

Reduced	O
levels	O
(	O
up	O
to	O
20	O
%	O
)	O
of	O
total	O
glutathione	O
(	O
total	O
GSH	O
)	O
,	O
and	O
elevation	O
of	O
conjugated	O
dienes	O
(	O
approximately	O
60	O
%	O
in	O
liver	O
by	O
single	O
dose	O
at	O
4	O
h	O
)	O
also	O
indicated	O
the	O
presence	O
of	O
an	O
oxidative	O
insult	O
.	O

Glutathione	O
-	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
activity	O
,	O
however	O
,	O
did	O
not	O
differ	O
from	O
control	O
values	O
for	O
any	O
dose	O
or	O
at	O
any	O
time	O
point	O
in	O
cerebral	O
and	O
hepatic	O
tissues	O
.	O

Pretreatment	O
of	O
rats	O
with	O
allopurinol	S-drug-EF-1
(	O
100	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
or	O
Vitamin	B-drug-EF-1
E	E-drug-EF-1
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
,	O
ig	O
,	O
for	O
3	O
days	O
and	O
a	O
dose	O
of	O
40	O
mg	O
/	O
kg	O
on	O
the	O
4th	O
day	O
)	O
provided	O
significant	O
protection	O
against	O
the	O
elevation	O
of	O
TBARS	O
levels	O
in	O
cerebral	O
and	O
hepatic	O
tissues	O
,	O
induced	O
by	O
single	O
high	O
dose	O
of	O
oral	O
cypermethrin	S-drug-EF-2
administration	O
within	O
4	O
h	O
.	O

Thus	O
,	O
the	O
results	O
suggest	O
that	O
cypermethrin	S-drug-EF-1
exposure	O
of	O
rats	O
results	O
in	O
free	O
radical	O
-	O
mediated	O
tissue	O
damage	O
,	O
as	O
indicated	O
by	O
elevated	O
cerebral	O
and	O
hepatic	O
lipid	O
peroxidation	O
,	O
which	O
was	O
prevented	O
by	O
allopurinol	S-drug-EF-2
and	O
Vitamin	B-drug-EF-2
E	E-drug-EF-2
.	O

Effect	O
of	O
ginsenosides	S-drug_n
on	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
subtypes	O
in	O
bovine	O
chromaffin	O
cells	O
.	O

In	O
previous	O
reports	O
we	O
have	O
shown	O
that	O
ginsenosides	S-drug_n
inhibit	O
high	O
threshold	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
channels	O
in	O
neuronal	O
cells	O
.	O

However	O
,	O
these	O
studies	O
did	O
not	O
show	O
whether	O
ginsenosides	S-drug_n
-	O
induced	O
inhibition	O
of	O
Ca	O
(	O
2	O
+	O
)	O
currents	O
discriminates	O
among	O
the	O
various	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
subtypes	O
,	O
although	O
it	O
is	O
known	O
that	O
there	O
are	O
at	O
least	O
five	O
different	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
subtypes	O
in	O
neuronal	O
cells	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
ginsenosides	S-drug_n
on	O
high	O
threshold	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
subtypes	O
using	O
their	O
selective	B-group
Ca	I-group
(	I-group
2	I-group
+	I-group
)	I-group
channel	I-group
blockers	E-group
nimodipine	S-drug
(	O
L	O
-	O
type	O
)	O
,	O
omega	B-drug_n
-	I-drug_n
conotoxin	I-drug_n
GVIA	E-drug_n
(	O
N	O
-	O
type	O
)	O
,	O
or	O
omega	B-drug_n
-	I-drug_n
agatoxin	I-drug_n
IVA	E-drug_n
(	O
P	O
-	O
type	O
)	O
in	O
bovine	O
chromaffin	O
cells	O
.	O

We	O
could	O
observe	O
that	O
ginsenosides	S-drug_n
inhibited	O
high	O
threshold	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
currents	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
IC	O
(	O
50	O
)	O
was	O
about	O
120	O
microgram	O
/	O
ml	O
.	O

Nimodipine	S-drug
had	O
no	O
effect	O
on	O
ginsenosides	S-drug_n
response	O
.	O

These	O
data	O
suggest	O
that	O
ginsenosides	S-drug_n
are	O
negatively	O
coupled	O
to	O
three	O
types	O
of	O
calcium	O
channels	O
in	O
bovine	O
chromaffin	O
cell	O
,	O
including	O
an	O
omega	B-drug_n
-	I-drug_n
conotoxin	I-drug_n
GVIA	E-drug_n
-	O
sensitive	O
(	O
N	O
-	O
type	O
)	O
channel	O
,	O
an	O
omega	B-drug_n
-	I-drug_n
agatoxin	I-drug_n
IVA	E-drug_n
-	O
sensitive	O
(	O
P	O
-	O
type	O
)	O
channel	O
and	O
nimodipine	S-drug
/	O
omega	B-drug_n
-	I-drug_n
conotoxin	I-drug_n
GVIA	E-drug_n
/	O
omega	B-drug_n
-	I-drug_n
agatoxin	I-drug_n
VIA	E-drug_n
-	O
resistant	O
(	O
presumptive	O
Q	O
-	O
type	O
)	O
channel	O
.	O

Thus	O
,	O
the	O
selective	O
regulation	O
of	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
subtypes	O
by	O
ginsenosides	S-drug_n
in	O
bovine	O
chromaffin	O
cell	O
could	O
be	O
the	O
cellular	O
basis	O
of	O
antistress	O
effects	O
induced	O
by	O
ginseng	S-drug
.	O

In	O
vitro	O
activity	O
of	O
KRM	B-drug_n
-	I-drug_n
1648	E-drug_n
,	O
either	O
singly	O
or	O
in	O
combination	O
with	O
ofloxacin	S-drug
,	O
against	O
Mycobacterium	O
ulcerans	O
.	O

The	O
antimicrobial	O
effect	O
of	O
a	O
benzoxazinorifamycin	S-drug_n
,	O
KRM	B-drug_n
-	I-drug_n
1648	E-drug_n
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
ofloxacin	S-drug
,	O
was	O
evaluated	O
in	O
vitro	O
against	O
two	O
type	O
strains	O
and	O
six	O
clinical	O
isolates	O
of	O
Mycobacterium	O
ulcerans	O
.	O

Growth	O
of	O
M	O
.	O

ulcerans	O
was	O
measured	O
by	O
plate	O
counts	O
and	O
the	O
BACTEC	O
radiometric	O
method	O
.	O

The	O
minimal	O
inhibitory	O
concentration	O
as	O
well	O
as	O
minimal	O
bactericidal	O
concentration	O
of	O
KRM	B-drug_n
-	I-drug_n
1648	E-drug_n
against	O
M	O
.	O

ulcerans	O
was	O
between	O
0.012	O
and	O
0.025	O
mg	O
/	O
l	O
,	O
while	O
corresponding	O
values	O
for	O
rifampicin	S-drug
and	O
rifabutin	S-drug
were	O
in	O
the	O
range	O
of	O
0.1	O
-	O
0.8	O
mg	O
/	O
l	O
and	O
0.1	O
-	O
0.4	O
mg	O
/	O
l	O
respectively	O
.	O

When	O
combined	O
with	O
ofloxacin	S-drug-EF-1
,	O
KRM	B-drug_n-EF-2
-	I-drug_n-EF-2
1648	E-drug_n-EF-2
exhibited	O
strong	O
synergistic	O
activity	O
while	O
only	O
additive	O
effects	O
were	O
observed	O
with	O
the	O
combination	O
of	O
rifampicin	S-drug-EF-1
(	O
or	O
rifabutin	S-drug-EF-1
)	O
and	O
ofloxacin	S-drug-EF-2
.	O

These	O
results	O
suggest	O
that	O
KRM	B-drug_n
-	I-drug_n
1648	E-drug_n
has	O
a	O
great	O
potential	O
in	O
the	O
treatment	O
of	O
M	O
.	O

ulcerans	O
infection	O
.	O

Inhibitory	O
effects	O
of	O
ruthenium	B-drug_n
red	E-drug_n
on	O
inositol	O
1,4	O
,	O
5	O
-	O
trisphosphate	O
-	O
induced	O
responses	O
in	O
rat	O
megakaryocytes	O
.	O

The	O
effects	O
of	O
ruthenium	B-drug_n
red	E-drug_n
(	O
RR	S-drug_n
)	O
on	O
inositol	B-drug_n
1,4,5	I-drug_n
-	I-drug_n
trisphosphate	E-drug_n
(	O
InsP	B-drug_n
(	I-drug_n
3	I-drug_n
)	E-drug_n
)	O
-	O
induced	O
responses	O
were	O
studied	O
in	O
rat	O
bone	O
marrow	O
megakaryocytes	O
with	O
the	O
patch	O
-	O
clamp	O
whole	O
-	O
cell	O
recording	O
technique	O
in	O
combination	O
with	O
fura	O
-	O
2	O
microfluorometry	O
.	O

Internal	O
application	O
of	O
InsP	B-drug_n
(	I-drug_n
3	I-drug_n
)	E-drug_n
(	O
100	O
microM	O
)	O
increased	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
concentration	O
(	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
)	O
and	O
activated	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
K	O
(	O
+	O
)	O
current	O
.	O

Administering	O
InsP	B-drug_n-EF-1
(	I-drug_n-EF-1
3	I-drug_n-EF-1
)	E-drug_n-EF-1
together	O
with	O
RR	S-drug_n-EF-2
(	O
100	O
-	O
500	O
microM	O
)	O
inhibited	O
InsP	O
(	O
3	O
)	O
-	O
induced	O
responses	O
(	O
both	O
Ca	O
(	O
2	O
+	O
)	O
and	O
current	O
responses	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

Pretreatment	O
of	O
megakaryocytes	O
with	O
extracellular	O
RR	S-drug_n-EF-1
(	O
50	O
microM	O
)	O
also	O
inhibited	O
InsP	B-drug_n-EF-2
(	I-drug_n-EF-2
3	I-drug_n-EF-2
)	E-drug_n-EF-2
-	O
induced	O
responses	O
.	O

Intracellular	O
and	O
extracellular	O
application	O
of	O
RR	S-drug_n
reduced	O
ADP	O
-	O
induced	O
increases	O
in	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
.	O

In	O
contrast	O
,	O
in	O
isolated	O
single	O
pancreatic	O
acinar	O
cells	O
,	O
RR	S-drug_n
had	O
no	O
effect	O
on	O
InsP	B-drug_n
(	I-drug_n
3	I-drug_n
)	E-drug_n
-	O
induced	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
site	O
of	O
the	O
inhibitory	O
action	O
of	O
RR	S-drug_n
is	O
at	O
the	O
InsP	O
(	O
3	O
)	O
receptor	O
,	O
or	O
its	O
closely	O
associated	O
proteins	O
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
RR	S-drug_n
is	O
a	O
useful	O
pharmacological	O
tool	O
with	O
which	O
to	O
examine	O
the	O
InsP	B-drug_n
(	I-drug_n
3	I-drug_n
)	E-drug_n
-	O
mediated	O
responses	O
of	O
megakaryocytes	O
.	O

Effect	O
of	O
rofecoxib	S-drug
on	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
in	O
healthy	O
volunteers	O
.	O

The	O
authors	O
examined	O
the	O
effect	O
of	O
the	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
inhibitor	O
,	O
rofecoxib	S-drug
,	O
at	O
steady	O
state	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
following	O
a	O
single	O
dose	O
in	O
healthy	O
subjects	O
.	O

Each	O
healthy	O
subject	O
(	O
N	O
=	O
10	O
)	O
received	O
rofecoxib	S-drug
(	O
75	O
mg	O
once	O
daily	O
)	O
or	O
placebo	O
for	O
11	O
days	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
balanced	O
,	O
two	O
-	O
period	O
crossover	O
study	O
.	O

A	O
single	O
0.5	O
mg	O
oral	O
dose	O
of	O
digoxin	S-drug
elixir	O
was	O
administered	O
on	O
the	O
7th	O
day	O
of	O
each	O
11	O
-	O
day	O
period	O
.	O

Each	O
treatment	O
period	O
was	O
separated	O
by	O
14	O
to	O
21	O
days	O
.	O

Samples	O
for	O
plasma	O
and	O
urine	O
immunoreactive	O
digoxin	S-drug
concentrations	O
were	O
collected	O
through	O
120	O
hours	O
following	O
the	O
digoxin	S-drug
dose	O
.	O

No	O
statistically	O
significant	O
differences	O
between	O
treatment	O
groups	O
were	O
observed	O
for	O
any	O
of	O
the	O
calculated	O
digoxin	S-drug
pharmacokinetic	O
parameters	O
.	O

For	O
digoxin	S-drug
AUC	O
(	O
0	O
-	O
infinity	O
)	O
,	O
AUC	O
(	O
0	O
-	O
24	O
)	O
,	O
and	O
Cmax	O
,	O
the	O
geometric	O
mean	O
ratios	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
for	O
(	O
rofecoxib	S-drug
+	O
digoxin	S-drug
/	O
placebo	O
+	O
digoxin	S-drug
)	O
were	O
1.04	O
(	O
0.94	O
,	O
1.14	O
)	O
,	O
1.02	O
(	O
0.94	O
,	O
1.09	O
)	O
,	O
and	O
1.00	O
(	O
0.91	O
,	O
1.10	O
)	O
,	O
respectively	O
.	O

The	O
digoxin	S-drug
median	O
tmax	O
was	O
0.5	O
hours	O
for	O
both	O
treatments	O
.	O

The	O
harmonic	O
mean	O
elimination	O
half	O
-	O
life	O
was	O
45.7	O
and	O
43.4	O
hours	O
for	O
rofecoxib	S-drug
+	O
digoxin	S-drug
and	O
placebo	O
+	O
digoxin	S-drug
treatments	O
,	O
respectively	O
.	O

Digoxin	S-drug
is	O
eliminated	O
renally	O
.	O

The	O
mean	O
(	O
SD	O
)	O
cumulative	O
urinary	O
excretion	O
of	O
immunoreactive	O
digoxin	S-drug
after	O
concurrent	O
treatment	O
with	O
rofecoxib	S-drug
or	O
placebo	O
was	O
228.2	O
(	O
+	O
/	O
-	O
30.8	O
)	O
and	O
235.1	O
(	O
+	O
/	O
-	O
39.1	O
)	O
micrograms	O
/	O
120	O
hours	O
,	O
respectively	O
.	O

Transient	O
and	O
minor	O
adverse	O
events	O
occurred	O
with	O
similar	O
frequency	O
on	O
placebo	O
and	O
rofecoxib	S-drug
treatments	O
,	O
and	O
no	O
treatment	O
-	O
related	O
pattern	O
was	O
apparent	O
.	O

Rofecoxib	S-drug
did	O
not	O
influence	O
the	O
plasma	O
pharmacokinetics	O
or	O
renal	O
elimination	O
of	O
a	O
single	O
oral	O
dose	O
of	O
digoxin	S-drug
.	O

Concomitant	O
cyclophosphamide	S-drug
,	O
doxorubicin	S-drug
,	O
vincristine	S-drug
,	O
and	O
prednisone	S-drug
chemotherapy	O
plus	O
highly	B-group
active	I-group
antiretroviral	E-group
therapy	O
in	O
patients	O
with	O
human	O
immunodeficiency	O
virus	O
-	O
related	O
,	O
non	O
-	O
Hodgkin	O
lymphoma	O
.	O

BACKGROUND	O
:	O
The	O
feasibility	O
and	O
efficacy	O
of	O
concomitant	O
chemotherapy	O
and	O
highly	B-group
active	I-group
antiretroviral	E-group
therapy	O
(	O
HAART	O
)	O
is	O
still	O
unknown	O
in	O
patients	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
related	O
malignancies	O
.	O

To	O
evaluate	O
the	O
impact	O
of	O
chemotherapy	O
plus	O
HAART	O
on	O
the	O
clinical	O
course	O
of	O
patients	O
with	O
HIV	O
-	O
related	O
,	O
systemic	O
,	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
HIV	O
-	O
NHL	O
)	O
,	O
the	O
authors	O
compared	O
retrospectively	O
a	O
group	O
of	O
24	O
patients	O
with	O
HIV	O
-	O
NHL	O
who	O
were	O
treated	O
with	O
the	O
cyclophosphamide	S-drug
,	O
doxorubicin	S-drug
,	O
vincristine	S-drug
,	O
and	O
prednisone	S-drug
(	O
CHOP	O
)	O
chemotherapy	O
regimen	O
plus	O
HAART	O
with	O
a	O
group	O
of	O
80	O
patients	O
who	O
were	O
treated	O
with	O
CHOP	O
chemotherapy	O
or	O
a	O
CHOP	O
-	O
like	O
regimen	O
(	O
i.e	O
.	O
,	O
cyclophosphamide	S-drug
,	O
doxorubicin	S-drug
,	O
teniposide	S-drug
,	O
and	O
prednisone	S-drug
with	O
vincristine	S-drug
plus	O
bleomycin	S-drug
)	O
without	O
receiving	O
antiretroviral	S-group
therapy	O
.	O

METHODS	O
:	O
All	O
patients	O
were	O
enrolled	O
in	O
two	O
sequential	O
trials	O
performed	O
at	O
the	O
Aviano	O
Cancer	O
Center	O
,	O
Italy	O
,	O
from	O
April	O
1988	O
to	O
December	O
1998	O
.	O

HAART	O
was	O
included	O
with	O
combination	O
therapy	O
from	O
January	O
1997	O
.	O

Antiretroviral	S-group
regimens	O
consisted	O
of	O
two	O
reverse	B-group
transcriptase	I-group
inhibitors	E-group
and	O
one	O
protease	B-group
inhibitor	E-group
.	O

RESULTS	O
:	O
The	O
two	O
treatment	O
groups	O
were	O
well	O
matched	O
with	O
regard	O
to	O
patient	O
demographics	O
,	O
NHL	O
characteristics	O
,	O
HIV	O
status	O
,	O
and	O
treatment	O
,	O
i.e	O
.	O
,	O
the	O
number	O
of	O
cycles	O
and	O
chemotherapy	O
dose	O
.	O

The	O
response	O
rates	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Severe	O
anemia	O
(	O
Grade	O
3	O
-	O
4	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
criteria	O
)	O
was	O
significantly	O
greater	O
in	O
the	O
patients	O
who	O
received	O
CHOP	O
-	O
HAART	O
compared	O
with	O
the	O
patients	O
who	O
received	O
CHOP	O
alone	O
(	O
33	O
%	O
vs.	O
7	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.001	O
)	O
.	O

Leukopenia	O
was	O
similar	O
between	O
the	O
two	O
groups	O
,	O
but	O
colony	O
stimulating	O
factor	O
support	O
was	O
significantly	O
greater	O
in	O
the	O
CHOP	O
-	O
HAART	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
92	O
%	O
vs.	O
66	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.03	O
)	O
.	O

Seventeen	O
percent	O
of	O
CHOP	O
-	O
HAART	O
patients	O
developed	O
severe	O
autonomic	O
neurotoxicity	O
,	O
whereas	O
none	O
of	O
the	O
CHOP	O
patients	O
developed	O
neurotoxicity	O
(	O
P	O
=	O
0.002	O
)	O
.	O

At	O
similar	O
median	O
follow	O
-	O
up	O
,	O
opportunistic	O
infection	O
(	O
OI	O
)	O
rates	O
and	O
mortality	O
were	O
significantly	O
lower	O
in	O
the	O
CHOP	O
-	O
HAART	O
patients	O
than	O
in	O
the	O
CHOP	O
patients	O
(	O
18	O
%	O
vs.	O
52	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.05	O
;	O
and	O
38	O
%	O
vs.	O
85	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.001	O
)	O
.	O

The	O
median	O
survival	O
for	O
CHOP	O
-	O
HAART	O
patients	O
was	O
not	O
reached	O
,	O
whereas	O
the	O
medial	O
survival	O
of	O
CHOP	O
patients	O
was	O
7	O
months	O
(	O
P	O
=	O
0.03	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
CHOP	O
plus	O
HAART	O
is	O
feasible	O
and	O
may	O
reduce	O
the	O
morbidity	O
from	O
OIs	O
in	O
HIV	O
-	O
NHL	O
patients	O
.	O

However	O
,	O
careful	O
attention	O
must	O
be	O
directed	O
to	O
cross	O
toxicity	O
and	O
possible	O
pharmacokinetic	O
interactions	O
between	O
antiretroviral	S-group-AD-1
and	O
antineoplastic	B-group-AD-2
drugs	E-group-AD-2
.	O

The	O
impact	O
of	O
the	O
combined	O
chemotherapy	O
plus	O
HAART	O
treatment	O
on	O
patient	O
survival	O
needs	O
urgently	O
to	O
be	O
evaluated	O
in	O
prospective	O
studies	O
.	O

Acute	O
effect	O
of	O
different	O
antidepressants	S-group
on	O
glycemia	O
in	O
diabetic	O
and	O
non	O
-	O
diabetic	O
rats	O
.	O

Diabetic	O
patients	O
have	O
a	O
20	O
%	O
higher	O
risk	O
of	O
depression	O
than	O
the	O
general	O
population	O
.	O

Treatment	O
with	O
antidepressant	B-group-IN-1
drugs	E-group-IN-1
can	O
directly	O
interfere	O
with	O
blood	O
glucose	O
levels	O
or	O
may	O
interact	O
with	O
hypoglycemic	B-group-IN-2
agents	E-group-IN-2
.	O

The	O
treatment	O
of	O
depression	O
in	O
diabetic	O
patients	O
must	O
take	O
into	O
account	O
variations	O
of	O
glycemic	O
levels	O
at	O
different	O
times	O
and	O
a	O
comparison	O
of	O
the	O
available	O
antidepressant	B-group
agents	E-group
is	O
important	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
interference	O
of	O
antidepressants	S-group
with	O
blood	O
glucose	O
levels	O
of	O
diabetic	O
and	O
non	O
-	O
diabetic	O
rats	O
.	O

In	O
a	O
first	O
experiment	O
,	O
male	O
adult	O
Wistar	O
rats	O
were	O
fasted	O
for	O
12	O
h	O
.	O

Imipramine	S-drug
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
moclobemide	S-drug
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
clonazepam	S-drug
(	O
0.25	O
mg	O
/	O
kg	O
)	O
,	O
fluoxetine	S-drug
(	O
20	O
mg	O
/	O
kg	O
)	O
sertraline	S-drug
(	O
30	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	O
was	O
administered	O
.	O

After	O
30	O
min	O
,	O
fasting	O
glycemia	O
was	O
measured	O
.	O

An	O
oral	O
glucose	S-drug
overload	O
of	O
1	O
ml	O
of	O
a	O
50	O
%	O
glucose	S-drug
solution	O
was	O
given	O
to	O
rats	O
and	O
blood	O
glucose	O
was	O
determined	O
after	O
30	O
,	O
60	O
and	O
90	O
min	O
.	O

Imipramine	S-drug
and	O
clonazepam	S-drug
did	O
not	O
change	O
fasting	O
or	O
overload	O
glycemia	O
.	O

Fluoxetine	S-drug
and	O
moclobemide	S-drug
increased	O
blood	O
glucose	S-drug
at	O
different	O
times	O
after	O
the	O
glucose	O
overload	O
.	O

Sertraline	S-drug
neutralized	O
the	O
increase	O
of	O
glycemia	O
induced	O
by	O
oral	O
glucose	S-drug
overload	O
.	O

In	O
the	O
second	O
experiment	O
,	O
non	O
-	O
diabetic	O
and	O
streptozotocin	O
-	O
induced	O
diabetic	O
rats	O
were	O
fasted	O
,	O
and	O
the	O
same	O
procedures	O
were	O
followed	O
for	O
estimation	O
of	O
glucose	S-drug
tolerance	O
30	O
min	O
after	O
glucose	S-drug
overload	O
.	O

Again	O
,	O
sertraline	S-drug
neutralized	O
the	O
increase	O
in	O
glycemia	O
after	O
glucose	S-drug
overload	O
both	O
in	O
diabetic	O
and	O
non	O
-	O
diabetic	O
rats	O
.	O

These	O
data	O
raise	O
the	O
question	O
of	O
whether	O
sertraline	S-drug
is	O
the	O
best	O
choice	O
for	O
prolonged	O
use	O
for	O
diabetic	O
individuals	O
,	O
because	O
of	O
its	O
antihyperglycemic	O
effects	O
.	O

Clonazepam	S-drug
would	O
be	O
useful	O
in	O
cases	O
with	O
potential	O
risk	O
of	O
hypoglycemia	O
.	O

Activity	O
of	O
buforin	B-drug_n
II	E-drug_n
alone	O
and	O
in	O
combination	O
with	O
azithromycin	S-drug
and	O
minocycline	S-drug
against	O
Cryptosporidium	O
parvum	O
in	O
cell	O
culture	O
.	O

The	O
in	O
vitro	O
anti	O
-	O
cryptosporidial	O
activity	O
of	O
buforin	B-drug_n
II	E-drug_n
alone	O
and	O
in	O
combination	O
with	O
azithromycin	S-drug
and	O
minocycline	S-drug
was	O
investigated	O
.	O

Buforin	B-drug_n
II	E-drug_n
showed	O
moderate	O
activity	O
,	O
which	O
increased	O
with	O
increasing	O
concentration	O
to	O
55.7	O
%	O
suppression	O
of	O
growth	O
at	O
20	O
microM	O
.	O

Moreover	O
,	O
its	O
activity	O
was	O
enhanced	O
when	O
it	O
was	O
combined	O
with	O
either	O
azithromycin	S-drug
or	O
minocycline	S-drug
with	O
90	O
%	O
parasite	O
reduction	O
at	O
the	O
highest	O
concentration	O
tested	O
.	O

Buforin	B-drug_n-EF-1
II	E-drug_n-EF-1
may	O
be	O
active	O
in	O
inhibiting	O
Cryptosporidium	O
parvum	O
growth	O
in	O
vitro	O
upon	O
combination	O
with	O
either	O
azithromycin	S-drug-EF-2
or	O
minocycline	S-drug-EF-2
.	O

Effect	O
of	O
dofetillide	S-drug
on	O
the	O
pharmacokinetics	O
of	O
digoxin	S-drug
.	O

The	O
effect	O
of	O
dofetilide	S-drug
on	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
digoxin	S-drug
was	O
evaluated	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

Five	O
days	O
of	O
dofetilide	S-drug
treatment	O
did	O
not	O
significantly	O
affect	O
steady	O
-	O
state	O
pharmacokinetic	O
variables	O
of	O
digoxin	S-drug
compared	O
with	O
placebo	O
;	O

therefore	O
,	O
the	O
use	O
of	O
dofetilide	S-drug
does	O
not	O
necessitate	O
an	O
adjustment	O
in	O
digoxin	S-drug
dose	O
to	O
maintain	O
therapeutic	O
digoxin	O
levels	O
.	O

Anaesthesia	O
and	O
the	O
epileptic	O
pateint	O
.	O

A	O
review	O
.	O

A	O
review	O
is	O
presented	O
of	O
some	O
of	O
the	O
problems	O
that	O
may	O
arise	O
in	O
association	O
with	O
anaesthesia	O
for	O
epileptic	O
patients	O
.	O

There	O
is	O
the	O
possibility	O
of	O
precipitating	O
anticonvulsant	O
drug	O
toxicity	O
.	O

Numerous	O
drug	O
interactions	O
are	O
possible	O
with	O
some	O
anticonvulsant	B-group
agents	E-group
,	O
such	O
as	O
phenobarbitone	S-drug
and	O
phenytoin	S-drug
,	O
which	O
affect	O
hepatic	O
microsomal	O
enzyme	O
systems	O
.	O

There	O
is	O
the	O
risk	O
of	O
convulsions	O
occurring	O
in	O
susceptible	O
patients	O
following	O
the	O
use	O
of	O
the	O
new	O
anaesthetic	B-group
agents	E-group
which	O
are	O
capable	O
of	O
inducing	O
CNS	O
excitability	O
.	O

Interaction	O
of	O
ketamine	S-drug-IN-1
and	O
halothane	S-drug-IN-2
in	O
rats	O
.	O

The	O
interaction	O
of	O
intramuscularly	O
injected	O
ketamine	S-drug
and	O
its	O
N	O
-	O
demethylated	O
metabolite	O
(	O
metabolite	O
I	O
)	O
with	O
halothane	S-drug
was	O
evaluated	O
in	O
rats	O
.	O

Five	O
,	O
10	O
,	O
20	O
,	O
or	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	S-drug
alone	O
or	O
20	O
,	O
50	O
,	O
or	O
100	O
mg	O
/	O
kg	O
of	O
metabolite	O
I	O
alone	O
produced	O
less	O
than	O
10	O
minutes	O
of	O
hypnosis	O
.	O

However	O
,	O
halothane	S-drug-ME-1
anesthetic	O
requirement	O
(	O
i.e	O
.	O
,	O
MAC	O
)	O
was	O
depressed	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
as	O
much	O
as	O
56	O
%	O
1	O
-	O
2	O
hours	O
and	O
as	O
much	O
as	O
14	O
%	O
5	O
-	O
6	O
hours	O
after	O
injection	O
of	O
ketamine	S-drug-ME-2
,	O
50	O
mg	O
/	O
kg	O
,	O
im	O
.	O

The	O
reduction	O
in	O
MAC	O
was	O
correlated	O
with	O
brain	O
levels	O
of	O
ketamine	S-drug
or	O
metabolite	O
I	O
,	O
suggesting	O
a	O
ketamine	S-drug
:	O
metabolite	O
I	O
potency	O
ration	O
of	O
3	O
:	O
1	O
.	O

The	O
half	O
-	O
life	O
of	O
ketamine	S-drug-ME-1
in	O
plasma	O
and	O
brain	O
was	O
longer	O
in	O
the	O
presence	O
of	O
halothane	S-drug-ME-2
than	O
when	O
ketamine	S-drug
was	O
given	O
alone	O
.	O

It	O
is	O
concluded	O
that	O
ketamine	S-drug-EF-1
is	O
not	O
a	O
short	O
-	O
acting	O
drug	O
and	O
that	O
concomitant	O
use	O
with	O
halothane	S-drug-EF-2
would	O
be	O
expected	O
to	O
prolong	O
further	O
the	O
duration	O
of	O
its	O
action	O
on	O
the	O
central	O
nervous	O
system	O
.	O

Rifampin	S-drug-IN-1
and	O
warfarin	S-drug-IN-2
:	O
a	O
drug	O
interaction	O
.	O

The	O
drug	O
interaction	O
between	O
warfarin	S-drug-IN-1
and	O
rifampin	S-drug-IN-2
is	O
not	O
well	O
known	O
.	O

Rifampin	S-drug-ME-1
has	O
been	O
reported	O
to	O
increase	O
the	O
warfarin	S-drug-ME-2
requirements	O
in	O
human	O
subjects	O
ingesting	O
these	O
agents	O
simultaneously	O
.	O

The	O
concomitant	O
administration	O
of	O
rifampin	S-drug-ME-1
and	O
warfarin	S-drug-ME-2
resulted	O
in	O
the	O
need	O
for	O
an	O
unusually	O
high	O
maintenance	O
dose	O
of	O
warfarin	S-drug
(	O
20	O
mg	O
per	O
day	O
)	O
in	O
order	O
to	O
produce	O
a	O
therapeutic	O
effect	O
.	O

Withdrawal	O
of	O
rifampin	S-drug-ME-1
decreased	O
the	O
warfarin	S-drug-ME-2
requirement	O
by	O
50	O
%	O
.	O

This	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
ability	O
of	O
rifampin	S-drug-ME-1
to	O
induce	O
microsomal	O
enzymes	O
and	O
,	O
thus	O
,	O
the	O
catabolism	O
of	O
warfarin	S-drug-ME-2
.	O

The	O
effect	O
of	O
rifampin	S-drug-EF-1
on	O
the	O
warfarin	S-drug-EF-2
requirement	O
of	O
our	O
patient	O
appeared	O
to	O
be	O
maximal	O
5	O
to	O
7	O
days	O
after	O
the	O
initiation	O
of	O
rifampin	S-drug
and	O
extended	O
a	O
similar	O
length	O
of	O
time	O
after	O
rifampin	S-drug
withdrawal	O
.	O

This	O
interaction	O
appears	O
to	O
be	O
clinically	O
significant	O
.	O

Thiolated	B-drug_n
carboxymethylcellulose	E-drug_n
:	O
in	O
vitro	O
evaluation	O
of	O
its	O
permeation	O
enhancing	O
effect	O
on	O
peptide	O
drugs	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
sodium	B-drug_n
carboxymethylcellulose	E-drug_n
(	O
NaCMC	S-drug_n
)	O
and	O
carboxymethylcellulose	B-drug_n
-	I-drug_n
cysteine	E-drug_n
(	O
CMC	B-drug_n
-	I-drug_n
Cys	E-drug_n
)	O
conjugates	O
on	O
the	O
intestinal	O
permeation	O
of	O
sodium	B-drug
fluorescein	E-drug
(	O
NaFlu	S-drug
)	O
and	O
model	O
peptide	O
drugs	O
,	O
bacitracin	S-drug
and	O
insulin	S-drug
.	O

Cysteine	S-drug
was	O
covalently	O
linked	O
to	O
carbodiimide	O
activated	O
NaCMC	S-drug_n
.	O

Iodometric	O
titration	O
of	O
the	O
polymer	O
conjugates	O
was	O
used	O
to	O
determine	O
the	O
extent	O
of	O
immobilised	O
cysteine	S-drug
.	O

Permeation	O
studies	O
were	O
performed	O
on	O
guinea	O
pig	O
small	O
intestinal	O
mucosa	O
mounted	O
in	O
Ussing	O
-	O
type	O
chamber	O
.	O

Unmodified	O
NaCMC	S-drug_n
(	O
1	O
%	O
m	O
/	O
v	O
)	O
significantly	O
improved	O
the	O
transport	O
ratio	O
(	O
R	O
=	O
P	O
(	O
app	O
)	O
polymer	O
/	O
P	O
(	O
app	O
)	O
control	O
)	O
of	O
NaFlu	S-drug
to	O
1.3	O
and	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
NaCMC	S-drug_n
conjugated	O
with	O
cysteine	S-drug
further	O
enhanced	O
the	O
permeation	O
.	O

Cysteine	S-drug
conjugation	O
at	O
3.6	O
,	O
5.3	O
and	O
7.3	O
%	O
(	O
m	O
/	O
m	O
)	O
resulted	O
in	O
R	O
-	O
values	O
of	O
1.4	O
,	O
1.7	O
and	O
1.8	O
,	O
respectively	O
.	O

Decreasing	O
the	O
concentration	O
of	O
CMC	B-drug_n
-	I-drug_n
Cys	E-drug_n
,	O
exhibiting	O
7.3	O
%	O
(	O
m	O
/	O
m	O
)	O
of	O
immobilised	O
cysteine	S-drug
(	O
CMC	O
-	O
Cys7.3	O
)	O
from	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
to	O
0.5	O
%	O
(	O
m	O
/	O
v	O
)	O
decreased	O
the	O
R	O
-	O
value	O
of	O
NaFlu	S-drug
from	O
1.8	O
to	O
1.2	O
.	O

NaCMC	S-drug_n
at	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
in	O
the	O
presence	O
of	O
free	O
cysteine	S-drug
had	O
no	O
significant	O
effect	O
on	O
the	O
R	O
-	O
value	O
of	O
NaFlu	S-drug
compared	O
to	O
NaCMC	S-drug_n
alone	O
.	O

Formulation	O
of	O
fluorescence	O
labelled	O
bacitracin	S-drug
and	O
insulin	S-drug
in	O
unconjugated	O
NaCMC	S-drug_n
(	O
1	O
%	O
m	O
/	O
v	O
)	O
did	O
not	O
significantly	O
improve	O
the	O
permeation	O
,	O
however	O
in	O
the	O
presence	O
of	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
CMC	B-drug_n
-	I-drug_n
Cys7.3	O
a	O
significantly	O
improved	O
permeation	O
was	O
observed	O
(	O
R	O
=	O
1.3	O
)	O
.	O

Conjugation	O
at	O
NaCMC	S-drug_n
with	O
cysteine	S-drug
moieties	O
significantly	O
improves	O
the	O
intestinal	O
permeation	O
of	O
the	O
hydrophilic	O
molecule	O
NaFlu	S-drug
and	O
the	O
model	O
peptide	O
drugs	O
bacitracin	S-drug
and	O
insulin	S-drug
in	O
vitro	O
,	O
therefore	O
this	O
conjugated	O
system	O
maybe	O
useful	O
for	O
peroral	O
administration	O
of	O
peptide	O
drugs	O
in	O
the	O
future	O
.	O

Systemic	O
antibiotic	B-group
agents	E-group
.	O

Understanding	O
the	O
breadth	O
of	O
systemic	O
antimicrobial	B-group
agents	E-group
available	O
for	O
use	O
by	O
the	O
dermatologist	O
and	O
their	O
associated	O
side	O
-	O
effect	O
profiles	O
and	O
drug	O
interactions	O
allows	O
the	O
clinician	O
to	O
offer	O
patients	O
optimal	O
care	O
in	O
the	O
management	O
of	O
cutaneous	O
infectious	O
disease	O
.	O

Drug	O
interactions	O
:	O
How	O
to	O
identify	O
them	O
.	O

Interactions	O
between	O
theraputic	O
agents	O
have	O
been	O
recognized	O
as	O
increasingly	O
important	O
causes	O
of	O
drug	O
at	O
their	O
usual	O
recommended	O
dose	O
may	O
,	O
under	O
certain	O
conditions	O
,	O
produce	O
toxicity	O
of	O
life	O
-	O
endangering	O
proportions	O
.	O

While	O
the	O
recognition	O
of	O
drug	O
toxicity	O
resulting	O
from	O
interactions	O
is	O
of	O
importance	O
to	O
all	O
physciains	O
,	O
it	O
is	O
especially	O
so	O
for	O
the	O
clinician	O
responsible	O
for	O
the	O
welfare	O
of	O
those	O
in	O
the	O
aerospace	O
environment	O
.	O

This	O
paper	O
attempts	O
to	O
provide	O
a	O
basis	O
for	O
the	O
understanding	O
and	O
identifications	O
of	O
important	O
drug	O
interactions	O
.	O

Guidelines	O
are	O
provided	O
to	O
assist	O
the	O
clinician	O
in	O
his	O
logical	O
approach	O
to	O
the	O
identification	O
of	O
drug	O
interactions	O
when	O
serious	O
drug	O
toxicity	O
is	O
encountered	O
in	O
a	O
pateint	O
.	O

Only	O
with	O
knowledge	O
of	O
the	O
interaction	O
can	O
the	O
therapeutic	O
regimen	O
be	O
altered	O
so	O
as	O
to	O
provide	O
therapeutic	O
levels	O
of	O
necessary	O
drugs	O
while	O
avoiding	O
toxicity	O
.	O

Pharmacokinetic	O
Interaction	O
between	O
amprenavir	S-drug
and	O
rifabutin	S-drug
or	O
rifampin	S-drug
in	O
healthy	O
males	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
there	O
is	O
a	O
pharmacokinetic	O
interaction	O
when	O
amprenavir	S-drug
is	O
given	O
with	O
rifabutin	S-drug
or	O
rifampin	S-drug
and	O
to	O
determine	O
the	O
effects	O
of	O
these	O
drugs	O
on	O
the	O
erythromycin	O
breath	O
test	O
(	O
ERMBT	O
)	O
.	O

Twenty	O
-	O
four	O
healthy	O
male	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
two	O
cohorts	O
.	O

All	O
subjects	O
received	O
amprenavir	S-drug
(	O
1,200	O
mg	O
twice	O
a	O
day	O
)	O
for	O
4	O
days	O
,	O
followed	O
by	O
a	O
7	O
-	O
day	O
washout	O
period	O
,	O
followed	O
by	O
either	O
rifabutin	S-drug
(	O
300	O
mg	O
once	O
a	O
day	O
[	O
QD	O
]	O
)	O
(	O
cohort	O
1	O
)	O
or	O
rifampin	S-drug
(	O
600	O
mg	O
QD	O
)	O
(	O
cohort	O
2	O
)	O
for	O
14	O
days	O
.	O

Cohort	O
1	O
then	O
received	O
amprenavir	S-drug
plus	O
rifabutin	S-drug
for	O
10	O
days	O
,	O
and	O
cohort	O
2	O
received	O
amprenavir	S-drug
plus	O
rifampin	S-drug
for	O
4	O
days	O
.	O

Serial	O
plasma	O
and	O
urine	O
samples	O
for	O
measurement	O
of	O
amprenavir	S-drug
,	O
rifabutin	S-drug
,	O
and	O
rifampin	S-drug
and	O
their	O
25	B-drug_n
-	I-drug_n
O	I-drug_n
-	I-drug_n
desacetyl	I-drug_n
metabolites	E-drug_n
,	O
were	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

Rifabutin	S-drug
did	O
not	O
significantly	O
affect	O
amprenavir	S-drug
's	O
pharmacokinetics	O
.	O

Amprenavir	S-drug-ME-1
significantly	O
increased	O
the	O
area	O
under	O
the	O
curve	O
at	O
steady	O
state	O
(	O
AUC	O
(	O
ss	O
)	O
)	O
of	O
rifabutin	S-drug-ME-2
by	O
2.93	O
-	O
fold	O
and	O
the	O
AUC	O
(	O
ss	O
)	O
of	O
25	B-drug_n-ME-2
-	I-drug_n-ME-2
O	I-drug_n-ME-2
-	I-drug_n-ME-2
desacetylrifabutin	E-drug_n-ME-2
by	O
13.3	O
-	O
fold	O
.	O

Rifampin	S-drug-ME-1
significantly	O
decreased	O
the	O
AUC	O
(	O
ss	O
)	O
of	O
amprenavir	S-drug-ME-2
by	O
82	O
%	O
,	O
but	O
amprenavir	S-drug
had	O
no	O
effect	O
on	O
rifampin	S-drug
pharmacokinetics	O
.	O

Amprenavir	S-drug
decreased	O
the	O
results	O
of	O
the	O
ERMBT	O
by	O
83	O
%	O
.	O

The	O
results	O
of	O
the	O
ERMBT	O
after	O
2	O
weeks	O
of	O
rifabutin	S-drug
and	O
rifampin	S-drug
therapy	O
were	O
increased	O
187	O
and	O
156	O
%	O
,	O
respectively	O
.	O

Amprenavir	S-drug
plus	O
rifampin	S-drug
was	O
well	O
tolerated	O
.	O

Amprenavir	S-drug-EF-1
plus	O
rifabutin	S-drug-EF-2
was	O
poorly	O
tolerated	O
,	O
and	O
5	O
of	O
11	O
subjects	O
discontinued	O
therapy	O
.	O

Rifampin	S-drug-ME-1
markedly	O
increases	O
the	O
metabolic	O
clearance	O
of	O
amprenavir	S-drug-ME-2
,	O
and	O
coadministration	O
is	O
contraindicated	O
.	O

Amprenavir	S-drug-ME-1
significantly	O
decreases	O
clearance	O
of	O
rifabutin	S-drug-ME-2
and	O
25	B-drug_n-ME-2
-	I-drug_n-ME-2
O	I-drug_n-ME-2
-	I-drug_n-ME-2
desacetylrifabutin	E-drug_n-ME-2
,	O
and	O
the	O
combination	O
is	O
poorly	O
tolerated	O
.	O

Amprenavir	S-drug
inhibits	O
the	O
ERMBT	O
,	O
and	O
rifampin	S-drug
and	O
rifabutin	S-drug
are	O
equipotent	O
inducers	O
of	O
the	O
ERMBT	O
.	O

New	O
oral	O
therapies	O
for	O
type	O
2	O
diabetes	O
mellitus	O
:	O
The	O
glitazones	S-group
or	O
insulin	O
sensitizers	O
.	O

Type	O
2	O
diabetes	O
mellitus	O
is	O
a	O
growing	O
problem	O
not	O
only	O
in	O
the	O
United	O
States	O
but	O
also	O
across	O
the	O
world	O
.	O

There	O
is	O
now	O
strong	O
evidence	O
that	O
intensive	O
control	O
of	O
blood	O
glucose	O
can	O
significantly	O
reduce	O
and	O
retard	O
the	O
microvascular	O
complications	O
of	O
retinopathy	O
,	O
nephropathy	O
,	O
and	O
neuropathy	O
.	O

Ultimately	O
however	O
,	O
up	O
to	O
80	O
%	O
of	O
type	O
2	O
diabetics	O
die	O
from	O
macrovascular	O
cardiovascular	O
disease	O
.	O

This	O
increased	O
incidence	O
of	O
atherosclerotic	O
disease	O
is	O
intricately	O
associated	O
with	O
insulin	O
resistance	O
,	O
which	O
is	O
a	O
major	O
pathophysiologic	O
abnormality	O
in	O
type	O
2	O
diabetes	O
.	O

There	O
is	O
strong	O
evidence	O
that	O
insulin	O
resistance	O
is	O
involved	O
in	O
the	O
development	O
of	O
not	O
only	O
hyperglycemia	O
,	O
but	O
also	O
dyslipidemia	O
,	O
hypertension	O
,	O
hypercoagulation	O
,	O
vasculopathy	O
,	O
and	O
ultimately	O
atherosclerotic	O
cardiovascular	O
disease	O
.	O

This	O
cluster	O
of	O
metabolic	O
abnormalities	O
has	O
been	O
termed	O
the	O
insulin	O
resistance	O
or	O
cardiovascular	O
dysmetabolic	O
syndrome	O
.	O

The	O
thiazolidinediones	S-group
(	O
rosiglitazone	S-drug
and	O
pioglitazone	S-drug
)	O
,	O
a	O
new	O
class	O
of	O
oral	O
antidiabetic	B-group
agents	E-group
,	O
are	O
``	O
insulin	O
sensitizers	O
``	O

and	O
exert	O
direct	O
effects	O
on	O
the	O
mechanisms	O
of	O
insulin	O
resistance	O
.	O

These	O
effects	O
not	O
only	O
improve	O
insulin	O
sensitivity	O
and	O
glycemic	O
control	O
with	O
reduced	O
insulin	O
requirements	O
,	O
but	O
also	O
have	O
potentially	O
favorable	O
effects	O
on	O
other	O
components	O
of	O
the	O
cardiovascular	O
dysmetabolic	O
syndrome	O
.	O

Long	O
-	O
term	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
the	O
insulin	O
-	O
sensitizing	O
effects	O
of	O
the	O
glitazones	S-group
can	O
prevent	O
or	O
delay	O
premature	O
atherosclerotic	O
cardiovascular	O
disease	O
,	O
morbidity	O
,	O
and	O
death	O
.	O

Responses	O
to	O
arginine	S-drug
of	O
the	O
perfused	O
pancreas	O
of	O
the	O
genetically	O
diabetic	O
Chinese	O
hamster	O
.	O

Nonketotic	O
,	O
genetically	O
diabetic	O
Cinese	O
hamsters	O
show	O
subnormal	O
pancreatic	O
insulin	O
release	O
and	O
impaired	O
suppression	O
of	O
glucagon	O
in	O
response	O
to	O
glucose	O
.	O

To	O
study	O
the	O
pancreatic	O
effects	O
of	O
other	O
agents	O
,	O
dynamic	O
insulin	O
and	O
glucagon	O
release	O
was	O
measured	O
from	O
the	O
in	O
vitro	O
perfused	O
pancreases	O
of	O
normal	O
and	O
diabetic	O
Chinese	O
hamsters	O
in	O
response	O
to	O
various	O
combinations	O
of	O
arginine	S-drug
(	O
20mM	O
)	O
,	O
glucose	S-drug
(	O
100	O
or	O
150	O
mg.	O
per	O
100	O
ml	O
.	O
)	O
,	O
and	O
theophylline	S-drug
(	O
10	O
mM	O
)	O
.	O

Theophylline	S-drug
alone	O
caused	O
identical	O
insulin	O
and	O
glucagon	O
release	O
in	O
diabetics	O
and	O
normals	O
.	O

Glucose	S-drug
,	O
alone	O
and	O
in	O
the	O
presence	O
of	O
theophylline	S-drug
,	O
caused	O
subnormal	O
insulin	O
release	O
and	O
less	O
suppression	O
of	O
glucagon	O
release	O
in	O
the	O
diabectics	O
than	O
in	O
the	O
normals	O
.	O

Arginine	S-drug
,	O
in	O
the	O
presence	O
of	O
glucose	S-drug
and	O
theophylline	S-drug
,	O
caused	O
excessive	O
glucagon	O
release	O
but	O
nearly	O
normal	O
insulin	O
release	O
in	O
the	O
diabetics	O
.	O

Arginine	S-drug
,	O
in	O
the	O
absence	O
of	O
glucose	S-drug
or	O
theophylline	S-drug
,	O
caused	O
excessive	O
glucagon	O
release	O
in	O
the	O
diabetics	O
and	O
undetectable	O
insulin	O
release	O
in	O
either	O
diabetics	O
or	O
normals	O
.	O

Pancreatic	O
content	O
after	O
perfusion	O
did	O
not	O
correlate	O
with	O
release	O
during	O
perfusion	O
.	O

Infusion	O
of	O
arginine	S-drug
alone	O
markedly	O
decreased	O
the	O
amount	O
of	O
extractable	O
pancreatic	O
insulin	O
and	O
glucagon	O
.	O

These	O
results	O
indicate	O
that	O
the	O
pancreatic	O
alpha	O
cell	O
of	O
the	O
diabetic	O
Chinese	O
hamster	O
responds	O
excessively	O
to	O
arginine	S-drug
,	O
as	O
is	O
seen	O
in	O
the	O
human	O
diabetic	O
.	O

This	O
defect	O
is	O
not	O
related	O
to	O
acute	O
insulin	O
release	O
or	O
the	O
presence	O
of	O
glucose	S-drug
.	O

Further	O
,	O
these	O
results	O
confirm	O
that	O
the	O
diabetic	O
Chinese	O
hamster	O
's	O
alpha	O
and	O
beta	O
cells	O
respond	O
normally	O
to	O
theophylline	S-drug
,	O
but	O
are	O
relatively	O
insensitive	O
to	O
glucose	S-drug
.	O

Effects	O
of	O
etofibrate	S-drug
upon	O
the	O
metabolism	O
of	O
chylomicron	O
-	O
like	O
emulsions	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

Slow	O
chylomicron	O
intravascular	O
catabolism	O
has	O
been	O
associated	O
with	O
coronary	O
artery	O
disease	O
and	O
screening	O
for	O
drugs	O
that	O
can	O
speed	O
-	O
up	O
this	O
process	O
can	O
be	O
important	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
etofibrate	S-drug
upon	O
chylomicron	O
metabolism	O
was	O
tested	O
by	O
determination	O
of	O
the	O
plasma	O
kinetics	O
of	O
a	O
chylomicron	O
-	O
like	O
emulsion	O
model	O
in	O
12	O
patients	O
with	O
coronary	O
artery	O
disease	O
,	O
aged	O
59	O
+	O
/	O
-	O
11	O
years	O
,	O
(	O
total	O
cholesterol	O
:	O
240	O
+	O
/	O
-	O
41	O
mg	O
/	O
dl	O
;	O
triglycerides	O
:	O
188	O
+	O
/	O
-	O
42	O
mg	O
/	O
dl	O
)	O
submitted	O
to	O
a	O
randomized	O
,	O
crossover	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
with	O
administration	O
of	O
1	O
g	O
per	O
day	O
etofibrate	S-drug
or	O
placebo	O
for	O
1	O
-	O
month	O
.	O

A	O
1	O
-	O
month	O
washout	O
period	O
was	O
inserted	O
between	O
the	O
treatment	O
periods	O
.	O

Patients	O
were	O
intravenously	O
injected	O
a	O
chylomicron	O
-	O
like	O
emulsion	O
doubly	O
labeled	O
with	O
14C	O
-	O
cholesteryl	O
oleate	O
and	O
3H	O
-	O
triolein	O
at	O
baseline	O
and	O
after	O
treatments	O
.	O

After	O
etofibrate	S-drug
treatment	O
,	O
there	O
was	O
decrease	O
of	O
total	O
cholesterol	O
and	O
triglyceride	O
plasma	O
levels	O
and	O
a	O
trend	O
to	O
increase	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
plasma	O
levels	O
.	O

Etofibrate	S-drug-EF-1
elicited	O
62	O
%	O
enhancement	O
of	O
post	O
-	O
heparin	S-drug-EF-2
lipolytic	O
activity	O
and	O
100	O
%	O
increase	O
of	O
3H	O
-	O
triglyceride	O
fractional	O
clearance	O
rate	O
compared	O
with	O
placebo	O
treatment	O
.	O

14C	O
-	O
cholesterol	O
ester	O
fractional	O
clearance	O
rate	O
was	O
260	O
%	O
greater	O
after	O
etofibrate	S-drug
than	O
after	O
placebo	O
.	O

Therefore	O
,	O
a	O
potent	O
effect	O
of	O
etofibrate	S-drug
on	O
both	O
chylomicron	O
lipolysis	O
and	O
remnant	O
removal	O
was	O
achieved	O
,	O
indicating	O
that	O
this	O
drug	O
can	O
be	O
used	O
to	O
improve	O
this	O
metabolism	O
in	O
future	O
prospective	O
studies	O
.	O

The	O
mode	O
of	O
toxic	O
action	O
of	O
the	O
pesticide	O
gliftor	S-drug_n
:	O
the	O
metabolism	O
of	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
to	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
erythro	I-drug_n
-	I-drug_n
fluorocitrate	E-drug_n
.	O

The	O
biochemical	O
toxicology	O
of	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
,	O
a	O
known	O
metabolite	O
of	O
the	O
major	O
ingredient	O
of	O
the	O
pesticide	O
Gliftor	S-drug_n
(	O
1,3	B-drug_n
-	I-drug_n
difluoro	I-drug_n
-	I-drug_n
2	I-drug_n
-	I-drug_n
propanol	E-drug_n
)	O
,	O
was	O
investigated	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Rat	O
kidney	O
homogenates	O
supplemented	O
with	O
coenzyme	O
A	O
,	O
ATP	O
,	O
oxaloacetate	O
,	O
and	O
Mg2	O
+	O
converted	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
to	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
erythro	I-drug_n
-	I-drug_n
fluorocitrate	E-drug_n
in	O
vitro	O
.	O

Administration	O
of	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
(	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
to	O
rats	O
in	O
vivo	O
resulted	O
in	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
erythro	I-drug_n
-	I-drug_n
fluorocitrate	E-drug_n
synthesis	O
in	O
the	O
kidney	O
,	O
which	O
was	O
preceded	O
by	O
an	O
elevation	O
in	O
fluoride	O
levels	O
and	O
followed	O
by	O
citrate	O
accumulation	O
.	O

Animals	O
dosed	O
with	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
did	O
not	O
display	O
the	O
2	O
-	O
3	O
hour	O
lag	O
phase	O
in	O
either	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
erythro	I-drug_n
-	I-drug_n
fluorocitrate	E-drug_n
synthesis	O
or	O
in	O
citrate	O
and	O
fluoride	O
accumulation	O
characteristic	O
of	O
animals	O
dosed	O
with	O
1,3	B-drug_n
-	I-drug_n
difluoro	I-drug_n
-	I-drug_n
2	I-drug_n
-	I-drug_n
propanol	E-drug_n
.	O

We	O
demonstrate	O
that	O
the	O
conversion	O
of	O
1,3	B-drug_n
-	I-drug_n
difluoro	I-drug_n
-	I-drug_n
2	I-drug_n
-	I-drug_n
propanol	E-drug_n
to	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
by	O
an	O
NAD	O
+	O
-	O
dependent	O
oxidation	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
toxic	O
product	O
,	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
erythro	I-drug_n
-	I-drug_n
fluorocitrate	E-drug_n
from	O
1,3	B-drug_n
-	I-drug_n
difluoro	I-drug_n
-	I-drug_n
2	I-drug_n
-	I-drug_n
propanol	E-drug_n
.	O

Prior	O
administration	O
of	O
4	B-drug-EF-1
-	I-drug-EF-1
methylpyrazole	E-drug-EF-1
(	O
90	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
was	O
shown	O
to	O
prevent	O
the	O
conversion	O
of	O
1,3	B-drug_n-EF-2
-	I-drug_n-EF-2
difluoro	I-drug_n-EF-2
-	I-drug_n-EF-2
2	I-drug_n-EF-2
-	I-drug_n-EF-2
propanol	E-drug_n-EF-2
(	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
to	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
erythro	I-drug_n
-	I-drug_n
fluorocitrate	E-drug_n
in	O
vivo	O
and	O
to	O
eliminate	O
the	O
fluoride	O
and	O
citrate	O
elevations	O
seen	O
in	O
1,3	B-drug_n
-	I-drug_n
difluoro	I-drug_n
-	I-drug_n
2	I-drug_n
-	I-drug_n
propanol	E-drug_n
-	O
intoxicated	O
animals	O
.	O

However	O
,	O
administration	O
of	O
4	B-drug
-	I-drug
methylpyrazole	E-drug
(	O
90	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
to	O
rats	O
2	O
hours	O
prior	O
to	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
(	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
was	O
ineffective	O
in	O
preventing	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
erythro	I-drug_n
-	I-drug_n
fluorocitrate	E-drug_n
synthesis	O
and	O
did	O
not	O
diminish	O
fluoride	O
or	O
citrate	O
accumulation	O
in	O
vivo	O
.	O

We	O
conclude	O
that	O
the	O
prophylactic	O
and	O
antidotal	O
properties	O
of	O
4	B-drug-EF-1
-	I-drug-EF-1
methylpyrazole	E-drug-EF-1
seen	O
in	O
animals	O
treated	O
with	O
1,3	B-drug_n-EF-2
-	I-drug_n-EF-2
difluoro	I-drug_n-EF-2
-	I-drug_n-EF-2
2	I-drug_n-EF-2
-	I-drug_n-EF-2
propanol	E-drug_n-EF-2
derive	O
from	O
its	O
capacity	O
to	O
inhibit	O
the	O
NAD	O
+	O
-	O
dependent	O
oxidation	O
responsible	O
for	O
converting	O
1,3	B-drug_n
-	I-drug_n
difluoro	I-drug_n
-	I-drug_n
2	I-drug_n
-	I-drug_n
propanol	E-drug_n
to	O
1,3	B-drug_n
-	I-drug_n
difluoroacetone	E-drug_n
in	O
the	O
committed	O
step	O
of	O
the	O
toxic	O
pathway	O
.	O

Pharmacology	O
and	O
pharmacotherapy	O
of	O
cardiovascular	O
drugs	O
in	O
patients	O
with	O
chronic	O
renal	O
disease	O
.	O

Cardiovascular	O
disease	O
is	O
a	O
common	O
comorbidity	O
and	O
a	O
major	O
cause	O
of	O
mortality	O
in	O
patients	O
with	O
chronic	O
renal	O
disease	O
.	O

Drug	O
regimens	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
are	O
frequently	O
complex	O
and	O
can	O
be	O
significantly	O
affected	O
by	O
alterations	O
in	O
renal	O
function	O
.	O

In	O
addition	O
,	O
several	O
cardiovascular	O
drugs	O
directly	O
affect	O
renal	O
function	O
and	O
the	O
management	O
of	O
patients	O
with	O
renal	O
disease	O
.	O

This	O
article	O
reviews	O
the	O
impact	O
of	O
renal	O
disease	O
on	O
the	O
pharmacokinetics	O
of	O
cardiovascular	O
drugs	O
and	O
identifies	O
clinically	O
important	O
interactions	O
between	O
these	O
and	O
other	O
drugs	O
commonly	O
used	O
in	O
the	O
management	O
of	O
chronic	O
renal	O
disease	O
.	O

Several	O
classes	O
of	O
cardiovascular	O
drugs	O
are	O
also	O
discussed	O
in	O
relationship	O
to	O
their	O
differential	O
effects	O
on	O
the	O
management	O
and	O
progression	O
of	O
renal	O
disease	O
.	O

Green	B-drug
tea	I-drug
polyphenols	E-drug
as	O
potent	O
enhancers	S-drug
of	O
glucocorticoid	O
-	O
induced	O
mouse	O
mammary	O
tumor	O
virus	O
gene	O
expression	O
.	O

The	O
effect	O
of	O
natural	O
and	O
synthetic	O
galloyl	O
esters	O
on	O
glucocorticoid	O
-	O
induced	O
gene	O
expression	O
was	O
evaluated	O
by	O
using	O
rat	O
fibroblast	O
3Y1	O
cells	O
stably	O
transfected	O
with	O
a	O
luciferase	O
reporter	O
gene	O
under	O
the	O
transcriptional	O
regulation	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
promoter	S-drug
.	O

The	O
glucocorticoid	O
-	O
induced	O
gene	O
transcription	O
was	O
strongly	O
suppressed	O
by	O
synthetic	O
alkyl	O
esters	O
;	O

n	B-drug
-	I-drug
dodecyl	I-drug
gallate	E-drug
showed	O
the	O
most	O
potent	O
inhibition	O
(	O
66	O
%	O
inhibition	O
at	O
10	O
microM	O
)	O
,	O
which	O
was	O
far	O
more	O
potent	O
than	O
that	O
of	O
crude	O
tannic	B-drug
acid	E-drug
.	O

n	O
-	O
Octyl	O
and	O
n	O
-	O
cetyl	O
gallate	O
also	O
showed	O
good	O
inhibition	O
,	O
while	O
gallic	O
acid	O
itself	O
was	O
not	O
so	O
active	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
hydrophobic	O
side	O
chain	O
is	O
important	O
for	O
the	O
suppressive	O
effect	O
.	O

On	O
the	O
other	O
hand	O
,	O
surprisingly	O
,	O
green	B-drug
tea	I-drug
gallocatechins	E-drug
,	O
(	O
-	O
)	O
-	O
epigallocatechin	O
-	O
3	O
-	O
O	O
-	O
gallate	O
and	O
theasinensin	O
A	O
,	O
potently	O
enhanced	O
the	O
promoter	O
activity	O
(	O
182	O
and	O
247	O
%	O
activity	O
at	O
1	O
microM	O
,	O
respectively	O
)	O
.	O

The	O
regulation	O
of	O
the	O
level	O
of	O
the	O
glucocorticoid	O
-	O
induced	O
gene	O
expression	O
by	O
the	O
antioxidative	O
gallates	O
is	O
of	O
great	O
interest	O
from	O
a	O
therapeutic	O
point	O
of	O
view	O
.	O

Pharmacokinetic	O
interaction	O
between	O
single	O
oral	O
doses	O
of	O
diltiazem	S-drug-ME-1
and	O
sirolimus	S-drug-ME-2
in	O
healthy	O
volunteers	O
.	O

AIM	O
AND	O
BACKGROUND	O
:	O
The	O
pharmacokinetic	O
interaction	O
between	O
sirolimus	S-drug
,	O
a	O
macrolide	B-group
immunosuppressant	E-group
metabolized	O
by	O
CYP3A4	O
,	O
and	O
the	O
calcium	B-group
channel	I-group
blocker	E-group
diltiazem	S-drug
was	O
studied	O
in	O
18	O
healthy	O
subjects	O
.	O

Several	O
clinically	O
important	O
interactions	O
have	O
previously	O
been	O
reported	O
for	O
other	O
immunosuppressive	B-group
drugs	E-group
that	O
are	O
metabolized	O
by	O
the	O
same	O
enzyme	O
and	O
for	O
calcium	B-group
antagonists	E-group
.	O

METHODS	O
:	O
Healthy	O
subjects	O
who	O
were	O
20	O
to	O
43	O
years	O
old	O
participated	O
in	O
an	O
open	O
,	O
three	O
-	O
period	O
,	O
randomized	O
,	O
crossover	O
study	O
of	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
10	O
-	O
mg	O
oral	O
dose	O
of	O
sirolimus	S-drug
,	O
a	O
single	O
oral	O
120	O
-	O
mg	O
dose	O
of	O
diltiazem	S-drug
,	O
and	O
the	O
two	O
drugs	O
given	O
together	O
.	O

The	O
three	O
study	O
periods	O
were	O
separated	O
by	O
a	O
21	O
-	O
day	O
washout	O
phase	O
.	O

RESULTS	O
:	O
The	O
geometric	O
mean	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
whole	O
blood	O
sirolimus	S-drug-ME-1
area	O
under	O
the	O
plasma	O
concentration	O
time	O
-	O
curve	O
increased	O
60	O
%	O
(	O
35	O
%	O
-	O
90	O
%	O
)	O
,	O
from	O
736	O
to	O
1178	O
ng	O
x	O
h	O
/	O
mL	O
,	O
and	O
maximum	O
concentration	O
increased	O
43	O
%	O
(	O
14	O
%	O
-	O
81	O
%	O
)	O
,	O
from	O
67	O
to	O
96	O
ng	O
/	O
mL	O
,	O
with	O
diltiazem	S-drug-ME-2
coadministration	O
,	O
whereas	O
the	O
mean	O
elimination	O
half	O
-	O
life	O
of	O
sirolimus	S-drug
decreased	O
slightly	O
,	O
from	O
79	O
to	O
67	O
hours	O
.	O

Apparent	O
oral	O
clearance	O
and	O
volume	O
of	O
distribution	O
of	O
sirolimus	S-drug
decreased	O
with	O
38	O
%	O
and	O
45	O
%	O
,	O
respectively	O
,	O
when	O
sirolimus	S-drug-ME-1
was	O
given	O
with	O
diltiazem	S-drug-ME-2
.	O

The	O
plasma	O
maximum	O
concentration	O
and	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
of	O
diltiazem	S-drug
,	O
desacetyldiltiazem	S-drug_n
,	O
and	O
desmethyldiltiazem	S-drug_n
were	O
unchanged	O
after	O
coadministration	O
of	O
sirolimus	S-drug
,	O
and	O
no	O
potentiation	O
of	O
the	O
effects	O
of	O
diltiazem	S-drug
on	O
diastolic	O
or	O
systolic	O
blood	O
pressure	O
or	O
on	O
the	O
electrocardiographic	O
parameters	O
was	O
seen	O
.	O

CONCLUSIONS	O
:	O
Single	O
-	O
dose	O
diltiazem	S-drug-ME-1
coadministration	O
leads	O
to	O
higher	O
sirolimus	S-drug-ME-2
exposure	O
,	O
presumably	O
by	O
inhibition	O
of	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
sirolimus	S-drug
.	O

Because	O
of	O
the	O
pronounced	O
intersubject	O
variability	O
in	O
the	O
extent	O
of	O
the	O
sirolimus	S-drug-AD-1
-	O
diltiazem	S-drug-AD-2
interaction	O
,	O
whole	O
blood	O
sirolimus	S-drug
concentrations	O
should	O
be	O
monitored	O
closely	O
in	O
patients	O
treated	O
with	O
the	O
two	O
drugs	O
.	O

Fluvoxamine	S-drug-ME-1
inhibits	O
the	O
CYP2C9	O
catalyzed	O
biotransformation	O
of	O
tolbutamide	S-drug-ME-2
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
interaction	O
between	O
fluvoxamine	S-drug
and	O
tolbutamide	S-drug
to	O
confirm	O
that	O
fluvoxamine	S-drug
inhibits	O
CYP2C9	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
carried	O
out	O
as	O
an	O
open	O
,	O
randomized	O
,	O
crossover	O
design	O
with	O
14	O
healthy	O
participants	O
.	O

In	O
period	O
A	O
,	O
all	O
volunteers	O
took	O
500	O
mg	O
of	O
tolbutamide	S-drug
orally	O
.	O

In	O
period	O
B	O
,	O
the	O
volunteers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
.	O

Each	O
group	O
took	O
either	O
150	O
mg	O
or	O
75	O
mg	O
of	O
fluvoxamine	S-drug
a	O
day	O
for	O
5	O
days	O
(	O
day	O
-	O
3	O
to	O
day	O
2	O
)	O
.	O

The	O
groups	O
then	O
took	O
500	O
mg	O
of	O
tolbutamide	S-drug
as	O
a	O
single	O
dose	O
(	O
day	O
0	O
)	O
.	O

In	O
both	O
periods	O
,	O
blood	O
and	O
urine	O
were	O
sampled	O
at	O
regular	O
intervals	O
.	O

Plasma	O
was	O
analyzed	O
for	O
tolbutamide	S-drug
,	O
and	O
urine	O
was	O
analyzed	O
for	O
tolbutamide	S-drug
and	O
its	O
two	O
metabolites	O
,	O
4	B-drug_n
-	I-drug_n
hydroxytolbutamide	E-drug_n
and	O
carboxytolbutamide	S-drug_n
by	O
means	O
of	O
HPLC	O
.	O

RESULTS	O
:	O
During	O
treatment	O
with	O
fluvoxamine	S-drug-ME-1
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
median	O
of	O
the	O
total	O
clearance	O
of	O
tolbutamide	S-drug-ME-2
,	O
from	O
845	O
mL	O
/	O
h	O
to	O
688	O
mL	O
/	O
h	O
,	O
among	O
the	O
volunteers	O
who	O
received	O
75	O
mg	O
/	O
d	O
.	O

There	O
was	O
a	O
reduction	O
that	O
reached	O
borderline	O
statistical	O
significance	O
in	O
the	O
group	O
that	O
received	O
150	O
mg	O
/	O
d	O
of	O
tolbutamide	S-drug
.	O

The	O
clearance	O
by	O
means	O
of	O
4	B-drug_n
-	I-drug_n
hydroxytolbutamide	E-drug_n
and	O
carboxytolbutamide	S-drug_n
was	O
significantly	O
reduced	O
in	O
both	O
groups	O
(	O
ie	O
,	O
from	O
901	O
mL	O
/	O
h	O
to	O
318	O
mL	O
/	O
h	O
in	O
the	O
group	O
that	O
received	O
150	O
mg	O
of	O
tolbutamide	S-drug
per	O
day	O
and	O
from	O
723	O
mL	O
/	O
h	O
to	O
457	O
mL	O
/	O
h	O
in	O
the	O
group	O
that	O
received	O
75	O
mg	O
of	O
tolbutamide	S-drug
per	O
day	O
)	O
.	O

Thus	O
there	O
was	O
a	O
tendency	O
toward	O
a	O
more	O
pronounced	O
inhibition	O
of	O
the	O
4	O
-	O
hydroxylation	O
during	O
treatment	O
with	O
150	O
mg	O
/	O
d	O
of	O
fluvoxamine	S-drug
compared	O
with	O
75	O
mg	O
/	O
d	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

CONCLUSION	O
:	O
Fluvoxamine	S-drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP2C9	O
in	O
vivo	O
.	O

Longitudinal	O
assessment	O
of	O
everolimus	S-drug
in	O
de	O
novo	O
renal	O
transplant	O
recipients	O
over	O
the	O
first	O
post	O
-	O
transplant	O
year	O
:	O
pharmacokinetics	O
,	O
exposure	O
-	O
response	O
relationships	O
,	O
and	O
influence	O
on	O
cyclosporine	S-drug
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
characterize	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
everolimus	S-drug
and	O
cyclosporine	S-drug
(	O
INN	O
,	O
ciclosporin	S-drug
)	O
when	O
coadministered	O
in	O
de	O
novo	O
kidney	O
allograft	O
recipients	O
during	O
the	O
first	O
year	O
after	O
transplantation	O
.	O

METHOD	O
:	O
This	O
study	O
was	O
a	O
multicenter	O
randomized	O
double	O
-	O
blind	O
study	O
of	O
101	O
patients	O
who	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
everolimus	S-drug
tablets	O
at	O
doses	O
of	O
0.5	O
mg	O
,	O
1	O
mg	O
,	O
or	O
2	O
mg	O
twice	O
daily	O
with	O
cyclosporine	S-drug
and	O
prednisone	S-drug
.	O

Blood	O
sampling	O
for	O
the	O
pharmacokinetics	O
of	O
everolimus	S-drug
and	O
cyclosporine	S-drug
was	O
performed	O
on	O
day	O
1	O
,	O
on	O
weeks	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
and	O
on	O
months	O
2	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
.	O

Everolimus	S-drug
dose	O
-	O
proportionality	O
and	O
stability	O
over	O
time	O
were	O
assessed	O
in	O
the	O
context	O
of	O
linear	O
regression	O
and	O
ANOVA	O
models	O
.	O

Everolimus	S-drug
exposure	O
-	O
response	O
relationships	O
between	O
area	O
under	O
the	O
blood	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
and	O
changes	O
in	O
platelets	O
,	O
leukocytes	O
,	O
and	O
lipids	O
were	O
explored	O
with	O
the	O
median	O
-	O
effect	O
model	O
.	O

Potential	O
differences	O
in	O
cyclosporine	S-drug
dosing	O
and	O
pharmacokinetics	O
at	O
different	O
levels	O
of	O
everolimus	S-drug
exposure	O
were	O
assessed	O
in	O
the	O
context	O
of	O
ANOVA	O
.	O

RESULTS	O
:	O
Everolimus	S-drug
steady	O
state	O
was	O
reached	O
on	O
or	O
before	O
day	O
7	O
,	O
with	O
a	O
median	O
3	O
-	O
fold	O
accumulation	O
of	O
drug	O
exposure	O
compared	O
with	O
that	O
after	O
the	O
first	O
postoperative	O
dose	O
.	O

Both	O
steady	O
-	O
state	O
maximum	O
concentration	O
and	O
AUC	O
were	O
dose	O
proportional	O
over	O
the	O
full	O
dose	O
range	O
when	O
assessed	O
on	O
day	O
1	O
,	O
as	O
well	O
as	O
for	O
the	O
full	O
duration	O
of	O
the	O
study	O
at	O
steady	O
state	O
.	O

There	O
was	O
evidence	O
for	O
longitudinal	O
stability	O
in	O
AUC	O
of	O
everolimus	S-drug
during	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
interindividual	O
pharmacokinetic	O
variability	O
for	O
AUC	O
was	O
85.4	O
%	O
and	O
intraindividual	O
,	O
interoccasion	O
variability	O
was	O
40.8	O
%	O
.	O

Age	O
(	O
range	O
,	O
17	O
-	O
69	O
years	O
)	O
,	O
weight	O
(	O
range	O
,	O
49	O
-	O
106	O
kg	O
)	O
,	O
and	O
sex	O
(	O
65	O
men	O
and	O
36	O
women	O
)	O
were	O
not	O
significant	O
contributors	O
to	O
variability	O
.	O

There	O
was	O
an	O
increasing	O
incidence	O
of	O
transient	O
thrombocytopenia	O
(	O
or	O
=	O
100	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
with	O
increasing	O
everolimus	S-drug
AUC	O
(	O
P	O
=	O
.03	O
)	O
.	O

Cyclosporine	S-drug
doses	O
,	O
trough	O
concentrations	O
,	O
and	O
AUC	O
exhibited	O
similar	O
temporal	O
patterns	O
during	O
the	O
course	O
of	O
the	O
study	O
regardless	O
of	O
the	O
co	O
-	O
administered	O
everolimus	S-drug
dose	O
level	O
(	O
P	O
=	O
.13	O
,	O
.82	O
,	O
and	O
.76	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
Everolimus	S-drug
exhibited	O
dose	O
-	O
proportional	O
,	O
stable	O
exposure	O
during	O
the	O
first	O
post	O
-	O
transplant	O
year	O
.	O

For	O
a	O
4	O
-	O
fold	O
range	O
of	O
everolimus	S-drug
doses	O
there	O
were	O
no	O
differential	O
effects	O
on	O
cyclosporine	S-drug
dosing	O
or	O
pharmacokinetics	O
.	O

ADL	B-drug-EF-1
8	I-drug-EF-1
-	I-drug-EF-1
2698	E-drug-EF-1
,	O
a	O
trans	O
-	O
3,4	O
-	O
dimethyl	O
-	O
4	O
-	O
(	O
3	O
-	O
hydroxyphenyl	O
)	O
piperidine	O
,	O
prevents	O
gastrointestinal	O
effects	O
of	O
intravenous	O
morphine	S-drug-EF-2
without	O
affecting	O
analgesia	O
.	O

ADL	B-drug-EF-1
-	I-drug-EF-1
8	I-drug-EF-1
-	I-drug-EF-1
2698	E-drug-EF-1
is	O
a	O
novel	O
peripherally	B-group
restricted	I-group
opioid	I-group
antagonist	E-group
that	O
may	O
selectively	O
prevent	O
opioid	S-group-EF-2
-	O
induced	O
gastrointestinal	O
effects	O
without	O
reversing	O
analgesia	O
.	O

Gastrointestinal	O
transit	O
time	O
(	O
lactulose	O
hydrogen	O
breath	O
test	O
)	O
was	O
measured	O
in	O
14	O
volunteers	O
with	O
oral	O
and	O
intravenous	O
placebo	O
,	O
oral	O
placebo	O
and	O
intravenous	O
morphine	S-drug
(	O
0.05	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
oral	O
ADL	B-drug
8	I-drug
-	I-drug
2698	E-drug
(	O
4	O
mg	O
)	O
and	O
intravenous	O
morphine	S-drug
(	O
0.05	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
)	O
in	O
a	O
double	O
blind	O
,	O
cross	O
-	O
over	O
study	O
.	O

Morphine	S-drug
prolonged	O
gastrointestinal	O
transit	O
time	O
from	O
69	O
to	O
103	O
minutes	O
(	O
P	O
=	O
.005	O
)	O
;	O

Morphine	S-drug-EF-1
prolonged	O
gastrointestinal	O
transit	O
time	O
from	O
69	O
to	O
103	O
minutes	O
(	O
P	O
=	O
.005	O
)	O
;	O
this	O
was	O
prevented	O
by	O
ADL	B-drug-EF-2
8	I-drug-EF-2
-	I-drug-EF-2
2698	E-drug-EF-2
(	O
P	O
=	O
.004	O
)	O
.	O

Postoperatively	O
,	O
45	O
patients	O
were	O
randomly	O
assigned	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
to	O
receive	O
ADL	B-drug
8	I-drug
-	I-drug
2698	E-drug
(	O
4	O
mg	O
)	O
or	O
placebo	O
and	O
intravenous	O
morphine	S-drug
(	O
0.15	O
mg	O
/	O
kg	O
)	O
or	O
to	O
receive	O
oral	O
and	O
intravenous	O
placebo	O
.	O

Analgesia	O
and	O
pupil	O
constriction	O
were	O
measured	O
.	O

Morphine	S-drug
analgesia	O
and	O
pupil	O
constriction	O
were	O
unaffected	O
by	O
ADL	B-drug
8	I-drug
-	I-drug
2698	E-drug
and	O
differed	O
from	O
placebo	O
(	O
P	O
<	O
.002	O
)	O
.	O

We	O
conclude	O
that	O
ADL	B-drug-EF-1
8	I-drug-EF-1
-	I-drug-EF-1
2698	E-drug-EF-1
prevents	O
morphine	S-drug-EF-2
-	O
induced	O
increases	O
in	O
gastrointestinal	O
transit	O
time	O
by	O
means	O
of	O
selective	O
peripheral	O
opioid	O
anitagonism	O
without	O
affecting	O
central	O
opioid	O
analgesia	O
.	O

Restoration	O
of	O
vancomycin	S-drug
susceptibility	O
in	O
Enterococcus	O
faecalis	O
by	O
antiresistance	O
determinant	O
gene	O
transfer	O
.	O

We	O
assessed	O
the	O
ability	O
of	O
gene	O
transfer	O
to	O
reverse	O
vancomycin	S-drug
resistance	O
in	O
class	O
A	O
(	O
VanA	O
)	O
glycopeptide	O
-	O
resistant	O
Enterococcus	O
faecalis	O
.	O

Recombinant	O
shuttle	O
vectors	O
containing	O
a	O
vanH	O
promoter	O
-	O
vanA	O
antisense	O
gene	O
cassette	O
fully	O
restored	O
vancomycin	S-drug
susceptibility	O
through	O
a	O
combined	O
transcriptional	O
activator	O
binding	O
domain	O
decoy	O
and	O
inducible	O
vanA	O
antisense	O
RNA	O
effect	O
.	O

Rhabdomyolysis	O
secondary	O
to	O
a	O
drug	O
interaction	O
between	O
simvastatin	S-drug-EF-1
and	O
clarithromycin	S-drug-EF-2
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
rhabdomyolysis	O
resulting	O
from	O
concomitant	O
use	O
of	O
clarithromycin	S-drug
and	O
simvastatin	S-drug
.	O

CASE	O
SUMMARY	O
:	O
A	O
64	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
man	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
worsening	O
renal	O
failure	O
,	O
elevated	O
creatine	O
phosphokinase	O
,	O
diffuse	O
muscle	O
pain	O
,	O
and	O
severe	O
muscle	O
weakness	O
.	O

About	O
three	O
weeks	O
prior	O
to	O
admission	O
,	O
the	O
patient	O
was	O
started	O
on	O
clarithromycin	S-drug
for	O
sinusitis	O
.	O

The	O
patient	O
had	O
been	O
receiving	O
simvastatin	S-drug
for	O
approximately	O
six	O
months	O
.	O

He	O
was	O
treated	O
aggressively	O
with	O
intravenous	O
hydration	O
,	O
sodium	B-drug
bicarbonate	E-drug
,	O
and	O
hemodialysis	O
.	O

A	O
muscle	O
biopsy	O
revealed	O
necrotizing	O
myopathy	O
secondary	O
to	O
a	O
toxin	O
.	O

The	O
patient	O
continued	O
to	O
receive	O
intermittent	O
hemodialysis	O
until	O
his	O
death	O
from	O
infectious	O
complications	O
that	O
occurred	O
three	O
months	O
after	O
admission	O
.	O

There	O
were	O
several	O
factors	O
that	O
could	O
have	O
increased	O
his	O
risk	O
for	O
developing	O
rhabdomyolysis	O
,	O
including	O
chronic	O
renal	O
failure	O
.	O

DISCUSSION	O
:	O
Clarithromycin	S-drug-ME-1
is	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
the	O
major	O
enzyme	O
responsible	O
for	O
simvastatin	S-drug-ME-2
metabolism	O
.	O

The	O
concomitant	O
administration	O
of	O
macrolide	B-group-EF-1
antibiotics	E-group-EF-1
and	O
other	O
hydroxymethylglutaryl	B-group-EF-2
coenzyme	I-group-EF-2
A	I-group-EF-2
(	I-group-EF-2
HMG	I-group-EF-2
-	I-group-EF-2
CoA	I-group-EF-2
)	I-group-EF-2
reductase	I-group-EF-2
inhibitors	E-group-EF-2
have	O
resulted	O
in	O
previous	O
reports	O
of	O
rhabdomyolysis	O
.	O

Other	O
factors	O
may	O
increase	O
the	O
risk	O
of	O
this	O
drug	O
interaction	O
,	O
including	O
the	O
administration	O
of	O
other	O
medications	O
that	O
are	O
associated	O
with	O
myopathy	O
,	O
underlying	O
renal	O
insufficiency	O
,	O
and	O
administration	O
of	O
high	O
doses	O
of	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
.	O

CONCLUSIONS	O
:	O
Macrolide	B-group-ME-1
antibiotics	E-group-ME-1
inhibit	O
the	O
metabolism	O
of	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
that	O
are	O
metabolized	O
by	O
CYP3A4	O
(	O
i.e	O
.	O
,	O
atorvastatin	S-drug-ME-2
,	O
cerivastatin	S-drug-ME-2
,	O
lovastatin	S-drug-ME-2
,	O
simvastatin	S-drug-ME-2
)	O
.	O

This	O
interaction	O
may	O
result	O
in	O
myopathy	O
and	O
rhabdomyolysis	O
,	O
particularly	O
in	O
patients	O
with	O
renal	O
insufficiency	O
or	O
those	O
who	O
are	O
concurrently	O
taking	O
medications	O
associated	O
with	O
myopathy	O
.	O

Toxicity	O
of	O
cadmium	O
and	O
zinc	S-drug
to	O
encystment	O
and	O
in	O
vitro	O
excystment	O
of	O
Parorchis	O
acanthus	O
(	O
Digenea	O
:	O
Philophthalmidae	O
)	O
.	O

The	O
toxicity	O
of	O
cadmium	O
,	O
zinc	S-drug
and	O
cadmium	O
/	O
zinc	O
mixtures	O
at	O
concentrations	O
ranging	O
from	O
1000	O
to	O
50000	O
microg	O
/	O
l	O
were	O
investigated	O
against	O
cercariae	O
and	O
metacercariae	O
of	O
Parorchis	O
acanthus	O
obtained	O
from	O
the	O
dog	O
whelk	O
Nucella	O
lapillus	O
.	O

Cercarial	O
encystment	O
at	O
concentrations	O
of	O
25000	O
microg	O
/	O
l	O
or	O
higher	O
was	O
significantly	O
impaired	O
by	O
all	O
test	O
metals	O
;	O

however	O
,	O
at	O
lower	O
concentrations	O
only	O
zinc	S-drug
demonstrated	O
toxicity	O
.	O

Mixtures	O
of	O
cadmium	O
and	O
zinc	S-drug
had	O
a	O
synergistic	O
effect	O
compared	O
with	O
single	O
metal	O
toxicity	O
but	O
only	O
at	O
50000	O
microg	O
/	O
l	O
.	O

Excystment	O
in	O
vitro	O
was	O
only	O
significantly	O
affected	O
by	O
cercariae	O
exposed	O
to	O
cadmium	O
/	O
zinc	O
mixtures	O
whilst	O
encysting	O
.	O

Twenty	O
-	O
four	O
h	O
exposures	O
of	O
fully	O
formed	O
cysts	O
had	O
no	O
effect	O
on	O
excystment	O
in	O
vitro	O
.	O

Effects	O
on	O
in	O
vitro	O
excystment	O
rates	O
over	O
a	O
2	O
h	O
period	O
demonstrated	O
widespread	O
effects	O
for	O
cercariae	O
-	O
exposed	O
P	O
.	O

acanthus	O
.	O

No	O
effects	O
were	O
evident	O
on	O
excystment	O
rates	O
of	O
cyst	O
-	O
exposed	O
parasites	O
.	O

Toxicity	O
of	O
cadmium	O
and	O
zinc	S-drug
to	O
miracidia	O
of	O
Schistosoma	O
mansoni	O
.	O

The	O
specific	O
objectives	O
of	O
this	O
study	O
were	O
to	O
elucidate	O
metal	O
toxicity	O
to	O
hatching	O
,	O
survival	O
and	O
avoidance	O
behaviour	O
of	O
Schistosoma	O
mansoni	O
miracidia	O
.	O

The	O
toxicity	O
of	O
cadmium	O
,	O
zinc	S-drug
,	O
and	O
cadmium	O
/	O
zinc	O
mixtures	O
at	O
concentrations	O
ranging	O
from	O
10000	O
to	O
10	O
microg	O
/	O
l	O
was	O
investigated	O
.	O

Metal	O
mixture	O
toxicity	O
investigation	O
was	O
undertaken	O
with	O
equal	O
concentrations	O
of	O
the	O
metals	O
.	O

The	O
hatching	O
of	O
miracidia	O
from	O
eggs	O
was	O
inhibited	O
by	O
concentrations	O
of	O
1000	O
-	O
10000	O
microg	O
/	O
l	O
of	O
single	O
metals	O
.	O

Metal	O
mixtures	O
had	O
no	O
effect	O
on	O
egg	S-drug
hatching	O
.	O

Survival	O
of	O
miracidia	O
was	O
reduced	O
by	O
increasing	O
metal	O
concentration	O
except	O
at	O
concentrations	O
of	O
10	O
microg	O
/	O
l	O
for	O
single	O
metal	O
toxicity	O
where	O
survival	O
was	O
increased	O
above	O
the	O
control	O
.	O

Miracidia	O
demonstrated	O
a	O
rapid	O
avoidance	O
behaviour	O
when	O
briefly	O
exposed	O
to	O
heavy	O
metals	O
.	O

The	O
mechanisms	O
of	O
metal	O
toxicity	O
to	O
miracidia	O
are	O
briefly	O
discussed	O
.	O

[	O
Importance	O
of	O
pharmacogenetics	O
]	O
;	O
Pharmacogenetics	O
deals	O
with	O
the	O
differences	O
in	O
effect	O
of	O
drugs	O
caused	O
by	O
genetic	O
variation	O
.	O

Differences	O
can	O
occur	O
in	O
therapeutic	O
effect	O
and	O
in	O
adverse	O
events	O
.	O

Genetic	O
variation	O
in	O
metabolism	O
may	O
result	O
in	O
high	O
concentrations	O
of	O
drugs	O
and	O
an	O
increased	O
risk	O
of	O
adverse	O
effects	O
in	O
slow	O
metabolizers	O
,	O
which	O
is	O
important	O
when	O
using	O
for	O
example	O
antidepressants	S-group
or	O
chemotherapy	O
.	O

Genetic	O
variation	O
also	O
occurs	O
in	O
proteins	O
interacting	O
with	O
drugs	O
,	O
which	O
may	O
change	O
the	O
effect	O
of	O
e.g	O
.	O

asthma	O
drugs	O
and	O
antipsychotics	S-group
.	O

The	O
selection	O
of	O
drugs	O
and	O
their	O
dosages	O
may	O
be	O
improved	O
,	O
and	O
the	O
number	O
of	O
adverse	O
effects	O
reduced	O
by	O
pharmacogenetic	O
investigations	O
.	O

However	O
,	O
it	O
may	O
be	O
important	O
also	O
in	O
case	O
of	O
medical	O
examinations	O
for	O
insurances	O
and	O
job	O
appointments	O
,	O
since	O
some	O
patients	O
may	O
turn	O
out	O
to	O
need	O
expensive	O
drugs	O
or	O
to	O
be	O
susceptible	O
to	O
a	O
certain	O
disease	O
.	O

Therefore	O
,	O
the	O
use	O
of	O
genetic	O
data	O
in	O
these	O
instances	O
has	O
to	O
be	O
regulated	O
.	O

The	O
effects	O
of	O
concomitant	O
phenytoin	S-drug
administration	O
on	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
quetiapine	S-drug
.	O

Quetiapine	B-drug
fumarate	E-drug
(	O
'	O
Seroquel	S-brand
'	O
)	O
is	O
a	O
newly	O
introduced	O
atypical	B-group
antipsychotic	E-group
with	O
demonstrated	O
efficacy	O
in	O
the	O
treatment	O
of	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

It	O
is	O
extensively	O
metabolized	O
,	O
predominantly	O
by	O
cytochrome	O
P450	O
3A4	O
.	O

Therefore	O
,	O
concurrent	O
administration	O
of	O
drugs	O
that	O
induce	O
or	O
inhibit	O
this	O
enzyme	O
may	O
affect	O
quetiapine	S-drug
pharmacokinetics	O
.	O

This	O
study	O
demonstrated	O
that	O
the	O
potent	O
cytochrome	O
P450	O
enzyme	O
-	O
inducer	O
phenytoin	S-drug-ME-1
did	O
indeed	O
have	O
a	O
marked	O
effect	O
on	O
the	O
metabolism	O
of	O
quetiapine	S-drug-ME-2
,	O
resulting	O
in	O
a	O
5	O
-	O
fold	O
increase	O
in	O
clearance	O
when	O
administered	O
concomitantly	O
to	O
patients	O
with	O
DSM	O
-	O
IV	O
-	O
diagnosed	O
schizophrenia	O
,	O
schizoaffective	O
disorder	O
,	O
or	O
bipolar	O
disorder	O
.	O

These	O
results	O
indicate	O
that	O
dosage	O
adjustment	O
of	O
quetiapine	S-drug
may	O
be	O
necessary	O
when	O
the	O
two	O
drugs	O
are	O
given	O
concurrently	O
and	O
that	O
caution	O
may	O
be	O
required	O
when	O
administering	O
other	O
drugs	O
that	O
inhibit	O
or	O
induce	O
cytochromes	O
,	O
particularly	O
P450	O
3A4	O
.	O

Effect	O
of	O
coadministered	O
drugs	O
and	O
ethanol	S-drug
on	O
the	O
binding	O
of	O
therapeutic	O
drugs	O
to	O
human	O
serum	O
in	O
vitro	O
.	O

The	O
effects	O
of	O
coadministered	O
drugs	O
and	O
ethanol	S-drug
on	O
the	O
binding	O
of	O
therapeutic	O
drugs	O
to	O
human	O
serum	O
in	O
vitro	O
was	O
investigated	O
.	O

Acetaminophen	S-drug
,	O
lidocaine	S-drug
,	O
phenobarbital	S-drug
,	O
quinidine	S-drug
,	O
theophylline	S-drug
,	O
and	O
valproic	B-drug
acid	E-drug
were	O
added	O
to	O
pooled	O
human	O
serum	O
at	O
therapeutic	O
concentrations	O
.	O

To	O
each	O
preparation	O
was	O
added	O
one	O
additional	O
drug	O
at	O
three	O
concentrations	O
ranging	O
from	O
therapeutic	O
to	O
toxic	O
.	O

The	O
following	O
eight	O
target	O
drug	O
/	O
added	O
drug	O
combinations	O
were	O
studied	O
:	O
acetaminophen	S-drug
/	O
phenobarbital	S-drug
.	O

acetaminophen	S-drug
/	O
theophylline	S-drug
,	O
lidocaine	S-drug
/	O
quinidine	S-drug
,	O
phenobarbital	S-drug
/	O
acetaminophen	S-drug
,	O
phenobarbital	S-drug
/	O
valproic	B-drug
acid	E-drug
,	O
quinidine	S-drug
/	O
lidocaine	S-drug
,	O
theophylline	S-drug
/	O
acetaminophen	S-drug
,	O
and	O
valproic	B-drug
acid	E-drug
/	O
phenobarbital	S-drug
.	O

Each	O
serum	O
without	O
the	O
other	O
added	O
drug	O
as	O
well	O
as	O
the	O
serum	O
supplemented	O
with	O
the	O
other	O
drug	O
at	O
the	O
three	O
concentrations	O
was	O
dialyzed	O
against	O
phosphate	O
buffer	O
.	O

Similarly	O
dialyzed	O
were	O
phenobarbital	S-drug
,	O
quinidine	S-drug
,	O
and	O
theophylline	S-drug
,	O
both	O
alone	O
at	O
therapeutic	O
concentrations	O
in	O
serum	O
and	O
with	O
ethanol	S-drug
at	O
three	O
different	O
concentrations	O
in	O
serum	O
.	O

The	O
percentage	O
of	O
drug	O
binding	O
in	O
each	O
preparation	O
was	O
calculated	O
.	O

Acetaminophen	S-drug-ME-1
diminished	O
the	O
binding	O
of	O
theophylline	S-drug-ME-2
to	O
human	O
serum	O
by	O
a	O
net	O
change	O
of	O
5.7	O
%	O
(	O
percentage	O
increase	O
in	O
free	O
drug	O
fraction	O
[	O
FDF	O
]	O
,	O
11.0	O
%	O
)	O
at	O
662	O
micromol	O
/	O
L	O
and	O
by	O
a	O
net	O
change	O
of	O
7.1	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
13.7	O
%	O
)	O
at	O
1324	O
micromol	O
/	O
L	O
.	O

Theophylline	S-drug-ME-1
decreased	O
the	O
binding	O
of	O
acetaminophen	S-drug-ME-2
by	O
a	O
net	O
change	O
of	O
6.8	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
8.8	O
%	O
)	O
at	O
277.5	O
micromol	O
/	O
L	O
;	O

phenobarbital	S-drug
reduced	O
it	O
by	O
a	O
net	O
change	O
of	O
6.6	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
8.5	O
%	O
)	O
at	O
431	O
micromol	O
/	O
L	O
.	O

Valproic	B-drug-ME-1
acid	E-drug-ME-1
diminished	O
binding	O
of	O
phenobarbital	S-drug-ME-2
by	O
a	O
net	O
change	O
of	O
9.9	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
21.2	O
%	O
)	O
at	O
1732	O
micromol	O
/	O
L	O
.	O

No	O
significant	O
effects	O
were	O
noted	O
with	O
other	O
drug	O
combinations	O
or	O
with	O
the	O
addition	O
of	O
ethanol	S-drug
.	O

Coingestion	O
of	O
acetaminophen	S-drug-EF-1
with	O
theophylline	S-drug-EF-2
,	O
phenobarbital	S-drug-EF-1
with	O
acetaminophen	S-drug-EF-2
,	O
and	O
valproic	B-drug-EF-1
acid	E-drug-EF-1
with	O
phenobarbital	S-drug-EF-2
at	O
high	O
to	O
toxic	O
concentrations	O
decreases	O
the	O
binding	O
of	O
the	O
target	O
drug	O
.	O

The	O
resulting	O
increase	O
in	O
free	O
drug	O
concentration	O
may	O
lead	O
to	O
enhanced	O
drug	O
effect	O
in	O
vivo	O
.	O

Phenytoin	O
intoxication	O
induced	O
by	O
fluvoxamine	S-drug
.	O

A	O
patient	O
had	O
phenytoin	O
intoxication	O
after	O
administration	O
of	O
fluvoxamine	S-drug
,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
.	O

The	O
serum	O
concentration	O
of	O
phenytoin	S-drug
increased	O
dramatically	O
from	O
16.6	O
to	O
49.1	O
microg	O
/	O
mL	O
when	O
fluvoxamine	S-drug
was	O
coadministered	O
,	O
although	O
the	O
daily	O
dosage	O
of	O
phenytoin	S-drug
and	O
other	O
drugs	S-drug
had	O
not	O
changed	O
.	O

During	O
phenytoin	S-drug
and	O
fluvoxamine	O
treatment	O
,	O
ataxia	O
,	O
a	O
typical	O
side	O
effect	O
of	O
phenytoin	S-drug
,	O
was	O
observed	O
.	O

The	O
genotypes	O
of	O
CYP2C9	S-drug
and	O
2C19	O
,	O
the	O
enzymes	O
responsible	O
for	O
phenytoin	O
metabolism	O
,	O
were	O
homozygous	O
for	O
the	O
wild	O
-	O
type	O
alleles	O
(	O
CYP2C9	S-drug
*	O
1	O
/	O
*	O
1	O
and	O
2C19	O
*	O
1	O
/	O
*	O
1	O
)	O
.	O

The	O
interaction	O
may	O
be	O
a	O
result	O
of	O
inhibition	O
of	O
both	O
CYP2C9	S-drug
and	O
2C19	O
by	O
fluvoxamine	S-drug
.	O

Vancomycin	O
resistance	O
reversal	O
in	O
enterococci	O
by	O
flavonoids	O
.	O

The	O
development	O
of	O
clinical	O
vancomycin	O
-	O
resistant	O
strains	O
of	O
enterococci	O
(	O
VRE	O
)	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Here	O
we	O
show	O
that	O
a	O
combination	O
of	O
galangin	S-drug
or	O
3,7	O
-	O
dihydroxyflavone	O
with	O
vancomycin	S-drug
may	O
be	O
used	O
to	O
sensitize	O
resistant	O
strains	O
of	O
Enterococcus	O
faecalis	O
and	O
Enterococcus	O
faecium	O
to	O
the	O
level	O
of	O
vancomycin	O
-	O
sensitive	O
strains	O
.	O

Minimum	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
and	O
viable	O
counts	O
were	O
determined	O
in	O
Iso	O
-	O
sensitest	O
broth	O
using	O
a	O
microtitre	O
method	O
.	O

MICs	O
of	O
vancomycin	S-drug
against	O
67	O
%	O
of	O
resistant	O
clinical	O
isolates	O
and	O
a	O
type	O
strain	O
of	O
enterococci	O
were	O
lowered	O
from	O
>	O
250	O
microg	O
mL	O
(	O
-	O
1	O
)	O
to	O
1	O

4	O
microg	O
mL	O
(	O
-	O
1	O
)	O
in	O
the	O
presence	O
of	O
galangin	S-drug
(	O
12.5	O
microg	O
mL	O
(	O
-	O
1	O
)	O
)	O
or	O
3,7	O
-	O
dihydroxyflavone	O
(	O
6.25	O
microg	O
mL	O
(	O
-	O
1	O
)	O
)	O
.	O

Viable	O
counts	O
for	O
type	O
culture	O
E	O
.	O

faecalis	O
ATCC	O
51299	O
showed	O
the	O
flavonoids	O
alone	O
significantly	O
lowered	O
numbers	O
of	O
colony	O
forming	O
units	O
(	O
CFUs	O
)	O
.	O

CFUs	O
were	O
maintained	O
at	O
low	O
levels	O
(	O
10	O
(	O
3	O
)	O
CFU	O
mL	O
(	O
-	O
1	O
)	O
)	O
for	O
24	O
h	O
by	O
vancomycin	S-drug
/	O
flavone	O
combinations	O
.	O

This	O
combinational	O
action	O
in	O
reversing	O
vancomycin	O
resistance	O
of	O
enterococci	O
highlights	O
novel	O
drug	O
targets	O
and	O
has	O
importance	O
in	O
the	O
design	O
of	O
new	O
therapeutic	O
regimes	O
against	O
resistant	O
pathogens	O
.	O

Glucose	S-drug
and	O
insulin	S-drug
exert	O
additive	O
ocular	O
and	O
renal	O
vasodilator	O
effects	O
on	O
healthy	O
humans	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
There	O
is	O
evidence	O
that	O
insulin	S-drug
and	O
glucose	S-drug
cause	O
renal	O
and	O
ocular	O
vasodilation	O
.	O

There	O
is	O
,	O
however	O
,	O
currently	O
no	O
data	O
on	O
the	O
effect	O
of	O
combined	O
hyperglycaemia	O
and	O
hyperinsulinaemia	O
on	O
the	O
renal	O
and	O
ocular	O
blood	O
flow	O
seen	O
in	O
diabetic	O
patients	O
on	O
insulin	O
therapy	O
.	O

METHODS	O
:	O
We	O
carried	O
out	O
two	O
different	O
3	O
-	O
way	O
crossover	O
studies	O
in	O
healthy	O
subjects	O
(	O
each	O
,	O
n	O
=	O
9	O
)	O
.	O

In	O
study	O
one	O
,	O
hyperglycaemic	O
clamps	O
(	O
5.6	O
mmol	O
/	O
l	O
,	O
11.1	O
mmol	O
/	O
1	O
,	O
16.7	O
mmol	O
/	O
l	O
)	O
were	O
carried	O
out	O
during	O
placebo	O
or	O
insulin	S-drug
(	O
dose	O
1	O
:	O
1	O
mU	O
/	O
kg	O
/	O
min	O
;	O
dose	O
2	O
:	O
2	O
mU	O
/	O
kg	O
/	O
min	O
)	O
infusion	O
.	O

The	O
second	O
study	O
was	O
identical	O
but	O
endogenous	O
insulin	O
secretion	O
was	O
blocked	O
with	O
somatostatin	S-drug
.	O

The	O
renal	O
plasma	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
and	O
pulsatile	O
choroidal	O
blood	O
flow	O
were	O
measured	O
using	O
the	O
paraaminohippurate	O
method	O
,	O
the	O
inulin	O
method	O
and	O
a	O
laser	O
interferometric	O
measurement	O
of	O
fundus	O
pulsation	O
amplitude	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Insulin	S-drug
increased	O
renal	O
plasma	O
flow	O
and	O
fundus	O
pulsation	O
amplitude	O
but	O
not	O
the	O
glomerular	O
filtration	O
rate	O
.	O

Hyperglycaemia	O
increased	O
all	O
the	O
renal	O
and	O
ocular	O
parameters	O
studied	O
.	O

Haemodynamic	O
effects	O
of	O
glucose	S-drug
and	O
insulin	S-drug
were	O
additive	O
when	O
somatostatin	S-drug
was	O
co	O
-	O
administered	O
but	O
not	O
under	O
basal	O
conditions	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Glucose	S-drug
and	O
insulin	S-drug
can	O
exert	O
additive	O
vasodilator	O
properties	O
on	O
renal	O
and	O
ocular	O
circulation	O
.	O

To	O
find	O
out	O
whether	O
this	O
observation	O
is	O
related	O
to	O
the	O
increased	O
regional	O
perfusion	O
in	O
diabetes	O
longitudinal	O
studies	O
on	O
patients	O
with	O
Type	O
I	O
(	O
insulin	O
-	O
dependent	O
)	O
diabetes	O
mellitus	O
are	O
needed	O
.	O

Lack	O
of	O
interaction	O
between	O
levofloxacin	S-drug
and	O
oxycodone	S-drug
:	O
pharmacokinetics	O
and	O
drug	O
disposition	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
a	O
significant	O
reduction	O
in	O
the	O
oral	O
bioavailability	O
of	O
trovafloxacin	S-drug-ME-1
and	O
ciprofloxacin	S-drug-ME-1
when	O
administered	O
concomitantly	O
with	O
an	O
intravenous	O
opiate	S-group-ME-2
such	O
as	O
morphine	S-drug-ME-2
.	O

This	O
decrease	O
in	O
absorption	O
results	O
in	O
a	O
36	O
%	O
and	O
50	O
%	O
lower	O
AUC	O
for	O
trovafloxacin	S-drug
and	O
ciprofloxacin	S-drug
,	O
respectively	O
,	O
which	O
could	O
cause	O
clinical	O
failures	O
.	O

The	O
authors	O
investigated	O
the	O
possibility	O
of	O
a	O
similar	O
interaction	O
between	O
oxycodone	S-drug
and	O
levofloxacin	S-drug
.	O

Eight	O
healthy	O
volunteers	O
were	O
randomized	O
in	O
an	O
open	O
-	O
label	O
,	O
two	O
-	O
way	O
crossover	O
study	O
to	O
receive	O
oxycodone	S-drug
,	O
5	O
mg	O
p.o	O
.	O

Q4H	O
,	O
and	O
levofloxacin	S-drug
,	O
500	O
mg	O
p.o	O
.	O

1	O
hour	O
after	O
starting	O
the	O
oxycodone	S-drug
or	O
levofloxacin	S-drug
500	O
mg	O
p.o	O
.	O

alone	O
.	O

Blood	O
samples	O
were	O
drawn	O
at	O
0	O
,	O
0.5	O
,	O
1	O
,	O
1.5	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
8	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
hours	O
for	O
Cmax	O
,	O
tmax	O
,	O
and	O
AUC	O
determinations	O
.	O

There	O
was	O
not	O
a	O
significant	O
difference	O
(	O
p	O
>	O
0.05	O
)	O
in	O
AUC	O
(	O
48.59	O
+	O
/	O
-	O
8.52	O
vs.	O
49.9	O
+	O
/	O
-	O
9.93	O
)	O
,	O
Cmax	O
(	O
7.73	O
+	O
/	O
-	O
2.6	O
vs.	O
6.6	O
+	O
/	O
-	O
2.0	O
)	O
,	O
and	O
tmax	O
(	O
1.1	O
+	O
/	O
-	O
0.6	O
vs.	O
1.6	O
+	O
/	O
-	O
1.1	O
)	O
for	O
levofloxacin	S-drug
versus	O
levofloxacin	S-drug
/	O
oxycodone	S-drug
regimens	O
.	O

It	O
was	O
concluded	O
that	O
oral	O
oxycodone	S-drug
and	O
levofloxacin	S-drug
can	O
be	O
administered	O
concomitantly	O
without	O
a	O
significant	O
decrease	O
in	O
AUC	O
,	O
Cmax	O
,	O
or	O
tmax	O
.	O

Lack	O
of	O
an	O
effect	O
of	O
azithromycin	S-drug
on	O
the	O
disposition	O
of	O
zidovudine	S-drug
and	O
dideoxyinosine	S-drug
in	O
HIV	O
-	O
infected	O
patients	O
.	O

Two	O
studies	O
were	O
conducted	O
in	O
HIV	O
-	O
infected	O
subjects	O
to	O
assess	O
the	O
potential	O
for	O
azithromycin	S-drug
to	O
interact	O
with	O
zidovudine	S-drug
and	O
dideoxyinosine	S-drug
.	O

Both	O
studies	O
used	O
12	O
subjects	O
.	O

The	O
zidovudine	S-drug
study	O
dosed	O
subjects	O
with	O
1200	O
mg	O
/	O
day	O
of	O
azithromycin	S-drug
(	O
n	O
=	O
7	O
)	O
(	O
later	O
changed	O
to	O
600	O
mg	O
/	O
day	O
[	O
n	O
=	O
5	O
]	O
)	O
for	O
Days	O
8	O
to	O
21	O
of	O
a	O
21	O
-	O
day	O
course	O
of	O
100	O
mg	O
,	O
five	O
times	O
/	O
day	O
of	O
zidovudine	S-drug
.	O

Subjects	O
treated	O
with	O
200	O
mg	O
of	O
dideoxyinosine	S-drug
twice	O
daily	O
for	O
21	O
days	O
received	O
1200	O
mg	O
of	O
azithromycin	S-drug
or	O
an	O
equivalent	O
amount	O
of	O
placebo	O
/	O
day	O
for	O
Days	O
8	O
to	O
21	O
.	O

Antiretroviral	S-group
plasma	O
and	O
urine	O
sampling	O
were	O
conducted	O
on	O
Days	O
1	O
,	O
7	O
,	O
and	O
21	O
for	O
zidovudine	S-drug
and	O
on	O
Days	O
7	O
and	O
21	O
for	O
dideoxyinosine	S-drug
.	O

Peripheral	O
mononuclear	O
cells	O
were	O
also	O
collected	O
for	O
quantitation	O
of	O
phosphorylated	O
zidovudine	S-drug
.	O

Azithromycin	S-drug-ME-1
had	O
no	O
significant	O
impact	O
on	O
the	O
Cmax	O
and	O
AUC	O
of	O
zidovudine	S-drug
,	O
although	O
it	O
significantly	O
decreased	O
the	O
zidovudine	S-drug-ME-2
tmax	O
by	O
44	O
%	O
and	O
increased	O
the	O
intracellular	O
exposure	O
to	O
phosphorylated	O
zidovudine	S-drug-ME-2
by	O
110	O
%	O
.	O

Azithromycin	S-drug
had	O
no	O
significant	O
effect	O
on	O
dideoxyinosine	S-drug
pharmacokinetics	O
.	O

Based	O
on	O
the	O
results	O
of	O
these	O
studies	O
,	O
it	O
is	O
concluded	O
that	O
azithromycin	S-drug
may	O
be	O
safely	O
coadministered	O
with	O
both	O
zidovudine	S-drug
and	O
dideoxyinosine	S-drug
.	O

Effect	O
of	O
diazepam	S-drug
and	O
midazolam	S-drug
on	O
the	O
antinociceptive	O
effect	O
of	O
morphine	S-drug
,	O
metamizol	S-drug
and	O
indomethacin	S-drug
in	O
mice	O
.	O

The	O
influence	O
of	O
midazolam	S-drug
and	O
diazepam	S-drug
on	O
antinociceptive	O
effect	O
of	O
morphine	S-drug
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
metamizol	S-drug
(	O
500	O
mg	O
/	O
kg	O
)	O
and	O
indomethacin	S-drug
(	O
10	O
mg	O
/	O
kg	O
)	O
was	O
investigated	O
in	O
a	O
mouse	O
model	O
using	O
the	O
tail	O
-	O
flick	O
and	O
hot	O
-	O
plate	O
tests	O
.	O

All	O
drugs	O
were	O
injected	O
intraperitoneally	O
.	O

Benzodiazepines	S-group
were	O
administered	O
to	O
mice	O
30	O
min	O
before	O
applying	O
the	O
analgesic	B-group
drugs	E-group
.	O

Measurement	O
of	O
nociception	O
was	O
performed	O
within	O
2	O
h	O
after	O
benzodiazepine	S-group
administration	O
.	O

Diazepam	S-drug-EF-1
at	O
doses	O
of	O
0.25	O
mg	O
/	O
kg	O
and	O
2.5	O
mg	O
/	O
kg	O
injected	O
with	O
morphine	S-drug-EF-2
was	O
found	O
to	O
decrease	O
the	O
antinociceptive	O
effect	O
of	O
morphine	S-drug
.	O

Similarly	O
,	O
diazepam	S-drug-EF-1
decreased	O
the	O
antinociceptive	O
effect	O
of	O
metamizol	S-drug-EF-2
(	O
only	O
in	O
the	O
tail	O
-	O
flick	O
test	O
)	O
and	O
indomethacin	S-drug-EF-2
.	O

Midazolam	S-drug-EF-1
used	O
at	O
doses	O
of	O
1.25	O
mg	O
/	O
kg	O
and	O
2.5	O
mg	O
/	O
kg	O
decreased	O
the	O
antinociceptive	O
effect	O
of	O
morphine	S-drug-EF-2
,	O
metamizol	S-drug-EF-2
(	O
only	O
in	O
the	O
tail	O
-	O
flick	O
test	O
)	O
and	O
indomethacin	S-drug-EF-2
.	O

Pharmacological	O
treatment	O
of	O
depression	O
:	O
the	O
role	O
of	O
paroxetine	S-drug
.	O

Depression	O
is	O
reaching	O
epidemic	O
proportions	O
in	O
the	O
western	O
world	O
.	O

With	O
each	O
successive	O
generation	O
more	O
people	O
are	O
becoming	O
more	O
severely	O
depressed	O
at	O
a	O
younger	O
age	O
.	O

Influence	O
of	O
estradiol	S-drug
and	O
progesterone	S-drug
on	O
the	O
sensitivity	O
of	O
rat	O
thoracic	O
aorta	O
to	O
noradrenaline	S-drug
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
low	O
and	O
high	O
doses	O
of	O
estradiol	S-drug
,	O
and	O
of	O
progesterone	S-drug
on	O
the	O
response	O
to	O
noradrenaline	S-drug
in	O
rat	O
thoracic	O
aorta	O
.	O

Two	O
weeks	O
after	O
bilateral	O
ovariectomy	O
,	O
female	O
rats	O
received	O
a	O
s.c	O
.	O

injection	O
of	O
vehicle	O
(	O
corn	O
oil	O
,	O
0.1	O
mL	O
/	O
day	O
)	O
,	O
estradiol	S-drug
(	O
10	O
microg	O
/	O
kg	O
/	O
day	O
or	O
4	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
/	O
or	O
progesterone	S-drug
(	O
20	O
mg	O
/	O
kg	O
/	O
day	O
)	O
,	O
for	O
eight	O
days	O
.	O

On	O
the	O
ninth	O
day	O
,	O
the	O
rats	O
were	O
sacrificed	O
and	O
aortic	O
rings	O
,	O
with	O
or	O
without	O
endothelium	O
,	O
were	O
used	O
to	O
generate	O
concentration	O
-	O
response	O
curves	O
to	O
noradrenaline	S-drug
.	O

Aortic	O
rings	O
with	O
intact	O
endothelium	O
from	O
the	O
high	O
-	O
dose	O
(	O
4	O
mg	O
/	O
kg	O
/	O
day	O
)	O
estradiol	S-drug-EF-1
group	O
were	O
supersensitive	O
to	O
noradrenaline	S-drug-EF-2
compared	O
to	O
the	O
vehicle	O
or	O
low	O
-	O
dose	O
(	O
10	O
microg	O
/	O
kg	O
/	O
day	O
)	O
estradiol	O
groups	O
(	O
pD2	O
values	O
=	O
7.86	O
+	O
/	O
-	O
0.09	O
,	O
7.30	O
+	O
/	O
-	O
0.11	O
and	O
7.35	O
+	O
/	O
-	O
0.04	O
,	O
respectively	O
)	O
.	O

Endothelium	O
-	O
intact	O
aortic	O
rings	O
from	O
high	O
-	O
estradiol	S-drug-EF-1
rats	O
were	O
supersensitive	O
to	O
noradrenaline	S-drug-EF-2
when	O
compared	O
to	O
vehicle	O
-	O
,	O
progesterone	S-drug
-	O
and	O
progesterone	S-drug
+	O
high	O
-	O
estradiol	S-drug
-	O
treated	O
rats	O
(	O
pD2	O
values	O
=	O
7.77	O
+	O
/	O
-	O
0.12	O
,	O
7.21	O
+	O
/	O
-	O
0.13	O
,	O
6.93	O
+	O
/	O
-	O
0.04	O
and	O
7.22	O
+	O
/	O
-	O
0.18	O
,	O
respectively	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
pD2	O
values	O
for	O
noradrenaline	S-drug
in	O
aortic	O
rings	O
without	O
endothelium	O
.	O

Both	O
of	O
these	O
effects	O
were	O
endothelium	O
-	O
dependent	O
.	O

[	O
Drug	O
treatment	O
of	O
erection	O
disorders	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
]	O
Erectile	O
dysfunction	O
is	O
a	O
frequent	O
condition	O
in	O
cardiovascular	O
patients	O
.	O

Since	O
the	O
arrival	O
of	O
oral	O
erection	B-group
-	I-group
supporting	I-group
medication	E-group
,	O
patients	O
want	O
to	O
know	O
how	O
safe	O
sexual	O
activity	O
is	O
in	O
cardiovascular	O
disease	O
in	O
general	O
and	O
during	O
use	O
of	O
erection	B-group
-	I-group
supporting	I-group
medication	E-group
in	O
particular	O
.	O

Sexual	O
intercourse	O
with	O
a	O
steady	O
partner	O
causes	O
no	O
more	O
cardiovascular	O
risk	O
than	O
normal	O
daily	O
activities	O
such	O
as	O
ironing	O
,	O
2	O
kilometers	O
of	O
walking	O
without	O
climbing	O
,	O
paperhanging	O
,	O
playing	O
golf	O
or	O
gardening	O
.	O

The	O
relative	O
risk	O
of	O
myocardial	O
infarction	O
during	O
sexual	O
activity	O
is	O
not	O
significantly	O
higher	O
than	O
for	O
healthy	O
persons	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
morbidity	O
and	O
mortality	O
is	O
not	O
higher	O
among	O
users	O
of	O
sildenafil	S-drug
.	O

Sildenafil	S-drug-AD-1
is	O
contraindicated	O
in	O
patients	O
using	O
long	B-group-AD-2
-	I-group-AD-2
acting	I-group-AD-2
nitrates	E-group-AD-2
or	O
who	O
may	O
need	O
to	O
use	O
short	B-group-AD-2
-	I-group-AD-2
acting	I-group-AD-2
nitrates	E-group-AD-2
,	O
because	O
the	O
combination	O
may	O
cause	O
a	O
sharp	O
fall	O
of	O
the	O
blood	O
pressure	O
.	O

No	O
interactions	O
have	O
been	O
observed	O
with	O
beta	B-group
-	I-group
receptor	I-group
blockers	E-group
,	O
calcium	B-group
antagonists	E-group
,	O
thiazide	S-group
and	O
loop	B-group
diuretics	E-group
and	O
ACE	B-group
inhibitors	E-group
.	O

Before	O
prescribing	O
a	O
symptomatic	O
(	O
pharmaceutical	O
)	O
treatment	O
for	O
patients	O
with	O
an	O
erection	O
disorder	O
,	O
attention	O
should	O
be	O
given	O
tot	O
the	O
sexological	O
,	O
psychological	O
and	O
medical	O
backgrounds	O
of	O
the	O
disorder	O
.	O

Secondary	O
prevention	O
of	O
atherosclerotic	O
risk	O
factors	O
is	O
also	O
important	O
:	O
regulation	O
of	O
blood	O
pressure	O
and	O
blood	O
sugar	O
level	O
,	O
hyperlipidaemia	O
and	O
obesity	O
,	O
as	O
well	O
as	O
a	O
change	O
of	O
lifestyle	O
(	O
giving	O
up	O
smoking	O
,	O
adapting	O
of	O
diet	O
and	O
more	O
physical	O
exertion	O
)	O
.	O

Patients	O
with	O
a	O
very	O
low	O
cardiac	O
capacity	O
should	O
be	O
advised	O
to	O
refrain	O
from	O
treatment	O
of	O
the	O
erection	O
disorder	O
.	O

Influence	O
of	O
coadministration	O
of	O
fluoxetine	S-drug
on	O
cisapride	S-drug
pharmacokinetics	O
and	O
QTc	O
intervals	O
in	O
healthy	O
volunteers	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
fluoxetine	S-drug
on	O
the	O
pharmacokinetics	O
and	O
cardiovascular	O
safety	O
of	O
cisapride	S-drug
at	O
steady	O
state	O
in	O
healthy	O
men	O
.	O

DESIGN	O
:	O
Open	O
-	O
label	O
,	O
three	O
-	O
phase	O
,	O
sequential	O
study	O
.	O

SETTING	O
:	O
Clinical	O
research	O
center	O
.	O

SUBJECTS	O
:	O
Twelve	O
healthy	O
male	O
volunteers	O
.	O

INTERVENTIONS	O
:	O
Each	O
subject	O
was	O
treated	O
according	O
to	O
the	O
following	O
sequence	O
:	O
baseline	O
;	O

phase	O
1	O
(	O
days	O
1	O
-	O
6	O
)	O
:	O
cisapride	S-drug
10	O
mg	O
4	O
times	O
/	O
day	O
;	O

washout	O
(	O
days	O
7	O
-	O
13	O
)	O
;	O

phase	O
2	O
(	O
days	O
14	O
-	O
44	O
)	O
:	O
fluoxetine	S-drug
20	O
mg	O
/	O
day	O
;	O

and	O
phase	O
3	O
(	O
days	O
45	O
-	O
52	O
)	O
:	O
cisapride	S-drug
10	O
mg	O
4	O
times	O
/	O
day	O
(	O
days	O
45	O
-	O
51	O
)	O
plus	O
fluoxetine	S-drug
20	O
mg	O
/	O
day	O
(	O
days	O
45	O
-	O
52	O
)	O
.	O

MEASUREMENTS	O
and	O
MAIN	O
RESULTS	O
:	O
Blood	O
samples	O
were	O
drawn	O
and	O
12	O
-	O
lead	O
electrocardiograms	O
performed	O
at	O
specified	O
time	O
points	O
after	O
the	O
last	O
morning	O
dose	O
of	O
cisapride	S-drug
in	O
phases	O
1	O
and	O
3	O
.	O

Blood	O
samples	O
also	O
were	O
taken	O
before	O
morning	O
doses	O
on	O
the	O
3rd	O
,	O
4th	O
,	O
and	O
5th	O
days	O
of	O
phases	O
1	O
and	O
3	O
.	O

Electrocardiograms	O
were	O
done	O
at	O
baseline	O
and	O
on	O
the	O
last	O
day	O
of	O
the	O
washout	O
period	O
and	O
phase	O
2	O
.	O

Coadministration	O
of	O
fluoxetine	S-drug-ME-1
significantly	O
decreased	O
cisapride	S-drug-ME-2
plasma	O
concentrations	O
.	O

There	O
were	O
no	O
clinically	O
significant	O
changes	O
in	O
corrected	O
QT	O
intervals	O
during	O
administration	O
of	O
cisapride	S-drug
alone	O
or	O
with	O
fluoxetine	S-drug
.	O

Cisapride	S-drug
was	O
well	O
tolerated	O
when	O
administered	O
alone	O
or	O
with	O
fluoxetine	S-drug
.	O

CONCLUSION	O
:	O
Cisapride	S-drug
can	O
be	O
administered	O
safely	O
to	O
patients	O
receiving	O
low	O
therapeutic	O
dosages	O
of	O
fluoxetine	S-drug
.	O

Olanzapine	S-drug
:	O
an	O
updated	O
review	O
of	O
its	O
use	O
in	O
the	O
management	O
of	O
schizophrenia	O
.	O

Olanzapine	S-drug
,	O
a	O
thienobenzodiazepine	B-group
derivative	E-group
,	O
is	O
a	O
second	B-group
generation	I-group
(	I-group
atypical	I-group
)	I-group
antipsychotic	I-group
agent	E-group
which	O
has	O
proven	O
efficacy	O
against	O
the	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

Compared	O
with	O
conventional	B-group
antipsychotics	E-group
,	O
it	O
has	O
greater	O
affinity	O
for	O
serotonin	O
5	O
-	O
HT2A	O
than	O
for	O
dopamine	O
D2	O
receptors	O
.	O

In	O
large	O
,	O
well	O
controlled	O
trials	O
in	O
patients	O
with	O
schizophrenia	O
or	O
related	O
psychoses	O
,	O
olanzapine	S-drug
5	O
to	O
20	O
mg	O
/	O
day	O
was	O
significantly	O
superior	O
to	O
haloperidol	S-drug
5	O
to	O
20	O
mg	O
/	O
day	O
in	O
overall	O
improvements	O
in	O
psychopathology	O
rating	O
scales	O
and	O
in	O
the	O
treatment	O
of	O
depressive	O
and	O
negative	O
symptoms	O
,	O
and	O
was	O
comparable	O
in	O
effects	O
on	O
positive	O
psychotic	O
symptoms	O
.	O

The	O
1	O
-	O
year	O
risk	O
of	O
relapse	O
(	O
rehospitalisation	O
)	O
was	O
significantly	O
lower	O
with	O
olanzapine	S-drug
than	O
with	O
haloperidol	S-drug
treatment	O
.	O

In	O
the	O
first	O
double	O
-	O
blind	O
comparative	O
study	O
(	O
28	O
-	O
week	O
)	O
of	O
olanzapine	S-drug
and	O
risperidone	S-drug
,	O
olanzapine	S-drug
10	O
to	O
20	O
mg	O
/	O
day	O
proved	O
to	O
be	O
significantly	O
more	O
effective	O
than	O
risperidone	S-drug
4	O
to	O
12	O
mg	O
/	O
day	O
in	O
the	O
treatment	O
of	O
negative	O
and	O
depressive	O
symptoms	O
but	O
not	O
on	O
overall	O
psychopathology	O
symptoms	O
.	O

In	O
contrast	O
,	O
preliminary	O
results	O
from	O
an	O
8	O
-	O
week	O
controlled	O
study	O
suggested	O
risperidone	S-drug
2	O
to	O
6	O
mg	O
/	O
day	O
was	O
superior	O
to	O
olanzapine	S-drug
5	O
to	O
20	O
mg	O
/	O
day	O
against	O
positive	O
and	O
anxiety	O
/	O
depressive	O
symptoms	O
(	O
p	O
<	O
0.05	O
)	O
,	O
although	O
consistent	O
with	O
the	O
first	O
study	O
,	O
both	O
agents	O
demonstrated	O
similar	O
efficacy	O
on	O
measures	O
of	O
overall	O
psychopathology	O
.	O

Improvements	O
in	O
general	O
cognitive	O
function	O
seen	O
with	O
olanzapine	S-drug
treatment	O
in	O
a	O
1	O
-	O
year	O
controlled	O
study	O
of	O
patients	O
with	O
early	O
-	O
phase	O
schizophrenia	O
,	O
were	O
significantly	O
greater	O
than	O
changes	O
seen	O
with	O
either	O
risperidone	S-drug
or	O
haloperidol	S-drug
.	O

However	O
,	O
preliminary	O
results	O
from	O
an	O
8	O
-	O
week	O
trial	O
showed	O
comparable	O
cognitive	O
enhancing	O
effects	O
of	O
olanzapine	S-drug
and	O
risperidone	S-drug
treatment	O
in	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
.	O

Several	O
studies	O
indicate	O
that	O
olanzapine	S-drug
has	O
benefits	O
against	O
symptoms	O
of	O
aggression	O
and	O
agitation	O
,	O
while	O
other	O
studies	O
strongly	O
support	O
the	O
effectiveness	O
of	O
olanzapine	S-drug
in	O
the	O
treatment	O
of	O
depressive	O
symptomatology	O
.	O

Olanzapine	S-drug
is	O
associated	O
with	O
significantly	O
fewer	O
extrapyramidal	O
symptoms	O
than	O
haloperidol	S-drug
and	O
risperidone	S-drug
.	O

In	O
addition	O
,	O
olanzapine	S-drug
is	O
not	O
associated	O
with	O
a	O
risk	O
of	O
agranulocytosis	O
as	O
seen	O
with	O
clozapine	S-drug
or	O
clinically	O
significant	O
hyperprolactinaemia	O
as	O
seen	O
with	O
risperidone	S-drug
or	O
prolongation	O
of	O
the	O
QT	O
interval	O
.	O

The	O
most	O
common	O
adverse	O
effects	O
reported	O
with	O
olanzapine	S-drug
are	O
bodyweight	O
gain	O
,	O
somnolence	O
,	O
dizziness	O
,	O
anticholinergic	O
effects	O
(	O
constipation	O
and	O
dry	O
mouth	O
)	O
and	O
transient	O
asymptomatic	O
liver	O
enzyme	O
elevations	O
.	O

In	O
comparison	O
with	O
haloperidol	S-drug
,	O
the	O
adverse	O
events	O
reported	O
significantly	O
more	O
frequently	O
with	O
olanzapine	S-drug
in	O
>	O
or	O
=	O
3.5	O
%	O
of	O
patients	O
were	O
dry	O
mouth	O
,	O
bodyweight	O
gain	O
and	O
increased	O
appetite	O
and	O
compared	O
with	O
risperidone	S-drug
,	O
only	O
bodyweight	O
gain	O
occurred	O
significantly	O
more	O
frequently	O
with	O
olanzapine	S-drug
.	O

The	O
high	O
acquisition	O
cost	O
of	O
olanzapine	S-drug
is	O
offset	O
by	O
reductions	O
in	O
other	O
treatment	O
costs	O
(	O
inpatient	O
and	O
/	O
or	O
outpatient	O
services	O
)	O
of	O
schizophrenia	O
.	O

Pharmacoeconomic	O
analyses	O
indicate	O
that	O
olanzapine	S-drug
does	O
not	O
significantly	O
increase	O
,	O
and	O
may	O
even	O
decrease	O
,	O
the	O
overall	O
direct	O
treatment	O
costs	O
of	O
schizophrenia	O
,	O
compared	O
with	O
haloperidol	S-drug
.	O

Compared	O
with	O
risperidone	S-drug
,	O
olanzapine	S-drug
has	O
also	O
been	O
reported	O
to	O
decrease	O
overall	O
treatment	O
costs	O
,	O
despite	O
the	O
several	O
-	O
fold	O
higher	O
daily	O
acquisition	O
cost	O
of	O
the	O
drug	O
.	O

Olanzapine	S-drug
treatment	O
improves	O
quality	O
of	O
life	O
in	O
patients	O
with	O
schizophrenia	O
and	O
related	O
psychoses	O
to	O
a	O
greater	O
extent	O
than	O
haloperidol	S-drug
,	O
and	O
to	O
broadly	O
the	O
same	O
extent	O
as	O
risperidone	S-drug
.	O

CONCLUSIONS	O
:	O
Olanzapine	S-drug
demonstrated	O
superior	O
antipsychotic	O
efficacy	O
compared	O
with	O
haloperidol	S-drug
in	O
the	O
treatment	O
of	O
acute	O
phase	O
schizophrenia	O
,	O
and	O
in	O
the	O
treatment	O
of	O
some	O
patients	O
with	O
first	O
-	O
episode	O
or	O
treatment	O
-	O
resistant	O
schizophrenia	O
.	O

The	O
reduced	O
risk	O
of	O
adverse	O
events	O
and	O
therapeutic	O
superiority	O
compared	O
with	O
haloperidol	S-drug
and	O
risperidone	S-drug
in	O
the	O
treatment	O
of	O
negative	O
and	O
depressive	O
symptoms	O
support	O
the	O
choice	O
of	O
olanzapine	S-drug
as	O
a	O
first	O
-	O
line	O
option	O
in	O
the	O
management	O
of	O
schizophrenia	O
in	O
the	O
acute	O
phase	O
and	O
for	O
the	O
maintenance	O
of	O
treatment	O
response	O
.	O

The	O
emerging	O
roles	O
of	O
non	B-group
-	I-group
nucleoside	I-group
reverse	I-group
transcriptase	I-group
inhibitors	E-group
in	O
antiretroviral	S-group
therapy	O
.	O

The	O
availability	O
of	O
potent	O
non	B-group
-	I-group
nucleoside	I-group
reverse	I-group
transcriptase	I-group
inhibitor	E-group
(	O
NNRTI	S-group
)	O
-	O
based	O
regimens	O
for	O
antiretroviral	S-group
therapy	O
and	O
concerns	O
regarding	O
protease	B-group
inhibitor	E-group
(	O
PI	S-group
)	O
-	O
related	O
metabolic	O
disturbances	O
have	O
led	O
to	O
significant	O
shifts	O
in	O
treatment	O
practices	O
in	O
HIV	O
infection	O
.	O

NNRTI	S-group
-	O
based	O
regimens	O
may	O
have	O
several	O
advantages	O
over	O
PI	S-group
-	O
based	O
therapy	O
for	O
initial	O
or	O
prolonged	O
therapy	O
,	O
including	O
more	O
convenient	O
administration	O
regimens	O
,	O
lower	O
tablet	O
volume	O
,	O
fewer	O
drug	O
interactions	O
,	O
and	O
central	O
nervous	O
system	O
penetration	O
.	O

No	O
data	O
from	O
prospective	O
clinical	O
trials	O
currently	O
exist	O
comparing	O
the	O
3	O
approved	O
agents	O
(	O
efavirenz	S-drug
,	O
nevirapine	S-drug
or	O
delavirdine	S-drug
)	O
.	O

Both	O
efavirenz	S-drug
and	O
nevirapine	S-drug
have	O
been	O
compared	O
to	O
triple	O
therapy	O
with	O
the	O
PI	S-group
indinavir	S-drug
over	O
48	O
weeks	O
as	O
initial	O
therapy	O
,	O
with	O
similar	O
responses	O
being	O
observed	O
with	O
nevirapine	S-drug
regimens	O
and	O
superiority	O
observed	O
with	O
efavirenz	S-drug
.	O

A	O
smaller	O
24	O
-	O
week	O
study	O
has	O
suggested	O
nevirapine	S-drug
may	O
be	O
superior	O
to	O
the	O
PI	S-group
nelfinavir	S-drug
.	O

Limited	O
comparative	O
data	O
in	O
patients	O
with	O
high	O
viral	O
loads	O
treated	O
with	O
nevirapine	S-drug
-	O
or	O
delavirdine	S-drug
-	O
based	O
regimens	O
currently	O
exist	O
.	O

However	O
,	O
cohort	O
data	O
and	O
selected	O
patient	O
data	O
from	O
clinical	O
trials	O
suggest	O
comparable	O
activity	O
to	O
PI	S-group
-	O
based	O
regimens	O
in	O
these	O
patients	O
.	O

The	O
superiority	O
of	O
efavirenz	S-drug
over	O
indinavir	S-drug
-	O
based	O
regimens	O
has	O
been	O
observed	O
in	O
comparative	O
data	O
in	O
a	O
subset	O
of	O
patients	O
with	O
high	O
viral	O
loads	O
.	O

In	O
treatment	O
-	O
experienced	O
patients	O
,	O
available	O
uncontrolled	O
data	O
suggest	O
these	O
agents	O
contribute	O
to	O
regimen	O
efficacy	O
in	O
NNRTI	S-group
-	O
na	O
ve	O
,	O
treatment	O
-	O
experienced	O
patients	O
.	O

Efavirenz	S-drug
has	O
demonstrated	O
superiority	O
over	O
nelfinavir	S-drug
in	O
nucleoside	O
-	O
experienced	O
patients	O
,	O
although	O
combining	O
these	O
2	O
agents	O
may	O
represent	O
the	O
best	O
approach	O
in	O
these	O
circumstances	O
.	O

The	O
tolerability	O
of	O
NNRTIs	S-group
appears	O
generally	O
good	O
with	O
few	O
individuals	O
discontinuing	O
in	O
clinical	O
studies	O
as	O
a	O
result	O
of	O
adverse	O
drug	O
events	O
.	O

The	O
majority	O
of	O
adverse	O
events	O
with	O
NNRTIs	S-group
occur	O
within	O
the	O
first	O
month	O
,	O
and	O
are	O
predictable	O
and	O
manageable	O
without	O
therapy	O
interruption	O
.	O

[	O
Pharmacologic	O
interactions	O
in	O
chronic	O
treatments	O
:	O
corrective	O
measures	O
for	O
its	O
prevention	O
in	O
a	O
basic	O
area	O
of	O
rural	O
health	O
]	O
OBJECTIVES	O
:	O
To	O
identify	O
the	O
pharmacological	O
interactions	O
of	O
clinical	O
relevance	O
(	O
PICR	O
)	O
in	O
the	O
medication	O
authorization	O
cards	O
(	O
MAC	O
)	O
of	O
the	O
chronically	O
ill	O
and	O
to	O
establish	O
strategies	O
to	O
minimise	O
their	O
appearance	O
.	O

DESIGN	O
:	O
Cross	O
-	O
sectional	O
descriptive	O
study	O
.	O

SETTING	O
:	O
Rural	O
primary	O
care	O
centre	O
.	O

PATIENTS	O
:	O
Random	O
sample	O
of	O
626	O
MAC	O
out	O
of	O
a	O
total	O
of	O
1306	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
In	O
December	O
1998	O
,	O
the	O
following	O
was	O
gathered	O
for	O
every	O
MAC	O
with	O
more	O
than	O
one	O
drug	O
treatment	O
:	O
age	O
,	O
sex	O
,	O
number	O
of	O
drugs	O
,	O
intrinsic	O
value	O
,	O
drugs	O
prescribed	O
,	O
daily	O
dose	O
and	O
pharmacological	O
interactions	O
(	O
PI	O
)	O
,	O
classified	O
(	O
using	O
the	O
scale	O
of	O
Hansten	O
1996	O
)	O
into	O
light	O
and	O
clinically	O
relevant	O
.	O

Statistical	O
analysis	O
:	O
Mantel	O
-	O
Haenszel	O
(	O
alpha	O
=	O
0.05	O
)	O
.	O

Patients	O
'	O
mean	O
age	O
was	O
69.1	O
(	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
1.2	O
)	O
.	O

Mean	O
number	O
of	O
drugs	O
per	O
MAC	O
was	O
4	O
(	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
0.2	O
)	O
.	O

341	O
PI	O
affecting	O
197	O
patients	O
(	O
31.5	O
%	O
,	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
3.6	O
)	O
were	O
identified	O
.	O

24.9	O
%	O
(	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
4.5	O
)	O
were	O
PICR	O
,	O
detected	O
in	O
11.7	O
%	O
(	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
2.5	O
)	O
of	O
the	O
MAC	O
.	O

The	O
existence	O
of	O
PI	O
was	O
related	O
to	O
the	O
number	O
of	O
drugs	O
prescribed	O
to	O
each	O
patient	O
(	O
p	O
<	O
0.01	O
)	O
.	O

There	O
were	O
26	O
PI	O
with	O
drugs	O
of	O
low	O
intrinsic	O
value	O
(	O
7.6	O
%	O
;	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
2.8	O
)	O
.	O

74.1	O
%	O
(	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
9.3	O
)	O
of	O
the	O
total	O
PICR	O
could	O
be	O
avoided	O
by	O
simple	O
recommendations	O
;	O

and	O
the	O
remaining	O
25.9	O
%	O
(	O
95	O
%	O
CI	O
,	O
+	O
/	O
-	O
9.3	O
)	O
by	O
monitoring	O
and	O
follow	O
-	O
up	O
of	O
patients	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
important	O
to	O
identify	O
the	O
medications	O
most	O
commonly	O
involved	O
in	O
the	O
PICR	O
so	O
as	O
to	O
establish	O
corrective	O
measures	O
to	O
minimise	O
the	O
risks	O
arising	O
from	O
multiple	O
medication	O
.	O

Four	O
educational	O
messages	O
advise	O
on	O
over	O
60	O
%	O
of	O
the	O
PICR	O
detected	O
.	O

Prescribing	O
.	O

Keys	O
to	O
maximizing	O
benefit	O
while	O
avoiding	O
adverse	O
drug	O
effects	O
.	O

When	O
prescribing	O
for	O
older	O
patients	O
,	O
some	O
physicians	O
are	O
overly	O
cautious	O
,	O
and	O
this	O
strategy	O
can	O
result	O
in	O
a	O
less	O
than	O
optimal	O
treatment	O
outcome	O
.	O

The	O
reluctance	O
to	O
treat	O
aggressively	O
is	O
understandable	O
because	O
the	O
geriatric	O
population	O
is	O
susceptible	O
to	O
adverse	O
drug	O
reactions	O
.	O

The	O
key	O
to	O
maximizing	O
therapy	O
lies	O
in	O
individualizing	O
it	O
as	O
much	O
as	O
possible	O
.	O

There	O
are	O
a	O
number	O
of	O
steps	O
physicians	O
can	O
take	O
to	O
ensure	O
that	O
their	O
patients	O
are	O
not	O
being	O
undertreated	O
.	O

These	O
steps	O
include	O
regular	O
reevaluations	O
of	O
dosages	O
and	O
plasma	O
drug	O
concentrations	O
,	O
recognition	O
and	O
understanding	O
of	O
drug	O
side	O
effects	O
,	O
and	O
avoidance	O
of	O
certain	O
agents	O
.	O

Close	O
monitoring	O
allows	O
physicians	O
to	O
minimize	O
risks	O
,	O
maximize	O
benefits	O
,	O
and	O
get	O
the	O
most	O
out	O
of	O
what	O
modern	O
medications	O
can	O
do	O
to	O
help	O
older	O
patients	O
.	O

Sildenafil	B-drug
citrate	E-drug
:	O
a	O
therapeutic	O
update	O
.	O

BACKGROUND	O
:	O
Since	O
its	O
approval	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
in	O
March	O
1998	O
,	O
sildenafil	B-drug
citrate	E-drug
has	O
been	O
used	O
by	O
millions	O
of	O
men	O
for	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
.	O

Recent	O
studies	O
and	O
consensus	O
reports	O
have	O
expanded	O
our	O
understanding	O
of	O
its	O
efficacy	O
,	O
safety	O
,	O
contraindications	O
,	O
and	O
drug	O
interactions	O
.	O

OBJECTIVE	O
:	O
This	O
paper	O
reviews	O
recent	O
studies	O
of	O
the	O
efficacy	O
of	O
sildenafil	S-drug
,	O
its	O
adverse	O
effects	O
and	O
drug	O
interactions	O
,	O
and	O
socioeconomic	O
factors	O
involved	O
in	O
its	O
use	O
,	O
with	O
a	O
focus	O
on	O
specific	O
patient	O
populations	O
(	O
prostate	O
cancer	O
,	O
diabetes	O
mellitus	O
,	O
ischemic	O
heart	O
disease	O
,	O
spinal	O
cord	O
injuries	O
,	O
neurologic	O
disorders	O
)	O
.	O

METHODS	O
:	O
Clinical	O
studies	O
,	O
case	O
reports	O
,	O
and	O
commentaries	O
and	O
editorials	O
concerning	O
sildenafil	S-drug
published	O
in	O
the	O
international	O
literature	O
between	O
January	O
1999	O
and	O
August	O
2000	O
were	O
identified	O
through	O
searches	O
of	O
MEDLINE	O
,	O
PREMEDLINE	O
,	O
and	O
International	O
Pharmaceutical	O
Abstracts	O
,	O
using	O
the	O
terms	O
sildenafil	S-drug
,	O
Viagra	S-brand
,	O
and	O
erectile	O
dysfunction	O
.	O

RESULTS	O
:	O
Sildenafil	S-drug
has	O
demonstrated	O
effectiveness	O
in	O
men	O
with	O
erectile	O
dysfunction	O
associated	O
with	O
prostatectomy	O
,	O
radiation	O
therapy	O
,	O
diabetes	O
mellitus	O
,	O
certain	O
neurologic	O
disorders	O
,	O
and	O
drug	O
therapy	O
(	O
eg	O
,	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
[	O
SSRIs	S-group
]	O
)	O
.	O

It	O
has	O
not	O
been	O
as	O
effective	O
in	O
women	O
with	O
sexual	O
dysfunction	O
,	O
with	O
the	O
exception	O
of	O
SSRI	S-group
-	O
associated	O
sexual	O
dysfunction	O
.	O

Some	O
disorders	O
unrelated	O
to	O
sexual	O
dysfunction	O
(	O
eg	O
,	O
esophageal	O
motility	O
dysfunction	O
)	O
may	O
also	O
respond	O
to	O
sildenafil	S-drug
.	O

In	O
the	O
general	O
population	O
,	O
sildenafil	S-drug
is	O
considered	O
to	O
have	O
an	O
acceptable	O
tolerability	O
profile	O
;	O

however	O
,	O
patients	O
with	O
moderate	O
to	O
severe	O
cardiovascular	O
disease	O
or	O
those	O
taking	O
nitrate	S-group-EF-1
therapy	O
are	O
at	O
increased	O
risk	O
for	O
potentially	O
serious	O
cardiovascular	O
adverse	O
effects	O
with	O
sildenafil	S-drug-EF-2
therapy	O
.	O

In	O
addition	O
,	O
patients	O
taking	O
drugs	O
that	O
inhibit	O
the	O
cytochrome	O
P450	O
3A4	O
isozyme	O
,	O
which	O
metabolizes	O
sildenafil	S-drug
,	O
may	O
experience	O
increased	O
drug	O
concentrations	O
and	O
possible	O
toxicity	O
from	O
normal	O
doses	O
of	O
sildenafil	S-drug
.	O

CONCLUSIONS	O
:	O
Sildenafil	S-drug
is	O
an	O
effective	O
first	O
-	O
line	O
therapy	O
for	O
erectile	O
dysfunction	O
in	O
men	O
.	O

The	O
decision	O
to	O
prescribe	O
this	O
agent	O
should	O
include	O
such	O
considerations	O
as	O
the	O
cost	O
-	O
risk	O
-	O
benefit	O
balance	O
,	O
patient	O
access	O
,	O
drug	O
distribution	O
pathways	O
,	O
and	O
prescription	O
drug	O
coverage	O
.	O

Acute	O
hydrocortisone	S-drug
administration	O
does	O
not	O
affect	O
subjective	O
responses	O
to	O
d	B-drug
-	I-drug
amphetamine	E-drug
in	O
humans	O
.	O

RATIONALE	O
:	O
Stress	O
and	O
glucocorticoids	S-group
facilitate	O
and	O
reinstate	O
psychostimulant	O
self	O
-	O
administration	O
in	O
rodents	O
.	O

However	O
,	O
the	O
effects	O
of	O
stress	O
and	O
glucocorticoids	S-group
on	O
the	O
subjective	O
and	O
behavioral	O
effects	O
of	O
psychostimulants	S-group
have	O
not	O
been	O
well	O
studied	O
in	O
humans	O
.	O

OBJECTIVES	O
:	O
To	O
examine	O
the	O
effects	O
of	O
acute	O
hydrocortisone	S-drug
pretreatment	O
on	O
the	O
subjective	O
and	O
behavioral	O
effects	O
of	O
d	B-drug
-	I-drug
amphetamine	E-drug
.	O

METHODS	O
:	O
Hydrocortisone	S-drug
(	O
100	O
mg	O
)	O
and	O
d	B-drug
-	I-drug
amphetamine	E-drug
(	O
20	O
mg	O
)	O
were	O
administered	O
orally	O
to	O
16	O
healthy	O
male	O
and	O
female	O
volunteers	O
in	O
a	O
four	O
-	O
session	O
,	O
placebo	O
-	O
controlled	O
,	O
within	O
-	O
subject	O
,	O
crossover	O
design	O
.	O

To	O
prevent	O
stomach	O
irritation	O
,	O
subjects	O
received	O
rantidine	B-drug
hydrochloride	E-drug
before	O
each	O
experimental	O
session	O
.	O

Dependent	O
measures	O
included	O
self	O
-	O
reported	O
mood	O
and	O
subjective	O
effects	O
(	O
Addiction	O
Research	O
Center	O
inventory	O
,	O
the	O
profile	O
of	O
mood	O
states	O
,	O
and	O
a	O
series	O
of	O
visual	O
analogue	O
scales	O
)	O
,	O
vital	O
signs	O
,	O
salivary	O
cortisol	O
,	O
and	O
psychomotor	O
performance	O
.	O

RESULTS	O
:	O
Hydrocortisone	S-drug
elevated	O
salivary	O
cortisol	O
levels	O
,	O
produced	O
modest	O
dysphoria	O
,	O
and	O
reduced	O
subjects	O
'	O
reports	O
of	O
wanting	O
more	O
drug	O
.	O

However	O
,	O
hydrocortisone	S-drug
pretreatment	O
did	O
not	O
affect	O
any	O
of	O
the	O
physiological	O
,	O
behavioral	O
,	O
or	O
subjective	O
effects	O
of	O
d	B-drug
-	I-drug
amphetamine	E-drug
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
the	O
effects	O
of	O
glucocorticoids	S-group
in	O
rodent	O
studies	O
,	O
these	O
results	O
indicate	O
that	O
an	O
acute	O
increase	O
in	O
cortisol	O
does	O
not	O
enhance	O
the	O
psychostimulant	O
effects	O
of	O
d	B-drug
-	I-drug
amphetamine	E-drug
in	O
humans	O
.	O

The	O
effects	O
of	O
ketamine	S-drug
and	O
of	O
Innovar	S-brand
anesthesia	O
on	O
digitalis	S-group
tolerance	O
in	O
dogs	O
.	O

In	O
a	O
comparison	O
of	O
digitalis	S-group
tolerance	O
in	O
dogs	O
anesthetized	O
with	O
ketamine	S-drug-EF-1
,	O
Innovar	B-brand-EF-1
Vet	E-brand-EF-1
,	O
or	O
pentobarbital	S-drug-EF-1
,	O
the	O
dosage	O
of	O
ouabain	S-drug-EF-2
needed	O
to	O
cause	O
ventricular	O
tachycardia	O
was	O
significantly	O
higher	O
,	O
as	O
was	O
the	O
LD50	O
of	O
ouabain	S-drug
,	O
with	O
ketamine	S-drug
or	O
Innovar	S-brand
than	O
with	O
pentobarbital	S-drug
.	O

Ventricular	O
tachycardia	O
induced	O
by	O
ouabain	S-drug-EF-1
was	O
generally	O
converted	O
to	O
sinus	O
rhythm	O
following	O
administration	O
of	O
Innovar	S-brand-EF-2
,	O
ketamine	S-drug-EF-2
,	O
or	O
droperidol	S-drug-EF-2
but	O
not	O
after	O
administration	O
of	O
fentayl	S-drug
alone	O
or	O
after	O
pentobarbital	S-drug
.	O

Interaction	O
between	O
oxytocin	S-drug
and	O
antidiuretic	O
hormone	O
and	O
its	O
effect	O
on	O
the	O
milk	O
secretion	O
by	O
alveoli	O
of	O
the	O
mammary	O
gland	O
of	O
lactating	O
rats	O
.	O

Interaction	O
between	O
exogenous	O
and	O
endogenous	O
oxytocin	S-drug
and	O
vasopressin	O
was	O
found	O
to	O
affect	O
the	O
mechanism	O
of	O
milk	O
ejection	O
by	O
the	O
alveoli	O
of	O
the	O
mammary	O
gland	O
in	O
lactating	O
rats	O
.	O

Inhibition	O
and	O
stimulation	O
of	O
the	O
effect	O
of	O
oxytocin	S-drug
on	O
milk	O
ejection	O
by	O
vasopressin	O
was	O
demonstrated	O
.	O

On	O
the	O
basis	O
of	O
the	O
principles	O
observed	O
the	O
concentrations	O
fo	O
these	O
hormones	O
were	O
investigated	O
in	O
the	O
plasma	O
of	O
dogs	O
deprived	O
of	O
water	O
for	O
3	O
days	O
and	O
then	O
allowed	O
to	O
drink	O
.	O

Interaction	O
of	O
clindamycin	S-drug-IN-1
and	O
gentamicin	S-drug-IN-2
in	O
vitro	O
.	O

The	O
minimal	O
inhibitory	O
concentrations	O
of	O
clindamycin	S-drug
and	O
gentamicin	S-drug
alone	O
and	O
in	O
combinations	O
were	O
determined	O
by	O
a	O
microdilution	O
method	O
for	O
163	O
aerobic	O
,	O
facultative	O
,	O
and	O
anaerobic	O
clinical	O
isolates	O
.	O

All	O
77	O
strains	O
of	O
Staphylococcus	O
aureus	O
,	O
Diplococcus	O
pneumoniae	O
,	O
Streptococcus	O
pyogenes	O
,	O
and	O
anaerobic	O
bacteria	O
(	O
except	O
for	O
three	O
strains	O
of	O
Clostridium	O
)	O
were	O
inhibited	O
by	O
1.6	O
mug	O
or	O
less	O
of	O
clindamycin	S-drug
per	O
ml	O
.	O

Gentamicin	S-drug
did	O
not	O
interfere	O
with	O
the	O
activity	O
of	O
clindamycin	S-drug
within	O
the	O
range	O
of	O
concentrations	O
tested	O
(	O
0.1	O
to	O
100	O
mug	O
/	O
ml	O
)	O
;	O

for	O
some	O
strains	O
combinations	O
were	O
synergistic	O
.	O

Sixty	O
-	O
two	O
(	O
94	O
%	O
)	O
of	O
66	O
strains	O
of	O
Enterobacteriaceae	O
and	O
Pseudomonas	O
aeruginosa	O
were	O
inhibited	O
by	O
6.2	O
mug	O
or	O
less	O
of	O
gentamicin	S-drug
per	O
ml	O
.	O

Combinations	O
of	O
clindamycin	S-drug-EF-1
and	O
gentamicin	S-drug-EF-2
were	O
indifferent	O
for	O
29	O
strains	O
and	O
synergistic	O
for	O
33	O
strains	O
.	O

All	O
20	O
strains	O
of	O
enterococcus	O
,	O
three	O
strains	O
of	O
Clostridium	O
,	O
three	O
strains	O
of	O
Escherichia	O
coli	O
,	O
and	O
one	O
strain	O
of	O
Proteus	O
rettgeri	O
were	O
resistant	O
to	O
both	O
clindamycin	S-drug
(	O
minimal	O
inhibitory	O
concentration	O
greater	O
than	O
3.1	O
mug	O
/	O
ml	O
)	O
and	O
gentamicin	S-drug
(	O
minimal	O
inhibitory	O
concentration	O
greater	O
than	O
6.2	O
mug	O
/	O
ml	O
)	O
.	O

Combinations	O
of	O
clindamycin	S-drug-EF-1
and	O
gentamicin	S-drug-EF-2
were	O
indifferent	O
for	O
16	O
and	O
synergistic	O
for	O
11	O
of	O
the	O
resistant	O
strains	O
.	O

Except	O
for	O
clindamycin	S-drug
-	O
sensitive	O
isolates	O
,	O
synergy	O
was	O
usually	O
observed	O
only	O
at	O
concentrations	O
of	O
one	O
or	O
both	O
drugs	O
which	O
are	O
not	O
readily	O
obtainable	O
in	O
vivo	O
.	O

Antagonism	O
was	O
never	O
observed	O
.	O

Molecular	O
basis	O
for	O
the	O
selective	O
toxicity	O
of	O
amphotericin	B-drug
B	E-drug
for	O
yeast	O
and	O
filipin	S-drug_n
for	O
animal	O
cells	O
.	O

Among	O
the	O
polyene	B-group
antibiotics	E-group
,	O
many	O
,	O
like	O
filipin	S-drug_n
,	O
can	O
not	O
be	O
used	O
clinically	O
because	O
they	O
are	O
toxic	O
;	O

amphotericin	B-drug
B	E-drug
,	O
however	O
,	O
is	O
useful	O
in	O
therapy	O
of	O
human	O
fungal	O
infections	O
because	O
it	O
is	O
less	O
toxic	O
.	O

Both	O
the	O
toxicity	O
of	O
filipin	S-drug_n
and	O
the	O
therapeutic	O
value	O
of	O
amphotericin	B-drug
B	E-drug
can	O
be	O
rationalized	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
by	O
the	O
following	O
observations	O
:	O
(	O
i	O
)	O
these	O
polyene	B-group
antibiotics	E-group
showed	O
differential	O
effects	O
on	O
cells	O
;	O

filipin	S-drug_n
was	O
more	O
potent	O
in	O
lysing	O
human	O
red	O
blood	O
cells	O
,	O
whereas	O
amphotericin	B-drug
B	E-drug
was	O
more	O
potent	O
in	O
inhibiting	O
yeast	O
cell	O
growth	O
;	O

and	O
(	O
ii	O
)	O
the	O
effects	O
of	O
filipin	S-drug_n
were	O
more	O
efficiently	O
inhibited	O
by	O
added	O
cholesterol	O
,	O
the	O
major	O
membrane	O
sterol	O
in	O
human	O
cells	O
,	O
whereas	O
the	O
effects	O
of	O
amphotericin	B-drug
B	E-drug
were	O
more	O
efficiently	O
inhibited	O
by	O
ergosterol	O
,	O
the	O
major	O
membrane	O
sterol	O
in	O
yeast	O
.	O

The	O
simplest	O
inference	O
is	O
that	O
the	O
toxicity	O
and	O
effectiveness	O
of	O
polyenes	O
are	O
determined	O
by	O
their	O
relative	O
avidities	O
for	O
the	O
predominant	O
sterol	O
in	O
cell	O
membranes	O
.	O

Studies	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
miconazole	S-drug
:	O
effect	O
of	O
miconazole	S-drug
on	O
respiration	O
and	O
cell	O
permeability	O
of	O
Candida	O
albicans	O
.	O

The	O
antifungal	B-group
drug	E-group
,	O
miconazole	B-drug
nitrate	E-drug
,	O
inhibits	O
the	O
growth	O
of	O
several	O
species	O
of	O
Candida	O
.	O

Candida	O
albicans	O
,	O
one	O
of	O
the	O
pathogenic	O
species	O
,	O
was	O
totally	O
inhibited	O
at	O
a	O
concentration	O
of	O
approximately	O
10	O
mug	O
/	O
ml	O
.	O

Endogenous	O
respiration	O
was	O
unaffected	O
by	O
the	O
drug	O
at	O
a	O
concentration	O
as	O
high	O
as	O
100	O
mug	O
/	O
ml	O
,	O
whereas	O
exogenous	O
respiration	O
was	O
markedly	O
sensitive	O
and	O
inhibited	O
to	O
an	O
extent	O
of	O
85	O
%	O
.	O

The	O
permeability	O
of	O
the	O
cell	O
membrane	O
was	O
changed	O
as	O
evidenced	O
by	O
the	O
leakage	O
of	O
260	O
-	O
nm	O
absorbing	O
materials	O
,	O
amino	O
acids	O
,	O
proteins	O
,	O
and	O
inorganic	O
cations	O
.	O

The	O
results	O
we	O
present	O
clearly	O
show	O
that	O
the	O
drug	O
alters	O
the	O
cellular	O
permeability	O
,	O
and	O
thus	O
the	O
exogenous	O
respiration	O
becomes	O
sensitive	O
to	O
the	O
drug	O
.	O

Effect	O
of	O
probenecid	S-drug
on	O
the	O
apparent	O
volume	O
of	O
distribution	O
and	O
elimination	O
of	O
cloxacillin	S-drug
.	O

According	O
to	O
Gibaldi	O
et	O
al	O
.	O

(	O
1968	O
,	O
1970	O
)	O
,	O
the	O
higher	O
serum	O
concentrations	O
of	O
penicillins	S-group-ME-1
and	O
cephaloridine	S-drug-ME-1
reached	O
after	O
administration	O
of	O
probenecid	S-drug-ME-2
are	O
due	O
not	O
only	O
to	O
slower	O
renal	O
elimination	O
but	O
also	O
to	O
an	O
altered	O
distribution	O
in	O
the	O
body	O
.	O

To	O
determine	O
whether	O
probenecid	S-drug
has	O
a	O
direct	O
effect	O
on	O
the	O
distribution	O
of	O
cloxacillin	S-drug
,	O
the	O
elimination	O
and	O
distribution	O
of	O
cloxacillin	S-drug
was	O
studied	O
in	O
six	O
patients	O
,	O
five	O
lacking	O
kidney	O
function	O
and	O
one	O
with	O
a	O
partially	O
impaired	O
renal	O
function	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
probenecid	S-drug
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
mean	O
values	O
of	O
the	O
volume	O
of	O
distribution	O
of	O
cloxacillin	S-drug
with	O
and	O
without	O
probenecid	S-drug
(	O
13.0	O
and	O
12.6	O
liters	O
,	O
respectively	O
)	O
.	O

Thus	O
,	O
the	O
hypothesis	O
of	O
Gibaldi	O
et	O
al	O
.	O

could	O
not	O
be	O
confirmed	O
for	O
cloxacillin	S-drug
in	O
patients	O
lacking	O
kidney	O
function	O
.	O

In	O
spite	O
of	O
the	O
absence	O
of	O
kidney	O
function	O
,	O
the	O
value	O
of	O
the	O
elimination	O
rate	O
constant	O
was	O
significantly	O
decreased	O
in	O
the	O
presence	O
of	O
probenecid	S-drug
(	O
from	O
0.326	O
to	O
0.263	O
/	O
h	O
)	O
.	O

This	O
might	O
be	O
explained	O
by	O
a	O
blockade	O
by	O
probenecid	S-drug-ME-1
of	O
the	O
elimination	O
of	O
cloxacillin	S-drug-ME-2
by	O
the	O
liver	O
.	O

Behavioral	O
mechanisms	O
underlying	O
the	O
link	O
between	O
smoking	O
and	O
drinking	O
.	O

Many	O
people	O
use	O
both	O
alcohol	S-drug
and	O
nicotine	S-drug
(	O
i.e	O
.	O
,	O
cigarettes	O
and	O
other	O
tobacco	O
products	O
)	O
.	O

The	O
behavioral	O
effects	O
of	O
these	O
two	O
drugs	O
differ	O
,	O
and	O
they	O
do	O
not	O
act	O
on	O
the	O
same	O
target	O
sites	O
in	O
the	O
brain	O
,	O
although	O
they	O
may	O
share	O
,	O
or	O
partly	O
share	O
,	O
certain	O
properties	O
.	O

The	O
initiation	O
of	O
alcohol	S-drug
or	O
nicotine	S-drug
use	O
may	O
be	O
precipitated	O
by	O
similar	O
personality	O
characteristics	O
in	O
the	O
user	O
,	O
such	O
as	O
impulsivity	O
and	O
sensation	O
seeking	O
.	O

Moreover	O
,	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dependence	O
may	O
be	O
similar	O
for	O
alcohol	S-drug
and	O
nicotine	S-drug
.	O

Thus	O
,	O
certain	O
factors	O
,	O
such	O
as	O
reinforcing	O
drug	O
effects	O
,	O
conditioning	O
processes	O
,	O
automatic	O
behavior	O
,	O
and	O
stress	O
,	O
may	O
influence	O
the	O
development	O
of	O
dependence	O
on	O
both	O
drugs	O
.	O

Other	O
factors	O
,	O
such	O
as	O
tolerance	O
and	O
sensitization	O
to	O
the	O
drugs	O
'	O
actions	O
and	O
the	O
development	O
of	O
withdrawal	O
symptoms	O
,	O
may	O
also	O
contribute	O
to	O
dependence	O
.	O

This	O
review	O
discusses	O
the	O
actions	O
of	O
the	O
two	O
drugs	O
on	O
certain	O
brain	O
chemical	O
(	O
i.e	O
.	O
,	O
neurotransmitter	O
)	O
systems	O
and	O
the	O
extent	O
to	O
which	O
the	O
effects	O
of	O
the	O
two	O
drugs	O
may	O
interact	O
.	O

[	O
Dose	O
-	O
time	O
effects	O
of	O
competitive	O
displacement	O
of	O
radiopertechnetate	S-drug
by	O
sodium	B-drug_n
perchlorate	E-drug_n
following	O
oral	O
and	O
intravenous	O
administration	O
]	O
The	O
effect	O
of	O
various	O
doses	O
of	O
sodium	B-drug_n
perchlorate	E-drug_n
in	O
several	O
dose	O
fractions	O
on	O
the	O
extent	O
and	O
the	O
time	O
scale	O
of	O
displacement	O
of	O
radiopertechnetate	S-drug
,	O
in	O
dependence	O
on	O
application	O
mode	O
,	O
was	O
studied	O
.	O

An	O
intravenous	O
dose	O
of	O
50	O
mg	O
perchlorate	S-drug_n
was	O
in	O
respect	O
of	O
competitive	O
suppression	O
of	O
organs	O
actively	O
concentrating	O
pertechnetate	S-drug
as	O
effective	O
as	O
intravenous	O
1000	O
mg	O
ClO	O
-	O
4	O
-	O
simultaneously	O
or	O
1000	O
mg	O
orally	O
30	O
min	O
before	O
the	O
injection	O
of	O
radiopertechnetate	S-drug
.	O

An	O
intravenous	O
injection	O
of	O
perchlorate	S-drug_n-ME-1
given	O
later	O
also	O
produces	O
a	O
complete	O
and	O
immediately	O
beginning	O
depletion	O
of	O
pertechnetate	S-drug-ME-2
already	O
accumulated	O
in	O
the	O
thyroid	O
,	O
within	O
a	O
period	O
of	O
195	O
min	O
after	O
99m	O
-	O
TcO	O
-	O
4	O
-	O
injection	O
with	O
a	O
corresponding	O
increase	O
in	O
blood	O
levels	O
.	O

20	O
mg	O
result	O
in	O
incomplete	O
depletion	O
which	O
becomes	O
complete	O
after	O
a	O
second	O
additional	O
dose	O
.	O

The	O
intravenous	O
application	O
of	O
perchlorate	S-drug_n
offers	O
advantages	O
in	O
clinical	O
use	O
.	O

Herbal	O
remedies	O
,	O
nephropathies	O
,	O
and	O
renal	O
disease	O
.	O

The	O
use	O
of	O
herbal	O
remedies	O
is	O
becoming	O
increasingly	O
popular	O
in	O
the	O
United	O
States	O
.	O

Research	O
has	O
shown	O
that	O
herbal	O
remedy	O
use	O
may	O
be	O
associated	O
with	O
acute	O
renal	O
failure	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
herbal	O
remedies	O
may	O
be	O
detrimental	O
for	O
the	O
patient	O
with	O
compromised	O
renal	O
function	O
.	O

Patients	O
with	O
renal	O
insufficiency	O
or	O
renal	O
failure	O
may	O
be	O
at	O
risk	O
for	O
further	O
kidney	O
damage	O
as	O
well	O
as	O
complications	O
related	O
to	O
interactions	O
of	O
herbal	O
remedies	O
with	O
complex	O
renal	O
therapy	O
regimens	O
.	O

This	O
article	O
will	O
describe	O
the	O
escalating	O
use	O
of	O
herbal	O
therapy	O
and	O
the	O
hazards	O
of	O
herbal	O
remedy	O
use	O
among	O
patients	O
.	O

Sirolimus	S-drug
:	O
mammalian	O
target	O
of	O
rapamycin	S-drug
inhibitor	O
to	O
prevent	O
kidney	O
rejection	O
.	O

Current	O
immunosuppressive	O
therapies	O
are	O
effective	O
but	O
can	O
be	O
associated	O
with	O
significant	O
adverse	O
reactions	O
.	O

Sirolimus	S-drug
works	O
differently	O
from	O
the	O
immunosuppressants	S-group
currently	O
available	O
,	O
and	O
except	O
for	O
increased	O
lipid	O
levels	O
,	O
the	O
adverse	O
reaction	O
profile	O
of	O
sirolimus	S-drug
does	O
not	O
appear	O
to	O
overlap	O
to	O
any	O
great	O
extent	O
with	O
that	O
associated	O
with	O
cyclosporine	S-drug
or	O
tacrolimus	S-drug
.	O

While	O
additional	O
research	O
is	O
needed	O
,	O
the	O
initial	O
clinical	O
data	O
in	O
kidney	O
recipients	O
suggest	O
that	O
sirolimus	S-drug
,	O
in	O
combination	O
with	O
cyclosporine	S-drug
or	O
tacrolimus	S-drug
,	O
might	O
have	O
the	O
potential	O
to	O
reduce	O
the	O
frequency	O
of	O
rejection	O
episodes	O
,	O
permit	O
reductions	O
in	O
cyclosporine	S-drug
or	O
tacrolimus	S-drug
dosage	O
,	O
and	O
permit	O
steroid	O
withdrawal	O
(	O
Kelly	O
,	O
1999	O
)	O
.	O

The	O
effects	O
of	O
chlordiazepoxide	S-drug
,	O
amphetamine	S-drug
and	O
cocaine	S-drug
on	O
bar	O
-	O
press	O
behavior	O
in	O
normal	O
and	O
genetically	O
nervous	O
dogs	O
.	O

Studies	O
on	O
two	O
strains	O
of	O
pointer	O
dogs	O
have	O
demonstrated	O
that	O
administration	O
of	O
a	O
benzodiazepine	S-group
(	O
chlordiazepoxide	S-drug
)	O
facilitates	O
acquisition	O
of	O
goal	O
-	O
directed	O
behavior	O
in	O
``	O
genetically	O
nervous	O
``	O

subjects	O
.	O

Continued	O
admistration	O
of	O
the	O
drug	O
is	O
required	O
to	O
maintain	O
barpress	O
response	O
in	O
this	O
strain	O
of	O
dogs	O
.	O

The	O
concomitant	O
administration	O
of	O
either	O
cocaine	S-drug
or	O
amphetamine	S-drug
,	O
compounds	O
which	O
inhibit	O
neuronal	O
reuptake	O
of	O
norepinephrine	O
,	O
disrupts	O
the	O
behavioral	O
response	O
of	O
the	O
genetically	O
nervous	O
E	O
-	O
strain	O
subjects	O
to	O
a	O
far	O
greater	O
extent	O
than	O
the	O
stable	O
A	O
-	O
strain	O
subjects	O
.	O

It	O
is	O
also	O
shown	O
that	O
after	O
14	O
days	O
of	O
daily	O
administration	O
of	O
chlordiazepoxide	S-drug
,	O
withdrawal	O
of	O
the	O
drug	O
not	O
only	O
re	O
-	O
results	O
in	O
almost	O
complete	O
loss	O
of	O
bar	O
-	O
press	O
response	O
in	O
the	O
E	O
-	O
strain	O
subjects	O
but	O
also	O
results	O
in	O
a	O
temporary	O
decrease	O
in	O
the	O
acquired	O
behavioral	O
response	O
of	O
the	O
stable	O
A	O
-	O
strain	O
subjects	O
.	O

Development	O
and	O
pharmacology	O
of	O
fluvastatin	S-drug
.	O

Fluvastatin	S-drug
is	O
the	O
first	O
synthetic	B-group
3	I-group
-	I-group
hydroxy	I-group
-	I-group
3	I-group
-	I-group
methylglutaryl	I-group
coenzyme	I-group
A	I-group
(	I-group
HMGCoA	I-group
)	I-group
reductase	I-group
inhibitor	E-group
to	O
be	O
approved	O
for	O
clinical	O
use	O
,	O
and	O
has	O
been	O
studied	O
extensively	O
in	O
humans	O
since	O
1986	O
.	O

It	O
is	O
structurally	O
distinct	O
from	O
the	O
other	O
currently	O
available	O
HMGCoA	B-group
reductase	I-group
inhibitors	E-group
(	O
lovastatin	S-drug
,	O
simvastatin	S-drug
,	O
and	O
pravastatin	S-drug
)	O
,	O
leading	O
to	O
unique	O
biopharmaceutical	O
properties	O
relative	O
to	O
the	O
other	O
agents	O
of	O
this	O
class	O
.	O

Absorption	O
of	O
fluvastatin	S-drug
is	O
virtually	O
complete	O
across	O
all	O
species	O
,	O
including	O
man	O
,	O
and	O
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
food	O
.	O

Systemic	O
exposure	O
is	O
limited	O
,	O
as	O
fluvastatin	S-drug
is	O
subject	O
to	O
first	O
-	O
pass	O
metabolism	O
,	O
and	O
the	O
plasma	O
half	O
-	O
life	O
of	O
the	O
drug	O
is	O
approximately	O
30	O
minutes	O
.	O

Some	O
95	O
%	O
of	O
a	O
single	O
dosage	O
of	O
fluvastatin	S-drug
is	O
excreted	O
via	O
the	O
biliary	O
route	O
,	O
with	O
less	O
than	O
2	O
%	O
of	O
this	O
being	O
the	O
parent	O
compound	O
.	O

Additionally	O
,	O
there	O
is	O
no	O
evidence	O
of	O
circulating	O
active	O
metabolites	O
or	O
accumulation	O
during	O
chronic	O
dosing	O
.	O

Studies	O
of	O
the	O
effect	O
of	O
food	O
on	O
the	O
pharmacokinetics	O
of	O
fluvastatin	S-drug
have	O
demonstrated	O
marked	O
reductions	O
in	O
the	O
rate	O
of	O
bioavailability	O
-	O
-	O
from	O
40	O
%	O
to	O
60	O
%	O
;	O

however	O
,	O
a	O
comparison	O
of	O
fluvastatin	S-drug
administration	O
with	O
the	O
evening	O
meal	O
or	O
at	O
bedtime	O
has	O
revealed	O
no	O
significant	O
differences	O
in	O
the	O
extent	O
of	O
bioavailability	O
(	O
area	O
under	O
the	O
curve	O
)	O
of	O
these	O
two	O
regimens	O
.	O

Furthermore	O
,	O
no	O
significant	O
difference	O
in	O
pharmacodynamic	O
effect	O
(	O
reduction	O
in	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
levels	O
)	O
could	O
be	O
ascertained	O
between	O
mealtime	O
dosing	O
and	O
bedtime	O
dosing	O
.	O

The	O
pharmacokinetics	O
of	O
fluvastatin	S-drug
have	O
also	O
been	O
assessed	O
in	O
various	O
demographic	O
groups	O
.	O

Relative	O
to	O
the	O
general	O
population	O
,	O
plasma	O
concentrations	O
of	O
fluvastatin	S-drug
do	O
not	O
vary	O
as	O
a	O
function	O
of	O
either	O
age	O
or	O
gender	O
.	O

In	O
addition	O
,	O
administration	O
to	O
a	O
patient	O
population	O
with	O
hepatic	O
insufficiency	O
resulted	O
in	O
a	O
2.5	O
-	O
fold	O
increase	O
in	O
both	O
the	O
rate	O
and	O
extent	O
of	O
bioavailability	O
relative	O
to	O
controls	O
.	O

Also	O
,	O
although	O
minimal	O
alterations	O
of	O
fluvastatin	S-drug
clearance	O
in	O
patients	O
with	O
renal	O
insufficiency	O
are	O
anticipated	O
due	O
to	O
limited	O
renal	O
excretion	O
(	O
5	O
%	O
)	O
,	O
a	O
study	O
in	O
this	O
patient	O
group	O
is	O
currently	O
underway	O
to	O
examine	O
this	O
further	O
.	O

Interaction	O
studies	O
have	O
been	O
performed	O
with	O
fluvastatin	S-drug
and	O
several	O
drugs	O
with	O
which	O
it	O
might	O
be	O
coadministered	O
.	O

Cholestyramine	S-drug-ME-1
,	O
an	O
anionic	O
-	O
binding	O
resin	O
,	O
has	O
a	O
considerable	O
effect	O
in	O
lowering	O
the	O
rate	O
and	O
extent	O
of	O
fluvastatin	S-drug-ME-2
bioavailability	O
.	O

Although	O
this	O
effect	O
was	O
noted	O
even	O
when	O
cholestyramine	S-drug-EF-1
was	O
given	O
4	O
hours	O
prior	O
to	O
fluvastatin	S-drug-EF-2
,	O
this	O
regimen	O
did	O
not	O
result	O
in	O
diminished	O
efficacy	O
.	O

Further	O
,	O
no	O
effects	O
on	O
either	O
warfarin	S-drug
levels	O
or	O
prothrombin	O
times	O
were	O
observed	O
in	O
a	O
study	O
involving	O
concomitant	O
administration	O
of	O
warfarin	S-drug
and	O
fluvastatin	S-drug
.	O

Moreover	O
,	O
additional	O
interaction	O
studies	O
with	O
niacin	S-drug
and	O
propranolol	S-drug
have	O
not	O
demonstrated	O
any	O
effect	O
on	O
fluvastatin	S-drug
plasma	O
levels	O
,	O
and	O
administration	O
to	O
a	O
patient	O
population	O
chronically	O
receiving	O
digoxin	S-drug
resulted	O
in	O
no	O
difference	O
in	O
the	O
extent	O
of	O
bioavailability	O
of	O
digoxin	S-drug
relative	O
to	O
control	O
data	O
.	O

The	O
results	O
generated	O
to	O
date	O
in	O
clinical	O
pharmacokinetic	O
studies	O
with	O
fluvastatin	S-drug
thus	O
support	O
its	O
use	O
in	O
a	O
broad	O
population	O
of	O
hypercholesterolaemic	O
patients	O
.	O

Tumor	O
phenotype	O
and	O
susceptibility	O
to	O
progression	O
as	O
an	O
expression	O
of	O
subpopulations	O
of	O
initiated	O
murine	O
cells	O
.	O

Currently	O
,	O
it	O
is	O
conceived	O
that	O
a	O
number	O
of	O
events	O
,	O
or	O
hits	O
,	O
are	O
required	O
for	O
the	O
induction	O
of	O
tumors	O
by	O
chemical	O
agents	O
.	O

The	O
first	O
phase	O
of	O
this	O
sequence	O
,	O
initiation	O
,	O
is	O
considered	O
to	O
result	O
from	O
at	O
least	O
one	O
event	O
in	O
the	O
genetic	O
apparatus	O
.	O

Analyses	O
of	O
this	O
sequence	O
,	O
however	O
,	O
usually	O
give	O
little	O
consideration	O
to	O
the	O
nature	O
of	O
the	O
target	O
cell	O
or	O
to	O
the	O
characteristics	O
of	O
the	O
resultant	O
tumors	O
.	O

Vesselinovitch	O
et	O
al	O
.	O

(	O
Cancer	O
Res	O
.	O
,	O
38	O
:	O
2003	O
-	O
2010	O
,	O
1978	O
)	O
have	O
reported	O
that	O
a	O
single	O
,	O
small	O
pulse	O
of	O
carcinogen	O
can	O
induce	O
early	O
and	O
numerous	O
liver	O
tumors	O
when	O
administered	O
neonatally	O
to	O
mice	O
with	O
a	O
genetic	O
predisposition	O
to	O
hepatotumorigenesis	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
nonpredisposed	O
strain	O
C57BL	O
/	O
6N	O
was	O
also	O
shown	O
to	O
be	O
highly	O
susceptible	O
to	O
diethylnitrosamine	O
during	O
the	O
neonatal	O
period	O
.	O

C57BL	O
/	O
6N	O
demonstrated	O
large	O
numbers	O
of	O
two	O
of	O
the	O
three	O
types	O
of	O
liver	O
tumors	O
seen	O
in	O
livers	O
of	O
genetically	O
predisposed	O
mice	O
,	O
one	O
of	O
which	O
required	O
the	O
additional	O
stimulus	O
of	O
dietary	O
phenobarbital	S-drug
for	O
growth	O
.	O

Tumors	O
of	O
more	O
malignant	O
phenotype	O
were	O
demonstrated	O
only	O
in	O
genetically	O
predisposed	O
mice	O
(	O
C57BL	O
/	O
6N	O
X	O
C3H	O
/	O
HeN	O
F1	O
)	O
that	O
received	O
one	O
dose	O
of	O
carcinogen	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
phenotype	O
of	O
a	O
tumor	O
that	O
results	O
from	O
a	O
pulse	O
of	O
a	O
chemical	O
carcinogen	O
may	O
depend	O
upon	O
the	O
target	O
cell	O
.	O

The	O
initiated	O
cells	O
that	O
result	O
from	O
this	O
hit	O
may	O
vary	O
from	O
those	O
that	O
demonstrate	O
very	O
little	O
progression	O
in	O
cell	O
type	O
and	O
may	O
or	O
may	O
not	O
require	O
exogenous	O
enhancement	O
of	O
growth	O
to	O
those	O
that	O
can	O
progress	O
very	O
rapidly	O
to	O
fully	O
malignant	O
behavior	O
.	O

The	O
latter	O
might	O
arise	O
from	O
a	O
hit	O
in	O
a	O
genetically	O
initiated	O
cell	O
,	O
the	O
result	O
of	O
which	O
is	O
a	O
more	O
rapid	O
progression	O
in	O
tumor	O
type	O
.	O

Analgesic	O
effects	O
of	O
antihistaminics	S-group
.	O

The	O
literature	O
provides	O
considerable	O
evidence	O
indicating	O
that	O
several	O
,	O
but	O
not	O
all	O
antihistaminics	S-group
,	O
are	O
indeed	O
analgesic	B-group
agents	E-group
and	O
some	O
are	O
analgesic	B-group
adjuvants	E-group
as	O
well	O
.	O

Those	O
for	O
which	O
effectiveness	O
is	O
reported	O
includes	O
diphenhydramine	S-drug
,	O
hydroxyzine	S-drug
,	O
orphenadrine	S-drug
,	O
pyrilamine	S-drug
,	O
phenyltoloxamine	S-drug_n
,	O
promethazine	S-drug
,	O
methdilazine	S-drug
,	O
and	O
tripelennamine	S-drug
.	O

The	O
proposed	O
mechanisms	O
of	O
analgesic	O
action	O
of	O
antihistaminics	S-group
are	O
reviewed	O
and	O
discussed	O
.	O

The	O
literature	O
suggests	O
that	O
more	O
than	O
one	O
mechanism	O
of	O
action	O
exists	O
for	O
them	O
.	O

There	O
is	O
considerable	O
evidence	O
suggesting	O
that	O
histaminergic	O
and	O
serotoninergic	O
central	O
pathways	O
are	O
involved	O
in	O
nociception	O
and	O
that	O
antihistaminic	S-group
drugs	O
can	O
modulate	O
their	O
responses	O
(	O
1	O
)	O
.	O

The	O
evidence	O
for	O
a	O
role	O
for	O
norepinephrine	O
and	O
dopamine	O
and	O
the	O
effects	O
of	O
antihistaminics	S-group
on	O
them	O
are	O
less	O
well	O
established	O
.	O

Still	O
other	O
pathways	O
have	O
been	O
proposed	O
.	O

A	O
greater	O
understanding	O
of	O
pain	O
mechanisms	O
will	O
aid	O
in	O
elucidating	O
the	O
role	O
of	O
antihistaminics	S-group
in	O
analgesia	O
.	O

[	O
The	O
GABA	O
-	O
ergic	O
system	O
and	O
brain	O
edema	O
]	O
It	O
has	O
been	O
shown	O
in	O
rats	O
with	O
experimental	O
toxic	O
and	O
traumatic	O
edemas	O
that	O
picrotoxin	S-drug_n-EF-1
(	O
1	O
mg	O
/	O
kg	O
)	O
removes	O
the	O
antiedematous	O
action	O
of	O
diazepam	S-drug-EF-2
,	O
phenazepam	S-drug_n-EF-2
,	O
phenibut	S-drug_n-EF-2
and	O
amizyl	S-drug_n-EF-2
and	O
reduces	O
the	O
action	O
of	O
phentolamine	S-drug-EF-2
.	O

When	O
the	O
dose	O
of	O
picrotoxin	S-drug_n
is	O
minimized	O
to	O
0.5	O
mg	O
/	O
kg	O
such	O
an	O
effect	O
is	O
not	O
observed	O
.	O

Prolonged	O
daily	O
administration	O
of	O
picrotoxin	S-drug_n
in	O
a	O
dose	O
of	O
1	O
mg	O
/	O
kg	O
results	O
in	O
the	O
development	O
of	O
brain	O
edema	O
.	O

It	O
is	O
recommended	O
that	O
GABA	O
-	O
positive	O
drugs	O
be	O
included	O
into	O
a	O
complex	O
of	O
treatment	O
measures	O
for	O
edema	O
.	O

[	O
Stimulation	O
by	O
cerulein	S-drug_n
-	O
-	O
an	O
analog	O
of	O
the	O
octapeptide	O
cholecystokinin	O
-	O
-	O
of	O
3H	B-drug_n
-	I-drug_n
spiroperidol	E-drug_n
binding	O
after	O
the	O
long	O
-	O
term	O
administration	O
of	O
neuroleptics	S-group
]	O
It	O
has	O
been	O
established	O
in	O
experiments	O
on	O
white	O
male	O
rats	O
that	O
prolonged	O
administration	O
(	O
twice	O
a	O
day	O
for	O
14	O
days	O
)	O
of	O
haloperidol	S-drug
(	O
0.25	O
mg	O
/	O
kg	O
)	O
and	O
pyreneperone	S-drug_n
(	O
0.25	O
mg	O
/	O
kg	O
)	O
resulted	O
in	O
the	O
reduced	O
interaction	O
between	O
3H	B-drug_n
-	I-drug_n
spiroperidol	E-drug_n
and	O
low	O
affinity	O
binding	O
sites	O
for	O
apomorphine	S-drug
in	O
subcortical	O
structures	O
,	O
whereas	O
3H	B-drug_n
-	I-drug_n
spiroperidol	E-drug_n
binding	O
with	O
high	O
affinity	O
binding	O
sites	O
for	O
apomorphine	S-drug
increased	O
both	O
in	O
the	O
frontal	O
cortex	O
and	O
subcortical	O
structures	O
of	O
the	O
forebrain	O
.	O

After	O
prolonged	O
administration	O
of	O
neuroleptics	S-group
the	O
displacing	O
effect	O
of	O
cerulein	S-drug_n
,	O
an	O
analog	O
of	O
cholecystokinin	O
octapeptide	O
,	O
was	O
replaced	O
by	O
the	O
stimulant	O
action	O
on	O
3H	B-drug_n
-	I-drug_n
spiroperidol	E-drug_n
binding	O
.	O

It	O
is	O
assumed	O
that	O
increased	O
interaction	O
between	O
3H	B-drug_n
-	I-drug_n
spiroperidol	E-drug_n
and	O
high	O
affinity	O
binding	O
sites	O
for	O
apomorphine	S-drug
on	O
dopamine2	O
-	O
and	O
serotonin2	O
-	O
receptors	O
underlies	O
the	O
antipsychotic	O
action	O
of	O
neuroleptics	S-group
after	O
their	O
prolonged	O
administration	O
.	O

Cholecystokinin	O
octapeptide	O
is	O
a	O
necessary	O
factor	O
for	O
realization	O
of	O
this	O
action	O
of	O
neuroleptics	S-group
.	O

Dual	O
effect	O
of	O
ouabain	S-drug
on	O
the	O
palytoxin	S-drug_n
-	O
induced	O
contraction	O
and	O
norepinephrine	O
release	O
in	O
the	O
guinea	O
-	O
pig	O
vas	O
deferens	O
.	O

Palytoxin	S-drug_n
(	O
PTX	S-drug_n
)	O
,	O
C129H223N3O54	O
,	O
isolated	O
from	O
marine	O
coelenterates	O
of	O
Palythoa	O
tuberculosa	O
,	O
caused	O
a	O
first	O
rapid	O
contraction	O
followed	O
by	O
the	O
slow	O
phasic	O
contraction	O
of	O
guinea	O
-	O
pig	O
vas	O
deferens	O
.	O

In	O
the	O
presence	O
of	O
ouabain	S-drug-EF-1
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
,	O
PTX	S-drug_n-EF-2
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
failed	O
to	O
cause	O
the	O
first	O
contraction	O
;	O

however	O
,	O
the	O
second	O
contraction	O
was	O
potentiated	O
.	O

In	O
the	O
presence	O
of	O
phentolamine	S-drug
(	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
the	O
second	O
contraction	O
was	O
inhibited	O
selectively	O
.	O

When	O
ouabain	S-drug-EF-1
was	O
applied	O
to	O
the	O
muscle	O
in	O
the	O
presence	O
of	O
phentolamine	S-drug-EF-2
,	O
both	O
first	O
and	O
second	O
contractile	O
responses	O
to	O
PTX	S-drug_n
were	O
abolished	O
.	O

When	O
the	O
muscle	O
was	O
exposed	O
to	O
the	O
potassium	O
-	O
depleted	O
solution	O
,	O
the	O
first	O
contractile	O
response	O
to	O
PTX	S-drug_n
was	O
rather	O
potentiated	O
.	O

PTX	S-drug_n
caused	O
the	O
release	O
of	O
norepinephrine	O
from	O
the	O
muscle	O
.	O

Exposure	O
of	O
the	O
muscle	O
to	O
ouabain	S-drug-EF-1
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
markedly	O
increased	O
the	O
PTX	S-drug_n-EF-2
-	O
induced	O
release	O
.	O

It	O
is	O
indicated	O
that	O
the	O
first	O
and	O
second	O
contractile	O
responses	O
to	O
PTX	S-drug_n
have	O
entirely	O
different	O
properties	O
.	O

The	O
second	O
response	O
is	O
due	O
to	O
a	O
release	O
of	O
norepinephrine	O
from	O
nerves	O
and	O
was	O
potentiated	O
by	O
ouabain	S-drug
through	O
the	O
increase	O
in	O
the	O
norepinephrine	O
release	O
,	O
whereas	O
the	O
first	O
response	O
was	O
not	O
due	O
to	O
the	O
norepinephrine	O
release	O
but	O
presumably	O
to	O
a	O
direct	O
action	O
on	O
smooth	O
muscle	O
cell	O
and	O
was	O
inhibited	O
by	O
ouabain	S-drug
.	O

The	O
mechanism	O
of	O
the	O
action	O
of	O
PTX	S-drug_n
was	O
discussed	O
in	O
the	O
relation	O
with	O
Na	O
,	O
K	O
-	O
ATPase	O
.	O

[	O
Quantitative	O
approach	O
to	O
treatment	O
with	O
incisive	O
neuroleptics	S-group
by	O
therapeutic	O
monitoring	O
]	O
;	O
The	O
problems	O
encountered	O
during	O
the	O
longterm	O
treatment	O
of	O
psychotic	O
patients	O
with	O
neuroleptics	S-group
are	O
illustrated	O
by	O
six	O
typical	O
case	O
reports	O
.	O

A	O
group	O
of	O
patients	O
who	O
had	O
had	O
a	O
new	O
acute	O
episode	O
despite	O
seemingly	O
adequate	O
treatment	O
were	O
selected	O
.	O

In	O
these	O
six	O
cases	O
it	O
was	O
demonstrated	O
that	O
the	O
neuroleptics	S-group
dosage	O
was	O
inappropriate	O
,	O
being	O
either	O
too	O
high	O
or	O
too	O
low	O
as	O
judged	O
from	O
the	O
plasma	O
concentrations	O
.	O

Ways	O
of	O
improving	O
the	O
adequacy	O
of	O
the	O
treatment	O
of	O
psychotic	O
patients	O
with	O
neuroleptics	S-group
are	O
discussed	O
.	O

Intestinal	O
absorption	O
of	O
arsenate	S-drug_n
in	O
the	O
chick	O
.	O

The	O
intestinal	O
absorption	O
of	O
arsenate	S-drug_n
(	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
)	O
has	O
been	O
investigated	O
in	O
the	O
chick	O
by	O
means	O
of	O
the	O
in	O
situ	O
ligated	O
duodenal	O
loop	O
technique	O
.	O

By	O
this	O
procedure	O
,	O
it	O
was	O
observed	O
that	O
arsenate	S-drug_n
is	O
rapidly	O
and	O
essentially	O
completely	O
absorbed	O
(	O
80	O
-	O
95	O
%	O
)	O
from	O
the	O
lumen	O
at	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
concentrations	O
up	O
to	O
5	O
mM	O
,	O
declining	O
to	O
about	O
50	O
%	O
absorption	O
at	O
50	O
mM	O
.	O

Transfer	O
from	O
the	O
intestinal	O
lumen	O
to	O
the	O
mucosal	O
cells	O
at	O
low	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
concentration	O
(	O
0.1	O
mM	O
)	O
is	O
rapid	O
,	O
while	O
transfer	O
from	O
the	O
mucosal	O
cells	O
to	O
the	O
body	O
occurs	O
more	O
slowly	O
.	O

At	O
stable	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
concentrations	O
greater	O
than	O
1	O
mM	O
,	O
fractional	O
mucosal	O
cell	O
accumulation	O
of	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
remains	O
constant	O
,	O
while	O
fractional	O
transfer	O
to	O
the	O
body	O
declines	O
.	O

However	O
,	O
total	O
mucosal	O
accumulation	O
of	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
and	O
that	O
transferred	O
to	O
the	O
body	O
increase	O
in	O
a	O
linear	O
logarithmic	O
fashion	O
from	O
0.05	O
to	O
5	O
mm	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
.	O

The	O
results	O
indicate	O
that	O
As	B-drug_n
(	I-drug_n
V	I-drug_n
)	E-drug_n
readily	O
penetrates	O
both	O
the	O
mucosal	O
and	O
serosal	O
surfaces	O
of	O
the	O
epithelial	O
membrane	O
.	O

Furthermore	O
,	O
arsenate	S-drug_n
and	O
phosphate	S-drug
do	O
not	O
appear	O
to	O
share	O
a	O
common	O
transport	O
pathway	O
in	O
the	O
duodenum	O
and	O
no	O
evidence	O
was	O
obtained	O
for	O
any	O
interaction	O
between	O
the	O
two	O
at	O
this	O
level	O
.	O

Vitamin	B-drug-ME-1
D3	E-drug-ME-1
administration	O
to	O
rachitic	O
chicks	O
was	O
effective	O
in	O
significantly	O
elevating	O
duodenal	O
arsenate	S-drug_n-ME-2
absorption	O
,	O
acting	O
primarily	O
to	O
enhance	O
serosal	O
transport	O
.	O

Spermine	S-drug
promotes	O
the	O
translocation	O
of	O
phosphatidate	O
phosphohydrolase	O
from	O
the	O
cytosol	O
to	O
the	O
microsomal	O
fraction	O
of	O
rat	O
liver	O
and	O
it	O
enhances	O
the	O
effects	O
of	O
oleate	O
in	O
this	O
respect	O
.	O

Spermine	S-drug
(	O
0.5	O
-	O
2	O
mM	O
)	O
promoted	O
the	O
translocation	O
of	O
phosphatidate	O
phosphohydrolase	O
from	O
the	O
soluble	O
to	O
the	O
microsomal	O
fraction	O
in	O
a	O
cell	O
-	O
free	O
system	O
derived	O
from	O
rat	O
liver	O
.	O

By	O
contrast	O
,	O
spermidine	S-drug_n
(	O
1	O
mM	O
)	O
and	O
putrescine	S-drug_n
(	O
1	O
mM	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
translocation	O
when	O
added	O
alone	O
.	O

Spermine	S-drug
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
spermidine	S-drug_n
,	O
enhanced	O
the	O
translocating	O
action	O
of	O
oleate	O
and	O
increased	O
its	O
effectiveness	O
in	O
transferring	O
the	O
phosphohydrolase	O
from	O
the	O
soluble	O
to	O
the	O
microsomal	O
fraction	O
.	O

It	O
is	O
proposed	O
that	O
the	O
phosphohydrolase	O
becomes	O
metabolically	O
active	O
when	O
it	O
combines	O
with	O
membranes	O
and	O
that	O
polyamines	O
might	O
help	O
to	O
regulate	O
this	O
interaction	O
.	O

This	O
could	O
facilitate	O
the	O
action	O
of	O
fatty	O
acids	O
and	O
enable	O
cells	O
to	O
increase	O
their	O
capacity	O
for	O
triacylglycerol	O
synthesis	O
to	O
match	O
an	O
increased	O
availability	O
of	O
fatty	O
acids	O
.	O

Influence	O
of	O
calcium	B-group
-	I-group
channel	I-group
blockers	E-group
on	O
platelet	O
function	O
and	O
arachidonic	O
acid	O
metabolism	O
.	O

Available	O
data	O
indicate	O
that	O
platelet	O
function	O
and	O
arachidonic	O
acid	O
metabolism	O
are	O
important	O
factors	O
in	O
hemostasis	O
and	O
regulation	O
of	O
vascular	O
tone	O
.	O

Plasma	O
membrane	O
and	O
intracellular	O
mobilization	O
of	O
calcium	O
ions	O
are	O
intimately	O
related	O
to	O
platelet	O
activation	O
and	O
release	O
of	O
platelet	O
contents	O
.	O

Release	O
of	O
arachidonic	O
acid	O
from	O
membrane	O
phospholipids	O
as	O
well	O
as	O
subsequent	O
synthesis	O
and	O
release	O
of	O
vasoconstrictor	O
thromboxane	O
A2	O
are	O
also	O
regulated	O
by	O
movement	O
of	O
calcium	O
ions	O
.	O

Adenosine	O
3	O
'	O
:	O
5	O
'	O
-	O
cyclic	O
phosphate	O
in	O
turn	O
controls	O
levels	O
of	O
free	O
calcium	O
ions	O
in	O
platelets	O
and	O
regulates	O
calcium	O
-	O
dependent	O
reactions	O
.	O

Slow	B-group
-	I-group
channel	I-group
calcium	I-group
blockers	E-group
,	O
such	O
as	O
verapamil	S-drug
,	O
diltiazem	S-drug
and	O
nifedipine	S-drug
,	O
inhibit	O
platelet	O
activation	O
in	O
vitro	O
,	O
and	O
decrease	O
platelet	O
adhesion	O
intravascularly	O
.	O

These	O
agents	O
have	O
also	O
been	O
shown	O
to	O
decrease	O
platelet	O
nucleotide	O
release	O
and	O
thromboxane	O
A2	O
generation	O
.	O

Some	O
preliminary	O
data	O
suggest	O
that	O
calcium	B-group
blockers	E-group
also	O
increase	O
generation	O
of	O
vasodilator	O
and	O
platelet	O
antiaggregant	O
prostacyclin	O
,	O
which	O
could	O
contribute	O
to	O
decrease	O
in	O
platelet	O
function	O
.	O

These	O
effects	O
of	O
calcium	B-group
blockers	E-group
on	O
platelet	O
function	O
and	O
arachidonic	O
acid	O
metabolism	O
could	O
contribute	O
in	O
part	O
to	O
their	O
efficacy	O
in	O
patients	O
with	O
ischemic	O
heart	O
disease	O
.	O

Differential	O
actions	O
of	O
intrathecal	O
naloxone	S-drug
on	O
blocking	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	B-drug_n
-	I-drug_n
endorphin	E-drug_n
and	O
morphine	S-drug
in	O
rats	O
.	O

In	O
the	O
present	O
study	O
,	O
it	O
is	O
proposed	O
that	O
the	O
opioids	S-group
applied	O
to	O
supraspinal	O
brain	O
sites	O
produced	O
their	O
analgesic	O
effects	O
by	O
the	O
activation	O
of	O
different	O
descending	O
pain	O
inhibitory	O
systems	O
.	O

The	O
blockade	O
of	O
the	O
spinal	O
endorphinergic	O
system	O
by	O
intrathecal	O
naloxone	S-drug
on	O
the	O
production	O
of	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	B-drug_n
-	I-drug_n
endorphin	E-drug_n
and	O
morphine	S-drug
was	O
then	O
studied	O
.	O

Intraventricular	O
injection	O
of	O
beta	B-drug_n
-	I-drug_n
endorphin	E-drug_n
and	O
morphine	S-drug
produced	O
an	O
inhibition	O
of	O
the	O
tail	O
-	O
flick	O
response	O
to	O
the	O
heat	O
stimulus	O
in	O
rats	O
.	O

Intrathecal	O
injection	O
of	O
naloxone	S-drug-EF-1
at	O
doses	O
of	O
0.4	O
to	O
40	O
micrograms	O
caused	O
a	O
dose	O
-	O
related	O
blockade	O
of	O
the	O
inhibition	O
of	O
the	O
tail	O
-	O
flick	O
response	O
induced	O
by	O
intraventricular	O
injection	O
of	O
beta	B-drug_n-EF-2
-	I-drug_n-EF-2
endorphin	E-drug_n-EF-2
,	O
and	O
a	O
high	O
dose	O
of	O
naloxone	S-drug-EF-1
(	O
40	O
micrograms	O
)	O
completely	O
blocked	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	B-drug_n-EF-2
-	I-drug_n-EF-2
endorphin	E-drug_n-EF-2
(	O
16	O
micrograms	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
intrathecal	O
naloxone	S-drug-EF-1
(	O
12	O
-	O
120	O
micrograms	O
)	O
had	O
only	O
a	O
very	O
weak	O
effect	O
on	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
morphine	S-drug-EF-2
(	O
40	O
micrograms	O
)	O
.	O

Intraventricular	O
injection	O
of	O
naloxone	S-drug-EF-1
at	O
doses	O
of	O
1.2	O
to	O
12	O
micrograms	O
equally	O
antagonized	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
the	O
tail	O
-	O
flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta	B-drug_n-EF-2
-	I-drug_n-EF-2
endorphin	E-drug_n-EF-2
and	O
morphine	S-drug-EF-2
.	O

The	O
results	O
indicate	O
that	O
a	O
spinal	O
naloxone	S-drug
-	O
sensitive	O
endorphinergic	O
system	O
is	O
involved	O
in	O
the	O
production	O
of	O
beta	B-drug_n
-	I-drug_n
endorphin	E-drug_n
but	O
not	O
morphine	S-drug
-	O
induced	O
tail	O
-	O
flick	O
inhibition	O
,	O
and	O
suggest	O
that	O
intraventricular	O
beta	B-drug_n
-	I-drug_n
endorphin	E-drug_n
and	O
morphine	S-drug
elicit	O
their	O
pharmacological	O
actions	O
via	O
the	O
activation	O
of	O
different	O
descending	O
pain	O
inhibitory	O
systems	O
;	O

descending	O
epsilon	O
and	O
mu	O
systems	O
for	O
beta	B-drug_n
-	I-drug_n
endorphin	E-drug_n
and	O
morphine	S-drug
,	O
respectively	O
,	O
are	O
proposed	O
.	O

Neurochemical	O
and	O
functional	O
consequences	O
following	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,5,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
(	O
MPTP	S-drug_n
)	O
and	O
methamphetamine	S-drug
.	O

The	O
neurochemical	O
and	O
functional	O
consequences	O
following	O
MPTP	S-drug_n
administration	O
to	O
the	O
rat	O
were	O
evaluated	O
and	O
compared	O
to	O
similar	O
effects	O
following	O
methamphetamine	S-drug
administration	O
.	O

It	O
was	O
observed	O
that	O
MPTP	S-drug_n-EF-1
induced	O
long	O
lasting	O
depletions	O
of	O
striatal	O
dopamine	O
concentrations	O
and	O
this	O
neurotoxic	O
effect	O
could	O
be	O
prevented	O
by	O
pargyline	S-drug-EF-2
pretreatment	O
.	O

The	O
MPTP	S-drug-EF-1
-	O
induced	O
neuronal	O
damage	O
produced	O
a	O
tolerance	O
to	O
the	O
disruptive	O
effects	O
of	O
amphetamine	S-drug-EF-2
and	O
a	O
supersensitivity	O
to	O
the	O
disruptive	O
effects	O
of	O
apomorphine	S-drug-EF-2
in	O
rats	O
responding	O
in	O
a	O
schedule	O
controlled	O
paradigm	O
.	O

Methamphetamine	S-drug-EF-1
,	O
like	O
MPTP	S-drug_n
,	O
produced	O
depletions	O
of	O
striatal	O
dopamine	O
but	O
these	O
actions	O
were	O
potentiated	O
by	O
pargyline	S-drug-EF-2
pretreatment	O
.	O

These	O
observations	O
are	O
discussed	O
in	O
reference	O
to	O
possible	O
deleterious	O
effects	O
following	O
the	O
administration	O
of	O
pargyline	S-drug
to	O
patients	O
with	O
Parkinson	O
's	O
Disease	O
.	O

Jacalin	S-drug_n
:	O
an	O
IgA	O
-	O
binding	O
lectin	O
.	O

We	O
previously	O
reported	O
that	O
seeds	O
of	O
Artocarpus	O
integrifolia	O
(	O
jackfruit	O
)	O
contain	O
a	O
lectin	O
,	O
which	O
we	O
call	O
jacalin	S-drug_n
,	O
that	O
is	O
both	O
a	O
potent	O
T	O
cell	O
mitogen	O
and	O
an	O
apparently	O
T	O
cell	O
-	O
independent	O
activator	O
of	O
human	O
B	O
cells	O
for	O
the	O
secretion	O
of	O
immunoglobulins	O
.	O

During	O
the	O
above	O
experiments	O
we	O
noted	O
a	O
massive	O
precipitation	O
in	O
cell	O
cultures	O
stimulated	O
with	O
greater	O
than	O
or	O
equal	O
to	O
100	O
micrograms	O
of	O
lectin	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
the	O
precipitate	O
is	O
formed	O
after	O
the	O
interaction	O
of	O
jacalin	S-drug_n
and	O
the	O
serum	O
protein	O
added	O
to	O
the	O
culture	O
medium	O
.	O

More	O
importantly	O
,	O
we	O
demonstrate	O
that	O
IgA	O
is	O
probably	O
the	O
major	O
serum	O
constituent	O
precipitated	O
by	O
the	O
lectin	O
and	O
that	O
no	O
IgG	O
or	O
IgM	O
can	O
be	O
detected	O
in	O
the	O
precipitates	O
.	O

In	O
secretions	O
such	O
as	O
colostrum	O
,	O
IgA	O
is	O
the	O
only	O
protein	O
precipitated	O
by	O
jacalin	S-drug_n
.	O

On	O
the	O
basis	O
of	O
this	O
specificity	O
we	O
describe	O
a	O
simple	O
and	O
reliable	O
affinity	O
chromatography	O
procedure	O
for	O
the	O
purification	O
of	O
both	O
human	O
serum	O
and	O
colostrum	O
IgA	O
.	O

Jacalin	S-drug_n
is	O
a	O
D	O
-	O
Gal	O
binding	O
lectin	O
and	O
should	O
be	O
a	O
useful	O
tool	O
for	O
studying	O
of	O
serum	O
and	O
secretory	O
IgA	O
.	O

Cancer	O
in	O
the	O
elderly	O
:	O
basic	O
science	O
and	O
clinical	O
aspects	O
.	O

The	O
incidence	O
of	O
cancer	O
increases	O
progressively	O
with	O
age	O
.	O

Rearrangements	O
of	O
genomes	O
have	O
been	O
found	O
to	O
accompany	O
cellular	O
aging	O
.	O

These	O
factors	O
,	O
in	O
concert	O
with	O
age	O
-	O
dependent	O
alterations	O
in	O
immune	O
function	O
and	O
host	O
defense	O
,	O
may	O
help	O
to	O
explain	O
the	O
increased	O
risk	O
of	O
malignant	O
disease	O
in	O
aged	O
persons	O
.	O

The	O
clinical	O
presentation	O
and	O
natural	O
history	O
of	O
neoplasia	O
are	O
also	O
affected	O
by	O
aging	O
.	O

This	O
conference	O
reviews	O
recent	O
developments	O
in	O
these	O
areas	O
,	O
examines	O
the	O
effects	O
of	O
drug	O
use	O
in	O
the	O
elderly	O
and	O
implications	O
for	O
management	O
,	O
and	O
discusses	O
current	O
information	O
on	O
how	O
age	O
may	O
influence	O
the	O
response	O
of	O
cancer	O
to	O
therapy	O
.	O

Dexamethasone	S-drug-EF-1
and	O
retinyl	B-drug-EF-1
acetate	E-drug-EF-1
similarly	O
inhibit	O
and	O
stimulate	O
EGF	S-drug_n-EF-2
-	O
or	O
insulin	S-drug-EF-2
-	O
induced	O
proliferation	O
of	O
prostatic	O
epithelium	O
.	O

Prostatic	O
epithelium	O
proliferates	O
in	O
a	O
defined	O
medium	O
consisting	O
of	O
basal	O
medium	O
RPMI1640	O
containing	O
transferrin	S-drug_n
(	O
1	O
microgram	O
/	O
ml	O
)	O
,	O
EGF	S-drug_n
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
and	O
insulin	S-drug
(	O
3.7	O
micrograms	O
/	O
ml	O
or	O
0.1	O
IU	O
/	O
ml	O
)	O
.	O

Although	O
neither	O
dexamethasone	S-drug-EF-1
nor	O
retinyl	B-drug-EF-1
acetate	E-drug-EF-1
affected	O
the	O
proliferation	O
of	O
prostatic	O
epithelium	O
in	O
RPMI1640	O
containing	O
transferrin	S-drug_n
alone	O
,	O
they	O
modify	O
the	O
mitogenic	O
effect	O
of	O
EGF	S-drug_n-EF-2
and	O
insulin	S-drug-EF-2
.	O

Dexamethasone	S-drug-EF-1
at	O
10	O
(	O
-	O
10	O
)	O
M	O
or	O
retinyl	B-drug-EF-1
acetate	E-drug-EF-1
at	O
about	O
3	O
X	O
10	O
(	O
-	O
9	O
)	O
M	O
inhibits	O
proliferation	O
stimulated	O
by	O
EGF	S-drug_n-EF-2
.	O

Higher	O
concentrations	O
of	O
dexamethasone	S-drug-EF-1
(	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
or	O
retinyl	B-drug-EF-1
acetate	E-drug-EF-1
(	O
3	O
X	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
enhance	O
the	O
mitogenic	O
activity	O
of	O
EGF	S-drug_n-EF-2
.	O

Dexamethasone	S-drug
had	O
a	O
similar	O
effect	O
in	O
the	O
presence	O
of	O
insulin	S-drug
.	O

However	O
,	O
retinyl	B-drug-EF-1
acetate	E-drug-EF-1
stimulated	O
,	O
but	O
did	O
not	O
significantly	O
inhibit	O
,	O
proliferation	O
in	O
the	O
presence	O
of	O
insulin	S-drug-EF-2
.	O

These	O
results	O
suggest	O
that	O
both	O
dexamethasone	S-drug-EF-1
and	O
retinyl	B-drug-EF-1
acetate	E-drug-EF-1
,	O
and	O
possibly	O
other	O
glucocorticoids	S-group-EF-1
and	O
retinoids	S-group-EF-1
,	O
may	O
regulate	O
the	O
proliferation	O
of	O
prostate	O
epithelium	O
by	O
a	O
dose	O
-	O
dependent	O
modification	O
of	O
the	O
activity	O
of	O
insulin	S-drug-EF-2
and	O
EGF	S-drug_n-EF-2
.	O

Pharmacokinetics	O
of	O
calcium	B-group
-	I-group
entry	I-group
blockers	E-group
.	O

Effective	O
use	O
of	O
drugs	O
in	O
therapy	O
depends	O
not	O
only	O
on	O
clinical	O
acumen	O
but	O
also	O
on	O
the	O
availability	O
of	O
relevant	O
pharmacokinetic	O
and	O
pharmacodynamic	O
data	O
.	O

Such	O
information	O
assists	O
in	O
development	O
of	O
safe	O
dosing	O
regimens	O
,	O
prediction	O
of	O
abnormal	O
handling	O
of	O
drugs	O
in	O
states	O
of	O
disease	O
and	O
disorder	O
and	O
anticipation	O
of	O
drug	O
interactions	O
.	O

For	O
the	O
calcium	B-group
-	I-group
entry	I-group
blocking	I-group
agents	E-group
now	O
available	O
in	O
the	O
United	O
States	O
(	O
verapamil	S-drug
,	O
nifedipine	S-drug
and	O
diltiazem	S-drug
)	O
,	O
these	O
data	O
appeared	O
well	O
after	O
clinical	O
patterns	O
of	O
use	O
evolved	O
.	O

Nonetheless	O
,	O
their	O
relevance	O
continues	O
to	O
be	O
demonstrated	O
by	O
the	O
dependence	O
of	O
each	O
agent	O
on	O
intact	O
liver	O
blood	O
flow	O
and	O
function	O
for	O
normal	O
rates	O
of	O
elimination	O
;	O

by	O
the	O
nonlinear	O
kinetic	O
characteristics	O
for	O
verapamil	S-drug
and	O
diltiazem	S-drug
(	O
and	O
probably	O
for	O
nifedipine	S-drug
,	O
as	O
well	O
)	O
and	O
the	O
derivative	O
implications	O
for	O
decreased	O
dosing	O
frequency	O
requirements	O
;	O

and	O
by	O
observations	O
now	O
appearing	O
on	O
the	O
relation	O
between	O
plasma	O
drug	O
levels	O
and	O
drug	O
effects	O
,	O
both	O
therapeutic	O
and	O
toxic	O
.	O

Such	O
data	O
are	O
discussed	O
herein	O
,	O
with	O
emphasis	O
on	O
those	O
aspects	O
that	O
impact	O
on	O
the	O
clinical	O
use	O
of	O
the	O
calcium	B-group
-	I-group
entry	I-group
antagonists	E-group
.	O

Selective	O
survival	O
in	O
pentazocine	S-drug
and	O
tripelennamine	S-drug
of	O
Pseudomonas	O
aeruginosa	O
serotype	O
O11	O
from	O
drug	O
addicts	O
.	O

The	O
growth	O
of	O
Pseudomonas	O
aeruginosa	O
,	O
particularly	O
serotype	O
O11	O
,	O
in	O
pentazocine	S-drug
and	O
tripelennamine	S-drug

was	O
evaluated	O
as	O
a	O
possible	O
explanation	O
for	O
the	O
association	O
of	O
deep	O
-	O
seated	O
infection	O
with	O
this	O
organism	O
and	O
abuse	O
of	O
these	O
drugs	O
.	O

The	O
mean	O
reduction	O
of	O
growth	O
caused	O
by	O
the	O
drugs	O
was	O
1,000	O
-	O
fold	O
greater	O
for	O
49	O
Pseudomonas	O
strains	O
from	O
normal	O
subjects	O
than	O
for	O
32	O
strains	O
from	O
drug	O
addicts	O
(	O
4.2	O
vs.	O
1.3	O
logs	O
of	O
reduction	O
at	O
2	O
hr	O
,	O
P	O
less	O
than	O
.0005	O
)	O
.	O

A	O
common	O
phenotypic	O
subset	O
of	O
the	O
serotype	O
O11	O
strains	O
from	O
drug	O
addicts	O
was	O
especially	O
resistant	O
to	O
the	O
inhibitory	O
effects	O
.	O

Twelve	O
strains	O
of	O
Staphylococcus	O
aureus	O
(	O
a	O
frequent	O
cause	O
of	O
infection	O
in	O
heroin	S-drug_n
,	O
but	O
not	O
in	O
pentazocine	S-drug-EF-1
and	O
tripelennamine	S-drug-EF-2
,	O
addicts	O
)	O
were	O
completely	O
inhibited	O
by	O
the	O
drug	O
combination	O
.	O

Dose	O
-	O
response	O
curves	O
(	O
derived	O
from	O
the	O
results	O
of	O
using	O
the	O
tablets	O
as	O
well	O
as	O
pure	O
powders	O
)	O
showed	O
that	O
tripelennamine	S-drug-EF-1
was	O
responsible	O
for	O
the	O
inhibitory	O
activity	O
,	O
which	O
was	O
partially	O
antagonized	O
by	O
pentazocine	S-drug-EF-2
.	O

We	O
conclude	O
that	O
an	O
ability	O
of	O
some	O
P	O
.	O

aeruginosa	O
serotype	O
O11	O
strains	O
,	O
but	O
not	O
S	O
.	O

aureus	O
,	O
to	O
survive	O
in	O
pentazocine	S-drug
and	O
tripelennamine	S-drug
may	O
explain	O
in	O
part	O
a	O
shift	O
from	O
S	O
.	O

aureus	O
to	O
P	O
.	O

aeruginosa	O
as	O
common	O
pathogens	O
of	O
drug	O
addicts	O
in	O
areas	O
where	O
abuse	O
of	O
this	O
combination	O
of	O
drugs	O
has	O
increased	O
.	O

Pharmacokinetic	O
evaluation	O
of	O
the	O
digoxin	S-drug
-	O
amiodarone	S-drug
interaction	O
.	O

Amiodarone	S-drug-ME-1
is	O
known	O
to	O
raise	O
serum	O
digoxin	S-drug-ME-2
levels	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
pharmacokinetic	O
basis	O
of	O
this	O
interaction	O
in	O
10	O
normal	O
subjects	O
.	O

The	O
pharmacokinetic	O
variables	O
for	O
digoxin	S-drug
were	O
determined	O
after	O
a	O
1.0	O
mg	O
intravenous	O
dose	O
of	O
digoxin	S-drug
in	O
each	O
subject	O
,	O
before	O
and	O
after	O
oral	O
amiodarone	S-drug
,	O
400	O
mg	O
daily	O
for	O
3	O
weeks	O
.	O

During	O
amiodarone	S-drug-ME-1
administration	O
,	O
systemic	O
clearance	O
of	O
digoxin	S-drug-ME-2
was	O
reduced	O
from	O
234	O
+	O
/	O
-	O
72	O
ml	O
/	O
min	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
to	O
172	O
+	O
/	O
-	O
33	O
ml	O
/	O
min	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

This	O
was	O
due	O
to	O
reductions	O
in	O
both	O
renal	O
clearance	O
(	O
from	O
105	O
+	O
/	O
-	O
39	O
to	O
84	O
+	O
/	O
-	O
15	O
ml	O
/	O
min	O
)	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
nonrenal	O
clearance	O
(	O
from	O
130	O
+	O
/	O
-	O
38	O
to	O
88	O
+	O
/	O
-	O
20	O
ml	O
/	O
min	O
)	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Digoxin	S-drug
half	O
-	O
life	O
of	O
elimination	O
was	O
prolonged	O
from	O
34	O
+	O
/	O
-	O
13	O
to	O
40	O
+	O
/	O
-	O
16	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Digoxin	S-drug
volume	O
of	O
distribution	O
was	O
not	O
significantly	O
changed	O
.	O

Amiodarone	S-drug
caused	O
a	O
three	O
-	O
to	O
fivefold	O
increase	O
in	O
serum	O
reverse	O
triiodothyronine	O
levels	O
,	O
but	O
changes	O
in	O
thyroid	O
function	O
were	O
not	O
quantitatively	O
related	O
to	O
the	O
changes	O
in	O
digoxin	S-drug
pharmacokinetics	O
.	O

These	O
alterations	O
in	O
digoxin	S-drug-ME-1
pharmacokinetics	O
produced	O
by	O
amiodarone	S-drug-ME-2
explain	O
the	O
increase	O
in	O
serum	O
digoxin	S-drug
level	O
that	O
has	O
been	O
observed	O
when	O
this	O
drug	O
combination	O
has	O
been	O
used	O
clinically	O
.	O

Misonidazole	S-drug_n-EF-1
protects	O
mouse	O
tumour	O
and	O
normal	O
tissues	O
from	O
the	O
toxicity	O
of	O
oral	O
CCNU	S-drug-EF-2
.	O

Because	O
the	O
nitrosourea	S-group
CCNU	S-drug
is	O
given	O
exclusively	O
by	O
the	O
oral	O
route	O
in	O
man	O
,	O
we	O
have	O
carried	O
out	O
studies	O
in	O
mice	O
on	O
the	O
antitumour	O
activity	O
,	O
acute	O
toxicity	O
and	O
pharmacokinetics	O
of	O
oral	O
CCNU	S-drug
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
the	O
chemosensitizer	O
misonidazole	S-drug_n
.	O

In	O
both	O
plasma	O
and	O
KHT	O
tumour	O
the	O
peak	O
concentration	O
and	O
``	O
early	O
``	O

AUC	O
for	O
total	O
nitrosoureas	S-group
were	O
about	O
1.4	O
-	O
1.5	O
fold	O
greater	O
for	O
the	O
oral	O
compared	O
to	O
the	O
i.p	O
.	O

route	O
.	O

These	O
differences	O
were	O
reflected	O
in	O
the	O
roughly	O
twofold	O
greater	O
antitumour	O
activity	O
for	O
the	O
oral	O
route	O
.	O

In	O
contrast	O
,	O
acute	O
toxicity	O
tests	O
showed	O
that	O
oral	O
CCNU	S-drug
was	O
1.45	O
times	O
less	O
toxic	O
to	O
normal	O
tissue	O
,	O
although	O
the	O
dose	O
-	O
limiting	O
organ	O
may	O
be	O
different	O
for	O
the	O
two	O
routes	O
.	O

Misonidazole	S-drug_n-EF-1
reduced	O
the	O
antitumour	O
activity	O
of	O
oral	O
CCNU	S-drug-EF-2
by	O
dose	O
modifying	O
factors	O
(	O
DMF	O
)	O
of	O
0.58	O
-	O
0.71	O
.	O

Similarly	O
,	O
the	O
acute	O
toxicity	O
was	O
also	O
diminished	O
by	O
a	O
DMF	O
of	O
0.74	O
.	O

Misonidazole	S-drug_n-ME-1
has	O
a	O
complex	O
effect	O
on	O
oral	O
CCNU	S-drug-ME-2
pharmacokinetics	O
.	O

The	O
plasma	O
and	O
tumour	O
total	O
nitrosourea	S-group
peak	O
concentrations	O
were	O
reduced	O
by	O
1.5	O
and	O
1.7	O
fold	O
respectively	O
.	O

Misonidazole	S-drug_n
also	O
reduced	O
the	O
``	O
early	O
``	O

nitrosourea	S-group
AUC	O
,	O
with	O
the	O
extent	O
of	O
the	O
reduction	O
depending	O
on	O
the	O
minimum	O
effective	O
concentration	O
(	O
MEC	O
)	O
chosen	O
.	O

For	O
example	O
,	O
the	O
plasma	O
nitrosourea	S-group
AUC	O
was	O
reduced	O
by	O
factors	O
of	O
1.05	O
and	O
9.6	O
for	O
MEC	O
values	O
of	O
1	O
and	O
2	O
micrograms	O
ml	O
-	O
1	O
respectively	O
.	O

We	O
propose	O
these	O
pharmacokinetic	O
changes	O
to	O
be	O
the	O
underlying	O
mechanism	O
for	O
the	O
reduction	O
of	O
oral	O
CCNU	S-drug-ME-1
cytotoxicity	O
by	O
misonidazole	S-drug_n-ME-2
.	O

Clinical	O
trials	O
of	O
such	O
combinations	O
should	O
be	O
accompanied	O
by	O
detailed	O
pharmacokinetic	O
evaluation	O
.	O

Enhanced	O
theophylline	S-drug-ME-1
clearance	O
secondary	O
to	O
phenytoin	S-drug-ME-2
therapy	O
.	O

This	O
report	O
describes	O
two	O
cases	O
in	O
which	O
theophylline	S-drug-ME-1
clearance	O
accelerated	O
markedly	O
with	O
concomitant	O
phenytoin	S-drug-ME-2
administration	O
.	O

Maximum	O
calculated	O
theophylline	S-drug
clearance	O
ranged	O
from	O
2	O
1	O
/	O
2	O
to	O
3	O
1	O
/	O
2	O
times	O
baseline	O
.	O

Onset	O
of	O
the	O
interaction	O
began	O
within	O
five	O
days	O
of	O
beginning	O
concurrent	O
therapy	O
.	O

With	O
combined	O
use	O
,	O
clinicians	O
should	O
be	O
aware	O
,	O
when	O
phenytoin	S-drug-EF-1
is	O
added	O
,	O
of	O
the	O
potential	O
for	O
reexacerbation	O
of	O
pulmonary	O
symptomatology	O
due	O
to	O
lowered	O
serum	O
theophylline	S-drug-EF-2
concentrations	O
.	O

Stereoselective	O
behavioral	O
effects	O
of	O
N	B-drug_n
-	I-drug_n
allylnormetazocine	E-drug_n
in	O
pigeons	O
and	O
squirrel	O
monkeys	O
.	O

The	O
behavioral	O
effects	O
of	O
the	O
stereoisomers	O
of	O
N	B-drug_n
-	I-drug_n
allylnormetazocine	E-drug_n
(	O
NANM	S-drug_n
)	O
were	O
compared	O
with	O
those	O
of	O
phencyclidine	S-drug_n
(	O
PCP	S-drug_n
)	O
in	O
pigeons	O
and	O
squirrel	O
monkeys	O
responding	O
under	O
a	O
multiple	O
fixed	O
-	O
interval	O
fixed	O
-	O
ratio	O
(	O
FI	O
FR	O
)	O
schedule	O
of	O
food	O
presentation	O
.	O

Intermediate	O
doses	O
of	O
(	B-drug_n
+	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
or	O
PCP	S-drug_n
produced	O
transient	O
increases	O
in	O
FI	O
responding	O
in	O
monkeys	O
and	O
sustained	O
increases	O
in	O
FI	O
responding	O
in	O
pigeons	O
;	O

higher	O
doses	O
decreased	O
FI	O
and	O
FR	O
responding	O
in	O
both	O
species	O
.	O

In	O
contrast	O
to	O
its	O
enantiomer	O
,	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
failed	O
to	O
increase	O
FI	O
responding	O
significantly	O
in	O
either	O
species	O
;	O

at	O
high	O
doses	O
,	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
decreased	O
FI	O
and	O
FR	O
responding	O
.	O

In	O
monkeys	O
,	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
was	O
about	O
10	O
times	O
more	O
potent	O
than	O
(	B-drug_n
+	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
in	O
decreasing	O
responding	O
,	O
whereas	O
in	O
pigeons	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
was	O
about	O
equipotent	O
with	O
(	B-drug_n
+	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
.	O

In	O
both	O
species	O
,	O
(	B-drug_n-EF-1
-	I-drug_n-EF-1
)	I-drug_n-EF-1
-	I-drug_n-EF-1
NANM	E-drug_n-EF-1
,	O
but	O
not	O
(	B-drug_n
+	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
,	O
antagonized	O
the	O
rate	O
-	O
decreasing	O
effects	O
of	O
morphine	S-drug-EF-2
on	O
FI	O
and	O
FR	O
responding	O
.	O

In	O
monkeys	O
,	O
the	O
effects	O
of	O
(	B-drug_n-EF-1
-	I-drug_n-EF-1
)	I-drug_n-EF-1
-	I-drug_n-EF-1
NANM	E-drug_n-EF-1
,	O
but	O
not	O
(	B-drug_n
+	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
or	O
PCP	S-drug_n
,	O
were	O
antagonized	O
by	O
naloxone	S-drug-EF-2
;	O

the	O
doses	O
of	O
naloxone	S-drug-EF-1
required	O
to	O
antagonize	O
the	O
effects	O
of	O
(	B-drug_n-EF-2
-	I-drug_n-EF-2
)	I-drug_n-EF-2
-	I-drug_n-EF-2
NANM	E-drug_n-EF-2
were	O
more	O
than	O
100	O
times	O
higher	O
than	O
those	O
required	O
to	O
antagonize	O
the	O
effects	O
of	O
morphine	S-drug-EF-2
.	O

In	O
pigeons	O
,	O
naloxone	S-drug
did	O
not	O
systematically	O
alter	O
the	O
effects	O
of	O
(	B-drug_n
-	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
,	O
(	B-drug_n
+	I-drug_n
)	I-drug_n
-	I-drug_n
NANM	E-drug_n
or	O
PCP	S-drug_n
.	O

Haloperidol	S-drug-EF-1
reduced	O
or	O
eliminated	O
the	O
increases	O
in	O
FI	O
responding	O
produced	O
by	O
intermediate	O
doses	O
of	O
either	O
(	B-drug_n-EF-2
+	I-drug_n-EF-2
)	I-drug_n-EF-2
-	I-drug_n-EF-2
NANM	E-drug_n-EF-2
or	O
PCP	S-drug_n-EF-2
in	O
pigeons	O
,	O
but	O
did	O
not	O
antagonize	O
the	O
decreases	O
in	O
FI	O
or	O
FR	O
responding	O
produced	O
by	O
high	O
doses	O
of	O
PCP	O
or	O
either	O
stereoisomer	O
of	O
NANM	S-drug_n
.	O

The	O
results	O
demonstrate	O
a	O
high	O
degree	O
of	O
stereoselectivity	O
in	O
the	O
behavioral	O
effects	O
of	O
NANM	S-drug_n
.	O

The	O
levorotatory	O
isomer	O
had	O
opioid	O
-	O
antagonist	O
and	O
non	O
-	O
opioid	O
agonist	O
effects	O
in	O
pigeons	O
and	O
mixed	O
opioid	O
agonist	O
-	O
antagonist	O
effects	O
in	O
monkeys	O
.	O

The	O
dextrorotatory	O
isomer	O
,	O
on	O
the	O
other	O
hand	O
,	O
had	O
effects	O
similar	O
to	O
those	O
of	O
PCP	S-drug_n
in	O
both	O
species	O
.	O

Increased	O
hepatotoxicity	O
of	O
acetaminophen	S-drug-EF-1
by	O
concomitant	O
administration	O
of	O
caffeine	S-drug-EF-2
in	O
the	O
rat	O
.	O

Since	O
caffeine	S-drug
is	O
frequently	O
co	O
-	O
administered	O
with	O
acetaminophen	S-drug
,	O
it	O
is	O
of	O
clinical	O
interest	O
to	O
study	O
the	O
effect	O
of	O
caffeine	S-drug
on	O
the	O
hepatotoxicity	O
of	O
acetaminophen	S-drug
.	O

In	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
fasted	O
for	O
18	O
h	O
,	O
concomitant	O
administration	O
of	O
caffeine	S-drug
(	O
0.1	O
g	O
/	O
kg	O
,	O
i.p	O
.	O
)	O

as	O
judged	O
by	O
increased	O
serum	O
enzyme	O
activities	O
and	O
increased	O
incidence	O
of	O
hepatic	O
necrosis	O
.	O

Careful	O
observations	O
on	O
hepatotoxicity	O
are	O
suggested	O
when	O
acetaminophen	S-drug-EF-1
is	O
prescribed	O
with	O
caffeine	S-drug-EF-2
.	O

High	O
-	O
dose	O
cisplatin	S-drug-EF-1
with	O
sodium	B-drug-EF-2
thiosulfate	E-drug-EF-2
protection	O
.	O

Nephrotoxicity	O
frequently	O
limits	O
the	O
dose	O
of	O
cisplatin	S-drug
to	O
less	O
than	O
120	O
mg	O
/	O
m2	O
per	O
injection	O
.	O

Sodium	B-drug-EF-1
thiosulfate	E-drug-EF-1
is	O
a	O
neutralizing	O
agent	O
for	O
cisplatin	S-drug-EF-2
that	O
protects	O
against	O
renal	O
damage	O
.	O

To	O
determine	O
whether	O
injection	O
of	O
thiosulfate	S-drug
would	O
permit	O
larger	O
doses	O
of	O
cisplatin	S-drug
to	O
be	O
administered	O
,	O
a	O
fixed	O
9.9	O
-	O
g	O
/	O
m2	O
dose	O
of	O
thiosulfate	S-drug
was	O
given	O
intravenously	O
over	O
three	O
hours	O
concurrently	O
with	O
escalating	O
doses	O
of	O
cisplatin	S-drug
.	O

Cisplatin	S-drug
was	O
administered	O
over	O
the	O
last	O
two	O
hours	O
of	O
the	O
thiosulfate	S-drug
infusion	O
.	O

Using	O
this	O
technique	O
,	O
it	O
was	O
possible	O
to	O
escalate	O
the	O
cisplatin	S-drug
dose	O
to	O
225	O
mg	O
/	O
m2	O
before	O
dose	O
-	O
limiting	O
toxicities	O
were	O
encountered	O
.	O

Comparison	O
of	O
cisplatin	S-drug
pharmacokinetics	O
in	O
patients	O
treated	O
with	O
202.5	O
mg	O
/	O
m2	O
plus	O
thiosulfate	S-drug
to	O
those	O
in	O
patients	O
treated	O
with	O
100	O
mg	O
/	O
m2	O
without	O
thiosulfate	S-drug
indicated	O
that	O
there	O
were	O
no	O
changes	O
in	O
the	O
elimination	O
rate	O
constant	O
,	O
volume	O
of	O
distribution	O
,	O
or	O
total	O
body	O
clearance	O
of	O
cisplatin	S-drug
.	O

The	O
total	O
drug	O
exposure	O
for	O
the	O
plasma	O
was	O
approximately	O
twofold	O
at	O
the	O
higher	O
cisplatin	S-drug
dose	O
.	O

This	O
study	O
demonstrates	O
that	O
concurrent	O
administration	O
of	O
thiosulfate	S-drug-ME-1
permits	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
dose	O
and	O
total	O
exposure	O
to	O
cisplatin	S-drug-ME-2
.	O

Interferon	O
induction	O
:	O
tool	O
for	O
establishing	O
interactions	O
among	O
homopolyribonucleotides	O
.	O

Hitherto	O
unrecognized	O
interactions	O
between	O
homopolyribonucleotides	O
and	O
complexes	O
thereof	O
are	O
suggested	O
by	O
interferon	O
induction	O
data	O
obtained	O
in	O
a	O
highly	O
sensitive	O
assay	O
system	O
of	O
primary	O
rabbit	O
kidney	O
cell	O
cultures	O
superinduced	O
by	O
metabolic	O
inhibitors	O
.	O

Repeated	O
oral	O
administration	O
of	O
coumaphos	S-drug_n
in	O
sheep	O
:	O
interactions	O
of	O
coumaphos	S-drug_n
with	O
bishydroxycoumarin	S-drug
,	O
trichlorfon	S-drug_n
,	O
and	O
phenobarbital	B-drug
sodium	E-drug
.	O

Interactions	O
between	O
treatments	O
with	O
coumaphos	S-drug_n
,	O
bishydroxycoumarin	S-drug
(	O
an	O
anticoagulant	S-group
)	O
,	O
trichlorfon	S-drug_n
(	O
an	O
organophosphorous	B-group
compound	E-group
)	O
,	O
and	O
phenobarbital	B-drug
sodium	E-drug
(	O
an	O
inducer	O
of	O
microsomal	O
enzymes	O
)	O
were	O
investigated	O
in	O
sheep	O
.	O

A	O
daily	O
dose	O
of	O
2	O
mg	O
of	O
coumaphos	S-drug_n
/	O
kg	O
of	O
body	O
weight	O
for	O
6	O
days	O
did	O
not	O
affect	O
the	O
plasma	O
enzymes	O
or	O
the	O
antiprothrombinemic	O
effect	O
of	O
bishydroxy	B-drug
-	I-drug
coumarin	E-drug
in	O
wethers	O
.	O

The	O
treatment	O
of	O
ewes	O
with	O
an	O
intravenous	O
(	O
IV	O
)	O
injection	O
of	O
trichlorfon	S-drug_n-EF-1
,	O
insufficient	O
to	O
produce	O
significant	O
inhibition	O
of	O
erythrocyte	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
,	O
appeared	O
to	O
produce	O
additive	O
effects	O
with	O
those	O
produced	O
by	O
subsequent	O
treatment	O
with	O
4	O
mg	O
of	O
coumaphos	S-drug_n-EF-2
/	O
kg	O
/	O
day	O
.	O

In	O
ewes	O
given	O
40	O
mg	O
of	O
phenobarbital	B-drug-EF-1
sodium	E-drug-EF-1
/	O
kg	O
for	O
5	O
days	O
intraperitoneally	O
(	O
IP	O
)	O
,	O
the	O
anticholinesterase	O
effect	O
of	O
4	O
mg	O
of	O
coumaphos	S-drug_n-EF-2
/	O
kg	O
was	O
significantly	O
reduced	O
and	O
signs	O
of	O
toxicity	O
were	O
not	O
present	O
.	O

Treatment	O
with	O
daily	O
doses	O
of	O
2	O
mg	O
of	O
coumaphos	S-drug_n
/	O
kg	O
for	O
6	O
days	O
did	O
not	O
modify	O
the	O
anticholinesterase	O
effect	O
of	O
a	O
2nd	O
series	O
of	O
treatments	O
given	O
6	O
weeks	O
later	O
.	O

Diagnostic	O
,	O
treatment	O
and	O
aftercare	O
approaches	O
to	O
cocaine	S-drug
abuse	O
.	O

The	O
general	O
public	O
feels	O
that	O
cocaine	S-drug
is	O
not	O
particularly	O
dangerous	O
because	O
it	O
does	O
not	O
produce	O
a	O
well	O
defined	O
physical	O
dependency	O
and	O
abstinence	O
syndrome	O
.	O

However	O
,	O
when	O
addiction	O
is	O
defined	O
as	O
compulsion	O
,	O
loss	O
of	O
control	O
and	O
continued	O
use	O
in	O
spite	O
of	O
adverse	O
consequences	O
,	O
cocaine	S-drug
drug	O
hunger	O
can	O
be	O
seen	O
as	O
an	O
agent	O
of	O
addictive	O
disease	O
.	O

Withdrawal	O
from	O
cocaine	S-drug
dependence	O
usually	O
involves	O
depression	O
,	O
anxiety	O
and	O
lethargy	O
.	O

These	O
usually	O
clear	O
within	O
a	O
week	O
,	O
leaving	O
only	O
the	O
``	O
drug	O
hunger	O
``	O

to	O
contend	O
with	O
.	O

Medication	O
is	O
rarely	O
needed	O
.	O

When	O
cocaine	S-drug
is	O
the	O
primary	O
addiction	O
,	O
after	O
withdrawal	O
the	O
most	O
effective	O
treatment	O
is	O
group	O
therapy	O
with	O
other	O
recovering	O
cocaine	O
abusers	O
.	O

We	O
incorporate	O
the	O
principles	O
of	O
recovery	O
and	O
define	O
positive	O
and	O
constructive	O
alternatives	O
in	O
dealing	O
with	O
cocaine	O
hunger	O
.	O

Recovery	O
programs	O
should	O
be	O
flexible	O
and	O
involve	O
individual	O
and	O
family	O
education	O
on	O
recovery	O
and	O
the	O
nature	O
of	O
addictive	O
disease	O
.	O

Exercise	O
that	O
produces	O
cardiopulmonary	O
stimulation	O
is	O
a	O
helpful	O
means	O
of	O
reducing	O
drug	O
hunger	O
and	O
anxiety	O
during	O
recovery	O
therapy	O
.	O

Failure	O
of	O
neomycin	S-drug
to	O
modify	O
ACTH	S-group
induced	O
hypertension	O
in	O
sheep	O
.	O

Studies	O
in	O
rats	O
have	O
shown	O
that	O
neomycin	S-drug-EF-1
administration	O
attenuates	O
certain	O
types	O
of	O
adrenocortical	B-group
steroid	E-group
dependent	O
hypertension	O
,	O
including	O
ACTH	S-drug-EF-2
hypertension	O
.	O

The	O
effects	O
of	O
oral	O
neomycin	S-drug
on	O
ACTH	S-group
induced	O
hypertension	O
were	O
examined	O
in	O
conscious	O
sheep	O
.	O

Neomycin	S-drug
has	O
no	O
effect	O
on	O
the	O
blood	O
pressure	O
or	O
metabolic	O
responses	O
to	O
ACTH	S-group
in	O
sheep	O
.	O

Changes	O
in	O
urinary	O
homocysteine	O
following	O
synthetic	B-group
steroidal	I-group
estrogen	E-group
and	O
progestogen	O
administration	O
to	O
rats	O
.	O

The	O
present	O
work	O
involved	O
the	O
administration	O
of	O
both	O
ethynyl	B-drug
estradiol	E-drug
and	O
levonorgestrel	S-drug
to	O
groups	O
of	O
rats	O
,	O
followed	O
by	O
determination	O
of	O
the	O
homocysteine	O
excretion	O
rate	O
in	O
urine	O
.	O

The	O
results	O
indicate	O
that	O
a	O
statistically	O
significant	O
difference	O
exists	O
between	O
the	O
excreted	O
levels	O
of	O
homocysteine	O
in	O
the	O
urine	O
of	O
both	O
control	O
and	O
levonorgestrel	S-drug
-	O
treated	O
rats	O
and	O
the	O
levels	O
shown	O
by	O
rats	O
treated	O
with	O
ethynyl	B-drug
estradiol	E-drug
.	O

The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
,	O
especially	O
with	O
respect	O
to	O
observations	O
which	O
indicate	O
that	O
homocysteine	O
may	O
be	O
a	O
precipitating	O
factor	O
in	O
the	O
development	O
of	O
thrombosis	O
.	O

Also	O
included	O
in	O
this	O
paper	O
is	O
a	O
study	O
which	O
confirms	O
the	O
identity	O
of	O
the	O
HPLC	O
peak	O
as	O
being	O
homocysteine	O
by	O
forming	O
a	O
radioactive	O
derivative	O
of	O
this	O
particular	O
sulphydryl	O
-	O
containing	O
amino	O
acid	O
,	O
and	O
then	O
analysing	O
the	O
resulting	O
mixture	O
by	O
TLC	O
.	O

Altered	O
responsiveness	O
to	O
alcohol	S-drug
after	O
exposure	O
to	O
organic	O
lead	O
.	O

Ethyl	B-drug
alcohol	E-drug
is	O
known	O
to	O
effect	O
the	O
functional	O
integrity	O
of	O
the	O
limbic	O
system	O
,	O
particularly	O
the	O
hippocampus	O
,	O
and	O
to	O
alter	O
behaviors	O
which	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
limbic	O
function	O
.	O

Organometals	O
also	O
compromise	O
the	O
limbic	O
system	O
and	O
result	O
in	O
deficits	O
in	O
learning	O
and	O
memory	O
.	O

Since	O
both	O
alcohol	S-drug
and	O
organoleads	O
are	O
present	O
in	O
the	O
environment	O
and	O
seem	O
to	O
influence	O
limbic	O
integration	O
,	O
the	O
interaction	O
of	O
these	O
two	O
compounds	O
was	O
assessed	O
in	O
the	O
present	O
experiment	O
.	O

Thirty	O
male	O
rats	O
of	O
the	O
Fischer	O
-	O
344	O
strain	O
were	O
divided	O
into	O
three	O
equal	O
groups	O
and	O
were	O
given	O
injections	O
of	O
trimethyl	B-drug_n
lead	E-drug_n
(	O
TML	S-drug_n
)	O
(	O
8.0	O
or	O
17.0	O
mg	O
/	O
kg	O
/	O
ml	O
SC	O
)	O
or	O
the	O
saline	O
vehicle	O
.	O

Fourteen	O
days	O
later	O
,	O
all	O
animals	O
were	O
challenged	O
with	O
a	O
single	O
hypnotic	O
dose	O
of	O
ethanol	S-drug
(	O
3.5	O
g	O
/	O
kg	O
IP	O
)	O
.	O

The	O
20	O
%	O
v	O
/	O
v	O
solution	O
of	O
alcohol	S-drug
was	O
prepared	O
in	O
water	O
from	O
a	O
stock	O
solution	O
of	O
95	O
%	O
ethanol	S-drug
.	O

The	O
latency	O
to	O
loss	O
of	O
the	O
righting	O
reflex	O
and	O
duration	O
of	O
sleep	O
time	O
were	O
recorded	O
while	O
the	O
rats	O
were	O
kept	O
in	O
sound	O
-	O
attenuating	O
chambers	O
.	O

The	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
TML	S-drug_n
manifested	O
significantly	O
longer	O
latencies	O
to	O
lose	O
the	O
righting	O
reflex	O
and	O
shorter	O
durations	O
of	O
sleep	O
than	O
did	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
exposure	O
to	O
environmental	O
lead	S-drug_n-EF-1
may	O
alter	O
the	O
biological	O
and	O
behavioral	O
responsiveness	O
of	O
an	O
animal	O
to	O
alcohol	S-drug-EF-2
.	O

Cholinergic	O
role	O
in	O
alcohol	S-drug
's	O
effects	O
on	O
evoked	O
potentials	O
in	O
visual	O
cortex	O
of	O
the	O
albino	O
rat	O
.	O

Photic	O
evoked	O
potentials	O
were	O
recorded	O
from	O
the	O
visual	O
cortex	O
of	O
chronically	O
implanted	O
albino	O
rats	O
.	O

Since	O
photic	O
evoked	O
potential	O
components	O
are	O
representations	O
of	O
neural	O
pathways	O
which	O
are	O
activated	O
during	O
photic	O
stimulation	O
,	O
study	O
of	O
the	O
effects	O
of	O
alcohol	S-drug
on	O
these	O
components	O
may	O
help	O
to	O
trace	O
pathways	O
which	O
are	O
affected	O
by	O
alcohol	S-drug
.	O

In	O
the	O
present	O
study	O
,	O
evoked	O
potentials	O
were	O
recorded	O
at	O
5	O
,	O
20	O
,	O
and	O
40	O
min	O
following	O
IP	O
injections	O
of	O
saline	O
,	O
ethanol	S-drug
(	O
2.0	O
g	O
/	O
kg	O
)	O
,	O
physostigmine	S-drug
(	O
0.6	O
mg	O
/	O
kg	O
)	O
or	O
atropine	S-drug
(	O
15.0	O
mg	O
/	O
kg	O
)	O
on	O
separate	O
days	O
.	O

Ethanol	S-drug
depressed	O
the	O
amplitudes	O
of	O
most	O
evoked	O
potential	O
components	O
in	O
comparison	O
to	O
saline	O
administration	O
.	O

Component	O
P2	O
,	O
however	O
,	O
was	O
increased	O
in	O
amplitude	O
.	O

Physostigmine	S-drug
briefly	O
reduced	O
the	O
amplitude	O
of	O
most	O
components	O
,	O
including	O
P2	O
.	O

In	O
contrast	O
,	O
atropine	S-drug
increased	O
the	O
amplitudes	O
of	O
components	O
P1	O
and	O
P2	O
,	O
while	O
decreasing	O
components	O
N1	O
,	O
N2	O
and	O
N3	O
for	O
varying	O
durations	O
of	O
time	O
.	O

Physostigmine	S-drug-EF-1
pretreatment	O
augmented	O
the	O
depressant	O
effect	O
of	O
alcohol	S-drug-EF-2
on	O
the	O
early	O
components	O
P1	O
and	O
N1	O
,	O
while	O
attenuating	O
alcohol	S-drug-EF-2
's	O
influence	O
on	O
components	O
P2	O
and	O
P3	O
.	O

Pretreatment	O
with	O
atropine	S-drug
likewise	O
further	O
reduced	O
the	O
amplitudes	O
of	O
components	O
P1	O
and	O
N1	O
,	O
and	O
produced	O
a	O
similar	O
effect	O
on	O
component	O
N3	O
.	O

Atropine	S-drug
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
alcohol	S-drug
,	O
produced	O
approximately	O
the	O
same	O
degree	O
of	O
enhancement	O
of	O
component	O
P2	O
.	O

In	O
comparison	O
to	O
saline	O
values	O
,	O
all	O
three	O
agents	O
produced	O
reliable	O
increases	O
in	O
peak	O
latency	O
for	O
most	O
of	O
the	O
components	O
,	O
with	O
only	O
N3	O
showing	O
no	O
effects	O
.	O

The	O
amplitude	O
data	O
from	O
this	O
study	O
suggest	O
that	O
ethanol	S-drug
's	O
augmentation	O
of	O
component	O
P2	O
may	O
result	O
,	O
at	O
least	O
in	O
part	O
,	O
from	O
alterations	O
in	O
cholinergic	O
functions	O
.	O

Hypothermia	O
as	O
an	O
index	O
of	O
the	O
disulfiram	S-drug
-	O
ethanol	S-drug
reaction	O
in	O
the	O
rat	O
.	O

Decreased	O
core	O
temperature	O
in	O
female	O
rats	O
was	O
investigated	O
as	O
one	O
possible	O
index	O
of	O
the	O
disulfiram	S-drug
-	O
ethanol	S-drug
reaction	O
(	O
DER	O
)	O
.	O

Core	O
temperature	O
was	O
decreased	O
in	O
rats	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
when	O
ethanol	S-drug-EF-1
was	O
administered	O
to	O
rats	O
treated	O
with	O
disulfiram	S-drug-EF-2
8	O
hours	O
before	O
the	O
ethanol	S-drug
challenge	O
.	O

The	O
decrease	O
in	O
temperature	O
began	O
within	O
20	O
minutes	O
after	O
ethanol	S-drug
administration	O
,	O
reaching	O
a	O
maximal	O
decrease	O
between	O
60	O
and	O
120	O
minutes	O
post	O
ethanol	S-drug
.	O

The	O
core	O
temperature	O
returned	O
to	O
normal	O
300	O
minutes	O
after	O
ethanol	S-drug
.	O

The	O
blood	O
pressure	O
(	O
carotid	O
cannulation	O
)	O
decreased	O
along	O
with	O
the	O
core	O
temperature	O
.	O

Maximal	O
hypotension	O
was	O
found	O
120	O
minutes	O
post	O
ethanol	S-drug
,	O
and	O
returned	O
to	O
normal	O
300	O
minutes	O
after	O
ethanol	S-drug
.	O

Heart	O
rate	O
increased	O
initially	O
and	O
returned	O
to	O
normal	O
40	O
minutes	O
after	O
ethanol	S-drug
challenge	O
.	O

Excretion	O
of	O
thioethers	O
in	O
urine	O
after	O
exposure	O
to	O
electrophilic	O
chemicals	O
.	O

Electrophilic	O
agents	O
-	O
-	O
a	O
class	O
of	O
chemicals	O
that	O
includes	O
most	O
genotoxic	O
compounds	O
-	O
-	O
can	O
be	O
inactivated	O
by	O
reaction	O
with	O
glutathione	O
or	O
other	O
SH	O
-	O
bearing	O
molecules	O
.	O

The	O
conjugates	O
so	O
formed	O
often	O
appear	O
in	O
the	O
urine	O
as	O
mercapturic	O
acids	O
or	O
other	O
thioether	O
products	O
.	O

This	O
paper	O
critically	O
reviews	O
the	O
suitability	O
of	O
the	O
urinary	O
thioether	O
assay	O
as	O
a	O
method	O
for	O
the	O
detection	O
of	O
exposure	O
to	O
electrophilic	O
agents	O
or	O
their	O
precursors	O
.	O

In	O
practice	O
,	O
the	O
greatest	O
value	O
of	O
the	O
thioether	O
assay	O
appears	O
to	O
lie	O
in	O
its	O
signal	O
function	O
.	O

This	O
is	O
demonstrated	O
for	O
cigarette	O
smokers	O
and	O
industrial	O
workers	O
involved	O
in	O
chemical	O
waste	O
incineration	O
.	O

Whenever	O
increased	O
thioether	O
excretion	O
is	O
observed	O
,	O
it	O
is	O
likely	O
to	O
be	O
due	O
to	O
exposure	O
to	O
one	O
or	O
more	O
suspect	O
compounds	O
.	O

However	O
,	O
when	O
the	O
thioether	O
concentration	O
ranges	O
within	O
the	O
limits	O
of	O
the	O
normal	O
value	O
,	O
one	O
must	O
not	O
conclude	O
that	O
there	O
is	O
no	O
,	O
or	O
negligible	O
,	O
exposure	O
.	O

More	O
specific	O
applications	O
of	O
the	O
assay	O
of	O
thio	O
compounds	O
in	O
urine	O
allow	O
development	O
of	O
selective	O
methods	O
that	O
may	O
be	O
useful	O
for	O
biological	O
monitoring	O
.	O

Interaction	O
on	O
the	O
antinociceptive	O
effect	O
between	O
neurotensin	S-drug_n-EF-1
and	O
enkephalins	S-drug_n-EF-2
or	O
tuftsin	S-drug_n-EF-2
.	O

The	O
aim	O
of	O
this	O
paper	O
was	O
to	O
study	O
the	O
interaction	O
between	O
neurotensin	S-drug_n
and	O
both	O
enkephalins	S-drug_n
or	O
its	O
synthetic	O
analogue	O
D	B-drug_n
-	I-drug_n
Ala2	I-drug_n
-	I-drug_n
metenkephalinamide	E-drug_n
,	O
or	O
tuftsin	S-drug_n
,	O
on	O
the	O
antinonciceptive	O
effect	O
of	O
these	O
peptides	O
in	O
mice	O
after	O
intracisternal	O
injection	O
.	O

Antinociception	O
was	O
measured	O
by	O
the	O
hot	O
-	O
plate	O
method	O
.	O

It	O
was	O
shown	O
that	O
neurotensin	S-drug_n-EF-1
antagonized	O
evidently	O
the	O
antinociceptive	O
effect	O
of	O
enkephalins	S-drug_n-EF-2
and	O
their	O
analogue	O
.	O

On	O
the	O
contrary	O
,	O
neurotensin	S-drug_n-EF-1
and	O
tuftsin	S-drug_n-EF-2
were	O
agonists	O
in	O
induction	O
of	O
analgesia	O
.	O

It	O
is	O
concluded	O
that	O
neurotensin	S-drug_n-EF-1
modulates	O
in	O
an	O
opposite	O
way	O
the	O
function	O
of	O
the	O
enkephalinergic	O
neurons	O
and	O
the	O
central	O
action	O
of	O
tuftsin	S-drug_n-EF-2
.	O

Drug	O
-	O
lab	O
interactions	O
:	O
implications	O
for	O
nutrition	O
support	O
.	O

Acetylcysteine	S-drug
interference	O
with	O
urine	O
ketone	O
test	O
.	O

It	O
is	O
important	O
that	O
health	O
care	O
professionals	O
be	O
aware	O
of	O
the	O
potential	O
for	O
medications	O
to	O
interfere	O
with	O
clinical	O
laboratory	O
tests	O
.	O

Medications	O
can	O
cause	O
in	O
vivo	O
effects	O
when	O
the	O
concentration	O
or	O
activity	O
of	O
the	O
analyte	O
is	O
altered	O
before	O
the	O
analysis	O
and	O
therefore	O
the	O
assay	O
result	O
is	O
true	O
and	O
accurate	O
.	O

An	O
in	O
vitro	O
effect	O
occurs	O
when	O
the	O
medication	O
interferes	O
with	O
the	O
assay	O
,	O
and	O
the	O
result	O
is	O
erroneous	O
and	O
can	O
not	O
be	O
interpreted	O
.	O

This	O
report	O
describes	O
a	O
recently	O
identified	O
case	O
of	O
interference	O
of	O
acetylcysteine	S-drug
with	O
the	O
urine	O
test	O
for	O
ketones	O
and	O
demonstrates	O
the	O
importance	O
of	O
a	O
thorough	O
medication	O
review	O
in	O
evaluating	O
abnormal	O
laboratory	O
tests	O
.	O

[	O
2	O
epidemics	O
of	O
arsenical	O
encephalopathy	O
in	O
the	O
treatment	O
of	O
trypanosomiasis	O
,	O
Uganda	O
,	O
1992	O
-	O
1993	O
]	O
Since	O
1988	O
,	O
the	O
french	O
non	O
-	O
governmental	O
organisation	O
M	O
decins	O
Sans	O
Fronti	O
res	O
is	O
running	O
a	O
control	O
program	O
of	O
human	O
african	O
trypanosomiasis	O
in	O
the	O
district	O
of	O
Moyo	O
,	O
North	O
-	O
Uganda	O
.	O

Between	O
1988	O
and	O
1993	O
,	O
more	O
than	O
7,000	O
patients	O
were	O
diagnosed	O
and	O
treated	O
.	O

Since	O
1988	O
,	O
it	O
has	O
been	O
noted	O
that	O
incidence	O
of	O
melarsoprol	S-drug
reaction	O
had	O
increased	O
systematically	O
between	O
June	O
and	O
October	O
of	O
each	O
year	O
,	O
indicating	O
strong	O
seasonal	O
variation	O
.	O

In	O
1992	O
and	O
1993	O
,	O
two	O
outbreaks	O
of	O
arsenical	O
reactive	O
encephalopathy	O
(	O
ARE	O
)	O
occurred	O
in	O
the	O
sleeping	O
sickness	O
center	O
of	O
Adjumani	O
.	O

The	O
incidence	O
of	O
ARE	O
suddenly	O
exceeded	O
10	O
%	O
of	O
the	O
patients	O
treated	O
by	O
melarsoprol	S-drug
during	O
August	O
1992	O
and	O
September	O
1993	O
.	O

The	O
onset	O
of	O
80	O
%	O
of	O
those	O
``	O
epidemic	O
``	O

cases	O
,	O
occurred	O
between	O
the	O
5th	O
and	O
the	O
11th	O
day	O
of	O
treatment	O
.	O

Two	O
retrospective	O
studies	O
were	O
conducted	O
in	O
1992	O
(	O
75	O
cases	O
)	O
and	O
in	O
1993	O
(	O
51	O
cases	O
)	O
.	O

Among	O
the	O
risk	O
factors	O
studied	O
,	O
two	O
appear	O
to	O
increase	O
the	O
risk	O
of	O
ARE	O
:	O
the	O
prescription	O
of	O
thiabendazole	S-drug-EF-1
to	O
treat	O
strongyloidiasis	O
during	O
the	O
melarsoprol	S-drug-EF-2
cure	O
and	O
the	O
bad	O
general	O
clinical	O
conditions	O
of	O
patients	O
.	O

These	O
observations	O
suggest	O
that	O
exogenous	O
co	O
-	O
factors	O
could	O
be	O
involved	O
in	O
the	O
occurrence	O
of	O
ARE	O
.	O

Recommendations	O
were	O
to	O
avoid	O
administration	O
of	O
diffusible	O
anti	B-group
-	I-group
helminthic	E-group
treatment	O
during	O
the	O
cure	O
,	O
and	O
to	O
improve	O
the	O
general	O
conditions	O
of	O
patients	O
before	O
the	O
cure	O
of	O
melarsoprol	S-drug
.	O

Interactions	O
of	O
cobalt	S-drug-ME-1
and	O
iron	S-drug-ME-2
in	O
absorption	O
and	O
retention	O
.	O

The	O
effects	O
of	O
supplementary	O
oral	O
cobalt	S-drug
and	O
iron	S-drug
,	O
as	O
well	O
as	O
the	O
interaction	O
between	O
both	O
at	O
the	O
absorption	O
site	O
,	O
fecal	O
and	O
urinary	O
excretion	O
as	O
well	O
as	O
the	O
retention	O
of	O
these	O
trace	O
elements	O
were	O
determined	O
by	O
using	O
four	O
diets	O
containing	O
either	O
9	O
or	O
63	O
micrograms	O
/	O
kg	O
of	O
Co	S-drug
and	O
48	O
or	O
446	O
mg	O
/	O
kg	O
of	O
Fe	S-drug
over	O
a	O
period	O
of	O
19	O
days	O
in	O
a	O
total	O
of	O
24	O
rats	O
.	O

Retention	O
was	O
calculated	O
by	O
the	O
balance	O
technique	O
and	O
by	O
the	O
comparative	O
slaughter	O
technique	O
.	O

After	O
one	O
day	O
,	O
fecal	O
as	O
well	O
as	O
urinary	O
excretion	O
of	O
both	O
elements	O
had	O
already	O
responded	O
to	O
the	O
dietary	O
treatments	O
,	O
with	O
constant	O
values	O
being	O
reached	O
after	O
approximately	O
three	O
days	O
.	O

Cobalt	S-drug
excretion	O
was	O
enhanced	O
by	O
supplementary	O
cobalt	S-drug
;	O

fecal	O
excretion	O
,	O
too	O
,	O
was	O
increased	O
by	O
supplementary	O
iron	S-drug
;	O

whereas	O
urinary	O
excretion	O
was	O
decreased	O
in	O
both	O
cases	O
.	O

Additional	O
iron	S-drug-ME-1
significantly	O
inhibited	O
the	O
absorption	O
of	O
cobalt	S-drug-ME-2
in	O
both	O
dietary	O
cobalt	S-drug-ME-2
treatments	O
.	O

The	O
lower	O
rate	O
of	O
absorption	O
in	O
the	O
groups	O
receiving	O
446	O
mg	O
Fe	S-drug-ME-1
instead	O
of	O
48	O
mg	O
of	O
Fe	S-drug
per	O
kg	O
diet	O
resulted	O
in	O
a	O
decreased	O
renal	O
excretion	O
of	O
cobalt	S-drug-ME-2
.	O

Consequently	O
,	O
the	O
effect	O
of	O
iron	S-drug-ME-1
on	O
the	O
retention	O
of	O
cobalt	S-drug-ME-2
was	O
lower	O
than	O
on	O
absorption	O
.	O

This	O
suggests	O
that	O
interactions	O
between	O
the	O
two	O
elements	O
only	O
take	O
place	O
at	O
the	O
site	O
of	O
absorption	O
.	O

Because	O
of	O
the	O
low	O
dietary	O
cobalt	S-drug
concentration	O
as	O
compared	O
to	O
the	O
iron	S-drug
contents	O
of	O
the	O
diets	O
,	O
no	O
effect	O
of	O
cobalt	S-drug
on	O
iron	S-drug
absorption	O
and	O
excretion	O
occurred	O
.	O

Differences	O
in	O
iron	S-drug
balance	O
were	O
only	O
observed	O
between	O
both	O
dietary	O
concentrations	O
,	O
showing	O
a	O
higher	O
absolute	O
but	O
a	O
lower	O
relative	O
absorption	O
as	O
well	O
as	O
retention	O
in	O
the	O
groups	O
fed	O
further	O
Fe	S-drug
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Effect	O
of	O
estradiol	S-drug
on	O
endotoxin	S-drug_n
-	O
induced	O
changes	O
in	O
steroid	O
hormone	O
levels	O
and	O
lethality	O
in	O
male	O
rats	O
.	O

We	O
examined	O
the	O
effect	O
of	O
exogenous	O
estradiol	S-drug
on	O
the	O
changes	O
in	O
serum	O
steroid	O
hormone	O
levels	O
induced	O
by	O
a	O
nonlethal	O
dose	O
of	O
Escherichia	O
coli	O
endotoxin	S-drug_n
in	O
male	O
rats	O
and	O
the	O
deaths	O
due	O
to	O
nonlethal	O
and	O
lethal	O
doses	O
of	O
endotoxin	S-drug_n
.	O

Injection	O
of	O
estradiol	S-drug-EF-1
5	O
min	O
before	O
a	O
nonlethal	O
dose	O
of	O
endotoxin	S-drug_n-EF-2
changed	O
the	O
serum	O
sex	O
steroid	O
hormone	O
response	O
of	O
male	O
rats	O
to	O
endotoxin	S-drug_n
.	O

The	O
serum	O
estrogen	O
concentrations	O
of	O
estradiol	S-drug-ME-1
+	O
endotoxin	S-drug_n-ME-2
-	O
treated	O
rats	O
decreased	O
by	O
50	O
%	O
,	O
while	O
those	O
of	O
the	O
endotoxin	S-drug_n
-	O
treated	O
rats	O
increased	O
(	O
2	O
-	O
to	O
5	O
-	O
fold	O
)	O
.	O

The	O
serum	O
androgen	O
concentrations	O
of	O
estradiol	S-drug
+	O
endotoxin	S-drug_n
-	O
treated	O
rats	O
did	O
not	O
change	O
significantly	O
,	O
while	O
those	O
of	O
endotoxin	S-drug_n
-	O
treated	O
rats	O
dropped	O
to	O
30	O
-	O
40	O
%	O

0.001	O
.	O

Exogenous	O
estradiol	S-drug-EF-1
also	O
appeared	O
to	O
influence	O
the	O
percentage	O
of	O
endotoxin	S-drug_n-EF-2
-	O
induced	O
deaths	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

It	O
reduced	O
the	O
number	O
of	O
deaths	O
induced	O
by	O
nonlethal	O
(	O
2	O
mg	O
/	O
kg	O
)	O
dose	O
of	O
endotoxin	S-drug_n
but	O
increased	O
the	O
number	O
of	O
deaths	O
induced	O
by	O
a	O
highly	O
lethal	O
dose	O
(	O
8	O
mg	O
/	O
kg	O
)	O
.	O

These	O
results	O
,	O
together	O
with	O
the	O
known	O
relationships	O
between	O
estrogen	S-group
and	O
the	O
immune	O
response	O
,	O
suggest	O
that	O
estrogens	S-group
affect	O
the	O
course	O
of	O
septic	O
shock	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
have	O
either	O
protective	O
or	O
deleterious	O
effect	O
.	O

Analysis	O
of	O
16,16	B-drug_n
-	I-drug_n
dimethylprostaglandin	I-drug_n
E2	E-drug_n
-	O
induced	O
diarrhea	O
in	O
cecectomized	O
rats	O
.	O

The	O
16,16	B-drug_n
-	I-drug_n
dimethylprostaglandin	I-drug_n
E2	E-drug_n
(	O
dmPGE2	S-drug_n
)	O
-	O
induced	O
diarrhea	O
was	O
analyzed	O
in	O
cecectomized	O
rats	O
prepared	O
by	O
resecting	O
the	O
cecum	O
and	O
its	O
vasculature	O
without	O
disturbing	O
the	O
ileocecal	O
junction	O
.	O

dmPGE2	S-drug_n
(	O
0.1	O
-	O
1.0	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O

dose	O
-	O
dependently	O
increased	O
the	O
number	O
of	O
defecation	O
episodes	O
and	O
induced	O
a	O
soft	O
and	O
watery	O
stool	O
in	O
cecectomized	O
rats	O
.	O

At	O
0.3	O
mg	O
/	O
kg	O
,	O
the	O
diarrhea	O
-	O
inducing	O
effects	O
of	O
dmPGE2	S-drug_n
were	O
more	O
pronounced	O
in	O
cecectomized	O
than	O
in	O
control	O
rats	O
.	O

When	O
given	O
i.p	O
.	O
,	O
dmPGE2	S-drug_n
(	O
0.3	O
mg	O
/	O
kg	O
)	O
induced	O
a	O
watery	O
stool	O
in	O
cecectomized	O
and	O
control	O
rats	O
with	O
the	O
same	O
efficacy	O
,	O
although	O
these	O
effects	O
were	O
short	O
-	O
lasting	O
as	O
compared	O
to	O
oral	O
administration	O
.	O

Castor	B-drug
oil	E-drug
(	O
4	O
ml	O
/	O
kg	O
,	O
p.o	O
.	O
)	O

also	O
induced	O
diarrhea	O
,	O
but	O
did	O
not	O
produce	O
a	O
watery	O
stool	O
in	O
cecectomized	O
rats	O
.	O

There	O
were	O
no	O
differences	O
between	O
cecectomized	O
and	O
control	O
rats	O
in	O
basal	O
small	O
intestinal	O
transits	O
or	O
in	O
dmPGE2	S-drug_n
(	O
0.3	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
-	O
induced	O
enhancements	O
.	O

Moreover	O
,	O
the	O
basal	O
and	O
dmPGE2	S-drug_n
-	O
induced	O
jejunal	O
net	O
fluid	O
transfers	O
were	O
the	O
same	O
in	O
cecectomized	O
and	O
in	O
control	O
rats	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
enhanced	O
secretion	O
of	O
colonic	O
fluid	O
by	O
dmPGE2	S-drug_n
,	O
given	O
intraluminally	O
,	O
was	O
only	O
half	O
of	O
that	O
in	O
control	O
rats	O
,	O
whereas	O
the	O
colonic	O
transit	O
-	O
enhancing	O
effect	O
of	O
dmPGE2	S-drug_n
in	O
cecectomized	O
rats	O
was	O
more	O
pronounced	O
than	O
in	O
control	O
rats	O
at	O
15	O
but	O
not	O
at	O
30	O
min	O
after	O
its	O
administration	O
.	O

The	O
basal	O
colonic	O
fluid	O
contents	O
and	O
transits	O
were	O
the	O
same	O
in	O
cecectomized	O
and	O
in	O
control	O
rats	O
.	O

Loperamide	S-drug
and	O
morphine	S-drug
(	O
0.1	O
and	O
1.0	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O

Loperamide	S-drug-EF-1
and	O
morphine	S-drug-EF-1
(	O
0.1	O
and	O
1.0	O
mg	O
/	O
kg	O
,	O
s.c.	O
)	O
inhibited	O
the	O
dmPGE2	S-drug_n-EF-2
(	O
0.3	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
-	O
induced	O
diarrhea	O
in	O
cecectomized	O
rats	O
.	O

N	B-drug_n
-	I-drug_n
methyllevallorphan	E-drug_n
(	O
5	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O

N	B-drug_n-EF-1
-	I-drug_n-EF-1
methyllevallorphan	E-drug_n-EF-1
(	O
5	O
mg	O
/	O
kg	O
,	O
s.c.	O
)	O
completely	O
antagonized	O
the	O
inhibitory	O
effect	O
of	O
loperamide	S-drug-EF-2
and	O
partly	O
antagonized	O
the	O
effect	O
of	O
morphine	S-drug-EF-2
.	O

These	O
results	O
suggest	O
that	O
oral	O
administration	O
of	O
dmPGE2	S-drug_n
induces	O
a	O
more	O
pronounced	O
secretory	O
diarrhea	O
in	O
cecectomized	O
than	O
in	O
control	O
rats	O
,	O
probably	O
due	O
to	O
the	O
lack	O
of	O
the	O
reservoir	O
function	O
of	O
the	O
cecum	O
in	O
the	O
operated	O
animals	O
.	O

This	O
secretory	O
diarrhea	O
model	O
is	O
suitable	O
for	O
evaluating	O
the	O
antidiarrheal	O
activity	O
of	O
drugs	O
.	O

Therapeutic	O
drug	O
monitoring	O
can	O
avoid	O
iatrogenic	O
alterations	O
caused	O
by	O
99mTc	B-drug-EF-1
-	I-drug-EF-1
methylene	I-drug-EF-1
diphosphonate	E-drug-EF-1
(	O
MDP	O
)	O
-	O
gentamicin	S-drug-EF-2
interaction	O
.	O

Gentamicin	S-drug
is	O
an	O
aminoglycoside	B-group
antibiotic	E-group
used	O
to	O
treat	O
a	O
wide	O
variety	O
of	O
infections	O
caused	O
by	O
gram	O
-	O
negative	O
organisms	O
,	O
but	O
it	O
is	O
potentially	O
toxic	O
to	O
the	O
kidneys	O
.	O

Due	O
to	O
its	O
nephrotoxicity	O
,	O
gentamicin	S-drug-ME-1
may	O
cause	O
abnormal	O
renal	O
uptake	O
to	O
be	O
seen	O
on	O
99mTc	B-drug-ME-2
-	I-drug-ME-2
MDP	E-drug-ME-2
bone	O
scintigraphy	O
.	O

The	O
presence	O
of	O
the	O
radiopharmaceutical	S-group
in	O
the	O
kidneys	O
,	O
along	O
with	O
an	O
increase	O
in	O
renal	O
retention	O
,	O
tend	O
to	O
produce	O
scintigraphic	O
results	O
that	O
falsely	O
identify	O
characteristics	O
related	O
to	O
diseases	O
such	O
as	O
renal	O
vascular	O
,	O
or	O
urinary	O
tract	O
obstruction	O
,	O
and	O
even	O
renal	O
cancer	O
.	O

An	O
altered	O
biodistribution	O
may	O
provide	O
misleading	O
information	O
that	O
can	O
either	O
mask	O
or	O
mimic	O
certain	O
disease	O
symptoms	O
.	O

A	O
method	O
to	O
maximize	O
the	O
therapeutic	O
benefit	O
of	O
gentamicin	S-drug
while	O
minimizing	O
the	O
risk	O
of	O
nephrotoxicity	O
and	O
the	O
appearance	O
of	O
a	O
hot	O
kidney	O
on	O
scintigraphy	O
is	O
desirable	O
.	O

Serial	O
pharmacokinetic	O
dosing	O
has	O
been	O
proposed	O
as	O
a	O
method	O
to	O
accomplish	O
this	O
goal	O
.	O

Therapeutic	O
drug	O
monitoring	O
(	O
TDM	O
)	O
of	O
gentamicin	S-drug
therapy	O
,	O
and	O
bone	O
scintigraphy	O
employing	O
99mTc	B-drug
-	I-drug
MDP	E-drug
as	O
the	O
radiopharmaceutical	S-group
was	O
carried	O
out	O
in	O
22	O
patients	O
.	O

The	O
data	O
presented	O
here	O
demonstrate	O
that	O
with	O
serial	O
pharmacokinetic	O
dosing	O
of	O
gentamicin	S-drug
,	O
the	O
iatrogenic	O
alteration	O
caused	O
by	O
gentamicin	S-drug
therapy	O
can	O
be	O
avoided	O
.	O

Immunosuppressive	B-group
drugs	E-group
and	O
their	O
complications	O
.	O

Drugs	O
that	O
suppress	O
the	O
immune	O
system	O
are	O
widely	O
used	O
.	O

They	O
are	O
part	O
of	O
the	O
treatment	O
of	O
patients	O
with	O
organ	O
transplants	O
,	O
malignancy	O
,	O
and	O
increasingly	O
those	O
with	O
conditions	O
such	O
as	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
and	O
liver	O
and	O
bowel	O
disease	O
in	O
which	O
inflammation	O
is	O
an	O
aetiological	O
factor	O
.	O

Because	O
of	O
the	O
broadening	O
indications	O
for	O
immunosuppressive	B-group
drugs	E-group
,	O
and	O
the	O
prolonged	O
survival	O
in	O
conditions	O
for	O
which	O
they	O
are	O
being	O
used	O
,	O
many	O
patients	O
on	O
immunosuppression	O
are	O
now	O
cared	O
for	O
in	O
the	O
community	O
or	O
seen	O
in	O
non	O
-	O
specialist	O
hospitals	O
,	O
usually	O
in	O
close	O
collaboration	O
with	O
a	O
specialist	O
.	O

This	O
article	O
looks	O
at	O
five	O
commonly	O
used	O
immunosuppressive	B-group
drugs	E-group
in	O
turn	O
(	O
corticosteroids	S-group
,	O
cyclosporin	S-drug
,	O
azathioprine	S-drug
,	O
methotrexate	S-drug
,	O
cyclophosphamide	S-drug
)	O
,	O
discussing	O
the	O
main	O
,	O
non	O
-	O
infection	O
,	O
unwanted	O
effects	O
,	O
ways	O
to	O
avoid	O
them	O
and	O
what	O
to	O
do	O
if	O
problems	O
arise	O
.	O

The	O
management	O
of	O
infection	O
is	O
dealt	O
with	O
as	O
a	O
separate	O
section	O
.	O

Interaction	O
of	O
the	O
constituents	O
of	O
alcoholic	O
beverages	O
in	O
the	O
promotion	O
of	O
liver	O
damage	O
.	O

Little	O
has	O
been	O
studied	O
of	O
the	O
adverse	O
effects	O
of	O
the	O
exposure	O
of	O
the	O
liver	O
to	O
the	O
interaction	O
of	O
ethanol	S-drug
with	O
its	O
congeners	O
and	O
acetaldehyde	S-drug_n
,	O
coexisting	O
in	O
the	O
contents	O
of	O
alcoholic	O
beverages	O
.	O

Twenty	O
four	O
male	O
Wistar	O
rats	O
were	O
divided	O
into	O
four	O
groups	O
.	O

Two	O
groups	O
(	O
SH	O
/	O
DA	O
;	O
SH	O
/	O
FA	O
)	O
were	O
submitted	O
to	O
daily	O
treatment	O
with	O
synthetic	O
hydroalcoholic	O
solutions	O
containing	O
ethanol	S-drug
,	O
methanol	S-drug_n
,	O
higher	O
alcohols	S-drug_n
and	O
acetaldehyde	S-drug_n
in	O
the	O
same	O
proportions	O
as	O
those	O
found	O
in	O
most	O
common	O
distilled	O
and	O
fermented	O
alcoholic	O
beverages	O
;	O

the	O
third	O
group	O
(	O
SH	O
/	O
EA	O
)	O
was	O
treated	O
with	O
a	O
hydroalcoholic	O
solution	O
of	O
ethanol	S-drug
;	O

the	O
fourth	O
group	O
served	O
as	O
control	O
and	O
received	O
an	O
equivalent	O
volume	O
of	O
an	O
isocaloric	O
solution	O
of	O
dextrose	S-drug
.	O

All	O
the	O
animals	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
9th	O
week	O
of	O
the	O
experiment	O
.	O

The	O
ratio	O
between	O
the	O
liver	O
weight	O
and	O
body	O
weight	O
was	O
found	O
to	O
be	O
lower	O
in	O
the	O
treated	O
animals	O
than	O
in	O
the	O
control	O
group	O
.	O

The	O
histology	O
of	O
the	O
liver	O
was	O
altered	O
in	O
the	O
three	O
groups	O
which	O
were	O
submitted	O
to	O
treatment	O
with	O
the	O
hydroalcoholic	O
solutions	O
,	O
with	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
the	O
groups	O
.	O

These	O
results	O
suggest	O
that	O
the	O
hepatoxicity	O
of	O
ethanol	S-drug-EF-1
in	O
alcoholic	O
beverages	O
is	O
enhanced	O
by	O
interaction	O
with	O
its	O
congeners	O
and	O
acetaldehyde	S-drug_n-EF-2
;	O

they	O
also	O
suggest	O
that	O
alcoholic	O
beverages	O
are	O
not	O
equivalent	O
in	O
their	O
potential	O
to	O
cause	O
liver	O
damage	O
.	O

Induction	O
of	O
apoptosis	O
in	O
breast	O
cancer	O
cells	O
in	O
response	O
to	O
vitamin	B-group
D	E-group
and	O
antiestrogens	S-group
.	O

1,25	O
-	I-drug
Dihydroxycholecalciferol	I-drug
D3	E-drug
(	O
1,25	B-drug
(	I-drug
OH	I-drug
)	I-drug
2D3	E-drug
)	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	B-group
D	E-group
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
breast	O
cancer	O
cell	O
growth	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

We	O
have	O
shown	O
that	O
MCF	O
-	O
7	O
cells	O
treated	O
with	O
100	O
nM	O
1,25	B-drug
(	I-drug
OH	I-drug
)	I-drug
2D3	E-drug
exhibit	O
characteristic	O
apoptotic	O
morphology	O
(	O
pyknotic	O
nuclei	O
,	O
chromatin	O
and	O
cytoplasmic	O
condensation	O
,	O
nuclear	O
matrix	O
protein	O
reorganization	O
)	O
within	O
48	O
h	O
.	O

In	O
the	O
experiments	O
reported	O
here	O
,	O
we	O
examined	O
the	O
interactions	O
between	O
1,25	B-drug
(	I-drug
OH	I-drug
)	I-drug
2D3	E-drug
and	O
the	O
antiestrogen	S-group
4	B-drug_n
-	I-drug_n
hydroxytamoxifen	E-drug_n
(	O
TAM	S-drug_n
)	O
,	O
which	O
also	O
induces	O
apoptosis	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
TAM	S-drug_n-EF-1
significantly	O
potentiates	O
the	O
reduction	O
in	O
cell	O
number	O
induced	O
by	O
1,25	B-drug-EF-2
(	I-drug-EF-2
OH	I-drug-EF-2
)	I-drug-EF-2
2D3	E-drug-EF-2
alone	O
.	O

Combined	O
treatment	O
with	O
1,25	B-drug-EF-1
(	I-drug-EF-1
OH	I-drug-EF-1
)	I-drug-EF-1
2D3	E-drug-EF-1
and	O
TAM	S-drug_n-EF-2
enhances	O
the	O
degree	O
of	O
apoptosis	O
assessed	O
using	O
morphological	O
markers	O
that	O
identify	O
chromatin	O
and	O
nuclear	O
matrix	O
protein	O
condensation	O
.	O

We	O
have	O
selected	O
a	O
subclone	O
of	O
MCF	O
-	O
7	O
cells	O
resistant	O
to	O
1,25	B-drug
(	I-drug
OH	I-drug
)	I-drug
2D3	E-drug
(	O
MCF	O
-	O
7D3Res	O
)	O
.	O

These	O
cells	O
express	O
the	O
vitamin	O
D	O
receptor	O
and	O
exhibit	O
doubling	O
times	O
comparable	O
to	O
the	O
parental	O
MCF	O
-	O
7	O
cells	O
,	O
even	O
when	O
grown	O
in	O
100	O
mM	O
1,25	B-drug
(	I-drug
OH	I-drug
)	I-drug
2D3	E-drug
.	O

Treatment	O
of	O
both	O
parental	O
and	O
resistant	O
MCF	O
-	O
7	O
cells	O
with	O
TAM	S-drug_n
induces	O
apoptosis	O
and	O
clusterin	O
.	O

These	O
data	O
emphasize	O
that	O
apoptosis	O
can	O
be	O
induced	O
in	O
MCF	O
-	O
7	O
cells	O
either	O
by	O
activation	O
of	O
vitamin	B-group
-	I-group
D	E-group
-	O
mediated	O
signalling	O
or	O
disruption	O
of	O
estrogen	S-group
-	O
dependent	O
signalling	O
.	O

Pharmacokinetic	O
profile	O
of	O
etodolac	S-drug
in	O
special	O
populations	O
.	O

The	O
pharmacokinetics	O
of	O
etodolac	S-drug
in	O
healthy	O
normal	O
volunteers	O
has	O
been	O
extensively	O
studied	O
and	O
is	O
well	O
described	O
.	O

Etodolac	S-drug
is	O
characterised	O
by	O
a	O
high	O
oral	O
bioavailability	O
,	O
low	O
clearance	O
,	O
a	O
small	O
volume	O
of	O
distribution	O
,	O
and	O
a	O
7	O
-	O
hour	O
half	O
-	O
life	O
.	O

It	O
is	O
essentially	O
completely	O
metabolised	O
,	O
therefore	O
little	O
is	O
excreted	O
unchanged	O
.	O

Etodolac	S-drug
is	O
highly	O
protein	O
bound	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
disease	O
states	O
or	O
concomitant	O
drug	O
administration	O
on	O
a	O
patient	O
's	O
response	O
to	O
etodolac	S-drug
,	O
additional	O
pharmacokinetic	O
studies	O
were	O
carried	O
out	O
in	O
special	O
populations	O
.	O

Since	O
etodolac	S-drug
has	O
a	O
well	O
-	O
defined	O
pharmacokinetic	O
-	O
pharmacodynamic	O
relationship	O
,	O
measurement	O
of	O
pharmacokinetic	O
parameters	O
is	O
clinically	O
relevant	O
.	O

Data	O
from	O
studies	O
to	O
date	O
show	O
that	O
disease	O
states	O
,	O
underlying	O
conditions	O
,	O
and	O
concomitantly	O
administered	O
highly	O
protein	O
-	O
bound	O
drugs	O
have	O
essentially	O
no	O
effect	O
on	O
etodolac	S-drug
pharmacokinetics	O
.	O

Therefore	O
,	O
etodolac	S-drug
can	O
generally	O
be	O
given	O
without	O
the	O
need	O
for	O
dosage	O
modifications	O
in	O
special	O
populations	O
such	O
as	O
uncompromised	O
elderly	O
patients	O
,	O
those	O
with	O
moderate	O
renal	O
impairment	O
,	O
and	O
patients	O
with	O
stable	O
hepatic	O
disease	O
.	O

Effects	O
of	O
xanthine	B-group
derivatives	E-group
in	O
a	O
light	O
/	O
dark	O
test	O
in	O
mice	O
and	O
the	O
contribution	O
of	O
adenosine	O
receptors	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
adenosine	O
receptor	O
antagonists	O
,	O
caffeine	S-drug
,	O
theophylline	S-drug
,	O
8	B-drug_n
-	I-drug_n
phenyltheophylline	E-drug_n
,	O
and	O
8	B-drug_n
-	I-drug_n
cyclopentyl	I-drug_n
-	I-drug_n
1,3	I-drug_n
-	I-drug_n
dipropylxanthine	E-drug_n
(	O
DPCPX	S-drug_n
)	O
,	O
in	O
a	O
light	O
/	O
dark	O
test	O
in	O
mice	O
.	O

All	O
antagonists	O
decreased	O
the	O
time	O
spent	O
in	O
the	O
light	O
zone	O
in	O
this	O
test	O
,	O
which	O
suggested	O
that	O
these	O
compounds	O
have	O
anxiogenic	O
effects	O
.	O

The	O
anxiogenic	O
effects	O
of	O
theophylline	S-drug-EF-1
were	O
reduced	O
by	O
pretreatment	O
with	O
CGS	B-drug_n-EF-2
21680	E-drug_n-EF-2
,	O
an	O
A2	O
-	O
selective	O
agonist	O
,	O
but	O
not	O
by	O
N6	B-drug_n
-	I-drug_n
cyclopentyladenosine	E-drug_n
(	O
CPA	S-drug_n
)	O
,	O
an	O
A1	O
-	O
selective	O
agonist	O
.	O

However	O
,	O
the	O
antagonism	O
of	O
the	O
theophylline	S-drug-EF-1
-	O
induced	O
anxiogenic	O
effects	O
by	O
CGS21680	S-drug_n-EF-2
was	O
only	O
observed	O
in	O
the	O
time	O
spent	O
in	O
the	O
light	O
zone	O
,	O
and	O
DPCPX	S-drug_n
-	O
induced	O
anxiogenic	O
effects	O
were	O
neither	O
reversed	O
by	O
CGS	B-drug
21680	E-drug
nor	O
by	O
CPA	S-drug_n
.	O

Finally	O
,	O
it	O
is	O
notable	O
that	O
xanthine	O
-	O
derived	O
adenosine	O
antagonists	O
tested	O
here	O
commonly	O
showed	O
anxiogenic	O
effects	O
in	O
the	O
light	O
/	O
dark	O
test	O
in	O
mice	O
.	O

It	O
is	O
suggested	O
that	O
there	O
is	O
a	O
minor	O
contribution	O
of	O
adenosine	O
receptors	O
to	O
these	O
effects	O
,	O
although	O
theophylline	S-drug
-	O
induced	O
anxiogenic	O
effects	O
were	O
antagonized	O
by	O
an	O
A2	O
receptor	O
agonist	O
.	O

[	O
The	O
effect	O
of	O
sandimmune	S-brand
on	O
the	O
activity	O
of	O
mixed	O
-	O
function	O
mono	O
-	O
oxidases	O
in	O
the	O
liver	O
microsomes	O
]	O
The	O
effects	O
of	O
the	O
immunodepressant	S-group
-	O
-	O
the	O
drug	O
sandimmune	S-brand
-	O
-	O
on	O
hepatic	O
microsomal	O
monooxygenase	O
activities	O
were	O
studied	O
.	O

The	O
agent	O
was	O
found	O
to	O
produce	O
some	O
inhibiting	O
activity	O
against	O
hepatic	O
microsomal	O
7	O
-	O
ethoxycoumarine	O
deethylase	O
in	O
male	O
Wistar	O
rats	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
.	O

When	O
given	O
in	O
a	O
dose	O
of	O
50	O
mg	O
/	O
kg	O
,	O
sandimmune	S-brand
produced	O
no	O
statistically	O
significant	O
effect	O
on	O
the	O
duration	O
of	O
hexanal	O
-	O
induced	O
sleep	O
in	O
mice	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
agent	O
has	O
slight	O
effects	O
on	O
the	O
tested	O
activities	O
.	O

[	O
The	O
effect	O
of	O
cimetidine	S-drug
on	O
the	O
renal	O
excretion	O
of	O
verografin	S-drug
and	O
iodamide	S-drug
in	O
dogs	O
]	O
The	O
intravenous	O
injection	O
of	O
cimetidine	S-drug-ME-1
in	O
a	O
dose	O
of	O
20	O
mg	O
/	O
kg	O
enhanced	O
verografine	S-drug-ME-2
and	O
iodamide	S-drug-ME-2
excretion	O
in	O
chronic	O
canine	O
experiments	O
.	O

The	O
higher	O
verografine	S-drug
and	O
iodamide	S-drug
excretion	O
was	O
due	O
to	O
their	O
increased	O
renal	O
tubular	O
secretion	O
.	O

In	O
dogs	O
,	O
cimetidine	S-drug
unchanged	O
the	O
secretion	O
of	O
cardiotrast	S-drug
,	O
a	O
test	O
agent	O
for	O
anionic	O
transport	O
.	O

Possible	O
extrarenal	O
mechanisms	O
of	O
action	O
of	O
cimetidine	S-drug
on	O
verografine	S-drug
and	O
iodamide	S-drug
transport	O
were	O
also	O
examined	O
.	O

[	O
Hippocampus	O
as	O
interaction	O
sites	O
between	O
cerebral	O
memory	O
systems	O
]	O
Most	O
of	O
the	O
current	O
theories	O
assume	O
that	O
there	O
are	O
multiple	O
forms	O
of	O
memory	O
that	O
are	O
supported	O
by	O
separate	O
brain	O
systems	O
and	O
have	O
different	O
characteristics	O
.	O

Animals	O
studies	O
on	O
the	O
various	O
dual	O
-	O
memory	O
theories	O
have	O
been	O
carried	O
out	O
mainly	O
on	O
the	O
basis	O
of	O
hippocampal	O
system	O
function	O
.	O

Specifically	O
,	O
they	O
have	O
focused	O
on	O
aspects	O
of	O
learning	O
and	O
memory	O
that	O
are	O
impaired	O
(	O
vs.	O
spared	O
)	O
by	O
lesions	O
of	O
the	O
hippocampal	O
formation	O
.	O

However	O
,	O
there	O
are	O
several	O
instances	O
in	O
the	O
animal	O
literature	O
showing	O
that	O
hippocampal	O
lesions	O
actually	O
produced	O
enhanced	O
learning	O
and	O
memory	O
function	O
.	O

Moreover	O
,	O
the	O
acquisition	O
of	O
tasks	O
that	O
are	O
facilitated	O
by	O
hippocampal	O
lesions	O
(	O
or	O
dysfunction	O
)	O
is	O
nevertheless	O
associated	O
,	O
in	O
intact	O
subjects	O
,	O
with	O
specific	O
neurobiological	O
alterations	O
in	O
the	O
hippocampus	O
.	O

This	O
problem	O
has	O
been	O
analysed	O
using	O
two	O
different	O
tasks	O
in	O
mice	O
:	O
a	O
bar	O
-	O
press	O
conditioning	O
and	O
a	O
spatial	O
discrimination	O
task	O
.	O

Results	O
showed	O
that	O
,	O
depending	O
on	O
the	O
task	O
considered	O
,	O
the	O
same	O
pharmacological	O
treatment	O
produced	O
either	O
a	O
facilitation	O
or	O
an	O
impairment	O
of	O
acquisition	O
.	O

Moreover	O
,	O
each	O
task	O
induced	O
significant	O
alterations	O
in	O
hippocampal	O
adenylate	O
cyclase	O
activity	O
but	O
in	O
opposite	O
directions	O
.	O

Together	O
with	O
previous	O
findings	O
,	O
these	O
results	O
suggest	O
that	O
the	O
hippocampus	O
is	O
involved	O
in	O
both	O
the	O
so	O
-	O
called	O
``	O
hippocampal	O
-	O
dependent	O
``	O

``	O
hippocampal	O
-	O
independent	O
``	O

forms	O
of	O
memory	O
.	O

It	O
is	O
postulated	O
that	O
some	O
of	O
the	O
observed	O
training	O
-	O
induced	O
neurobiological	O
alterations	O
might	O
reflect	O
the	O
interaction	O
between	O
two	O
(	O
or	O
more	O
)	O
competing	O
memory	O
systems	O
at	O
the	O
hippocampal	O
level	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
its	O
proposed	O
specific	O
information	O
processing	O
functions	O
(	O
i.e	O
.	O
,	O
relational	O
)	O
,	O
the	O
hippocampus	O
would	O
play	O
a	O
role	O
in	O
addressing	O
information	O
to	O
the	O
brain	O
memory	O
system	O
that	O
,	O
in	O
a	O
given	O
situation	O
,	O
has	O
the	O
best	O
adaptive	O
value	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Magnesium	S-drug
and	O
therapeutics	O
.	O

Two	O
different	O
types	O
of	O
therapy	O
with	O
magnesium	S-drug
are	O
used	O
:	O
physiological	O
oral	O
magnesium	S-drug
supplementation	O
which	O
is	O
totally	O
atoxic	O
since	O
it	O
palliates	O
magnesium	S-drug
deficiencies	O
by	O
simply	O
normalizing	O
the	O
magnesium	S-drug
intake	O
and	O
pharmacological	O
magnesium	S-drug
therapy	O
which	O
may	O
induce	O
toxicity	O
since	O
it	O
creates	O
iatrogenic	O
magnesium	S-drug
overload	O
.	O

Primary	O
and	O
secondary	O
magnesium	S-drug
deficiencies	O
constitute	O
the	O
sole	O
indication	O
of	O
physiological	O
oral	O
magnesium	S-drug
therapy	O
.	O

It	O
is	O
therefore	O
necessary	O
to	O
be	O
well	O
acquainted	O
with	O
the	O
clinical	O
and	O
paraclinical	O
pattern	O
of	O
magnesium	S-drug
deficit	O
and	O
to	O
discriminate	O
between	O
magnesium	S-drug
deficiency	O
due	O
to	O
an	O
insufficient	O
magnesium	S-drug
intake	O
which	O
only	O
requires	O
oral	O
physiological	O
supplementation	O
and	O
magnesium	S-drug
depletion	O
related	O
to	O
a	O
dysregulation	O
of	O
the	O
control	O
mechanisms	O
of	O
magnesium	S-drug
status	O
which	O
requires	O
more	O
or	O
less	O
specific	O
regulation	O
of	O
its	O
causal	O
dysregulation	O
.	O

Physiological	O
oral	O
magnesium	S-drug
load	O
constitutes	O
the	O
best	O
tool	O
for	O
diagnosis	O
of	O
magnesium	S-drug
deficiency	O
and	O
the	O
first	O
step	O
of	O
its	O
treatment	O
.	O

Physiological	O
oral	O
magnesium	S-drug
supplementation	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
is	O
easy	O
and	O
can	O
be	O
carried	O
out	O
in	O
the	O
diet	O
or	O
with	O
magnesium	B-drug
salts	O
,	O
with	O
practically	O
only	O
one	O
contra	O
-	O
indication	O
:	O
overt	O
renal	O
failure	O
.	O

Specific	O
and	O
aspecific	O
treatments	O
of	O
magnesium	S-drug
depletion	O
are	O
tricky	O
using	O
for	O
example	O
magnesium	B-group
sparing	I-group
diuretics	E-group
,	O
pharmacological	O
doses	O
of	O
vitamin	B-drug
B6	E-drug
,	O
physiological	O
doses	O
of	O
vitamin	B-group
D	E-group
and	O
of	O
selenium	S-drug
.	O

In	O
order	O
to	O
use	O
the	O
pharmacological	O
properties	O
of	O
induced	O
therapeutic	O
hypermagnesaemia	O
,	O
high	O
oral	O
doses	O
of	O
magnesium	S-drug
(	O
>	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
are	O
advisable	O
for	O
chronic	O
indications	O
and	O
the	O
parenteral	O
route	O
is	O
suitable	O
for	O
acute	O
indications	O
.	O

There	O
are	O
3	O
types	O
of	O
indications	O
:	O
specific	O
(	O
for	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
magnesium	S-drug
deficit	O
i.e	O
.	O
acute	O
)	O
,	O
pharmacological	O
(	O
i.e	O
.	O
without	O
alterations	O
of	O
magnesium	S-drug
status	O
)	O
and	O
mixed	O
-	O
-	O
pharmacological	O
and	O
aetiopathogenic	O
-	O
-	O
(	O
for	O
example	O
complications	O
of	O
chronic	O
alcoholism	O
)	O
.	O

Today	O
pharmacological	O
magnesium	S-drug
therapy	O
mainly	O
concerns	O
the	O
obstetrical	O
,	O
cardiological	O
and	O
anaesthesiological	O
fields	O
.	O

The	O
main	O
indications	O
are	O
eclampsia	O
,	O
some	O
dysrhythmias	O
(	O
torsades	O
de	O
pointe	O
particularly	O
)	O
and	O
myocardial	O
ischaemias	O
.	O

But	O
it	O
is	O
now	O
difficult	O
to	O
situate	O
the	O
exact	O
place	O
of	O
the	O
pharmacological	O
indications	O
of	O
magnesium	S-drug
.	O

Magnesium	S-drug
infusions	O
can	O
only	O
be	O
envisaged	O
in	O
intensive	O
care	O
units	O
with	O
careful	O
monitoring	O
of	O
pulse	O
,	O
arterial	O
pressure	O
,	O
deep	O
tendon	O
reflexes	O
,	O
hourly	O
diuresis	O
,	O
electrocardiogram	O
and	O
respiratory	O
recordings	O
.	O

High	O
oral	O
magnesium	S-drug
doses	O
besides	O
their	O
laxative	O
action	O
may	O
bring	O
latent	O
complications	O
which	O
may	O
reduce	O
lifespan	O
.	O

There	O
may	O
remain	O
some	O
indications	O
of	O
the	O
laxative	O
and	O
antacid	O
properties	O
of	O
non	O
soluble	O
magnesium	S-drug
,	O
particularly	O
during	O
intermittent	O
haemodialysis	O
.	O

Lastly	O
local	O
use	O
of	O
the	O
mucocutaneous	O
and	O
cytoprotective	O
properties	O
of	O
magnesium	S-drug
is	O
still	O
valid	O
,	O
in	O
cardioplegic	B-drug
solutions	E-drug
and	O
for	O
preservation	O
of	O
transplants	O
particularly	O
.	O

Interaction	O
between	O
glycine	S-drug-EF-1
and	O
glutamate	S-drug-EF-2
in	O
the	O
development	O
of	O
spontaneous	O
motility	O
in	O
chick	O
embryos	O
.	O

In	O
this	O
study	O
we	O
investigated	O
whether	O
also	O
glycine	S-drug
fulfils	O
the	O
function	O
as	O
co	O
-	O
activator	O
in	O
glutamatergic	O
activation	O
of	O
NMDA	O
receptors	O
in	O
the	O
neuronal	O
apparatus	O
of	O
spontaneous	O
motility	O
in	O
chick	O
embryos	O
.	O

The	O
successive	O
application	O
of	O
glycine	S-drug
(	O
5	O
or	O
10	O
mg	O
/	O
kg	O
egg	O
weight	O
(	O
e.w	O
.	O
)	O

and	O
glutamate	S-drug
(	O
15	O
mg	O
/	O
kg	O
e.w	O
.	O
)	O

The	O
successive	O
application	O
of	O
glycine	S-drug-EF-1
(	O
5	O
or	O
10	O
mg	O
/	O
kg	O
egg	O
weight	O
(	O
e.w	O
.	O
)	O
and	O
glutamate	S-drug-EF-2
(	O
15	O
mg	O
/	O
kg	O
e.w	O
.	O
)	O
in	O
a	O
10	O
min	O
interval	O
significantly	O
increased	O
the	O
activation	O
of	O
spontaneous	O
motility	O
of	O
17	O
-	O
day	O
-	O
old	O
chick	O
embryos	O
in	O
comparison	O
with	O
the	O
effect	O
of	O
glutamate	S-drug
alone	O
.	O

This	O
effect	O
did	O
not	O
depend	O
on	O
the	O
order	O
of	O
application	O
of	O
the	O
drugs	O
.	O

In	O
13	O
-	O
day	O
-	O
old	O
embryos	O
,	O
glycine	S-drug
was	O
ineffective	O
in	O
both	O
doses	O
.	O

It	O
is	O
concluded	O
from	O
these	O
results	O
that	O
the	O
modulatory	O
effect	O
of	O
glycine	S-drug
is	O
evidently	O
a	O
later	O
developmental	O
acquisition	O
(	O
after	O
day	O
15	O
of	O
incubation	O
)	O
in	O
the	O
embryogenesis	O
of	O
NMDA	O
-	O
ergic	O
activation	O
of	O
spontaneous	O
motility	O
in	O
chick	O
embryos	O
similarly	O
as	O
glycinergic	O
inhibition	O
.	O

Evidence	O
for	O
reduction	O
of	O
norepinephrine	S-drug
uptake	O
sites	O
in	O
the	O
failing	O
human	O
heart	O
.	O

OBJECTIVES	O
.	O

This	O
study	O
investigated	O
the	O
role	O
of	O
neuronal	O
uptake	O
of	O
norepinephrine	S-drug
(	O
uptake	O
-	O
1	O
)	O
in	O
human	O
heart	O
failure	O
as	O
a	O
local	O
factor	O
for	O
altering	O
concentrations	O
of	O
norepinephrine	O
at	O
the	O
cardiac	O
myocyte	O
membranes	O
.	O

BACKGROUND	O
.	O

Several	O
beta	O
-	O
adrenergic	O
neuroeffector	O
defects	O
occur	O
in	O
heart	O
failure	O
.	O

Whether	O
an	O
alteration	O
in	O
norepinephrine	S-drug
uptake	O
-	O
1	O
occurs	O
is	O
still	O
unresolved	O
.	O

METHODS	O
.	O

The	O
role	O
of	O
norepinephrine	S-drug
uptake	O
-	O
1	O
was	O
studied	O
in	O
electrically	O
stimulated	O
(	O
1	O
Hz	O
,	O
37	O
degrees	O
C	O
)	O
human	O
ventricular	O
cardiac	O
preparations	O
and	O
isolated	O
myocardial	O
membranes	O
.	O

RESULTS	O
.	O

The	O
effectiveness	O
of	O
norepinephrine	S-drug
in	O
increasing	O
the	O
force	O
of	O
contraction	O
was	O
decreased	O
in	O
relation	O
to	O
the	O
degree	O
of	O
heart	O
failure	O
.	O

In	O
contrast	O
,	O
the	O
potency	O
of	O
norepinephrine	S-drug
was	O
increased	O
in	O
failing	O
hearts	O
(	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
IV	O
)	O
in	O
relation	O
to	O
the	O
concentrations	O
producing	O
50	O
%	O
of	O
the	O
maximal	O
effect	O
(	O
EC50	O
)	O
.	O

The	O
EC50	O
values	O
for	O
isoproterenol	S-drug
,	O
which	O
is	O
not	O
a	O
substrate	O
for	O
norepinephrine	S-drug
uptake	O
-	O
1	O
,	O
were	O
reduced	O
in	O
myocardium	O
in	O
functional	O
classes	O
II	O
to	O
III	O
and	O
IV	O
compared	O
with	O
those	O
in	O
nonfailing	O
myocardium	O
.	O

The	O
uptake	O
inhibitors	O
cocaine	S-drug-EF-1
and	O
desipramine	S-drug-EF-1
(	O
3	O
mumol	O
/	O
liter	O
)	O
potentiated	O
the	O
positive	O
inotropic	O
effects	O
of	O
norepinephrine	S-drug-EF-2
in	O
nonfailing	O
myocardium	O
(	O
p	O
<	O
0.05	O
)	O
but	O
not	O
in	O
functional	O
class	O
IV	O
myocardium	O
.	O

Radioligand	O
binding	O
experiments	O
using	O
the	O
uptake	O
inhibitor	O
hydrogen	O
-	O
3	O
mazindol	S-drug
revealed	O
a	O
significant	O
decrease	O
by	O
approximately	O
30	O
%	O
in	O
norepinephrine	S-drug
uptake	O
-	O
1	O
carrier	O
density	O
in	O
functional	O
classes	O
II	O
to	O
III	O
and	O
IV	O
myocardium	O
versus	O
nonfailing	O
myocardium	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
.	O

In	O
human	O
heart	O
failure	O
,	O
there	O
is	O
a	O
presynaptic	O
defect	O
in	O
the	O
sympathetic	O
nervous	O
system	O
,	O
leading	O
to	O
reduced	O
uptake	O
-	O
1	O
activity	O
.	O

This	O
defect	O
in	O
the	O
failing	O
heart	O
can	O
be	O
mimicked	O
by	O
the	O
effects	O
of	O
uptake	O
blocking	O
agents	O
,	O
such	O
as	O
cocaine	S-drug
and	O
desipramine	S-drug
,	O
in	O
the	O
nonfailing	O
heart	O
only	O
.	O

Compromised	O
norepinephrine	S-drug
uptake	O
-	O
1	O
in	O
functional	O
class	O
IV	O
can	O
not	O
be	O
further	O
increased	O
by	O
cocaine	S-drug
and	O
desipramine	S-drug
.	O

The	O
pathophysiologic	O
consequences	O
could	O
be	O
an	O
increased	O
synaptic	O
concentration	O
of	O
norepinephrine	S-drug
predisposing	O
to	O
adenylyl	O
cyclase	O
desensitization	O
.	O

[	O
A	O
pharmacological	O
analysis	O
of	O
the	O
effect	O
of	O
angiotensin	S-drug_n
on	O
stimulated	O
gastric	O
secretion	O
]	O
Chronic	O
experiments	O
on	O
dogs	O
with	O
gastric	O
fistulas	O
were	O
carried	O
out	O
to	O
study	O
the	O
influence	O
of	O
angiotensin	B-drug_n
1	E-drug_n
and	O
angiotensin	B-drug_n
2	E-drug_n
on	O
pentagastrin	S-drug
-	O
and	O
histamine	S-drug
-	O
induced	O
gastric	O
acid	O
secretion	O
.	O

It	O
was	O
established	O
that	O
both	O
angiotensins	O
inhibited	O
gastric	O
acid	O
secretion	O
stimulated	O
by	O
pentagastrin	S-drug
but	O
not	O
by	O
histamine	S-drug
.	O

Comparative	O
analysis	O
of	O
the	O
effects	O
of	O
stimulation	O
and	O
inhibition	O
of	O
cholino	O
-	O
and	O
adrenoreceptors	O
on	O
this	O
inhibitory	O
action	O
of	O
angiotensins	S-drug_n
suggested	O
the	O
mediation	O
of	O
angiotensin	S-drug_n
influence	O
through	O
the	O
modulation	O
of	O
cholinergic	O
reactions	O
of	O
parietal	O
cells	O
in	O
the	O
stomach	O
.	O

Interaction	O
of	O
gentamycin	S-drug-IN-1
and	O
atracurium	S-drug-IN-2
in	O
anaesthetised	O
horses	O
.	O

Evoked	O
hind	O
limb	O
digital	O
extensor	O
tension	O
(	O
hoof	O
twitch	O
)	O
was	O
maintained	O
at	O
40	O
%	O
of	O
baseline	O
for	O
1	O
h	O
by	O
atracurium	S-drug
infusion	O
in	O
7	O
horses	O
anaesthetised	O
with	O
halothane	S-drug
.	O

After	O
1	O
h	O
,	O
atracurium	S-drug
was	O
discontinued	O
and	O
hoof	O
twitch	O
allowed	O
to	O
recover	O
to	O
75	O
%	O
.	O

Atracurium	S-drug
was	O
again	O
given	O
by	O
infusion	O
to	O
maintain	O
40	O
%	O
twitch	O
for	O
a	O
second	O
hour	O
,	O
then	O
2	O
mg	O
gentamycin	S-drug
/	O
kg	O
bwt	O
were	O
given	O
i.v	O
.	O

Atracurium	S-drug
infusion	O
was	O
continued	O
for	O
a	O
third	O
hour	O
,	O
and	O
then	O
hoof	O
twitch	O
was	O
again	O
allowed	O
to	O
recover	O
spontaneously	O
to	O
75	O
%	O
.	O

Gentamycin	S-drug
reduced	O
twitch	O
strength	O
from	O
40	O
+	O
/	O
-	O
1	O
%	O
(	O
mean	O
+	O
/	O
-	O
sem	O
)	O
to	O
29	O
+	O
/	O
-	O
4	O
%	O
within	O
7.0	O
+	O
/	O
-	O
1.5	O
min	O
(	O
P	O
=	O
0.02	O
)	O
.	O

Twitch	O
gradually	O
returned	O
to	O
pre	O
-	O
gentamycin	S-drug
strength	O
over	O
the	O
course	O
of	O
the	O
next	O
hour	O
.	O

Recovery	O
of	O
hoof	O
twitch	O
from	O
50	O
%	O
to	O
75	O
%	O
took	O
7.7	O
+	O
/	O
-	O
0.7	O
min	O
for	O
atracurium	S-drug
alone	O
and	O
11.5	O
+	O
/	O
-	O
2.7	O
min	O
for	O
atracurium	S-drug-EF-1
plus	O
gentamycin	S-drug-EF-2
(	O
P	O
=	O
0.03	O
)	O
.	O

Recovery	O
from	O
50	O
%	O
twitch	O
to	O
75	O
%	O
fade	O
recovery	O
took	O
13.8	O
+	O
/	O
-	O
0.8	O
min	O
for	O
atracurium	S-drug
alone	O
and	O
13.7	O
+	O
/	O
-	O
1.2	O
min	O
for	O
atracurium	S-drug-EF-1
plus	O
gentamycin	S-drug-EF-2
.	O

At	O
75	O
%	O
recovery	O
of	O
fade	O
,	O
hoof	O
twitch	O
was	O
87	O
+	O
/	O
-	O
3	O
%	O
for	O
atracurium	S-drug
alone	O
and	O
82	O
+	O
/	O
-	O
4	O
%	O
for	O
atracurium	S-drug-EF-1
plus	O
gentamycin	S-drug-EF-2
.	O

Reversal	O
of	O
the	O
block	O
with	O
edrophonium	S-drug
and	O
subsequent	O
recovery	O
of	O
the	O
horses	O
from	O
anaesthesia	O
were	O
uneventful	O
.	O

It	O
was	O
concluded	O
that	O
,	O
although	O
gentamycin	S-drug-EF-1
did	O
augment	O
the	O
neuromuscular	O
blockade	O
of	O
atracurium	S-drug-EF-2
,	O
the	O
effect	O
was	O
minimal	O
.	O

Anticoagulants	S-group
.	O

Treatment	O
plans	O
for	O
patients	O
taking	O
anticoagulants	S-group
can	O
become	O
complicated	O
.	O

Anticoagulants	S-group
predispose	O
a	O
patient	O
to	O
bleeding	O
problems	O
.	O

Many	O
drugs	O
used	O
in	O
dentistry	O
can	O
not	O
be	O
taken	O
concomitantly	O
with	O
these	O
medications	O
.	O

Administration	O
of	O
lithium	S-drug
prophylaxis	O
.	O

Successful	O
prophylaxis	O
of	O
manic	O
-	O
depressive	O
disorder	O
requires	O
more	O
than	O
the	O
prescription	O
of	O
lithium	B-drug
carbonate	E-drug
.	O

The	O
administrative	O
arrangements	O
in	O
an	O
area	O
of	O
Scotland	O
were	O
accompanied	O
by	O
a	O
300	O
%	O
increase	O
in	O
the	O
frequency	O
of	O
admissions	O
for	O
mania	O
,	O
whereas	O
in	O
an	O
area	O
of	O
the	O
West	O
Midlands	O
,	O
a	O
large	O
decrease	O
was	O
achieved	O
.	O

[	O
Multiple	O
occupational	O
exposure	O
to	O
solvents	O
]	O
This	O
article	O
review	O
papers	O
published	O
over	O
the	O
last	O
20	O
years	O
on	O
multiple	O
occupational	O
exposure	O
to	O
solvents	O
.	O

At	O
low	O
-	O
levels	O
of	O
exposure	O
the	O
toxicokinetic	O
interferences	O
between	O
solvents	O
have	O
generally	O
not	O
been	O
observed	O
in	O
man	O
and	O
presumably	O
a	O
threshold	O
limit	O
exists	O
.	O

Conversely	O
,	O
at	O
exposure	O
levels	O
close	O
to	O
the	O
``	O
limit	O
values	O
``	O

metabolic	O
interference	O
has	O
sometimes	O
been	O
observed	O
and	O
the	O
behaviour	O
of	O
the	O
biological	O
indicators	O
differs	O
from	O
what	O
would	O
be	O
expected	O
.	O

Toxicodynamic	O
interference	O
between	O
solvents	O
can	O
give	O
rise	O
to	O
additive	O
,	O
potentiation	O
,	O
synergistic	O
,	O
antagonistic	O
effects	O
.	O

For	O
the	O
identification	O
of	O
``	O
limit	O
values	O
``	O
,	O
it	O
has	O
generally	O
been	O
suggested	O
in	O
the	O
literature	O
that	O
the	O
possible	O
effects	O
deriving	O
from	O
multiple	O
exposure	O
be	O
considered	O
as	O
additive	O
.	O

However	O
,	O
numerous	O
potentiation	O
effects	O
have	O
frequently	O
been	O
reported	O
for	O
combined	O
exposure	O
to	O
substances	O
of	O
widespread	O
use	O
.	O

In	O
this	O
paper	O
lists	O
of	O
multiple	O
exposure	O
in	O
which	O
the	O
doses	O
of	O
the	O
substances	O
,	O
the	O
types	O
of	O
interferences	O
and	O
the	O
behaviour	O
of	O
the	O
biological	O
levels	O
have	O
been	O
drawn	O
up	O
and	O
proposed	O
as	O
a	O
tool	O
for	O
easy	O
consultation	O
.	O

Determinants	O
of	O
cellular	O
sensitivity	O
to	O
topoisomerase	B-group
-	I-group
targeting	I-group
antitumor	I-group
drugs	E-group
.	O

It	O
is	O
now	O
clear	O
that	O
topoisomerase	O
activity	O
level	O
is	O
an	O
important	O
determinant	O
of	O
sensitivity	O
to	O
topo	O
drugs	O
.	O

The	O
regulation	O
of	O
topoisomerases	O
is	O
no	O
doubt	O
complex	O
and	O
multifaceted	O
and	O
is	O
probably	O
accomplished	O
through	O
redundancy	O
at	O
many	O
control	O
levels	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
altered	O
topo	O
I	O
expression	O
in	O
certain	O
tumor	O
types	O
is	O
unknown	O
,	O
but	O
may	O
be	O
related	O
to	O
the	O
central	O
importance	O
of	O
topoisomerases	O
in	O
proliferating	O
cell	O
functions	O
(	O
transcription	O
,	O
replication	O
,	O
etc	O
.	O
)	O
,	O
and	O
the	O
aberrant	O
and	O
chronic	O
activation	O
of	O
these	O
functions	O
as	O
a	O
result	O
of	O
specific	O
tumorigenic	O
alterations	O
.	O

Small	O
differences	O
in	O
sensitivity	O
to	O
chemotherapy	O
can	O
have	O
a	O
dramatic	O
effect	O
on	O
cure	O
rates	O
,	O
and	O
therefore	O
subtle	O
cell	O
type	O
-	O
specific	O
differences	O
may	O
be	O
important	O
determinants	O
of	O
drug	O
sensitivity	O
.	O

Whether	O
abnormal	O
topoisomerase	O
quantity	O
and	O
specific	O
activity	O
are	O
associated	O
with	O
resistance	O
or	O
sensitivity	O
to	O
topoisomerase	O
-	O
targeted	O
chemotherapy	O
in	O
the	O
clinic	O
is	O
now	O
being	O
studied	O
.	O

Determinants	O
downstream	O
of	O
cleavable	O
complex	O
formation	O
that	O
affect	O
the	O
sensitivity	O
of	O
tumor	O
versus	O
normal	O
cells	O
to	O
topo	O
drugs	O
in	O
particular	O
and	O
DNA	O
-	O
damaging	O
agents	O
in	O
general	O
are	O
little	O
known	O
.	O

The	O
goal	O
of	O
enhancing	O
selective	O
tumor	O
cell	O
killing	O
relative	O
to	O
the	O
normal	O
cells	O
that	O
are	O
dose	O
limiting	O
may	O
be	O
achieved	O
either	O
by	O
overcoming	O
tumor	O
cell	O
resistance	O
or	O
by	O
protecting	O
normal	O
cells	O
.	O

Both	O
of	O
these	O
strategies	O
will	O
become	O
more	O
feasible	O
as	O
specific	O
molecular	O
differences	O
between	O
tumor	O
and	O
normal	O
cells	O
are	O
being	O
rapidly	O
identified	O
and	O
new	O
combination	O
therapies	O
that	O
take	O
advantage	O
of	O
these	O
differences	O
are	O
being	O
designed	O
and	O
tested	O
.	O

Acid	O
-	O
catalyzed	O
ethanolysis	O
of	O
temazepam	S-drug-ME-1
in	O
anhydrous	O
and	O
aqueous	O
ethanol	S-drug-ME-2
solutions	O
.	O

The	O
benzodiazepines	S-group
are	O
a	O
family	O
of	O
anxiolytic	S-group
and	O
hypnotic	B-group
drugs	E-group
.	O

When	O
taken	O
concurrently	O
with	O
ethanol	S-drug
,	O
a	O
pharmacological	O
interaction	O
may	O
occur	O
,	O
potentiating	O
the	O
central	O
nervous	O
system	O
depression	O
produced	O
by	O
either	O
drug	O
.	O

In	O
addition	O
to	O
this	O
pharmacological	O
interaction	O
,	O
this	O
report	O
describes	O
a	O
novel	O
chemical	O
reaction	O
between	O
temazepam	S-drug-ME-1
(	O
a	O
benzodiazepine	S-group
)	O
and	O
ethanol	S-drug-ME-2
under	O
acidic	O
conditions	O
similar	O
to	O
those	O
found	O
in	O
vivo	O
,	O
resulting	O
in	O
a	O
3	O
-	O
ethoxylated	O
product	O
.	O

Optimal	O
conditions	O
,	O
kinetics	O
,	O
equilibrium	O
,	O
and	O
the	O
mechanism	O
of	O
this	O
acid	O
-	O
catalyzed	O
ethanolysis	O
are	O
reported	O
.	O

The	O
results	O
raise	O
the	O
possibility	O
that	O
the	O
ethanolysis	O
reaction	O
may	O
occur	O
in	O
the	O
stomach	O
of	O
people	O
who	O
consume	O
alcohol	S-drug-ME-1
and	O
3	B-group-ME-2
-	I-group-ME-2
hydroxy	I-group-ME-2
-	I-group-ME-2
1,4	I-group-ME-2
-	I-group-ME-2
benzodiazepine	E-group-ME-2
on	O
a	O
regular	O
basis	O
.	O

The	O
acid	O
-	O
catalyzed	O
ethanol	S-drug
-	O
drug	O
reaction	O
is	O
a	O
relatively	O
unexplored	O
area	O
and	O
may	O
alter	O
the	O
pharmacological	O
action	O
of	O
some	O
drugs	O
.	O

